-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 LSw1J5S5lsjYL/y8kN9gYxD/LRA3skOs0rG/qJP3HCohry2UPSrTp7P+eciX3HS/
 1TYupcnEXvJgsIXtFN/Qiw==

<SEC-DOCUMENT>0000950123-09-063573.txt : 20091117
<SEC-HEADER>0000950123-09-063573.hdr.sgml : 20091117
<ACCEPTANCE-DATETIME>20091117170627
ACCESSION NUMBER:		0000950123-09-063573
CONFORMED SUBMISSION TYPE:	F-1
PUBLIC DOCUMENT COUNT:		98
FILED AS OF DATE:		20091117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Concord Medical Services Holdings Ltd
		CENTRAL INDEX KEY:			0001472072
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		F-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-163155
		FILM NUMBER:		091191131

	BUSINESS ADDRESS:	
		STREET 1:		ROOM 2001-2002, 20TH FLOOR, TOWER A
		STREET 2:		GLOBAL TRADE CTR, 36 NORTH THIRD RING RD
		CITY:			DONGCHENG DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100013
		BUSINESS PHONE:		(86)10-5825-6867

	MAIL ADDRESS:	
		STREET 1:		ROOM 2001-2002, 20TH FLOOR, TOWER A
		STREET 2:		GLOBAL TRADE CTR, 36 NORTH THIRD RING RD
		CITY:			DONGCHENG DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100013
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1
<SEQUENCE>1
<FILENAME>h03611fv1.htm
<DESCRIPTION>F-1
<TEXT>
<HTML>
<HEAD>
<TITLE>fv1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">As filed
    with the Securities and Exchange Commission on November&#160;17,
    2009</FONT></B>
</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Registration No.&#160;333-&#160;&#160;&#160;&#160;&#160;</B>
</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 14pt">SECURITIES AND EXCHANGE
    COMMISSION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">Washington,&#160;D.C.
    20549</FONT></B>
</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 18pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times"><FONT style="white-space: nowrap">Form&#160;F-1</FONT><BR>
    <BR>
    <FONT style="font-size: 12pt">REGISTRATION STATEMENT<BR>
    UNDER<BR>
    THE SECURITIES ACT OF 1933</FONT></FONT></B>
</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 24pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Concord
    Medical Services Holdings Limited</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Exact name of registrant as
    specified in its charter)</FONT></I>
</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Not Applicable</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Translation of
    registrant&#146;s name into English)</FONT></I>
</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="35%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="31%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="31%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    <B>Cayman Islands</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>8011</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>Not Applicable</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(State or other jurisdiction
    of<BR>
    incorporation or organization)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(Primary Standard Industrial<BR>
    Classification Code Number)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(I.R.S. Employer<BR>
    Identification Number) </FONT></I>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>18/F, Tower A, Global Trade Center</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>36 North Third Ring Road East, Dongcheng District</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Beijing 100013</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>People&#146;s Republic of China</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>(86 10)&#160;5903-6688</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Address, including zip code,
    and telephone number, including area code, of registrant&#146;s
    principal executive offices)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>National Registered Agents, Inc.</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>875 Avenue of the Americas, Suite&#160;501</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>New York, New York 10001</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="white-space: nowrap">(888)&#160;336-3926</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I><FONT style="font-size: 8pt">(Name, address, including zip
    code, and telephone number, including area code, of agent for
    service)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Copies to:</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="49%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="center" valign="top">
    <B>Leiming Chen</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>Portia Ku</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <B>Simpson Thacher&#160;&#038; Bartlett LLP</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>O&#146;Melveny &#038; Myers LLP</B>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="center" valign="top">
    <B>35th&#160;Floor, ICBC Tower</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>37/F Plaza 66, 1266 Nanjing Road W</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <B>3 Garden Road</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>Shanghai, People&#146;s Republic of China</B>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="center" valign="top">
    <B>Central, Hong Kong</B>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>(86 10) 2307-7000</B>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
    <B><FONT style="white-space: nowrap">(852)&#160;2514-7600</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Approximate date of commencement of proposed sale to the
    public: </B>As soon as practicable after the effective date of
    this registration statement
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If any of the securities being registered on this form are to be
    offered on a delayed or continuous basis pursuant to
    Rule&#160;415 under the Securities Act of 1933, check the
    following
    box.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is filed to register additional securities for an
    offering pursuant to Rule&#160;462(b) under the Securities Act,
    check the following box and list the Securities Act registration
    statement number of the earlier effective registration statement
    for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<U>&#160;&#160;</U>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(c) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earlier effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<U>&#160;&#160;</U>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If this Form is a post-effective amendment filed pursuant to
    Rule&#160;462(d) under the Securities Act, check the following
    box and list the Securities Act registration statement number of
    the earliest effective registration statement for the same
    offering.&#160;&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;<U>&#160;&#160;</U>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CALCULATION
    OF REGISTRATION FEE</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutterright -->
    <TD width="30%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="16%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    <B>Title of Each Class of<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    <B>Proposed Maximum Aggregate<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    <B>Amount of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Securities to be Registered</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Offering
    Price<SUP style="font-size: 85%; vertical-align: top">(1)</SUP></B>

</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>registration fee</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom" style="border-top: 1px solid #000000">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Ordinary shares, par value US$0.0001 per
    share<SUP style="font-size: 85%; vertical-align: top">(2)(3)</SUP></B>

</DIV>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    <B>US$100,000,000</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    <B>US$5,580</B>
</TD>
</TR>
<TR style="font-size: 1pt">
<TD colspan="7" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD colspan="7" align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Estimated solely for the purpose of
    determining the amount of registration fee in accordance with
    Rule&#160;457(o) under the Securities Act of 1933.
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Includes ordinary shares initially
    offered and sold outside the United States that may be resold
    from time to time in the United States either as part of their
    distribution or within 40&#160;days after the later of the
    effective date of this registration statement and the date the
    shares are first bona fide offered to the public, and also
    includes ordinary shares that may be purchased by the
    underwriters pursuant to an over-allotment option. These
    ordinary shares are not being registered for the purposes of
    sales outside of the United States.
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">American depositary shares issuable
    upon deposit of the ordinary shares registered hereby will be
    registered under a separate registration statement on
    <FONT style="white-space: nowrap">Form&#160;F-6</FONT>
    (Registration
    <FONT style="white-space: nowrap">No.&#160;333-&#160;&#160;&#160;&#160;&#160;).</FONT>
    Each American depositary share
    represents&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ordinary shares.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 17%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>The Registrant hereby amends this Registration Statement on
    such date or dates as may be necessary to delay its effective
    date until the Registrant shall file a further amendment which
    specifically states that this Registration Statement shall
    thereafter become effective in accordance with Section&#160;8(a)
    of the Securities Act of 1933, as amended or until the
    Registration Statement shall become effective on such date as
    the Securities and Exchange Commission, acting pursuant to such
    Section&#160;8(a), may determine.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER><!-- callerid=999 iwidth=540 length=0 -->
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE style="color: #FF0000" width="100%" border="1" cellpadding="5"><TR><TD>
<B><FONT style="font-size: 8pt; font-family: Arial, Helvetica; color: #F93F26">The
information in this prospectus is not complete and may be
changed. Neither we nor the selling shareholders may sell these
securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus
is not an offer to sell these securities and we are not
soliciting offers to buy these securities in any state where the
offer or sale is not permitted.<BR>
</FONT></B>
</TD></TR></TABLE>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 89%; margin-left: 5%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 12pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times; color: #F93F26">PROSPECTUS
    (Subject to Completion) <BR>
    <FONT style="font-size: 11pt">Issued&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2009</FONT></FONT></I>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 18pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">American
    Depositary Shares</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611h0361100.gif" alt="(CONCORD MEDICAL SERVICES HOLDING LIMITED LOGO)"><FONT style="font-size: 18pt">
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 24pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concord
    Medical Services Holdings Limited</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 12pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">REPRESENTING&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ORDINARY SHARES</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Concord Medical Services Holding Limited is
    offering&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    American Depositary Shares, or ADSs, and the selling
    shareholders are
    offering&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ADSs. Each ADS
    represents&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ordinary shares, par value US$0.0001 per share. This is our
    initial public offering and no public market exists for our ADSs
    or our ordinary shares. We anticipate that the initial public
    offering price will be between US$&#160;&#160;&#160;&#160;&#160;
    and US$&#160;&#160;&#160;&#160;&#160; per ADS.</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have applied to list the ADSs on the New York Stock
    Exchange under the symbol &#145;&#145;CCM.&#148;</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 12pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Investing in the ADSs involves risks. See &#147;Risk
    Factors&#148; beginning on page 18.</I></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">PRICE
    US$&#160;&#160;&#160;&#160;&#160; AN ADS</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Underwriting<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Discounts<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Proceeds to<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Price to<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>and<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Proceeds to<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><I>Selling<BR>
    </I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Public</I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Commissions</I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Company</I></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><I>Shareholders</I></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Per ADS
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US<I>$</I>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US<I>$</I>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US<I>$</I>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US<I>$</I>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US<I>$</I>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US<I>$</I>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US<I>$</I>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US<I>$</I>
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and the selling shareholders have granted the underwriters
    the right to purchase up
    to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additional
    ADSs to cover over-allotments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Securities and Exchange Commission and state securities
    regulators have not approved or disapproved these securities, or
    determined if this prospectus is truthful or complete. Any
    representation to the contrary is a criminal offense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters expect to deliver the ADSs to purchasers on or
    about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2009.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 20%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=480 length=96 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="33%"></TD>
    <TD width="33%"></TD>
    <TD width="33%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">    <I><FONT style="font-size: 18pt; font-family: 'Times New Roman', Times">MORGAN
    STANLEY</FONT></I></TD>
    <TD nowrap align="center">    <I><FONT style="font-size: 18pt; font-family: 'Times New Roman', Times">
    J.P.MORGAN</FONT></I></TD>
    <TD nowrap align="right">    <I><FONT style="font-size: 18pt; font-family: 'Times New Roman', Times">
    CICC</FONT></I></TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2009
    </FONT>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">
<IMG src="h03611h03611146.gif" alt="(GRAPHICS)">
</DIV>


<TABLE width="90%">
<TR>
<TD style="font-size: 1pt; color: #FFFFFF">
Cms
O J centers in .30 cities*
Concord Medical operates the largest network of radiotherapy and diagnostic imaging centers in
China**
1 As ot September&nbsp;30,2009.
&#148; In terms of revenues and the total number of centers in operation in 2008, according to a
Frost &#038;
Sullivan report commissioned by Concord Medical.</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 89%; margin-left: 5%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>



<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#101'>Prospectus Summary</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#102'>Risk Factors</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#103'>Special Note Regarding Forward-Looking
    Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#104'>Use of Proceeds</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#105'>Dividend Policy</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#106'>Capitalization</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#107'>Dilution</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#108'>Exchange Rate Information</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#109'>Enforceability of Civil Liabilities</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#110'>Our History and Corporate Structure</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#111'>Selected Consolidated Financial and Operating
    Data</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#112'>Management&#146;s Discussion and Analysis of
    Financial Condition and Results of Operations</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#113'>Our Industry</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#114'>Business</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    97
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#115'>Regulation of Our Industry</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    113
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#116'>Management</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#117'>Principal and Selling Shareholders</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    128
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#118'>Related Party Transactions</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    131
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#130'>Description of Share Capital</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    133
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#119'>Description of American Depositary Shares</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#120'>Shares Eligible for Future Sale</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    152
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#121'>Taxation</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    154
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#122'>Underwriting</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    160
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#123'>Expenses Related to this Offering</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    166
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#124'>Legal Matters</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#125'>Experts</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#126'>Where You Can Find Additional Information</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    168
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#127'>Index to Consolidated Financial Statements of
    Concord Medical Services Holdings Limited</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#128'>Index to Consolidated Financial Statements of
    China Medstar Pte. Limited</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-74
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#129'>Index to Unaudited Pro Forma Condensed Combined
    Financial Statement of Concord Medical Services Holdings
    Limited</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    P-1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv3w1.htm">EX-3.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv3w2.htm">EX-3.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w2.htm">EX-4.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w4.htm">EX-4.4</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w5.htm">EX-4.5</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w6.htm">EX-4.6</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w7.htm">EX-4.7</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w8.htm">EX-4.8</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w9.htm">EX-4.9</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w10.htm">EX-4.10</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w11.htm">EX-4.11</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w12.htm">EX-4.12</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w13.htm">EX-4.13</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w14.htm">EX-4.14</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w15.htm">EX-4.15</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w16.htm">EX-4.16</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv4w17.htm">EX-4.17</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv8w2.htm">EX-8.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w1.htm">EX-10.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w3.htm">EX-10.3</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w4.htm">EX-10.4</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w5.htm">EX-10.5</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w6.htm">EX-10.6</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w7.htm">EX-10.7</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w8.htm">EX-10.8</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w9.htm">EX-10.9</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w10.htm">EX-10.10</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w11.htm">EX-10.11</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w12.htm">EX-10.12</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w13.htm">EX-10.13</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w14.htm">EX-10.14</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w15.htm">EX-10.15</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w16.htm">EX-10.16</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w17.htm">EX-10.17</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w18.htm">EX-10.18</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv10w19.htm">EX-10.19</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv21w1.htm">EX-21.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv23w1.htm">EX-23.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv23w4.htm">EX-23.4</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="h03611exv23w5.htm">EX-23.5</A></FONT></TD></TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 21%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=456 length=96 -->

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You should rely only on the information contained in this
    prospectus or any free writing prospectus filed with the
    Securities and Exchange Commission, or the SEC, in connection
    with this offering. We have not authorized anyone to provide you
    with information that is different from that contained in this
    prospectus or in any filed free writing prospectus. We are
    offering to sell, and seeking offers to buy, the ADSs only in
    jurisdictions where offers and sales are permitted. The
    information contained in this prospectus or in any filed free
    writing prospectus is current only as of its date, regardless of
    the time of its delivery or of any sale of the ADSs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have not taken any action to permit a public offering of the
    ADSs outside of the Untied States or to permit the possession or
    distribution of this prospectus or any filed free writing
    prospectus outside the United States. Persons outside of the
    United States who come into possession of this prospectus or any
    filed free writing prospectus must inform themselves about and
    observe any restrictions relating to the offering of the ADSs
    and the distribution of this prospectus or any filed free
    writing prospectus outside of the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Until
    </B>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    <B>(the 25th&#160;day after the date of this prospectus), all
    dealers that buy, sell or trade ADSs, whether or not
    participating in this offering, may be required to deliver a
    prospectus. This is in addition to the obligation of dealers to
    deliver a prospectus when acting as underwriters and with
    respect to their unsold allotments or subscriptions.</B>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    i
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<A name='101'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROSPECTUS
    SUMMARY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The following summary is qualified in its entirety by, and
    should be read in conjunction with, the more detailed
    information and financial statements appearing elsewhere in this
    prospectus. In addition to this summary, we urge you to read the
    entire prospectus carefully, especially the risks of investing
    in the ADSs discussed under &#147;Risk Factors,&#148; before
    deciding whether to buy our ADSs. Unless the context indicates
    otherwise, all share and per share data in this prospectus give
    effect to a 1-for-100 share split that became effective on
    November&#160;17, 2009.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Business</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We operate the largest network of radiotherapy and diagnostic
    imaging centers in China in terms of revenues and the total
    number of centers in operation in 2008, according to a report by
    Frost&#160;&#038; Sullivan commissioned by us. As of
    September&#160;30, 2009, our network comprised 83&#160;centers
    based in 55&#160;hospitals, spanning 36&#160;cities across
    21&#160;provinces and administrative regions in China. These
    hospitals are substantially comprised of 3A hospitals, the
    highest ranked hospitals by quality and size in China as
    determined in accordance with the standards of the Ministry of
    Health, or the MOH. Cancer was the leading cause of death in
    China in 2008 according to the MOH, and there is a relatively
    low penetration of radiotherapy and diagnostic imaging equipment
    compared to developed countries. We believe that our leading
    network and our experience and expertise uniquely position us to
    address the underserved market in China for radiotherapy and
    diagnostic imaging services.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Most of the centers in our network are established through
    long-term lease and management services arrangements entered
    into with our hospital partners. Under these arrangements, we
    receive a contracted percentage of each center&#146;s revenue
    net of specified operating expenses. Each center is located on
    the premises of our hospital partners and is typically equipped
    with a primary unit of advanced radiotherapy and diagnostic
    imaging equipment, such as a linear accelerator, head gamma
    knife system, body gamma knife system, positron emission
    tomography-computed tomography scanner, or PET-CT scanner, or
    magnetic resonance imaging scanner, or MRI scanner. We provide
    clinical support services to doctors who work in the centers in
    our network, which include developing treatment protocols for
    doctors and organizing joint diagnosis between doctors in our
    network and clinical research. In addition, we help recruit and
    determine the compensation of doctors and other medical
    personnel in our network and are typically in charge of most of
    the non-clinical aspects of the centers&#146; daily operations,
    including marketing, training and administrative duties. Our
    hospital partners are responsible for the centers&#146; clinical
    activities, the medical decisions made by doctors, and the
    employment of the doctors in accordance with regulations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that our success is largely due to the high quality
    clinical care provided at our network of centers and our
    market-oriented management culture and practices. Many of the
    doctors who work in our network have extensive clinical
    experience in radiotherapy, some of whom are recognized as
    leading experts in radiation oncology in China. We enhance the
    quality of clinical care in our network through established
    training of, and on-going clinical education for, doctors in our
    network. We believe that our market-oriented management culture
    and practices allow us to manage centers more efficiently and
    offer more consistent and better patient services than our
    competitors. We believe that our success has given us a strong
    reputation within the medical community, which in turn gives us
    a competitive advantage in gaining patient referrals and
    establishing new centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To complement our organic growth, we have also selectively
    acquired businesses to expand our network. In July 2008, we
    acquired China Medstar Pte. Ltd., or China Medstar, a company
    then publicly listed on the Alternative Investment Market of the
    London Stock Exchange, or the AIM, for approximately
    &#163;17.1&#160;million or approximately RMB238.7&#160;million
    (US$35.0&#160;million). At the time of the acquisition, China
    Medstar jointly managed 23 centers with its hospital partners
    across 14&#160;cities in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To further enhance our reputation and to employ high quality
    doctors, we plan to establish and operate specialty cancer
    hospitals in China. We intend for our specialty cancer hospitals
    to be centers of excellence. Our first specialty cancer
    hospital, the Chang&#146;an CMS International Cancer Center, in
    Xi&#146;an, Shaanxi Province, is expected to commence operation
    in early 2010. We are also in the process of establishing the
    Beijing Proton Medical Center, another specialty cancer
    hospital, which is expected to commence operation in 2012. We
    expect that the Beijing Proton Medical Center will be the first
    proton beam therapy treatment center in China equipped with a
    proton beam therapy system licensed for clinical use.
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business has grown significantly in recent years through
    development of new centers, increases in the number of patient
    cases of existing centers and acquisitions. We have increased
    the number of centers in our network from 41 at the end of 2007
    to 72 at the end of 2008 and to 83 as of September&#160;30,
    2009. Our total net revenues were RMB67.4&#160;million,
    RMB14.0&#160;million and RMB171.8&#160;million
    (US$25.2&#160;million) for the period from January&#160;1, 2007
    to October&#160;30, 2007, the period from September&#160;10,
    2007 to December&#160;31, 2007 and for the year ended
    December&#160;31, 2008. Our total net revenues increased to
    RMB205.7&#160;million (US$30.1&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB102.0&#160;million for the
    same period in 2008, due primarily to an increase in the number
    of centers in our network, including centers added to our
    network as a result of our acquisition of China Medstar, and an
    increase in the number of patient cases in existing centers. For
    periods prior to October&#160;30, 2007, our predecessor is
    deemed the reporting entity for financial reporting purposes as
    a result of our reorganization. We report the financial
    statements of our successor entity from September&#160;10, 2007,
    the date of inception of our successor entity. For additional
    information as to our history and reorganization and our
    financial presentation, see &#147;Our History and Corporate
    Structure&#148; and &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Industry</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The radiotherapy and diagnostic imaging market in China has
    several favorable characteristics. The market is expected to
    grow, with a compound annual growth rate, or CAGR, of 22.4%
    between 2008 and 2015, according to a report by
    Frost&#160;&#038; Sullivan, due to the increasing incidence rate
    of cancer in China and awareness among physicians and patients
    and their adoption of advanced radiotherapy and diagnostic
    imaging technologies, rising household disposable income and
    government healthcare expenditures that will increase the
    affordability of such cancer treatment and diagnosis
    technologies. Moreover, China&#146;s relatively underdeveloped
    medical infrastructure has resulted in significant unmet demand
    for cancer radiotherapy and diagnostic imaging services, with
    the per capita number of units of such medical equipment in
    China being significantly lower than in developed countries. For
    example, Frost&#160;&#038; Sullivan estimates that China had
    only 0.7 linear accelerators per million people at the end of
    2008 compared to 9.5 in the United States, 6.6 in Japan, 5.6 in
    France and 3.0 in the United Kingdom. Hospitals in China often
    lack the financial resources to purchase, and the experienced
    radiation oncologists and radiologists to operate, advanced
    radiotherapy and diagnostic imaging equipment. We believe that
    we are well positioned to benefit from these market dynamics
    through our ability to provide equipment and expertise to
    hospitals in China to establish and operate radiotherapy and
    diagnostic imaging centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Competitive Strengths</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the following competitive strengths have, and
    will continue to, uniquely position us to capitalize on growth
    opportunities in the cancer treatment market in China:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="3%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    leading market position and successful track record;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    doctors with extensive cancer treatment experience developed and
    supported by our network;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    market-oriented management of centers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    successful track record of new center development and
    acquisitions; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    strong and experienced management team.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Strategies</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to further strengthen our leading position in
    radiotherapy and diagnostic imaging market in China by pursuing
    the following strategies:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    continue to develop new radiotherapy and diagnostic imaging
    centers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    increase marketing efforts to drive growth in patient cases at
    our existing centers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    establish specialty cancer hospitals;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    introduce advanced cancer treatment options and diagnostic
    technology in our network;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    complement our development of new centers with selected
    acquisitions.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Challenges</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the following are some of the major risks and
    uncertainties that may materially affect us:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we may encounter difficulties in successfully opening new
    centers or renewing agreements for existing centers due to the
    limited number of suitable hospital partners and their potential
    ability to finance the purchase of medical equipment directly;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we have historically derived a significant portion of our
    revenues from centers located at a limited number of our
    hospital partners and regions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we conduct our business in a heavily regulated industry;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any failure by our hospital partners to make contracted payments
    to us or any disputes over, or significant delays in receiving,
    such payments could have a material adverse effect on our
    business and financial condition;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our business may be harmed by technological and therapeutic
    changes or by shifts in doctors&#146; or patients&#146;
    preferences for alternative treatments.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See &#147;Risk Factors&#148; and other information included in
    this prospectus for a discussion of these and other risks and
    uncertainties.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    History and Corporate Structure</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Concord Medical Services Holdings Limited, or Concord Medical,
    was incorporated in the Cayman Islands on November&#160;27, 2007
    and became our ultimate holding company on March&#160;7, 2008,
    when the shareholders of Ascendium Group Limited, or Ascendium,
    a holding company incorporated in the British Virgin Islands on
    September&#160;10, 2007, exchanged all of their shares for
    shares of Concord Medical. Prior to that, on October&#160;30,
    2007, Ascendium had acquired 100% of the equity interest in Our
    Medical Services,&#160;Ltd., or OMS, resulting in a change in
    control. We refer to this transaction as the OMS reorganization
    in this prospectus. Prior to the OMS reorganization, OMS,
    together with Shenzhen Aohua Medical
    Services&#160;Co.,&#160;Ltd., or Aohua Medical, in which OMS
    effectively held all of the equity interest at the time,
    operated all of our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aohua Medical was incorporated by OMS on July&#160;23, 1997 and
    OMS contributed RMB4.8&#160;million to Aohua Medical,
    representing 90% of the equity interest in Aohua Medical. The
    other 10% of Aohua Medical was held by two nominees who acted as
    the custodians of such equity interest. On June&#160;10, 2009,
    this 10% equity interest was transferred to our subsidiary
    Shenzhen Aohua Medical Leasing and Services&#160;Co.,&#160;Ltd.,
    or Aohua Leasing. The two nominees have not maintained their
    required capital contributions at any time subsequent to the
    incorporation of Aohua Medical. Due to this capital deficiency
    as well as other legal conditions, the two nominees had no legal
    rights to participate either retrospectively or prospectively at
    any time in any profits or losses of Aohua Medical  or to share
    in any residual assets or any proceeds in the event that Aohua
    Medical encountered a liquidation event. For these reasons, we
    do not account for this 10% equity interest as a minority
    interest in our consolidated results of operations or financial
    position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, our subsidiary Ascendium acquired 100% of
    the equity interest in China Medstar together with its wholly
    owned PRC subsidiary, Medstar (Shanghai) Leasing Co., Ltd., or
    Shanghai Medstar, for approximately &#163;17.1&#160;million or
    approximately RMB238.7&#160;million (US$35.0&#160;million).
    China Medstar, through its then subsidiary Shanghai Medstar,
    engaged in the provision of medical equipment leasing and
    management services to hospitals in the PRC. On August&#160;17,
    2009, 100% of the equity interest in Shanghai Medstar was
    transferred from China Medstar to Ascendium.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;28, 2008, we acquired control of Beijing Xing
    Heng Feng Medical Technology Co., Ltd., or Xing Heng Feng
    Medical, through our subsidiaries Aohua Leasing and CMS Hospital
    Management Co., Ltd., or CMS Hospital Management, by acquiring
    100% of its equity interest, which corresponded to its then
    paid-in registered capital. We paid total consideration of
    approximately RMB35.0&#160;million (US$5.1&#160;million) for
    this acquisition.
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We currently conduct substantially all of our operations through
    the following subsidiaries in the PRC:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Shenzhen Aohua Medical Services Co., Ltd., our wholly owned
    subsidiary incorporated in the PRC that engages in the provision
    of radiotherapy and diagnostic center management services to
    hospitals in the PRC;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Shenzhen Aohua Medical Leasing and Services Co., Ltd., our
    wholly owned subsidiary incorporated in the PRC that engages in
    the provision of radiotherapy and diagnostic equipment leasing
    services to hospitals in the PRC;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Medstar (Shanghai) Leasing Co., Ltd., our wholly owned
    subsidiary incorporated in the PRC that engages in the sale of
    medical equipment and the provision of radiotherapy and
    diagnostic equipment leasing and management services to
    hospitals in the PRC;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    CMS Hospital Management Co., Ltd., our wholly owned subsidiary
    incorporated in the PRC that engages in the provision of
    radiotherapy and diagnostic equipment management services to
    hospitals in the PRC;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Beijing Xing Heng Feng Medical Technology Co., Ltd., our wholly
    owned subsidiary incorporated in the PRC that engages in the
    provision of radiotherapy and diagnostic equipment management
    services to hospitals in the PRC.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following diagram illustrates our corporate structure and
    the place of organization of each of our subsidiaries as of the
    date of this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611h0361101.gif" alt="">
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Corporate
    Information</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our principal executive offices are located at 18/F, Tower A,
    Global Trade Center, 36&#160;North Third Ring Road East,
    Dongcheng District, Beijing, People&#146;s Republic of China,
    100013. Our telephone number at this address is
    <FONT style="white-space: nowrap">(86&#160;10)&#160;5903-6688</FONT>
    and our fax number is
    <FONT style="white-space: nowrap">(86&#160;10)&#160;5957-5252.</FONT>
    Our registered office in the Cayman Islands is at Scotia Centre,
    4th&#160;Floor, P.O.&#160;Box&#160;2804, George Town, Grand
    Cayman, Cayman Islands KY1-1112.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Investor inquiries should be directed to us at the address and
    telephone number of our principal executive offices set forth
    above. Our website is www.cmsholdings.com. The information
    contained on our website is not part of this prospectus. Our
    agent for service of process in the United States is National
    Registered Agents, Inc., located at 875 Avenue of the Americas,
    Suite&#160;501, New York, New York 10001.
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Conventions
    That Apply to This Prospectus</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, references in this prospectus to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;ADRs&#148; are to the American depositary receipts, which,
    if issued, evidence our ADSs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;ADSs&#148; are to our American depositary shares, each of
    which
    represents&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ordinary shares;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;China&#148; and the &#147;PRC&#148; are to the
    People&#146;s Republic of China, excluding, for the purposes of
    this prospectus only, Taiwan and the special administrative
    regions of Hong Kong and Macau;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;ordinary shares&#148; are to our ordinary shares, par
    value US$0.0001 per share;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;PRC subsidiaries&#148; are to our subsidiaries
    incorporated in the People&#146;s Republic of China, including
    Aohua Medical, Aohua Leasing, Shanghai Medstar, CMS Hospital
    Management Co., Ltd., or CMS Hospital Management, and Xing Heng
    Feng Medical;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;RMB&#148; and &#147;Renminbi&#148; are to the legal
    currency of China;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;US$&#148; and &#147;U.S.&#160;dollars&#148; are to the
    legal currency of the United States;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;we,&#148; &#147;us,&#148; &#147;our company&#148; and
    &#147;our&#148; are to Concord Medical Services Holdings
    Limited, its predecessor entities and its consolidated
    subsidiaries;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    &#147;&#163;&#148; is to the legal currency of the United
    Kingdom of Great Britain and Northern Ireland.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise indicated, information in this prospectus:
    (i)&#160;assumes that the underwriters do not exercise their
    option to purchase up to an
    additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ADSs
    representing&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ordinary shares from us and the selling shareholders; and
    (ii)&#160;does not include 4,765,800 ordinary shares reserved
    for issuance under our 2008&#160;share incentive plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus contains translations of certain Renminbi
    amounts into U.S.&#160;dollars at specified rates. For all dates
    through December&#160;31, 2008, all translations from Renminbi
    to U.S.&#160;dollars were made at the noon buying rate in the
    City of New York for cable transfers in Renminbi per
    U.S.&#160;dollar as certified for customs purposes by the
    Federal Reserve Bank of New York, or the noon buying rate. For
    January&#160;1, 2009 and all later dates and periods, the
    exchange rate refers to the noon buying rate as set forth in the
    H.10 statistical release of the Federal Reserve Board. Unless
    otherwise stated, the translation of Renminbi into
    U.S.&#160;dollars has been made at the noon buying rate in
    effect on September&#160;30, 2009, which was RMB6.8262 to
    US$1.00. We make no representation that the Renminbi or
    U.S.&#160;dollar amounts referred to in this prospectus could
    have been or could be converted into U.S.&#160;dollars or
    Renminbi, as the case may be, at any particular rate or at all.
    See &#147;Risk Factors&#160;&#151; Risks Related to Doing
    Business in China&#160;&#151; Fluctuations in the value of the
    Renminbi may have a material adverse effect on your
    investment.&#148; On November&#160;13, 2009, the noon buying
    rate was RMB6.8260 to US$1.00.
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">THE
    OFFERING</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="36%"></TD>
    <TD width="1%"></TD>
    <TD width="63%"></TD>
</TR>

<TR>
    <TD valign="top">
    Price per ADS</TD>
    <TD></TD>
    <TD valign="bottom">
    We currently estimate that the initial public offering price
    will be between
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    and
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    ADS offered by us</TD>
    <TD></TD>
    <TD valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ADSs</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    ADS offered by the selling shareholders</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ADSs</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    The ADSs</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    Each ADS
    represents&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ordinary shares, par value US$0.0001 per share. The ADSs may be
    evidenced by an ADR.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    The depositary will be the holder of the ordinary shares
    underlying the ADSs and you will have the rights of an ADS
    holder as provided in the deposit agreement among us, the
    depositary and owners and beneficial owners of ADSs from time to
    time.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    You may surrender your ADSs to the depositary to withdraw the
    ordinary shares underlying your ADSs. The depositary will charge
    you a fee for such an exchange.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    We may amend or terminate the deposit agreement for any reason
    without your consent. If an amendment becomes effective, you
    will be bound by the deposit agreement as amended if you
    continue to hold your ADSs.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    To better understand the terms of the ADSs, you should carefully
    read the section in this prospectus entitled &#147;Description
    of American Depositary Shares.&#148; We also encourage you to
    read the deposit agreement, which is an exhibit to the
    registration statement that includes this prospectus.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Over-allotment option</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    We and the selling shareholders have granted the underwriters an
    option, exercisable within 30&#160;days from the date of this
    prospectus, to purchase up to an aggregate
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    additional ADSs
    representing&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ordinary shares</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Ordinary shares outstanding<BR>
    immediately after the<BR>
    offering</DIV>
</TD>
    <TD></TD>
    <TD valign="top">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ordinary shares
    (or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ordinary shares if the underwriters exercise the option to
    purchase additional ADSs in full), excluding ordinary shares
    reserved for issuance under our 2008&#160;share incentive plan.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    ADSs outstanding immediately<BR>
    after the offering</DIV>
</TD>
    <TD></TD>
    <TD valign="top">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ADSs
    (or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ADSs if the underwriters exercise the option to purchase
    additional ADSs in full).</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Use of proceeds</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    We will receive net proceeds from this offering of approximately
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million,
    after deducting the underwriting discounts and commissions and
    estimated aggregate offering expenses payable by us. We intend
    to use a portion of the net proceeds we receive from this
    offering for the following purposes:</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    &#149;&#160;approximately US$20&#160;million to
    US$25&#160;million to develop our Chang&#146;an CMS
    International Cancer Center; and</DIV>
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    &#149;&#160;approximately US$25&#160;million to
    US$30&#160;million to develop our Beijing Proton Medical Center.</DIV>
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    We will use the remaining portion of the net proceeds we receive
    from this offering for the expansion of our network of centers
    and for general corporate purposes, including potential
    acquisitions of, or </TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="36%"></TD>
    <TD width="1%"></TD>
    <TD width="63%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    investments in, other businesses or technologies that we believe
    will complement our current operations and expansion strategies.
    See &#147;Use of Proceeds&#148; for additional information.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    We will not receive any of the proceeds from the sale of the
    ADSs by the selling shareholders.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Listing</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    We have applied to have our ADSs traded on the New York Stock
    Exchange, or the NYSE. Our ordinary shares will not be listed on
    any exchange or quoted for trading on any over-the-counter
    trading system.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    NYSE trading symbol</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    CCM</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    <FONT style="white-space: nowrap">Lock-up</FONT></DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    We, our directors, executive officers and all existing
    shareholders have agreed with the underwriters, subject to
    certain exceptions, not to sell, transfer or dispose of any of
    our ADSs, ordinary shares or similar securities for a period of
    180&#160;days after the date of this prospectus. See
    &#147;Underwriting.&#148;</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Reserved ADSs</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    At our request, the underwriters have reserved for sale, at the
    public offering price, up to an aggregate
    of&#160;&#160;&#160;&#160;&#160; ADSs offered by this prospectus
    to our directors, officers, employees, business associates and
    related persons through a reserved share program.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Depositary</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    JPMorgan Chase Bank, N. A.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Payment and settlement</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    The ADSs are expected to be delivered against payment
    on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    2009. The ADSs will be deposited with a custodian for, and
    registered in the name of a nominee of, The Depository
    Trust&#160;Company, or DTC, in New York, New York. Initially,
    beneficial interests in the ADSs will be shown on, and transfers
    of these beneficial interest will be effected through, records
    maintained by DTC and its direct and indirect participants.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -5%; margin-left: 5%">
    Risk factors</DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    See &#147;Risk Factors&#148; and other information included in
    this prospectus for a discussion of factors you should carefully
    consider before deciding to invest in the ADSs.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    CONSOLIDATED FINANCIAL AND OPERATING DATA</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Concord Medical was incorporated on November&#160;27, 2007. On
    March&#160;7, 2008, the shareholders of Ascendium exchanged
    their shares in Ascendium for shares of Concord Medical. As a
    result, Concord Medical became our ultimate holding company. Our
    financial statements have been prepared as if the current
    corporate structure had been in existence from
    September&#160;10, 2007, the date on which Ascendium was
    incorporated. Prior to the OMS reorganization, which became
    effective on October&#160;30, 2007, OMS, together with Aohua
    Medical, in which OMS effectively held all of the equity
    interest at the time, operated all of the business of our
    company. As a result of the OMS reorganization, there was a
    change in control of OMS with the Ascendium shareholders
    effectively acquiring OMS from the OMS shareholders. For
    additional information relating to our history and
    reorganization, see &#147;Our History and Corporate
    Structure.&#148; For financial statements reporting purposes,
    OMS is deemed to be the predecessor reporting entity for periods
    prior to October&#160;30, 2007. In our discussion for the year
    ended December&#160;31, 2007, we refer to certain financial
    statement line items as &#147;combined&#148; for comparative
    purposes, which do not comply with U.S.&#160;GAAP. The unaudited
    combined amounts represent the addition of the amounts for
    certain financial statement line items of OMS, our predecessor,
    for the period from January&#160;1, 2007 to October&#160;30,
    2007, and the amounts for the corresponding line items of
    Concord Medical for the period from September&#160;10, 2007 to
    December&#160;31, 2007. We have included these unaudited
    combined amounts as we believe they are helpful for the reader
    to gain a better understanding of results of operations for a
    complete fiscal year and to improve the comparative analysis
    against the results of operations for the year ended
    December&#160;31, 2008. These unaudited combined amounts do not
    purport to represent what our financial position, results of
    operations or cash flows would have been if the OMS
    reorganization had occurred on January&#160;1, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following summary consolidated statements of operations and
    other consolidated financial data for the period from
    January&#160;1, 2007 to October&#160;30, 2007, for the period
    from September&#160;10, 2007 to December&#160;31, 2007 and for
    the year ended December&#160;31, 2008 (other than the net loss
    per ADS data) and the summary consolidated balance sheet data as
    of December&#160;31, 2007 and 2008 have been derived from our
    audited consolidated financial statements, which are included
    elsewhere in this prospectus. The following summary consolidated
    statements of operations and other consolidated financial data
    for the nine months ended September&#160;30, 2008 and 2009
    (other than the net loss per ADS data) and summary consolidated
    balance sheet data as of September&#160;30, 2009 have been
    derived from our unaudited condensed consolidated financial
    statements, which are included elsewhere in this prospectus. We
    have prepared the unaudited condensed consolidated financial
    statements on the same basis as our audited consolidated
    financial statements. The unaudited condensed consolidated
    financial statements include all adjustments, consisting only of
    normal and recurring adjustments, which we consider necessary
    for a fair presentation of our financial position and operating
    results for the periods presented. You should read the summary
    consolidated financial data in conjunction with those financial
    statements and the related notes and &#147;Management&#146;s
    Discussion and Analysis of Financial Condition and Results of
    Operations&#148; included elsewhere in this prospectus. Our
    consolidated financial statements are prepared and presented in
    accordance with United&#160;States generally accepted accounting
    principles, or US&#160;GAAP. Our historical results are not
    necessarily indicative of our results expected for future
    periods.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="37%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD colspan="34" align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Concord<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>January&#160;1,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>September&#160;10,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>October&#160;30,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="32" align="center" valign="bottom">
    <B>(in thousands, except share, per share and per ADS data)</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    <B>Summary Consolidated Statements of Operations Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Revenues, net of business tax, value-added tax and related
    surcharges:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,716
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,092
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,322
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,422
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,405
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    205,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,396
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,046
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,669
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (42,144
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,174
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,003
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,388
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,987
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,416
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,914
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24,330
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,597
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,680
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,361
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (62,541
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,162
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Gross profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,075
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,632
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143,116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,601
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (757
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,358
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (805
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,275
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,463
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (654
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    General and administrative
    expenses<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,467
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (57,171
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (65,638
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,764
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,468
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,687
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,884
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Operating income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,938
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (47,859
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,921
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Other (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (649
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,143
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    578
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,262
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,275
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (626
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    (Loss) income before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,064
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,627
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,691
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income tax (expense) benefit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,832
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,418
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,611
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,734
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,770
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Net (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,896
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,343
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (39,604
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (262,286
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,851
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (44,646
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (38,383
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,623
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Net income (loss) attributable to ordinary shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,896
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (496,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72,667
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (222,270
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,914
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Earning (loss) per share&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.97
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.58
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.26
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.06
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Earning (loss) per ADS&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Shares used in computation&#160;&#151; basic and
    diluted<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,621,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    ADSs used in computation&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Our general and administrative
    expenses include share-based compensation expenses related to
    certain share options granted in 2007 that amounted to
    RMB49.5&#160;million, RMB4.2&#160;million (US$0.6&#160;million)
    and RMB4.2&#160;million in 2007, 2008 and for the nine months
    ended September&#160;30, 2008, respectively. We did not
    recognize any
    <FONT style="white-space: nowrap">share-based</FONT>
    compensation expenses for the nine months ended
    September&#160;30, 2009.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">On November&#160;17, 2009, we
    effected a share split whereby all of our issued and outstanding
    704,281 ordinary shares of a par value of US$0.01 per share were
    split into 70,428,100 ordinary shares of US$0.0001 par value per
    share and the number of our authorized shares were increased
    from 4,500,000 to 450,000,000. The share split has been
    retroactively reflected in this prospectus so that share number,
    per share price and par value data are presented as if the share
    split had occurred from our inception.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="46%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Actual</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>Pro Forma as<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>As of September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom">
    <B>Adjusted as of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">September&#160;30,
    2009<SUP style="font-size: 85%; vertical-align: top">(1)</SUP></FONT></B>

</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="27" nowrap align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Summary Consolidated Balance Sheet Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    285,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,135
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    492,978
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72,219
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    466,487
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Property, plant and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    349,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,661
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,661
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Acquired intangible assets, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    181,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,450
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,450
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543,023
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,673,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term bank borrowings, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,836
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term bank borrowings, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,635
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;A contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    269,017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,409
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;B contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    434,036
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total shareholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    591,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total liabilities and shareholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543,023
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,673,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Pro forma as adjusted summary
    consolidated balance sheet data take into account (i)&#160;the
    automatic conversion of all our outstanding contingently
    redeemable convertible preferred shares
    into&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    of our ordinary shares immediately upon the completion of this
    offering and (ii)&#160;the issuance and sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ordinary
    shares in the form of ADSs by us in this offering, assuming an
    initial public offering price of
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
    ADS, the midpoint of the estimated range of the initial public
    offering price, after deducting estimated underwriting discounts
    and commissions and estimated aggregate offering expenses
    payable by us and assuming no exercise of the underwriters&#146;
    option to purchase additional ADSs and no other change to the
    number of ADSs sold by us as set forth on the cover of this
    prospectus. Assuming the number of ADSs offered by us as set
    forth on the cover page of this prospectus remains the same, and
    after deduction of underwriting discounts and commissions and
    the estimated offering expenses payable by us, a US$1.00
    increase (decrease) in the assumed initial public offering price
    of
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS would increase (decrease) each of cash, total current
    assets, total assets, total shareholders&#146; equity and total
    liabilities and shareholders&#146; equity by
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="37%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="30" align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="23" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>from<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>January&#160;1,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>September&#160;10,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>October&#160;30,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="28" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Selected Consolidated Statements of Cash Flow Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,774
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,308
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash used in investing
    activities<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (50,452
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30,441
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (376,371
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (55,136
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (300,692
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (223,426
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32,731
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    649,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95,147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    278,407
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,448
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,698
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (834
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,949
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (191
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net increase (decrease) in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    314,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (864
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68,288
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,004
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Net cash used in investing
    activities in 2008 and for the nine months ended September 30,
    2008 and 2009 includes cash used for acquisitions, net of cash
    acquired, of RMB231.5&#160;million (US$33.9&#160;million),
    RMB219.1&#160;million and RMB21.5 million (US$3.2 million),
    respectively.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="28%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="34" align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Concord<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>from January&#160;1,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>September&#160;10,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>October&#160;30,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December 31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="32" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Non-GAAP&#160;Financial Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Adjusted
    EBITDA<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,844
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,753
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59,597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    144,167
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    85,188
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174,455
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,556
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Adjusted EBITDA is defined as net
    (loss) income plus interest, taxes, depreciation and
    amortization, share-based compensation expenses and other
    adjustments. Adjusted EBITDA is used by management to evaluate
    our financial performance and determine the allocation of
    resources and provides the management with the ability to
    determine our return on capital expenditure relating to our
    purchase of medical equipment used in our network of centers and
    businesses acquired. Items that are eliminated from the
    calculation of Adjusted EBITDA are collectively managed by our
    senior executive officers, taking into consideration our
    strategic, business and financial goals. Depreciation and
    amortization are primarily managed by our chief executive
    officer, our chief operating officer and our chief financial
    officer. Share-based compensation expense is primarily managed
    by our chief executive officer and our financial officers.
    Interest expense and income, income tax expense or benefit and
    all other items eliminated from the calculation of Adjusted
    EBITDA are primarily managed by our chief executive officer, our
    financial controller and corporate vice president. In addition,
    we believe that Adjusted EBITDA will be a key metric analyzed in
    determining the amount of new debt financing that may be
    available to us and, therefore, we believe this measure provides
    investors with additional information about our ability to fund
    our growth through debt financing, if needed. Furthermore,
    Adjusted EBITDA eliminates the impact of items that we do not
    consider indicative of the performance of our network of
    centers. For example, depreciation and amortization expenses
    relating to the medical equipment used in our network of centers
    and acquired intangibles represented historical accrued
    expenditures that are not indicative of the operating
    performance of our network of centers during the periods
    presented. We believe investors will similarly use Adjusted
    EBITDA as one of the key metrics to evaluate our financial
    performance and to compare our current operating results with
    corresponding historical periods and with other companies in the
    healthcare services industry. The presentation of Adjusted
    EBITDA should not be construed as an indication that our future
    results will be unaffected by other charges and gains we
    consider to be outside the ordinary course of our business.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The use of Adjusted EBITDA has
    certain limitations. Items excluded from Adjusted EBITDA are
    significant components in understanding and assessing our
    operating and financial performance. Depreciation and
    amortization expense, income tax expense, interest expense and
    interest income as well as share-based compensation expenses
    have been and will be incurred in our business and are not
    reflected in the presentation of Adjusted EBITDA. Each of these
    items should also be considered in the overall evaluation of our
    results. Additionally, Adjusted EBITDA does not consider capital
    expenditures and other investing activities and should not be
    considered as a measure of our liquidity. We compensate for
    these limitations by providing the relevant disclosure of our
    depreciation and amortization expense, interest expense and
    interest income, income tax expense, capital expenditures as
    well as share-based compensation expenses and other relevant
    items both in our reconciliations to the U.S. GAAP financial
    measures and in our consolidated financial statements, all of
    which should be considered when evaluating our performance. The
    term Adjusted EBITDA is not defined under U.S.&#160;GAAP, and
    Adjusted EBITDA is not a measure of net income, operating
    income, operating performance or liquidity presented in
    accordance with U.S.&#160;GAAP. When assessing our operating and
    financial performance, you should not consider this data in
    isolation or as a substitute for our net income, operating
    income or any other operating performance measure that is
    calculated in accordance with U.S.&#160;GAAP. In addition, our
    Adjusted EBITDA may not be comparable to Adjusted EBITDA or
    similarly titled measures utilized by other companies since such
    other companies may not calculate Adjusted EBITDA in the same
    manner as we do.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The following table is a
    reconciliation of Adjusted EBITDA to net income, the most
    directly comparable financial measure calculated and presented
    in accordance with U.S.&#160;GAAP:
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 6pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="21%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD colspan="34" align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Concord<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="19" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>January&#160;1,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>October&#160;30,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December 31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="32" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -6pt; margin-left: 6pt">
    Net (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,896
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Interest expense, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    939
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    279
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,057
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Income tax expense (benefit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (182
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,832
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,335
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,418
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,611
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,770
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,906
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,086
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,992
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,126
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,585
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,129
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Share-based compensation expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    617
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 13pt">
    Other adjustments*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,555
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,925
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,603
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,114
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -6pt; margin-left: 6pt">
    Adjusted EBITDA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,844
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,753
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59,597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    144,167
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    85,188
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174,455
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,556
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#160;&#160;&#160;&#160;<FONT style="word-spacing: 100pt; white-space: nowrap; font-size: 1pt; color: #000000"><U>&#173;
    &#173;</U></FONT><!-- callerid=128 iwidth=456 length=48 -->
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;*&#160;&#160;Other
    adjustments include change in fair value of convertible notes,
    foreign exchange loss and other income.
    </FONT>
</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>As of September&#160;30,<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Operating
    Data<SUP style="font-size: 85%; vertical-align: top">(1)</SUP></B>

</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Number of primary medical equipment owned:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Linear accelerators
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Head gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Body gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    PET-CT scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    MRI scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Others<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    64
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Number of patient cases treated or diagnosed by our primary
    medical equipment:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Linear accelerators
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    697
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,554
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Head gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,455
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Body gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,635
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,057
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,706
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    PET-CT scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,766
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    MRI scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,830
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,827
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="29%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD colspan="26" align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from <BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>September&#160;1,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>to October&#160;30,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD colspan="26" align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="24" align="center" valign="bottom">
    <B>(in RMB thousands)</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total net revenues generated by our primary medical equipment
    under lease and management services arrangements:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Linear accelerators
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,206
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    877
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,506
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,588
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Head gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,408
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,139
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Body gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,537
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,102
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,071
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    PET-CT scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    578
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,289
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    MRI scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,899
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    437
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,123
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,515
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,618
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Others<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    391
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,423
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,755
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,970
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total net revenues&#160;&#151; lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Excluding data from seven, eight
    and two centers under service-only agreements as of
    December&#160;31, 2007, December&#160;31, 2008 and
    September&#160;30, 2009, respectively.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Other primary medical equipment
    used includes computed tomography scanners, or CT scanners, and
    emission computed tomography scanners, or ECT scanners, for
    diagnostic imaging, electroencephalography for the diagnosis of
    epilepsy, thermotherapy to increase the efficacy of and for pain
    relief after radiotherapy and chemotherapy, high intensity
    focused ultrasound therapy for the treatment of cancer,
    stereotactic radiofrequency ablation for the treatment of
    Parkinson&#146;s Disease and refraction and tonometry for the
    diagnosis of ophthalmic conditions.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    UNAUDITED PRO FORMA CONSOLIDATED COMBINED FINANCIAL DATA<BR>
    FOR THE YEAR ENDED DECEMBER 31, 2008</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following summary unaudited pro forma combined financial
    information has been derived by the application of pro forma
    adjustments to the historical consolidated financial statements
    of Concord Medical and the financial statements of China Medstar
    for the year ended December&#160;31, 2008. Concord
    Medical&#146;s and China Medstar&#146;s historical information
    has been derived from their respective audited financial
    statements, included elsewhere in this prospectus. The unaudited
    pro forma combined income statement data give effect to our
    acquisition of China Medstar as if it had been completed on
    January&#160;1, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following unaudited pro forma combined financial information
    should be read in conjunction with our and China Medstar&#146;s
    historical financial statements and the related notes and
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations&#148; included elsewhere in
    this prospectus. The preparation of the unaudited pro forma
    combined financial data appearing below is based on financial
    statements prepared in accordance with U.S.&#160;GAAP. These
    principles require the use of estimates that affect the reported
    amounts of assets, liabilities, revenues and expenses. Actual
    results could differ from those estimates. While the unaudited
    pro forma combined financial information is helpful in showing
    the financial characteristics of the combined companies, it is
    not intended to show how the combined companies would have
    actually performed if the events described above had in fact
    occurred on the dates assumed or to project the results of
    operations for any future date or period. We have included in
    the unaudited pro forma combined financial statements all the
    adjustments, consisting of normal recurring adjustments,
    necessary for a fair presentation of the results of operations
    in the historical periods. The actual consolidated results of
    operations may differ significantly from the pro forma amounts
    reflected below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="42%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Pro Forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>China Medstar</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Adjustment</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Seven-month<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">December&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">July&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" nowrap align="center" valign="bottom">
    <B>(in thousands, except share, per share and per ADS data)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Summary Unaudited Pro Forma Condensed Combined Statement of
    Operations Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Revenue, net of business tax, value-added tax and related
    surcharges:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,745
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    203,806
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,856
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,026
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,148
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,873
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    234,662
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,377
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,046
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,806
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,624
</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34,228
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,743
</TD>
<TD nowrap align="left" valign="bottom">
    )<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26,240
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,844
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (117
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,597
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (60,585
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,875
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Gross profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,501
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,581
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,078
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,340
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (27,209
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,986
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Operating income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    139,790
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,478
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,455
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,585
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,040
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,324
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (325
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (230
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (81
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Loss from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    462
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other income (expense)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (200
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,534
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,104
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Income before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138,385
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,273
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Income tax expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,445
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21<SUP style="font-size: 85%; vertical-align: top">(2</SUP>

</TD>
<TD nowrap align="left" valign="bottom">
    <SUP style="font-size: 85%; vertical-align: top">)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31,759
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,653
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net income from continuing operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,655
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,620
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Pro forma income per share from continuing operations</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.27
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Weighted average number of ordinary shares outstanding:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<!-- XBRL Pagebreak End -->

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The aggregate purchase price of
    approximately &#163;17.1&#160;million (RMB238.7&#160;million or
    US$35.0&#160;million) for the purchase of China Medstar is
    comprised of the following:
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="86%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,210
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,107
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Long-term receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,397
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,377
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    217,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,931
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other intangible assets- customer relationships and operating
    leases
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,380
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Deposit for property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,505
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,089
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,529
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,835
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Liabilities assumed
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (233,323
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34,180
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total consideration paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    238,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The preliminary purchase price
    allocation and preliminary intangible asset valuations described
    above were based on valuation work determined by us with the
    assistance of American Appraisal China Limited, an independent
    valuation firm. The valuation report utilizes and considers
    generally accepted valuation methodologies such as the income,
    market, cost and actual transaction of shares approach. We have
    incorporated certain assumptions which include projected cash
    flows and replacement costs.
    </FONT></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">This adjustment of
    RMB5.6&#160;million reflects an additional seven full months of
    amortization of the acquired intangibles recorded as a result of
    our acquisition of China Medstar on July&#160;31, 2008 as if the
    acquisition had been consummated on January&#160;1, 2008.
    </FONT></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">This adjustment of
    RMB5.7&#160;million reflects an additional reduction in
    depreciation expense as if the acquisition had been consummated
    on January&#160;1, 2008 related to medical equipment because the
    assigned estimated fair values are lower than the net book
    values as at the acquisition date.
    </FONT></TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Reflects the adjustment to income
    tax expense based on the pro forma adjusting entries to
    depreciation expense and amortization expense discussed above.
    </FONT></TD>
</TR>

</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
</DIV><!-- End box 1 -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='102'>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RISK
    FACTORS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Our Company</FONT></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    encounter difficulties in successfully opening new centers or
    renewing agreements for existing centers due to the limited
    number of suitable hospital partners and their potential ability
    to finance the purchase of medical equipment
    directly.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our growth was driven by our ability to expand our network of
    radiotherapy and diagnostic imaging centers by primarily
    entering into new agreements with top-tier hospitals in China,
    which are 3A hospitals, the highest ranked hospitals by quality
    and size in China as determined in accordance with the standards
    of the MOH. The agreements that hospitals enter into with us and
    our competitors are typically long-term in nature with terms of
    up to 20&#160;years. As a result, in any locality or at any
    given time, there may only be a limited number of top-tier
    hospitals that have not yet entered into long-term agreements
    with us or our competitors and with which we are able to enter
    into new agreements. In addition, quotas imposed by government
    authorities as to the number and type of certain medical
    equipment that can be purchased, such as head gamma knife
    systems or PET-CT scanners, will further limit the number of
    top-tier hospitals that we or our competitors can enter into
    agreements within a given period. See &#147;&#151;&#160;Risks
    Related to Our Industry&#160;&#151; Healthcare administrative
    authorities in China currently set procurement quotas for
    certain types of medical equipment.&#148; Due to the limited
    supply of suitable top-tier hospitals and increasing
    competition, we may not be able to enter into agreements with
    new hospital partners or renew agreements with existing hospital
    partners on terms as favorable as those that we have been able
    to obtain in the past, or at all. Agreements with our hospital
    partners for three of the centers in our network, which
    accounted for 7.3% of our total net revenues in the nine months
    ended September 30, 2009, will expire in 2010. Some of our
    competitors may have greater financial resources than us, which
    may provide them with an advantage in negotiating new agreements
    with hospitals, including our existing hospital partners. In
    addition, if adequate funding becomes available for hospitals to
    purchase medical equipment directly, hospitals may choose to
    purchase and manage radiotherapy and diagnostic imaging
    equipment on their own instead of entering into or renewing
    agreements with us or our competitors. If we are unable to
    compete effectively in entering into agreements with new
    hospital partners or to renew existing agreements on favorable
    terms, or at all, or if hospitals choose to purchase and manage
    their own medical equipment, our growth prospects could be
    materially and adversely affected. Finally, the development of
    new centers generally involves a ramp-up period during which
    time the operating efficiency of such centers may be lower than
    our established centers, which may negatively affect our
    profitability.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    have historically derived a significant portion of our revenues
    from centers located at a limited number of our hospital
    partners and regions in which we operate and our accounts
    receivable are also concentrated with a few hospital
    partners.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have historically derived a large portion of our total net
    revenues from a limited number of our partner hospitals. For the
    period from January&#160;1, 2007 to October&#160;30, 2007, the
    period from September&#160;10, 2007 to December&#160;31, 2007,
    for the year ended December&#160;31, 2008 and for the nine
    months ended September&#160;30, 2008 and 2009, net revenues
    derived from our top five hospital partners amounted to
    approximately 61.6%, 64.7%, 37.8%, 42.2% and 34.1% of our total
    net revenues, respectively. For these same five periods, three,
    three, one, one and two of our hospital partners, respectively,
    accounted for more than 10.0% of our total net revenues, and our
    largest hospital partner accounted for 21.7%, 24.2%, 13.5%,
    14.4% and 10.7% of our total net revenues during those periods,
    respectively. In addition, centers located in Beijing, Henan
    province and Guangdong province accounted for 26.1%, 11.0% and
    8.0% of our total net revenues in 2008, respectively, and 21.9%,
    10.6% and 9.0% of our total net revenues for the nine months
    ended September&#160;30, 2009, respectively. We may continue to
    experience such revenue concentration in the future. Due to the
    concentration of our revenues and dependence on a limited number
    of hospital partners, any one or more of the following events,
    among others, may cause material fluctuations or declines in our
    revenues and could have a material adverse effect on our
    financial condition, results of operations and prospects:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reduction in the number of patient cases at the centers located
    at these partner hospitals;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    loss of key experienced medical professionals;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    decrease in the profitability of such centers;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    failure to maintain or renew our agreements with these hospital
    partners;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any failure of these hospital partners to pay us our contracted
    percentage of any such center&#146;s revenue net of specified
    operating expenses;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any regulatory changes in the geographic areas where our
    hospital partners are located;&#160;or
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any other disputes with these hospital partners.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, three of our hospital partners, including two of
    our top five hospital partners, accounted for 36.4% of our total
    accounts receivable as of September&#160;30, 2009. Any
    significant delay in the payment of such accounts receivable
    could have a material impact on our financial condition and
    results of operations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    conduct our business in a heavily regulated
    industry.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The operation of our network of centers is subject to various
    laws and regulations issued by a number of government agencies
    at the national and local levels. Such rules and regulations
    relate mainly to the procurement of large medical equipment, the
    pricing of medical services, the operation of radiotherapy and
    diagnostic imaging equipment, the licensing and operation of
    medical institutions, the licensing of medical staff and the
    prohibition on non-profit civilian medical institutions from
    entering into cooperation agreements with third parties to set
    up for-profit centers that are not independent legal entities.
    Our growth prospects may be constrained by such rules and
    regulations, particularly those relating to the procurement of
    large medical equipment. See &#147;Regulation of Our
    Industry&#148; for a discussion of the regulations applicable to
    us and our business. Also, for a detailed discussion of the
    specific regulatory risks we face, see &#147;&#151;&#160;Risks
    Related to Our Industry.&#148; If we or our hospital partners
    fail to comply with such applicable laws and regulations, we
    could be required to make significant changes to our business
    and operations or suffer fines or penalties, including the
    potential loss of our business licenses, the suspension from use
    of our medical equipment, and the suspension or cessation of
    operations at centers in our network. In addition, many of the
    agreements we have entered into with our hospital partners
    provide for termination in the event of major government policy
    changes that cause the agreements to become inexecutable. Our
    hospital partners may invoke such termination right to our
    disadvantage.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    depend on our hospital partners to recruit and retain qualified
    doctors and other medical professionals to ensure the high
    quality of treatment services provided in our network of
    centers.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our success is dependent in part upon our hospital
    partners&#146; ability to recruit and retain doctors and other
    medical professionals and on our and our hospital partners&#146;
    ability to train and manage these medical professionals.
    Although we may help our hospital partners to identify and
    recruit suitable, qualified doctors and other medical
    professionals, almost all of these medical professionals are
    employed by our partner hospitals rather than by us. As a
    result, we may have little control over whether such medical
    professionals will continue to work in the centers in our
    network. In addition, there is a limited pool of qualified
    medical professionals with expertise and experience in
    radiotherapy and diagnostic imaging in China, and our hospital
    partners face competition for such qualified medical
    professionals from other public hospitals, private healthcare
    providers, research and academic institutions and other
    organizations. In the event that our hospital partners fail to
    recruit and retain a sufficient number of these medical
    professionals, the resulting shortage could adversely affect the
    operation of centers in our network and our growth prospects.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Any
    failure by our hospital partners to make contracted payments to
    us or any disputes over, or significant delays in receiving,
    such payments could have a material adverse effect on our
    business and financial condition.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Most of the centers in our network are established through
    long-term lease and management services arrangements entered
    into with our hospital partners. We also provide management
    services to certain radiotherapy and diagnostic imaging centers
    through service-only agreements. Payments for treatment and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    diagnostic imaging services provided in the centers in our
    network are typically collected by our hospital partners who
    then pass on to us our contracted percentage of such revenue net
    of specific operating expenses on a periodic basis. Our total
    outstanding accounts receivable from our hospital partners were
    RMB92.8&#160;million (US$13.6&#160;million) and
    RMB119.1&#160;million (US$17.5&#160;million) as of
    December&#160;31, 2008 and September&#160;30, 2009,
    respectively. As of September&#160;30, 2009, approximately 22.6%
    of our accounts receivable reported on our consolidated balance
    sheet as of December&#160;31, 2008 were still outstanding. The
    average turnover days of the accounts receivable for the nine
    months ended September&#160;30, 2009 were 117&#160;days. Any
    failure by our hospital partners to pay us our contracted
    percentage, or any disputes over or significant delays in
    receiving such payments from our hospital partners, for any
    reason, could negatively impact our financial condition.
    Accordingly, any failure by us to maintain good working
    relationships with our hospital partners, or any dissatisfaction
    on the part of our hospital partners with our services, could
    negatively affect the operation of the centers and our ability
    to collect revenue, reduce the likelihood that our agreements
    with hospital partners will be renewed, damage our reputation
    and otherwise have a material adverse effect on our business,
    financial condition and results of operation.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    not be able to effectively manage the expansion of our
    operations through new acquisitions or joint ventures or to
    successfully realize the anticipated benefits of any such
    acquisition or joint venture.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have historically complemented our organic development of new
    centers through the selective acquisition of complementary
    businesses or assets or the formation of joint ventures, and we
    may continue to do so in the future. For example, we recently
    experienced a significant growth in our business and increase in
    our results of operations as a result of our acquisition of
    China Medstar and other businesses. The identification of
    suitable acquisition targets or joint venture candidates can be
    difficult, time consuming and costly, and we may not be able to
    successfully capitalize on identified opportunities. We may not
    be able to continue to grow our business as anticipated if we
    are unable to successfully identify and complete potential
    acquisitions in the future. Even if we successfully complete an
    acquisition or establish a joint venture, we may not be able to
    successfully integrate the acquired businesses or assets or
    cooperate successfully with the joint venture partner.
    Integration of the acquired business or assets or cooperation
    with the joint venture partners can be expensive, time consuming
    and may strain our resources. Such integration or cooperation
    could also require significant attention from our management
    team, which may prevent key members of our management from
    focusing on other important aspects of our business.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, we may be unable to successfully integrate or
    retain employees or management of the acquired businesses or
    assets or retain the acquired entity&#146;s patients, suppliers
    or other partners. Consequently, we may not achieve the
    anticipated benefits of any acquisitions or joint ventures.
    Furthermore, future acquisitions or joint ventures could result
    in potentially dilutive issuances of equity or equity-linked
    securities or the incurrence of debt, contingent liabilities or
    expenses, or other charges, any of which could have a material
    adverse effect on our business, financial condition and results
    of operations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    not be successful in negotiating the conversion of a few of our
    cooperation agreements with our partner hospitals into lease and
    management agreements due to regulatory changes.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since the effectiveness in September 2000 of the
    <I>Implementation Opinions on the Classified Management of Urban
    Medical Institutions</I>, which was promulgated by the MOH, the
    State Administration of Traditional Chinese Medicine, the
    Ministry of Finance and the National Development Reform
    Committee, or NDRC, non-profit civilian medical institutions are
    no longer permitted to enter into cooperation agreements or to
    continue to operate under existing cooperation agreements with
    third parties pursuant to which the parties jointly invest in or
    cooperate to set up for-profit centers or units that are not
    independent legal entities. However, according to the
    <I>Opinions on Certain Issues Regarding Classified Management of
    Urban Medical Institutions </I>issued in July 2001 by the same
    authorities, a non-profit civilian medical institution may, if
    lacking sufficient funds to purchase medical equipment outright,
    enter into a leasing agreement pursuant to which the medical
    institution leases medical equipment from its partner at market
    rates. To comply with these regulatory changes, we have
    transitioned most of our cooperation agreements with non-profit
    civilian hospitals to lease and management agreements. However,
    we are still negotiating the transition of our cooperation
    agreements relating to 13 of our centers located at eight of our
    partner hospitals, which centers&#146; combined revenues in 2008
    and for the nine months ended September&#160;30, 2009
    constituted approximately 17.3% and 11.6% of our total net
    revenues during those two periods, respectively. Although
    neither we nor any of our hospital partners have incurred any
    penalties to date for continuing to operate under cooperation
    agreements at
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    these centers, there can be no assurance that we will not incur
    penalties in the future or that we will be able to successfully
    negotiate the conversion of these agreements. If we are unable
    to successfully negotiate the conversion of our cooperation
    agreements with these hospitals or if government authorities
    decide to assess penalties against either us or our hospital
    partners or to suspend the operation of these centers before we
    are able to complete the transition, our business, financial
    condition and results of operation could be materially and
    adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are not aware of any similar restriction on cooperation
    agreements imposed on military hospitals, which are hospitals
    owned and regulated by the military but are otherwise the same
    as other government-owned civilian hospitals open to the public,
    by military healthcare administrative authorities. Accordingly,
    we have maintained our cooperation agreements with nine military
    hospitals as of September&#160;30, 2009. However, as military
    hospitals are also government-owned, if military hospitals are
    required by military healthcare administrative authorities to
    transition away from cooperation agreements in the future, we
    will have to negotiate a similar conversion of the agreements
    with our military hospital partners. If we are unable to
    successfully negotiate lease and management or other alternative
    agreements with our existing military hospital partners on terms
    not less favorable than those under our cooperation agreements,
    our business, financial condition and results of operation may
    be adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    cannot assure you that government authorities will not interpret
    regulations differently from us to find that our lease and
    management agreements are still not in compliance with relevant
    regulations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Based on the opinion of our PRC counsel, Jingtian&#160;&#038;
    Gongcheng Attorneys At Law, we believe that our lease and
    management agreements with civilian public hospital partners,
    which terms continue to provide that our revenues from
    hospital-based centers are to be calculated based on contracted
    percentages of each center&#146;s revenue net of specified
    operating expenses, are in compliance with the <I>Implementation
    Opinions on the Classified Management of Urban Medical
    Institutions </I>and the <I>Opinions on Certain Issues Regarding
    Classified Management of Urban Medical Institutions</I>.
    However, we and our PRC counsel cannot assure you that the MOH
    or other competent authorities will not interpret these
    regulations differently to find that our lease and management
    agreements are still not in compliance with such regulations, in
    which instance, such authorities could, among other things,
    declare our lease and management agreements to be void, order
    our civilian hospital partners to terminate such agreements with
    us, order our civilian hospitals partners to suspend or cease
    operation of the centers governed by such agreements, suspend
    the use of our medical equipment, or confiscate revenues
    generated under the noncompliant agreements. Furthermore, we may
    have to change our business model which may not be successful.
    If any of the above were to occur, our business, financial
    condition and results of operation could be materially and
    adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">There
    may be corrupt practices in the healthcare industry in China,
    which may place us at a competitive disadvantage if our
    competitors engage in such practices and may harm our reputation
    if our hospital partners and the medical personnel who work in
    our centers, over whom we have limited control, engage in such
    practices.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There may be corrupt practices in the healthcare industry in
    China. For example, in order to secure agreements with hospital
    partners or to increase direct sales of medical equipment or
    patient referrals, our competitors, other service providers or
    their personnel or equipment manufacturers may engage in corrupt
    practices in order to influence hospital personnel or other
    decision-makers in violation of the anti-corruption laws of
    China and the U.S.&#160;Foreign Corrupt Practices Act, or the
    FCPA. We have adopted a policy regarding compliance with the
    anti-corruption laws of China and the FCPA to prevent, detect
    and correct such corrupt practice. However, as competition
    persists and intensifies in our industry, we may lose potential
    hospital partners, patient referrals and other opportunities to
    the extent that our competitors engage in such practices or
    other illegal activities. In addition, our partner hospitals or
    the doctors or other medical personnel who work in our network
    of centers may engage in corrupt practices without our knowledge
    to procure the referral of patients to centers in our network.
    Although our policies prohibit such practices, we have limited
    control over the actions of our hospital partners or over the
    actions of the doctors and other medical personnel who work in
    our network of centers since they are not employed by us. If any
    of them were to engage in such illegal practices with respect to
    patient referrals or other matters, we or the centers in our
    network may be subject to sanctions or fines and our reputation
    could be adversely affected by any negative publicity stemming
    from such incidents.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We are
    planning to establish and operate specialty cancer hospitals
    that will be majority owned by us and are subject to significant
    risks.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As part of our growth strategy we plan to establish specialty
    cancer hospitals that will focus on providing radiotherapy
    services as well as diagnostic imaging services, chemotherapy
    and surgery. In addition, at the Beijing Proton Medical Center,
    one of our planned specialty cancer hospitals, we plan to offer
    proton beam therapy treatment services with which we have had no
    prior experience. Since we do not have experience in operating
    our own specialty cancer hospital, or in providing many of the
    services that we plan to offer in our specialty cancer
    hospitals, such as chemotherapy treatments, surgical procedures
    or proton beam therapy, we may not be able to provide as high a
    level of service quality for those treatment options as for the
    other treatments that are currently offered at our network of
    centers, which may result in damage to our reputation and our
    future growth prospects. In addition, we may not be successful
    in recruiting qualified medical professionals to effectively
    provide the services that we intend to offer in our specialty
    cancer hospitals. Furthermore, although our brand name is well
    known among referring doctors, patients are not currently
    familiar with our brand as we do not carry our own brand name in
    our network of centers under our existing agreements with our
    hospital partners. Therefore, when we establish our own
    specialty cancer hospitals under our brand name, we may not be
    able to immediately gain wide acceptance among patients and,
    thus, may be unable to attract a sufficient number of patients
    to our new hospitals.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We could also face increased exposure to liability claims at our
    specialty cancer hospitals, including claims for medical
    malpractice. We may need to obtain medical malpractice insurance
    and other types of insurance that we do not currently carry,
    each of which could increase our expenses and decrease our
    profitability. In addition, there can be no assurance that such
    insurance will be available at a reasonable price or that we
    will be able to maintain adequate levels of liability insurance
    coverage, if at all. In addition, our specialty cancer hospitals
    will also be required to obtain various quotas, permits and
    authorizations, which are currently the responsibility of our
    hospital partners under our existing agreements. See
    &#147;&#151;&#160;Risks Related to Our Industry&#160;&#151;
    Healthcare administrative authorities in China currently set
    procurement quotas for certain types of medical equipment&#148;
    and &#147;&#151;&#160;Risks Related to Our Industry&#160;&#151;
    We or our hospital partners may be unable to obtain various
    permits and authorizations from regulatory authorities in China
    relating to our medical equipment, which could delay the
    installation or interrupt the operation of our equipment.&#148;
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Finally, if our plans change for any reason or the anticipated
    timetable or costs of development change for our specialty
    cancer hospitals, our business and future prospects may be
    negatively impacted. We currently expect to obtain bank loans of
    approximately RMB190.0&#160;million (US$27.8&#160;million) in
    2010 to fund the development of our specialty cancer hospitals.
    We may not be able to obtain such loans on terms acceptable to
    us, or at all. Furthermore, such loans would increase our
    interest expenses and could subject us to various covenants that
    may, among other things, restrict our ability to pay dividends
    or to obtain additional financing. If we are not able to obtain
    these bank loans, we may not be able to complete the planned
    specialty cancer hospitals on our expected timeline, or at all.
    There can be no assurance that the planned specialty cancer
    hospitals will be completed or that, if completed, they will
    achieve sufficient patient cases to generate positive operating
    margins. In addition, as our currently planned specialty cancer
    hospitals are to be established through joint ventures with
    other parties, we also may not be successful in cooperating with
    such joint venture partners in operating our specialty cancer
    hospitals. See &#147;&#151;&#160;Risk Factors Related to Our
    Business&#160;&#151; We may not be able to effectively manage
    the expansion of our operations through any new acquisitions or
    joint ventures, which we may not be able to successfully
    execute.&#148;
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    rely on the doctors and other medical professionals providing
    services in our network of centers to make proper clinical
    decisions and we rely on our hospital partners to maintain
    proper control over the clinical aspects of the operation of our
    network of centers.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We rely on the doctors and other medical professionals who work
    in our network to make proper clinical decisions regarding the
    diagnosis and treatment of their patients. Although we develop
    treatment protocols for doctors, provide periodic training for
    medical professionals in our network of centers on proper
    treatment procedures and techniques and host seminars and
    conferences to facilitate consultation among doctors providing
    services in our network of centers, we ultimately rely on our
    hospital partners to maintain proper control over the clinical
    activities of each center and over the doctors and other medical
    professionals who work in such centers. Any incorrect clinical
    decisions on the part of doctors and other medical professionals
    or any failure by
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    our hospital partners to properly manage the clinical activities
    of each center may result in unsatisfactory treatment outcomes,
    patient injury or possibly death. Although part of the liability
    for any such incidents may rest with our partner hospitals and
    the doctors and other medical professionals they employ, we may
    be made a party to any such liability claim which, regardless of
    its merit or eventual outcome, could result in significant legal
    defense costs for us, harm our reputation, and otherwise have a
    material adverse effect on our business, financial condition and
    results of operations. The centers in our network have
    experienced claims as to a limited number of medical disputes
    since they commenced operations. As of September&#160;30, 2009,
    three centers in our network agreed to pay an aggregate amount
    of approximately RMB100,000 (US$14,649) to settle such claims.
    Any expenses resulting from such liability claims are generally
    required to be accounted for as expenses of the relevant center,
    which could reduce our revenue derived from such center. We do
    not carry malpractice or other liability insurance at many of
    the centers in our network, and at those centers that do carry
    such insurance, it may not be sufficient to cover any potential
    liability that may result from such claims. For our specialty
    cancer hospitals that are currently under development, we will
    likely face direct liability claims for any such incidents.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Any
    failures or defects of the medical equipment in our network of
    centers or any failure of the medical personnel who work at the
    centers in our network to properly operate our medical equipment
    could subject us to liability claims and we may not have
    sufficient insurance to cover any potential
    liability.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business exposes us to liability risks that are inherent in
    the operation of complex medical equipment, which may contain
    defects or experience failures. We rely to a large degree on
    equipment manufacturers to provide technical training to the
    medical technicians who work in our network of centers on the
    proper operation of our complex medical systems. If such medical
    technicians are not properly and adequately trained by the
    equipment manufacturers or by us, they may misuse or
    ineffectively use the complex medical equipment in our network
    of centers. These medical technicians may also make errors in
    the operation of the complex medical equipment even if they are
    properly trained. Any medical equipment defects or failures or
    any failure of the medical personnel who work in the centers to
    properly operate the medical equipment could result in
    unsatisfactory treatment outcomes, patient injury or possibly
    death. Although the liability for any such incidents rests with
    the equipment manufacturers or the medical technicians, we may
    be made a party to any such liability claim which, regardless of
    its merit or eventual outcome, could result in significant legal
    defense costs for us, harm our reputation, and otherwise have a
    material adverse effect on our business, financial condition and
    results of operations. In addition, any expenses resulting from
    such liability claims may be accounted for as expenses of the
    center, which could reduce our revenue derived from such center.
    We do not carry product liability insurance at any of the
    centers in our network.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Any
    downtime for maintenance and repair of our medical equipment
    could lead to business interruptions that could be expensive and
    harmful to our reputation and to our business.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Significant downtime associated with the maintenance and repair
    of medical equipment used in our network of centers would result
    in the inability of the centers to provide radiotherapy
    treatment or diagnostic imaging services to patients in a timely
    manner. We primarily rely on equipment manufacturers or third
    party service companies for maintenance and repair services. The
    failure of manufacturers or third party service companies to
    provide timely repairs on our equipment could interrupt the
    operation of centers in our network for extended periods of
    time. Such extended downtime could result in lost revenues for
    us and our partner hospitals, dissatisfaction on the part of
    patients and our partner hospitals and damage to the reputation
    of the centers in our network, our partner hospitals and our
    company.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    rely on a limited number of equipment
    manufacturers.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Much of the medical equipment used in our centers is highly
    complex and is produced by a limited number of equipment
    manufacturers in the global marketplace. These equipment
    manufacturers provide training on the proper operation of our
    medical equipment to the medical personnel who work in the
    centers in our network as well as maintenance and repair
    services for such equipment. Any disruption in the supply of the
    medical equipment or services from these manufacturers may delay
    the development of new centers or negatively affect the
    operation of existing centers and could have a material adverse
    effect on our business, financial condition and results of
    operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    business depends substantially on the continuing efforts of our
    executive officers and other key personnel, and our business may
    be severely disrupted if we lose their services.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We depend on key members of our management team, which includes
    Mr.&#160;Jianyu Yang, a director and our chief executive officer
    and president, Dr.&#160;Zheng Cheng, a co-chairman of our board
    of directors and our chief operating officer, Mr.&#160;Steve
    Sun, a co-chairman of our board of directors and our chief
    financial officer, Mr.&#160;Jing Zhang, a director and our
    executive president, Mr.&#160;Yaw Kong Yap, a director and our
    financial controller, and Mr.&#160;Boxun Zhang, our corporate
    vice president, as well as other key personnel for the continued
    growth of our business. The loss of any of these members of our
    management team or other key employees could delay the
    implementation of our business strategy and adversely affect our
    operations. Our future success will also depend in large part on
    our continued ability to attract and retain highly qualified
    management personnel. The process of hiring suitable, qualified
    personnel is often lengthy and such talented and highly
    qualified management personnel is often in short supply in
    China. If our recruitment and retention efforts are unsuccessful
    in the future, it may be more difficult for us to execute our
    business strategy. Although none of the key members of our
    management team is nearing retirement age in the near future and
    we are not aware of any key members of our management team or
    other key personnel planning to retire or leave us, if one or
    more of such personnel are unable or unwilling to continue in
    their present positions, we may not be able to replace them
    readily, if at all. Consequently, our business may be severely
    disrupted, and we may incur additional expenses to recruit and
    retain new officers. In addition, we do not maintain key
    employee insurance. We have entered into employment agreements
    and confidentiality agreements with all of the key members of
    our management team and other key personnel. However, if any
    disputes arise between any of our key members of our management
    team or other key personnel and us, we cannot assure you, in
    light of uncertainties associated with the PRC legal system, the
    extent to which any of these agreements could be enforced in
    China, where all key members of our management team and other
    key personnel reside and hold some of their assets. See
    &#147;&#151;&#160;Risks Related to Doing Business in
    China&#160;&#151; Uncertainties with respect to the PRC legal
    system could have a material adverse effect on us.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    reported earnings could decline if we recognize impairment
    losses on intangible assets and goodwill relating to the OMS
    reorganization and other acquisitions.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of the OMS reorganization in October 2007 and our
    acquisitions of China Medstar and other businesses in 2008, we
    have recorded goodwill as well as certain acquired intangibles,
    which intangibles are amortized over their respective estimated
    useful lives. In addition, we may continue to selectively
    acquire complementary businesses in the future that may result
    in increases in recorded goodwill and acquired intangibles. Such
    goodwill is tested for impairment by us annually or more
    frequently if an event occurs or a circumstance develops that
    would require more frequent assessments. Examples of such events
    or circumstances include, but are not limited to, a significant
    adverse change in the legal or business climate, an adverse
    regulatory action or unanticipated competition. See
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations&#160;&#151; Critical
    Accounting Policies&#160;&#151; Goodwill;&#160;&#151; Acquired
    Intangible Assets, net.&#148; In the future, we could recognize
    impairment losses on the intangible assets and goodwill, which
    could result in a charge to our reported results of operations
    and cause our reported earnings to decline.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We do
    not have insurance coverage for some of our medical equipment
    and do not carry any business interruption
    insurance.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not have insurance for six units of our medical equipment,
    which are electroencephalography and thermotherapy equipment
    from which centers we derived less than 1.0% of our total
    revenues in 2008 and for the nine months ended
    September&#160;30, 2009. Damage to, or the loss of, such
    uninsured equipment due to natural disasters, such as fires,
    floods or earthquakes, could have an adverse effect on our
    financial condition and results of operation. In addition, the
    operations in our network of centers may be particularly
    vulnerable to natural disasters that disrupt transportation
    since many patients travel long distances to reach such centers.
    Also, we do not have any business interruption insurance. Any
    business disruption could result in substantial expenses and
    diversion of resources and could have a material adverse effect
    on our business, financial condition and results of operations.
    For example, the strong earthquake that struck Sichuan Province
    in May 2008 resulted in the suspension of operations at three of
    our centers in Chengdu, the provincial capital of Sichuan
    Province, for approximately one month due to the diversion of
    hospital resources toward the treatment of earthquake victims.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Most
    of our radiotherapy and diagnostic imaging equipment contains
    radioactive materials or emits radiation during
    operation.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Most of the radiotherapy and diagnostic imaging equipment in our
    network of centers, including gamma knife systems, proton beam
    therapy systems, linear accelerators and PET-CT systems, contain
    radioactive materials or emit radiation during operation.
    Radiation and radioactive materials are extremely hazardous
    unless properly managed and contained. Any accident or
    malfunction that results in radiation contamination could cause
    significant harm to human beings and could subject us to
    significant legal expenses and result in harm to our reputation.
    Although equipment manufacturers and our hospital partners and
    their staff may bear some or all of the liability and costs
    associated with any accidents or malfunctions, if we are found
    to be liable in any way we may also face severe fines, legal
    reparations and possible suspension of our operating permits,
    all of which could have a material and adverse effect on our
    business, results of operations and financial condition. Also,
    certain of our medical equipment require the periodic
    replacement of their radioactive source materials. We do not
    directly oversee the handling of radioactive materials during
    the replacement or reloading process or during the disposal
    process, and any failure on the part of our hospital partners to
    handle or dispose of such radioactive materials in accordance
    with PRC laws and regulations may have an adverse effect on the
    operation of such centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Any
    change in the regulations governing the use of medical data in
    China, which are still in development, could adversely affect
    our ability to use our medical data and could potentially
    subject us to liability for our past use of such medical
    data.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The centers in our network collect and store medical data from
    radiotherapy treatments for purposes of analysis, use in
    training doctors providing services in our network and improving
    the effectiveness of the treatments provided in our network of
    centers. In addition, doctors in our network utilize such
    medical data to conduct clinical research. We do not make any
    such medical data public and only keep such medical data for our
    internal use and for research purposes by doctors upon the
    approval of our medical affairs department and our hospital
    partners. Chinese regulations governing the use of such medical
    data are still in development but currently do not impose any
    restrictions on the internal use of such data by us as long as
    we have the permission of our hospital partners who have
    ownership of such data. Any change in the regulations governing
    the use of such medical data could adversely affect our ability
    to use such medical data and could subject us to liability for
    past use of such data, either of which could have a material
    adverse effect on our business, operations and financial results.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    directors, executive officers and significant shareholders have
    substantial influence over our company and their interests may
    not be aligned with the interests of our other
    shareholders.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of the date of this prospectus, our directors, executive
    officers and significant shareholders beneficially owned
    approximately 59.4% of our outstanding share capital prior to
    this offering and will beneficially own
    approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%
    of our outstanding share capital upon completion of this
    offering, assuming no exercise of the over-allotment option. As
    such, they have substantial influence over our business,
    including decisions regarding mergers, consolidations and the
    sale of all or substantially all of our assets, election of
    directors and other significant corporate actions. This
    concentration of ownership may discourage, delay or prevent a
    change in control of our company, which could deprive our
    shareholders of an opportunity to receive a premium for their
    shares as part of a sale of our company and might reduce the
    price of our ADSs. These actions may be taken even if they are
    opposed by our other shareholders, including those who purchase
    ADSs in this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    articles of association contain anti-takeover provisions that
    could adversely affect the rights of holders of our ordinary
    shares and ADSs.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our third amended and restated articles of association will
    become effective immediately upon the completion of this
    offering. Our new articles of association limit the ability of
    others to acquire control of our company or cause us to engage
    in change-of-control transactions. These provisions could have
    the effect of depriving our shareholders of an opportunity to
    sell their shares at a premium over prevailing market prices by
    discouraging third parties from seeking to obtain control of our
    company in a tender offer or similar transaction. For example,
    our board of directors has the authority, without further action
    by our shareholders, to issue preferred shares in one or more
    series and to fix their designations, powers, preferences,
    privileges, and relative participating, optional or special
    rights and the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    qualifications, limitations or restrictions, including dividend
    rights, conversion rights, voting rights, terms of redemption
    and liquidation preferences, any or all of which may be greater
    than the rights associated with our ordinary shares, in the form
    of ADS or otherwise. Preferred shares could be issued quickly
    with terms calculated to delay or prevent a change in control of
    our company or to make removal of management more difficult. If
    our board of directors issues preferred shares, the price of our
    ADSs may fall and the voting and other rights of the holders of
    our ordinary shares and ADSs may be adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    be unable to establish and maintain an effective system of
    internal control over financial reporting, and as a result we
    may be unable to accurately report our financial results or
    prevent fraud.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, we have been a private company with
    limited accounting personnel and other resources with which to
    address our internal controls and procedures. In connection with
    the audits of our consolidated financial statements for the
    period from January&#160;1, 2007 to December&#160;31, 2008, our
    independent registered public accounting firm communicated to us
    a material weakness and certain significant and other
    deficiencies in our internal control procedures, which could
    adversely affect our ability to initiate, authorize, record,
    process and report financial data reliably in accordance with
    U.S.&#160;GAAP. As a result, there is more than a remote
    likelihood that a more than inconsequential misstatement of our
    consolidated financial statements will not be prevented or
    detected. Specifically, the material weakness identified
    consists of an ineffective control environment over financial
    reporting due to (i)&#160;an insufficient number of financial
    reporting personnel with an appropriate level of knowledge,
    experience and training; (ii)&#160;insufficient controls around
    the establishment and maintenance of an oversight function and
    communication of internal controls, policies and procedures to
    support our financial reporting obligations; and (iii)&#160;a
    lack of a comprehensive set of internal control policies and
    procedures and related controls to monitor the operating
    effectiveness of these controls. The significant deficiencies
    identified consist of (i)&#160;a lack of a timely formal review
    process for outstanding accounts receivable; (ii)&#160;a lack of
    a process to document investment proposals and lack of a formal
    policy for equipment impairment assessment; and (iii)&#160;a
    lack of controls over agreements and contracts with our hospital
    partners. We are in the process of remediating such material
    weakness and significant and other deficiencies. See
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations&#160;&#151; Internal Control
    Over Financial Reporting.&#148; However, the remedial measures
    that we have taken or intend to take may not fully address such
    material weakness and significant and other deficiencies, and
    additional material weakness and significant and other
    deficiencies, in our internal control over financial reporting
    may be identified in the future.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon the completion of this offering, we will become a public
    company in the United States subject to the Sarbanes-Oxley Act
    of 2002, or the Sarbanes-Oxley Act. Section&#160;404 of the
    Sarbanes-Oxley Act, or Section&#160;404, will require that we
    include a management assessment of, and a report by our
    independent registered public accounting firm on, the
    effectiveness of our internal control over financial reporting
    in our annual report on
    <FONT style="white-space: nowrap">Form&#160;20-F</FONT>
    beginning with our annual report for the fiscal year ending
    December&#160;31, 2010. During the assessment process that we
    will undertake for compliance with Section&#160;404, we may
    identify material weaknesses or significant deficiencies in our
    internal control over financial reporting that we may not be
    able to remediate in time to meet the deadline imposed by
    Section&#160;404, and our management may conclude that our
    internal control over financial reporting is not effective. In
    addition, even if our management concludes that our internal
    control over financial reporting is effective, our independent
    registered public accounting firm may determine that our
    internal controls over financial reporting is not effective and
    may issue an adverse opinion on the effectiveness of our
    internal control over financial reporting. Our failure to
    establish and maintain effective internal control over financial
    reporting could increase the risk of material misstatements in
    our financial statements and cause failure to meet our financial
    and other reporting obligations, which would likely cause
    investors to lose confidence in our reported financial
    information and lead to a significant decline in the trading
    price of our ADSs.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, unlike most companies, our internal controls over
    financial reporting will need to be designed to cover a
    significant number of our hospital partners located in cities
    throughout China due to the fact that we are heavily dependent
    on timely and accurate receipt of key financial information from
    our hospital partners so we can complete our financial reporting
    process. We may identify control deficiencies as a result of the
    assessment process that we will undertake to comply with
    Section&#160;404, including but not limited to internal audit
    resources and formalized and documented closing and reporting
    processes. We plan to remediate control deficiencies identified
    in
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    time to meet the deadline imposed by the requirements of
    Section&#160;404 but we may be unable to do so. Our failure to
    establish and maintain effective internal control over financial
    reporting could result in the loss of investor confidence in the
    reliability of our financial reporting processes, which in turn
    could harm our business and negatively impact the trading price
    of our ADSs.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    require additional funding to finance our operations, which
    financing may not be available on terms acceptable to us or at
    all, and if we are able to raise funds, the value of your
    investment in us may be negatively impacted.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business operations may require expenditures that exceed our
    available capital resources. We currently expect to obtain bank
    loans of approximately RMB190.0&#160;million
    (US$27.8&#160;million) in 2010 to fund the development of our
    specialty cancer hospitals. Although we currently do not expect
    that we will require funding in addition to these bank loans to
    finance our future growth, to the extent that our funding
    requirements exceed our financial resources, we will be required
    to seek additional financing or to defer planned expenditures.
    There can be no assurance that we can obtain these bank loans or
    additional funds on terms acceptable to us, or at all. In
    addition, our ability to raise additional funds in the future is
    subject to a variety of uncertainties, including, but not
    limited to:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our future financial condition, results of operations and cash
    flows;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    general market conditions for capital raising and debt financing
    activities; and
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    economic, political and other conditions in China and elsewhere.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Furthermore, if we raise additional funds through equity or
    <FONT style="white-space: nowrap">equity-linked</FONT>
    financings, your equity interest in our company may be diluted.
    Alternatively, if we raise additional funds by incurring debt
    obligations, we may be subject to various covenants under the
    relevant debt instruments that may, among other things, restrict
    our ability to pay dividends or obtain additional financing.
    Servicing such debt obligations could also be burdensome to our
    operations. If we fail to service such debt obligations or are
    unable to comply with any of these covenants, we could be in
    default under such debt obligations and our liquidity and
    financial condition could be materially and adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>We have granted security interests over certain of our
    medical equipment in order to secure bank borrowings. Any
    failure to satisfy our obligations under such borrowings could
    lead to the forced sale of such equipment.</I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to secure bank loans in an aggregate amount of
    RMB112.8&#160;million (US$16.5&#160;million) and
    RMB179.8&#160;million (US$26.3&#160;million) as of
    December&#160;31, 2008 and September&#160;30, 2009,
    respectively, we have granted security interests in equipment
    with a net carrying value of RMB81.6&#160;million
    (US$12.0&#160;million) and RMB217.6&#160;million
    (US$31.9&#160;million), respectively, representing 23.4% and
    39.0% of the net value of our net property, plant and equipment
    of RMB349.1&#160;million (US$51.1&#160;million) and
    RMB557.4&#160;million (US$81.7&#160;million), respectively. Any
    failure on our part to satisfy our obligations under these loans
    could lead to the forced sale of our medical equipment that
    secure these loans, the suspension of the operation of the
    centers in which such medical equipment is used, or otherwise
    damage our relationship with our hospital partners and our
    reputation in the medical community, all of which could have a
    material adverse effect on our business, financial condition and
    results of operation. We may grant additional security interests
    in our equipment in order to secure future bank borrowings,
    including the bank borrowings of approximately
    RMB190.0&#160;million (US$27.8&#160;million) that we expect to
    obtain in 2010 to fund the development of our specialty cancer
    hospitals.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Our business may be adversely affected by fluctuations in
    the value of the Renminbi as a significant portion of our
    capital expenditures relates to the purchase of medical
    equipment priced in U.S.&#160;dollars.</I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A significant portion of our capital expenditures relates to the
    purchase of radiotherapy and diagnostic imaging equipment from
    manufacturers outside of China. As the price of such equipment
    is denominated almost exclusively in U.S.&#160;dollars, any
    depreciation in the value of the Renminbi against the
    U.S.&#160;dollar could cause a significant increase our capital
    expenditures, reduce the profitability of our network of centers
    and have a material and adverse effect on our business, results
    of operations and financial condition.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If we
    grant employee share options, restricted shares or other equity
    incentives in the future, our net income could be adversely
    affected.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We adopted our 2008&#160;share incentive plan on
    October&#160;16, 2008. We are required to account for
    share-based compensation in accordance with Financial Accounting
    Standards Board, or FASB, Statement No.&#160;123(R), Share-Based
    Payment, which requires a company to recognize, as an expense,
    the fair value of share options and other equity incentives to
    employees based on the fair value of equity awards on the date
    of the grant, with the compensation expense recognized over the
    period in which the recipient is required to provide service in
    exchange for the equity award. We have not issued any share
    options under our 2008&#160;share incentive plan. However, we
    granted share options in 2007, before adopting our
    2008&#160;share incentive plan, to certain executive officers
    that were subsequently exercised in 2008. As a result, we have
    incurred share-based compensation expenses of approximately
    RMB49.5&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007 and RMB4.2&#160;million
    (US$0.6&#160;million) in 2008 related to such options, which
    resulted in us incurring a net loss for the period from
    September&#160;10, 2007 to December&#160;31, 2007 of
    RMB48.3&#160;million. If we grant more options, restricted
    shares or other equity incentives in the future, we could incur
    significant compensation charges and our results of operations
    could be adversely affected. See &#147;Management&#146;s
    Discussion and Analysis of Financial Condition and Results of
    Operations&#160;&#151; Critical Accounting Policies&#148; and
    Note&#160;19 to our consolidated financial statements included
    in this prospectus for a more detailed presentation of
    accounting for our share-based compensation plan.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We are
    a Cayman Islands company and, because judicial precedent
    regarding the rights of shareholders is more limited under
    Cayman Islands law than that under U.S. law, you may have less
    protection for your shareholder rights than you would under U.S.
    law.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our corporate affairs are governed by our memorandum and
    articles of association, as amended and restated from time to
    time, the Companies Law (as amended) of the Cayman Islands and
    the common law of the Cayman Islands. The rights of shareholders
    to take action against the directors, actions by minority
    shareholders and the fiduciary responsibilities of our directors
    to us under Cayman Islands law are to a large extent governed by
    the common law of the Cayman Islands. The common law of the
    Cayman Islands is derived in part from comparatively limited
    judicial precedent in the Cayman Islands as well as from English
    common law, which has persuasive, but not binding, authority on
    a court in the Cayman Islands. The rights of our shareholders
    and the fiduciary responsibilities of our directors under Cayman
    Islands law are not as clearly established as they would be
    under statutes or judicial precedent in some jurisdictions in
    the United States. In particular, the Cayman Islands has a less
    developed body of securities laws than the United States. In
    addition, some U.S.&#160;states, such as Delaware, have more
    fully developed and judicially interpreted bodies of corporate
    law than the Cayman Islands.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of all of the above, public shareholders may have
    more difficulty in protecting their interests in the face of
    actions taken by management, members of the board of directors
    or controlling shareholders than they would as shareholders of a
    U.S.&#160;public company.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">You
    may have difficulty enforcing judgments obtained against
    us.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are a Cayman Islands company and substantially all of our
    assets are located outside of the United States. Substantially
    all of our current operations are conducted in the PRC. In
    addition, most of our directors and officers are nationals and
    residents of countries other than the United States. As a
    result, it may be difficult for you to effect service of process
    within the United States upon these persons. It may also be
    difficult for you to enforce judgments obtained in
    U.S.&#160;courts based on the civil liability provisions of the
    U.S.&#160;federal securities laws against us and our officers
    and directors, most of whom are not residents in the United
    States and the substantial majority of whose assets are located
    outside of the United States. In addition, there is uncertainty
    as to whether the courts of the Cayman Islands or the PRC would
    recognize or enforce judgments of U.S.&#160;courts against us or
    such persons predicated upon the civil liability provisions of
    the securities laws of the United States or any state and it is
    uncertain whether such Cayman Islands or PRC courts would be
    competent to hear original actions brought in the Cayman Islands
    or the PRC against us or such persons predicated upon the
    securities laws of the United States or any state. See
    &#147;Enforceability of Civil Liabilities.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We are
    exempt from certain corporate governance requirements of the
    NYSE.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are exempt from certain corporate governance requirements of
    the NYSE by virtue of being a foreign private issuer. We are
    required to provide a brief description of the significant
    differences between our corporate governance practices and the
    corporate governance practices required to be followed by
    U.S.&#160;domestic companies under the NYSE rules. The standards
    applicable to us are considerably different than the standards
    applied to U.S.&#160;domestic issuers. The significantly
    different standards applicable to us do not require us to:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    have a majority of the board be independent (other than due to
    the requirements for the audit committee under the United States
    Securities Exchange Act of 1934, as amended, or the Exchange
    Act);
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    have a minimum of three members in our audit committee;
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    have a compensation committee, a nominating or corporate
    governance committee;
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    provide annual certification by our chief executive officer that
    he or she is not aware of any non-compliance with any corporate
    governance rules of the NYSE;
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    have regularly scheduled executive sessions with only
    non-management directors;
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    have at least one executive session of solely independent
    directors each year;
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    seek shareholder approval for (i)&#160;the implementation and
    material revisions of the terms of share incentive plans,
    (ii)&#160;the issuance of more than 1% of our outstanding
    ordinary shares or 1% of the voting power outstanding to a
    related party, (iii)&#160;the issuance of more than 20% of our
    outstanding ordinary shares, and (iv)&#160;an issuance that
    would result in a change of control;
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    adopt and disclose corporate governance guidelines;&#160;or
</TD>
</TR>

<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    adopt and disclose a code of business conduct and ethics for
    directors, officers and employees.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to rely on all such exemptions provided by the NYSE to
    a foreign private issuer, except that we will establish a
    compensation committee, seek shareholder approval for the
    implementation of share incentive plans and for the increase in
    the number of shares available to be granted under share
    incentive plans and adopt and disclose corporate governance
    guidelines and a code of business conduct and ethics for
    directors, officers and employees. As a result, you may not be
    provided with the benefits of certain corporate governance
    requirements of the NYSE.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    be classified as a passive foreign investment company, which
    could result in adverse United States federal income tax
    consequences to United States Holders.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not expect to be considered a &#147;passive foreign
    investment company,&#148; or PFIC, for United States federal
    income tax purposes for our taxable year ending
    December&#160;31, 2009. However, we must make a separate
    determination each year as to whether we are a PFIC and we
    cannot assure you that we will not be a PFIC for our taxable
    year ending December&#160;31, 2009 or any future taxable year. A
    <FONT style="white-space: nowrap">non-U.S.&#160;corporation</FONT>
    will be considered a PFIC for any taxable year if either
    (i)&#160;at least 75% of its gross income is passive income or
    (ii)&#160;at least 50% of the value of its assets (based on an
    average of the quarterly values of the assets during a taxable
    year) is attributable to assets that produce or are held for the
    production of passive income. The market value of our assets may
    be determined in large part by the market price of our ADSs and
    ordinary shares, which is likely to fluctuate after this
    offering. In addition, the composition of our income and assets
    will be affected by how, and how quickly, we spend the cash we
    raise in this offering. If we are treated as a PFIC for any
    taxable year during which United States Holders (as defined in
    &#147;Taxation&#160;&#151; United States Federal Income
    Taxation&#148;) hold ADSs or ordinary shares, certain adverse
    United States federal income tax consequences could apply to
    such United States Holders. See &#147;Taxation&#160;&#151;
    United States Federal Income Taxation&#160;&#151; Passive
    Foreign Investment Company.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Our Industry</FONT></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Healthcare
    administrative authorities in China currently set procurement
    quotas for certain types of medical equipment.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The procurement, installation and operation of large medical
    equipment in China are regulated by the <I>Rules on Procurement
    and Use of Large Medical Equipment </I>issued on
    December&#160;31, 2004 by the MOH, the NDRC, and the Ministry of
    Finance. Pursuant to these rules, quotas for large medical
    equipment are set by the NDRC and the MOH or the relevant
    provincial healthcare administrative authorities, and hospitals
    must obtain a large medical equipment procurement license prior
    to the procurement of any such equipment. For medical equipment
    classified as Class&#160;A large medical equipment, which
    includes gamma knife systems, proton beam therapy systems and
    PET-CT scanners, procurement planning and approval are conducted
    by the MOH and the NDRC and large medical equipment procurement
    licenses are issued by the MOH. For medical equipment classified
    as Class&#160;B large medical equipment, which includes linear
    accelerators and MRI and CT scanners, procurement planning and
    approval are conducted by the relevant provincial healthcare
    administrative authorities with ratification by the MOH and the
    large medical equipment procurement licenses are issued by the
    relevant provincial healthcare administrative authorities. These
    rules apply to all public and private civilian medical
    institutions, whether non-profit or for-profit. Although these
    rules do not directly apply to military hospitals in China,
    which are hospitals owned and regulated by the military but are
    otherwise the same as other government-owned civilian hospitals
    open to the public, they are used as a reference by the
    healthcare administrative authority of the general logistics
    department of the PRC People&#146;s Liberation Army, or the PLA,
    in approving the procurement of such medical equipment. The
    procurement regulations stipulate that from 2007 to 2010, the
    issuance of procurement licenses for no more than 60 head gamma
    knife systems shall be approved nationwide. Of these 60 systems,
    37 have already been allocated as of the date of this
    prospectus, out of which four have been allocated to our
    hospital partners. In addition, procurement regulations
    stipulate that from 2008 to 2010, the total number of
    <FONT style="white-space: nowrap">PET-CT</FONT> large
    medical equipment procurement licenses issued in China cannot
    exceed&#160;38. Of these 38&#160;systems, 26&#160;have already
    been allocated as of the date of this prospectus, out of which
    none has been allocated to our hospital partners since all of
    our partner hospitals where our
    <FONT style="white-space: nowrap">PET-CT</FONT>
    scanners are located are military hospitals as of the date of
    this prospectus. There is currently no guidance as to the total
    number of Class&#160;A large medical equipment procurement
    licenses that may be issued for other types of Class&#160;A
    large medical equipment that the centers in our network operate.
    In addition, many provincial administrative authorities do not
    provide the general public with information on their procurement
    planning and quotas for Class&#160;B large medical equipment
    procurement licenses, if any. Although we do not expect the
    current number of procurement licenses available to have a
    significant impact on our existing expansion plan until the end
    of 2010, any unexpected change as to the number of procurement
    licenses currently available as a result of any change in
    government policy, increases in competition and the number of
    applicants for the procurement licenses or other factors, or any
    failure of our hospital partners to obtain such licenses as
    expected, could all adversely affect our existing expansion plan
    resulting in a material and adverse effect on our business,
    financial condition and results of operations. In addition, the
    limitation on the number of procurement licenses available and
    any adverse change to such procurement licenses available in the
    future may affect our expansion plan after 2010, which could
    have a material adverse effect on our future prospects.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, for most of the medical equipment that we intend to
    install and operate in our specialty cancer hospitals, we will
    need to obtain large medical equipment procurement licenses from
    the MOH or provincial level healthcare administrative
    authorities. Such licenses might not be obtained in a timely
    manner or at all, which could delay or prevent the opening of
    our specialty cancer hospitals, and could have a material
    adverse effect on our growth strategy and results of operations.
    See &#147;&#151;&#160;Risks Related to Our Business&#160;&#151;
    We are planning to establish and operate specialty cancer
    hospitals that are majority owned by us and are subject to
    significant risks.&#148;
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Certain
    of our hospital partners have not received large medical
    equipment procurement licenses or interim procurement permits
    for some of the medical equipment in our network of centers
    which could result in fines or the suspension from use of such
    medical equipment.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The quota requirement for large medical equipment procurement
    became effective in March 2005. A medical institution that
    houses equipment purchased prior to that time is required to
    retroactively apply for and obtain a large medical equipment
    procurement license. If a medical institution is unable to
    obtain a procurement license as a result of a
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    lack of procurement quotas for such medical equipment allocated
    to the region in which the medical institution is located, an
    interim procurement permit for large medical equipment must be
    obtained in lieu thereof. As of the date of this prospectus, of
    the 73&#160;units of medical equipment in the centers in our
    network that are subject to large medical equipment procurement
    quota requirements, 41 were issued with a procurement license,
    three were issued with an interim procurement permit subsequent
    to the implementation of the quota requirement, 21 were issued
    with procurement permits or authorizations by competent
    regulatory authorities prior to the implementation of the quota
    requirement but have not received new procurement licenses or
    interim procurement permits under the quota requirements that
    became effective in 2005, and eight, which accounted for
    approximately 8.4% and 7.2% of our total net revenues in 2008
    and for the nine months ended September&#160;30, 2009,
    respectively, have not yet been issued with any procurement
    license or permit. Although our hospital partners have applied
    to the competent regulatory authorities for procurement licenses
    for these last 29 centers, we cannot assure you that they will
    be successful. If our hospital partners fail to receive either a
    procurement license or an interim procurement permit, the
    centers in our network operating such medical equipment may be
    required to discontinue operations and may be deprived of the
    revenue derived from the operation of such equipment or assessed
    a fine, any of which could have a material adverse effect on our
    business, financial condition and results of operation.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Based on the opinion of our PRC counsel, Jingtian&#160;&#038;
    Gongcheng Attorneys At Law, we believe that the 21&#160;units of
    equipment, for which procurement permits or authorizations were
    obtained from the regulatory authorities prior to the
    implementation of the quota requirement but no new procurement
    licenses or interim procurement permits under the 2005 quota
    requirements have been issued, are unlikely to face fines or
    other penalties from such regulatory authorities, although we
    cannot be certain. These 21&#160;units of equipment accounted
    for approximately 28.6% and 19.6% of our total net revenues in
    2008 and for the nine months ended September&#160;30, 2009,
    respectively. In addition, for the three&#160;units of medical
    equipment that were issued with interim procurement permits
    subsequent to the implementation of the quota requirement, the
    relevant regulations require that hospitals pay taxes derived
    from the use of equipment covered by such interim permits, which
    may increase the operating costs of the centers in our network
    that operate such equipment. Also, upon the expiration of the
    useful life of medical equipment issued with interim procurement
    permits, hospitals are not permitted to replace such medical
    equipment with a newer model, in which case we may not be able
    to continue or renew our agreements with such hospital partners
    with interim procurement permits for medical equipment reaching
    the end of its life unless they are able to obtain a new
    procurement license.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Pricing
    for the services provided by our network of centers may be
    adversely affected by reductions in treatment fees set by the
    Chinese government.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Centers in our network are primarily located in non-profit
    civilian and military hospitals in China. The medical service
    fees charged by these non-profit hospitals are subject to price
    ceilings set by the relevant provincial or regional price
    control authorities and healthcare administrative authorities in
    accordance with the <I>Opinion Concerning the Reform of Medical
    Service Pricing Management </I>issued on July&#160;20, 2000 by
    the NDRC and the MOH. See &#147;Regulation of Our
    Industry.&#148; These price ceilings can be adjusted by those
    authorities downwards or upwards from time to time. For example,
    in 2006, treatment fees for the head gamma knife in one of the
    centers in our network decreased by approximately 30% and in
    2007, and treatment fees for the body gamma knife in one of the
    centers in our network decreased by approximately 25%. However,
    overall, the average medical service fees for each of the
    treatments and diagnostic imaging services provided across our
    network of centers have remained stable since 2007. The relevant
    price control authorities and healthcare administrative
    authorities provide notices to hospitals, who in turn provide
    immediate notice to us, as to any change in the pricing ceiling
    for medical services. The timing between when notices are
    provided by the relevant price control authorities and
    healthcare administrative authorities and the effective date of
    such pricing change varies in different cities and regions as
    well as the relevant medical services in question, but typically
    ranges from one to three months. If treatment fees for the
    services provided by the centers in our network are reduced by
    the government, our contracted percentage of each center&#146;s
    revenue net of specified operating expenses may decrease,
    hospitals may be discouraged from entering into or renewing
    their agreements with us, and our business, financial condition
    and results of operations may be materially and adversely
    affected.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    business may be harmed by technological and therapeutic changes
    or by shifts in doctors&#146; or patients&#146; preferences for
    alternative treatments.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The treatment of cancer patients is subject to potentially
    revolutionary technological and therapeutic changes. Future
    technological developments could render our equipment and the
    services provided in our network of centers obsolete. We may
    incur significant costs in replacing or modifying equipment in
    which we have already made a substantial investment prior to the
    end of its anticipated useful life. In addition, there may be
    significant advances in other cancer treatment methods, such as
    chemotherapy, surgery, biological therapy, or in cancer
    prevention techniques, which could reduce demand or even
    eliminate the need for the radiotherapy services that we
    provide. Also, patients and doctors may choose alternative
    cancer therapies over radiotherapy due to any number of reasons.
    Any shifts in doctors&#146; or patients&#146; preferences for
    other cancer therapies over radiotherapy may have a material
    adverse effect on our business, financial condition and results
    of operations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    technology used in some of our radiotherapy equipment,
    particularly our body gamma knife and our proton beam therapy
    system, has been in use for a limited period of time and the
    international medical community has not yet developed a large
    quantity of peer-reviewed literature that supports their safe
    and effective use.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The technology in some of our radiotherapy equipment,
    particularly the body gamma knife system and the proton beam
    therapy system, has been in use for a limited period of time,
    and the international medical community has not yet developed a
    large quantity of peer-reviewed literature that supports their
    safe and effective use. As a result, such technology may not
    continue to gain acceptance by doctors and patients in China or
    may lose any acceptance such technology has previously gained if
    negative information were to emerge concerning their
    effectiveness or safety. As our agreements with manufacturers do
    not directly address such contingencies, we cannot assure you
    that equipment manufacturers would allow us to return their
    equipment or to otherwise reimburse us for any losses that we
    may suffer under all such circumstances. Since each unit of our
    medical equipment represents a significant investment, any of
    the foregoing could have a material adverse effect on our
    business, financial condition and results of operation.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    business may be adversely affected by impending healthcare
    reforms in China.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January 2009, the Chinese government approved in principle a
    healthcare reform plan to address the affordability of
    healthcare services, the rural healthcare system and healthcare
    service quality in China. In March, 2009, the Chinese government
    published the healthcare reform plan for 2009 to 2010, which
    broadly addressed medical insurance coverage, essential
    medicines, provision of basic healthcare services and reform of
    public hospitals. The published healthcare reform plan also
    called for additional government spending on healthcare over the
    next three years of RMB850.0&#160;billion to support the reform
    plan. Many details related to the implementation of the
    healthcare reform plan are not yet clear. Any policy changes
    that, for example, reduce treatment fees or provide more funding
    for hospitals to purchase their own equipment, may have a
    material and adverse effect on our business, financial condition
    and results of operations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Some details of the implementation of the healthcare reform that
    have been published, including a policy drafted jointly by five
    ministries, including the Ministry of Finance, NDRC and MOH,
    providing general principles and guidelines for government
    subsidies and investments in the public healthcare system, a
    policy statement allowing doctors to practice in up to three
    hospital within the same province, and the release of a list of
    307 essential drugs whose prices are subject to central
    government guidelines and provincial government tenders. The
    distribution of these drugs is expected to encompass all
    government-owned healthcare facilities by 2020.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the government has implemented a pilot plan as to
    the new rural healthcare insurance program whereby patients are
    required to pay hospitals only a portion of their medical
    expenses upfront and hospitals are required to seek payment of
    the balance from the government. Any resulting disputes or late
    or delinquent reimbursement payments may affect the collection
    of revenue at our network of centers and could increase our
    accounts receivables days.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We or
    our hospital partners may be unable to obtain various permits
    and authorizations from regulatory authorities in China relating
    to our medical equipment, which could delay the installation or
    interrupt the operation of our equipment.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For our hospital-based centers, our hospital partners are
    required to obtain a radiation safety permit from the Ministry
    of Environmental Protection, or MEP, and a radiotherapy permit
    from the competent healthcare administrative authorities in
    order to operate the medical equipment in our network of centers
    that contains radioactive materials or emit radiation during
    operation. Our hospital partners are also required to obtain a
    radiation worker permit from the competent provincial healthcare
    administrative authorities for each medical technician who
    operates such equipment. Any failure on the part of our hospital
    partners to obtain approvals or renewals of these permits from
    the MEP or the competent healthcare administrative authorities
    could delay the installation, or interrupt the operation, of our
    medical equipment, either of which could have a material adverse
    effect on our business, financial condition and results of
    operation.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each of our planned specialty cancer hospitals that will be
    majority owned by us will be required to obtain a radiation
    safety permit from the MEP and a radiotherapy permit as well as
    a medical institution practicing license and radiation worker
    permits for our staff from the relevant provincial healthcare
    administrative authorities. Any failure on our part to obtain
    approvals or renewals of these permits could delay the opening,
    or interrupt the operation, of our specialty cancer hospitals,
    which could have a material adverse effect on our business,
    financial condition and results of operation. For more
    information on risks related to our planned specialty cancer
    hospitals, see &#147;&#151;&#160;Risks Related to Our
    Business&#160;&#151; We are planning to establish and operate
    specialty cancer hospitals that are majority owned by us and are
    subject to significant risks.&#148;
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If the
    government and public insurers in the PRC do not continue to
    provide sufficient coverage and reimbursement for the
    radiotherapy and diagnostic imaging services provided by our
    network of centers, our revenues could be adversely
    affected.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Although self payments account for a high percentage of total
    medical expenses in China, approximately 20.4% of total medical
    expenses were sourced from direct payments by the government and
    approximately 34.5% of total medical expenses were sourced from
    government-directed public medical insurance schemes, commercial
    insurance plans and employers in 2007, according to the MOH. For
    public servants and others covered by <I>1989 Administrative
    Measure on Public Health Service </I>and the <I>1997 Circular of
    Reimbursement Coverage of Large Medical Equipment of Public
    Health Service</I>, the government currently either fully or
    partially reimburses medical expenses for certain approved
    cancer diagnosis and radiotherapy treatment services, including
    treatments utilizing linear accelerators and diagnostic imaging
    services utilizing CT and MRI scanners. However, gamma knife
    treatments and PET scans are currently not eligible for
    reimbursement under this plan. Urban residents in China are
    covered by one of two urban public medical insurance schemes and
    rural residents are covered under a new rural healthcare
    insurance program launched in 2003. The urban employees basic
    medical insurance scheme, which covers employed urban residents,
    partially reimburses urban workers for treatments utilizing
    linear accelerators and gamma knife systems and diagnostic
    imaging services utilizing CT and MRI scanners, with
    reimbursement levels varying from province to province. For
    urban non-workers and rural residents, the types of cancer
    diagnosis and radiotherapy treatments that are covered are
    generally set with reference to the policy for urban employees
    in the same region of the country, but the reimbursement levels
    for covered medical expenses for urban non-workers and rural
    residents, which vary widely from region to region and treatment
    to treatment, are generally lower than those for urban employees
    in the same region. See &#147;Regulation of Our
    Industry&#160;&#151; Medical Insurance Coverage&#148; for more
    information. We cannot assure you that the current coverage or
    reimbursement levels for cancer diagnosis or radiotherapy
    treatments will persist. If the national or provincial
    authorities in China decide to reduce the coverage or
    reimbursement levels for the radiotherapy and diagnostic imaging
    services provided by our network of centers, patients may opt
    for or be forced to resort to other forms of cancer therapy and
    our business, financial condition and results of operation could
    be materially and adversely affected.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Doing Business in China</FONT></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Adverse
    changes in political, economic and other policies of the Chinese
    government could have a material adverse effect on the overall
    economic growth of China, which could materially and adversely
    affect the growth of our business and our competitive
    position.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All of our business operations are conducted in China.
    Accordingly, our business, financial condition, results of
    operations and prospects are affected significantly by economic,
    political and legal developments in China. The Chinese economy
    differs from the economies of most developed countries in many
    respects, including:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the degree of government involvement;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the level of development;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the growth rate;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the control of foreign exchange;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the allocation of resources;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an evolving regulatory system;&#160;and
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    lack of sufficient transparency in the regulatory process.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    While the Chinese economy has experienced significant growth in
    the past 30&#160;years, growth has been uneven, both
    geographically and among various sectors of the economy. The
    Chinese economy has also experienced certain adverse effects due
    to the recent global financial crisis. The Chinese government
    has implemented various measures to encourage economic growth
    and guide the allocation of resources. Some of these measures
    benefit the overall Chinese economy, but may also have a
    negative effect on us. For example, our financial condition and
    results of operations may be adversely affected by government
    control over capital investments or changes in tax regulations
    that are applicable to us.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Chinese economy has been transitioning from a planned
    economy to a more market-oriented economy. Although in recent
    years the Chinese government has implemented measures
    emphasizing the utilization of market forces for economic
    reform, the reduction of state ownership of productive assets
    and the establishment of sound corporate governance in business
    enterprises, a substantial portion of the productive assets in
    China is still owned by the Chinese government. The continued
    control of these assets and other aspects of the national
    economy by the Chinese government could materially and adversely
    affect our business. The Chinese government also exercises
    significant control over Chinese economic growth through the
    allocation of resources, controlling payment of foreign
    currency-denominated obligations, setting monetary policy and
    providing preferential treatment to particular industries or
    companies.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any adverse change in the economic conditions or government
    policies in China could have a material adverse effect on
    overall economic growth and the level of healthcare investments
    and expenditures in China, which in turn could lead to a
    reduction in demand for our products and consequently have a
    material adverse effect on our businesses.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Uncertainties
    with respect to the PRC legal system could have a material
    adverse effect on us.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The PRC legal system is based on written statutes. Prior court
    decisions may be cited for reference but have limited
    precedential value. In 1979, the PRC government began to
    promulgate a comprehensive system of laws and regulations
    governing economic matters in general. The overall effect of
    legislation since then has been to significantly enhance the
    protections afforded to various forms of foreign investments in
    China. We conduct all of our business through our subsidiaries
    established in China. These subsidiaries are generally subject
    to laws and regulations applicable to foreign investment in
    China and, in particular, laws applicable to foreign-invested
    enterprises. However, since these laws and regulations are
    relatively new and the PRC legal system continues to rapidly
    evolve, the interpretations of many laws, regulations and rules
    are not always uniform and enforcement of these laws,
    regulations and rules involves uncertainties, which may limit
    legal protections available to us. In
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    addition, some regulatory requirements issued by certain PRC
    government authorities may not be consistently applied by other
    government authorities (including local government authorities),
    thus making strict compliance with all regulatory requirements
    impractical, or in some circumstances, impossible. For example,
    we may have to resort to administrative and court proceedings to
    enforce the legal protection that we enjoy either by law or
    contract. However, since PRC administrative and court
    authorities have significant discretion in interpreting and
    implementing statutory and contractual terms, it may be more
    difficult to evaluate the outcome of administrative and court
    proceedings and the level of legal protection we enjoy than in
    more developed legal systems. These uncertainties may impede our
    ability to enforce the contracts we have entered into with our
    business partners, customers and suppliers. In addition, such
    uncertainties, including the inability to enforce our contracts,
    together with any development or interpretation of PRC law that
    is adverse to us, could materially and adversely affect our
    business and operations. Furthermore, intellectual property
    rights and confidentiality protections in China may not be as
    effective as in the United States or other countries.
    Accordingly, we cannot predict the effect of future developments
    in the PRC legal system, including the promulgation of new laws,
    changes to existing laws or the interpretation or enforcement
    thereof, or the preemption of local regulations by national
    laws. These uncertainties could limit the legal protections
    available to us and other foreign investors, including you. In
    addition, any litigation in China may be protracted and result
    in substantial costs and diversion of our resources and
    management attention.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    approval of the PRC Securities Regulatory Commission, or the
    CSRC, may be required in connection with this offering under a
    recently adopted PRC regulation.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;8, 2006, six PRC regulatory agencies, including
    the CSRC, promulgated the &#147;Provisions Regarding Mergers and
    Acquisitions of Domestic Enterprises by Foreign Investors,&#148;
    or the M&#038;A rule, which took effect on September&#160;8,
    2006, to more effectively regulate foreign investment in PRC
    domestic enterprises. The M&#038;A rule also contains a
    provision requiring offshore special purpose vehicles, or SPVs,
    formed for overseas listing purposes and controlled by PRC
    individuals to obtain the approval of the CSRC prior to publicly
    listing their securities on an overseas stock exchange.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The application of this M&#038;A rule is currently unclear.
    However, our PRC counsel, Jingtian&#160;&#038; Gongcheng
    Attorneys At Law, has advised us that based on its understanding
    of the current PRC laws, rules and regulations and the M&#038;A
    rule, the M&#038;A rule does not require us to obtain prior CSRC
    approval for the listing and trading of our ADSs on the NYSE,
    because our acquisition of the equity interest in our PRC
    subsidiaries is not subject to the M&#038;A rule due to the fact
    that each of them was already a foreign-invested enterprise
    before September&#160;8, 2006, the effective date of the
    M&#038;A rule. Jingtian&#160;&#038; Gongcheng Attorneys At Law
    has further advised us that their opinions summarized above are
    subject to the timing and content of any new laws, rules and
    regulations or clear implementations and interpretations from
    the CSRC in any form relating to the M&#038;A rule.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, if the CSRC or another PRC regulatory agency
    subsequently determines that prior CSRC approval was required,
    we may face regulatory actions or other sanctions from the CSRC
    or other PRC regulatory agencies. These regulatory agencies may
    impose fines and penalties on our operations, limit our
    operating privileges, delay or restrict the repatriation of the
    proceeds from this offering into China or payment or
    distribution of dividends by our PRC subsidiaries, or take other
    actions that could have a material adverse effect on our
    business, financial condition, results of operations, reputation
    and prospects, as well as the trading price of our ADSs. The
    CSRC or other PRC regulatory agencies also may take actions
    requiring us, or making it advisable for us, to halt this
    offering before settlement and delivery of the ADSs offered
    hereby. Consequently, if you engage in market trading or other
    activities in anticipation of and prior to settlement and
    delivery, you do so at the risk that settlement and delivery may
    not occur. Also, if the CSRC later requires that we obtain its
    approval, we may be unable to obtain a waiver of the CSRC
    approval requirements, if and when procedures are established to
    obtain such a waiver. Any uncertainties or negative publicity
    regarding this CSRC approval requirement could have a material
    adverse effect on the trading price of our ADSs.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We cannot predict when the CSRC may promulgate additional
    implementing rules or other guidance, if at all. If implementing
    rules or guidance is issued prior to the completion of this
    offering and consequently we conclude we are required to obtain
    CSRC approval, this offering will be delayed until we obtain
    CSRC approval, which may take several months or longer.
    Furthermore, any delay in the issuance of such implementing
    rules or guidance may create additional uncertainties with
    respect to this offering. Moreover, implementing rules or
    guidance, to the extent
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    issued, may fail to resolve current ambiguities under the
    M&#038;A Rule. Uncertainties
    <FONT style="white-space: nowrap">and/or</FONT>
    negative publicity regarding the M&#038;A Rule could have a
    material adverse effect on the trading price of our ADSs.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    M&#038;A rule establishes more complex procedures for some
    acquisitions of Chinese companies by foreign investors, which
    could make it more difficult for us to pursue growth through
    acquisitions in China.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The M&#038;A rule establishes additional procedures and
    requirements that could make some acquisitions of Chinese
    companies by foreign investors more time-consuming and complex,
    including requirements in some instances that the Ministry of
    Commerce be notified in advance of any change-of-control
    transaction in which a foreign investor takes control of a
    Chinese domestic enterprise. We may grow our business in part by
    acquiring complementary businesses. Complying with the
    requirements of the M&#038;A rule to complete such transactions
    could be time-consuming, and any required approval processes,
    including obtaining approval from the Ministry of Commerce, may
    delay or inhibit our ability to complete such transactions,
    which could affect our ability to expand our business or
    maintain our market share.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Recent
    PRC regulations, particularly SAFE Circular No.&#160;75 relating
    to acquisitions of PRC companies by foreign entities, may limit
    our ability to acquire PRC companies and adversely affect the
    implementation of our strategy as well as our business and
    prospects.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2005, the State Administration of Foreign Exchange, or the
    SAFE issued a number of rules regarding offshore investments by
    PRC residents. The currently effective rule, <I>the Notice on
    Issues Relating to the Administration of Foreign Exchange in
    Fund-Raising and Return Investment Activities of Domestic
    Residents Conducted Via Offshore Special Purpose Companies</I>,
    known as SAFE Circular No.&#160;75, was issued on
    October&#160;21, 2005 and further clarified by Circular
    No.&#160;106 issued by the SAFE on May&#160;29, 2007. SAFE
    Circular No.&#160;75 requires PRC residents to register with and
    receive approvals from the SAFE in connection with certain
    offshore investment activities. Since we are a Cayman Islands
    company that is controlled by PRC residents, we are affected by
    the registration requirements imposed by SAFE Circular
    No.&#160;75. Also, any failure by our shareholders who are PRC
    residents to comply with SAFE Circular No.&#160;75, or change in
    SAFE policy and regulations in respect of SAFE Circular
    No.&#160;75, could adversely affect us in a variety of ways.
    SAFE Circular No.&#160;75 provides, among other things, that
    prior to establishing or assuming control of an offshore company
    for the purpose of transferring to that offshore company assets
    of, or equity interests in, an enterprise in the PRC, each PRC
    resident (whether a natural or legal person) who is an ultimate
    controller of the offshore company must complete prescribed
    registration procedures with the relevant local branch of the
    SAFE. Such PRC resident must amend his or her SAFE registration
    under certain circumstances, including upon any further transfer
    of equity interests in, or assets of, an onshore enterprise to
    the offshore company as well as any material change in the
    capital of the offshore company, including by way of a transfer
    or swap of shares, a merger or division, a long-term equity or
    debt investment or the creation of any security interests in
    favor of third parties. The registration and filing procedures
    under SAFE rules are prerequisites for other approval and
    registration procedures necessary for capital inflow from the
    offshore entity, such as inbound investments or shareholder
    loans, or capital outflow to the offshore entity, such as the
    payment of profits or dividends, liquidating distributions,
    equity sale proceeds, or the return of funds upon a capital
    reduction. SAFE Circular No.&#160;75 applies retroactively and
    to indirect shareholdings. PRC residents who have established or
    acquired direct or indirect control of offshore companies that
    have made onshore investments in the PRC in the past are
    required to complete the registration procedures by
    March&#160;31, 2006. The failure or inability of a PRC resident
    shareholder to receive any required approvals or make any
    required registrations could subject the PRC subsidiary to fines
    and legal sanctions, restrict the offshore company&#146;s
    additional investments in the PRC subsidiary, or limit the PRC
    subsidiary&#146;s ability to make distributions or pay dividends
    offshore. Due in part to the uncertainties relating to the
    interpretation and implementation of SAFE Circular No.&#160;75,
    its effect on companies such as ours is difficult to predict.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Currently, several of our shareholders who are residents in the
    PRC and are subject to the above registration or amendment of
    registration requirements have applied to SAFE&#146;s local
    branches to make the required make-up SAFE registration with
    respect to their existing investments in our company. Because of
    the current suspension of acceptance of such make-up
    registration by the SAFE authorities due to reportedly
    forthcoming new SAFE regulations, such shareholders&#146;
    applications are still pending. We cannot assure you that these
    shareholders&#146;
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    pending applications will eventually be approved by the
    authorities. Furthermore, there may be additional PRC
    shareholders, whose identities we may not be aware of and whose
    actions we do not control, who are not in compliance with the
    registration procedures set forth in SAFE Circular No.&#160;75.
    If the SAFE determines that any of our PRC shareholders failed
    to make filings that they should have made with respect to any
    of our offshore entities, we could be subject to fines and legal
    penalties, or the SAFE could impose restrictions on our foreign
    exchange activities, including the payment of dividends and
    other distributions to us or our affiliates and our PRC
    subsidiaries&#146; ability to receive capital from us. Any of
    these actions could, among other things, materially and
    adversely affect our business operations, acquisition
    opportunities and financing alternatives.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">PRC
    regulation of loans and direct investment by offshore holding
    companies to PRC entities may delay or prevent us from using the
    proceeds of this offering to make loans or additional capital
    contributions to our PRC subsidiaries.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In utilizing the proceeds from this public offering or any
    further offerings, as an offshore holding company of our PRC
    subsidiaries, we may make loans to our PRC subsidiaries, or we
    may make additional capital contributions to our PRC
    subsidiaries. Any loans to our PRC subsidiaries are subject to
    PRC regulations and approvals. For example, loans by us to our
    wholly owned PRC subsidiaries in China, each of which is a
    foreign-invested enterprise, to finance their activities cannot
    exceed statutory limits and must be registered with the SAFE or
    its local counterpart.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may also decide to finance our PRC subsidiaries through
    capital contributions. These capital contributions must be
    approved by the Ministry of Commerce in China or its local
    counterpart. We cannot assure you that we will be able to obtain
    these government registrations or approvals on a timely basis,
    if at all, with respect to future loans or capital contributions
    by us to our subsidiaries or any of their respective
    subsidiaries. If we fail to receive such registrations or
    approvals, our ability to use the proceeds of this offering and
    to capitalize our PRC operations may be negatively affected,
    which could adversely and materially affect our liquidity and
    our ability to fund and expand our business.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Governmental
    control of currency conversion may limit our ability to use our
    revenues effectively and the ability of our PRC subsidiaries to
    obtain financing.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We receive all of our revenues in Renminbi, which currently is
    not a freely convertible currency. Restrictions on currency
    conversion imposed by the PRC government may limit our ability
    to use revenues generated in Renminbi to fund our expenditures
    denominated in foreign currencies or our business activities
    outside China, if any. Under China&#146;s existing foreign
    exchange regulations, Renminbi may be freely converted into
    foreign currency for payments relating to &#147;current account
    transactions,&#148; which include among other things dividend
    payments and payments for the import of goods and services, by
    complying with certain procedural requirements. Our PRC
    subsidiaries are able to pay dividends in foreign currencies to
    us without prior approval from the SAFE, by complying with
    certain procedural requirements. Our PRC subsidiaries may also
    retain foreign currency their respective current account bank
    accounts for use in payment of international current account
    transactions. However, we cannot assure you that the PRC
    government will not take measures in the future to restrict
    access to foreign currencies for current account transactions.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Conversion of Renminbi into foreign currencies, and of foreign
    currencies into Renminbi, for payments relating to &#147;capital
    account transactions,&#148; which principally includes
    investments and loans, generally requires the approval of SAFE
    and other relevant PRC governmental authorities. Restrictions on
    the convertibility of the Renminbi for capital account
    transactions could affect the ability of our PRC subsidiaries to
    make investments overseas or to obtain foreign currency through
    debt or equity financing, including by means of loans or capital
    contributions from us. In particular, if our PRC subsidiaries
    borrow foreign currency from us or other foreign lenders, they
    must do so within approved limits that satisfy their approval
    documentation and PRC debt to equity ratio requirements.
    Further, such loans must be registered with the SAFE or its
    local counterpart. In practice, it could be time-consuming to
    complete such SAFE registration process.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we finance our PRC subsidiaries through additional capital
    contributions, the amount of these capital contributions must be
    approved by the Ministry of Commerce in China or its local
    counterpart. On August&#160;29, 2008,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    SAFE promulgated Circular 142, a notice regulating the
    conversion by a foreign-invested company of foreign currency
    into Renminbi by restricting how the converted Renminbi may be
    used. The notice requires that Renminbi converted from the
    foreign currency-denominated capital of a foreign-invested
    company may only be used for purposes within the business scope
    approved by the applicable governmental authority and may not be
    used for equity investments within the PRC unless specifically
    provided for otherwise in its business scope. In addition, SAFE
    strengthened its oversight of the flow and use of Renminbi funds
    converted from the foreign currency-denominated capital of a
    foreign-invested company. The use of such Renminbi may not be
    changed without approval from SAFE, and may not be used to repay
    Renminbi loans if the proceeds of such loans have not yet been
    used for purposes within the company&#146;s approved business
    scope. Violations of Circular 142&#160;may result in severe
    penalties, including substantial fines as set forth in the
    Foreign Exchange Administration Regulations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We cannot assure you that we will be able to complete the
    necessary government registrations or obtain the necessary
    government approvals on a timely basis, if at all, with respect
    to future loans by us to our PRC subsidiaries or with respect to
    future capital contributions by us to our PRC subsidiaries. If
    we fail to complete such registrations or obtain such approvals,
    our ability to use the proceeds we receive from this offering
    and to capitalize or otherwise fund our PRC operations may be
    negatively affected, which could adversely and materially affect
    our liquidity and our ability to fund and expand our business
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fluctuations
    in the value of the Renminbi may have a material adverse effect
    on your investment.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The value of the Renminbi against the U.S.&#160;dollar and other
    currencies may fluctuate and is affected by, among other things,
    changes in China&#146;s political and economic conditions. The
    conversion of Renminbi into foreign currencies, including
    U.S.&#160;dollars, has historically been set by the
    People&#146;s Bank of China. On July&#160;21, 2005, the PRC
    government changed its policy of pegging the value of the
    Renminbi to the U.S.&#160;dollar. Under the new policy, the
    Renminbi is permitted to fluctuate within a band against a
    basket of certain foreign currencies, determined by the Bank of
    China, against which it can rise or fall by as much as 0.3% each
    day.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There remains significant international pressure on the PRC
    government to further liberalize its currency policy, which
    could result in a further and more significant appreciation in
    the value of the Renminbi against the U.S.&#160;dollar. In
    addition, as we rely entirely on dividends paid to us by our PRC
    subsidiaries, any significant revaluation of the Renminbi may
    have a material adverse effect on our revenues and financial
    condition, and the value of any dividends payable on our ADSs in
    foreign currency terms. For example, to the extent that we need
    to convert U.S.&#160;dollars that we receive from our initial
    public offering into Renminbi for our operations, appreciation
    of the Renminbi against the U.S.&#160;dollar would have an
    adverse effect on the Renminbi amount that we receive from the
    conversion. Conversely, if we decide to convert our Renminbi
    into U.S.&#160;dollars for the purpose of making payments for
    dividends on our ordinary shares or ADSs or for other business
    purposes, appreciation of the U.S.&#160;dollar against the
    Renminbi would have a negative effect on the U.S.&#160;dollar
    amount available to us. In addition, appreciation or
    depreciation in the value of the Renminbi relative to the
    U.S.&#160;dollar would affect our financial results reported in
    U.S.&#160;dollar terms without giving effect to any underlying
    change in our business or results of operations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    increase in the PRC enterprise income tax and the
    discontinuation of the preferential tax treatment currently
    available to us could, in each case, result in a decrease of our
    net income and materially and adversely affect our financial
    condition and results of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our PRC subsidiaries are incorporated in the PRC and are
    governed by applicable PRC income tax laws and regulations.
    Prior to January&#160;1, 2008, entities established in the PRC
    were generally subject to a 30% state and 3% local enterprise
    income tax rate. There were various preferential tax treatments
    promulgated by national tax authorities that were available to
    foreign-invested enterprises or enterprises located in certain
    areas of China. In addition, some local tax authorities may
    allow enterprises registered in their tax jurisdiction to enjoy
    lower preferential tax treatments according to local
    preferential tax policy. For example, Shanghai Medstar was
    entitled to a reduced enterprise income tax rate of 15% before
    January&#160;1, 2008 due to its status as a foreign-invested
    manufacturing enterprise registered in the Shanghai Waigaoqiao
    free trade zone.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The PRC Enterprise Income Tax Law, or the EIT Law, was enacted
    on March&#160;16, 2007 and became effective on January&#160;1,
    2008. The implementation regulations under the EIT Law issued by
    the PRC State Council became
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    effective January&#160;1, 2008. Under the EIT Law and the
    implementation regulations, the PRC has adopted a uniform tax
    rate of 25% for all enterprises (including foreign-invested
    enterprises) and revoked the previous tax exemption, reduction
    and preferential treatments applicable to foreign-invested
    enterprises. However, there is a transition period for
    enterprises, whether foreign-invested or domestic, that received
    preferential tax treatments granted in accordance with the then
    prevailing tax laws and regulations prior to January&#160;1,
    2008. Enterprises that were subject to an enterprise income tax
    rate lower than 25% prior to January&#160;1, 2008&#160;may
    continue to enjoy the lower rate and gradually transition to the
    new tax rate within five years after the effective date of the
    EIT Law. In 2009, our subsidiaries Aohua Medical and Shanghai
    Medstar each had a preferential income tax rate of 20% that is
    scheduled to increase to 22% in 2010, 24% in 2011 and 25% in
    2012. We cannot assure you that the preferential income tax
    rates that we enjoy will not be phased out at a faster rate or
    will not be discontinued altogether, either of which could
    result in a decrease of our net income and materially and
    adversely affect our financial condition and results of
    operations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Also, the reduced enterprise income tax rate of 15%, as
    described above, that our subsidiary Shanghai Medstar enjoyed
    before January&#160;1, 2008, for which only foreign-invested
    manufacturing enterprises registered in the Shanghai Waigaoqiao
    free trade zone were eligible, was granted based on Shanghai tax
    authorities&#146; local preferential tax policy. It is uncertain
    whether the transitional tax rates under the EIT Law would apply
    to companies that enjoyed a preferential reduced tax rate of 15%
    under a local preferential tax policy. If Shanghai Medstar
    cannot enjoy the such transitional tax rates under the EIT Law,
    it will be subject to the standard enterprise income tax rate,
    which is currently 25%, and our income tax expenses would
    increase, which would have a material adverse effect on our net
    income and results of operation. In addition, under current PRC
    regulations, if it is determined that a taxpayer has underpaid
    tax due to prior incorrect advice from relevant tax authorities,
    the taxpayer may still be required to retroactively pay the full
    amount of unpaid tax within three years of such determination,
    although the taxpayer would not be subject to any penalty or
    late payment fee. If we are required to make such retroactive
    tax payments due to the retroactive cancellation of Shanghai
    Medstar&#146;s preferential reduced enterprise income tax rate
    of 15%, our financial condition and results of operation could
    be materially and adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    rely on dividends paid by our subsidiaries for our cash needs,
    and any limitation on the ability of our subsidiaries to make
    payments to us could have a material adverse effect on our
    ability to conduct our business.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We conduct all of our business through our consolidated
    subsidiaries incorporated in China. We rely on dividends paid by
    these consolidated subsidiaries for our cash needs, including
    the funds necessary to pay any dividends and other cash
    distributions to our shareholders, to service any debt we may
    incur and to pay our operating expenses. The payment of
    dividends by entities established in China is subject to
    limitations. Regulations in China currently permit payment of
    dividends only out of accumulated profits as determined in
    accordance with accounting standards and regulations in China.
    Each of our PRC subsidiaries, including wholly foreign-owned
    enterprises, or WFOEs, and joint venture enterprises is also
    required to set aside at least 10% of its after-tax profit based
    on PRC accounting standards each year to its general reserves or
    statutory capital reserve fund until the aggregate amount of
    such reserves reaches 50% of its respective registered capital.
    Our statutory reserves are not distributable as loans, advances
    or cash dividends. We anticipate that in the foreseeable future
    our PRC subsidiaries will need to continue to set aside 10% of
    their respective
    <FONT style="white-space: nowrap">after-tax</FONT>
    profits to their statutory reserves. In addition, if any of our
    PRC subsidiaries incurs debt on its own behalf in the future,
    the instruments governing the debt may restrict its ability to
    pay dividends or make other distributions to us. Any limitations
    on the ability of our PRC subsidiaries to transfer funds to us
    could materially and adversely limit our ability to grow, make
    investments or acquisitions that could be beneficial to our
    business, pay dividends and otherwise fund and conduct our
    business.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, under the EIT law, the <I>Notice of the State
    Administration of Taxation on Negotiated Reduction of Dividends
    and Interest Rates</I>, or Notice 112, which was issued on
    January&#160;29, 2008, the <I>Arrangement between the PRC and
    the Hong Kong Special Administrative Region on the Avoidance of
    Double Taxation and Prevention of Fiscal Evasion</I>, or the
    Double Taxation Arrangement (Hong Kong), which became effective
    on December&#160;8, 2006, and the <I>Notice of the State
    Administration of Taxation Regarding Interpretation and
    Recognition of Beneficial Owners under Tax Treaties</I>, or
    Notice 601, which became effective on October 27, 2009,
    dividends from our PRC subsidiaries paid to us through our Hong
    Kong subsidiary may be subject to a withholding tax at a rate of
    10%, or at
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    a rate of 5% if our Hong Kong subsidiary is considered as a
    &#147;beneficial owner&#148; that is generally engaged in
    substantial business activities and entitled to treaty benefits
    under the Double Taxation Arrangement (Hong Kong). Furthermore,
    the ultimate tax rate will be determined by treaty between the
    PRC and the tax residence of the holder of the PRC subsidiary.
    We are actively monitoring the proposed withholding tax and are
    evaluating appropriate organizational changes to minimize the
    corresponding tax impact.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Dividends
    we receive from our operating subsidiaries located in the PRC
    may be subject to PRC withholding tax.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The EIT Law provides that a maximum income tax rate of 20% may
    be applicable to dividends payable to non-PRC investors that are
    &#147;non-resident enterprises,&#148; to the extent such
    dividends are derived from sources within the PRC, and the State
    Council has reduced such rate to 10%, in the absence of any
    applicable tax treaties that may reduce such rate, through the
    implementation regulations. We are a Cayman Islands holding
    company and substantially all of our income may be derived from
    dividends we receive from our operating subsidiaries located in
    the PRC. If we are required under the EIT Law to pay income tax
    for any dividends we receive from our subsidiaries, the amount
    of dividends, if any, we may pay to our shareholders and ADS
    holders may be materially and adversely affected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to the Double Taxation Arrangement (Hong Kong), Notice
    112 and Notice&#160;601, dividends paid to enterprises
    incorporated in Hong Kong are subject to a withholding tax of 5%
    provided that a Hong Kong resident enterprise owns over 25% of
    the PRC enterprise distributing the dividend and can be
    considered as a &#147;beneficial owner&#148; and entitled to
    treaty benefits under the Double Taxation Arrangement (Hong
    Kong). Thus, as Cyber Medical Network Limited, or Cyber Medical,
    is a Hong Kong company and owns 100% of CMS Hospital Management,
    under the aforementioned arrangement dividends paid to us
    through Cyber Medical by CMS Hospital Management may be subject
    to the 5% income tax if we and Cyber Medical are considered as
    &#147;non-resident enterprises&#148; under the EIT Law and Cyber
    Medical is considered as a &#147;beneficial owner&#148; and
    entitled to treaty benefits under the Double Taxation
    Arrangement (Hong Kong). If Cyber Medical is not regarded as the
    beneficial owner of any such dividends, it will not be entitled
    to the treaty benefits under the Double Taxation Arrangement
    (Hong Kong). As a result, such dividends would be subject to
    normal withholding income tax of 10% as provided by the PRC
    domestic law rather than the favorable rate of 5% applicable
    under the Double Taxation Arrangement (Hong Kong).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The British Virgin Islands, where OMS, the direct holding
    company of Aohua Medical and Aohua Leasing, is incorporated,
    does not have a tax treaty with the PRC. Thus, if OMS is
    considered a &#147;non-resident enterprise&#148; under the EIT
    law, the 10% withholding tax would be imposed on our dividend
    income received from Aohua Medical and Aohua Leasing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    be classified as a &#147;resident enterprise&#148; for PRC
    enterprise income tax purposes, which could result in
    unfavorable tax consequences to us and our non-PRC
    shareholders.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The EIT Law provides that enterprises established outside of
    China whose &#147;de facto management bodies&#148; are located
    in China are considered &#147;resident enterprises&#148; and are
    generally subject to the uniform 25% enterprise income tax rate
    on their worldwide income. In addition, a recent circular issued
    by the State Administration of Taxation on April&#160;22, 2009
    regarding the standards used to classify certain
    Chinese-invested enterprises controlled by Chinese enterprises
    or Chinese group enterprises and established outside of China as
    &#147;resident enterprises&#148; clarified that dividends and
    other income paid by such &#147;resident enterprises&#148; will
    be considered to be PRC source income, subject to PRC
    withholding tax, currently at a rate of 10%, when recognized by
    non-PRC enterprise shareholders. This recent circular also
    subjects such &#147;resident enterprises&#148; to various
    reporting requirements with the PRC tax authorities. Under the
    implementation regulations to the enterprise income tax, a
    &#147;de facto management body&#148; is defined as a body that
    has material and overall management and control over the
    manufacturing and business operations, personnel and human
    resources, finances and properties of an enterprise. In
    addition, the recent circular mentioned above sets out criteria
    for determining whether &#147;de facto management bodies&#148;
    are located in China for overseas incorporated, domestically
    controlled enterprises. However, as this circular only applies
    to enterprises established outside of China that are controlled
    by PRC enterprises or groups of PRC enterprises, it remains
    unclear how the tax authorities will determine the location of
    &#147;de facto management bodies&#148; for overseas incorporated
    enterprises that are controlled by
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    individual PRC residents like us and some of our subsidiaries.
    Therefore, although substantially all of our management is
    currently located in the PRC, it remains unclear whether the PRC
    tax authorities would require or permit our overseas registered
    entities to be treated as PRC resident enterprises. We do not
    currently consider our company to be a PRC resident enterprise.
    However, if the PRC tax authorities disagree with our assessment
    and determine that we are a &#147;resident enterprise,&#148; we
    may be subject to enterprise income tax at a rate of 25% on our
    worldwide income and dividends paid by us to our non-PRC
    shareholders as well as capital gains recognized by them with
    respect to the sale of our shares may be subject to a PRC
    withholding tax. This will have an impact on our effective tax
    rate, a material adverse effect on our net income and results of
    operations, and may require us to withhold tax on our non-PRC
    shareholders.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Dividends
    payable by us to our foreign investors and gains on the sale of
    our ADSs or ordinary shares may become subject to taxes under
    PRC tax laws.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the EIT Law and implementation regulations issued by the
    State Council, a 10% PRC income tax is applicable to dividends
    payable to investors that are &#147;non-resident
    enterprises,&#148; which do not have an establishment or place
    of business in the PRC or which have such establishment or place
    of business but have income not effectively connected with the
    establishment or place of business, to the extent such dividends
    are derived from sources within the PRC. Similarly, any gain
    realized on the transfer of ADSs or shares by such investors is
    also subject to a 10% PRC income tax if such gain is regarded as
    income derived from sources within the PRC. It is unclear
    whether dividends paid on our ordinary shares or ADSs, or any
    gain realized from the transfer of our ordinary shares or ADSs,
    would be treated as income derived from sources within the PRC
    and would as a result be subject to PRC tax. If we are
    considered a PRC &#147;resident enterprise,&#148; then any
    dividends paid to our overseas shareholders or ADS holders that
    are &#147;non-resident enterprises&#148; may be regarded as
    being derived from PRC sources and, as a result, would be
    subject to PRC withholding tax at a rate of 10%. In addition, if
    we are considered a PRC &#147;resident enterprise,&#148;
    non-resident enterprise shareholders of our ordinary shares or
    ADSs may be eligible for the benefits of income tax treaties
    entered into between China and other countries. If we are
    required under the EIT Law to withhold PRC income tax on
    dividends payable to our non-PRC investors that are
    &#147;non-resident enterprises,&#148; or if you are required to
    pay PRC income tax on the transfer of our ordinary shares or
    ADSs, the value of your investment in our ordinary shares or
    ADSs may be materially and adversely affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If we
    are found to have failed to comply with applicable laws, we may
    incur additional expenditures or be subject to significant fines
    and penalties.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our operations are subject to PRC laws and regulations
    applicable to us. However, the scope of many PRC laws and
    regulations are uncertain, and their implementation could differ
    significantly in different localities. In certain instances,
    local implementation rules and their implementation are not
    necessarily consistent with the regulations at the national
    level. Although we strive to comply with all applicable PRC laws
    and regulations, we cannot assure you that the relevant PRC
    government authorities will not determine that we have not been
    in compliance with certain laws or regulations.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    face risks related to natural disasters and health epidemics in
    China, which could have a material adverse effect on our
    business and results of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business could be materially and adversely affected by
    natural disasters or the outbreak of health epidemics in China.
    For example, in May 2008, Sichuan Province experienced a strong
    earthquake, measuring approximately 8.0 on the Richter scale,
    that caused widespread damage and casualties. In addition, as
    our network of radiotherapy and diagnostic imaging centers are
    located in hospitals across China, our operations may be
    particularly vulnerable to any health epidemic. In the last
    decade, the PRC has suffered health epidemics related to the
    outbreak of avian influenza and severe acute respiratory
    syndrome, or SARS. In April 2009, an outbreak of the H1N1 virus,
    also commonly referred to as &#147;swine flu&#148;, occurred in
    Mexico and has spread to other countries, including China. If
    the outbreak of swine flu were to become widespread in China or
    increase in severity, it could have an adverse effect on
    economic activity in China, and our business and operations
    could be adversely affected. Any future natural disasters or
    health epidemics in the PRC could also have a material adverse
    effect on our business and results of operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to This Offering</FONT></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">There
    has been no public market for our ordinary shares or ADSs prior
    to this offering, and you may not be able to resell our ADSs at
    or above the price you paid, or at all.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this initial public offering, there has been no public
    market for our ordinary shares or ADSs. We have applied for our
    ADSs to be included for listing on the NYSE. Our ordinary shares
    will not be listed on any exchange or quoted for trading on any
    over-the-counter trading system. If an active trading market for
    our ADSs does not develop after this offering, the market price
    and liquidity of our ADSs will be materially and adversely
    affected.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The initial public offering price for our ADSs will be
    determined by negotiations between us and the underwriters and
    may bear no relationship to the market price for our ADSs after
    this initial public offering. We cannot assure you that an
    active trading market for our ADSs will develop or that the
    market price of our ADSs will not decline below the initial
    public offering price.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    market price for our ADSs may be volatile.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The market price for our ADSs is likely to be highly volatile
    and subject to wide fluctuations in response to factors
    including the following:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    announcements of technological or competitive developments;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    regulatory developments in China affecting us or our competitors;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    announcements of studies and reports relating to the
    effectiveness or safety of the services provided in our network
    of centers or those of our competitors;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    actual or anticipated fluctuations in our quarterly operating
    results and changes or revisions of our expected results;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in financial estimates by securities research analysts;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in the economic performance or market valuations of
    other medical services companies;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    addition or departure of our senior management and other key
    personnel;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    release or expiry of
    <FONT style="white-space: nowrap">lock-up</FONT> or
    other transfer restrictions on our outstanding ordinary shares
    or ADSs;&#160;and
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    sales or perceived sales of additional ordinary shares or ADSs.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the securities market has from time to time
    experienced significant price and volume fluctuations that are
    not related to the operating performance of particular
    companies. These market fluctuations may also have a material
    adverse effect on the market price of our ADSs. In the past,
    following periods of volatility in the market price of a
    company&#146;s securities, shareholders have often instituted
    securities class action litigation against that company. If we
    were involved in a class action suit or other securities
    litigation, it would divert the attention of our senior
    management, require us to incur significant expense and, whether
    or not adversely determined, could have a material adverse
    effect on our business, financial condition, results of
    operations and prospects.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Because
    the initial public offering price is substantially higher than
    our net tangible book value per share, you will incur immediate
    and substantial dilution.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you purchase ADSs in this offering, you will pay more for
    your ADSs than the amount paid by our existing shareholders for
    their ordinary shares on a per ADS basis. As a result, you will
    experience immediate and substantial dilution of approximately
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS (assuming no exercise of the underwriters&#146; option
    to purchase additional ADSs), representing the difference
    between our net tangible book value per ADS as of
    September&#160;30, 2009, or dilution of approximately
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS assuming the full exercise by the underwriters of the
    over-allotment option, representing the difference between our
    net tangible book value per ADS as of September&#160;30, 2009,
    after giving effect to this offering. In addition, you may
    experience further dilution to the extent that our ordinary
    shares are issued upon the exercise of stock options. See
    &#147;Dilution&#148; for a more complete description.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    42
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Substantial
    future sales or perceived sales of our ADSs in the public market
    could cause the price of our ADSs to decline.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sales of our ADSs or ordinary shares in the public market after
    this offering, or the perception that these sales could occur,
    could cause the market price of our ADSs to decline. Upon
    completion of this offering, we will
    have&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ordinary shares outstanding,
    including&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ordinary shares represented
    by&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ADSs. All ADSs sold in this offering will be freely transferable
    without restriction or additional registration under the
    Securities Act of 1933, as amended, or the Securities Act. The
    remaining ordinary shares outstanding after this offering will
    be available for sale, upon the expiration of the
    <FONT style="white-space: nowrap">180-day</FONT>
    <FONT style="white-space: nowrap">lock-up</FONT>
    period beginning from the date of this prospectus, subject to
    volume and other restrictions as applicable under Rule&#160;144
    and Rule&#160;701 under the Securities Act. Any or all of these
    shares may be released prior to expiration of the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period at the discretion of the underwriters. To the extent
    shares are released before the expiration of the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period and these shares are sold into the market, the market
    price of our ADSs could decline.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Holders
    of ADSs have fewer rights than shareholders and must act through
    the depositary to exercise those rights.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of ADSs do not have the same rights as our shareholders
    and may only exercise voting rights with respect to the
    underlying ordinary shares in accordance with the provisions of
    the deposit agreement. Under the deposit agreement, if the vote
    is by show of hands, the depositary will vote the deposited
    securities in accordance with the voting instructions received
    from a majority of holders of ADSs that provided timely voting
    instructions. If the vote is by poll, the depositary will vote
    the deposited securities in accordance with the voting
    instructions it timely receives from ADS holders. In the event
    of poll voting, deposited securities for which no instructions
    are received will not be voted. Under our third amended and
    restated articles of association, the minimum notice period
    required to convene a general meeting is seven days. When a
    general meeting is convened, you may not receive sufficient
    notice of a shareholders&#146; meeting to permit you to your
    ordinary shares to allow you to cast your vote with respect to
    any specific matter. In addition, the depositary and its agents
    may not be able to send voting instructions to you or carry out
    your voting instructions in a timely manner. We will make all
    reasonable efforts to cause the depositary to extend voting
    rights to you in a timely manner, but we cannot assure you that
    you will receive the voting materials in time to ensure that you
    can instruct the depositary to vote your shares. Furthermore,
    the depositary and its agents will not be responsible for any
    failure to carry out any instructions to vote, for the manner in
    which any vote is cast or for the effect of any such vote. As a
    result, you may not be able to exercise your right to vote and
    you may lack recourse if your ordinary shares are not voted as
    you requested. In addition, in your capacity as an ADS holder,
    you will not be able to call a shareholder meeting.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">You
    may be subject to limitations on transfers of your
    ADSs.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Your ADSs are transferable on the books of the depositary.
    However, the depositary may close its transfer books at any time
    or from time to time when it deems is expedient to do so in
    connection with the performance of its duties. In addition, the
    depositary may refuse to deliver, transfer or register transfers
    of ADSs generally when our books or the books of the depositary
    are closed, or at any time if we or the depositary deem it
    advisable to do so because of any requirement of law or of any
    government or governmental body, or under any provision of the
    deposit agreement, or for any other reason.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Your
    right to participate in any future rights offerings may be
    limited, which may cause dilution to your holdings and you may
    not receive cash dividends if it is impractical to make them
    available to you.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may, from time to time, distribute rights to our
    shareholders, including rights to acquire our securities.
    However, we cannot make any such rights available to you in the
    United States unless we register such rights and the securities
    to which such rights relate under the Securities Act or an
    exemption from the registration requirements is available. Also,
    under the deposit agreement, the depositary bank will not make
    rights available to you unless the distribution to ADS holders
    of both the rights and any related securities are either
    registered under the Securities Act, or exempted from
    registration under the Securities Act. We are under no
    obligation to file a registration statement with respect to any
    such rights or securities or to endeavor to cause such a
    registration statement to be
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    43
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    declared effective. Moreover, we may not be able to establish an
    exemption from registration under the Securities Act.
    Accordingly, you may be unable to participate in our rights
    offerings and may experience dilution in your holdings.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, the depositary has agreed to pay to you the cash
    dividends or other distributions it or the custodian receives on
    our ordinary shares or other deposited securities after
    deducting its fees and expenses. You will receive these
    distributions in proportion to the number of ordinary shares
    your ADSs represent. However, the depositary may, at its
    discretion, decide that it is inequitable or impractical to make
    a distribution available to any holders of ADSs. For example,
    the depositary may determine that it is not practicable to
    distribute certain property through the mail, or that the value
    of certain distributions may be less than the cost of mailing
    them. In these cases, the depositary may decide not to
    distribute such property and you will not receive such
    distribution.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    have not determined any specific use for a portion of the net
    proceeds to us from this offering and we may use such portion of
    the net proceeds in ways with which you may not
    agree.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have not allocated a portion of the net proceeds to us from
    this offering for any specific purpose. Rather, our management
    will have considerable discretion in the application of such
    portion of the net proceeds received by us. See &#147;Use of
    Proceeds.&#148; You will not have the opportunity, as part of
    your investment decision, to assess whether such proceeds are
    being used appropriately. You must rely on the judgment of our
    management regarding the application of such proceeds that we
    receive from this offering. Such proceeds may be used for
    corporate purposes that do not improve our profitability or
    increase our ADS price or may also be placed in investments that
    do not produce income or that may lose value.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    will incur increased costs as a result of being a public
    company.</FONT></I></B>
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, we will become a public
    company in the United States. As a public company, we will incur
    significant legal, accounting and other expenses that we did not
    incur as a private company. In addition, the Sarbanes-Oxley Act
    of 2002, or the Sarbanes-Oxley Act, as well as rules and
    regulations implemented by the SEC and the NYSE, require
    significantly heightened corporate governance practices to be
    kept by public companies. We expect that these rules and
    regulations will increase our legal, accounting and financial
    compliance costs and will make certain corporate activities more
    time-consuming and costly. Compliance with these rules and
    requirements may be especially difficult and costly for us
    because we may have difficulty locating sufficient personnel in
    China with experience and expertise relating to U.S.&#160;GAAP
    and U.S.&#160;public-company reporting requirements, and such
    personnel may command high salaries relative to what similarly
    experienced personnel would command in the United States. If we
    cannot employ sufficient personnel to ensure compliance with
    these rules and regulations, we may need to rely more on outside
    legal, accounting and financial experts, which may be very
    costly. In addition, we will incur additional costs associated
    with our public company reporting requirements. We cannot
    predict or estimate the amount of additional costs that we may
    incur or the timing of such costs. If we fail to comply with
    these rules and requirements, or are perceived to have
    weaknesses with respect to our compliance, we could become the
    subject of a governmental enforcement action and investor
    confidence could be negatively impacted and the market price of
    our ADSs could decline.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    44
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='103'>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SPECIAL
    NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus contains forward-looking statements that relate
    to our current expectations and views of future events. The
    forward-looking statements are contained principally in the
    sections entitled &#147;Prospectus Summary,&#148; &#147;Risk
    Factors,&#148; &#147;Use of Proceeds,&#148;
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations&#148;, &#147;Our
    Industry&#148; and &#147;Business.&#148; These statements relate
    to events that involve known and unknown risks, uncertainties
    and other factors, including those listed under &#147;Risk
    Factors,&#148; which may cause our actual results, performance
    or achievements to be materially different from any future
    results, performance or achievements expressed or implied by the
    forward-looking statements.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In some cases, these forward-looking statements can be
    identified by words or phrases such as &#147;may,&#148;
    &#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148;
    &#147;aim,&#148; &#147;estimate,&#148; &#147;intend,&#148;
    &#147;plan,&#148; &#147;believe,&#148; &#147;potential,&#148;
    &#147;continue,&#148; &#147;is/are likely to&#148; or other
    similar expressions. We have based these forward-looking
    statements largely on our current expectations and projections
    about future events and financial trends that we believe may
    affect our financial condition, results of operations, business
    strategy and financial needs. These forward-looking statements
    include, among other things, statements relating to:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the risks, challenges and uncertainties in the radiotherapy and
    diagnostic imaging industry and for our business generally;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our beliefs regarding our strengths and strategies;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our current expansion strategy, including our ability to expand
    our network of centers and to establish specialty cancer
    hospitals;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to maintain strong working relationships with our
    hospital partners;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our expectations regarding patients&#146; and their referring
    doctors&#146; demand for and acceptance of the radiotherapy and
    diagnostic imaging services offered by our centers;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in the healthcare industry in China, including changes
    in the healthcare policies and regulations of the PRC government;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    technological or therapeutic changes affecting the field of
    cancer treatment and diagnostic imaging;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to comply with all relevant environmental, health
    and safety laws and regulations;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to obtain and maintain permits, licenses and
    registrations to carry on our business;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our planned use of proceeds;
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our future prospects, business development, results of
    operations and financial condition;&#160;and
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    fluctuations in general economic and business conditions in
    China.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The forward-looking statements made in this prospectus relate
    only to events or information as of the date on which the
    statements are made in this prospectus. Except as required by
    law, we undertake no obligation to update or revise publicly any
    forward-looking statements, whether as a result of new
    information, future events or otherwise, after the date on which
    the statements are made or to reflect the occurrence of
    unanticipated events. You should read this prospectus and the
    documents that we reference in this prospectus and have filed as
    exhibits to the registration statement, of which this prospectus
    is a part, completely and with the understanding that our actual
    future results may be materially different from what we expect.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    45
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='104'>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">USE OF
    PROCEEDS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We estimate that we will receive net proceeds from this offering
    of approximately
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million,
    after deducting the underwriting discounts and commissions and
    estimated offering expenses payable by us. These estimates are
    based upon an assumed initial offering price of
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS, the midpoint of the range shown on the front cover page
    of this prospectus. A US$1.00 increase (decrease) in the assumed
    initial public offering price of
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS would increase (decrease) the net proceeds to us from
    this offering by
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million,
    after deducting the estimated underwriting discounts and
    commissions and estimated offering expenses payable by us and
    assuming no exercise of the underwriters&#146; option to
    purchase additional ADSs and no other change to the number of
    ADSs offered by us as set forth on the cover page of this
    prospectus.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to use a portion of the net proceeds we receive from
    this offering for the following purposes:
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approximately US$20&#160;million to US$25&#160;million to
    develop our Chang&#146;an CMS International Cancer
    Center;&#160;and
</TD>
</TR>


<TR style="line-height: 8pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approximately US$25&#160;million to US$30&#160;million to
    develop our Beijing Proton Medical Center.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will use the remaining portion of the net proceeds we receive
    from this offering for the expansion of our network of centers
    and for general corporate purposes, including potential
    acquisitions of, or investments in, other businesses or
    technologies that we believe will complement our current
    operations and expansion strategies.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The foregoing use of our net proceeds from this offering
    represents our current intentions based upon our present plans
    and business condition. The amounts and timing of any
    expenditure will vary depending on the amount of cash generated
    from our operations, competitive developments and the rate of
    growth, if any, of our business. Accordingly, our management
    will have significant discretion in the allocation of the net
    proceeds we will receive from this offering. Depending on future
    events and other changes in the business climate, we may
    determine at a later time to use the net proceeds for different
    purposes. Pending their use, we intend to place our net proceeds
    in short-term bank deposits.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In utilizing the proceeds of this offering, we, as an offshore
    holding company, are permitted under PRC laws and regulations to
    provide funding to our PRC subsidiaries only through loans or
    capital contributions and to other entities only through loans.
    Subject to satisfaction of applicable government registration
    and approval requirements, we may extend inter-company loans to
    our PRC subsidiaries or make additional capital contributions to
    our PRC subsidiaries to fund their capital expenditures or
    working capital. We cannot assure you that we will be able to
    obtain these government registrations or approvals on a timely
    basis, if at all. See &#147;Risk Factors&#160;&#151; Risks
    Related to Doing Business in China&#160;&#151; PRC regulation of
    loans and direct investment by offshore holding companies to PRC
    entities may delay or prevent us from using the proceeds of this
    offering to make loans or additional capital contributions to
    our PRC subsidiaries
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will not receive any of the proceeds from the sale of the
    ADSs by the selling shareholders.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    46
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='105'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DIVIDEND
    POLICY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our board of directors has complete discretion on whether to pay
    dividends on our ordinary shares. If our board of directors
    decides to pay dividends on our ordinary shares, the form,
    frequency and amount will depend upon our future operations and
    earnings, capital requirements and surplus, general financial
    condition, contractual restrictions and other factors that the
    board of directors may deem relevant. Shareholders of our
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares are entitled to an annual dividend
    equal to the higher of (a)&#160;the product of the number of
    ordinary shares into which such Series&#160;A and Series&#160;B
    contingently redeemable convertible preferred shares may then be
    converted multiplied by the dividend amount declared on each
    ordinary share or (b)&#160;the product of the original issuance
    price of each Series&#160;A and Series&#160;B contingently
    redeemable convertible preferred share multiplied by 5%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2009, we declared a dividend on our
    ordinary shares that amounted to an aggregate of approximately
    US$2.4&#160;million, or approximately US$0.0357 per share,
    payable to holders of our ordinary shares on record as of
    November&#160;17, 2009. On November&#160;17, 2009, we also
    declared a dividend that amounted to an aggregate of
    approximately US$1.6&#160;million payable to shareholders of our
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares. Such dividend was declared
    pursuant to rights granted to our Series&#160;A and
    Series&#160;B contingently redeemable convertible preferred
    shareholders. Dividends declared for our ordinary shares and our
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares are expected to be paid on or about
    November&#160;27, 2009. Other than such dividends, we have never
    declared or paid any other dividends since our incorporation,
    nor do we have any present plan to pay any cash dividends on our
    ordinary shares in the foreseeable future. We currently intend
    to retain most, if not all, of our available funds and any
    future earnings to operate and expand our business. If we pay
    any dividends, we will pay our ADS holders to the same extent as
    holders of our ordinary shares, subject to the terms of the
    deposit agreement, including the fees and expenses payable
    thereunder. See &#147;Description of American Depositary
    Shares.&#148; Cash dividends on our ordinary shares, if any,
    will be paid in U.S.&#160;dollars.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are a holding company incorporated in the Cayman Islands. In
    order for us to distribute any dividends to our shareholders and
    ADS holders, we will rely on dividends distributed by our PRC
    subsidiaries. Certain payments from our PRC subsidiaries to us
    are subject to PRC taxes, such as withholding income tax. In
    addition, regulations in the PRC currently permit payment of
    dividends of a PRC company only out of accumulated profits as
    determined in accordance with its articles of association and
    the accounting standards and regulations in China. Each of our
    PRC subsidiaries is required to set aside at least 10% of its
    after-tax profit based on PRC accounting standards every year to
    a statutory common reserve fund until the aggregate amount of
    such reserve fund reaches 50% of the registered capital of such
    subsidiary. Such statutory reserves are not distributable as
    loans, advances or cash dividends. Also, our PRC subsidiaries
    may set aside a portion of its after-tax profits to staff
    welfare and bonus funds, which allocated portion may not be
    distributed as cash dividends. The amount to be provided is
    discretionary and is determined by each such subsidiary&#146;s
    ultimate decision-making body each calendar year. Instruments
    governing debt incurred by our PRC subsidiaries may also
    restrict their ability to pay dividends or make other
    distributions to us. See &#147;Risk Factors&#160;&#151; Risks
    Related to Doing Business in China&#160;&#151; We rely on
    dividends paid by our subsidiaries for our cash needs, and any
    limitation on the ability of our subsidiaries to make payments
    to us could have a material adverse effect on our ability to
    conduct our business.&#148; Under PRC tax law, dividends paid
    from our PRC subsidiaries to us through our Hong Kong
    subsidiary, Cyber Medical Network Limited, or Cyber Medical, are
    subject to a 5% withholding tax, provided that such Hong Kong
    subsidiary is not considered to be a PRC tax resident enterprise
    and is considered to be a &#147;beneficial owner&#148; and
    entitled to treaty benefits under the Double Taxation
    Arrangement (Hong Kong). Any dividends paid by our PRC
    subsidiaries to us through our non-Hong Kong subsidiaries
    outside of China will be subject to a 10% withholding tax,
    provided that such subsidiaries outside of China are not
    considered to be a PRC tax resident enterprise. Such withholding
    tax on dividends may be exempted or reduced by the PRC State
    Council. However, if we or our subsidiaries outside of China are
    considered to be a PRC tax resident enterprise
    &#147;domiciled&#148; in the PRC for tax purposes, then any
    dividends we pay to our overseas shareholders or ADS holders
    that are non-PRC resident enterprise may be regarded as income
    derived from sources within the PRC, and as a result subject to
    PRC withholding tax at a rate of up to 10%. The ultimate tax
    rate will be determined by a treaty between the PRC and the tax
    residence of the holder of the PRC subsidiary. For additional
    information, see &#147;Taxation&#160;&#150; People&#146;s
    Republic of China Taxation.&#148; We are actively monitoring
    withholding taxes and evaluating appropriate organizational
    changes to minimize the corresponding tax impact.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    47
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='106'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CAPITALIZATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our capitalization as of
    September&#160;30, 2009:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on an actual basis; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    on a pro forma as adjusted basis to reflect (i)&#160;the
    automatic conversion of all our outstanding contingently
    redeemable convertible preferred shares into 41,027,400 of our
    ordinary shares immediately upon the completion of this offering
    and (ii)&#160;the issuance and sale
    of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ordinary shares in the form of ADSs by us in this offering,
    assuming an initial public offering price of
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS, the midpoint of the estimated range of the initial
    public offering price, after deducting estimated underwriting
    discounts and commissions and estimated aggregate offering
    expenses payable by us and assuming no exercise of the
    underwriters&#146; option to purchase additional ADSs and no
    other change to the number of ADSs sold by us as set forth on
    the cover page of this prospectus.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The pro forma and pro forma as adjusted information below is
    illustrative only and our capitalization following the
    completion of this offering is subject to adjustment based on
    the actual initial public offering price of our ADSs and other
    terms of this offering determined at pricing. You should read
    this table together with our consolidated financial statements
    and the related notes included elsewhere in this prospectus and
    the information under &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations.&#148;
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="60%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of September&#160;30, 2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Actual</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Pro Forma as Adjusted</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term bank borrowings, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Obligations under capitalized leases, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;A contingently redeemable convertible preferred
    shares: US$0.01&#160;par value, 200,000&#160;shares authorized;
    176,942&#160;shares issued and outstanding on an actual basis;
    and nil shares issued and outstanding on a pro forma as adjusted
    basis
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    269,017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;B contingently redeemable convertible preferred
    shares: US$0.01&#160;par value, 300,000&#160;shares authorized;
    233,332&#160;shares issued and outstanding on an actual basis;
    and nil shares issued and outstanding on a pro forma as adjusted
    basis
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    434,036
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ordinary shares: US$0.0001&#160;par value,
    450,000,000&#160;shares authorized; 70,428,100&#160;shares
    issued and outstanding on an actual basis;
    and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    issued and outstanding on a pro forma as adjusted
    basis<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Additional paid-in
    capital<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accumulated other comprehensive (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (592
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (591
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (517,640
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75,831
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (517,640
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75,831
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total shareholders&#146;
    equity<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    591,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
    capitalization<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,408,266
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    206,303
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">On November&#160;17, 2009, we
    effected a share split whereby all of our issued and outstanding
    704,281 ordinary shares of a par value of US$0.01 per share were
    split into 70,428,100 ordinary shares of US$0.0001 par value per
    share and the number of our authorized shares were increased
    from 4,500,000 to 450,000,000. The share split has been
    retroactively reflected in this prospectus so that share number,
    per share price and par value data are presented as if the share
    split had occurred from our inception.
    </FONT></TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Assuming the number of ADSs offered
    by us as set forth on the cover page of this prospectus remains
    the same, and after deduction of underwriting discounts and
    commissions and the estimated offering expenses payable by us, a
    US$1.00 increase (decrease) in the assumed initial public
    offering price of
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS would increase (decrease) each of additional paid-in
    capital, total shareholders&#146; equity and total
    capitalization by
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    48
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='107'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DILUTION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you invest in our ADSs, your interest will be diluted to the
    extent of the difference between the initial public offering
    price per ADS and our net tangible book value per ADS after this
    offering. Dilution results from the fact that the initial public
    offering price per ordinary share is substantially in excess of
    the book value per ordinary share attributable to the existing
    shareholders for our presently outstanding ordinary shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our net tangible book value as of September&#160;30, 2009 was
    approximately RMB806.4&#160;million (US$118.1&#160;million), or
    RMB11.45 (US$1.68) per ordinary share and
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS. Net tangible book value represents the amount of our
    total consolidated tangible assets, minus the amount of our
    total consolidated liabilities. Without taking into account any
    other changes in such net tangible book value after
    September&#160;30, 2009 other than to give effect to (i) the
    conversion of all of our outstanding contingently redeemable
    convertible preferred shares into ordinary shares, which will
    occur upon the completion of this offering, and (ii) our sale of
    the ADSs offered in this offering at the assumed initial public
    offering price of
    $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS, the midpoint of the estimated range of the initial
    public offering price, and after deduction of underwriting
    discounts and commissions and estimated offering expenses of
    this offering payable by us, our adjusted net tangible book
    value as of September&#160;30, 2009 would have increased to
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    million or
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ordinary share and
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS. This represents an immediate increase in net tangible
    book value of
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ordinary share and
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS, to the existing shareholder and an immediate dilution
    in net tangible book value of
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ordinary share and
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS, to investors purchasing ADSs in this offering. The
    following table illustrates such per share dilution:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Estimated initial public offering price per ordinary share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net tangible book value per ordinary share as of
    September&#160;30, 2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amount of dilution in net tangible book value per ordinary share
    to new investors in this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amount of dilution in net tangible book value per ADS to new
    investors in this offering
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A US$1.00 increase (decrease) in the assumed initial public
    offering price of
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS would increase (decrease) our pro forma net tangible
    book value after giving effect to the offering by
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million,
    or by
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ordinary share and by
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS, assuming no change to the number of ADSs offered by us
    as set forth on the cover page of this prospectus, and after
    deducting underwriting discounts and commissions and other
    expenses of the offering. The pro forma information discussed
    above is illustrative only. Our net tangible book value
    following the completion of this offering is subject to
    adjustment based on the actual initial public offering price of
    our ADSs and other terms of this offering determined at pricing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table summarizes, on a pro forma basis as of
    September&#160;30, 2009, the differences between existing
    shareholders and the new investors with respect to the number of
    ordinary shares (in the form of ADSs or shares) purchased from
    us, the total consideration paid and the average price per
    ordinary share and per ADS. In the case of ADS purchased by new
    investors, the consideration and price amounts are paid before
    deducting estimated underwriting discounts and commissions and
    estimated offering expenses, assuming an initial public offering
    price of
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS, the midpoint of the estimated range of the initial
    public offering price. The total number of ordinary shares in
    the following table does not include ordinary shares underlying
    the ADSs issuable upon the exercise of the option to purchase
    additional ADSs granted to the underwriters. The information in
    the following table is illustrative only and the total
    consideration paid and the average price per ordinary share and
    per
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    49
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    ADS for new investors is subject to adjustment based on the
    actual initial public offering price of our ADSs and the number
    of ordinary shares newly issued and to be sold in this offering
    as determined at pricing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="28%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Ordinary Shares Purchased</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total Consideration</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>per Ordinary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Number</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Percent</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Amount</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Percent</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Share</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">per ADSs</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Existing shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    New investors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A US$1.00 increase (decrease) in the assumed initial public
    offering price of
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS would increase (decrease) total consideration paid by
    new investors, total consideration paid by all shareholders and
    the average price per ADS paid by all shareholders by
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million,
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;million
    and
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
    respectively, assuming no change in the number of ADSs sold by
    us as set forth on the cover page of this prospectus and without
    deducting underwriting discounts and commissions and other
    expenses of the offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The dilution to new investors will be
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ordinary share and
    US$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    per ADS, if the underwriters exercise in full their option to
    purchase additional ADSs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The discussion and tables above also assume no exercise of any
    outstanding share options. As of September&#160;30, 2009, there
    were 4,765,800&#160;ordinary shares available for future
    issuance upon the exercise of future grants under our share
    incentive plan. To the extent that any of these options are
    granted and exercised, there will be further dilution to new
    investors.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    50
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='108'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXCHANGE
    RATE INFORMATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business is primarily conducted in China and all of our
    revenues are denominated in Renminbi. Periodic reports made to
    shareholders will be expressed in Renminbi with translations of
    Renminbi amounts into U.S.&#160;dollars at the then current
    exchange rate solely for the convenience of the reader.
    Conversions of Renminbi into U.S.&#160;dollars in this
    prospectus are based on, for all dates through December&#160;31,
    2008, at the noon buying rate in the City of New York for cable
    transfers in Renminbi per U.S.&#160;dollar as certified for
    customs purposes by the Federal Reserve Bank of New York, or the
    noon buying rate, and for January&#160;1, 2009 and all later
    dates and periods, the noon buying rate as set forth in the H.10
    statistical release of the Federal Reserve Board. Unless
    otherwise noted, all translations from Renminbi to
    U.S.&#160;dollars and from U.S.&#160;dollars to Renminbi in this
    prospectus were made at a rate of RMB6.8262 to US$1.00, the noon
    buying rate in effect as of September&#160;30, 2009. We make no
    representation that any Renminbi or U.S.&#160;dollar amounts
    could have been, or could be, converted into U.S.&#160;dollars
    or Renminbi, as the case may be, at any particular rate, the
    rates stated below, or at all. The PRC government imposes
    control over its foreign currency reserves in part through
    direct regulation of the conversion of Renminbi into foreign
    exchange and through restrictions on foreign trade. On
    November&#160;13, 2009, the noon buying rate was RMB6.8260 to
    US$1.00.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information concerning exchange
    rates between the RMB and the U.S.&#160;dollar for the periods
    indicated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="53%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Noon Buying Rate</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Period</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Period End</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Average<SUP style="font-size: 85%; vertical-align: top">(1)</SUP></FONT></B>

</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Low</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">High</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom">
    <B>(RMB per US$1.00)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2004
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2768
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2774
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2005
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.0702
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.1826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.0702
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2006
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.8041
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.9579
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.0702
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.8041
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.2946
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.5806
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.8127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.2946
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.9193
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.2946
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.7800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009 (through September&#160;30)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8470
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    May
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8227
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8221
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8265
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    June
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8302
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8334
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8371
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8264
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    July
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8319
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.9186
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8342
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    August
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8299
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8323
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8299
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    September
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8303
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    October
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8264
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8292
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8248
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    November (through November&#160;13)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8260
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8265
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 9pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 9pt">Annual averages are calculated from
    month-end rates. Monthly averages are calculated using the
    average of the daily rates during the relevant period.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    51
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='109'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">ENFORCEABILITY
    OF CIVIL LIABILITIES</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are incorporated in the Cayman Islands to take advantage of
    certain benefits associated with being a Cayman Islands exempted
    company, such as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    political and economic stability;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an effective judicial system;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a favorable tax system;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the absence of exchange control or currency restrictions; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the availability of professional and support services.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, certain disadvantages accompany incorporation in the
    Cayman Islands. These disadvantages include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the Cayman Islands has a less developed body of securities laws
    as compared to the United States and provides significantly less
    protection to investors;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Cayman Islands companies do not have standing to sue before the
    federal courts of the United States.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our constituent documents do not contain provisions requiring
    that disputes, including those arising under the securities laws
    of the United States, between us, our officers, directors and
    shareholders, be arbitrated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Substantially all of our current operations are conducted in
    China, and substantially all of our assets are located in China.
    A majority of our directors and officers are nationals or
    residents of jurisdictions other than the United States and a
    substantial portion of their assets are located outside the
    United States. As a result, it may be difficult for a
    shareholder to effect service of process within the United
    States upon us or such persons, or to enforce against us or them
    judgments obtained in United States courts, including judgments
    predicated upon the civil liability provisions of the securities
    laws of the United States or any state in the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have appointed National Registered Agents, Inc. as our agent
    to receive service of process with respect to any action brought
    against us in the United States District Court for the Southern
    District of New York under the federal securities laws of the
    United States or of any state in the United States or any action
    brought against us in the Supreme Court of the State of New York
    in the County of New York under the securities laws of the State
    of New York.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Walkers, our counsel as to Cayman Islands law, and
    Jingtian&#160;&#038; Gongcheng Attorneys At Law, our counsel as
    to PRC law, have advised us, respectively, that there is
    uncertainty as to whether the courts of the Cayman Islands and
    the PRC, respectively, would:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    recognize or enforce judgments of United States courts obtained
    against us or our directors or officers predicated upon the
    civil liability provisions of the securities laws of the United
    States or any state in the United States;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    entertain original actions brought in each respective
    jurisdiction against us or our directors or officers predicated
    upon the securities laws of the United States or any state in
    the United States.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Walkers has further advised us that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a final and conclusive judgment in the federal or state courts
    of the United States under which a sum of money is payable,
    other than a sum payable in respect of taxes, fines, penalties
    or similar charges, and which was neither obtained in a waiver
    nor is of a kind of enforcement which is contrary to natural
    justice or the public policy of the Cayman Islands, may be
    subject to enforcement proceedings as a debt in the courts of
    the Cayman Islands under common law; and
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    52
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    it is unlikely that a monetary award ordered by a
    U.S.&#160;court as a result of a fine or a penalty arising under
    the U.S.&#160;federal securities laws would be recognized as
    valid, or enforced, by the courts of the Cayman Islands.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Jingtian&#160;&#038; Gongcheng Attorneys At Law has advised us
    further that the recognition and enforcement of foreign
    judgments are provided for under the PRC Civil Procedures Law.
    PRC courts may recognize and enforce foreign judgments in
    accordance with the requirements of the PRC Civil Procedures Law
    based either on treaties between the PRC and the country where
    the judgment is made or on reciprocity between jurisdictions,
    provided that the foreign judgments do not violate the basic
    principles of laws of the PRC or its sovereignty, security or
    social and public interests. As there is currently no treaty or
    other form of reciprocity between the PRC and the United States
    governing the recognition of judgments, there is uncertainty on
    whether
    <FONT style="white-space: nowrap">and/or</FONT> upon
    what basis a PRC court would enforce judgments rendered by
    courts in the United States.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    53
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='110'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">OUR
    HISTORY AND CORPORATE STRUCTURE</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    History</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Concord Medical was incorporated in the Cayman Islands on
    November&#160;27, 2007 and became our ultimate holding company
    on March&#160;7, 2008, when the shareholders of Ascendium, a
    holding company incorporated in the British Virgin Islands on
    September&#160;10, 2007, exchanged all of their shares for
    shares of Concord Medical. Prior to that, on October&#160;30,
    2007, Ascendium had acquired 100% of the equity interest in Our
    Medical Services, Ltd., or OMS, resulting in a change in
    control. We refer to this transaction as the OMS reorganization
    in this prospectus. Prior to the OMS reorganization, OMS,
    together with Aohua Medical, in which OMS effectively held all
    of the equity interest at the time, operated all of our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aohua Medical was incorporated by OMS on July&#160;23, 1997 and
    OMS contributed RMB4.8&#160;million to Aohua Medical,
    representing 90% of the equity interest in Aohua Medical. The
    other 10% of Aohua Medical was held by two nominees who acted as
    the custodians of such equity interest. On June&#160;10, 2009,
    this 10% equity interest was transferred to our subsidiary
    Shenzhen Aohua Medical Leasing and Services Co., Ltd., or Aohua
    Leasing. The two nominees have not maintained their required
    capital contributions at any time subsequent to the
    incorporation of Aohua Medical. Due to this capital deficiency
    as well as other legal conditions, the two nominees had no legal
    rights to participate either retrospectively or prospectively at
    any time in any profits or losses of Aohua Medical or to share
    in any residual assets or any proceeds in the event that Aohua
    Medical encountered a liquidation event. For these reasons, we
    do not account for this 10% equity interest as a minority
    interest in our consolidated results of operations or financial
    position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, our subsidiary Ascendium acquired 100% of
    the equity interest in China Medstar, a Singapore company,
    together with its wholly owned PRC subsidiary, Medstar
    (Shanghai) Leasing Co., Ltd., or Shanghai Medstar, for
    approximately &#163;17.1&#160;million or approximately
    RMB238.7&#160;million (US$35.0&#160;million). China Medstar,
    through its then subsidiary Shanghai Medstar, engaged in the
    provision of medical equipment leasing and management services
    to hospitals in the PRC. On August&#160;17, 2009, 100% of the
    equity interest in Shanghai Medstar was transferred from China
    Medstar to Ascendium.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;28, 2008, we acquired control of Beijing Xing
    Heng Feng Medical Technology Co., Ltd., or Xing Heng Feng
    Medical, through our subsidiaries Aohua Leasing and CMS Hospital
    Management Co., Ltd., or CMS Hospital Management, by acquiring
    100% of its equity interest, which corresponded to its then
    paid-in registered capital. We paid total consideration of
    approximately RMB35.0&#160;million (US$5.1&#160;million) for
    this acquisition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We currently conduct substantially all of our operations through
    the following subsidiaries in the PRC:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Shenzhen Aohua Medical Services Co., Ltd., our wholly owned
    subsidiary incorporated in the PRC that engages in the provision
    of radiotherapy and diagnostic center management services to
    hospitals in the PRC;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Shenzhen Aohua Medical Leasing and Services Co., Ltd., our
    wholly owned subsidiary incorporated in the PRC that engages in
    the provision of radiotherapy and diagnostic equipment leasing
    services to hospitals in the PRC;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Medstar (Shanghai) Leasing Co., Ltd., our wholly owned
    subsidiary incorporated in the PRC that engages in the sale of
    medical equipment and the provision of radiotherapy and
    diagnostic equipment leasing and management services to
    hospitals in the PRC;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    CMS Hospital Management Co., Ltd., our wholly owned subsidiary
    incorporated in the PRC that engages in the provision of
    radiotherapy and diagnostic equipment management services to
    hospitals in the PRC;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Beijing Xing Heng Feng Medical Technology Co., Ltd., our wholly
    owned subsidiary incorporated in the PRC that engages in the
    provision of radiotherapy and diagnostic equipment management
    services to hospitals in the PRC.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    54
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Corporate Structure</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following diagram illustrates our corporate structure and
    the place of organization of each of our subsidiaries as of the
    date of this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611h0361101.gif" alt="">
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    55
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='111'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SELECTED
    CONSOLIDATED FINANCIAL AND OPERATING DATA</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following tables set forth the selected consolidated
    financial and operating data of us and our predecessor, OMS, for
    the periods indicated. Concord Medical was incorporated on
    November&#160;27, 2007. On March&#160;7, 2008, the shareholders
    of Ascendium exchanged their shares in Ascendium for shares of
    Concord Medical at the rate of 10&#160;shares in Concord Medical
    for one share in Ascendium. As a result, Concord Medical became
    our ultimate holding company. Our financial statements have been
    prepared as if the current corporate structure had been in
    existence from September&#160;10, 2007, the date on which
    Ascendium was incorporated. Prior to the OMS reorganization,
    which became effective on October&#160;30, 2007, OMS, together
    with Aohua Medical, in which OMS effectively held all of the
    equity interest at the time, operated all of the business of our
    company. As a result of the OMS reorganization, there was a
    change in control of OMS with the Ascendium shareholders
    effectively acquiring OMS from the OMS shareholders. For
    additional information relating to our history and
    reorganization, see &#147;Our History and Corporate
    Structure.&#148; For financial statements reporting purposes,
    OMS is deemed to be the predecessor reporting entity for periods
    prior to October&#160;30, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following selected consolidated statements of operations and
    other consolidated financial data for the period from
    January&#160;1, 2007 to October&#160;30, 2007, for the period
    from September&#160;10, 2007 to December&#160;31, 2007 and for
    the year ended December&#160;31, 2008 (other than the net loss
    per ADS data) and the selected consolidated balance sheet data
    as of December&#160;31, 2007 and 2008 have been derived from our
    audited consolidated financial statements, which are included
    elsewhere in this prospectus. The following selected
    consolidated statements of operations for the year ended
    December&#160;31, 2006 and the selected consolidated balance
    sheet data as of December&#160;31, 2006 have been derived from
    our unaudited consolidated financial statements, which are not
    included in this prospectus. The following selected consolidated
    statements of operations and other consolidated financial data
    for the nine months ended September&#160;30, 2008 and 2009
    (other than the net loss per ADS data) and selected consolidated
    balance sheet data as of September&#160;30, 2009 have been
    derived from our unaudited interim condensed consolidated
    financial statements, which are included elsewhere in this
    prospectus. We have prepared the unaudited interim condensed
    consolidated financial statements on the same basis as our
    audited consolidated financial statements. The unaudited interim
    condensed consolidated financial statements include all
    adjustments, consisting only of normal and recurring
    adjustments, which we consider necessary for a fair presentation
    of our financial position and operating results for the periods
    presented. You should read the selected consolidated financial
    data in conjunction with those financial statements and the
    related notes and &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations&#148;
    included elsewhere in this prospectus. Our historical results do
    not necessarily indicate our results expected for any future
    periods. Our consolidated financial statements are prepared and
    presented in accordance with U.S.&#160;GAAP. The consolidated
    financial statements of each of us and our predecessor are
    prepared and presented in accordance with U.S.&#160;GAAP. Our
    historical results are not necessarily indicative of our results
    expected for any future periods.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    56
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="32%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="33" nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>October&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Year Ended December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="31" nowrap align="center" valign="bottom">
    <B>(in thousands, except share, per share and per ADS data) </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    <B>Selected Consolidated Statements of Operations Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Revenues, net of business tax, value-added tax and related
    surcharges:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61,440
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,716
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,092
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    876
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,422
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    205,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,388
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,396
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,046
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,669
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (42,144
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,174
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,003
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,388
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,987
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,412
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,416
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,914
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,597
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,680
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,361
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (62,541
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,162
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Gross profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,904
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,632
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143,116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,267
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,601
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (757
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (805
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,275
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,463
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (654
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    General and administrative
    expenses<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,600
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,467
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (57,171
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,764
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,468
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,687
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,884
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Operating income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,037
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,938
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (47,859
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,710
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (954
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (279
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,455
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,092
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,293
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,880
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (715
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (341
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (460
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (325
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (218
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    (Loss) gain from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (469
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    392
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    823
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Other income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income (loss) before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,926
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,627
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,691
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income tax (expenses) benefit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,097
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,418
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,611
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,734
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,770
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Net income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,343
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (39,604
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (262,286
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,851
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (44,646
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (38,383
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,623
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Net income (loss) attributable to ordinary shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (496,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72,667
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (222,270
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,914
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Earning (loss) per share&#160;&#151; basic and
    diluted<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.97
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.26
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.06
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Earning (loss) per ADS&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Shares used in computation&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,621,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    ADSs used in computation&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Our general and administrative
    expenses include share-based compensation expenses related to
    certain share options granted in 2007 that amounted to
    RMB49.5&#160;million, RMB4.2&#160;million (US$0.6&#160;million)
    and RMB4.2&#160;million in 2007, 2008 and for the nine months
    ended September&#160;30, 2008, respectively. We did not
    recognize any share-based compensation expenses in 2006 and for
    the nine months ended September&#160;30, 2009.
    </FONT></TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt"> On November&#160;17, 2009, we
    effected a share split whereby all of our issued and outstanding
    704,281 ordinary shares of a par value of US$0.01 per share were
    split into 70,428,100 ordinary shares of US$0.0001 par value per
    share and the number of our authorized shares were increased
    from 4,500,000 to 450,000,000. The share split has been
    retroactively reflected in this prospectus so that share number,
    per share price and par value data are presented as if the share
    split had occurred from our inception.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    57
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2006</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Selected Consolidated Balance Sheet Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    285,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,333
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,135
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    492,978
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72,219
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    466,487
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Property, plant and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    231,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    349,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,661
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Acquired intangible assets, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    181,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,450
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    256,330
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543,023
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,673,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Long-term bank borrowings, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,836
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Long-term bank borrowings, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,635
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Series&#160;A contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    269,017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,409
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Series&#160;B contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    434,036
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total shareholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    134,264
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    591,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total liabilities and shareholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    256,330
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543,023
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,673,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="23%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="29" align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>October&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Selected Consolidated Statements of Cash Flow Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,774
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,308
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash used in investing
    activities<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (50,452
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30,441
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (376,371
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (55,136
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (300,692
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (223,426
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32,731
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    649,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95,147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    278,407
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,448
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,698
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (834
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,949
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (191
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net increase (decrease) in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    314,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (864
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68,288
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,004
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Net cash used in investing
    activities in 2008 and for the nine months ended September 30,
    2008 and 2009 includes acquisition, net of cash acquired, of
    RMB231.5&#160;million (US$33.9&#160;million).
    RMB219.2&#160;million and RMB21.5&#160;million
    (US$3.2&#160;million), respectively.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    58
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="48%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As of September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-size: 9pt">Operating
    Data<SUP style="font-size: 85%; vertical-align: top">(1)</SUP></FONT></B>

</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Number of primary medical equipment owned:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Linear accelerators
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Head gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Body gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    PET-CT scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    MRI scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Others<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    64
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="48%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Number of patient cases treated or diagnosed by our primary
    medical equipment:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Linear accelerators
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    697
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,554
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Head gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,455
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Body gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,635
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,057
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,706
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    PET-CT scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,766
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    MRI scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,830
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,827
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="29%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD colspan="26" align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from <BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>September&#160;1,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>to October&#160;30,<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD colspan="26" align="center" valign="bottom">
    &nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="24" align="center" valign="bottom">
    <B>(in RMB thousands)</B>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total net revenues generated by our primary medical equipment
    under lease and management services arrangements:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Linear accelerators
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,206
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    877
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,506
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,588
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Head gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,408
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,139
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Body gamma knife systems
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,537
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,102
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,071
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    PET-CT scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    578
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,289
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    MRI scanners
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,899
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    437
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,123
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,515
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,618
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Others<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    391
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,423
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,755
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,970
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Total net revenues&#160;&#151; lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Excluding data from seven, eight
    and two centers under service-only agreements as of
    December&#160;31, 2007, December&#160;31, 2008 and
    September&#160;30, 2009, respectively.
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Other primary medical equipment
    used includes CT scanners and ECT scanners for diagnostic
    imaging, electroencephalography for the diagnosis of epilepsy,
    thermotherapy to increase the efficacy of and for pain relief
    after radiotherapy and chemotherapy, high intensity focused
    ultrasound therapy for the treatment of cancer, stereotactic
    radiofrequency ablation for the treatment of Parkinson&#146;s
    Disease and refraction and tonometry for the diagnosis of
    ophthalmic conditions.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    59
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='112'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANAGEMENT&#146;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION<BR>
    AND RESULTS OF OPERATIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>You should read the following discussion and analysis of our
    financial condition and results of operations in conjunction
    with the section entitled &#147;Selected Consolidated Financial
    Data&#148; and our consolidated financial statements and the
    related notes included elsewhere in this prospectus. This
    discussion contains forward-looking statements that involve
    risks and uncertainties. Our actual results and the timing of
    selected events could differ materially from those anticipated
    in these forward-looking statements as a result of various
    factors, including those set forth under &#147;Risk
    Factors&#148; and elsewhere in this prospectus.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Concord Medical was incorporated on November&#160;27, 2007. On
    March&#160;7, 2008, the shareholders of Ascendium exchanged
    their shares in Ascendium for shares of Concord Medical. As a
    result, Concord Medical became our ultimate holding company. Our
    financial statements have been prepared as if the current
    corporate structure had been in existence from
    September&#160;10, 2007, the date on which Ascendium was
    incorporated. Prior to the OMS reorganization, which became
    effective on October&#160;30, 2007, OMS, together with Aohua
    Medical, in which OMS effectively held all of the equity
    interest at the time, operated all of the business of our
    company. As a result of the OMS reorganization, there was a
    change in control of OMS with the Ascendium shareholders
    effectively acquiring OMS from the OMS shareholders. For
    additional information relating to our history and
    reorganization, see &#147;Our History and Corporate
    Structure.&#148; In our discussion for the year ended
    December&#160;31, 2007, we refer to certain financial statement
    line items as &#147;combined&#148; for comparative purposes,
    which do not comply with U.S.&#160;GAAP. The unaudited combined
    amounts represent the addition of the amounts for certain
    financial statement line items of OMS, our predecessor, for the
    period from January&#160;1, 2007 to October&#160;30, 2007, and
    the amounts for the corresponding line items of Concord Medical
    for the period from September&#160;10, 2007 to December&#160;31,
    2007. We have included these unaudited combined amounts as we
    believe they are helpful for the reader to gain a better
    understanding of results of operations for a complete fiscal
    year and to improve the comparative analysis against the results
    of operations for the year ended December&#160;31, 2008. These
    unaudited combined amounts do not purport to represent what our
    financial position, results of operations or cash flows would
    have been if our reorganization had occurred on January&#160;1,
    2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We operate the largest network of radiotherapy and diagnostic
    imaging centers in China in terms of revenues and the total
    number of centers in operation in 2008, according to a report by
    Frost&#160;&#038; Sullivan commissioned by us. Most of the
    centers in our network are established through long-term lease
    and management services arrangements typically ranging from six
    to 20&#160;years entered into with hospitals. Under these
    arrangements, we receive a contracted percentage of each
    center&#146;s revenue net of specified operating expenses. Such
    contracted percentages typically range from 50% to 90% and are
    adjusted based on a declining scale over the term of the
    arrangement but in certain circumstances, are fixed for the
    duration of the arrangement. Each center is located on the
    premises of our hospital partners and is typically equipped with
    a primary unit of advanced radiotherapy or diagnostic imaging
    equipment, such as a linear accelerator, head gamma knife
    system, body gamma knife system, PET-CT scanner or MRI scanner.
    We manage each center jointly with our hospital partner and we
    purchase the medical equipment used in our network of centers
    and lease such equipment to our hospital partners.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To complement our organic growth, we have also selectively
    acquired businesses to expand our network. In July 2008, we
    acquired China Medstar, a company then publicly listed on the
    AIM, for approximately &#163;17.1&#160;million or approximately
    RMB238.7&#160;million (US$35.0&#160;million). At the time of the
    acquisition, China Medstar jointly managed 23 centers with its
    hospital partners across 14&#160;cities in China. In addition to
    our acquisition of China Medstar, we have also acquired other
    businesses in 2008, including Xing Heng Feng Medical, a company
    that managed two centers providing
    <FONT style="white-space: nowrap">PET-CT</FONT> scan
    diagnosis with its hospital partners, in October 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To further enhance our reputation as a leading provider of
    radiotherapy treatment service and attract high quality doctors,
    we plan to establish and operate specialty cancer hospitals in
    China. Our first specialty cancer hospital, the Chang&#146;an
    CMS International Cancer Center, in Xi&#146;an, Shaanxi
    Province, is expected to commence operation in early 2010. In
    addition, we are in the process of establishing another
    specialty cancer hospital, the Beijing Proton Medical Center,
    which is expected to commence operation in 2012.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    60
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business has grown significantly in recent years through
    development of new centers, increases in the number of patient
    cases in our network and acquisitions. We have increased the
    number of centers in our network from 41 at the end of 2007 to
    72&#160;at the end of 2008 and to 83 as of September&#160;30,
    2009. Our total net revenues were RMB67.4&#160;million,
    RMB14.0&#160;million and RMB171.8&#160;million
    (US$25.2&#160;million) for the period from January&#160;1, 2007
    to October&#160;30, 2007, the period from September&#160;10,
    2007 to December&#160;31, 2007 and in 2008, respectively. Our
    total net revenues in 2008 on a pro forma basis, which gives
    effect to our acquisition of China Medstar as if it had been
    completed on January&#160;1, 2008, were RMB234.7&#160;million
    (US$34.4&#160;million). Our total net revenues increased to
    RMB205.7&#160;million (US$30.1&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB102.0&#160;million for the
    same period in 2008, due primarily to an increase in the number
    of centers in our network, including centers added to our
    network as a result of our acquisition of China Medstar, and an
    increase in the number of patient cases in existing centers. On
    a pro forma basis, which gives effect to our acquisition of
    China Medstar as if it had been completed on January 1, 2008,
    our total net revenues for the nine months ended
    September&#160;30, 2008 were RMB164.9&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Factors
    Affecting Our Results of Operations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our financial performance and results of operations are
    generally affected by the number of cancer patients in China.
    According to a report by Frost&#160;&#038; Sullivan, patients
    diagnosed with cancer in China increased from approximately
    2.8&#160;million patients in 2003 to 3.5&#160;million patients
    in 2008. Frost&#160;&#038; Sullivan further estimates that new
    cancer cases will increase to approximately 4.1&#160;million in
    China in 2015. Based on a survey conducted by the MOH, the
    increase in cancer cases is primarily attributable to
    demographic changes and urbanization. With the continued
    increase in disposable income, government healthcare spending
    and medical insurance coverage, there has been a considerable
    increase in demand for cancer diagnosis and treatments and we
    have been able to grow our business significantly by providing
    high quality radiotherapy and diagnostic imaging services in
    China to address such needs. In addition, public hospitals
    generally lack the financial resources to purchase, or the
    expertise to operate, radiotherapy and diagnostic imaging
    centers. Such factors combined have contributed favorably to the
    growth of our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the radiotherapy and diagnostic imaging market
    will continue to be favorable in the future. However, changes in
    the cancer treatment market in China, whether due to changes in
    government policy or any decrease in the number of cancer cases
    treated by radiotherapy in China, may have an adverse effect on
    our results of operations. See &#147;Regulation of Our
    Industry.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to general industry and regulatory factors, our
    financial performance and results of operations are affected by
    company-specific factors. We believe that the most significant
    of these factors are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to expand our network of centers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the number of patient cases treated in our network;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the operational arrangements with our hospital partners;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the range and mix of services provided in our network;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the cost of our medical equipment.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    Ability to Expand Our Network of Centers</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our ability to expand our network of centers is one of the most
    important factors affecting our results of operation and
    financial condition. Historically, our business growth has been
    primarily driven by developing new centers through entering into
    new arrangements with hospital partners or acquisitions from
    third parties and we expect this to continue to be the key
    driver for our future growth. Each additional center that we
    develop increases the number of patient cases treated in our
    network and contributes to our continued revenue growth.
    However, new centers developed through our entering into new
    arrangements with hospital partners generally involve a ramp-up
    period during which time the operating efficiency of such
    centers may be lower than that of our established centers, which
    may negatively affect our profitability. In addition, if we
    establish additional centers through acquisition, our acquired
    intangible assets will increase and the resulting amortization
    expenses may, to a significant extent, offset
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    61
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    the benefit of the increase in revenues generated from centers
    established through acquisitions. Further, other factors such as
    the financial resources and know-how of hospitals in China to
    purchase medical equipment directly and to operate radiotherapy
    and diagnostic imaging centers independently, and the number of
    units of radiotherapy and diagnostic imaging equipment that are
    allocated by the PRC government for purchase, will also affect
    our ability to expand our network. Our ability to expand our
    network will depend on a number of factors, such as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the reputation of our existing network of centers and doctors
    providing services in our network of centers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our financial resources;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to timely establish and manage new centers in
    conjunction with our hospital partners;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our relationship with our hospital partners.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2008, we added 32 new centers under lease and management
    services arrangements, of which 25 were added through various
    acquisitions in 2008. During the nine months ended
    September&#160;30, 2009, we added 19 new centers to our network
    under similar lease and management services arrangements, five
    of which were converted in August 2009 from six centers that
    were previously managed under service-only agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Number of Patient Cases Treated in Our Network</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Increasing the number of patient cases diagnosed and treated at
    our existing centers is important for the continued growth of
    our business. The number of patient cases is primarily driven by
    doctor referrals. Doctors decide whether to refer patients to
    centers in our network based on factors such as the reputation
    of the center, the location of the center and the reputation of
    the doctors who provide services in the center. In addition, the
    referring doctors&#146; awareness of the efficacy and benefits
    of radiotherapy treatments and their preference as to other
    cancer treatment methods also contribute to their willingness to
    refer cases for diagnosis and treatment to the centers in our
    network. Accordingly, we have focused our marketing efforts on
    increasing referring doctors&#146; awareness of the efficacy of
    radiotherapy treatments and the advantages of the treatment
    options available to their patients in our network of centers.
    There is also typically a
    <FONT style="white-space: nowrap">ramp-up</FONT>
    period for newly established centers during which time
    acceptance by doctors and patients of such new centers gradually
    pick up and the number of patient cases increase.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Operational Arrangements with Our Hospital
    Partners</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The majority of our total net revenues is derived from our lease
    and management services arrangements with our hospital partners
    which typically range from six to 20&#160;years and under which
    we receive a contracted percentage of each center&#146;s revenue
    net of specified operating expenses. Such contracted percentages
    typically ranges from 50% to 90% and are typically adjusted
    based on a declining scale over the term of the arrangement but
    in certain circumstances, are fixed for the duration of the
    arrangement. In the event that specified operating expenses
    exceed the revenues of the center, we would collect no revenues
    from such center. As a result, our ability to negotiate a higher
    contracted percentage and our ability to contain operating
    expenses will have a significant effect on our revenues and
    profitability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In negotiations with hospitals as to our contracted percentage,
    we consider factors such as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the size and location of potential hospital partner;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the length of the arrangement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the type of medical equipment to be installed in the
    hospital&#146;s center;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the capabilities of the doctors that will provide services at
    the centers;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the potential growth of such center.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our ability to achieve a higher contracted percentage also
    depends on our bargaining power relative to our potential
    hospital partners and on the purchase price of the medical
    equipment to be used at the new centers. We believe that our
    contracted percentage of centers&#146; revenue for new
    arrangements will generally decline over time as the purchase
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    62
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    prices of the primary medical equipment used in our network of
    centers decrease due to technological advancement and increased
    competition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also provide management services to a small number of centers
    through service-only agreements where we receive a management
    fee equal to a contracted percentage of each center&#146;s
    revenue net of specified operating expenses. Such service-only
    agreements typically increase our profitability as we do not own
    the medical equipment used by such centers, and thus do not
    incur the associated depreciation expenses. However,
    service-only agreements are usually short-term in nature, and
    the risk of non-renewal of such agreements is high. We also
    typically receive a lower contracted percentage under such
    service-only agreements compared to the percentage we receive
    from centers managed under lease and management services
    arrangements. Accordingly, we do not intend to substantially
    increase the number of service-only agreements in the future. In
    addition, we have in August 2009 converted six centers under
    service-only agreements to five centers managed under lease and
    management services arrangements by purchasing from
    Chang&#146;an Hospital Co., Ltd., or Chang&#146;an Hospital, six
    units of radiotherapy and diagnostic imaging equipment that were
    located at the six centers managed under service-only agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Further, we are also currently in the process of establishing
    specialty cancer hospitals that will be majority owned and
    operated by us. For such hospitals, we will need to hire a
    significant number of medical and other personnel and incur
    other
    <FONT style="white-space: nowrap">start-up</FONT>
    costs that will result in an increase in our operating expenses
    without a corresponding increase in revenues during the initial
    <FONT style="white-space: nowrap">ramp-up</FONT>
    period. As a result, our profitability may be negatively
    affected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Range and Mix of Services Provided in Our Network</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The medical service fees charged for the services provided in
    our network of centers vary by the type of medical equipment
    used as well as the provinces or regions in China in which such
    centers are located due to the varying applicable price
    ceilings. Medical service fees in China are subject to
    government controlled price ceilings established by the relevant
    government authorities in the different provinces and regions.
    See &#147;Regulation of Our Industry&#160;&#151; Pricing of
    Medical Services.&#148; The maximum medical service fees for the
    same treatment using the same equipment may differ between
    provinces and regions. Centers established in provinces or
    regions with a significantly higher price ceiling may result in
    an increase in our revenues derived from such centers and higher
    profit margin for the centers, resulting in an increase in our
    profitability. In addition, certain medical services allow us to
    charge higher fees than other types of medical services. For
    example, medical service fees for treatments provided through
    head gamma knife systems typically range from approximately
    RMB9,000 to RMB20,000 per patient case, with each treatment
    lasting one session for approximately 10 to 30 minutes, medical
    service fees for treatments provided through body gamma knife
    systems typically range from approximately RMB12,500 to
    RMB25,000 per patient case, with each treatment lasting five to
    10 sessions and 10 to 20 minutes each, and medical service fees
    for treatments provided through linear accelerators range from
    approximately RMB8,000 to RMB20,000 per patient case, with each
    treatment lasting from 20 to 40 sessions and 10 to 20 minutes
    each. In addition, linear accelerators can be integrated with
    specialized computer software and advanced imaging and detection
    equipment to provide more effective and advanced treatments such
    as three-dimensional conformal radiation therapy, which
    significantly increase the medical service fees per treatment.
    Furthermore, diagnostic imaging services typically have a lower
    profit margin than radiotherapy treatment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Cost of Our Medical Equipment</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Depreciation expense associated with the medical equipment that
    we purchase and use in the centers represents a significant
    portion of our cost of revenues. Our ability to reduce the price
    of medical equipment purchased, thereby reducing the
    depreciation expense associated with the medical equipment
    purchased, will serve to increase our profitability. Our
    extensive network of centers has provided us with increased
    bargaining power with equipment manufacturers. We have entered
    into strategic agreements with certain medical equipment
    manufacturers in order to lower the average cost of our
    equipment. Such agreements provide that we will receive
    preferential pricing if we purchase a certain number of units of
    equipment from a manufacturer within a given period of time.
    However, we are not required by such agreements to commit to
    purchase a minimum number of units of equipment from such
    manufacturers or precluded from purchasing equipment from other
    manufacturers. We aim to continue to enter into additional
    strategic agreements with medical equipment manufacturers to
    further
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    63
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    reduce the cost of our equipment in the future. Furthermore, we
    expect the purchase prices of our primary medical equipment to
    decrease over time as a result of technological advancement and
    increased competition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Financial
    Impact of Our Reorganization and Acquisitions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to the OMS reorganization on October&#160;30, 2007, OMS,
    together with Aohua Medical, in which OMS effectively held all
    of the equity interest at the time, operated all of our
    business. As part of the OMS reorganization, there was a change
    in control of OMS whereby the Ascendium shareholders effectively
    acquired OMS from the OMS shareholders through the issuance of
    Ascendium shares. For financial statements reporting purposes,
    OMS is deemed to be our predecessor reporting entity for periods
    prior to October&#160;30, 2007. The purchase price for the
    acquisition was determined to be RMB393.4&#160;million
    (US$57.6&#160;million), which represented the fair value of the
    Ascendium shares issued as consideration to the OMS
    shareholders. This transaction established a new basis of
    accounting with the purchase price allocated to OMS&#146;s
    tangible and identifiable intangible assets and liabilities
    based on their estimated fair value as of October&#160;30, 2007,
    including RMB259.3&#160;million as to goodwill,
    RMB132.0&#160;million as to other intangible assets&#160;&#151;
    customer relationships and operating leases and
    RMB53.8&#160;million (new basis) in property, plant and
    equipment. The effect of the new basis includes the reduction of
    the book value of medical equipment used in our network of
    centers to their fair value as at October&#160;30, 2007, which
    reduces the depreciation expenses of the medical equipment, and
    results in an incremental amortization expense of the acquired
    intangible assets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We completed the following acquisition of four businesses in
    2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    China Medstar in July 2008 for approximately
    &#163;17.1&#160;million or approximately RMB238.7&#160;million
    (US$35.0&#160;million);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Xing Heng Feng Medical in October 2008 for approximately
    RMB35.0&#160;million (US$5.1&#160;million);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    certain medical equipment located in Tianjin People&#146;s
    Liberation Army 272 Hospital and the related business from a
    third party for RMB14.0&#160;million
    (US$2.1&#160;million);&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    certain medical equipment located in People&#146;s Liberation
    Army 254 Hospital and the related business from another third
    party for RMB4.0&#160;million (US$0.6&#160;million).
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The consideration paid for each acquisition was allocated to the
    net assets acquired at estimated fair value, with the acquired
    intangible assets amortized over the period of expected benefits
    to be realized. The results of operations of China Medstar were
    consolidated into our results of operations commencing in August
    2008 and the results of operations of Xing Heng Feng Medical
    were consolidated into our results of operations commencing in
    November 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Revenues</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The majority of our revenues are directly related to the number
    of patient cases treated in our network. We receive a contracted
    percentage of each center&#146;s revenue net of specified
    operating expenses. Such revenues are derived from medical
    service fees received by our hospital partners for the services
    provided in the centers. The specified operating expenses of
    centers typically include variable expenses, such as salaries
    and benefits of the medical and other personnel at the center,
    the cost of medical consumables, marketing expenses, training
    expenses, utility expenses and routine equipment repair and
    maintenance expenses. Corporate level expenses that cannot be
    directly attributable to one center are typically accounted for
    as our cost of revenues. In addition, under certain lease and
    management services arrangements with our hospital partners,
    certain of the center-incurred expenses may be accounted for as
    our cost of revenues rather than as the expenses of the centers.
    Our contracted percentages typically range from 50% to 90% and
    are typically adjusted on a declining scale over the term of the
    arrangement. In certain circumstances, the contracted percentage
    is fixed for the duration of the arrangement. Revenues derived
    from such centers are accounted for as &#147;lease and
    management services&#148; on our consolidated statement of
    operation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also provide management services to a limited number of
    centers through service-only agreements under which the medical
    equipment is owned by the hospital or other third parties. We
    typically receive a management fee from each center equal to a
    contracted percentage of the center&#146;s revenue net of
    specified operating expenses. We
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    64
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    also provide management services to Chang&#146;an Hospital
    through a service-only agreement under which we receive a
    management fee equal to a percentage of the total revenues of
    the general hospital. Revenues derived from providing management
    services through service-only agreements are accounted for as
    &#147;management services&#148; on our consolidated statement of
    operation. As of September&#160;30, 2009, we managed two centers
    under service-only agreements. We converted six centers managed
    under service-only agreements in August 2009 to five centers
    managed under lease and management services arrangement by
    purchasing the medical equipment housed in the six centers. As a
    result, we expect our total net revenues from management
    services to decrease in the near future due to a decrease in the
    number of centers under service-only agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also generate revenues, which are reported as net, from the
    sale of medical equipment we have purchased to hospitals and
    receive commissions from manufacturers for acting as their agent
    for the sale of such medical equipment to hospitals. We
    typically enter into a separate purchase agreement with
    manufacturers or the distributors of such manufacturers each
    time we purchase medical equipment for sale.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth the breakdown of our total net
    revenues for the periods indicated:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="23%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=11 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=11 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=11 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=11 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007<SUP style="font-size: 85%; vertical-align: top">(1)</SUP></B>

</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="38" align="center" valign="bottom">
    <B>(in thousands, except for percentages)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,716
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,092
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,322
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,405
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    205,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represent the addition of the
    amounts for the specific line items of OMS, our predecessor, for
    the period from January&#160;1, 2007 to October&#160;30, 2007,
    and the amounts for the corresponding line items of Concord
    Medical for the period from September&#160;10, 2007 to
    December&#160;31, 2007. For the period from September&#160;10,
    2007, the date of inception of Ascendium, to October&#160;30,
    2007, during which period the financial statements of our
    predecessor and those of Concord Medical overlap, Ascendium did
    not engage in any business or operations. The unaudited combined
    financial data for the year ended December&#160;31, 2007 do not
    comply with U.S. GAAP.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Fees for medical services provided at the centers are paid
    directly to our hospital partners by patients and we are not
    responsible for patient billing and fee collection. Medical
    service fees in China are typically paid in full upfront by
    patients prior to receiving services. Generally, patients claim
    reimbursements, if any is available under the applicable public
    or private medical insurance plans. As a result, hospitals do
    not generally experience bad debt problems. However, the
    healthcare reform announced by the PRC government in January
    2009 has introduced pilot public medical insurance plans. Under
    these plans patients are only responsible for paying their
    deductible amounts upfront and hospitals are responsible for
    seeking reimbursements from the relevant government authorities
    after the treatments are provided. Certain of the hospitals in
    which some of the centers in our network are based, as well as
    Chang&#146;an Hospital, are involved in such pilot medical
    insurance plan. We do not expect such change in payment timing
    to have a direct effect on our ability to collect our contracted
    percentage from our hospital partners. However, the ability of
    our hospital partners to collect medical service fees from the
    government authorities in a timely manner may affect the timing
    of payments made by our hospital partners to us as a result.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the past, we have recorded limited amounts of uncollectible
    accounts receivable. Our allowance for doubtful accounts
    amounted to RMB3.8&#160;million (US$0.6&#160;million) as of
    December&#160;31, 2008 and September&#160;30, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have historically derived a large portion of our total net
    revenues from a limited number of our hospital partners. For the
    period from January&#160;1, 2007 to October&#160;30, 2007, the
    period from September&#160;10, 2007 to December&#160;31, 2007,
    for the year ended December&#160;31, 2008 and for the nine
    months ended September&#160;30, 2008 and 2009, net revenue
    derived from our top five hospital partners amounted to
    approximately 61.6%, 64.7%, 37.8%, 42.2% and 34.1%,
    respectively, of our total net revenues. For these same five
    periods, three, three, one, one and two,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    65
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    respectively, of our hospital partners, accounted for more than
    10.0% of our total net revenues, and our largest hospital
    partner accounted for 21.7%, 24.2%, 13.5%, 14.4% and 10.7%,
    respectively, of our total net revenues during those periods. We
    expect this revenue concentration to decline over time as our
    network of centers continues to expand.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our largest hospital partner in terms of revenue contribution
    for the nine months ended September&#160;30, 2009 was the
    Chinese People&#146;s Liberation Army Navy General Hospital. We
    have entered into lease and management services arrangements for
    six centers with such hospital partner, with terms that range
    from 10 to 20&#160;years. A lease and management services
    arrangement for one of the centers was newly entered into in
    July 2009 and such center has not begun operation as of
    September&#160;30, 2009, but is expected to begin operation at
    the end of 2009. We receive from our largest hospital partner a
    contracted percentage of each center&#146;s revenue net of
    specified operating expenses, which include variable expenses
    such as the salaries and benefits of the medical and other
    personnel at the center, the cost of medical consummables,
    marketing expenses, training expenses, utility expenses and
    routine equipment repair and maintenance expenses. The
    contracted percentages are typically adjusted based on a
    declining scale over the term of the arrangements. Typically,
    these arrangements may be terminated upon the mutual agreement
    of the parties if the centers experience an operating loss for a
    specified period of time or failed to achieve certain operating
    targets. In addition, the arrangements typically can be
    terminated upon the default or failure by either party to
    perform its respective obligations under the arrangement. Under
    the arrangements for certain centers and in the event of early
    termination as a result of adjustments of relevant policies, our
    largest hospital partner may be required to purchase the medical
    equipment from us at the price set forth in the agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Chang&#146;an Hospital accounted for approximately 10.1% of our
    total net revenues for the nine months ended September&#160;30,
    2009. We provide management services to Chang&#146;an Hospital
    through a service-only agreement and receive a management fee
    equal to a percentage of the total revenues of Chang&#146;an
    Hospital. In addition, we will be eligible to receive annual
    bonuses from Chang&#146;an Hospital calculated on the basis of
    the annual growth rates of Chang&#146;an Hospital&#146;s total
    revenues. Under the service-only agreement, we are required to
    pay a performance deposit of RMB15.0&#160;million
    (US$2.2&#160;million), which will be refunded to us after the
    termination or expiration of the service-only agreement. The
    service-only agreement can be terminated upon the default or
    failure by either party to perform its respective obligations
    under the agreement. We also managed six centers in
    Chang&#146;an Hospital prior to August 2009 through service-only
    agreements. In August 2009, we purchased the six units of the
    medical equipment housed in these six centers from Chang&#146;an
    Hospital. Two of the six units of medical equipment were
    combined into one center and we subsequently entered into a
    long-term lease and management services arrangement with
    Chang&#146;an Hospital to manage all the five centers. Under the
    lease and management services arrangement with Chang&#146;an
    Hospital, we receive a contracted percentage of each
    center&#146;s revenue net of specified operating expenses. The
    contracted percentage is adjusted based on a declining scale
    over the term of the arrangement. The arrangement may be
    terminated due to changes in government policies that prohibit
    the lease of such medical equipment and Chang&#146;an Hospital
    will be required to pay us the remaining amounts due under the
    arrangements. In addition, the arrangement can be terminated by
    us upon the default or failure by Chang&#146;an Hospital to
    perform its obligations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are subject to approximately 5% business tax and related
    surcharges on certain of our revenues. Such taxes and surcharges
    amounted to RMB0.4&#160;million, RMB0.2&#160;million,
    RMB4.5&#160;million (US$0.7&#160;million), RMB1.9&#160;million
    and RMB7.5&#160;million (US$1.1&#160;million) for the period
    from January&#160;1, 2007 to October&#160;30, 2007, the period
    from September&#160;10, 2007 to December&#160;31, 2007, in 2008
    and for the nine months ended September&#160;30, 2008 and 2009,
    respectively, and are deducted prior to deriving our total net
    revenues. In addition, revenue derived from the sale of medical
    equipment are net of value-added tax of 17% which amounted to
    RMB0.9&#160;million (US$0.1&#160;million) and
    RMB0.1&#160;million (US$15,000) in 2008 and for the nine months
    ended September&#160;30, 2009, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are also currently in the process of establishing two
    specialty cancer hospitals in China that will be majority owned
    and operated by us. The Chang&#146;an CMS International Cancer
    Center is expected to commence operation in early 2010 and the
    Beijing Proton Medical Center is expected to commence operation
    in 2012. We expect such specialty cancer hospitals to contribute
    favorably to our total net revenues in the future.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    66
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cost of
    Revenues and Operating Expenses</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our cost of revenues and
    operating expenses in absolute amounts and as percentage of our
    total net revenues for the periods indicated:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="28%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=11 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=11 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=11 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=11 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007<SUP style="font-size: 85%; vertical-align: top">(1)</SUP></B>

</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Net Revenues</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="38" align="center" valign="bottom">
    <B>(in thousands, except for percentages)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,304
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,046
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,669
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,174
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,002
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,497
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,987
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,330
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,597
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,680
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,361
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,541
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,162
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Gross Profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,075
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,632
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143,116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,497
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    805
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,463
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    654
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    General and administrative
    expenses<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,869
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,764
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,687
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,884
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total operating expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,366
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,569
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represent the addition of the
    amounts for the specific line items of OMS, our predecessor, for
    the period from January&#160;1, 2007 to October&#160;30, 2007,
    and the amounts for the corresponding line items of Concord
    Medical for the period from September&#160;10, 2007 to
    December&#160;31, 2007. For the period from September&#160;10,
    2007, the date of inception of Ascendium, to October&#160;30,
    2007, during which the financial statements of our predecessor
    and those of Concord Medical overlap, Ascendium did not engage
    in any business or operations. The unaudited combined financial
    data for the year ended December&#160;31, 2007 do not comply
    with U.S. GAAP.
    </FONT></TD>
</TR>





<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Our general and administrative
    expenses include share-based compensation expenses related to
    certain share options granted in 2007 that amounted to
    RMB49.5&#160;million, RMB4.2&#160;million (US$0.6&#160;million)
    and RMB4.2&#160;million in 2007, 2008 and for the nine months
    ended September&#160;30, 2008, respectively. We did not
    recognize any share-based compensation expenses for the nine
    months ended September&#160;30, 2009.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Cost
    of Revenues</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our cost of revenues primarily consists of the amortization of
    acquired intangibles and the depreciation of medical equipment
    purchased, installed and operated in our network of centers.
    With the exception of the amortization of acquired intangible
    assets, we expect such cost of revenues to increase in the
    future in line with the growth in our total net revenues as we
    continue to expand our network of centers and purchase more
    medical equipment. Our cost of revenues also include salaries
    and benefits for personnel employed by us and assigned to
    centers in our network, such as our project managers, as well as
    other costs that include certain training, marketing and selling
    and equipment repair and maintenance expenses that are not
    accounted for as the centers&#146; operating expenses in
    accordance with the terms of our lease and management services
    arrangements with our hospital partners. In addition, certain
    expenses are allocated as our cost of revenues instead of
    centers&#146; operating expenses if such expenses are incurred
    across several centers and cannot be allocated to one individual
    center. In addition, as a result of the OMS reorganization, the
    acquisitions of China Medstar, Xing Heng Feng Medical and
    certain other businesses, our cost of revenues also include
    amortization of acquired intangibles during the period starting
    from September&#160;10, 2007 to December&#160;31, 2007. We
    expect our amortization of acquired intangibles in connection
    with the OMS reorganization and the acquisition of China Medstar
    and other businesses in 2008 to be between approximately
    RMB25.9&#160;million (US$3.9&#160;million) and
    RMB18.7&#160;million (US$2.8&#160;million) annually between 2009
    and 2013.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Once our specialty cancer hospitals are established, our cost of
    revenues will also include costs associated with the operations
    of such hospitals. We expect such costs of revenue to include
    depreciation and amortization of the properties, buildings and
    equipment that are used by our specialty cancer hospitals, the
    salaries and benefits
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    67
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    associated with our medical and non-medical personnel and
    overhead costs, which include the cost of materials for medical
    procedures and utility, repair and maintenance expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Selling
    Expenses</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Selling expenses consist primarily of expenses associated with
    the development of new centers and specialty cancer hospitals,
    such as salaries and benefits for our business development
    personnel, marketing expenses and travel related expenses.
    Selling expenses have increased in absolute amount from 2007 to
    2008 and from the nine months ended September&#160;30, 2008 to
    the nine months ended September&#160;30, 2009 as a result of
    increased efforts to expand our network of centers and our
    specialty cancer hospitals. We expect our selling expenses to
    increase in absolute amount in the future, in line with the
    expansion of our network and the growth in our total net
    revenues.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">General
    and Administrative Expenses</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    General and administrative expenses consist primarily of
    salaries and benefits for our finance, human resources and
    administrative personnel, fees and expenses of legal, accounting
    and other professional services, insurance expenses, travel
    related expenses, depreciation of equipment and facilities used
    for administrative purposes, and other expenses. Our general and
    administrative expenses also include share-based compensation
    expenses in 2007, 2008 and for the nine months ended
    September&#160;30, 2008 that amounted to RMB49.5&#160;million,
    RMB4.2&#160;million (US$0.6&#160;million) and
    RMB4.2&#160;million, respectively, which significantly increased
    our general and administrative expenses for those periods. See
    &#147;&#151;&#160;Share-based Compensation.&#148; Without taking
    into account the share-based compensation expenses, our general
    and administrative expenses have increased in absolute dollar
    terms as we have recruited additional general and administrative
    employees and have incurred additional costs related to the
    growth of our business. We expect such expenses to continue to
    increase in absolute dollar terms in the future, in line with
    the expansion of our network of centers and the growth in our
    total net revenues.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Share-based
    Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2007, OMS, the predecessor of our company,
    adopted a share option plan, or the OMS option plan, pursuant to
    which OMS granted to three of its executive directors,
    Mr.&#160;Haifeng Liu, Mr.&#160;Jianyu Yang and Mr.&#160;Steve
    Sun, or the OMS grantees, options to purchase a total of up to
    25,000,000 ordinary shares, or the OMS share options, to
    purchase the ordinary shares of OMS at an exercise price of
    US$0.80 per share, which the board of OMS determined to become
    vested upon the satisfaction of a number of performance
    conditions that related to the completion of the OMS
    reorganization, achievement of net profit target of OMS, and the
    raising of new financing. The OMS share options were exercisable
    from the date of completion of the 2007 audited consolidated
    financial statements of OMS to December&#160;31, 2008 and were
    transferrable to any individuals designated by the OMS grantees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;18, 2008, the board of directors of OMS
    contemplated that the OMS grantees had achieved all performance
    conditions outlined in the OMS option plan. However, as the
    capital structure of our company had changed at that time such
    that we had replaced OMS as the ultimate holding company of our
    subsidiaries, the board of directors of OMS resolved that the
    OMS option plan would be settled in vested options to purchase
    21,184,600 ordinary shares to purchase shares of our company,
    with each option having an exercise price of US$0.79 exercisable
    before December&#160;31, 2008. On the same day, two of the OMS
    grantees, Mr.&#160;Jianyu Yang and Mr.&#160;Steve Sun, exercised
    their respective options to purchase an aggregate of
    6,355,400&#160;ordinary shares of our company, with total
    proceeds from such exercise received by us amounting to
    approximately RMB34.4&#160;million (US$5.0&#160;million). We
    recorded share-based compensation expense of approximately
    RMB49.5&#160;million in 2007 related to these options granted,
    which was recorded in general and administrative expenses. The
    third OMS grantee, Mr.&#160;Haifeng Liu, sold all of his vested
    options to purchase 14,829,200 ordinary shares of our company to
    three former directors of China Medstar who are now our
    directors and executive officers as employment incentive for
    such directors. The three executive directors subsequently
    exercised the vested options with total proceeds from such
    exercise received by us amounting to approximately
    US$11.7&#160;million. Given the transfer of the OMS share
    options to the three directors was provided as an employment
    incentive, we recorded additional share-based compensation
    expense of approximately RMB4.2&#160;million
    (US$0.6&#160;million) in 2008, which was recorded in general and
    administrative expenses.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    68
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;16, 2008, our board of directors adopted the
    2008&#160;share incentive plan, which was subsequently amended
    on November&#160;17, 2009 to increase the number of ordinary
    shares available for grant under the plan. The plan provides for
    the grant of options, share appreciation rights, or other
    share-based awards to key employees, directors or consultants.
    Our board of directors and shareholders authorized the issuance
    of up to 4,765,800 ordinary shares upon exercise of awards
    granted under our 2008&#160;share incentive plan. As of the date
    of this prospectus, no awards have been granted under our
    2008&#160;share incentive plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Accretion
    of Series&#160;A and Series&#160;B Contingently Redeemable
    Convertible Preferred Shares</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the terms of the Amended and Restated Shareholders&#146;
    Agreement dated as of October&#160;20, 2008, which was
    subsequently amended on November&#160;17, 2009, by and among us,
    our shareholders and certain other parties named therein,
    holders of the Series&#160;A and Series&#160;B redeemable
    convertible preferred shares have the right to require us to
    repurchase their preferred shares if (i)&#160;three years after
    the closing date of the subscription of the Series&#160;B
    contingently redeemable convertible preferred shares a qualified
    initial public offering has not taken place, (ii)&#160;any of
    certain of our key directors has resigned which resulted in or
    would be likely to result in a material adverse effect on our
    business, or (iii)&#160;we or any of our subsidiaries have
    breached or failed to be in compliance with any applicable laws
    which has had or would be reasonably likely to have a material
    adverse effect on our business. In the event of a repurchase
    under this right, we are required to repurchase all of the
    outstanding Series&#160;A or Series&#160;B contingently
    redeemable convertible preferred shares at a repurchase price
    equal to the original issue price of the preferred shares, plus
    an amount which would have accrued on the original issue price
    at a compound annual rate of at least 12.5% from the date of
    issuance up to and including the date on which such repurchase
    price is paid. The accretion of the Series&#160;A and
    Series&#160;B contingently redeemable convertible preferred
    shares is reflected as a charge against net income (loss)
    attributable to ordinary shareholders and totaled
    RMB270.3&#160;million (US$39.6&#160;million) and
    RMB304.8&#160;million (US$44.6&#160;million) in 2008 for
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares, respectively. Such accretion
    charge is not expected to continue after our initial public
    offering since all of our Series&#160;A and Series&#160;B
    contingently redeemable convertible preferred shares will be
    converted into ordinary shares at that time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Taxation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Cayman
    Islands</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are incorporated in the Cayman Islands. Under the current law
    of the Cayman Islands, we are not subject to income or capital
    gains tax. In addition, dividend payments made by us are not
    subject to withholding tax in the Cayman Islands.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">British
    Virgin Islands</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain of our subsidiaries are established in the British
    Virgin Islands and under the current laws of the British Virgin
    Islands, such subsidiaries are not subject to income tax.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Hong
    Kong</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We did not have any assessable profits subject to the Hong Kong
    profits tax in 2007 and 2008. We do not anticipate having any
    income subject to income taxes in Hong Kong in the foreseeable
    future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Singapore</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We did not have any assessable profits subject to the Singapore
    profits tax in 2007 and 2008. We do not anticipate having any
    income subject to income taxes in Singapore in the foreseeable
    future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">People&#146;s
    Republic of China</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our PRC subsidiaries are incorporated in the PRC and are
    governed by applicable PRC income tax laws and regulations. The
    EIT Law was enacted on March&#160;16, 2007 and became effective
    on January&#160;1, 2008. The implementation regulations under
    the EIT Law issued by the PRC State Council became effective
    January&#160;1, 2008. Under the EIT Law and the implementation
    regulations, the PRC has adopted a uniform tax rate of 25% for
    all
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    69
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    enterprises (including foreign-invested enterprises) and has
    revoked the previous tax exemption, reduction and preferential
    treatments applicable to foreign-invested enterprises. However,
    there is a transition period for enterprises, whether
    foreign-invested or domestic, that were registered on or before
    March&#160;16, 2007 and received preferential tax treatments
    granted by relevant tax authorities prior to January&#160;1,
    2008. Some enterprises that were subject to an enterprise income
    tax rate lower than 25% prior to January&#160;1, 2008&#160;may
    continue to enjoy the lower rate and gradually transition to the
    new tax rate within five years after the effective date of the
    EIT Law. In 2008, our subsidiaries Aohua Medical and Shanghai
    Medstar each had a preferential income tax rate of 18% that is
    scheduled to increase to 20% in 2009, 22% in 2010, 24% in 2011
    and 25% in 2012. Our other PRC subsidiaries are subject to the
    tax rate of 25% in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The EIT Law provides that enterprises established outside of
    China whose &#147;de facto management bodies&#148; are located
    in China are considered &#147;resident enterprises&#148; and are
    generally subject to the uniform 25% enterprise income tax rate
    on their worldwide income. In addition, a recent circular issued
    by the State Administration of Taxation regarding the standards
    used to classify certain Chinese-invested enterprises controlled
    by Chinese enterprises or Chinese group enterprises and
    established outside of China as &#147;resident enterprises&#148;
    clarified that dividends and other income paid by such
    &#147;resident enterprises&#148; will be considered to be PRC
    source income, subject to PRC withholding tax, currently at a
    rate of 10%, when recognized by non-PRC enterprise shareholders.
    This recent circular also subjects such &#147;resident
    enterprises&#148; to various reporting requirements with the PRC
    tax authorities. Under the implementation regulations to the EIT
    Law, a &#147;de facto management body&#148; is defined as a body
    that has material and overall management and control over the
    manufacturing and business operations, personnel and human
    resources, finances and properties of an enterprise. In
    addition, the recent circular mentioned above details that
    certain Chinese-invested enterprises controlled by Chinese
    enterprises or Chinese group enterprises will be classified as
    &#147;resident enterprises&#148; if all of the following are
    located or resident in China: senior management personnel and
    departments that are responsible for daily production, operation
    and management; financial and personnel decision making bodies;
    key properties, accounting books, company seal, and minutes of
    board meetings and shareholders&#146; meetings; and half or more
    of the directors with voting rights or senior management.
    However, as this circular only applies to enterprises
    established outside of China that are controlled by PRC
    enterprises or groups of PRC enterprises, it remains unclear how
    the tax authorities will determine the location of &#147;de
    facto management bodies&#148; for overseas incorporated
    enterprises that are controlled by individual PRC residents like
    us and some of our subsidiaries. Therefore, although
    substantially all of our management is currently located in the
    PRC, it remains unclear whether the PRC tax authorities would
    require or permit our overseas registered entities to be treated
    as PRC resident enterprises. If the PRC tax authorities
    determine that we are a &#147;resident enterprise,&#148; we may
    be subject to enterprise income tax at a rate of 25% on our
    worldwide income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the EIT Law, a maximum withholding income tax rate of 20%
    may be applicable to dividends payable to non-PRC investors that
    are &#147;non-resident enterprises,&#148; to the extent such
    dividends are derived from sources within the PRC, and the State
    Council has reduced such rate to 10% through the implementation
    regulations. We are a Cayman Islands holding company and
    substantially all of our income may be derived from dividends we
    receive from our operating subsidiaries located in the PRC.
    According to the <I>Double Taxation Arrangement (Hong Kong)</I>,
    dividends paid to enterprises incorporated in Hong Kong are
    subject to a withholding tax of 5% provided that a Hong Kong
    resident enterprise owns no less than 25% of the PRC enterprise
    distributing the dividend and can be considered as a
    &#147;beneficial owner&#148; and entitled to treaty benefits
    under the Double Taxation Arrangement (Hong Kong). Thus,
    dividends paid to us through our Hong Kong subsidiary by our
    subsidiaries in China may be subject to the 5% income tax if the
    Cayman Islands holding company and our Hong Kong subsidiary are
    considered as &#147;non-resident enterprises&#148; under the EIT
    Law and our Hong Kong subsidiary is considered to be a
    &#147;beneficial owner&#148; and entitled to treaty benefits
    under the Double Taxation Arrangement (Hong Kong). If we are
    required under the EIT Law to pay income tax for any dividends
    we receive from our subsidiaries, it will materially and
    adversely affect the amount of dividends, if any, we may pay to
    our shareholders and ADS holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Critical
    Accounting Policies</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We prepare our consolidated financial statements in accordance
    with U.S.&#160;GAAP, which requires us to make judgments,
    estimates and assumptions that affect (i)&#160;the reported
    amounts of assets and liabilities, (ii)&#160;disclosure of
    contingent assets and liabilities at the end of each reporting
    period and (iii)&#160;the reported amounts of revenue and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    70
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    expenses during each reporting period. We continually evaluate
    these estimates and assumptions based on historical experience,
    knowledge and assessment of current business and other
    conditions, expectations regarding the future based on available
    information and reasonable assumptions, which together form a
    basis for making judgments about matters not readily apparent
    from other sources. Since the use of estimates is an integral
    component of the financial reporting process, actual results
    could differ from those estimates. Some of our accounting
    policies require higher degrees of judgment than others in their
    application. When reviewing our financial statements, you should
    consider (i)&#160;our selection of critical accounting policies,
    (ii)&#160;the judgment and other uncertainties affecting the
    application of such policies and (iii)&#160;the sensitivity of
    reported results to changes in conditions and assumptions. We
    consider the policies discussed below to be critical to an
    understanding of our financial statements as their application
    places the most significant demands on the judgment of our
    management.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Revenue</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Lease and Management Services.</I>&#160;&#160;The majority of
    our revenues are derived directly from hospitals that enter into
    medical equipment lease and management service arrangements with
    us. A lease and management service arrangement will typically
    include the purchase and installation of diagnostic imaging
    <FONT style="white-space: nowrap">and/or</FONT>
    radiation oncology system (&#147;medical equipment&#148;) at the
    hospital, and the full-time deployment of a qualified system
    technician that are responsible for certain management services
    of managing radiotherapy or diagnostic services such that the
    hospital and doctors can provide specialized services to their
    patients. Under lease and management service arrangements with
    independent hospitals, with terms ranging from six to
    20&#160;years in duration, we receive a specified percentage of
    the net profit of the hospital unit that delivers the diagnostic
    imaging
    <FONT style="white-space: nowrap">and/or</FONT>
    radiation oncology services determined in accordance with the
    terms of the arrangement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have determined that the lease and management service
    arrangements contain a lease of medical equipment pursuant to
    FASB&#160;ASC Subtopic 840-10, Leases&#160;&#151; Overall
    (&#147;ASC&#160;840-10&#148;) (formerly referenced as
    <FONT style="white-space: nowrap">EITF&#160;01-8,</FONT>
    &#147;Determining Whether an Arrangement Contains a Lease&#148;,
    or
    <FONT style="white-space: nowrap">EITF&#160;01-8).</FONT>
    The hospital has the ability and the right to operate the
    medical equipment while obtaining more than a minor amount of
    the output. The arrangement also contains a non-lease
    deliverable as the management service element. The arrangement
    consideration is allocated between the lease element and the
    non-lease deliverables on a relative fair value basis.
    FASB&#160;ASC&#160;840 Leases, (&#147;ASC&#160;840&#148;)
    (formerly referenced as SFAS&#160;13, &#147;Accounting for
    leases&#148; or SFAS&#160;13) is applied to the lease elements
    of the arrangement and SEC Staff Accounting
    Bulletin&#160;No.&#160;104, or SAB&#160;104, is applied to other
    elements of the arrangement not within the scope of ASC&#160;840.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenues generated by the lease arrangement are based purely on
    a profit share formula. Certain of the lease and management
    services arrangements may include a transfer of ownership or
    bargain purchase option at the end of the lease term. Due to the
    length of the lease term, the collectibility of these minimum
    lease payments are not considered predictable and there are
    important uncertainties regarding the future costs to be
    incurred by us relating to the arrangement. Therefore, the
    lessor&#146;s additional criteria for capital lease
    classification in FASB&#160;ASC 840-10-25-42 to 840-10-25-44,
    Leases&#160;&#151; Overall&#160;&#151; Recognition&#160;&#151;
    Lessors (&#147;ASC&#160;840-10-25-42 to
    ASC&#160;840-10-25-44&#148;) (formerly referenced as
    SFAS&#160;13&#160;par. 8 (a)&#160;and (b))&#160;was not met even
    if any of the ASC&#160;840-10-25-1, Leases&#160;&#151;
    Overall&#160;&#151; Recognition&#160;&#151; General
    (&#147;ASC&#160;840-10-25-1&#148;) (formerly referenced as
    SFAS&#160;13 par.&#160;7) criteria for capital leases are met.
    Consequently, we account for all lease arrangements as operating
    leases. As the collectability of the minimum lease rental is not
    considered predictable, and the remaining rental is considered
    contingent, we recognize revenue when the lease payments under
    the arrangement become due, that is, when the profit share under
    the arrangement is determined and agreed upon by both parties to
    the agreement. For the service element of the arrangement,
    revenue is only considered determinable at the time the payments
    under the arrangement become due, that is, when the profit share
    under the arrangement is determined and agreed upon by both
    parties. Revenue is recognized when determined if all other
    basic criteria have also been met.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenue derived from the lease and management service
    arrangement is recorded under &#147;Lease and management
    service&#148; in the consolidated statements of operations and
    is recorded net of business tax of 5%
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Management Services.</I>&#160;&#160;To a lesser extent, we
    provide stand-alone management services to certain hospitals
    which are already in possession of medical equipment. The fee
    for the management service arrangement is either based on a
    contracted percentage of monthly revenue generated by the
    specified hospital unit (&#147;revenue share&#148;) or in
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    71
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    limited instances on a fixed monthly fee. The consideration that
    is based on a contracted percentage of revenue is recognized
    when the monthly fees under the arrangement become due, when the
    revenue share under the arrangement is determined and agreed
    upon by both parties to the arrangement. Revenue derived from
    stand-alone management services is recorded under
    &#147;Management Services&#148; in the consolidated statements
    of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Medical Equipment Sales.</I>&#160;&#160;Revenues arising from
    sales of medical equipment and services are recognized when
    there is persuasive evidence of an arrangement, the fee is fixed
    or determinable, collectability is reasonably assured and the
    delivery of the medical equipment or services has occurred. When
    the fees associated with an arrangement containing extended
    payment terms are not considered to be fixed or determinable at
    the outset of arrangement, revenue is recognized as payments
    become due, and all of the other criteria above have been met.
    Pursuant to the application of FASB ASC Subtopic 605-45, Revenue
    Recognition&#160;&#151; Principal Agent Consideration
    (&#147;ASC&#160;605-45&#148;), (formerly referenced as
    <FONT style="white-space: nowrap">EITF&#160;99-19,</FONT>
    &#147;Reporting Revenue Gross as Principal versus Net as an
    Agent&#148;, or
    <FONT style="white-space: nowrap">EITF&#160;99-19,)</FONT>
    we record revenue related to medical equipment sales on a net
    basis when the equipment is delivered to the customer and the
    sales price is determinable. Revenue derived from Medical
    Equipment sales is recorded under &#147;Other&#148; in the
    consolidated statements of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounts
    receivable and allowance for doubtful accounts</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We consider many factors in assessing the collectability of our
    receivables due from our customers, such as the aging of the
    amounts due, the customer&#146;s payment history and
    credit-worthiness. An allowance for doubtful accounts is
    recorded in the period in which uncollectability is determined
    to be probable. Accounts receivable balances are written off
    after all collection efforts have been exhausted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Goodwill</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Goodwill represents the excess of the purchase price over the
    fair value of net tangible and identifiable intangible assets
    acquired in a business combination. Under FASB ASC&#160;350,
    Intangibles&#160;&#151; Goodwill and other, (formerly referenced
    as Statement of Financial Accounting Standards No.&#160;142
    &#147;Goodwill and Other Intangible Assets&#148;, or
    SFAS&#160;142,) goodwill is tested for impairment annually or
    more frequently if events or changes in circumstances indicate
    that it might be impaired. We assess goodwill for impairment in
    accordance with ASC&#160;350 at the reporting unit level.
    ASC&#160;350 describes the reporting unit as an operating
    segment or one level below the operating segment, depending on
    whether certain criteria are met. We determined that we have
    only one reporting unit and have assigned goodwill to the
    reporting unit and tested for impairment annually as of
    December&#160;31.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An impairment loss must be measured if the sum of the expected
    future undiscounted cash flows from the use and eventual
    disposition of the asset is less than the net book value of the
    asset. The amount of the impairment loss will generally be
    measured as the difference between the net book value of the
    asset and their estimated fair value. The Company determined it
    has one reporting unit in which all goodwill was tested for
    impairment at each reporting period end resulting in no
    impairment charge.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Acquired
    Intangible Asset, net</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We depreciate and amortize our property, plant and equipment and
    acquired intangibles over the shorter of their estimated useful
    lives or contract terms using the straight-line method of
    accounting of the assets which closely approximates the pattern
    in which the economic benefits of the asset are consumed. We
    make estimates of the useful lives in order to determine the
    amount of depreciation and amortization expense to be recorded
    during each reporting period. We estimate the useful lives at
    the time the assets are acquired based on historical experience
    with similar assets as well as anticipated technological or
    other changes. If technological changes were to occur more
    rapidly than anticipated or in a different form than
    anticipated, we might shorten the useful lives assigned to these
    assets, which would result in the recognition of increased
    depreciation and amortization expense in future periods. There
    has been no change to the estimated useful lives during the
    period presented.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We evaluate long-lived assets, including property, plant and
    equipment and acquired intangibles, which are subject to
    depreciation and amortization, for impairment whenever events or
    changes in circumstances indicate that the carrying amount of an
    asset may not be recoverable. We assess recoverability by
    comparing the carrying amount of an asset to its estimated
    undiscounted future cash flows expected to be generated by the
    asset. If the carrying
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    72
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    amount of an asset exceeds its estimated undiscounted future
    cash flows, we recognize an impairment charge based on the
    amount by which the carrying amount of the asset exceeds the
    fair value of the asset. We estimate the fair value of the asset
    based on the best information available, including prices for
    similar assets and in the absence of an observable market price,
    the results of using a present value technique to estimate the
    fair value of the asset.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Share-based
    Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We account for share-based compensation under FASB ASC&#160;718,
    (&#147;ASC&#160;718&#148;) Compensation&#160;&#151; Stock
    Compensation (formerly referenced as Statement of Financial
    Accounting Standards
    <FONT style="white-space: nowrap">No.&#160;123-R,</FONT>
    &#147;Share-Based Payment&#148;, or SFAS&#160;No.&#160;123R).
    Under ASC&#160;718, the cost of all share-based payment
    transactions must be recognized in our consolidated financial
    statements based on their grant-date fair value over the
    required period, which is generally the period from the date of
    grant to the date when the share compensation is no longer
    contingent upon additional service from the employee, or the
    vesting period. This statement also requires us to adopt a fair
    value- based method of measuring the compensation expense
    related to share-based compensation. For options granted to
    employees, we record share-based compensation expenses for the
    fair value of the options at the grant date. Currently,
    consistent with the job functions of the grantees, we categorize
    these share-based compensation expenses in our general and
    administrative expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The determination of fair value of equity awards such as options
    requires making complex and subjective judgments about the
    projected financial and operating results of the subject
    company. It also requires making certain assumptions such as
    cost of capital, general market and macroeconomic conditions,
    industry trends, comparable companies, share price volatility of
    the subject company, expected lives of options and discount
    rates. These assumptions are inherently uncertain. Changes in
    these assumptions could significantly affect the amount of
    employee share-based compensation expense we recognize on our
    consolidated financial statements. We engaged an independent
    valuation firm to assist us in assessing the fair value of our
    share options and underlying ordinary shares on a
    contemporaneous basis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Changes in our estimates and assumptions regarding the expected
    volatility of our ordinary shares could significantly impact the
    estimated fair values of our share options and, as a result, our
    net income and the net income available to our ordinary
    shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Business
    combinations</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have made a number of acquisitions and may make strategically
    important acquisitions in the future. When recording an
    acquisition, we allocate the purchase price of the acquired
    company to the tangible and identifiable intangible assets
    acquired and liabilities assumed based on their estimated fair
    values. With the assistance of a valuation firm, we determined
    the fair values of identifiable intangible assets, including
    acquired lease agreements. These valuations require us to make
    significant estimates and assumptions which include future
    expected cash flows from the acquired lease agreements, discount
    rates, and assumptions regarding the period of time the acquired
    lease agreements, services agreements and customer relationships
    will continue. Such assumptions may be incomplete or inaccurate,
    and unanticipated events and circumstances may occur which may
    affect the accuracy or validity of such assumptions and
    estimates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Assessing
    the Fair Value of the Company&#146;s Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Determining the fair value of our ordinary shares also requires
    making complex and subjective judgments regarding projected
    financial and operating results, our unique business risks, the
    liquidity of our shares and our operating history and prospects
    at the time of grant. The assumptions used in deriving the fair
    value of our ordinary shares include: i)&#160;there will be no
    material change in the existing political, legal, technological,
    fiscal or economic condition of China that may adversely affect
    our business; ii)&#160;the contracts and agreements we entered
    into will be honored; and iii)&#160;our competitive advantages
    and disadvantages do not change significantly during the period
    under consideration. These assumptions are inherently uncertain.
    If different assumptions were used, our share-based compensation
    expenses, net income and income per share could have been
    significantly different.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In determining our enterprise value at each measurement date,
    the independent valuation firm considered the results of both
    the income approach (discounted cash flow method) and the market
    approach (guideline company
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    73
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    method). There was no significant difference between the
    enterprise value of our valuation derived using the income
    approach and the enterprise value derived using the market
    approach. For the market approach, the independent valuation
    firm considered the market profile and performance of guideline
    companies with businesses similar to those of us to derive
    market multiples and then calculated the following three
    multiples for the guideline companies: enterprise value to sales
    multiple, enterprise value to earnings before interest, tax,
    depreciation and amortization, or EBITDA, multiple and
    enterprise value to earnings before interest and tax, or EBIT,
    multiple. Due to the different growth rates, profit margins and
    risk levels of us and the guideline companies, price multiple
    adjustments were made.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the income approach, the value depends on the present worth
    of future economic benefits to be derived from our projected
    sales income. Indications of value are developed by discounting
    projected future net cash flows available for payment of
    shareholders&#146; interest to their present worth at a discount
    rate that reflects a number of factors, including the current
    cost of financing and the risk considered inherent in the
    business. A discount rate represents an estimate of the rate of
    return required by a third party investor for an investment of
    this type. The rate of return expected from an investment by an
    investor relates to the perceived risk of the investment. The
    calculation of the discount rate is based on the
    weighted-average cost of capital, or WACC, of the company. The
    WACC takes into account both the cost of equity and the cost of
    debt depending on the capital structure of the company. To
    determine the cost of equity, the independent valuation firm
    applied the Capital Asset Pricing Model, which takes into
    account the risk free rates, beta of selected comparable medical
    equipment leasing companies, market returns in comparative
    markets in each respective valuation periods and our company
    specific risks, including business risk, small size risk and
    country risk. The independent valuation firm determined our
    company&#146;s WACC, which was used a discount rate, of 19% to
    22%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The independent valuation firm also applied a discount for lack
    of marketability of 17% to 19% in the valuation of our
    enterprise value between November 2007 and October 2008 to
    reflect the fact that there is no readily available market for
    shares in a closely held company like ours. Because ownership
    interests in closely held companies are typically not readily
    marketable compared to similar public companies, we believe, a
    share in a privately held company is usually worth less than an
    otherwise comparable share in a publicly held company and,
    therefore, applied a discount for the lack of marketability of
    the privately held shares. When determining the discount for
    lack of marketability, the Black-Scholes option model was used.
    Under option pricing method, the cost of the put option, which
    can hedge the price change before the privately held shares can
    be sold, was considered as a basis to determine the discount for
    lack of marketability. The option pricing method was used
    because it takes into account certain company-specific factors,
    including the size of our business and volatility of the share
    price of comparable companies engaged in the same industry.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Significant
    Factors, Assumptions and Methodologies Used in Determining the
    Fair Value of Series&#160;A and B Contingently Redeemable
    Convertible Preferred Shares, Employee Share Options and
    Convertible Notes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Because the interest in the equity value of our company includes
    both contingently redeemable convertible preferred shares and
    ordinary shares, the fair value of the equity interest is
    allocated to contingently redeemable convertible preferred
    shares and ordinary shares using the option-pricing method.
    Under the option-pricing method, the independent valuation firm
    treats ordinary shares and contingently redeemable convertible
    preferred shares as call options on our company&#146;s value,
    with exercise prices based on the value of the liquidation
    preference of the contingently redeemable convertible preferred
    shares. Because a call option is used, the Black-Scholes model,
    which is commonly adopted in the option-pricing method, is
    applied to price the call option. The independent valuation firm
    considered various terms of the contingently redeemable
    convertible preferred shares and ordinary shares, including the
    level of seniority, dividend policy, conversion ratios,
    probability of the completion of an IPO, special redemption
    terms and preferential allocation upon liquidation of the
    enterprise in the option-pricing method.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have granted employee share options which are required to be
    recorded at the fair value of the options measured on the grant
    date. An independent valuation firm applied a Binomial-Lattice
    model to estimate the fair value of the share-based awards on
    the respective grant dates. The Binomial-Lattice model requires
    certain subjective inputs including the risk-free interest rate,
    the company&#146;s dividend yield, the sub optimal early
    exercise factor, and the expected volatility range of our
    ordinary shares. We applied a risk-free rate as relevant to
    conducting
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    74
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    financing activities in China. Our company has not declared
    dividends since inception and therefore the dividend yield was
    assessed to be nil. The sub optimal early exercise factor is an
    estimate that an employee will exercise the share option
    immediately once the company&#146;s underlying share price
    reaches 1.5 times the exercise price.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The expected volatility of our ordinary shares was based on the
    price volatility of the shares of comparable companies in the
    medical equipment leasing business, which are listed and
    publicly traded over the most recent period, equal to the
    expected term to expiry of the issued share options. These
    companies were used for comparative purposes because we did not
    have a trading history at the time the share options were issued
    and, therefore, did not have sufficient share price history to
    calculate our own historical volatility. The selection of such
    comparable companies is highly subjective. The estimated fair
    value of our ordinary shares on the date of grant was determined
    by contemporaneous valuations as of their respective measurement
    dates, performed by an independent valuation firm.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Tranche&#160;A and Tranche&#160;B Convertible Notes, or
    convertible notes, are accounted for in accordance with FASB
    ASC&#160;480, Distinguishing Liabilities from Equity,
    &#147;ASC&#160;480&#148; (formerly referenced as SFAS&#160;150,
    &#147;Accounting for Certain Financial Instruments with
    Characteristics of both Liabilities and Equity&#148; or
    SFAS&#160;150,) as a liability recorded at fair value, because
    the convertible notes are convertible into Series&#160;A
    Preferred Shares which are redeemable instruments. An
    independent valuation firm determined the fair value of the
    convertible notes using the binomial model, which requires the
    development of a complex model requiring many highly subjective
    inputs including identifying conditions that lead to specific
    outcomes and the respective probabilities of achieving those
    conditions. Some of the conditions that may lead to differences
    in the fair value of the convertible notes include the
    underlying value of a Series&#160;A contingently redeemable
    preferred share, the probability of completing an initial public
    offering, the level of net income earned in 2008, and the value
    of the underlying debt component.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Internal
    Control Over Financial Reporting</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, we have been a private company with
    limited accounting personnel and other resources to address our
    internal controls and procedures. In connection with the audits
    of our consolidated financial statements for the period from
    January&#160;1, 2007 to December&#160;31, 2008, our independent
    registered public accounting firm identified and communicated to
    us a material weakness and certain significant and other
    deficiencies. As a result, there is more than a remote
    likelihood that a more than inconsequential misstatement of our
    consolidated financial statements will not be prevented or
    detected. Specifically, the material weakness identified
    consists of an ineffective control environment over financial
    reporting due to (i)&#160;an insufficient number of financial
    reporting personnel with an appropriate level of knowledge,
    experience and training; (ii)&#160;insufficient controls around
    the establishment and maintenance of an oversight function and
    communication of internal controls, policies and procedures to
    support our financial reporting obligations; and (iii)&#160;a
    lack of a comprehensive set of internal control policies and
    procedures and related controls to monitor the operating
    effectiveness of these controls. The significant deficiencies
    identified consist of (i)&#160;a lack of a timely formal review
    process for outstanding accounts receivable; (ii)&#160;a lack of
    a process to document investment proposals and lack of a formal
    policy for equipment impairment assessment; and (iii)&#160;a
    lack of controls over agreements and contracts with our hospital
    partners.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Following the identification of the material weakness and the
    significant and other deficiencies, we are in the process of
    implementing a number of measures to improve our internal
    control over financial reporting, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    hiring a professional consulting firm to help us to improve
    internal control in preparation for compliance with the
    Sarbanes-Oxley Act and other applicable SEC rules and
    regulations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    hiring additional qualified personnel with U.S.&#160;GAAP
    expertise and SEC reporting experience to further build an
    internal finance team and a dedicated internal audit department;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    improving internal control procedures and standards, including
    compiling an internal accounting policies and procedures manual,
    and implementing policies as to the inspections and reporting of
    the medical equipment used in our network of centers;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    75
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enhancing the periodic and systematic physical inspections of
    the medical equipment used in our network of centers to monitor
    the working condition of the equipment and to report damages in
    a timely manner;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enhancing the management of agreements with our hospital
    partners and establishing standard policies and procedures
    governing agreement terms and approval process;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    conducting accounting and financial reporting training for our
    existing personnel as part of our commitment to provide ongoing
    U.S.&#160;GAAP trainings to our employees.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, upon the completion of this offering, we will
    appoint an independent director with extensive knowledge of
    U.S.&#160;GAAP and SEC reporting experience and will establish
    an audit committee under our board of directors in accordance
    with the applicable SEC and NYSE requirements to provide
    adequate independent oversight with respect to our accounting
    and financial reporting. However, the process of designing and
    implementing an effective financial reporting system is a
    continuous effort that requires us to anticipate and react to
    changes in our business and the economic and regulatory
    environments and to devote significant resources to maintain a
    financial reporting system that is adequate to satisfy our
    reporting obligations. The remedial measures that we intend to
    take may not fully address the material weaknesses or
    significant and other deficiencies that have been identified by
    our independent registered public accounting firm, and material
    weaknesses or significant deficiencies in our internal control
    over financial reporting may be identified in the future. See
    Risk Factors &#147;Risks Related to Our Company&#160;&#151; We
    may be unable to establish and maintain an effective system of
    internal control over financial reporting, and as a result we
    may be unable to accurately report our financial results or
    prevent fraud.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    76
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Consolidated
    Results of Operations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth a summary of our statements of
    income for the periods indicated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="35%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=11 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=11 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=11 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=11 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=12 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=12 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=12 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=12 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=13 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=13 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=13 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=13 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=14 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=14 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=14 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=14 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=15 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=15 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=15 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=15 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Concord Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="30" nowrap align="center" valign="bottom">
    <B>Concord Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="30" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>October&#160;30, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>%</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>%</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>%</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>%</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>%</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>%</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="55" nowrap align="center" valign="bottom">
    <B>(in thousands, except for percentages)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    <B>Summary Consolidated Statements of Operation Data</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Revenues, net of business tax, value-added tax and related
    surcharges:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,716
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,092
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,322
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67.422
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,405
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    205,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,396
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,304
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (27.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,046
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,669
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (42,144
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,174
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,003
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,388
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,987
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,416
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,914
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24,330
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,597
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,680
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,361
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (27.8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (62,541
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,162
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Gross profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,075
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,632
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143,116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,601
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (757
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,358
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (805
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,275
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,463
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (654
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 14pt">
    General and administrative
    expenses<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,467
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (57,171
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (408.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (65,638
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (80.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,764
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,468
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,687
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,884
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Operating income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,938
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (47,859
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (342.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,921
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (954
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (279
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,233
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,455
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,092
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,293
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,880
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (715
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (341
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (341
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (460
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (325
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (218
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    (Loss) gain from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,580
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    392
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    823
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Other income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income (loss) before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (346.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,064
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,627
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,691
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Income tax (expenses) benefit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,832
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,418
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,611
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,734
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,770
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Net income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (345.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,896
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (35.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Our general and administrative
    expenses include share-based compensation expenses related to
    certain share options granted in 2007 that amounted to RMB49.5
    million, RMB4.2 million (US$0.6 million) and RMB4.2&#160;million
    in 2007, 2008 and for the nine months ended September&#160;30,
    2008, respectively. We did not recognize any share-based
    compensation expenses for the nine months ended
    September&#160;30, 2009.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    77
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of our acquisition of China Medstar on July&#160;31,
    2008, China Medstar became our consolidated subsidiary and its
    results of operations from August 2008 to December&#160;31, 2008
    have been consolidated in our results of operations for the year
    ended December&#160;31, 2008. As a result, our results of
    operations for the year ended December&#160;31, 2008 and for the
    nine months ended September&#160;30, 2009 are not necessarily
    comparable to our results of operations for the year ended
    December&#160;31, 2007 as presented on a &#147;combined&#148;
    basis and for the nine months ended September&#160;30, 2008,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Nine
    Months Ended September&#160;30, 2009 Compared to Nine Months
    Ended September&#160;30, 2008</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Total Net Revenues.</I>&#160;&#160;Our total net revenues
    increased by 101.6% to RMB205.7&#160;million
    (US$30.1&#160;million) for the nine months ended
    September&#160;30, 2009 from RMB102.0&#160;million for the same
    period in 2008 principally as a result of an increase in the
    number of centers in our network, including the 23&#160;centers
    added as a result of our acquisition of China Medstar, and an
    increase in patient cases from existing centers. The increase in
    our total net revenues was also due to the increase in
    management services as a result of revenues derived from
    Chang&#146;an Hospital during the nine months ended
    September&#160;30, 2009 that we did not have during the same
    period in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Cost of Revenues.</I>&#160;&#160;Total cost of revenues
    increased by 120.5% to RMB62.5&#160;million
    (US$9.2&#160;million) for the nine months ended
    September&#160;30, 2009 from RMB28.4&#160;million for the same
    period in 2008. This increase was due primarily to an increase
    in our cost of revenues for lease and management services to
    RMB42.1&#160;million (US$6.2&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB14.7&#160;million for the
    same period in 2008. This was a result of an increase in the
    number of centers in our network principally as a result of our
    acquisition of China Medstar and the resulting increase in
    salaries and benefits to additional personnel employed by us and
    assigned to the centers, as well as other expenses associated
    with marketing and training activities. The increase in our cost
    of revenues is also due to an increase in amortization of
    acquired intangibles to RMB20.4&#160;million
    (US$3.0&#160;million) from RMB13.7&#160;million as a result of
    our acquisition of China Medstar in August 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost of revenues as a percentage of our total net revenues
    increased to 30.4% for the nine months ended September&#160;30,
    2009 from 27.8% for the same period in 2008. This increase was
    due primarily to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an increase in the number of new centers that are in operation
    and the higher cost of revenues as a percentage of total net
    revenues associated with such centers during their
    <FONT style="white-space: nowrap">ramp-up</FONT>
    period; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an increase in the number of new centers that offer diagnostic
    imaging services, which have a higher cost of revenues as a
    percentage of total net revenues as compared to radiotherapy
    treatments.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This increase in cost of revenues as a percentage of total net
    revenues was partially offset by an increase in net revenues
    derived from centers managed under service-only agreements as a
    percentage of our total net revenues to 9.8% for the nine months
    ended September&#160;30, 2009 from 7.4% for the same period in
    2008. Centers managed under service-only agreements have a lower
    cost of revenues as a percentage of total net revenues as
    compared to centers managed under lease and management services
    arrangements. This is because we do not purchase the medical
    equipment used in the centers managed under service-only
    agreements and, as a result, do not incur the associated
    equipment deprecation and amortization expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gross Profit and Gross Margin.</I>&#160;&#160;As a result of
    the foregoing, our gross profit increased by 94.4% to
    RMB143.1&#160;million (US$21.0&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB73.6&#160;million for the
    same period in 2008. Our gross margin decreased to 69.6% for the
    nine months ended September&#160;30, 2009 from 72.2% for the
    same period in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Operating Expenses.</I>&#160;&#160;Our operating expenses
    increased by 53.4% to RMB24.2&#160;million (US$3.5&#160;million)
    for the nine months ended September&#160;30, 2009 from
    RMB15.7&#160;million for the same period in 2008 due primarily
    to an increase in salaries and benefits payment associated with
    an increased headcount primarily as a result our acquisition of
    China Medstar. Operating expenses as a percentage of our total
    net revenues decreased to 11.7% for the nine months ended
    September&#160;30, 2009 from 15.4% for the same period in 2008
    due primarily to increased economies of scale.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    78
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Selling Expenses.</I>&#160;&#160;Our selling expenses
    increased by 36.3% to RMB4.5&#160;million (US$0.6&#160;million)
    for the nine months ended September&#160;30, 2009 from
    RMB3.3&#160;million for the same period in 2008. This increase
    in our selling expenses was due primarily to an increase in
    salaries and benefits payment associated with an increased
    headcount as a result of our acquisition of China Medstar, an
    increase in marketing expenses and salaries and benefits payment
    in connection with an increase in our business development
    efforts for the nine months ended September&#160;30, 2009 as
    compared to the same period in 2008 to increase the number of
    new centers and for the development of specialty cancer
    hospitals. Selling expenses as a percentage of our total net
    revenues decreased to 2.1% for the nine months ended
    September&#160;30, 2009 from 3.2% for the same period in 2008.
    This was due primarily to increased economies of scale.
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>General and Administrative Expenses.</I>&#160;&#160;Our
    general and administrative expenses increased by 57.9% to
    RMB19.7&#160;million (US$2.9&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB12.5&#160;million for the
    same period in 2008. This increase was due primarily to
    increases in salaries and benefits payment in connection with
    the increased headcount of our personnel and their travel
    related expenses principally as a result of our acquisition of
    China Medstar and also in connection with the continued
    expansion of our business. Our general and administrative
    expenses include charges of RMB4.2&#160;million for the nine
    months ended September&#160;30, 2008 related to share-based
    compensation. General and administrative expenses as a
    percentage of our total net revenues decreased to 9.6% for the
    nine months ended September&#160;30, 2009 from 12.2% for the
    same period in 2008. This was due primarily to
    <FONT style="white-space: nowrap">share-based</FONT>
    compensation expenses that were incurred during the nine months
    ended September&#160;30, 2008 that we did not incur for the same
    period in 2009.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Operating Income.</I>&#160;&#160;As a result of the
    foregoing, our operating income increased by 105.5% to
    RMB119.0&#160;million (US$17.4&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB57.9&#160;million for the
    same period in 2008. Operating margin increased to 57.9% for the
    nine months ended September&#160;30, 2009 from 56.8% for the
    same period in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest Expense.</I>&#160;&#160;Our interest expense
    decreased by 7.8% to RMB4.9&#160;million (US$0.7&#160;million)
    for the nine months ended September&#160;30, 2009 from
    RMB5.3&#160;million for the same period in 2008. This decrease
    was due primarily to a decrease in interest rate on our
    borrowings for the nine months ended September&#160;30, 2009
    from the same period in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Change in Fair Value of Convertible Notes.</I>&#160;&#160;We
    recorded a gain of RMB0.5&#160;million from change in fair value
    of convertible notes for the nine months ended
    September&#160;30, 2008. As all convertible notes were converted
    into our Series&#160;A contingently redeemable preferred shares
    in 2008, we did not record such gain for the nine months ended
    September&#160;30, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Foreign Exchange Loss.</I>&#160;&#160;Our foreign exchange
    loss increased by 1,182.4% to RMB0.2&#160;million (US$32,000)
    for the nine months ended September&#160;30, 2009 from RMB17,000
    for the same period in 2008. This was due primarily to
    deprecation of our cash balances held in U.S. dollars against
    the Renminbi.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gain from Disposal of Equipment.</I>&#160;&#160;We recorded a
    gain of RMB0.4&#160;million from the disposal of equipment for
    the nine months ended September&#160;30, 2008 while we did not
    dispose of any equipment for the same period in 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest Income.</I>&#160;&#160;Our interest income increased
    by 609.5% to RMB0.8&#160;million (US$0.1&#160;million) for the
    nine months ended September&#160;30, 2009 from RMB0.1 million
    for the same period in 2008. This increase was due primarily to
    an increase in cash balances during the nine months ended
    September&#160;30, 2009 as compared to the same period in 2008
    primarily as a result of proceeds received from the issuance of
    our Series B contingently convertible preferred shares in
    October 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Income Tax Expense.</I>&#160;&#160;Our income tax expense
    increased by 104.1% to RMB25.7&#160;million
    (US$3.8&#160;million) for the nine months ended
    September&#160;30, 2009 from RMB12.6&#160;million for the same
    period in 2008. This increase was due primarily to increase in
    our taxable profits and to a lesser extent, a higher effective
    enterprise income tax rate for the nine months ended
    September&#160;30, 2009 as compared to the same period in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Net Income and Net Margin.</I>&#160;&#160;As a result of the
    foregoing, our net income increased by 122.3% to
    RMB89.0&#160;million (US$13.0&#160;million) for the nine months
    ended September&#160;30, 2009 from RMB40.0&#160;million
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    79
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    for the same period in 2008. Net margin increased to 43.3% for
    the nine months ended September&#160;30, 2009 from 39.2% for the
    same period in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Year Ended December&#160;31, 2008 (Successor Period) Compared to
    the Period From January&#160;1, 2007 to October&#160;30, 2007
    (Predecessor Period)&#160;and the Period from September&#160;10,
    2007 to December&#160;31, 2007 (Successor Period)</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Total Net Revenues.</I>&#160;&#160;Our total net revenues
    were RMB171.8&#160;million (US$25.2&#160;million) in 2008. Our
    total net revenues from leasing and management services were
    RMB155.1&#160;million (US$22.7&#160;million) in 2008, which
    accounted for approximately 37.6% of the total medical service
    fees received in our network of centers in 2008. Our total net
    revenues were RMB67.4&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and
    RMB14.0&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2008, our total net revenues increased due to the addition of
    China Medstar&#146;s network of 23&#160;centers that became
    consolidated in our results of operations from August 2008
    onwards, the revenue contribution from the additional centers
    established by us during 2008 and an increase in patient cases
    for existing centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our total net revenues also increased due to additional revenue
    from management services provided under service-only agreements
    as a result of an increase in the number of patients at centers
    managed under service-only agreements and revenue derived from
    Chang&#146;an Hospital that we began to manage in 2008. Total
    net revenues derived from our management services increased from
    6.4% for the period from January&#160;1, 2007 to
    October&#160;30, 2007, to 7.0% for the period from
    September&#160;10, 2007 to December&#160;31, 2007 and to 7.4% in
    2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Cost of Revenues.</I>&#160;&#160;Our cost of revenues was
    RMB45.6&#160;million (US$6.7&#160;million) in 2008. Our cost of
    revenues was RMB20.4&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and
    RMB3.9&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007. Our cost of revenue as a percentage
    of total net revenues was 26.5% in 2008. Our cost of revenues as
    a percentage of total net revenues was 30.3% for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and 28.0% for the
    period from September&#160;10, 2007 to December&#160;31, 2007.
    Our cost of revenue as a percentage of our total net revenues
    for the period from September&#160;10, 2007 to December&#160;31,
    2007 and in 2008 was affected by the downward purchase price
    adjustment to the fair value of the medical equipment used in
    our network of centers and a decrease in depreciation expenses
    as a result, which was partially offset by the increase in
    amortization of acquired intangibles. Our cost of revenues as a
    percentage of total net revenues is also affected by the
    increase in net revenues derived from service-only agreements as
    a percentage of our total revenue. Service-only agreements do
    not require us to the purchase medical equipment and, as a
    result, we do not incur the associated depreciation expenses for
    the medical equipment used in centers that we manage under
    service-only agreements, resulting in a lower cost of revenues
    as a percentage of total net revenues.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gross Profit and Gross Margin.</I>&#160;&#160;As a result of
    the foregoing, our gross profit was RMB126.2&#160;million
    (US$18.5&#160;million) in 2008. Our gross profit was
    RMB47.0&#160;million for the period from January&#160;1, 2007 to
    October&#160;30, 2007 and RMB10.1&#160;million for the period
    from September&#160;10, 2007 to December&#160;31, 2007. Our
    gross margin was 73.5% in 2008. Our gross margin was 69.7% for
    the period from January&#160;1, 2007 to October&#160;30, 2007
    and 72.0% for the period from September&#160;10, 2007 to
    December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Operating Expenses.</I>&#160;&#160;Our operating expenses
    were RMB24.4&#160;million (US$3.6&#160;million) in 2008. Our
    operating expenses were RMB10.1&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and
    RMB57.9&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007. Our operating expenses as a
    percentage of total net revenues were 14.2% in 2008. Our
    operating expenses as a percentage of total net revenues were
    14.9% for the period from January&#160;1, 2007 to
    October&#160;30, 2007 and 414.3% for the period from
    September&#160;10, 2007 to December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Selling Expenses.</I>&#160;&#160;Our selling expenses were
    RMB5.5&#160;million (US$0.8&#160;million) in 2008. Our selling
    expenses were RMB1.6&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and
    RMB0.8&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007. Our selling expenses as a percentage
    of total net revenues were 3.2% in 2008. Our selling expenses as
    a percentage of total net revenues were 2.4% for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and 5.4% for the
    period from September&#160;10, 2007 to December&#160;31, 2007.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    80
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>General and Administrative Expenses.</I>&#160;&#160;Our
    general and administrative expenses were RMB18.9&#160;million
    (US$2.8&#160;million) in 2008. Our general and administrative
    expenses were RMB8.5&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and
    RMB57.2&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007. Our general and administrative
    expenses as a percentage of total net revenues were 11.0% in
    2008. Our general and administrative expenses as a percentage of
    total net revenues were 12.6% for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and 408.9% for the
    period from September&#160;10, 2007 to December&#160;31, 2007.
    The general and administrative expenses for the period from
    September&#160;10, 2007 to December&#160;31, 2007 were affected
    by the share-based compensation expenses from the grant of
    certain OMS share options, which amounted to
    RMB49.5&#160;million. The general and administrative expenses in
    2008 were also affected by the share-based compensation expenses
    that amounted to RMB4.2&#160;million (US$0.6&#160;million) from
    the transfer of vested options of certain OMS share options to
    three of our executive directors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Operating (Loss) Income.</I>&#160;&#160;As a result of the
    foregoing, our operating income was RMB101.8&#160;million
    (US$14.9&#160;million) in 2008. Our operating income was
    RMB36.9&#160;million for the period from January&#160;1, 2007 to
    October&#160;30, 2007 and we had an operating loss of
    RMB47.9&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest Expense.</I>&#160;&#160;Our interest expenses was
    RMB7.5&#160;million (US$1.1&#160;million) in 2008. Our interest
    expenses was RMB1.0&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and
    RMB0.3&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Change in Fair Value of Convertible Notes.</I>&#160;&#160;We
    recorded a loss from change in fair value of convertible notes
    of RMB0.5&#160;million (US$68,000) in 2008. We recorded a loss
    from change in fair value of convertible notes was
    RMB0.3&#160;million for the period from September&#160;10, 2007
    to December&#160;31, 2007 while we did not record such loss for
    the period from January&#160;1, 2007 to October&#160;30, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Foreign Exchange Loss.</I>&#160;&#160;Our foreign exchanges
    loss was RMB0.3&#160;million (US$48,000) in 2008. Our foreign
    exchange loss was RMB4,000 for the period from
    September&#160;10, 2007 to December&#160;31, 2007 while we did
    not record any foreign exchange loss for the period from
    January&#160;1, 2007 to October&#160;30, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>(Loss) Gain from Disposal of Equipment.</I>&#160;&#160;Our
    gain from disposal of equipment under capital lease was
    RMB0.7&#160;million (US$0.1&#160;million) in 2008. Our loss from
    disposal of equipment under capital lease was
    RMB1.6&#160;million for the period from January&#160;1, 2007 to
    October&#160;30, 2007 and was RMB25,000 for the period from
    September&#160;10, 2007 to December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest Income.</I>&#160;&#160;Our interest income was
    RMB0.4&#160;million (US$63,000) in 2008. Our interest income was
    RMB15,000 for the period from January&#160;1, 2007 to
    October&#160;30, 2007 while we did not record such income for
    the period from September&#160;10, 2007 to December&#160;31,
    2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Income.</I>&#160;&#160;We had other income of
    RMB7.7&#160;million (US$1.1&#160;million) in 2008 that was the
    result of restitution payments from certain employees and former
    employees related to the return of corporate funds that they had
    misappropriated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Income Tax Expense.</I>&#160;&#160;Our income tax expense was
    RMB23.3&#160;million (US$3.4&#160;million) in 2008. Our income
    tax expense was RMB15.0&#160;million for the period from
    January&#160;1, 2007 to October&#160;30, 2007 and our income tax
    benefit was RMB0.2&#160;million for the period from
    September&#160;10, 2007 to December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Net (Loss) Income and Net Margin.</I>&#160;&#160;As a result
    of the foregoing, our net income was RMB79.1&#160;million
    (US$11.6&#160;million) in 2008. Our net income was
    RMB19.4&#160;million for the period from January&#160;1, 2007 to
    October&#160;30, 2007 and our net loss was RMB48.3&#160;million
    for the period from September&#160;10, 2007 to December&#160;31,
    2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Year
    Ended December&#160;31, 2008 Compared to Year Ended
    December&#160;31, 2007 on a Combined Basis</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Total Net Revenues.</I>&#160;Our total net revenues increased
    by 110.0% to RMB171.8&#160;million (US$25.2&#160;million) in
    2008 from RMB81.4&#160;million in 2007. This increase was due
    primarily to the increase in lease and management services
    revenues which was a result of the network of 23 centers of
    China Medstar that are consolidated in our
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    81
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    results of operations from August 2008, seven new centers that
    we established in 2008 and an increase in patient cases from
    existing centers. The increase in our total net revenues was
    also due to the increase in an increase in the number of
    patients for centers managed under service-only agreements and
    revenues derived from Chang&#146;an Hospital that we began to
    manage in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Cost of Revenues.</I>&#160;Total cost of revenues increased
    by 87.7% to RMB45.6&#160;million (US$6.7&#160;million) in 2008
    from RMB24.3&#160;million in 2007. This increase in our cost of
    revenues was due primarily to an increase in amortization of
    acquired intangibles to RMB20.9&#160;million
    (US$3.1&#160;million) from RMB2.0&#160;million as a result of
    the OMS reorganization, our acquisition of China Medstar in 2008
    and an increase in the number of centers in our network from
    2007 to 2008, which has resulted in an increase in salaries and
    benefits to additional personnel employed by us and assigned to
    the centers and other expenses associated with marketing and
    training activities. Cost of revenues as a percentage of our
    total net revenues decreased to 26.5% in 2008 from 29.9% in
    2007. This decrease was due primarily to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the downward purchase price adjustment to the fair value of the
    medical equipment used in our network of centers and a decrease
    in depreciation expenses as a result;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an increase in net revenues derived from centers managed under
    service-only agreements as a percentage of our total net
    revenues to 7.4% in 2008 from 6.5% in 2007. Centers managed
    under service-only agreements have a lower cost of revenues as a
    percentage of total net revenues as compared to centers managed
    under lease and management services arrangements. This is
    because we do not purchase the medical equipment used in the
    centers managed under service-only agreements and, as a result,
    do not incur the associated equipment depreciation
    expenses;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our acquisition of China Medstar, which had a lower cost of
    revenues as a percentage of total net revenues as compared to
    our company. This was because of the higher cost of certain of
    our installed medical equipment as compared to the cost of China
    Medstar&#146;s medical equipment, which had a higher
    depreciation expenses.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Gross Profit and Gross Margin.</I>&#160;As a result of the
    foregoing, our gross profit increased by 121.1% to
    RMB126.2&#160;million (US$18.5&#160;million) in 2008 from
    RMB57.1&#160;million in 2007. Our gross margin increased to
    73.5% in 2008 from 70.1% in 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Operating Expenses.</I>&#160;Our operating expenses decreased
    by 64.1% to RMB24.4&#160;million (US$3.6&#160;million) in 2008
    from RMB68.0&#160;million in 2007 due primarily to a significant
    decrease in our general and administrative expenses as a result
    of a decrease in share-based compensation expenses in 2008 as
    compared to 2007. Operating expenses as a percentage of our
    total net revenues decreased to 14.2% in 2008 from 83.5% in 2007
    due primarily to a decrease in share-based compensation expenses
    in 2008 as compared to 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>Selling Expenses.</I>&#160;Our selling expenses increased by
    129.0% to RMB5.5&#160;million (US$0.8&#160;million) in 2008 from
    RMB2.4&#160;million in 2007. This increase in our selling
    expenses was due primarily to an increase in marketing expenses
    and salaries and benefits payment in connection with an increase
    in our business development efforts in 2008 as compared to 2007
    to increase the number of new centers and for the development of
    specialty cancer hospitals. Selling expenses as a percentage of
    our total net revenues in 2008 remained in line with 2007 and
    increased slightly to 3.2% in 2008 from 2.9% in 2007.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <I>General and Administrative Expenses.</I>&#160;Our general and
    administrative expenses decreased by 71.3% to
    RMB18.9&#160;million (US$2.8&#160;million) in 2008 from
    RMB65.6&#160;million in 2007. Our general and administrative
    expenses include charges of RMB4.2&#160;million
    (US$0.6&#160;million) and RMB49.5&#160;million in 2008 and 2007,
    respectively, related to share-based compensation. Our general
    and administrative expenses, not including the share-based
    compensation expenses, have also increased in 2008 from 2007,
    which was due primarily to increases in salaries and benefits
    payments in connection with the increased headcount of our
    personnel as well as their travel related expenses.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Operating Income (Loss).</I>&#160;As a result of the
    foregoing, we had operating income of RMB101.8&#160;million
    (US$14.9&#160;million) in 2008 as compared to an operating loss
    of RMB10.9&#160;million in 2007. Operating margin in 2008 was
    59.3% as compared to a negative 13.4% in 2007.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    82
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest Expense.</I>&#160;Our interest expense increased by
    504.6% to RMB7.5&#160;million (US$1.1&#160;million) in 2008 from
    RMB1.2&#160;million in 2007. This increase was due primarily to
    increased bank borrowings in 2008 and the increase in the
    average balance of convertible notes that were outstanding
    during 2008 as compared to 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Change in Fair Value of Convertible
    Notes.</I>&#160;&#160;Loss from change in fair value of
    convertible notes we recorded increased by 36.1% to
    RMB0.5&#160;million (US$68,000) in 2008 from RMB0.3&#160;million
    in 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Foreign Exchange Loss.</I>&#160;Our foreign exchange loss
    increased by 8,025.0% to RMB0.3&#160;million (US$48,000) in 2008
    from RMB4,000 in 2007. This increase was due primarily to an
    increase in average foreign currency balance in 2008 as compared
    to 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>(Loss) Gain from Disposal of Equipment.</I>&#160;We recorded
    a gain of RMB0.7&#160;million (US$0.1&#160;million) from the
    disposal of equipment in 2008 while we incurred a loss of
    RMB1.6&#160;million from the disposal of equipment in 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Interest Income.</I>&#160;Our interest income increased by
    2,766.7% to RMB0.4&#160;million in 2008 from RMB15,000 in 2007.
    This increase was due primarily to an increase in cash balances
    in 2008 as compared to 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Income.</I>&#160;We had other income of
    RMB7.7&#160;million (US$1.1&#160;million) in 2008 that was the
    result of restitution payments from certain employees and former
    employees related to the return of corporate funds that they had
    misappropriated. We did not record such other income in 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Income Tax Expense.</I>&#160;Our income tax expense increased
    by 57.3% to RMB23.3&#160;million (US$3.4&#160;million) in 2008
    from RMB14.8&#160;million in 2007. This increase was due
    primarily to increase in our taxable profits and higher
    effective enterprise income tax rate in 2008 as compared to 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Net (Loss) Income and Net Margin.</I>&#160;As a result of the
    foregoing, our net income was RMB79.1&#160;million
    (US$11.6&#160;million) in 2008 as compared to a net loss of
    RMB28.9&#160;million in 2007. Net margin was 46.0% 2008 as
    compared to negative 35.5% in 2007.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    83
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Selected
    Quarterly Results</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our unaudited consolidated
    quarterly results for the seven quarters ended
    September&#160;30, 2009. You should read the following table in
    conjunction with our audited consolidated financial statements
    and related notes contained elsewhere in this prospectus. The
    consolidated quarterly results information includes all
    adjustments, consisting only of normal recurring adjustments,
    that we consider necessary for a fair presentation of our
    financial position and operating results for the quarters
    presented. These quarterly operating results are not indicative
    of results that may be expected for any future quarters or for a
    full year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="26" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September.&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="26" align="center" valign="bottom">
    <B>(in RMB thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Revenues, net of business tax, value-added tax and related
    surcharges:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,672
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,813
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,811
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,349
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,696
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,892
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,751
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,755
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,158
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,323
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,689
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,873
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    137
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    408
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,685
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,564
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69,796
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,751
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    71,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,989
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,092
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,244
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,375
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,171
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,270
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,703
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Amortization of acquired intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,008
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,008
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,655
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,826
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,882
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,882
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,624
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (35
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,107
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,350
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,904
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,236
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,056
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,156
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,329
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Gross profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,578
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,214
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,560
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,695
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,761
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (799
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,053
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,423
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,222
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,316
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,476
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,407
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,742
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,319
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,401
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,754
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,722
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,211
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Operating income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,372
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,419
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,098
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,625
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,368
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,973
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,006
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,732
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,162
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,638
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,571
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (883
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,297
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (878
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Foreign exchange (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (76
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    109
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (46
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (312
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    542
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (97
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Gain from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    265
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    266
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    314
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    423
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Income before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,272
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,945
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,777
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,548
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,762
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Income tax expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,062
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,651
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,898
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,724
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,709
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,826
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,199
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,348
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,621
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,047
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,839
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,936
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    84
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our unaudited consolidated
    selected quarterly results, as a percentage of our total net
    revenues, for the seven quarters ended September&#160;30, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="37%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="26" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Three Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>March&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>June&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Revenues, net of business tax, value-added tax and related
    surcharges:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91.1
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89.6
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94.4
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    87.1
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84.9
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92.7
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90.9
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cost of revenues:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Amortization of acquired intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17.7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10.8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9.7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (27.7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24.7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30.8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Gross profit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    71.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Operating expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10.6
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Operating income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4.8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.7
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Foreign exchange (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Gain from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Income before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    71.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Income tax expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11.2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.0
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12.3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13.1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56.0
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business is subject to seasonality factors that have
    resulted in fluctuations in our total net revenues and net
    income in the seven quarters ended September&#160;30, 2009. Our
    network of centers typically treats fewer patients during the
    first quarter as compared to other quarters as a result of the
    Chinese New Year holidays in the first quarter of every year.
    Patients typically choose not to undergo radiotherapy treatment
    or receive diagnostic imaging services during holidays. We
    believe that our revenues will continue to be affected in the
    future by the seasonality of our business. Our business is also
    subject to the effect of acquisitions. We experienced a
    significant increase in our total net revenues and results of
    operations in the three months ended December&#160;31, 2008,
    which was primarily the result of our acquisition of China
    Medstar that added 23 centers into our network of centers. We
    plan to continue the expansion of our network of centers through
    selective strategic acquisitions in the future, and therefore
    our results in future quarters may be materially impacted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our cost of revenues varies from quarter to quarter and does not
    necessarily correspond to changes in our total net revenues. Our
    cost of revenues are primarily comprised of depreciation and
    amortization expenses associated with the costs of the medical
    equipment and our acquired intangible assets, which are not
    necessarily indicative of the performance of our network of
    centers during the relevant quarter.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    85
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Liquidity
    and Capital Resources</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth a summary of our net cash flows
    for the periods indicated:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="37%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Predecessor</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical (Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>October 30,&#160;2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="26" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,774
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,308
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash used in investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (50,452
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30,441
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (376,371
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (55,136
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (300,692
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (223,426
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32,731
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    649,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95,147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    278,407
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,448
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,698
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (834
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,949
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (191
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net increase (decrease) in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    314,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (864
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68,288
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,004
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash at beginning of the period/year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Cash at end of the period/year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    285,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To date, we have financed our operations primarily through cash
    flows from operations and short- and long-term bank borrowings,
    as well as the issuance of convertible notes and contingently
    redeemable convertible preferred shares. As of December&#160;31,
    2007 and 2008 and as of September&#160;30, 2009, we had
    RMB39.8&#160;million, RMB354.0&#160;million
    (US$51.9&#160;million) and RMB285.7&#160;million
    (US$41.9&#160;million) in cash, respectively. As of
    September&#160;30, 2009, we had RMB30.0&#160;million
    (US$4.4&#160;million) in short-term borrowings outstanding and
    RMB149.8&#160;million (US$21.9&#160;million) in long-term
    borrowings outstanding, including the current portion of such
    long-term borrowings outstanding. As of December&#160;31, 2008,
    we had RMB20.8&#160;million (US$3.0&#160;million) in short-term
    bank borrowings outstanding and RMB92.0&#160;million
    (US$13.5&#160;million) in long-term bank borrowings outstanding,
    including the current portion of such long-term borrowings
    outstanding. We did not have any short-term and long-term bank
    borrowings outstanding as of December&#160;31, 2007. Our cash
    primarily consists of cash on hand and bank deposits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Operating
    Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The primary factors affecting our operating cash flow is the
    amount and timing of payments of our contractual percentage of
    each center&#146;s revenue net of specified operating expenses
    that we received from our hospital partners and cash payments
    that we made in connection with establishing new centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from operating activities increased by 281.8%
    to RMB104.5&#160;million (US$15.3&#160;million) for the nine
    months ended September&#160;30, 2009 from RMB27.4&#160;million
    for the same period in 2008. Net cash generated from operating
    activities for the nine months ended September&#160;30, 2009 was
    due primarily to cash received from an increased number of
    hospital partners which, in turn, was primarily a result of our
    acquisition of China Medstar. This increase was partially offset
    by an increase in accounts receivable and a decrease in accrued
    expenses and other liabilities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from operating activities in 2008 was
    RMB46.8&#160;million (US$6.9&#160;million). Net cash generated
    from operating activities was due primarily to cash received
    from our hospital partners, which was partially offset by
    deposits made by us that amounted to RMB15.0&#160;million
    (US$2.2&#160;million) to Chang&#146;an Hospital as performance
    guarantee, a decrease in accounts payable that amounted to
    RMB20.2&#160;million (US$3.0&#160;million) and an increase in
    accounts receivable that amounted to RMB19.3&#160;million
    (US$2.8&#160;million).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from operating activities for the period from
    September&#160;10, 2007 to December&#160;31, 2007 was
    RMB6.1&#160;million. Net cash generated from operating
    activities was due primarily to an increase in accrued expenses
    and other liabilities that amounted to RMB2.0&#160;million and a
    decrease in advance made to a hospital of RMB2.7&#160;million.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    86
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from operating activities for the period from
    January&#160;1, 2007 to October&#160;30, 2007 was
    RMB44.6&#160;million. Net cash generated from operating
    activities was due primarily to cash received from our hospital
    partners and an increase in accrued expenses and other
    liabilities of RMB4.1&#160;million, which was partially offset
    by an increase in accounts receivable of RMB5.4&#160;million and
    an increase in prepayments and other current assets of
    RMB4.8&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Investing
    Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used in investing activities for the nine months ended
    September&#160;30, 2009 was RMB223.4&#160;million
    (US$32.7&#160;million). Net cash used in investing activities
    for the nine months ended September&#160;30, 2009 was due
    primarily to (i)&#160;deposits paid for the purchase of medical
    equipment for new centers that amounted to RMB116.1&#160;million
    (US$17.0&#160;million), (ii)&#160;the purchase of medical
    equipment for new centers (including the purchase from
    Chang&#146;an Hospital of the six units of radiotherapy and
    diagnostic imaging equipment) that amounted to
    RMB74.0&#160;million (US$10.8&#160;million) and (iii)&#160;the
    payment of the remaining acquisition consideration for Xing Heng
    Feng Medical and certain other business of RMB21.5&#160;million
    (US$3.2&#160;million).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used in investing activities in 2008 was
    RMB376.4&#160;million (US$55.1&#160;million). Net cash used in
    investing activities in 2008 was due primarily to our
    acquisitions of China Medstar, Xing Heng Feng Medical and
    certain other businesses to expand our network that amounted to
    RMB231.5&#160;million (US$33.9&#160;million), deposits paid for
    the purchase of medical equipment for new centers that amounted
    to RMB95.1&#160;million (US$13.9&#160;million) and the purchase
    of medical equipment for new centers that amounted to
    RMB31.6&#160;million (US$4.6&#160;million).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used in investing activities for the period from
    September&#160;10, 2007 to December&#160;31, 2007 was
    RMB30.4&#160;million. Net cash used in investing activities for
    the period was due primarily to the purchase of medical
    equipment for new centers that amounted to RMB22.5&#160;million
    and the deposits paid for the purchase of medical equipment for
    new centers that amounted to RMB13.6&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash used in investing activities for the period from
    January&#160;1, 2007 to October&#160;30, 2007 was
    RMB50.5&#160;million. Net cash used in investing activities for
    the period was due primarily to the purchase of medical
    equipment for new centers that amounted to RMB43.4&#160;million
    and the deposits paid for the purchase of medical equipment for
    new centers that amounted to RMB13.0&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Financing
    Activities</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from financing activities for the nine months
    ended September&#160;30, 2009 was RMB50.8&#160;million
    (US$7.4&#160;million). Net cash generated from financing
    activities for the nine months ended September&#160;30, 2009 was
    due primarily to the proceeds from long-term bank borrowings of
    RMB128.8&#160;million (US$18.9&#160;million) and the proceeds
    from short-term bank borrowings of RMB19.0&#160;million
    (US$2.8&#160;million), which were partially offset by the
    repayment of long-term bank borrowings of RMB70.9&#160;million
    (US$10.4&#160;million), the repayment of short-term bank
    borrowings of RMB9.8&#160;million (US$1.4&#160;million) and an
    increase in restricted cash of RMB7.2&#160;million
    (US$1.1&#160;million).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from financing activities in 2008 was
    RMB649.5&#160;million (US$95.1&#160;million). Net cash generated
    from financing activities in 2008 was due primarily to proceeds
    received from the issuance of our Series&#160;A and
    Series&#160;B contingently redeemable convertible preferred
    shares and convertible notes that amounted to
    RMB613.2&#160;million (US$89.8&#160;million), proceeds received
    from the exercise of share options that amounted to
    RMB114.6&#160;million (US$16.8&#160;million) and proceeds from
    short-term bank borrowings of RMB20.8&#160;million
    (US$3.0&#160;million), which was partially offset by repayments
    of loans from certain related parties that amounted to
    RMB41.7&#160;million (US$6.1&#160;million), the repayment of
    long-term bank borrowings of RMB37.9&#160;million
    (US$5.6&#160;million) and the repayment of short-term bank
    borrowings of RMB21.5&#160;million (US$3.1&#160;million).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from financing activities for the period from
    September&#160;10, 2007 to December&#160;31, 2007 was
    RMB63.2&#160;million. Net cash generated from financing
    activities for the period was due primarily to proceeds received
    from the issuance of our convertible notes that amounted to
    RMB36.5&#160;million and loan received from certain shareholders
    that amounted to RMB32.4&#160;million.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    87
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Net cash generated from financing activities for the period from
    January&#160;1, 2007 to October&#160;30, 2007 was
    RMB6.0&#160;million. Net cash generated from financing
    activities for the period was due primarily to loan received
    from certain shareholders that amounted to RMB6.8&#160;million
    which was partially offset by repayment of obligations under
    capitalized leases of RMB0.8&#160;million.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Acquisitions
    and Capital Expenditures</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In July 2008, we acquired China Medstar for
    &#163;17.1&#160;million, or approximately RMB238.7&#160;million
    (US$35.0&#160;million) in cash. The transaction was accepted by
    the shareholders of China Medstar and closed on July&#160;31,
    2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also acquired control of Xing Heng Feng Medical in October
    2008 for total consideration of RMB35.0&#160;million
    (US$5.1&#160;million). As of December&#160;31, 2008,
    RMB18.0&#160;million (US$2.6&#160;million) of the acquisition
    consideration was still payable which was subsequently paid in
    January 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also acquired certain other businesses related to
    radiotherapy and diagnostic imaging centers managed by third
    parties for total consideration of RMB14.0&#160;million
    (US$2.0&#160;million). As of September&#160;30, 2009, the
    acquisition consideration of RMB6.5&#160;million
    (US$1.0&#160;million) was still payable. We expect to pay the
    remaining RMB6.5&#160;million (US$1.0&#160;million) before the
    end of 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2007 and 2008 and for the nine months ended
    September&#160;30, 2009, our capital expenditures totaled
    RMB65.9&#160;million, RMB31.6&#160;million (US$4.6&#160;million)
    and RMB74.0&#160;million (US$10.8&#160;million), respectively.
    In past years, our capital expenditures related primarily to the
    purchase of medical equipment and the acquisition of assets from
    third parties. Capital expenditure decreased in 2008 as compared
    to 2007 due to our expansion of our network through the
    acquisitions of China Medstar, Xing Heng Feng Medical and other
    businesses in 2008. In August 2009, we purchased from
    Chang&#146;an Hospital the six units of radiotherapy and
    diagnostic imaging equipment that were located at the six
    centers that we previously managed under service-only agreements
    with Chang&#146;an Hospital. The total agreed upon consideration
    for such equipment was approximately RMB72.7&#160;million
    (US$10.7&#160;million), of which RMB50.0&#160;million
    (US$7.3&#160;million) was paid as of September&#160;30, 2009. We
    paid an additional RMB20.0&#160;million (US$2.9&#160;million) of
    the consideration in October 2009 and we expect to pay the
    remaining RMB2.7&#160;million (US$0.5&#160;million) before the
    end of 2009. We subsequently entered into a long-term lease and
    management services arrangement with Chang&#146;an Hospital
    pursuant to which we leased these six units of equipment to
    Chang&#146;an Hospital. Two of the six units of equipment were
    combined into one center and we provide lease and management
    services to the five remaining centers in which these six units
    of equipment are located. We estimate that our aggregate capital
    expenditures for the balance of 2009 and in 2010 will be
    approximately RMB1,200.0&#160;million (US$175.8&#160;million),
    which we will use mainly for the continued expansion of our
    network, including for the purchase of medical equipment and for
    the establishment of our specialty cancer hospitals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that our current levels of cash and cash flows from
    operations, combined with the net proceeds from this offering
    and bank loans of approximately RMB190.0&#160;million
    (US$27.8&#160;million) that we expect to obtain in 2010 to fund
    the development of our specialty cancer hospitals, will be
    sufficient to meet our anticipated cash needs for at least the
    next 12&#160;months following this offering. However, we may
    need additional cash resources in the future if we experience
    changed business conditions or other developments or if we find
    and wish to pursue opportunities for investment, acquisition,
    strategic cooperation or other similar actions. If we ever
    determine that our cash requirements exceed our amounts of cash
    on hand, we may seek to issue debt or equity securities or
    obtain a credit facility. Any issuance of equity or
    equity-linked securities could cause dilution for our
    shareholders. Any incurrence of indebtedness could increase our
    debt service obligations and cause us to be subject to
    restrictive operating and finance covenants. It is possible
    that, when we need additional cash resources, financing will
    only be available to us in amounts or on terms that would not be
    acceptable to us or financing will not be available at all.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    88
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Contractual
    Obligations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth our contractual obligations at
    December&#160;31, 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom">
    <B>Contractual Obligations</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Less Than<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>More Than<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">1&#160;Year</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">1-3&#160;Year</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">3-5&#160;Year</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">5&#160;Years</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Total</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom">
    <B>(in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Short-term debt obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term debt obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91,960
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Capital lease obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,562
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,392
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating lease obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,547
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Purchase obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    115,919
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    115,919
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,343
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,385
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,536
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,264
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our short- and long-term debt obligations as of
    December&#160;31, 2008 represent bank borrowings obtained by our
    subsidiary Shanghai Medstar. All such borrowings were entered
    into with the Agricultural Bank of China and are secured by
    medical equipment under capital lease. Our short-term bank
    borrowing outstanding as of December&#160;31, 2008 had a
    weighted average interest rate of 6.66% per annum. Our long-term
    bank borrowing outstanding as of December&#160;31, 2008 had a
    weighted average interest rate of 7.47% per annum.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of September&#160;30, 2009, we had RMB30.0&#160;million
    (US$4.4&#160;million) in short-term borrowings outstanding and
    RMB149.8&#160;million (US$21.9&#160;million) in long-term
    borrowings outstanding, including the current portion of such
    long-term borrowings outstanding. Our short-term borrowing bore
    a weighted average interest of 5.07% per annum and our long-term
    borrowings bore weighted average interest of 5.18% per annum.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shanghai Medstar entered into three additional long-term
    borrowing arrangements with the Agricultural Bank of China with
    a total amount of RMB53.8&#160;million (US$7.9&#160;million),
    all with a term to maturity of three years. These long-term
    borrowing arrangements each has a variable annual interest rate
    equal to 90% of the benchmark lending rate of the People&#146;s
    Bank of China adjusted every three months. Shanghai Medstar is
    required to make monthly payments beginning in October 2009 in
    an amount equal to RMB170,000 (US$24,900) and a final payment of
    RMB50,000 (US$7,300) related to one of the borrowings and
    monthly payments beginning in November 2009 in an amount equal
    to RMB1.2&#160;million (US$0.2&#160;million) and a final payment
    of RMB0.4 million (US$0.1&#160;million) related to another
    borrowing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shanghai Medstar also entered into a short-term loan agreement
    in June 2009 with HSBC Bank (China) Company Limited for
    RMB15.0&#160;million (US$2.2&#160;million) that matures in June
    2010 bearing interest at a rate of 5.16%, secured by account
    receivables of Shanghai Medstar and guaranteed by Aohua Medical.
    This borrowing contains restrictive covenants requiring the
    maintenance of tangible net worth of RMB400.0&#160;million and
    RMB180.0&#160;million by China Medstar and Aohua Medical,
    respectively, and a total liability to tangible net worth ratio
    of 0.5 times and 0.36 times at all time for China Medstar and
    Aohua Medical, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aohua Medical has entered into a long-term loan agreement in
    January 2009 with China Construction Bank, Shenzhen Branch for
    RMB20.0&#160;million (US$2.9&#160;million) that matures in
    January 2012. This long-term borrowing has a variable annual
    interest rate equal to 110% of the benchmark lending rate of the
    People&#146;s Bank of China, adjusted every 12&#160;months,
    secured by accounts receivable of Aohua Medical and Aohua
    Leasing and guaranteed by Aohua Leasing. Aohua Medical is
    required to make monthly repayments as to the principal of the
    borrowing beginning on the fourth month after the loan is
    obtained.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aohua Medical obtained a bank loan facility in the principal
    amount of RMB20.0&#160;million (US$2.9&#160;million) from China
    Merchant Bank Company Limited in September 2009 that expires in
    September 2010. This bank loan facility is guaranteed by Aohua
    Leasing. Interest rate for this bank loan facility is to be
    determined in accordance with the specific loan agreement
    entered into every time the facility is drawn down. As of
    September&#160;30, 2009, Aohua Medical had drawn down
    RMB4.0&#160;million (US$0.6&#160;million) of this facility.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    89
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aohua Leasing entered into a RMB100.0&#160;million
    (US$14.6&#160;million) banking facility with China Construction
    Bank in August 2009 that matures in August 2012. This banking
    facility bears interest rate equal to a floating rate of the
    People&#146;s Bank of China&#146;s benchmark lending rate
    adjusted every twelve months, which was 5.4% in August 2009. We
    expect to use this banking facility for the purchase of medical
    equipment in the future and any amount drawn under the facility
    will be secured by the respective medical equipment to be
    purchased and accounts receivable of Aohua Leasing, as well as
    guaranteed by Aohua Medical and Shanghai Medstar. Aohua Leasing
    is required under the facility agreement to make quarterly
    repayments of the principal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aohua Leasing obtained a trade financing facility in the
    principal amount of RMB20.0&#160;million (US$2.9&#160;million)
    from China Construction Bank in August 2009 that expires in
    2010. Under this trade financing facility, Aohua Leasing is
    required to pay a management fee to China Construction Bank in
    an amount equal to 5.5% of the total principal amount under this
    facility. This trade financing facility is secured by accounts
    receivable of Aohua Leasing and guaranteed by Aohua Medical and
    Shanghai Medstar.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect to obtain bank loans of approximately
    RMB90.0&#160;million (US$13.2&#160;million) in 2010 to fund the
    development of the Chang&#146;an CMS International Cancer
    Center. We also expect to obtain bank loans of approximately
    RMB100.0&#160;million (US$14.6&#160;million) in 2010 to fund the
    development of the Beijing Proton Medical Center.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the nine months ended September&#160;30, 2009, we entered
    into two non-cancellable corporate office operating leases with
    a lease term of two and three years, respectively. As of
    September&#160;30, 2009, our operating lease obligation for the
    remainder of 2009, 2010, 2011 and 2012 was RMB1.3 million
    (US$0.2 million), RMB5.1 million (US$0.8 million), RMB4.8
    million (US$0.7 million) and RMB2.3 million (US$0.3 million),
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of September&#160;30, 2009, we had purchase obligation for
    certain medical equipment that amounted to RMB102.7 million
    (US$15.0 million), which are all scheduled to be paid within one
    year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Off-Balance
    Sheet Arrangements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not engage in trading activities involving non-exchange
    traded contracts or interest rate swap transactions or foreign
    currency forward contracts. In the ordinary course of our
    business, we do not enter into transactions involving, or
    otherwise form relationships with, unconsolidated entities or
    financials partnerships that are established for the purpose of
    facilitating off-balance sheet arrangements or other
    contractually narrow or limited purposes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Inflation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In recent years, China has not experienced significant
    inflation, and thus inflation has not had a material impact on
    our results of operations. According to the National Bureau of
    Statistics of China, the change in China&#146;s Consumer Price
    Index was 1.5%, 4.8% and 5.9% in the years 2006, 2007 and 2008,
    respectively. If inflation continues to rise, it may materially
    and adversely affect our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Quantitative
    and Qualitative Disclosure about Market Risk</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Foreign
    Exchange Risk</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All of our revenues and substantially all of our expenditures
    are denominated in Renminbi. However, the price of medical
    equipment that we purchase from foreign manufacturers is
    denominated in U.S.&#160;dollars. We pay for such equipment in
    Renminbi through importers at a pre-determined exchange rate
    that is typically agreed to at the time of purchase that will be
    adjusted to a certain extent if there is significant fluctuation
    as to the exchange rate. As a result, fluctuations in the
    exchange rate between the U.S.&#160;dollar and the Renminbi will
    affect the cost of such medical equipment to us and will affect
    our results of operation and financial condition. Such
    fluctuations will also affect us with respect to the translation
    of the net proceeds that we will receive from this offering into
    Renminbi. The Renminbi&#146;s exchange rate with the
    U.S.&#160;dollar and other currencies is affected by, among
    other things, changes in China&#146;s political and economic
    conditions. See &#147;Risk Factors&#160;&#151; Risks Related to
    Doing Business in China&#160;&#151; Fluctuations in the value of
    the Renminbi may have a material adverse effect on your
    investment.&#148; Any significant revaluation of the Renminbi
    may materially and adversely affect our cash flows, revenues,
    earnings and financial
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    90
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    position, and the value of, and any dividends payable on, our
    ADSs in U.S.&#160;dollars. Based on the amount of our cash
    denominated in U.S.&#160;dollar as of September&#160;30, 2009, a
    10% change in the exchange rates between the Renminbi and the
    U.S.&#160;dollar would result in an increase or decrease of
    RMB24.3&#160;million (US$3.6&#160;million) in our total cash
    position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The functional currency of our company and our subsidiaries,
    including Ascendium, CMS Holdings, OMS, Cyber Medical and China
    Medstar, is the U.S.&#160;Dollar. Our PRC subsidiaries have
    determined their functional currencies to be the Renminbi based
    on the criteria of Statement of Financial Accounting Standards
    No.&#160;52, &#147;Foreign Currency Translation,&#148; or
    SFAS&#160;52. We use the Renminbi as our reporting currency. We
    use the monthly average exchange rate for the year and the
    exchange rate at the balance sheet date to translate the
    operating results and financial position of our PRC
    subsidiaries, respectively. Translation differences are recorded
    in accumulated other comprehensive income, a component of
    shareholders&#146; equity. Transactions denominated in foreign
    currencies are remeasured into our functional currency at the
    exchange rates prevailing on the transaction dates. Foreign
    currency denominated financial assets and liabilities are
    remeasured at the balance sheet date exchange rate. Exchange
    gains and losses are included in the consolidated statements of
    income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Interest
    Rate Risk</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our exposure to interest rate risk relates to interest expenses
    incurred by our short-term and long-term bank borrowings and
    interest income on our interest-bearing bank deposits. We have
    not used any derivative financial instruments or engaged in any
    interest rate hedging activities to manage our interest rate
    risk exposure. Our future interest expense on our short-term and
    long-term borrowings may increase or decrease due to changes in
    market interest rates. During 2008, our short-term and long-term
    bank borrowings, all of which were denominated in Renminbi, had
    a weighted average interest rate of 6.66% per annum and 7.47%
    per annum, respectively. Our future interest income on our
    interest-bearing cash and pledged deposit balances may increase
    or decrease due to changes in market interest conditions. We
    monitor interest rates in conjunction with our cash requirements
    to determine the appropriate level of bank borrowings relative
    to other sources of funds. Based on our outstanding borrowings
    during the six months ended September&#160;30, 2009, a 10%
    change in the interest rates would result in an increase or
    decrease of RMB0.5&#160;million (US$0.1&#160;million) of our
    total amount of interest expense for the nine months ended
    September&#160;30, 2009. Based on our outstanding interest
    earning instruments during the nine months ended
    September&#160;30, 2009, a 10% change in the interest rates
    would result in an increase or decrease of RMB 82,000
    (US$12,000) in our total amount of interest income for the nine
    months ended September&#160;30, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There have been no developments to recently issued accounting
    standards, including the expected dates of adoption and
    estimated effects on the Group&#146;s consolidated financial
    statements, from those disclosed in the Group&#146;s
    consolidated financial statements for the year ended
    December&#160;31, 2008, except for the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In April 2009, the Financial Accounting Standards Board
    (&#147;FASB&#148;) issued Accounting Standards Codification
    (&#147;ASC&#148;)
    <FONT style="white-space: nowrap">805-20,</FONT>
    &#147;Accounting for Assets Acquired and Liabilities Assumed in
    a Business Combination That Arise from Contingencies&#148; to
    amend SFAS 141 (revised 2007)&#160;&#147;Business
    Combinations.&#148; ASC
    <FONT style="white-space: nowrap">805-20</FONT>
    addresses the initial recognition, measurement and subsequent
    accounting for assets and liabilities arising from contingencies
    in a business combination, and requires that such assets
    acquired or liabilities assumed be initially recognized at fair
    value at the acquisition date if fair value can be determined
    during the measurement period. If the acquisition-date fair
    value cannot be determined, the asset acquired or liability
    assumed arising from a contingency is recognized only if certain
    criteria are met. ASC
    <FONT style="white-space: nowrap">805-20</FONT> also
    requires that a systematic and rational basis for subsequently
    measuring and accounting for the assets or liabilities be
    developed depending on their nature. The Company does not
    anticipate that the adoption of this statement will have a
    material impact on its consolidated financial statements, absent
    any material business combinations.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2009, the FASB issued SFAS&#160;No.&#160;166,
    &#147;Accounting for Transfers of Financial Assets&#160;&#151;
    an amendment of FASB Statement No. 140&#148;
    (&#147;SFAS&#160;166&#148;). SFAS&#160;166 seeks to improve the
    relevance, representational faithfulness, and comparability of
    the information that a reporting entity provides in its
    financial statements about a transfer of financial assets; the
    effects of a transfer on its financial position, financial
    performance, and cash flows; and a transferor&#146;s continuing
    involvement, if any, in transferred
</TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    91
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    financial assets. Specifically, SFAS&#160;166 eliminates the
    concept of a qualifying special-purpose entity, creates more
    stringent conditions for reporting a transfer of a portion of a
    financial asset as a sale, clarifies other sale-accounting
    criteria, and changes the initial measurement of a
    transferor&#146;s interest in transferred financial assets. The
    Company does not anticipate that the adoption of this statement
    will have a material impact on its consolidated financial
    statements.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2009, the FASB issued SFAS&#160;No.&#160;167,
    &#147;Amendments to FASB Interpretation No.&#160;46(R)&#148;
    (&#147;SFAS&#160;167&#148;). SFAS&#160;167 amends FASB
    Interpretation No.&#160;46(R), &#147;Variable Interest
    Entities&#148; for determining whether an entity is a variable
    interest entity (&#147;VIE&#148;) and requires an enterprise to
    perform an analysis to determine whether the enterprise&#146;s
    variable interest or interests give it a controlling financial
    interest in a VIE. Under SFAS&#160;167, an enterprise has a
    controlling financial interest when it has a)&#160;the power to
    direct the activities of a VIE that most significantly impact
    the entity&#146;s economic performance and b)&#160;the
    obligation to absorb losses of the entity or the right to
    receive benefits from the entity that could potentially be
    significant to the VIE. SFAS 167 also requires an enterprise to
    assess whether it has an implicit financial responsibility to
    ensure that a VIE operates as designed when determining whether
    it has power to direct the activities of the VIE that most
    significantly impact the entity&#146;s economic performance.
    SFAS&#160;167 also requires ongoing assessments of whether an
    enterprise is the primary beneficiary of a VIE, requires
    enhanced disclosures and eliminates the scope exclusion for
    qualifying special-purpose entities. The Company is currently
    evaluating the impact the adoption of SFAS&#160;167 will have on
    its consolidated financial statements.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2009, the FASB issued Statement of Financial Accounting
    Standard (&#147;SFAS&#148;) No.&#160;168, The FASB Accounting
    Standards
    Codification<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    and the Hierarchy of Generally Accepted Accounting Principles, a
    replacement of FASB Statement No.&#160;162. This statement
    modifies the Generally Accepted Accounting Principles
    (&#147;GAAP&#148;) hierarchy by establishing only two levels of
    GAAP, authoritative and nonauthoritative accounting literature.
    Effective July 2009, the FASB Accounting Standards
    Codification<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    (&#147;ASC&#148;), also known collectively as the
    &#147;Codification,&#148; is considered the single source of
    authoritative U.S.&#160;accounting and reporting standards,
    except for additional authoritative rules and interpretive
    releases issued by the SEC. Nonauthoritative guidance and
    literature would include, among other things, FASB Concepts
    Statements, American Institute of Certified Public Accountants
    Issue Papers and Technical Practice Aids and accounting
    textbooks. The Codification was developed to organize
    U.S.&#160;GAAP pronouncements by topic so that users can more
    easily access authoritative accounting guidance. It is organized
    by topic, subtopic, section, and paragraph, each of which is
    identified by a numerical designation. This statement applies
    beginning in third quarter 2009. All accounting references have
    been updated, and therefore U.S.&#160;GAAP standards have been
    replaced with ASC references. This standard had no impact on the
    Company&#146;s financial position, results of operations or cash
    flows.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In August 2009, the FASB issued Accounting Standards Update
    <FONT style="white-space: nowrap">No.&#160;2009-5,</FONT>
    &#147;Measuring Liabilities at Fair Value&#148; (&#147;ASU
    <FONT style="white-space: nowrap">2009-05&#148;).</FONT>
    ASU <FONT style="white-space: nowrap">2009-05</FONT>
    amends Accounting Standards Codification Topic 820, &#147;Fair
    Value Measurements.&#148; Specifically, ASU
    <FONT style="white-space: nowrap">2009-05</FONT>
    provides clarification that in circumstances in which a quoted
    price in an active market for the identical liability is not
    available, a reporting entity is required to measure fair value
    using one or more of the following methods: 1)&#160;a valuation
    technique that uses a)&#160;the quoted price of the identical
    liability when traded as an asset or b)&#160;quoted prices for
    similar liabilities or similar liabilities when traded as assets
    <FONT style="white-space: nowrap">and/or</FONT>
    2)&#160;a valuation technique that is consistent with the
    principles of Topic 820 of the Accounting Standards Codification
    (e.g. an income approach or market approach). ASU
    <FONT style="white-space: nowrap">2009-05</FONT> also
    clarifies that when estimating the fair value of a liability, a
    reporting entity is not required to adjust to include inputs
    relating to the existence of transfer restrictions on that
    liability. The Company does not anticipate that the adoption of
    this statement will have a material impact on its consolidated
    financial statements.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In September 2009, the Emerging Issues Task Force (EITF) reached
    final consensus on ASC
    <FONT style="white-space: nowrap">605-25,</FONT>
    &#147;Revenue Arrangements with Multiple Deliverables.&#148; ASC
    <FONT style="white-space: nowrap">605-25</FONT>
    addresses how to determine whether an arrangement involving
    multiple deliverables contains more than one unit of accounting,
    and how the arrangement consideration should be allocated among
    the separate units of accounting.
    <FONT style="white-space: nowrap">EITF&#160;08-1</FONT>
    may be applied retrospectively or prospectively for new or
    materially modified arrangements and early adoption is
    permitted. The Company does not anticipate that the adoption of
    this statement will have a material impact on its consolidated
    financial statements.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    92
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='113'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">OUR
    INDUSTRY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cancer was the leading cause of death in China in 2008 according
    to the MOH. Approximately 3.5&#160;million patients were
    diagnosed with cancer in 2008 in China, according to a
    commissioned report by Frost&#160;&#038; Sullivan.
    Frost&#160;&#038; Sullivan also estimated that the cancer
    radiotherapy and diagnostic imaging market in China was
    RMB16.6&#160;billion (US$2.4&#160;billion) in 2008 and is
    expected to grow to RMB68.3&#160;billion (US$10.0&#160;billion)
    in 2015, representing a CAGR of 22.4%. Among the factors
    contributing to this growth rate are significant projected
    growth in the number of new cancer cases due to the continued
    aging and urbanization of the Chinese population, increased
    affordability of cancer diagnosis and treatment as a result of
    rising disposable income and increased government expenditure on
    healthcare and growing awareness and adoption of advanced cancer
    diagnosis and treatment modalities by Chinese patients and
    physicians.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cancer in
    China</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cancer was the leading cause of death in China in 2008. Based on
    MOH data, cancer accounted for 2.1&#160;million deaths, or 26.2%
    of total deaths in China in 2008. There were approximately
    3.5&#160;million patients diagnosed with cancer in China in
    2008, according to a report by Frost&#160;&#038; Sullivan.
    Frost&#160;&#038; Sullivan further estimates that new cancer
    cases will increase to approximately 4.1&#160;million in China
    in 2015, representing CAGR of 2.6%, compared to an estimated
    CAGR of 1.5% for the United States over the same period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to a survey conducted by the MOH in 2008, the increase
    in cancer cases in China is primarily attributable to
    demographic changes and urbanization, since elderly and urban
    populations exhibit higher rates of cancer compared to the
    overall population. With respect to demographic changes,
    China&#146;s population increased by 9.6% from approximately
    1.2&#160;billion in 1995 to approximately 1.3&#160;billion in
    2008, while the number of individuals over 65&#160;years old
    increased by 46.8% from 75.1&#160;million to 110.2&#160;million
    over the same period. In contrast, according to United States
    Census Bureau, the U.S.&#160;population increased by 14.1% from
    266.6&#160;million in 1995 to 304.1&#160;million in 2008, while
    the number of individuals over 65&#160;years old increased by
    15.2% from 33.8&#160;million to 38.9&#160;million over the same
    period. Additionally, China&#146;s urban population increased by
    72.5% from 351.7&#160;million in 1995 to 606.7&#160;million in
    2008. According to the MOH, tobacco usage and environmental
    pollution have also contributed to higher rates of cancer for
    China&#146;s urban residents. All of these factors suggest a
    significant increase in potential demand for cancer diagnosis
    and treatment in the future.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cancer
    Diagnosis and Treatment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Modern cancer treatments rely heavily on the utilization of
    advanced diagnostic imaging technologies such as computerized
    tomography, or CT, magnetic resonance imaging, or MRI and
    positron emission tomography, or PET. Principal cancer
    treatments include various types of radiotherapy, chemotherapy
    and surgery, which may be used alone or in combination with each
    other. With respect to radiotherapy, there are several different
    treatment options, including gamma knife systems and linear
    accelerators, as well as the more advanced proton therapy
    systems. The choice of cancer treatment options depends upon the
    location of the tumor in the body, the type of the tumor and the
    stage of the disease, as well as the general state of health of
    the patient. The WHO reported in its 2008 World Cancer Report
    that a little over 50% of all patients who develop cancer will
    require some type of radiotherapy during their illness.
    According to a report by Frost&#160;&#038; Sullivan, the
    percentage of cancer patients who underwent surgery,
    chemotherapy and radiotherapy in China in 2008 was approximately
    74.0%, 70.3% and 32.6%, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Radiotherapy (also called &#147;radiation therapy&#148; or
    &#147;radiation treatment&#148;) utilizes focused doses of
    intense radiation to kill cancer cells and shrink tumors.
    Radiotherapy can be used to treat almost every type of malignant
    solid tumor as well as benign tumors. Advances in different
    imaging modalities (e.g., PET-CT) and the integrated use of
    these modalities with radiotherapy are expected to enhance the
    precision of radiotherapy treatments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Provision
    of Healthcare Services in China</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Healthcare services in China are provided primarily at
    hospitals. Patients visit the hospital for both in-patient and
    most out-patient care. Physicians are typically employed by
    hospitals and work on the hospital premises. According to the
    MOH and the general logistics department of the PLA, at the end
    of 2008, there were approximately 19,800 hospitals in China,
    including approximately 115 specialty cancer hospitals.
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    93
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Approximately 80% of hospitals in China are owned by the
    government, government agencies, government controlled
    corporations or the military. Such hospitals (including military
    hospitals) typically serve the general public. While these
    hospitals are owned in some way by the government, they receive
    little direct government funding and are individually financed.
    These government hospitals also operate largely independently of
    each other and generally do not operate as groups of hospitals
    under common control. Ownership of privately-owned hospitals in
    China is also fragmented, with a lack of dominant groups of
    hospitals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China has a relatively underdeveloped medical infrastructure,
    which has resulted in significant unmet demand for medical
    services in China. According to the WHO, there were 22 hospital
    beds per 10,000&#160;people in China in 2008 versus 31, 39, 86
    and 140 hospital beds per 10,000 people in the United States,
    the United Kingdom, Korea and Japan, respectively. The average
    occupancy rate for China&#146;s hospitals in 2008 was 74.6%,
    while the average occupancy rate for China&#146;s specialty
    cancer hospitals during that same period was a much higher
    104.1%, according to the MOH.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The largest portion of healthcare expenses in China is funded by
    private individuals. The MOH reported that in 2007, self payment
    accounted for 45.2% of China&#146;s total medical expenses,
    whereas payment by public medical insurance schemes, commercial
    insurance plans and employers accounted for another 34.5%, and
    the direct payment by the government accounted for the remaining
    20.4%. In China, most patients currently pay medical expenses
    out-of-pocket prior to receiving medical services and later seek
    insurance reimbursement, to the extent, if any, that they are
    covered by medical insurance schemes. The up-front collection of
    medical fees, whether or not the patient is insured, together
    with China&#146;s lack of emergency medical treatment laws such
    as those in the United States, which require the treatment of
    the uninsured, results in very low bad debt and charity care
    expenditures for hospitals and other healthcare service
    providers in China. Due to cultural factors, the high percentage
    of out-of-pocket expenses and the need to pay for medical
    services upfront, family members of Chinese patients frequently
    contribute to the payment of healthcare expenses, particularly
    in the case of non-discretionary healthcare expenses, such as
    the diagnosis and treatment of cancer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611h0361104.gif" alt="PIE CHART">
</DIV>



<DIV align="left" style="margin-left: 21%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 8pt">Source: MOH
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Radiotherapy
    and Diagnostic Imaging in China</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Chinese radiotherapy and diagnostic imaging market has grown
    steadily over the years. According to a report by
    Frost&#160;&#038; Sullivan, there were approximately
    1,187&#160;linear accelerators, 159 head gamma knife systems, 86
    body gamma knife systems, 122 PET-CT scanners and 2,260 MRI
    scanners installed across the country in 2008. CAGRs of such
    installed equipment were 16.4%, 18.9%, 16.0%, 16.9% and 22.6%
    from 2003 to 2008, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    94
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611h0361105.gif" alt="PIE CHART">
</DIV>



<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 8pt">Source: Frost&#160;&#038; Sullivan,
    2008
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Despite this high level of growth, the number of units of
    radiotherapy and diagnostic imaging equipment per capita in
    China is significantly lower than in developed countries. The
    Frost&#160;&#038; Sullivan report estimates that at the end of
    2008, China had only 0.7 linear accelerators per million people,
    compared to 9.5 in the United States, 6.6 in Japan, 5.6 in
    France and 3.0 in the United Kingdom during the same period. The
    relatively low penetration of radiotherapy equipment in China
    contributes to the low rate of treatment using radiotherapy
    received by cancer patients in China. We also believe that a
    generally low level of education amongst Chinese physicians
    about advanced radiotherapy is a key contributor to the
    relatively low rate of usage of radiotherapy for the treatment
    of cancer patients in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611h0361106.gif" alt="PIE CHART">
</DIV>



<DIV align="left" style="margin-left: 2%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 8pt">Source: Frost&#160;&#038; Sullivan,
    2008
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The vast majority of radiotherapy and diagnostic imaging
    services are performed in hospitals. Hospitals are motivated to
    offer high-end services such as radiotherapy and diagnostic
    imaging services to attract patients and increase hospital
    revenues. The challenge, however, is that many hospitals in
    China cannot fund expensive equipment purchases due to limited
    operating cash flows, inability to raise equity funding, limited
    access to debt financing and the absence of vendor financing.
    Hospitals in China generally also lack experienced radiologists
    and technicians and management experience in operating
    radiotherapy and diagnostic imaging centers.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    95
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    While most of the expenses for radiotherapy and diagnostic
    imaging services are paid up-front by patients, some
    reimbursement is available to patients through
    government-directed insurance schemes. We believe that
    radiotherapy modalities including head gamma knife systems, body
    gamma knife systems and linear accelerators are currently
    covered by most government-directed medical insurance schemes in
    China, but reimbursement rates differ depending on geographical
    locations. MRI scans are commonly covered by various
    government-directed medical insurance schemes in China, while
    PET-CT scans are generally not covered by such schemes. For more
    information, see &#147;Regulation of Our Industry&#160;&#151;
    Medical Insurance Coverage.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to a report by Frost&#160;&#038; Sullivan, the China
    cancer radiotherapy and diagnostic imaging market is expected to
    continue to grow. It is estimated that the linear accelerator
    market will increase from RMB4.2&#160;billion
    (US$612.7&#160;million) in 2008 to RMB 17.9&#160;billion
    (US$2.6&#160;billion) in 2015, representing a CAGR of 23.0%. The
    gamma knife systems market is expected to grow from
    RMB1.3&#160;billion (US$194.9&#160;million) in 2008 to
    RMB6.7&#160;billion (US$977.6&#160;million) in 2015,
    representing a CAGR of 25.9%. The diagnostic imaging market,
    primarily consisting of MRI, PET-CT and CT, is expected to grow
    from RMB10.7&#160;billion (US$1.6&#160;billion) in 2008 to
    RMB23.9&#160;billion (US$3.5&#160;billion) in 2015, representing
    a CAGR of 12.1%. The following are the primary factors
    contributing to the growing demand for cancer radiotherapy and
    diagnostic imaging services:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <B>Increasing cancer incidence rate:</B> The cancer incidence
    rate in China has grown from approximately 0.216% in 2003 to
    approximately 0.260% in 2008, an increase of 20.4%, according to
    a report by Frost&#160;&#038; Sullivan. It is expected that
    demographic changes and urbanization will lead to further
    increases in the number of cancer cases in China.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <B>Increasing physician adoption of advanced diagnostic imaging
    equipment: </B>With the modernization of medical care in China,
    more physicians are expected to utilize more advanced diagnostic
    imaging equipment, such as MRI and PET-CT.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <B>Increasing percentage of cancer patients treated with
    radiotherapy:</B> The percentage of cancer patients treated with
    radiotherapy is expected to increase due to improving awareness
    of radiotherapy among the doctors and patients, and increased
    availability of radiotherapy and diagnostic imaging equipment.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    <B>Increasing affordability and potentially increased
    accessibility:</B> China&#146;s rising disposable income and
    increasing government expenditure on healthcare are also
    expected to stimulate the overall demand for radiotherapy and
    diagnostic imaging services. In addition, China recently
    approved a new round of healthcare reforms that encourage the
    investment of private capital in non-profit hospitals, which may
    potentially increase the accessibility of radiotherapy and
    diagnostic imaging services to patients.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    96
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='114'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">BUSINESS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We operate the largest network of radiotherapy and diagnostic
    imaging centers in China in terms of revenue and the total
    number of centers in operation in 2008, according to a report by
    Frost&#160;&#038; Sullivan commissioned by us. As of
    September&#160;30, 2009, our network comprised 83&#160;centers
    based in 55&#160;hospitals, spanning 36&#160;cities across
    21&#160;provinces and administrative regions in China. These
    hospitals are substantially comprised of 3A hospitals, the
    highest ranked hospitals by quality and size in China as
    determined in accordance with the standards of the MOH. Cancer
    was the leading cause of death in China in 2008 according to the
    MOH, and there is a relatively low penetration of radiotherapy
    and diagnostic imaging equipment compared to developed
    countries. We believe that our leading network and our
    experience and expertise uniquely position us to address the
    underserved market in China for radiotherapy and diagnostic
    imaging services.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Most of the centers in our network are established through
    long-term lease and management services arrangements entered
    into with our hospital partners. Under these arrangements, we
    receive a contracted percentage of each center&#146;s revenue
    net of specified operating expenses. Each center is located on
    the premises of our hospital partners and is typically equipped
    with a primary unit of advanced radiotherapy and diagnostic
    imaging equipment, such as a linear accelerator, head gamma
    knife system, body gamma knife system, PET-CT scanner or MRI
    scanner. We provide clinical support services to doctors who
    work in the centers in our network, which include developing
    treatment protocols for doctors and organizing joint diagnosis
    between doctors in our network and clinical research. In
    addition, we help recruit and determine the compensation of
    doctors and other medical personnel in our network and are
    typically in charge of most of the non-clinical aspects of the
    centers&#146; daily operations, including marketing, training
    and administrative duties. Our hospital partners are responsible
    for the centers&#146; clinical activities, the medical decisions
    made by doctors, and the employment of the doctors in accordance
    with regulations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that our success is largely due to the high quality
    clinical care provided at our network of centers and our
    market-oriented management culture and practices. Many of the
    doctors who work in our network have extensive clinical
    experience in radiotherapy, some of whom are recognized as
    leading experts in radiation oncology in China. We enhance the
    quality of clinical care in our network through established
    training of, and on-going clinical education for, doctors in our
    network. We believe that our market-oriented management culture
    and practices allow us to manage centers more efficiently and
    offer more consistent and better patient services than our
    competitors. We believe that our success has given us a strong
    reputation within the medical community, which in turn gives us
    a competitive advantage in gaining patient referrals and
    establishing new centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To complement our organic growth, we have also selectively
    acquired businesses to expand our network. In July 2008, we
    acquired China Medstar, a company then publicly listed on the
    AIM, for approximately &#163;17.1&#160;million or approximately
    RMB238.7&#160;million (US$35.0&#160;million). At the time of the
    acquisition, China Medstar jointly managed 23 centers with its
    hospital partners across 14&#160;cities in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To further enhance our reputation and to employ high quality
    doctors, we plan to establish and operate specialty cancer
    hospitals in China. We intend for our specialty cancer hospitals
    to be centers of excellence. Our first specialty cancer
    hospital, the Chang&#146;an CMS International Cancer Center, in
    Xi&#146;an, Shaanxi Province, is expected to commence operation
    in early 2010. We are also in the process of establishing the
    Beijing Proton Medical Center, another specialty cancer
    hospital, which is expected to commence operation in 2012. We
    expect that the Beijing Proton Medical Center will be the first
    proton beam therapy treatment center in China equipped with a
    proton beam therapy system licensed for clinical use.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our business has grown significantly in recent years through
    development of new centers, increases in the number of patient
    cases in our network and acquisitions. We have increased the
    number of centers in our network from 41 at the end of 2007 to
    72 at the end of 2008 and to 83 as of September&#160;30, 2009.
    Our total net revenues were RMB67.4&#160;million,
    RMB14.0&#160;million and RMB171.8&#160;million
    (US$25.2&#160;million) for the period from January&#160;1, 2007
    to October&#160;30, 2007, the period from September&#160;10,
    2007 to December&#160;31, 2007 and for the year ended
    December&#160;31, 2008. Our total net revenues increased to
    RMB205.7&#160;million (US$30.1&#160;million) for the nine
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    97
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    months ended September&#160;30, 2009 from RMB102.0&#160;million
    for the same period in 2008, due primarily to an increase in the
    number of centers in our network, including centers added to our
    network as a result of our acquisition of China Medstar, and an
    increase in the number of patient cases in existing centers. For
    periods prior to October&#160;30, 2007, our predecessor is
    deemed the reporting entity for financial reporting purposes as
    a result of the OMS reorganization. We report the financial
    statements of our successor entity from September&#160;10, 2007,
    the date of inception of our successor entity. For additional
    information relating to our history and reorganization and our
    financial presentation, see &#147;Our History and Corporate
    Structure&#148; and &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Market
    Opportunities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As discussed in the &#147;Our Industry&#148; section of this
    prospectus, the radiotherapy and diagnostic imaging market in
    China has several favorable characteristics. The market is
    expected to experience significant growth due to an increasing
    incidence rate of cancer and increasing adoption and
    affordability of advanced radiotherapy and diagnostic imaging
    technologies. Moreover, most hospitals lack the financial
    resources to purchase, or the expertise to operate, advanced
    radiotherapy and diagnostic imaging equipment. These
    deficiencies, together with the generally low level of awareness
    amongst doctors in China about the efficacy of advanced
    radiotherapy, has resulted in a relatively low usage rate of
    radiotherapy for the treatment of cancer patients in China. We
    believe that our ability to provide the necessary equipment and
    expertise to hospitals in China to establish and jointly manage
    radiotherapy centers will allow us to benefit from these
    positive market dynamics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Competitive
    Strengths</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that the following competitive strengths have, and
    will continue to, uniquely position us to capitalize on growth
    opportunities in the cancer treatment market in China:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Leading
    Market Position and Successful Track Record</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    According to a report by Frost&#160;&#038; Sullivan, we operate
    the largest network of radiotherapy and diagnostic imaging
    centers in China in terms of revenues and the number of centers
    in operation in 2008. As of September&#160;30, 2009, our network
    comprised 83&#160;centers based in 55&#160;hospitals, spanning
    36&#160;cities across 21&#160;provinces and administrative
    region in China. Our network includes 73 radiotherapy and
    diagnostic imaging centers and 10&#160;centers that provide
    other treatment and diagnostic services, such as
    electroencephalography for the diagnosis of epilepsy,
    thermotherapy to increase the efficacy of and for pain relief
    after radiotherapy and chemotherapy, high intensity focused
    ultrasound therapy for the treatment of cancer, stereotactic
    radiofrequency ablation for the treatment of Parkinson&#146;s
    Disease and refraction and tonometry for the diagnosis of
    ophthalmic conditions. According to a report by Frost &#038;
    Sullivan, we were the first company to have established such an
    extensive network of centers across China. Our first center was
    established in 1997, and more than half of the centers in our
    network have been in operation for over five years. The doctors
    in our network have performed over 48,000 radiotherapy
    treatments and over 100,000 diagnostic imaging scans since the
    beginning of 2007. We believe that we have a strong reputation
    within the medical community in China, due to the large number
    of cancer patients treated in our network and the extensive
    clinical experience of the doctors in our network of centers. We
    believe that our market leading position, successful track
    record and the strong reputation of centers in our network
    provide us with a significant advantage relative to our
    competitors in establishing new centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Doctors
    with Extensive Cancer Treatment Experience Developed and
    Supported by Our Network</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are over 240&#160;doctors, including radiation oncologists
    and neurosurgeons, who work in our network, some of whom are
    leading experts in their respective fields in China. We provide
    training, ongoing clinical education, including regularly
    scheduled network-wide clinical education conferences and
    seminars, where medical personnel from our network of centers
    and outside medical experts in China are invited to share their
    clinical experience. These efforts enable the doctors in our
    network to increase their clinical knowledge. We also organize
    and sponsor clinical research conducted by doctors in our
    network. The clinical expertise of the doctors in our network is
    supplemented by their ability to consult with each other and
    thereby enhancing the clinical care they provide to their
    patients.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    98
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Market-oriented
    Management of Centers</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We bring a market-oriented management culture and practices to
    the operation of our centers, driven by patient needs and market
    conditions. As a result, we believe that the centers in our
    network are run more efficiently and provide better patient
    services as compared to other public hospitals. Such
    market-oriented management practices include staffing most
    centers in our network with dedicated marketing professionals
    who promote our services to potential referring doctors. In
    addition, the compensation for the staff in each center,
    including doctors, is partially based on such center&#146;s
    operating performance whereby the staff in each center typically
    receives bonuses based on the monthly revenue generated by such
    center, the number of patients treated or received diagnostic
    imaging services in a given month, the annual profit target of
    the center and other performance metrics as determined by us,
    such as staff&#146;s compliance with the operating procedures of
    the centers, the quality of treatments and services provided,
    the staff&#146;s research activities conducted at the centers
    and the timely maintenance of records. Our market-oriented
    management practices also, unlike most other public hospitals in
    China, focus on providing high quality patient services, which
    we believe is a key component in establishing a strong
    reputation as to our network of centers and a key factor in
    doctors&#146; decisions to refer patients to centers in our
    network.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Successful
    Track Record of New Center Development and
    Acquisitions</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have grown our business through development of new centers
    and through selective acquisitions of businesses and assets from
    third parties. Such development and acquisitions are subject to
    an extensive internal evaluation and approval process that
    involves a team of dedicated business development professionals,
    a team of project evaluation professionals and our senior
    management. In 2008, we added 32 new centers under lease and
    management services arrangements of which 25 were added through
    acquisitions. Our acquisitions in 2008 include China Medstar and
    its network of 23 centers located in 14&#160;cities across China
    which we have we successfully integrated into our network. This
    acquisition significantly expanded our network of centers,
    broadened our service offerings by significantly increasing the
    number of centers in our network that provide treatments through
    the use of linear accelerators and diagnostic imaging services
    using MRI scanners, and strengthened our management team. During
    the nine months ended September&#160;30, 2009, we added 19 new
    centers to our network under lease and management arrangements,
    five of which were converted in August 2009 from six centers
    that were previously managed under service-only agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Strong
    and Experienced Management Team</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are led by a strong management team of experienced
    professionals with complementary skill sets. Several of our
    senior executives have experience as senior managers of
    companies publicly listed on the stock exchanges in China, on
    the AIM and on the NYSE. Two members of our senior management
    team founded one of the first companies in China engaged in
    developing and providing management services to radiotherapy and
    diagnostic imaging centers and both have more than 10&#160;years
    of experience in establishing and managing such centers. Our
    senior management team is supported by a team of experienced
    professionals who have worked for many years in the radiotherapy
    market in China, including several former doctors who bring to
    our network clinical experience and strong relationships with
    directors and senior managers of hospitals around China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Business
    Strategies</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to further strengthen our leading position in the
    radiotherapy and diagnostic imaging market in China by pursuing
    the following strategies:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Continue
    to Develop New Radiotherapy and Diagnostic Imaging
    Centers</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that there are significant opportunities to grow our
    business through the continued expansion of our network of
    radiotherapy and diagnostic imaging centers. We have a dedicated
    business development team that is primarily responsible for
    identifying, evaluating, and negotiating opportunities to
    develop new centers with new hospital partners. As of
    September&#160;30, 2009, we have entered into agreements to
    establish additional 30 new centers in China, and we expect five
    of these centers to commence operation by the end of 2009. We
    plan to increase the number of centers in our nationwide network
    of centers in China to at least 200 over the next three years.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    99
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Increase
    Marketing Efforts to Drive Growth in Patient Cases at Our
    Existing Centers</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We plan to continue our center-based marketing efforts to
    increase the number of patients diagnosed and treated in our
    network of centers. Most centers in our network are staffed with
    dedicated marketing personnel employed by us and responsible for
    promoting the radiotherapy and diagnostic imaging services
    offered at the centers to both referring doctors and patients.
    These marketing personnel help to educate referring doctors and
    patients on the types of cancer that are suitable for
    radiotherapy and the benefits of radiotherapy. At the corporate
    level, we support the center-based marketing efforts by
    arranging for radiotherapy experts to participate in academic
    conferences and seminars hosted by different centers in our
    network for referring doctors as well as helping the individual
    centers prepare relevant marketing materials. We plan to
    increase center-based marketing efforts to enhance the awareness
    and understanding of cancer diagnosis and treatment and thus
    increase the patient cases at our centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Establish
    Specialty Cancer Hospitals</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are in the process of establishing specialty cancer hospitals
    in China that will be majority owned by us. We intend for our
    specialty cancer hospitals to be our centers of excellence that
    will focus on providing radiotherapy services as well as
    diagnostic imaging services, chemotherapy and surgery in order
    to provide a comprehensive treatment program for cancer
    patients. We believe that establishing specialty cancer
    hospitals will allow us to further strengthen our reputation
    amongst patients and within the medical community in China and
    develop our corporate brand. We have established a dedicated
    hospital investment team focused on identifying and evaluating
    potential opportunities to develop additional specialty cancer
    hospitals. Our first two specialty cancer hospitals, the
    Chang&#146;an CMS International Cancer Center and the Beijing
    Proton Medical Center, are expected to be operational in early
    2010 and in 2012, respectively. We also plan to establish
    additional specialty cancer hospitals in key cities across China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Introduce
    Advanced Cancer Treatment Options and Diagnostic Technology in
    Our Network</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to introduce the most technologically advanced medical
    equipment in China to enhance the quality of treatment available
    to patients. For example, our Beijing Proton Medical Center is
    expected to be the first proton beam therapy system in China
    licensed for clinical use. We believe that introducing such
    technology will allow us to offer cancer patients some of the
    most advanced medical care available in China, attract
    additional patients and strengthen our leadership position and
    reputation in the radiotherapy market in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Complement
    Our Development of New Centers with Selected
    Acquisitions</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We intend to selectively pursue strategic acquisitions that will
    complement our efforts to develop new centers. Given the
    fragmentation of the industry in which we operate, there are a
    large number of
    <FONT style="white-space: nowrap">stand-alone</FONT>
    centers and companies that manage small networks of centers that
    we believe may be attractive acquisition targets. We intend to
    acquire the businesses or assets of existing centers that are
    based in leading hospitals located in densely populated cities
    in China. We believe that our past acquisition experience will
    aid us in identifying potential opportunities in the future and
    successfully integrate newly acquired businesses or assets into
    our existing network.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Network of Centers and Specialty Cancer Hospitals</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of September&#160;30, 2009, we operated an extensive network
    of 83&#160;centers based in 55 hospitals, spanning
    36&#160;cities across 21&#160;provinces and administrative
    regions in China. These hospitals are substantially comprised of
    3A&#160;hospitals, the highest ranked hospitals by quality and
    size in China as determined in accordance with the standards of
    the MOH. Our network includes 73 radiotherapy and diagnostic
    imaging centers and 10 centers that provide other treatment and
    diagnostic services, such as electroencephalography for the
    diagnosis of epilepsy, thermotherapy to increase the efficacy of
    and for pain relief after radiotherapy and chemotherapy, high
    intensity focused ultrasound therapy for the treatment of
    cancer, stereotactic radiofrequency ablation for the treatment
    of Parkinson&#146;s Disease and refraction and tonometry for the
    diagnosis of ophthalmic conditions. Each center is typically
    equipped with a primary unit of medical equipment, such as a
    linear accelerator, head gamma knife system, body gamma knife
    system, PET-CT scanner or MRI scanner. Each center is located on
    the premises of our hospital partners with the facilities of the
    centers provided by the hospitals. Each center is usually
    comprised of a
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    100
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    treatment area, a patient preparation and observation room,
    working areas for the center&#146;s doctors and other personnel
    and a waiting and reception area.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to our network of centers, we plan to establish and
    operate specialty cancer hospitals that will be majority owned
    by us. We are currently in the process of establishing two such
    hospitals, the Chang&#146;an CMS International Cancer Center in
    Xi&#146;an, Shaanxi Province and the Beijing Proton Medical
    Center in Beijing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following chart illustrates our network of centers as of
    September&#160;30, 2009:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611h0361111.gif" alt="(MAPS)">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 8pt">Note: Bracketed numbers indicate
    the number of centers in cities with more than one center.
    </FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    Arrangements with Hospital Partners</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Lease and Management Services Arrangements.</I>&#160;&#160;As
    of September&#160;30, 2009, we had 81&#160;centers that were
    established under lease and management services arrangements. We
    typically establish such centers with civilian hospitals by
    entering into a lease agreement and a management agreement.
    Centers at military hospitals, which are owned and regulated by
    the military but are otherwise the same as other
    government-owned hospitals open to the public, are typically
    established under a cooperation agreement. The reason for the
    two different contractual structures is to comply with the
    different regulations governing civilian and military hospitals
    in China. See &#147;Regulations of Our Industry&#160;&#151;
    Regulation of Medical Institutions&#160;&#151; Restrictions on
    Cooperation Agreements.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under these lease and management services arrangements, we are
    responsible for purchasing the medical equipment used in the
    centers. We lease this medical equipment to the hospitals for a
    fixed period of time and establish and manage the centers in
    conjunction with our hospital partners. These arrangements are
    typically long-term in nature, ranging from six to
    20&#160;years. We receive from the hospital a contracted
    percentage of each center&#146;s revenue net of specified
    operating expenses. Such contracted percentage typically ranges
    from 50% to 90% and are typically adjusted based on a declining
    scale over the term of the arrangement but in some instances,
    are fixed for the duration of the arrangement. The specified
    operating expenses of centers typically include variable
    expenses
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    101
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    such as the salaries and benefits of the medical and other
    personnel at the center, the cost of medical consumables,
    marketing expenses, training expenses, utility expenses and
    routine equipment repair and maintenance expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Typically, these lease and management services arrangements may
    be terminated upon the mutual agreement of the parties if the
    centers experience an operating loss for a specified period of
    time or fail to achieve certain operating targets. In addition,
    the arrangements typically can be terminated upon the default or
    failure by either party to perform its respective obligations
    under the arrangement. In the event of termination, most
    arrangements call for the parties to reach a mutual agreement as
    to the resolution of the remaining obligations of the parties or
    the division of assets that have been acquired for the centers.
    Under certain of these arrangements, our hospital partners are
    required to compensate us based on the average contracted
    percentage for an agreed upon period of time if we are not
    responsible for the early termination. Since the beginning of
    2007, we have terminated the agreements of five&#160;centers in
    our network with our hospital partners primarily due to the
    unsatisfactory performances of the centers located in these
    hospitals. Excluding acquired centers, as of September&#160;30,
    2009, we entered into agreements with hospital partners to
    establish 49 new centers since the beginning of 2007 all of
    which remain in force. 19 of such centers are already in
    operation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Service-Only Arrangements.</I>&#160;&#160;From time to time,
    we provide management services to radiotherapy and diagnostic
    imaging centers under service-only agreements. As of
    September&#160;30, 2009, we had such agreements for two centers.
    Unlike the centers established under lease and management
    services arrangements, we do not purchase and lease to the
    hospitals the medical equipment used at the centers established
    under service-only agreements. Rather, we only manage such
    centers in exchange for a management fee typically consisting of
    a contracted percentage of the revenue net of specified
    operating expenses of the center. In addition, as compared to
    our lease and management services arrangements, the terms of the
    service-only agreements are typically shorter. We enter into
    such service-only agreements on a strategic basis to expand the
    coverage of our network. We will continue from time to time
    enter into additional strategic service-only agreements with
    other hospitals in the future. As part of our arrangement to
    establish our first speciality cancer hospital, Chang&#146;an
    CMS International Cancer Center, we entered into service-only
    agreements in 2008 to provide management services to a general
    hospital in Xi&#146;an, Chang&#146;an Hospital, and six
    radiotherapy and diagnostic imaging centers located in such
    hospitals.  We receive a management fee from the Chang&#146;an
    Hospital that is equal to a percentage of its total revenues.
    For additional information, see &#147;&#151;&#160;Specialty
    Cancer Hospitals.&#148; In August 2009, we purchased from
    Chang&#146;an Hospital the six units of radiotherapy and
    diagnostic imaging equipment that were located at the six
    centers that we managed under service-only agreements with
    Chang&#146;an Hospital. The total agreed upon consideration for
    such equipment was approximately RMB72.7&#160;million
    (US$10.6&#160;million), of which RMB50.0&#160;million
    (US$7.3&#160;million) was paid as of September&#160;30, 2009. We
    paid an additional RMB20.0&#160;million (US$2.9&#160;million) of
    the consideration in October 2009 and we expect to pay the
    remaining RMB2.7&#160;million (US$0.5&#160;million) before the
    end of 2009. We subsequently entered into a long-term lease and
    management services arrangement with Chang&#146;an Hospital
    pursuant to which we leased these six units of equipment to
    Chang&#146;an Hospital. Two of the six units of equipment were
    combined into one center and we provide lease and management
    services to the five centers in which these six units of
    equipment are located.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Specialty
    Cancer Hospitals</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are currently in the process of establishing specialty cancer
    hospitals that will focus on providing radiotherapy services as
    well as diagnostic imaging services, chemotherapy and surgery.
    We intend for these specialty cancer hospitals to provide a
    complete and coordinated treatment program for cancer patients.
    We intend for these hospitals to be centers of excellence in our
    network providing cancer treatments to patients using the latest
    radiotherapy technology in China. Typically, in China the
    various specialist doctors such as surgeons, radiation
    oncologists or medical oncologists who provide care to a given
    cancer patient do not collaborate. We believe that the quality
    of cancer treatment will be greatly improved at our specialty
    cancer hospitals, because we will employ and manage the various
    specialist doctors directly and thereby promote the appropriate
    coordination of their services for the benefit of cancer
    patients. We believe that these hospitals will play an important
    role in further strengthening our reputation as the leading
    provider of radiotherapy services in China and developing our
    corporate brand. These specialty cancer hospitals will be
    majority owned and operated by us. We will purchase all of the
    medical equipment for these hospitals and will employ and manage
    all of the personnel, including doctors, nurses, medical
    technicians
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    102
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    and administrative personnel. The specialty cancer hospitals
    will be licensed as for-profit hospitals in China and will be
    subject to the relevant PRC laws and regulations and permits
    requirements. As for-profit hospitals, the medical service fees
    of our specialty cancer hospitals will not be subject to price
    controls but will be subject to certain taxes not applicable to
    non-profit hospitals. We plan to fund the development of our
    specialty cancer hospitals with proceeds raised from this
    offering and with bank loans.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Chang&#146;an CMS International Cancer
    Center.</I>&#160;&#160;We have entered into a framework
    agreement and a supplemental agreement with Chang&#146;an
    Hospital, a private hospital serving the northeastern region of
    China, and Xi&#146;an Century Friendship Medical Technology
    R&#038;D Co., Ltd., or Xi&#146;an Century Friendship, a
    subsidiary of Chang&#146;an Hospital, to establish a specialty
    cancer hospital, the Chang&#146;an CMS International Cancer
    Center, in Xi&#146;an, Shaanxi Province. Chang&#146;an Hospital
    is controlled by Chang&#146;an Information Industry (Group) Co.,
    Ltd., or Chang&#146;an Information Industry, a China-based
    conglomerate engaged in information technology, real estate and
    the medical industries. The Chang&#146;an CMS International
    Cancer Center is expected to have a gross floor area of
    approximately 12,000&#160;square meters with over 300 licensed
    patient beds. The Chang&#146;an CMS International Cancer Center
    is expected to provide treatments for a wide range of tumor
    types using a variety of radiotherapy equipment as well as
    chemotherapy and surgery. Due to the treatment methods used,
    many patients visiting the Chang&#146;an CMS International
    Cancer Center are expected to require hospitalization.
    Initially, the hospital will have a MM50 intensity-modulated
    radiation therapy system, a Novalis intensity-modulated
    radiation therapy system and PET-CT, MRI and CT scanners. We
    expect the hospital to initially employ about
    500&#160;employees, including over 300&#160;doctors and other
    medical professionals. We expect the Chang&#146;an CMS
    International Cancer Center to be operational in early 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the framework agreement, Xi&#146;an Century Friendship
    will establish a wholly owned subsidiary to be tentatively named
    &#147;Chang&#146;an Huaxiang Medical Services Co., Ltd.&#148; or
    &#147;Chang&#146;an CMS Medical Services Co., Ltd.&#148; and
    will transfer all land and properties in connection with
    establishing the specialty cancer hospital to such subsidiary.
    Thereafter, such subsidiary will change its name to the
    Chang&#146;an CMS International Cancer Center. The framework
    agreement contemplates that we will acquire equity interest in
    Chang&#146;an CMS International Cancer Center for a
    consideration of RMB34.8&#160;million (US$5.1&#160;million).
    However, prior to the purchase of such equity interest, the
    Chang&#146;an CMS International Cancer Center must first be
    established and a subsequent share transfer agreement will need
    to be entered into. Chang&#146;an CMS International Cancer
    Center will then increase its registered capital and we and
    Xi&#146;an Century Friendship will contribute other properties,
    such as equipment, land or cash, to subscribe for such increased
    capital. As a result, we will own approximately 52.0% and
    Xi&#146;an Century Friendship will own approximately 48.0% of
    the equity interest in Chang&#146;an CMS International Cancer
    Center. We are required under the framework agreement to pay a
    deposit of RMB15.0&#160;million (US$2.2&#160;million) to
    Xi&#146;an Century Friendship. Such deposit can be later
    converted as contribution to subscribe for the additional
    increase in registered capital in Chang&#146;an CMS
    International Cancer Center. A supplemental agreement to the
    framework agreement was subsequently entered into where
    Xi&#146;an Century Friendship transferred its rights and
    obligations under the framework agreement and any other
    agreements contemplated under the framework agreement to its
    subsidiary that will be tentatively named &#147;Xi&#146;an
    Wanjie Huaxiang Medical Investment Co., Ltd.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of September&#160;30, 2009, we paid RMB18.0&#160;million
    (US$2.6&#160;million) towards the establishment of the
    Chang&#146;an CMS International Cancer Center. We and the other
    parties to the agreements are currently in the process of
    applying for the relevant permits and licenses in order to
    establish the Chang&#146;an CMS International Cancer Center as
    an independent for-profit hospital in the PRC. Total development
    costs for the completion of the Chang&#146;an CMS International
    Cancer Center are expected to be approximately
    RMB250.0&#160;million (US$36.6&#160;million). We plan to fund
    the development of the Chang&#146;an CMS International Cancer
    Center with proceeds raised from this offering and with bank
    loans. We expect to obtain bank loans of approximately
    RMB90.0&#160;million (US$13.2&#160;million) in 2010 to fund the
    hospital&#146;s development.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Beijing Proton Medical Center.</I>&#160;&#160;We have also
    entered into a framework agreement with Chang&#146;an
    Information Industry to establish the Beijing Proton Medical
    Center. The Beijing Proton Medical Center will allow us to bring
    the latest in radiotherapy treatment technology to China and
    increase the radiotherapy treatment options available to cancer
    patients. The Beijing Proton Medical Center is expected to be
    operational in 2012 and is expected to be the first proton beam
    therapy system in China licensed for clinical use. The Beijing
    Proton Medical
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    103
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Center is expected to have a gross floor area of approximately
    12,700&#160;square meters and have 50 licensed patient beds. The
    Beijing Proton Medical Center will primarily offer treatments
    using a proton beam therapy system, which treatments are
    designed to be non-invasive and usually do not require
    hospitalization. As a result, the Beijing Proton Medical Center
    will not require the use of as many patient beds as the
    Chang&#146;an CMS International Cancer Center. In addition, the
    proton beam therapy system occupies a much larger installation
    area than the radiotherapy and diagnostic imaging equipment that
    is to be used in the Chang&#146;an CMS International Cancer
    Center, which reduced physical areas for licensed beds that can
    be made available in the Beijing Proton Medical Center.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The framework agreement contemplates that we are to invest
    equity capital to the Beijing Proton Medical Center project that
    was previously invested and developed by Chang&#146;an
    Information Industry, Hong Kong Jian Chang Group Ltd. and
    China-Japan Friendship Hospital. We will then obtain
    approximately 93.0% of the equity interest in Beijing Century
    Friendship Science&#160;&#038; Technology Development Co., Ltd.,
    or Beijing Century Friendship, which will in turn own
    approximately 55.0% of the Beijing Proton Medical Center. The
    remaining approximately 7.0% of the equity interest in Beijing
    Century Friendship will be owned by Xi&#146;an Wanjie Changxin
    Medical Development Co., Ltd., or Xi&#146;an Wanjie Changxin, a
    subsidiary of Chang&#146;an Information Industry. As a result,
    we will ultimately own approximately 51.2% of the Beijing Proton
    Medical Center, with the remaining equity interest owned by
    Xi&#146;an Wanjie Changxin, Hong Kong Jian Chang Group Ltd. and
    China-Japan Friendship Hospital.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The framework agreement provides that it will only become
    effective upon our payment of RMB10.0&#160;million
    (US$1.5&#160;million) in deposit to Chang&#146;an Information
    Industry. As of the date of this prospectus, we have not made
    such deposits.  However, we have, as of September&#160;30, 2009,
    provided Beijing Century Friendship with interest-free loans of
    RMB14.6&#160;million (US$2.1&#160;million) for working capital
    purposes towards establishing the Beijing Proton Medical Center.
    All outstanding amounts of such loans are expected to be repaid
    before the end 2009. We are currently waiting for the relevant
    permits and approvals to be obtained by the other shareholders
    to the Beijing Proton Medical Center. We plan to enter into
    additional definitive agreements as to the establishment of the
    Beijing Proton Medical Center after the relevant permits and
    approvals are obtained. Total development costs for the
    completion of Beijing Proton Medical Center are expected to be
    approximately RMB500.0&#160;million (US$73.2&#160;million) to
    RMB600.0&#160;million (US$87.9&#160;million). We plan to fund
    the development of the Beijing Proton Medical Center with
    proceeds raised from this offering and with bank loans. We
    expect to obtain bank loans of approximately
    RMB100.0&#160;million (US$14.6&#160;million) in 2010 to fund the
    hospital&#146;s development.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Business Arrangements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have, from time to time, purchased medical equipment from
    manufacturers or distributors for re-sale to hospitals, and have
    contractual relationships with certain equipment manufacturers,
    acted as a distributor of such manufacturer&#146;s equipment in
    selling medical equipment to hospitals. Although we may continue
    these activities on a limited basis in the future, we do not
    expect these activities to represent an important part of our
    business going forward.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Service
    Offerings in Our Network</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each of the centers in our network is typically equipped with a
    primary unit of medical equipment, such as a linear accelerator,
    head gamma knife system, body gamma knife system,
    <FONT style="white-space: nowrap">PET-CT</FONT>
    scanner or MRI scanner. Set forth below is a summary of the
    principal treatment and diagnostic imaging modalities provided
    at our centers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Linear
    Accelerators External Beam Radiotherapy</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of September&#160;30, 2009, we owned 16&#160;linear
    accelerators. Linear accelerators use microwave technology to
    deliver a high-energy x-ray beam directed at the tumor. Linear
    accelerators can be used to treat tumors in the brain or
    elsewhere in the body. A typical course of treatment given to a
    patient ranges from 20 to 40 daily sessions and with each
    session lasting for 10 to 20 minutes. Since linear accelerators
    move during treatment, they are not as precise as gamma knife
    systems. However, linear accelerators are capable of treating
    larger tumors. Linear accelerators can also be integrated with
    specialized computer software and advanced imaging and detection
    equipment to provide more effective and advanced treatments.
    Such advanced treatments include three-dimensional conformal
    radiation therapy, which uses imaging equipment to create
    detailed, three-dimensional representations of the tumor and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    104
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    surrounding organs. The radiation beam can then be shaped to
    match the patient&#146;s tumor, thereby reducing the radiation
    damage to healthy tissues. In general, such advanced modalities
    increase the medical service fees that can be charged as
    compared to the maximum medical service fees that can be charged
    for treatments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Gamma
    Knife Radiosurgery</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A gamma knife is used in radiosurgery for the treatment of
    tumors and other abnormal growths. A gamma knife uses multiple
    radiation sources, which differentiates it from traditional
    radiotherapy where only a single radiation source is used. These
    radioactive sources, which are typically cobalt-60, a
    radioactive isotope, emit gamma rays that are passed through a
    collimator unit to produce a highly-focused beam of radiation.
    The individual beams then converge to deliver an extremely
    concentrated dose of radiation to locations within the patient
    that are identified using imaging guidance systems, such as
    PET-CT or MRI scanners. The intense radiation produced by a
    gamma knife at a precise target point destroys tumor cells,
    while minimizing damage to the surrounding healthy tissues. The
    treatment procedure is minimally or non-invasive and may be used
    as a primary or supplementary treatment option for cancer
    patients. The treatment requires no general anesthesia and
    provides an alternative treatment option to patients who may not
    be good candidates for surgery. In addition, the gamma knife
    procedure usually involves shorter patient hospitalization, is
    more cost effective than surgery and avoids many of the
    potential risks and complications that are associated with other
    treatment options. Our network of centers currently operates two
    types of gamma knife systems, head gamma knife systems and body
    gamma knife systems. As of September&#160;30, 2009, we owned 26
    gamma knife systems, including 16 head gamma knife systems and
    10 body gamma knife systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Head Gamma Knife Systems.</I>&#160;&#160;Head gamma knife
    systems are primarily used for the treatment of brain tumors.
    The treatment is typically completed in one 10 to 30 minute
    session rather than in multiple daily sessions spanning several
    weeks during which time small doses of radiation are given at
    each session. Head gamma knife systems can also be used to treat
    other conditions, such as certain types of brain lesions,
    trigeminal neuralgia (facial pain) and arteriovenous
    malformations (abnormal connection between veins and arteries).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Body Gamma Knife Systems.</I>&#160;&#160;Body gamma knife
    systems are used for the treatment of tumors located in the body
    but outside of the brain. Treatments using the body gamma knife
    are provided over a course of multiple sessions spanning several
    weeks. The radiation that converges from the individual beams is
    less concentrated than in head gamma knife systems due to the
    difficulty of fixing and restricting the movement of the body.
    This is a widely used technology in China that was developed
    domestically and approved by the PRC State Food and Drug
    Administration, or the SFDA. However, the body gamma knife
    system has not been broadly introduced and widely adopted
    outside of China. We believe this is because the Chinese
    manufacturers of body gamma knife system have determined that
    the time and cost of gaining approval for use of the body gamma
    knife system in countries other than China are likely
    commercially prohibitive. In addition, potential gamma knife
    system manufacturers outside of China may not have historically
    viewed clinical studies conducted by users of body gamma knife
    systems in China as sufficiently convincing for them to try to
    develop such systems outside of China. As a result, we believe
    that the international medical community has not yet had the
    opportunity to develop a large quantity of peer-reviewed
    literature that supports the safe and effective use of body
    gamma knife system and to adopt such technology outside of China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Proton
    Beam Therapy</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Proton beam therapy is a form of external beam radiotherapy that
    uses beams of protons rather than the x-ray beams used by linear
    accelerators. The advantages of proton beam therapy compared to
    other types of external beam radiotherapy is that a proton
    beam&#146;s signature energy distribution curve, known as the
    &#147;Bragg peak,&#148; allows for greater accuracy in targeting
    tumor cells so that healthy tissue is exposed to a smaller
    dosage. Proton beam therapy can focus cell damage caused by the
    proton beam at the precise depth of the tissue where the tumor
    is situated, while tissues located before the Bragg peak receive
    a reduced dose and tissues situated after the peak receive none.
    These advantages make proton beam therapy a preferred option for
    treating certain types of cancers where conventional
    radiotherapy would damage surrounding tissues to an unacceptable
    level, such as tumors near optical nerves, the spinal cord or
    central nervous system and in the head and neck area, as well as
    prostate cancer and cancer in pediatric cases. Proton beam
    therapy is not a widely utilized treatment modality, with only
    approximately 30 proton
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    105
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    beam therapy treatment centers in operation or under
    construction worldwide. We plan to enter into the proton therapy
    market with the construction of our Beijing Proton Medical
    Center. See &#147;&#151;Our Network of Centers and Specialty
    Cancer Hospitals &#151;Specialty Cancer Hospitals.&#148;
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Diagnostic
    Imaging</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our network of centers employs a wide range of diagnostic
    imaging equipment. Such equipment includes some of the most
    advanced diagnostic imaging technology available in China,
    including PET-CT scanners. A PET-CT scanner is a device that
    combines a positron emission tomography, or PET, scanner and a
    computed tomography, or CT, scanner in one unit. PET-CT scanners
    allow the functional imaging obtained by PET scanning, which
    depicts the spatial distribution of metabolic or biochemical
    activities in the body, to be more precisely aligned or
    correlated with the anatomic imaging obtained by a CT scanner.
    Other diagnostic imaging services offered in our centers include
    MRI, CT and ECT. MRI scanners use a powerful magnetic field,
    radio frequency pulses and computers to produce detailed
    pictures of organs, soft tissues, bone and virtually all other
    internal body structures. MRI technology, which does not involve
    radiation, is typically able to provide a much greater level of
    contrast between the different soft tissues of the body than CT,
    making it especially useful in neurological or oncological
    imaging. As of September&#160;30, 2009, we owned seven PET-CT
    scanners and 16&#160;MRI scanners.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Other
    Treatment and Diagnostic Modalities</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our network also includes centers that provide other treatments
    and diagnostic services through the use of other types of
    medical equipment. Such equipment currently includes
    electroencephalography for the diagnosis of epilepsy,
    thermotherapy to increase the efficacy of and for pain relief
    after radiotherapy and chemotherapy, high intensity focused
    ultrasound therapy for the treatment of cancer, stereotactic
    radiofrequency ablation for the treatment of Parkinson&#146;s
    Disease and refraction and tonometry for the diagnosis of
    ophthalmic conditions. In 2008 and for the nine months ended
    September&#160;30, 2009, revenues derived from centers that
    provide such other services were less than 3.6% and 2.5%,
    respectively, of our total net revenues.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Medical
    Equipment Procurement</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The medical equipment used in our network of centers is highly
    complex and there are usually a limited number of manufacturers
    worldwide that produce such equipment. We typically purchase the
    medical equipment used in our network directly from domestic
    manufacturers and through importers from overseas manufacturers.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with the relevant PRC laws and regulations, the
    procurement, installation and operation of Class&#160;A or
    Class&#160;B large medical equipment by hospitals in China are
    subject to procurement quotas or procurement planning and a
    large medical equipment procurement license must be obtained
    prior to the purchase of such medical equipment. For medical
    equipment classified as Class&#160;A large medical equipment,
    which includes gamma knife systems, proton beam therapy systems
    and PET-CT scanners, quotas are set by the MOH and the NDRC and
    large medical equipment procurement licenses are issued by the
    MOH. For medical equipment classified as Class&#160;B large
    medical equipment, which includes linear accelerators and MRI
    and CT scanners, procurement planning and approval is conducted
    by the relevant provincial healthcare administrative authorities
    with ratification by the MOH and the large medical equipment
    procurement licenses are issued by the relevant provincial
    healthcare administrative authorities. A large medical equipment
    procurement license is not required for medical equipment that
    is not classified as either Class&#160;A or Class&#160;B large
    medical equipment. These rules concerning procurement of large
    medical equipment apply to all public and private medical
    institutions in China, whether non-profit or for-profit, except
    for military hospitals in China, which have a separate
    procurement system. See &#147;Regulation of Our
    Industry&#160;&#151; Regulation of Medical
    Institutions&#160;&#151; Large Medical Equipment Procurement
    License.&#148;
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Once non-profit hospitals have obtained large medical equipment
    procurement licenses, the purchase of medical equipment for such
    hospitals is conducted through a collective tender process. The
    tender process is centralized in accordance with relevant PRC
    laws and regulations and is supervised by the MOH for
    Class&#160;A large medical equipment. For Class&#160;B large
    medical equipment, the tender process is supervised by the
    relevant provincial heath administrative authorities. Equipment
    purchases by military hospitals are also conducted through a
    centralized collective tender process supervised by the general
    logistics department of the PLA. The government or military
    authority will appoint an agent to manage the tender process who
    must be certified by the government and qualified to conduct the
    tender process. The agent publicizes information relevant to the
    tender process, such as the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    106
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    type of equipment requested by the hospital and the desired
    commercial terms. The manufacturers will prepare the tender
    document according to the agent&#146;s requirement and submit
    their bids to the agent on or before the specified date. The
    agent will then consult with industry experts in evaluating each
    bid and the industry experts will make a determination on the
    winning manufacturer. When the tender process is complete, the
    results are publicly announced and an import permit is issued
    for the equipment of the winning manufacturer. We then begin
    negotiations with such manufacturer or its importer on the
    purchase price and the purchasing terms for the equipment based
    on the general commercial terms submitted by such manufacturer
    in the tender process.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Operation
    of Radiotherapy and Diagnostic Imaging Centers in Our
    Network</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a brief summary of the various aspects of the
    operations of the radiotherapy and diagnostic imaging centers in
    our network.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Management
    Structure</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We manage each of the radiotherapy and diagnostic centers
    jointly with our hospital partners. Our hospital partners
    appoint a medical director to each center and are responsible
    for the centers&#146; clinical activities, the medical decisions
    made by doctors, and the employment of doctors in accordance
    with the licencing regulations. We provide clinical support to
    doctors, including developing treatment protocols for doctors
    and organizing joint diagnosis between doctors in our network
    and clinical research. We appoint either an operations director
    or a project manager to each center. Such director or manager
    provides most of the non-clinical aspects of the centers&#146;
    day-to-day operations, which include marketing, providing
    training and clinical education to doctors and other medical
    personnel in the centers and other general administrative duties
    such as arranging for the repair and maintenance of medical
    equipment. Budgets for each center are established annually
    based on discussions between our hospital partners and us. Costs
    incurred at the centers usually require approval of both our
    hospital partners and us. As a matter of practice, certain major
    expenditures of the center are subject to further approval by
    our hospital partners&#146; management and our management.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have established operating procedures and a comprehensive
    quality assurance program to ensure that our centers operate
    efficiently and provide consistent and high quality services.
    The operating procedures cover the use and maintenance of the
    medical equipment and interactions with patients, from initial
    patient appointment and registration to post-treatment
    <FONT style="white-space: nowrap">follow-up.</FONT>
    The operations director or project manager of each center is
    primarily responsible for ensuring the adherence to our
    operating procedures and comprehensive quality assurance program.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    At the corporate level, we have established a dedicated
    operations department to supervise and provide support to ensure
    the effective operation of each center. We actively monitor the
    activities of each center and conduct scheduled annual
    evaluations for all centers. These evaluations focus on whether
    the applicable procedures are followed and whether our operating
    personnel are performing at the expected level. In addition to
    the scheduled annual review, we also conduct unscheduled
    evaluations for certain randomly selected centers. The results
    of these evaluations are used to help determine the compensation
    received by our operations directors or project managers and our
    other employees at the centers. We receive weekly reports on the
    operating activities for each center, which help us identify
    opportunities for continued improvement with regards to various
    aspects of each center&#146;s operations. We also have a risk
    management department that helps to ensure that we meet
    applicable PRC laws and regulations and compliance standards for
    the operation of our business. We have also adopted a code of
    ethics.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For our specialty cancer hospitals Chang&#146;an CMS
    International Cancer Center and Beijing Proton Medical Center,
    we will have full operating control over all clinical and
    non-clinical aspects of such hospitals&#146; operation,
    including direct supervision over medical decisions made by
    doctors.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Staffing</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition to the operations director or project manager
    appointed by us to each center, we also typically staff each
    center with dedicated marketing and accounting personnel. Our
    hospital partners appoint medical directors to the centers and,
    except in very limited cases, they also assign all of the
    doctors and other medical personnel to the centers. However, we
    also help our hospital partners to recruit many of the doctors
    or medical personnel providing services at the center. We
    provide feedback to our hospital partners as to the suitability
    and performance of the doctors and other medical personnel at
    each center, and work with our hospital partners to ensure that
    each center is staffed with the most qualified and suitable
    personnel. In addition, we help our hospital partners to
    determine the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    107
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    compensation of doctors and other medical personnel providing
    services in our network of centers. We also, on a very limited
    basis, enter into employment agreements with doctors to work at
    centers in our network after consulting with our hospital
    partners where such centers are based.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are currently in the process of establishing specialty cancer
    hospitals. We will be responsible for employing and managing all
    personnel of these specialty cancer hospitals, including doctors
    and other medical personnel.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Medical
    Affairs</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have a medical affairs department to support the training,
    clinical education and clinical research activities of our
    network of centers. Prior to setting up a new center, we arrange
    training for the medical professionals of such new center at
    certain established centers in our network designated as
    training centers. This provides the medical professionals of
    such new center with the opportunity to gain hands-on clinical
    experience in advanced radiotherapy treatment and diagnostic
    imaging technologies and to benefit from the considerable
    clinical knowledge of the doctors and other medical personnel at
    the designated training centers. The doctors at the designated
    training centers will evaluate the performance of the medical
    professionals of the new center and ensure that they can provide
    high quality clinical care. In addition, we also arrange
    training for the medical staff with the medical equipment
    manufacturers. We also periodically provide
    <FONT style="white-space: nowrap">follow-up</FONT>
    training at selected centers and host academic conferences and
    semi-annual academic seminars where doctors and other medical
    personnel from our network of centers and medical experts in
    China are invited to share their knowledge and clinical
    experience. From time to time, we invite experts from
    professional or academic institutions, such as the Oncology
    Hospital of the Chinese Academy of Medical Science, to give
    lectures and provide guidance as to the latest developments and
    trends in radiotherapy treatments.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe that a well-managed clinical research program
    enhances the reputation of doctors in our network, which in turn
    enhances the reputation of our network of centers. We maintain a
    database of radiotherapy treatments. This collection of data can
    be used, upon approval by us and our hospital partners, to
    conduct cross-center clinical research and statistical analysis
    to determine the efficacy and potential of treatment methods
    offered in our network. We actively organize, encourage and
    assist doctors in our network to engage in clinical research and
    to publish their results. We assist in coordinating the clinical
    research efforts between different radiotherapy and diagnostic
    imaging centers in our network, which is critical for certain
    research initiatives that require a significant amount of
    clinical data that would be difficult for one center to collect.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Doctors in China have historically had very limited
    opportunities for discussions or consultations with doctors
    outside of their own hospital. Our network offers doctors the
    opportunity to consult with each other on challenging cases and
    treatments. In addition, we have developed treatment protocols
    that are introduced to each center and can be followed by
    doctors in our network of centers. We also evaluate the clinical
    activities of each center as part of our annual evaluations to
    ensure that high quality treatments or services are provided to
    patients. We also publish an internal quarterly magazine titled
    &#147;Stereotactic Radiosurgery&#148; that highlights the
    different clinical cases being treated in our centers and the
    latest developments in radiosurgery treatment. We further assist
    in the publication of other literature related to radiosurgery.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Marketing</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Marketing efforts for each center in our network are primarily
    initiated and implemented by the marketing personnel or the
    operations director or project manager situated at each center
    with the support of our headquarters. Each center&#146;s
    marketing efforts are directed at other doctors in the hospital
    where the center is based and at other local hospitals. These
    marketing efforts are focused on informing such doctors of the
    applicability and benefits of radiotherapy and the expertise and
    experience of the doctors at the centers. We also create and
    distribute educational materials and brochures and engage in
    consumer advertising and educational campaigns through
    television, magazines and electronic media.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each center is required to report its marketing activities to
    us, and we closely monitor such activities and give approval for
    major marketing initiatives. We also oversee the budget for
    marketing activities at the centers. We assist the centers by
    providing relevant content for marketing materials and help to
    coordinate with leading experts in the medical community to
    attend conferences or seminars hosted by the centers. As our
    network of centers continues to expand and as we begin operating
    our specialty cancer hospitals, we plan to begin centralizing
    certain of the marketing and advertising efforts.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    108
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounting
    and Payment Collection</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our hospital partners are responsible for patient billing and
    fee collections and for delivering to us our contracted
    percentage of medical fees based on our arrangements with them.
    We typically appoint accounting personnel to each of our centers
    who are in charge of keeping books and records as to the
    revenues and expenses of the center. We reconcile the accounting
    records for each center in our network with our hospital
    partners periodically. After the revenue net of specified
    operating expenses of a center is agreed upon between us and our
    hospital partner, we will bill our hospital partner for our
    portion of the revenue determined based on our contracted
    percentage. Our hospital partners will then go through their
    internal approval process, which usually takes about
    45&#160;days from the time of billing before making payments to
    us. We have implemented accounting procedures at each of the
    centers in our network, and perform periodic reviews to ensure
    that such activities are properly conducted. For our specialty
    cancer hospitals, we will be responsible for patient billing and
    fee collection.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Medical
    Equipment Maintenance and Repair</FONT></I></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Equipment maintenance and repair are typically carried out by
    the equipment manufacturers or third party service companies.
    The manufacturers typically provide equipment warranties for a
    period of one year. After the warranty period expires, we
    typically enter into service agreements with the manufacturers
    or third party service companies to provide periodic maintenance
    and repair services. We have also established a dedicated
    engineering team that is responsible for the general preventive
    maintenance of medical equipment used in our network of centers.
    Our engineering team serves as an initial point of contact when
    problems are encountered and coordinates with equipment
    manufacturers or a third party service company to ensure that
    problems are resolved in a timely manner whenever they arise.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pricing
    of Medical Service</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Medical service fees generated through the use of both
    Class&#160;A and Class&#160;B large medical equipment at
    non-profit civilian hospitals and military hospitals are subject
    to the pricing guidance of the relevant provincial or regional
    price control authorities and healthcare administrative
    authorities. The pricing guidance sets forth the range of
    medical service fees that can be charged by non-profit civilian
    medical institutions and military hospitals. See
    &#147;Regulation of Our Industry&#160;&#151; Pricing of Medical
    Services.&#148; The relevant price control authorities and
    healthcare administrative authorities provide notices to
    hospitals, which in turn provide immediate notices to us, as to
    any change in the pricing ceiling for medical services. The
    timing between when notices are provided by the relevant price
    control authorities and healthcare administrative authorities
    and the effective date of such pricing change varies in
    different cities and regions as well as the relevant medical
    services in question, but typically ranges from one to three
    months. For-profit hospitals or centers based in for-profit
    hospitals in China, such as our planned specialty cancer
    hospitals, are not subject to such pricing restrictions and are
    entitled to set medical service fees based on their cost
    structures, market demand and other factors.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Business
    Development</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have a business development team responsible for pursuing
    opportunities to develop centers with hospitals and a hospital
    investment team responsible for pursuing opportunities to
    establish specialty cancer hospitals. When examining potential
    opportunities, we take into account factors that include:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    population density, demographics and the level of economic
    development of the regions or cities in which such new centers
    would be located;&#160;and
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the reputation of the potential hospital partner and its
    doctors, nurses and other personnel and the number of licensed
    patient beds and patient volume.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    After each potential opportunity is identified and evaluated by
    the business development team or the hospital investment team,
    as applicable, the opportunity is presented to our investment
    evaluation committee for review. Our investment evaluation
    committee is comprised of several of our senior executives and
    members of our board of directors, and includes Mr.&#160;Steve
    Sun, the chairman of the committee, Mr.&#160;Jing Zhang,
    Dr.&#160;Zheng Cheng, Mr.&#160;Yaw Kong Yap and Ms. Elaine Zong.
    New projects need to be approved by a super-majority approval of
    our investment evaluation committee and by our chief executive
    officer.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    109
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employees</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our employees consist of all personnel that work in our
    headquarters and our regional offices and certain personnel that
    work in our network of centers. Our employees in our network are
    generally the operations directors or project managers and the
    marketing, accounting or administrative personnel of the
    centers. We had 57, 58, 130 and 150&#160;employees as of
    December&#160;31, 2006, 2007 and 2008 and September&#160;30,
    2009, respectively. The following table set forth certain
    information about our employees by function as of the period
    indicated:
</DIV>

<DIV style="margin-top: 2pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="66%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="17%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As of September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>% of Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Employees</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Administration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18.7
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Financial control
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Marketing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Business development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Medical development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100.0
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into employment agreements with each of our
    employees. We may terminate the employment of any of our
    employees in the event that such employee&#146;s actions have
    resulted in material and demonstrable harm to our interests or
    if the employee has not performed as expected. An employee may
    typically terminate his or her employment at any time for any
    material breach of the employment agreement by us. The employee
    may also terminate the employment agreement at any time without
    cause upon 30&#160;days prior notice. Each of our employees who
    have access to sensitive and confidential information has also
    entered into a non-disclosure and confidentiality agreement with
    us. For information as to employment agreements with our
    executive officers, see &#147;Management&#160;&#151; Employment
    Agreements.&#148; We are required under PRC law to make
    contributions to our employee benefit plans based on specified
    percentages of the salaries, bonuses, housing allowances and
    certain other allowances of our employees, up to a maximum
    amount specified by the respective local government authorities.
    The total amount of the contributions that we made to employee
    benefit plans in 2007, 2008 and for the nine months ended
    September&#160;30, 2009 was RMB0.1&#160;million,
    RMB0.2&#160;million (US$36,000) and RMB1.7&#160;million
    (US$0.3&#160;million), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 8%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our success depends to a significant extent upon, among other
    factors, our ability to attract, retain and motivate qualified
    personnel. Many of our employees have extensive industry
    experience, and we place a strong emphasis on continuously
    improving our employees&#146; expertise by providing periodic
    training to enhance their skills and knowledge. Our employees
    are not covered by any collective bargaining agreement. We
    believe that we have a good relationship with our employees. All
    of our employees are based in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with applicable PRC laws and regulations, the MOH
    oversees the activities of doctors in China. The relevant local
    healthcare administrative authorities above the county level are
    responsible for the supervision of doctors located in their
    regions. Doctors in China are regulated by a registration system
    and each doctor may only practice medicine in the sole medical
    institution where such doctor is registered. Doctors are not
    permitted to be registered in more than one medical institution.
    However, doctors may, upon the approval of the medical
    institution with which they are registered, enter into
    consulting agreements with third parties to engage in medical
    practice for another institution. We enter into such consulting
    contracts with doctors from time to time to provide expert
    assistance and consultation to our company and our network of
    centers. In very limited cases, we enter into employment
    agreements with doctors to work at centers in our network after
    consulting with our hospital partners where such centers are
    based. These doctors register their practice with the hospitals
    in accordance with applicable PRC laws and regulations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Competition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The radiotherapy and diagnostic imaging market in China is
    fragmented and the competition is intense. The centers in our
    network compete primarily on a regional or local basis with
    government-owned and private hospitals that offer radiotherapy
    and diagnostic imaging services either directly or in
    conjunction with third parties, such as
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    110
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China Renji Medical Group Ltd. and Jiancheng Investment Co. In
    addition, since hospitals typically establish radiotherapy and
    diagnostic imaging centers located on their premises through
    long term lease and management services arrangements with us or
    our competitors, in a given locality over a given period there
    may only be a limited number of top-tier hospitals who have not
    yet entered into long-term arrangements with us or other
    companies like us with whom we are still able to enter into new
    arrangements. In addition, quotas as to the number and type of
    certain medical equipment that can be purchased by us or our
    hospital partners, such as head gamma knife systems of PET-CT
    scanners, further limit the number of top-tier hospitals that we
    or our competitors can enter into arrangements with in a given
    period. We primarily compete with our competitors on the range
    of the option of services provided by us and our competitors,
    the reputation of centers in our network among doctors and
    patients in China and level of patient service and satisfaction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, we also compete with those who offer other types of
    available treatment methods that we do not offer, such as
    chemotherapy, surgery, different forms of radiotherapy that we
    do not currently offer, other alternative treatment methods
    commercialized in recent years and certain treatments that are
    currently in the experimental stage. These treatments may be
    more effective or less costly, or both, compared to the
    treatment methods that our centers provide.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Environmental
    Matters</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The MOH enacted the <I>Administrative Measures on Medical Wastes
    Management of Medical Institutions </I>in 2003, which sets forth
    the management of and criteria for the disposal of medical waste
    generated in the operation of medical institutions. As the
    supervising authority, the environmental protection authority at
    the county or higher levels is responsible for environmental
    inspections of hospitals within their jurisdictions. The MOH and
    the environmental protection authorities have also promulgated a
    series of specific regulations on the disposal of dangerous
    medical waste and the requirements of vehicles used to transport
    medical wastes. In addition, certain of the medical equipment
    used in our network of centers, such as gamma knife systems, use
    radioactive sources. In accordance with the <I>Regulation on
    Radioisotope and Radiation Equipment Safety and Protection
    </I>promulgated by the PRC State Council in 2005, these
    radioactive sources should be returned to the manufacturer of
    such radioactive materials or sent to dedicated radioactive
    waste disposal units appointed by the MEP. Radioactive materials
    are generally obtained from, and returned to, the medical
    equipment manufacturers or other third parties, which then have
    the ultimate responsibility for their proper disposal. However,
    as all centers in our network are located on the premises of our
    hospital partners, we do not directly oversee the disposal of
    certain medical waste generated in the centers. The failure of
    any of our hospital partners to dispose of such waste in
    accordance with PRC laws and regulations may have an adverse
    effect on the operation of centers in our network. See
    &#147;Risk Factors&#160;&#151; Risks Related to Our
    Company&#160;&#151; Most of our radiotherapy and diagnostic
    imaging equipment contains radioactive materials or emits
    radiation during operation.&#148; For our specialty cancer
    hospitals, we will be responsible for the disposal of the
    medical waste generated.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Insurance</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We maintain property insurance on many of the medical equipment
    used in our network of centers to protect against loss in the
    event of fire, earthquake, flood and a wide range of natural
    disasters. We do not typically maintain any professional
    malpractice liability insurance since we do not employ the
    doctors and other medical personnel providing services in the
    centers, except in very limited cases and the centers are
    located on the premises of our hospital partners. Accordingly,
    we are not directly responsible for any incidents that occur in
    the course of providing treatment. However, as certain
    agreements entered into with our hospital partners require us to
    share in the expenses related to medical disputes and for such
    expenses to be included as the expenses of the centers, we have
    obtained malpractice liability insurance for a limited number of
    centers. We do not maintain product liability insurance for the
    medical equipment. We do not maintain real property insurance on
    the centers as this is the responsibility of our hospital
    partners. We do not maintain business interruption insurance or
    key employee insurance for our executive offices as we believe
    it is not the normal industry practice in China to maintain such
    insurance. We consider our current insurance coverage to be
    adequate. However, uninsured damage to any of the medical
    equipment in our network of centers or inadequate insurance
    carried by our partner hospitals as to their respective centers
    could result in significant disruption to the operation of
    centers in our network and result in a material adverse effect
    to our business, financial condition and results of operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    111
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into framework agreements to establish specialty
    cancer hospitals that are to be majority-owned by us. We will
    employ all of the personnel of such hospitals, including
    doctors, nurses and medical technicians. As a result, we plan to
    obtain professional malpractice liability insurance for such
    specialty cancer hospitals. However, there can be no assurance
    that such insurance will be available at a reasonable price or
    that we will be able to maintain adequate levels of professional
    and general liability insurance coverage.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Facilities</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our principal headquarters are located at 18/F, Tower A, Global
    Trade Center, 36 North Third Ring Road East, Dongcheng District,
    Beijing, 100013. We occupy and use this office space with a
    gross floor area of approximately 624&#160;square meters,
    pursuant to a lease agreement entered into on December&#160;27,
    2006 and expiring on February&#160;8, 2010. We also entered into
    lease agreements on March&#160;25, 2009 for a period of three
    years for additional office space located in the same building
    with an aggregate gross floor area of approximately
    1,931&#160;square meters. The following table sets forth our
    other leased properties as of the date of this prospectus:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="31%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="32%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Location</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Size (in square
    meters)</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Expiration Date</FONT></B>
</DIV>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Beijing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    286
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    July 2010
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shanghai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    16
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    November 2009
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shanghai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    34
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    May 2010
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shanghai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    195
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    January 2011
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shenzhen
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    522
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="bottom">
    November 2012
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The centers in our network typically have gross floor area
    ranging from approximately 100 to 400&#160;square meters
    depending on the services provided at the center. We also
    currently provide management services to a general hospital in
    Xi&#146;an, Chang&#146;an Hospital, that has a gross floor area
    of approximately 12,000&#160;square meters. We have entered into
    agreements to establish and operate two specialty cancer
    hospitals that are to be majority owned by us. The Chang&#146;an
    CMS International Cancer Center has a planned gross floor area
    of approximately 12,000&#160;square meters and the Beijing
    Proton Medical Center has a planned gross floor area of
    approximately 12,700&#160;square meters. We expect the land use
    rights for properties occupied by our specialty cancer hospitals
    to be owned by our specialty cancer hospitals. For additional
    information on our centers and specialty cancer hospitals,
    please see &#147;&#160;&#151; Our Network of Centers and
    Specialty Cancer Hospitals.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Intellectual
    Property</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have applied to the PRC Trademark Office of the State
    Administration for Industry and Commerce for the registration of
    our trademark &#147;Medstar&#148; to protect our corporate name.
    We also own the rights to 146 domain names that we use in
    connection with the operation of our business. Many of the
    domain names that we own include domain names in Chinese that
    contain relevant key words associated with various types of
    cancer, radiotherapy, gamma knife systems, linear accelerators
    or other medical equipment used or treatments and services
    provided in our network. We believe that such domain names
    provide us with the opportunity to enhance our marketing efforts
    for the treatments and services provided in our network and
    enhance patients&#146; knowledge as to cancers, the benefits of
    radiotherapy and the various treatment options that are
    available. Other than the use of our trademark and domain names,
    our business generally is not dependent upon any patents,
    licensed technology or other intellectual property. As we begin
    to operate specialty cancer hospitals under our own brand name
    in the future and as our brand name gains more recognition among
    the general public, we will work to increase, maintain and
    enforce our rights in our trademark portfolio, the protection of
    which is important to our reputation and branding strategy and
    the continued growth of our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Legal and
    Administrative Proceedings</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are not currently involved in any material litigation,
    arbitration or administrative proceedings. We may from time to
    time become a party to various litigation, arbitration or
    administrative proceedings arising in the ordinary course of our
    business.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    112
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='115'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">REGULATION&#160;OF
    OUR INDUSTRY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">General
    Regulatory Environment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China&#146;s healthcare industry is regulated by various
    government agencies, including the Ministry of Health, or MOH.
    The MOH has branch offices across China that oversee the
    healthcare industry at the provincial and county levels, which
    branch offices, together with the MOH, we refer to as the
    healthcare administrative authorities. The healthcare
    administrative authorities and other government agencies, such
    as the National Development and Reform Commission, or NDRC, the
    State Food and Drug Administration, or SFDA, the Ministry of
    Environmental Protection, or MEP, and the Ministry of Commerce,
    or MOFCOM, have promulgated rules and regulations relating to
    the procurement of large medical equipment, the pricing of
    medical services, the operation of radiotherapy equipment, the
    licensing and operation of medical institutions and the
    licensing of medical staff.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Permits
    Required by Our Company</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Medical
    Equipment Operating Enterprise Permits</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The SFDA categorizes medical equipment into three classes
    according to the level of control by the government authorities
    that, in the judgment of the SFDA, is required for their safe
    and effective operation. Class&#160;I medical equipment are
    those medical equipment that require only an ordinary level of
    control in order to ensure their safe and effective operation.
    Class&#160;II medical equipment are those medical equipment that
    require a heightened level of control in order to ensure their
    safe and effective operation. Class&#160;III medical equipment
    are those medical equipment that are used to support or maintain
    human life, are implanted into the human body or otherwise pose
    a potential danger to the human body. Class&#160;III medical
    equipment require strict control in order to ensure their safe
    and effective operation. In order to ensure an adequate level of
    control in the operation of Class&#160;II and Class&#160;III
    medical equipment, enterprises that engage in the operation of
    such equipment, which include gamma knife systems, linear
    accelerators, MRI systems and
    <FONT style="white-space: nowrap">PET-CT</FONT>
    systems, must each obtain a medical equipment operating
    enterprise permit from the relevant provincial drug supervision
    and administration agency. As a result, our subsidiaries
    Shanghai Medstar, Aohua Medical, Xing Heng Feng Medical and
    Aohua Leasing must each obtain a medical equipment operating
    enterprise permit from the relevant provincial drug supervision
    and administration agency pursuant to the <I>Medical Equipment
    Supervision and Administration Regulation</I> effective as of
    April&#160;1, 2000. Each such permit is valid for a term of five
    years and, prior to expiration, must be reviewed by and an
    extension of its term must be obtained from the relevant
    authorities. All of our aforementioned subsidiaries have
    received a medical equipment operating enterprise permit.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Radiation
    Safety Permits</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As organizations that produce, sell or use radioactive materials
    or devices in the PRC, our subsidiaries Shanghai Medstar, Aohua
    Medical and Aohua Leasing are required to obtain radiation
    safety permits from the relevant national or provincial
    environmental protection authorities pursuant to the
    <I>Regulation on Radioisotope and Radiation Equipment Safety and
    Protection </I>issued on September&#160;14, 2005 by the PRC
    State Council and the <I>Rules on Radioisotopes and Radiation
    Device Safety Permit </I>issued on January&#160;18, 2006 by the
    State Environmental Protection Administration (now the MEP) and
    amended on December&#160;6, 2008 by the MEP. Each such radiation
    safety permit is valid for a term of five years and, prior to
    expiration, must be reviewed by and an extension of its term
    must be obtained from the relevant authorities. All of our
    forementioned subsidiaries have received a radiation safety
    permit.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any organization that is subject to radiation safety permitting
    requirements is required to strictly observe state regulations
    regarding individual radiation dosage monitoring and health
    administration, conduct individual dosage monitoring and
    occupational health examinations for its staff that are directly
    involved in the production, sale or use of radioactive materials
    or devices and maintain individual dosage files and occupational
    health files. Any used radioactive source materials must be
    returned to the manufacturer or the original exporter of the
    equipment. If return to the manufacturer or the original
    exporter is not possible, the used radioactive materials must be
    delivered to a qualified radioactive waste consolidation and
    storage unit for storage.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    113
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Leasing
    Company Permit</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As foreign-invested companies engaged in the leasing or
    financial leasing business, certain of our subsidiaries must
    obtain a Foreign-invested Enterprise Approval Certificate from
    the MOFCOM or its competent local branch. Each such certificate
    will specify the permitted business scope of the
    foreign-invested company as either leasing or financial leasing.
    Foreign-invested leasing companies, such as our subsidiary,
    Aohua Medical, are permitted to operate their businesses for no
    more than 30&#160;years after obtaining such certificates, after
    which time they are required to apply for and obtain an
    extension of the term of their certificate. Foreign-invested
    leasing companies are also required to observe the rules for the
    registered capital and total investment provided in the
    <I>Company Law </I>issued by the Standing Committee of National
    People&#146;s Congress of the PRC on December&#160;29, 1993, as
    amended from time to time, and other relevant regulations.
    Foreign-invested financial leasing companies, such as our
    subsidiaries Aohua Leasing and Shanghai Medstar are, in addition
    to the aforementioned requirements for foreign-invested leasing
    companies, subject to the additional requirements of maintaining
    a registered capital level of at least US$10&#160;million,
    having qualified professionals and having senior managers with
    professional qualifications and with no less than 3&#160;years
    of management experience. Our subsidiaries Aohua Leasing and
    Shanghai Medstar have each obtained a foreign-invested financial
    leasing company permit and our subsidiary Aohua Medical has
    obtained a foreign-invested leasing company permit.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Regulation
    of Medical Institutions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Distinction
    between For-Profit and Non-Profit Medical
    Institutions</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Medical institutions in China can be divided into three main
    categories: public non-profit medical institutions, private
    non-profit medical institutions and for-profit medical
    institutions. Medical institutions falling under each category
    have differing registered business purposes and governing
    financial, tax, pricing and accounting standards than medical
    institutions falling under one of the other categories. Public
    non-profit medical institutions, including those owned by the
    government and military hospitals, are set up and operated to
    provide a public service and are eligible for financial
    subsidies from the government. In contrast, private non-profit
    medical institutions are not eligible for government financial
    subsidies. Both public and private non-profit medical
    institutions are required to set their medical service fees
    within a range stipulated by the relevant governmental price
    control authorities, to implement financial and accounting
    systems in accordance with standards promulgated by government
    authorities and to retain any profits for the continued
    development of such institutions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For-profit medical institutions are permitted to set prices for
    their medical services in accordance with the market, to
    implement financial and accounting systems in accordance with
    market practice for business enterprises and to distribute
    profits to their shareholders. Like private non-profit medical
    institutions, for-profit medical institutions are not entitled
    to government financial subsidies. The specialty cancer
    hospitals that we plan to develop will be established as
    for-profit medical institutions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Medical
    Institution Practicing License</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the <I>Regulation on Medical Institution </I>issued
    on February&#160;26, 1994 by the PRC State Council, any
    organization or individual that intends to establish a medical
    institution must obtain a medical institution practicing license
    from the relevant healthcare administrative authorities. In
    determining whether to approve any application, the relevant
    healthcare administrative authorities are to consider whether
    the proposed medical institution comports with the population,
    medical resources, medical needs and geographic distribution of
    existing medical institutions in the regions for which such
    authorities are responsible as well as whether the proposed
    medical institution meets the basic medical standards set by the
    MOH. The independent specialty cancer hospitals that we intend
    to establish would each need to obtain such a medical
    institution practicing license.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Large
    Medical Equipment Procurement License</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The procurement, installation and operation in China of large
    medical equipment, which is defined as any medical equipment
    valued at over RMB5.0&#160;million or listed in the medical
    equipment administration catalogue of the MOH, is regulated by
    the <I>Rules on Procurement and Use of Large Medical
    Equipment</I> issued on December&#160;31, 2004 by the MOH, the
    NDRC and the Ministry of Finance, which became effective on
    March&#160;1, 2005. Pursuant to these rules, quotas for large
    medical equipment are set by the MOH and the NDRC or the
    relevant provincial
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    114
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    healthcare administrative authorities, and hospitals must obtain
    a large medical equipment procurement license prior to the
    procurement of any such equipment that is covered by the rules
    on procurement. For large medical equipment classified as
    Class&#160;A large medical equipment, which includes gamma knife
    systems, proton beam therapy systems and PET-CT scanners, quotas
    are set by the MOH and the NDRC and large medical equipment
    procurement licenses are issued by the MOH. For large medical
    equipment classified as Class&#160;B large medical equipment,
    which includes linear accelerators and MRI and CT scanners,
    procurement planning and approval is conducted by the relevant
    provincial healthcare administrative authorities with
    ratification by the MOH and the large medical equipment
    procurement licenses are issued by the relevant provincial
    healthcare administrative authorities. However, many provincial
    administrative authorities do not provide the general public
    with information on their procurement planning and quotas for
    Class&#160;B large medical equipment procurement licenses, if
    any. A large medical equipment procurement license is not
    required for medical equipment that is not classified as either
    Class&#160;A or Class&#160;B large medical equipment. These
    rules concerning procurement of large medical equipment apply to
    all public and private medical institutions in China, whether
    non-profit or for-profit, except for military hospitals which
    have a separate procurement system. See &#147;&#160;&#151;
    Regulation of Military Hospitals.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with the
    <I><FONT style="white-space: nowrap">2008-2010</FONT>
    National PET-CT Procurement Plan </I>issued on May&#160;13, 2008
    by the MOH and the NDRC, the total number of PET-CT large
    medical equipment procurement licenses issued in China cannot
    exceed 38 from the date of the plan through the end of 2010. In
    accordance with the <I>National Gamma Ray Stereotactic Head
    Radiosurgery System Procurement Plan </I>issued on
    March&#160;20, 2007 by the MOH and the NDRC, from the date of
    the plan through the end of 2010, the total number of large
    medical equipment procurement licenses issued for head gamma
    knife systems cannot exceed 60 nationwide. Procurement
    applications for head gamma knife equipment must be filed with
    the relevant provincial healthcare administrative authorities
    along with a feasibility report, which must be reviewed by such
    provincial authorities before it is submitted to the MOH for
    approval. There is currently no guidance as to the total number
    of large medical equipment procurement licenses that may be
    issued for other types of medical equipment that the centers in
    our network operate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    With respect to any Class A or Class B large medical equipment
    purchased before the <I>Rules on Procurement and Use of Large
    Medical Equipment </I>came into effect on March&#160;1, 2005,
    the medical institution that houses such equipment must apply to
    the MOH or the relevant provincial healthcare administrative
    authorities for a large medical equipment procurement license
    for such equipment. If such medical institution is unable to
    obtain a procurement license as a result of a lack of
    procurement quotas for such medical equipment allocated to the
    region in which the medical institution is located, an interim
    procurement permit for large medical equipment is required to be
    obtained in lieu thereof. Moreover, any medical institution
    holding an interim permit must pay taxes on income derived from
    the use of the equipment covered by the interim permit and, upon
    the expiration of the useful life of such medical equipment, the
    medical institution must dispose of such equipment and is not
    permitted to replace it with a newer model. Some of our medical
    equipment have not yet received a large medical equipment
    procurement license or an interim permit. For more information,
    see &#147;Risk Factors&#160;&#151; Risks Related to Our
    Industry&#160;&#151; Certain of our hospital partners have not
    received large medical equipment procurement licenses or interim
    procurement permits for some of the medical equipment in our
    network of centers which could result in fines or the suspension
    from use of such medical equipment.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Radiotherapy
    Permit</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Medical institutions that engage in radiotherapy are governed by
    the <I>Regulatory Rules on Radiotherapy </I>issued on
    January&#160;24, 2006 by the MOH and are required to obtain a
    radiotherapy permit from the relevant healthcare administrative
    authorities. These rules require such medical institutions to
    possess qualifications sufficient for radiotherapy work, which
    include having adequate facilities for housing radiotherapy
    equipment as well as having qualified, properly trained
    personnel. Medical institutions that operate medical equipment
    containing radioactive materials are also required to obtain a
    radiation safety permit. See &#147;&#160;&#151; Permits Required
    by Our Company&#160;&#151; Radiation Safety Permits.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Radiation
    Worker Permit</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Medical institutions that engage in the operation of medical
    equipment that contains radioactive materials or emits radiation
    during operation are required to obtain a radiation worker
    permit from the competent healthcare administrative authorities
    for each medical technician who operates such equipment.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    115
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Regulation
    of Military Hospitals</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The procurement, installation and operation of large medical
    equipment by medical institutions of the PLA is regulated by the
    healthcare administrative authority of the general logistics
    department of the PLA with reference to the <I>Rules on
    Procurement and Use of Large Medical Equipment</I>. The general
    logistic department of the PLA issues a large equipment
    application permit to those military hospitals approved for
    procurement. The procurement planning records and annual reviews
    are provided to the MOH for its records.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Restrictions
    on Cooperation Agreements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Since the effectiveness in September 2000 of the
    <I>Implementation Opinions on the Management by Classification
    of Urban Medical Institutions </I>by the MOH, the State
    Administration of Traditional Chinese Medicine, the Ministry of
    Finance and the NDRC, non-profit medical institutions other than
    military hospitals have been prohibited from entering into new
    cooperation agreements or continuing to operate under existing
    cooperation agreements with third parties pursuant to which the
    parties jointly invest in or cooperate to set up for-profit
    centers or units that are not independent legal entities.
    However, according to the <I>Opinions on Certain Issues
    Regarding Management by Classification of Urban Medical
    Institutions </I>issued on July&#160;20, 2001 by the MOH, the
    State Administration of Traditional Chinese Medicine, the
    Ministry of Finance and the NDRC, a non-profit medical
    institution that lacks sufficient funds to purchase medical
    equipment outright may enter into a leasing agreement pursuant
    to which the medical institution leases medical equipment at
    market rates. In response to this regulatory change, we have
    replaced the majority of our cooperation agreements with
    non-profit civilian hospitals with leasing and management
    agreements. See &#147;Risk Factors&#160;&#151; Risks Related to
    Our Company&#160;&#151; We may not be successful in negotiating
    the conversion of a few of our cooperation agreements with our
    partner hospitals into lease and management arrangements due to
    regulatory changes.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    of Doctors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Doctors in China must obtain a doctor practitioner or assistant
    doctor practitioner license in accordance with the <I>Law on
    Medical Practitioners</I>, effective as of May&#160;1, 1999, and
    the <I>Interim Measures for Registration of Medical
    Practitioners</I>, effective as of July&#160;16, 1999.
    Currently, each doctor is required to practice in the medical
    institution specified in such doctor&#146;s registration. If a
    doctor intends to change such doctor&#146;s practice location,
    including but not limited to moving to or from a non-profit
    medical institution or to or from a for-profit medical
    institution, practice classification, practice scope or other
    registered matters, such doctor is required to apply for such
    change with the competent healthcare administrative authorities.
    However, with the approval of the medical institution with which
    a doctor is affiliated, such doctor may, within such
    doctor&#146;s scope of practice, undertake outside
    consultations, including diagnostic and treatment activities,
    for patients of another medical institution.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pricing
    of Medical Services</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the <I>Opinion Concerning the Reform of Medical
    Service Pricing Management </I>issued by the NDRC and the MOH on
    July&#160;20, 2000, medical services fees generated through the
    use of both Class&#160;A and Class&#160;B large medical
    equipment at non-profit medical institutions and military
    hospitals are subject to the pricing guidelines of the relevant
    provincial or regional price control authorities and healthcare
    administrative authorities. The pricing guidance sets forth the
    range of medical services fees that can be charged by non-profit
    medical institutions and military hospitals. For-profit medical
    institutions are not subject to such pricing restrictions and
    are entitled to set medical services fees based on their cost
    structures, market demand and other factors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Medical
    Insurance Coverage</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China has a complex medical insurance system that is currently
    undergoing reform. Typically, those covered by medical insurance
    must pay for medical services out of their own pocket at the
    time services are rendered and must then seek reimbursement from
    the relevant insurer. For public servants and others covered by
    the <I>1989 Administrative Measure on State Provision of
    Healthcare </I>and the <I>1997 Circular on Reimbursement
    Coverage of Large Medical Equipment under State Provision of
    Healthcare</I>, the PRC government currently either fully or
    partially reimburses medical expenses for certain approved
    cancer diagnosis and radiotherapy treatment services, including
    treatments utilizing linear accelerators and diagnostic imaging
    services utilizing CT and MRI scanners. However, gamma knife
    treatments and PET scans are currently not eligible for
    reimbursement under this plan.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    116
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Urban residents in China that are not covered by the <I>1989
    Administrative Measure on State Provision of Healthcare </I>and
    the <I>1997 Circular on Reimbursement Coverage of Large Medical
    Equipment under State Provision of Healthcare </I>are covered by
    one of two nationwide public medical insurance schemes, which
    are the <I>Urban Employees Basic Medical Insurance Program
    </I>and the <I>Urban Residents Basic Medical Insurance
    Program</I>. Rural residents in China are covered under a new
    <I>Rural Cooperative Medical Program </I>launched in 2003. The
    <I>Urban Employees Basic Medical Insurance Program</I>, which
    covers employed urban residents, partially reimburses urban
    workers for treatments utilizing linear accelerators and gamma
    knife systems and diagnostic imaging services utilizing CT and
    MRI scanners, with reimbursement levels varying from province to
    province. However, diagnostic imaging services utilizing PET and
    PET-CT scans are currently not reimbursable under the <I>Urban
    Employees Basic Medical Insurance Program</I>. For urban
    non-workers who are covered by the <I>Urban Residents Basic
    Medical Insurance Program</I> and rural residents who are
    covered by the new <I>Rural Cooperative Medical Program</I>, the
    types of cancer diagnosis and radiotherapy treatments that are
    covered are generally set with reference to the policy for urban
    employees in the same region of the country. However, the
    reimbursement levels for covered medical expenses for urban
    non-workers and rural residents, which vary widely from region
    to region and treatment to treatment, are generally lower than
    those for urban employees in the same region. Currently no
    reimbursement is
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    117
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    available for proton beam therapy treatments. The table below
    summarizes certain key aspects of these three medical insurance
    programs:
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="26%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="22%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="22%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="22%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Urban Employees Basic Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Urban Residents Basic Medical<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Insurance Program</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Insurance Program</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Rural Cooperative Medical Program</B>
</DIV>
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Launch Time
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    1998
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    2003
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    Participants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Urban employees
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Urban non-employees
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Rural residents
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    Participation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Mandatory
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Voluntary
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Voluntary
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    Number of People covered<BR>
    in 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Approximately 200.0&#160;million (33.0% of China&#146;s urban
    population)
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Approximately 118.3&#160;million (19.5% of China&#146;s urban
    population)
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Approximately 815&#160;million (91.5% of China&#146;s rural
    population)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    Total reimbursement<BR>
    amount in 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    RMB208.4&#160;billion
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    N/A
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    RMB66.2&#160;billion
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    Funding
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
<DIV style="text-indent: -3pt; margin-left: 3pt;">
Employers and employees:<BR>&#149;&#160;&#160;&#160;employer contributes approximately 6% of each employee&#146;s total salary; and<BR>
</DIV>
<DIV style="text-indent: -3pt; margin-left: 3pt;">
&#149;&#160;&#160;&#160;employee contributes approximately 2% of such employee&#146;s total salary.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
<DIV style="text-indent: -3pt; margin-left: 3pt;">
Households and the government:<BR>&#149;&#160;&#160;&#160;monthly premium are paid by each household; and<BR>
</DIV>
<DIV style="text-indent: -3pt; margin-left: 3pt;">
&#149;&#160;&#160;&#160;government subsidizes no less than RMB80&#160;per person annually and RMB40&#160;per person annually for the mid/western regions of China, with greater subsidies provided to low-income families and disabled persons.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
<DIV style="text-indent: -3pt; margin-left: 3pt;">
Individuals and the government:<BR>&#149;&#160;&#160;&#160;individual pays no less than RMB20 per year and local government subsidizes no less than RMB40 per person annually; and<BR>
</DIV>
<DIV style="text-indent: -3pt; margin-left: 3pt;">
&#149;&#160;&#160;&#160;government subsidizes RMB40 per person annually for the middle and western regions of the country and a smaller amount for the eastern region.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    General Reimbursement Policy
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
<DIV style="text-indent: -3pt; margin-left: 3pt;">
Reimbursement comes from two sources&#160;&#151; individual&#146;s reimbursement account and the social medical expense pool:<BR>&#149;&#160;&#160;&#160;All of the employee&#146;s contribution and 30% of the employer&#146;s contribution are allocated to the individual&#146;s reimbursement account; the reimbursement cap from the individual account is the balance of that account; and<BR>
</DIV>
<DIV style="text-indent: -3pt; margin-left: 3pt;">
&#149;&#160;&#160;&#160;The remaining 70% of the employers&#146; contribution is aggregated into a social medical expense pool; the reimbursement cap from the social medical expense pool for an individual participant in a calendar year is around four times the regional average annual salary.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    There is no specific requirement or guidance from the central
    government. Reimbursement policy is separately determined by
    local governments.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    The central government suggests that, beginning in the second
    half of 2009, the reimbursement cap for all regions should be no
    less than six times the average annual per capita net  income of
    rural residents in the region.
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="top" style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    Examples of Local Reimbursement Policy
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <U>Shanghai:</U> reimbursement cap from the social medical
    expense pool for an individual participant in a calendar year is
    approximately four times the average annual salary in Shanghai
    from the previous year.<BR>
    <U>Inner Mongolia:</U> reimbursement cap from the social medical
    expense pool for an individual participant in a calendar year is
    RMB25,000.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <U>Jiangsu Province:</U> approximately 50% to 60% of medical
    expense can be reimbursed by the program.<BR>
    <U>Sichuan Province:</U> approximately 60% (and not less than
    50%) of medical expense can be reimbursed by the program.<BR>
    <U>Guangdong Province:</U> approximately 40% to 60% of medical
    expense can be reimbursed by the program; maximum reimbursement
    amount is approximately two times the average annual salary in
    Guangdong province from the previous year.
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <U>Guangdong Province:</U> maximum reimbursement amount is
    approximately RMB50,000&#160;per person per year.<BR>
    <U>Hubei Province:</U> maximum reimbursement amount for
    hospitalization is approximately RMB30,000 per person per
    year.<BR>
    <U>Anhui Province:</U> maximum reimbursement amount for
    hospitalization is approximately RMB30,000 per person per year.
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 3pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    Sources: </TD>
    <TD align="left">
    MOH, Ministry of Human Resources and Social Security, National
    Bureau of Statistics, and various other central and local PRC
    government websites.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    118
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Foreign
    Exchange Control and Administration</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the <I>Foreign Exchange Administration Regulation
    </I>promulgated on January&#160;29, 1996, as amended on
    January&#160;14, 1997 and August&#160;5, 2008, and various
    regulations issued by the SAFE and other relevant PRC government
    authorities, the Renminbi is freely convertible only with
    respect to current account items, such as trade-related receipts
    and payments, interest and dividends. Capital account items,
    such as direct equity investments, loans and repatriations of
    investments, require the prior approval of the SAFE or its local
    branches for conversion of Renminbi into foreign currency, such
    as U.S.&#160;dollars, and remittance of the foreign currency
    outside the PRC. Payments for transactions that take place
    within the PRC must be made in Renminbi. Foreign exchange
    transactions under the capital account are still subject to
    limitations and require approvals from, or registration with,
    the SAFE and other relevant PRC governmental authorities, or
    their competent local branches.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;29, 2008, the SAFE promulgated SAFE Circular
    No.&#160;142, a notice regulating the conversion by a
    foreign-invested company of foreign currency into Renminbi by
    restricting how converted Renminbi may be used. This notice
    requires that Renminbi converted from the foreign
    currency-denominated capital of a foreign-invested company only
    be used for purposes within the business scope approved by the
    applicable governmental authority and may not be used for equity
    investments within the PRC unless specifically provided for
    otherwise in its business scope. In addition, the SAFE
    strengthened its oversight of the flow and use of Renminbi funds
    converted from the foreign currency-denominated capital of a
    foreign-invested company. The use of such Renminbi may not be
    changed without SAFE&#146;s approval and may not be used to
    repay Renminbi loans if the proceeds of such loans have not yet
    been used for purposes within the company&#146;s approved
    business scope. Violations of SAFE Circular No.&#160;142 may
    result in severe penalties, including substantial fines as set
    forth in the <I>Foreign Exchange Administration Regulation</I>.
    As a result, SAFE Circular No.&#160;142 may significantly limit
    our ability to transfer the net proceeds from this offering to
    our PRC subsidiaries, which may adversely affect the continued
    growth of our business.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to SAFE Circular No.&#160;75, (i)&#160;a PRC resident
    must register with the local SAFE branch before establishing or
    controlling an overseas special purpose vehicle, or SPV, for the
    purpose of obtaining overseas equity financing using the assets
    of or equity interests in a domestic enterprise; (ii)&#160;when
    a PRC resident contributes the assets of or its equity interests
    in a domestic enterprise into an SPV, or engages in overseas
    financing after contributing assets or equity interests into an
    SPV, such PRC resident must register his or her interest in the
    SPV and any subsequent change thereto with the local SAFE
    branch; and (iii)&#160;when the SPV experiences a material
    event, such as a change in share capital, merger or acquisition,
    share transfer or exchange, spin-off or long-term equity or debt
    investment, the PRC resident must, within 30&#160;days after the
    occurrence of such event, register such event with the local
    SAFE branch. On May&#160;29, 2007, the SAFE issued guidance to
    its local branches for the implementation of the SAFE Circular
    No.&#160;75, which guidance provides for more standardized,
    specific and stringent supervision regarding such registration
    requirements and requires PRC residents holding any equity
    interests or options in SPVs, directly or indirectly,
    controlling or nominal, to register with the SAFE.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Currently, several of our shareholders who are residents in the
    PRC and are subject to the above registration or amendment of
    registration requirements, have applied to SAFE&#146;s local
    branches to make the required SAFE registration with respect to
    their investments in our company. Because of the current
    suspension of acceptance of such registrations by the SAFE
    authorities due to reportedly forthcoming new SAFE regulations,
    such shareholders&#146; applications are still pending. We
    cannot assure you that these shareholders&#146; pending
    applications will eventually be approved by the authorities. See
    &#147;Risk Factors&#160;&#151; Risks Related to Doing Business
    in China&#160;&#151; Recent PRC regulations, particularly SAFE
    Circular No.&#160;75 relating to acquisitions of PRC companies
    by foreign entities, may limit our ability to acquire PRC
    companies and adversely affect the implementation of our
    strategy as well as our business and prospects.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Dividend
    Distributions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the <I>Foreign Exchange Administration Regulation
    </I>promulgated in 1996, as amended in 1997 and 2008, and
    various regulations issued by the SAFE and other relevant PRC
    government authorities, the PRC government imposes restrictions
    on the convertibility of Renminbi into foreign currencies and,
    in certain cases, on the remittance of currency out of China.
    Our PRC subsidiaries are regulated under the <I>Foreign
    Investment Enterprise Law</I>, which was issued on
    April&#160;12, 1986 and amended on October&#160;31, 2000, the
    <I>Implementation Rules of the Foreign Investment Enterprise
    Law</I>, which was issued on October&#160;28, 1990 and amended
    on April&#160;12, 2001, and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    119
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    the newly revised <I>PRC Company Law</I>, which became effective
    as of January&#160;1, 2006. Pursuant to these regulations, each
    of our PRC subsidiaries must allocate at least 10.0% of its
    after-tax profits to a statutory common reserve fund. When the
    accumulated amount of the statutory common reserve fund exceeds
    50.0% of the registered capital of such subsidiary, no further
    allocation is required. Funds allocated to a statutory common
    reserve fund may not be distributed to equity owners as cash
    dividends. Furthermore, each of our PRC subsidiaries may
    allocate a portion of its after-tax profits, as determined by
    such subsidiary&#146;s ultimate decision-making body, to its
    staff welfare and bonus funds, which allocated portion may not
    be distributed as cash dividends.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Regulations
    Relating to Employee Share Options</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the <I>Administration Measure for Individual Foreign
    Exchange</I> issued in December 2006 and the <I>Implementation
    Rules of Administration Measure for Individual Foreign
    Exchange</I>, issued in January 2007 by the SAFE, all foreign
    exchange matters relating to employee stock award plans or stock
    option plans for PRC residents may only be transacted upon the
    approval of the SAFE or its authorized branch. On March&#160;28,
    2007, the SAFE promulgated the <I>Application Procedure of
    Foreign Exchange Administration for Domestic Individuals
    Participating in Employee Stock Award Plan or Stock Option Plan
    of Overseas-Listed Company</I>, or the Stock Option Rule. Under
    the Stock Option Rule, PRC citizens who participate in employee
    stock award and share option plans of an overseas
    publicly-listed company must register with the SAFE and complete
    certain related procedures. These procedures must be conducted
    by a PRC agent designated by the subsidiary of such overseas
    publicly-listed company with which the PRC citizens affiliate.
    The PRC agent may be a subsidiary of such overseas
    publicly-listed company, any such PRC subsidiary&#146;s trade
    union having legal person status, a trust and investment company
    or other financial institution qualified to act as a custodian
    of assets. Such participant&#146;s foreign exchange income
    received from the sale of shares or dividends distributed by the
    overseas publicly-listed company must first be remitted into a
    collective foreign exchange account opened and managed by the
    PRC agent prior to any distribution of such income to such
    participants in a foreign currency or in Renminbi.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to Circular No.&#160;106, employee stock award plans of
    SPVs and employee share option plans of SPVs must be filed with
    the SAFE while applying for the registration for the
    establishment of the SPVs. After employees exercise their
    options, they must apply for an amendment to the registration
    for the SPV with the SAFE. We intend to comply with these
    regulations and to ask our PRC optionees to comply with these
    regulations. However, as these rules have only been recently
    promulgated, it is currently unclear how these rules will be
    interpreted and implemented. If the applicable authorities
    determine that we or our PRC optionees have failed to comply
    with these regulations, we or our PRC optionees may be subject
    to fines and legal sanctions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Provisions
    Regarding Mergers and Acquisitions of Domestic Enterprises by
    Foreign Investors and Overseas Listings</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;8, 2006, six PRC regulatory agencies, including
    the PRC Ministry of Commerce, the State Assets Supervision and
    Administration Commission, the State Administration for
    Taxation, the State Administration for Industry and Commerce,
    the CSRC and the SAFE, jointly issued the <I>Regulations on
    Mergers and Acquisitions of Domestic Enterprises by Foreign
    Investors</I>, or the M&#038;A Rule, which became effective on
    September&#160;8, 2006. The M&#038;A Rule, among other things,
    includes provisions that require any offshore special purpose
    vehicle, or SPV, formed for the purpose of an overseas listing
    of equity interests in a PRC company that is controlled directly
    or indirectly by one or more PRC companies or individuals, to
    obtain the approval of the CSRC prior to the listing and trading
    of such SPV&#146;s securities on an overseas stock exchange. The
    application of the M&#038;A Rule is currently unclear. However,
    our PRC counsel, Jingtian&#160;&#038; Gongcheng Attorneys At
    Law, has advised us that based on its understanding of the
    current PRC laws, rules and regulations and the M&#038;A Rule,
    the M&#038;A Rule does not require that we obtain prior CSRC
    approval for the listing and trading of our ADSs on the NYSE,
    because our acquisition of the equity interest in our PRC
    subsidiaries is not subject to the M&#038;A Rule due to the fact
    that each of them was already a foreign-invested enterprise
    before September&#160;8, 2006, the effective date of the
    M&#038;A Rule. Jingtian&#160;&#038; Gongcheng Attorneys At Law
    has further advised us that their opinions summarized above are
    subject to the timing and content of any new laws, rules and
    regulations or clear implementations and interpretations from
    the CSRC in any form relating to the M&#038;A Rule.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    120
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Regulation
    of Loans between a Foreign Company and its Chinese
    Subsidiary</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A loan made by foreign investors as shareholders in a
    foreign-invested enterprise is considered to be foreign debt in
    China and is subject to several Chinese laws and regulations,
    including the <I>Foreign Exchange Administration Regulation of
    1996 </I>and its amendments of 1997 and 2008, the <I>Interim
    Measures on Foreign Debts Administration of 2003</I>, or the
    Interim Measures, the <I>Statistical Monitoring of Foreign Debts
    Tentative Provisions of 1987 </I>and its implementing rules of
    1998, the <I>Administration Provisions on the Settlement, Sale
    and Payment of Foreign Exchange of 1996</I>, and the <I>Notice
    of the SAFE on Issues Related to Perfection of Foreign Debts
    Administration</I>, dated October&#160;21, 2005.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under these rules and regulations, a shareholder loan in the
    form of foreign debt made to a Chinese entity does not require
    the prior approval of the SAFE. However, such foreign debt must
    be registered with and recorded by the SAFE or its local branch
    in accordance with relevant PRC laws and regulations. Our PRC
    subsidiaries can legally borrow foreign exchange loans up to
    their respective borrowing limits, which is defined as the
    difference between the amount of their respective &#147;total
    investment&#148; and &#147;registered capital&#148; as approved
    by the MOFCOM, or its local counterparts. Interest payments, if
    any, on the loans are subject to a 10% withholding tax unless
    any such foreign shareholder&#146;s jurisdiction of
    incorporation has a tax treaty with China that provides for a
    different withholding arrangement. Pursuant to Article&#160;18
    of the Interim Measures, if the amount of foreign exchange debt
    of our PRC subsidiaries exceeds their respective borrowing
    limits, we are required to apply to the relevant Chinese
    authorities to increase the total investment amount and
    registered capital to allow the excess foreign exchange debt to
    be registered with the SAFE.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Taxation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For a discussion of applicable PRC tax regulations, see
    &#147;Management&#146;s Discussion and Analysis of Financial
    Condition and Results of Operations&#160;&#151; Taxation.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Regulation
    on Employment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On June&#160;29, 2007, the National People&#146;s Congress
    promulgated the <I>Labor Contract Law of PRC</I>, or the Labor
    Law, which became effective as of January&#160;1, 2008. On
    September&#160;18, 2008, the PRC State Council issued the <I>PRC
    Labor Contract Law Implementation Rules</I>, which became
    effective as of the date of issuance. The Labor Law and its
    implementation rules are intended to give employees long-term
    job security by, among other things, requiring employers to
    enter into written contracts with their employees and
    restricting the use of temporary workers. The Labor Law and its
    implementation rules impose greater liabilities on employers,
    require certain terminations to be based upon seniority rather
    than merit and significantly affect the cost of an
    employer&#146;s decision to reduce its workforce. Employment
    contracts lawfully entered into prior to the implementation of
    the Labor Law and continuing after the date of its
    implementation remain legally binding and the parties to such
    contracts are required to continue to perform their respective
    obligations thereunder. However, employment relationships
    established prior to the implementation of the Labor Law without
    a written employment agreement were required to be memorialized
    by a written employment agreement that satisfies the
    requirements of the Labor Law within one month after it became
    effective on January&#160;1, 2008.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    121
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='116'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANAGEMENT</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Directors
    and Executive Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information regarding our
    directors and executive officers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="31%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="59%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Name</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Age</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Position/Title</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director, chief executive officer and president
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Co-chairman of the board of directors and chief operating officer
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Steve Sun
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Co-chairman of the board of directors and chief financial officer
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Jing Zhang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and executive president
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yaw Kong Yap
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and financial controller
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shirley Chen
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Feng Xiao
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine Zong
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Wai Hong Ku
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Denny Lee*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Independent Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Boxun Zhang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Corporate vice president
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Mr.&#160;Denny Lee has accepted our
    appointment to be the independent director of our company,
    effective upon commencement of the trading of our ADSs on the
    NYSE.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Dr.&#160;Jianyu Yang </I>has served as a director of our
    company and our chief executive officer and president since
    2007. Prior to joining our company, Dr.&#160;Yang served as
    chief executive officer of Eguard Resource Development Co.,
    Ltd., a PRC company listed on the Shenzhen Stock Exchange in
    China principally engaged in the provision of comprehensive
    solutions in recycling, re-use of solid wastes and wastewater
    since 2003, vice president of Beijing Sound Environmental Group
    Co. Ltd. from 2002 to 2003, assistant to the general manager of
    Xiangcai Securities Co., Ltd. from 2000 to 2002, and senior
    economist at China Agricultural Bank from 1999 to 2000.
    Dr.&#160;Yang received a doctorate degree in economics from
    Liaoning University in 1999 in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Dr.&#160;Zheng Cheng </I>has served as co-chairman of our
    board of directors and our chief operating officer since 2008.
    Dr.&#160;Cheng was a co-founder of China Medstar. Prior to
    founding China Medstar in 1996, Dr.&#160;Cheng had served as
    division chief of steel products of China National Defense
    Military Material General Company from 1992 to 1996 and military
    physician in the Department of Cerebral Surgery of the Beijing
    Air Force General Hospital from 1986 to 1992 and in the
    No.&#160;1 Field Clinic of Yunnan Laoshan Frontier in 1986.
    Dr.&#160;Cheng received his bachelor&#146;s degree in clinical
    neurosurgery from the First Military Medical University of the
    People&#146;s Liberation Army of China in 1986. Dr.&#160;Cheng
    is a qualified clinical surgeon in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Steve Sun </I>has served as co-chairman of our board
    of directors since 2008 and our chief financial officer since
    2009. Mr.&#160;Sun was a director and the president of Aohua
    Medical from 2006 to 2008. Prior to joining our company,
    Mr.&#160;Sun had served as the chief operating officer of
    Sunshine100 Real Estate Group, a Beijing-based real estate
    company, from 2004 to 2005 and executive vice president of AE
    Capital Markets Inc., a New York-based investment bank, from
    1997 to 2000. Mr.&#160;Sun received a master&#146;s degree in
    business management from the University of Chicago in 1996, a
    master&#146;s degree in operational research from Xidian
    University in 1985 and a bachelor&#146;s degree in mathematics
    from Heilongjiang University in 1983.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Jing Zhang </I>has served as a director of our
    company and our executive president since 2008. Mr.&#160;Zhang
    was a co-founder of China Medstar. Prior to founding China
    Medstar in 1996, Mr.&#160;Zhang was in charge of research and
    development at the Institute of Chemistry of Beijing Timber
    General Co., Ltd. from 1987 to 1996. Mr.&#160;Zhang received a
    bachelor&#146;s degree in polymer chemistry from the Beijing
    Institute of Chemical Technology in 1987.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Yaw Kong Yap </I>has served as a director of our
    company and our financial controller since 2008. Mr.&#160;Yap
    joined China Medstar in 2005 and served as its chief financial
    officer prior to our acquisition of China Medstar. Prior to
    joining China Medstar, Mr.&#160;Yap had served as the chief
    executive officer of Advanced Produce Centre Development Pte,
    Ltd., a Singapore real estate company, from 2003 to 2005, the
    chief financial officer of Global Fruits Pte Limited from 1999
    to 2003, the regional financial controller of America Air
    Filtration Asia from 1996 to 1998 and the financial controller
    of Chevalier International (USA) Ltd. from 1991 to 1996.
    Mr.&#160;Yap received
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    122
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    a bachelor&#146;s degree from Indiana University of Pennsylvania
    in the United States in 1990. Mr.&#160;Yap was a Certified
    Public Accountant in the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Ms.&#160;Shirley Chen </I>has served as a director of our
    company since 2007. Ms.&#160;Chen is also currently a managing
    director of China International Capital Corporation Limited, or
    CICC, and head of private equity and chief executive officer of
    CICC Investment Group Company Limited, an affiliate of CICC.
    Ms.&#160;Chen joined CICC in 2003 and was a managing director of
    its Investment Banking Department. Prior to joining CICC, she
    was a director of Credit Suisse First Boston and worked in its
    Investment Banking Division in New York and Hong Kong from 1995
    to 2002. Ms.&#160;Chen received an M.B.A. degree from Yale
    University&#146;s School of Management, a master of law degree
    in International Economic Law from Wuhan University and a
    bachelor of law degree in International Law from Wuhan
    University in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Feng Xiao </I>has served as a director of our
    company since 2008. Mr.&#160;Xiao is also currently a managing
    director of the Carlyle Group, focusing on growth capital
    investments in China. Mr.&#160;Xiao had served as a vice
    president at CICC from 2000 to 2005, where he had been involved
    in the restructuring and listing of a number of leading Chinese
    companies, and worked at as a lawyer and a registered trademark
    agent at China Patent Agent (HK) Limited from 1995 to 1998.
    Mr.&#160;Xiao received an M.B.A. degree from the China Europe
    International Business School in 1999 and a bachelor&#146;s
    degree in both computer science and English from Tsinghua
    University in 1995. Mr.&#160;Xiao also holds a lawyer&#146;s
    qualification certificate in China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Ms.&#160;Elaine Zong </I>has served as a director of our
    company since 2008. Ms.&#160;Zong is also currently a managing
    director of C.V. Starr Investment Advisors (Asia) Limited,
    focusing on private equity investments in China. Ms.&#160;Zong
    had served as senior vice president at Deutsche Bank from 2005
    to 2006, as vice president at Merrill Lynch from 2001 to 2003,
    and as an associate in the investment banking division of
    J.P.&#160;Morgan from 1998 to 2001. Ms.&#160;Zong received an
    M.B.A. degree from the University of Chicago in the United
    States in 1998 and a bachelor&#146;s degree in economics from
    Fudan University of China in 1992. Ms.&#160;Zong is a Chartered
    Financial Analyst.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Wai Hong Ku </I>has served as a director of our
    company since 2005. Mr.&#160;Ku is also currently a member of
    the board of directors and the general manager of Yanli Paper
    (China) Limited. Mr.&#160;Ku was the general manager of Fengjia
    Industries Co., Ltd. from 1992 to 1995 and was a project
    planning manager and the general manager of Zhong Fa Development
    Company of Addi Lee&#160;&#038; Partners Limited from 1979 to
    1992, responsible for the development of hotels and other
    properties.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Denny Lee</I> will become an independent
    non-executive director of our company upon commencement of the
    trading of our ADSs on the NYSE. Mr.&#160;Lee is currently a
    non-executive director of Netease.com, Inc., a company listed on
    the Nasdaq Global Select Market, and an independent director and
    chairman of the audit committee of New Oriental Education &#038;
    Technology Group Inc., Acorn International, Inc. and Gushan
    Environmental Energy Limited, which are all companies listed on
    the NYSE. Previously, Mr.&#160;Lee was the chief financial
    officer of Netease.com until June 2007 and the financial
    controller of Netease.com from November 2001 to April 2002.
    Prior to joining Netease.com in 2001, Mr.&#160;Lee worked in the
    Hong Kong office of KPMG for more than ten years. Mr.&#160;Lee
    graduated from the Hong Kong Polytechnic University majoring in
    accounting and is a member of The Hong Kong Institute of
    Certified Public Accountants and The Chartered Association of
    Certified Accountants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Mr.&#160;Boxun Zhang </I>has served as corporate vice
    president of our company since August 2009. Prior to joining our
    company, from 2006 to August 2009, Mr.&#160;Zhang served as the
    director of financial and business analysis, financial
    controller and investment controller of Suntech Power Holdings
    Co., Ltd, a Cayman Islands company listed on the NYSE
    principally engaged in the design, manufacture and sale of solar
    energy products. Mr.&#160;Zhang previously worked for the
    investment bank department of Credit Suisse from 2004 to 2005
    and was a senior auditor for PricewaterhouseCooper from 1998 to
    2002. Mr.&#160;Zhang received his MBA degree from Cass Business
    School in the United Kingdom in 2004 and a bachelor&#146;s
    degree in accounting and auditing from Wuhan University in China
    in 1998.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    123
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The address of our directors and executive officers is Concord
    Medical Services Holdings Limited, 18/F, Tower A, Global Trade
    Center, 36 North Third Ring Road East, Dongcheng District,
    Beijing, People&#146;s Republic of China, 100013.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Duties of
    Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under Cayman Islands law, our directors have a fiduciary duty to
    act honestly, in good faith and with a view to our best
    interests. Our directors also have a duty to exercise the skill
    they actually possess and such care and diligence that a
    reasonably prudent person would exercise in comparable
    circumstances. In fulfilling their duty of care to us, our
    directors must ensure compliance with our memorandum and
    articles of association, as amended and restated from time to
    time. A shareholder has the right to seek damages if a duty owed
    by our directors is breached.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The functions and powers of our board of directors include,
    among others:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    convening shareholders&#146; annual general meetings and
    reporting its work to shareholders at such meetings;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    declaring dividends and distributions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    appointing officers and determining the term of office of
    officers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    exercising the borrowing powers of our company and mortgaging
    the property of our company; and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approving the transfer of shares of our company, including
    registering such shares in our share register.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board of
    Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon the completion of this offering, we expect that our board
    of directors will have 10&#160;directors, consisting of one
    independent directors. Our board of directors will establish an
    audit committee and a compensation committee upon the completion
    of this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Audit
    Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our audit committee will initially consist of Mr.&#160;Denny
    Lee, Mr.&#160;Feng Xiao and Mr.&#160;Wai Hong Ku. Mr.&#160;Denny
    Lee will be the chairman of our audit committee and meets the
    criteria of an audit committee financial expert as set forth
    under the applicable rules of the SEC. Mr.&#160;Denny Lee
    satisfies the requirements for an &#147;independent
    director&#148; within the meaning of Section&#160;303A of the
    NYSE Listed Company Manual and will meet the criteria for
    independence set forth in
    <FONT style="white-space: nowrap">Rule&#160;10A-3</FONT>
    of the Exchange Act. Our board of directors has determined that
    the simultaneous service by Mr.&#160;Denny Lee on the audit
    committee of three other public companies would not impair his
    ability to effectively serve on our audit committee. Our audit
    committee will consist of two independent directors within
    90&#160;days of our initial public offering and solely of
    independent directors within one year of our initial public
    offering. The audit committee oversees our accounting and
    financial reporting processes and the audits of the financial
    statements of our company. The audit committee is responsible
    for, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    selecting our independent registered public accounting firm and
    pre-approving all auditing and non-auditing services permitted
    to be performed by our independent registered public accounting
    firm;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing with our independent registered public accounting firm
    any audit problems or difficulties and management&#146;s
    response;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and approving all proposed related-party transactions,
    as defined in Item&#160;404 of
    <FONT style="white-space: nowrap">Regulation&#160;S-K</FONT>
    under the Securities Act;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    discussing the annual audited financial statements with
    management and our independent registered public accounting firm;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing major issues as to the adequacy of our internal
    controls and any special audit steps adopted in light of
    significant control deficiencies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    annually reviewing and reassessing the adequacy of our audit
    committee charter;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    such other matters that are specifically delegated to our audit
    committee by our board of directors from time to time;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    124
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    meeting separately and periodically with management and our
    internal auditor and independent registered public accounting
    firm;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reporting regularly to the full board of directors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our compensation committee will initially consist of
    Ms.&#160;Shirley Chen and Mr.&#160;Feng Xiao. Ms.&#160;Shirley
    Chen will be the chairperson of our compensation committee. Our
    compensation committee assists the board in reviewing and
    approving the compensation structure of our directors and
    executive officers, including all forms of compensation to be
    provided to our directors and executive officers. Members of the
    compensation committee are not prohibited from direct
    involvement in determining their own compensation. Our chief
    executive officer may not be present at any committee meeting
    during which his compensation is deliberated. The compensation
    committee is responsible for, among other things:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    approving and overseeing the compensation package for our
    executive officers;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and making recommendations to the board with respect
    to the compensation of our directors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing and approving corporate goals and objectives relevant
    to the compensation of our chief executive officer, evaluating
    the performance of our chief executive officer in light of those
    goals and objectives, and setting the compensation level of our
    chief executive officer based on such evaluation;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reviewing periodically and making recommendations to the board
    regarding any long-term incentive compensation or equity plans,
    programs or similar arrangements, annual bonuses, employee
    pension and welfare benefit plans.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Interested
    Transactions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A director may vote in respect of any contract or transaction in
    which he or she is interested, provided that the nature of the
    interest of any directors in such contract or transaction is
    disclosed by him or her at or prior to its consideration and any
    vote on that matter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Remuneration
    and Borrowing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The directors may determine remuneration to be paid to the
    directors. The compensation committee assists the directors in
    reviewing and approving the compensation structure for the
    directors. The directors may exercise all the powers of the
    company to borrow money and to mortgage or charge its
    undertaking, property and uncalled capital, and to issue
    debentures or other securities whether outright or as security
    for any debt obligations of our company or of any third party.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Qualification</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There is no shareholding qualification for directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Terms of
    Directors and Executive Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive officers are elected by and serve at the
    discretion of the board of directors. Our directors are not
    subject to a term of office and hold office until such time as
    they resign or are removed from office without cause by special
    resolution or the unanimous written resolution of all
    shareholders or with cause by ordinary resolution or the
    unanimous written resolutions of all shareholders. A director
    will be removed from office automatically if, among other
    things, the director (i)&#160;becomes bankrupt or makes any
    arrangement or composition with his creditors or (ii)&#160;dies
    or is found by our company to be or becomes of unsound mind. We
    have not entered into any service agreements with our directors
    that provide for any type of compensation upon termination.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employment
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have entered into employment agreements with all of our
    executive officers. Under these agreements, each of our
    executive officers is employed for a non-fixed period of time.
    These employment agreements can be terminated in accordance with
    the <I>Labor Contract Law of the PRC </I>and other relevant
    regulations. Under the Labor Contract Law, we can terminate
    without any prior notice the employment agreement with any of
    our executive officers in the event that
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    125
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    such officer&#146;s actions have resulted in material and
    demonstrable harm to our interest. Under certain circumstances,
    including where the officer has not performed as expected and,
    upon internal reassignment or training, still fails to be
    qualified for the job, we may also terminate the employment
    agreement with any of our executive officers upon providing 30
    days notice or paying one month in severance. Our executive
    officer may typically terminate his or her employment at any
    time if we fail to provide labor protection or work conditions
    as stipulated in the employment agreement. The executive
    officers may also terminate the employment agreement at any time
    without cause upon 30 days notice. Usually, if we terminate the
    employment agreement of any of our executive officers, we have
    to pay them certain severance pay in proportion to their working
    years with us, except where such officer&#146;s actions have
    resulted in material and demonstrable harm to our interests,
    among other circumstances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each executive officer has agreed to hold, both during and
    subsequent to the terms of his or her agreement, in confidence
    and not to use, except in pursuance of his or her duties in
    connection with the employment, any of our confidential
    information, technological secrets, commercial secrets and
    know-how. Each of our executive officers has entered into a
    confidentiality agreement with us. Our executive officers have
    also agreed to disclose to us all inventions, designs and
    techniques resulted from work performed by them, and to assign
    us all right, title and interest of such inventions, designs and
    techniques.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    of Directors and Executive Officers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2008, the aggregate cash compensation to all of our directors
    and our executive officers was RMB1.2&#160;million
    (US$0.2&#160;million). For share-based compensation, see
    &#147;&#160;&#151; Share Incentive Plans.&#148; The total amount
    accrued in 2008 for pension, retirement or other similar
    benefits to our directors and our executive officers was
    approximately RMB240,000 (US$35,000).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Share
    Incentive Plans</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">OMS
    Share Option Plan</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2007, OMS, the predecessor of our company,
    adopted a share option plan, or the OMS option plan, pursuant to
    which OMS granted to three of its executive directors,
    Mr.&#160;Haifeng Liu, Mr.&#160;Jianyu Yang and Mr.&#160;Steve
    Sun, or the OMS grantees, options to purchase a total of up to
    25,000,000 ordinary shares, or the OMS share options, to
    purchase the ordinary shares of OMS at an exercise price of
    US$0.80 per share, which the board of OMS determined to become
    vested upon the satisfaction of a number of performance
    conditions that related to the completion of the OMS
    reorganization, achievement of net profit target of OMS, and the
    raising of new financing. The OMS share options were exercisable
    from the date of completion of the 2007 audited consolidated
    financial statements of OMS to December&#160;31, 2008 and were
    transferrable to any individuals designated by the OMS grantees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;18, 2008, the board of directors of OMS
    contemplated that the OMS grantees had achieved certain
    performance conditions outlined in the OMS option plan. However,
    as the capital structure of our company had changed at that time
    such that we had replaced OMS as the ultimate holding company of
    our subsidiaries, the board of directors of OMS resolved that
    the OMS option plan would be settled in vested options to
    purchase 21,184,600 ordinary shares to purchase shares of our
    company, with each option having an exercise price of US$0.79
    exercisable before December&#160;31, 2008. On the same day, two
    of the OMS grantees, Mr.&#160;Jianyu Yang and Mr.&#160;Steve
    Sun, exercised their respective options to purchase an aggregate
    of 6,355,400&#160;ordinary shares of our company, with total
    proceeds from such exercise received by us amounting to
    approximately RMB34.4&#160;million (US$5.0&#160;million). We
    recorded share-based compensation expense of approximately
    RMB49.5&#160;million in 2007 related to these options granted,
    which was recorded in general and administrative expenses. The
    third OMS grantee, Mr.&#160;Haifeng Liu, sold all of his vested
    options to purchase 14,829,200 ordinary shares of our company to
    three former directors of China Medstar who are now our
    directors and executive officers as employment incentive for
    such directors. The three executive directors subsequently
    exercised the vested options with total proceeds from such
    exercise received by us amounting to approximately
    US$11.7&#160;million. Given the transfer of the OMS share
    options to the three directors was provided as an employment
    incentive, we recorded additional share-based compensation
    expense of approximately RMB4.2&#160;million
    (US$0.6&#160;million) in 2008, which was recorded in general and
    administrative expenses.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    126
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">2008&#160;Share
    Incentive Plan</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The 2008&#160;share incentive plan was adopted by our
    shareholders on October&#160;16, 2008. Our share incentive plan
    provides for the grant of options, share appreciation rights, or
    other share-based awards, referred to as &#147;awards.&#148; The
    purpose of the plan is to aid us in recruiting and retaining key
    employees, directors or consultants and to motivate such persons
    to exert their best efforts on behalf of our company by
    providing incentives through the granting of awards. Our board
    of directors believes that our company will benefit from the
    added interest that such persons will have in the welfare of the
    company as a result of their proprietary interest in the
    company&#146;s success.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Termination of Awards.</I>&#160;Options have specified terms
    set forth in a share option agreement. If the recipient&#146;s
    employment with the company is terminated for any reason, the
    recipient&#146;s vested options shall remain exercisable subject
    to the provisions of the plan and the option agreement and the
    recipient&#146;s unvested options shall terminate without
    consideration. If the options are not exercised or purchased by
    the last day of the exercise period, they will terminate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Administration.</I>&#160;Our 2008&#160;share incentive plan
    is currently administered by our board of directors and, after
    this offering, will be administered by the compensation
    committee of our board of directors. Our board of directors or
    the compensation committee is authorized to interpret the plan,
    to establish, amend and rescind any rules and regulations
    relating to the plan, and to make any other determinations that
    it deems necessary or desirable for the administration of the
    plan. Our board of directors or the compensation committee will
    determine the provisions, terms and conditions of each award
    consistent with the provisions of the plan, including, but not
    limited to, the exercise price for an option, vesting schedule,
    forfeiture provisions, form of payment of exercise price and
    other applicable terms.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Option Exercise.</I>&#160;The term of options granted under
    the 2008&#160;share incentive plan may not exceed eight years
    from the date of grant. The consideration to be paid for our
    ordinary shares upon exercise of an option or purchase of shares
    underlying the option may include cash, check or other
    cash-equivalent, consideration received by us in a cashless
    exercise and, to the extent permitted by our board of directors
    or the compensation committee and subject to the provisions of
    the option agreement, ordinary shares or a combination of
    ordinary shares and cash or cash-equivalent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Change in Control.</I>&#160;If a third-party acquires us
    through the purchase of all or substantially all of our assets,
    a merger or other business combination or if during any two
    consecutive year period individuals who at the beginning of such
    period constituted the board of directors cease for any reason
    to constitute a majority of our board of directors, then, if so
    determined by our board of directors or the compensation
    committee with respect to the applicable award agreement or
    otherwise, any outstanding awards that are unexercisable or
    otherwise unvested or subject to lapse restrictions will
    automatically be deemed exercisable or otherwise vested or no
    longer subject to lapse restrictions, as the case may be, as of
    immediately prior to such change in control. Our board of
    directors or the compensation committee may also, in its sole
    discretion, decide to cancel such awards for fair value, provide
    for the issuance of substitute awards that will substantially
    preserve the otherwise applicable terms of any affected awards
    previously granted, or provide that affected options will be
    exercisable for a period of at least 15&#160;days prior to the
    change in control but not thereafter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Amendment and Termination of Plan.</I>&#160;Our board of
    directors may at any time amend, alter or discontinue our
    2008&#160;share incentive plan. Amendments or alterations to our
    2008&#160;share incentive plan are subject to shareholder
    approval if they increase the total number of shares reserved
    for the purposes of the plan or change the maximum number of
    shares for which awards may be granted to any participant. Any
    amendment, alteration or termination of our 2008&#160;share
    incentive plan must not adversely affect awards already granted
    without written consent of the recipient of such awards. Unless
    terminated earlier, our 2008&#160;share incentive plan shall
    continue in effect for a term of ten years from the date of its
    adoption.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our board of directors and shareholders authorized the issuance
    of up to 4,765,800 ordinary shares upon exercise of awards
    granted under our 2008&#160;share incentive plan. As of the date
    of this prospectus, no awards have been granted under our
    2008&#160;share incentive plan.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    127
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='117'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PRINCIPAL
    AND SELLING SHAREHOLDERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information with respect to the
    beneficial ownership of our ordinary shares, as of the date of
    this prospectus, assuming the conversion of all outstanding
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares into ordinary shares, by:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each of our directors and executive officers;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each person known to us to own beneficially more than 5.0% of
    our ordinary shares; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each other selling shareholders.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Beneficial ownership is determined in accordance with rules and
    regulations of the SEC. In computing the number of shares
    beneficially owned by a person or the percentage ownership of
    that person, we have included shares that the person has the
    right to acquire within 60&#160;days of this offering, including
    through the exercise of any option, warrant or other right or
    the conversion of any other security. These shares, however, are
    not included in the computation of the percentage ownership of
    any other person. The calculation of the number of shares also
    assumes the conversion of all of our Series&#160;A and
    Series&#160;B contingently redeemable convertible preferred
    shares into our ordinary shares upon the completion of this
    offering. Percentage of beneficial ownership of each listed
    person prior to this offering is based on 111,455,500 ordinary
    shares outstanding as of the date of this prospectus, including
    41,027,400 ordinary shares convertible from our outstanding
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares. Percentage of beneficial ownership
    of each listed person after the offering is based
    on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ordinary shares outstanding immediately after the closing of
    this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table below does not reflect the exercise of the
    underwriters&#146; option to purchase up to an
    additional&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ADSs, of
    which&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ADSs would be sold by us
    and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    ADSs would be sold by the selling shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="51%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Ordinary Shares Beneficially<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Ordinary Shares Being Sold<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Ordinary Shares Beneficially<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Owned Prior to This Offering</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>in This Offering</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Owned After This Offering</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Number</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">%</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Number</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">%</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Number</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">%</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Directors and Executive Officers:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Jianyu
    Yang<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,065,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Zheng
    Cheng<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,319,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Steve
    Sun<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,065,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Jing
    Zhang<SUP style="font-size: 85%; vertical-align: top">(4)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,979,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yaw Kong
    Yap<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shirley
    Chen<SUP style="font-size: 85%; vertical-align: top">(6)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,533,817
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Feng
    Xiao<SUP style="font-size: 85%; vertical-align: top">(7)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,172,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Elaine
    Zong<SUP style="font-size: 85%; vertical-align: top">(8)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,418,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Wai Hong
    Ku<SUP style="font-size: 85%; vertical-align: top">(9)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,889,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Boxun
    Zhang<SUP style="font-size: 85%; vertical-align: top">(10)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All directors and executive officers as a group
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,239,521
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Principal and Selling Shareholders:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Carlyle
    Entities<SUP style="font-size: 85%; vertical-align: top">(11)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,172,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23.5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Notable Enterprise
    Limited<SUP style="font-size: 85%; vertical-align: top">(12)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,321,300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Starr Investments Cayman II,
    Inc.<SUP style="font-size: 85%; vertical-align: top">(13)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,418,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Grand Best Group
    Limited<SUP style="font-size: 85%; vertical-align: top">(14)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,215,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CZY Investments
    Limited<SUP style="font-size: 85%; vertical-align: top">(15)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,319,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CICC Sun Company
    Limited<SUP style="font-size: 85%; vertical-align: top">(16)</SUP>

</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,177,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Upon exercise of all options
    granted, would beneficially own less than 1.0% of our
    outstanding ordinary shares.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 4,065,800 ordinary
    shares held by Daketala International Investment Holdings Ltd.,
    a limited liability company organized under the laws of the
    British Virgin Islands wholly owned by Dr.&#160;Yang. 2,910,800
    of the ordinary shares held by Daketala International
    </FONT></TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    128
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Investment Holdings Ltd. have been
    pledged to certain of our shareholders in connection with the
    issuance of our Series&#160;B contingently redeemable
    convertible preferred shares on October&#160;20, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 7,319,900 ordinary
    shares held by CZY Investment Ltd., a limited liability company
    organized under the laws of the British Virgin Islands wholly
    owned by Mr.&#160;Cheng. 6,369,500 of the ordinary shares held
    by CZY Investment Ltd. have been pledged to certain of our
    shareholders in connection with the issuance of our
    Series&#160;B contingently redeemable convertible preferred
    shares on October&#160;20, 2008. In addition, 2,191,500 of the
    ordinary shares held by CZY Investment Ltd. have been pledged to
    certain of our shareholders as security for a loan.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 4,065,800 ordinary
    shares held by Dragon Image Investment Ltd., a limited liability
    company organized under the laws of the British Virgin Islands
    wholly owned by Mr.&#160;Sun. 3,193,800 of the ordinary shares
    held by Dragon Image Investment Ltd. have been pledged to
    certain of our shareholders in connection with the issuance of
    our Series&#160;B contingently redeemable convertible preferred
    shares on October&#160;20, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 2,979,900 ordinary
    shares held by Thousand Ocean Group Limited, a limited liability
    company organized under the laws of the British Virgin Islands
    wholly owned by Mr.&#160;Zhang. 1,675,000 of the ordinary shares
    held by Thousand Ocean Group Limited have been pledged to
    certain of our shareholders in connection with the issuance of
    our Series&#160;B contingently redeemable convertible preferred
    shares on October&#160;20, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents ordinary shares held by
    Top Mount Group Limited, a limited liability company organized
    under the laws of the British Virgin Islands wholly owned by
    Mr.&#160;Yap. Certain portion of the ordinary shares held by Top
    Mount Group Limited have been pledged to certain of our
    shareholders in connection with the issuance of our
    Series&#160;B contingently redeemable convertible preferred
    shares on October&#160;20, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(6)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 6,616,900 and 323,200
    ordinary shares held by CICC Sun Company Limited and Perfect Key
    Holdings Limited, respectively, issuable upon conversion of all
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares held by such shareholders and
    560,300 and 33,417 ordinary shares, respectively, held by such
    shareholders. For a description of the beneficial ownership of
    our ordinary shares by CICC Sun Company Limited, see Note 16
    below. Ms.&#160;Shirley Chen disclaims beneficial ownership of
    our ordinary shares held by CICC Sun Company Limited except to
    the extent of her pecuniary interest in these shares. Perfect
    Key Holdings Limited is a limited liability company organized
    under the laws of the British Virgin Islands in which
    Ms.&#160;Shirley Chen holds 47.4% beneficial ownership.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(7)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 23,085,700 and 920,600
    ordinary shares held by Carlyle Asia Growth Partners III, L.P.
    and CAGP III Co-Investment, L.P., respectively, issuable upon
    conversion of all Series&#160;A and Series&#160;B contingently
    redeemable convertible preferred shares held by such
    shareholders and 2,083,300 and 83,100 ordinary shares,
    respectively, held by such shareholders. Carlyle Asia Growth
    Partners III, L.P. and CAGP III Co-Investment, L.P. are
    collectively referred to in this prospectus as the Carlyle
    Entities. For a description of the beneficial ownership of our
    ordinary shares by the Carlyle Entities, see Note&#160;10 below.
    Mr.&#160;Feng Xiao disclaims beneficial ownership of our
    ordinary shares held by the Carlyle Entities, except to the
    extent of his pecuniary interest in these shares.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(8)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 9,722,200 ordinary
    shares issuable upon conversion of all Series B contingently
    redeemable convertible preferred shares held by Starr
    Investments Cayman II, Inc. and 695,800 ordinary shares held by
    such shareholder. For a description of the beneficial ownership
    of our ordinary shares by Starr Investments Cayman II, Inc., see
    Note&#160;12 below. Ms.&#160;Elaine Zong disclaims beneficial
    ownership of our ordinary shares held by Starr Investments
    Cayman II, Inc. except to the extent of her pecuniary interest
    in these shares.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">&#160;&#160;(9)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 9,215,800 ordinary
    shares held by Grand Best Group Limited, a limited liability
    company organized under the laws of the British Virgin Islands.
    For a description of the beneficial ownership of our ordinary
    shares held by Grand Best Group Limited, see Note&#160;13 below.
    Mr.&#160;Ku owns 31.4% of the equity interest in Grand Best
    Group Limited.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(10)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents ordinary shares held by
    Triumph Concept Investment Limited, a limited liability company
    organized under the laws of the British Virgin Islands wholly
    owned by Mr.&#160;Zhang.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(11)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 23,085,700 and 920,600
    ordinary shares held by Carlyle Asia Growth Partners III, L.P.
    and CAGP III Co-Investment, L.P., respectively, issuable upon
    conversion of all Series&#160;A and Series&#160;B contingently
    redeemable convertible preferred shares held by such
    shareholders and 2,083,300 and 83,100 ordinary shares,
    respectively, held by such shareholders. The general partner of
    each Carlyle Entity is CAGP General Partner, L.P., which is in
    turn managed by its general partner, CAGP Ltd. The directors of
    CAGP Ltd. are Mr.&#160;William E. Conway, Jr., Mr.&#160;Daniel
    A. D&#146;Aniello, Mr.&#160;David Rubenstein, Mr.&#160;Jeffery
    Ferguson and Mr.&#160;Curtis L. Buser. The address of the
    Carlyle Entities is Walker House, PO&#160;Box&#160;908GT, Mary
    Street, George Town, Grand Cayman, Cayman Islands.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(12)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Notable Enterprise Limited is a
    limited liability company organized under the laws of the
    British Virgin Islands wholly owned by Ms.&#160;Bona Lau.
    Ms.&#160;Lau is the daughter of Mr.&#160;Haifeng Liu, the
    chairman of Aohua Medical from December 2005 to December 2007
    and our director until July 2009. Prior to serving as chairman
    of Aohua Medical, Mr.&#160;Liu was detained in March 2004 by the
    authorities of Luoyang city, Henan Province, for alleged
    misappropriation of funds while serving as chairman of a company
    unrelated to Aohua Medical or us. Mr.&#160;Liu was released in
    June 2005 by the local prosecutor without an indictment due to
    insufficient evidence. Notable Enterprise Limited was originally
    owned by Mr.&#160;Liu, who irrevocably transferred all of his
    interest in Notable Enterprise Limited to Ms.&#160;Lau in
    November 2007 for consideration not significantly lower than the
    then fair market value. At the time of the transfer, Notable
    Enterprise Limited indirectly held a 44.2% equity interest in
    OMS. The address of Notable Enterprise Limited is
    P.O.&#160;Box&#160;957, Offshore Incorporations Centre, Road
    Town, Tortola, British Virgin Islands. 134,478 of the ordinary
    shares held by Notable Enterprise Limited have been pledged to
    certain of our shareholders in connection with the issuance of
    our Series&#160;B contingently redeemable convertible preferred
    shares on October&#160;20, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(13)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 9,722,200 ordinary
    shares issuable upon conversion of all Series B contingently
    redeemable convertible preferred shares held by Starr
    Investments Cayman II, Inc. and 695,800 ordinary shares held by
    such shareholder. Starr Investments Cayman II, Inc. is
    ultimately controlled by Starr International Company, Inc. whose
    voting shareholders (none of whom control 10% or more
    individually) are Mr.&#160;Maurice R. Greenberg, Mr.&#160;Edward
    E. Matthews, Mr.&#160;Howard I. Smith, Mr.&#160;John J. Roberts,
    Mr.&#160;Houghton Freeman, Mr.&#160;Joseph C. H. Johnson,
    Mr.&#160;Cesar Zalamea, Mr.&#160;Peter Hammer, Mr.&#160;Michael
    Morrison, Mr.&#160;Bertil P. Lundqvist and Ms.&#160;Florence
    Davis. The address of Starr Investments Cayman II, Inc. is
    Avalon Management Limited, Landmark Square, 64 Earth Close, West
    Bay Beach, Grand Cayman, KY1-1107, Cayman Islands
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(14)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Grand Best Group Limited is a
    limited liability company organized under the laws of the
    British Virgin Islands. The shareholders of Grand Best Group
    Limited are Ku Wai Hong, Ever Bounteous Group Limited, Iu Kong,
    Cheng Mai Yue, Wang Rong Kang, Brave Faith
    </FONT></TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    129
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Development Limited, Echolac
    Company Limited and Huang Pei Lin. The address of Grand Best
    Group Limited is Portcullis TrustNet Chambers, P.O.
    Box&#160;3444, Road Town, Tortola, British Virgin Islands.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(15)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">CZY Investments Limited is a
    limited liability company organized under the laws of the
    British Virgin Islands wholly owned by Dr.&#160;Zheng Cheng. The
    address of CZY Investments Limited is P.O.&#160;Box&#160;957,
    Offshore Incorporations Centre, Road Town, Tortola, British
    Virgin Islands.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(16)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents 6,616,900 ordinary
    shares issuable upon conversion of all Series A and
    Series&#160;B contingently redeemable convertible preferred
    shares held by CICC Sun Company Limited and 560,300 ordinary
    shares held by such shareholder. CICC Sun Company Limited is
    wholly owned by China International Capital Corporation Limited,
    one of our underwriters, in which Morgan Stanley, another
    underwriter to this offering, beneficially owns 34.0% of its
    equity interest. China International Capital Corporation Limited
    has ultimate investment and voting power over the shares held by
    CICC Sun Company Limited. The address of CICC Sun Company
    Limited is 2/F., Abbott Building, Road Town, Tortola, British
    Virgin Islands.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each selling shareholder named above acquired its shares in
    offerings which were exempted from registration under the
    Securities Act because they involved either private placements
    or offshore sales to
    <FONT style="white-space: nowrap">non-U.S.&#160;persons.</FONT>
    As of the date of this prospectus, none of our outstanding
    ordinary shares is held by record holders in the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Two of our shareholders, namely CICC Sun Company Limited and
    Perfect Key Holdings Limited, have informed us that they are
    affiliated with registered broker-dealers or are in the business
    of underwriting securities. Neither of these shareholders were
    affiliated or otherwise related to us prior to their purchase of
    our Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares. These shareholders purchased our
    Series&#160;A and Series&#160;B contingently redeemable
    convertible preferred shares directly from us in their ordinary
    course of business and, at the time of the purchase, neither of
    these shareholders had agreements or understandings, directly or
    indirectly, with any person to distribute our Series&#160;A and
    Series&#160;B contingently redeemable convertible preferred
    shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    None of our shareholders will have different voting rights from
    other shareholders after the closing of this offering. We are
    not aware of any arrangement that may, at a subsequent date,
    result in a change of control of our company.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    130
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='118'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RELATED
    PARTY TRANSACTIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Non-Interest
    Bearing Borrowings from Related Parties</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We borrowed RMB38.7&#160;million from Shenzhen Hai Ji Tai
    Technology Co., Ltd., or Hai Ji Tai, in 2007 for working capital
    purposes. Hai Ji Tai is wholly-owned by Mr.&#160;Haifeng Liu who
    was the chairman of Aohua Medical from December 2005 to December
    2007 and our director until July 2009. This borrowing was repaid
    in full in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We borrowed RMB4.0&#160;million in 2007 from Mr.&#160;Haifeng
    Liu for working capital purposes. We repaid RMB2.0&#160;million
    of such borrowing in 2008 and the remaining balance of
    RMB2.0&#160;million (US$0.3&#160;million) in full in August 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We borrowed RMB1.0&#160;million and RMB4.0&#160;million from
    Dr.&#160;Jianyu Yang, our director, chief executive officer and
    president, in 2007 and 2008, respectively, for working capital
    purposes. These borrowings were repaid in full in 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China Medstar has, in connection with payments of certain
    professional fees related to a private placement transaction in
    2004, borrowed from Beijing Medstar Hi-Tech Investment Co.,
    Ltd., a company majority owned by Dr.&#160;Zheng Cheng, our
    co-chairman and chief operating officer. As of
    September&#160;30, 2009, the remaining balance was
    RMB0.2&#160;million (US$29,000). In addition, in connection with
    payment of certain fees related to China Medstar&#146;s initial
    public offering on the AIM, China Medstar has borrowed from
    Dr.&#160;Zheng Cheng. As of September&#160;30, 2009, the
    remaining balance was RMB1.4&#160;million (US$0.2&#160;million).
    Furthermore, in connection with certain administrative expenses
    related to China Medstar in 2006 and 2007, China Medstar
    borrowed from Mr.&#160;Yaw Kong Yap, our director and financial
    controller. As of September&#160;30, 2009, the remaining balance
    was RMB60,000 (US$9,000). These loans are unsecured,
    interest-free and repayable on demand and are all based on oral
    agreements between the parties. We expect to repay all such
    borrowings by the end of 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Medical
    Equipment Sale and Purchase Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;31, 2007, we entered into a long-term sale and
    purchase agreement with Our Medical New Technology Co., Ltd.
    under which we agreed to purchase gamma knife systems at agreed
    upon prices and Our Medical New Technology Co., Ltd. also agreed
    to provide to us relevant maintenance and repair services and
    training. Our Medical New Technology is controlled by
    Mr.&#160;Haifeng Liu, who was a director of our company until
    July 2009. We made deposits of RMB11.5&#160;million,
    RMB0.7&#160;million, RMB1.7&#160;million (US$0.3&#160;million)
    and RMB11.4&#160;million (US$1.7&#160;million) to Our New
    Medical Technology Co., Ltd. under this agreement for the period
    from January&#160;1, 2007 to October&#160;30, 2007, the period
    from September&#160;10, 2007 to December&#160;31, 2007, in 2008
    and for the nine months ended September&#160;30, 2009,
    respectively. Deposits held by Our New Medical Technology
    Co.,&#160;Ltd. as of December&#160;31, 2007 and 2008 and
    September&#160;30, 2009 were RMB15.9&#160;million,
    RMB17.6&#160;million (US$2.6&#160;million) and
    RMB16.4&#160;million (US$2.4&#160;million). In addition,
    RMB12.7&#160;million (US$1.9&#160;million) of the deposits paid
    to Our New Medical Technology Co., Ltd. were used for the
    purchase of radioactive source material used in our medical
    equipment during the nine months ended September 30, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Reorganization
    and Private Placement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See &#147;Our History and Corporate Structure&#148; and
    &#147;Description of Share Capital&#160;&#151; History of
    Securities Issuances&#160;&#151; Convertible Loan and Preferred
    Shares.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Shareholders&#146;
    Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the issuance of our Series&#160;B
    contingently redeemable convertible preferred shares, we entered
    into an Amended and Restated Shareholders&#146; Agreement dated
    as of October&#160;20, 2008, which was subsequently amended on
    November&#160;17, 2009, by and among us, the Carlyle Entities,
    Starr Investments Cayman II, Inc., CICC Sun Company Limited and
    certain of our other shareholders and other parties named
    therein. Under this shareholders&#146; agreement, our board of
    directors shall consist of up to eleven directors, out of which
    one of such director shall be designated by the Carlyle
    Entities, another shall be designated by CICC Sun Company
    Limited and another shall be designated by Starr Investments
    Cayman II, Inc. Prior to the completion of this offering, our
    existing shareholders are prohibited from transferring their
    shares without the prior consent of each of the Carlyle
    Entities, Starr Investments Cayman II, Inc. and CICC Sun Company
    Limited. These parties and our other existing
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    131
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    shareholders hold certain rights of first refusal with respect
    to any such proposed transfers. In addition, the Carlyle
    Entities, Starr Investments Cayman II, Inc. and CICC Sun Company
    Limited have certain co-sale rights with respect to any proposed
    share transfers by any of our other existing shareholders. We
    have also granted under this shareholders&#146; agreement
    certain registration rights to the Carlyle Entities, Starr
    Investments Cayman II, Inc. and CICC Sun Company Limited. See
    &#147;Description of Share Capital&#160;&#151; Registration
    Rights.&#148; Except for the registration rights and the right
    to designate directors, all other shareholders&#146; rights
    under the shareholders agreement will automatically terminate
    upon the completion of this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Share
    Incentives</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For a discussion of the share option plan adopted in 2007 by
    OMS, our predecessor, and our 2008&#160;share incentive plan,
    see &#147;Management&#160;&#151; Share Incentive Plans.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    132
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='130'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DESCRIPTION
    OF SHARE CAPITAL</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are a Cayman Islands exempted company with limited liability
    and our affairs are governed by our memorandum and articles of
    association, as amended and restated from time to time, and the
    Companies Law (as amended) of the Cayman Islands, which is
    referred to as the Companies Law below. Our registered office is
    in the Cayman Islands is at Scotia Centre, 4th&#160;Floor,
    P.O.&#160;Box&#160;2804, George Town, Grand Cayman, Cayman
    Islands KY1-1112.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2009, we effected a share split whereby all
    of our issued and outstanding 704,281 ordinary shares of a par
    value of US$0.01 per share were split into 70,428,100 ordinary
    shares of US$0.0001 par value per share and the number of our
    authorized ordinary shares were increased from 4,500,000 to
    450,000,000. As of September&#160;30, 2009 and give effect to
    the share split, our authorized share capital consists of
    450,500,000&#160;shares, comprised of (i)&#160;450,000,000
    ordinary shares, each with a par value of US$0.0001, of which
    70,428,100 such shares are issued and outstanding;
    (ii)&#160;200,000 Series&#160;A contingently redeemable
    convertible preferred shares authorized, each with a par value
    of US$0.01, of which 176,942 such shares are issued and
    outstanding; and (iii)&#160;300,000 Series&#160;B contingently
    redeemable convertible preferred shares authorized, each with a
    par value of US$0.01, of which 233,332 such shares are issued
    and outstanding. As of the date hereof, our authorized share
    capital consists of 450,500,000&#160;shares, comprised of
    (i)&#160;450,000,000 ordinary shares, each with a par value of
    US$0.0001, of which 70,428,100&#160;such shares are issued and
    outstanding; (ii)&#160;200,000 Series&#160;A contingently
    redeemable convertible preferred shares authorized, each with a
    par value of US$0.01, of which 176,942&#160;such shares are
    issued and outstanding; and (iii)&#160;300,000 Series&#160;B
    contingently redeemable convertible preferred shares authorized,
    each with a par value of US$0.01, of which 233,332&#160;such
    shares are issued and outstanding. Upon completion of this
    offering, all of our issued and outstanding Series&#160;A and
    Series&#160;B contingently redeemable convertible preferred
    shares will automatically convert into ordinary shares, at a
    <FONT style="white-space: nowrap">1-to-100</FONT>
    conversion rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, we will adopt our third
    amended and restated memorandum and articles of association,
    which will replace the current memorandum and articles of
    association in its entirety. The following are summaries of
    material provisions of our third amended and restated memorandum
    and articles of association and the Companies Law insofar as
    they relate to the material terms of our ordinary shares that we
    expect will become effective upon the closing of this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Ordinary
    Shares</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">General</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All of our outstanding ordinary shares are fully paid and
    non-assessable. Certificates representing the ordinary shares
    are issued in registered form. Our shareholders who are
    non-residents of the Cayman Islands may freely hold and transfer
    their ordinary shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Dividends</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The holders of our ordinary shares are entitled to such
    dividends as may be declared by our board of directors subject
    to the Companies Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Voting
    Rights</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each holder of ordinary shares is entitled to one vote on all
    matters upon which the ordinary shares are entitled to vote.
    Each holder is entitled to have one vote for each share
    registered in his name on the register of members. Voting at any
    meeting of shareholders is by show of hands unless a poll is
    demanded by the chairman of our board of directors or by any
    shareholder present in person or by proxy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A quorum is required for a meeting of shareholders. Shareholders
    who hold at least one-third of our ordinary shares at the
    meeting present in person or by proxy or, if a corporation or
    other non-natural person, by its duly authorized representative
    constitutes a quorum. Shareholders&#146; meetings are held
    annually and may be convened by our board of directors on its
    own initiative or upon a request to the directors by
    shareholders holding in the aggregate at least ten percent of
    our ordinary shares. At least seven days advanced notice is
    required prior to convening our annual general meeting and other
    shareholders meetings.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    133
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An ordinary resolution of the shareholders requires the
    affirmative vote of a simple majority of the votes attaching to
    the ordinary shares cast in a general meeting to pass. A special
    resolution requires the affirmative vote of not less than
    two-thirds of the votes cast attaching to the ordinary shares to
    pass.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Transfer
    of Ordinary Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the restrictions of our articles of association, as
    applicable, any of our shareholders may transfer all or any of
    such shareholder&#146;s ordinary shares by an instrument of
    transfer in the usual or common form or any other form approved
    by our board.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our board of directors may, in its absolute discretion, decline
    to register any transfer of any ordinary share which is not
    fully paid up or on which we have a lien. Our directors may also
    decline to register any transfer of any ordinary share unless:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the instrument of transfer is lodged with us, accompanied by the
    certificate for the ordinary shares to which it relates and such
    other evidence as our board of directors may reasonably require
    to show the right of the transferor to make the transfer;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the instrument of transfer is in respect of only one class of
    ordinary shares;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the instrument of transfer is properly stamped, if required;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in the case of a transfer to joint holders, the number of joint
    holders to whom the ordinary share is to be transferred does not
    exceed four; or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the ordinary shares transferred are free of any lien in favor of
    us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If our directors refuse to register a transfer they shall,
    within two months after the date on which the instrument of
    transfer was lodged, send notice of such refusal to both the
    transferor and transferee. The registration of transfers may, on
    14&#160;days&#146; notice, given by advertisement in one or more
    newspapers or by electronic means, be suspended and the register
    closed at such times and for such periods as our board of
    directors may from time to time determine, provided, however,
    that the registration of transfers shall not be suspended nor
    the register closed for more than 30&#160;days in any year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Liquidation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On a return of capital in connection with the winding up of the
    company or otherwise (other than in connection with conversion,
    redemption or purchase of ordinary shares), assets available for
    distribution to the holders of ordinary shares shall be
    distributed among them on a pro rata basis. If our assets
    available for distribution are insufficient to repay all of the
    <FONT style="white-space: nowrap">paid-up</FONT>
    capital, the assets will be distributed so that the losses are
    borne by our shareholders proportionately.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Calls
    on Ordinary Shares and Forfeiture of Ordinary
    Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our board of directors may from time to time call upon
    shareholders for any amounts unpaid on their ordinary shares in
    a notice served to such shareholders at least 14&#160;days prior
    to the specified time of payment. Ordinary shares that have been
    called upon and remain unpaid are subject to forfeiture.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Redemption
    of Ordinary Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the provisions of the Companies Law, we may under the
    terms of our third amended and restated memorandum and articles
    of association to be adopted upon the completion of this
    offering:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    issue ordinary shares on terms that they are to be redeemed or
    are liable to be redeemed at our option or at the option of the
    shareholders, on such terms and in such manner as we may, before
    the issue of such ordinary shares, determine;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    purchase our own ordinary shares (including any redeemable
    shares) on such terms and in such manner as we may determine and
    agree with our shareholders; and
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    134
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    make a payment in respect of the redemption or purchase of our
    own ordinary shares in any manner authorized by the Companies
    Law, including out of our capital, profits or the proceeds of a
    fresh issue of ordinary shares.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Variations
    of Rights of Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All or any of the special rights attached to any class of shares
    may, subject to the provisions of the Companies Law, be varied
    either with the unanimous written consent of the holders of the
    issued shares of that class or with the sanction of a special
    resolution passed at a general meeting of the holders of the
    shares of that class.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Inspection
    of Books and Records</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Holders of our ordinary shares have no general right under
    Cayman Islands law to inspect or obtain copies of our list of
    shareholders or our corporate records. However, we will provide
    our shareholders with annual audited financial statements. See
    &#147;Where You Can Find Additional Information.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Changes
    in Capital</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may from time to time by ordinary resolutions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    increase the share capital by such sum, to be divided into
    shares of such classes and amount, as the resolution shall
    prescribe;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    consolidate and divide all or any of our share capital into
    shares of a larger amount than our existing shares;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    convert all or any of our paid up shares into stock and
    reconvert that stock into paid up shares of any denomination;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    sub-divide our existing shares, or any of them into shares of a
    smaller amount that is fixed by the third amended and restated
    memorandum and articles of association; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cancel any shares that, at the date of the passing of the
    resolution, have not been taken or agreed to be taken by any
    person and diminish the amount of our share capital by the
    amount of the shares so cancelled.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the Companies Law and our third amended and restated
    memorandum and articles of association with respect to matters
    to be dealt with by ordinary resolution, we may, by special
    resolution, reduce our share capital and any capital redemption
    reserve in any manner authorized by law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Issuance
    of Additional Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our third amended and restated memorandum of association
    authorizes our board of directors to issue additional ordinary
    shares from time to time as our board of directors shall
    determine, to the extent there are available authorized but
    unissued shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our third amended and restated memorandum of association
    authorizes our board of directors to establish from time to time
    one or more series of preferred shares and to determine, with
    respect to any series of preferred shares, the terms and rights
    of that series, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the designation of the series;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the number of shares of the series;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the dividend rights, dividend rates, conversion rights, voting
    rights; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the rights and terms of redemption and liquidation preferences.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our board of directors may issue preferred shares without action
    by our shareholders to the extent there are available authorized
    but unissued preferred shares. In addition, the issuance of
    preferred shares may be used as an anti-takeover device without
    further action on the part of the shareholders. Issuance of
    these shares may dilute the voting power of holders of ordinary
    shares.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    135
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Actions
    Requiring the Approval of a Supermajority of Our Board of
    Directors</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Actions require the approval of a supermajority of at least
    two-thirds of our board of directors, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the appointment or removal of either our chief executive officer
    or chief financial officer;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any anti-takeover action in response to a takeover attempt;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any merger resulting in our shareholders immediately prior to
    such merger holding less than a majority of the voting power of
    the outstanding share capital of the surviving business entity;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the sale or transfer of all or substantially all of our assets;
    and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any change in the number of directors on our board of directors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Exempted
    Company</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are an exempted company with limited liability under the
    Companies Law. The Companies Law distinguishes between ordinary
    resident companies and exempted companies. Any company that is
    registered in the Cayman Islands but conducts business mainly
    outside of the Cayman Islands may apply to be registered as an
    exempted company. The requirements for an exempted company are
    essentially the same as for an ordinary company except for the
    exemptions and privileges listed below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company does not have to file an annual return of
    its shareholders with the Registrar of Companies;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company&#146;s register of members is not open to
    inspection;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company does not have to hold an annual general
    meeting;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company may issue negotiable or bearer shares or
    shares with no par value;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company may obtain an undertaking against the
    imposition of any future taxation (such undertakings are usually
    given for 20&#160;years in the first instance);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company may register by way of continuation in
    another jurisdiction and be deregistered in the Cayman Islands;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company may register as a limited duration company;
    and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an exempted company may register as a segregated portfolio
    company.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#147;Limited liability&#148; means that the liability of each
    shareholder is limited to the amount unpaid by the shareholder
    on the shares of the company. We are subject to reporting and
    other informational requirements of the Exchange Act, as
    applicable to foreign private issuers. We currently intend to
    comply with NYSE rules, in lieu of following home country
    practice after the closing of our initial public offering. NYSE
    rules require that every company traded on the NYSE hold an
    annual general meeting of shareholders. In addition, our third
    amended and restated articles of association, which, upon
    receiving the requisite shareholder approval, are expected to
    become effective immediately upon the closing of this offering,
    will allow directors or shareholders to call special shareholder
    meetings pursuant to the procedures set forth in such articles.
    We believe that the differences with respect to our being a
    Cayman Islands exempted company as opposed to a Delaware
    corporation do not pose additional material risks to investors,
    other than the risks described under &#147;Risk
    Factors&#160;&#151; Risks Related to This Offering.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Differences
    in Corporate Law</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Companies Law is modeled after that of English law but does
    not follow many recent English law statutory enactments. In
    addition, the Companies Law differs from laws applicable to
    United States corporations and their shareholders. Set forth
    below is a summary of the significant differences between the
    provisions of the Companies Law applicable to us and the laws
    applicable to companies incorporated in the United States and
    their shareholders.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    136
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Mergers
    and Similar Arrangements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Companies Law permits mergers and consolidations between
    Cayman Islands companies and between Cayman Islands companies
    and non-Cayman Islands companies. For these purposes,
    (a)&#160;&#147;merger&#148; means the merging of two or more
    constituent companies and the vesting of their undertaking,
    property and liabilities in one of such companies as the
    surviving company and (b)&#160;a &#147;consolidation&#148; means
    the combination of two or more constituent companies into a
    consolidated company and the vesting of the undertaking,
    property and liabilities of such companies to the consolidated
    company. In order to effect such a merger or consolidation, the
    directors of each constituent company must approve a written
    plan of merger or consolidation, which must then be authorized
    by either (i)&#160;a special resolution of the shareholders of
    each constituent company voting together as one class if the
    shares to be issued to each shareholder in the consolidated or
    surviving company will have the same rights and economic value
    as the shares held in the relevant constituent company or
    (ii)&#160;a shareholder resolution of each constituent company
    passed by a majority in number representing 75% in value of the
    shareholders voting together as one class. The plan of merger or
    consolidation must be filed with the Registrar of Companies
    together with a declaration as to the solvency of the
    consolidated or surviving company, a list of the assets and
    liabilities of each constituent company and an undertaking that
    a copy of the certificate of merger or consolidation will be
    given to the members and creditors of each constituent company
    and published in the Cayman Islands Gazette. Dissenting
    shareholders have the right to be paid the fair value of their
    shares (which, if not agreed between the parties, will be
    determined by the Cayman Islands court) if they follow the
    required procedures, subject to certain exceptions. Court
    approval is not required for a merger or consolidation which is
    effected in compliance with these statutory procedures.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, there are statutory provisions that facilitate the
    reconstruction and amalgamation of companies, provided that the
    arrangement is approved by a majority in number of each class of
    shareholders and creditors with whom the arrangement is to be
    made, and who must in addition represent three-fourths in value
    of each such class of shareholders or creditors, as the case may
    be, that are present and voting either in person or by proxy at
    a meeting, or meetings, convened for that purpose. The convening
    of the meetings and subsequently the arrangement must be
    sanctioned by the Grand Court of the Cayman Islands. While a
    dissenting shareholder has the right to express to the court the
    view that the transaction ought not be approved, the court can
    be expected to approve the arrangement if it determines that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the statutory provisions as to the dual majority vote have been
    met;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the shareholders have been fairly represented at the meeting in
    question;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the arrangement is such that a businessman would reasonably
    approve; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the arrangement is not one that would more properly be
    sanctioned under some other provision of the Companies Law.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    When a take-over offer is made and accepted by holders of 90.0%
    of the shares (within four months after the making of the
    offer), the offeror may, within a two month period, require the
    holders of the remaining shares to transfer such shares on the
    terms of the offer. An objection can be made to the Grand Court
    of the Cayman Islands, but this is unlikely to succeed unless
    there is evidence of fraud, bad faith or collusion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the arrangement and reconstruction is approved, the
    dissenting shareholder would have no rights comparable to
    appraisal rights, which would otherwise ordinarily be available
    to dissenting shareholders of United States corporations,
    providing rights to receive payment in cash for the judicially
    determined value of the shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Shareholders&#146;
    Suits</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are not aware of any reported class action or derivative
    action having been brought in a Cayman Islands court. In
    principle, we will normally be the proper plaintiff and a
    derivative action may not be brought by a minority shareholder.
    However, based on English authorities, which would in all
    likelihood be of persuasive authority in the Cayman Islands,
    there are exceptions to the foregoing principle, including when:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a company acts or proposes to act illegally or ultra vires;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    137
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the act complained of, although not ultra vires, could be duly
    effected if authorized by a special or ordinary resolution that
    has not been obtained; and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    those who control the company are perpetrating a &#147;fraud on
    the minority.&#148;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Indemnification
    of Directors and Executive Officers and Limitation of
    Liability</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cayman Islands law does not limit the extent to which a
    company&#146;s articles of association may provide for
    indemnification of officers and directors, except to the extent
    any such provision may be held by the Cayman Islands courts to
    be contrary to public policy, such as a provision purporting to
    provide indemnification against civil fraud or the consequences
    of committing a crime. Our third amended and restated memorandum
    and articles of association permit indemnification of officers
    and directors against all actions, proceedings, costs, charges,
    expenses, losses, damages or liabilities incurred or sustained
    in their capacities as such unless such losses or damages arise
    from dishonesty, fraud or default of such directors or officers.
    This standard of conduct is generally the same as permitted
    under the Delaware General Corporation Law for a Delaware
    corporation. In addition, we have entered into indemnification
    agreements with our directors and senior executive officers that
    provide such persons with additional indemnification beyond that
    provided in our third amended and restated memorandum and
    articles of association.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Insofar as indemnification for liabilities arising under the
    Securities Act may be permitted to our directors, officers or
    persons controlling us under the foregoing provisions, we have
    been informed that in the opinion of the SEC such
    indemnification is against public policy as expressed in the
    Securities Act and is therefore unenforceable as a matter of
    United States law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Anti-takeover
    Provisions in Our Third Amended and Restated Memorandum and
    Articles of Association</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Some provisions of our third amended and restated memorandum and
    articles of association may discourage, delay or prevent a
    change in control of our company or management that shareholders
    may consider favorable, including provisions that authorize our
    board of directors to issue preferred shares in one or more
    series and to designate the price, rights, preferences,
    privileges and restrictions of such preferred shares without any
    further vote or action by our shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    However, under Cayman Islands law, our directors may only
    exercise the rights and powers granted to them under our third
    amended and restated memorandum and articles of association, as
    amended and restated from time to time, for what they believe in
    good faith to be in the best interests of our company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Directors&#146;
    Fiduciary Duties</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under Delaware corporate law, a director of a Delaware
    corporation has a fiduciary duty to the corporation and its
    shareholders. This duty has two components: the duty of care and
    the duty of loyalty. The duty of care requires that a director
    act in good faith, with the care that an ordinarily prudent
    person would exercise under similar circumstances. Under this
    duty, a director must inform himself of, and disclose to
    shareholders, all material information reasonably available
    regarding a significant transaction. The duty of loyalty
    requires that a director act in a manner he reasonably believes
    to be in the best interests of the corporation. He must not use
    his corporate position for personal gain or advantage. This duty
    prohibits self-dealing by a director and mandates that the best
    interest of the corporation and its shareholders take precedence
    over any interest possessed by a director, officer or
    controlling shareholder and not shared by the shareholders
    generally. In general, actions of a director are presumed to
    have been made on an informed basis, in good faith and in the
    honest belief that the action taken was in the best interests of
    the corporation. However, this presumption may be rebutted by
    evidence of a breach of one of the fiduciary duties. Should such
    evidence be presented concerning a transaction by a director, a
    director must prove the procedural fairness of the transaction,
    and that the transaction was of fair value to the corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a matter of Cayman Islands law, a director of a Cayman
    Islands company is in the position of a fiduciary with respect
    to the company and, therefore, he owes the following duties to
    the company&#160;&#151; a duty to act bona fide in the best
    interests of the company, a duty not to make a profit based on
    his position as director (unless the company permits him to do
    so) and a duty not to put himself in a position where the
    interests of the company conflict with his personal interest or
    his duty to a third party. A director of a Cayman Islands
    company owes to the company a duty to
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    138
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    act with skill and care. It was previously thought that a
    director need not exhibit in the performance of his duties a
    greater degree of skill than may reasonably be expected from a
    person of his knowledge and experience. However, English and
    Commonwealth courts have moved away from this subjective
    standard and towards an objective, reasonable director standard
    with regard to the required skill and care and these
    authorities, objective approach is likely to be followed in the
    Cayman Islands.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Shareholder
    Action by Written Consent</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, a corporation may
    eliminate the right of shareholders to act by written consent
    through amendment to its certificate of incorporation. Cayman
    Islands law and our third amended and restated articles of
    association provide that shareholders may approve corporate
    matters by way of a unanimous written resolution signed by or on
    behalf of each shareholder who would have been entitled to vote
    on such matter at a general meeting without a meeting being held.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Shareholder
    Proposals</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, a shareholder has
    the right to put any proposal before the shareholders at the
    annual meeting, provided that such shareholder complies with the
    notice provisions in the governing documents. A special meeting
    may be called by the board of directors or any other person
    authorized to do so in the governing documents, but shareholders
    may be precluded from calling special meetings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cayman Islands law and our third amended and restated articles
    of association allow our shareholders holding not less than
    10.0% of the paid up voting share capital of the Company to
    require the company to call a shareholder&#146;s meeting. As an
    exempted Cayman Islands company, we are not obliged by law to
    call shareholders&#146; annual general meetings. However, our
    third amended and restated articles of association require us to
    call such meetings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Cumulative
    Voting</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, cumulative voting
    for elections of directors is not permitted unless the
    corporation&#146;s certificate of incorporation specifically
    provides for it. Cumulative voting potentially facilitates the
    representation of minority shareholders on a board of directors
    since it permits a minority shareholder to cast all the votes to
    which such shareholder is entitled on a single director, which
    increases such shareholder&#146;s voting power with respect to
    electing such director. There are no prohibitions in relation to
    cumulative voting under the laws of the Cayman Islands, but our
    third amended and restated articles of association do not
    provide for cumulative voting. As a result, our shareholders are
    not afforded any less protections or rights on this issue than
    shareholders of a Delaware corporation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Removal
    of Directors</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, a director of a
    corporation with a classified board may be removed only for
    cause with the approval of a majority of the outstanding shares
    entitled to vote, unless the certificate of incorporation
    provides otherwise. Under our third amended and restated
    articles of association, directors can be removed without cause,
    but only by the vote of holders of two-thirds of our shares,
    cast at a general meeting, or by the unanimous written
    resolution of all shareholders, or with cause, by the ordinary
    resolution or the unanimous written resolution of all
    shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Transactions
    with Interested Shareholders</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Delaware General Corporation Law contains a business
    combination statute applicable to Delaware public corporations
    whereby, unless the corporation has specifically elected not to
    be governed by such statute by amendment to its certificate of
    incorporation, it is prohibited from engaging in certain
    business combinations with an &#147;interested shareholder&#148;
    for three years following the date that such person becomes an
    interested shareholder. An interested shareholder generally is a
    person or a group who or which owns or has owned 15.0% or more
    of the target&#146;s outstanding voting stock within the past
    three years. This has the effect of limiting the ability of a
    potential acquirer to make a two-tiered bid for the target in
    which all shareholders would not be treated equally. The statute
    does not apply if, among other things, prior to the date on
    which such shareholder becomes an interested shareholder, the
    board of directors approves either the business combination or
    the transaction which resulted in the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    139
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    person becoming an interested shareholder. This encourages any
    potential acquirer of a Delaware public corporation to negotiate
    the terms of any acquisition transaction with the target&#146;s
    board of directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cayman Islands law has no comparable statute. As a result, we
    cannot avail ourselves of the types of protections afforded by
    the Delaware business combination statute. However, although
    Cayman Islands law does not regulate transactions between a
    company and its significant shareholders, it does provide that
    such transactions must be entered into bona fide in the best
    interests of the company and not with the effect of constituting
    a fraud on the minority shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Dissolution;
    Winding up</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, unless the board of
    directors approves the proposal to dissolve, dissolution must be
    approved by shareholders holding 100% of the total voting power
    of the corporation. Only if the dissolution is initiated by the
    board of directors may it be approved by a simple majority of
    the corporation&#146;s outstanding shares. Delaware law allows a
    Delaware corporation to include in its certificate of
    incorporation a supermajority voting requirement in connection
    with dissolutions initiated by the board. Under the Companies
    Law of the Cayman Islands and our third amended and restated
    articles of association, our company may be dissolved,
    liquidated or wound up by the vote of holders of two-thirds of
    our shares voting at a meeting or the unanimous written
    resolution of all shareholders or by an ordinary resolution on
    the basis that we are unable to pay our debts as they fall due.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Variation
    of Rights of Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, a corporation may
    vary the rights of a class of shares with the approval of a
    majority of the outstanding shares of such class, unless the
    certificate of incorporation provides otherwise. Under Cayman
    Islands law and our third amended and restated articles of
    association, if our share capital is divided into more than one
    class of shares, we may vary the rights attached to any class
    only with the vote at a class meeting of holders of two-thirds
    of the shares of such class or unanimous written resolution of
    all shareholders of that class.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Amendment
    of Governing Documents</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Delaware General Corporation Law, a corporation&#146;s
    governing documents may be amended with the approval of a
    majority of the outstanding shares entitled to vote, unless the
    certificate of incorporation provides otherwise. As permitted by
    Cayman Islands law, our third amended and restated memorandum
    and articles of association may only be amended with a special
    resolution at a meeting or the unanimous written resolution of
    all shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Rights
    of Non-resident or Foreign Shareholders</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are no limitations imposed by our third amended and
    restated memorandum and articles of association on the rights of
    non-resident or foreign shareholders to hold or exercise voting
    rights on our shares. In addition, there are no provisions in
    our third amended and restated memorandum and articles of
    association governing the ownership threshold above which
    shareholder ownership must be disclosed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">History
    of Securities Issuances</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a summary of our securities issuances since our
    inception in November 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Ordinary
    Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March&#160;8, 2008, we issued a total of 49,999,900 ordinary
    shares to certain of our officers, directors and other minority
    shareholders in connection with our incorporation for an
    aggregate subscription amount of US$4,999.99.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;18, 2008, we issued a total of 21,184,600
    ordinary shares to certain of our officers in connection with
    the exercise of share options for an aggregate subscription
    amount of US$16,735,834.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2009, we effected a share split whereby all
    of our issued and outstanding 704,281 ordinary shares of a par
    value of US$0.01 per share were split into 70,428,100 ordinary
    shares of US$0.0001 par value per share and the number of our
    authorized ordinary shares were increased from 4,500,000 to
    450,000,000.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    140
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Convertible
    Loan and Preferred Shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;16, 2007, pursuant to the Convertible Loan
    Agreement dated as of November&#160;16, 2007, our predecessor,
    OMS, issued two convertible loan promissory notes to the Carlyle
    Entities for total consideration of US$5.0&#160;million. The
    proceeds from the issuance of the convertible loan promissory
    notes were primarily used to fund the growth of OMS. On
    April&#160;3, 2008, pursuant to the Series&#160;A Preferred
    Shares Subscription Agreement dated as of February&#160;5, 2008,
    as amended on April&#160;2, 2008 and on October&#160;20, 2008,
    we issued a total of 81,952 Series&#160;A contingently
    redeemable convertible preferred shares to the Carlyle Entities
    and CICC Sun Company Limited for total consideration of
    US$10.0&#160;million and the conversion of the two convertible
    loan promissory notes issued to the Carlyle Entities by OMS on
    November&#160;16, 2007 plus accrued interest. The proceeds from
    the issuance of Series&#160;A contingently redeemable
    convertible preferred shares were primarily used to fund our
    growth. Also, on June&#160;18, 2008, we re-designated 756,500
    ordinary shares as 7,565 Series&#160;A contingently redeemable
    convertible preferred shares, which were transferred by Notable
    Enterprise Limited, a British Virgin Islands company controlled
    by Ms.&#160;Bona Lau, to the CICC Sun Company Limited as part of
    the issuance of our Series&#160;A contingently redeemable
    convertible preferred shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;10, 2008, pursuant to the Convertible Loan
    Agreement dated as of April&#160;10, 2008, we issued two
    convertible loan promissory notes to the Carlyle Entities for
    total consideration of US$20.0&#160;million. On July&#160;30,
    2008, we issued a total of 87,425 Series&#160;A contingently
    redeemable convertible preferred shares to the Carlyle Entities
    as a result of the conversion of the convertible loan promissory
    notes issued by us on April&#160;10, 2008 plus accrued interest.
    The proceeds from the issuance of the convertible loan
    promissory notes were primarily used to fund our growth.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;20, 2008, pursuant to the Series&#160;B
    Preferred Shares Subscription Agreement, dated as of
    October&#160;10, 2008, as amended on October&#160;20, 2008, we
    issued a total of 233,332 Series&#160;B contingently redeemable
    convertible preferred shares to the Carlyle Entities, Starr
    Investments Cayman II, Inc. and CICC Sun Company Limited for
    total consideration of US$60&#160;million. The proceeds from the
    issuance of Series&#160;B contingently redeemable convertible
    preferred shares were primarily used to fund our growth.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In connection with the issuance of our Series&#160;B
    contingently redeemable convertible preferred shares, certain of
    our directors and principal shareholders have entered into an
    agreement to provide each of CICC Sun Company Limited, Carlyle
    Asia Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc., or the preferred
    shareholders, with a right to adjust their shareholding in our
    company based on our results of operations in 2008 and 2009.
    This performance adjustment provision specifies that in the
    event our results of operations are less than certain predefined
    amounts, these directors and principal shareholders will
    transfer a certain portion of their ordinary shares in our
    company to the preferred shareholders. As security for this
    performance adjustment provision, these directors or principal
    shareholders have pledged a certain percentage of their ordinary
    shares in our company to the preferred shareholders. The pledged
    shares will be released after our results of operations for 2009
    are determined or upon the occurrence of this offering. On
    November&#160;6, 2009, pursuant to the share charge agreements,
    certain of our directors or principal shareholders have
    transferred an aggregate of 3,493,000 ordinary shares to the
    preferred shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our directors or principal shareholders have also entered into
    share charge agreements that pledge a certain portion of their
    ordinary shares to the preferred shareholders against the
    occurrence of any dispute or litigation in connection with any
    acquisition by us or our subsidiaries which had been consummated
    prior to the closing of our issuance of Series&#160;B
    contingently redeemable convertible preferred shares. These
    share charge agreements will terminate on November&#160;10, 2014
    or upon the occurrence of certain other conditions specified in
    the relevant share charge agreement. See &#147;Principal and
    Selling Shareholders&#148; for additional information as to the
    ordinary shares pledged by our directors or principal
    shareholders. On November&#160;6, 2009, pursuant to the share
    charge agreements, certain of our directors or principal
    shareholders have transferred an aggregate of 3,493,000 ordinary
    shares to the preferred shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Share
    Options</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2007, OMS, the predecessor of our company,
    adopted a share option plan, or the OMS option plan, pursuant to
    which OMS granted to three of its executive directors,
    Mr.&#160;Haifeng Liu, Mr.&#160;Jianyu Yang
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    141
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    and Mr.&#160;Steve Sun, or the OMS grantees, options to purchase
    a total of up to 25,000,000 ordinary shares, or the OMS share
    options, to purchase the ordinary shares of OMS at an exercise
    price of US$0.80 per share, which the board of OMS determined to
    become vested upon the satisfaction of a number of performance
    conditions that related to the completion of the OMS
    reorganization, achievement of net profit target of OMS, and the
    raising of new financing. The exercise price was the equivalent
    of US$80.00 per share in our company giving effect to the OMS
    reorganization and the share exchange from Ascendium to our
    company at a rate of 10&#160;shares in our company to one share
    in Ascendium. The OMS share options were exercisable from the
    date of completion of the 2007 audited consolidated financial
    statements of OMS to December&#160;31, 2008 and were
    transferrable to any individuals designated by the OMS grantees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;18, 2008, the board of directors of OMS
    contemplated that the OMS grantees had achieved certain
    performance conditions outlined in the OMS option plan. However,
    as the capital structure of our company had changed at that time
    such that we had replaced OMS as the ultimate holding company of
    our subsidiaries, the board of directors of OMS resolved that
    the OMS option plan would be settled in vested options to
    purchase 21,184,600 ordinary shares to purchase shares of our
    company, with each option having an exercise price of US$0.79
    exercisable before December&#160;31, 2008. On the same day, two
    of the OMS grantees, Mr.&#160;Jianyu Yang and Mr.&#160;Steve
    Sun, exercised their respective options to purchase an aggregate
    of 6,355,400&#160;ordinary shares of our company, with total
    proceeds from such exercise received by us amounting to
    approximately RMB34.4&#160;million (US$5.0&#160;million). We
    recorded share-based compensation expense of approximately
    RMB49.5&#160;million in 2007 related to these options granted,
    which was recorded in general and administrative expenses. The
    third OMS grantee, Mr.&#160;Haifeng Liu, sold all of his vested
    options to purchase 14,829,200 ordinary shares of our company to
    three former directors of China Medstar who are now our
    directors and executive officers as employment incentive for
    such directors. The three executive directors subsequently
    exercised the vested options with total proceeds from such
    exercise received by us amounting to approximately
    US$11.7&#160;million. Given the transfer of the OMS share
    options to the three directors was provided as an employment
    incentive, we recorded additional share-based compensation
    expense of approximately RMB4.2&#160;million
    (US$0.6&#160;million) in 2008, which was recorded in general and
    administrative expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have adopted a 2008&#160;share incentive plan on
    October&#160;16, 2008, which was subsequently amended on
    November&#160;17, 2009 to increase the number of ordinary shares
    that may be granted under the plan. We have not granted any
    options to purchase our ordinary shares under our
    2008&#160;share incentive plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For additional information as to the issuance of our share
    options, see &#147;Management&#160;&#151; Share Incentive
    Plans.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to our current shareholder agreement entered into on
    October&#160;20, 2008 and as amended on November&#160;17, 2009,
    we have granted the Carlyle Entities, Starr Investments Cayman
    II, Inc., CICC Sun Company Limited and Perfect Key Holdings
    certain registration rights. No later than 181&#160;days after
    this initial public offering or the expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements entered into in connection with this public offering,
    whichever date is later, we shall file a shelf registration
    statement with the SEC covering the resale of all of our
    registrable securities held by the Carlyle Entities, Starr
    Investments Cayman II, Inc., CICC Sun Company Limited and
    Perfect Key Holdings. We shall use our best efforts to cause
    such shelf registration statement to become effective on or
    prior to the 180th&#160;day following the completion of this
    initial public offering and to keep such shelf registration
    statement in effect until all of the registrable securities held
    by each of the Carlyle Entities, Starr Investments Cayman II,
    Inc., CICC Sun Company Limited and Perfect Key Holdings have
    been resold. We shall pay all registration expenses incurred in
    connection with the foregoing.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    142
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='119'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">DESCRIPTION
    OF AMERICAN DEPOSITARY SHARES</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">American
    Depositary Receipts</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    JPMorgan Chase Bank, N.A., as depositary will issue the ADSs
    which you will be entitled to receive in this offering. Each ADS
    will represent an ownership
    interest&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    in ordinary share which we will deposit with the custodian, as
    agent of the depositary, under the deposit agreement among
    ourselves, the depositary and yourself as an ADR holder. In the
    future, each ADS will also represent any securities, cash or
    other property deposited with the depositary but which they have
    not distributed directly to you. Unless specifically requested
    by you, all ADSs will be issued on the books of our depositary
    in book-entry form and periodic statements will be mailed to you
    which reflect your ownership interest in such ADSs. In our
    description, references to American depositary receipts or ADRs
    shall include the statements you will receive which reflect your
    ownership of ADSs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary&#146;s office is located at 4 New York Plaza, New
    York, NY 10004.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You may hold ADSs either directly or indirectly through your
    broker or other financial institution. If you hold ADSs
    directly, by having an ADS registered in your name on the books
    of the depositary, you are an ADR holder. This description
    assumes that you hold your ADSs directly. If you hold the ADSs
    through your broker or financial institution nominee, you must
    rely on the procedures of such broker or financial institution
    to assert the rights of an ADR holder described in this section.
    You should consult with your broker or financial institution to
    find out what those procedures are.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As an ADR holder, we will not treat you as a shareholder of ours
    and you will not have any shareholder rights. Cayman Island law
    governs shareholder rights. Because the depositary or its
    nominee will be the shareholder of record for the shares
    represented by all outstanding ADSs, shareholder rights rest
    with such record holder. Your rights are those of an ADR holder.
    Such rights derive from the terms of the deposit agreement to be
    entered into among us, the depositary and all registered holders
    from time to time of ADSs issued under the deposit agreement.
    The obligations of the depositary and its agents are also set
    out in the deposit agreement. Because the depositary or its
    nominee will actually be the registered owner of the ordinary
    shares, you must rely on it to exercise the rights of a
    shareholder on your behalf. The deposit agreement and the ADSs
    are governed by laws of the State of New&#160;York.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following is a summary of the material terms of the deposit
    agreement. Because it is a summary, it does not contain all the
    information that may be important to you. For more complete
    information, you should read the entire deposit agreement and
    the form of ADR which contains the terms of your ADSs. You can
    read a copy of the deposit agreement which is filed as an
    exhibit to the registration statement of which this prospectus
    forms a part. You may also obtain a copy of the deposit
    agreement at the SEC&#146;s Public Reference Room which is
    located at 100&#160;F&#160;Street, NE, Washington, DC 20549. You
    may obtain information on the operation of the Public Reference
    Room by calling the SEC at
    <FONT style="white-space: nowrap">1-800-732-0330.</FONT>
    You may also find the registration statement and the attached
    deposit agreement on the SEC&#146;s website at
    <FONT style="white-space: nowrap">http://www.sec.gov.</FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Share
    Dividends and Other Distributions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">How
    will I receive dividends and other distributions on the shares
    underlying my ADSs?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may make various types of distributions with respect to our
    securities. The depositary has agreed that, to the extent
    practicable, it will pay to you the cash dividends or other
    distributions it or the custodian receives on shares or other
    deposited securities, after converting any cash received into
    U.S.&#160;dollars and, in all cases, making any necessary
    deductions provided for in the deposit agreement. You will
    receive these distributions in proportion to the number of
    underlying securities that your ADSs represent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Except as stated below, the depositary will deliver such
    distributions to ADR holders in proportion to their interests in
    the following manner:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Cash.</I>&#160;&#160;The depositary will distribute any
    U.S.&#160;dollars available to it resulting from a cash dividend
    or other cash distribution or the net proceeds of sales of any
    other distribution or portion thereof (to the extent
    applicable), on an averaged or other practicable basis, subject
    to (i)&#160;appropriate adjustments for taxes withheld,
    (ii)&#160;such distribution being impermissible or impracticable
    with respect to certain registered ADR holders, and
    (iii)&#160;deduction of the depositary&#146;s expenses in
    (1)&#160;converting any foreign currency to U.S.&#160;dollars to
    the extent that it determines that such
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    143
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    conversion may be made on a reasonable basis,
    (2)&#160;transferring foreign currency or U.S.&#160;dollars to
    the United States by such means as the depositary may determine
    to the extent that it determines that such transfer may be made
    on a reasonable basis, (3)&#160;obtaining any approval or
    license of any governmental authority required for such
    conversion or transfer, which is obtainable at a reasonable cost
    and within a reasonable time and (4)&#160;making any sale by
    public or private means in any commercially reasonable manner.
    <I>If exchange rates fluctuate during a time when the depositary
    cannot convert a foreign currency, you may lose some or all of
    the value of the distribution.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Shares.</I>&#160;&#160;In the case of a distribution in
    shares, the depositary will issue additional ADRs to evidence
    the number of ADSs representing such shares. Only whole ADSs
    will be issued. Any shares which would result in fractional ADSs
    will be sold and the net proceeds will be distributed in the
    same manner as cash to the ADR holders entitled thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Rights to receive additional shares.</I>&#160;&#160;In the
    case of a distribution of rights to subscribe for additional
    shares or other rights, if we provide evidence satisfactory to
    the depositary that it may lawfully distribute such rights, the
    depositary will distribute warrants or other instruments in the
    discretion of the depositary representing such rights. However,
    if we do not furnish such evidence, the depositary may:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    sell such rights if practicable and distribute the net proceeds
    in the same manner as cash to the ADR holders entitled
    thereto;&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if it is not practicable to sell such rights, do nothing and
    allow such rights to lapse, in which case ADR holders will
    receive nothing.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have no obligation to file a registration statement under the
    Securities Act in order to make any rights available to ADR
    holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Other Distributions.</I>&#160;&#160;In the case of a
    distribution of securities or property other than those
    described above, the depositary may either (i)&#160;distribute
    such securities or property in any manner it deems equitable and
    practicable or (ii)&#160;to the extent the depositary deems
    distribution of such securities or property not to be equitable
    and practicable, sell such securities or property and distribute
    any net proceeds in the same way it distributes cash.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the depositary determines that any distribution described
    above is not practicable with respect to any specific registered
    ADR holder, the depositary may choose any method of distribution
    that it deems practicable for such ADR holder, including the
    distribution of foreign currency, securities or property, or it
    may retain such items, without paying interest on or investing
    them, on behalf of the ADR holder as deposited securities, in
    which case the ADSs will also represent the retained items.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any U.S.&#160;dollars will be distributed by checks drawn on a
    bank in the United States for whole dollars and cents.
    Fractional cents will be withheld without liability and dealt
    with by the depositary in accordance with its then current
    practices.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The depositary is not responsible if it decides that it is
    unlawful or impractical to make a distribution available to any
    ADR holders.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>There can be no assurance that the depositary will be able to
    convert any currency at a specified exchange rate or sell any
    property, rights, shares or other securities at a specified
    price, nor that any of such transactions can be completed within
    a specified time period.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Deposit,
    Withdrawal and Cancellation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">How
    does the depositary issue ADSs?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary will issue ADSs if you or your broker deposit
    shares or evidence of rights to receive shares with the
    custodian and pay the fees and expenses owing to the depositary
    in connection with such issuance. In the case of the ADSs to be
    issued under this prospectus, we will arrange with the
    underwriters named herein to deposit such shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shares deposited in the future with the custodian must be
    accompanied by certain delivery documentation, including
    instruments showing that such shares have been properly
    transferred or endorsed to the person on whose behalf the
    deposit is being made.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    144
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The custodian will hold all deposited shares (including those
    being deposited by or on our behalf in connection with this
    offering) for the account of the depositary. ADR holders thus
    have no direct ownership interest in the shares and only have
    such rights as are contained in the deposit agreement. The
    custodian will also hold any additional securities, property and
    cash received on or in substitution for the deposited shares.
    The deposited shares and any such additional items are referred
    to as &#147;deposited securities&#148;.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon each deposit of shares, receipt of related delivery
    documentation and compliance with the other provisions of the
    deposit agreement, including the payment of the fees and charges
    of the depositary and any taxes or other fees or charges owing,
    the depositary will issue an ADR or ADRs in the name or upon the
    order of the person entitled thereto evidencing the number of
    ADSs to which such person is entitled. All of the ADSs issued
    will, unless specifically requested to the contrary, be part of
    the depositary&#146;s direct registration system, and a
    registered holder will receive periodic statements from the
    depositary which will show the number of ADSs registered in such
    holder&#146;s name. An ADR holder can request that the ADSs not
    be held through the depositary&#146;s direct registration system
    and that a certificated ADR be issued.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">How do
    ADR holders cancel an ADS and obtain deposited
    securities?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    When you turn in your ADR certificate at the depositary&#146;s
    office, or when you provide proper instructions and
    documentation in the case of direct registration ADSs, the
    depositary will, upon payment of certain applicable fees,
    charges and taxes, deliver the underlying shares to you or upon
    your written order. In the case of certificated ADSs, delivery
    will be made at the custodian&#146;s office. At your risk,
    expense and request, the depositary may deliver deposited
    securities at such other place as you may request.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary may only restrict the withdrawal of deposited
    securities in connection with:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    temporary delays caused by closing our transfer books or those
    of the depositary or the deposit of shares in connection with
    voting at a shareholders&#146; meeting, or the payment of
    dividends;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the payment of fees, taxes and similar charges;&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    compliance with any U.S.&#160;or foreign laws or governmental
    regulations relating to the ADRs or to the withdrawal of
    deposited securities.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This right of withdrawal may not be limited by any other
    provision of the deposit agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Record
    Dates</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary may, after consultation with us if practicable,
    fix record dates for the determination of the registered ADR
    holders who will be entitled (or obligated, as the case may be):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to receive any distribution on or in respect of shares,
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to give instructions for the exercise of voting rights at a
    meeting of holders of shares,&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to pay the fee assessed by the depositary for administration of
    the ADR program and for any expenses as provided for in the ADR,
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    to receive any notice or to act in respect of other matters all
    subject to the provisions of the deposit agreement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Voting
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">How do
    I vote?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you are an ADR holder and the depositary asks you to provide
    it with voting instructions, you may instruct the depositary how
    to exercise the voting rights for the shares which underlie your
    ADSs. As soon as practicable after receiving notice of any
    meeting or solicitation of consents or proxies from us, the
    depositary will distribute to the registered ADR holders a
    notice stating such information as is contained in the voting
    materials received by the depositary and describing how you may
    instruct the depositary to exercise the voting rights for the
    shares which underlie your ADSs, including instructions for
    giving a discretionary proxy to a person designated by us. For
    instructions to be valid, the depositary must receive them in
    the manner and on or before the date specified. The
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    145
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    depositary will try, as far as is practical, subject to the
    provisions of and governing the underlying shares or other
    deposited securities, to vote or to have its agents vote the
    shares or other deposited securities as you instruct.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary will only vote or attempt to vote as you
    instruct. The depositary will not itself exercise any voting
    discretion. Furthermore, neither the depositary nor its agents
    are responsible for any failure to carry out any voting
    instructions, for the manner in which any vote is cast or for
    the effect of any vote.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There is no guarantee that you will receive voting materials in
    time to instruct the depositary to vote and it is possible that
    you, or persons who hold their ADSs through brokers, dealers or
    other third parties, will not have the opportunity to exercise a
    right to vote.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Reports
    and Other Communications</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Will
    ADR holders be able to view our reports?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary will make available for inspection by ADR holders
    at the offices of the depositary and the custodian the deposit
    agreement, the provisions of or governing deposited securities,
    and any written communications from us which are both received
    by the custodian or its nominee as a holder of deposited
    securities and made generally available to the holders of
    deposited securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additionally, if we make any written communications generally
    available to holders of our shares, and we furnish copies
    thereof (or English translations or summaries) to the
    depositary, it will distribute the same to registered ADR
    holders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Fees and
    Expenses</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">What
    fees and expenses will I be responsible for
    paying?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary may charge each person to whom ADSs are issued,
    including, without limitation, issuances against deposits of
    shares, issuances in respect of share distributions, rights and
    other distributions, issuances pursuant to a stock dividend or
    stock split declared by us or issuances pursuant to a merger,
    exchange of securities or any other transaction or event
    affecting the ADSs or deposited securities, and each person
    surrendering ADSs for withdrawal of deposited securities or
    whose ADRs are cancelled or reduced for any other reason, $5.00
    for each 100 ADSs (or any portion thereof) issued, delivered,
    reduced, cancelled or surrendered, as the case may be. The
    depositary may sell (by public or private sale) sufficient
    securities and property received in respect of a share
    distribution, rights
    <FONT style="white-space: nowrap">and/or</FONT> other
    distribution prior to such deposit to pay such charge.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following additional charges shall be incurred by the ADR
    holders, by any party depositing or withdrawing shares or by any
    party surrendering ADSs or to whom ADSs are issued (including,
    without limitation, issuance pursuant to a stock dividend or
    stock split declared by us or an exchange of stock regarding the
    ADRs or the deposited securities or a distribution of ADSs),
    whichever is applicable:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee of up to US$1.50 per ADR or ADRs for transfers of
    certificated or direct registration ADRs;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee of up to US$0.05 per ADS for any cash distribution made
    pursuant to the deposit agreement;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee of up to US$0.05 per ADS per calendar year (or portion
    thereof) for services performed by the depositary in
    administering the ADRs (which fee may be charged on a periodic
    basis during each calendar year and shall be assessed against
    holders of ADRs as of the record date or record dates set by the
    depositary during each calendar year and shall be payable in the
    manner described in the next succeeding provision);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement of such fees, charges and expenses as are incurred
    by the depositary
    <FONT style="white-space: nowrap">and/or</FONT> any
    of the depositary&#146;s agents (including, without limitation,
    the custodian and expenses incurred on behalf of holders in
    connection with compliance with foreign exchange control
    regulations or any law or regulation relating to foreign
    investment) in connection with the servicing of the shares or
    other deposited securities, the delivery of deposited securities
    or otherwise in connection with the depositary&#146;s or its
    custodian&#146;s compliance with applicable law, rule or
    regulation (which charge shall be assessed on a proportionate
    basis against holders as of the record date or dates set by the
    depositary and shall be payable at the sole discretion of the
    depositary by billing such holders or by deducting such charge
    from one or more cash dividends or other cash distributions);
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    146
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a fee for the distribution of securities (or the sale of
    securities in connection with a distribution), such fee being in
    an amount equal to the fee for the execution and delivery of
    ADSs which would have been charged as a result of the deposit of
    such securities (treating all such securities as if they were
    shares) but which securities or the net cash proceeds from the
    sale thereof are instead distributed by the depositary to those
    holders entitled thereto;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    stock transfer or other taxes and other governmental charges;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    cable, telex and facsimile transmission and delivery charges
    incurred at your request in connection with the deposit or
    delivery of shares;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfer or registration fees for the registration of transfer
    of deposited securities on any applicable register in connection
    with the deposit or withdrawal of deposited securities;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    expenses of the depositary in connection with the conversion of
    foreign currency into U.S.&#160;dollars.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will pay all other charges and expenses of the depositary and
    any agent of the depositary (except the custodian) pursuant to
    agreements from time to time between us and the depositary. The
    charges described above may be amended from time to time by
    agreement between us and the depositary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our depositary has agreed to reimburse us for certain expenses
    we incur that are related to establishment and maintenance of
    the ADR program, including investor relations expenses and
    exchange application and listing fees. Neither the depositary
    nor we can determine the exact amount to be made available to us
    because (i)&#160;the number of ADSs that will be issued and
    outstanding, (ii)&#160;the level of fees to be charged to
    holders of ADSs and (iii)&#160;our reimbursable expenses related
    to the ADR program are not known at this time. The depositary
    collects its fees for issuance and cancellation of ADSs directly
    from investors depositing shares or surrendering ADSs for the
    purpose of withdrawal or from intermediaries acting for them.
    The depositary collects fees for making distributions to
    investors by deducting those fees from the amounts distributed
    or by selling a portion of distributable property to pay the
    fees. The depositary may collect its annual fee for depositary
    services by deduction from cash distributions, or by directly
    billing investors, or by charging the book-entry system accounts
    of participants acting for them. The depositary may generally
    refuse to provide services to any holder until the fees and
    expenses owing by such holder for those services or otherwise
    are paid.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Payment
    of Taxes</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    ADR holders must pay any tax or other governmental charge
    payable by the custodian or the depositary on any ADS or ADR,
    deposited security or distribution. If an ADR holder owes any
    tax or other governmental charge, the depositary may
    (i)&#160;deduct the amount thereof from any cash distributions,
    or (ii)&#160;sell deposited securities (by public or private
    sale) and deduct the amount owing from the net proceeds of such
    sale. In either case the ADR holder remains liable for any
    shortfall. Additionally, if any tax or governmental charge is
    unpaid, the depositary may also refuse to effect any
    registration, registration of transfer,
    <FONT style="white-space: nowrap">split-up</FONT> or
    combination of deposited securities or withdrawal of deposited
    securities until such payment is made. If any tax or
    governmental charge is required to be withheld on any cash
    distribution, the depositary may deduct the amount required to
    be withheld from any cash distribution or, in the case of a
    non-cash distribution, sell the distributed property or
    securities (by public or private sale) to pay such taxes and
    distribute any remaining net proceeds to the ADR holders
    entitled thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    By holding an ADR or an interest therein, you will be agreeing
    to indemnify us, the depositary, its custodian and any of our or
    their respective directors, employees, agents and affiliates
    against, and hold each of them harmless from, any claims by any
    governmental authority with respect to taxes, additions to tax,
    penalties or interest arising out of any refund of taxes,
    reduced rate of withholding at source or other tax benefit
    obtained.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Reclassifications,
    Recapitalizations and Mergers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we take certain actions that affect the deposited securities,
    including (i)&#160;any change in par value,
    <FONT style="white-space: nowrap">split-up,</FONT>
    consolidation, cancellation or other reclassification of
    deposited securities or (ii)&#160;any distributions not made to
    holders of ADRs or (iii)&#160;any recapitalization,
    reorganization, merger, consolidation, liquidation,
    receivership, bankruptcy or sale of all or substantially all of
    our assets, then the depositary may choose to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (1)&#160;amend the form of ADR;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    147
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (2)&#160;distribute additional or amended ADRs;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (3)&#160;distribute cash, securities or other property it has
    received in connection with such actions;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (4)&#160;sell any securities or property received and distribute
    the proceeds as cash;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (5)&#160;none of the above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the depositary does not choose any of the above options, any
    of the cash, securities or other property it receives will
    constitute part of the deposited securities and each ADS will
    then represent a proportionate interest in such property.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Amendment
    and Termination</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">How
    may the deposit agreement be amended?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may agree with the depositary to amend the deposit agreement
    and the ADSs without your consent for any reason. ADR holders
    must be given at least 30&#160;days notice of any amendment that
    imposes or increases any fees or charges (other than stock
    transfer or other taxes and other governmental charges, transfer
    or registration fees, cable, telex or facsimile transmission
    costs, delivery costs or other such expenses), or otherwise
    prejudices any substantial existing right of ADR holders. Such
    notice need not describe in detail the specific amendments
    effectuated thereby, but must give ADR holders a means to access
    the text of such amendment. If an ADR holder continues to hold
    an ADR or ADRs after being so notified, such ADR holder is
    deemed to agree to such amendment and to be bound by the deposit
    agreement as so amended. Notwithstanding the foregoing, if any
    governmental body or regulatory body should adopt new laws,
    rules or regulations which would require amendment or supplement
    of the deposit agreement or the form of ADR to ensure compliance
    therewith, we and the depositary may amend or supplement the
    deposit agreement and the ADR at any time in accordance with
    such changed laws, rules or regulations, which amendment or
    supplement may take effect before a notice is given or within
    any other period of time as required for compliance. No
    amendment, however, will impair your right to surrender your
    ADSs and receive the underlying securities, except in order to
    comply with mandatory provisions of applicable law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">How
    may the deposit agreement be terminated?</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary may, and shall at our written direction,
    terminate the deposit agreement and the ADRs by mailing notice
    of such termination to the registered holders of ADRs at least
    30&#160;days prior to the date fixed in such notice for such
    termination; provided, however, if the depositary shall have
    (i)&#160;resigned as depositary under the deposit agreement,
    notice of such termination by the depositary shall not be
    provided to registered holders unless a successor depositary
    shall not be operating under the deposit agreement within
    45&#160;days of the date of such resignation, and (ii)&#160;been
    removed as depositary under the deposit agreement, notice of
    such termination by the depositary shall not be provided to
    registered holders of ADRs unless a successor depositary shall
    not be operating under the deposit agreement on the
    90th&#160;day after our notice of removal was first provided to
    the depositary. After termination, the depositary&#146;s only
    responsibility will be (i)&#160;to deliver deposited securities
    to ADR holders who surrender their ADRs, and (ii)&#160;to hold
    or sell distributions received on deposited securities. As soon
    as practicable after the expiration of six months from the
    termination date, the depositary will sell the deposited
    securities which remain and hold the net proceeds of such sales
    (as long as it may lawfully do so), without liability for
    interest, in trust for the ADR holders who have not yet
    surrendered their ADRs. After making such sale, the depositary
    shall have no obligations except to account for such proceeds
    and other cash.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    148
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Limitations
    on Obligations and Liability to ADR Holders</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Limits
    on our obligations and the obligations of the depositary; limits
    on liability to ADR holders and holders of ADSs</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to the issue, registration, registration of transfer,
    <FONT style="white-space: nowrap">split-up,</FONT>
    combination, or cancellation of any ADRs, or the delivery of any
    distribution in respect thereof, and from time to time, we or
    the depositary or its custodian may require:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    payment with respect thereto of (i)&#160;any stock transfer or
    other tax or other governmental charge, (ii)&#160;any stock
    transfer or registration fees in effect for the registration of
    transfers of shares or other deposited securities upon any
    applicable register and (iii)&#160;any applicable fees and
    expenses described in the deposit agreement;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the production of proof satisfactory to it of (i)&#160;the
    identity of any signatory and genuineness of any signature and
    (ii)&#160;such other information, including without limitation,
    information as to citizenship, residence, exchange control
    approval, beneficial ownership of any securities, compliance
    with applicable law, regulations, provisions of or governing
    deposited securities and terms of the deposit agreement and the
    ADRs, as it may deem necessary or proper;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    compliance with such regulations as the depositary may establish
    consistent with the deposit agreement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The issuance of ADRs, the acceptance of deposits of shares, the
    registration, registration of transfer,
    <FONT style="white-space: nowrap">split-up</FONT> or
    combination of ADRs or the withdrawal of shares, may be
    suspended, generally or in particular instances, when the ADR
    register or any register for deposited securities is closed or
    when any such action is deemed advisable by the depositary;
    provided that the ability to withdrawal shares may only be
    limited under the following circumstances: (i)&#160;temporary
    delays caused by closing transfer books of the depositary or our
    transfer books or the deposit of shares in connection with
    voting at a shareholders&#146; meeting, or the payment of
    dividends, (ii)&#160;the payment of fees, taxes, and similar
    charges, and (iii)&#160;compliance with any laws or governmental
    regulations relating to ADRs or to the withdrawal of deposited
    securities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The deposit agreement expressly limits the obligations and
    liability of the depositary, ourselves and our respective
    agents. Neither we nor the depositary nor any such agent will be
    liable if:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any present or future law, rule, regulation, fiat, order or
    decree of the United States, the Cayman Islands, The
    People&#146;s Republic of China (including the Hong Kong Special
    Administrative Region, the People&#146;s Republic of China) or
    any other country, or of any governmental or regulatory
    authority or securities exchange or market or automated
    quotation system, the provisions of or governing any deposited
    securities, any present or future provision of our charter, any
    act of God, war, terrorism or other circumstance beyond our, the
    depositary&#146;s or our respective agents&#146; control shall
    prevent, delay or subject to any civil or criminal penalty any
    act which the deposit agreement or the ADRs provide shall be
    done or performed by us, the depositary or our respective agents
    (including, without limitation, voting);
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    it exercises or fails to exercise discretion under the deposit
    agreement or the ADR;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    it performs its obligations under the deposit agreement and ADRs
    without gross negligence or bad faith;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    it takes any action or refrains from taking any action in
    reliance upon the advice of or information from legal counsel,
    accountants, any person presenting shares for deposit, any
    registered holder of ADRs, or any other person believed by it to
    be competent to give such advice or information;&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    it relies upon any written notice, request, direction or other
    document believed by it to be genuine and to have been signed or
    presented by the proper party or parties.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Neither the depositary nor its agents have any obligation to
    appear in, prosecute or defend any action, suit or other
    proceeding in respect of any deposited securities or the ADRs.
    We and our agents shall only be obligated to appear in,
    prosecute or defend any action, suit or other proceeding in
    respect of any deposited securities or the ADRs, which in our
    opinion may involve us in expense or liability, if indemnity
    satisfactory to us against all expense (including fees and
    disbursements of counsel) and liability is furnished as often as
    may be required. The depositary and its agents may fully respond
    to any and all demands or requests for information maintained by
    or on its behalf in
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    149
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    connection with the deposit agreement, any registered holder or
    holders of ADRs, any ADRs or otherwise related to the deposit
    agreement or ADRs to the extent such information is requested or
    required by or pursuant to any lawful authority, including
    without limitation laws, rules, regulations, administrative or
    judicial process, banking, securities or other regulators. The
    depositary shall not be liable for the acts or omissions made by
    any securities depository, clearing agency or settlement system
    in connection with or arising out of book-entry settlement of
    deposited securities or otherwise. Furthermore, the depositary
    shall not be responsible for, and shall incur no liability in
    connection with or arising from, the insolvency of any custodian
    that is not a branch or affiliate of JPMorgan Chase Bank, N.A.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additionally, none of us, the depositary or the custodian shall
    be liable for the failure by any registered holder of ADRs or
    beneficial owner therein to obtain the benefits of credits on
    the basis of
    <FONT style="white-space: nowrap">non-U.S.&#160;tax</FONT>
    paid against such holder&#146;s or beneficial owner&#146;s
    income tax liability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Neither we nor the depositary shall incur any liability for any
    tax consequences that may be incurred by holders or beneficial
    owners on account of their ownership of ADRs or ADSs. Neither
    the depositary nor its agents will be responsible for any
    failure to carry out any instructions to vote any of the
    deposited securities, for the manner in which any such vote is
    cast or for the effect of any such vote. Neither the depositary
    nor any of its agents shall be liable to registered holders of
    ADRs or beneficial owners of interests in ADSs for any indirect,
    special, punitive or consequential damages (including, without
    limitation, lost profits) of any form incurred by any person or
    entity, whether or not foreseeable and regardless of the type of
    action in which such a claim may be brought.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary may own and deal in any class of our securities
    and in ADSs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Disclosure
    of Interest in ADSs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To the extent that the provisions of or governing any deposited
    securities may require disclosure of or impose limits on
    beneficial or other ownership of deposited securities, other
    shares and other securities and may provide for blocking
    transfer, voting or other rights to enforce such disclosure or
    limits, you agree to comply with all such disclosure
    requirements and ownership limitations and to comply with any
    reasonable instructions we may provide in respect thereof. We
    reserve the right to instruct you to deliver your ADSs for
    cancellation and withdrawal of the deposited securities so as to
    permit us to deal with you directly as a holder of shares and,
    by holding an ADS or an interest therein, you will be agreeing
    to comply with such instructions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Books of
    Depositary</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary or its agent will maintain a register for the
    registration, registration of transfer, combination and
    <FONT style="white-space: nowrap">split-up</FONT> of
    ADRs, which register shall include the depositary&#146;s direct
    registration system. Registered holders of ADRs may inspect such
    records at the depositary&#146;s office at all reasonable times,
    but solely for the purpose of communicating with other holders
    in the interest of the business of our company or a matter
    relating to the deposit agreement. Such register may be closed
    from time to time, when deemed expedient by the depositary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The depositary will maintain facilities for the delivery and
    receipt of ADRs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pre-release
    of ADSs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In its capacity as depositary, the depositary shall not lend
    shares or ADSs; provided, however, that the depositary may
    (i)&#160;issue ADSs prior to the receipt of shares and
    (ii)&#160;deliver shares prior to the receipt of ADSs for
    withdrawal of deposited securities, including ADSs which were
    issued under (i)&#160;above but for which shares may not have
    been received (each such transaction a &#147;pre-release&#148;).
    The depositary may receive ADSs in lieu of shares under
    (i)&#160;above (which ADSs will promptly be canceled by the
    depositary upon receipt by the depositary) and receive shares in
    lieu of ADSs under (ii)&#160;above. Each such pre-release will
    be subject to a written agreement whereby the person or entity
    (the &#147;applicant&#148;) to whom ADSs or shares are to be
    delivered (a)&#160;represents that at the time of the
    pre-release the applicant or its customer owns the shares or
    ADSs that are to be delivered by the applicant under such
    pre-release, (b)&#160;agrees to indicate the depositary as owner
    of such shares or ADSs in its records and to hold such shares or
    ADSs in trust for the depositary until such shares or ADSs are
    delivered to the depositary or the custodian,
    (c)&#160;unconditionally guarantees to deliver to the depositary
    or the custodian, as applicable, such shares or ADSs, and
    (d)&#160;agrees to any additional restrictions or requirements
    that the depositary deems appropriate. Each such pre-release
    will be at all times fully collateralized with cash,
    U.S.&#160;government securities or such other collateral as the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    150
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    depositary deems appropriate, terminable by the depositary on
    not more than five (5)&#160;business days&#146; notice and
    subject to such further indemnities and credit regulations as
    the depositary deems appropriate. The depositary will normally
    limit the number of ADSs and shares involved in such pre-release
    at any one time to thirty percent (30%) of the ADSs outstanding
    (without giving effect to ADSs outstanding under
    (i)&#160;above), provided, however, that the depositary reserves
    the right to change or disregard such limit from time to time as
    it deems appropriate. The depositary may also set limits with
    respect to the number of ADSs and shares involved in pre-release
    with any one person on a
    <FONT style="white-space: nowrap">case-by-case</FONT>
    basis as it deems appropriate. The depositary may retain for its
    own account any compensation received by it in conjunction with
    the foregoing. Collateral provided pursuant to (b)&#160;above,
    but not the earnings thereon, shall be held for the benefit of
    the registered holders of ADRs (other than the applicant).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Appointment</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the deposit agreement, each registered holder of ADRs and
    each person holding an interest in ADSs, upon acceptance of any
    ADSs (or any interest therein) issued in accordance with the
    terms and conditions of the deposit agreement will be deemed for
    all purposes to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    be a party to and bound by the terms of the deposit agreement
    and the applicable ADR or ADRs,&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    appoint the depositary its attorney-in-fact, with full power to
    delegate, to act on its behalf and to take any and all actions
    contemplated in the deposit agreement and the applicable ADR or
    ADRs, to adopt any and all procedures necessary to comply with
    applicable laws and to take such action as the depositary in its
    sole discretion may deem necessary or appropriate to carry out
    the purposes of the deposit agreement and the applicable ADR and
    ADRs, the taking of such actions to be the conclusive
    determinant of the necessity and appropriateness thereof.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Governing
    Law</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The deposit agreement and the ADRs shall be governed by and
    construed in accordance with the laws of the State of New York.
    In the deposit agreement, we have submitted to the jurisdiction
    of the courts of the State of New York and appointed an agent
    for service of process on our behalf.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    151
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='120'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SHARES
    ELIGIBLE FOR FUTURE SALE</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, we will
    have&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    outstanding ADSs representing
    approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;%
    of our ordinary shares in issue. All of the ADSs sold in this
    offering will be freely transferable by persons other than our
    &#147;affiliates&#148; without restriction or further
    registration under the Securities Act. Sales of substantial
    amounts of our ADSs in the public market could adversely affect
    prevailing market prices of our ADSs. Prior to this offering,
    there has been no public market for our ordinary shares or the
    ADSs, and although we have applied to list the ADSs on the NYSE,
    we cannot assure you that a regular trading market will develop
    in the ADSs. We do not expect that a trading market will develop
    for our ordinary shares not represented by the ADSs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times"><FONT style="white-space: nowrap">Lock-up</FONT>
    Agreements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our directors, executive officers and all existing shareholders
    have signed
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements under which they have agreed, subject to certain
    exceptions, not to transfer or dispose of, directly or
    indirectly, any of our ordinary shares, in the form of ADSs or
    otherwise, or any securities convertible into or exchangeable or
    exercisable for our ordinary shares, in the form of ADSs or
    otherwise, for a period of 180&#160;days after the date of this
    prospectus. The
    <FONT style="white-space: nowrap">180-day</FONT>
    <FONT style="white-space: nowrap">lock-up</FONT>
    period may be extended under certain circumstances described in
    &#147;Underwriting&#148;. After the expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    period, the ordinary shares or ADSs held by our directors,
    executive officers or principal shareholders may be sold subject
    to the restrictions under Rule&#160;144 under the Securities
    Act, or Rule&#160;144, or by means of registered public
    offerings.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Rule&#160;144</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, under Rule&#160;144 as currently in effect, a person
    who has beneficially owned our restricted securities for at
    least six months is entitled to sell the restricted securities
    without registration under the Securities Act, subject to
    certain restrictions. Persons who are our affiliates (including
    persons beneficially owning 10.0% or more of our outstanding
    shares) may sell within any three-month period a number of
    restricted securities that does not exceed the greater of the
    following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    1.0% of the number of our ordinary shares then outstanding, in
    the form of ADSs or otherwise, which will equal
    approximately&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    immediately after this offering,
    or&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares
    if the underwriters exercise their option to purchase additional
    ADSs in full;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the average weekly trading volume of our ADSs on
    the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
    during the four calendar weeks preceding the date on which
    notice of the sale is filed with the SEC.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Such sales are also subject to manner-of-sale provisions, notice
    requirements and the availability of current public information
    about us. The manner-of-sale provisions require the securities
    to be sold either in &#147;brokers&#146; transactions&#148; as
    such term is defined under the Securities Act, through
    transactions directly with a market maker as such term is
    defined under the Exchange Act or through a riskless principal
    transactions as described in Rule&#160;144. In addition, the
    manner-of-sale provisions require the person selling the
    securities not to solicit or arrange for the solicitation of
    orders to buy the securities in anticipation of or in connection
    with such transaction or make any payment in connection with the
    offer or sale of the securities to any person other than the
    broker or dealer who executes the order to sell the securities.
    If the amount of securities to be sold in reliance upon
    Rule&#160;144 during any period of three months exceeds
    5,000&#160;shares or other units or has an aggregate sale price
    in excess of US$50,000, three copies of a notice on
    Form&#160;144 should be filed with the SEC. If such securities
    are admitted to trading on any national securities exchange, one
    copy of such notice also shall be transmitted to the principal
    exchange on which such securities are admitted. The
    Form&#160;144 should be signed by the person for whose account
    the securities are to be sold and should be transmitted for
    filing concurrently with either the placing with a broker of an
    order to execute a sale of securities or the execution directly
    with a market maker of such a sale.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Persons who are not our affiliates and have beneficially owned
    our restricted securities for more than six months but not more
    than one year may sell the restricted securities without
    registration under the Securities Act subject to the
    availability of current public information about us. Persons who
    are not our affiliates and have beneficially owned our
    restricted securities for more than one year may freely sell the
    restricted securities without registration under the Securities
    Act.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    152
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Rule&#160;701</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Beginning 90&#160;days after the date of this prospectus,
    persons other than affiliates who purchased ordinary shares
    under a written compensatory plan or contract may be entitled to
    sell such shares in the United States in reliance on
    Rule&#160;701 under the Securities Act, or Rule&#160;701.
    Rule&#160;701 permits affiliates to sell their shares satisfying
    the requirements of Rule&#160;701 under Rule&#160;144 without
    complying with the holding period requirements of Rule&#160;144.
    Rule&#160;701 further provides that non-affiliates may sell
    these shares in reliance on Rule&#160;144 subject only to its
    manner-of-sale requirements. However, these shares would remain
    subject to
    <FONT style="white-space: nowrap">lock-up</FONT>
    arrangements and would only become eligible for sale when the
    <FONT style="white-space: nowrap">lock-up</FONT>
    period expires.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Registration
    Rights</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon completion of this offering, certain holders of our
    ordinary shares, or their transferees will be entitled to
    request that we register their shares under the Securities Act,
    following the expiration of the
    <FONT style="white-space: nowrap">lock-up</FONT>
    agreements described above. See &#147;Description of Share
    Capital&#160;&#151; Registration Rights.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    153
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='121'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">TAXATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The following are the material Cayman Islands, People&#146;s
    Republic of China and United States federal income tax
    consequences of an investment in our ADSs or ordinary shares is
    based upon laws and relevant interpretations thereof in effect
    as of the date of this prospectus, all of which are subject to
    change or different interpretations, possibly with retroactive
    effect. This summary does not deal with all possible tax
    consequences relating to an investment in our ADSs or ordinary
    shares, such as the tax consequences under U.S.&#160;state,
    local and other tax laws, or tax laws of jurisdictions other
    than the Cayman Islands, the People&#146;s Republic of China and
    the United States. To the extent the discussion relates to
    matters of Cayman Islands tax law, it constitutes the opinion of
    Walkers, our Cayman Islands counsel.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Cayman
    Islands Taxation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Cayman Islands currently levy no taxes on individuals or
    corporations based upon profits, income, gains or appreciation,
    and there is no taxation in the nature of inheritance tax or
    estate duty. No Cayman Islands stamp duty will be payable unless
    an instrument is executed in, brought to, or produced before a
    court of the Cayman Islands. The Cayman Islands are not parties
    to any double tax treaties. There are no exchange control
    regulations or currency restrictions in the Cayman Islands.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">People&#146;s
    Republic of China Taxation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The PRC Enterprise Income Tax Law, or the EIT Law, and the
    implementation regulations for the EIT Law issued by the PRC
    State Council, became effective as of January&#160;1, 2008. The
    new EIT law and its implementation regulation impose a single
    uniform income tax rate of 25% on all Chinese enterprises,
    including foreign-invested enterprises, and levies a withholding
    tax rate of 10% on dividends payable by Chinese subsidiaries to
    their non-PRC enterprise shareholders except with respect to any
    such non-PRC enterprise shareholder whose jurisdiction of
    incorporation has a tax treaty with China that provides for a
    different withholding agreement. The EIT Law provides that
    enterprises established outside of China whose &#147;de facto
    management bodies&#148; are located in China are considered
    &#147;resident enterprises&#148; and are generally subject to
    the uniform 25% enterprise income tax rate on their worldwide
    income. Under the implementation regulations for the EIT Law
    issued by the PRC State Council, a &#147;de facto management
    body&#148; is defined as a body that has material and overall
    management and control over the manufacturing and business
    operations, personnel and human resources, finances and treasury
    and assets of an enterprise. On April&#160;22, 2009, the State
    Administration of Taxation promulgated a circular which sets out
    criteria for determining whether &#147;de facto management
    bodies&#148; are located in China for overseas incorporated,
    domestically controlled enterprises. However, as this circular
    only applies to enterprises incorporated under the laws of
    foreign countries or regions that are controlled by PRC
    enterprises or groups of PRC enterprises, it remains unclear how
    the tax authorities will determine the location of &#147;de
    facto management bodies&#148; for overseas incorporated
    enterprises that are controlled by individual PRC residents like
    us and some of our subsidiaries. Therefore, although
    substantially all of our operational management is currently
    based in the PRC, it is unclear whether PRC tax authorities
    would require (or permit) us to be treated as a PRC resident
    enterprise. We do not currently consider our company to be a PRC
    resident enterprise. However, if the Chinese tax authorities
    disagree with our assessment and determine that we are a PRC
    resident enterprise, we may be subject to a 25% enterprise
    income tax on our global income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the EIT Law and implementation regulations issued by the
    State Council, a 10% PRC income tax is applicable to dividends
    payable to investors that are &#147;non-resident
    enterprises,&#148; which do not have an establishment or place
    of business in the PRC, or which have such establishment or
    place of business but the relevant income is not effectively
    connected with the establishment or place of business, to the
    extent such dividends have their sources within the PRC.
    Furthermore, a circular issued by the Ministry of Finance and
    the State Administration of Taxation on February&#160;22, 2008
    stipulates that undistributed earnings generated prior to
    January&#160;1, 2008 are exempt from enterprise income tax. We
    are a holding company incorporated in the Cayman Islands, which
    indirectly holds, through Ascendium, Cyber Medical and OMS, our
    equity interests in our PRC subsidiaries. Our business
    operations are principally conducted through PRC subsidiaries.
    Thus, dividends for earnings accumulated beginning on
    January&#160;1, 2008 payable to us by our subsidiaries in China,
    if any, will be subject to the 10% income tax if we are
    considered as &#147;non-resident enterprises&#148; under the EIT
    Law. Under the EIT law, the Notice 112, which was issued on
    January&#160;29, 2008 and the Double Taxation Arrangement (Hong
    Kong), which became effective on December&#160;8, 2006,
    dividends from our PRC subsidiaries paid to us through our Hong
    Kong subsidiary may be subject to a 10%
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    154
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    withholding tax or a 5% withholding tax if our Hong Kong
    subsidiary can be considered as a &#147;beneficial owner&#148;
    and entitled to treaty benefits under the Double Taxation
    Arrangement (Hong Kong). Under the existing implementation rules
    of the EIT Law, it is unclear what will constitute income
    derived from sources within the PRC. Accordingly dividends paid
    by us to our non-PRC resident enterprise ADS holders and
    ordinary shareholders may be deemed to be derived from sources
    within the PRC and, therefore, be subject to the 10% PRC income
    tax.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Similarly, any gain realized on the transfer of our ADSs or
    ordinary shares by our non-PRC resident enterprise ADS holders
    and ordinary shareholders may also be subject to the 10% PRC
    income tax if such gain is regarded as income derived from
    sources within the PRC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">United
    States Federal Income Taxation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following discussion describes the material United States
    federal income tax consequences of the ownership of our ordinary
    shares and ADSs as of the date hereof. The discussion is
    applicable to United States Holders (as defined below) who hold
    our ordinary shares or ADSs as capital assets. As used herein,
    the term &#147;United States Holder&#148; means a holder of an
    ordinary share or ADS that is for United States federal income
    tax purposes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an individual citizen or resident of the United States;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a corporation (or other entity treated as a corporation for
    United States federal income tax purposes) created or organized
    in or under the laws of the United States, any state thereof or
    the District of Columbia;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an estate the income of which is subject to United States
    federal income taxation regardless of its source;&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a trust if it (1)&#160;is subject to the primary supervision of
    a court within the United States and one or more United States
    persons have the authority to control all substantial decisions
    of the trust or (2)&#160;has a valid election in effect under
    applicable United States Treasury regulations to be treated as a
    United States person.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This discussion does not represent a detailed description of the
    United States federal income tax consequences applicable to you
    if you are subject to special treatment under the United States
    federal income tax laws, including if you are:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a dealer in securities or currencies;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a financial institution;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a regulated investment company;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a real estate investment trust;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an insurance company;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a tax exempt organization;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a person holding our ordinary shares or ADSs as part of a
    hedging, integrated or conversion transaction, a constructive
    sale or a straddle;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a trader in securities that has elected the mark-to-market
    method of accounting for your securities;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a person liable for alternative minimum tax;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a person who owns or is deemed to own more than 10% of our
    voting stock;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a partnership or other pass-through entity for United States
    federal income tax purposes;&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a person whose &#147;functional currency&#148; is not the United
    States dollar.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The discussion below is based upon the provisions of the
    Internal Revenue Code of 1986, as amended (the
    &#147;Code&#148;), and regulations, rulings and judicial
    decisions thereunder as of the date hereof, and such authorities
    may be replaced, revoked or modified so as to result in United
    States federal income tax consequences different from those
    discussed below. In addition, this discussion is based, in part,
    upon representations made by the depositary to us and assumes
    that the deposit agreement, and all other related agreements,
    will be performed in accordance with their terms.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    155
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If a partnership holds ordinary shares or ADSs, the tax
    treatment of a partner will generally depend upon the status of
    the partner and the activities of the partnership. If you are a
    partner of a partnership holding our ordinary shares or ADSs,
    you should consult your tax advisors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This discussion does not contain a detailed description of all
    the United States federal income tax consequences to you in
    light of your particular circumstances and does not address the
    effects of any state, local or
    <FONT style="white-space: nowrap">non-United</FONT>
    States tax laws. <B>If you are considering the purchase,
    ownership or disposition of our ordinary shares or ADSs, you
    should consult your own tax advisors concerning the United
    States federal income tax consequences to you in light of your
    particular situation as well as any consequences arising under
    the laws of any other taxing jurisdiction.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The United States Treasury has expressed concerns that
    intermediaries in the chain of ownership between the holder of
    an ADS and the issuer of the security underlying the ADS may be
    taking actions that are inconsistent with the claiming of
    foreign tax credits for United States holders of ADSs. Such
    actions would also be inconsistent with the claiming of the
    reduced rate of tax described below, applicable to dividends
    received by certain non-corporate holders. Accordingly, the
    analysis of the creditability of PRC taxes, if any, and the
    availability of the reduced tax rate for dividends received by
    certain non-corporate holders, each described below, could be
    affected by actions taken by intermediaries in the chain of
    ownership between the holder of an ADS and our company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">ADSs</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you hold ADSs, for United States federal income tax purposes,
    you generally will be treated as the owner of the underlying
    ordinary shares that are represented by such ADSs. Accordingly,
    deposits or withdrawals of ordinary shares for ADSs will not be
    subject to United States federal income tax.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Taxation
    of Dividends</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subject to the discussion under &#147;&#151; Passive Foreign
    Investment Company&#148; below, the gross amount of
    distributions on the ADSs or ordinary shares (including amounts
    withheld to reflect PRC withholding taxes) will be taxable as
    dividends, to the extent paid out of our current or accumulated
    earnings and profits as determined under United States federal
    income tax principles. Such income will be includable in your
    gross income as ordinary income on the day actually or
    constructively received by you, in the case of the ordinary
    shares, or by the depositary, in the case of ADSs. Such
    dividends will not be eligible for the dividends-received
    deduction allowed to corporations under the Code. To the extent
    that the amount of the distribution exceeds our current and
    accumulated earnings and profits for a taxable year, as
    determined under United States federal income tax principles, it
    will be treated first as a tax-free return of your tax basis in
    your ADSs or ordinary shares, and to the extent the amount of
    the distribution exceeds your tax basis, the excess will be
    taxed as capital gain. We do not expect to keep earnings and
    profits in accordance with United States federal income tax
    principles. Therefore, you should expect that a distribution
    will be treated as a dividend (as discussed above).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    With respect to non-corporate United States Holders, certain
    dividends received in taxable years beginning before
    January&#160;1, 2011 from a qualified foreign corporation may be
    subject to reduced rates of taxation. A foreign corporation is
    treated as a qualified foreign corporation with respect to
    dividends received from that corporation on shares (or ADSs
    backed by such shares) that are readily tradable on an
    established securities market in the United States. Based on
    United States Treasury Department guidance, we expect that our
    ADSs (which we have applied to list on the NYSE), but not our
    ordinary shares, will be readily tradable on an established
    securities market in the United States. Thus, we believe that
    dividends we pay on our Shares that are represented by ADSs, but
    not on our ordinary shares that are not so represented, will
    meet such conditions required for the reduced tax rates. There
    can be no assurance that our ADSs will be considered readily
    tradable on an established securities market in later years. A
    qualified foreign corporation also includes a foreign
    corporation that is eligible for the benefits of certain income
    tax treaties with the United States. In the event that we are
    deemed to be a PRC &#147;resident enterprise&#148; under PRC tax
    law (see discussion under &#147;Taxation&#160;&#151;
    People&#146;s Republic of China Taxation&#148;), we may be
    eligible for the benefits of the income tax treaty between the
    United States and the PRC and, if we are eligible for such
    benefits, dividends we pay on our ordinary shares, regardless of
    whether such ordinary shares are represented by ADSs, would be
    subject to the reduced rates of taxation. Non-corporate United
    States Holders that do not meet a minimum holding period
    requirement during which they are not protected from the risk of
    loss or that elect to treat the dividend
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    156
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    income as &#147;investment income&#148; pursuant to
    Section&#160;163(d)(4) of the Code will not be eligible for the
    reduced rates of taxation regardless of our status as a
    qualified foreign corporation. In addition, the rate reduction
    will not apply to dividends if the recipient of a dividend is
    obligated to make related payments with respect to positions in
    substantially similar or related property. This disallowance
    applies even if the minimum holding period has been met.
    Moreover, non-corporate United States Holders will not be
    eligible for reduced rates of taxation on any dividends received
    from us in taxable years beginning prior to January&#160;1, 2011
    if we are a PFIC in the taxable year in which such dividends are
    paid or in the preceding taxable year. You should consult your
    own tax advisors regarding the application of these rules given
    your particular circumstances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event that we are deemed to be a PRC &#147;resident
    enterprise&#148; under PRC tax law, you may be subject to PRC
    withholding taxes on dividends paid to you with respect to the
    ADSs or ordinary shares (see discussion under
    &#147;Taxation&#160;&#151; People&#146;s Republic of China
    Taxation&#148;). However, you may be able to obtain a reduced
    rate of PRC withholding taxes under the treaty between the
    United States and the PRC if certain requirements are met. In
    addition, subject to certain conditions and limitations, PRC
    withholding taxes on dividends may be treated as foreign taxes
    eligible for credit against your United States federal income
    tax liability. For purposes of calculating the foreign tax
    credit, dividends paid on the ADSs or ordinary shares will be
    treated as foreign-source income and will generally constitute
    passive category income. Furthermore, in certain circumstances,
    if you have held the ADSs or ordinary shares for less than a
    specified minimum period during which you are not protected from
    risk of loss, or are obligated to make payments related to the
    dividends, you will not be allowed a foreign tax credit for any
    PRC withholding taxes imposed on dividends paid on the ADSs or
    ordinary shares. The rules governing the foreign tax credit are
    complex. You are urged to consult your tax advisors regarding
    the availability of the foreign tax credit under your particular
    circumstances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Passive
    Foreign Investment Company</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Based on the projected composition of our income and valuation
    of our assets, including goodwill, we do not expect to be a
    passive foreign investment company, or a PFIC, for United States
    federal income tax purposes for our current taxable year ending
    December&#160;31, 2009, and we do not expect to become one in
    the future, although there can be no assurance in this regard.
    If we are a PFIC for any taxable year during which you hold our
    ADSs or ordinary shares, you will be subject to special tax
    rules discussed below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, we will be a PFIC for any taxable year in which:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at least 75% of our gross income is passive income;&#160;or
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at least 50% of the value of our assets (based on an average of
    the quarterly values) is attributable to assets that produce or
    are held for the production of passive income.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For this purpose, passive income generally includes dividends,
    interest, royalties and rents (other than royalties and rents
    derived in the active conduct of a trade or business and not
    derived from a related person). If we own at least 25% (by
    value) of the stock of another corporation, we will be treated
    for purposes of the PFIC tests, as owning our proportionate
    share of the other corporation&#146;s assets and receiving our
    proportionate share of the other corporation&#146;s income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The determination of whether we are a PFIC is made annually.
    Accordingly, it is possible that we may become a PFIC in the
    current or any future taxable year due to changes in our asset
    or income composition. Because we have valued our goodwill based
    on the market value of our equity, a decrease in the price of
    our ADSs or ordinary shares may result in our becoming a PFIC.
    In addition, the composition of our income and assets will be
    affected by how, and how quickly, we spend the cash we raise in
    this offering. If we are a PFIC for any taxable year during
    which you hold our ADSs or ordinary shares, you will be subject
    to special tax rules discussed below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we are a PFIC for any taxable year during which you hold our
    ADSs or ordinary shares, you will be subject to special tax
    rules with respect to any &#147;excess distribution&#148;
    received and any gain realized from a sale or other disposition,
    including a pledge, of ADSs or ordinary shares. Distributions
    received in a taxable year that are greater than 125% of the
    average annual distributions received during the shorter of the
    three preceding taxable years or
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    157
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    your holding period for the ADSs or ordinary shares will be
    treated as excess distributions. Under these special tax rules:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the excess distribution or gain will be allocated ratably over
    your holding period for the ADSs or ordinary shares;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the amount allocated to the current taxable year, and any
    taxable year prior to the first taxable year in which we were a
    PFIC, will be treated as ordinary income;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the amount allocated to each other year will be subject to tax
    at the highest tax rate in effect for that year and the interest
    charge generally applicable to underpayments of tax will be
    imposed on the resulting tax attributable to each such year.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, non-corporate United States Holders will not be
    eligible for reduced rates of taxation on any dividends received
    from us in taxable years beginning prior to January&#160;1, 2011
    if we are a PFIC in the taxable year in which such dividends are
    paid or in the preceding taxable year. You will be required to
    file Internal Revenue Service Form&#160;8621 if you hold our
    ADSs or ordinary shares in any year in which we are classified
    as a PFIC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If we are a PFIC for any taxable year during which you hold our
    ADSs or ordinary shares and any of our
    <FONT style="white-space: nowrap">non-United</FONT>
    States subsidiaries is also a PFIC, a United States Holder would
    be treated as owning a proportionate amount (by value) of the
    shares of the lower-tier&#160;PFIC for purposes of the
    application of these rules. You are urged to consult your tax
    advisors about the application of the PFIC rules to any of our
    subsidiaries.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In certain circumstances, in lieu of being subject to the excess
    distribution rules discussed above, you may make an election to
    include gain on the stock of a PFIC as ordinary income under a
    mark-to-market method, provided that such stock is regularly
    traded on a qualified exchange. Under current law, the
    mark-to-market election may be available to holders of ADSs
    because we have applied to list the ADSs on the NYSE, which
    constitutes a qualified exchange, although there can be no
    assurance that the ADSs will be &#147;regularly traded&#148; for
    purposes of the mark-to-market election. It should be noted that
    we have applied to list only the ADSs, and not the ordinary
    shares, on the NYSE. Consequently, if you are a holder of
    ordinary shares that are not represented by ADSs, you generally
    will not be eligible to make a mark-to-market election. If you
    make an effective mark-to-market election, you will include in
    each year as ordinary income the excess of the fair market value
    of your ADSs at the end of the year over your adjusted tax basis
    in the ADSs. You will be entitled to deduct as an ordinary loss
    each year the excess of your adjusted tax basis in the ADSs over
    their fair market value at the end of the year, but only to the
    extent of the net amount previously included in income as a
    result of the mark-to-market election. If you make an effective
    mark-to-market election, any gain you recognize upon the sale or
    other disposition of ADSs will be treated as ordinary income and
    any loss will be treated as ordinary loss, but only to the
    extent of the net amount previously included in income as a
    result of the mark-to-market election.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Your adjusted tax basis in the ADSs will be increased by the
    amount of any income inclusion and decreased by the amount of
    any deductions under the mark-to-market rules. If you make a
    mark-to-market election it will be effective for the taxable
    year for which the election is made and all subsequent taxable
    years unless the ADSs are no longer regularly traded on a
    qualified exchange or the Internal Revenue Service consents to
    the revocation of the election. You are urged to consult your
    tax advisors about the availability of the mark-to-market
    election and whether making the election would be advisable in
    your particular circumstances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Alternatively, you can sometimes avoid the rules described above
    by electing to treat us as a &#147;qualified electing fund&#148;
    under Section&#160;1295 of the Code. However, this option is not
    available to you because we do not intend to comply with the
    requirements necessary to permit you to make this election. You
    are urged to consult your tax advisors concerning the United
    States federal income tax consequences of holding ADSs or
    ordinary shares if we are considered a PFIC in any taxable year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Taxation
    of Capital Gains</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For United States federal income tax purposes and subject to the
    discussion under &#147;&#160;&#151; Passive Foreign Investment
    Company&#148; above, you will recognize taxable gain or loss on
    any sale or exchange of ADSs or ordinary shares in an amount
    equal to the difference between the amount realized for the ADSs
    or ordinary shares and your tax basis in the ADSs or ordinary
    shares. Such gain or loss will generally be capital gain or
    loss. Capital gains of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    158
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    non-corporate United States Holders derived with respect to
    capital assets held for more than one year are eligible for
    reduced rates of taxation. The deductibility of capital losses
    is subject to limitations. Any gain or loss recognized by you
    will generally be treated as United States source gain or loss.
    However, in the event that we are deemed to be a PRC
    &#147;resident enterprise&#148; under PRC tax law, we may be
    eligible for the benefits of the income tax treaty between the
    United States and the PRC. Under that treaty, if any PRC tax was
    to be imposed on any gain from the disposition of the ADSs or
    ordinary shares, the gain may be treated as PRC-source income.
    You are urged to consult your tax advisors regarding the tax
    consequences if a foreign tax is imposed on gain on a
    disposition of our ADSs or ordinary shares, including the
    availability of the foreign tax credit under your particular
    circumstances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Information
    Reporting and Backup Withholding</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, information reporting will apply to dividends in
    respect of our ADSs or ordinary shares and to the proceeds from
    the sale, exchange or redemption of our ADSs or ordinary shares
    that are paid to you within the United States (and in certain
    cases, outside the United States), unless you are an exempt
    recipient such as a corporation. A backup withholding tax may
    apply to such payments if you fail to provide a taxpayer
    identification number or certification of other exempt status or
    fail to report in full dividend and interest income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any amounts withheld under the backup withholding rules will be
    allowed as a refund or a credit against your United States
    federal income tax liability provided the required information
    is furnished to the Internal Revenue Service.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    159
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='122'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">UNDERWRITING</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the terms and subject to the conditions contained in an
    underwriting agreement dated the date of this prospectus, the
    underwriters named below have severally agreed to purchase, and
    we and the selling shareholders have agreed to sell to them,
    severally, the number of ADSs indicated below:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="89%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Name</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">ADSs</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Morgan Stanley&#160;&#038; Co. International plc
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    J.P. Morgan Securities Inc.
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    China International Capital Corporation Hong Kong Securities
    Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 45pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters are collectively referred to as the
    &#147;underwriters.&#148; The underwriters are offering the ADSs
    subject to their acceptance of the ADSs from us and the selling
    shareholders and subject to prior sale. The underwriting
    agreement provides that the obligations of the several
    underwriters to pay for and accept delivery of the ADSs offered
    by this prospectus are subject to the approval of certain legal
    matters by their counsel and to certain other conditions,
    including the absence of any material adverse change in our
    business and the receipt of certain certificates, opinions and
    letters from us, our counsel and the independent accountants.
    The underwriters are obligated, severally and not jointly, to
    take and pay for all of the ADSs offered by this prospectus if
    any such ADSs are taken. The underwriters are not required,
    however, to take or pay for the ADSs covered by the
    underwriters&#146; over-allotment option described below. Morgan
    Stanley&#160;&#038; Co. International plc and China
    International Capital Corporation Hong Kong Securities Limited
    will offer the ADSs in the United States through their
    registered broker-dealers in the United States.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters initially propose to offer part of the ADSs
    directly to the public at the initial public offering price
    listed on the cover page of this prospectus and part to certain
    dealers at a price that represents a concession not in excess of
    US$&#160;&#160;  per ADS under the initial public offering
    price. After the initial offering of the ADSs, the offering
    price and other selling terms may from time to time be varied by
    the underwriters.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and the selling shareholders have granted to the underwriters
    an option, exercisable for 30&#160;days from the date of this
    prospectus, to purchase up to an aggregate
    of&#160;&#160;&#160;&#160;&#160;&#160;additional ADSs at the
    public offering price of US$&#160;&#160;  per ADS, less
    underwriting discounts and commissions. The underwriters may
    exercise this option solely for the purpose of covering
    over-allotments, if any, made in connection with the offering of
    the ADSs offered by this prospectus. To the extent the option is
    exercised, each underwriter will become obligated, subject to
    certain conditions, to purchase about the same percentage of the
    additional ADSs as the number listed next to the
    underwriter&#146;s name in the preceding table bears to the
    total number of ADSs listed in the preceding table. If the
    underwriters&#146; option is exercised in full, the total price
    to the public would be US$&#160;&#160; , the total
    underwriters&#146; discounts and commissions would be
    US$&#160;&#160;  and the total proceeds to us (before expenses)
    would be US$&#160;&#160; . We will not receive any of the
    proceeds from the sale of the ADSs by the selling shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The table below shows the per ADS and total underwriting
    discounts and commissions that we and the selling shareholders
    will pay to the underwriters. The underwriting discounts and
    commissions are determined by negotiations among us, the selling
    shareholders and the underwriters and are a percentage of the
    offering price to the public. Among the factors considered in
    determining the discounts and commissions are the size of the
    offering, the nature of the security to be offered and the
    discounts and commissions charged in comparable transactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These amounts are shown assuming both no exercise and full
    exercise of the underwriters&#146; option to purchase additional
    ADSs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="60%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="7%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="7%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Underwriting Discounts and
    Commissions</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">No Exercise</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Full Exercise</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Per ADS
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total by us
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total by the selling shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    160
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The underwriters have informed us that they do not intend sales
    to discretionary accounts to exceed five&#160;percent of the
    total number of ADSs offered by them.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The total expenses of the offering payable by us, excluding
    underwriting discounts and commissions, will be approximately
    US$&#160;&#160;&#160;&#160;&#160;&#160;million. Expenses include
    the SEC and the Financial Industry Regulatory Authority, or
    FINRA, filing fees, the NYSE listing fee, and printing, legal,
    accounting and miscellaneous expenses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have applied for approval for listing the ADSs on the NYSE
    under the symbol &#147;CCM.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have agreed that, without the prior written consent of the
    underwriters, we will not, during the period ending
    180&#160;days after the date of this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    offer, pledge, sell, contract to sell, sell any option or
    contract to purchase, purchase any option or contract to sell,
    grant any option, right or warrant to purchase, lend or
    otherwise transfer or dispose of, directly or indirectly, any
    ordinary shares or ADSs or any securities convertible into or
    exercisable or exchangeable for ordinary shares or ADSs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into any swap or other arrangement that transfers to
    another, in whole or in part, any of the economic consequences
    of ownership of the ordinary shares or ADSs;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    file any registration statement with the SEC relating to the
    offering of any ordinary shares, ADSs or any securities
    convertible into or exercisable or exchangeable for ordinary
    shares or ADSs (other than a registration statement on
    <FONT style="white-space: nowrap">Form&#160;S-8).</FONT>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    whether any such transaction described above is to be settled by
    delivery of ordinary shares, ADSs, or such other securities, in
    cash or otherwise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The restrictions described in the immediately preceding
    paragraph do not apply to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    ADSs to be sold by us to the underwriters in the offering;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transactions by the selling shareholders relating to ordinary
    shares, ADSs or other securities acquired in open market
    transactions after the completion of the offering, provided that
    no filing under Section 16(a) of the Exchange Act shall be
    required or shall be voluntarily made in connection with
    subsequent sales of ordinary shares, ADSs or other securities
    acquired in such open market transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the issuance by us of ordinary shares issuable upon the exercise
    of an option or warrant or the conversion of any outstanding
    securities, provided that such recipients shall agree in writing
    to be subject to the restrictions described above;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the grant or issuance by us of options, shares, restricted
    shares, restricted share units, share appreciation rights,
    performance units or performance shares under our equity plans
    and the shares or other securities issued upon exercise or
    conversion of any of the foregoing, provided that such
    recipients shall agree in writing to be subject to the
    restrictions described above.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each of our directors, executive officers and existing
    shareholders has agreed that, without the prior written consent
    of the underwriters, such director, officer, or shareholder will
    not, during the period ending 180&#160;days after the date of
    this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    offer, pledge, sell, contract to sell, sell any option or
    contract to purchase, purchase any option or contract to sell,
    grant any option, right or warrant to purchase, lend or
    otherwise transfer or dispose of, directly or indirectly, any
    ordinary shares or ADSs or any securities convertible into or
    exercisable or exchangeable for ordinary shares or ADSs; or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enter into any swap or other arrangement that transfers to
    another, in whole or in part, any of the economic consequences
    of ownership of the ordinary shares or ADSs.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    whether any such transaction described above is to be settled by
    delivery of ordinary shares, ADSs, or such other securities, in
    cash or otherwise.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    161
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The restrictions described in the immediately preceding
    paragraph generally do not apply to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the ordinary shares as represented by the ADSs to be sold in
    this offering;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transactions relating to ordinary shares, ADSs or other
    securities acquired in open market transactions after the
    completion of the offering, provided that no filing under
    Section&#160;16(a) of the Exchange Act will be required or will
    be voluntarily made in connection with subsequent sales of
    ordinary shares, ADSs or other securities acquired in such open
    market transactions;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the exercise of rights to acquire ordinary shares, ADSs or other
    securities of our company issued pursuant to any of our share
    option or similar equity incentive or compensation plan for the
    issuance of share options or equity grants, provided that, in
    each case, such plan is in effect as of the date of and
    disclosed in the prospectus, and that any subsequent sale,
    transfer or disposition of any securities issued upon exercise
    of such equity incentive grants should be subject to the
    restrictions described above;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers of our ordinary shares or ADSs to shareholders who are
    our existing shareholders prior to the offering or partners,
    members, stockholders or affiliates (as defined in
    <FONT style="white-space: nowrap">Rule&#160;12b-2</FONT>
    of the Exchange Act) of such existing shareholders, provided
    that each transferee should agree in writing to be subject to
    the restrictions described above, and that no filing under
    Section&#160;16(a) of the Exchange Act reporting a reduction in
    beneficial ownership of ordinary shares or ADSs will be required
    or will be voluntarily made during the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers of our ordinary shares, ADSs or any security
    convertible into our ordinary shares or ADSs (i)&#160;to an
    immediate family member or a trust formed for the benefit of an
    immediate family member, (ii)&#160;as a bona fide gift or
    (iii)&#160;through will or intestacy, provided that each
    transferee or donee should agree in writing to be subject to the
    restrictions described above, and that no filing under
    Section&#160;16(a) of the Exchange Act reporting a reduction in
    beneficial ownership of our ordinary shares or ADSs will be
    required or will be voluntarily made during the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    transfers or distributions of our ordinary shares, ADSs or any
    security convertible into our ordinary shares or ADSs to
    partners, members, stockholders or affiliates, provided that
    each transferee or distributee should agree in writing to be
    subject to the restrictions described above, and that no filing
    under Section&#160;16(a) of the Exchange Act reporting a
    reduction in beneficial ownership of our ordinary shares or ADSs
    should be required or should be voluntarily made during the
    applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the establishment of a trading plan pursuant to
    <FONT style="white-space: nowrap">Rule&#160;10b5-1</FONT>
    under the Exchange Act for the sale of our ordinary shares or
    ADSs, provided that such plan does not provide for the transfer
    of our ordinary shares or ADSs during the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The foregoing
    <FONT style="white-space: nowrap">lock-up</FONT>
    period will be extended under certain circumstances. If
    (1)&#160;during the last 17&#160;days of the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period, we issue an earnings release or material news or a
    material event relating to us occurs; or (2)&#160;prior to the
    expiration of the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period, we announce that we will release earnings results during
    the <FONT style="white-space: nowrap">16-day</FONT>
    period beginning on the last day of the applicable
    <FONT style="white-space: nowrap">lock-up</FONT>
    period, the
    <FONT style="white-space: nowrap">lock-up</FONT> will
    continue to apply until the expiration of the
    <FONT style="white-space: nowrap">18-day</FONT>
    period beginning on the issuance of the earnings release or the
    occurrence of the material news or material event unless the
    extension is waived in writing by the underwriters.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To facilitate this offering of the ADSs, the underwriters may
    engage in transactions that stabilize, maintain or otherwise
    affect the price of the ADSs. Specifically, the underwriters may
    sell more ADSs than they are obligated to purchase under the
    underwriting agreement, creating a short position. A short sale
    is covered if the short position is no greater than the number
    of ADSs available for purchase by the underwriters under the
    over- allotment option. The underwriters can close out a covered
    short sale by exercising the over-allotment option or purchasing
    ADSs in the open market. In determining the source of ADSs to
    close out a covered short sale, the underwriters will consider,
    among other things, the open market price of ADSs compared to
    the price available under the over-allotment option. The
    underwriters may also sell ADSs in excess of the over-allotment
    option, creating a naked short position. The underwriters must
    close out any naked short position by purchasing ADSs in the
    open market. A naked short position is more likely to be created
    if the underwriters are concerned that there may be downward
    pressure on the price of the ADSs in the open market after
    pricing that could adversely affect investors who purchase in
    this
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    162
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    offering. In addition, to stabilize the price of the ADSs, the
    underwriters may bid for, and purchase, ADSs in the open market.
    Finally, the underwriting syndicate may reclaim selling
    concessions allowed to an underwriter or a dealer for
    distributing the ADSs in this offering, if the syndicate
    repurchases previously distributed ADSs to cover syndicate short
    positions or to stabilize the price of the ADSs. Any of these
    activities may stabilize or maintain the market price of the
    ADSs above independent market levels. The underwriters are not
    required to engage in these activities, and may end any of these
    activities at any time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    From time to time, the underwriters may have provided, and may
    continue to provide, investment banking and other financial
    advisory services to us, our officers or our directors for which
    they have received or will receive customary fees and
    commissions. The CICC Sun Company Limited, which is a major
    shareholder of our company, is an affiliate of China
    International Capital Corporation Hong Kong Securities Limited,
    one of the underwriters for this offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We and the selling shareholders have agreed to indemnify the
    underwriters against certain liabilities, including liabilities
    under the Securities Act and liabilities incurred in connection
    with the directed share program referred to below. If we or the
    selling shareholders are unable to provide this indemnification,
    we and the selling shareholders will contribute to payments that
    the underwriters may be required to make for these liabilities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    At our request, the underwriters have reserved for sale, at the
    initial public offering price, up
    to&#160;&#160;&#160;&#160;&#160;&#160;ADSs offered by this
    prospectus to our directors, officers, employees, business
    associates and related persons. We will pay all fees and
    disbursements of counsel incurred by the underwriters in
    connection with offering the ADSs to such persons. Any sales to
    these persons will be made by Morgan Stanley&#160;&#038; Co.
    International plc through a directed share program. The number
    of ADSs available for sale to the general public will be reduced
    to the extent such persons purchase such reserved ADSs. Any
    reserved ADSs not so purchased will be offered by the
    underwriters to the general public on the same basis as the
    other ADSs offered by this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The address of Morgan Stanley&#160;&#038; Co. International plc
    is 25 Cabot Square, Canary Wharf, London E14 4QA, United
    Kingdom. The address of J.P.&#160;Morgan Securities Inc. is 383
    Madison Avenue, New York, New York 10179, United States of
    America. The address of China International Capital Corporation
    Hong Kong Securities Limited is 29th&#160;Floor, One
    International Finance Center, 1 Harbour View Street, Central,
    Hong Kong, People&#146;s Republic of China.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Electronic
    Offer, Sale and Distribution of ADSs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A prospectus in electronic format may be made available on the
    websites maintained by one or more of the underwriters. The
    underwriters may agree to allocate a number of ADSs to
    underwriters for sale to their online brokerage account holders.
    Internet distributions will be allocated by the underwriters
    that may make Internet distributions on the same basis as other
    allocations. In addition, ADSs may be sold by the underwriters
    to securities dealers who resell ADSs to online brokerage
    account holders. Other than the prospectus in electronic format,
    the information on any underwriter&#146;s or selling group
    member&#146;s website and any information contained in any other
    website maintained by any underwriter or selling group member is
    not part of the prospectus or the registration statement of
    which this prospectus forms a part, has not been approved
    <FONT style="white-space: nowrap">and/or</FONT>
    endorsed by us or any underwriter or selling group member in its
    capacity as underwriter or selling group member and should not
    be relied upon by investors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Pricing
    of the Offering</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to this offering, there has been no public market for the
    ordinary shares or ADSs. The initial public offering price is
    determined by negotiations between us and the underwriters.
    Among the factors considered in determining the initial public
    offering price are our future prospects and those of our
    industry in general, our sales, earnings, certain other
    financial and operating information in recent periods, the
    price-earnings ratios, price-sales ratios and market prices of
    securities and certain financial and operating information of
    companies engaged in activities similar to ours.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Selling
    Restrictions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No action has been taken in any jurisdiction (except in the
    United States) that would permit a public offering of the ADSs,
    or the possession, circulation or distribution of this
    prospectus or any other material relating to us or the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    163
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    ADSs in any jurisdiction where action for that purpose is
    required. Accordingly, the ADSs may not be offered or sold,
    directly or indirectly, and neither this prospectus nor any
    other offering material or advertisements in connection with the
    ADSs may be distributed or published, in or from any country or
    jurisdiction except in compliance with any applicable rules and
    regulations of any such country or jurisdiction.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>European Economic Area.</I>&#160;&#160;In relation to each
    Member State of the European Economic Area which has implemented
    the Prospectus Directive, or a Relevant Member State, from and
    including the date on which the Prospectus Directive is
    implemented in that Relevant Member State, or the Relevant
    Implementation Date, an offer of the ADSs to the public may not
    be made in that Relevant Member State prior to the publication
    of a prospectus in relation to the ADSs which has been approved
    by the competent authority in that Relevant Member State or,
    where appropriate, approved in another Relevant Member State and
    the competent authority in that Relevant Member State has been
    notified, all in accordance with the Prospectus Directive,
    except that it may, with effect from and including the Relevant
    Implementation Date, make an offer of the ADS to the public in
    that Relevant Member State at any time,
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="3%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (a)&#160;
</TD>
    <TD align="left">
    to legal entities which are authorized or regulated to operate
    in the financial markets or, if not so authorized or regulated,
    whose corporate purpose is solely to invest in securities;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (b)&#160;
</TD>
    <TD align="left">
    to any legal entity which has two or more of (1)&#160;an average
    of at least 250&#160;employees during the last financial year;
    (2)&#160;a total balance sheet of more than &#128;43,000,000 and
    (3)&#160;an annual net turnover of more than &#128;50,000,000,
    as shown in its last annual or consolidated accounts;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="3%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (c)&#160;
</TD>
    <TD align="left">
    to fewer than 100 natural or legal persons (other than qualified
    investors as defined in the Prospectus Directive;&#160;or
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (d)&#160;
</TD>
    <TD align="left">
    in any other circumstances which do not require the publication
    by the company of a prospectus pursuant to Article&#160;3 of the
    Prospectus Directive;
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    provided that no such offer of ADSs shall result in a
    requirement for the publication by the company of a prospectus
    pursuant to Article&#160;3 of the Prospectus Directive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For purposes of the above provision, the expression &#147;an
    offer of ADSs to the public&#148; in relation to any ADSs in any
    Relevant Member State means the communication in any form and by
    any means of sufficient information on the terms of the offer
    and the ADSs to be offered so as to enable an investor to decide
    to purchase or subscribe the ADSs, as the same may be varied in
    that Member State by any measure implementing the Prospectus
    Directive in that Member State, and the expression
    &#147;Prospectus Directive&#148; means Directive
    <FONT style="white-space: nowrap">2003/71/EC</FONT>
    and includes any relevant implementing measure in each Relevant
    Member State.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>United Kingdom.</I>&#160;&#160;An offer of the ADSs may not
    be made to the public in the United Kingdom within the meaning
    of Section&#160;102B of the Financial Services and Markets Act
    2000, as amended, or the FSMA, except to legal entities which
    are authorized or regulated to operate in the financial markets
    or, if not so authorized or regulated, whose corporate purpose
    is solely to invest in securities or otherwise in circumstances
    which do not require the publication by the company of a
    prospectus pursuant to the Prospectus Rules of the Financial
    Services Authority, or the FSA.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An invitation or inducement to engage in investment activity
    (within the meaning of Section&#160;21 of FSMA) may only be
    communicated to persons who have professional experience in
    matters relating to investments falling within
    Article&#160;19(5) of the Financial Services and Markets Act
    2000 (Financial Promotion) Order 2005 or in circumstances in
    which Section&#160;21 of FSMA does not apply to the company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All applicable provisions of the FSMA with respect to anything
    done by the underwriters in relation to the ADSs must be
    complied with in, from or otherwise involving the United Kingdom.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Japan.</I>&#160;&#160;The underwriters will not offer or sell
    any of our ADSs directly or indirectly in Japan or to, or for
    the benefit of any Japanese person or to others, for re-offering
    or re-sale directly or indirectly in Japan or to any Japanese
    person, except, in each case, pursuant to an exemption from the
    registration requirements of, and otherwise in compliance with,
    the Securities and Exchange Law of Japan and any other
    applicable laws and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    164
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    regulations of Japan. For purposes of this paragraph,
    &#147;Japanese person&#148; means any person resident in Japan,
    including any corporation or other entity organized under the
    laws of Japan.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Hong Kong.</I>&#160;&#160;Our ADSs may not be offered or sold
    in Hong Kong, by means of any document, other than (a)&#160;to
    &#147;professional investors&#148; as defined in the Securities
    and Futures Ordinance (Cap. 571)&#160;of Hong Kong and any rules
    made under that Ordinance or (b)&#160;in other circumstances
    which do not result in the document being a
    &#147;prospectus&#148; as defined in the Companies Ordinance
    (Cap. 32)&#160;of Hong Kong or which do not constitute an offer
    to the public within the meaning of that Ordinance. No
    advertisement, invitation or document relating to our ADSs may
    be issued, whether in Hong Kong or elsewhere, which is directed
    at, or the contents of which are likely to be read by, the
    public in Hong Kong (except if permitted to do so under the laws
    of Hong Kong) other than with respect to our ADSs which are or
    are intended to be disposed of only to persons outside Hong Kong
    or only to &#147;professional investors&#148; as defined in the
    Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong)
    or any rules made under that Ordinance. The contents of this
    prospectus have not been reviewed by any regulatory authority in
    Hong Kong. You are advised to exercise caution in relation to
    the offer. If you are in any doubt about any of the contents of
    this prospectus, you should obtain independent professional
    advice.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Singapore.</I>&#160;&#160;This prospectus has not been
    registered as a prospectus with the Monetary Authority of
    Singapore. Accordingly, this prospectus and any other document
    or material in connection with the offer or sale, or invitation
    for subscription or purchase, of the ADSs may not be circulated
    or distributed, nor may the ADSs be offered or sold, or be made
    the subject of an invitation for subscription or purchase,
    whether directly or indirectly, to persons in Singapore other
    than (i)&#160;to an institutional investor under
    Section&#160;274 of the Securities and Futures Act,
    Chapter&#160;289 of Singapore, or the SFA; (ii)&#160;to a
    relevant person, or any person pursuant to Section&#160;275(1A),
    and in accordance with the conditions, specified in
    Section&#160;275 of the SFA; or (iii)&#160;otherwise pursuant
    to, and in accordance with the conditions of, any other
    applicable provision of the SFA.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Where the ADSs are subscribed or purchased under
    Section&#160;275 by a relevant person which is:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="3%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (a)&#160;
</TD>
    <TD align="left">
    a corporation (which is not an accredited investor) the sole
    business of which is to hold investments and the entire share
    capital of which is owned by one or more individuals, each of
    whom is an accredited investor;&#160;or
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (b)&#160;
</TD>
    <TD align="left">
    a trust (where the trustee is not an accredited investor) whose
    sole purpose is to hold investments and each beneficiary is an
    accredited investor,
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    shares, debentures and units of shares and debentures of that
    corporation or the beneficiaries&#146; rights and interest in
    that trust shall not be transferable for six&#160;months after
    that corporation or that trust has acquired the ADSs under
    Section&#160;275 except:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (1)&#160;
</TD>
    <TD align="left">
    to an institutional investor (for corporations, under 274 of the
    SFA) or to a relevant person defined in Section&#160;275(2) of
    the SFA, or to any person pursuant to an offer that is made on
    terms that such shares, debentures and units of shares and
    debentures of that corporation or such rights and interest in
    that trust are acquired at a consideration of not less than
    S$200,000 (or its equivalent in a foreign currency) for each
    transaction, whether such amount is to be paid for in cash or by
    exchange of securities or other assets, and further for
    corporations, in accordance with the conditions specified in
    Section&#160;275 of the SFA;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (2)&#160;
</TD>
    <TD align="left">
    where no consideration is or will be given for the
    transfer;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (3)&#160;
</TD>
    <TD align="left">
    where the transfer is by operation of law.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Cayman Islands.</I>&#160;&#160;This prospectus does not
    constitute a public offer of the ADSs or ordinary shares,
    whether by way of sale or subscription, in the Cayman Islands.
    Each underwriter has represented and agreed that it has not
    offered or sold, and will not offer or sell, directly or
    indirectly, any ADSs or ordinary shares to any member of the
    public in the Cayman Islands.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>People&#146;s Republic of China.</I>&#160;&#160;This
    prospectus may not be circulated or distributed in the PRC and
    the ADSs may not be offered or sold, and will not offer or sell
    to any person for re-offering or resale directly or indirectly
    to any resident of the PRC except pursuant to applicable laws
    and regulations of the PRC. For the purpose of this paragraph,
    PRC does not include Taiwan and the special administrative
    regions of Hong Kong and Macau.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    165
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='123'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXPENSES
    RELATED TO THIS OFFERING</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Set forth below is an itemization of the total expenses,
    excluding underwriting discount, which are expected to be
    incurred in connection with the offer and sale of the ADSs by us
    and the selling shareholders. With the exception of the SEC
    registration fee and the Financial Industry Regulatory Authority
    Inc. filing fee, all amounts are estimates.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="84%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    SEC registration fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    5,580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    NYSE listing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Financial Industry Regulatory Authority Inc. filing fee
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Printing and engraving expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Legal fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounting fees and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Miscellaneous
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    166
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='124'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">LEGAL
    MATTERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Certain other legal matters as to the United States federal and
    New York law in connection with this offering will be passed
    upon for us by Simpson Thacher&#160;&#038; Bartlett LLP. Certain
    legal matters as to the United States federal and New York law
    in connection with this offering will be passed upon for the
    underwriters by O&#146;Melveny&#160;&#038; Myers LLP. The
    validity of the ordinary shares represented by the ADSs offered
    in this offering and certain other legal matters as to Cayman
    Islands law will be passed upon for us by Walkers. Legal matters
    as to PRC law will be passed upon for us by Jingtian&#160;&#038;
    Gongcheng Attorneys At Law and for the underwriters by
    Commerce&#160;&#038; Finance Law Offices. Simpson
    Thacher&#160;&#038; Bartlett LLP may rely upon Walkers with
    respect to matters governed by Cayman Islands law and
    Jingtian&#160;&#038; Gongcheng Attorneys At Law with respect to
    matters governed by PRC law. O&#146;Melveny&#160;&#038; Myers
    LLP may rely upon Commerce&#160;&#038; Finance Law Offices with
    respect to matters governed by PRC law.
</DIV>

<A name='125'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXPERTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The consolidated financial statements of Concord Medical
    Services Holdings Limited (successor company) at
    December&#160;31, 2007 and 2008, for the period from
    September&#160;10, 2007 to December&#160;31, 2007 and for the
    year ended December&#160;31, 2008, Our Medical Services Limited
    and its subsidiaries (predecessor company) for the period from
    January&#160;1, 2007 to October&#160;30, 2007, and China Medstar
    Limited as of December&#160;31, 2007 and July&#160;31, 2008 and
    for the year and the seven months period then ended, appearing
    in this Prospectus and Registration Statement have been audited
    by Ernst&#160;&#038; Young Hua Ming, an independent registered
    public accounting firm, as set forth in their reports thereon
    appearing elsewhere herein, and are included in reliance upon
    such reports given on the authority of such firm as experts in
    accounting and auditing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The offices of Ernst&#160;&#038; Young Hua Ming are located at
    21/F China Resources Building, No.&#160;5001 Shennan Dong Road,
    Shenzhen 518001, China.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    167
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='126'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">WHERE YOU
    CAN FIND ADDITIONAL INFORMATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have filed with the SEC a registration statement on
    <FONT style="white-space: nowrap">Form&#160;F-1,</FONT>
    including relevant exhibits and schedules under the Securities
    Act with respect to underlying ordinary shares represented by
    the ADSs, to be sold in this offering. We have also filed with
    the SEC a related registration statement on F-6 to register the
    ADSs. This prospectus, which constitutes a part of the
    registration statement, does not contain all of the information
    contained in the registration statement. You should read the
    registration statement and its exhibits and schedules for
    further information with respect to us and our ADSs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Immediately upon completion of this offering, we will become
    subject to periodic reporting and other informational
    requirements of the Exchange Act as applicable to foreign
    private issuers. Accordingly, we will be required to file
    reports, including annual reports on
    <FONT style="white-space: nowrap">Form&#160;20-F,</FONT>
    and other information with the SEC. All information filed with
    the SEC can be inspected and copied at the public reference
    facilities maintained by the SEC at 100&#160;F&#160;Street,
    N.E., Washington,&#160;D.C. 20549. You can request copies of
    these documents upon payment of a duplicating fee, by writing to
    the SEC. Please call the SEC at
    <FONT style="white-space: nowrap">1-800-SEC-0330</FONT>
    for further information on the operation of the public reference
    rooms. Additional information may also be obtained over the
    Internet at the SEC&#146;s website at www.sec.gov.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a foreign private issuer, we are exempt under the Exchange
    Act from, among other things, the rules prescribing the
    furnishing and content of proxy statements, and our executive
    officers, directors and principal shareholders are exempt from
    the reporting and short-swing profit recovery provisions
    contained in Section&#160;16 of the Exchange Act. In addition,
    we will not be required under the Exchange Act to file periodic
    reports and financial statements with the SEC as frequently or
    as promptly as U.S.&#160;companies whose securities are
    registered under the Exchange Act. However, we intend to furnish
    the depositary with our annual reports, which will include a
    review of operations and annual audited consolidated financial
    statements prepared in conformity with U.S.&#160;GAAP, and all
    notices of shareholders&#146; meeting and other reports and
    communications that are made generally available to our
    shareholders. The depositary will make such notices, reports and
    communications available to holders of ADSs and, upon our
    written request, will mail to all record holders of ADSs the
    information contained in any notice of a shareholders&#146;
    meeting received by the depositary from us.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    168
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<A name='127'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INDEX TO
    CONSOLIDATED FINANCIAL STATEMENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="91%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Page</FONT></B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <U>Audited Consolidated Financial Statements</U>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#301'>Report of Independent Registered Public
    Accounting Firm</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-2
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#302'>Consolidated Balance Sheets as of
    December&#160;31, 2007 and 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-3
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#303'>Consolidated Statement of Operations for the
    period from January&#160;1, 2007 to October&#160;30, 2007 for
    Our Medical Services Limited and its subsidiaries
    (predecessor)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#303'>Consolidated Statements of Operations for the
    period from September&#160;10, 2007 to December&#160;31, 2007
    and for the year ended December&#160;31, 2008 for Concord
    Medical Services Holdings Limited (successor)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#305'>Consolidated Statement of Cash Flows for the
    period from January&#160;1, 2007 to October&#160;30, 2007 for
    Our Medical Services Limited and its subsidiaries
    (predecessor)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-7
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#305'>Consolidated Statements of Cash Flows for the
    period from September&#160;10, 2007 to December&#160;31, 2007
    and for the year ended December&#160;31, 2008 for Concord
    Medical Services Holdings Limited (successor)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-7
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#304'>Consolidated Statement of Changes in
    Shareholders&#146; Equity for the period from January&#160;1,
    2007 to October&#160;30, 2007 for Our Medical Services Limited
    and its subsidiaries (predecessor)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-9
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#304'>Consolidated Statements of Changes in
    Shareholders&#146; Equity for the period from September&#160;10,
    2007 to December&#160;31, 2007 and for the year ended
    December&#160;31, 2008 for Concord Medical Services Holdings
    Limited (successor)</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-9
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#306'>Notes to the Consolidated Financial Statements
    for the years ended December&#160;31, 2007 and 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-10
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <U>Unaudited Condensed Consolidated Financial Statements</U>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#307'>Unaudited Condensed Consolidated Balance Sheets
    as at December 31, 2008 and September&#160;30, 2009</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-52
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#308'>Unaudited Condensed Consolidated Statements of
    Operations for the nine months ended September&#160;30, 2008 and
    2009</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-54
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#309'>Unaudited Condensed Consolidated Statements of
    Cash Flows for the nine months ended September&#160;30, 2008 and
    2009</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-56
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#310'>Unaudited Condensed Consolidated Statements of
    Changes in Shareholders&#146; Equity for the year ended
    December&#160;31, 2008 and the nine months ended
    September&#160;30, 2008 and 2009</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-58
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#311'>Notes to Unaudited Condensed Consolidated
    Financial Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-59
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='301'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">REPORT OF
    INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To the Shareholders and the Board of Directors of
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Concord Medical Services Holdings Limited (successor company)
    and Our Medical Services Limited (predecessor company):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have audited the accompanying consolidated balance sheets of
    Concord Medical Services Holdings Limited (the
    &#147;Company&#148;) and its subsidiaries (together, the
    &#147;Group&#148;) as of December&#160;31, 2007 and 2008, and
    the related consolidated statements of operations, cash flows
    and changes in shareholders&#146; equity for the period from
    September&#160;10, 2007 to December&#160;31, 2007 and for the
    year ended December&#160;31, 2008. We have also audited the
    consolidated statements of operations, cash flows, and changes
    in shareholders&#146; equity of Our Medical Services Limited and
    its subsidiaries (predecessor company) for the period from
    January&#160;1, 2007 to October&#160;30, 2007. These
    consolidated financial statements are the responsibility of the
    Company&#146;s management. Our responsibility is to express an
    opinion on these financial statements based on our audits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We conducted our audits in accordance with the standards of the
    Public Company Accounting Oversight Board (United States). Those
    standards require that we plan and perform the audit to obtain
    reasonable assurance about whether the financial statements are
    free of material misstatement. We were not engaged to perform an
    audit of the Group&#146;s internal control over financial
    reporting. Our audits included consideration of internal control
    over financial reporting as a basis for designing audit
    procedures that are appropriate in the circumstances, but not
    for the purpose of expressing an opinion on the effectiveness of
    the Group&#146;s internal control over financial reporting.
    Accordingly, we express no such opinion. An audit also includes
    examining, on a test basis, evidence supporting the amounts and
    disclosures in the financial statements, assessing the
    accounting principles used and significant estimates made by
    management, and evaluating the overall financial statement
    presentation. We believe that our audits provide a reasonable
    basis for our opinion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In our opinion, such consolidated financial statements of the
    successor company referred to above present fairly, in all
    material respects, the financial position of Concord Medical
    Services Holdings Limited and its subsidiaries as of
    December&#160;31, 2007 and 2008 and the results of their
    operations and cash flows for the period from September&#160;10,
    2007 to December&#160;31, 2007 and for the year ended
    December&#160;31, 2008 in conformity with U.S.&#160;generally
    accepted accounting principles. Further, in our opinion, the
    predecessor company&#146;s financial statements referred to
    above present fairly, in all material respects, the results of
    operations and cash flows of Our Medical Services Limited and
    its subsidiaries for the period from January&#160;1, 2007 to
    October&#160;30, 2007 in conformity with U.S.&#160;generally
    accepted accounting principles.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Ernst&#160;&#038;
    Young Hua Ming</DIV>
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shenzhen, the People&#146;s Republic of China
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    October&#160;16, 2009
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    except for Note&#160;26, as to which the date is,
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    November&#160;17, 2009
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<A name='302'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    BALANCE SHEETS</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    </A><B>(Amounts in thousands of Renminbi (&#147;RMB&#148;) and
    US dollar (&#147;US$&#148;) except for number of shares)</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro Forma as at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Note</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(unaudited)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(Note 2)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="25" align="center" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>ASSETS</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Current Assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    343,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accounts receivable (net of allowance of RMB3,808, RMB3,830
    (US$561), for 2007 and 2008, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Prepayment and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,132
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,566
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred tax assets, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,201
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,649
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total Current Assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,135
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    492,978
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72,219
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Non-current assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Property, plant and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    349,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4, 8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Acquired intangible assets, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    181,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deposits for non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9, 20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,540
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,445
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,530
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543,023
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="25">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="25" align="center" valign="bottom">
    <B>LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Current Liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Short-term bank borrowing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,047
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term bank borrowings, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,836
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,741
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accrual for purchase of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,881
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    276
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Obligations under capital leases, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,979
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Income tax payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,033
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,041
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,496
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred revenue, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Payable for acquisition of a subsidiary and business components
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,104
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Dividends payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,788
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Amounts due to related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total current liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,372
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190,533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    BALANCE SHEETS&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>(Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;) except for number of shares)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro Forma as at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Note</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(unaudited)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(Note 2)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Non-Current Liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term bank borrowings, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred revenue, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,524
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,314
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    925
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Obligations under capitalized leases, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,631
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,707
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Lease deposit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    471
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,941
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    148,145
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    283,916
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Commitments and contingencies</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;A contingently redeemable convertible preferred
    shares (par value of US$0.01 per share; Authorized&#160;&#151;
    nil and 200,000&#160;shares as at December&#160;31, 2007 and
    2008, respectively; Issued and outstanding&#160;&#151; nil and
    176,942&#160;shares as at December&#160;31, 2007 and 2008,
    respectively; pro forma nil (unaudited). As at December&#160;31,
    2008, aggregate liquidation preference and redemption amounts
    were US$54,573 and US$38,147, respectively (2007-nil))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;B contingently redeemable convertible preferred
    shares (par value of US$0.01 per share; Authorized&#160;&#151;
    nil and 300,000&#160;shares as at December&#160;31, 2007 and
    2008, respectively; Issued and outstanding&#160;&#151; nil and
    233,332&#160;shares as at December&#160;31, 2007 and 2008,
    respectively; pro forma nil (unaudited). As at December&#160;31,
    2008, aggregate liquidation preference and redemption amounts
    were US$90,583 and US$61,390, respectively (2007-nil))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Shareholders&#146; Equity:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Ordinary shares (par value of US$0.0001 per share at
    December&#160;31, 2007 and 2008; Authorized&#160;&#151;
    450,000,000&#160;shares at December&#160;31, 2007 and 2008;
    Issued and outstanding&#160;&#151; 50,000,000 and
    70,428,100&#160;shares at December&#160;31, 2007 and 2008,
    respectively, 111,455,500&#160;shares for pro forma (unaudited))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    443,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,778,581
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    260,552
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accumulated other comprehensive (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,822
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (560
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,822
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (560
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (544,363
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (79,746
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (544,363
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (79,746
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total shareholders&#146; equity</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,230,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    180,258
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total liabilities and shareholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    543,023
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<A name='303'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF OPERATIONS</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    </A><B>(Amounts in thousands of Renminbi (&#147;RMB&#148;) and
    US dollar (&#147;US$&#148;),</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>except for number of shares and per share data)</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Notes</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>October&#160;30, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Year Ended December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Predecessor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Revenues, Net of Business Tax, Value-Added Tax and Related
    Surcharges:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,716
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,422
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Cost of Revenues:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,396
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,908
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,046
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,669
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,003
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,416
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,914
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,597
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,680
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Gross profit</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Operating Expenses:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,601
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (757
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (805
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,467
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (57,171
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,764
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Operating income (loss)</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,938
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (47,859
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest expense (including related party amounts of RMB8, RMB96
    and RMB2,991 (US$438) for the period from January&#160;1 to
    October&#160;30, 2007 (predecessor), September&#160;10 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor), respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (954
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (279
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,455
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,092
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (341
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (325
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    (Loss) gain from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Other income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Income (loss) before income taxes</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Income tax (expense) benefit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,418
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Net income (loss)</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF OPERATIONS&#160;&#151;&#160;(Continued)</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>(Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;),</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>except for number of shares and per share data)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="47%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="12%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Notes</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>October&#160;30, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Year Ended December&#160;31, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(Successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Predecessor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,343
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (39,604
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (44,646
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Net income (loss) attributable to ordinary shareholders</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (496,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72,667
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Income (loss) per share</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.97
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.26
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Weighted Average Number of Ordinary Shares Outstanding:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Basic and diluted shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Pro forma loss per share</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Basic and diluted on an as converted basis (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4.87
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.71
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    <B>Weighted average number of ordinary shares outstanding used
    in computation of:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Pro forma basic and diluted on an as converted basis (unaudited)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98,508,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98,508,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    F-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<A name='305'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF CASH FLOWS</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    </A><B>(Amounts in thousands of Renminbi (&#147;RMB&#148;) and
    US dollar (&#147;US$&#148;))</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="17%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">December 31, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">December&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    CASH FLOWS FROM OPERATING ACTIVITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Adjustments to reconcile net income (loss) to net cash generated
    from operating activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    617
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Imputed interest on amounts due to related parties (note&#160;20)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    438
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Depreciation of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,906
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,629
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Amortization of acquired intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,002
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,497
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Loss (gain) on disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,555
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (658
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (96
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Deferred tax expense (benefit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,472
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,608
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,080
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (744
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    341
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    464
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    131
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Changes in operating assets and liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Increase in accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,416
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,771
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,283
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,825
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Increase (decrease) in prepayments and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,782
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,043
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,376
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Increase in deposits for non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (280
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (621
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (91
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Decrease in accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,221
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,962
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Increase (decrease) in accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,095
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,049
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,709
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,008
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Decrease in deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,666
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (244
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Decrease in lease deposit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Increase in income tax payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,605
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    962
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,265
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    771
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,593
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,774
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    CASH FLOWS FROM INVESTING ACTIVITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Payment under arrangement with Chang&#146;an Hospital
    (note&#160;25)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,821
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,050
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Acquisitions, net of cash acquired (note&#160;4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (231,481
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (33,911
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Acquisition of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (43,398
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,466
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31,575
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,625
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Deposits for the purchase of non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,031
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,573
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (95,110
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,933
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 29pt">
    Proceeds from disposal of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,977
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,598
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,616
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    383
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net cash used in investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (50,452
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (30,441
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (376,371
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (55,136
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF CASH FLOWS&#160;&#151; (Continued)</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>(Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;))</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="17%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">December 31, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">December&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    CASH FLOWS FROM FINANCING ACTIVITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Proceeds from issuance of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Proceeds from issuance of Series&#160;A contingently redeemable
    convertible preferred shares (net of paid issuance costs of
    RMB2,449)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,913
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Proceeds from issuance of Series&#160;B contingently redeemable
    convertible preferred shares (net of paid issuance costs of
    RMB5,664)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    405,331
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59,379
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Proceeds from short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,047
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Proceeds from long-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,460
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,093
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Repayment of obligations under capitalized leases
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (786
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,698
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,525
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (809
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Repayment of long-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (37,890
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,551
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Repayment of short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,500
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,150
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Proceeds from exercise of share options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Increase (decrease) in amounts due to related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,806
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (41,700
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,109
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    649,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95,147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,698
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (834
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Net increase in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    314,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cash at beginning of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cash at end of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Supplemental schedule of cash flows information:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Income tax paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (737
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,688
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,712
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (946
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (184
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,538
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (518
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Supplemental schedule of non-cash activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Acquisition of property, plant and equipment and other
    intangible assets through utilization of deposits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,961
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,601
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,413
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Acquisition of property, plant and equipment under capitalized
    lease
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Conversion of convertible notes into Series&#160;A contingently
    redeemable convertible preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,795
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='304'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#146;
    EQUITY<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="42%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Retained<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Earnings<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ordinary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ordinary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid-in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Comprehensive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Cumulative<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shareholders&#146;<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Income(loss)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Equity</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Predecessor&#160;&#151; Our Medical Services, Limited</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    RMB
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    RMB
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    RMB
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    RMB
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    RMB
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Balance as of January&#160;1, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,779
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    134,264
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Imputed interest on related parties&#146; loan (note&#160;20)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Balance as of October&#160;30, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45,787
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    107,874
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    153,702
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Successor&#160;&#151; Concord Medical Services Holdings,
    Limited</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Reorganization (note&#160;1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    347,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (107,874
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    239,733
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,179
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Imputed interest on related parties&#146; loan (note&#160;20)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Balance as of December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    443,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Imputed interest on related parties&#146; loan (note&#160;20)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Exercise of share options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,184,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Redesignation of 756,500 ordinary shares to Series&#160;A
    contingently redeemable convertible preferred shares
    (note&#160;15)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (756,500
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Recognition of beneficial conversion feature upon issuance of
    Series&#160;A contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,317
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,317
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Recognition of beneficial conversion feature upon issuance of
    Series&#160;B contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    295,019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    295,019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares (note&#160;14)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,343
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,343
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares (note&#160;14)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Balance as of December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,822
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (544,363
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Balance as of December&#160;31, 2008, in US$
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (560
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (79,746
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='306'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ORGANIZATION
    AND BASIS OF PRESENTATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying consolidated financial statements include the
    financial statements of Concord Medical Services Holdings
    Limited (the &#147;Company&#148;) and its subsidiaries,
    including Ascendium Group Limited (&#147;Ascendium&#148;), China
    Medical Services Holdings Limited (&#147;CMS Holdings&#148;),
    Our Medical Services Limited (&#147;OMS&#148;), China Medstar
    Pte Limited (&#147;China Medstar&#148;), Cyber Medical Networks
    Limited (&#147;Cyber&#148;), CMS Hospital Management Co., Ltd.
    (&#147;CHM&#148;), Shenzhen Aohua Medical Services Co., Ltd
    (&#147;AMS&#148;), Shenzhen Aohua Medical Leasing&#160;&#038;
    Services Limited (&#147;AML&#148;), Medstar (Shanghai) Leasing
    Co., Ltd. (&#147;MSC&#148;) and Beijing Xing Heng Feng Medical
    Technology Co., Ltd. (&#147;XHF&#148;). The Company and its
    subsidiaries are collectively referred to as the
    &#147;Group&#148;.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group is principally engaged in the leasing of radiotherapy
    and diagnostic imaging equipment and the provision of management
    services to hospitals located in the People&#146;s Republic of
    China (&#147;PRC&#148;). The Group develops and operates its
    business through its subsidiaries. Details of the Company&#146;s
    subsidiaries as of December&#160;31, 2008 are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="19%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="31%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Percentage of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Date of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Place of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ownership by the<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Company</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Establishment</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Establishment</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Company</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Principal Activities</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ascendium
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    September 10, 2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    BVI
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Investment Holding
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    OMS
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    August 22, 1996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    BVI
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Investment Holding
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    China Medstar
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    August 8, 2003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Singapore
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Investment Holding
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cyber
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    May 26, 2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Hong Kong
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Investment Holding
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CMS Holdings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    July 18, 2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Hong Kong
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Investment Holding
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    AMS
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    July 23, 1997
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    PRC
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Leasing of medical equipment and<BR>
    &#160;&#160;provision of management services
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    AML
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    February 21, 2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    PRC
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Leasing of medical equipment and<BR>
    &#160;&#160;provision of management services
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    MSC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    March 21, 2003
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    PRC
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Leasing and sales of medical<BR>
    equipment, provision of<BR>
    management services
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CHM
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    July 23, 2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    PRC
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Provision of management services
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    XHF
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    July 26, 2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    PRC
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Provision of management services
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to October&#160;30, 2007, OMS was owned by a group of
    individuals (the &#147;OMS Individual Shareholders&#148;)
    through two intermediate investment holding companies
    (&#147;IIHC&#148;), there was no ultimate controlling
    shareholder of OMS in accordance with EITF Issue
    <FONT style="white-space: nowrap">No.&#160;02-5,</FONT>
    &#147;Definition of &#145;Common Control&#146; in Relation to
    FASB Statement No.&#160;141&#148; (&#147;SFAS&#160;141&#148;).
    OMS together with AMS, OMS&#146; wholly owned subsidiary, were
    the predecessors of the Group and operated the business of the
    Group prior to the reorganization on October&#160;30, 2007 (the
    &#147;Reorganization&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ascendium is a limited liability company that was incorporated
    in the British Virgin Islands (the &#147;BVI&#148;) on
    September&#160;10, 2007. The Reorganization agreement provided
    that Ascendium (a shell company owned by a nominee shareholder
    prior to the Reorganization), upon completion of the
    Reorganization, be owned by a group of individuals
    (&#147;Ascendium&#146;s shareholders&#148;), who as a group are
    substantively different than the shareholders of the IIHC (IIHC
    directly owned 100% of OMS prior to October&#160;30, 2007). In
    accordance with the Reorganization agreement, Ascendium&#146;s
    shareholders acquired 100% ownership in OMS in exchange for
    issuing Ascendium shares to a portion of the IIHC shareholders.
    The agreement also provided for the settlement of certain
    unspecified obligations amongst the IIHC shareholders and IIHC.
    The majority of Ascendium&#146;s shareholdings was acquired by a
    number of indirect shareholders of OMS, however because there
    was no controlling shareholder and the differences in
    shareholders is substantive, Ascendium accounted for the
    acquisition of 100% of OMS. The aggregate
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    purchase price for the acquisition on October&#160;30, 2007 was
    determined to be RMB393,435 (US$57,636), which represents the
    fair value of the Ascendium shares issued as consideration. The
    following table presents the allocation of the purchase price to
    the estimated fair values of the assets acquired and liabilities
    assumed, which were determined by the Group with the assistance
    of American Appraisal China (&#147;American Appraisal&#148;)
    Limited, an independent valuation firm. The total purchase price
    was allocated to OMS&#146;s tangible and identifiable intangible
    assets and liabilities based on their estimated fair values as
    of October&#160;30, 2007 as set forth below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,253
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,458
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,786
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,879
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other intangible assets- customer relationships and operating
    leases
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    132,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,337
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit for property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,753
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,035
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (58,792
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,612
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,104
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Liabilities assumed
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (92,584
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,563
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total consideration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    393,435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company was incorporated under the law of the Cayman Islands
    on November&#160;27, 2007. On March&#160;7, 2008, all the then
    existing shareholders of Ascendium exchanged their respective
    shares of Ascendium for shares of the Company at a ratio of
    10&#160;shares in the Company in return for each share in
    Ascendium. As a result, Ascendium became the wholly-owned
    subsidiary of the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, the Group acquired 100% of the equity
    interest in China Medstar. On October&#160;28, 2008, the Group
    consummated 100% of the equity interest in XHF. The acquisitions
    were accounted for using the purchase method of accounting
    pursuant to Statement of Financial Accounting Standards (the
    &#147;SFAS&#148;) No.&#160;141 &#147;Business Combinations&#148;
    (&#147;SFAS&#160;141&#148;). The acquired assets and liabilities
    of China Medstar and XHF were recorded at estimated fair values
    on their respective acquisition dates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shenzhen Aohua Medical Services (&#147;AMS&#148;) was
    incorporated by OMS on July&#160;23, 1997 and OMS contributed
    RMB4.8&#160;million representing 90% equity interest in AMS.
    Since the incorporation of AMS, 10% of its equity interest was
    held by two third party nominees who acted as the custodians of
    such equity interest. The two nominees did not maintain their
    required capital contributions at any time subsequent to the
    incorporation of AMS. In December 2007, the Group entered into
    an agreement with the two nominees to obtain title of their 10%
    equity interest. The two nominees agreed to complete all legal
    procedures required to effect legal transfer of the shares to
    OMS in return for a fee of RMB 4.2&#160;million. The transfer of
    the 10% equity interest in AMS was on June&#160;10, 2009 upon
    approval by the Shenzhen Industrial and Commercial
    Administration Bureau, and the Group paid the Minority
    Shareholders the 4.2&#160;million fee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Due to the two nominees failure to complete their capital
    injection obligations as required by PRC Company Law, it is in
    the Company&#146;s view that the two nominees never possessed
    any ordinary shareholding rights, including dividend or voting
    rights. Consequently, OMS effectively controlled 100% of the
    equity of AMS prior to the legal reacquisition of shares
    subsequent to December&#160;31, 2008. As such, the Group&#146;s
    consolidated financial statements do not present a minority
    interest for the financial statement periods presented.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    OF SIGNIFICANT ACCOUNTING POLICIES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Basis
    of presentation and use of estimates</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying consolidated financial statements have been
    prepared in accordance with United States generally accepted
    accounting principles (&#147;U.S.&#160;GAAP&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The preparation of consolidated financial statements in
    conformity with U.S.&#160;GAAP requires management to make
    estimates and assumptions that affect the reported amounts of
    assets and liabilities, disclosures of contingent assets and
    liabilities at the balance sheet dates and the reported amounts
    of revenues and expenses during the reporting periods.
    Significant estimates and assumptions reflected in the
    Company&#146;s financial statements include, but are not limited
    to, purchase price allocation, revenue recognition, allowance
    for doubtful accounts, useful lives of property, plant and
    equipment and acquired intangible assets, realization of
    deferred tax assets, share-based compensation expense, and the
    valuation of the Company&#146;s acquired tangible and intangible
    assets&#160;and liabilities and ordinary shares, Series&#160;A
    and B contingently redeemable convertible preferred shares and
    convertible notes. Actual results could materially differ from
    those estimates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Predecessor financial information is presented on the
    historical basis of accounting compared to the Successor
    financial information, which reflects the fair value of the net
    assets acquired on the date of the Reorganization rather than
    their historical cost.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The financial position, results of operations, statement of cash
    flows and related disclosures for periods prior to
    October&#160;30, 2007, the effective date of the Reorganization
    are presented as those of the &#147;Predecessor&#148;. The
    financial position, results of operations, statement of cash
    flows and related disclosures subsequent to October&#160;30,
    2007 (September&#160;10, 2007&#160;&#151; December&#160;31,
    2007)&#160;are presented as those of the &#147;Successor&#148;,
    which was a shell company prior to October&#160;30, 2007. The
    consolidated financial statements of the Successor as of
    December&#160;31, 2007 and for the period from
    September&#160;10, 2007 reflect the new basis of accounting in
    accordance with SFAS&#160;141. Accordingly, the fair value of
    net assets as of October&#160;30, 2007 have been recorded in the
    financial statements for the period commencing on
    September&#160;10, 2007. The consolidated financial statements
    of the Predecessor are presented using the Company&#146;s
    historic basis of accounting. Therefore, the results of the
    Successor are not comparable to the results of the Predecessor
    due to the difference in the new basis of presentation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Principles
    of Consolidation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The consolidated financial statements of the group include the
    financial statements of the Company and its subsidiaries. All
    transactions and balances between the Company and its
    subsidiaries have been eliminated upon consolidation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Foreign
    Currency Translation and Transactions</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s PRC subsidiaries determine their functional
    currencies to be the Chinese Renminbi (&#147;RMB&#148;) based on
    the criteria of SFAS&#160;52, &#147;Foreign Currency
    Translation&#148;. The Company uses the RMB as its reporting
    currency. The Company uses the monthly average exchange rate for
    the year and the exchange rate at the balance sheet date to
    translate the operating results and financial position,
    respectively. Translation differences are recorded in
    accumulated other comprehensive income, a component of
    shareholders&#146; equity. Functional currency of the Company
    and its subsidiaries, Ascendium, CMS Holdings, OMS, Cyber and
    China Medstar, is the United States dollar (&#147;US$&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Transactions denominated in foreign currencies are remeasured
    into the functional currency at the exchange rates prevailing on
    the transaction dates. Foreign currency denominated financial
    assets and liabilities are remeasured at the exchange rates
    prevailing at the balance sheet date. Exchange gains and losses
    are included in the consolidated statements of operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Convenience
    translation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amounts in U.S.&#160;dollars (&#147;US$&#148;) are presented for
    the convenience of the reader and are translated at the noon
    buying rate of RMB6.8262 to US$1.00 on September&#160;30, 2009
    in the City of New York for cable transfers of RMB as certified
    for customs purposes by the Federal Reserve Bank of New York. No
    representation is made that the RMB amounts could have been, or
    could be, converted into US$ at such rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Cash</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cash consists of cash deposits, which are unrestricted as to
    withdrawal and use.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounts
    receivable and allowance for doubtful accounts</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group considers many factors in assessing the collectability
    of its receivables due from its customers, such as, the age of
    the amounts due, the customer&#146;s payment history and
    credit-worthiness. An allowance for doubtful accounts is
    recorded in the period in which uncollectability is determined
    to be probable. Accounts receivable balances are written off
    after all collection efforts have been exhausted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Leases</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with SFAS&#160;13 &#147;Accounting for
    Leases&#148; (&#147;SFAS&#160;13&#148;), leases for a lessee are
    classified at the inception date as either a capital lease or an
    operating lease. The Company assesses a lease to be a capital
    lease if any of the following conditions exist:
    a)&#160;ownership is transferred to the lessee by the end of the
    lease term, b)&#160;there is a bargain purchase option,
    c)&#160;the lease term is at least 75% of the property&#146;s
    estimated remaining economic life or d)&#160;the present value
    of the minimum lease payments at the beginning of the lease term
    is 90% or more of the fair value of the leased property to the
    lessor at the inception date. A capital lease is accounted for
    as if there was an acquisition of an asset and an incurrence of
    an obligation at the inception of the lease. The capitalized
    lease obligation reflects the present value of future rental
    payments, discounted at the appropriate interest rates. The cost
    of the asset is amortized over the lease term. However, if
    ownership is transferred at the end of the lease term, the cost
    of the asset is amortized as set out below under property, plant
    and equipment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Property,
    Plant and Equipment, net</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property, plant and equipment are stated at cost and are
    depreciated using the straight-line method over the estimated
    useful lives of the assets, as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="35%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="20%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Category</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Estimated useful life</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Estimated residual
    value</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Medical equipment*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Shorter of customer contract or 6-20&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Electronic and office equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5 years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5-10
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Motor vehicles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5 years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5-10
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    shorter of lease term or 5&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=468 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">*&#160;
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The cost of the asset is amortized
    over the lease term. However, if ownership is transferred at the
    end of the lease term, the cost of the asset is amortized over
    the shorter of customer contract or the useful life of the asset
    which ranges from 6-20&#160;years.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Repair and maintenance costs are charged to expense as incurred,
    whereas the cost of renewals and betterments that extends the
    useful lives of property, plant and equipment are capitalized as
    additions to the related assets. Retirements, sales and
    disposals of assets are recorded by removing the cost and
    accumulated depreciation from the asset and accumulated
    depreciation accounts with any resulting gain or loss reflected
    in the consolidated statements of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost incurred in constructing new facilities, including progress
    payment, interest and other costs relating to the construction
    are capitalized and transferred to fixed assets on completion.
    Total interest costs incurred and capitalized
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    during the period from January 1 to October&#160;30, 2007
    (predecessor), the period from September&#160;10, 2007 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor) amounted to approximately
    nil, nil and RMB2,179 (US$319), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Goodwill</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Goodwill represents the excess of the purchase price over the
    estimated fair value of net tangible and identifiable intangible
    assets acquired. The Company&#146;s goodwill and acquisition
    related intangible assets outstanding at December&#160;31, 2007
    and 2008 were related to the Company&#146;s Reorganization, and
    acquisition of China Medstar, XHF and other businesses (see
    notes&#160;1 and 4). In accordance with the provisions of
    Statement of Financial Accounting Standards (SFAS) No.&#160;142,
    <I>Goodwill and Other Intangible Assets </I>(SFAS&#160;142),
    goodwill amounts are not amortized, but rather are tested for
    impairment at least annually or more frequently if there are
    indicators of impairment present. An impairment loss must be
    measured if the sum of the expected future undiscounted cash
    flows from the use and eventual disposition of the asset is less
    than the net book value of the asset. The amount of the
    impairment loss will generally be measured as the difference
    between the net book value of the asset and their estimated fair
    value. The Company determined it has one reporting unit in which
    all goodwill was tested for impairment at each reporting period
    end resulting in no impairment charges.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Acquired
    Intangible Assets, net</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acquired intangible assets relate to customer relationships and
    operating leases that are not considered to have an indefinite
    useful life. These intangible assets are amortized on a straight
    line basis over the economic life. The customer relationship
    assets relate to the ability to sell existing and future
    versions of products to existing customers and has been
    estimated using the income method. Operating leases relate to
    favorable operating lease terms based on market conditions that
    existed on the date of acquisition and are amortized over the
    term of the leases.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Impairment
    of Long-Lived Assets and Acquired Intangibles</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group evaluates its long-lived assets or asset group
    including acquired intangibles with finite lives for impairment
    whenever events or changes in circumstances (such as a
    significant adverse change to market conditions that will impact
    the future use of the assets) indicate that the carrying amount
    of a group of long-lived assets may not be fully recoverable.
    When these events occur, the Group evaluates the impairment by
    comparing the carrying amount of the assets to future
    undiscounted cash flows expected to result from the use of the
    assets and their eventual disposition. If the sum of the
    expected undiscounted cash flows is less than the carrying
    amount of the assets, the Group recognizes an impairment loss
    based on the excess of the carrying amount of the asset group
    over its fair value, generally based upon discounted cash flows.
    No such impairment charge was recognized for any of the periods
    presented.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fair
    Value of Financial Instruments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The carrying amounts of the Group&#146;s financial instruments,
    including cash, accounts receivable, accounts payable and
    accrued expenses and other liabilities approximate fair value
    because of their short maturities. The carrying amounts of the
    Group&#146;s short-term and long-term bank borrowings bear
    interest at floating rates and therefore approximate the fair
    value of these obligations based upon management&#146;s best
    estimates of interest rates that would be available for similar
    debt obligations at December&#160;31, 2007 and 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Revenue
    Recognition</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The majority of the Group&#146;s revenues are derived directly
    from hospitals that enter into medical equipment lease and
    management service arrangements with the Company. A lease and
    management service arrangement will typically include the
    purchase and installation of diagnostic imaging
    <FONT style="white-space: nowrap">and/or</FONT>
    radiation oncology system (&#147;medical equipment&#148;) at the
    hospital, and the full-time deployment of a qualified system
    technician that is responsible for certain management services
    related to the radiotherapy or diagnostic services being
    performed the hospital centers&#146;
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    doctors to their patients. To a lesser extent, revenues are
    generated from stand-alone management service arrangements where
    a hospital has previously acquired the equipment from the
    Company or through another vendor or sale of medical equipment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenues arising from sales of medical equipment and services
    are recognized when there is persuasive evidence of an
    arrangement, the fee is fixed or determinable, collectability is
    reasonably assured and the delivery of the medical equipment or
    services has occurred. When the fees associated with an
    arrangement containing extended payment terms are not considered
    to be fixed or determinable at the outset of arrangement,
    revenue is recognized as payments become due, and all of the
    other criteria above have been met.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group is subject to approximately 5% business tax and
    related surcharges on the revenue earned from provision of
    leasing and management services. The Group has recognized
    revenues net of these business taxes and other surcharges. Such
    business tax and related surcharges for the period from
    January&#160;1, 2007 to October&#160;30, 2007 (predecessor),
    September&#160;10, 2007 to December&#160;31, 2007 (successor)
    and the year ended December&#160;31, 2008 (successor) are
    approximately RMB428, RMB208 and RMB4,500 (US$659),
    respectively. In the event that revenue recognition is deferred
    to a later period, the related business tax and other surcharges
    and fees are also deferred and will be recognized only upon
    recognition of the deferred revenue.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Lease and
    management services</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group enters into both leases and management service
    arrangements with independent hospitals consisting of terms that
    range from 6 to 20&#160;years. Pursuant to these arrangements,
    the Group receives a percentage of the net profit (&#147;profit
    share&#148; as defined in the arrangement) of the hospital unit
    that delivers the diagnostic imaging
    <FONT style="white-space: nowrap">and/or</FONT>
    radiation oncology services determined in accordance with the
    terms of the arrangement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to
    <FONT style="white-space: nowrap">EITF&#160;01-8,</FONT>
    &#147;Determining Whether an Arrangement Contains a Lease&#148;
    <FONT style="white-space: nowrap">(&#147;EITF&#160;01-8&#148;)</FONT>
    the Group determined that the Lease and management service
    arrangements contain a lease of medical equipment. The hospital
    has the ability and right to operate the medical equipment while
    obtaining more than a minor amount of the output. The
    arrangement also contains a non-lease deliverable being the
    management service element. The arrangement consideration should
    be allocated between the lease element and the non-lease
    deliverables on a relative fair value basis, however because all
    of the consideration is earned through the contingent rent
    feature discussed below, there is no impact of such allocation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    SFAS&#160;13, &#147;Accounting for Leases&#148;
    (&#147;SFAS&#160;13&#148;) is applied to the lease elements of
    the arrangement and U.S.&#160;Securities and Exchange Commission
    (&#147;SEC&#148;) Staff Accounting Bulletin&#160;No.&#160;104
    (&#147;SAB&#160;104&#148;) is applied to other elements of the
    arrangement not within the scope of SFAS&#160;13.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The lease rentals and management service receivable under the
    lease arrangement are based entirely on a profit share formula
    (&#147;contingent rent feature&#148;). The profitability of the
    business unit is not only dependent on the medical equipment
    placed at the hospital, but also the hospital&#146;s ability to
    manage the costs and appoint doctors and clinical staff to
    operate the equipment. Certain of the lease and management
    service arrangements may include a transfer of ownership or
    bargain purchase option at the end of the lease term. Due to the
    length of the lease term, the collectability of these minimum
    lease payments are not considered reasonably predictable and
    there are also important uncertainties regarding the future
    costs to be incurred by the Group relating to the arrangement.
    Given these uncertainties, the Group accounts for all of these
    lease arrangements as operating leases.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As the collectability of the minimum lease rental is not
    considered predictable, and the remaining rental is considered
    contingent, the Group recognizes revenue when a lease payment
    under the arrangement become fixed, i.e. when the profit share
    under the arrangement is determined and agreed upon by both
    parties to the agreement. Similarly, for the service element of
    the arrangement, revenue is only considered determinable at the
    time a payment under the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    arrangement becomes fixed, i.e. when the profit share under the
    arrangement is determined and agreed upon by both parties.
    Revenue is recognized when it is determined that the basic
    criteria, referred to above, have also been met.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Management
    Services</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group provides stand-alone management services to certain
    hospitals which are already in possession of radiotherapy and
    diagnostic equipment. The fee for the management service
    arrangement is either based on a contracted percentage of
    monthly revenue generated by the specified hospital unit
    (&#147;revenue share&#148;) or in limited instances on a fixed
    monthly fee. The consideration that is based on a contracted
    percentage of revenue is recognized when the monthly fees under
    the arrangement become due, i.e. when the revenue share under
    the arrangement is determined and agreed upon by both parties to
    the agreement. Fixed monthly fees are recognized ratably over
    the service term.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Medical
    equipment sales</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the application of Emerging Issues Task Force
    Consensus
    <FONT style="white-space: nowrap">99-19,</FONT>
    &#147;Reporting Revenue Gross as Principal versus Net as an
    Agent&#148;
    <FONT style="white-space: nowrap">(&#147;EITF&#160;99-19&#148;),</FONT>
    the Group records revenue related to medical equipment sales on
    a net basis when the equipment is delivered to the customer and
    the sales price is determinable. During the periods from January
    1 to October&#160;30, 2007 (predecessor), September 10 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor), the Company had medical
    equipment sales, of nil, nil and RMB 1,725, net of 17%
    value-added tax of approximately nil, nil and RMB863 (US$126)
    taxes, respectively. Revenue derived from medical equipment
    sales is recorded under &#147;Other&#148; in the consolidated
    statements of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cost
    relating to lease and management service arrangement</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The cost of medical equipment that is leased under an operating
    lease is included in property, plant and equipment in the
    balance sheet. The medical equipment is depreciated using the
    Group&#146;s depreciation policy. The costs of the management
    service component is recognized as an expense as incurred.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cost of
    management services</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Costs of management services mainly include the labor costs of
    technicians and management staff.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cost of
    equipment sales</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost of equipment sales, recorded net against the related
    revenue, include the cost of the equipment purchased and other
    direct costs involved in the equipment sales.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Income
    Taxes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group follows the liability method of accounting for income
    taxes. Under this method, deferred tax assets and liabilities
    are determined based on the difference between the financial
    reporting and tax bases of assets and liabilities using enacted
    tax rates that will be in effect in the period in which the
    differences are expected to reverse. The Group records a
    valuation allowance to offset deferred tax assets if based on
    the weight of available evidence, it is more-likely-than-not
    that some portion, or all, of the deferred tax assets will not
    be realized. The effect on deferred taxes of a change in tax
    rate is recognized in tax expense in the period that includes
    the enactment date of the change in tax rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;1, 2007, the Group adopted FASB Interpretation
    No.&#160;48, &#147;Accounting for Uncertainty in Income
    Taxes&#160;&#151; an interpretation of FASB Statement
    No.&#160;109&#148; (&#147;FIN&#160;48&#148;), which clarifies
    the accounting and disclosure for uncertainty in income taxes.
    Interest and penalties arising from underpayment of income taxes
    shall be computed in accordance with the related PRC tax law.
    The amount of interest expense is computed by applying the
    applicable statutory rate of interest to the difference between
    the tax position recognized and the amount previously taken or
    expected to be taken in a tax return. Interest and penalties
    recognized in accordance with FIN&#160;48 is classified in the
    financial statements as income tax expense.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with the provisions of FIN&#160;48, the Group
    recognizes in its financial statements the impact of a tax
    position if a tax return position or future tax position is
    &#147;more likely than not&#148; to prevail based on the facts
    and technical merits of the position. Tax positions that meet
    the &#147;more likely than not&#148; recognition threshold are
    measured at the largest amount of tax benefit that has a greater
    than fifty percent likelihood of being realized upon settlement.
    The Group&#146;s estimated liability for unrecognized tax
    benefits which is included in the &#147;accrued expenses and
    other liabilities&#148; account is periodically assessed for
    adequacy and may be affected by changing interpretations of
    laws, rulings by tax authorities, changes
    <FONT style="white-space: nowrap">and/or</FONT>
    developments with respect to tax audits, and expiration of the
    statute of limitations. The outcome for a particular audit
    cannot be determined with certainty prior to the conclusion of
    the audit and, in some cases, appeal or litigation process. The
    actual benefits ultimately realized may differ from the
    Group&#146;s estimates. As each audit is concluded, adjustments,
    if any, are recorded in the Group&#146;s financial statements.
    Additionally, in future periods, changes in facts,
    circumstances, and new information may require the Group to
    adjust the recognition and measurement estimates with regard to
    individual tax positions. Changes in recognition and measurement
    estimates are recognized in the period in which the changes
    occur.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Share-based
    compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group&#146;s employees participate in the Company&#146;s
    share-based scheme which is more fully discussed in
    note&#160;19. Share-based awards granted to employees are
    accounted for under SFAS&#160;No.&#160;123(R) &#147;Share-Based
    Payment&#148; (&#147;SFAS&#160;123(R)&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with SFAS&#160;123(R), all grants of share-based
    awards to employees are recognized in the financial statements
    based on their grant date fair values which are calculated using
    an option pricing model. The Group has elected to recognize
    compensation expense using the straight-line method for all
    share options granted with graded vesting based on service
    conditions. For share-based awards whose vesting is contingent
    on performance conditions, their fair value is estimated on the
    date of grant using an option pricing model. To the extent the
    required vesting conditions are not met resulting in the
    forfeiture of the share-based awards, previously recognized
    compensation expense relating to those awards are reversed.
    SFAS&#160;123(R) requires forfeitures to be estimated at the
    time of grant and revised, if necessary, in subsequent period if
    actual forfeitures differ from initial estimates. Share-based
    compensation expense was recorded net of estimated forfeitures
    such that expense was recorded only for those share-based awards
    that are expected to vest.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Income
    (loss) per Share</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Income (loss) per share is computed in accordance with
    SFAS&#160;No.&#160;128, &#147;Earnings per Share&#148;. Basic
    income (loss) per ordinary share is computed by dividing income
    (loss) attributable to holders of ordinary shares by the
    weighted average number of ordinary shares outstanding during
    the period. Diluted income (loss) per ordinary share reflects
    the potential dilution that could occur if securities or other
    contracts to issue ordinary shares were exercised or converted
    into ordinary shares. Ordinary shares issuable upon the
    conversion of the contingently redeemable convertible preferred
    shares are included in the computation of diluted income (loss)
    per ordinary share on an &#147;if-converted&#148; basis when the
    impact is dilutive. The dilutive effect of outstanding
    share-based awards is reflected in the diluted income (loss) per
    share by application of the treasury stock method.
    Two-Class&#160;Method prescribed under
    <FONT style="white-space: nowrap">EITF&#160;03-6,</FONT>
    Participating Securities and the Two-Class&#160;Method under
    FASB Statement No.&#160;128, is used to calculate income (loss)
    per share data for preferred shares that are participating
    securities in the event the Group has reportable net income.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Unaudited
    Pro Forma Shareholders&#146; Equity</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If an initial public offering is completed, all of the
    Series&#160;A and Series B contingently redeemable convertible
    preferred shares outstanding will automatically convert into
    ordinary shares and all accrued but unpaid 5% fixed dividend
    attributable to preferred share holders will be paid
    immediately. Unaudited pro forma shareholders&#146; equity as of
    December&#160;31, 2008, as adjusted for the assumed conversion
    of the contingently redeemable convertible preferred shares and
    payment of the accrued but unpaid fixed dividend attributable to
    preferred shareholders, is set forth on the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    consolidated balance sheets. Unaudited pro forma income (loss)
    per share for year ended December&#160;31, 2008, as adjusted for
    the assumed conversion of the contingently redeemable
    convertible preferred shares as of January&#160;1, 2008, is set
    forth on the consolidated statements of operations (see
    note&#160;24).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Comprehensive
    Income</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Comprehensive income is defined to include all changes in equity
    except those resulting from investments by owners and
    distributions to owners. Among other disclosures,
    SFAS&#160;No.&#160;130 &#147;Reporting Comprehensive
    Income&#148; requires that all items that are required to be
    recognized under current accounting standards as components of
    comprehensive income be reported in a financial statement that
    is displayed with the same prominence as other financial
    statements. During the periods presented, the Group&#146;s
    comprehensive income includes net income and foreign currency
    translation adjustments and is presented in the statement of
    changes in shareholders&#146; equity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;4, 2007 the FASB issued SFAS&#160;No.&#160;141
    (Revised 2007), &#147;Business Combinations&#148;
    (SFAS&#160;141(R)). This Statement will apply to all
    transactions in which an entity obtains control of one or more
    other businesses. In general, SFAS&#160;No.&#160;141(R) requires
    the acquiring entity in a business combination to recognize the
    fair value of all the assets acquired and liabilities assumed in
    the transaction; establishes the acquisition date as the fair
    value measurement point; and modifies the disclosure
    requirements. Additionally, it changes the accounting treatment
    for transaction costs, acquired contingent arrangements,
    in-process research and development, restructuring costs,
    changes in deferred tax asset valuation allowances as a result
    of business combination, and changes in income tax uncertainties
    after the acquisition date. SFAS&#160;141(R) applies
    prospectively to business combinations for which the acquisition
    date is on or after the beginning of the first annual reporting
    period beginning on or after December&#160;15, 2008. Earlier
    adoption is prohibited. However, accounting for changes in
    valuation allowances for acquired deferred tax assets and the
    resolution of uncertain tax positions for prior business
    combinations will impact tax expense instead of impacting
    goodwill. The Group is currently assessing the impact, if any,
    that the adoption of SFAS&#160;141(R) will have on its
    consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;4, 2007 the FASB issued SFAS&#160;No.&#160;160,
    &#147;Non-controlling Interests in Consolidated Financial
    Statements&#160;&#151; An Amendment of ARB No. 51&#148;
    (&#147;SFAS&#160;160&#148;). SFAS&#160;160 establishes new
    accounting and reporting standards for the non-controlling
    interest in a subsidiary and for the deconsolidation of a
    subsidiary. Specifically, this statement requires the
    recognition of a non-controlling interest (minority interest) as
    equity in the consolidated financial statements and separate
    from the parent&#146;s equity. The amount of net income
    attributable to the non-controlling interest will be included in
    consolidated net income on the face of the statement of
    operations. SFAS&#160;160 clarifies that changes in a
    parent&#146;s ownership interest in a subsidiary that do not
    result in deconsolidation are equity transactions if the parent
    retains its controlling financial interest. In addition, this
    statement requires that a parent recognize a gain or loss in net
    income when a subsidiary is deconsolidated. Such gain or loss
    will be measured using the fair value of the non-controlling
    equity investment on the deconsolidation date. SFAS&#160;160
    also includes expanded disclosure requirements regarding the
    interests of the parent and its non-controlling interest.
    SFAS&#160;160 is effective for fiscal years, and interim periods
    within those fiscal years, beginning on or after
    December&#160;15, 2008 and will be applied prospectively with
    the exception of the presentation and disclosure requirements,
    which must be applied retrospectively for all periods presented.
    Earlier adoption is prohibited. The Company is currently
    assessing the impact, if any, the adoption of SFAS&#160;160 will
    have on its consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2008, the FASB issued SFAS&#160;No.&#160;161,
    &#147;Disclosures About Derivative Instruments and Hedging
    Activities&#148;, an amendment of FASB Statement No.&#160;133
    (&#147;SFAS&#160;161&#148;). SFAS&#160;161 requires enhanced
    disclosures to help investors better understand the effect of an
    entity&#146;s derivative instruments and related hedging
    activities on its financial position, financial performance, and
    cash flows. SFAS&#160;161 is effective for financial statements
    issued for fiscal years
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    and interim periods beginning after November&#160;15, 2008, with
    early application encouraged. The Group is currently assessing
    the impact, if any, that the adoption of SFAS&#160;No.&#160;161
    will have on its consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2008, the FASB issued FASB Staff Position
    <FONT style="white-space: nowrap">No.&#160;FAS&#160;142-3,</FONT>
    Determination of the Useful Life of Intangible Assets (&#147;FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3&#148;).</FONT>
    FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3</FONT>
    amends the factors that should be considered in developing
    renewal or extension assumptions used to determine the useful
    life of a recognized intangible asset under FASB Statement
    No.&#160;142, &#147;Goodwill and Other Intangible Assets,&#148;
    and requires enhanced disclosures relating to: (a)&#160;the
    entity&#146;s accounting policy on the treatment of costs
    incurred to renew or extend the term of a recognized intangible
    asset; (b)&#160;in the period of acquisition or renewal, the
    weighted-average period prior to the next renewal or extension
    (both explicit and implicit), by major intangible asset class;
    and (c)&#160;for an entity that capitalizes renewal or extension
    costs, the total amount of costs incurred in the period to renew
    or extend the term of a recognized intangible asset for each
    period for which a statement of financial position is presented,
    by major intangible asset class. FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3</FONT>
    must be applied prospectively to all intangible assets acquired
    as of and subsequent to fiscal years beginning after
    December&#160;15, 2008, and interim periods within those fiscal
    years. Early adoption is prohibited. The Group is currently
    evaluating the impact that FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3</FONT>
    will have on the consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2009, the FASB issued SFAS&#160;No.&#160;168, &#147;The
    FASB Accounting Standards
    Codification<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    and the Hierarchy of Generally Accepted Accounting
    Principles&#160;&#151; a replacement of FASB Statement
    No.&#160;162.&#148; The FASB Accounting Standards
    Codification<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    (Codification) will become the source of authoritative United
    States GAAP recognized by the FASB to be applied by
    nongovernmental entities. This Statement and the Codification
    will not change GAAP. This Statement is effective for interim
    and annual periods ending after September&#160;15, 2009. The
    Codification will not change GAAP and therefore should not
    impact the Group&#146;s consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2009, the FASB issued Staff Position
    <FONT style="white-space: nowrap">No.&#160;FAS&#160;157-4,</FONT>
    Determining Fair Value When the Volume and Level of Activity for
    the Asset or Liability Have Significantly Decreased and
    Identifying Transactions That Are Not Orderly (&#147;FSP
    <FONT style="white-space: nowrap">FAS&#160;157-4&#148;).</FONT>
    FSP
    <FONT style="white-space: nowrap">FAS&#160;157-4</FONT>
    relates to determining fair values when there is no active
    market or where the price inputs being used represent distressed
    sales. It reaffirms what SFAS&#160;No.&#160;157&#160;states is
    the objective of fair value measurement&#160;&#151; to reflect
    how much an asset would be sold for in an orderly transaction
    (as opposed to a distressed or forced transaction) at the date
    of the financial statements under current market conditions.
    Specifically, it reaffirms the need to use judgment to ascertain
    if a formerly active market has become inactive and in
    determining fair values when markets have become inactive. This
    guidance is effective for interim and annual periods ending
    after June&#160;15, 2009, but entities may early adopt this
    guidance for the interim and annual periods ending after
    March&#160;15, 2009. The Group is currently evaluating the
    impact that FSP
    <FONT style="white-space: nowrap">FAS&#160;157-4</FONT>
    will have on the consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In May 2009, the FASB issued SFAS&#160;No.&#160;165
    &#147;Subsequent Events&#148; (&#147;SFAS 165&#148;).
    SFAS&#160;165 names the two types of subsequent events either as
    recognized subsequent events or non-recognized subsequent events
    and modifies the definition of subsequent events as events or
    transactions that occur after the balance sheet date, but before
    the financial statements are issued. The statement also requires
    entities to disclose the date through which an entity has
    evaluated subsequent events and the basis for that date.
    SFAS&#160;165 is effective on a prospective basis for interim or
    annual financial periods ending after June&#160;15, 2009. The
    Company does not believe that the application of SFAS&#160;165
    will have a material impact on the Company&#146;s consolidated
    financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">3.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">CONCENTRATION
    OF RISKS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concentration
    of credit risk</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Assets that potentially subject the Group to significant
    concentration of credit risk primarily consist of cash and
    accounts receivable. As of December&#160;31, 2008, substantially
    all of the Group&#146;s cash was deposited in financial
    institutions located in the PRC and in Hong Kong, which
    management believes are of high credit quality. Accounts
    receivable are typically unsecured and are derived from revenue
    earned from hospitals in the PRC. The risk with respect to
    accounts receivable is mitigated by credit evaluations the Group
    performs on its customers and its ongoing
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    monitoring of outstanding balances. As of December&#160;31, 2007
    and 2008, the Company had deposits with and receivables due from
    one of its customers (see note&#160;9).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concentration
    of customers</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group currently generates a substantial portion of its
    revenue from a limited number of customers. As a percentage of
    revenues, the top five customers accounted for 62% for the
    period from January&#160;1, 2007 to October&#160;30, 2007
    (predecessor), 65% for the period from September&#160;10, 2007
    to December&#160;31, 2007 (successor) and 38% for the year ended
    December&#160;31, 2008 (successor). The loss of revenue from any
    of these customers would have a significant negative impact on
    the Group&#146;s business. However, arrangements with customers
    are mostly long-term in nature. Due to the Group&#146;s
    dependence on a limited number of customers and the contingent
    fees received based on variables the Group does not control, any
    negative events with respect to the Group&#146;s customers may
    cause material fluctuations or declines in the Group&#146;
    revenue and have a material adverse effect on the Group&#146;s
    financial condition and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concentration
    of suppliers</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A significant portion of the Group&#146;s medical equipment are
    sourced from its three largest suppliers who collectively
    accounted for 100% of the total medical equipment purchases of
    the Group for the period from January&#160;1, 2007 to
    October&#160;30, 2007 (predecessor), 100%&#160;for the period
    from September&#160;10, 2007 to December&#160;31, 2007
    (successor) and 96% of the total medical equipment purchases of
    the Group for the year ended December&#160;31, 2008 (successor).
    Failure to develop or maintain the relationships with these
    suppliers may cause the Group to identify other suppliers in
    order to expand its business with new hospitals. Any disruption
    in the supply of the medical equipment to the Group may
    adversely affect the Group&#146;s business, financial condition
    and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Current
    vulnerability due to certain other concentrations</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group&#146;s operations may be adversely affected by
    significant political, economic and social uncertainties in the
    PRC. Although the PRC government has been pursuing economic
    reform policies for more than 20&#160;years, no assurance can be
    given that the PRC government will continue to pursue such
    policies or that such policies may not be significantly altered,
    especially in the event of a change in leadership, social or
    political disruption or unforeseen circumstances affecting the
    PRC&#146;s political, economic and social conditions. There is
    also no guarantee that the PRC government&#146;s pursuit of
    economic reforms will be consistent or effective.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group transacts all of its business in RMB, which is not
    freely convertible into foreign currencies. On January&#160;1,
    1994, the PRC government abolished the dual rate system and
    introduced a single rate of exchange as quoted daily by the
    People&#146;s Bank of China (the &#147;PBOC&#148;). However, the
    unification of the exchange rates does not imply that the RMB
    may be readily convertible into United States dollars or other
    foreign currencies. All foreign exchange transactions continue
    to take place either through the PBOC or other banks authorized
    to buy and sell foreign currencies at the exchange rates quoted
    by the PBOC. Approval of foreign currency payments by the PBOC
    or other institutions requires submitting a payment application
    form together with suppliers&#146; invoices, shipping documents
    and signed contracts.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additionally, the value of the RMB is subject to changes in
    central government policies and international economic and
    political developments affecting supply and demand in the PRC
    foreign exchange trading system market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A medical-related business is subject to significant
    restrictions under current PRC laws and regulations. Currently,
    the Group conducts its operations in China through contractual
    arrangements entered into with hospitals in the PRC. The
    relevant regulatory authorities may find the current contractual
    arrangements and businesses to be in violation of any existing
    or future PRC laws or regulations. If so, the relevant
    regulatory authorities would have broad discretion in dealing
    with such violations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">4.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ACQUISITIONS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Acquisition
    of China Medstar</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China Medstar was a publicly listed company on the Alternative
    Investment Market (the &#147;AIM&#148;) of the London Stock
    Exchange in the United Kingdom. Consistent with the
    Company&#146;s business, MSC, the wholly-owned subsidiary of
    China Medstar, was also principally engaged in leasing of
    medical equipment to hospitals and provision of management
    services in the PRC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In July 2008, the Group acquired China Medstar for cash
    consideration of &#163;17.1&#160;million, (US$34,975) or
    62&#160;pence per share in exchange for 100% of Medstar&#146;s
    issued and outstanding share capital. On July&#160;31, 2008, the
    Company completed the acquisition of China Medstar at which
    China Medstar became a 100% owned subsidiary of the Group. The
    acquisition of China Medstar was designed to complement the
    Group&#146;s existing network of treatment and diagnostic lease
    and management service arrangements. The results of China
    Medstar&#146;s operations have been included in the
    Company&#146;s consolidated financial statements commencing
    August&#160;1, 2008, the acquisition date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The purchase price allocation for the acquisition is primarily
    based on valuations determined by the Group with the assistance
    of American Appraisal. The consideration paid by the Company was
    more than the fair value of the net identifiable assets which
    led to the realization of goodwill. The purchase price was
    allocated to net assets acquired at fair value as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="82%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,210
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,107
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term receivables
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,397
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,377
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    217,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,931
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other intangible assets- customer relationships and operating
    lease
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,380
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit for property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,505
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,089
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,529
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,835
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Liabilities assumed
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (233,323
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34,180
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total consideration paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    238,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company, with the assistance of American Appraisal,
    determined the fair value of the acquired customer relationships
    and operating lease agreements (acquired intangibles) to be
    approximately RMB52,380 (US$7,673). The Company amortizes
    acquisition related intangible assets on a straight line basis
    over the economic life.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following unaudited pro forma consolidated financial
    information reflects the Group&#146;s consolidated results of
    operations for the period from September&#160;10, 2007 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor) as if the acquisition of
    China Medstar had occurred September&#160;10, 2007 and
    January&#160;1, 2008, respectively. These unaudited pro forma
    results have been prepared for information purposes only and do
    not purport to be indicative of what the Company&#146;s
    consolidated results of operations would have been had the
    acquisition of China Medstar actually taken place on
    September&#160;10, 2007 and January&#160;1, 2008, respectively,
    and may not be indicative of future results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenues, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,392
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    234,662
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,377
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net (loss) income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,638
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,620
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss attributable to ordinary shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,610
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (603,628
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (88,428
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per common share&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.91
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10.50
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Acquisition
    of XHF</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    XHF was established in Beijing, the PRC on July&#160;27, 2007 as
    a limited liability company. The registered and paid-in capital
    of XHF amounted to RMB10,000 (US$1,465). Similarly, XHF is
    principally engaged in the provision of leasing of medical
    equipment and management services. On October&#160;28, 2008, the
    Group consummated 100% of the equity interest of XHF for cash
    consideration of approximately RMB34,979 (US$5,124). As at
    December&#160;31, 2008, RMB18,016 (US$2,639) was recorded in
    &#147;Payable for acquisition of a subsidiary and business
    components&#148; which was paid in first half of 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company, with the assistance of American Appraisal,
    determined the fair value of the acquired customer relationships
    to be approximately RMB18,000 (US$2,637). The Company amortizes
    acquisition related intangible assets on a straight basis over
    the economic life.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unaudited pro forma consolidated financial information has not
    been provided due to the overall insignificance of the
    acquisition relative to the Company&#146;s results of operations
    and financial condition for the year ended December&#160;31,
    2008. The results of XHF&#146;s operations have been included in
    the Company&#146;s consolidated financial statements since
    October&#160;28, 2008, the acquisition date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The purchase price allocation for the acquisition is primarily
    based on valuations determined by the Group with the assistance
    of American Appraisal. The purchase price was allocated to net
    assets acquired at estimated fair value as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="84%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,906
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,598
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,680
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,239
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other intangible assets&#160;&#151; customer contracts and
    customer relationships
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Liabilities assumed
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,895
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,207
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total cash consideration
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,979
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,124
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Other
    acquisitions</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In order to expand the Group&#146;s network in cancer
    radiotherapy and diagnosis, on March&#160;31, 2008, the Group
    acquired certain medical equipment located in Tianjin People
    Liberation Army 272 Hospital and the related business
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    F-22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    from a third party for cash consideration of RMB14,000
    (US$2,051). As at December&#160;31, 2008, the Company had RMB
    10,000 (US$1,465) recorded in &#147;Payable for acquisition of a
    subsidiary and business components&#148; relating to these
    acquisitions. On August&#160;31, 2008, the Group acquired
    certain medical equipment located in People Liberation Army 254
    Hospital and the related business from another third party for
    cash consideration of RMB3,980 (US$583). These acquired assets
    and activities were considered to constitute businesses in
    accordance with
    <FONT style="white-space: nowrap">EITF&#160;98-3</FONT>
    &#147;Determining Whether a Nonmonetary Transaction Involves
    Receipt of Productive Assets or of a Business&#148;.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company, with the assistance of American Appraisal,
    determined the estimated fair value of the goodwill and
    intangible assets to be approximately RMB8,766 (US$1,284) and
    RMB1,957 (US$287), respectively. The Company amortizes
    acquisition related intangible assets based on the benefits
    expected to be realized, considering the related cash flows over
    the life of each relationship, up to a period of 12&#160;years.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">5.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ACCOUNTS
    RECEIVABLE</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,818
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96,602
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,152
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Allowance for doubtful accounts
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,808
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,830
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (561
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounts receivable, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Movement in allowance for doubtful accounts:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance at beginning of the period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,528
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,808
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Provisions
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,280
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance at end of the period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,808
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,830
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    561
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">6.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">PREPAYMENT
    AND OTHER CURRENT ASSETS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prepayment and other current assets consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposits to a hospital*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,197
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Prepayments to suppliers**
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,953
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,458
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Advance to the hospitals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,217
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,568
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred cost
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,005
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,026
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Others
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,915
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,040
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,325
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,132
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,566
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=468 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">*&#160;
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amount represents an
    interest-free cash deposit paid to a customer hospital pursuant
    to the management service contract to which the deposit is
    repayable at the termination of the service contract (see
    note&#160;25.)
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">**
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amount represents interest-free
    non-refundable partial payments to suppliers associated with
    contracts the Group enters into for the future scheduled
    delivery of medical equipment for sales. The remaining
    contractual obligations associated with these purchase contracts
    are approximately RMB4,200 (US$615) which is included in the
    amount disclosed as Purchase Commitments at note&#160;22. The
    risk of loss arising from non-performance by or bankruptcy of
    the suppliers is assessed prior to ordering the equipment. To
    date, the Group has not experienced any loss on advances to
    suppliers.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">7.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">PROPERTY,
    PLANT AND EQUIPMENT, NET</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property, plant and equipment consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Medical equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    299,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,816
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Electronic and office equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,186
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    278
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Motor vehicles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvement and building improvement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    113
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    173
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Construction in progress
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,702
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    367,384
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,819
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: Accumulated depreciation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (999
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,263
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,675
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    349,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Depreciation expenses were approximately RMB17,906, RMB1,084 and
    RMB17,629 (US$2,583) for the period from January&#160;1, 2007 to
    October&#160;30, 2007 (predecessor), September&#160;10, 2007 to
    December&#160;31, 2007 (successor) and for the year ended
    December&#160;31, 2008 (successor), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As at December&#160;31, 2008, certain of the Group&#146;s
    property, plant and equipment with a net book value of
    approximately RMB81,595 (US$11,953) (2007: Nil) were pledged as
    security for bank borrowings of RMB112,760 (US$16,519) (2007:
    Nil).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As at December&#160;31, 2008, the Company held equipment under
    operating lease contracts with customers with an original cost
    of RMB299,100 (US$43,816) and accumulated depreciation of
    RMB17,705 (US$2,594). As at December&#160;31, 2007, the Company
    held equipment under operating lease contracts with customers
    with an original cost of RMB54,225 and accumulated depreciation
    of RMB939.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">8.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">OTHER
    INTANGIBLE ASSETS AND GOODWILL</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Goodwill is comprised of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="46%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>to December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30,</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance at beginning of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill recognized upon Reorganization (note&#160;1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill recognized upon acquisition of China Medstar
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,107
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill recognized upon acquisition of XHF (note&#160;4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,906
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,598
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill recognized in other business acquisitions (note&#160;4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,766
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance at end of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    259,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No impairment loss was recognized in any of the periods
    presented.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acquired intangible assets consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Customer relationship intangibles&#160;&#151; OMS (note&#160;1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,872
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating lease intangibles&#160;&#151; OMS (note&#160;1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,465
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Customer relationship intangibles&#160;&#151; China Medstar and
    other acquisitions (note&#160;4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,259
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating lease intangibles&#160;&#151; China Medstar and other
    acquisitions (note&#160;4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: Accumulated amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,499
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,296
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    181,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Acquired intangible amortization expenses were approximately
    nil, RMB2,002 and RMB20,894 (US$3,061) for the period from
    January&#160;1, 2007 to October&#160;30, 2007 (predecessor),
    September&#160;10, 2007 to December&#160;31, 2007 (successor)
    and for the year ended December&#160;31, 2008 (successor),
    respectively. The estimated annual amortization expenses for the
    above intangible assets for each of the five succeeding years
    are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="82%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amortization</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,493
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,881
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,815
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,390
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2012
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,390
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2013
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,862
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,763
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,454
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,352
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">9.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">DEPOSITS
    FOR NON-CURRENT ASSETS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Deposits for non-current assets consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit for purchase of property, plant and equipment *
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,461
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    128,749
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,861
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit held by a related party **
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,904
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,630
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other ***
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,365
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,494
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=468 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">*&#160;
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents interest-free
    non-refundable partial payments to suppliers associated with
    contracts the Company enters into for the future scheduled
    delivery of medical equipment to customers. The remaining
    contractual obligations associated with these purchase contracts
    are approximately RMB50,220 (US$7,357) which is included in the
    amount disclosed as Purchase Commitments in Note&#160;22. The
    risk of loss arising from non-performance by or bankruptcy of
    the suppliers is assessed prior to ordering the equipment. To
    date, the Group has not experienced any loss on deposit to
    suppliers.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">**
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">On October&#160;31, 2007, the Group
    entered into a long-term sale and purchase agreement with Our
    Medical, under which the Group agreed to purchase gamma knife
    systems at agreed upon prices and Our Medical also agreed to
    provide the Group relevant maintenance and repair services and
    training. Our Medical is controlled by an individual who was a
    director of the Group until July 2009.
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">***
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The Group has entered into two
    distinct framework agreements with Chang&#146;an Hospital Co.
    Ltd. (&#147;Chang&#146;an&#148;) towards the development and
    construction of the following two medical facilities:
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    On December&#160;18, 2007, the Group entered into a framework
    agreement to build a proton treatment center in Beijing,
    pursuant to which the Group paid deposits to a subsidiary of
    Chang&#146;an Information Industry (Group) Co., Ltd.,
    (&#147;Chang&#146;an Information&#148;) to be used towards the
    construction of the proton treatment center (&#147;Beijing
    Proton Medical Center&#148;). Total deposits paid as of
    December&#160;31, 2008 pursuant to this arrangement amounted to
    RMB3,821 (US$560).
</TD>
</TR>





<TR valign="top" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    On July&#160;1, 2008, the Group entered into a framework
    agreement with Chang&#146;an to build a cancer center in
    northwest China, the Chang&#146;an CMS International Cancer
    Center (&#147;CCICC&#148;) pursuant to which the Group paid
    security deposits to Chang&#146;an totaling RMB17,000
    (US$2,490), which were been recorded as a non-current deposit as
    of December&#160;31, 2008. (See note&#160;25.)
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">10.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">BANK
    BORROWINGS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="9%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="8" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,760
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Comprised of:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Short-term
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,047
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Long-term, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,836
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,640
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,883
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Long-term, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,760
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All bank borrowings were originally obtained by MSC and assumed
    by the Company and are from financial institutions in the PRC
    and are secured by equipment with a net carrying value of
    RMB81,595 (US$11,953) (2007: Nil). As at December&#160;31, 2008,
    the Company had RMB39,840 (US$5,836) due within one year and
    RMB52,120 (US$7,636) due between one and two years. These
    arrangements do not have any financial reporting or
    administrative covenants restricting the Company&#146;s
    operating, investing and financing activities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The short-term bank borrowing outstanding at December&#160;31,
    2008 bore weighted average interest at 6.66% per annum, and was
    denominated in RMB. The long-term bank borrowings outstanding at
    December&#160;31, 2008 bore weighted average interest at 7.47%
    per annum and were denominated in RMB.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">11.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ACCRUED
    EXPENSES AND OTHER LIABILITIES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The components of accrued expenses and other liabilities are as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accrued expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    553
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Salary and welfare payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,152
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Business and other taxes payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,879
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,368
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Unrecognized tax benefit and related interest and penalty
    (note&#160;17)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,509
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other accruals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,942
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,174
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    905
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,979
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">12.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">OBLIGATIONS
    UNDER CAPITAL LEASES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company has three capital lease obligations with three
    independent financing companies, collateralized by the
    respective medical equipment with an aggregate net book value of
    approximately RMB 31,610 (US$4,631) as at December&#160;31,
    2008. These obligations have stated interest rates ranging
    between 6.3% and 12.53%, are payable in 3 to 56&#160;monthly
    installments, and mature between March 2009 and August 2013.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Future minimum lease payments, together with the present value
    of the net minimum lease payments under capital leases, at
    December&#160;31, 2008, are summarized as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Minimum Lease Payments</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    745
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,781
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    554
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,781
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    554
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2012
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,781
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    554
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2013
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,611
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total capital lease payments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: imputed interest
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (537
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,252
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,719
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (545
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,707
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    At December&#160;31, 2008, the Company held equipment under
    capital lease contracts with an original cost of RMB39,799
    (US$5,830) and accumulated depreciation of RMB8,739 (US$1,280).
    At December&#160;31, 2007, the Company held equipment under
    capitalized lease contracts with an original cost of RMB23,675
    (US$3,468) and accumulated depreciation of RMB6,959 (US$1,019).
    The depreciation and amortization expenses of medical equipment
    under capital leases are included in cost of
    revenues&#160;&#151; depreciation and amortization expenses
    lease and management services.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">13.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">CONVERTIBLE
    NOTES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Tranche&#160;A
    Convertible Notes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2007, OMS issued notes convertible into
    Series&#160;A contingently redeemable convertible preferred
    shares (the &#147;Series&#160;A Preferred Shares&#148;) with a
    principal amount of US$5,000 (the &#147;Tranche&#160;A
    Convertible Notes&#148;) to Carlyle Asia Growth Partners III,
    L.P. (hereafter, &#147;Carlyle Asia&#148;) and CAGP III
    Co-Investment, L.P. (&#147;CAGP&#148;, an affiliate of Carlyle
    Asia, together with Carlyle Asia, &#147;Carlyle&#148;) for cash
    consideration of US$5,000. The Tranche&#160;A Convertible Notes
    bear compound interest on the principal amount at a rate of 10%
    per annum. The maturity date of the Tranche&#160;A Convertible
    Notes is December&#160;31, 2008, provided they are not
    previously converted into Series A Preferred Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Automatic
    Conversion</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Tranche&#160;A Convertible Notes, including any accrued and
    unpaid interest, are automatically convertible upon the issuance
    of Series&#160;A Preferred Shares at a conversion price that is
    not fixed until the issuance date of Series&#160;A Preferred
    Shares; the conversion price will be the then subscription price
    of the Series&#160;A Preferred Shares. On April&#160;10, 2008,
    the Company issued a tranche of Series&#160;A Preferred Shares
    at US$188 per share. Concurrently, the conversion price of the
    Tranche&#160;A Convertible Notes was renegotiated and modified
    to a conversion price of US$179 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;10, 2008, the total principal and accrued and
    unpaid interest of the Tranche&#160;A Convertible Notes
    amounting to US$5,172 was converted into 28,882 Series&#160;A
    Preferred Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Tranche&#160;B
    Convertible Notes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;2, 2008, the Company issued notes convertible into
    Series&#160;A Preferred Shares (&#147;Tranche&#160;B Convertible
    Notes&#148;) to Carlyle with a principal amount of US$20,000.
    The Tranche&#160;B Convertible Notes bear compound interest on
    the principal amount at a rate of 9% per annum. The maturity
    date of the Tranche&#160;B Convertible Notes is
    December&#160;31, 2009, provided they are not previously
    converted into Series&#160;A Preference Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Conversion</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Carlyle shall have the right, at its sole option, to convert the
    Tranche&#160;B Convertible Notes into Series&#160;A Preferred
    Shares at any time starting from the closing of the subscription
    of the Series&#160;A Preferred Shares on April&#160;10, 2008 to
    August&#160;30, 2008 at an initial conversion price of $235 per
    share. If an initial public offering (&#147;IPO&#148;) of the
    Company occurs after August&#160;31, 2008, all the principal and
    accrued and unpaid interest shall be automatically converted
    into a number of Series&#160;A Preferred Shares at a conversion
    price that is not fixed, calculated according to a formula based
    on the Group&#146;s 2008&#160;net income as disclosed in the IPO.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, Carlyle exercised its conversion right
    and the total principal and accrued and unpaid interest of the
    Tranche&#160;B Convertible Notes amounting to US$20,547 was
    converted into 87,425 Series&#160;A Preferred Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Accounting
    for the Tranche&#160;A and Tranche&#160;B Convertible
    Notes</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Tranche&#160;A and Tranche&#160;B Convertible Notes
    (collectively the &#147;Convertible Notes&#148;) were accounted
    for in accordance with SFAS&#160;150, &#147;Accounting for
    Certain Financial Instruments with Characteristics of both
    Liabilities and Equity&#148; (&#147;SFAS&#160;150&#148;) as a
    liability recorded at fair value, because the Convertible Notes
    are convertible into Series&#160;A Preferred Shares, which are
    redeemable instruments.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The movement of Convertible Notes presented on the consolidated
    balance sheets is as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as at September&#160;10, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Issuance of Tranche&#160;A Convertible Notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Fair value loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    341
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign exchange translation gain
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as at December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Issuance of Tranche&#160;B Convertible Notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Fair value loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    464
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign exchange translation gain
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,476
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion to Series&#160;A Preferred Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (176,082
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as at December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance as at December&#160;31, 2008 in US$
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">14.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">CONTINGENTLY
    REDEEMABLE CONVERTIBLE PREFERRED SHARES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2008, OMS issued an aggregate of 53,070 Series&#160;A
    contingently redeemable convertible preferred shares
    (&#147;Series&#160;A Preferred Shares&#148;) to Carlyle and CICC
    Sun Company Limited (&#147;CICC&#148;) for total cash proceeds
    of US$10,000, each investor subscribing for US$5,000. As
    discussed in note 13, the aggregate principal and accrued and
    unpaid interest relating to the Tranche&#160;A Convertible Notes
    were converted into 28,882 Series&#160;A Preferred Shares on
    April&#160;10, 2008 and all the principal and accrued and unpaid
    interest relating to the Tranche&#160;B Convertible Notes were
    converted into 87,425 Series&#160;A Preferred Shares on
    July&#160;31, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Concurrent with the issuance of the Series&#160;A Preferred
    Shares, one of the Company&#146;s major shareholders transferred
    additional Series&#160;A Preferred Shares to CICC in return for
    services rendered relating to the placement of Series&#160;A
    Preferred Shares and the Tranche&#160;B Convertible Notes. The
    total additional shares to be transferred represented 1.3% of
    the then if-converted outstanding ordinary shares. This transfer
    agreement was settled on June&#160;18, 2008. The Company agreed
    that a relative of a director of the Company shall transfer
    7,565 of her own holdings of the Company&#146;s ordinary shares,
    which were redesignated as Series&#160;A Preferred Shares, and
    issued to CICC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In October 2008, the Company issued an aggregate of 233,332
    Series&#160;B contingently redeemable convertible preferred
    shares (the &#147;Series&#160;B Preferred Shares&#148;) to
    Carlyle, Starr Investments Cayman II, Inc. (&#147;Starr&#148;),
    and CICC for cash consideration of US$25,000, US$25,000 and
    US$10,000, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The key terms of the Series&#160;A Preferred Shares and the
    Series&#160;B Preferred Shares (collectively the &#147;Preferred
    Shares&#148;) summarized below are defined in the Amended and
    Restated Shareholders&#146; Agreement and the Company&#146;s
    Second Amended and Restated Memorandum and Articles of
    Association adopted by special resolution passed on
    October&#160;20, 2008, signed among the Company, Carlyle, Starr
    and CICC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Voting
    rights</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The holder of each Preferred Share shall be entitled to the
    number of votes equal to the number of ordinary shares into
    which such Preferred Share could be converted.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Dividends</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A qualified initial public offering (&#147;QIPO&#148;) is
    defined as a firm-commitment underwritten IPO led by the Board,
    yielding a valuation of the Company of not less than US$450,000
    immediately prior to the consummation of such IPO, or any other
    IPO approved by holders of at least 70% of the then outstanding
    Series&#160;B Preferred Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each holder of Preferred Shares shall be entitled to receive a
    dividend on an annual basis, in respect of each Preferred Share,
    of an amount equal to the higher of: (a)&#160;the product of the
    number of ordinary shares into which such Preferred Share may
    then be converted multiplied by the dividend per ordinary share
    declared on the ordinary shares; or (b)&#160;the product of the
    original issuance price of each Preferred Share multiplied by
    5%. Dividends are payable annually on April 30 in the following
    financial year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Liquidation
    Preference</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of any liquidation, dissolution or winding up of
    the Company, each holder of Preferred Shares shall be entitled
    to receive, prior to and in preference to any distribution of
    any of the assets or surplus funds of the Company to the holders
    of the ordinary shares, the amount equal to the sum of 150%
    times the original price of each Preferred Share plus all
    accrued but unpaid dividends thereon and all interest accrued on
    such unpaid dividends, taking into account adjustments for share
    splits, share dividends, recapitalizations, share consolidations
    and other capital reorganizations (&#147;Liquidation
    Preference&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Conversion</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each Preferred Share shall be convertible, at the option of the
    holder at any time into a number of fully paid and
    non-assessable ordinary shares at an initial conversion ratio of
    1:100 (the &#147;Conversion Ratio&#148;), subject to adjustments
    for anti-dilution, as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;if there was a share split or reverse share split, the
    conversion price should be adjusted proportionally;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;if new equity or equity-linked securities (either
    ordinary or preferred shares, but not including securities
    issued to employees pursuant to employee benefit plans) were
    subsequently issued at a lower price than the then-Conversion
    Price of any class of Preferred Shares, the Conversion Price of
    such Preferred Shares shall be adjusted to the price of the
    newly issued shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All Preferred Shares outstanding immediately prior to the
    closing of the QIPO shall, on and with effect from the closing
    of the qualified initial public offering, be automatically
    converted into ordinary shares at the then Conversion Ratio.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Redemption</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon the occurrence of any Put Trigger Event as defined below,
    each holder of Preferred Shares shall have the right to require
    the Company to purchase all the Preferred Shares held by the
    Preferred Shareholders at a rate of return of 12.5%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#147;Put Trigger Event&#148; means any of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;the Company has not completed a qualified initial
    public offering by the third anniversary of the closing date of
    the subscription of the Series&#160;B Preferred Shares;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;any of certain key directors has resigned from the
    Company and its subsidiaries, which resignation, in the sole
    determination of a majority of the Investors, has resulted in or
    would be likely to result in, a material adverse effect;&#160;or
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iii)&#160;the Company or any of its Subsidiaries has breached
    or failed to be in compliance with any applicable laws that has
    had or would be reasonably likely to have, a material adverse
    effect.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Earning
    adjustments</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If the Group&#146;s 2008 adjusted net income (pro forma adjusted
    net income including 2008&#160;net income of China Medstar for
    the whole year) falls below US$21,430 or if the Group&#146;s
    2009 adjusted net income falls below US$34,000, the controlling
    shareholders shall transfer a number of ordinary shares and cash
    to the Series&#160;A Preferred shareholders and Series B
    preferred shareholders, to a maximum of approximately
    198,200,000 ordinary shares as well as pay cash to the Preferred
    shareholders to a maximum of US$18,000. The Company has no legal
    obligation to indemnify the controlling shareholders for such
    cash payment. The above earnings adjustments automatically
    terminate upon occurrence of a qualified IPO.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Accounting
    for the contingently redeemable convertible preferred
    shares</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Preferred Shares have been classified as mezzanine equity
    because their redemption is contingent on certain events which
    are not within the control of the Company. The Preferred Shares
    are not currently redeemable because none of the Put Trigger
    Events have occurred and, to date, the Company has determined
    that they are not probable of occurring. The initial carrying
    value of the preferred shares is accreted using the effective
    interest method to the redemption amount over the earliest
    redemption date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The initial carrying values of the Preferred Shares is the
    issuance price at their respective issuance dates less the
    attributable issuance costs. The Company evaluated the Preferred
    Shares to determine if there were any embedded derivatives
    requiring bifurcation and to determine if there was any
    beneficial conversion feature. The Company determined that the
    conversion option of the Preference Shares did not qualify for
    the scope exception of SFAS&#160;133 paragraph&#160;11(a)
    because the conversion price may be adjusted if the
    Company&#146;s ordinary or preference shares are subsequently
    issued at a lower price than the original conversion price.
    However, the conversion option of the Preferred Shares did not
    qualify for derivative accounting because the Preferred Shares
    are not readily convertible into cash as there is not a market
    mechanism in place for trading its shares. The redemption option
    of the Preferred Shares did not qualify for derivative
    accounting because the option was not considered to require a
    principal repayment involving a substantial premium or discount.
    The liquidation preference of the Series&#160;A Preferred Shares
    that may be triggered if the Company is placed in liquidation,
    dissolution or winding up was evaluated to be an embedded
    derivative to be bifurcated. As at December&#160;31, 2008, the
    Company has assessed the value of this embedded derivative to be
    insignificant and will continually assess the value of this
    embedded derivative at each balance sheet date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A beneficial conversion feature exists when the effective
    conversion price of the Preferred Shares is lower than the fair
    value of the ordinary shares at April&#160;2, 2009 and
    July&#160;31, 2009 for the Series&#160;A Preferred Shares and
    October&#160;17, 2008 for the Series&#160;B Preferred Shares.
    The intrinsic value of the beneficial conversion feature is
    allocated from the carrying value of the Preferred Shares as a
    contribution to additional
    <FONT style="white-space: nowrap">paid-in-capital.</FONT>
    Since the conversion price of the Preferred Shares is subject to
    additional Preferred Shares from the Earnings Adjustments, the
    effective conversion price used to calculate the beneficial
    conversion feature is determined at the commitment date as the
    most favorable conversion price that would be in effect at the
    conversion date, assuming there are no changes to the current
    circumstances except for the passage of time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company determined the fair value of ordinary shares based
    on valuations performed with assistance from American Appraisal.
    In accordance with
    <FONT style="white-space: nowrap">EITF&#160;98-5,</FONT>
    Accounting for Convertible Securities with Beneficial Conversion
    Features or Contingently Adjustable Conversion Ratios
    <FONT style="white-space: nowrap">(&#147;EITF&#160;98-5&#148;),</FONT>
    if the intrinsic value of the beneficial conversion feature is
    greater than the proceeds allocated to the Preferred Shares, the
    amount of discount assigned to the beneficial conversion feature
    is limited to the amount of the proceeds allocated to the
    Preferred Shares. The cumulative preferred dividends were
    recorded as a reduction of income available to ordinary
    shareholders. The discount resulting from the beneficial
    conversion feature to the Preferred Shares is then accreted to
    the earliest conversion date. For the year ended
    December&#160;31, 2008, total beneficial conversion feature
    recorded for the Series&#160;A
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    and Series&#160;B Preferred Shares was RMB253,317 (US$37,110)
    and RMB295,019 (US$43,219), respectively, which was immediately
    accreted at the issuance date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    An accretion charge to increase the carrying value of the
    Preferred Shares to their expected redemption amount is recorded
    as a reduction to retained earnings from the date of issuance to
    the earliest redemption date of the Preferred Shares using the
    effective interest method. For the year ended December&#160;31,
    2008, accretion recorded to the expected redemption amount for
    the Series&#160;A and Series&#160;B Preferred Shares amounted to
    RMB17,026 (US$2,494) and RMB9,744 (US$1,427), of which RMB6,801
    (US$996) and RMB3,987 (US$584) was recorded as dividends
    payable, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The balance and changes in balance of the Series&#160;A
    Preferred Shares and Series&#160;B Preferred Shares are as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="71%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Series A<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Series B<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mezzanine equity&#160;&#151; Balance as at December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of Convertible Notes into Series&#160;A Preferred
    Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Issuance of Series&#160;A Preferred Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: Series&#160;A Preferred Shares issuance costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,964
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,964
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Issuance of Series&#160;B Preferred Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,021
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,021
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: Series&#160;B Preferred Shares issuance costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,677
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,677
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Redesignation of 756,500 ordinary shares to Series&#160;A
    Preferred Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Allocation of proceeds to beneficial conversion feature
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (253,317
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (295,019
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (548,336
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion of beneficial conversion feature
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,317
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    295,019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    548,336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion of 5% fixed dividend
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,987
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,788
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion to the redemption amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,982
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    261,159
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    415,088
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    676,247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mezzanine equity&#160;&#151; Balance as at December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    665,459
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mezzanine equity&#160;&#151; Balance as at December&#160;31,
    2008, in US$
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    97,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend payable&#160;&#151; Balance as at December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,987
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,788
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend payable&#160;&#151; Balance at the end of
    December&#160;31, 2008, in US$
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">15.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SHAREHOLDERS&#146;
    EQUITY</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Share
    exchange</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All share and per share data before March&#160;7, 2008 are
    presented to give retroactive effect to the share exchange
    between Ascendium and the Company at a rate of 10&#160;shares in
    the Company to 1&#160;share in Ascendium which included all
    shares of OMS exchanged into shares of Ascendium at a rate of 1
    to 1 on November&#160;8, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Redesignation
    of 756,500 ordinary shares</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On June&#160;18, 2008, the Company redesignated 756,500 ordinary
    shares held by a relative of a director of the Company into
    7,565 Series&#160;A Preferred Shares which were issued to CICC
    as consideration for services related to the Series&#160;A
    Preferred Shares subscription and issuance of the Tranche&#160;B
    Convertible Notes. The aggregate fair value of the 7,565
    Series&#160;A Preferred Shares issued to CICC of RMB8,734
    (US$1,279) was considered issuance costs and was allocated on a
    pro rata basis between the US$10&#160;million subscription
    amount of the Series&#160;A Preferred Shares and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    the US$20&#160;million subscription amount of the Tranche&#160;B
    Convertible Notes, respectively. The issuance costs related to
    the Series&#160;A Preferred Shares of RMB2,911 (US$426) were
    charged against the gross proceeds of the offering. The debt
    issuance costs related to the Tranche&#160;B Convertible Notes
    are amortized into interest expense over the term of the loan
    until maturity on December&#160;31, 2009. Total interest expense
    recorded was RMB895 (US$131). On July&#160;31, 2008, when the
    Tranche&#160;B Convertible Notes were converted into
    Series&#160;A Preferred Shares, the unamortized balance of the
    debt issuance costs was charged against the conversion amount of
    the Series&#160;A Preferred Shares. The fair value of the 7,565
    Series&#160;A Preferred Shares issued to CICC was determined
    with assistance from American Appraisal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">16.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">RESTRICTED
    NET ASSETS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s ability to pay dividends is primarily
    dependent on the Company receiving distributions of funds from
    its subsidiaries. Relevant PRC statutory laws and regulations
    permit payments of dividends by the Group&#146;s PRC
    subsidiaries only out of their retained earnings, if any, as
    determined in accordance with PRC accounting standards and
    regulations. The results of operations reflected in the
    financial statements prepared in accordance with U.S.&#160;GAAP
    differ from those reflected in the statutory financial
    statements of the Company&#146;s subsidiaries.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with the PRC Regulations on Enterprises with
    Foreign Investment and their articles of association, a foreign
    invested enterprise established in the PRC is required to
    provide certain statutory reserves, namely general reserve fund,
    the enterprise expansion fund and staff welfare and bonus fund
    which are appropriated from net profit as reported in the
    enterprise&#146;s PRC statutory accounts. A foreign invested
    enterprise is required to allocate at least 10% of its annual
    after-tax profit to the general reserve until such reserve has
    reached 50% of its respective registered capital based on the
    enterprise&#146;s PRC statutory accounts. Appropriations to the
    enterprise expansion fund and staff welfare and bonus fund are
    at the discretion of the board of directors for all foreign
    invested enterprises. The aforementioned reserves can only be
    used for specific purposes and are not distributable as cash
    dividends. MSC, CHM, AMS, XHF and AML were established as a
    foreign invested enterprise and therefore are subject to the
    above mandated restrictions on distributable profits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of these PRC laws and regulations that require
    annual appropriations of 10% of after-tax income to be set aside
    prior to payment of dividends as general reserve fund, the
    Company&#146;s PRC subsidiaries are restricted in their ability
    to transfer a portion of their net assets to the Company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amounts restricted include paid-in capital, statutory reserve
    funds and net assets of the Company&#146;s PRC subsidiaries, as
    determined pursuant to PRC generally accepted accounting
    principles, totaling approximately RMB680,476 (US$99,686) as of
    December&#160;31, 2008; therefore in accordance with
    Rules&#160;504 and 4.08 (e) (3)&#160;of
    <FONT style="white-space: nowrap">Regulation&#160;S-X,</FONT>
    the condensed parent company only financial statements as of
    December&#160;31, 2008 and 2007 and for each of the two years in
    the period ended December&#160;31, 2008 are disclosed in
    note&#160;26.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">17.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">TAXATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Enterprise
    income tax:</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cayman
    Islands</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the current laws of the Cayman Islands, the Company is not
    subject to tax on income or capital gains. In addition, upon
    payments of dividends by the Company to its shareholders, no
    Cayman Islands withholding tax will be imposed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">British
    Virgin Islands</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the current laws of the British Virgin Islands, Ascendium
    and OMS are not subject to tax on income or capital gains. In
    addition, upon payments of dividends by these companies to their
    shareholders, no British Virgin Islands withholding tax will be
    imposed.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Hong
    Kong</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    CMS Holdings and Cyber are incorporated in Hong Kong and do not
    conduct any substantive operations of their own.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No provision for Hong Kong profits tax has been made in the
    financial statements as the Company has no assessable profits
    for the year ended December&#160;31, 2008. In addition, upon
    payment of dividends by CMS Holdings and Cyber to their
    shareholder, no Hong Kong withholding tax will be imposed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Singapore</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China Medstar is incorporated in Singapore and does not conduct
    any substantive operations of its own.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No provision for Singapore profits tax has been made in the
    financial statements as the Company has no assessable profits
    for the year ended December&#160;31, 2008. In addition, upon
    payments of dividends by China Medstar to its shareholder, no
    Singapore withholding tax will be imposed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">China</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to January&#160;1, 2008, PRC enterprise income tax,
    &#147;EIT&#148;, was generally assessed at the rate of 33% of
    taxable income. However, as foreign enterprises located in the
    Shenzhen Special Economic Zone or Pudong New District of
    Shanghai, AMS and MSC are entitled to preferential EIT rate of
    15%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2007, a new enterprise income tax law (the &#147;New
    EIT Law&#148;) in the PRC was enacted which was effective on
    January&#160;1, 2008. The New EIT Law applies a uniform 25% EIT
    rate to both foreign invested enterprises and domestic
    enterprises. The new law provides a five-year transition period
    from its effective date for those enterprises which were
    established before the promulgation date of the new tax law and
    which were entitled to a preferential tax treatment such as a
    reduced tax rate or a tax holiday. Based on the transitional
    rule, certain categories of enterprises, including the foreign
    invested enterprise located in Shenzhen Special Economic Zone
    and Pudong New District, which previously enjoyed a preferential
    tax rate of 15% are eligible for a five-year transition period
    during which the income tax rate will be gradually increased to
    the unified rate of 25%. Specifically, the applicable rates for
    AMS and MSC would be 18%, 20%, 22%, 24% and 25% for 2008, 2009,
    2010, 2011, 2012 and thereafter, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    AMS and MSC have accounted for their current and deferred income
    tax based on the five-year transitional tax rates, as applicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dividends paid by PRC subsidiaries of the Group out of the
    profits earned after December&#160;31, 2007 to non-PRC tax
    resident investors would be subject to PRC withholding tax. The
    withholding tax would be 10%, unless a foreign investor&#146;s
    tax jurisdiction has a tax treaty with China that provides for a
    lower withholding tax rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Income (loss) before income taxes consists of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="39%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="19%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non&#160;&#151; PRC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54,205
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (928
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    PRC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,697
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    108,739
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The current and deferred components of the income tax
    expense/(benefit) appearing in the consolidated statements of
    operations are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="39%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="19%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="7%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current tax expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,542
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,426
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,159
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax expense (benefit)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,472
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,608
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,060
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (741
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (182
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,335
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,418
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A reconciliation of the differences between the statutory tax
    rate and the effective tax rate for EIT is as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="39%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="19%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    &nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income (loss) before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,508
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax computed at applicable tax rates (33% or 25%)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,367
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (16,007
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,601
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effect of different tax rates in different jurisdictions
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,887
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,548
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    227
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-deductible expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    234
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,181
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    173
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effect of preferential tax rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,328
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,057
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,684
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,272
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effect of tax rate changes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,248
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (378
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (55
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest and penalty on unrecognized tax benefits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    812
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    186
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,067
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,014
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (182
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,335
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,418
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Reconciliation of accrued unrecognized tax benefits is as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="18%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Years Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance&#160;&#151; beginning
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,552
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,941
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    471
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Additions based on tax positions related to the current year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,393
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Addition arising from business acquisitions
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance&#160;&#151; end
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,941
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,905
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,890
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group has recorded an unrecognized tax benefit of
    approximately RMB3,218 and RMB12,905 (US$1,890) in 2007 and
    2008, respectively, which is included in the account of
    &#147;accrued expenses and other liabilities&#148;. In 2007 and
    2008, RMB2,821 and RMB10,064 (US$1,474), respectively, would
    impact the effective tax rate, if recognized in
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    connection with the normal tax return preparation. Included in
    the balance at December&#160;31, 2007 and 2008 are approximately
    RMB397 and RMB2,841 (US$416), respectively, of tax positions for
    which the ultimate deductibility is highly certain but for which
    there is uncertainty about the timing of such deductibility.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    It is possible that the amount of unrecognized tax benefits will
    change in the next twelve months. However, an estimate of the
    range of the possible change cannot be made at this time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the period from January 1 to October&#160;30, 2007
    (predecessor), the period September 10 to December&#160;31, 2007
    (successor) and the year ended December&#160;31, 2008
    (successor), the Company recognized approximately RMB812, RMB186
    and RMB4,067 (US$595) in income tax expenses for interest and
    penalties related to uncertain tax positions. The Company
    accrued interest and penalties of approximately RMB1,774 and
    RMB7,604 (US$1,114), including approximately RMB1,762 (US$258)
    assumed in the acquisition of China Medstar, at
    December&#160;31, 2007, and 2008, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate amount and per share effect of the tax holidays
    are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="18%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Years Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" nowrap align="center" valign="bottom">
    <B>(amounts in thousands except for the per share data)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    The aggregate amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,676
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,488
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,684
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,272
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    The aggregate effect on basic and diluted earnings per share:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    -Basic
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.03
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.02
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    -Diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.03
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.02
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The components of deferred taxes are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="63%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB(&#146;000)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB(&#146;000)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$(&#146;000)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accrued expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    516
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    685
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    994
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    146
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    380
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,201
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    570
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax liability, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred cost
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,240
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (182
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, current portion, net*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,201
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,649
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,765
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    552
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,044
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenue, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,105
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,841
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    270
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    530
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    87
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,155
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,245
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred cost
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,240
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,523
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (223
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29,945
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (44,750
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,556
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,735
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,400
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,135
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (53,920
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (67,673
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,914
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion, net **
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax liabilities, non-current portion, net **
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15,765
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,078
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,941
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=468 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">As at December&#160;31, 2007 and
    2008, deferred tax assets, current portion of approximately nil
    and RMB1,240 (US$182) have been offset against deferred tax
    liabilities, current portion relating to a particular tax-paying
    component of an enterprise and within a particular tax
    jurisdiction, respectively.
    </FONT></TD>
</TR>




<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">**
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">As at December&#160;31, 2007 and
    2008, deferred tax assets, non-current portion of approximately
    RMB38,155 and RMB47,595 (US$6,972) have been offset against
    deferred tax liabilities, non-current portion relating to a
    particular tax-paying component of an enterprise and within a
    particular tax jurisdiction, respectively.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aggregate undistributed earnings of the Company&#146;s
    subsidiaries located in the PRC that are available for
    distribution at December&#160;31, 2008 are considered to be
    indefinitely reinvested under Accounting Principles Board
    Opinion No.&#160;23 &#147;Accounting for Income
    Taxes&#160;&#151; Special Areas&#148; and accordingly, no
    provision has been made for taxes that would be payable upon the
    distribution of those amounts to any entity within the Group
    outside the PRC. Unrecognized deferred tax liabilities for
    temporary differences related to investments in foreign
    subsidiaries were not recorded because the determination of that
    amount is not practicable.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group does not have any present plan to pay any cash
    dividends on its ordinary shares in the foreseeable future. It
    intends to retain most of its available funds and any future
    earnings for use in the operation and expansion of its business.
    As of December&#160;31, 2008, the Group has not declared any
    dividends.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Business
    taxes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Generally revenue earned from the provision of leasing and
    management services is subject to 5% business tax regulations
    promulgated by the State Council of the PRC. Guoshuihan [1999]
    No.&#160;3402 issued by State Administration of Tax (the
    &#147;SAT&#148;) provided for an exemption to allow certain
    qualified profit sharing cooperation arrangements under existing
    PRC tax regulation to be exempt from paying business taxes. One
    of the Group&#146;s subsidiaries has not recorded any business
    taxes on certain of its leasing and management services on the
    basis that revenue generated from these exceptional profit
    sharing cooperation arrangements with hospitals are exempt from
    business taxes. Based on the above, management believes that it
    is not probable the SAT will challenge this subsidiary&#146;s
    business tax exemption status for those exceptional profit
    sharing cooperation arrangements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">18.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Income</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;21, 2008, the Company was awarded a settlement
    from the Intermediate Court of Shenzhen city, Guangdong Province
    in the amount of RMB7,734 (US$1,133) for the reimbursement of
    amounts that were misappropriated by employees. These activities
    occurred during fiscal 2005 or before and were discovered in
    July 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">19.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Employee
    Share Options</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">OMS
    Share Options</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2007, OMS, the predecessor of Ascendium and
    the Company, adopted a share option plan pursuant to which OMS
    granted three executive directors (&#147;Grantees&#148;)
    25,000,000 options in aggregate (&#147;OMS Share Options&#148;)
    to purchase ordinary shares of OMS at an exercise price of
    US$0.80 per share. The OMS Share Options vest upon the
    achievement of certain performance conditions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The OMS Share Options are exercisable from the date they vest
    until their expiry on December&#160;31, 2008 and are
    transferrable to any individuals designated by Grantees. As at
    December&#160;31, 2007, the OMS Share Options vested because all
    performance conditions had been met. The aggregate fair value of
    the options on the grant date of November&#160;17, 2007 was
    RMB49,526 (US$7,255), which was recorded as compensation expense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In August 2008, Concord agreed to issue 21,184,600 vested
    options (&#147;Concord Options&#148;) with an exercise price of
    US$0.79 per share to the Grantees in exchange for their vested
    OMS Share Options. Since the fair value of the Concord Options
    RMB36,207 (US$5,304) was less than the fair value of the OMS
    Share Options RMB45,970 (US$6,734), the difference of RMB9,763
    (US$1,430) has been credited to Additional Paid-In Capital.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Of the 21,184,600 vested Concord Options issued, 6,355,400
    Concord Options were exercised immediately resulting in total
    proceeds of RMB34,382 (US$5,037) being paid to the Company. The
    remaining 14,829,200 vested Concord Options, which were held by
    a significant shareholder of Concord, were sold to three
    directors of Concord for an amount which was less than the fair
    value of the Concord Options (the &#147;Concord Options
    Transfer&#148;). The difference represented a benefit that the
    shareholder conveyed to the three directors to compensate them
    for assuming directorship roles with the Company. The three
    directors signed employment contracts with the Company but the
    contractual terms did not contain a required service period. At
    the date of the Concord Options Transfer, the fair value of the
    Concord Options (RMB25,460 (US$3,730)) calculated using an
    option pricing model exceeded the consideration paid by the
    directors (RMB21,245 (US$3,112)) with the difference of RMB4,215
    (US$617) being recognized immediately as compensation expense
    since the options had vested. An offsetting credit was
    recognized in Additional Paid-In Capital to reflect the
    contribution made by the shareholder for providing a benefit to
    directors of the Company in accordance
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    with SAB&#160;Topic 5T <I>&#147;Accounting for Expenses or
    Liabilities Paid by Principal Stockholder(s)&#148;</I>. The
    three directors immediately exercised the 14,829,200 Concord
    Options and paid total proceeds of US$11,715 (RMB79,662) in
    aggregate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company calculated the estimated grant date fair value of
    the share-based awards in 2007 and 2008 using a Binomial-Lattice
    Model based on the following weighted average assumptions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="53%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>November&#160;17,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>August&#160;18,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>August&#160;18,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2008<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>2008<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">OMS Options</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">OMS Options</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Concord Options</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.17
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.94
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.94
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility range
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38.34
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39.53
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39.53
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sub optimal early exercise factor
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.5 times
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.5 times
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.5 times
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The volatility assumption was estimated based on the price
    volatility of ordinary shares of comparable companies in the
    health care industry. The sub optimal early exercise factor was
    estimated based on the vesting and contractual terms of the
    awards and management&#146;s expectation of exercise behavior of
    the grantees. The risk-free rate was based on the market yield
    of China Sovereign Bonds denominated in US$ with maturity terms
    equal to the expected term of the option awards. Forfeitures
    were estimated based on historical experience. The fair value of
    the ordinary shares, at the option grant dates, was determined
    with assistance from an independent valuation firm, American
    Appraisal. The weighted-average grant-date fair value of stock
    options granted during the period from September 10 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor) were RMB1.29 (US$0.19) and
    RMB1.71 (US$0.25) per share, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    No compensation expense was recorded by the predecessor entity
    for the period from January 1 to October&#160;30, 2007 since no
    share-based awards were issued. Total share-based compensation
    expense of RMB49,526 and RMB4,215 was recognized in the period
    from September 10 to December&#160;31, 2007 (successor) and in
    the year ended December&#160;31, 2008 (successor), respectively,
    in general and administrative expenses.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table summarizes employee share-based awards
    activities during the period from January 1 to October&#160;30,
    2007 (predecessor), September 10 to December&#160;31, 2007
    (successor) and the year ended December&#160;31, 2008
    (successor):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="26%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-size: 9pt">Share Options Granted to<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Number of<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Weighted-Average<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Weighted-Average<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Contractual<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Aggregate Intrinsic<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Employees</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercise Price</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Grant-date Fair Value</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Term (Years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Value</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding, January&#160;1, 2007 and October&#160;30, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Granted&#160;&#151; OMS Options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.09
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding, December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expiration of OMS Options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,000,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.26
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Grant of Concord Options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,184,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exercised of Concord Options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,184,600
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.79
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    0.25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    US$
</TD>
<TD nowrap align="right" valign="bottom">
    10,793
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding, December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate intrinsic value is calculated as the difference
    between the exercise price of the underlying awards and the fair
    value of the Company&#146;s shares that would have been received
    by the option holders if all in-the-money options had been
    exercised on December&#160;31, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concord
    2008&#160;Share Incentive Plan</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;16, 2008, the Board of Directors adopted the
    2008&#160;Share Incentive Plan (&#147;The 2008&#160;Share
    Incentive Plan&#148;). The 2008&#160;Share Incentive Plan
    provides for the granting of options, share appreciation rights,
    or other share-based awards to key employees, directors or
    consultants. The total number of Concord ordinary shares that
    may be issued under the 2008&#160;Share Incentive Plan is up to
    1,321,800 ordinary shares. As of December&#160;31, 2008, no
    awards have been granted under the 2008&#160;Share Incentive
    Plan.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">20.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">RELATED
    PARTY TRANSACTIONS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    a)&#160;Related parties
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Name of Related
    Parties</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Relationship with the
    Group</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A relative of a shareholder of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and shareholder of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and shareholder of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Yaw Kong Yap
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and shareholder of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shenzhen Hai Ji Tai Technology Co., Ltd. (&#147;Haijitai&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company owned by Mr. Haifeng Liu
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Beijing Medstar Hi-Tech Investment Co., Ltd. (&#147;Beijing
    Medstar&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company under the control of Mr. Zheng Cheng
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Our Medical New Technology Co, Ltd (&#147;Our Medical&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company under the control of Mr. Haifeng Liu
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    b)&#160;The Group had the following related party transactions
    for the years ended December&#160;31, 2007 and 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="41%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="18%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Short-term interest-free loans borrowed from:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Haijitai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    586
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Repayment of interest-free loans borrowed from:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Haijitai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,669
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    732
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-current deposits made to:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Our Medical
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,521
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    706
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,726
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Imputed interest, calculated using incremental borrowing rates
    ranging from 6.57% to 7.48%, amounting to approximately RMB8,
    RMB96, and RMB2,991 (US$438) for the period from January 1 to
    October&#160;30, 2007 (predecessor), September 10 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor), respectively, were recorded
    with an offsetting credit to Additional Paid-in Capital.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    c)&#160;The Group had the following related party balances at
    the end of the period:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amount due to related parties:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Haijitai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Beijing Medstar
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,351
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Yaw Kong Yap
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposits held by a related party:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Our Medical
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,904
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,630
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All balances with the related parties as of December&#160;31,
    2007 and 2008 were unsecured, interest-free and have no fixed
    terms of repayment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">21.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">EMPLOYEE
    DEFINED CONTRIBUTION PLAN</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Full time employees of the Group in the PRC participate in a
    government mandated defined contribution plan, pursuant to which
    certain pension benefits, medical care, employee housing fund
    and other welfare benefits are provided to employees. Chinese
    labor regulations require that the PRC subsidiaries of the Group
    make contributions to the government for these benefits based on
    certain percentages of the employees&#146; salaries. The Group
    has no legal obligation for the benefits beyond the
    contributions made. The total amounts for such employee
    benefits, which were expensed as incurred, were approximately
    RMB208, RMB35 and RMB938 (US$137) for the period from January 1
    to October&#160;30, 2007 (predecessor), September 10 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Obligations for contributions to defined contribution retirement
    plans for full-time employees in Singapore are recognized as
    expense in the statements of operations as incurred. The total
    amounts for such employee benefits, who is also a Director of
    the Company, were approximately nil, nil and RMB14 (US$2) for
    the period from January&#160;1, 2007 to October&#160;30, 2007
    (predecessor), the period from September 10 to December&#160;31,
    2007 (successor) and the year ended December&#160;31, 2008
    (successor), respectively.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-42
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">22.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">COMMITMENTS
    AND CONTINGENCIES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Operating
    lease commitments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Future minimum payments under non-cancelable operating leases
    with initial terms in excess of one year consist of the
    following at December&#160;31, 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    396
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,512
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2012
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,547
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    959
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Payments under operating leases are expensed on a straight-line
    basis over the periods of their respective leases. The terms of
    the leases do not contain material rent escalation clauses or
    contingent rents. For the years ended December&#160;31, 2007 and
    2008, total rental expenses for all operating leases amounted to
    approximately RMB711 and RMB2,620 (US$384), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Purchase
    commitments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group has commitments to purchase certain medical equipment
    of approximately RMB115,919 (US$16,981) at of December&#160;31,
    2008, which are scheduled to be paid in one year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Income
    taxes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2008, the Group has recognized
    approximately RMB20,509 (US$3,004) as an accrual for
    unrecognized tax benefits (note&#160;17). The final outcome of
    the tax uncertainty is dependent upon various matters including
    tax examinations, interpretation of tax laws or expiration of
    status of limitation. However, due to the uncertainties
    associated with the status of examinations, including the
    protocols of finalizing audits by the relevant tax authorities,
    there is a high degree of uncertainty regarding the future cash
    outflows associated with these tax uncertainties. As of
    December&#160;31, 2008, the Group classified the RMB20,509
    (US$3,004) accrual as a current liability.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">23.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SEGMENT
    REPORTING</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with SFAS&#160;No.&#160;131, &#147;Disclosures
    About Segments of an Enterprise and Related Information&#148;,
    the Group chief operating decision maker has been identified as
    the chief executive officer, who reviews consolidated results
    when making decisions about allocating resources and assessing
    performance of the Group; hence, the Group has only one
    reportable segment. The Group operates and manages its business
    as a single segment that includes primarily lease rental,
    management services and equipment sales.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Lease and management services accounted for 94%, 93% and 90% of
    the Group&#146;s net revenue for the period from January 1 to
    October&#160;30, 2007 (predecessor), September 10 to
    December&#160;31, 2007 (successor) and the year ended
    December&#160;31, 2008 (successor), respectively. Any
    significant reduction in sales from this service could have a
    substantial negative impact on the Group&#146;s results of
    operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Hospital A represented the largest customer of the Group which
    individually accounted for approximately RMB23,191 (US$3,397) or
    more than 10% of the Group&#146;s consolidated revenues for the
    years ended December&#160;31, 2008. Hospital A, Hospital B and
    Hospital C represented the largest customers of the Group
    accounting for RMB3,387, RMB1,683 and RMB1,911, respectively,
    each of which is more than 10% of the Group&#146;s consolidated
    revenues for the period from September 10 to December&#160;31,
    2007 (successor). Hospital&#160;A, Hospital&#160;C and
    Hospital&#160;D represented the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-43
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    largest customers of the Group accounting for RMB14,641,
    RMB8,062 and RMB7,767 or more than 10% of the Group&#146;s
    consolidated revenues for the period from January 1 to
    October&#160;30, 2007 (predecessor).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Geographic disclosures:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As the Group primarily generates its revenues from customers in
    the PRC, no geographical segments are presented. All of the
    Group&#146;s long-lived assets are located in the PRC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">24.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">INCOME
    (LOSS) PER SHARE</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Basic and diluted loss per share for each of the periods
    presented is calculated as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="17%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>January&#160;1, 2007 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">October&#160;30, 2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">For the Year Ended
    December&#160;31,</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(predecessor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom">
    <B>(amounts in thousands except for the number of shares and per
    share data)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Numerator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income (loss) attributable to ordinary shareholders used in
    calculating loss per ordinary share&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (496,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72,667
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Denominator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average number of ordinary shares outstanding used in
    calculating basic and diluted loss per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Basic and diluted income (loss) per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.97
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8.63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1.26
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the period from September&#160;10 to December&#160;31, 2007
    (successor), the diluted income (loss) per share is the same as
    basic loss per share because the if-converted method would not
    be applied as the effect of the convertible notes would be
    anti-dilutive. The share options should not be included in the
    calculation of diluted income (loss) per share because the
    company incurred a net loss and, therefore, the effect would be
    anti-dilutive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2008, the basic loss per share was calculated using the two
    class method because the Preferred Shares were participating
    securities. The losses were not allocated to holders of the
    Preferred Shares because they are not obligated to fund the
    losses of the Group and the contractual principal and mandatory
    redemption amount of Preferred Shares are not reduced as a
    result of losses incurred by the Group. Diluted loss per share
    is the same as basic loss per share because the effects of the
    Preferred Shares were anti-dilutive when computed on an &#147;if
    converted&#148; basis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2008, the Company issued Series&#160;A and Series&#160;B
    contingently redeemable convertible preferred shares (see
    note&#160;14). Each Preferred Share shall be convertible, at the
    option of the holder thereof, at any time after the closing of
    the subscription, into a number of fully paid and non-assessable
    ordinary Shares at a ratio 1:1 and is subject to adjustment
    pursuant to anti-dilution provisions. One hundred per cent of
    each class of the Preferred Shares which are outstanding
    immediately prior to the closing of the qualified initial public
    offering shall, on and with effect from the closing of the
    qualified initial public offering, be automatically converted
    into ordinary shares. Assuming the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-44
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    conversion had occurred &#147;on a hypothetical&#148; basis on
    January&#160;1, 2008, the pro-forma basic and diluted loss per
    share for the year ended December&#160;31, 2008 is calculated as
    follows (unaudited):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(pro forma)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB (unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Numerator</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss attributable to ordinary shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (496,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma adjustments:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;A contingently redeemable convertible preferred
    shares&#160;&#151; accretion to redemption amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,225
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;B contingently redeemable convertible preferred
    shares&#160;&#151; accretion to redemption amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss for pro forma basic and diluted loss per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (480,054
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Denominator</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average number of ordinary shares outstanding used in
    calculating basic loss per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of Series&#160;A preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,694,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of Series&#160;B preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,333,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average number of ordinary shares outstanding used in
    calculating basic and diluted loss per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98,508,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma loss per share&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4.87
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma loss per share&#160;&#151; basic and diluted (in US$)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.71
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">25.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ARRANGEMENT
    WITH CHANG&#146;AN HOSPITAL CO., LTD.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group has entered into the following agreements with
    Chang&#146;an Hospital Co., Ltd. (&#147;Chang&#146;an&#148;), a
    general hospital located in Xi&#146;an in Shaanxi province in
    the PRC, which is also a significant customer of the Group, and
    certain of its affiliated entities, including the controlling
    parent of Chang&#146;an, Chang&#146;an Information Industry
    (Group) Co., Ltd., (&#147;Chang&#146;an Information&#148;), a
    China-based conglomerate engaged in information technology, real
    estate and the medical industries; a subsidiary of
    Chang&#146;an, Xi&#146;an Century Friendship Medical Technology
    R&#038;D Co., Ltd. (&#147;Xi&#146;an&#148;), and another
    subsidiary controlled by Chang&#146;an Information, Beijing
    Century Friendship Science&#160;&#038; Technology Development
    Co., Ltd., (&#147;Beijing Century&#148;):
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Management
    agreements to provide stand-alone management
    services</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group entered into a Medical Equipment Entrusted Management
    Agreement on March&#160;1, 2007 with Xi&#146;an and
    Chang&#146;an to provide management services with respect to
    radiotherapy and diagnostic equipment owned by Xi&#146;an
    located in the oncology center of Chang&#146;an. Commencing
    January&#160;1, 2010 or an agreed upon earlier date, Concord has
    the option to purchase the radiotherapy and diagnostic equipment
    owned by Xi&#146;an at fair value if the Chang&#146;an oncology
    center&#146;s annualized revenues achieves a certain targeted
    level. Total management services revenue recognized under this
    contract was RMB8,000 (US$1,172) for year ended
    December&#160;31, 2008. Accounts receivable related to this
    contract as at December&#160;31, 2008 was RMB4,000 (US$586). On
    August&#160;25, 2009, the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-45
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Group exercised its option under the Medical Equipment Entrusted
    Management Agreement and converted the stand-alone management
    services arrangement into a lease and service arrangement. (See
    note 26.)
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;1, 2008, the Company signed an Entrusted
    Management Contract with Xi&#146;an and Chang&#146;an to provide
    general administrative management services to Chang&#146;an.
    Under this arrangement, the Group earns a certain percentage of
    total monthly revenues of Chang&#146;an Hospital. In accordance
    with the contract, the Group paid a performance guarantee
    deposit of RMB15,000 (US$2,197) to a related party of
    Xi&#146;an, which is refundable 15&#160;days after the
    cancellation or expiration of the contract (January&#160;15,
    2010). Total revenue recognized during the year ended
    December&#160;31, 2008 under this contract was RMB2,000 (US$293)
    and the ending accounts receivable relating to this contract as
    at December&#160;31, 2008 was nil.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Beijing
    Proton Medical Center</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;18, 2007, the Group entered into a framework
    agreement with Chang&#146;an Information to build a Beijing
    Proton Medical Center (&#147;Proton Center&#148;). The Proton
    Center will initially be established by Chang&#146;an
    Information with a total registered capital of RMB100,000. The
    parties agreed that after certain capital injections from the
    Group, the Company will hold a 51.2% interest in the Proton
    Center, while Jian Chang Group Limited, a related party of
    Chang&#146;an, will hold 28.8% and China-Japan Friendship
    Hospital, a state-owned hospital, will hold 20.0%. Once the
    Proton Center commences operations, the Group shall own a 51.2%
    controlling interest in the Proton Center and will consolidate
    the operating results and financial position within the Group.
    Additional contractual arrangements will be entered into by the
    Group once all relevant permits and approvals are obtained. In
    order for this framework agreement to become effective, the
    Group is required to pay a deposit of RMB10,000 (US$1,465); this
    deposit was not paid as of December&#160;31, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To assist with this project, the Group has made deposits to
    Beijing Century in the amount of RMB3,821 (US$560) as of
    December&#160;31, 2008 towards certain setup and construction
    costs. All of the deposits are guaranteed by Chang&#146;an
    Information and are due back to the Group by December&#160;31,
    2009.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Chang&#146;an
    CMS International Cancer Center</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;1, 2008, the Group entered into a framework
    agreement with Xi&#146;an to build a cancer center in northwest
    China, to be called Chang&#146;an CMS International Cancer
    Center (&#147;CCICC&#148;). Although the CCICC will initially be
    established by Xi&#146;an, the parties agreed that after certain
    initial capital injections estimated at RMB34,800 (US$5,098)
    from the Group, the Company shall hold a controlling interest of
    52% in the CCICC, while Xi&#146;an will hold a non-controlling
    interest of 48%. Similarly, the Group anticipates having to
    consolidate the operating results and financial position of the
    CCICC when the Group obtains a controlling interest. As of
    December&#160;31, 2008, Xi&#146;an is waiting for all relevant
    permits and approvals to be obtained prior to the legal
    establishment of the CCICC, upon which, additional contractual
    arrangements will be entered into by the Group. As of
    December&#160;31, 2008, the Group paid a deposit of RMB15,000
    (US$2,197) to a related party of Xi&#146;an in accordance with
    the framework agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are no other obligations under the current framework
    agreement and the agreement does not specify a contractual
    completion date for the deposit to be repaid to the Group. If
    the CCICC is established, the RMB15,000 deposit will be applied
    against future capital injections beyond the initial capital
    investment estimate of RMB34,800. The Group has also paid
    deposits to Xi&#146;an to be used towards setup and construction
    costs of the CCICC amounting to RMB2,000 (US$293) as of
    December&#160;31, 2008.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-46
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group had the following transactions with Chang&#146;an and
    its affiliated companies for the six months ended
    December&#160;31, 2007 and 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="79%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For The Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Management services revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Medical Equipment Entrusted Management Agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,172
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entrusted Management Contract
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total management services revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,465
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounts receivable due from Chang&#146;an
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    586
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group had the following deposits on loan with Chang&#146;an
    and its affiliated companies as at December&#160;31, 2007 and
    2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="76%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="8" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current&#160;&#160;&#151;  Entrusted Management Contract
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,197
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-current&#160;&#160;&#151;  Proton Center and CCICC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,050
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">26.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SUBSEQUENT
    EVENTS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subsequent to the year end, the Group made aggregate deposits in
    the amounts of RMB1,000 (US$146) and RMB10,800 (US$1,582) to
    Chang&#146;an and its affiliated companies towards the setup of
    the CCICC and Proton Center, respectively. These deposits are
    due to be repaid back to the Group by December&#160;31, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January and May 2009, the Group entered into two
    non-cancellable corporate office operating leases with a lease
    term of two to three years. These leases have no renewal
    options, material rent escalation clauses or contingent rents.
    Upon termination of the leases, they are renewable at fair value
    upon negotiation with the lessor.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In January and June 2009, the Group entered into two new bank
    borrowings with PRC financial institutions with an aggregate
    principal amount of RMB35,000 (US$5,127). The weighted average
    interest rate of these two new bank borrowings was 5.59%. Both
    bank financing arrangements are secured by certain accounts
    receivable pledged to the bank and restricted cash deposited
    with each of the respective financial institutions. One of these
    new borrowing arrangements were entered into by a subsidiary of
    the Group, MSC, which requires MSC and AMS, another subsidiary
    of the Group, in accordance with PRC GAAP, to maintain a
    financial reporting covenant of tangible net worth of at least
    RMB400,000 and RMB180,000 and total gearing ratio of less than
    0.5 and 0.36, respectively. Tangible net worth is calculated as
    the sum of issued share capital and reserves less goodwill and
    intangible assets and any amount due from shareholders and the
    total gearing ratio is calculated as the ratio of total
    liabilities to tangible net worth.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In August 2009, the Group obtained a RMB100,000 (US$14,649)
    banking facility with a financial institution in the PRC for a
    term of 3&#160;years. The facility bears interest at a floating
    rate of the PBOC benchmark lending rate which was 5.4% in August
    2009 when the banking facility was obtained. Proceeds of this
    facility will be used towards future purchases of equipment and
    any drawdowns of the facility will be secured by those
    respective equipment. As at October&#160;16, 2009, the Group had
    drawn down RMB54,980 (US$8,054) of this facility.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-47
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In August 2009, the Group exercised its option in the Medical
    Equipment Entrusted Management Agreement and entered into an
    Equipment Purchase Agreement with Xi&#146;an and Chang&#146;an
    to acquire certain radiotherapy and diagnostic equipment owned
    by Xi&#146;an for total proceeds of RMB72,716 (US$10,652) to be
    paid in cash. Upon exercise, the Group converted the stand-alone
    management services arrangement into a lease and service
    agreement with Xi&#146;an and Chang&#146;an. This new lease and
    management service agreement provides the Group with a
    percentage of net profit generated by the oncology center.
    Commencing September 2009, the Group will record all revenue
    associated with this arrangement within lease and management
    services. (See note&#160;25 for amounts previously recorded as
    management services.)
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2009, the Company&#146;s Board of Directors
    approved the following resolutions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To distribute an interim dividend to the holders of the ordinary
    shares as at November&#160;17, 2009 in the sum of
    (i)&#160;US$2,391,534 to the holders of the ordinary shares; and
    (ii)&#160;US$1,590,676 to the holders of the Series&#160;A and B
    Preferred Shares, such dividend to be payable in cash on or
    about November&#160;27, 2009.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Amended the Articles of Association to reflect a 100-for-one
    stock split of the Company&#146;s ordinary shares whereby each
    ordinary share of the Company is subdivided into 100&#160;shares
    at a par value of US$0.0001. All shares and per share amounts
    presented in the accompanying consolidated financial statements
    have been revised on a retroactive basis to reflect the effect
    of the share split. The par value per ordinary share has been
    retroactively revised as if it had been adjusted in proportion
    to the
    <FONT style="white-space: nowrap">100-for-one</FONT>
    share split.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Amended the Company&#146;s 2008&#160;Share Incentive Plan, to
    increase the total number of ordinary shares that may be issued
    under the 2008&#160;Share Incentive Plan from 1,321,800 ordinary
    shares to 4,765,800 ordinary shares.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">27.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">PARENT
    COMPANY ONLY CONDENSED FINANCIAL INFORMATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Condensed
    balance sheet</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>ASSETS</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Current Assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    274,515
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Amount due from subsidiary
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total current assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    441,655
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    64,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Non-Current Assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Investment in subsidiaries
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    395,208
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    763,010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111,777
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Deposit for non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,746
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    431,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,242,411
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-48
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="65%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="line-height: 9pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
    <B>LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Current Liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    78
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Amounts due to subsidiaries
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Dividend payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,788
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,580
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total current liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,932
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,748
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Non-Current Liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Convertible loan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,932
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,748
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Commitments and Contingencies</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Series&#160;A contingently redeemable convertible preferred
    shares (par value of US$0.01 per share; Authorized&#160;&#151;
    nil and 200,000&#160;shares as at December&#160;31, 2007 and
    2008, respectively; Issued and outstanding&#160;&#151; nil and
    176,942&#160;shares as at December&#160;31, 2007 and 2008,
    respectively. As at December&#160;31, 2008, aggregate
    liquidation preference and redemption amounts were US$54,573 and
    US$38,147, respectively (2007-nil))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,262
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Series&#160;B contingently redeemable convertible preferred
    shares (par value of US$0.01 per share; Authorized&#160;&#151;
    nil and 300,000&#160;shares as at December&#160;31, 2007 and
    2008, respectively; Issued and outstanding&#160;&#151; nil and
    233,332&#160;shares as at December&#160;31, 2007 and 2008,
    respectively. As at December&#160;31, 2008, aggregate
    liquidation preference and redemption amounts were US$90,583 and
    US$61,390, respectively (2007-nil))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Shareholders&#146; Equity:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Ordinary shares (par value of US$0.0001 per share as at
    December&#160;31, 2007 and 2008, respectively;
    Authorized&#160;&#151; 450,000,000&#160;shares as at
    December&#160;31, 2007 and 2008; Issued and
    outstanding&#160;&#151; 50,000,000 and 70,428,100&#160;shares as
    at December&#160;31, 2007 and 2008, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    443,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated other comprehensive income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,822
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (560
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Retained earnings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (544,363
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (79,746
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total shareholders&#146; equity</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total liabilities, preferred shares and shareholders&#146;
    equity</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    431,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,242,411
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182,006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    F-49
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Condensed
    statements of operations</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="58%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="18%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, 2007<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>For the Years Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">to December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>(successor)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (53,862
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,593
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (673
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Operating loss</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (53,862
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,593
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (673
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Equity in profit of subsidiaries
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,877
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    84,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,413
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    364
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (895
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (131
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Change in fair value of convertible note
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (341
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (74
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Net (loss) income</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,583
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,343
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (39,604
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (44,646
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Net loss attributable to ordinary shareholders</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (496,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72,667
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-50
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE CONSOLIDATED FINANCIAL STATEMENTS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Condensed
    statements of cash flows</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>For the Period from<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;10, to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(successor) </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net cash used in investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (448,224
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (65,662
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    727,849
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,636
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (826
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net increase in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    274,515
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash at beginning of the year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash at end of the year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    274,515
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Supplemental schedule of non-cash activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of convertible notes into Series&#160;A contingently
    redeemable convertible preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,795
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Proceeds from convertible notes paid directly to a subsidiary of
    the Company
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,523
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Basis of
    Presentation</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the presentation of the parent company only condensed
    financial information, the Company records its investment in
    subsidiaries under the equity method of accounting as prescribed
    in APB opinion No.&#160;18, &#147;The Equity Method of
    Accounting for Investments in Common Stock&#148;. Such
    investment is presented on the balance sheet as &#147;Investment
    in Subsidiaries&#148; and the subsidiaries profit or loss as
    &#147;Equity in profit or loss of subsidiaries&#148; on the
    statement of income. The parent company only financial
    statements should be read in conjunction with the Company&#146;s
    consolidated financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-51
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='307'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">UNAUDITED
    CONDENSED CONSOLIDATED BALANCE SHEETS<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and US dollar
    (&#147;US$&#148;) except for number of shares)</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="51%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro Forma as at</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Note</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008*</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="25" align="center" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>ASSETS</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    285,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    250,276
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,664
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Restricted cash, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    295
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounts receivable (net of allowance of RMB3,830 (US$561) as of
    December&#160;31, 2008 and September&#160;30, 2009)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92,772
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    119,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Prepayment and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,566
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,869
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,331
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,649
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,776
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    407
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total current assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    492,978
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    466,487
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Non-Current Assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Restricted cash, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    767
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property, plant and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    349,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,661
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    300,163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    43,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acquired intangible assets, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    181,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    161,450
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposits for non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147,851
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,659
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,648
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,445
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,782
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,578
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred initial public offering expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,207
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,642
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,673,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="25" align="center" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>LIABILITIES AND SHAREHOLDERS&#146;&#160;EQUITY</B>
</DIV>
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Current Liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Short-term bank borrowing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term bank borrowings, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,741
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accrual for purchase of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,881
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,839
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,785
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Obligations under capital leases, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    525
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,221
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,041
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,864
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,349
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred revenue, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,962
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Payable for acquisition of business components
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    952
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividends payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,788
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,428
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,190
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amounts due to related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total current liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    190,533
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    238,060
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,874
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-52
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS&#160;&#151;
    (Continued)<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="45%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As at<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Pro Forma as at September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">Note</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008*</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Non-Current Liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term bank borrowings, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred revenue, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,314
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,470
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Obligations under capitalized leases, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,656
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,719
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,277
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Lease deposit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,665
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    283,916
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    378,619
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,465
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Commitments and Contingencies</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;A contingently redeemable convertible preferred
    shares (par value of US$0.01 per share; Authorized&#160;&#151;
    200,000&#160;shares as at December&#160;31, 2008 and
    September&#160;30, 2009; Issued and outstanding&#160;&#151;
    176,942&#160;shares as at December&#160;31, 2008 and
    September&#160;30, 2009; pro forma nil (unaudited))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    254,358
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    269,017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Series&#160;B contingently redeemable convertible preferred
    shares (par value of US$0.01 per share; Authorized&#160;&#151;
    300,000&#160;shares as at December&#160;31, 2008 and
    September&#160;30, 2009; Issued and outstanding&#160;&#151;
    233,332&#160;shares as at December&#160;31, 2008 and
    September&#160;30, 2009; pro forma nil (unaudited))
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    411,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    434,036
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Shareholders&#146; Equity:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Ordinary shares (par value of US$0.0001 per share at
    December&#160;31, 2008 and September&#160;30, 2009;
    Authorized&#160;&#151; 450,000,000&#160;shares at
    December&#160;31, 2008 and September&#160;30, 2009; Issued and
    outstanding&#160;&#151; 70,428,100&#160;shares at
    December&#160;31, 2008 and September&#160;30, 2009,
    111,455,500&#160;shares for pro forma)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,816,229
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    266,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,822
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (592
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (592
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (544,363
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (517,640
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75,831
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (517,640
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75,831
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Total shareholders&#146; equity</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    591,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,294,635
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    189,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total liabilities and shareholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,514,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,673,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    245,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">*&#160;
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Amounts for the year ended
    December&#160;31, 2008 were derived from the December&#160;31,
    2008 audited consolidated financial statements.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-53
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='308'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;),<BR>
    except for number of shares and per share data)</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Note</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Revenues, Net of Business Tax, Value-Added Tax and Related
    Surcharges:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,937
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,092
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,096
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    91
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    205,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Cost of Revenues:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (42,144
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,174
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,388
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,987
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,361
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (62,541
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,162
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Gross profit</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,632
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143,116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Operating Expenses:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,275
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,463
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (654
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,468
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,687
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,884
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Operating Income</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,889
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    118,966
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest expense (including related party amounts of RMB2,425
    and RMB 54 (US$8) for the nine months ended September&#160;30,
    2008 and 2009, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,293
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,880
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (715
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (13
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (218
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gain from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    392
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    116
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    823
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Income before income taxes</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,627
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,691
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,801
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,611
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,734
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,770
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Net income</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-54
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;),<BR>
    except for number of shares and per share data)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Note</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>USD <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (262,286
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,851
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,494
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (38,383
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,623
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Net (loss) income attributable to ordinary shareholders</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (222,270
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,914
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Income (loss) per share</B> Basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.06
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Weighted Average Number of Ordinary Shares Outstanding:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Basic and diluted shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,621,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Pro forma income per share</B> Basic and diluted on an as
    converted basis
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Weighted Average Number of Ordinary Shares Outstanding Used
    in Computation of:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma basic and diluted on an as converted basis
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111,455,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111,455,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See accompanying notes to unaudited condensed consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-55
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='309'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">UNAUDITED
    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and US dollar
    (&#147;US$&#148;))</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="62%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>CASH FLOWS FROM OPERATING ACTIVITIES</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,031
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Adjustments to reconcile net income to net cash generated from
    operating activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Imputed interest on amounts due to related parties (note&#160;10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,425
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Depreciation of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,413
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,142
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Amortization of acquired intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,987
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Gain on disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (392
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred tax benefit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,830
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,014
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (295
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    464
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Changes in operating assets and liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,623
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26,355
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,861
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in prepayments and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (49,570
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,828
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,586
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in other non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (500
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,035
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (152
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase (decrease) in accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,057
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,543
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (812
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase (decrease) in deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (105
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (15
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Decrease in lease deposit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    (Decrease) increase in income tax payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (121
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,823
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,308
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>CASH FLOWS FROM INVESTING ACTIVITIES</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Purchase of subsidiaries, net of cash acquired
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (219,163
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,534
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,155
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deposits with Chang&#146;an Hospital and its affiliated
    companies (note&#160;15)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (300
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,800
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,729
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Acquisition of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,439
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (74,033
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,845
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deposits for the purchase of non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (71,406
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (116,059
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,002
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from disposal of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,616
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net cash used in investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (300,692
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (223,426
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (32,731
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-56
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">UNAUDITED
    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS&#160;&#151;
    (Continued)<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and US dollar
    (&#147;US$&#148;))</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="62%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>For the Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>CASH FLOWS FROM FINANCING ACTIVITIES</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from issuance of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,241
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from issuance of Series&#160;A contingently redeemable
    convertible preferred shares (net of paid issuance costs of
    RMB2,449)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Payment of issuance cost of convertible shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (529
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (77
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Payment of deferred initial public offering costs
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,355
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (491
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,783
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from long-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    128,780
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Repayment of obligations under capitalized leases
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,703
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,074
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (450
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Repayment of long-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,260
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (70,948
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,393
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Repayment of short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,800
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,436
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in amounts due to related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,000
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (293
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Increase in restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,245
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,061
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from exercise of share options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,458
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    278,407
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,448
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,949
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (191
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net decrease in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (864
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (68,288
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,004
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash at beginning of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    353,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash at end of period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,928
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    285,703
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,854
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Supplemental schedule of cash flows information:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,346
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,787
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,045
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,671
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,771
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (699
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Supplemental schedule of non-cash activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acquisition of property, plant and equipment included in accrual
    for purchase of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,777
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acquisition of property, plant and equipment through utilization
    of deposits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,712
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    152,181
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of convertible notes into Series&#160;A contingently
    redeemable convertible preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    176,082
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-57
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='310'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF<BR>
    CHANGES IN SHAREHOLDERS<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) and US
    dollar (&#147;US$&#148;))</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="44%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Retained<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Earnings<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ordinary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ordinary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid-in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Comprehensive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(Cumulative<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shareholders&#146;<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Income(loss)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Equity</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    443,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (48,326
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    394,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,810
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,810
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,206
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Imputed interest on related parties&#146; loan (note&#160;10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,425
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,425
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Exercise of share options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,184,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,606
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Redesignation of 756,500 ordinary shares to Series&#160;A
    contingently redeemable convertible preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (756,500
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Recognition of beneficial conversion feature upon issuance of
    Series&#160;A contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,317
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,317
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares (note&#160;6)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (262,286
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (262,286
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of September&#160;30, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    817,565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,663
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270,596
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    541,361
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,841
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,841
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,894
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Imputed interest on related parties&#146; loan
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    566
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    566
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Recognition of beneficial conversion feature upon issuance of
    Series&#160;B contingently redeemable convertible preferred
    shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    295,019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    295,019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,057
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,057
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (304,763
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,822
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (544,363
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (215
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (215
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,742
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Imputed interest on related parties&#146; loan (note&#160;10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;A contingently redeemable convertible
    preferred shares (note&#160;6)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,851
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,851
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Accretion of Series&#160;B contingently redeemable convertible
    preferred shares (note&#160;6)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (38,383
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (38,383
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of September&#160;30, 2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,113,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,037
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (517,640
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    591,582
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of September&#160;30, 2009, in US$
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,078
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (590
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (75,831
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    86,664
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-58
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='311'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    OF SIGNIFICANT ACCOUNTING POLICIES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Basis
    of Presentation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying unaudited condensed consolidated financial
    statements include the financial statements of Concord Medical
    Services Holdings Limited (the &#147;Company&#148;) and its
    subsidiaries (the &#147;Group&#148;). These unaudited condensed
    consolidated financial statements of the Group have been
    prepared in accordance with U.S.&#160;generally accepted
    accounting principles (&#147;U.S.&#160;GAAP&#148;) for interim
    financial information using accounting policies that are
    consistent with those used in the preparation of the
    Group&#146;s audited consolidated financial statements for the
    year ended December&#160;31, 2008. Accordingly, these unaudited
    condensed consolidated financial statements do not include all
    of the information and footnotes required by U.S.&#160;GAAP for
    complete financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the opinion of management, the accompanying unaudited
    condensed consolidated financial statements contain all normal
    recurring adjustments necessary to present fairly the financial
    position, operating results and cash flows of the Group for each
    of the periods presented. The results of operations for the nine
    months ended September&#160;30, 2009 are not necessarily
    indicative of results to be expected for any other interim
    period or for the year ending December&#160;31, 2009. The
    consolidated balance sheet as of December&#160;31, 2008 was
    derived from the audited consolidated financial statements at
    that date but does not include all of the disclosures required
    by U.S.&#160;GAAP for complete financial statements. These
    unaudited condensed consolidated financial statements should be
    read in conjunction with the Group&#146;s consolidated financial
    statements for the year ended December&#160;31, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Subsequent events have been evaluated through the date these
    unaudited condensed consolidated financial statements were
    issued, November&#160;6, 2009.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Principles
    of Consolidation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The condensed consolidated financial statements of the Group
    include the financial statements of the Company and its
    subsidiaries. All transactions and balances between the Company
    and its subsidiaries have been eliminated upon consolidation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Convenience
    Translation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amounts in U.S.&#160;dollars (&#147;US$&#148;) are presented for
    the convenience of the reader and are translated at the noon
    buying rate of RMB6.8262 to US$1.00 on September&#160;30, 2009
    in the City of New York for cable transfers of RMB as certified
    for customs purposes by the Federal Reserve Bank of New York. No
    representation is made that the RMB amounts could have been, or
    could be, converted into US$ at such rate.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Restricted
    Cash</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Short-term and Long-term restricted cash represents cash
    collateral deposits required to be maintained pursuant to
    certain contractual financing arrangements the Group entered
    into with certain financial institutions (see note&#160;5.)
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Deferred
    Initial Public Offering Expenses</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Deferred initial public offering expenses represent incremental
    costs incurred by the Group directly attributable to the
    Company&#146;s initial public offering. The deferred initial
    public offering costs will be charged against the gross proceeds
    of such offering.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-59
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There have been no developments to recently issued accounting
    standards, including the expected dates of adoption and
    estimated effects on the Group&#146;s consolidated financial
    statements, from those disclosed in the Group&#146;s
    consolidated financial statements for the year ended
    December&#160;31, 2008, except for the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In April 2009, the Financial Accounting Standards Board
    (&#147;FASB&#148;) issued Accounting Standards Codification
    (&#147;ASC&#148;)
    <FONT style="white-space: nowrap">805-20,</FONT>
    &#147;Accounting for Assets Acquired and Liabilities Assumed in
    a Business Combination That Arise from Contingencies&#148; to
    amend SFAS 141 (revised 2007)&#160;&#147;Business
    Combinations.&#148; ASC
    <FONT style="white-space: nowrap">805-20</FONT>
    addresses the initial recognition, measurement and subsequent
    accounting for assets and liabilities arising from contingencies
    in a business combination, and requires that such assets
    acquired or liabilities assumed be initially recognized at fair
    value at the acquisition date if fair value can be determined
    during the measurement period. If the acquisition-date fair
    value cannot be determined, the asset acquired or liability
    assumed arising from a contingency is recognized only if certain
    criteria are met. ASC
    <FONT style="white-space: nowrap">805-20</FONT> also
    requires that a systematic and rational basis for subsequently
    measuring and accounting for the assets or liabilities be
    developed depending on their nature. The Company does not
    anticipate that the adoption of this statement will have a
    material impact on its consolidated financial statements, absent
    any material business combinations.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2009, the FASB issued SFAS&#160;No.&#160;166,
    &#147;Accounting for Transfers of Financial Assets&#160;&#151;
    an amendment of FASB Statement No. 140&#148;
    (&#147;SFAS&#160;166&#148;). SFAS&#160;166 seeks to improve the
    relevance, representational faithfulness, and comparability of
    the information that a reporting entity provides in its
    financial statements about a transfer of financial assets; the
    effects of a transfer on its financial position, financial
    performance, and cash flows; and a transferor&#146;s continuing
    involvement, if any, in transferred financial assets.
    Specifically, SFAS&#160;166 eliminates the concept of a
    qualifying special-purpose entity, creates more stringent
    conditions for reporting a transfer of a portion of a financial
    asset as a sale, clarifies other sale-accounting criteria, and
    changes the initial measurement of a transferor&#146;s interest
    in transferred financial assets. The Company does not anticipate
    that the adoption of this statement will have a material impact
    on its consolidated financial statements.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2009, the FASB issued SFAS&#160;No.&#160;167,
    &#147;Amendments to FASB Interpretation No.&#160;46(R)&#148;
    (&#147;SFAS&#160;167&#148;). SFAS&#160;167 amends FASB
    Interpretation No.&#160;46(R), &#147;Variable Interest
    Entities&#148; for determining whether an entity is a variable
    interest entity (&#147;VIE&#148;) and requires an enterprise to
    perform an analysis to determine whether the enterprise&#146;s
    variable interest or interests give it a controlling financial
    interest in a VIE. Under SFAS&#160;167, an enterprise has a
    controlling financial interest when it has a)&#160;the power to
    direct the activities of a VIE that most significantly impact
    the entity&#146;s economic performance and b)&#160;the
    obligation to absorb losses of the entity or the right to
    receive benefits from the entity that could potentially be
    significant to the VIE. SFAS 167 also requires an enterprise to
    assess whether it has an implicit financial responsibility to
    ensure that a VIE operates as designed when determining whether
    it has power to direct the activities of the VIE that most
    significantly impact the entity&#146;s economic performance.
    SFAS&#160;167 also requires ongoing assessments of whether an
    enterprise is the primary beneficiary of a VIE, requires
    enhanced disclosures and eliminates the scope exclusion for
    qualifying special-purpose entities. The Company is currently
    evaluating the impact the adoption of SFAS&#160;167 will have on
    its consolidated financial statements.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In June 2009, the FASB issued
    <FONT style="white-space: nowrap">ASC&#160;105-10,</FONT>
    &#147;Generally Accepted Accounting Principles,&#148; previously
    referenced as FASB Statement No.&#160;168, The FASB Accounting
    Standards
    Codification<SUP style="font-size: 85%; vertical-align: top">TM</SUP>

    and the Hierarchy of Generally Accepted Accounting Principles, a
    replacement of FASB Statement No.&#160;162. This statement
    modifies the Generally Accepted Accounting Principles
    (&#147;GAAP&#148;) hierarchy by establishing only two levels of
    GAAP, authoritative and nonauthoritative accounting literature.
    Effective July 2009, the FASB Accounting Standards
    Codification<SUP style="font-size: 85%; vertical-align: top">TM</SUP>

    (&#147;ASC&#148;), also known collectively as the
    &#147;Codification,&#148; is considered
</TD>
</TR>
<!-- XBRL Paragraph Pagebreak -->

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-60
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    the single source of authoritative U.S.&#160;accounting and
    reporting standards, except for additional authoritative rules
    and interpretive releases issued by the SEC. Nonauthoritative
    guidance and literature would include, among other things, FASB
    Concepts Statements, American Institute of Certified Public
    Accountants Issue Papers and Technical Practice Aids and
    accounting textbooks. The Codification was developed to organize
    U.S.&#160;GAAP pronouncements by topic so that users can more
    easily access authoritative accounting guidance. It is organized
    by topic, subtopic, section, and paragraph, each of which is
    identified by a numerical designation. This statement applies
    beginning in third quarter 2009. All accounting references have
    been updated, and therefore U.S.&#160;GAAP standards have been
    replaced with ASC references. This standard had no impact on the
    Company&#146;s financial position, results of operations or cash
    flows.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In August 2009, the FASB issued Accounting Standards Update
    <FONT style="white-space: nowrap">No.&#160;2009-5,</FONT>
    &#147;Measuring Liabilities at Fair Value&#148; (&#147;ASU
    <FONT style="white-space: nowrap">2009-05&#148;).</FONT>
    ASU <FONT style="white-space: nowrap">2009-05</FONT>
    amends Accounting Standards Codification Topic 820, &#147;Fair
    Value Measurements.&#148; Specifically, ASU
    <FONT style="white-space: nowrap">2009-05</FONT>
    provides clarification that in circumstances in which a quoted
    price in an active market for the identical liability is not
    available, a reporting entity is required to measure fair value
    using one or more of the following methods: 1)&#160;a valuation
    technique that uses a)&#160;the quoted price of the identical
    liability when traded as an asset or b)&#160;quoted prices for
    similar liabilities or similar liabilities when traded as assets
    <FONT style="white-space: nowrap">and/or</FONT>
    2)&#160;a valuation technique that is consistent with the
    principles of Topic 820 of the Accounting Standards Codification
    (e.g. an income approach or market approach). ASU
    <FONT style="white-space: nowrap">2009-05</FONT> also
    clarifies that when estimating the fair value of a liability, a
    reporting entity is not required to adjust to include inputs
    relating to the existence of transfer restrictions on that
    liability. The Company does not anticipate that the adoption of
    this statement will have a material impact on its consolidated
    financial statements.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    In September 2009, the Emerging Issues Task Force (EITF) reached
    final consensus on ASC
    <FONT style="white-space: nowrap">605-25,</FONT>
    &#147;Revenue Arrangements with Multiple Deliverables.&#148; ASC
    <FONT style="white-space: nowrap">605-25</FONT>
    addresses how to determine whether an arrangement involving
    multiple deliverables contains more than one unit of accounting,
    and how the arrangement consideration should be allocated among
    the separate units of accounting.
    <FONT style="white-space: nowrap">EITF&#160;08-1</FONT>
    may be applied retrospectively or prospectively for new or
    materially modified arrangements and early adoption is
    permitted. The Company does not anticipate that the adoption of
    this statement will have a material impact on its consolidated
    financial statements.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">BUSINESS
    COMBINATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, the Company completed the acquisition of
    China Medstar at which time China Medstar became a 100% owned
    subsidiary of the Group. The results of China Medstar&#146;s
    operations have been included in the Company&#146;s consolidated
    financial statements commencing August&#160;1, 2008, the
    acquisition date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following unaudited pro forma condensed consolidated
    financial information reflects the Group&#146;s condensed
    consolidated results of operations for the period from
    January&#160;1, 2008 to September&#160;30, 2008 (successor) as
    if the acquisition of China Medstar had occurred on
    January&#160;1, 2008. The unaudited pro forma results have been
    prepared for information purposes only and do not purport to be
    indicative of what the Company&#146;s condensed consolidated
    results of operations would have been had the acquisition of
    China Medstar actually taken place on January&#160;1, 2008, and
    may not be indicative of future results of operations. Due to
    the overall insignificance of the acquisitions and their
    respective
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-61
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    results of operations individually and in the aggregate of XHF
    and other entities for the year ended December&#160;31, 2008,
    unaudited pro forma consolidated financial information has not
    been provided.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenues, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    164,867
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,152
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,573
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,899
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss attributable to ordinary shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (194,274
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,460
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per common share&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.20
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (0.47
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">3.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">PROPERTY,
    PLANT AND EQUIPMENT, NET</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property, plant and equipment consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="60%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">September 30, 2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Medical equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    299,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    524,514
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,838
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Electronic and office equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,154
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Motor vehicles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvement and building improvement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,552
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Construction in progress
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,029
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,883
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,702
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    367,384
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    609,623
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89,307
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: Accumulated depreciation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,263
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52,190
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,646
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    349,121
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    557,433
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,661
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Depreciation expenses were approximately RMB9,413 and RMB35,101
    (US$5,142) for nine months ended September&#160;30, 2008 and
    2009, respectively. As at December&#160;31, 2008 and
    September&#160;30, 2009, certain of the Group&#146;s property,
    plant and equipment were pledged as security for bank borrowings
    (see note&#160;5.) As at December&#160;31, 2008 and
    September&#160;30, 2009, the Company held equipment under
    operating lease contracts with customers with an original cost
    of RMB299,100 and RMB241,414 (US$35,366) and accumulated
    depreciation of RMB17,705 and RMB23,786 (US$3,485), respectively.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-62
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">4.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">DEPOSITS
    FOR NON-CURRENT ASSETS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Deposits for non-current assets consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">September&#160;30,
    2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit for purchase of property, plant and equipment*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    128,749
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98,822
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit held by a related party **
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,630
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,420
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,405
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other ***
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,609
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,777
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    147,851
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,659
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=468 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">*&#160;
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Represents interest-free
    non-refundable partial payments to suppliers associated with
    contracts the Group enters into for the future scheduled
    delivery of medical equipment to customers. As at
    September&#160;30, 2009, the remaining contractual obligations
    associated with these purchase contracts are approximately
    RMB102,688 (US$15,043) which is included in the amount disclosed
    as Purchase commitments in note&#160;12. The risk of loss
    arising from non-performance by or bankruptcy of the suppliers
    is assessed prior to ordering the equipment. To date, the Group
    has not experienced any loss on deposit to suppliers.
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">**
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">On October&#160;31, 2008, the Group
    entered into a long-term sale and purchase agreement with Our
    Medical New Technology, under which the Group agreed to purchase
    gamma knife systems at agreed upon prices and Our Medical New
    Technology also agreed to provide the Group relevant maintenance
    and repair services and training. Our Medical New Technology is
    controlled by an individual who is a relative of a shareholder
    of the company. (See note&#160;10.)
    </FONT></TD>
</TR>




<TR>
    <TD align="right" valign="top">
    <FONT style="font-size: 8pt">***
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The Group has entered into two
    distinct framework agreements with Chang&#146;an Hospital Co.
    Ltd. (&#147;Chang&#146;an&#148;) and Chang&#146;an Information
    Industry (Group) Co., Ltd., (&#147;Chang&#146;an
    Information&#148;) towards the development and construction of
    the following two medical facilities:
    </FONT></TD>
</TR>

</TABLE>



<DIV align="left" style="margin-left: 3%; margin-right: 0%; text-indent: 0%; font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;18, 2007, the Group entered into a framework
    agreement to build a proton treatment center in Beijing,
    pursuant to which the Group paid deposits to a subsidiary of
    Chang&#146;an Information to be used towards the construction of
    the proton treatment center (&#147;Beijing Proton Medical
    Center&#148;). Total deposits paid as of December&#160;31, 2008
    and September&#160;30, 2009 pursuant to this arrangement
    amounted to RMB3,821 and RMB14,615 (US$2,141), respectively.
</DIV>



<DIV align="left" style="margin-left: 3%; margin-right: 0%; text-indent: 0%; font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;1, 2008, the Group entered into a framework
    agreement with Chang&#146;an to build a cancer center in
    northwest China, the Chang&#146;an CMS International Cancer
    Center (&#147;CCICC&#148;) pursuant to which the Group paid
    deposits to Chang&#146;an totaling RMB17,000 and RMB18,000
    (US$2,635), which have been recorded as a non-current deposit as
    of December&#160;31, 2008 and September&#160;30, 2009,
    respectively. (See note 15.)
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">5.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">BANK
    BORROWINGS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="55%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="15%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">September&#160;30,
    2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,760
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    179,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Comprised of:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Short-term
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,395
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Long-term, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,640
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    74,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,970
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    104,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,369
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    112,760
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    179,792
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All bank borrowings at December&#160;31, 2008 and
    September&#160;30, 2009 are obtained from financial institutions
    in the PRC and are secured by equipment with a net book value of
    RMB81,595 and RMB217,646 (US$31,884), accounts receivable with
    carrying value of nil and RMB10,131 (US$1,484), and restricted
    cash with carrying value of nil and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-63
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    RMB7,245 (US$1,062), respectively. Restricted cash is classified
    as current and non-current in the amounts of RMB2,012 (US$295)
    and RMB5,233 (US$767), respectively, based on the classification
    of the underlying financing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As at December&#160;31, 2008 and September&#160;30, 2009, the
    short-term bank borrowing bore a weighted average interest of
    6.66% and 5.07% per annum, and the long-term bank borrowings
    bore weighted average interest of 7.47% and 5.18% per annum,
    respectively. All borrowings are denominated in RMB.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group entered into four new bank borrowings with PRC
    financial institutions during the nine months ended
    September&#160;30, 2009 with an aggregate principal amount of
    RMB155,000, of which RMB93,980 (US$13,768) was drawn down as at
    September&#160;30, 2009. The weighted average interest rate of
    these four new bank borrowings was 5.47%. The three bank
    financing arrangements are secured by certain accounts
    receivable and restricted cash deposited with each of the
    respective financial institutions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    One of these new borrowing arrangements were entered into by a
    subsidiary of the Group, MSC, which requires MSC and AMS,
    another subsidiary of the Group, in accordance with PRC GAAP, to
    maintain a financial reporting covenant of tangible net worth of
    at least RMB400,000 and RMB180,000 and total gearing ratio of
    less than 0.5 and 0.36, respectively. Tangible net worth is
    calculated as the sum of issued share capital and reserves less
    goodwill and intangible assets and any amount due from
    shareholders and the total gearing ratio is calculated as the
    ratio of total liabilities to tangible net worth. The Group was
    in compliance of these financial covenants as of
    September&#160;30, 2009. The remaining bank borrowings do not
    have any financial reporting or administrative covenants
    restricting the Company&#146;s operating, investing and
    financing activities.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">6.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">CONTINGENTLY
    REDEEMABLE CONVERTIBLE PREFERRED SHARES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Background</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2007, OMS, a subsidiary of the Group,
    issued notes convertible into Series&#160;A contingently
    redeemable convertible preferred shares (the &#147;Series&#160;A
    Preferred Shares&#148;) with a principal amount of US$5,000 (the
    &#147;Tranche&#160;A Convertible Notes&#148;) to Carlyle Asia
    Growth Partners III, L.P. (hereafter, &#147;Carlyle Asia&#148;)
    and CAGP III Co- Investment, L.P. (an affiliate of Carlyle Asia,
    together with Carlyle Asia, &#147;Carlyle&#148;) for cash
    consideration of US$5,000. On April&#160;10, 2008, the total
    principal and accrued and unpaid interest of the Tranche&#160;A
    Convertible Notes amounting to US$5,171 were converted into
    28,882 Series&#160;A Preferred Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;2, 2008, the Company issued notes convertible into
    Series&#160;A Preferred Shares (&#147;Tranche&#160;B Convertible
    Notes&#148;) at the holder&#146;s option to Carlyle with a
    principal amount of US$20,000. On July&#160;31, 2008, Carlyle
    exercised its conversion right and the total principal and
    accrued and unpaid interest of the Tranche&#160;B Convertible
    Notes amounting to US$20,547 was converted into 87,425
    Series&#160;A Preferred Shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;10, 2008, OMS issued an aggregate of 53,070
    Series&#160;A Preferred Shares to Carlyle and CICC Sun Company
    Limited (&#147;CICC&#148;) for total cash proceeds of US$10,000.
    On June&#160;18, 2008, the Company agreed that a relative of a
    director of the Company shall transfer 756,500 of her own
    holdings of the Company&#146;s ordinary shares, which were
    redesignated as 7,565 Series&#160;A Preferred Shares, and issued
    to CICC.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;20, 2008, the Company issued an aggregate of
    233,332 Series&#160;B contingently redeemable convertible
    preferred shares (the &#147;Series&#160;B Preferred
    Shares&#148;) to Carlyle, Starr Investments Cayman II, Inc.
    (&#147;Starr&#148;), and CICC for cash consideration of
    US$25,000, US$25,000 and US$10,000, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounting
    for the contingently redeemable convertible preferred
    shares</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Preferred Shares have been classified as mezzanine equity
    recorded at the subscription amount, less issuance costs, and is
    accreted to the redemption amount using the effective interest
    method. The redemption amount for the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-64
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Preferred Shares provides the shareholder with a 12.5%
    compounded annual return on the original subscription price or
    converted value, of which 5% is payable as a fixed dividend. For
    the nine months ended September&#160;30, 2008 and 2009, the
    Group recorded accretion related to its Series&#160;A Preferred
    Shares in the amount of RMB8,969 and RMB23,851 (US$3,494), of
    which RMB3,655 and RMB9,192 (US$1,347) were recorded as
    dividends payable, respectively. Similarly, for the nine months
    ended September&#160;30, 2009, the Group recorded accretion
    expense for its Series&#160;B Preferred Shares in the amount of
    RMB38,383 (US$5,623), of which RMB15,448 (US$2,263) was recorded
    as dividends payable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A beneficial conversion feature exists when the effective
    conversion price of the Preferred Shares is lower than the fair
    value of the ordinary shares on their issuance date. The
    effective conversion price of the Series&#160;A Preferred
    Shares, after considering the impact of all adjustments to the
    conversion price, was lower than the average estimated fair
    value of US$0.95 per ordinary share. The allocation of the
    beneficial conversion feature is recorded to additional paid-in
    capital. Because the Preferred Shares do not have a stated
    redemption date, the beneficial conversion feature is accreted
    to the earliest conversion date, which was upon issuance. For
    the nine months ended September&#160;30, 2008, the aggregate
    beneficial conversion feature in relation to the April 2008 and
    June 2008 issuances of Series&#160;A Preferred Shares amounted
    to RMB253,317 (US$37,110).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Upon the occurrence of a Put Trigger Event, each holder of
    Preferred Shares shall have the right to require the Company to
    purchase all the Preferred Shares held by the Preferred
    Shareholders at a rate of return of 12.5%. A Put Trigger Event
    means any of the non-completion of a qualified initial public
    offering by the third anniversary of the closing date of the
    subscription of the Preferred Shares, the resignation of certain
    key directors of the Company and its subsidiaries which would
    likely to result in a material adverse effect, or the breach or
    failure to comply with any applicable laws that has had or would
    be reasonably likely to have, a material adverse effect. As at
    December&#160;31, 2008 and September&#160;30, 2009, the
    Series&#160;A Preferred Shares redemption amounts were US$38,147
    and US$41,638, and similarly, the Series&#160;B Preferred Shares
    redemption amounts were US$61,390 and US$67,008, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the case of liquidation, dissolution or winding up of the
    Company, each holder of Preferred Shares shall be entitled to
    receive, prior to and in preference to any distribution of any
    of the assets or surplus of funds of the Company to the holders
    of the ordinary shares, the amount equal to the sum of 150%
    times the original price of each Preferred share plus all
    accrued but unpaid dividends thereon. As at December&#160;31,
    2008 and September&#160;30, 2009, aggregate liquidation
    preference amounts for the Series&#160;A Preferred Shares were
    US$54,573 and US$55,471, respectively, and similarly, the
    aggregate liquidation preference amounts for the Series&#160;B
    Preferred Shares were US$90,583 and US$92,846, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">7.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">RESTRICTED
    NET ASSETS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with the PRC Regulations on Enterprises with
    Foreign Investment and their articles of association, a foreign
    invested enterprise established in the PRC is required to
    provide certain statutory reserves, namely general reserve fund,
    the enterprise expansion fund and staff welfare and bonus fund
    which are appropriated from net profit as reported in the
    enterprise&#146;s PRC statutory accounts. A foreign invested
    enterprise is required to allocate at least 10% of its annual
    after-tax profit to the general reserve until such reserve has
    reached 50% of its respective registered capital based on the
    enterprise&#146;s PRC statutory accounts. Appropriations to the
    enterprise expansion fund and staff welfare and bonus fund are
    at the discretion of the board of directors for all foreign
    invested enterprises.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As a result of these PRC laws and regulations that require
    annual appropriations of 10% of after-tax income to be set aside
    prior to payment of dividends as general reserve fund, the
    Company&#146;s PRC subsidiaries are restricted in their ability
    to transfer a portion of their net assets to the Company.
    Amounts restricted include paid-in capital, statutory reserve
    funds and net assets of the Company&#146;s PRC subsidiaries, as
    determined pursuant to PRC generally accepted
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-65
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    accounting principles, totaling approximately RMB680,476 and
    RMB912,850 (US$133,727) as of December&#160;31, 2008 and
    September&#160;30, 2009, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">8.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">TAXATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the nine months ended September&#160;30, 2009, the Group
    has no additional unrecognized tax benefits relating to
    uncertain tax positions except for accruing interests related to
    unsolved previous year unrecognized tax benefits. Also, the
    Group does not expect that the amount of unrecognized tax
    benefits will increase significantly within the next
    12&#160;months.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2008 and September&#160;30, 2009, the
    Group has recognized approximately RMB20,509 and RMB21,647
    (US$3,171) as an accrual for unrecognized tax benefits,
    respectively. The final outcome of the tax uncertainty is
    dependent upon various matters including tax examinations,
    interpretation of tax laws or expiration of status of
    limitation. However, due to the uncertainties associated with
    the status of examinations, including the protocols of
    finalizing audits by the relevant tax authorities, there is a
    high degree of uncertainty regarding the future cash outflows
    associated with these tax uncertainties. As of
    September&#160;30, 2009, the Group classified the RMB21,647
    (US$3,171) accrual as a current liability.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">9.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">EMPLOYEE
    SHARE OPTIONS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On October&#160;16, 2008, the Board of Directors adopted the
    2008&#160;Share Incentive Plan (&#147;The 2008&#160;Share
    Incentive Plan&#148;). The 2008&#160;Share Incentive Plan
    provides for the granting of options, share appreciation rights,
    or other share-based awards to key employees, directors or
    consultants. The total number of the ordinary shares of the
    Company that may be issued under the 2008&#160;Share Incentive
    Plan is up to 1,321,800. As of September&#160;30, 2009, no
    awards have been granted under the 2008&#160;Share Incentive
    Plan.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">10.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">RELATED
    PARTY TRANSACTIONS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    a)&#160;&#160;Related parties
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Name of Related
    Parties</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Relationship with the
    Group</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A relative of shareholder of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and shareholder of the Company
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and shareholder of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Yaw Kong Yap
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and shareholder of the Company
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shenzhen Hai Ji Tai Technology Co., Ltd. (&#147;Haijitai&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company owned by Mr. Haifeng Liu
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Beijing Medstar Hi-Tech Investment Co., Ltd. (&#147;Beijing
    Medstar&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company under the control of Mr. Zheng Cheng
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Our Medical New Technology Co., Ltd
    (&#147;Our&#160;Medical&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company under the control of Mr. Haifeng Liu
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-66
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    b)&#160;&#160;
</TD>
    <TD align="left">
    The Group had the following related party transactions for the
    nine months ended September&#160;30, 2008 and 2009:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Short-term interest-free loans borrowed from:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Repayment of interest-free loans borrowed from:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Haijitai
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mr. Jianyu Yang
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-current deposits made to:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Our Medical
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,442
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,676
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Purchase of radioactive material source through utilization of
    non-current deposits from :
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Our Medical
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Imputed interest, calculated using incremental borrowing rates
    ranging from 6.57% to 7.48%, amounting to approximately
    RMB2,425, and RMB54 (US$8)for the nine months ended
    September&#160;30, 2008 and 2009 respectively, were recorded
    with an offsetting credit to Additional Paid-in Capital.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    c)&#160;&#160;The Group had the following related party balances:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="51%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="17%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">December&#160;31,
    2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">September&#160;30,
    2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amount due to related parties:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Beijing Medstar
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mr. Haifeng Liu
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mr. Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,351
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,351
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    198
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Mr. Yaw Kong Yap
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposits held by a related party:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Our Medical
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,630
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16,420
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,405
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All balances with the related parties as of December&#160;31,
    2008 and September&#160;30, 2009 were unsecured, interest-free
    and have no fixed terms of repayment.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">11.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">EMPLOYEE
    DEFINED CONTRIBUTION PLAN</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Full time employees of the Group in the PRC participate in a
    government mandated defined contribution plan, pursuant to which
    certain pension benefits, medical care, employee housing fund
    and other welfare benefits are provided to employees. Chinese
    labor regulations require that the PRC subsidiaries of the Group
    make contributions to
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-67
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    the government for these benefits based on certain percentages
    of the employees&#146; salaries. The Group has no legal
    obligation for the benefits beyond the contributions made. The
    total amounts for such employee benefits, which were expensed as
    incurred, were approximately RMB480 and RMB1,694 (US$248) for
    the nine months ended September&#160;30, 2008 and 2009,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Obligations for contributions to defined contribution retirement
    plans for full-time employees in Singapore are recognized as
    expense in the statements of operations as incurred. The total
    amounts for such employee benefits, who is also a Director of
    the Company, were approximately RMB15 and RMB40 (US$6) for the
    nine months ended September&#160;30, 2008 and 2009, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">12.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">COMMITMENTS
    AND CONTINGENCIES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Operating
    lease commitments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the nine months ended September&#160;30, 2009, the Group
    entered into two non-cancellable corporate office operating
    leases with a lease term of two and three years, respectively.
    These leases have no renewal options, material rent escalation
    clauses or contingent rents. Upon termination of the leases,
    they are renewable at fair value upon negotiation with the
    lessor.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Future minimum payments under non-cancelable operating leases
    with initial terms in excess of one year consist of the
    following at September&#160;30, 2009:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="84%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Three months ended December&#160;31,
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Year ended December&#160;31,
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,148
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    754
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,763
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    698
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2012
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,305
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    338
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,552
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,986
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Payments under operating leases are expensed on a straight-line
    basis over the periods of their respective leases. For the nine
    months ended September&#160;30, 2008 and 2009, total rental
    expenses for all operating leases amounted to approximately
    RMB1,581 and RMB3,830 (US$561), respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Purchase
    commitments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group has commitments to purchase certain medical equipment
    of approximately RMB102,688 (US$15,043) as of September&#160;30,
    2009, which are scheduled to be paid within one year.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">13.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SEGMENT
    REPORTING</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group&#146;s chief operating decision maker operates,
    evaluates performance, allocates resources, and manages its
    business as a single segment which includes primarily lease,
    management services and equipment sales.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Lease and management services accounted for approximately 90%
    and 90% of the Group&#146;s net revenue for the nine months
    ended September&#160;30, 2008 and 2009, respectively. Any
    significant reduction in sales from this service could have a
    substantial negative impact on the Group&#146;s results of
    operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-68
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Hospital A and Hospital B represented the two largest customers
    of the Group accounting for approximately RMB21,988 (US$3,221)
    and RMB20,861 (US$3,056), respectively, each of which is more
    than 10% of the Group&#146;s consolidated revenues for nine
    months ended September&#160;30, 2009. Hospital A represented the
    largest customer of the Group accounting for approximately
    RMB14,644 of revenues, which is greater than 10% of the
    Group&#146;s consolidated revenues for the nine months ended
    September&#160;30, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Geographic disclosures:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As the Group primarily generates its revenues from customers in
    the PRC, no geographical segments are presented. All of the
    Group&#146;s long-lived assets are located in the PRC.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">14.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">(LOSS)
    INCOME PER SHARE (UNAUDITED)</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Basic and diluted (loss) income per share for each of the
    periods presented is calculated as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="61%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom">
    <B>(amounts in thousands except for the number of shares and per
    share data)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Numerator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -20pt; margin-left: 20pt">
    Net (loss) income attributable to ordinary shareholders used in
    calculating loss per ordinary share&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (222,270
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,914
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Denominator:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -20pt; margin-left: 20pt">
    Weighted average number of ordinary shares outstanding used in
    calculating basic and diluted loss per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,621,700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Basic and diluted (loss) income per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3.67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.06
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the nine months ended September&#160;30, 2008, the diluted
    loss per share is the same as basic loss per share because the
    if-converted method would not be applied as the effect of the
    convertible notes would be anti-dilutive. The share options
    should not be included in the calculation of diluted loss per
    share because the company incurred a net loss and, therefore,
    the effect would be anti-dilutive.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the nine months ended September&#160;30, 2009, the basic
    income per share was calculated using the two class method
    because the Preferred Shares were participating securities.
    Diluted income per share is the same as basic income per share
    because the effects of the Preferred Shares were anti-dilutive
    when computed on an &#147;if converted&#148; basis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In 2008, the Company issued Series&#160;A and Series&#160;B
    contingently redeemable convertible preferred shares. Each
    Preferred Share shall be convertible, at the option of the
    holder thereof, at any time after the closing of the
    subscription, into a number of fully paid and non-assessable
    ordinary shares at a ratio 1:100 and is subject to adjustment
    pursuant to anti-dilution provisions. One hundred percent of
    each class of the Preferred Shares which are outstanding
    immediately prior to the closing of the qualified initial public
    offering shall, on and with effect from the closing of the
    qualified initial public offering, be automatically converted
    into ordinary shares. Assuming the conversion had occurred
    &#147;on a
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-69
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    hypothetical&#148; basis on January&#160;1, 2009, the pro-forma
    basic and diluted loss per share for the nine months ended
    September&#160;30, 2009 is calculated as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="82%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>For the Nine<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Months Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(pro forma) <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(amounts in <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>thousands except <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>for the number of <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>shares and per <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>share data)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Numerator</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income attributable to ordinary shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma adjustments:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;A contingently redeemable convertible preferred
    shares&#160;&#151; accretion to redemption amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,851
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;B contingently redeemable convertible preferred
    shares&#160;&#151; accretion to redemption amount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,383
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net income for pro forma basic and diluted income per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    88,957
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Denominator</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average number of ordinary shares outstanding used in
    calculating basic income per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,428,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of Series&#160;A preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,694,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Conversion of Series&#160;B preferred shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,333,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average number of ordinary shares outstanding used in
    calculating basic and diluted income per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    111,455,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma income per share&#160;&#151; basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pro forma income per share&#160;&#151; basic and diluted (in US$)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">15.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ARRANGEMENT
    WITH CHANG&#146;AN HOSPITAL CO., LTD.</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group has entered into the following agreements with
    Chang&#146;an Hospital Co., Ltd. (&#147;Chang&#146;an&#148;), a
    general hospital located in Xi&#146;an in Shaanxi province in
    the PRC, which is also a significant customer of the Group, and
    certain of its related parties, including the controlling parent
    of Chang&#146;an, Chang&#146;an Information Industry (Group)
    Co., Ltd., (&#147;Chang&#146;an Information&#148;), a
    China-based conglomerate engaged in information technology, real
    estate and the medical industries; a subsidiary of
    Chang&#146;an, Xi&#146;an Century Friendship Medical Technology
    R&#038;D Co., Ltd.
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-70
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (&#147;Xi&#146;an&#148;), and another subsidiary controlled by
    Chang&#146;an Information, Beijing Century Friendship
    Science&#160;&#038; Technology Development Co., Ltd.,
    (&#147;Beijing Century&#148;):
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Management
    agreements to provide stand-alone management
    services</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group entered into a Medical Equipment Entrusted Management
    Agreement on March&#160;1, 2007 with Xi&#146;an and
    Chang&#146;an to provide management services with respect to
    radiotherapy and diagnostic equipment owned by Xi&#146;an
    located in the oncology center of Chang&#146;an. Commencing
    January&#160;1, 2010 or an agreed upon earlier date, Concord has
    the option to purchase the radiotherapy and diagnostic equipment
    owned by Xi&#146;an at fair value if the Chang&#146;an oncology
    center&#146;s annualized revenues achieves a certain targeted
    level. Total management services revenue recognized under this
    contract was RMB6,135 and RMB10,921 (US$1,600) for the nine
    months ended September&#160;30, 2008 and 2009, respectively.
    Accounts receivable related to this contract as at
    December&#160;31, 2008 and September&#160;30, 2009 was RMB4,000
    and RMB10,921 (US$1,600), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;25, 2009, the Group entered into an Equipment
    Purchase Agreement with Xi&#146;an and Chang&#146;an to acquire
    the radiotherapy and diagnostic equipment for a total cash
    consideration of RMB72,716 (US$10,646), of which RMB50,000
    (US$7,325) was paid in September 2009. Concurrently, the Group
    also converted the stand-alone management services arrangement
    into a lease and management service agreement, which provides
    the Group with a percentage of net profit generated by
    Chang&#146;an&#146;s oncology center. Commencing September 2009,
    the Group records all revenue associated with this arrangement
    as lease and management services revenue. The depreciation
    expense of the associated equipment is recorded as lease and
    management services cost of revenues. Total lease and management
    service revenue recognized under this lease and management
    service agreement was RMB2,036 (US$298) for the nine months
    ended September&#160;30, 2009. Accounts receivable related to
    this contract as at September&#160;30, 2009 was RMB2,036
    (US$298).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;1, 2008, the Company signed an Entrusted
    Management Contract with Xi&#146;an and Chang&#146;an to provide
    general administrative management services to Chang&#146;an.
    Under this arrangement, the Group earns a certain percentage of
    total monthly revenues of Chang&#146;an Hospital. In accordance
    with the contract, the Group paid a performance guarantee
    deposit of RMB15,000 (US$2,197) to a related party of
    Xi&#146;an, which is refundable 15&#160;days after the
    cancellation or expiration of the contract (January&#160;15,
    2010). Total revenue recognized during the nine months ended
    September&#160;30, 2009 under this contract was RMB9,024
    (US$1,322). Accounts receivable related to this contract as at
    September&#160;30, 2009 was RMB9,024 (US$1,322).
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Beijing
    Proton Medical Center</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;18, 2007, the Group entered into a framework
    agreement with Chang&#146;an Information to build a Beijing
    Proton Medical Center (&#147;Proton Center&#148;). The Proton
    Center will initially be established by Chang&#146;an
    Information with a total registered capital of RMB100,000. The
    parties agreed that after certain capital injections from the
    Group are made for purposes of financing the construction and
    center development costs, the Company will hold a 51.2% interest
    in the Proton Center, while Jian Chang Group Limited, a related
    party of Chang&#146;an, will hold 28.8% and China-Japan
    Friendship Hospital, a state-owned hospital, will hold 20.0%.
    Once the Proton Center commences operations, the Group shall own
    a 51.2% controlling interest in the Proton Center and will
    consolidate the operating results and financial position within
    the Group. Additional contractual arrangements will be entered
    into by the Group once all relevant permits and approvals are
    obtained. In order for this framework agreement to become
    effective, the Group is required to pay a deposit of RMB10,000
    (US$1,465); this deposit was not paid as of December&#160;31,
    2008 and September&#160;30, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To assist with the project, the Group has made deposits to
    Beijing Century in the amounts of RMB3,821 and RMB14,615
    (US$2,141) as of December&#160;31, 2008 and September&#160;30,
    2009, respectively, towards certain setup and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-71
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    construction costs of the Proton Center; these deposits are due
    back to the Group by December&#160;31, 2009. All of the deposits
    are guaranteed by Chang&#146;an Information.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Chang&#146;an
    CMS International Cancer Center</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;1, 2008, the Group entered into a framework
    agreement with Xi&#146;an to build a cancer center in northwest
    China, to be called Chang&#146;an CMS International Cancer
    Center (&#147;CCICC&#148;). Although the CCICC will initially be
    established by Xi&#146;an, the parties agreed that after certain
    initial capital injections estimated at RMB34,800 (US$5,098)
    from the Group are made, the Company shall hold a controlling
    interest of 52% in the CCICC, while Xi&#146;an will hold a
    non-controlling interest of 48%. Similarly, the Group
    anticipates having to consolidate the operating results and
    financial position of the CCICC when the Group obtains a
    controlling interest. As of September&#160;30, 2009, Xi&#146;an
    is waiting for all relevant permits and approvals to be obtained
    prior to the legal establishment the CCICC, upon which,
    additional contractual arrangements will be entered into by the
    Group. As of December&#160;31, 2008 and September&#160;30, 2009,
    the Group paid a deposit of RMB15,000 (US$2,197) to a related
    party of Xi&#146;an in accordance with the framework agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are no other obligations under the current framework
    agreement and the agreement does not specify a contractual
    completion date for the deposit to be repaid to the Group. If
    the CCICC is established, the RMB15,000 deposit will be applied
    against future capital injections beyond the initial capital
    investment estimate of RMB34,800. The Group has also paid
    deposits to Xi&#146;an to be used towards setup and construction
    costs of the CCICC amounting to RMB2,000 and RMB3,000 (US$439)
    as of December&#160;31, 2008 and September&#160;30, 2009,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group had the following transactions with Chang&#146;an and
    its affiliated companies for the nine months ended
    September&#160;30, 2008 and 2009:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="62%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Nine Months Ended September&#160;30,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Management services revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Medical Equipment Entrusted Management Agreement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,135
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,921
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Entrusted Management Contract
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,024
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,322
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Lease and management service revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,036
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    298
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,135
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,981
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,220
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Accounts receivable due from Chang&#146;an
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,981
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,220
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group had the following deposits on loan with Chang&#146;an
    and its affiliated companies as at December&#160;31, 2008 and
    September&#160;30, 2009:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="54%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December 31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>September&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2009</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$ <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(unaudited)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current&#160;&#151; Entrusted Management Contract
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,197
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-current&#160;&#151; Proton Center and CCICC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32,615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,778
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35,821
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-72
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED<BR>
    <BR>
    NOTES&#160;TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
    (Amount in thousands of Renminbi (&#147;RMB&#148;) and United
    States Dollar (&#147;US$&#148;),<BR>
    except for number of shares)&#160;&#151; (Continued)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">16.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SUBSEQUENT
    EVENTS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with ASC subtopic
    <FONT style="white-space: nowrap">855-10</FONT>
    <FONT style="white-space: nowrap">(&#147;ASC&#160;855-10&#148;),</FONT>
    <I>Subsequent Events: Overall </I>(Pre-Codification:
    SFAS&#160;165), the Company evaluated subsequent events through
    November&#160;17, 2009, which was the date that the consolidated
    interim financial statements were available to be issued. The
    Company had the following significant subsequent events:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On November&#160;17, 2009, the Company&#146;s Board of Directors
    approved the following resolutions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    To distribute an interim dividend to the holders of the ordinary
    shares as at November&#160;17, 2009 in the sum of
    (i)&#160;US$2,391,534 to the holders of the ordinary shares; and
    (ii)&#160;US$1,590,676 to the holders of the Series&#160;A and B
    Preferred Shares, such dividend to be payable in cash on or
    about November&#160;27, 2009.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Amended the Articles of Association to reflect a 100-for-one
    stock split of the Company&#146;s ordinary shares whereby each
    ordinary share of the Company is subdivided into 100&#160;shares
    at a par value of US$0.0001. All shares and per share amounts
    presented in the accompanying consolidated financial statements
    have been revised on a retroactive basis to reflect the effect
    of the share split. The par value per ordinary share has been
    retroactively revised as if it had been adjusted in proportion
    to the
    <FONT style="white-space: nowrap">100-for-one</FONT>
    share split.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Amended the Company&#146;s 2008&#160;Share Incentive Plan, to
    increase the total number of ordinary shares that may be issued
    under the 2008 Incentive Plan from 1,321,800 ordinary shares to
    4,765,800 ordinary shares
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-73
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times"> CHINA
    MEDSTAR PTE. LIMITED</FONT></B>
</DIV>

<A name='128'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INDEX TO
    CONSOLIDATED FINANCIAL STATEMENTS</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="91%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Page</FONT></B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#312'>Report of Independent Registered Public
    Accounting Firm</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-75
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#313'>Consolidated Balance Sheets as of
    December&#160;31, 2007 and as of July&#160;31, 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-76
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#314'>Consolidated Statements of Operations for the
    year ended December&#160;31, 2007 and the seven month period
    ended July&#160;31, 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-78
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#315'>Consolidated Statements of Cash Flows for the
    year ended December&#160;31, 2007 and the seven month period
    ended July&#160;31, 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-79
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#316'>Consolidated Statements of Changes in
    Shareholders&#146; Equity for the year ended December&#160;31,
    2007 and the seven month period ended July&#160;31, 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-81
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#317'>Notes to the Consolidated Financial Statements
    for the year ended December&#160;31, 2007 and the seven month
    period ended July&#160;31, 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-82
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-74
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='312'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">REPORT OF
    INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors and Shareholders of
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    China Medstar Limited
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have audited the accompanying consolidated balance sheets of
    China Medstar Limited (the &#147;Company&#148;) and its
    subsidiaries (together, the &#147;Group&#148;) as of
    December&#160;31, 2007 and July&#160;31, 2008, and the related
    consolidated statements of operations, cash flows and changes in
    shareholders&#146; equity for the year and the seven months
    period then ended. These financial statements are the
    responsibility of the Company&#146;s management. Our
    responsibility is to express an opinion on these financial
    statements based on our audits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We conducted our audits in accordance with the standards of the
    Public Company Accounting Oversight Board (United States). Those
    standards require that we plan and perform the audit to obtain
    reasonable assurance about whether the financial statements are
    free of material misstatement. We were not engaged to perform an
    audit of the Group&#146;s internal control over financial
    reporting. Our audits included consideration of internal control
    over financial reporting as a basis for designing audit
    procedures that are appropriate in the circumstances, but not
    for the purpose of expressing an opinion on the effectiveness of
    the Group&#146;s internal control over financial reporting.
    Accordingly, we express no such opinion. An audit also includes
    examining, on a test basis, evidence supporting the amounts and
    disclosures in the financial statements, assessing the
    accounting principles used and significant estimates made by
    management, and evaluating the overall financial statement
    presentation. We believe that our audits provide a reasonable
    basis for our opinion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In our opinion, the financial statements referred to above
    present fairly, in all material respects, the consolidated
    financial position of the Group at December&#160;31, 2007 and
    July&#160;31, 2008 and the consolidated results of their
    operations and their cash flows for the year and the seven
    months period then ended in conformity with U.S.&#160;generally
    accepted accounting principles.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Ernst&#160;&#038;
    Young Hua Ming</DIV>
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shenzhen, the People&#146;s Republic of China
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    September&#160;3, 2009
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-75
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">


    <A name='313'><B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    BALANCE SHEETS</A><BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and U.S. Dollars
    (&#147;US$&#148;))</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="41%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As at<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at July&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Notes</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="17" align="center" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>ASSETS</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Current assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,926
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,869
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    49,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,285
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Prepayment and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,780
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,095
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred tax assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Current assets held for sale
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total current assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,212
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Non-current assets:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Property, plant and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    216,918
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    284,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,707
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deposits for property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,505
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred tax assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Non-current assets held for sale
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,435
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,229
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,059
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total assets</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    347,306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460,012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-76
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    BALANCE SHEETS&#160;&#151; (Continued)<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and U.S. Dollars
    (&#147;US$&#148;) except for number of shares)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As at<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at July&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Notes</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="17" align="center" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Current liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Long-term bank borrowings, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,623
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,320
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,830
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,733
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,238
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accrual for purchase of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,595
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,259
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,825
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Income tax payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,605
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,743
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    694
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenue, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    737
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,622
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Current liabilities of discontinued operation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Amounts due to related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,881
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,033
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total current liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    123,724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,124
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Non-current liabilities:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Long-term bank borrowings, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    103,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,099
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenue, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,683
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,344
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    490
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Lease deposits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,118
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,185
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    467
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total liabilities</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    149,504
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    233,323
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,180
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Commitments and contingencies</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Minority interests</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,179
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Shareholders&#146; equity:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Share capital (Issued and outstanding&#160;&#151;
    27,564,138&#160;shares as at December&#160;31, 2007 and
    July&#160;31, 2008; nil par value)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,979
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,237
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,962
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (929
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (682
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Retained earnings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,112
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total shareholders&#146; equity</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    195,623
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    226,689
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Total liabilities and shareholders&#146; equity</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    347,306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    460,012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,389
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-77
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">


    <A name='314'><B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF OPERATIONS<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    </A><B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and U.S. Dollars
    (&#147;US$&#148;))</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Seven Month Period Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Notes</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">July&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Revenues, net of business tax, value-added tax and related
    surcharge:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,357
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,745
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,141
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,169
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,148
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,451
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,873
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,210
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Cost of revenues:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,484
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,806
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,169
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Others
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,781
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,265
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,178
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Gross profit</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,186
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Operating expenses:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2,911
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,581
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (232
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,224
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,340
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,221
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Operating profit</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,579
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    351
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,204
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,585
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (233
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loss from disposal of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (400
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (49
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (230
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Other expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (200
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Income from continuing operations before income taxes</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Income tax expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (922
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,445
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,237
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Income from continuing operations</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,822
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,655
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Discontinued operations:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loss from discontinued operations, net of taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (193
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (683
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Gain on disposal of discontinued operations, net of taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,122
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    164
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>(Loss) gain from discontinued operations</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (193
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    439
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    64
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Net income</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,629
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,115
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying notes are an integral part of the consolidated
    financial statements
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-78
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">


    <A name='315'><B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF CASH FLOWS</A><BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and U.S. Dollars
    (&#147;US$&#148;))</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Seven Month Period Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">July&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    CASH FLOWS FROM OPERATING ACTIVITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,629
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,115
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Add/less: net loss (income) from discontinued operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    193
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (439
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (64
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Income from continuing operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,822
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,655
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Adjustments to reconcile income from continuing operations to
    net cash generated from operating activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,725
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    399
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Depreciation and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,180
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,857
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Loss on disposal of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Deferred tax (benefit) expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,776
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Changes in operating assets and liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Increase in accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,196
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,694
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,204
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Increase in prepayment and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (803
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,083
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (159
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Decrease in other non-current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,613
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,205
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    177
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    (Decrease) increase in accounts payable and note payables
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,803
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,506
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Increase in accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    270
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,964
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    (Decrease) increase in deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (826
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,545
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    519
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Increase in amounts due to related parties
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    188
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    108
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    Increase in long term lessee deposits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    117
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    156
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 28pt">
    (Decrease) increase in income tax payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (762
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net cash generated from operating activities from continuing
    operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,953
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,012
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,033
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net cash used in operating activities from discontinued
    operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,684
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    413
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net cash generated from operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,269
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,425
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    CASH FLOWS FROM INVESTING ACTIVITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Acquisition of property, plant and equipment, net of related
    payables
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,661
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26,351
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,860
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Deposits for the purchase of property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (81,637
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (72,713
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,652
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Proceeds from disposal of fixed assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    158
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net cash used in investing activities from continuing operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (101,140
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (99,064
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,512
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net cash used in investing activities from discontinued
    operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (317
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (77
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 19pt">
    Net cash used in investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (101,457
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (99,141
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,523
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-79
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF CASH FLOWS&#160;&#151; (Continued)<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and U.S. Dollars
    (&#147;US$&#148;))</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Seven Month Period<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>January&#160;1 to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">July&#160;31, 2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    CASH FLOWS FROM FINANCING ACTIVITIES
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Decrease in restricted cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from long-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    135,200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,780
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loans from Ascendium and other unrelated parties (note&#160;7)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loans from related party
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,274
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,798
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Repayment of long-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (103,985
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (33,613
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,924
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Repayment of short-term bank borrowings
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,222
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net cash used in financing activities from continuing operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,993
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,441
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,510
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net cash generated from financing activities from discontinued
    operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,350
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net cash generated from financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,343
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,441
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,510
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exchange rate effect on cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,384
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (67
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net decrease in cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,461
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,342
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (929
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash at beginning of the year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,387
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,926
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,798
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash at end of the year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25,926
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,869
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Supplemental schedule of cash flow information:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,502
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,979
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (876
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,204
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,585
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (232
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Supplemental schedule of non-cash activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acquisition of property, plant and equipment included in accrued
    expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,403
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acquisition of property, plant and equipment and other
    intangible assets through utilization of deposits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,809
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,015
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-80
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">


    <A name='316'><B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; EQUITY</A><BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">(Amounts
    in thousands of Renminbi (&#147;RMB&#148;) and U.S. Dollars
    (&#147;US$&#148;) except for number of shares)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="34%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Ordinary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Share<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid-In<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Comprehensive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Retained<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shareholder&#146;s<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Income (Loss)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Earnings</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Equity</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of January&#160;1, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,564,138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,708
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (353
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,129
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    181,041
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,629
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,629
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (576
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (576
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Share-based compensation (note&#160;10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,564,138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,237
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (929
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    195,623
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Net income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,094
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Foreign currency translation adjustments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Total comprehensive income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,341
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Share-based compensation (note&#160;10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,725
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,725
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of July&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,564,138
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    129,557
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,962
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (682
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    226,689
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Balance as of July&#160;31, 2008, in US$
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,979
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,218
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (100
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,112
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-81
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

    <A name='317'><B>NOTES TO THE CONSOLIDATED FINANCIAL
    STATEMENTS</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    </A><B>(Amounts in thousands of Renminbi (&#147;RMB&#148;), and
    U.S.&#160;Dollars (&#147;US$&#148;) except for number of
    shares</B>
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ORGANIZATION
    AND BASIS OF PRESENTATION</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying consolidated financial statements include the
    financial statements of China Medstar Limited (the
    &#147;Company&#148;, or &#147;China Medstar&#148;) and its
    subsidiaries, Medstar (Shanghai) Leasing Co., Ltd. (formerly
    Shanghai Medstar Investment Management Limited Company,
    &#147;MSC&#148;) and Medstar (Beijing) International Anti-Aging
    Health Bio-tech Inc. (&#147;Anti-Aging&#148;). The Company and
    its subsidiaries are collectively referred to as the
    &#147;Group&#148;.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company was incorporated in the Republic of Singapore on
    August&#160;7, 2003 as an investment holding company. In
    November 2006, the Company completed an initial public offering
    and became a listed company with its shares trading in
    Alternative Investment Market (the &#147;AIM&#148;) of the
    London Stock Exchange in United Kingdom.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, Ascendium Group Limited
    (&#147;Ascendium&#148;) acquired the Company for cash
    consideration of &#163;17.1&#160;million, (RMB238,747 or
    US$34,975) or 62 pence per share in exchange for 100% of the
    Company&#146;s issued and outstanding share capital. Immediately
    prior to the acquisition, China Medstar delisted its ordinary
    shares from trading on the AIM and converted from being public
    limited company to a private limited company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group is principally engaged in the leasing of radiotherapy
    and diagnostic imaging equipment and the provision of management
    services to hospitals located in the People&#146;s Republic of
    China (&#147;PRC&#148;). The Group develops and operates its
    business through its subsidiaries. Details of the Company&#146;s
    subsidiaries as of December&#160;31, 2007 and July&#160;31, 2008
    are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=01 type=body -->
    <TD width="13%" align="left">&nbsp;</TD>	<!-- colindex=01 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="19%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="26%">&nbsp;</TD>	<!-- colindex=06 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Percentage of Ownership by the Company</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Date of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Place of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Company</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Establishment</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Establishment</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Principal Activities</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    MSC
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    March 21, 2003
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    PRC
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    100%
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    100%
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Leasing and sales of medical equipment, provision of<BR>
    management services
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    Anti-Aging
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    September 29, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    PRC
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    53%
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    &#151;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Provision of technology and consultancy services
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;30, 2008, the Group entered into an agreement to
    sell its 53% interest in Anti-Aging. Accordingly, the disposal
    was accounted for as a discontinued operation (See note&#160;9).
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SUMMARY
    OF SIGNIFICANT ACCOUNTING POLICIES</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Basis
    of presentation and use of estimates</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The accompanying consolidated financial statements have been
    prepared in accordance with United States generally accepted
    accounting principles (&#147;U.S.&#160;GAAP&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The preparation of consolidated financial statements in
    conformity with U.S.&#160;GAAP requires management to make
    estimates and assumptions that affect the reported amounts of
    assets and liabilities, disclosures of contingent assets and
    liabilities at the balance sheet dates and the reported amounts
    of revenues and expenses during the reporting periods.
    Significant estimates and assumptions reflected in the
    Company&#146;s financial statements include, but are not limited
    to, revenue recognition, allowance for doubtful accounts, useful
    lives of property, plant and equipment, realization of deferred
    tax assets and share-based compensation expenses. Actual results
    could materially differ from those estimates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Principles
    of Consolidation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The consolidated financial statements include the financial
    statements of the Company and its subsidiaries. All transactions
    and balances between the Company and its subsidiaries have been
    eliminated upon consolidation.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-82
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Foreign
    Currency Translation and Transactions</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s PRC subsidiaries determine their functional
    currencies to be the Chinese Renminbi (&#147;RMB&#148;) based on
    the criteria of SFAS&#160;52, &#147;Foreign Currency
    Translation&#148;. The Company uses the RMB as its reporting
    currency. The Company uses the monthly average exchange rate for
    the year and the exchange rate at the balance sheet date to
    translate the operating results and financial position,
    respectively. Translation differences are recorded in
    accumulated other comprehensive income, a component of
    shareholders&#146; equity. Functional currency of the Company is
    United States dollars (&#147;US$&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Transactions denominated in foreign currencies are remeasured
    into the functional currency at the exchange rates prevailing on
    the transaction dates. Foreign currency denominated financial
    assets and liabilities are remeasured at the exchange rates
    prevailing at the balance sheet date. Exchange gains and losses
    are included in the consolidated statements of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Convenience
    translation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Amounts in US$ are presented for the convenience of the reader
    and are translated at the noon buying rate of RMB6.8262 to
    US$1.00 on September&#160;30, 2009 in the City of New York for
    cable transfers of RMB as certified for customs purposes by the
    Federal Reserve Bank of New York. No representation is made that
    the RMB amounts could have been, or could be, converted into US$
    at such rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Cash</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cash consists of cash on hand and bank deposits, which are
    unrestricted as to withdrawal and use.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Accounts
    receivable and allowance for doubtful accounts</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group considers many factors in assessing the collectability
    of its receivables due from its customers, such as, the aging of
    the amounts due, the customer&#146;s payment history and
    credit-worthiness. An allowance for doubtful accounts is
    recorded in the period in which uncollectability is determined
    to be probable. Accounts receivable balances are written off
    after all collection efforts have been exhausted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Leases</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with SFAS&#160;13 &#147;Accounting for
    Leases&#148; (&#147;SFAS&#160;13&#148;), leases for a lessee are
    classified at the inception date as either a capital lease or an
    operating lease. The Company assesses a lease to be a capital
    lease if any of the following conditions exists:
    a)&#160;ownership is transferred to the lessee by the end of the
    lease term, b)&#160;there is a bargain purchase option,
    c)&#160;the lease term is at least 75% of the property&#146;s
    estimated remaining economic life or d)&#160;the present value
    of the minimum lease payments at the beginning of the lease term
    is 90% or more of the fair value of the leased property to the
    lessor at the inception date. A capital lease is accounted for
    as if there was an acquisition of an asset and an incurrence of
    an obligation at the inception of the lease. The capitalized
    lease obligation reflects the present value of future rental
    payments, discounted at the appropriate interest rates. The cost
    of the asset is amortized over the lease term. However, if
    ownership is transferred at the end of the lease term, the cost
    of the asset is amortized as set out below under property, plant
    and equipment.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-83
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Property,
    Plant and Equipment, net</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property, plant and equipment are stated at cost and are
    depreciated using the straight-line method over the estimated
    useful lives of the assets, as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="37%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=align1 -->
    <TD width="10%" align="left">&nbsp;</TD>	<!-- colindex=03 type=align2 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Category</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Estimated Useful Life</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="4" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Estimated Residual
    Value</FONT></B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Medical equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Shorter of customer contract or 6-12&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    &#151;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Electronic and office equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    5&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    5-10
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Shorter of lease term or 5&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    &#151;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 12%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=468 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    The cost of the asset is amortized over the lease term. However,
    if ownership is transferred at the end of the lease term, the
    cost of the asset is amortized over the shorter of customer
    contract or 6-12&#160;years.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Repair and maintenance costs are charged to expense as incurred,
    whereas the cost of renewals and betterment that extends the
    useful lives of property, plant and equipment are capitalized as
    additions to the related assets. Retirements, sales and
    disposals of assets are recorded by removing the cost and
    accumulated depreciation from the asset and accumulated
    depreciation accounts with any resulting gain or loss reflected
    in the consolidated statements of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost incurred in constructing new facilities, including progress
    payment, interest and other costs relating to the construction
    are capitalized and transferred to fixed assets on completion.
    Total interest costs incurred and capitalized during the year
    ended December&#160;31, 2007 and the period from January 1 to
    July&#160;31, 2008 amounted to approximately RMB 1,235 and
    RMB4,489 (US$658), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Impairment
    of Long-Lived Assets</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group evaluates its long-lived assets or asset group for
    impairment whenever events or changes in circumstances (such as
    a significant adverse change to market conditions that will
    impact the future use of the assets) indicate that the carrying
    amount of a group of long-lived assets may not be fully
    recoverable. When these events occur, the Group evaluates the
    impairment by comparing the carrying amount of the assets to
    future undiscounted net cash flows expected to result from the
    use of the assets and their eventual disposition. If the sum of
    the expected undiscounted cash flows is less than the carrying
    amount of the assets, the Group recognizes an impairment loss
    based on the excess of the carrying amount of the asset group
    over its fair value, generally based upon discounted cash flows.
    No such impairment charge was recognized for any of the periods
    presented.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Fair
    Value of Financial Instruments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The carrying amounts of the Group&#146;s financial instruments,
    including cash, accounts receivable, accounts payable, accrued
    and other liabilities, and amounts due to related parties
    approximate fair value because of their short maturities. The
    carrying amounts of the Group&#146;s short-term and long-term
    bank borrowings bear interest at floating rates and therefore
    approximate the fair value of these obligations based upon
    management&#146;s best estimates of interest rates that would be
    available for similar debt obligations at December&#160;31, 2007
    and 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Revenue
    Recognition</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The majority of the Group&#146;s revenues are derived directly
    from hospitals that enter into medical equipment lease and
    management service arrangements with the Company. A lease and
    management service arrangement will typically include the
    purchase and installation of diagnostic imaging
    <FONT style="white-space: nowrap">and/or</FONT>
    radiation oncology system (&#147;medical equipment&#148;) at the
    hospital, and the full-time deployment of a qualified system
    technician that is responsible for certain management services
    of managing radiotherapy or diagnostic services such that the
    hospital and doctors can provide specialized services to their
    patients. To a lesser extent, revenues are generated from
    stand-alone management service arrangements where the hospital
    has previously acquired the equipment from the Company or
    through another vendor or sale of medical equipment.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-84
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenues arising from sales of medical equipment and services
    are recognized when there is persuasive evidence of an
    arrangement, the fee is fixed or determinable, collectability is
    reasonably assured and the delivery of the medical equipment or
    services has occurred. When the fees associated with an
    arrangement containing extended payment terms are not considered
    to be fixed or determinable at the outset of arrangement,
    revenue is recognized as payments become due, and all of the
    other criteria above have been met.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group is subject to approximately 5% business tax and
    related surcharges on the revenue earned from provision of
    leasing and management services. The Group has recognized
    revenues net of these business taxes and other surcharges. Such
    business tax and related surcharges for the year ended
    December&#160;31, 2007 and the seven month period ended
    July&#160;31, 2008 are approximately RMB3,763, RMB2,856
    (US$418), respectively. In the event that revenue recognition is
    deferred to a later period, the related business tax and other
    surcharges and fees is also deferred and will be recognized only
    upon recognition of the deferred revenue.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Lease and
    management services</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group enters into a lease and management service
    arrangements with independent hospitals with terms ranging from
    6 to 20&#160;years, pursuant to which the Group receives a
    percentage of the net profit (&#147;profit share&#148; as
    defined in the arrangement) of the hospital unit that delivers
    the diagnostic imaging
    <FONT style="white-space: nowrap">and/or</FONT>
    radiation oncology services determined in accordance with the
    terms of the arrangement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to
    <FONT style="white-space: nowrap">EITF&#160;01-8,</FONT>
    &#147;Determining Whether an Arrangement Contains a Lease&#148;
    <FONT style="white-space: nowrap">(&#147;EITF&#160;01-8&#148;)</FONT>
    the Group determined that the Lease and management service
    arrangements contain a lease of medical equipment. The hospital
    has ability and right to operate the medical equipment while
    obtaining more than a minor amount of the output. The
    arrangement also contains a non-lease deliverable being the
    management service element. The arrangement consideration should
    be allocated between the lease element and the non-lease
    deliverables on a relative fair value basis, however because all
    of the consideration is earned through the contingent rent
    feature discussed below, there is no impact of such allocation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    SFAS&#160;13, &#147;Accounting for Leases&#148;
    (&#147;SFAS&#160;13&#148;) is applied to the lease elements of
    the arrangement and U.S.&#160;Securities and Exchange Commission
    (&#147;SEC&#148;) Staff Accounting Bulletin&#160;No. 104
    (&#147;SAB&#160;104&#148;) is applied to other elements of the
    arrangement not within the scope of SFAS 13.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The lease element of rentals and management service receivable
    under the lease arrangement are based purely on a profit share
    formula (&#147;contingent rent feature&#148;). The profitability
    of the business unit is not only dependent on the medical
    equipment placed at the hospital, but also the hospital&#146;s
    ability to manage the costs and appoint doctors and clinical
    staff to operate the equipment. Certain of the lease and
    management service arrangements may include a transfer of
    ownership or bargain purchase option at the end of the lease
    term. Due to the length of the lease term, the collectibility of
    these minimum lease payments are not considered predictable and
    there are important uncertainties regarding the future costs to
    be incurred by the Group relating to the arrangement. Therefore,
    the lessor&#146;s additional criteria for capital lease
    classification in SFAS&#160;13&#160;par. 8 (a)&#160;and
    (b)&#160;was not met even if any of the SFAS&#160;13&#160;par. 7
    criteria for capital leases are met. Consequently, the Group
    accounts for all lease arrangements as operating leases.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As the collectability of the minimum lease rental is not
    considered predictable, and the remaining rental is considered
    contingent, the Group recognizes revenue when the lease payments
    under the arrangement become due, i.e. when the profit share
    under the arrangement is determined and agreed upon by both
    parties to the agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For the service element of the arrangement, as discussed above,
    revenue is only considered determinable at the time the
    consideration under the arrangement becomes known, i.e. when the
    profit share under the arrangement is determined and agreed upon
    by both parties. Revenue is recognized when determined if all
    other basic criteria have also been met.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Revenue derived from the lease and management service
    arrangement is recorded under &#147;Lease and management
    service&#148; in the consolidated statements of operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-85
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Management
    Services</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group provides stand-alone management services to certain
    hospitals which are already in possession of radiotherapy and
    diagnostic equipment. The fee for the management service
    arrangement is either based on a contracted percentage of
    monthly revenue generated by the specified hospital unit
    (&#147;revenue share&#148;) or in limited instances on a fixed
    monthly fee. The consideration that is based on a contracted
    percentage of revenue is recognized when the monthly fees under
    the arrangement become due, i.e. when the revenue share under
    the arrangement is determined and agreed upon by both parties to
    the agreement. Fixed monthly fees are recognized ratably over
    the service term. Revenue derived from stand-alone management
    services is recorded under &#147;Management Service&#148; in the
    consolidated statements of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Medical
    equipment sales</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the application of Emerging Issues Task Force
    Consensus
    <FONT style="white-space: nowrap">99-19,</FONT>
    &#147;Reporting Revenue Gross as Principal versus Net as an
    Agent&#148;
    <FONT style="white-space: nowrap">(&#147;EITF&#160;99-19&#148;),</FONT>
    the Group records revenue related to medical equipment sales on
    a net basis when the equipment is delivered to the customer and
    the sales price is determinable. During the year ended
    December&#160;31, 2007 and the seven month period ended
    July&#160;31, 2008, the Company had medical equipment sales, of
    RMB3,094, RMB6,148 (US$901), net of 17% value-added tax of
    approximately RMB1,865, RMB6,150 (US$901), respectively. Revenue
    derived from medical equipment sales is recorded under
    &#147;Other, net&#148; in the consolidated statements of
    operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cost
    relating to lease and management service arrangement</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The cost of medical equipment that is leased under an operating
    lease is included in property, plant and equipment in the
    balance sheet. The medical equipment is depreciated using the
    Group&#146;s depreciation policy. In determining the
    Group&#146;s normal depreciation policy, the planned use of the
    asset, the lease term and its related useful life is taken into
    account. The costs of the management service component is
    recognized as an expense as incurred.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cost of
    management services</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Costs of management services mainly include the labor costs of
    technicians and management staff.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Cost of
    equipment sales</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cost of equipment sales, recorded net against the related
    revenue, include the cost of the equipment purchased and other
    direct costs involved in the equipment sales.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Income
    Taxes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group follows the liability method of accounting for income
    taxes. Under this method, deferred tax assets and liabilities
    are determined based on the difference between the financial
    reporting and tax bases of assets and liabilities using enacted
    tax rates that will be in effect in the period in which the
    differences are expected to reverse. The Group records a
    valuation allowance to offset deferred tax assets if based on
    the weight of available evidence, it is more-likely-than-not
    that some portion, or all, of the deferred tax assets will not
    be realized. The effect on deferred taxes of a change in tax
    rate is recognized in tax expense in the period that includes
    the enactment date of the change in tax rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On January&#160;1, 2007, the Group adopted FASB Interpretation
    No.&#160;48, &#147;Accounting for Uncertainty in Income
    Taxes&#160;&#151; an interpretation of FASB Statement
    No.&#160;109&#148; (&#147;FIN&#160;48&#148;), which clarifies
    the accounting and disclosure for uncertainty in income taxes.
    Interest and penalties arising from underpayment of income taxes
    shall be computed in accordance with the related PRC tax law.
    The amount of interest expense is computed by applying the
    applicable statutory rate of interest to the difference between
    the tax position recognized and the amount previously taken or
    expected to be taken in a tax return. Interest and penalties
    recognized in accordance with FIN&#160;48 is classified in the
    financial statements as income tax expense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with the provisions of FIN&#160;48, the Group
    recognizes in its financial statements the impact of a tax
    position if a tax return position or future tax position is
    &#147;more likely than not&#148; to prevail based on the facts
    and technical
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-86
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    merits of the position. Tax positions that meet the &#147;more
    likely than not&#148; recognition threshold are measured at the
    largest amount of tax benefit that has a greater than fifty
    percent likelihood of being realized upon settlement. The
    Group&#146;s estimated liability for unrecognized tax benefits
    which is included in the &#147;accrued expenses and other
    liabilities&#148; account is periodically assessed for adequacy
    and may be affected by changing interpretations of laws, rulings
    by tax authorities, changes
    <FONT style="white-space: nowrap">and/or</FONT>
    developments with respect to tax audits, and expiration of the
    statute of limitations. The outcome for a particular audit
    cannot be determined with certainty prior to the conclusion of
    the audit and, in some cases, appeal or litigation process. The
    actual benefits ultimately realized may differ from the
    Group&#146;s estimates. As each audit is concluded, adjustments,
    if any, are recorded in the Group&#146;s financial statements.
    Additionally, in future periods, changes in facts,
    circumstances, and new information may require the Group to
    adjust the recognition and measurement estimates with regard to
    individual tax positions. Changes in recognition and measurement
    estimates are recognized in the period in which the changes
    occur.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Share-based
    compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s employees and non-employees participate in
    the Company&#146;s share-based scheme which is more fully
    discussed in note&#160;10. Share-based awards granted to
    employees are accounted for under SFAS&#160;No.&#160;123(R)
    &#147;Share-Based Payment&#148; (&#147;SFAS&#160;123(R)&#148;).
    Share-based awards granted to employees and non-employees are
    accounted for under SFAS&#160;No.&#160;123(R) &#147;Share-Based
    Payment&#148; (&#147;SFAS&#160;123(R)&#148;) and EITF Issue
    <FONT style="white-space: nowrap">No.&#160;96-18</FONT>
    &#147;Accounting for Equity Instruments That Are Issued to Other
    Than Employees for Acquiring, or in Conjunction with Selling,
    Goods or Services&#148;
    <FONT style="white-space: nowrap">(&#147;EITF&#160;96-18&#148;),</FONT>
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with SFAS&#160;123(R), all grants of share-based
    awards to employees are recognized in the financial statements
    based on their grant date fair values which are calculated using
    an option pricing model. The Group has elected to recognize
    compensation expense using the straight-line method for all
    share options granted with graded vesting based on service
    conditions. To the extent the required vesting conditions are
    not met resulting in the forfeiture of the share-based awards,
    previously recognized compensation expense relating to those
    awards are reversed. SFAS&#160;123(R) requires forfeitures to be
    estimated at the time of grant and revised, if necessary, in
    subsequent period if actual forfeitures differ from initial
    estimates. Share-based compensation expense was recorded net of
    estimated forfeitures such that expense was recorded only for
    those share-based awards that are expected to vest.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In accordance with
    <FONT style="white-space: nowrap">EITF&#160;96-18,</FONT>
    grants of share-based awards to non-employees are measured at
    fair value at the earlier of the performance commitment date and
    the date when performance is complete.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Comprehensive
    Income</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Comprehensive income is defined to include all changes in equity
    except those resulting from investments by owners and
    distributions to owners. Among other disclosures,
    SFAS&#160;No.&#160;130, &#147;Reporting Comprehensive
    Income&#148;, requires that all items that are required to be
    recognized under current accounting standards as components of
    comprehensive income be reported in a financial statement that
    is displayed with the same prominence as other financial
    statements. During the periods presented, the Company&#146;s
    comprehensive income represents its net income and foreign
    currency translation adjustments and is presented in the
    statement of changes in shareholders&#146; equity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Recent
    Accounting Pronouncements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;4, 2007 the FASB issued SFAS&#160;No.&#160;141
    (Revised 2007), &#147;Business Combinations&#148;
    (SFAS&#160;141(R)). This Statement will apply to all
    transactions in which an entity obtains control of one or more
    other businesses. In general, SFAS&#160;No.&#160;141(R) requires
    the acquiring entity in a business combination to recognize the
    fair value of all the assets acquired and liabilities assumed in
    the transaction; establishes the acquisition date as the fair
    value measurement point; and modifies the disclosure
    requirements. Additionally, it changes the accounting treatment
    for transaction costs, acquired contingent arrangements,
    in-process research and development, restructuring costs,
    changes in deferred tax asset valuation allowances as a result
    of business combination, and changes in income tax uncertainties
    after the acquisition date. SFAS&#160;141(R) applies
    prospectively to business combinations for which the acquisition
    date is on or after the beginning of the first annual reporting
    period beginning on or after December&#160;15,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-87
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2008. Earlier adoption is prohibited. However, accounting for
    changes in valuation allowances for acquired deferred tax assets
    and the resolution of uncertain tax positions for prior business
    combinations will impact tax expense instead of impacting
    goodwill. The Company is currently assessing the impact, if any,
    that the adoption of SFAS&#160;141(R) will have on its financial
    statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On December&#160;4, 2007 the FASB issued SFAS&#160;No.&#160;160,
    &#147;Non-controlling Interests in Consolidated Financial
    Statements&#160;&#151; An Amendment of ARB No.&#160;51&#148;
    (&#147;SFAS&#160;160&#148;). SFAS&#160;160 establishes new
    accounting and reporting standards for the non-controlling
    interest in a subsidiary and for the deconsolidation of a
    subsidiary. Specifically, this statement requires the
    recognition of a non-controlling interest (minority interest) as
    equity in the consolidated financial statements and separate
    from the parent&#146;s equity. The amount of net income
    attributable to the non-controlling interest will be included in
    consolidated net income on the face of the statement of
    operations. SFAS&#160;160 clarifies that changes in a
    parent&#146;s ownership interest in a subsidiary that do not
    result in deconsolidation are equity transactions if the parent
    retains its controlling financial interest. In addition, this
    statement requires that a parent recognize a gain or loss in net
    income when a subsidiary is deconsolidated. Such gain or loss
    will be measured using the fair value of the non-controlling
    equity investment on the deconsolidation date. SFAS&#160;160
    also includes expanded disclosure requirements regarding the
    interests of the parent and its non-controlling interest.
    SFAS&#160;160 is effective for fiscal years, and interim periods
    within those fiscal years, beginning on or after
    December&#160;15, 2008 and will be applied prospectively with
    the exception of the presentation and disclosure requirements,
    which must be applied retrospectively for all periods presented.
    Earlier adoption is prohibited. The Company is currently
    assessing the impact, if any, that the adoption of SFAS&#160;160
    will have on its financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2008, the FASB issued FASB Staff Position
    <FONT style="white-space: nowrap">No.&#160;FAS&#160;142-3,</FONT>
    Determination of the Useful Life of Intangible Assets (&#147;FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3&#148;).</FONT>
    FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3</FONT>
    amends the factors that should be considered in developing
    renewal or extension assumptions used to determine the useful
    life of a recognized intangible asset under FASB Statement
    No.&#160;142, &#147;Goodwill and Other Intangible Assets,&#148;
    and requires enhanced disclosures relating to: (a)&#160;the
    entity&#146;s accounting policy on the treatment of costs
    incurred to renew or extend the term of a recognized intangible
    asset; (b)&#160;in the period of acquisition or renewal, the
    weighted-average period prior to the next renewal or extension
    (both explicit and implicit), by major intangible asset class;
    and (c)&#160;for an entity that capitalizes renewal or extension
    costs, the total amount of costs incurred in the period to renew
    or extend the term of a recognized intangible asset for each
    period for which a statement of financial position is presented,
    by major intangible asset class. FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3</FONT>
    must be applied prospectively to all intangible assets acquired
    as of and subsequent to fiscal years beginning after
    December&#160;15, 2008, and interim periods within those fiscal
    years. Early adoption is prohibited. The Group is currently
    evaluating the impact that FSP
    <FONT style="white-space: nowrap">FAS&#160;142-3</FONT>
    will have on the consolidated financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In May 2009, the FASB issued SFAS&#160;No.&#160;165
    &#147;Subsequent Events&#148; (&#147;SFAS&#160;165&#148;).
    SFAS&#160;165 names the two types of subsequent events either as
    recognized subsequent events or non-recognized subsequent events
    and modifies the definition of subsequent events as events or
    transactions that occur after the balance sheet date, but before
    the financial statements are issued. The statement also requires
    entities to disclose the date through which an entity has
    evaluated subsequent events and the basis for that date.
    SFAS&#160;165 is effective on a prospective basis for interim or
    annual financial periods ending after June&#160;15, 2009. The
    Company does not believe that the application of SFAS&#160;165
    will have a significant impact on its financial position and
    results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In June 2009, the FASB issued SFAS&#160;No.&#160;168, &#147;The
    FASB Accounting Standards
    Codification<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    and the Hierarchy of Generally Accepted Accounting
    Principles&#160;&#151; a replacement of FASB Statement
    No.&#160;162.&#148; The FASB Accounting Standards
    Codification<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    (Codification) will become the source of authoritative United
    States GAAP recognized by the FASB to be applied by
    nongovernmental entities. This Statement and the Codification
    will not change GAAP. This Statement is effective for interim
    and annual periods ending after September&#160;15, 2009. The
    Codification will not change GAAP and therefore should not
    impact the Company&#146;s consolidated financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-88
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">3.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">CONCENTRATION
    OF RISKS</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concentration
    of Credit Risk</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Assets that potentially subject the Group to significant
    concentration of credit risk primarily consist of cash and
    accounts receivable. As of July&#160;31, 2008, substantially all
    of the Group&#146;s cash were deposited in financial
    institutions located in the PRC and in Singapore, which
    management believes are of high credit quality. Accounts
    receivable are typically unsecured and are derived from revenue
    earned from customers in the PRC. The risk with respect to
    accounts receivable is mitigated by credit evaluations the Group
    performs on its customers and its ongoing monitoring process of
    outstanding balances.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concentration
    of Customers</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group currently generates a substantial portion of its
    revenue from a limited number of customers. As a percentage of
    revenues, the top five customers accounted for 58% for the year
    ended December&#160;31, 2007 and 52% for the period from January
    1 to July&#160;31, 2008. The loss of revenue from any of these
    customers would have a significant negative impact on the
    Group&#146;s business. However arrangements with customers are
    mostly long-term in nature. Due to the Group&#146;s dependence
    on a limited number of customers and the contingent fees based
    on variables the Group does not control of certain contracts,
    any negative events with respect to the Group&#146;s customers
    may cause material fluctuations or declines in the Group&#146;s
    revenue and have a material adverse effect on the Group&#146;s
    financial condition and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Concentration
    of Suppliers</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A significant portion of the Group&#146;s medical equipment are
    sourced from its three largest suppliers who collectively
    accounted for 100% of the total medical equipment purchases of
    the Group for the year ended December&#160;31, 2007 and 96% of
    the total medical equipment purchases of the Group for the
    period from January 1 to July&#160;31, 2008. Failure to develop
    or maintain the relationships with these suppliers may cause the
    Group to be unable to expand its business with new hospitals.
    Any disruption in the supply of the medical equipment to the
    Group may adversely affect the Group&#146;s business, financial
    condition and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Current
    vulnerability due to certain other concentrations</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group&#146;s operations may be adversely affected by
    significant political, economic and social uncertainties in the
    PRC. Although the PRC government has been pursuing economic
    reform policies for more than 20&#160;years, no assurance can be
    given that the PRC government will continue to pursue such
    policies or that such policies may not be significantly altered,
    especially in the event of a change in leadership, social or
    political disruption or unforeseen circumstances affecting the
    PRC&#146;s political, economic and social conditions. There is
    also no guarantee that the PRC government&#146;s pursuit of
    economic reforms will be consistent or effective.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group transacts all of its business in RMB, which is not
    freely convertible into foreign currencies. On January&#160;1,
    1994, the PRC government abolished the dual rate system and
    introduced a single rate of exchange as quoted daily by the
    People&#146;s Bank of China (the &#147;PBOC&#148;). However, the
    unification of the exchange rates does not imply that the RMB
    may be readily convertible into United States dollars or other
    foreign currencies. All foreign exchange transactions continue
    to take place either through the PBOC or other banks authorized
    to buy and sell foreign currencies at the exchange rates quoted
    by the PBOC. Approval of foreign currency payments by the PBOC
    or other institutions requires submitting a payment application
    form together with suppliers&#146; invoices, shipping documents
    and signed contracts.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Additionally, the value of the RMB is subject to changes in
    central government policies and international economic and
    political developments affecting supply and demand in the PRC
    foreign exchange trading system market.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A medical-related business is subject to significant
    restrictions under current PRC laws and regulations. Currently,
    the Group conducts its operations in China through contractual
    arrangements entered into with
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-89
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    hospitals in the PRC. The relevant regulatory authorities may
    find the current contractual arrangements and businesses to be
    in violation of any existing or future PRC laws or regulations.
    If so, the relevant regulatory authorities would have broad
    discretion in dealing with such violations.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">4.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">PREPAYMENT
    AND OTHER CURRENT ASSETS</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prepayment and other current assets consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="66%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at July&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Advance to suppliers
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,564
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,564
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    376
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Receivable arising from disposal of a subsidiary (note&#160;9)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,950
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    432
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Others
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,216
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,963
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,780
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,477
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,095
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">5.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">PROPERTY,
    PLANT AND EQUIPMENT, NET</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Property, plant and equipment consist of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at July&#160;31</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Medical equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    210,176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    286,581
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,983
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Electronic and office equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    448
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    448
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvement and building improvement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    528
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    528
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Construction in progress
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,718
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,678
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    284,637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    367,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,804
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Less: Accumulated depreciation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (67,719
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (82,576
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,097
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    216,918
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    284,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,707
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Depreciation expenses were approximately RMB23,180 and RMB14,857
    (US$2,176) for the year ended December&#160;31, 2007 and for the
    period from January 1 to July&#160;31, 2008, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As at July&#160;31, 2008, the Company held equipment under
    operating lease contracts with customers with an original cost
    of RMB286,581 (US$41,983) and accumulated depreciation of
    RMB82,254 (US$12,050). As at December&#160;31, 2007, the Company
    held equipment under operating lease contracts with customers
    with an original cost of RMB210,176 and accumulated depreciation
    of RMB67,490.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-90
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL,n -->
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">6.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">BANK
    BORROWINGS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at July&#160;31</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Short-term
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,150
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,623
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,320
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,830
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,123
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,820
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89,600
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    103,070
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,099
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    123,723
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    143,890
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,079
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All bank borrowings were obtained from financial institutions in
    the PRC and secured by the equipment under capital lease with
    net carrying value of RMB117,226 (US$17,173) (2007: RMB118,001).
    As at July&#160;31, 2008, the Company had RMB19,320 (US$2,830)
    and RMB103,070 (US$15,099) of long term facilities due within 1
    and 2&#160;years, respectively. These arrangements do not have
    any financial reporting or administrative covenants restricting
    the Company&#146;s operating, investing and financing activities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The short-term bank borrowing outstanding as of July&#160;31,
    2008 bore weighted average interest at 7.29% per annum, and was
    denominated in RMB. The long-term bank borrowings outstanding as
    of July&#160;31, 2008 bore weighted average interest at 7.48%
    per annum and were denominated in RMB.
</DIV>
<!-- XBRL,n -->
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">7.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ACCRUED
    EXPENSES AND OTHER LIABILITIES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The components of accrued expenses and other liabilities are as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As at December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>As at July&#160;31</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Unrecognized tax benefit and related interest and penalty
    (note&#160;8)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,692
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Loans from Ascendium and other unrelated parties*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Others
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,769
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,032
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,825
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=468 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The amount represents interest-free
    loans borrowed from an unrelated party. Such loan is for working
    capital purpose and is repayable on demand. The balance was
    settled by the end of December&#160;31, 2008.
    </FONT></TD>
</TR>

</TABLE>
<!-- XBRL,n -->
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">8.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">TAXATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Singapore</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company is incorporated in Singapore and does not conduct
    any substantive operations of its own. As the Company has no
    assessable profits for the year ended December&#160;31, 2007 and
    the period from January 1 to July&#160;31, 2008, no provision
    for tax has been made in the financial statements. In addition,
    upon payments of dividends by China Medstar to its shareholder,
    no Singapore withholding tax will be imposed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">China</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to January&#160;1, 2008, PRC enterprise income tax,
    &#147;EIT&#148;, was generally assessed at the rate of 33% of
    taxable income. However, as foreign enterprises located in
    Pudong New District of Shanghai, MSC is entitled to preferential
    EIT rate of 15%.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-91
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In March 2007, a new enterprise income tax law (the &#147;New
    EIT Law&#148;) in the PRC was enacted which was effective on
    January&#160;1, 2008. The New EIT Law applies a uniform 25% EIT
    rate to both foreign invested enterprises and domestic
    enterprises. The new law provides a five-year transition period
    from its effective date for those enterprises which were
    established before the promulgation date of the new tax law and
    which were entitled to a preferential tax treatment such as a
    reduced tax rate or a tax holiday. Based on the transitional
    rule, certain categories of enterprises, including the foreign
    invested enterprise located in Pudong New District, which
    previously enjoyed a preferential tax rate of 15% are eligible
    for a five-year transition period during which the income tax
    rate will gradually be increased to the unified rate of 25%.
    Specifically, the applicable rates for MSC would be 18%, 20%,
    22%, 24% and 25% for 2008, 2009, 2010, 2011, 2012 and
    thereafter, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    MSC has accounted for their current and deferred income tax
    based on the five-year transitional tax rate, as applicable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In general, the PRC tax authorities have up to five years to
    conduct examinations of the PRC entities&#146; tax filings.
    Accordingly, MSC&#146;s tax years from 2003 to 2008 remain
    subject to examination by the tax authorities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Income from continuing operations before income taxes consists
    of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Period From<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>January&#160;1 to July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-PRC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,175
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,392
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    PRC
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,919
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39,492
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,785
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The current and deferred components of the income tax expense
    (benefit) appearing in the consolidated statements of operations
    are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended <BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Period From<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>January&#160;1 to July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current tax expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,698
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,234
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax (benefit) expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,776
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    922
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,445
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,237
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A reconciliation of the differences between the statutory tax
    rate and the effective tax rate for EIT is as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Period From<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>January&#160;1 to July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income from continuing operations before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,744
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Income tax computed at applicable tax rates (33% or 25%)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,025
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,322
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-deductible expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,285
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,572
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    230
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effect of preferential tax rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,431
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,009
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (441
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Effect of tax rate changes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,137
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    168
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Interest and penalty on unrecognized tax benefits
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    689
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    922
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,445
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,237
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-92
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Reconciliation of accrued unrecognized tax benefits is as
    follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>Unrecognized Tax Benefits</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">RMB(&#146;000)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">US$(&#146;000)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance&#160;&#151; January&#160;1, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    175
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Additions based on tax positions related to the current year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance&#160;&#151; December&#160;31, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,619
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    237
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Additions based on tax positions related to the current period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    675
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    99
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Balance&#160;&#151; July&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,294
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of December&#160;31, 2007 and July&#160;31, 2008, the Group
    has recognized a provision of RMB1,619 and RMB2,294 (US$336) for
    unrecognized tax benefits, of which RMB185 and RMB306 (US$45)
    would impact the effective tax rate, if ultimately recognized.
    Included in the balance at December&#160;31, 2007 and
    July&#160;31, 2008 are approximately RMB1,434 and RMB1,988
    (US$291), respectively, of tax positions for which the ultimate
    deductibility is highly certain but for which there is
    uncertainty about the timing of such deductibility. The Company
    had approximately RMB1,073 and RMB1,761 (US$258) for the payment
    of interest and penalty accrued at December&#160;31, 2007, and
    July&#160;31, 2008, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    It is possible that the amount of unrecognized tax benefits will
    change in the next twelve months. However, an estimate of the
    range of the possible change cannot be made at this time.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Deferred taxes reflect the tax effects of temporary differences
    between the carrying amounts of assets and liabilities for
    financial reporting purposes and the amounts used for income tax
    purposes. The components of deferred taxes are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="56%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>As at July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    216
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, current portion, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,917
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,810
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    558
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred cost, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,664
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,198
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (175
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,174
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,642
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    680
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenue, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    320
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    272
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,526
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,103
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dividends paid by PRC subsidiaries of the Group out of the
    profits earned after December&#160;31, 2007 to non-PRC tax
    resident investors would be subject to PRC withholding tax. The
    withholding tax would be 10%, unless a foreign investor&#146;s
    tax jurisdiction has a tax treaty with China that provides for a
    lower withholding tax rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Aggregate undistributed earnings of the Company&#146;s
    subsidiary located in the PRC that are available for
    distribution at July&#160;31, 2008 are considered to be
    indefinitely reinvested under Accounting Principles Board
    Opinion No.&#160;23 &#147;Accounting for Income
    Taxes&#160;&#151; Special Areas&#148; and accordingly, no
    provision has been made for taxes that would be payable upon the
    distribution of those amounts to any entity within the Group
    outside the PRC. Unrecognized deferred tax liabilities for
    temporary differences related to investments in foreign
    subsidiaries were not recorded because the determination of that
    amount is not practicable.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-93
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group does not have any present plan to pay any cash
    dividends on its ordinary shares in the foreseeable future. It
    intends to retain most of its available funds and any future
    earnings for use in the operation and expansion of its business.
    As of July&#160;31, 2008, the Group has not declared any
    dividends.
</DIV>
<!-- XBRL,n -->
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">9.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">DISCONTINUED
    OPERATIONS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;30, 2008, the Group entered into an agreement to
    sell all its 53% interest in Anti-Aging to an independent third
    party for RMB2,950 (US$432), which resulted in a gain on
    disposal of RMB1,122 (US$164), net of income tax expense of
    RMB54 (US$8). Accordingly, as of December&#160;31, 2007, the
    Company has accounted for Anti-Aging as discontinued operations.
    The assets and liabilities of Anti-Aging as at December&#160;31,
    2007 have been reclassified as assets held for sale and
    liabilities of discontinued operations, respectively, and the
    results of operations of Anti-Aging have been removed from the
    Company&#146;s results of continuing operations and cash flows
    for the year ended December&#160;31, 2007. Subsequent to the
    year end, RMB1,000 (US$146) was collected from the seller such
    that the outstanding receivable amount is RMB1,950 (US$286).
    Anti-Aging was established in September 2007 and thus did not
    generate any revenue in any of the periods presented.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The assets and liabilities of Anti-Aging reported as
    <FONT style="white-space: nowrap">held-for-sale</FONT>
    include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="86%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>As at December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current assets held for sale
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,211
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Prepayment and other current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Current assets held for sale
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Non-current assets held for sale
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Property, plant and equipment, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    316
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accrued expenses and other liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL,n -->
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">10.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SHARE
    BASED COMPENSATION</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company&#146;s 2006&#160;Share Option Plan (the
    &#147;Plan&#148;) was adopted on November&#160;24, 2006 and is
    administered by the Remuneration Committee (the
    &#147;Committee&#148;). Employees (including executive
    Directors) and non-executive Directors of the Company, employees
    of Group companies, subject to certain conditions, are eligible
    to participate in the Plan. Options granted from the Plan a
    maximum life of ten years from the date of grant. Options
    granted to employees cliff vest at the end of three years of
    continued employment.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-94
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table summarizes the activity of employee
    share-based awards granted in November 2006, for the year ended
    December&#160;31, 2007 and the period from January 1 to
    July&#160;31, 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="31%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=03 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=03 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=04 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=04 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=05 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=05 type=quadright -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=06 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=maindata -->
    <TD width="5%">&nbsp;</TD>	<!-- colindex=06 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Weighted-Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Weighted Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-size: 9pt">Share Options<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Weighted-Average<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Grant-Date Fair<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Remaining<BR>
    </FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Aggregated<BR>
    </FONT></B>
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>granted to<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Contractual Term<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Intrinsic Value<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>employees</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Number of Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(GB pound)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(GB pound)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(Years)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(GB pound)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding, January&#160;1, 2007
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    872,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.78
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.36
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding, January&#160;1, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    872,853
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.78
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.36
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.9
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cancellation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (872,853
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.78
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.36
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.3
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding, July&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
<TD>
&nbsp;
</TD>
<TD>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company also granted 1,240,386 options to two non-employees
    with exercise prices ranging from GBP0.78 to GBP1.97 on
    November&#160;27, 2006. The options had expiring terms ranging
    from 3 to 4&#160;years. The vesting of the options was subject
    to the successful completion of the Company&#146;s initial
    public offering which was completed on November&#160;30, 2006.
    The options were issued to these two non-employees as
    compensation for services which relate directly to the
    Company&#146;s initial public offering. Accordingly, the fair
    value of the options, representing a share issuance cost,
    results in an offsetting amount being recognized in
    shareholders&#146; equity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to Ascendium&#146;s acquisition of the Company, all
    employee and non-employee holders of share options under the
    Plan voluntarily waived their rights related to each of their
    respective share options and did not receive any compensation in
    return. The waiver from the option holders has been accounted
    for as a cancellation of stock options and thus all unrecognized
    share-based compensation cost relating to unvested stock options
    amounting to approximately RMB 2,248 (US$329) was immediately
    recognized to expense on the date of the waiver.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The fair value of each option award to employees was estimated
    using the Black&#160;&#151; Scholes Option Pricing Model by
    management of the Company. The volatility assumption was
    estimated based on the Company&#146;s historical price
    volatility of the Company&#146;s shares and therefore did not
    have data to calculate expected volatility of the price of the
    underlying ordinary shares over the expected term of the option.
    The expected term was estimated based on the vesting terms,
    contractual terms and management&#146;s expectation of exercise
    behavior of the option grantees. The risk-free rate was based on
    the market yield of UK Guilt Stock with maturity terms equal to
    the expected term of the option awards. Forfeitures were
    estimated based on historical experience. The grant date fair
    value of the share options granted in the last year in which
    options were granted (the year ended December&#160;31,
    2006)&#160;is as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.7
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Nil
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility range
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.5&#160;years
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Total share-based compensation expense of RMB1,529 and RMB2,725
    (US$399) recognized in the year ended December&#160;31, 2007 and
    the period from January 1 to July&#160;31, 2008, respectively,
    were recorded in general and administrative expenses.
</DIV>
<!-- XBRL,n -->
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">11.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">RELATED
    PARTY TRANSACTIONS</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    a)&#160;Related parties
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-95
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Name of related
    parties</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Relationship with the
    Group</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Yap Yaw Kong
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director of the Company
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Beijing Medstar Hi-Tech Investment Co., Ltd. (&#147;Beijing
    Medstar&#148;)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    A company under the control of a director of the Company
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    b)&#160;The Group had the following related party balances at
    the end of the period:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="59%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As at December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>As at July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2007</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amount due to related parties:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Beijing Medstar
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Zheng Cheng
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Mr. Yap Yaw Kong
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    220
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ascendium
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,274
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,798
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,881
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,033
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All amounts due to related parties as of December&#160;31, 2007
    and July&#160;31, 2008 were unsecured, interest-free and have no
    fixed terms of repayment.
</DIV>
<!-- XBRL,n -->
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">12.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">EMPLOYEE
    DEFINED CONTRIBUTION PLAN</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Full time employees of the Group in the PRC participate in a
    government mandated defined contribution plan, pursuant to which
    certain pension benefits, medical care, employee housing fund
    and other welfare benefits are provided to employees. Chinese
    labor regulations require that the PRC subsidiaries of the Group
    make contributions to the government for these benefits based on
    certain percentages of the employees&#146; salaries. The Group
    has no legal obligation for the benefits beyond the
    contributions made. The total amounts for such employee
    benefits, which were expensed as incurred, were approximately
    RMB1,103 and RMB637 (US$93) for the year ended December&#160;31,
    2007 and the period from January 1 to July&#160;31, 2008,
    respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Obligations for contributions to defined contribution retirement
    plans for full-time employees in Singapore are recognized as
    expenses in the income statement as incurred. The total amounts
    for such employee benefits were approximately RMB42 and RMB55
    (US$8) for the year ended December&#160;31, 2007 and the period
    from January 1 to July&#160;31, 2008, respectively.
</DIV>
<!-- XBRL,n -->
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">13.&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">COMMITMENTS
    AND CONTINGENCIES</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Operating
    lease commitments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Future minimum payments under non-cancelable operating leases
    with initial terms in excess of one year consist of the
    following at July&#160;31, 2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">RMB</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">US$</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Period from August 1 to December&#160;31, 2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    127
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,322
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    340
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Payments under operating leases are expensed on a straight-line
    basis over the periods of their respective leases. The terms of
    the leases do not contain material rent escalation or contingent
    rents. For the year ended December&#160;31,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    F-96
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CHINA
    MEDSTAR LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS&#160;&#151;
    (Continued)</B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    2007 and the period from January 1 to July&#160;31, 2008, total
    rental expenses for all operating leases amounted for
    approximately RMB1,919 and RMB1,147 (US$168), respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Purchase
    commitments</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Group has commitments to purchase certain medical equipment
    of approximately RMB37,916 (US$5,554), which are scheduled to be
    paid within one year.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Income
    taxes</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of July&#160;31, 2008, the Group has recognized approximately
    RMB4,056 (US$594) accrual for unrecognized tax benefits and
    related interest and penalty (note&#160;8). The final outcome of
    the tax uncertainty is dependent upon various matters including
    tax examinations, interpretation of tax laws or expiration of
    status of limitation. However, due to the uncertainties
    associated with the status of examinations, including the
    protocols of finalizing audits by the relevant tax authorities,
    there is a high degree of uncertainty regarding the future cash
    outflows associated with these tax uncertainties. As of
    July&#160;31, 2008, the Group classified the RMB4,056 (US$594)
    accrual as a current liability.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    F-97
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='129'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INDEX TO
    UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF
    OPERATIONS</FONT></B>
</DIV>
</A><DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="94%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 10pt">Page</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#403'>Introduction to Unaudited Pro Forma Condensed
    Combined Financial Information</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    P-2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#401'>Unaudited Pro Forma Condensed Combined Statement
    of Operations for the year ended December&#160;31, 2008</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    P-3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#402'>Notes to the Unaudited Pro Forma Condensed
    Combined Financial Information </A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    P-4
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    P-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='403'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">UNAUDITED
    PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On July&#160;31, 2008, the Group acquired China Medstar Pte.
    Ltd. (&#147;China Medstar&#148;) for cash consideration of
    approximately &#163;17.1&#160;million or 62&#160;pence per share
    in exchange for 100% of China Medstar&#146;s issued and
    outstanding share capital. The following unaudited pro forma
    condensed consolidated statement of operations gives effect to
    the acquisition of China Medstar, accounted for under the
    purchase method in accordance with SFAS No.&#160;141
    &#147;Business Combinations&#148; (&#147;SFAS&#160;141&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following unaudited pro forma condensed combined statement
    of operations for the year ended December&#160;31, 2008 assumes
    that the acquisition of China Medstar was consummated on
    January&#160;1, 2008. The historical results of the Company and
    China Medstar were derived from the consolidated statements of
    operations for the year ended December&#160;31, 2008,
    respectively, included elsewhere in this prospectus.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The pro forma information is presented solely for informational
    purposes and is not necessarily indicative of the combined
    results of operations that might have been achieved for the
    periods indicated, nor is it necessarily indicative of the
    future results of the combined company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The pro forma adjustments are based upon available information
    and certain assumptions we believe are reasonable under the
    circumstances. The unaudited pro forma condensed combined
    statement of operations should be read in conjunction with the
    accompanying notes and assumptions and the historical financial
    statements of the Company and China Medstar.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    P-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='401'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Unaudited
    Pro Forma Condensed Combined Statement of Operations<BR>
    for the Year Ended December&#160;31, 2008<BR>
    (Amounts in thousands of Renminbi (&#147;RMB&#148;) except for
    number of shares)</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="42%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Pro forma<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Concord Medical</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>China Medstar</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Adjustment</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Notes</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Combined</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>For the seven<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>For the Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>month period<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>ended July&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B><FONT style="font-size: 9pt">2008</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Revenue, net of business tax, value-added tax and related
    surcharges:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    155,061
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,745
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    203,806
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,677
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,980
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,657
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,148
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total net revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    171,789
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,873
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    234,662
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Cost of revenue:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Lease and management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (25,046
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,806
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,624
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34,228
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Amortization of acquired intangibles
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,743
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26,240
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Management services
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (54
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (63
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (117
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total cost of sales
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,597
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (14,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (60,585
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Gross profit</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,192
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    174,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Operating expenses:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Selling expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,497
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,581
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,078
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (18,869
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,340
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (27,209
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Operating income</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,083
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    139,790
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,455
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,585
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (9,040
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Change in fair value of convertible notes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Foreign exchange loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (325
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (230
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (555
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Loss from disposal of equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (658
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Interest income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    430
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    462
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Other income (expense)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (200
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,534
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Income before income taxes</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,404
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    138,385
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Income tax expense
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (23,335
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (8,445
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (2
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31,759
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Net income from continuing operations</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,655
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    106,626
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Pro forma income per share from continuing operations</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.85
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Weighted average number of ordinary shares outstanding:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,481,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    P-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 88%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='402'>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Note&#160;1</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The aggregate purchase price of approximately
    &#163;17.1&#160;million (RMB238,747 or US$34,975) for the
    purchase of China Medstar is comprised of the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="82%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>RMB</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>US$</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Goodwill
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,210
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,107
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,053
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,287
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Long-term receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,397
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,377
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    217,965
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,931
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other intangible assets- customer relationships
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    and operating leases
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    52,380
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deposit for property, plant and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,505
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,233
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax assets, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,089
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Deferred tax liabilities, non-current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (12,529
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,835
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Liabilities assumed
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (233,323
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (34,180
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total consideration paid
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    238,747
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The preliminary purchase price allocation and preliminary
    intangible asset valuations described above were based on
    valuation work determined by the Company with the assistance of
    American Appraisal China Limited, an independent valuation firm.
    The valuation report utilizes and considers generally accepted
    valuation methodologies such as the income, market, cost and
    actual transaction of shares approach. We have incorporated
    certain assumptions which include projected cash flows and
    replacement costs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This adjustment of RMB5,743 reflects an additional seven full
    months of amortization of the acquired intangibles recorded as a
    result of our acquisition of China Medstar on July&#160;31, 2008
    as if the acquisition had been consummated on January&#160;1,
    2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This adjustment of RMB 5,624 reflects an additional reduction in
    depreciation expense as if the acquisition had been consummated
    on January&#160;1, 2008 related to medical equipment because the
    assigned estimated fair values are lower than the net book
    values as at the acquisition date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Note&#160;2</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Reflects the adjustment to income tax expense based on the pro
    forma adjusting entries to depreciation expense and amortization
    expense discussed above.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    P-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="h03611h0361108.gif" alt="(CMS LOGO)">
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PART&#160;II</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">INFORMATION
    NOT REQUIRED IN PROSPECTUS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ITEM&#160;6&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">INDEMNIFICATION
    OF DIRECTORS AND OFFICERS</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Cayman Islands law does not limit the extent to which a
    company&#146;s articles of association may provide for
    indemnification of officers and directors, except to the extent
    any such provision may be held by the Cayman Islands courts to
    be contrary to public policy, such as to provide indemnification
    against civil fraud or the consequences of committing a crime.
    Our third amended and restated memorandum and articles of
    association, which will become effective upon the closing of
    this offering, will provide for indemnification of officers and
    directors for losses, damages, costs and expenses incurred in
    their capacities as such, except through their own dishonesty,
    fraud or default.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the form of indemnification agreements filed as
    Exhibit&#160;10.2 to this registration statement, we will agree
    to indemnify our directors and executive officers against
    certain liabilities and expenses incurred by such persons in
    connection with claims made by reason of their being such a
    director or executive officer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The form of underwriting agreement to be filed as
    Exhibit&#160;1.1 to this registration statement will also
    provide for indemnification of us and our officers and directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Insofar as indemnification for liabilities arising under the
    Securities Act may be permitted to directors, officers or
    persons controlling us under the foregoing provisions, we have
    been informed that in the opinion of the SEC such
    indemnification is against public policy as expressed in the
    Securities Act and is therefore unenforceable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ITEM&#160;7&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">RECENT
    SALES OF UNREGISTERED SECURITIES</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the past three years, we have issued the following
    securities (including options to acquire our ordinary shares).
    We believe that each of the following issuances was exempt from
    registration under the Securities Act in reliance on
    Regulation&#160;S under the Securities Act or under
    Section&#160;4(2) of the Securities Act regarding transactions
    not involving a public offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="32%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="12%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Underwriting<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Date of Sale or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B>Consideration in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Discount and<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Purchaser</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Issuance</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number of Securities</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">U.S. dollars</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Commission</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Certain director of the registrant
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    November 27, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    1 ordinary share*
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.05
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Notable Enterprise Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    March 8, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    225,000 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Dragon Image Investment Ltd.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    March 8, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    37,500 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Daketala International Investment Holdings Ltd.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    March 8, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    37,500 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Certain directors of the registrant and other minority
    shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    March 8, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    199,999 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(1)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,999.99
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Carlyle Asia Growth Partners III, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 3, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    53,292 Series A contingently redeemable convertible preferred
    shares<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,808,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CAGP III Co-Investment, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 3, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    2,125 Series A contingently redeemable convertible preferred
    shares<SUP style="font-size: 85%; vertical-align: top">(2)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    191,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CICC Sun Company Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 3, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    26,535 Series A contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Carlyle Asia Growth Partners III, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 10, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    convertible loan promissory
    note<SUP style="font-size: 85%; vertical-align: top">(3)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,233,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CAGP III Co-Investment, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    April 10, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    convertible loan promissory
    note<SUP style="font-size: 85%; vertical-align: top">(4)</SUP>

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    767,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CZY Investments Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    109,736 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,669,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Daketala International Investment Holdings Ltd.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    47,030 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,715,370
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Thousand Ocean Group Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    32,624 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,577,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Dragon Image Investment Ltd.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    16,524 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,305,396
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Top Mount Group Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    August 18, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    5,932 ordinary
    shares<SUP style="font-size: 85%; vertical-align: top">(5)</SUP>*

</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    468,628
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="32%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="13%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="24%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="12%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Underwriting<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Date of Sale or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B>Consideration in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Discount and<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Purchaser</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Issuance</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number of Securities</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">U.S. dollars</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Commission</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Carlyle Asia Growth Partners III, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    October 20, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    93,493 Series B contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    24,041,250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CAGP III Co-Investment, L.P.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    October 20, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    3,728 Series B contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    958,750
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    CICC Sun Company Limited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    October 20, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    38,889 Series B contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Starr Investments Cayman II, Inc.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    October 20, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD align="right" valign="bottom">
    97,222 Series B contingently redeemable convertible preferred
    shares
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    n/a
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(1)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Issued in connection with a share
    swap with Ascendium Group Limited as part of the reorganization
    to establish Concord Medical Services Holding Limited as our
    ultimate holding company.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(2)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The numbers of Series&#160;A
    contingently redeemable convertible preferred shares issued to
    Carlyle Asia Growth Partners III, L.P. and CAGP III
    Co-Investment, L.P. on April&#160;3, 2008 also include
    Series&#160;A contingently redeemable convertible preferred
    shares issued as a result of the conversion of two convertible
    loan promissory notes issued on November&#160;16, 2007 by our
    predecessor, Our Medical Services, Ltd., or OMS, plus accrued
    interest. OMS received consideration for the issuance of such
    convertible loan promissory notes in the amount of $4,808,250
    and $191,750 from Carlyle Asia Growth Partners III, L.P. and
    CAGP III Co-Investment, L.P., respectively.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(3)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The convertible loan promissory
    note was converted into 84,072 of our Series&#160;A contingently
    redeemable convertible preferred shares on July&#160;30, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(4)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">The convertible loan promissory
    note was converted into 3,353 of our Series&#160;A contingently
    redeemable convertible preferred shares on July&#160;30, 2008.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">(5)
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Issued as settlement for the share
    options issued to certain of our directors under the share
    option plan adopted by our predecessor company, Our Medical
    Services Limited, on November&#160;17, 2007.
    </FONT></TD>
</TR>





<TR>
    <TD valign="top">
    <FONT style="font-size: 8pt">*
    </FONT></TD>
    <TD></TD>
    <TD valign="bottom">
    <FONT style="font-size: 8pt">Does not take into account the
    share split effective on November&#160;17, 2009 whereby all of
    our issued and outstanding 704,281 ordinary shares of a par
    value of US$0.01 per share were split into 70,428,100 ordinary
    shares of US$0.0001 par value per share and the number of our
    authorized ordinary shares were increased from 4,500,000 to
    450,000,000.
    </FONT></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ITEM&#160;8&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">EXHIBITS&#160;AND
    FINANCIAL STATEMENT SCHEDULES</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    See Exhibit&#160;Index beginning on
    <FONT style="white-space: nowrap">page&#160;II-7</FONT>
    of this registration statement.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial
    Statement Schedules
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Schedules have been omitted because the information required to
    be set forth therein is not applicable or is shown in our
    consolidated financial statements or the notes thereto.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">ITEM&#160;9&#160;&#160;</FONT></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">UNDERTAKINGS</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes to provide to the
    underwriter at the closing specified in the underwriting
    agreements, certificates in such denominations and registered in
    such names as required by the underwriter to permit prompt
    delivery to each purchaser.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Insofar as indemnification for liabilities arising under the
    Securities Act may be permitted to directors, officers and
    controlling persons of the registrant under the provisions
    described in Item&#160;6, or otherwise, the registrant has been
    advised that in the opinion of the SEC such indemnification is
    against public policy as expressed in the Securities Act and is
    therefore unenforceable. In the event that a claim for
    indemnification against such liabilities (other than the payment
    by the registrant of expenses incurred or paid by a director,
    officer or controlling person of the registrant in the
    successful defense of any action, suit or proceeding) is
    asserted by such director, officer or controlling person in
    connection with the securities being registered, the registrant
    will, unless in the opinion of its counsel the matter has been
    settled by controlling precedent, submit to a court of
    appropriate jurisdiction the question whether such
    indemnification by it is against public policy as expressed in
    the Securities Act and will be governed by the final
    adjudication of such issue.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    II-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The undersigned registrant hereby undertakes that:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (1)&#160;For purposes of determining any liability under the
    Securities Act, the information omitted from the form of
    prospectus filed as part of this registration statement in
    reliance upon Rule&#160;430A and contained in a form of
    prospectus filed by the registrant under Rule&#160;424(b)(1) or
    (4)&#160;or 497(h) under the Securities Act shall be deemed to
    be part of this registration statement as of the time it was
    declared effective.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (2)&#160;For the purpose of determining any liability under the
    Securities Act, each post-effective amendment that contains a
    form of prospectus shall be deemed to be a new registration
    statement relating to the securities offered therein, and the
    offering of such securities at that time shall be deemed to be
    the initial bona fide offering thereof.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (3)&#160;For the purpose of determining liability under the
    Securities Act of 1933 to any purchaser, each prospectus filed
    pursuant to Rule&#160;424(b) as part of a registration statement
    relating to an offering, other than registration statements
    relying on Rule&#160;430B or other than prospectuses filed in
    reliance on Rule&#160;430A, shall be deemed to be part of and
    included in the registration statement as of the date it is
    first used after effectiveness, provided, however, that no
    statement made in a registration statement or prospectus that is
    part of the registration statement or made in a document
    incorporated or deemed incorporated by reference into the
    registration statement or prospectus that is part of the
    registration statement will, as to a purchaser with a time of
    contract of sale prior to such first use, supersede or modify
    any statement that was made in the registration statement or
    prospectus that was part of the registration statement or made
    in any such document immediately prior to such date of first use.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (4)&#160;For the purpose of determining liability of the
    registrant under the Securities Act of 1933 to any purchaser in
    the initial distribution of the securities, the undersigned
    registrant undertakes that in a primary offering of securities
    of the undersigned registrant pursuant to this registration
    statement, regardless of the underwriting method used to sell
    the securities to the purchaser, if the securities are offered
    or sold to such purchaser by means of any of the following
    communications, the undersigned registrant will be a seller to
    the purchaser and will be considered to offer or sell such
    securities to such purchaser:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (i)&#160;Any preliminary prospectus or prospectus of the
    undersigned registrant relating to the offering required to be
    filed pursuant to Rule 424;
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (ii)&#160;Any free writing prospectus relating to the offering
    prepared by or on behalf of the undersigned registrant or used
    or referred to by the undersigned registrant;
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iii)&#160;The portion of any other free writing prospectus
    relating to the offering containing material information about
    the undersigned registrant or its securities provided by or on
    behalf of the undersigned registrant;&#160;and
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    (iv)&#160;Any other communication that is an offer in the
    offering made by the undersigned registrant to the purchaser.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SIGNATURES</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act, the
    registrant certifies that it has reasonable grounds to believe
    that it meets all of the requirements for filing on
    <FONT style="white-space: nowrap">Form&#160;F-1</FONT>
    and has duly caused this registration statement to be signed on
    its behalf by the undersigned, thereunto duly authorized, in the
    City of Beijing, People&#146;s Republic of China, on
    November&#160;17, 2009.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 38%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="38%"></TD>
    <TD width="4%"></TD>
    <TD width="58%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Jianyu
    Yang</FONT></DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 42%; width: 48%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=222 -->

<DIV align="left" style="margin-left: 42%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Name:&#160;&#160;&#160;&#160;&#160;Jianyu Yang
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="42%"></TD>
    <TD width="7%"></TD>
    <TD width="51%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Director, Chief Executive Officer and President
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">POWER OF
    ATTORNEY</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each person whose signature appears below constitutes and
    appoints each of Jianyu Yang and Steve Sun as an
    attorney-in-fact, each with full power of substitution, for him
    or her in any and all capacities, to do any and all acts and all
    things and to execute any and all instruments which said
    attorney and agent may deem necessary or desirable to enable the
    registrant to comply with the Securities Act of 1933, as amended
    (the &#147;Securities Act&#148;), and any rules, regulations and
    requirements of the Securities and Exchange Commission
    thereunder, in connection with the registration under the
    Securities Act of ordinary shares of the registrant (the
    &#147;Shares&#148;), including, without limitation, the power
    and authority to sign the name of each of the undersigned in the
    capacities indicated below to the Registration Statement on
    <FONT style="white-space: nowrap">Form&#160;F-1</FONT>
    (the &#147;Registration Statement&#148;) to be filed with the
    Securities and Exchange Commission with respect to such Shares,
    to any and all amendments or supplements to such Registration
    Statement, whether such amendments or supplements are filed
    before or after the effective date of such Registration
    Statement, to any related Registration Statement filed pursuant
    to Rule&#160;462(b) under the Securities Act, and to any and all
    instruments or documents filed as part of or in connection with
    such Registration Statement or any and all amendments thereto,
    whether such amendments are filed before or after the effective
    date of such Registration Statement; and each of the undersigned
    hereby ratifies and confirms all that such attorney and agent
    shall do or cause to be done by virtue hereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to the requirements of the Securities Act of 1933, this
    registration statement has been signed by the following persons
    in the capacities indicated on November&#160;17, 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="9%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="35%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="52%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Signature</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Title</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 12pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Jianyu
    Yang</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Jianyu Yang
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Director, Chief Executive Officer and President<BR>
    (principal executive officer)
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Zheng
    Cheng</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Zheng Cheng
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Co-Chairman and Chief Operating Officer
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Steve
    Sun</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Steve Sun
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Co-Chairman and Chief Financial Officer<BR>
    (principal financial and accounting officer)
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Jing
    Zhang</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Jing Zhang
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Director and Executive President
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Yaw
    Kong Yap</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Yaw Kong Yap
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Director and Financial Controller
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="9%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="35%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="52%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Signature</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Title</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 12pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Shirley
    Chen</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Shirley Chen
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Feng
    Xiao</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Feng Xiao
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Elaine
    Zong</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Elaine Zong
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;<FONT style="font-variant: SMALL-CAPS">Wai
    Hong Ku</FONT></DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=201 iwidth=206 length=0 -->Name:
    Wai Hong Ku
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SIGNATURE
    OF AUTHORIZED U.S. REPRESENTATIVE</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the Securities Act of 1933, the undersigned, the duly
    authorized representative in the United States of Concord
    Medical Services Holdings Limited, has signed this registration
    statement or amendment thereto in Newark, Delaware, on
    November&#160;17, 2009.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Authorized U.S. Representative
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    PUGLISI &#038; ASSOCIATES
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Donald
    J. Puglisi</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Name:&#160;&#160;&#160;&#160;&#160;Donald J. Puglisi
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="8%"></TD>
    <TD width="43%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    Title:&#160;
</TD>
    <TD align="left">
    Managing Director
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CONCORD
    MEDICAL SERVICES HOLDINGS LIMITED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">EXHIBIT&#160;INDEX</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Exhibit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Description of
    Document</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    1.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Underwriting Agreement
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Second Amended and Restated Memorandum and Articles of
    Association of the Registrant, as currently in effect
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.2
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Secretary&#146;s Certificate of the Registrant dated as of
    November&#160;17, 2009 as to the Amendment to the Second Amended
    and Restated Memorandum and Articles of Association of the
    Registrant
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    3.3*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Third Amended and Restated Memorandum and Articles of
    Association of the Registrant
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Registrant&#146;s American Depository Receipt (included
    in Exhibit&#160;4.3)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.2
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Specimen Certificate for Ordinary Shares of the Registrant
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.3*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Deposit Agreement among the Registrant, the Depositary
    and Owners and Beneficial Owners of the American Depository
    Shares issued thereunder
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.4
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;A Preferred Shares Subscription Agreement, dated as
    of February&#160;5, 2008, as amended on April&#160;2, 2008 and
    on October&#160;20, 2008, among CICC Sun Company Limited,
    Carlyle Asia Growth Partners III, L.P., CAGP III Co-Investment,
    L.P., Liu Haifeng, Steve Sun, Yang Jianyu, Bona Liu, Our Medical
    Services, Ltd., Ascendium Group Limited, Shenzhen Aohua Medical
    Services Co., Ltd. and Concord Medical Services Holdings Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.5
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;1 to Series&#160;A Preferred Shares
    Subscription Agreement, dated as of April&#160;2, 2008, among
    CICC Sun Company Limited, Carlyle Asia Growth Partners III,
    L.P., CAGP III Co-Investment, L.P., Liu Haifeng, Steve Sun, Yang
    Jianyu, Bona Liu, Our Medical Services, Ltd., Ascendium Group
    Limited, Shenzhen Aohua Medical Services Co., Ltd. and Concord
    Medical Services Holdings Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.6
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment No.&#160;2 to Series&#160;A Preferred Shares
    Subscription Agreement, dated as of October&#160;20, 2008, among
    CICC Sun Company Limited, Carlyle Asia Growth Partners III,
    L.P., CAGP III Co-Investment, L.P., Liu Haifeng, Steve Sun, Yang
    Jianyu, Bona Liu, Our Medical Services, Ltd., Ascendium Group
    Limited, Shenzhen Aohua Medical Services Co., Ltd. and Concord
    Medical Services Holdings Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.7
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Series&#160;B Preferred Shares Subscription Agreement, dated as
    of October&#160;10, 2008, as amended on October&#160;20, 2008,
    among CICC Sun Company Limited, Carlyle Asia Growth Partners
    III, L.P., CAGP III Co-Investment, L.P., Starr Investments
    Cayman II, Inc., Concord Medical Services Holdings Limited and
    other persons named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.8
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment to Series&#160;B Preferred Shares Subscription
    Agreement, dated as of October&#160;20, 2008, among CICC Sun
    Company Limited, Carlyle Asia Growth Partners III, L.P., CAGP
    III Co-Investment, L.P., Starr Investments Cayman II, Inc.,
    Concord Medical Services Holdings Limited and other persons
    named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.9
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Shareholders Agreement, dated as of
    October&#160;20, 2008, among Concord Medical Services Holdings
    Limited, Carlyle Asia Growth Partners III, L.P., CAGP III
    Co-Investment, CICC Sun Company Limited, Perfect Key Holdings
    Limited, Starr Investments Cayman II, Inc. and certain other
    persons named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.10
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by CZY Investments
    Limited in favor of CICC Sun Company Limited, Carlyle Asia
    Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.11
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Daketala
    International Investment Holdings Ltd. in favor of CICC Sun
    Company Limited, Carlyle Asia Growth Partners III, L.P., CAGP
    III Co-Investment, L.P. and Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.12
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Dragon Image
    Investment Ltd. in favor of CICC Sun Company Limited, Carlyle
    Asia Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.13
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Notable
    Enterprise Limited in favor of CICC Sun Company Limited, Carlyle
    Asia Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.14
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Thousand Ocean
    Group Limited in favor of CICC Sun Company Limited, Carlyle Asia
    Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Exhibit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Description of
    Document</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.15
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Share Charge, dated as of November 10, 2008, by Top Mount Group
    Limited in favor of CICC Sun Company Limited, Carlyle Asia
    Growth Partners III, L.P., CAGP III Co-Investment, L.P. and
    Starr Investments Cayman II, Inc.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.16
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Deed of Amendment, dated as of September&#160;14, 2009, among
    CICC Sun Company Limited, Carlyle Asia Growth Partners III,
    L.P., CAGP III Co-Investment, L.P., Starr Investments Cayman II,
    Inc. and Notable Enterprise Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.17
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Deed of Partial Release, dated as of September&#160;14, 2009, by
    CICC Sun Company Limited, Carlyle Asia Growth Partners III,
    L.P., CAGP III Co-Investment, L.P. and Starr Investments Cayman
    II, Inc. in favor of CZY Investment Limited
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    4.18*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amendment to Amended and Restated Shareholders Agreement, dated
    as of November&#160;17, 2009, among Concord Medical Services
    Holdings Limited, Carlyle Asia Growth Partners&#160;III, L.P.,
    CAGP&#160;III Co-Investment, CICC Sun Company Limited, Perfect
    Key Holdings Limited, Starr Investments Cayman II, Inc. and
    certain other persons named therein
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    5.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Walkers regarding the validity of the ordinary shares
    being registered
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    8.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Walkers regarding certain Cayman Islands tax matters
    (included in Exhibit&#160;5.1)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    8.2
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Opinion of Simpson Thacher&#160;&#038; Bartlett LLP regarding
    certain U.S. tax matters
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2008&#160;Share Incentive Plan adopted as of October&#160;16,
    2008
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Indemnification Agreement with the Registrant&#146;s
    directors and officers
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.3
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Medical Equipment Lease Agreement
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.4
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Equipment Management Services Agreement
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.5
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Service-only Management Agreement
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.6
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Summary of the Oral Agreement entered into between China Medstar
    Pte. Ltd. and Beijing Medstar Hi-Tech Investment Co., Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.7
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Summary of the Oral Agreement entered into between China Medstar
    Pte. Ltd. and Cheng Zheng
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.8
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Summary of the Oral Agreement entered into between China Medstar
    Pte. Ltd. and Yaw Kong Yap
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.9&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Medical Equipment Lease Agreement, dated as of
    August 25, 2009, by and between Medstar (Shanghai) Leasing Co.,
    Ltd. and Chang&#146;an Hospital Co., Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.10&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Service-Only Management Agreement, dated as of
    August 1, 2008, among CMS Hospital Management Co., Ltd.,
    Xi&#146;an Wanjiechangxin Medical Services Company Limited and
    Chang&#146;an Hospital Co., Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.11&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Agreement Concerning the Establishment of the
    Aohai Radiotherapy Treatment and Diagnosis Research Center,
    dated as of September 19, 1995, by and between the Chinese
    People&#146;s Liberation Army Navy General Hospital and Beijing
    Our Medical Equipment Development Company, which transferred its
    interest in the agreement to Shenzhen Aohua Medical Services
    Co., Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.12&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement Concerning the Development
    of the Aohai Radiotherapy Treatment and Diagnosis Research
    Center, dated as of March 18, 1999, by and between Shenzhen
    Aohua Medical Services Co., Ltd. and the Chinese People&#146;s
    Liberation Army Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.13&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement Concerning the Development
    of the Aohai Radiotherapy Treatment and Diagnosis Research
    Center, dated as of September 27, 2003, by and between Shenzhen
    Aohua Medical Services Co., Ltd. and the Chinese People&#146;s
    Liberation Army Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.14&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Medical Equipment Lease Agreement, dated as of
    September 29, 2006, by and between Shanghai Medstar Investment
    Management Co., Ltd., the predecessor of Medstar (Shanghai)
    Leasing Co., Ltd., and the Chinese People&#146;s Liberation Army
    Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.15&#134;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement Concerning the Development
    of the Aohai Radiotherapy Treatment and Diagnosis Research
    Center, dated as of July 8, 2009, by and between Shenzhen Aohua
    Medical Services Co., Ltd. and the Chinese People&#146;s
    Liberation Army Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.16
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement to the Service-only
    Management Agreement, dated as of August 1, 2008, among
    Xi&#146;an Wanjiechangxin Medical Services Company Limited,
    Chang&#146;an Hospital Co., Ltd. and CMS Hospital Management
    Co., Ltd.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.17
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Agreement Regarding the Transfer of Equity in
    Aohai Radiotherapy Treatment and Diagnosis Research Center,
    dated as of May 5, 1997, among Beijing Our Medical Equipment
    Development Company, Shenzhen Aohua Medical Services Co., Ltd.
    and the Chinese People&#146;s Liberation Army Navy General
    Hospital.
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="8%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="90%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 10pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Exhibit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Number</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B><FONT style="font-size: 10pt">Description of
    Document</FONT></B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.18
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement to the Supplemental
    Agreement Concerning the Development of the Aohai Radiotherapy
    Treatment and Diagnosis Research Center, dated as of September
    15, 2004, by and between Shenzhen Aohua Medical Services Co.,
    Ltd. and the Chinese People&#146;s Liberation Army Navy General
    Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    10.19
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Translation of Supplemental Agreement to the Cooperation
    Contract Concerning the Aohai Radiotherapy Treatment and
    Diagnosis Research Center, dated as of August 16, 2003, by and
    between Shenzhen Aohua Medical Services Co., Ltd. and the
    Chinese People&#146;s Liberation Army Navy General Hospital.
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    21.1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Subsidiaries of the Registrant
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Independent Registered Public Accounting Firm
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Walkers (included in Exhibit&#160;5.1)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.3
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Simpson Thacher&#160;&#038; Bartlett LLP (included in
    Exhibit&#160;8.2)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.4
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Jingtian&#160;&#038; Gongcheng Attorneys At Law
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    23.5
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Frost &#038; Sullivan
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    24.1
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Powers of Attorney (included on the signature page in
    Part&#160;II of this registration statement)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    99.1*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Code of Business Conduct and Ethics
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    99.2*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Form of Opinion of Jingtian &#038; Gongcheng Attorneys At Law
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 10%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=48 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 06 -->

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    To be submitted by amendment</TD>
</TR>




<TR>
    <TD valign="top">
    &#134; </TD>
    <TD></TD>
    <TD valign="bottom">
    Confidential treatment has been requested for portions of this
    document.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    II-9
</DIV><!-- END PAGE WIDTH -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>h03611exv3w1.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;3.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SECOND AMENDED AND RESTATED<BR>
MEMORANDUM AND ARTICLES OF ASSOCIATION</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>OF</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CONCORD MEDICAL SERVICES<BR>
HOLDINGS LIMITED</B>

</DIV>
<DIV align="center" style="font-size: 10pt"><IMG src="h03611h0361146.gif" alt="(CHINESE CHARACTER)"></DIV>



<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Incorporated on the 27th day of November, 2007</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Amended and restated on the 31st day of March, 2008</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Further amended and restated on the 20th day of October, 2008</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INCORPORATED IN THE CAYMAN ISLANDS</B>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>THE COMPANIES LAW (2007 Revision)<BR>
Company Limited by Shares</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SECOND AMENDED AND RESTATED MEMORANDUM OF<BR>
ASSOCIATION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>OF</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>CONCORD MEDICAL SERVICES<BR>
HOLDINGS LIMITED</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><IMG src="h03611h0361147.gif" alt="(CHINESE CHARACTER)"></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;The name of the Company is CONCORD MEDICAL SERVICES HOLDINGS LIMITED <IMG src="h03611h0361146.gif" alt="(CHINESE CHARACTER)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;The Registered Office of the Company shall be at the offices of Offshore Incorporations
(Cayman) Limited, Scotia Centre, 4th Floor, P.O. Box 2804, George Town, Grand Cayman KY1-1112,
Cayman Islands or at such other place as the Directors may from time to time decide.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;The objects for which the Company is established are unrestricted and shall include, but
without limitation, the following:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) To carry on the business of an investment company and to act as promoters and
entrepreneurs and to carry on business as financiers, capitalists, concessionaires,
merchants, brokers, traders, dealers, agents, importers and exporters and to undertake and
carry on and execute all kinds of investment, financial, commercial, mercantile, trading
and other operations.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) To carry on whether as principals, agents or otherwise howsoever the business of
realtors, developers, consultants, estate agents or managers, builders, contractors,
engineers, manufacturers, dealers in or vendors of all types of property including
services.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) To exercise and enforce all rights and powers conferred by or incidental to the
ownership of any shares, stock, obligations or other securities including without
prejudice to the generality of the foregoing all such powers of veto or control as may be
conferred by virtue of the holding by the Company of some special proportion of the issued
or nominal amount thereof, to provide managerial and other executive, supervisory and
consultant services for or in relation to any company in which the Company is interested
upon such terms as may be thought fit.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) To purchase or otherwise acquire, to sell, exchange, surrender, lease, mortgage,
charge, convert, turn to account, dispose of and deal with real and personal property and
rights of all kinds and, in
particular, mortgages, debentures, produce, concessions, options, contracts, patents,
annuities, licences, stocks, shares, bonds, policies, book debts, business concerns,
undertakings, claims, privileges and choses in action of all kinds.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) To subscribe for, conditionally or unconditionally, to underwrite, issue on
commission or otherwise, take, hold, deal in and convert stocks, shares and securities of
all kinds and to enter into partnership or into any arrangement for sharing profits,
reciprocal concessions or cooperation with any person or company and to promote and aid in
promoting, to constitute, form or organize any company, syndicate or partnership of any
kind, for the purpose of acquiring and undertaking any property and liabilities of the
Company or of advancing, directly or indirectly, the objects of the Company or for any
other purpose which the Company may think expedient.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) To stand surety for or to guarantee, support or secure the performance of all or
any of the obligations of any person, firm or company whether or not related or affiliated
to the Company in any manner and whether by personal covenant or by mortgage, charge or
lien upon the whole or any part of the undertaking, property and assets of the Company,
both present and future, including its uncalled capital or by any such method and whether
or not the Company shall receive valuable consideration thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) To engage in or carry on any other lawful trade, business or enterprise which may
at any time appear to the Directors of the Company capable of being conveniently carried
on in conjunction with any of the aforementioned businesses or activities or which may
appear to the Directors or the Company likely to be profitable to the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the interpretation of this Second Amended and Restated Memorandum of Association in general
and of this Clause 3 in particular no object, business or power specified or mentioned shall be
limited or restricted by reference to or inference from any other object, business or power, or the
name of the Company, or by the juxtaposition of two or more objects, businesses or powers and that,
in the event of any ambiguity in this clause or elsewhere in this Second Amended and Restated
Memorandum of Association, the same shall be resolved by such interpretation and construction as
will widen and enlarge and not restrict the objects, businesses and powers of and exercisable by
the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;Except as prohibited or limited by the Companies Law (2007 Revision), the Company shall
have full power and authority to carry out any object and shall have and be capable of from time to
time and at all times exercising any and all of the powers at any time or from time to time
exercisable by a natural person or body corporate in doing in any part of the world whether as
principal, agent, contractor or otherwise whatever may be considered by it necessary for the
attainment of its objects
and whatever else may be considered by it as incidental or conducive thereto or consequential
thereon, including, but without in any way restricting the generality of the foregoing, the power
to make any alterations or amendments to this Second Amended and Restated Memorandum of Association
and the Articles of Association of the Company considered necessary or convenient in the manner set
out in the Articles of Association of the Company, and the power to do any of the following acts or
things, viz: to pay all expenses of and incidental to the promotion, formation and incorporation of
the Company; to register the Company to do business in any other jurisdiction; to sell, lease or
dispose of any property of the Company; to draw, make, accept, endorse, discount, execute and issue
promissory notes, debentures, bills of exchange, bills of lading, warrants and other negotiable or
transferable instruments; to lend money or other assets and to act as guarantors; to borrow or
raise money on the security of the undertaking or on all or any of the assets of the Company
including uncalled capital or without security; to invest monies of the Company in such manner as
the Directors determine; to promote other companies; to sell the undertaking of the Company for
cash or any other consideration; to distribute assets in specie to Members of the Company; to make
charitable or benevolent donations; to pay pensions or gratuities or provide other benefits in cash
or kind to Directors, officers, employees, past or present and their families; to purchase
Directors and officers liability insurance and to carry on any trade or business and generally to
do all acts and things which, in the opinion of the Company or the Directors, may be conveniently
or profitably or usefully acquired and dealt with, carried on, executed or done by the Company in
connection with the business aforesaid; <I>provided </I>that the Company shall only carry on the
businesses for which a license is required under the laws of the Cayman Islands when so licensed
under the terms of such laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;The liability of each Member is limited to the amount from time to time unpaid on such
Member&#146;s shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;The share capital of the Company is US$50,000.00 divided into 5,000,000 shares of a nominal
or par value of US$0.01 each of which 4,500,000 are designated as Ordinary Shares of a nominal or
par value of US$0.01 each, 200,000 are designated as Series&nbsp;A Redeemable Convertible Preferred
Shares of a nominal or par value of US$0.01 each and 300,000 are designated as Series&nbsp;B Redeemable
Convertible Preferred Shares of nominal or par value of US$0.01 each with power for the Company
insofar as is permitted by law, to redeem or purchase any of its shares and to increase or reduce
the said capital subject to the provisions of the Companies Law (2007 Revision) and the Articles of
Association and to issue any part of its capital, whether original, redeemed or increased with or
without any preference, priority or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">special privilege or subject to any postponement of rights or
to any conditions or restrictions and so that unless the conditions of issue shall otherwise
expressly declare every issue of shares whether declared to be preference or otherwise shall be
subject to the powers hereinbefore contained; <I>provided </I>that, notwithstanding any provision to the
contrary contained in this Second Amended and Restated Memorandum of Association, the Company shall
have no power to issue bearer shares, warrants, coupons or certificates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;Since the Company is exempted, its operations will be carried on subject to the provisions
of Section&nbsp;193 of the Companies Law (2007 Revision) and, subject to the provisions of the Companies
Law (2007 Revision) and the Articles of Association, it shall have the power to register by way of
continuation as a body corporate limited by shares under the laws of any jurisdiction outside the
Cayman Islands and to be deregistered in the Cayman Islands.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We, the undersigned, are desirous of being formed into a Company pursuant to this Memorandum
of Association and the Companies Law (2007 Revision), and we hereby agree to take the numbers of
shares set opposite our name below.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><DIV style="margin-left:50px; text-indent:-0px"><B>&nbsp;Signature, Name, Occupation,</B></div></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Number of Shares Taken</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><DIV style="margin-left:60px; text-indent:-0px"><B>and Address of Subscriber</B></div></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>by Each Subscriber</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">For and on behalf of<BR>
Offshore Incorporations (Cayman) Limited
Corporation<BR>
of Scotia Centre, 4th Floor,<BR>
P.O. Box 2804,<BR>
George Town,<BR>
Grand Cayman KY1-1112<BR>
CAYMAN ISLANDS <BR><BR><BR>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ONE</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(Sd.) Authorized Signatory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">DATED 27 Nov 2007
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">WITNESS to the above signature :-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Sd.) Sharon Kyberd<BR>
of Scotia Centre, 4th Floor,<BR>
P.O. Box 2804,<BR>
George Town,<BR>
Grand Cayman KY1-1112<BR>
CAYMAN ISLANDS</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">I, Joy A. Rankine, Asst. Registrar of Companies in and for the Cayman Islands, DO HEREBY CERTIFY
that this is a true copy of the Memorandum of Association of this Company duly<BR>
incorporated on the 27th November&nbsp;2007
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD colspan="3">Asst. REGISTRAR OF COMPANIES (SD.)</TD>
</TR>

</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>THE COMPANIES LAW (2007 Revision)<BR>
Company Limited by Shares</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SECOND AMENDED AND RESTATED ARTICLES OF ASSOCIATION</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>OF</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>CONCORD MEDICAL SERVICES<BR>
HOLDINGS LIMITED</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><IMG src="h03611h0361149.gif" alt="(CHINESE CHARACTER)"></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. In these Articles Table A in the Schedule to the Statute does not apply and, unless there
be something in the subject or context inconsistent therewith,
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person directly or indirectly
controlling, controlled by or under common control with such Person, <I>provided </I>that no
securityholder of the Company shall be deemed an Affiliate of any other securityholder solely by
reason of any investment in the Company. For the purpose of this definition, the term &#147;<B>control</B>&#148;
(including, with correlative meanings, the terms &#147;<B>controlling</B>&#148;, &#147;<B>controlled by</B>&#148; and &#147;<B>under common
control with</B>&#148;), as used with respect to any Person, shall mean the possession, directly or
indirectly, of the power to direct or cause the direction of the management and policies of such
Person, whether through the ownership of voting securities, by contract or otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Aggregate Ownership</B>&#148; means, with respect to any Member or group of Members, and with respect
to any class of Company Securities, the total amount of such class of Company Securities
&#147;beneficially owned&#148; (as such term is defined in Rule&nbsp;13d-3 of the Exchange Act) (without
duplication) by such Member or group of Members as of the date of such calculation, calculated on a
Fully-Diluted basis.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Amended and Restated Shareholders&#146; Agreement</B>&#148; means that certain Shareholders&#146; Agreement
dated as of October&nbsp;20, 2008 among the Company, the Investors, the Other Members and certain other
Persons specified therein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Articles</B>&#148; means these Second Amended and Restated Articles, as from time to time altered.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Auditors</B>&#148; means the persons for the time being performing the duties of auditors of the
Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Board of Directors</B>&#148; means the board of directors of the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Business Day</B>&#148; means a day, other than Saturday, Sunday or other day on which commercial banks
in either the US, Hong Kong or the PRC are authorized or required by applicable law to close.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Carlyle</B>&#148; means, collectively, Carlyle Asia Growth Partners III, L.P., a limited partnership
formed under the laws of the Cayman Islands, and CAGP III Co-Investment, L.P., a limited
partnership formed under the laws of the Cayman Islands.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Carlyle Director</B>&#148; shall have the meaning ascribed to it in Article&nbsp;71.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>CICC</B>&#148; means, collectively, CICC Sun Company Limited, a company incorporated under the laws of
the British Virgin Islands, and Perfect Key.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>CICC Director</B>&#148; shall have the meaning ascribed to it in Article&nbsp;71.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Closing</B>&#148; shall have the meaning ascribed to it in the Series&nbsp;B Subscription Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Closing Date</B>&#148; shall have the meaning ascribed to it in the Series&nbsp;B Subscription Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Company</B>&#148; means Concord Medical Services Holdings Company <IMG src="h03611h0361150.gif" alt="(CHINESE CHARACTER)"> a company
incorporated under the laws of the Cayman Islands (registered number 200093), whose registered
office is at c/o Offshore Incorporations (Cayman) Limited, Scotia Centre, 4th Floor, P.O. Box 2804,
George Town, Grand Cayman KY1-1112, Cayman Islands.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Company Securities</B>&#148; means (i)&nbsp;the Ordinary Shares and the Preferred Shares, (ii)&nbsp;securities
convertible into or exchangeable for Ordinary Shares and/or Preferred Shares, (iii)&nbsp;any other
equity or equity-linked security issued by the Company and (iv)&nbsp;options, warrants or other rights
to acquire Ordinary Shares, Preferred Shares or any other equity or equity-linked security issued
by the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Controlling Members</B>&#148; means, collectively, the following Persons:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) CZY Investments Limited, a company incorporated under the laws of the British Virgin
Islands (&#147;<B>CZY</B>&#148;);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Daketala International Investment Holdings Ltd., a company incorporated under the laws of
the British Virgin Islands (&#147;<B>Daketala</B>&#148;);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) Dragon Image Investment Ltd., a company incorporated under the laws of the British Virgin
Islands (&#147;<B>Dragon Image</B>&#148;);
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) Thousand Ocean Group Limited, a company incorporated under the laws of the British Virgin
Islands (&#147;<B>TOG</B>&#148;);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) Top Mount Group Limited, a company incorporated under the laws of the British Virgin
Islands (&#147;<B>TMG</B>&#148;); and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) Notable Enterprise Limited, a company incorporated under the laws of the British Virgin
Islands (&#147;<B>Notable</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Conversion</B>&#148; means the conversion of the Preferred Shares into Ordinary Shares pursuant to
Article&nbsp;106, 108 or 109.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Conversion Date</B>&#148; shall have the meaning ascribed to it in Article&nbsp;107.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Conversion Notice</B>&#148; shall have the meaning ascribed to it in Article&nbsp;107.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Conversion Price</B>&#148; means initially (x)&nbsp;US$184 for Series&nbsp;A Shares and (y)&nbsp;US$257 for Series&nbsp;B
Shares, in each case subject to adjustment from time to time pursuant to Article&nbsp;111.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Conversion Ratio</B>&#148; shall have the meaning ascribed to it in Article&nbsp;106.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Conversion Rights</B>&#148; means the rights of holders of Preferred Shares set forth in Article&nbsp;106.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Convertible Loan Agreement</B>&#148; means the Convertible Loan Agreement by and among the Company,
Carlyle and other Persons specified therein dated as of April&nbsp;10, 2008, as amended by the Amendment
to Convertible Loan Agreement by and among the Company, Carlyle and other Persons specified therein
dated as of the Closing Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>debenture</B>&#148; means debenture stock, mortgages, bonds and any other such securities of the
Company whether constituting a charge on the assets of the Company or not.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Directors</B>&#148; means the directors for the time being of the Company and shall include the
alternate directors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Drag-Along Portion</B>&#148; shall have the meaning ascribed to it in Article&nbsp;15.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Drag-Along Rights</B>&#148; shall have the meaning ascribed to it in Article&nbsp;15.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Drag-Along Sale</B>&#148; shall have the meaning ascribed to it in Article&nbsp;15.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Drag-Along Sale Notice</B>&#148; shall have the meaning ascribed to it in Article&nbsp;15.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Drag-Along Sale Notice Period</B>&#148; shall have the meaning ascribed to it in Article&nbsp;15.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Drag-Along Sale Price</B>&#148; shall have the meaning ascribed to it in Article&nbsp;15.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Drag-Along Sellers</B>&#148; shall have the meaning ascribed to it in Article&nbsp;15.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Drag-Along Transferee</B>&#148; shall have the meaning ascribed to it in Article&nbsp;15.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Dragged Members</B>&#148; shall have the meaning ascribed to it in Article&nbsp;15.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934 of the United States of America, as
amended.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Exercise Notice</B>&#148; shall have the meaning ascribed to it in Article&nbsp;11(b).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Fixed Dividend</B>&#148; shall have the meaning ascribed to it in Article&nbsp;123.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Fully-Diluted</B>&#148; means, with respect to any class of Company Securities, all outstanding shares
of such class and all shares issuable in respect of securities convertible into or exchangeable for
shares of such class, all share appreciation rights, options, warrants and other rights to purchase
or subscribe for such Company Securities or securities convertible into or exchangeable for such
Company Securities; <I>provided </I>that, if any of the foregoing share appreciation rights, options,
warrants or other rights to purchase or subscribe for such Company Securities are subject to
vesting, the Company Securities subject to vesting shall be included in the definition of
&#147;Fully-Diluted&#148; only upon and to the extent of such vesting.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Hong Kong</B>&#148; means the Hong Kong Special Administrative Region.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Indemnified Person</B>&#148; shall have the meaning ascribed to it in Article&nbsp;148.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Initial Ownership</B>&#148; means, with respect to any Member and any class of Company Securities, the
Aggregate Ownership of such class by such Member as of the Closing Date, or in the case of any
Person that shall become a Member on a later date, as of such later date, in each case taking into
account any share split, share dividend, reverse share split or similar event.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Investor Directors</B>&#148; shall have the meaning ascribed to it in Article&nbsp;71.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Investors</B>&#148; means Carlyle, CICC and Starr.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IPO</B>&#148; means an initial public offering and listing of the Ordinary Shares (or, in lieu thereof
and as mutually agreed by the Investors and the Company, equity securities of (i)&nbsp;any holding
company holding the issued share capital of the Company or (ii)&nbsp;any Subsidiary of the Company) on
an internationally recognized stock exchange.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Issuance Notice</B>&#148; shall have the meaning ascribed to it in Article&nbsp;11(a).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Key Men</B>&#148; means, collectively, Mr.&nbsp;Cheng Zheng <IMG src="h03611h0361151.gif" alt="(CHINESE CHARACTER)">  Mr.&nbsp;Yang Jianyu <IMG src="h03611h0361152.gif" alt="(CHINESE CHARACTER)"> Mr.
Steven Xiaodi Sun, Mr.&nbsp;Zhang Jing <IMG src="h03611h0361153.gif" alt="(CHINESE CHARACTER)"> and Mr.&nbsp;Yap Yaw Kong <IMG src="h03611h0361154.gif" alt="(CHINESE CHARACTER)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Liquidation Preference</B>&#148; shall have the meaning ascribed to it in Article&nbsp;145.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Major Member</B>&#148; shall have the meaning ascribed to it in Article&nbsp;11(a).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Material Adverse Effect</B>&#148; means a material adverse effect on the condition (financial or
otherwise), business, assets, results of operations or prospects of the Company and its
Subsidiaries, taken as a whole.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Member</B>&#148; shall have the meaning ascribed to it in the Statute.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>month</B>&#148; means calendar month.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Ordinary Resolution</B>&#148; means a resolution passed at a general meeting of Members (or, if so
specified, a meeting of Members holding a class of shares) of the Company by a simple majority of
the votes cast or such higher majority as is required in accordance with these Articles, or a
written resolution passed by the unanimous consent of all Members (or, if so specified, all Members
holding such class of shares) entitled to vote.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Ordinary Shares</B>&#148; means ordinary shares, par value US$0.01 per share, of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Other Members</B>&#148; means Members other than the Investors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>paid-up</B>&#148; means paid-up and/or credited as paid-up.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Perfect Key</B>&#148; means Perfect Key Holdings Limited, a company incorporated under the laws of the
British Virgin Islands.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Permitted Transferee</B>&#148; means,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) with respect to CAGP or CAGP Co-Invest, (i)&nbsp;any of its general or limited partner (a
&#147;<B>Carlyle Partner</B>&#148;), and any company, partnership or other
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">entity that is an Affiliate of CAGP or
CAGP Co-Invest or any Carlyle Partner (collectively, &#147;<B>Carlyle Affiliates</B>&#148;), (ii)&nbsp;any managing
director, general partner, director, limited partner, officer or employee of Carlyle or any Carlyle
Affiliate, or any spouse, lineal descendant, sibling, parent, heir, executor, administrator,
testamentary trustee, legatee or beneficiary of any of the foregoing persons described in this
clause (ii) (collectively, &#147;<B>Carlyle Associates</B>&#148;), or (iii)&nbsp;any trust the ultimate beneficiaries of
which, or any company, limited liability company or
partnership the ultimate shareholders, members or general or limited partners of which,
include only CAGP, CAGP Co-Invest, Carlyle Affiliates and/or Carlyle Associates;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) with respect to CICC Sun and Perfect Key, (i)&nbsp;any of its shareholders, and any company,
partnership or other entity that is an Affiliate of CICC Sun or Perfect Key or any of its
shareholders (collectively, &#147;<B>CICC Affiliates</B>&#148;), (ii)&nbsp;any managing director, general partner,
director, limited partner, officer or employee of CICC or any CICC Affiliate, or any spouse, lineal
descendant, sibling, parent, heir, executor, administrator, testamentary trustee, legatee or
beneficiary of any of the foregoing persons described in this clause (ii) (collectively, &#147;<B>CICC
Associates</B>&#148;), or (iii)&nbsp;any trust the ultimate beneficiaries of which, or any company, limited
liability company or partnership the ultimate shareholders, members or general or limited partners
of which, include only CICC Sun, Perfect Key, CICC Affiliates and/or CICC Associates;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C) with respect to Starr, (i)&nbsp;any of its shareholders, and any company, partnership or other
entity that is an Affiliate of Starr or any of its shareholders (collectively, &#147;<B>Starr Affiliates</B>&#148;),
(ii)&nbsp;any managing director, general partner, director, limited partner, officer or employee of
Starr or any Starr Affiliate, or any spouse, lineal descendant, sibling, parent, heir, executor,
administrator, testamentary trustee, legatee or beneficiary of any of the foregoing persons
described in this clause (ii) (collectively, &#147;<B>Starr Associates</B>&#148;), or (iii)&nbsp;any trust the ultimate
beneficiaries of which, or any company, limited liability company or partnership the ultimate
shareholders, members or general or limited partners of which, include only Starr, Starr Affiliates
and/or Starr Associates; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D) with respect to each of the Controlling Members, (i)&nbsp;any company or other entity that is
wholly-owned, either directly or indirectly, by the ultimate individual shareholder of such
Controlling Member on the Closing Date (collectively, &#147;<B>Controlling Member Affiliates</B>&#148;), (ii)&nbsp;any
spouse, lineal descendant, sibling, parent, heir, executor, administrator, testamentary trustee,
legatee or beneficiary of such ultimate individual shareholder (collectively, &#147;<B>Controlling Member
Associates</B>&#148;), or (iii)&nbsp;any trust the ultimate beneficiaries of which, or any company, limited
liability company or partnership the ultimate shareholders, members or general or limited partners
of which, include only such ultimate individual shareholder, such Controlling Member Affiliates
and/or such Controlling Member Associates.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Person</B>&#148; means an individual, corporation, limited liability company, partnership,
association, trust or other entity or organization, including a government or political subdivision
or an agency or instrumentality thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>PRC</B>&#148; means the People&#146;s Republic of China, excluding, for purposes of these Articles only,
Hong Kong, the Macau Special Administrative Region and Taiwan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Preferred Shares</B>&#148; means the Series&nbsp;A Shares and the Series&nbsp;B Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Pro Rata Share</B>&#148; shall have the meaning ascribed to it in Article&nbsp;11(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Purchase Price</B>&#148; means, with respect to any holder of any Preferred Shares at any time, the
weighted average per share price at which such holder has acquired all Preferred Shares of such
class, as the case may be, then held by such holder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Purchaser</B>&#148; shall have the meaning ascribed to it in Article&nbsp;16(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Put Interest</B>&#148; shall have the meaning ascribed to it in Article&nbsp;16(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Put Notice</B>&#148; shall have the meaning ascribed to it in Article&nbsp;16(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Put Price</B>&#148; shall have the meaning ascribed to it in Article&nbsp;16(e).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Put Right</B>&#148; shall have the meaning ascribed to it in Article&nbsp;16(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Putting Member</B>&#148; shall have the meaning ascribed to it in Article&nbsp;16(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Put Trigger Event</B>&#148; means any of the following:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the Company has not completed a QPO by the third anniversary of the Closing
Date;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) any of the Key Men has resigned from the Company and its Subsidiaries, which
resignation, in the sole determination of a majority of the Investors, has resulted in or
would be likely to result in, a Material Adverse Effect; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the Company or any of its Subsidiaries has breached or failed to be in
compliance with any applicable laws that has had or would be reasonably likely to have, a
Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>QPO</B>&#148; means a firm-commitment underwritten IPO (i)&nbsp;led by internationally reputable
underwriters, approved by the Board (which shall include a majority of the Investor Directors), and
yielding a valuation of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company at not less than US$450&nbsp;million immediately prior to the
consummation of such IPO, or (ii)&nbsp;any other IPO approved by holders of at least 70% of the then
outstanding Series&nbsp;B Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Rate of Return</B>&#148; means, at the time of calculation, the annual percentage rate, which when
utilized to calculate the present value of a series of cash inflows and the present value of a
series of cash outflows shall cause the present value of such cash inflows to equal the present
value of such cash outflows. The Rate of Return shall be compounded annually, calculated on a
daily basis based on a 360&nbsp;day year, and shall be calculated in US dollars, with any cash inflow or
cash
outflow denominated in a currency other than US dollars translated for purposes of the
calculation into US dollars at the Relevant Exchange Rate in effect as of the date of the cash
inflow or cash outflow.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Register of Members</B>&#148; means the register of members of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>registered office</B>&#148; means the registered office for the time being of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Relevant Exchange Rate</B>&#148; means, (i)&nbsp;with respect to RMB and any calculation date, the spot
exchange rate between RMB and US dollars as quoted by the People&#146;s Bank of China on such date, and
(ii)&nbsp;with respect to any other currency and any calculation date, the &#147;noon buying rate&#148; for
purchases of such currency on such date published by the Federal Reserve Bank of New York.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Replacement Nominee</B>&#148; shall have the meaning ascribed to it in Article&nbsp;99(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>RMB</B>&#148; means renminbi, the lawful currency of the PRC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFO Non-Selling Member</B>&#148; shall have the meaning ascribed to it in Article&nbsp;13(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFO Offer Notice</B>&#148; shall have the meaning ascribed to it in Article&nbsp;13(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFO Offer Period</B>&#148; shall have the meaning ascribed to it in Article&nbsp;13(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFO Offer Price</B>&#148; shall have the meaning ascribed to it in Article&nbsp;13(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFO Offered Securities</B>&#148; shall have the meaning ascribed to it in Article&nbsp;13(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFO Seller</B>&#148; shall have the meaning ascribed to it in Article&nbsp;13(a).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFR Member</B>&#148; shall have the meaning ascribed to it in Article&nbsp;12(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFR Non-Selling Member</B>&#148; shall have the meaning ascribed to it in Article&nbsp;12(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFR Offer</B>&#148; shall have the meaning ascribed to it in Article&nbsp;12(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFR Offer Notice</B>&#148; shall have the meaning ascribed to it in Article&nbsp;12(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFR Offer Price</B>&#148; shall have the meaning ascribed to it in Article&nbsp;12(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFR Offer Pro Rata Portion</B>&#148; shall have the meaning ascribed to it in Article&nbsp;12(b).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFR Offered Securities</B>&#148; shall have the meaning ascribed to it in Article&nbsp;12(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ROFR Seller</B>&#148; shall have the meaning ascribed to it in Article&nbsp;12(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Seal</B>&#148; means the common seal of the Company and includes every duplicate seal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Secretary</B>&#148; means any person appointed to perform the duties of Secretary of the Company and
includes an Assistant Secretary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Series&nbsp;A Shares</B>&#148; means the Series&nbsp;A redeemable convertible preferred shares, par value
US$0.01 per share, of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Series&nbsp;A Subscription Agreement</B>&#148; means the Share Subscription Agreement by and among the
Company, Carlyle, CICC and other Persons specified therein dated as of February&nbsp;5, 2008, as amended
by the Amendment to Share Subscription Agreement by and among the Company, Carlyle, CICC and other
Persons specified therein dated as of April&nbsp;2, 2008 and the Amendment No.&nbsp;2 to Share Subscription
Agreement by and among the Company, Carlyle, CICC and other Persons specified therein dated as of
the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Series&nbsp;B Shares</B>&#148; means the Series&nbsp;B redeemable convertible preferred shares, par value
US$0.01 per share, of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Series&nbsp;B Subscription Agreement</B>&#148; means the Share Subscription Agreement by and among the
Company, the Investors and other Persons specified therein dated as of October&nbsp;10, 2008, as amended
by the Amendment to Share Subscription Agreement by and among the Company, the Investors and other
Persons specified therein dated as of October&nbsp;20, 2008.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>share</B>&#148; includes a fraction of a share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Share Charge Agreements</B>&#148; means, collectively:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;the two Share Charge Agreements by and among the Investors and CZY to be entered into
pursuant to the Series&nbsp;B Subscription Agreement,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;the two Share Charge Agreements by and among the Investors and Daketala to be entered into
pursuant to the Series&nbsp;B Subscription Agreement,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;the two Share Charge Agreements by and among the Investors and Dragon Image to be entered
into pursuant to the Series&nbsp;B Subscription Agreement,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;the two Share Charge Agreements by and among the Investors and TOG to be entered into
pursuant to the Series&nbsp;B Subscription Agreement,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;the two Share Charge Agreements by and among the Investors and TMG to be entered into
pursuant to the Series&nbsp;B Subscription Agreement, and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;the two Share Charge Agreements by and among the Investors and Notable to be entered into
pursuant to the Series&nbsp;B Subscription Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Special Resolution</B>&#148; means a resolution passed at a general meeting of Members (or, if so
specified, a meeting of Members holding a class of shares) of the Company by not less than two
thirds of the votes cast or such higher majority as is required in accordance with these Articles,
or a written resolution passed by unanimous consent of all Members (or, if so specified, all
Members holding such class of shares) entitled to vote.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Starr</B>&#148; means Starr Cayman Investments Cayman II, Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Starr Director</B>&#148; shall have the meaning ascribed to it in Article&nbsp;71.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Statute</B>&#148; means the Companies Law of the Cayman Islands as amended and every statutory
modification or re-enactment thereof for the time being in force.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Subsidiary</B>&#148; means, with respect to any Person, any entity of which securities or other
ownership interests having ordinary voting power to elect a majority of the board of directors or
other persons performing similar functions are at the time directly or indirectly owned by such
Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Tag-Along Notice</B>&#148; shall have the meaning ascribed to it in Article&nbsp;14(a)(i).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Tag-Along Notice Period</B>&#148; shall have the meaning ascribed to it in Article&nbsp;14(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Tag-Along Offer</B>&#148; shall have the meaning ascribed to it in Article&nbsp;14(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Tag-Along Portion</B>&#148; shall have the meaning ascribed to it in Article&nbsp;14(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Tag-Along Response Notice</B>&#148; shall have the meaning ascribed to it in Article&nbsp;14(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Tag-Along Right</B>&#148; shall have the meaning ascribed to it in Article&nbsp;14(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Tag-Along Sale</B>&#148; shall have the meaning ascribed to it in Article&nbsp;14(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Tag-Along Seller</B>&#148; shall have the meaning ascribed to it in Article&nbsp;14(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Tagging Person</B>&#148; shall have the meaning ascribed to it in Article&nbsp;14(a)(ii).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party</B>&#148; means a prospective purchaser(s) of Company Securities in an arm&#146;s-length
transaction from a Member, other than a Permitted Transferee of such Member.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Top Management</B>&#148; shall have the meaning ascribed to it in Article&nbsp;87(d).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Transfer</B>&#148; means, with respect to any Company Securities, (i)&nbsp;when used as a verb, to sell,
assign, dispose of, exchange, pledge, encumber, hypothecate or otherwise transfer such Company
Securities or any participation or interest therein, whether directly or indirectly, or agree or
commit to do any of the foregoing and (ii)&nbsp;when used as a noun, a direct or indirect sale,
assignment, disposition, exchange, pledge, encumbrance, hypothecation, or other transfer of such
Company Securities or any participation or interest therein or any agreement or commitment to do
any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>US dollars</B>&#148; or &#147;<B>US$</B>&#148; means the lawful currency of the United States of America.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>written</B>&#148; and &#147;<B>in writing</B>&#148; include all modes of representing or reproducing words in visible
form.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Words importing the singular number only include the plural number and vice versa.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Words importing the masculine gender only include the feminine gender.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;The business of the Company may be commenced as soon after incorporation as the Directors
shall see fit, notwithstanding that part only of the shares may have been allotted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;The Directors may pay, out of the capital or any other monies of the Company, all expenses
incurred in or about the formation and establishment of the Company including the expenses of
registration.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATES FOR SHARES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;Certificates representing shares of the Company shall be in such form as shall be
determined by the Directors. Such certificates may be under Seal. All certificates for shares
shall be consecutively numbered or otherwise identified and shall specify the shares to which they
relate. The name and address of the person to whom the shares represented thereby are issued, with
the number of shares and date of
issue, shall be entered in the Register of Members. All certificates surrendered to the
Company for transfer shall be cancelled and no new certificate shall be issued until the former
certificate for a like number of shares shall have been surrendered and cancelled. The Directors
may authorize certificates to be issued with the seal and authorized signature(s) affixed by some
method or system of mechanical process.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;Notwithstanding Article&nbsp;4, if a share certificate be defaced, lost or destroyed, it may be
renewed on payment of a fee of one US dollar (US$1.00) or such less sum and on such terms (if any)
as to evidence and indemnity and the payment of the expenses incurred by the Company in
investigating evidence, as the Directors may prescribe.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ISSUE OF SHARES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.&nbsp;Subject to Article&nbsp;87, the provisions in the Memorandum of Association and any direction
that may be given by the Company in general meeting and without prejudice to any special rights
previously conferred on the holders of existing shares, the Directors may allot, issue, grant
options over or otherwise dispose of shares of the Company (including fractions of a share) with or
without preferred, deferred or other special rights or restrictions, whether in regard to dividend,
voting, return of capital or otherwise and to such persons, at such times and on such other terms
as they think proper; <I>provided </I>that, notwithstanding any provision to the contrary contained in
these Articles of Association, the Company shall be precluded from issuing bearer shares, warrants,
coupons or certificates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.&nbsp;The Company shall maintain a Register of Members and every person whose name is entered as
a Member in the Register of Members shall be entitled without payment to receive within two months
after allotment or lodgement of transfer (or within such other period as the conditions of issue
shall provide) one certificate for all his shares or several certificates each for one or more of
his shares upon payment of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">fifty cents (US$0.50) for every certificate after the first certificate
or such less sum as the Directors shall from time to time determine; <I>provided </I>that in respect of a
share or shares held jointly by several persons the Company shall not be bound to issue more than
one certificate and delivery of a certificate for such share(s) to one of the several joint holders
shall be sufficient delivery to all such holders.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TRANSFER OF SHARES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.&nbsp;The instrument of transfer of any share shall be in writing and shall be executed by or on
behalf of the transferor and the transferor shall be deemed to remain the holder of a share until
the name of the transferee is entered in the Register of Members.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.&nbsp;The Directors may in their absolute discretion decline to register any Transfer of shares
that that is not permitted by the Amended and Restated Shareholders&#146; Agreement and these Articles;
<I>provided </I>that the Directors shall be obligated to register immediately any Transfer of shares to be
effected pursuant to the
Share Charge Agreements upon delivery to the Company of the instrument of transfer referred to
in Article 8 above duly executed by the transferor and the transferee of the relevant shares to be
Transferred. If the Directors refuse to register a Transfer, they shall notify the transferee
within two months of such refusal. The Company shall not, and shall cause its registered agent not
to, give any effect in the Register of Members to any attempted Transfer of any Company Securities
not in compliance with the Amended and Restated Shareholders&#146; Agreement and these Articles.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TRANSFER RESTRICTIONS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.&nbsp;Restrictions on Transfer
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) None of the Members shall Transfer any Company Securities (or solicit any offers
in respect of any Transfer of any Company Securities), except in compliance with the
United States Securities Act of 1933, as amended, any other applicable securities or &#147;blue
sky&#148; laws, and the terms and conditions of these Articles.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any attempt to Transfer any Company Securities not in compliance with this
Agreement shall be null and void, and the Company shall not, and shall cause any transfer
agent not to, give any effect in the Company&#146;s register of members to such attempted
Transfer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) None of the Other Members may, without the prior written consent of each
Investor, directly or indirectly Transfer any Company Securities (or solicit any offers in
respect of any Transfer of any Company Securities) prior to the completion of the QPO.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Within the two years following the completion of the QPO, so long as the
Aggregate Ownership of Ordinary Shares by any Investor is at least 20% of such Investor&#146;s
Initial Ownerships of Ordinary Shares, without the prior written consent of such Investor,
no Controlling Member or any of its Permitted Transferees may directly or indirectly
Transfer (<FONT style="font-family: symbol">&#97;</FONT>) in any single transaction or in a series of transactions, whether or not
related, Company Securities representing 50% or more of the Initial Ownership of Ordinary
Shares of such Controlling Member or (<FONT style="font-family: symbol">&#98;</FONT>) any Company Securities if the Controlling Members
have Transferred an aggregate amount of Company Securities representing 20% or more of
their aggregate Initial Ownership of Ordinary Shares, except for Transfers (i)&nbsp;pursuant to
Article&nbsp;4 of the Series&nbsp;A Subscription Agreement, (ii)&nbsp;pursuant to Article&nbsp;3 of the Series
B Subscription Agreement, (iii)&nbsp;pursuant to Section&nbsp;11.06 of the Convertible Loan
Agreement, (iv)&nbsp;pursuant to Section&nbsp;6.09 of the Amended and Restated Shareholders&#146;
Agreement, (v)&nbsp;to transferees pursuant to the Share Charge Agreements, (vi)&nbsp;to any
employees of the Company or its Subsidiaries as share based compensation or incentive,
(vii)&nbsp;to any other Controlling Member or the Permitted Transferees of any other
Controlling Member or (viii)&nbsp;to any
Permitted Transferee of such Controlling Member, <I>provided </I>that (A)&nbsp;such Permitted
Transferee shall have agreed in writing to be bound by the terms of the Amended and
Restated Shareholders&#146; Agreement in the form of Exhibit&nbsp;A attached thereto and (B)&nbsp;if such
Permitted Transferee ceases to be a Permitted Transferee of such Controlling Member, the
Company Securities previously Transferred shall be immediately Transferred, to the extent
permitted by applicable laws, to such Controlling Member or another Person who qualifies
as a Permitted Transferee of such Controlling Member. Any such Transfer by the
Controlling Member shall be subject to (i)&nbsp;the rules and regulations of the stock exchange
where the QPO takes place and (ii)&nbsp;the applicable laws in the jurisdiction in which such
stock exchange is located.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) None of the Other Members may, directly or indirectly Transfer any Company
Securities if as a result of such Transfer there shall be a Change of Control (as defined
in the Amended and Restated Shareholders&#146; Agreement), unless such Transfer has otherwise
satisfied the other provisions of these Articles and the transferee agrees to purchase all
Company Securities then held by the Investors at a price agreed to by the Investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.&nbsp;Preemptive Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company shall give each Member notice (an &#147;<B>Issuance Notice</B>&#148;) of any proposed
issuance by the Company of any Company Securities at least 30 Business Days prior to the
proposed
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">issuance date. The Issuance Notice shall specify the price at which such Company
Securities are to be issued and the other material terms of the issuance. Subject to
Article 11(f) below, each of the Controlling Members and the Investors (each, a &#147;<B>Major
Member</B>&#148;) shall be entitled to purchase up to such Major Member&#146;s Pro Rata Share of the
Company Securities proposed to be issued, at the price and on the terms specified in the
Issuance Notice. &#147;<B>Pro Rata Share</B>&#148; means, with respect to any Major Member, the fraction
that results from dividing (i)&nbsp;such Major Member&#146;s Aggregate Ownership (immediately before
giving effect to such issuance) of Ordinary Shares by (ii)&nbsp;the Aggregate Ownership
(immediately before giving effect to such issuance) of Ordinary Shares by all Members.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each Major Member who desires to purchase any or all of its Pro Rata Share of the
Company Securities specified in the Issuance Notice shall deliver notice to the Company
(each an &#147;<B>Exercise Notice</B>&#148;) of its election to purchase such Company Securities within 10
Business Days of receipt of the Issuance Notice. The Exercise Notice shall specify the
number of Company Securities to be purchased by such Major Member and shall constitute
exercise by such Major Member of its rights under this Article&nbsp;11 and a binding agreement
of such Major Member to purchase, at the price and on the terms specified in the Issuance
Notice, the number of
 shares (or amount) of Company Securities specified in the Exercise Notice. If, at
the termination of such ten-Business-Day period, any Major Member shall not have delivered
an Exercise Notice to the Company, such Major Member shall be deemed to have waived all of
its rights under this Article&nbsp;11 with respect to the purchase of such Company Securities.
Promptly following the termination of such ten-Business Day period, the Company shall
deliver to each Major Member a copy of all Exercise Notices it received.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If any Major Member fails to exercise its preemptive rights under this Article&nbsp;11
or elects to exercise such rights with respect to less than such Major Member&#146;s Pro Rata
Share, the Company shall, within 2 Business Days after the expiration of the
10-Business-Day period, notify each other Major Member who has delivered an Exercise
Notice to exercise its rights to purchase its entire Pro Rata Share, that such Major
Member shall be entitled to purchase from the Company its pro rata portion (which means
the fraction that results from dividing (i)&nbsp;such Major Member&#146;s Aggregate Ownership
(immediately before giving effect to such issuance) of Ordinary Shares by (ii)&nbsp;Aggregate
Ownership (immediately before giving effect to such issuance) of Ordinary Shares of all
Major Members exercising in full their preemptive rights with respect to their respective
Pro Rata Shares) of such Company Securities with respect to which the first mentioned
Major Member shall not have exercised its preemptive rights by delivering to the Company a
written notice within 5
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Business Days of receiving such further offer which shall set
forth the number (or amount) of Company Securities to be purchased by such other Major
Member in such further offer. The Company shall continue to offer additional pro rata
portions to Major Members choosing to purchase their full pro rata portions of such
Company Securities pursuant to this Article 11(c) until (i)&nbsp;all Company Securities
proposed to be issued by the Company and with respect to which Major Members were entitled
to exercise their rights under this Article&nbsp;11 have been purchased by Major Members or
(ii)&nbsp;all Major Members have purchased the maximum number of Company Securities indicated
in their respective Exercise Notice and other notices delivered in response to further
offers pursuant to this Article 11(c) whichever is earlier.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company shall have 90&nbsp;days from the date of the Issuance Notice to consummate
the proposed issuance of any or all of such Company Securities that the Major Members have
not elected to purchase at the price and upon terms that are not materially less favorable
to the Company than those specified in the Issuance Notice. If the Company proposes to
issue any such Company Securities after such 90-day period, it shall again comply with the
procedures set forth in this Article&nbsp;11.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) At the consummation of the issuance of such Company Securities, the Company shall
issue certificates representing the Company
Securities to be purchased by each Major Member exercising preemptive rights pursuant
to this Article&nbsp;11 registered in the name of such Major Member, and a copy of the updated
register of members of the Company reflecting the ownership of such Company Securities by
such Major Member, certified by a director of the Company as a true copy against payment
by such Major Member of the purchase price for such Company Securities in accordance with
the terms and conditions as specified in the Issuance Notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Notwithstanding the foregoing, no Major Member shall be entitled to purchase
Company Securities as contemplated by this Article&nbsp;11 in connection with issuances of
Company Securities (i)&nbsp;to employees of the Company or any Subsidiary of the Company
pursuant to employee benefit plans or arrangements approved by the Board pursuant to
Article 87(m) (including upon the exercise of employee stock options granted pursuant to
any such plans or arrangements) or (ii)&nbsp;pursuant to the QPO.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.&nbsp;Right of First Refusal.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) If, at any time prior to the QPO, any Other Member (the &#147;<B>ROFR Member</B>&#148;) receives
from or otherwise negotiates with a Third Party an offer to purchase any or all of the
Company Securities owned or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">held by such ROFR Member (a &#147;<B>ROFR Offer</B>&#148;) and such ROFR Member
(a &#147;<B>ROFR Seller</B>&#148;) intends to pursue such Transfer of such Company Securities to such Third
Party and such Transfer is permitted by Article&nbsp;10, such ROFR Seller shall give notice (a
&#147;<B>ROFR Offer Notice</B>&#148;) to each other Member (a &#147;<B>ROFR Non-Selling Member</B>&#148;) that such ROFR
Seller desires to accept the ROFR Offer and that sets forth the number and kind of Company
Securities (the &#147;<B>ROFR Offered Securities</B>&#148;), the price per share that such ROFR Seller
proposes to be paid for such ROFR Offered Securities (the &#147;<B>ROFR Offer Price</B>&#148;) and all
other material terms and conditions of the ROFR Offer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The giving of a ROFR Offer Notice to the ROFR Non-Selling Members shall
constitute an offer by such ROFR Seller to Transfer the ROFR Offered Securities, in whole
and not in part, to the ROFR Non-Selling Members, at the ROFR Offer Price and on the other
terms set forth in the ROFR Offer Notice. Such offer may be accepted at the ROFR Offer
Price by each of the ROFR Non-Selling Members on a pro rata basis based on the ROFR Offer
Pro Rata Portion of such ROFR Non-Selling Member. Such offer shall be irrevocable for 30
Business Days after receipt of such ROFR Offer Notice by each ROFR Non-Selling Member.
Each ROFR Non-Selling Member shall have the right to accept such offer (as provided above)
within such 30 Business-Day period. The offer may be accepted by giving an irrevocable
notice of acceptance to such ROFR Seller prior to the expiration of such 30 Business-Day
period. &#147;<B>ROFR Offer Pro Rata Portion</B>&#148; means, with respect to each ROFR Non-Selling
Member, the fraction that results from dividing (i)&nbsp;such ROFR Non-Selling Member&#146;s
Aggregate Ownership of Ordinary Shares, by (ii)&nbsp;the Aggregate Ownership of Ordinary Shares
by all ROFR Non-Selling Members.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any ROFR Non-Selling Member receiving the ROFR Offer Notice elects not to purchase
ROFR Offered Securities, the ROFR Seller shall, within one Business Day after the
expiration of the initial 30 Business-Day period, give notice to all ROFR Non-Selling
Members that did accept the initial offer, informing them that they have the right to
increase the number of ROFR Offered Securities that they accepted pursuant to the initial
offer. Each such ROFR Non-Selling Member shall then have five Business Days in which to
accept such second offer, by giving notice of acceptance to the ROFR Seller prior to the
expiration of such five Business-Day period, as to all of such ROFR Non-Selling Member&#146;s
portion of the ROFR Offered Securities not accepted pursuant to the initial offer (on the
basis of such ROFR Non-Selling Member&#146;s ROFR Offer Pro Rata Portion compared to the ROFR
Offer Pro Rata Portions of all other ROFR Non-Selling Members receiving the second
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">offer)
<I>plus </I>any additional portion not accepted by any other ROFR Non-Selling Shareholder during
such five Business-Day period.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any ROFR Non-Selling Member fails to notify the ROFR Seller prior to the
expiration of the initial 30 Business-Day period or the second five Business-Day period,
as applicable, referred to above, it shall be deemed to have declined the initial offer or
the second offer, as applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If any ROFR Non-Selling Member has accepted the initial offer or the second
offer, as the case may be, such ROFR Non-Selling Member shall purchase and pay, by bank or
certified check (in immediately available funds), for all ROFR Offered Securities that it
has accepted to purchase, within 30 Business Days after the expiration of the initial 30
Business-Day period or the second five Business-Day period, as applicable, <I>provided </I>that,
if the Transfer of such ROFR Offered Securities is subject to any prior regulatory
approval, the time period during which such Transfer may be consummated shall be extended
until the expiration of five Business Days after all such approvals shall have been
received.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) If the ROFR Non-Selling Members fail to exercise their rights of first refusal
hereunder with respect to any ROFR Offered Securities, the ROFR Seller shall have a
120-day period following the expiration of the initial 30 Business-Day period or the
second five Business-Day period, as applicable, during which to effect a Transfer to the
Third Party making the ROFR Offer of any or all of the ROFR Offered Securities on the same
or more favorable (as to the ROFR Seller) terms and conditions as were set forth in the
ROFR Offer Notice at a price not
less than the ROFR Offer Price, <I>provided </I>that (A)&nbsp;such Third Party shall have agreed
in writing to be bound by the terms of the Amended and Restated Shareholders&#146; Agreement
and (B)&nbsp;the Transfer to such Third Party is not in violation of applicable securities
laws. If the ROFR Seller does not consummate the Transfer of the ROFR Offered Securities
within such 120-day period, then the right of the ROFR Seller to Transfer such ROFR
Offered Securities shall terminate and the ROFR Seller shall again comply with the
procedures set forth in this Article&nbsp;12 with respect to any proposed Transfer of Company
Securities to a Third Party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) A ROFR Seller may Transfer ROFR Offered Securities in accordance with Article
12(d) for consideration other than cash only if such ROFR Seller has first obtained and
delivered to each ROFR Non-Selling Member an opinion of a mutually agreed upon investment
banking firm of international standing indicating that the fair market value of the
non-cash consideration that such ROFR Seller proposes to accept as
consideration for such
ROFR Offered Securities, together with any cash
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">consideration, is at least equal to, on a
per share basis, the ROFR Offer Price.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The provisions of this Article&nbsp;12 shall not apply to any Transfer by any
Controlling Member (i)&nbsp;pursuant to Article&nbsp;4 of the Series&nbsp;A Subscription Agreement, (ii)
pursuant to Article&nbsp;3 of the Series&nbsp;B Subscription Agreement, (iii)&nbsp;pursuant to Section
11.06 of the Convertible Loan Agreement, (iv)&nbsp;pursuant to Section&nbsp;6.09 of the Amended and
Restated Shareholders&#146; Agreement, (v)&nbsp;to Permitted Transferees of such Controlling Member
or (vi)&nbsp;to transferees pursuant to the Share Charge Agreements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;Right of First Offer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) If, at any time prior to the QPO, any Investor (the &#147;<B>ROFO Seller</B>&#148;) desires to
Transfer any Company Securities to any Third Party, such ROFO Seller shall give notice (a
&#147;<B>ROFO Offer Notice</B>&#148;) to the other Members (the &#147;<B>ROFO Non-Selling Members</B>&#148;) that such ROFO
Seller desires to make such a Transfer and that sets forth the number and kind of Company
Securities proposed to be Transferred by the ROFO Seller (the &#147;<B>ROFO Offered Securities</B>&#148;),
the cash price per share that such ROFO Seller proposes to be paid for such ROFO Offered
Securities (the &#147;<B>ROFO Offer Price</B>&#148;) and any other material terms sought by the ROFO
Seller.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The giving of a ROFO Offer Notice to the ROFO Non-Selling Members shall
constitute an offer by such ROFO Seller to Transfer the ROFO Offered Securities, in whole
and not in part, (i)&nbsp;first, to the other Investors and (ii)&nbsp;secondly, to the extent the
other Investors have not purchased all ROFO Offered Securities pursuant to this Article
within the first two Business Days of the ROFO Offer Period, to the other ROFO
Non-Selling Members, in each case at the ROFO Offer Price and on the other terms set
forth in the ROFO Offer Notice. Such offer may be accepted at the ROFO Offer Price (i)
first, by each other Investors on a <I>pro rata </I>basis (calculated by dividing (x)&nbsp;such other
Investor&#146;s Aggregate Ownership of Ordinary Shares by (y)&nbsp;the Aggregate Ownership of
Ordinary Shares by all Investors other than the ROFO Seller); and (ii)&nbsp;secondly, to the
extent the other Investors have not purchased all ROFO Offered Securities pursuant to this
Article within the first two Business Days of the ROFO Offer Period, by each of the ROFO
Non-Selling Members who is not an Investor, on a <I>pro rata </I>basis (calculated by dividing
(x)&nbsp;such ROFO Non-Selling Shareholder&#146;s Aggregate Ownership of Ordinary Shares by (y)&nbsp;the
Aggregate Ownership of Ordinary Shares by all such ROFO Non-Selling Members). Such offer
shall be irrevocable for five Business Days (the &#147;<B>ROFO Offer Period</B>&#148;) after receipt of
such ROFO Offer Notice by each ROFO Non-Selling Member. Each ROFO
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Non-Selling Member
shall have the right to accept such offer (as provided above) by giving an irrevocable
notice of acceptance to such ROFO Seller prior to the expiration of the ROFO Offer Period.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If the ROFO Non-Selling Members have elected to purchase all of the ROFO Offered
Securities, the ROFO Non-Selling Members shall purchase and pay, by bank or certified
check (in immediately available funds), for all ROFO Offered Securities within five
Business Days after the date on which all such ROFO Offered Securities have been accepted.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Upon the earlier to occur of (i)&nbsp;full rejection of the ROFO Offer by all
recipients thereof and (ii)&nbsp;the expiration of the ROFO Offer Period without ROFO
Non-Selling Members electing to purchase all of the ROFO Offered Securities, the ROFO
Seller shall have a 120-day period during which to effect a Transfer of any or all of the
ROFO Offered Securities on terms that are not materially less favorable (as to the ROFO
Seller) as were set forth in the ROFO Offer Notice, <I>provided </I>that, if the Transfer is
subject to regulatory approval, such 120-day period shall be extended until the expiration
of five Business Days after all such approvals shall have been received, but in no event
shall such period be extended for more than an additional one hundred and fifty (150)
days. If the ROFO Seller does not consummate the Transfer of the ROFO Offered Securities
in accordance with the foregoing time limitations, then the right of the ROFO Seller to
effect the Transfer of such ROFO Offered Securities pursuant to this Article 13(d) shall
terminate and the ROFO Seller shall again comply with the procedures set forth in this
Article&nbsp;13 with respect to any proposed Transfer of Company Securities to a Third Party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The provisions of this Article&nbsp;13 shall not apply to any Transfer of Company
Securities by any Investor (i)&nbsp;in the QPO or (ii)&nbsp;to any Permitted Transferee of such
Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;Tag-Along Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) If a Member other than any of the Investors (the &#147;<B>Tag-Along Seller</B>&#148;) proposes to
Transfer to any Person other than its Permitted Transferees, in a transaction otherwise
permitted by Article&nbsp;10, any Company Securities and the Investors have declined or failed
to exercise their rights of first refusal with respect to such Company Securities pursuant
to Article&nbsp;12 (a &#147;<B>Tag-Along Sale</B>&#148;),
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the Tag-Along Seller shall provide the Investors notice of the terms
and conditions of such proposed Transfer
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(&#147;<B>Tag-Along Notice</B>&#148;) and offer each
Tagging Person the opportunity to participate in such Transfer in accordance
with this Article&nbsp;14, and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) each of the Investors who have declined or failed to exercise its
rights of first refusal with respect to such Company Securities pursuant to
Article&nbsp;12, may elect, at its option, to participate in the proposed Transfer in
accordance with this Article&nbsp;14 (each such electing Member, a &#147;<B>Tagging Person</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Tag-Along Notice shall identify the number and class of Company Securities
proposed to be sold by the Tag-Along Seller and all other Company Securities subject to
the offer (&#147;<B>Tag-Along Offer</B>&#148;), the consideration for which the Transfer is proposed to be
made, and all other material terms and conditions of the Tag-Along Offer, including the
form of the proposed agreement, if any, and a firm offer by the proposed transferee to
purchase Company Securities from the Tagging Persons in accordance with this Article&nbsp;14.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From the date of its receipt of the Tag-Along Notice, each Tagging Person shall have
the right (a &#147;<B>Tag-Along Right</B>&#148;), exercisable by notice (&#147;<B>Tag-Along Response Notice</B>&#148;) given
to the Tag-Along Seller within 15 Business Days after its receipt of the Tag-Along Notice
(the &#147;<B>Tag-Along Notice Period</B>&#148;), to request that the Tag-Along Seller include in the
proposed Transfer up to a number of Company Securities representing such Tagging Person&#146;s
Tag-Along Portion, <I>provided </I>that each Tagging Person shall be entitled to include in the
Tag-Along Sale no more than its Tag-Along Portion of Company Securities and the Tag-Along
Seller shall be entitled to include the number of Company Securities proposed to be
Transferred by the Tag-Along Seller as set forth in the Tag-Along Notice (reduced, to the
extent necessary, so that each Tagging Person shall be able to include its Tag-Along
Portion) and such additional Company
Securities as permitted by Article&nbsp;14(d). Each Tag-Along Response Notice shall
include wire transfer or other instructions for payment or delivery of the purchase price
for the Company Securities to be sold in such Tag-Along Sale or, if such delivery is not
permitted by applicable law, an unconditional agreement to deliver such Company Securities
pursuant to this Article 14(a) at the closing for such Tag-Along Sale against delivery to
such Tagging Person of the consideration therefor. Each Tagging Person that exercises its
Tag-Along Rights hereunder shall deliver to the Tag-Along Seller, with its Tag-Along
Response Notice, the certificates representing the Company Securities of such Tagging
Person to be included in the Tag-Along Sale, together with a limited power-of-attorney
authorizing the Tag-Along Seller to Transfer such Company Securities on the terms set
forth in the Tag-Along Notice. Delivery of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Tag-Along Response Notice with such
certificates and limited power-of-attorney shall constitute an irrevocable acceptance of
the Tag-Along Offer by such Tagging Persons, subject to the provisions of this Article&nbsp;14.
&#147;<B>Tag-Along Portion</B>&#148; means, with respect to any Tagging Person in any Tag-Along Sale, that
number (or amount) of Company Securities proposed to be Transferred in such Tag-Along Sale
equal to (x)&nbsp;the Aggregate Ownership of such class of Company Securities by such Tagging
Person immediately prior to such Tag-Along Sale <I>multiplied by </I>(y)&nbsp;a fraction the numerator
of which is the maximum number of such class proposed to be Transferred by the Tag-Along
Seller in such Tag-Along Sale and the denominator of which is the Aggregate Ownership of
such class by the Investors and the Tag-Along Seller immediately prior to such Tag-Along
Sale.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, at the end of a 120-day period after such delivery of such Tag-Along Notice, the
Tag-Along Seller has not completed the Transfer of all Company Securities proposed to be
sold by the Tag-Along Seller and all Tagging Persons on substantially the same terms and
conditions set forth in the Tag-Along Notice, the Tag-Along Seller shall (i)&nbsp;return to
each Tagging Person the limited power-of-attorney and all certificates representing the
Company Securities that such Tagging Person delivered for Transfer pursuant to this
Article 14(a) and any other documents in the possession of the Tag-Along Seller executed
by the Tagging Persons in connection with the proposed Tag-Along Sale, and (ii)&nbsp;all the
restrictions on Transfer contained in these Articles or otherwise applicable at such time
with respect to such Company Securities shall continue in effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Concurrently with the consummation of the Tag-Along Sale, the Tag-Along Seller
shall (i)&nbsp;notify the Tagging Persons thereof, (ii)&nbsp;remit to the Tagging Persons the total
consideration for the Company Securities of the Tagging Persons Transferred pursuant
thereto, with the cash portion of the purchase price paid by wire transfer of immediately
available funds in accordance with the wire transfer instructions in the
applicable Tag-Along Response Notices and the non-cash portion of the purchase price
delivered to the Tagging Persons in manners specified in the relevant Tag-Along Response
Notices and (iii)&nbsp;promptly after the consummation of such Tag-Along Sale, furnish such
other evidence of the completion and the date of completion of such transfer and the terms
thereof as may be reasonably requested by the Tagging Persons.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If at the termination of the Tag-Along Notice Period, any of the Investors shall
not have elected to participate in the Tag-Along Sale, it shall be deemed to have waived
its rights under Article 14(a) with respect to the Transfer of its Company Securities
pursuant to such Tag-Along Sale.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) If (i)&nbsp;any Investor declines to exercise its Tag-Along Rights or (ii)&nbsp;any Tagging
Person elects to exercise its Tag-Along Rights with respect to less than such Tagging
Person&#146;s Tag-Along Portion, in each case within the Tag-Along Notice Period, the Tag-Along
Seller shall, on the Business Day immediately after the expiration of the Tag-Along Notice
Period, notify each Tagging Person who has elected to exercise its Tag-Along Rights with
respect to its Tag-Along Portion and such Tagging Person shall have the right to include
in the proposed Transfer an additional number of Company Securities representing its pro
rata portion (calculated by dividing (x)&nbsp;the Aggregate Ownership of such class of Company
Securities by such Tagging Person by (y)&nbsp;the Aggregate Ownership of such class by all
Tagging Persons who have elected to exercise their respective Tag-Along Rights in full) of
the Company Securities with respect to which Tag-Along Rights have not previously been
exercised during the Tag-Along Notice Period or during this subsequent offer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Tag-Along Seller shall Transfer, on behalf of itself and each Tagging Person,
the Company Securities subject to the Tag-Along Offer and elected to be Transferred on the
terms and conditions set forth in the Tag-Along Notice within 120&nbsp;days of delivery of the
Tag-Along Notice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) Upon the consummation of any Tag-Along Sale, all of the Members participating
therein will receive the same form and amount of consideration per share, or, if any
Members are given an option as to the form and amount of consideration to be received, all
Members participating therein will be given the same option.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) No Tagging Person shall be obligated to pay any expenses incurred in connection
with any Tag-Along Sale.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) Each Tagging Person shall (i)&nbsp;not be required to provide any representations or
indemnities in connection with any Tag-Along Sale other than representations and
indemnities concerning such Tagging
Person&#146;s title to the Company Securities to be Transferred by such Tagging Person in
such Tag-Along Sale, free and clear of any encumbrances and authority, power and right to
enter into and consummate the Transfer without contravention of any law or material
agreement and (ii)&nbsp;benefit from all of the same provisions of the definitive agreements as
the Tag-Along Seller.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) If a Controlling Member proposes to Transfer, in a transaction otherwise
permitted by Article&nbsp;10, a number of Company Securities in a single transaction or in a
series of related transactions such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">that such Controlling Member&#146;s Aggregate Ownership of
Ordinary Shares immediately after the consummation of such Transfer is less than 50% of
such Controlling Member&#146;s Initial Ownership of Ordinary Shares, each of the Investors
shall have the right to participate in such Transfer to sell all Company Securities held
by each respective Investor and all other provisions of this Article&nbsp;14 shall apply to
such Transfer <I>mutatis mutandis</I>. Any Transfer of Company Securities by a Controlling
Member that occurs within six months of any other Transfer of Company Securities by such
Controlling Member shall be conclusively deemed to be related to such previous transaction
for the purposes of this Article&nbsp;14(i).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.&nbsp;Drag-Along Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) If all of the Investors (the &#147;<B>Drag-Along Sellers</B>&#148;) propose to Transfer Company
Securities to one or more Third Parties (the &#147;<B>Drag-Along Transferee</B>&#148;) (a &#147;<B>Drag-Along
Sale</B>&#148;), the Drag-Along Sellers may at their collective option require all other Members
(the &#147;<B>Dragged Members</B>&#148;) (i)&nbsp;to Transfer the Drag-Along Portion of Company Securities
(&#147;<B>Drag-Along Rights</B>&#148;) then held by every Dragged Member, and (ii)&nbsp;subject to and at the
closing of the Drag-Along Sale, to exercise such number of options for Ordinary Shares
held by every Dragged Shareholder as is required in order that a sufficient number of
Ordinary Shares are available to Transfer the relevant Drag-Along Portion of Company
Securities of each such Dragged Member, in each case for the same consideration per unit
of the relevant class of Company Securities and otherwise on the same terms and conditions
as the Drag-Along Sellers, <I>provided </I>that any Dragged Member that holds options the
exercise price per share of which is greater than the per share price at which the
Ordinary Shares are directly or indirectly on an as converted basis to be Transferred to
the Drag-Along Transferee, if required by the Drag-Along Sellers to exercise such options,
may, in lieu of such exercise, submit to irrevocable cancellation thereof without any
liability for payment of any exercise price with respect thereto, and, <I>provided further</I>
that, with respect to any Transfer also governed by Article&nbsp;13, the Dragged Members having
a right of first offer under Article&nbsp;13 shall first have been afforded the opportunity to
acquire any Company Securities to be Transferred in the Drag-Along Sale in accordance with
the provisions of Article&nbsp;13. If the Drag-Along
Sale is not consummated with respect to any Ordinary Shares acquired upon exercise of
any options, or the Drag-Along Sale is not consummated, any options exercised or cancelled
in contemplation of such Drag-Along Sale shall be deemed not to have been exercised or
canceled, as applicable. &#147;<B>Drag-Along Portion</B>&#148; means, with respect to any Dragged Member,
(i)&nbsp;the Aggregate Ownership of Ordinary Shares by such Dragged Member <I>multiplied by </I>(ii)&nbsp;a
fraction the numerator of which is the aggregate number of Ordinary Shares proposed to be
sold by the Drag-Along Sellers
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">in the applicable Drag-Along Sale, calculated on a
Fully-Diluted basis, and the denominator of which is the Aggregate Ownership of Ordinary
Shares by the Drag-Along Sellers collectively.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Drag-Along Sellers shall provide notice of such Drag-Along Sale to the Dragged
Members (a &#147;<B>Drag-Along Sale Notice</B>&#148;) not later than 15 Business Days prior to the proposed
Drag-Along Sale. The Drag-Along Sale Notice shall identify the transferee, the number of
Company Securities subject to the Drag-Along Sale, the consideration for which a Transfer
is proposed to be made (the &#147;<B>Drag-Along Sale Price</B>&#148;) and all other material terms and
conditions of the Drag-Along Sale. The number of Company Securities to be sold by each
Dragged Member shall be the Drag-Along Portion that such Dragged Member owns. Each
Dragged Member shall be required to participate in the Drag-Along Sale on the terms and
conditions set forth in the Drag-Along Sale Notice and to tender its Company Securities as
set forth below. The price payable in such Transfer shall be the Drag-Along Sale Price.
Not later than 10 Business Days after the date of the Drag-Along Sale Notice (the
&#147;<B>Drag-Along Sale Notice Period</B>&#148;), each of the Dragged Members shall deliver to a
representative of the Drag-Along Sellers designated in the Drag-Along Sale Notice the
certificates representing the Company Securities of such Dragged Member required to be
included in the Drag-Along Sale and the relevant instruments of transfer, together with a
limited power-of-attorney authorizing the Drag-Along Sellers or their representative to
Transfer such Company Securities on the terms set forth in the Drag-Along Notice and wire
transfer or other instructions for payment or delivery of the consideration to be received
in such Drag-Along Sale, or, if such delivery is not permitted by applicable law, an
unconditional agreement to deliver such Company Securities pursuant to this clause (a)&nbsp;at
the closing for such Drag-Along Sale against delivery to such Dragged Member of the
consideration therefor.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Drag-Along Sellers shall have a period of 120&nbsp;days from the date of delivery
of the Drag-Along Sale Notice to consummate the Drag-Along Sale on the terms and
conditions set forth in such Drag-Along Sale Notice, <I>provided </I>that, if such Drag-Along
Sale is subject to regulatory approval, such 120-day period shall be extended until the
expiration of five Business Days after all such approvals have been
received, but in no event later than 270&nbsp;days following the date of delivery of the
Drag-Along Sale Notice. If the Drag-Along Sale shall not have been consummated during
such period, the Drag-Along Sellers shall return to each of the Dragged Members the
limited power-of-attorney and all certificates representing Company Securities that such
Dragged Member delivered for Transfer pursuant hereto and all related instruments of
transfer, together with any other documents in the possession of the Drag-
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Along Sellers
executed by such Dragged Member in connection with such proposed Transfer, and all the
restrictions on Transfer contained in these Articles or otherwise applicable at such time
with respect to such Company Securities owned by the Dragged Members shall again be in
effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Concurrently with the consummation of the Transfer of Company Securities pursuant
to this Article&nbsp;15, the Drag-Along Sellers shall give notice thereof to the Dragged
Members, shall remit to each of the Dragged Members that have surrendered their
certificates and other applicable instruments the total consideration (the cash portion of
which is to be paid by wire transfer in accordance with such Dragged Member&#146;s wire
transfer instructions) for the Company Securities Transferred pursuant hereto and shall
furnish such other evidence of the completion and time of completion of such Transfer and
the terms thereof as may be reasonably requested by such Dragged Member.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Notwithstanding anything contained in this Article&nbsp;15, there shall be no
liability on the part of the Drag-Along Sellers to the Dragged Members (other than the
obligation to return the limited power-of-attorney and the certificates and other
applicable instruments representing Company Securities received by the Drag-Along Sellers)
or any other Person if the Transfer of Company Securities pursuant to this Article&nbsp;15 is
not consummated for whatever reason, regardless of whether the Drag-Along Sellers have
delivered a Drag-Along Sale Notice. Whether to effect a Transfer of Company Securities
pursuant to this Article&nbsp;15 by the Drag-Along Sellers is in the sole and absolute
discretion of the Drag-Along Sellers.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Upon the consummation of any Drag-Along Sale, all of the Members participating
therein will receive the same form and amount of consideration per share, or, if any
Members are given an option as to the form and amount of consideration to be received, all
Members participating therein will be given the same option.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) No Dragged Member shall be obligated to pay any expenses incurred in connection
with any Drag-Along Sale.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) Each Dragged Member shall (i)&nbsp;not be required to provide any representations or
indemnities in connection with any Drag-Along
Sale other than representations and indemnities concerning such Dragged Member&#146;s
title to the Company Securities to be Transferred by such Dragged Member in such
Drag-Along Sale, free and clear of any encumbrances and authority, power and right to
enter into and consummate the Transfer without contravention of any law or material
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">agreement and (ii)&nbsp;benefit from all of the same provisions of the definitive agreements as
any Drag-Along Seller holding the same number and class of the Company Securities as such
Dragged Member.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) Notwithstanding anything to the contrary herein, the Drag-Along Rights
contemplated by this Article 15 shall be exercisable only in the event that the QPO has
not been consummated by the third anniversary date of the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.&nbsp;Put Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company shall promptly deliver written notice to each holder of Preferred
Shares upon the occurrence of any Put Trigger Event. At any time after the occurrence of
any Put Trigger Event, upon the request of any holder of Preferred Shares, each Other
Member shall use its best efforts to assist and cooperate with such holder to sell the
Company Securities then held by such holder to a Third Party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Without limiting the provisions in Article&nbsp;16(a), upon the occurrence of any Put
Trigger Event, each holder of Preferred Shares (the &#147;<B>Putting Member</B>&#148;) shall have the right
(the &#147;<B>Put Right</B>&#148;) to require the Other Members or the Company (the &#147;<B>Purchaser</B>&#148;) to
purchase all Company Securities held by such Putting Member (the &#147;<B>Put Interest</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) To exercise the Put Right, a Putting Member shall give notice (the &#147;<B>Put Notice</B>&#148;)
to the Other Members and the Company no later than 30 Business Days prior to the proposed
date of purchase. If any Putting Member requires the Company to purchase the Put Interest
of such Putting Member in the Put Notice, upon receipt of the Put Notice, the Company
shall be obligated to purchase the Put Interest on the proposed date of purchase in
accordance with the provisions of this Article&nbsp;16, unless such purchase by the Company
will violate or contravene the Companies Law of the Cayman Islands. If any Putting Member
requires the Other Members to purchase the Put Interest of such Putting Member in the Put
Notice, upon receipt of such Put Notice, the Other Members shall be obligated, jointly and
severally, to purchase such Put Interest on the proposed date of purchase in accordance
with the provisions of this Article&nbsp;16.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The purchase price payable per share of Company Securities by the Purchaser to
any Putting Member (the &#147;<B>Put Price</B>&#148;) shall guarantee a Rate of Return of at least 12.5%
for such Putting Member&#146;s
investment in its Put Interest. The Rate of Return shall (i)&nbsp;be calculated for the
period beginning on and including the respective dates on which such Put Interests were
issued by the Company and ending on and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">including the closing date for the purchase of
such Put Interest pursuant to this Article&nbsp;16; (ii)&nbsp;include as cash outflows all amounts
paid by such Putting Member or any other Person to the Company to acquire such Put
Interest (including Conversion Price, if applicable); (iii)&nbsp;include as cash inflows a
deemed terminal cash inflow equal to the Put Price; and (iv)&nbsp;include as cash inflows any
cash dividends or other cash distributions actually received by such Putting Member from
the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) No later than the proposed date of purchase, each Putting Member shall deliver to
the Purchaser certificates representing all Company Securities comprising its Put
Interest, together with all other documents required to be executed in connection with
such Transfer or, if such delivery is not permitted by applicable law, an unconditional
agreement to deliver such Company Securities pursuant to this Article&nbsp;16 at the closing
for such Transfer against delivery to such Putting Member of the consideration therefor.
In no event shall any Putting Member be obligated to make any representations and
warranties, or to provide any indemnities, with respect to any matters other than the
title to the Company Securities comprising the Put Interest held by such Putting Member
and the authority to sell such Company Securities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The closing for the purchase of any Put Interest pursuant to this Article&nbsp;16
shall occur as promptly as practicable, but in no event later than 30&nbsp;days after the date
of the Put Notice in respect of such Put Interest. At any such closing, the Purchaser
shall deliver to the relevant Putting Member the purchase price for the Put Interest of
such Putting Member by wire transfer of immediately available funds to such bank account
as such Putting Member shall have specified in writing no later than two Business Days
prior to the closing of such purchase.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) From the date of the Put Notice to the closing date of the purchase of any Put
Interest, the Putting Members shall have the sole right to (i)&nbsp;determine the declaration
or payment of any dividend or other distribution upon any capital stock of the Company or
any of its Subsidiaries, (ii)&nbsp;determine any spending by the Company or any of its
Subsidiaries, (iii)&nbsp;sell any assets of the Company or any of its Subsidiaries, (iv)
approve any withdrawal from or otherwise manage any bank account of the Company or any of
its Subsidiaries, and (v)&nbsp;otherwise manage the business of the Company and its
Subsidiaries.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>REDEEMABLE SHARES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.&nbsp;Subject to the provisions of the Statute and the Memorandum of Association and other
provisions of these Articles, (a)&nbsp;shares may be issued on the
terms that they are, or at the option of the Company or the holder are, to be redeemed
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">on such
terms and in such manner as the Company, before the issue of the shares, may by Special Resolution
determine; and (b)&nbsp;the Company may purchase its own shares (including fractions of a share),
including any redeemable shares, <I>provided </I>that the manner of purchase has first been authorized by
the Company in general meeting if such purchase is not expressly provided for in the Memorandum of
Association or these Articles, and may make payment therefor in any manner authorized by the
Statute, including out of capital.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>VARIATION OF RIGHTS OF SHARES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.&nbsp;The rights attached to a class of Preferred Shares may be varied with the consent in
writing of the holders of all of such class of Preferred Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.&nbsp;The rights conferred upon the holders of the shares of any class issued with preferred or
other rights shall not, unless otherwise expressly provided by the terms of issue of the shares of
that class, be deemed to be varied by the creation or issue of further shares ranking <I>pari passu</I>
therewith.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>NON-RECOGNITION OF TRUSTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.&nbsp;Other than the Share Charge, no person shall be recognized by the Company as holding any
share upon any trust and the Company shall not be bound by or be compelled in any way to recognize
(even when having notice thereof) any equitable, contingent, future, or partial interest in any
share, or any interest in any fractional part of a share, or (except only as is otherwise provided
by these Articles or the Statute) any other rights in respect of any share except an absolute right
to the entirety thereof in the registered holder.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LIEN ON SHARES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.&nbsp;The Company shall have a first and paramount lien and charge on all shares (whether fully
paid-up or not) registered in the name of a Member (whether solely or jointly with others) for all
debts, liabilities or engagements to or with the Company (whether presently payable or not) by such
Member or his estate, either alone or jointly with any other person, whether a Member or not, but
the Directors may at any time declare any share to be wholly or in part exempt from the provisions
of this Article. The registration of a transfer of any such share shall operate as a waiver of the
Company&#146;s lien (if any) thereon. The Company&#146;s lien (if any) on a share shall extend to all
dividends or other monies payable in respect thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.&nbsp;The Company may sell, in such manner as the Directors think fit, any shares on which the
Company has a lien, but no sale shall be made unless a sum in respect of which the lien exists is
presently payable, nor until the expiration of fourteen days after a notice in writing stating and
demanding payment of such part of the amount in respect of which the lien exists as is presently
payable, has been given to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the registered holder or holders for the time being of the share, or the person, of which the
Company has notice, entitled thereto by reason of his death or bankruptcy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.&nbsp;To give effect to any such sale the Directors may authorize some person to transfer the
shares sold to the purchaser thereof. The purchaser shall be registered as the holder of the
shares comprised in any such transfer, and he shall not be bound to see to the application of the
purchase money, nor shall his title to the shares be affected by any irregularity or invalidity in
the proceedings in reference to the sale.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24.&nbsp;The proceeds of such sale shall be received by the Company and applied in payment of such
part of the amount in respect of which the lien exists as is presently payable and the residue, if
any, shall (subject to a like lien for sums not presently payable as existed upon the shares before
the sale) be paid to the person entitled to the shares at the date of the sale.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CALL ON SHARES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25.&nbsp;The Directors may from time to time make calls upon the Members in respect of any monies
unpaid on their shares (whether on account of the nominal value of the shares or by way of premium
or otherwise) and not by the conditions of allotment thereof made payable at fixed terms; <I>provided</I>
that no call shall be payable at less than one month from the date fixed for the payment of the
last preceding call, and each Member shall (subject to receiving at least fourteen days notice
specifying the time or times of payment) pay to the Company at the time or times so specified the
amount called on the shares. A call may be revoked or postponed as the Directors may determine. A
call may be made payable by installments.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) A call shall be deemed to have been made at the time when the resolution of the
Directors authorizing such call was passed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The joint holders of a share shall be jointly and severally liable to pay all
calls in respect thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26.&nbsp;If a sum called in respect of a share is not paid before or on a day appointed for payment
thereof, the persons from whom the sum is due shall pay interest on the sum from the day appointed
for payment thereof to the time of actual payment at such rate not exceeding ten per cent per annum
as the Directors may determine, but the Directors shall be at liberty to waive payment of such
interest either wholly or in part.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27.&nbsp;Any sum which by the terms of issue of a share becomes payable on allotment or at any
fixed date, whether on account of the nominal value of the share or by way of premium or otherwise,
shall for the purposes of these Articles be deemed to be a call duly made, notified and payable on
the date on which by the terms of issue the same becomes payable, and in the case of non-payment
all the relevant provisions
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of these Articles as to payment of interest forfeiture or otherwise
shall apply as if such sum had become payable by virtue of a call duly made and notified.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28.&nbsp;The Directors may, on the issue of shares, differentiate between the holders as to the
amount of calls or interest to be paid and the times of payment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29.&nbsp;Subject to Article&nbsp;87, the Directors may, if they think fit, receive from any Member
willing to advance the same, all or any part of the monies uncalled and unpaid upon any shares held
by him, and upon all or any of the monies so advanced may (until the same would but for such
advances, become payable) pay interest at such rate not exceeding (unless the Company in general
meeting shall otherwise direct) seven per cent per annum, as may be agreed upon between the
Directors and the Member paying such sum in advance. No such sum paid in advance of calls shall
entitle the Member paying such sum to any portion of a dividend declared in respect of any period
prior to the date upon which such sum would, but for such payment, become presently payable.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FORFEITURE OF SHARES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30.&nbsp;If a Member fails to pay any call or installment of a call or to make any payment required
by the terms of issue on the day appointed for payment thereof, the Directors may, at any time
thereafter during such time as any part of the call, installment or payment remains unpaid, give
notice requiring payment of so much of the call, installment or payment as is unpaid, together with
any interest which may have accrued and all expenses that have been incurred by the Company by
reason of such non-payment. Such notice shall name a day (not earlier than the expiration of
fourteen days from the date of giving of the notice) on or before which the payment required by the
notice is to be made, and shall state that, in the event of non-payment at or before the time
appointed the shares in respect of which such notice was given will be liable to be forfeited.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) If the requirements of any such notice as aforesaid are not complied with, any
share in respect of which the notice has been given may at any time thereafter, before the
payment required by the notice has been made, be forfeited by a resolution of the
Directors to that effect. Such forfeiture shall include all dividends declared in respect
of the forfeited share and not actually paid before the forfeiture.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) A forfeited share may be sold or otherwise disposed of on such terms and in such
manner as the Directors think fit and at any time before a sale or disposition the
forfeiture may be cancelled on such terms as the Directors think fit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31.&nbsp;A Person whose shares have been forfeited shall cease to be a Member in respect of the
forfeited shares, but shall, notwithstanding, remain liable to pay to the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company all monies which,
at the date of forfeiture were payable by him to the Company in respect of the shares together with
interest thereon, but his liability shall cease if and when the Company shall have received payment
in full of all monies whenever payable in respect of the shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32.&nbsp;A certificate in writing under the hand of one Director or the Secretary of the Company
that a share in the Company has been duly forfeited on a date stated in the declaration shall be
conclusive evidence of the fact therein stated as against all persons claiming to be entitled to
the share. The Company may receive the consideration given for the share on any sale or
disposition thereof and may execute a transfer of the share in favor of the person to whom the
share is sold or disposed of and he shall thereupon be registered as the holder of the share and
shall not be bound to see to the application of the purchase money, if any, nor shall his title to
the share be affected by any irregularity or invalidity in the proceedings in reference to the
forfeiture, sale or disposal of the share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33.&nbsp;The provisions of this Article as to forfeiture shall apply in the case of non-payment of
any sum which, by the terms of issue of a share, becomes payable at a fixed time, whether on
account of the nominal value of the share or by way of premium as if the same had been payable by
virtue of a call duly made and notified.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>REGISTRATION OF EMPOWERING INSTRUMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;34.&nbsp;The Company shall be entitled to charge a fee not exceeding one US dollar (US$1.00) on the
registration of every probate, letters of administration, certificate of death or marriage, power
of attorney, notice in lieu of distringas, or other instrument.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TRANSMISSION OF SHARES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35.&nbsp;In case of the death of a Member, the survivor or survivors where the deceased was a joint
holder, and the legal personal representatives of the deceased where he was a sole holder, shall be
the only persons recognized by the Company as having any title to his interest in the shares, but
nothing herein contained shall release the estate of any such deceased holder from any liability in
respect of any shares which had been held by him solely or jointly with other persons.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;36.&nbsp;Any person becoming entitled to a share in consequence of the death or bankruptcy or
liquidation or dissolution of a Member (or in any other way than by transfer) may, upon such
evidence being produced as may from time to time be required by the Directors and subject as
hereinafter provided, elect either to be registered himself as holder of the share or to make such
transfer of the share to such other person nominated by him as the deceased or bankrupt person
could have made and to have such person registered as the transferee thereof, but the Directors
shall, in either case, have the same right to decline or suspend registration as they would have
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">had in the case of a transfer of the share by that Member before his death or bankruptcy as the
case may be. If the person so becoming entitled shall elect to be registered himself as holder, he
shall deliver or send to the Company a notice in writing signed by him stating that he so elects.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;37.&nbsp;A person becoming entitled to a share by reason of the death or bankruptcy or liquidation
or dissolution of the holder (or in any other case than by
transfer) shall be entitled to the same dividends and other advantages to which he would be
entitled if he were the registered holder of the share, except that he shall not, before being
registered as a Member in respect of the share, be entitled in respect of it to exercise any right
conferred by membership in relation to meetings of the Company; <I>provided </I>that the Directors may at
any time give notice requiring any such person to elect either to be registered himself or to
transfer the share and if the notice is not complied with within ninety days, the Directors may
thereafter withhold payment of all dividends, bonuses or other monies payable in respect of the
share until the requirements of the notice have been complied with.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENT OF MEMORANDUM OF ASSOCIATION,<BR>
CHANGE OF LOCATION OF REGISTERED OFFICE<BR>
&#038; ALTERATION OF CAPITAL</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;38.&nbsp;(a)&nbsp;Subject to and in so far as permitted by the provisions of the Statute and other
provisions of these Articles, the Company may from time to time by Special Resolution alter or
amend its memorandum of association, including, without restricting the generality of the
foregoing, the following:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) increase the share capital by such sum to be divided into shares of
such amount or without nominal or par value as the resolution shall prescribe
and with such rights, priorities and privileges annexed thereto, as the Company
by Special Resolution may determine.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) consolidate and divide all or any of its share capital into shares of
larger amount than its existing shares;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) by subdivision of its existing shares or any of them divide the whole
or any part of its share capital into shares of smaller amount than is fixed by
its memorandum of association or into shares without nominal or par value;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) cancel any shares which at the date of the passing of the resolution
have not been taken or agreed to be taken by any person.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) All new shares created hereunder shall be subject to the same provisions with
reference to the payment of calls, liens, transfer, transmission, forfeiture and otherwise
as the shares of the same class in the original share capital.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Without prejudice to Article&nbsp;17 hereof and subject to the provisions of the
Statute and other provisions of these Articles, the Company may by Special Resolution
reduce its share capital and any capital redemption reserve fund.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Subject to the provisions of the Statute, the Company may by resolution of the
Directors change the location of its registered office.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CLOSING REGISTER OF MEMBERS<BR>
OR FIXING RECORD DATE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;39.&nbsp;For the purpose of determining Members entitled to notice of or to vote at any meeting of
Members or any adjournment thereof, or Members entitled to receive payment of any dividend, or in
order to make a determination of Members for any other proper purpose, the Directors of the Company
may provide that the Register of Members shall be closed for transfers for a stated period but not
to exceed in any case 40&nbsp;days. If the Register of Members shall be so closed for the purpose of
determining Members entitled to notice of or to vote at a meeting of Members, such Register of
Members shall be so closed for at least ten days immediately preceding such meeting and the record
date for such determination shall be the date of the closure of the Register of Members.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;40.&nbsp;In lieu of or apart from closing the Register of Members, the Directors may fix in advance
a date as the record date for any such determination of Members entitled to notice of or to vote at
a meeting of the Members and for the purpose of determining the Members entitled to receive payment
of any dividend the Directors may, at or within 90&nbsp;days prior to the date of declaration of such
dividend fix a subsequent date as the record date for such determination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;41.&nbsp;If the Register of Members is not so closed and no record date is fixed for the
determination of Members entitled to notice of or to vote at a meeting of Members or Members
entitled to receive payment of a dividend, the date on which notice of the meeting is mailed or the
date on which the resolution of the Directors declaring such dividend is adopted, as the case may
be, shall be the record date for such determination of Members. When a determination of Members
entitled to vote at any meeting of Members has been made as provided in this section, such
determination shall apply to any adjournment thereof.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GENERAL MEETING</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;42.&nbsp;(a)&nbsp;Subject to paragraph (c)&nbsp;of this Article, the Company shall within one year of its
incorporation and in each year of its existence thereafter hold a general meeting as its annual
general meeting and shall specify the meeting as such in the notices calling it. The annual
general meeting shall be held at such time and place as the Directors shall appoint and if no other
time and place is prescribed by them, it shall be held at the registered office on the second
Wednesday in December of each year at ten o&#146;clock in the morning.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) At these meetings the report of the Directors (if any) shall be presented.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) If the Company is exempted as defined in the Statute, it may but shall not be
obliged to hold an annual general meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;43.&nbsp;The Directors may whenever they think fit, and they shall on the requisition of Members
holding at the date of the deposit of the requisition not less than one-tenth of such of the
paid-up capital of the Company as at the date of the deposit that carries the right of voting at
general meetings of the Company, proceed to convene a general meeting of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The requisition must state the objects of the meeting and must be signed by the
requisitionists and deposited at the registered office of the Company and may consist of
several documents in like form each signed by one or more requisitionists.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) If the Directors do not within 21&nbsp;days from the date of the deposit of the
requisition duly proceed to convene a general meeting, the requisitionists, or any of them
representing more than one-half of the total voting rights of all of them, may themselves
convene a general meeting, but any meeting so convened shall not be held after the
expiration of three months after the expiration of the said 21&nbsp;days.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) A general meeting convened as aforesaid by requisitionists shall be convened in
the same manner as nearly as possible as that in which general meetings are to be convened
by Directors.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>NOTICE OF GENERAL MEETINGS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44.&nbsp;At least five days notice shall be given of an annual general meeting or any other general
meeting. Every notice shall be exclusive of the day on which it is given or deemed to be given and
of the day for which it is given and shall specify the place, the day and the hour of the meeting
and the general nature of the business and shall be given in manner hereinafter mentioned or in
such other manner if any as may
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">be prescribed by the Company, <I>provided </I>that a general meeting of
the Company shall, whether or not the notice specified in this regulation has been given and
whether or not the provisions of Article&nbsp;43 have been complied with, be deemed to have been duly
convened if it is so agreed:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) in the case of a general meeting called as an annual general meeting, by all the
Members entitled to attend and vote thereat or their proxies; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) in the case of any other general meeting, by a majority in number of the Members
having a right to attend and vote at the meeting, being a majority together holding not
less than 90 per cent in nominal value or in the case of shares without nominal or par
value 90 per cent of the shares in issue, or their proxies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;45.&nbsp;The accidental omission to give notice of a general meeting to, or the non-receipt of
notice of a meeting by any person entitled to receive notice shall not invalidate the proceedings
of that meeting.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROCEEDINGS AT GENERAL MEETINGS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;46.&nbsp;No business shall be transacted at any general meeting unless a quorum of Members is
present at the time when the meeting proceeds to business; two or more Members holding at least 50
per cent in nominal value or in the case of shares without nominal or par value 50 per cent of the
shares in issue present in person or by proxy shall be a quorum; <I>provided </I>that if the Company has
one Member of record the quorum shall be that one Member present in person or by proxy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;47.&nbsp;A resolution (including a Special Resolution) in writing (in one or more counterparts)
signed by all Members for the time being entitled to receive notice of and to attend and vote at
general meetings (or being corporations by their duly authorized representatives) shall be as valid
and effective as if the same had been passed at a general meeting of the Company duly convened and
held.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48.&nbsp;If within half an hour from the time appointed for the meeting a quorum is not present,
the meeting, if convened upon the requisition of Members, shall be dissolved and in any other case
it shall stand adjourned to the same day in the next week at the same time and place or to such
other time or such other place as the Directors may determine and if at the adjourned meeting a
quorum is not present within half an hour from the time appointed for the meeting, the Members
present shall be a quorum.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49.&nbsp;The Chairman, if any, of the Board of Directors shall preside as Chairman at every general
meeting of the Company, or if there is no such Chairman, or if he shall not be present within
fifteen minutes after the time appointed for the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">holding of the meeting, or is unwilling to act,
the Directors present shall elect one of their number to be Chairman of the meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;50.&nbsp;If at any general meeting no Director is willing to act as Chairman or if no Director is
present within fifteen minutes after the time appointed for holding the meeting, the Members
present shall choose one of their number to be Chairman of the meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;51.&nbsp;The Chairman may, with the consent of any general meeting duly constituted hereunder, and
shall if so directed by the meeting, adjourn the meeting from time to time and from place to place,
but no business shall be transacted at any adjourned meeting other than the business left
unfinished at the meeting from which the adjournment took place. When a general meeting is
adjourned for 30&nbsp;days or more, notice of the adjourned meeting shall be given as in the case of an
original meeting; save as aforesaid it shall not be necessary to give any notice of an adjournment
or of the business to be transacted at an adjourned general meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;52.&nbsp;At any general meeting a resolution put to the vote of the meeting shall be decided on a
show of hands unless a poll is, before or on the declaration of the result of the show of hands,
demanded by the Chairman or any other Member present in person or by proxy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;53.&nbsp;Unless a poll be so demanded a declaration by the Chairman that a resolution has on a show
of hands been carried, or carried unanimously, or by a particular majority, or lost, and an entry
to that effect in the Company&#146;s minute book containing the minutes of the proceedings of the
meeting shall be conclusive evidence of that fact without proof of the number or proportion of the
votes recorded in favor of or against such resolution.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54.&nbsp;The demand for a poll may be withdrawn.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;55.&nbsp;Except as provided in Article&nbsp;56, if a poll is duly demanded it shall be taken in such
manner as the Chairman directs and the result of the poll shall be deemed to be the resolution of
the general meeting at which the poll was demanded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;56.&nbsp;A poll demanded on the election of a Chairman or on a question of adjournment shall be
taken forthwith. A poll demanded on any other question shall be taken at such time as the Chairman
of the general meeting directs and any business other than that upon which a poll has been demanded
or is contingent thereon may be proceeded with pending the taking of the poll.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;57.&nbsp;Notwithstanding any other provision herein to the contrary, the Company shall take no
action (including any action by the Board of Directors or any committee thereof) after the Closing
Date with respect to any of the following matters without the consent of the holders of the then
outstanding Series&nbsp;A Shares and the holders of not
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">less than 75% of the then outstanding Series&nbsp;B
Shares, provided where such matter is by applicable laws required to be determined by the members
of the Company, the consent of all holders of the Series&nbsp;A Shares then outstanding and the holders
of not less than 75% of the then outstanding Series&nbsp;B Shares shall be deemed obtained if the matter
is approved at a general meeting of the Company with the affirmative vote(s) of all holders of the
Series&nbsp;A Shares then outstanding and the holders of not
less than 75% of the then outstanding
Series&nbsp;B Shares or by way of a written resolution signed by all the holders of the Series&nbsp;A Shares
then outstanding and all the holders of the then outstanding Series&nbsp;B Shares:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) any event or action that may lead to any change in the capital structure of the
Company or any of its Subsidiaries, including (i)&nbsp;direct or indirect purchase, redemption,
retirement or other acquisition of any capital stock or registered capital, as applicable,
of the Company or any of its Subsidiaries or any obligation or security convertible or
exchangeable into any such capital stock, (ii)&nbsp;any creation, authorization, increase in
the authorized amount or issuance of shares of any class or series of capital stock or the
registered capital, as applicable, of the Company or any of its Subsidiaries, any
obligation or security convertible
into or exchangeable for shares of any class or series of capital stock of the
Company or any of its Subsidiaries, or any options, warrants or other rights to acquire
any class or series of capital stock of the Company or any of its Subsidiaries (except for
the issuance of Ordinary Shares upon the Conversion of any Preferred Shares pursuant to
these Articles) and (iii)&nbsp;any issuance of debt securities of the Company or any of its
Subsidiaries,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any amendment, alteration or repeal of any provision of the memorandum and
articles of association of the Company or similar constituent documents (including joint
venture contracts and related memorandum of understanding) of any of its Subsidiaries (in
each case including in connection with any merger, consolidation, business combination,
reorganization (including conversion) or other extraordinary corporate transaction) to the
extent such amendment, alteration or repeal changes in any material respects the rights,
preferences or privileges of CICC, Carlyle or Starr,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) any reorganization, recapitalization, reclassification, spin-off or combination
of any securities of the Company or any of its Subsidiaries (including any change to the
registered capital of any of its Subsidiaries formed under the laws of the PRC),
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) any liquidation, dissolution, winding up, commencement of bankruptcy, insolvency,
liquidation or similar proceedings with respect to the Company or any of its Subsidiaries,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) any change to the Company&#146;s name.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>VOTES OF MEMBERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58.&nbsp;Subject to any rights or restrictions for the time being attached to any class or classes
of shares, on a show of hands every Member of record present in person or by proxy at a general
meeting shall have one vote and on a poll every Member of record present in person or by proxy
shall have one vote for each share registered in his name in the Register of Members.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59.&nbsp;Without prejudice to Article&nbsp;58, each holder of Preferred Shares shall, for each Preferred
Share registered in its name in the Register of Members, have a number of votes equal to that
number of Ordinary Shares into which such Preferred Share could then be converted, and shall be
entitled to vote, together with holders of Ordinary Shares and not as a separate class (except as
specifically provided herein or as otherwise required by law), with respect to any question upon
which holders of Ordinary Shares have the right to vote. Fractional votes shall not, however, be
permitted and any fractional voting rights available on an as converted basis (after aggregating
all shares into which the Preferred Shares held by each holder could be converted) shall be rounded
down to the nearest whole number.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;60.&nbsp;In the case of joint holders of record the vote of the senior who tenders a vote, whether
in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders,
and for this purpose seniority shall be determined by the order in which the names stand in the
Register of Members.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;61.&nbsp;A Member of unsound mind, or in respect of whom an order has been made by any court,
having jurisdiction in lunacy, may vote, whether on a show of hands or on a poll, by his committee,
receiver, curator bonis, or other person in the nature of a committee, receiver or curator bonis
appointed by that court, and any such committee, receiver, curator bonis or other persons may vote
by proxy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;62.&nbsp;No Member shall be entitled to vote at any general meeting unless he is registered as a
member of the Company on the record date for such meeting nor unless all calls or other sums
presently payable by him in respect of shares in the Company have been paid.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63.&nbsp;No objection shall be raised to the qualification of any voter except at the general
meeting or adjourned general meeting at which the vote objected to is given or tendered and every
vote not disallowed at such general meeting shall be valid for all purposes. Any such objection
made in due time shall be referred to the Chairman of the general meeting whose decision shall be
final and conclusive.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;64.&nbsp;On a poll or on a show of hands votes may be given either personally or by proxy.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROXIES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;65.&nbsp;The instrument appointing a proxy shall be in writing and shall be executed under the hand
of the appointor or of his attorney duly authorized in writing, or, if the appointor is a
corporation under the hand of an officer or attorney duly authorized in that behalf. A proxy need
not be a Member of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;66.&nbsp;The instrument appointing a proxy shall be deposited at the registered office of the
Company or at such other place as is specified for that purpose in the notice convening the meeting
no later than the time for holding the meeting, or adjourned meeting; <I>provided </I>that the Chairman of
the meeting may at his discretion direct that an instrument of proxy shall be deemed to have been
duly deposited upon receipt of telex, cable or telecopy confirmation from the appointor that the
instrument of proxy duly signed is in the course of transmission to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;67.&nbsp;The instrument appointing a proxy may be in any usual or common form and may be expressed
to be for a particular meeting or any adjournment thereof or generally until revoked. An
instrument appointing a proxy shall be deemed to include the power to demand or join or concur in
demanding a poll.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;68.&nbsp;A vote given in accordance with the terms of an instrument of proxy shall be valid
notwithstanding the previous death or insanity of the principal or
revocation of the proxy or of the authority under which the proxy was executed, or the
transfer of the share in respect of which the proxy is given, provided that no intimation in
writing of such death, insanity, revocation or transfer as aforesaid shall have been received by
the Company at the registered office before the commencement of the general meeting, or adjourned
meeting at which it is sought to use the proxy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;69.&nbsp;Any corporation which is a Member of record of the Company may in accordance with its
articles or in the absence of such provision by resolution of its directors or other governing body
authorize such person as it thinks fit to act as its representative at any meeting of the Company
or of any class of Members of the Company, and the person so authorized shall be entitled to
exercise the same powers on behalf of the corporation which he represents as the corporation could
exercise if it were an individual Member of record of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;70.&nbsp;Shares of its own capital belonging to the Company or held by it in a fiduciary capacity
shall not be voted, directly or indirectly, at any meeting and shall not be counted in determining
the total number of outstanding shares at any given time.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>DIRECTORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;71.&nbsp;There shall be a Board of Directors consisting of up to eleven directors, of whom one
shall be designated by Carlyle (the &#147;<B>Carlyle Director</B>&#148;), one shall be designated by CICC (the &#147;<B>CICC
Director</B>&#148;) and one shall be designated by Starr (the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;<B>Starr Director</B>&#148; and, together with the
Carlyle Director and the CICC Director, the &#147;<B>Investor Directors</B>&#148;); <I>provided </I>that, subject to
Article&nbsp;87(c), the Company may from time to time by Ordinary Resolution increase or reduce the
limits in the number of Directors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;72.&nbsp;The remuneration to be paid to the Directors shall be such remuneration as the Directors
shall determine. Such remuneration shall be deemed to accrue from day to day. The Directors shall
also be entitled to be paid their traveling, hotel and other expenses properly incurred by them in
going to, attending and returning from meetings of the Directors, or any committee of the
Directors, or general meetings of the Company, or otherwise in connection with the business of the
Company, or to receive a fixed allowance in respect thereof as may be determined by the Directors
from time to time, or a combination partly of one such method and partly the other.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;73.&nbsp;The Directors may by resolution award special remuneration to any Director undertaking any
special work or services for, or undertaking any special mission on behalf of, the Company other
than his ordinary routine work as a Director. Any fees paid to a Director who is also counsel or
solicitor to the Company, or otherwise serves it in a professional capacity shall be in addition to
his remuneration as a Director.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;74.&nbsp;A Director or alternate Director may hold any other office or place of profit under the
Company (other than the office of Auditor) in conjunction with his
office of Director for such period and on such terms as to remuneration and otherwise as the
Directors may determine.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;75.&nbsp;A Director or alternate Director may act by himself or his firm in a professional capacity
for the Company and he or his firm shall be entitled to remuneration for professional services as
if he were not a Director or alternate Director.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;76.&nbsp;A shareholding qualification for Directors may be fixed by the Company in general meeting,
but unless and until so fixed no qualification shall be required.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;77.&nbsp;A Director or alternate Director may be or become a director or officer of or otherwise
interested in any company promoted by the Company or in which the Company may be interested as
shareholder or otherwise and no such Director or alternate Director shall be accountable to the
Company for any remuneration or other benefits received by him as a director or officer of, or from
his interest in, such other company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;78.&nbsp;No person shall be disqualified from the office of Director or alternate Director or
prevented by such office from contracting with the Company, either as vendor, purchaser or
otherwise, nor shall any such contract, or any contract or transaction entered into by or on behalf
of the Company in which any Director or alternate Director shall be in any way interested be or be
liable to, be avoided, nor
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shall any Director or alternate Director so contracting or being so
interested be liable to account to the Company for any profit realized by any such contract or
transaction by reason of such Director holding the office of Director or of the fiduciary relation
thereby established. A Director (or his alternate Director in his absence) shall be at liberty to
vote in respect of any contract or transaction in which he is so interested as aforesaid; <I>provided</I>
that the nature of the interest of any Director or alternate Director in any such contract or
transaction shall be disclosed by him or the alternate Director appointed by him at or prior to its
consideration and any vote thereon.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;79.&nbsp;A general notice that a Director or alternate Director is a shareholder of any specified
firm or company and is to be regarded as interested in any transaction with such firm or company
shall be sufficient disclosure under Article&nbsp;78 and after such general notice it shall not be
necessary to give special notice relating to any particular transaction.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ALTERNATE DIRECTORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;80.&nbsp;A Director who expects to be unable to attend Directors&#146; meetings because of absence,
illness or otherwise may appoint any person to be an alternate Director to act in his stead and
such appointee whilst he holds office as an alternate Director shall, in the event of absence
therefrom of his appointor, be entitled to attend meetings of the Directors and to vote thereat and
to do, in the place and stead of his appointor, any other act or thing which his appointor is
permitted or required to do by virtue of his being a Director as if the alternate Director were the
appointor, other than appointment of an alternate to himself, and he shall <I>ipso facto </I>vacate office
if and
when his appointor ceases to be a Director or removes the appointee from office. An
appointment and a termination of appointment of the alternate Director shall be by notice in
writing signed by such Director and either (a)&nbsp;sent to the Company or (b)&nbsp;accepted by the Board of
Directors by resolution thereof at the relevant meeting. Any person appointed as alternate
Director shall vacate his office as such alternate Director if and when the Director by whom he has
been appointed removes him or vacates office as Director.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>POWERS AND DUTIES OF DIRECTORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;81.&nbsp;The business of the Company shall be managed by the Directors (or a sole Director if only
one is appointed) who may pay all expenses incurred in promoting, registering and setting up the
Company, and may exercise all such powers of the Company as are not, from time to time by the
Statute, or by these Articles, or such regulations, being not inconsistent with the aforesaid, as
may be prescribed by the Company in general meeting, required to be exercised by the Company in
general meeting; <I>provided </I>that no regulations made by the Company in general meeting shall
invalidate any prior act of the Directors which would have been valid if that regulation had not
been made.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;82.&nbsp;The Directors may from time to time and at any time by powers of attorney appoint any
company, firm, person or body of persons, whether nominated directly or indirectly by the
Directors, to be the attorney or attorneys of the Company for such purpose and with such powers,
authorities and discretions (not exceeding those vested in or exercisable by the Directors under
these Articles) and for such period and subject to such conditions as they may think fit, and any
such powers of attorney may contain such provisions for the protection and convenience of persons
dealing with any such attorneys as the Directors may think fit and may also authorize any such
attorney to delegate all or any of the powers, authorities and discretions vested in him.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;83.&nbsp;All cheques, promissory notes, drafts, bills of exchange and other negotiable instruments
and all receipts for monies paid to the Company shall be signed, drawn, accepted, endorsed or
otherwise executed as the case may be in such manner as the Directors shall from time to time by
resolution determine.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;84.&nbsp;The Directors shall cause minutes to be made in books provided for the purpose:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) of all appointments of officers made by the Directors;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) of the names of the Directors (including those represented thereat by an
alternate or by proxy) present at each meeting of the Directors and of any committee of
the Directors;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) of all resolutions and proceedings at all meetings of the Company and of the
Directors and of committees of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;85.&nbsp;The Directors on behalf of the Company may pay a gratuity or pension or allowance on
retirement to any Director who has held any other salaried office or place of profit with the
Company or to his widow or dependants and may make contributions to any fund and pay premiums for
the purchase or provision of any such gratuity, pension or allowance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;86.&nbsp;The Directors may exercise all the powers of the Company to borrow money and to mortgage
or charge its undertaking, property and uncalled capital or any part thereof and to issue
debentures, debenture stock and other securities whether outright or as security for any debt,
liability or obligation of the Company or of any third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;87.&nbsp;Notwithstanding any other provision herein to the contrary, the Company shall take no
action (including any action by the Board of Directors or any committee thereof) after the Closing
Date with respect to any of the following matters without the affirmative approval of a majority of
the Board of Directors (which majority shall
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">include all Investor Directors, other than the matters
set forth under clause 87(bb) with respect to which such majority shall include a majority of the
Investor Directors):
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) any merger, consolidation, reorganization (including conversion) or other
business combination involving the Company or any of its Subsidiaries (other than of a
wholly owned Subsidiary of the Company with or into another wholly owned Subsidiary of the
Company) or any acquisition of the Company or any of its Subsidiaries by another entity by
means of any transaction or series of related transactions,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any material change in the business of the Company or any of its Subsidiaries,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) any material change to the Board of Directors or the board of directors of any
Subsidiary of the Company, including any increase or decrease of the size of the Board of
Directors or such board,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the termination of employment of, or the entering into of any employment
agreement or arrangement (or amendment or other modification thereto) with, the chairman
of the Board of Directors, the president, the chief executive officer, the chief financial
officer, the chief operating officer or individuals holding similar positions of the
Company or any of its Subsidiaries (the &#147;<B>Top Management</B>&#148;),
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) entry into any material plan for the future expansion of the Company or any of
its Subsidiaries,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) any plan on the IPO or any material change thereto or the consummation of the
IPO,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) any approval or modification of the annual budget of the Company or any of its
Subsidiaries (including (i)&nbsp;detailed budget for the line items in the balance sheet,
income statement and statement cash flow of the Company or any of its Subsidiaries, (ii)
budget for the annual total salary of the employees of the Company or any of its
Subsidiaries, the employee benefits plans and the compensation, benefits and incentive
plans for the Top Management of the Company or any of its Subsidiaries and (iii)&nbsp;separate
budget for certain lines items in the income statement of the Company or any of its
Subsidiaries, including R&#038;D and advertisement), and authorization of any expenditure by
the Company or any of its Subsidiaries if as a result thereof the aggregate amount of
expenditures in any category would exceed 10% of the amount budgeted therefor in the
approved operating budget,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) any acquisition, sale, lease or other material decisions regarding trademarks or
other intellectual property rights by the Company or any of its Subsidiaries,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the creation, incurrence, or assumption of any indebtedness of the Company or any
of its Subsidiaries after the Closing Date (i)&nbsp;causing the total liabilities to total
assets ratio of the Company and its Subsidiaries, taken as a whole, to exceed 65% or (ii)
after such total liabilities to total assets ratio has exceeded 65%,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) any change to the ownership of the Company Securities other than any Transfer of
Ordinary Shares by any Controlling Member or its Permitted Transferees to the Investors
pursuant to Article&nbsp;4 of the Series&nbsp;A Subscription Agreement, Article&nbsp;3 of the Series&nbsp;B
Subscription Agreement, Section&nbsp;11.06 of the Convertible Loan Agreement, Section&nbsp;6.09 of
the Amended and Restated Shareholders&#146; Agreement, the Share Charge Agreements or any
Transfer expressly permitted or required pursuant to these Articles,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) any loans or advances to, or guarantees for the benefit of, any shareholder,
director, member of the Top Management or their respective Affiliates by the Company or
any of its Subsidiaries, other than advances (i)&nbsp;to any such Person up to an aggregate
outstanding amount of RMB100,000 for each such Person at anytime and (ii)&nbsp;in an aggregate
amount for all such Persons not exceeding the amount expressly specified in the budget
approved by the Board of Directors pursuant to clause (g),
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l) any increase in the salary of any of the five most highly compensated employees
of the Company or any of its Subsidiaries by more than 15% in any 12-month period,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m) (i)&nbsp;the adoption of, or any amendment or other modification to, any share option
plan, employee share ownership plan or share
purchase or restricted share or share appreciation rights plan, or (ii)&nbsp;any issuance
of Ordinary Shares to any employees of the Company or any of its Subsidiaries, other than
pursuant to any such plan approved by the Board of Directors pursuant to clause (g),
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n) (i)&nbsp;any direct or indirect purchase or other acquisition by the Company or any of
its Subsidiaries of any notes, obligations, instruments, stock securities or ownership
interest (including any partnership, limited liability and joint venture interest) of any
Person (including the Company or any of its Subsidiaries) and (ii)&nbsp;any capital
contribution by the Company or any of its Subsidiaries to any Person (including the
Company or any of its Subsidiaries),
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o) any formation, acquisition or sale of any Subsidiaries by the Company or any of
its Subsidiaries,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p) any acquisition, sale, transfer, lease, pledge or other disposition by the
Company or any of its Subsidiaries (in a single transaction or a series of related
transactions) of any assets, business or operations in the aggregate with a value of more
than RMB15,000,000 (other than as expressly specified in the annual budget approved by the
Board of Directors pursuant to clause (g)),
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q) the creation of any lien on the assets or properties of the Company or any of its
Subsidiaries with an aggregate value exceeding RMB20,000,000 in connection with any bank
loans,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r) the declaration or payment of any dividend or other distribution upon any capital
stock of the Company or any of its Subsidiaries (other than (i)&nbsp;dividends and
distributions to the Company or a wholly owned Subsidiary of the Company by a wholly owned
Subsidiary of the Company and (ii)&nbsp;dividends on the Preferred Shares paid pursuant to
these Articles),
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s) the adoption, announcement or amendment of the loss recovery plan or any plan in
connection with the reserve fund, enterprise expansion fund and bonus and welfare fund for
employees,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) any adjustment to the operating budget of the Company or any of its Subsidiaries
upon the official written request of the Company; <I>provided that </I>any such consent granted
by the Board pursuant to this clause (v)&nbsp;shall be considered also a consent by the Board
of Directors to the corresponding adjustment to the annual budget pursuant to clause (g),
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u) any prepayment of purchase price in connection with purchase of goods and
services by the Company or any of its Subsidiaries to any single supplier, individually or
together with any other prepayment
to such supplier, in an amount exceeding RMB9,000,000 (excluding any payment after
the receipt and acceptance of purchased goods and services but prior to the receipt of the
related invoices or receipts),
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) any loans or advances to, or guarantees for the benefit of, any entity which is
an Affiliate of the Company (other than the wholly-owned Subsidiaries of the Company) by
the Company or any of its
Subsidiaries in an amount exceeding RMB1,000,000 to any single entity or in an
aggregate amount to all such entities exceeding RMB2,000,000 in any fiscal year,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w) any loans or advances to any entity that is not an Affiliate of the Company by
the Company or any of its Subsidiaries in an amount exceeding RMB500,000 to any single
entity or in an aggregate amount to all such entities exceeding RMB1,000,000 in any fiscal
year (other than advance trade payments in the ordinary course of business),
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) any use or lease by any Person other than the Company or its Subsidiaries free of
charge or at a price lower than the market price of the assets and properties of the
Company or any of its Subsidiaries with an aggregate fair market value exceeding
RMB5,000,000,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y) any indemnity to third party(ies) (i)&nbsp;causing the cumulative amount of indemnity
to all third parties to exceed RMB100,000 or (ii)&nbsp;after the cumulative amount of indemnity
to all third parties has exceeded RMB100,000,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z) any guarantees for the benefit of any entity that is not an Affiliate of the
Company,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aa) any donation or sponsorship in an amount exceeding RMB1,000,000 or in an
aggregate amount of RMB3,000,000 in any fiscal year by the Company and its Subsidiaries
(other than donation or sponsorship set forth in the annual budget approved by the Board
of Directors pursuant to Article&nbsp;87(g)),
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(bb) the appointment and removal of the Auditors,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(cc) any decisions on any matters relating to any material litigation,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(dd) any payment by the Company or any of its Subsidiaries to, or any sale, lease,
transfer or other disposition of any properties or assets of the Company or any of its
Subsidiaries to, or any purchase, lease or other acquisition by the Company or any of its
Subsidiaries of any properties or assets from, or any other transaction, contract,
agreement, loan, advance or guarantee with or for the benefit of,
any shareholder, director, officer, employee or any Affiliate of the foregoing, any
Affiliate of the Company or any of its Subsidiaries or the shareholder, director, officer
or employee of such Affiliate (other than transactions between the Company and any of its
wholly owned Subsidiaries or between any wholly owned Subsidiary of the Company and any
other wholly owned Subsidiary of the Company), and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ee) any agreement, indenture or other instrument that contains any provision that
would restrict either (i)&nbsp;the payment of dividends on, or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">the redemption of, the Series&nbsp;A
Shares and Series&nbsp;B Shares when due to the full extent required by the terms thereof or
(ii)&nbsp;the right of Carlyle, CICC and Starr under Article&nbsp;16(g).
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>MANAGEMENT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;88.&nbsp;The Directors may from time to time provide for the management of the affairs of the
Company in such manner as they shall think fit and the provisions contained in the three next
following paragraphs shall be without prejudice to the general powers conferred by this paragraph.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Directors from time to time and at any time may establish any committees,
local boards or agencies for managing any of the affairs of the Company and may appoint
any persons to be members of such committees or local boards or any managers or agents and
may fix their remuneration.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Directors from time to time and at any time may delegate to any such
committee, local board, manager or agent any of the powers, authorities and discretions
for the time being vested in the Directors and may authorize the members for the time
being of any such local board, or any of them to fill up any vacancies therein and to act
notwithstanding vacancies and any such appointment or delegation may be made on such terms
and subject to such conditions as the Directors may think fit and the Directors may at any
time remove any person so appointed and may annul or vary any such delegation, but no
person dealing in good faith and without notice of any such annulment or variation shall
be affected thereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Any such delegates as aforesaid may be authorized by the Directors to subdelegate
all or any of the powers, authorities, and discretions for the time being vested in them.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROCEEDINGS OF DIRECTORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;89.&nbsp;Except as otherwise provided by these Articles, the Directors shall meet together for the
despatch of business, convening, adjourning and otherwise regulating their meetings at least once
every calendar quarter. Subject to Articles 87 and 16(g),
questions arising at any meeting shall be decided by a majority of votes of the Directors and
alternate Directors present at a meeting at which there is a quorum, the vote of an alternate
Director not being counted if his appointor be present at such meeting; <I>provided </I>that a resolution
of the Directors in writing signed by a majority of all Directors (which majority shall include the
same number of Investor Directors as the number of Investor Directors required pursuant to these
Articles and the Amended and Restated Shareholders&#146; Agreement for a resolution adopted by the Board
of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Directors in a meeting of the Board of Directors) shall be as valid and effectual as if such
resolution had been passed at a meeting of the Directors duly convened and held so long as (x)&nbsp;a
copy of such resolution has been given or the contents thereof communicated to all the directors
for the time being entitled to receive notices of meetings of the Directors in the same manner as
notices of meetings are required to be given hereby and (y)&nbsp;no director has objected to such
resolution. Such written resolution may be contained in one document or in several documents in
like form each signed by one or more of the Directors or alternate Directors and for this purpose a
facsimile signature of a Director or an alternate Director shall be treated as valid. Each Director
shall have one vote and each alternate Director or proxy shall have one vote for every Director
whom he represents; <I>provided </I>that if such alternate Director is himself a Director then he shall
have one vote for every Director whom he represents in addition to any vote of his own. In case of
an equality of votes, the Chairman shall have a second or casting vote.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;90.&nbsp;A Director or alternate Director may, and the Secretary on the requisition of a Director
or alternate Director shall, at any time summon a meeting of the Directors. The Company shall give
at least ten Business Days written notice in writing to every Director and alternate Director which
notice shall set forth the general nature of the business to be considered unless notice is waived
by all the Directors (or their alternates) either at, before or after the meeting is held and,
<I>provided </I>that if notice is given in person, by cable, telex or telecopy the same shall be deemed to
have been given on the day it is delivered to the Directors or transmitting organization as the
case may be. The schedule of the meeting and all information related to the matters to be discussed
at the meeting shall be delivered along with the written notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;91.&nbsp;The quorum necessary for the transaction of the business of the Directors shall be a
majority of the Directors, with such majority including all Investor Directors. In the event that
a quorum is not established due to the absence of any Investor Director, a meeting may be
reconvened on the third Business Day after the date of the originally scheduled meeting and
attendance by such absent Investor Director shall not be required for the purposes of establishing
quorum at the reconvened meeting. A Director and his appointed alternate Director shall be
considered only one person for this purpose; <I>provided </I>that if there shall at any time be only a
sole Director the quorum shall be one. For the purposes of this Article an alternate Director or
proxy appointed by a Director shall be counted in a quorum at a meeting at which the Director
appointing him is not present.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;92.&nbsp;The continuing Directors may act notwithstanding any vacancy in their body, but if and so
long as their number is reduced below the number fixed by or
pursuant to these Articles as the necessary quorum of Directors, the continuing Directors or
Director may act for the purpose of increasing the number of Directors to that number, or of
summoning a general meeting of the Company, but for no other purpose.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->54<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;93.&nbsp;The Directors may elect a Chairman of their Board and determine the period for which he is
to hold office; but if no such Chairman is elected, or if at any meeting the Chairman is not
present within five minutes after the time appointed for holding the same, the Directors present
may choose one of their number to be Chairman of the meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;94.&nbsp;The Directors may delegate any of their powers to executive, compensation, audit and such
other committees consisting of such member or members of the Board of Directors (including
alternate Directors in the absence of their appointors) as they think fit; any committee so formed
shall in the exercise of the powers so delegated conform to any regulations that may be imposed on
it by the Directors. Each Investor Director shall be entitled to sit on any committee created by
the Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;95.&nbsp;A committee may meet and adjourn as it thinks proper. Questions arising at any meeting
shall be determined by a majority of votes of the members present, and in the case of an equality
of votes the Chairman shall have a second or casting vote.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;96.&nbsp;Members of the Board of Directors or of any committee thereof may participate in a meeting
of the Board or of such committee in person or by means of proxy, conference telephone or similar
communications equipment by means of which all persons participating in the meeting can hear each
other and participation in a meeting pursuant to this provision shall constitute presence in person
at such meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;97.&nbsp;A Director may be represented at any meetings of the Board of Directors by a proxy
appointed by him in which event the presence or vote of the proxy shall for all purposes be deemed
to be that of the Director. The provisions of Articles 65 through 68 shall <I>mutatis mutandis </I>apply
to the appointment of proxies by Directors.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>VACATION OF OFFICE OF DIRECTOR</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;98.&nbsp;The office of a Director shall be vacated:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) if he gives notice in writing to the Company that he resigns the office of
Director;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) if he absents himself (without being represented by proxy or an alternate
Director appointed by him) from three consecutive meetings of the Board of Directors
without special leave of absence from the Directors, and they pass a resolution that he
has by reason of such absence vacated office;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) if he dies, becomes bankrupt or makes any arrangement or composition with his
creditors generally;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) if he is found a lunatic or becomes of unsound mind; or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->55<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) if he is removed in accordance with these Articles.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.&nbsp;If, as a result of death, disability, retirement, resignation, removal or otherwise, there
shall exist or occur any vacancy on the Board of Directors:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Person or Persons entitled under these Articles to designate such Director
whose death, disability, retirement, resignation or removal resulted in such vacancy, may
designate another individual (the &#147;<B>Replacement Nominee</B>&#148;) to fill such vacancy and serve as
a director on the Board; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) subject to Article&nbsp;71, each Member, if it is then entitled to vote for the
election of directors to the Board of Directors, shall vote its shares, or execute proxies
or written consents, as the case may be, in order to ensure that the Replacement Nominee
be elected to the Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100.&nbsp;If the office of a Director is vacant and an individual has been nominated to fill such
vacancy, the first order of business of a meeting of the Directors shall be to fill such vacancy.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>APPOINTMENT AND REMOVAL OF DIRECTORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;101.&nbsp;If at any time any Member is entitled to vote for the election of Directors to the Board
of Directors, such Member shall vote its shares or execute proxies or written consents, as the case
may be, and take all other necessary action (including causing the Company to call a general
meeting of the Members) in order to ensure that the composition of the Board is as set forth in
Article&nbsp;71.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;102.&nbsp;The Company agrees to cause each individual designated pursuant to Article&nbsp;71 or Article
99 to be nominated to serve as a director on the Board, and to take all other necessary actions
(including calling a meeting of the Board and/or a general meeting of the Members) to ensure that
the composition of the Board is as set forth in Article&nbsp;71.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;103.&nbsp;Each Member, if at any time it is then entitled to vote for the removal of Directors from
the Board of Directors, (i)&nbsp;shall not vote any of its shares in favor of the removal of any
Director who shall have been designated pursuant to these Articles, unless the Person or Persons
entitled to designate or nominate such Director shall have consented to such removal in writing;
and (ii)&nbsp;if the Person or Persons entitled to designate any director pursuant to these Articles
shall request in writing the removal of such Director, such Member shall vote its shares in favor
of such removal.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->56<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SEAL</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;104.&nbsp;(a)&nbsp;The Company may, if the Board of Directors so determine, have a Seal which shall,
subject to paragraph (c)&nbsp;of this Article, only be used by the authority of the Directors or of a
committee of the Directors authorized by the Directors to act on behalf of the Board of Directors
and every instrument to which the Seal has been affixed shall be signed by one person who shall be
either a Director or the Secretary or Secretary-Treasurer or some person appointed by the Directors
for the purpose.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company may have for use in any place or places outside the Cayman Islands a
duplicate Seal or Seals each of which shall be a facsimile of the Common Seal of the
Company and, if the Directors so determine, with the addition on its face of the name of
every place where it is to be used.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) A Director, Secretary or other officer or representative or attorney may without
further authority of the Directors affix the Seal of the Company over his signature alone
to any document of the Company required to be authenticated by him under Seal or to be
filed with the Registrar of Companies in the Cayman Islands or elsewhere wheresoever.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>OFFICERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;105.&nbsp;The Company may have a Chief Executive Officer, a President, a Chief Operating Officer, a
Chief Financial Officer, a Secretary and an Assistant Secretary appointed by the Board of Directors
who may also from time to time appoint such other officers as they consider necessary, all for such
terms, at such remuneration and to perform such duties, and subject to such provisions as to
disqualification and removal as the Board of Directors from time to time prescribe.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CONVERSION RIGHTS OF PREFERRED SHARES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;106.&nbsp;Unless previously redeemed, subject as hereinafter provided, each Preferred Share shall,
at the option of the holder thereof at any time, be converted into a number of fully paid and
non-assessable Ordinary Shares at the ratio (the &#147;<B>Conversion Ratio</B>&#148;) equal to (x)&nbsp;the then
effective Liquidation Preference for such Preferred Share <I>divided </I>by (y)&nbsp;the then applicable
Conversion Price for such class of Preferred Shares. The initial Conversion Ratio for each
Preferred Share is 1:1 and is subject to adjustment pursuant to Article&nbsp;111. For the avoidance of
doubt, no payment (in addition to the surrender of the Preferred Shares so converted) shall be made
by the holders of Preferred Shares to the Company upon or in connection with the conversion of any
Preferred Shares into Ordinary Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;107.&nbsp;The Conversion Rights shall be exercisable by the holder of any Preferred Share by
delivering a notice (the &#147;<B>Conversion Notice</B>&#148;) to the Company.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->57<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The date on which the Conversion Notice is so given (or, if such date is not a Business Day, the
immediately following Business Day) shall be referred to as the &#147;<B>Conversion Date</B>&#148; in these
Articles. Conversion shall be deemed effective as of the Conversion Date. The Company shall amend
the Register of Members as soon as possible after the Conversion Date to reflect the Conversion and
in no case later than five Business Day after the Conversion Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;108.&nbsp;One hundred per cent (100%) of each class of the Preferred Shares which are outstanding
immediately prior to the closing of the QPO shall, on and with effect from the closing of the QPO,
be automatically converted into Ordinary Shares at the then-effective Conversion Ratio for such
class of Preferred Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;109.&nbsp;In addition to Article&nbsp;108, one hundred per cent (100%) of the Series&nbsp;B Shares shall be
automatically converted into Ordinary Shares at the then-effective Conversion Ratio for Series&nbsp;B
Shares upon the receipt by the Company of a written consent signed by holders of not less than 70%
of the Series&nbsp;B Shares then outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;110.&nbsp;Save for the Conversion pursuant to Article&nbsp;108 and Article&nbsp;109, each holder of Preferred
Shares shall, at the time of Conversion, deliver to the Company at its principal place of business
the Conversion Notice and the certificates for such Preferred Shares. The Company shall issue and
deliver to it (at the address on the Register of Members or such other address as may be specified
in the Conversion Notice) a certificate for the number of Ordinary Shares resulting from the
Conversion on or before 5:00 p.m. (Beijing time) on a day being one Business Days after the
Conversion Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;111.&nbsp;Anti-Dilution Provisions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Prior to and simultaneous with the Conversion, if the Company issues new equity
or equity-linked securities (including issuance of new equity or equity-linked securities
through the IPO) at a price per share lower than the then-current Conversion Price for any
class of Preferred Shares, the Conversion Price for such class to be in effect after such
issuance shall be reduced to such lower price. If any portion of such lower price is in a
form other than cash, the fair market value of such noncash consideration shall be
utilized in the foregoing computation. Such fair market value shall be determined by the
Board of Directors; <I>provided </I>that if the holders of not less than 25% of the outstanding
Preferred Shares of such class object to any such determination, the Board of Directors
shall retain an independent appraiser satisfactory to such holders to determine such fair
market value.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Prior to and simultaneous with the Conversion, if the Company (A)&nbsp;subdivides or
splits the outstanding Ordinary Shares, (B)&nbsp;combines or reclassifies the outstanding
Ordinary Shares into a smaller
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->58<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">number of shares, (C)&nbsp;issues any capital shares in a
reclassification of
Ordinary Shares (including any such reclassification in connection with a
consolidation or merger in which the Company is the surviving entity), or (D)&nbsp;consolidates
with, merges with or into or is converted into any other entity, the Conversion Price for
each class of Preferred Shares in effect at the time of the record date for such
subdivision, split, combination, consolidation, conversion, merger or reclassification
shall be adjusted so that the conversion of such class of Preferred Shares after such time
shall entitle each holder of such class of Preferred Shares to receive the aggregate
number of Ordinary Shares (or shares of any security into which such Ordinary Shares have
been combined, consolidated, converted, merged or reclassified) which, if such Preferred
Shares of such class had been converted immediately prior to such time, such holder would
have owned upon such Conversion and been entitled to receive by virtue of such
subdivision, split, combination, consolidation, conversion, merger or reclassification.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) This Article&nbsp;111 shall not apply to any issuance of new equity or equity-link
securities (i)&nbsp;to employees of the Company or any of its Subsidiaries pursuant to employee
benefit plans or arrangements approved by the Board of Directors as permitted by these
Articles, the Series&nbsp;A Subscription Agreement and the Series&nbsp;B Subscription Agreement
(including upon the exercise of employee stock options granted pursuant to any such plans
or arrangements) or (ii)&nbsp;upon the Conversion of any Preferred Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;112.&nbsp;The Ordinary Shares which are issued as a result of the Conversion shall rank <I>pari passu</I>
in all respects with the then outstanding Ordinary Shares. Subject to applicable laws, the
Conversion shall not require any consent or vote or approval of the holders of Ordinary Shares or
the Board of Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;113.&nbsp;The Company shall at all times reserve and keep available and free of pre-emptive rights
out of its authorized but unissued Ordinary Shares, solely for the purpose of effecting the
Conversion, such number of Ordinary Shares as shall from time to time be sufficient to effect the
Conversion of all of the then outstanding Preferred Shares, and if at any time the number of
authorized but unissued Ordinary Shares shall not be sufficient to effect the Conversion of all of
the then outstanding Preferred Shares, the Company and the Members shall take such action including
passing a Special Resolution or an Ordinary Resolution as may be necessary to increase the
Company&#146;s authorized share capital to such level so that the number of authorized but unissued
Ordinary Shares shall be sufficient for such purpose.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;114.&nbsp;The Company shall pay all taxes and expenses attributable to the issuance or delivery of
Ordinary Shares as required by law upon any Conversion.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->59<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>DIVIDENDS, DISTRIBUTIONS AND RESERVE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;115.&nbsp;Subject to the Statute and Articles 87 and 16(g), the Board of Directors may from time to
time declare dividends (including interim dividends) and distributions on shares of the Company
outstanding and authorize payment of the same out of the funds of the Company lawfully available
therefore.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;116.&nbsp;The Board of Directors may, before declaring any dividends or distributions, set aside
such sums as they think proper as a reserve or reserves which shall, at the discretion of the Board
of Directors, be applicable for any purpose of the Company and pending such application may, at the
like discretion, be employed in the business of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;117.&nbsp;No dividend or distribution shall be payable except out of the profits of the Company,
realized or unrealized, or out of the share premium account or as otherwise permitted by the
Statute.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;118.&nbsp;Subject to Article&nbsp;126 and any other rights of persons, if any, entitled to shares with
special rights as to dividends or distributions, if dividends or distributions are to be declared
on a class of shares, they shall be declared and paid according to the amounts paid or credited as
paid on the shares of such class outstanding on the record date for such dividend or distribution
as determined in accordance with these Articles but no amount paid or credited as paid on a share
in advance of calls shall be treated for the purpose of this Article as paid on the share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;119.&nbsp;The Directors may deduct from any dividend or distribution payable to any Member all sums
of money (if any) presently payable by him to the Company on account of calls or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;120.&nbsp;Subject to Articles 124 and 127, the Directors may declare that any dividend or
distribution be paid wholly or partly by the distribution of specific assets and in particular of
paid up shares, debentures, or debenture stock of any other company or in any one or more of such
ways and where any difficulty arises in regard to such distribution, the Directors may settle the
same as they think expedient and in particular may issue fractional certificates and fix the value
for distribution of such specific assets or any part thereof and may determine that cash payments
shall be made to any Members upon the footing of the value so fixed in order to adjust the rights
of all Members and may vest any such specific assets in trustees as may seem expedient to the
Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;121.&nbsp;Any dividend, distribution, interest or other monies payable in cash in respect of shares
may be paid by cheque sent through the post directed to the registered address of the holder or, in
the case of joint holders, to the holder who is first named on the Register of Members or to such
person and to such address as such holder or joint holders may in writing direct. Every such cheque
shall be made payable
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->60<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to the order of the person to whom it is sent. Any one of two or more joint
holders may
give effectual receipts for any dividends, bonuses, or other monies payable in respect of the
share held by them as joint holders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;122.&nbsp;Subject to Article&nbsp;125, no dividend or distribution shall bear interest against the
Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;123.&nbsp;Prior to the completion of the QPO, each holder of Preferred Shares shall be entitled to
receive, out of legally available funds, a dividend on an annual basis (the &#147;<B>Fixed Dividend</B>&#148;), in
respect of each Preferred Share, of an amount equal to the higher of:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the product of (x)&nbsp;the number of Ordinary Shares into which such Preferred Share
may then be converted <I>multiplied </I>by (y)&nbsp;the dividend per Ordinary Share declared on the
Ordinary Shares; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the product of (x)&nbsp;the Purchase Price of such holder for such Preferred Share
<I>multiplied </I>by (y)&nbsp;5%.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;124.&nbsp;The Fixed Dividend shall be payable in cash annually in arrears on April&nbsp;30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>
in the following financial year (any incomplete financial year shall be deemed to be a complete
financial year).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125.&nbsp;Any Fixed Dividend that the Company has failed to declare or pay pursuant to this Article
125 to any holder of Preferred Shares shall be owed by the Company to such holder of Preferred
Shares and shall accrue interest at a rate of 5% per annum. Any such owed Fixed Dividend and any
amounts of interest accrued thereon shall be paid by the Company in cash to such holder of
Preferred Shares as soon as possible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;126.&nbsp;The dividends (and interest on accrued but unpaid dividends) in respect of the Preferred
Shares pursuant to Articles 123, 124, 125 and 127 shall be paid in priority to any dividend or
distribution in respect of the Ordinary Shares or any other class or series of shares and no
dividend or distribution shall be paid or otherwise made on any Ordinary Shares or any other class
or series of shares unless and until all accrued but unpaid dividends (and interest thereon) in
respect of the Preferred Shares pursuant to Articles 123, 124, 125 and 127 shall have been paid.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;127.&nbsp;Notwithstanding anything to the contrary set forth herein, if the Company has not
completed the QPO within three years of the Closing Date, the Company shall, starting from January
1 of the calendar year immediately following such three-year period, declare and pay to all holders
of Preferred Shares on a <I>pro rata </I>basis an amount of dividend equal to the maximum amount permitted
by laws.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->61<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;128.&nbsp;For the purposes of Articles 115 through 131, (i)&nbsp;references to dividend shall mean any
cash dividend or other distribution in the form of cash paid or payable or made or to be made by
the Company out of profits or other reserves of the Company to holders of its shares or any class
of shares whether the same are designated as interim dividend, special dividend or final dividend;
(ii)&nbsp;references to
dividends being &#147;paid&#148; shall include distributions being made; (iii)&nbsp;if two or more dividends
on any class of shares of the Company are paid on the same date, such dividends shall, unless the
context otherwise requires, be deemed to be one dividend; (iv)&nbsp;if any dividend shall not when paid
by the Company be expressed to be in respect of a particular financial year, it shall be deemed to
be in respect of the preceding financial year; (v)&nbsp;if the Company introduces a scrip dividend
scheme or other arrangements are made, the effect of which is that all or any holders of any class
of shares of the Company are given the right to elect either to receive a cash dividend or to
receive an allotment of shares of the same class by way of capitalization of profits or other
reserves (including for this purpose capital redemption reserve fund), then the dividend shall be
deemed to be paid wholly in cash and in an amount equal to the cash dividend payable to holders of
such class of shares electing for the same.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;129.&nbsp;In the event of any dispute or uncertainty as to the amount or timing of any payment in
respect of the Preferred Shares pursuant to these Articles, the directors of the Company may refer
the same to the Auditors for the time being of the Company, acting as experts and not as
arbitrators, and their decision regarding the same shall be conclusive and binding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;130.&nbsp;Notwithstanding anything to the contrary herein, a holder of Preferred Shares may elect,
by delivering a written notice to the Company prior to April&nbsp;30<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> of any year, to defer
the payment of any dividend payable to such holder pursuant to other provisions set out herein
until the Conversion Date. Such deferred dividend shall not accrue interest.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;131.&nbsp;Articles 123 through 130 may be amended by a Special Resolution and the consent of
holders of all of the Series&nbsp;A Shares and the holders of all of the Series&nbsp;B Shares to meet the
budget requirements of the Company or to satisfy any requirement in connection with the QPO.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>BOOKS OF ACCOUNT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;132.&nbsp;The Board of Directors shall cause proper books of account to be kept with respect to:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) all sums of money received and expended by the Company and the matters in respect
of which the receipt or expenditure takes place;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) all sales and purchases of goods by the Company;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->62<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the assets and liabilities of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proper books shall not be deemed to be kept if there are not kept such books of account as are
necessary to give a true and fair view of the state of the Company&#146;s affairs and to explain its
transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;133.&nbsp;The Board of Directors shall from time to time determine whether and to what extent and
at what times and places and under what conditions or
regulations the accounts and books of the Company or any of them shall be open to the
inspection of Members not being Directors and no Member (not being a Director) shall have any right
of inspecting any account or book or document of the Company except as conferred by Statute or
authorized by the Directors or by the Company in general meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;134.&nbsp;The Board of Directors may from time to time cause to be prepared and to be laid before
the Company in general meeting profit and loss accounts, balance sheets, group accounts (if any)
and such other reports and accounts as may be required by law.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AUDIT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;135.&nbsp;Subject to Article&nbsp;87(bb), the Company may at any annual general meeting appoint an
Auditor or Auditors who shall hold office until the next annual general meeting and may fix his or
their remuneration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;136.&nbsp;Subject to Article&nbsp;87(bb), (a)&nbsp;the Directors may before the first annual general meeting
appoint an Auditor or Auditors who shall hold office until the first annual general meeting unless
previously removed by an ordinary resolution of the Members in general meeting in which case the
Members at that meeting may appoint Auditors; (b)&nbsp;the Directors may fill any casual vacancy in the
office of Auditor but while any such vacancy continues the surviving or continuing Auditor or
Auditors, if any, may act; and (c)&nbsp;the remuneration of any Auditor appointed by the Directors under
this Article may be fixed by the Directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;137.&nbsp;Every Auditor shall have a right of access at all times to the books and accounts and
vouchers of the Company and shall be entitled to require from the Directors and Officers of the
Company such information and explanation as may be necessary for the performance of the duties of
the Auditors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;138.&nbsp;Auditors shall at the next annual general meeting following their appointment and at any
other time during their term of office, upon request of the Directors or any general meeting of the
Members, make a report on the accounts of the Company in general meeting during their tenure of
office.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->63<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>NOTICES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;139.&nbsp;Notices shall be in writing and may be given by the Company to any Member either
personally or by sending it by post, cable, telex or telecopy to him or to his address as shown in
the Register of Members, such notice, if mailed, to be forwarded airmail if the address be outside
the Cayman Islands.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;140.&nbsp;Where a notice is sent by post, service of the notice shall be deemed to be effected by
properly addressing, pre-paying and posting a letter containing the notice, and to have been
effected at the expiration of 60 hours after the letter containing the same is posted as aforesaid.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Where a notice is sent by cable, telex, telecopy or electronic message, service
of the notice shall be deemed to be effected by properly addressing, and sending such
notice through a transmitting organization and to have been effected on the day the same
is sent as aforesaid.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;141.&nbsp;A notice may be given by the Company to the joint holders of record of a share by giving
the notice to the joint holder first named on the Register of Members in respect of the share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;142.&nbsp;A notice may be given by the Company to the person or persons which the Company has been
advised are entitled to a share or shares in consequence of the death or bankruptcy of a Member by
sending it through the post as aforesaid in a pre-paid letter addressed to them by name, or by the
title of representatives of the deceased, or trustee of the bankrupt, or by any like description at
the address supplied for that purpose by the persons claiming to be so entitled, or at the option
of the Company by giving the notice in any manner in which the same might have been given if the
death or bankruptcy had not occurred.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;143.&nbsp;Notice of every general meeting shall be given in any manner hereinbefore authorized to:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) every person shown as a Member in the Register of Members as of the record date
for such meeting except that in the case of joint holders the notice shall be sufficient
if given to the joint holder first named in the Register of Members.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) every person upon whom the ownership of a share devolves by reason of his being a
legal personal representative or a trustee in bankruptcy of a Member of record where the
Member of record but for his death or bankruptcy would be entitled to receive notice of
the meeting; and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->64<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">No other person shall be entitled to receive notices of general meetings.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>WINDING UP; LIQUIDATION PREFERENCE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;144.&nbsp;If the Company shall be wound up, subject to Article&nbsp;145 through 147, the liquidator may,
with the sanction of a Special Resolution and any other sanction required by the Statute, divide
amongst the Members in specie or kind the whole or any part of the assets of the Company (whether
they shall consist of property of the same kind or not) and may for such purpose set such value as
he deems fair upon any property to be divided as aforesaid and may determine how such division
shall be carried out as between the Members or different classes of Members. The liquidator may
with the like sanction, vest the whole or any part of such assets in trustees upon such trusts for
the benefit of the contributories as the liquidator, with the like sanction, shall think fit, but
so that no Member shall be compelled to accept any shares or other securities whereon there is any
liability.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;145.&nbsp;Upon the Company being placed in liquidation, dissolution or winding up (whether
voluntary or involuntary), each holder of Preferred Shares shall be entitled to receive, prior and
in preference to any distribution of any of the assets of the Company to the holders of Ordinary
Shares or any other class or series of shares, for each Preferred Share held by such holder an
amount equal to the sum of (x)&nbsp;150% times the Purchase Price of such holder for such Preferred
Share <I>plus </I>(y)&nbsp;all accrued but unpaid (including deferred) dividends thereon and all interest
accrued on such unpaid dividends (taking into account adjustments for share splits, share
dividends, recapitalizations, share consolidations and other capital reorganizations) (the
&#147;<B>Liquidation Preference</B>&#148;). If the Company has insufficient assets to permit payment of the full
amount of the Liquidation Preference for all Preferred Shares, the Company shall distribute ratably
its assets to all holders of Preferred Shares in proportion to the aggregate Liquidation Preference
that each such holder would otherwise have been entitled to receive.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;146.&nbsp;In addition, after payment has been made in full to the holders of the Preferred Shares
as provided in Article&nbsp;145, each holder of Preferred Shares shall for each Preferred Share held by
such holder, be entitled to participate with the holders of Ordinary Shares in the distribution of
any remaining funds and assets of the Company available for distribution to Members in an amount
equal to (x)&nbsp;the amount to be distributed per share to holders of the Ordinary Shares <I>multiplied </I>by
(y)&nbsp;the number of Ordinary Shares into which such Preferred Share may then be converted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;147.&nbsp;For the purposes of this Article&nbsp;147, liquidation, dissolution or winding up (whether
voluntary or involuntary) of the Company shall be deemed to have occurred upon (i)&nbsp;the acquisition
of the Company by another entity by means of any transaction or series of related transactions
(including, without limitation, any reorganization, conversion, merger or consolidation) as a
result of which the holders of capital shares of the Company immediately before such acquisition
fail to control 50%
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->65<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or more of the voting power of the company surviving such acquisition, (ii)&nbsp;a
sale, lease or other disposition of all or substantially all of the assets of the Company or (iii)
the sale of all or substantially all of the intellectual property rights owned or otherwise held by
the Company and its Subsidiaries or the licensing by the Company or any of its Subsidiaries of all
or substantially all of the intellectual property rights owned or otherwise held by the Company and
its Subsidiaries under an arrangement pursuant to which such intellectual property rights may not
be licensed by the Company and its Subsidiaries to another party. For the avoidance of doubt, a
sale of Company Securities, whether by the Company or by Members of the Company, or a sale of the
assets of the Company, in each case pursuant to Article&nbsp;15, shall not be deemed to be a
liquidation, dissolution or winding up of the Company.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INDEMNITY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;148.&nbsp;To the maximum extent permitted under applicable laws, the Directors and officers for the
time being of the Company, their Affiliates, any directors, officers, partners, members, employees,
agents and spouses of the foregoing, any trustee for the time being acting in relation to any of
the affairs of the foregoing and
their heirs, executors, administrators and personal representatives respectively (the
&#147;<B>Indemnified Persons</B>&#148;) shall be indemnified out of the assets of the Company from and against all
actions, proceedings, costs, charges, losses, damages and expenses which they or any of them shall
or may incur or sustain by reason of any act done or omitted in or about the execution of their
duty in their respective offices or trusts, except such (if any) as they shall incur or sustain by
or through their own willful neglect or default respectively and no Indemnified Person shall be
answerable for the acts, receipts, neglects or defaults of any other Indemnified Person or for
joining in any receipt for the sake of conformity or for the solvency or honesty of any banker or
other persons with whom any monies or effects belonging to the Company may be lodged or deposited
for safe custody or for any insufficiency of any security upon which any monies of the Company may
be invested or for any other loss or damage due to any such cause as aforesaid or which may happen
in or about the execution of his office or trust unless the same shall happen through the willful
neglect or default of such Indemnified Person.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FINANCIAL YEAR</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;149.&nbsp;Unless the Directors otherwise prescribe, the financial year of the Company shall end on
31st December in each year and, following the year of incorporation, shall begin on 1st January in
each year.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENTS OF ARTICLES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;150.&nbsp;Subject to the Statute and Article&nbsp;87, the Company may at any time and from time to time
by Special Resolution alter or amend these Articles in whole or in part.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->66<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;151.&nbsp;Notwithstanding anything to the contrary herein, any amendment or alternation of any
Article herein may be effected only with the consent of all holders of Preferred Shares, <I>provided</I>
where such matter is by applicable laws required to be determined by the members of the Company,
the consent of all holders of the Preferred Shares then outstanding shall be deemed obtained if the
matter is approved at a general meeting of the Company with the affirmative vote(s) of all holders
of the Preferred Shares then outstanding or by way of a written resolution signed by all the
holders of Preferred Shares then outstanding.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TRANSFER BY WAY OF CONTINUATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;152.&nbsp;If the Company is exempted as defined in the Statute, it shall, subject to the provisions
of the Statute and with the approval of a Special Resolution, have the power to register by way of
continuation as a body corporate under the laws of any jurisdiction outside the Cayman Islands and
to be deregistered in the Cayman Islands.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->67<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">For and on behalf of<BR>
Offshore Incorporations (Cayman) Limited<BR>
Corporation<BR>
of Scotia Centre, 4th Floor,<BR>
P.O. Box 2804,<BR>
George Town,<BR>
Grand Cayman KY1-1112<BR>
CAYMAN ISLANDS
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
(Sd.) Authorized Signatory
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">DATED <u>&nbsp;&nbsp;&nbsp;&nbsp;</u> <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> 2008
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">WITNESS to the above signature :-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Sd.) Sharon Kyberd</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">of Scotia Centre, 4th Floor,</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">P.O. Box 2804,</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">George Town,</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Grand Cayman KY1-1112</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAYMAN ISLANDS</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">I, Joy A. Rankine, Asst. Registrar of Companies in and for the Cayman Islands, DO HEREBY CERTIFY
that this is a true copy of these Articles of Association of this Company duly incorporated on the
<u>&nbsp;&nbsp;&nbsp;&nbsp;</u> <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> 2008
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
<FONT style="white-space: nowrap">Asst. REGISTRAR OF COMPANIES (SD.)</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->68<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>h03611exv3w2.htm
<DESCRIPTION>EX-3.2
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-3.2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;3.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CONCORD MEDICAL SERVICES HOLDINGS LIMITED</B><BR>
(the &#147;<B>Company</B>&#148;)
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">SECRETARY&#146;S CERTIFICATE

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The undersigned, being the Company Secretary of the Company, does hereby certify that the following
is an extract of the resolutions passed by the written resolutions of all the shareholders of the
Company on November&nbsp;17, 2009 and such resolutions have not been modified:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ORDINARY RESOLUTIONS:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>THAT </B>each of the 3,795,719 authorized but unissued Ordinary Shares of US$0.01 par value each in the
capital of the Company be and is hereby subdivided into 379,571,900 Ordinary Shares of US$0.0001
par value.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>THAT </B>each of the 704,281 issued Ordinary Shares of US$0.01 par value each in the capital of the
Company be and is hereby subdivided into 70,428,100 Ordinary Shares of US$0.0001 par value.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SPECIAL RESOLUTIONS:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>THAT </B>Article&nbsp;6 of the Articles of Association was replaced in its entirety with a new Article&nbsp;6 as
follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;The share capital of the Company is US$50,000.00 divided into 450,500,000 shares of which
450,000,000 are designated as Ordinary Shares of a nominal or par value of US$0.0001 each, 200,000
are designated as Series&nbsp;A Redeemable Convertible Preferred Shares of a nominal or par value of
US$0.01 each and 300,000 are designated as Series&nbsp;B Redeemable Convertible Preferred Shares of a
nominal or par value of US$0.01 each with power for the Company insofar as is permitted by law, to
redeem or purchase any of its shares and to increase or reduce the said capital subject to the
provisions of the Companies Law (as amended) and the Articles of Association of the Company and to
issue any part of its capital, whether original, redeemed or increased with or without any
preference, priority or special privilege or subject to any postponement of rights or to any
conditions or restrictions and so that unless the conditions of issue shall otherwise expressly
declare every issue of shares whether declared to be preference or otherwise shall be subject to
the powers hereinbefore contained; provided that, notwithstanding any provision to the contrary
contained; provided that, notwithstanding any provision to the contrary contained in this Second
Amended and Restated Memorandum of Association, the Company shall have no power to issue bearer
shares, warrants, coupons or certificates.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>THAT </B>the reference to the par value of US$0.01 was amended to US$0.0001 in the definition of
Ordinary Shares in the Articles of Association of the Company;
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page follows</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS WHEREOF, the undersigned Company Secretary certifies that the shareholders of the
Company have executed these resolutions on November&nbsp;17, 2009.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">                                          /s/ Shi Bo Tao
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left">Shi Bo Tao&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD colspan="2" align="left">Company Secretary&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>h03611exv4w2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.2</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>CONCORD MEDICAL SERVICES HOLDINGS LIMITED</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Certificate
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(the &#147;Company&#148;)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Ordinary Shares</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Number
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&#091;<B>&nbsp;&nbsp;</B>&#093;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&#091;<B>&nbsp;&nbsp;</B>&#093;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="white-space: nowrap">INCORPORATED IN THE CAYMAN ISLANDS UNDER THE COMPANIES LAW</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(AS AMENDED OR REVISED FROM TIME TO TIME<B>)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">THE AUTHORISED CAPITAL OF THE COMPANY IS US$&#091;<B>&nbsp;&nbsp;</B>&#093; DIVIDED INTO &#091;<B>&nbsp;&nbsp;</B>&#093; ORDINARY SHARES<BR>
OF A NOMINAL OR PAR VALUE OF US$0.0001 EACH (the &#147;Ordinary Shares&#148;)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THIS CERTIFIES THAT <B>&#091;shareholder&#093; </B>of &#091;<B>address</B>&#093; is the registered holder of <B>&#091;number of ordinary shares&#093; </B>Ordinary Shares of
par value <B>US$0.0001 </B>each subject to the Memorandum and Articles of Association of the Company, and transferable only on the
book of the Company by the holder hereof in person or by Attorney in accordance with the Memorandum and the Articles of
Association of the Company and upon surrender of this certificate to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">EXECUTED on behalf of the Company this <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> day of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> 20&#091; &#093;.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="74%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 1pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Director/Secretary</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
APPLICABLE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I)&nbsp;IN THE ABSENCE OF
(A)&nbsp;AN EFFECTIVE REGISTRATION STATEMENT FOR THE SHARES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE
SECURITIES LAWS OR (B)&nbsp;AN OPINION OF COUNSEL, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID
ACT AND APPLICABLE STATE SECURITIES LAWS OR (II)&nbsp;UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>5
<FILENAME>h03611exv4w4.htm
<DESCRIPTION>EX-4.4
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.4</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.4</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXECUTION COPY</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SHARE SUBSCRIPTION AGREEMENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>dated as of</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>February&nbsp;5, 2008</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>among</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CICC SUN COMPANY LIMITED,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CARLYLE ASIA GROWTH PARTNERS III, L.P.,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CAGP III CO-INVESTMENT, L.P.,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>LIU HAIFENG,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>STEVE SUN,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>YANG JIANYU,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>BONA LIU,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>OUR MEDICAL SERVICES, LTD.,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ASCENDIUM GROUP LIMITED,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>SHENZHEN AOHUA MEDICAL SERVICES CO., LTD.</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 0pt">(<IMG src="h03611h0361143.gif" alt="(CHINESE CHARACTER)">)
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>and</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CONCORD MEDICAL SERVICES HOLDINGS LIMITED</B>

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="92%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><FONT style="font-variant: SMALL-CAPS">Page</FONT></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 1 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Definitions</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;1.01<I>. Definitions</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;1.02<I>. Other Definitional and Interpretative Provisions</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 18pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 2 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Issuance and Subscription</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.01<I>. Issuance and Subscription</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.02. <I>Closing</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.03. <I>Additional Subscription Right</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 18pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 3 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top">
    <TD>&nbsp;</TD>
</tr>

<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Mandatory and Optional Additional Investments</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.01. <I>Mandatory Additional Investment</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.02. <I>Optional Additional Investment</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 19pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 4 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Earning Adjustments</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;4.01<I>. Calculation of 2008 Net Income</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;4.02<I>. Adjustment with respect to the Subscription</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;4.03<I>. Adjustment with respect to the Carlyle Loan Conversion</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;4.04<I>. Adjustment with respect to the Additional Investment</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;4.05. <I>Procedure of Adjustment</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 18pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 5 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Representations and Warranties Regarding the Group</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.01<I>. Corporate Status</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.02<I>. Power and Authority; Corporate Authorization</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.03<I>. Enforceability</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.04<I>. Noncontravention</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.05<I>. Governmental Authorization</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.06<I>. Capitalization of the Company</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.07<I>. Capitalization of the PRC Subsidiaries</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.08<I>. Other Group Company</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.09<I>. Financial Statements</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.10<I>. Books And Records</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.11<I>. No Material Adverse Effect</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.12<I>. No Material Liabilities</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.13<I>. Absence of Changes</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="92%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><FONT style="font-variant: SMALL-CAPS">Page</FONT></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.14<I>. Compliance with Laws</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.15<I>. No Litigation</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.16<I>. No Default</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.17<I>. Property; Liens</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.18<I>. Tax</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.19<I>. Affiliate Transactions</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.20<I>. Intellectual Property</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.21<I>. Contracts</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.22<I>. Environmental Matters</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.23<I>. Employees, Labor Matters, Etc.</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.24<I>. Licenses and Permits</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.25<I>. Representations</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.26<I>. Disclosure</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 18pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 6 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS">Representations and Warranties Regarding the Founders and the </font></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">Controlling Shareholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.01<I>. Power and Authority</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.02<I>. Enforceability</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.03<I>. Noncontravention</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.04<I>. Governmental Authorization</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.05<I>. Ownership of Shares</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 18pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 7 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS">Representations and Warranties of Investors </FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.01<I>. Corporate Status</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.02<I>. Power And Authority</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.03<I>. Enforceability</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.04<I>. Noncontravention</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.05<I>. Purchase for Investment</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.06<I>. Legends</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.07<I>. Litigation</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 18pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 8 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Covenants of the Group, Founders and Controlling Shareholders</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.01<I>. Conduct of the Company</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.02<I>. Use of Proceeds</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.03<I>. Information Rights</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.04<I>. Inspection Right</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.05<I>. Compliance with Law</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.06<I>. Books and Records</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.07<I>. Restructuring</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.08<I>. Other Transaction Documents</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.09<I>. Amended And Restated Memorandum And Articles</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="92%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><FONT style="font-variant: SMALL-CAPS">Page</FONT></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.10<I>. Adoption of International Accounting Standards</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.11<I>. IPO</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.12<I>. Acquisition of Shenzhen Our New Medical Technology Co. Ltd</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.13. <I>Employment Contracts</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.14<I>. Non-Competition Agreement</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.15<I>. Intellectual Property Rights</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.16<I>. Employee Stock Options</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 18pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 9 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Covenants of All Parties</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.01. <I>Best Efforts; Further Assurance</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.02. <I>Certain Filings</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.03. <I>Public Announcements</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 18pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 10 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Conditions to Closing</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Section&nbsp;10.01. <I>Conditions to Obligations of the Investors</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 18pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 11 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Survival; Indemnification</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.01. <I>Survival</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.02. <I>Indemnification</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.03. <I>Procedures</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 18pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 12 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Termination</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;12.01<I>. Grounds for Termination</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;12.02<I>. Effect of Termination</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">44</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 18pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 13 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Miscellaneous</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.01. <I>Notices</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.02. <I>Amendments and Waivers</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.03<I>. Disclosure Schedule&nbsp;References</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.04. <I>Expenses</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.05. <I>Successors and Assigns</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.06. <I>Governing Law</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.07. <I>Jurisdiction</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.08. <I>WAIVER OF JURY TRIAL</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.09. <I>Counterparts; Effectiveness; Third Party Beneficiaries</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.10. <I>Entire Agreement</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.11. <I>Severability</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->iii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="92%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><FONT style="font-variant: SMALL-CAPS">Page</FONT></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.12. <I>Specific Performance</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;13.13. <I>Joint Drafting</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;A
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Shareholders&#146; Agreement</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Annex I
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Section&nbsp;11.01 for the Amended and Restated Convertible Loan
Agreement</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Annex II
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Provisions to be Included in the Amended and Restated Memorandum
and Articles</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Disclosure Schedules
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->iv<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SHARE SUBSCRIPTION AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AGREEMENT (this &#147;<B>Agreement</B>&#148;) dated as of February&nbsp;5, 2008 among (1)&nbsp;CICC Sun Company Limited,
a company incorporated under the laws of the British Virgin Islands (&#147;<B>CICC</B>&#148;), (2)&nbsp;Carlyle Asia
Growth Partners III, L.P., a limited partnership formed under the laws of the Cayman Islands
(&#147;<B>CAGP</B>&#148;), (3)&nbsp;CAGP III Co-Investment III, L.P. (&#147;<B>CAGP Co-Invest</B>&#148;, together with CAGP, &#147;<B>Carlyle</B>&#148;),
(4)&nbsp;Liu Haifeng, a PRC citizen with passport number G19230849 (&#147;<B>Mr.&nbsp;Liu</B>&#148;), (5)&nbsp;Steve Sun, a US
citizen with passport number 203018867 (&#147;<B>Mr.&nbsp;Sun</B>&#148;), (6)&nbsp;Yang Jianyu, a PRC citizen with passport
number G04036294 (&#147;<B>Mr.&nbsp;Yang</B>&#148;, together with Mr.&nbsp;Liu and Mr.&nbsp;Sun, the &#147;<B>Founders</B>&#148;), (7)&nbsp;Bona Liu, a
New Zealand citizen with passport number EA713283, (&#147;<B>Ms.&nbsp;Liu</B>&#148;, together with Mr.&nbsp;Sun and Mr.&nbsp;Yang,
the &#147;<B>Controlling Shareholders</B>&#148;), (8)&nbsp;Our Medical Services, Ltd., a company formed under the Laws of
the British Virgin Islands (&#147;<B>OMS</B>&#148;), (9)&nbsp;Ascendium Group Limited, a company formed under the Laws of
the British Virgin Islands (&#147;<B>AGL</B>&#148;), (10)&nbsp;Shenzhen Aohua Medical Services Co., Ltd.
(<IMG src="h03611h0361144.gif" alt="(CHINESE CHARACTER)">), a Sino-foreign joint venture formed under the laws of the PRC
(&#147;<B>Aohua</B>&#148;), and (11)&nbsp;Concord Medical Services Holdings Limited, a company incorporated under the
laws of the Cayman Islands (the &#147;<B>Company</B>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>W I T N E S S E T H:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Carlyle, OMS, AGL, the
 Founders and certain other persons party thereto entered into
a Convertible Loan Agreement dated as of November&nbsp;16, 2006 (the &#147;<B>Existing Loan Agreement</B>&#148;) pursuant
to which Carlyle made a loan to the Company in the aggregate principal amount of US$5,000,000 (the
&#147;<B>Existing Carlyle Loan</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the existing
shareholders of AGL intend to transfer all of their equity interests in
AGL to the Company in exchange for corresponding equity interests in the Company, causing the
Company to become the sole shareholder of AGL (the &#147;<B>Restructuring</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, after the Restructuring, the parties to the Existing Loan Agreement intend to amend
and restate it by a new convertible loan agreement (the &#147;<B>Amended and Restated Convertible Loan
Agreement</B>&#148;) under which OMS will transfer its rights and obligations under the Existing Loan
Agreement to the Company and Section&nbsp;11.01 of the Existing Loan Agreement will be replaced in whole
by the provision set forth in <B>Annex I </B>attached hereto;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, after the Restructuring, the Company desires to issue and sell to each of CICC and
Carlyle and each of CICC and Carlyle desires to subscribe for a number of Series&nbsp;A redeemable
convertible preferred shares, par value
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">US$0.05 per share, of the Company (the &#147;<B>Series&nbsp;A Shares</B>&#148;), on the terms and conditions set
forth in this Agreement (the &#147;<B>Subscription</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, simultaneously with the consummation of the Subscription, the Existing Carlyle Loan
will be converted into a number of Series&nbsp;A Shares pursuant to the Amended and Restated Convertible
Loan Agreement (the &#147;<B>Carlyle Loan Conversion</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the promises and the mutual covenants and agreements
contained herein and intending to be legally bound hereby, the parties hereto agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 1</B><BR>
<FONT style="font-variant: SMALL-CAPS">Definitions</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.01<I>. Definitions. </I>(a)&nbsp;The following terms, as used herein, have the following
meanings:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person directly or indirectly
controlling, controlled by, or under common control with such Person; <I>provided </I>that (i)&nbsp;no
securityholder of the Company shall be deemed an Affiliate of any other securityholder of the
Company solely by reason of any equity or debt investment in the Company and (ii)&nbsp;with respect to
any Person who is an individual, the spouse or any lineal descendant, sibling or parent of such
Person shall also be deemed an Affiliate of such specified Person. For the purpose of this
definition, the term &#147;<B>control</B>&#148; (including, with correlative meanings, the terms &#147;<B>controlling</B>&#148;,
&#147;<B>controlled by</B>&#148; and &#147;<B>under common control with</B>&#148;), as used with respect to any Person, shall mean
the possession, directly or indirectly, of the power to direct or cause the direction of the
management and policies of such Person, whether through the ownership of voting interests, by
contract or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Amended and Restated Memorandum and Articles</B>&#148; means the Amended and Restated Memorandum and
Articles of the Company to be adopted by the board of directors and shareholders of the Company by
the Closing Date in a form agreed to by the Investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Balance Sheet</B>&#148; means the audited consolidated balance sheet of the Company and its
Subsidiaries as of June&nbsp;30, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Balance Sheet Date</B>&#148; means June&nbsp;30, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Business Day</B>&#148; means a day, other than Saturday, Sunday or other day on which commercial banks
in either the US, Hong Kong or the PRC are authorized or required by applicable Laws to close.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Carlyle Director</B>&#148; shall have the meaning ascribed to it in the Shareholders&#146; Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>CICC Director</B>&#148; shall have the meaning ascribed to it in the Shareholders&#146; Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Closing Date</B>&#148; means the date of Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Consent</B>&#148; means any consent, approval, authorization, waiver, permit, grant, franchise,
concession, agreement, license, certificate, exemption, order, registration, declaration, filing,
report or notice of, with or to any Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Contract</B>&#148; means, with respect to any specified Person, all loan agreements, indentures,
letters of credit (including related letter of credit applications and reimbursement obligations),
mortgages, security agreements, pledge agreements, deeds of trust, bonds, notes, guarantees, surety
obligations, warranties, licenses, franchises, permits, powers of attorney, purchase orders,
leases, and other agreements, contracts, instruments, obligations, offers, commitments,
arrangements and understandings, written or oral, to which the specified Person is a party or by
which it or any of its Properties may be bound or affected.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Conversion Date</B>&#148; means the date on which the Mandatory Convertible Loan is converted pursuant
to the Mandatory Convertible Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Environmental Laws</B>&#148; means any Laws or any agreement with any Governmental Authority or other
third party, relating to human health and safety, the environment or to Hazardous Substances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Environmental Permits</B>&#148; means all permits, licenses, franchises, certificates, approvals and
other similar authorizations of Governmental Authorities relating to or required by Environmental
Laws and affecting, or relating in any way to, the business of the Company or any of its
Subsidiaries as currently conducted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Existing Carlyle Loan Conversion Amount</B>&#148; means a number in RMB equal to the RMB equivalent of
the sum of (i)&nbsp;US$5,000,000 plus (ii)&nbsp;the accrued and unpaid interest on the Existing Carlyle Loan
as of the Closing Date calculated with the spot exchange rate between US dollars and RMB as quoted
by the People&#146;s Bank of China on November&nbsp;28, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Fully Diluted</B>&#148; means, with respect to any class of the Company Securities, the aggregate
amount of such class issued or issuable in respect of securities convertible into or exchangeable
for such class, all options, warrants and other rights to purchase or subscribe for such class or
securities convertible into or exchangeable for such class; <I>provided </I>that, if any of the foregoing
options, warrants or other rights to purchase or subscribe for such class of the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Securities are subject to vesting, the Company Securities subject to vesting shall be included
in the definition of &#147;Fully-Diluted&#148; only upon and to the extent of such vesting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>GAAP</B>&#148; means generally accepted accounting principles in the PRC, as in effect from time to
time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Government Official</B>&#148; means (i)&nbsp;any officer or employee of any Governmental Authority, or any
entity or enterprise owned or controlled by such Governmental Authority, or any instrumentality
thereof, or of a public international organization, or any natural person acting in an official
capacity for or on behalf of any such Governmental Authority, entity, enterprise or instrumentality
or any such public international organization; (ii)&nbsp;any candidate for political office; or (iii)
any person who holds or held a prominent public position in the PRC or any other country (including
its political subdivisions), including head of state, senior government, judicial or military
official, official of a political party, candidate for political office, or senior executive of a
state-owned enterprise of national importance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Governmental Authority</B>&#148; means any transnational, domestic or foreign national, provincial,
federal, state or local, governmental authority, department, court, agency or official, including
any political subdivision thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Group</B>&#148; means, collectively, the Company, AGL, OMS, Aohua and their respective Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Group Company</B>&#148; means any member of the Group.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Hazardous Substances</B>&#148; means any pollutant, contaminant, waste or chemical or any toxic,
radioactive, ignitable, corrosive, reactive or otherwise hazardous substance, waste or material, or
any substance, waste or material having any constituent elements displaying any of the foregoing
characteristics, including petroleum, its derivatives, by-products and other hydrocarbons, and any
substance, waste or material regulated under any Environmental Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Hong Kong</B>&#148; means the Hong Kong Special Administrative Region.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IFRS</B>&#148; means the International Financial Reporting Standards, as in effect from time to time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Indebtedness</B>&#148; means, with respect to any Person, without duplication, (i)&nbsp;all obligations of
such Person for borrowed money, or with respect to deposits or advances of any kind, (ii)&nbsp;all
obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (iii)&nbsp;all
obligations of such Person upon which interest charges are customarily paid (other than trade
payables incurred in the ordinary course of business consistent with past practices), (iv)&nbsp;all
obligations of such Person under conditional sale or other title retention agreements relating
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to any property purchased by such Person, (v)&nbsp;all obligations of such Person issued or assumed
as the deferred purchase price of property or services (excluding obligations of such Person to
creditors for raw materials, inventory, services and supplies incurred in the ordinary course of
business consistent with past practices), (vi)&nbsp;all lease obligations of such Person capitalized on
the books and records of such Person, (vii)&nbsp;all obligations of others secured by a Lien on property
or assets owned or acquired by such Person, whether or not the obligations secured thereby have
been assumed, (viii)&nbsp;all obligations of such Person under interest rate, currency or commodity
derivatives or hedging transactions (valued at the termination value thereof), (ix)&nbsp;all letters of
credit or performance bonds issued for the account of such Person (excluding letters of credit
issued for the benefit of suppliers to support accounts payable to suppliers incurred in the
ordinary course of business consistent with past practices) and (x)&nbsp;all guarantees and arrangements
having the economic effect of a guarantee of such Person of any Indebtedness of any other Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Intellectual Property Rights</B>&#148; means (i)&nbsp;inventions, whether or not patentable, reduced to
practice or made the subject of one or more pending patent applications, (ii)&nbsp;national and
multinational statutory invention registrations, patents and patent applications (including all
reissues, divisions, continuations, continuations-in-part, extensions and reexaminations thereof)
registered or applied for in the PRC and all other nations throughout the world, all improvements
to the inventions disclosed in each such registration, patent or patent application, (iii)
trademarks, service marks, trade dress, logos, domain names, trade names and corporate names
(whether or not registered) in the PRC and all other nations throughout the world, including all
variations, derivations, combinations, registrations and applications for registration of the
foregoing and all goodwill associated therewith, (iv)&nbsp;copyrights (whether or not registered) and
registrations and applications for registration thereof in the PRC and all other nations throughout
the world, including all derivative works, moral rights, renewals, extensions, reversions or
restorations associated with such copyrights, now or hereafter provided by law, regardless of the
medium of fixation or means of expression, (v)&nbsp;computer software (including source code, object
code, firmware, operating systems and specifications), (vi)&nbsp;trade secrets and, whether or not
confidential, business information (including pricing and cost information, business and marketing
plans and customer and supplier lists) and know-how (including manufacturing and production
processes and techniques and research and development information), (vii)&nbsp;industrial designs
(whether or not registered), (viii)&nbsp;databases and data collections, (ix)&nbsp;copies and tangible
embodiments of any of the foregoing, in whatever form or medium, (x)&nbsp;all rights to obtain and
rights to apply for patents, and to register trademarks and copyrights, (xi)&nbsp;all rights in all of
the foregoing provided by treaties, conventions and common law and (xii)&nbsp;all rights to sue or
recover and retain damages and costs and attorneys&#146; fees for past, present and future infringement
or misappropriation of any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Investors</B>&#148; means CICC, CAGP and CAGP Co-Invest.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IPO</B>&#148; means an initial public offering and listing of the Ordinary Shares (or, in lieu thereof
and as mutually agreed by the Investors and the Company, equity securities of (i)&nbsp;any holding
company holding the issued share capital of the Company or (ii)&nbsp;any Subsidiary of the Company) on
an internationally recognized stock exchange.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IPO Date</B>&#148; means the date on which the IPO is consummated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Laws</B>&#148; means any national, provincial, federal, state or local law (statutory, common or
otherwise), constitution, treaty, convention, ordinance, code, rule, regulation, order, injunction,
judgment, decree, ruling or other similar requirement enacted, adopted, promulgated or applied by
any Governmental Authority, as amended unless expressly specified otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licenses</B>&#148; means all licenses, consents, authorizations, confirmations, certificates or
approvals.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed Intellectual Property Rights</B>&#148; means all Intellectual Property Rights owned by a
third party and licensed or sublicensed to any Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Lien</B>&#148; means, with respect to any property or asset, any mortgage, lien, pledge, charge,
security interest, encumbrance or other adverse claim of any kind in respect of such property or
asset. For the purposes of this Agreement, a Person shall be deemed to own subject to a Lien any
property or asset which it has acquired or holds subject to the interest of a vendor or lessor
under any conditional sale agreement, capital lease or other title retention agreement relating to
such property or asset.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Mandatory Loan Conversion Amount</B>&#148; means, with respect to any conversion of the Mandatory
Convertible Loan pursuant to the Mandatory Convertible Loan Agreement, a number equal to the RMB
equivalent of the sum of (x)&nbsp;US$20,000,000 <I>plus </I>(y)&nbsp;the accrued but unpaid interest on the
Mandatory Convertible Loan as of the Conversion Date calculated with the spot exchange rate between
US dollars and RMB as quoted by the People&#146;s Bank of China on the Loan Extension Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Material Adverse Effect</B>&#148; means a material adverse effect on the condition (financial or
otherwise), business, assets, results of operations or prospects of the Company and its
Subsidiaries, taken as whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Ordinary Shares</B>&#148; means the ordinary shares, par value US$0.05 per share, of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Owned Intellectual Property Rights</B>&#148; means all Intellectual Property Rights owned by any Group
Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Person</B>&#148; means an individual, corporation, partnership, limited liability company,
association, trust or other entity or organization, including a Governmental Authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Pre-Closing Tax Period</B>&#148; means any Tax period ending on or before the Closing Date; and, with
respect to a Tax period that begins on or before the Closing Date and ends thereafter, the portion
of such Tax period ending on the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Pre-Conversion Shares</B>&#148; means, with respect to any conversion of the Mandatory Convertible
Loan pursuant to the Mandatory Convertible Loan Agreement, a number of the outstanding Ordinary
Shares as of the Conversion Date (without taking into effect of such conversion), calculated on a
Fully-Diluted basis (which for the purposes of this definition shall exclude any Ordinary Shares
issuable upon the exercise of any employee stock options).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>PRC</B>&#148; means the People&#146;s Republic of China, excluding, for purposes of this Agreement only,
Hong Kong, the Macau Special Administrative Region and Taiwan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Purchase Price</B>&#148; means, with respect to any Investor, the RMB equivalent of an amount of US
dollars set forth opposite the name of such Investor in Schedule&nbsp;1.01 calculated with the spot
exchange rate between US dollars and RMB as quoted by the People&#146;s Bank of China on the Closing
Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>RMB</B>&#148; means renminbi, the lawful currency of the PRC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Shareholders&#146; Agreement</B>&#148; means the Shareholders&#146; Agreement by and among the Company, the
Investors, the Controlling Shareholders and the other shareholders of the Company to be entered
into on the Closing Date substantially in the form attached as <B>Exhibit&nbsp;A </B>hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Subsidiary</B>&#148; means, with respect to any Person, any entity of which securities or other
ownership interests having ordinary voting power to elect a majority of the board of directors or
other persons performing similar functions are at the time directly or indirectly owned by such
Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Tax</B>&#148; means (a)&nbsp;taxes on income, profits and gains, and (b)&nbsp;all other taxes, levies, duties,
imposts, charges and withholdings of any nature, in each case imposed, levied, collected, withheld
or assessed by (or on behalf of) any Governmental Authority in any jurisdiction, including any
excise, customs, property, sales, transfer, franchise, turnover and payroll taxes and other
benefits related tax and stamp duties, and any payment whatsoever which the relevant Person may be
or become bound to make to any other Person as a result of the discharge by such other Person of
any tax which the relevant Person has failed to discharge, together with all penalties, charges and
interest relating to any of the foregoing or to any late or incorrect return in respect of any of
them, and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">regardless of whether such taxes, levies, duties, imposts, charges, withholdings, penalties
and interest are chargeable directly or primarily against or attributable directly or primarily to
the relevant Person or any other Person and of whether any amount in respect of them is recoverable
from any other Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Total Closing Investment</B>&#148; means the sum of (x)&nbsp;the RMB equivalent of US$10,000,000 calculated
with the spot exchange rate between US dollars and RMB as quoted by the People&#146;s Bank of China on
the Closing Date <I>plus </I>(y)&nbsp;the Existing Carlyle Loan Conversion Amount.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Transaction Documents</B>&#148; means this Agreement, the Shareholders&#146; Agreement, the Amended and
Restated Convertible Loan Agreement and the Amended and Restated Memorandum and Articles and each
and all other agreements, certificates or other documents required to be executed by any of the
foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>2008 Audited Financial Statements</B>&#148; means the consolidated financial statements of the
Company&#146;s fiscal year ending December&nbsp;31, 2008 audited in accordance with the IFRS applied on a
consistent basis by an internationally recognized accounting firm designated by the Investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>US</B>&#148; means the United States of America.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>US dollars</B>&#148; means United States dollars, the lawful currency of the US.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>US GAAP</B>&#148; means generally accepted accounting principles in the US, as in effect from time to
time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each of the following terms is defined in the Section set forth opposite such term:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Section</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Additional Carlyle Purchase Price</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.02</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Additional Carlyle Purchased Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.02</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Amended and Restated Convertible Loan Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Amended and Restated Memorandum and Articles</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">10.01</TD>
    <TD nowrap>(i)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">AGL</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Aohua</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Audited Financial Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5.09</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Books and Records</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5.10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CAGP</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CAGP Co-Invest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Carlyle</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Carlyle Loan Conversion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Recitals</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Section</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CICC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.02</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company Securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">5.06</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Controlling Shareholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Conversion Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">3.01(b)(iii)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Damages</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11.02</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">e-mail</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13.01</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Existing Carlyle Loan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Recitals</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Existing Loan Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Founders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Indemnified Party</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11.03</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Indemnifying Party</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11.03</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Investors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Intellectual Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">5.20</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Lease Permit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">5.01</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loan Extension Date</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">3.01</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mandatory Additional Investment Right</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">3.01</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mandatory Convertible Loan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">3.01</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mandatory Convertible Loan Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">3.01</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mr.&nbsp;Liu</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mr.&nbsp;Sun</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mr.&nbsp;Sun Holding Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">6.05</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mr.&nbsp;Yang</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mr.&nbsp;Yang Holding Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">6.05</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Ms.&nbsp;Liu</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Ms.&nbsp;Liu Holding Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">6.05</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">OMS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Optional Additional Investment Right</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.02</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Ordinary Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">PRC Subsidiary</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">5.01</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Purchased Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2.01</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Put Option</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.01</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Restructuring</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;A Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Recitals</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Subscription</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Subsidiary Securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">5.08</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Warranty Breach</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11.02</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.02<I>. Other Definitional and Interpretative Provisions. </I>The words &#147;hereof&#148;, &#147;herein&#148;
and &#147;hereunder&#148; and words of like import used in this Agreement shall refer to this Agreement as a
whole and not to any particular provision of this Agreement. The captions herein are included for
convenience of reference only and shall be ignored in the construction or interpretation hereof.
References to Articles, Sections, Exhibits and Schedules are to Articles, Sections,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibits and Schedules of this Agreement unless otherwise specified. All Exhibits and
Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this
Agreement as if set forth in full herein. Any capitalized terms used in any Exhibit or Schedule
but not otherwise defined therein, shall have the meaning as defined in this Agreement. Any
singular term in this Agreement shall be deemed to include the plural, and any plural term the
singular. Whenever the words &#147;include&#148;, &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they
shall be deemed to be followed by the words &#147;without limitation&#148;, whether or not they are in fact
followed by those words or words of like import. &#147;Writing&#148;, &#147;written&#148; and comparable terms refer
to printing, typing and other means of reproducing words (including electronic media) in a visible
form. References to any agreement or contract are to that agreement or contract as amended,
modified or supplemented from time to time in accordance with the terms hereof and thereof;
<I>provided </I>that with respect to any agreement or contract listed on any schedules hereto, all such
amendments, modifications or supplements must also be listed in the appropriate schedule.
References to any Person include the successors and permitted assigns of that Person. References
from or through any date mean, unless otherwise specified, from and including or through and
including, respectively. References to &#147;law&#148;, &#147;laws&#148; or to a particular statute or law shall be
deemed also to include an and all applicable Laws.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 2</B><BR>
<FONT style="font-variant: SMALL-CAPS">Issuance and Subscription</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.01<I>. Issuance and Subscription. </I>Upon the terms and subject to the conditions of
this Agreement, the Company agrees to issue and sell to each Investor, and each Investor agrees to
purchase from the Company and subscribe for a number of Series&nbsp;A Shares (such Investor&#146;s &#147;<B>Purchased
Shares</B>&#148;) equal to (x)&nbsp;the number of outstanding Ordinary Shares as of the Closing Date immediately
prior to the consummation of the Subscription and the Carlyle Loan Conversion, calculated on a
Fully-Diluted basis, <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which is equal to its Purchase
Price, and the denominator of which is equal to (i)&nbsp;RMB770,000,000 <I>minus </I>(ii)&nbsp;the RMB equivalent of
US$10,000,000 calculated with the spot exchange rate between US dollars and RMB as quoted by the
People&#146;s Bank of China on the Closing Date <I>minus </I>(iii)&nbsp;the Existing Carlyle Loan Conversion Amount.
Each Investor shall pay, as provided in Section&nbsp;2.02, the amount set forth opposite its the name
in Schedule&nbsp;1.01 in exchange for its Purchased Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.02. <I>Closing</I>. The closing (the &#147;<B>Closing</B>&#148;) of the issuance and subscription of the
Purchased Shares hereunder shall take place at a location to be mutually agreed to by the Investors
and the Company, as soon as possible, but in no event later than fifteen (15)&nbsp;Business Days, after
satisfaction of the conditions
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">set forth in Article&nbsp;10, or at such other time or place as the Investors and the Company may
agree. At the Closing:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) each Investor shall deliver to the Company an amount of US dollars equal to the
amount set forth opposite the name of such Investor in Schedule&nbsp;1.01 in immediately
available funds by wire transfer to an account specified in a written instrument signed by
a director of the Company and delivered to the Investors at least two Business Days prior
to the Closing or by other payment methods mutually agreed to between the Company and the
Investors prior to the Closing; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Company shall deliver to each Investor (i)&nbsp;a certificate representing such
Investor&#146;s Purchased Shares, duly authorized and validly issued, and (ii)&nbsp;a copy of the
updated register of members of the Company dated the Closing Date and duly certified by a
duly authorized director of the Company evidencing such Investor&#146;s ownership of its
Purchased Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.03. <I>Additional Subscription Right</I>. (a)&nbsp;If CICC fails to perform its obligations
under Section&nbsp;2.02(a), Carlyle shall have the right but not the obligation to subscribe for an
additional number of Series&nbsp;A Shares equal to the number of CICC&#146;s Purchased Shares and shall be
entitled to all the rights that CICC would have been entitled to hereunder if CICC had performed
its obligations under Section&nbsp;2.02(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If Carlyle fails to perform its obligations under Section&nbsp;2.02(a), CICC shall have the
right but not the obligation to subscribe for an additional number of Series&nbsp;A Shares equal to
Carlyle&#146;s Purchased Shares and shall be entitled to all the rights that Carlyle would have been
entitled to hereunder if Carlyle had performed its obligations under Section&nbsp;2.02(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If Carlyle or CICC, respectively, has exercised it right under this Section&nbsp;2.03, Carlyle
or CICC, respectively, shall have the right to organize and lead in the next round of investment in
the Company prior to the IPO.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 3</B><BR>
<FONT style="font-variant: SMALL-CAPS">Mandatory and Optional Additional Investments</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.01. <I>Mandatory Additional Investment</I>. (a)&nbsp;The Company shall have the right (the
&#147;<B>Mandatory Additional Investment Right</B>&#148;) to require Carlyle to extend to the Company a convertible
loan in the principal amount of US$20,000,000 (the &#147;<B>Mandatory Convertible Loan</B>&#148;) by March&nbsp;31, 2008
pursuant to the terms and conditions set forth in this Section&nbsp;3.01. The Company may exercise the
Mandatory Additional Investment Right by delivering to Carlyle a written notice setting forth the
date on which Carlyle will be required to extend the Mandatory Convertible Loan (the &#147;<B>Loan
Extension Date</B>&#148;), which written
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">notice shall be received by Carlyle no later than 5 Business Days prior to the Loan Extension
Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;On or before the Loan Extension Date, the Company and Carlyle shall enter into a loan
agreement (the &#147;<B>Mandatory Convertible Loan Agreement</B>&#148;) with customary terms and conditions
(including customary closing conditions such as the absence of any Material Adverse Effect between
the Closing Date and the Loan Extension Date), including the following terms:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Mandatory Convertible Loan shall bear interest on the principal amount from
the Loan Extension Date to the earlier of (A)&nbsp;the date on which the Mandatory Convertible
Loan is paid in full and (B)&nbsp;the date the Mandatory Convertible Loan is converted pursuant
to the conversion right set forth in Section&nbsp;3.01(b)(iii) or Section&nbsp;3.01(b)(iv), at a
rate per annum equal to 9%, computed on the basis of a 360-day year and the actual number
of days elapsed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Unless the Mandatory Convertible Loan is converted pursuant to Section
3.01(b)(iii) or Section&nbsp;3.01(b)(iv), the principal amount of and the accrued interest on
the Mandatory Convertible Loan shall be repaid by the Company on December&nbsp;31, 2009. The
Company may not prepay the Mandatory Convertible Loan prior to December&nbsp;31, 2009.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Carlyle shall have the right, at its sole option, to convert the Mandatory
Convertible Loan into a number of Ordinary Shares (the &#147;<B>Conversion Shares</B>&#148;) as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) Carlyle shall have the right, at its sole option, to convert the
Mandatory Convertible Loan into the Conversion Shares at any time during a
period starting from (and including) the day which immediately follows the
Closing Date to (and including) August&nbsp;31, 2008. If Carlyle exercises such
conversion right, the Mandatory Convertible Loan shall be converted into a
number of Conversion Shares equal to (x)&nbsp;the Pre-Conversion Shares <I>multiplied </I>by
(y)&nbsp;a ratio, the numerator of which is the Mandatory Loan Conversion Amount, and
the denominator of which is equal to (I)&nbsp;RMB1,100,000,000 <I>minus </I>(II)&nbsp;the
Mandatory Loan Conversion Amount, subject to Carlyle&#146;s right to acquire
additional Ordinary Shares from the Controlling Shareholders pursuant to Section
4.04; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) Carlyle shall have the right, at its sole option, to convert the
Mandatory Convertible Loan into the Conversion Shares at any time during a
period starting from (and including) the date on which the 2008 Audited
Financial Statements are completed to (and including) April&nbsp;29, 2009. If
Carlyle exercises
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">such conversion right, the Mandatory Convertible Loan shall be converted
into a number of Conversion Shares equal to (x)&nbsp;the Pre-Conversion Shares
<I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which is the Mandatory Loan
Conversion Amount, and the denominator of which is equal to (I)&nbsp;10 times of the
2008 Net Income (as defined below) <I>minus </I>(II)&nbsp;the Mandatory Loan Conversion
Amount.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) If the IPO Date occurs after August&nbsp;31, 2008 but prior to the completion of the
2008 Audited Financial Statements and the Mandatory Convertible Loan is outstanding as of
the IPO Date, the Mandatory Convertible Loan shall be automatically converted, on the IPO
Date, into a number of Ordinary Shares equal to (x)&nbsp;the Pre-Conversion Shares <I>multiplied</I>
by (y)&nbsp;a ratio, the numerator of which is the Mandatory Loan Conversion Amount, and the
denominator of which is equal to (I)&nbsp;10 times the projected consolidated after-tax net
income of the Company for the Company&#146;s fiscal year ending December&nbsp;31, 2008, as disclosed
to the public in the IPO (<I>provided </I>that the result of the calculation in this clause (I)
shall not exceed <FONT style="font-family: symbol">&#97;</FONT>  the number of the outstanding Ordinary Shares immediately prior to
the IPO Date <I>multiplied </I>by (&#181;) the lower end of the last price range disclosed to the
public in connection with the IPO) <I>minus </I>(II)&nbsp;the Mandatory Loan Conversion Amount,
subject to Carlyle&#146;s right to acquire additional Ordinary Shares from the Controlling
Shareholders pursuant to Section&nbsp;4.04.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.02. <I>Optional Additional Investment</I>. If the Company has not exercised the Mandatory
Additional Investment Right by March&nbsp;31, 2008, Carlyle shall have the right (the &#147;<B>Optional
Additional Investment Right</B>&#148;) to purchase and subscribe for, at any time by August&nbsp;31, 2008, a
number of Series&nbsp;A Shares (the &#147;<B>Additional Carlyle Purchased Shares</B>&#148;) for US$20,000,000. The
Additional Carlyle Purchased Shares shall equal to (x)&nbsp;the number of outstanding Ordinary Shares as
of the date of such purchase immediately prior to the consummation of such purchase, calculated on
a Fully-Diluted basis (which for the purposes of this Section&nbsp;3.02 shall exclude any Ordinary
Shares issuable upon the exercise of any employee stock options), <I>multiplied </I>by (y)&nbsp;a ratio, the
numerator of which is equal to the RMB equivalent of US$20,000,000 calculated with the spot
exchange rate between US dollars and RMB as quoted by the People&#146;s Bank of China on the date of
such purchase (the &#147;<B>Additional Carlyle Purchase Price</B>&#148;), and the denominator of which is equal to
(i)&nbsp;RMB1,100,000,000 <I>minus </I>(ii)&nbsp;the Additional Carlyle Purchase Price. In order to exercise the
Optional Additional Investment Right, Carlyle shall deliver a written notice to the Company no
later than 5 Business Days prior to the proposed purchase date set forth in such notice.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 4</B><BR>
<FONT style="font-variant: SMALL-CAPS">Earning Adjustments</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.01<I>. Calculation of 2008 Net Income. </I>As soon as practicable and in any event within
ninety (90)&nbsp;days after the end of the Company&#146;s fiscal year ending December&nbsp;31, 2008, the Company
shall complete the 2008 Audited Financial Statements and on the same date of such completion
calculate its consolidated after-tax net income for such fiscal year (the &#147;<B>2008 Net Income</B>&#148;) based
on the 2008 Audited Financial Statements; <I>provided </I>that (i)&nbsp;the 2008 Net Income shall be calculated
in accordance with IFRS and shall be audited by an internationally recognized accounting firm
designated by the Investors; (ii)&nbsp;the 2008 Net Income shall not include any earnings obtained
through any disposition of any assets or business of the Company or any of its Subsidiaries (except
for earnings obtained through the disposition of non-operating assets of an aggregate value not
exceeding 10% of the 2008 Net Income); (iii)&nbsp;the 2008 Net Income shall not include any
extraordinary or non-recurring earnings (such earnings shall exclude recurring earnings obtained
through any merger, amalgamation or other business combination between the Company or any of its
Subsidiaries and any other entity) obtained by the Company or any of its Subsidiaries; and (iv)&nbsp;any
preferred dividend set forth in the Amended and Restated Memorandum and Articles shall not be
deemed expenses for the purposes of determining the 2008 Net Income.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.02<I>. Adjustment with respect to the Subscription. </I>If the 2008 Net Income is lower
than RMB110,000,000, the Controlling Shareholders shall, jointly and severally,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;transfer to each Investor free of charge a number of Ordinary Shares equal to (x)&nbsp;the
number of such Investor&#146;s Purchased Shares, <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which is
equal to (i)&nbsp;RMB770,000,000 <I>minus </I>(ii)&nbsp;7 times the 2008 Net Income, and the denominator of which is
equal to (I)&nbsp;7 times the 2008 Net Income <I>minus </I>(II)&nbsp;the Total Closing Investment; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;pay to each Investor the US dollar equivalent (calculated with the spot exchange rate
between US dollars and RMB as quoted by the People&#146;s Bank of China on the date of such payment) of
an amount equal to (x)&nbsp;the Purchase Price of such Investor, <I>multiplied </I>by (y)&nbsp;a ratio, the
numerator of which is equal to (i)&nbsp;RMB770,000,000 <I>minus </I>(ii)&nbsp;7 times the 2008 Net Income, and the
denominator of which is equal to (I)&nbsp;RMB770,000,000 <I>minus </I>(II)&nbsp;the Total Closing Investment,
<I>multiplied </I>by (z)&nbsp;0.3.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.03<I>. Adjustment with respect to the Carlyle Loan Conversion. </I>If the 2008 Net Income
is lower than RMB110,000,000, the Controlling Shareholders shall, jointly and severally,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;transfer to Carlyle free of charge a number of Ordinary Shares equal to (x)&nbsp;the number of
Series&nbsp;A Shares Carlyle acquired as a result of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Carlyle Loan Conversion <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which is equal to (i)
RMB770,000,000 <I>minus </I>(ii)&nbsp;7 times the 2008 Net Income, and the denominator of which is equal to (I)
7 times the 2008 Net Income <I>minus </I>(II)&nbsp;the Total Closing Investment; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;pay to Carlyle the US dollar equivalent (calculated with the spot exchange rate between US
dollars and RMB as quoted by the People&#146;s Bank of China on the date of such payment) of an amount
equal to (x)&nbsp;the Existing Carlyle Loan Conversion Amount, <I>multiplied </I>by (y)&nbsp;a ratio, the numerator
of which is equal to (i)&nbsp;RMB770,000,000 <I>minus </I>(ii)&nbsp;7 times the 2008 Net Income, and the denominator
of which is equal to (I)&nbsp;RMB770,000,000 <I>minus </I>(II)&nbsp;the Total Closing Investment, <I>multiplied </I>by (z)
0.3.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.04<I>. Adjustment with respect to the Additional Investment. </I>If the 2008 Net Income
is lower than RMB110,000,000, and if either (A)&nbsp;Carlyle has extended the Mandatory Convertible Loan
and the Mandatory Convertible Loan has been converted by August&nbsp;31, 2008 pursuant to Section
3.01(b)(iii)(A) or after August&nbsp;31, 2008 pursuant to Section&nbsp;3.01(b)(iv) or (B)&nbsp;Carlyle has
purchased the Additional Carlyle Purchased Shares prior to August&nbsp;31, 2008 pursuant to Section
3.02, the Controlling Shareholders shall, jointly and severally,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;transfer to Carlyle free of charge a number of Ordinary Shares equal to (x)&nbsp;the Conversion
Shares or the Additional Carlyle Purchased Shares, as applicable, <I>multiplied </I>by (y)&nbsp;a ratio, the
numerator of which is equal to (i)&nbsp;RMB1,100,000,000 <I>minus </I>(ii)&nbsp;10 times the 2008 Net Income, and
the denominator of which is equal to (I)&nbsp;10 times the 2008 Net Income <I>minus </I>(II)&nbsp;the Mandatory Loan
Conversion Amount or the Additional Carlyle Purchase Price, as applicable; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;pay to Carlyle the US dollar equivalent (calculated with the spot exchange rate between US
dollars and RMB as quoted by the People&#146;s Bank of China on the date of such payment) of an amount
equal to (x)&nbsp;the Mandatory Loan Conversion Amount or the Additional Carlyle Purchase Price, as
applicable, <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which is equal to (i)&nbsp;RMB1,100,000,000
<I>minus </I>(ii)&nbsp;10 times the 2008 Net Income, and the denominator of which is equal to (I)
RMB1,100,000,000 <I>minus </I>(II)&nbsp;the Mandatory Loan Conversion Amount or the Additional Carlyle Purchase
Price, as applicable, <I>multiplied </I>by (z)&nbsp;0.3.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.05. <I>Procedure of Adjustment</I>. The adjustments set forth in Sections&nbsp;4.02, 4.03 and
4.04 shall be made within 5 Business Days of the day on which the 2008 Net Income becomes
available. On the date on which the adjustments are to be made, the Controlling Shareholders shall
(a)&nbsp;deliver to each Investor a certificate representing the sum of the Ordinary Shares that such
Investor is entitled to pursuant to Sections&nbsp;4.02, 4.03 and 4.04, as applicable, duly endorsed or
accompanied by stock powers duly endorsed in blank, with any required transfer stamps affixed
thereto, and (b)&nbsp;deliver to each Investor the sum
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of US dollars that such Investor is entitled to receive pursuant to Sections&nbsp;4.02, 4.03 and
4.04, as applicable, in immediately available funds by wire transfer to an account specified in
writing delivered by such Investor at least two Business Days prior to such adjustment date or by
other payment methods mutually agreed to between such Investor and the Controlling Shareholders.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 5</B><BR>
<FONT style="font-variant: SMALL-CAPS">Representations and Warranties Regarding the Group</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Founders, the Controlling Shareholders, AGL, OMS, Aohua and the Company represents
and warrants to the Investors as of the date hereof and as of the Closing Date that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.01<I>. Corporate Status.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company is a company duly organized and validly existing in good standing under the
laws of the Cayman Islands. Ascendium Group Limited is a company duly organized and validly
existing in good standing under the laws of the British Virgin Islands. Our Medical Services, Ltd.
is a company duly organized and validly existing in good standing under the laws of the British
Virgin Islands. Shenzhen Aohua Medical Services Co., Ltd. is a Sino-foreign joint venture duly
organized and validly existing under the laws of the PRC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Group Company has full corporate power and all Consents of the applicable
Governmental Authorities necessary to own, lease and operate the assets and properties that it now
owns, leases and operates, and to carry on its business as now conducted and currently proposed to
be conducted. Schedule&nbsp;5.01(b) contains a complete and correct list of all Consents of the PRC
Governmental Authorities held by each of the Subsidiaries of the any Group Company established
under the laws of the PRC (each, a &#147; <B>PRC Subsidiary</B>&#148;) material to the conduct of their respective
business and the termination date of each such Consent. Except for (i)&nbsp;the Consents set forth in
Schedule&nbsp;5.01(b) and (ii)&nbsp;the permit for lease of the assets and properties of the Group required
by the Laws of the PRC (the &#147;<B>Lease Permit</B>&#148;), no other Consent of the PRC Governmental Authorities
is necessary for, or otherwise material to, the conduct of such business. All the Consents set
forth in Schedule&nbsp;5.01(b) are valid and subsisting and have not been terminated or become void or
terminable for any reason and no notice of termination or alleged breach of any condition of any
such Consent or suspension in respect of any such Consent has been received by any PRC Subsidiary.
Each PRC Subsidiary is materially in compliance with all the terms and conditions of, or relating
to, all such Consents and none of the PRC Subsidiaries has any reason to believe that any of such
Consents listed on Schedule&nbsp;5.01(b) will not be renewed on or prior to its termination date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each Group Company (except for the PRC Subsidiaries) is permitted under the Laws of its
jurisdiction of organization to carry on business
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">outside such jurisdiction and is in good standing in each jurisdiction where such
qualification is necessary.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company has delivered to the Investors a true and complete copy of the memorandum and
articles of association and other organizational documents of each Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The minute books of each Group Company that have heretofore been made available to the
Investors contain complete and accurate records, in all material respects, of all meetings and
other corporate actions of the respective directors and shareholders of such Group Company, and
correctly reflect all actions taken by such directors and shareholders since the respective date of
incorporation of such Group Company. To the extent that such minute books are deficient, all
material information not contained in such minutes has been conveyed by the Company to the
Investors in written form.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.02<I>. Power and Authority; Corporate Authorization.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each Group Company has full corporate power and authority to execute and deliver this
Agreement and each other Transaction Document to which it is a party and to perform its obligations
hereunder and thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The execution and delivery of this Agreement and each other Transaction Document to which
it is a party, the performance of the obligations hereunder and thereunder, and the consummation of
the transactions contemplated hereby and thereby, have been duly authorized by all requisite
corporate actions of each Group Company and no other corporate proceedings on the part of such
Group Company are necessary to authorize such execution, delivery or performance or to consummate
such transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.03<I>. Enforceability.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each Group Company has duly executed and delivered this Agreement and will execute and
deliver each other Transaction Document to which it is a party by the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;This Agreement constitutes, and each other Transaction Document to which it is a party
(when executed) will constitute, the legal, valid and binding obligations of each Group Company,
enforceable against such Group Company in accordance with the terms hereof and thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.04<I>. Non-contravention. </I>The execution, delivery and performance by each Group
Company of this Agreement and each other Transaction Document to which it is a party, and the
consummation of the transactions contemplated hereby and thereby, do not and will not:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;conflict with, contravene, result in a violation or breach of or default (with or without
the giving of notice or the lapse of time or both); or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;result in the creation of any Lien (or any obligation to create any Lien) upon any of the
properties or assets of any Group Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in each case under (w)&nbsp;any Laws applicable to or binding on any Group Company or any of its
assets or properties, (x)&nbsp;any order, injunction, writ or decree of any Governmental Authority or
any arbitral award to which any Group Company or any of its assets or properties is subject, (y)
the organizational documents of ay Group Company or (z)&nbsp;any Contract, or any other agreement or
instrument to which any Group Company is a party or by which any of its assets or properties may be
bound.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.05<I>. Governmental Authorization. </I>No Consent by any Governmental Authority or any
other Person is necessary or required in connection with the execution, delivery or performance by,
or enforcement against, any Group Company under this Agreement or any other Transaction Document to
which it is a party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.06<I>. Capitalization of the Company.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;On the date hereof, the share capital of the Company consists of US$50,000.00 divided into
1,000,000 shares of nominal or par value of US$0.05 each, of which 1 share is issued and
outstanding as of the date hereof. On the Closing Date, the share capital of the Company shall
consist of Ordinary Shares and Series&nbsp;A Preferred Shares as provided in the Amended and Restated
Memorandum and Articles.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as set forth in this Section&nbsp;5.06, there are no outstanding (i)&nbsp;shares of capital
stock or voting securities of the Company, (ii)&nbsp;securities of the Company convertible into or
exchangeable for shares of capital stock or voting securities of the Company or (iii)&nbsp;options or
other rights to acquire from the Company, or other obligation of the Company to issue, any capital
stock, voting securities or securities convertible into or exchangeable for capital stock or voting
securities of the Company (the items in Section&nbsp;5.06(b)(i), 5.06(b)(ii) and 5.06(b)(iii) being
referred to collectively as the &#147;<B>Company Securities</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;On the Closing Date, the Conversion Date, the date Carlyle purchases the Additional
Carlyle Purchased Shares and upon the conversion of the Series&nbsp;A Shares in accordance with the
Amended and Restated Memorandum and Articles, the Investors will acquire good and valid title to
the Series&nbsp;A Shares and Ordinary Shares, free and clear of any Lien, and such Series&nbsp;A Shares and
Ordinary Shares will have been duly authorized, validly issued, fully paid and non-assessable.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;There are no preemptive rights or similar rights on the part of any Person with respect to
the share capital of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Except for this Agreement, there is no agreement, arrangement or obligation of any kind
(and no authorization therefore has been given) obligating the Company or any other Person:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) to issue or sell, or cause to be issued or sold, any Company Securities; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) to repurchase, redeem or otherwise acquire any outstanding Company Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.07<I>. Capitalization of the PRC Subsidiaries. </I>(a)&nbsp;The registered capital of each PRC
Subsidiary is as set forth in Schedule&nbsp;5.07(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All of the registered capital of each PRC Subsidiary has been timely contributed, such
contribution has been duly verified by a certified accountant registered in the PRC and the
accounting firm employing such accountant, and the report of the certified accountant evidencing
such verification has been registered with the relevant Governmental Authority. There are no
resolutions pending to increase the registered capital of any PRC Subsidiary; and there are no
dividends which have accrued or been declared but are unpaid on the registered capital of any PRC
Subsidiary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.08<I>. Other Group Company. </I>(a)&nbsp;All members of the Group and their respective
jurisdictions of incorporation are identified on Schedule&nbsp;5.08(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As of the date hereof and as of the Closing Date, (I)&nbsp;OMS beneficially owns and will own
of record 90% of the registered capital of Aohua; and (II)&nbsp;AGL beneficially owns and will own of
record 100% of the outstanding shares of OMS. As of the date hereof, the Controlling Shareholders
indirectly own 60% of the outstanding shares of AGL. Immediately prior to the Closing, (A)&nbsp;the
Controlling Shareholders will indirectly own 60% of the outstanding shares of the Company and (B)
the Company will directly own 100% of the outstanding shares of AGL. Except as set forth in the
immediately preceding sentence, all of the outstanding capital stock or other voting securities of
each Group Company (other than the Company) is and will be duly owned by the Company, directly or
indirectly, free and clear of any Lien and free of any other limitation or restriction (including
any restriction on the right to vote, sell or otherwise dispose of such capital stock or other
voting securities). There are no outstanding (i)&nbsp;securities of any Group Company convertible into
or exchangeable for shares of capital stock or voting securities of any Group Company (other than
the Company) or (ii)&nbsp;options or other rights to acquire from any Group Company, or other obligation
of any Group Company to issue, any capital stock, voting securities or securities convertible into
or exchangeable for capital stock or voting securities of any Group Company (other than the
Company) (the items in Section
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5.08(b)(i) and Section&nbsp;5.08(b)(ii) being referred to collectively as the &#147;<B>Subsidiary
Securities</B>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;There are no preemptive rights or similar rights on the part of any Person with respect to
the share capital of any Group Company (other than the Company).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;There is no agreement, arrangement or obligation of any kind (and no authorization
therefore has been given) obligating any Group Company or any other Person:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) to issue or sell, or cause to be issued or sold, any Subsidiary Securities; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) to repurchase, redeem or otherwise acquire any outstanding Subsidiary
Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Except for the Group Companies set forth on Schedule&nbsp;5.08(a), no Group Company owns or
controls, directly or indirectly, any equity or other ownership interest in any Person. There is
no agreement, arrangement or obligation of any kind (and no authorization therefor has been given)
obligating any Group Company to purchase or acquire the ownership of any equity or other ownership
interest in any Person or to make investments in any Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.09<I>. Financial Statements. </I>(a)&nbsp;Schedule&nbsp;5.09(a) sets forth a true, correct and
complete copy of (i)&nbsp;the audited consolidated financial statements (the &#147;<B>Audited Financial
Statements</B>&#148;) of Aohua for the fiscal years ended December&nbsp;31, 2005 and 2006 and for the six months
ended June&nbsp;30, 2007, and (ii)&nbsp;unaudited management accounts of the Company and its Subsidiaries for
the six months ended December&nbsp;31, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Audited Financial Statements (i)&nbsp;were prepared in accordance with GAAP consistently
applied throughout the period covered thereby; (ii)&nbsp;fairly present the financial condition of the
Group as of the respective date thereof and their results of operations for the period covered
thereby in accordance with GAAP consistently applied throughout the period covered thereby; and
(iii)&nbsp;show all Indebtedness and other liabilities, direct or contingent, of the Group as of the
respective date thereof, including liabilities for Taxes, commitments and Indebtedness.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The unaudited management accounts (i)&nbsp;were prepared in accordance with GAAP consistently
applied throughout the period covered thereby; (ii)&nbsp;fairly present the financial condition of the
Group as of the respective date thereof and their results of operations for the period covered
thereby in accordance with GAAP consistently applied throughout the period covered thereby; and
(iii)&nbsp;show all Indebtedness and other liabilities, direct or contingent,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of the Group as of the respective date thereof, including liabilities for Taxes, commitments
and Indebtedness.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.10<I>. Books And Records. </I>All accounts, ledgers, material files, documents,
instruments, papers, books and records relating to the business, operations, conditions (financial
or other) of the Group, results of operations, and assets and properties of the Group
(collectively, the &#147;<B>Books and Records</B>&#148;), each as supplied to the Investors, are true, correct,
complete and current; there are no inaccuracies or discrepancies of any kind contained or reflected
therein; and they have been maintained in accordance with relevant legal requirements and high
industry standards, including the maintenance of an adequate system of internal controls.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.11<I>. No Material Adverse Effect. </I>Since the Balance Sheet Date, there has been no
event, occurrence, development or state of circumstances or facts that has had or could reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.12<I>. No Material Liabilities. </I>No Group Company has any liabilities or obligations
of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or
otherwise, for an aggregate amount in excess of RMB10,000,000 other than liabilities and
obligations disclosed in the Audited Financial Statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.13<I>. Absence of Changes. </I>Since the Balance Sheet Date, each Group Company has
conducted its business in the ordinary course, in substantially the same manner in which it had
been previously conducted and there has not been:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;any amendment of the memorandum and articles of association or other similar
organizational documents (whether by merger, consolidation or otherwise) of any Group Company,
other than pursuant to the Restructuring;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;any splitting, combination or reclassification of any shares of capital stock of any Group
Company or declaration, setting aside or payment of any dividend or other distribution (whether in
cash, stock or property or any combination thereof) in respect of the capital stock of any Group
Company, or redemption, repurchase or other acquisition or offer to redeem, repurchase, or
otherwise acquire any Company Securities or any Subsidiary Securities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;(i)&nbsp;any issuance, delivery or sale, or authorization of the issuance, delivery or sale of,
any shares of any Company Securities or Subsidiary Securities, other than the issuance of
Subsidiary Securities to any Group Company or (ii)&nbsp;amendment of any term of any Company Security or
any Subsidiary Security (in each case, whether by merger, consolidation or otherwise);
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;any incurrence of any capital expenditures or any obligations or liabilities in respect
thereof by any Group Company, except for those contemplated by the capital expenditure budget for
the Group approved by a majority of the board of directors of the Company (which majority shall
include the directors to be designated by the Investors pursuant to the Shareholders&#146; Agreement)
(the &#147;<B>Capex Budget</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;any acquisition (by merger, consolidation, acquisition of stock or assets or otherwise),
directly or indirectly, by any Group Company of any assets, securities, properties, interests or
businesses, other than supplies in the ordinary course of business of such Group Company in a
manner that is consistent with past practice;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;any sale, lease or other transfer, or creation or incurrence of any Lien on, any assets,
securities, properties, interests or businesses of any Group Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;other than in connection with actions permitted by Section&nbsp;5.13(c) or Section&nbsp;5.13(d), the
making by any Group Company of any loans, advances or capital contributions to, or investments in,
any other Person, other than in the ordinary course of business consistent with past practice;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;except as disclosed in Schedule&nbsp;5.13(h), the creation, incurrence, assumption or
sufferance to exist by any Group Company of any Indebtedness;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;any damage, destruction or other casualty loss (whether or not covered by insurance)
affecting the business or assets of any Group Company that has had or could reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;(i)&nbsp;the entering into of any agreement or arrangement that limits or otherwise restricts
in any material respect any Group Company or any of its Affiliates or any successor thereto or that
could, after the Closing Date, limit or restrict in any material respect any Group Company, any
Investor or any of their respective Affiliates, from engaging or competing in any line of business,
in any location or with any Person or (ii)&nbsp;the entering into, amendment or modification in any
material respect or termination of any Major Contract or waiver, release or assignment of any
material rights, claims or benefits of any Group Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;(i)&nbsp;the grant or increase of any severance or termination pay to (or amend any existing
arrangement with) any director, officer or employee of any Group Company, (ii)&nbsp;any increase in
benefits payable under any existing severance or termination pay policies or employment agreements,
(iii)&nbsp;except as set forth in Schedule&nbsp;5.13(k)(iii), the entering into of any employment, deferred
compensation or other similar agreement (or amendment of any such existing agreement) with any
director, officer or employee of any Group Company, (iv)&nbsp;the establishment, adoption or amendment
(except as required by applicable
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Laws) of any collective bargaining, bonus, profit-sharing, thrift, pension, retirement,
deferred compensation, compensation, stock option, restricted stock or other benefit plan or
arrangement covering any director, officer or employee of any Group Company or (v)&nbsp;any 15% or
greater increase in compensation, bonus or other benefits payable to any director, officer or
employee of any Group Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;any labor dispute, other than routine individual grievances, or any activity or proceeding
by a labor union or representative thereof to organize any employees of any Group Company, which
employees were not subject to a collective bargaining agreement at the Balance Sheet Date, or any
material lockouts, strikes, slowdowns, work stoppages or threats thereof by or with respect to such
employees;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;any change in the Company&#146;s methods of accounting, except as required by concurrent
changes in GAAP as agreed to by its independent public accountants;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;any settlement, or offer or proposal to settle, (i)&nbsp;any material litigation,
investigation, arbitration, proceeding or other claim involving or against any Group Company, (ii)
any stockholder litigation or dispute against any Group Company or any of its officers or directors
or (iii)&nbsp;any litigation, arbitration, proceeding or dispute that relates to the transactions
contemplated hereby; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;any Tax election, change any annual tax accounting period made or changed, any method of
tax accounting adopted or changed, any Tax returns amended or claims for Tax refunds filed, any
closing agreement entered, any Tax claim, audit or assessment settled, or any right to claim a Tax
refund, offset or other reduction in Tax liability surrendered.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.14<I>. Compliance with Laws.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;All Group Companies are, and at all times have been, in compliance with all applicable
Laws in all material respects.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;No event has occurred or circumstance exists that (with or without notice or lapse of
time): (i)&nbsp;may constitute or result in a violation by any Group Company of, or a failure on the
part thereof to comply with, any applicable Laws in any material respect; or (ii)&nbsp;may give rise to
any obligation on the part of any Group Company to undertake, or to bear all or any portion of the
cost of, any remedial action of any nature. No Group Company has received any notice or other
communication (whether oral or written) from any Governmental Authority regarding: (x)&nbsp;any actual,
alleged, possible, or potential violation of, or failure to comply with, any applicable Laws; or
(y)&nbsp;any actual, alleged, possible, or potential obligation on the part of any Group Company to
undertake, or to bear all or any portion of the cost of, any remedial action of any nature.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;None of the Group Companies nor any of their respective directors, officers, agents,
employees, or any other Person associated with or acting for or on behalf of the foregoing, has
offered, paid, promised to pay, or authorized the payment of any money, or offered, given a promise
to give, or authorized the giving of anything of value, to any Government Official, to any
political party or official thereof or to any candidate for political office (or to any Person
where any Group Company or any of its directors, officers, agents, employees or other Person knew
or was aware of a high probability that all or a portion of such money or thing of value would be
offered, given or promised, directly or indirectly, to any Government Official, political party,
party official, or candidate for political office) for the purposes of:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) (x)&nbsp;influencing any act or decision of such Government Official, political party,
party official, or candidate in his or its official capacity; (y)&nbsp;inducing such Government
Official, political party, party official or candidate to do or omit to do any act in
violation of the lawful duty of such Government Official, political party, party official
or candidate; or (z)&nbsp;securing any improper advantage; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) inducing such Government Official, political party, party official, or candidate
to use his or its influence with any Governmental Authority to affect or influence any act
or decision of such Governmental Authority, in order to assist the Company or any of its
Subsidiaries in obtaining or retaining business for or with, or directing business to any
Group Company, except insofar as the payment, gift, offer or promise was lawful under the
Laws of the country in which the Government Official, political party, party official or
candidate for political office serves in such capacity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.15<I>. No Litigation. </I>There are no actions, suits, proceedings, claims or disputes
(or any basis therefor) pending or threatened or contemplated, at law, in equity, in arbitration or
before any Governmental Authority, by or against any Group Company, any of its directors or
officers or any of its assets or properties, that (a)&nbsp;purport to affect or pertain to this
Agreement or any other Transaction Document, or (b)&nbsp;either individually or in the aggregate, if
determined adversely, have had, or could reasonably be expected to have, a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.16<I>. No Default. </I>No Group Company is in default under or with respect to any
Contract that, either individually or in the aggregate, has had, or could reasonably be expected to
have, a Material Adverse Effect. No default has occurred and is continuing or would result from
the consummation of transactions contemplated in this Agreement and other Transaction Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.17<I>. Property; Liens. </I>(a)&nbsp;Each Group Company has (i)&nbsp;good record and marketable
title in fee simple to, or valid leasehold interests in, all real property and (ii)&nbsp;good and
marketable title to all other assets and properties, in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">each case owned by or reflected in the Books and Records of such Group Company as owned by
such Group Company, or necessary to, or used or currently intended to be used in, the ordinary
conduct of the business of such Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Group Company has maintained its assets and properties in good repair, working order
and operating condition subject only to ordinary wear and tear, and all such assets and properties
are fully adequate and suitable for the purpose for which they are presently being used.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;None of the assets or properties owned by or reflected in the Books and Records of any
Group Company as owned by any Group Company, or necessary to, or used or currently intended to be
used in, the ordinary conduct of the business of any Group Company is subject to any Lien.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.18<I>. Tax. </I>Each Group Company has filed all national, provincial and local Tax
returns and reports required to be filed under the applicable Laws, and have paid all national,
provincial and local Taxes, assessments, fees and other governmental charges levied or imposed upon
it or its assets or properties, revenue or income or otherwise due and payable in accordance with
the requirements of the relevant tax authorities. There is no proposed Tax assessment against any
Group Company. There has been no claim concerning any liability for Taxes of any Group Company
asserted, raised or threatened by any taxing authority and no circumstances exist to form the basis
for such a claim or issue which could be material to any Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.19<I>. Affiliate Transactions. </I>All Contracts or transactions that are in force on the
date hereof, to or by which any Group Company, on the one hand, and any Affiliate of any Group
Company, on the other hand, are or have been a party or otherwise bound or affected were on terms
and conditions as favorable to the Group as would have been obtainable by it at the time in a
comparable arm&#146;s-length commercial transaction with an unrelated party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.20<I>. Intellectual Property.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each Group Company owns or possesses sufficient legal rights to all Intellectual Property
Rights as are necessary to the conduct of its businesses as now conducted and as presently proposed
to be conducted. The consummation of the transactions contemplated by this Agreement and the other
Transaction Documents will not alter, encumber, impair or extinguish any Owned Intellectual
Property Rights or Licensed Intellectual Property Rights. None of such Intellectual Property
Rights is being infringed by third parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All of the Licensed Intellectual Property Rights are in full force and effect in
accordance with their terms, and are free and clear of any Liens. No Group Company is in default
under any Licensed Intellectual Property Right, and no such default is currently threatened.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The conduct by the Group of its business does not infringe the rights of any third party
in respect of any Intellectual Property Rights nor has any Group Company received any communication
that a claim or demand has been made, or threatened to be made to this effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;No Group Company owns any trademarks.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;No Group Company is registered by any Government Authority as the owner of any copyright.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Except for the domain names listed in Schedule&nbsp;5.20(f), which domain names have been
registered with the domain name registration institutions throughout the world, no Group Company is
the registered owner of any domain names. No Group Company is aware of any claim of any third
party in respect of the domain names listed in Schedule&nbsp;5.20(f).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.21<I>. Contracts.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Schedule&nbsp;5.21(a) lists all Contracts that are in force on the date hereof to which any
Group Company is party or by which any of its assets or properties may be bound or affected, that
(w)&nbsp;require the payment by or to any Group Company of aggregate amounts in excess of RMB1,000,000
on the date hereof or that have resulted in an obligation for any Group Company to pay, or the
right for any Group Company to receive, aggregate amounts in excess of RMB1,000,000, (x)&nbsp;is
material to the business, operations, results of operations, condition (financial or otherwise),
assets and properties or liabilities of the any Group Company, (y)&nbsp;imposes material obligations
(whether or not monetary) on any Group Company, or (z)&nbsp;is otherwise necessary or advisable for the
proper and efficient operation of any Group Company (each, a &#147;<B>Major Contract</B>&#148; and, collectively,
the &#147;<B>Major Contracts</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Major Contract: (i)&nbsp;is legal, valid, binding, enforceable and in full force and
effect; and (ii)&nbsp;will not cease to be legal, valid, binding, enforceable and in full force and
effect on identical terms as a result of the transactions contemplated in this Agreement and other
Transaction Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;No Group Company is in breach or default, or has repudiated any provision, of any such
Major Contract and no event has occurred which with notice or lapse of time would constitute a
breach or default, or permit termination, modification or acceleration under any such Major
Contract.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Schedule&nbsp;5.21(d) lists all Contracts (other than Major Contracts) which are in force on
the date hereof of the following types to which any Group Company is a party:
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Contracts that relate to the borrowing of money or extension of credit by any
Group Company in each case in excess of RMB1,000,000; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) material partnership, joint venture, distribution agreements, procurement
arrangements or other similar Contracts or arrangements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;None of the Contracts to which the Company or any of its Subsidiary is a party restricts
the right of any Group Company or its Affiliates to carry on or continue their respective business
in the normal course or to implement the respective business plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;No Group Company has delegated any power or issued any powers of attorney in favor of any
Person, other than powers of attorney issued to directors, officers, or employees of any Group
Company for purpose of executing contracts or agreements for and on behalf of such Group Company in
the ordinary course of business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;All the Major Contracts have been revised, amended or modified to satisfy the requirements
under the Laws of the PRC or as required from time to time by Governmental Authorities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.22<I>. Environmental Matters. </I>(a) (i)&nbsp;No notice, notification, demand, request for
information, citation, summons or order has been received, no complaint has been filed, no penalty
has been assessed and no investigation, action, claim, suit, proceeding or review is pending or
threatened by any Governmental Authority or other Person with respect to any matters relating to
any Group Company and relating to or arising out of any Environmental Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) There are no liabilities of or relating to any Group Company of any kind
whatsoever, whether accrued, contingent, absolute, determined, determinable or otherwise,
arising under or relating to any Environmental Law, and there are no facts, conditions,
situations or set of circumstances which could reasonably be expected to result in or be
the basis for any such liability.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) No polychlorinated biphenyls, radioactive material, lead, asbestos-containing
material, incinerator, sump, surface impoundment, lagoon, landfill, septic, wastewater
treatment or other disposal system or underground storage tank (active or inactive) is or
has been present at, on or under any property now or previously owned, leased or operated
by any Group Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) No Hazardous Substance has been discharged, disposed of, dumped, injected,
pumped, deposited, spilled, leaked, emitted or released at, on or under any property now
or previously owned, leased or operated by any Group Company in violation of any laws or
regulations.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Each Group Company is in compliance with all Environmental Laws and have obtained
and are in compliance with all Environmental Permits; such Environmental Permits are valid
and in full force and effect and will not be terminated or impaired or become terminable,
in whole or in part, as a result of the transactions contemplated hereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;There has been no environmental investigation, study, audit, test, review or other
analysis conducted in relation to the current or prior business of any Group Company or any
property or facility now or previously owned, leased or operated by any Group Company which has not
been delivered to the Investors at least 10&nbsp;days prior to the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;For purposes of this Section, the terms &#147;<B>Group Company</B>&#148; shall include any entity which is,
in whole or in part, a predecessor of such Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.23<I>. Employees, Labor Matters, Etc.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;There are no material labor disputes currently subject to any grievance procedure,
arbitration or litigation with respect to any employee of any Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;There are no written employment or consultancy agreements with respect to any employee of
any Group Company that cannot be terminated by such Group Company by giving notice of three months
or less to the other parties to such agreements without giving rise to any claim for damages or
compensation beyond such notice period, except required otherwise under applicable labor and
employment related laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.24<I>. Licenses and Permits. </I>All material Licenses of each Group Company necessary
for the due establishment of each Group Company and for the carrying on of the businesses and
operations by each Group Company in the manner and to the extent now carried on by such Group
Company and the acquisition and holding of the assets and properties of each Group Company have
been or will be properly obtained, are or will be in full force and effect and have been and will
be complied with in all material respects. There is no outstanding or anticipated investigation,
enquiry or proceeding which is reasonably likely to result in the suspension, cancellation,
modification or revocation of any such Licenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.25<I>. Representations</I>. The representations and warranties contained in this
Agreement, disregarding all qualifications and exceptions contained therein relating to materiality
or Material Adverse Effect, are true and correct with only such exceptions as would not in the
aggregate reasonably be expected to have a Material Adverse Effect.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.26<I>. Disclosure. </I>(a)&nbsp;The Company has provided to the Investors all documents and
information which the Investors have requested with respect to the decision of the Investors to
enter into this Agreement and other Transaction Documents. The Company has disclosed to the
Investors all agreements, instruments and corporate or other restrictions to which any Group
Company is subject and all other matters that, individually or in the aggregate, has had, or could
reasonably be expected to have, a Material Adverse Effect. All such information and statements in
such documents and this Agreement and other Transaction Documents (including all schedules and
exhibits hereto) are true, correct and complete.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;No report, financial statement, certificate or other information furnished (whether in
writing or orally) by or on behalf of any Group Company to the Investors in connection with this
Agreement or any other Transaction Document (as modified or supplemented by other information so
furnished) contains any material misstatement of fact or omits to state any material fact necessary
to make the statements therein, in the light of the circumstances under which they were made, not
misleading.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 6</B><BR>
<FONT style="font-variant: SMALL-CAPS">Representations and Warranties Regarding the Founders and the<BR>
Controlling Shareholders</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Founders and the Controlling Shareholders represents and warrants to the Investors
as of the date hereof and as of the Closing Date that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.01<I>. Power and Authority. </I>Each of the Founders and the Controlling Shareholders has
the legal right and full power and authority to execute and deliver this Agreement and each other
Transaction Document to which he or she is a party and to perform his or her obligations hereunder
and thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.02<I>. Enforceability.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each of the Founders and the Controlling Shareholders has duly executed and delivered this
Agreement and will execute and deliver each other Transaction Document to which he or she is a
party by the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;This Agreement constitutes, and each other Transaction Document to which such Founder or
Controlling Shareholder is a party (when executed) will constitute, the legal, valid and binding
obligations of such Founder or Controlling Shareholder, as applicable, enforceable against him or
her in accordance with the terms hereof and thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.03<I>. Non-contravention. </I>The execution, delivery and performance by each Founder and
each Controlling Shareholder of this
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Agreement and each other Transaction Document to which he or she is a party, and the
consummation of the transactions contemplated hereby and thereby, do not and will not:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;conflict with, contravene, result in a violation or breach of or default (with or without
the giving of notice or the lapse of time or both); or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;result in the creation of any Lien (or any obligation to create any Lien) upon any of the
properties or assets of such Founder or Controlling Shareholder;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in each case under (w)&nbsp;any Laws applicable to or binding on such Founder or Controlling
Shareholder or any of its assets or properties, (x)&nbsp;any order, injunction, writ or decree of any
Governmental Authority or any arbitral award to which such Founder or Controlling Shareholder or
any of his or her assets or properties is subject, or (y)&nbsp;any Contract, or any other agreement or
instrument to which he or she is a party or by which any of his or her assets or properties may be
bound.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.04<I>. Governmental Authorization. </I>No Consent by any Governmental Authority or any
other Person is necessary or required in connection with the execution, delivery or performance by,
or enforcement against, any Founder or Controlling Shareholder under this Agreement or any other
Transaction Document to which he or she is a party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.05<I>. Ownership of Shares.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;On the date hereof, (i)&nbsp;Ms.&nbsp;Liu, through Notable Enterprises Limited, a company formed
under the laws of the British Virgin Islands and wholly-owned by Ms.&nbsp;Liu (the &#147;<B>Ms.&nbsp;Liu Holding
Company</B>&#148;), owns 45% of the outstanding shares of AGL; (ii)&nbsp;Mr.&nbsp;Sun, through Dragon Image Investment
Ltd., a company formed under the laws of the British Virgin Islands and wholly-owned by Mr.&nbsp;Sun
(the &#147;<B>Mr.&nbsp;Sun Holding Company</B>&#148;), owns 7.5% of the outstanding shares of AGL; and (iii)&nbsp;Mr.&nbsp;Yang,
through Daketala International Investment Holdings Ltd., a company formed under the laws of the
British Virgin Islands and wholly-owned by Mr.&nbsp;Yang (the &#147;<B>Mr.&nbsp;Yang Holding Company</B>&#148;), owns 7.5% of
the outstanding shares of AGL, in each case free and clear of any Lien and any other limitation or
restriction (including any restriction on the right to vote, sell or otherwise dispose of such
shares).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Immediately prior to the Closing, (i)&nbsp;Ms Liu, through the Ms.&nbsp;Liu Holding Company, will
own 45% of the outstanding shares of the Company; (ii)&nbsp;Mr.&nbsp;Sun, through the Mr.&nbsp;Sun Holding
Company, will own 7.5% of the outstanding shares of the Company; and (iii)&nbsp;Mr.&nbsp;Yang, through the
Mr.&nbsp;Yang Holding Company, will own 7.5% of the outstanding shares of the Company, in each case free
and clear of any Lien and any other limitation or restriction
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(including any restriction on the right to vote, sell or otherwise dispose of such shares)
except for restrictions set forth in the Transaction Documents.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 7</B><BR>
<FONT style="font-variant: SMALL-CAPS">Representations and Warranties of Investors</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Investor represents and warrants to the Company as of the date hereof and as of the
Closing Date that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.01<I>. Corporate Status. </I>Such Investor is duly organized, validly existing and in
good standing under the laws of its jurisdictions of formation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.02<I>. Power And Authority. </I>Such Investor has the requisite power and authority to
execute and deliver this Agreement and other Transaction Documents to which it is a party and to
perform its obligations hereunder and thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.03<I>. Enforceability. </I>Such Investor has duly executed and delivered this Agreement.
This Agreement constitutes, and other Transaction Documents to which it is a party (when executed)
will constitute, the legal, valid and binding obligations of such Investor, enforceable against it
in accordance with the terms hereof and thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.04<I>. Non-contravention. </I>The execution, delivery and performance by such Investor of
this Agreement do not and will not in any material respect conflict with, contravene, result in a
violation or breach of or default (with or without the giving of notice or the lapse of time or
both) under (x)&nbsp;any Applicable Laws, (y)&nbsp;any order, injunction, writ or decree of any Governmental
Authority or any arbitral award to which such Investor is subject, or (z)&nbsp;the organization
documents of such Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.05<I>. Purchase for Investment</I>. Such Investor is purchasing the Series&nbsp;A Shares for
investment for its own account or for the accounts of its Permitted Transferees (as defined in the
Shareholders&#146; Agreement) and not with a view to, or for sale in connection with, any distribution
thereof (except for transfers to its Permitted Transferees). Such Investor (either alone or
together with its advisors) has sufficient knowledge and experience in financial and business
matters so as to be capable of evaluating the merits and risks of its investment in the Series&nbsp;A
Shares and is capable of bearing the economic risks of such investment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.06<I>. Legends. </I>Investors acknowledge that each certificate evidencing the securities
issued pursuant to this Agreement may bear the following legends:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&#147;THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND THE REGULATIONS PROMULGATED
THEREUNDER, AS IN EFFECT FROM TIME TO TIME (THE &#147;SECURITIES ACT&#148;) OR ANY SECURITIES LAWS OF ANY
STATE OF THE UNITED STATES. SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED WITHIN THE UNITED STATES OR TO ANY UNITED STATES PERSON EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Any legend required by any other applicable securities Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.07<I>. Litigation</I>. There is no action, suit, investigation or proceeding pending
against, or to the knowledge of such Investor threatened against or affecting, such Investor before
any arbitrator or any Governmental Authority which in any manner challenges or seeks to prevent,
enjoin, alter or materially delay the transactions contemplated by this Agreement and the other
Transaction Documents.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 8</B><BR>
<FONT style="font-variant: SMALL-CAPS">Covenants of the Group, Founders and Controlling Shareholders</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.01<I>. Conduct of the Company. </I>From the date hereof until the Closing Date, each
Group Company shall, and each of the Founders and Controlling Shareholders shall cause each Group
Company to, conduct its business in the ordinary course consistent with past practice and use its
best efforts to (i)&nbsp;preserve intact its present business organization, (ii)&nbsp;maintain in effect all
of its licenses, permits, consents, franchises, approvals and authorizations, (iii)&nbsp;preserve or
renew all of its registered patents, trademarks, tradenames, and service marks, (iv)&nbsp;keep available
the services of its directors, officers and key employees, (v)&nbsp;maintain satisfactory relationships
with its customers, lenders, suppliers and others having material business relationships with it,
(vi)&nbsp;manage its working capital (including the timing of collection of accounts receivable and of
the payment of accounts payable and the management of inventory) in the ordinary course of business
consistent with past practice and (vii)&nbsp;continue to make capital expenditures consistent with the
Capex Budget. Without limiting the generality of the foregoing, except as expressly contemplated
by this Agreement, each Group Company shall not, and each Founder and each Controlling Shareholder
shall cause each Group Company not to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend its articles of incorporation, bylaws or other similar organizational documents
(whether by merger, consolidation or otherwise);
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;split, combine or reclassify any of its or its Subsidiaries&#146; shares of capital stock or
declare, set aside or pay any dividend or other distribution (whether in cash, stock or property or
any combination thereof) in respect of its or its Subsidiaries capital stock, or redeem, repurchase
or otherwise acquire or offer to redeem, repurchase, or otherwise acquire any Company Securities or
any Subsidiary Securities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;(i)&nbsp;issue, deliver or sell, or authorize the issuance, delivery or sale of, any shares of
any Company Securities or Subsidiary Securities, other than the issuance of any Subsidiary
Securities to any Group Company or (ii)&nbsp;amend any term of any Company Security or any Subsidiary
Security (in each case, whether by merger, consolidation or otherwise);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;incur any capital expenditures or any obligations or liabilities in respect thereof,
except for (i)&nbsp;those contemplated by the Capex Budget and (ii)&nbsp;any unbudgeted capital expenditures
not to exceed RMB5,000,000 individually or RMB10,000,000 in the aggregate;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;acquire (by merger, consolidation, acquisition of stock or assets or otherwise), directly
or indirectly, any assets, securities, properties, interests or businesses, other than (i)&nbsp;supplies
in the ordinary course of business of such Group Company in a manner that is consistent with past
practice and (ii)&nbsp;acquisitions with a purchase price (including assumed indebtedness) that does not
exceed RMB1,000,000 individually or RMB2,000,000 in the aggregate;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;sell, lease or otherwise transfer, or create or incur any Lien on, any Group Company&#146;s
assets, securities, properties, interests or businesses;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;other than in connection with actions permitted by Section&nbsp;8.01(d) or Section&nbsp;8.01(e),
make any loans, advances or capital contributions to, or investments in, any other Person, other
than in the ordinary course of business consistent with past practice;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;create, incur, assume, suffer to exist or otherwise be liable with respect to any
Indebtedness;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;(i)&nbsp;enter into any agreement or arrangement that limits or otherwise restricts in any
material respect any Group Company or any of its Affiliates or any successor thereto or that could,
after the Closing Date, limit or restrict in any material respect any Group Company, any Investor
or any of their respective Affiliates, from engaging or competing in any line of business, in any
location or with any Person or (ii)&nbsp;enter into, amend or modify in any material respect or
terminate any contract required to be disclosed by Section&nbsp;5.21(a) or otherwise waive, release or
assign any material rights, claims or benefits of any Group Company;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;(i)&nbsp;grant or increase any severance or termination pay to (or amend any existing
arrangement with) any director, officer or employee of any Group Company except as required by law
or pursuant to the employment agreements disclosed in Schedule&nbsp;5.13(k)(iii), (ii)&nbsp;increase benefits
payable under any existing severance or termination pay policies or employment agreements, (iii)
enter into any employment, deferred compensation or other similar agreement (or amend any such
existing agreement) with any director, officer or employee of the any Group Company, (iv)
establish, adopt or amend (except as required by applicable Laws) any collective bargaining, bonus,
profit-sharing, thrift, pension, retirement, deferred compensation, compensation, stock option,
restricted stock or other benefit plan or arrangement covering any director, officer or employee of
any Group Company or (v)&nbsp;increase compensation, bonus or other benefits payable to any director,
officer or employee of any Group Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;change the Group&#146;s methods of accounting, except as required by concurrent changes in
GAAP, as agreed to by its independent public accountants;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;settle, or offer or propose to settle, (i)&nbsp;any material litigation, investigation,
arbitration, proceeding or other claim involving or against any Group Company, (ii)&nbsp;any stockholder
litigation or dispute against any Group Company or any of its officers or directors or (iii)&nbsp;any
litigation, arbitration, proceeding or dispute that relates to the transactions contemplated
hereby;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;make or change any Tax election, change any annual tax accounting period, adopt or change
any method of tax accounting, amend any Tax returns or file claims for Tax refunds, enter any
closing agreement, settle any Tax claim, audit or assessment, or surrender any right to claim a Tax
refund, offset or other reduction in Tax liability;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;take any action that would make any representation or warranty of any Group Company
hereunder, or omit to take any action necessary to prevent any representation or warranty of any
Group Company hereunder from being, inaccurate in any respect at, or as of any time before, the
Closing Date; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;agree, resolve or commit to do any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.02<I>. Use of Proceeds</I>. The entire proceeds from the sale of the Series&nbsp;A Shares
pursuant to Article&nbsp;2 and the additional investment pursuant to Article&nbsp;3 shall be deposited into
the Company&#146;s bank account and any withdrawals from such account shall require the prior written
consent by each of the Investors and the Company. No withdrawal from such account shall be allowed
unless (i)&nbsp;such withdrawal is permitted by, and the funds to be so withdrawn are to be used
pursuant to, a budget and business plan approved by the board of directors of the Company
(including the directors to be designated by the Investors pursuant to the Shareholders&#146; Agreement)
or (ii)&nbsp;such withdrawal has been made upon the prior written consent by each of the Company and the
Investors.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.03<I>. Information Rights. </I>The Company shall deliver to each Investor, in form and
detail satisfactory to the Investors, the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Quarterly Statements &#151; as soon as available, but in any event within 45&nbsp;days after the
end of each of the first three fiscal quarters of each fiscal year of the Company, duplicate copies
of
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) a consolidated balance sheet of the Group as at the end of such fiscal quarter,
and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the related consolidated statement of income and operations, shareholders&#146;
equity, cash flow and changes in financial position of the Group for such fiscal quarter
and (in the case of the second and third quarters) for the portion of the fiscal year
ending with such fiscal quarter, in each case setting forth in comparative form the
figures for the corresponding periods in the previous fiscal year, prepared in accordance
with GAAP (or U.S. GAAP or IFRS, after the adoption of such international accounting
principals by the Company pursuant to Section&nbsp;8.10) applied on a consistent basis, and
certified by the Chief Financial Officer of the Company as fairly presenting, in all
material respects, the financial position of the companies being reported on and their
results of operations and cash flows in accordance with the applicable accounting
principals then used by the Group, subject only to normal year-end audit adjustments and
the absence of footnotes;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Annual Statements &#151; as soon as available, but in any event within 90&nbsp;days after the end
of each fiscal year of the Company, duplicate copies of
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) a consolidated balance sheet of the Group as at the end of such fiscal year, and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the related consolidated statements of operations, shareholders&#146; equity, cash
flow and changes in financial position of the Group for such fiscal year, setting forth in
each case in comparative form the figures for the previous fiscal year, prepared in
accordance with the accounting principals then used by the Group applied on a consistent
basis, audited by, and accompanied by a report and opinion thereon of, a &#147;big four&#148;
international accounting firm or another accounting firm selected by the Investors, which
opinion shall state that such financial statements present fairly, in all material
respects, the financial position of the companies being reported upon and their results of
operations and cash flows and have been prepared in conformity with the applicable
accounting principals applied on a consistent basis, that the examination of such
accountants in connection with such financial statements has been made in accordance with
generally accepted auditing standards, that such report and opinion are not subject to any
&#147;going concern&#148; or like qualification or exception or any qualification or exception as to
the scope
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">of such audit, and that such audit provides a reasonable basis for such opinion in
the circumstances;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Audit Reports, etc. &#151; as soon as available, but in any event within five Business Days
after receipt thereof, copies of all management letters and reports submitted to any Group Company
by independent certified public accountants in connection with any annual, interim or special audit
of the Group made by such accountants;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Notices from Governmental Authority &#151; as soon as available, but in any event within five
days of receipt thereof, copies of any notice to any Group Company from any Governmental Authority
relating to any order, ruling, statute or other Laws that could reasonably be expected to have a
Material Adverse Effect;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Notice of Litigation &#151; as soon as possible, but in any event within five Business Days,
after any Group Company receives actual notice (written or oral) of any proceeding(s) being
instituted against any Group Company in any national, provincial, or local court or before any
commission or other regulatory body (national, provincial, or local) or arbitration body.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Requested Information &#151; with reasonable promptness, such other data and information
relating to the business, operations, affairs, financial condition, assets or property of any Group
Company or relating to the ability of any Group Company, any Founder or any Controlling Shareholder
to perform its or his or her obligations under this Agreement as from time to time may be
reasonably requested by Investors;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Monthly Reports &#151; within five Business Days of the end of each calendar month, (i)&nbsp;a
monthly report of cash receipts and cash disbursements of the Group for the calendar month most
recently ended and (ii)&nbsp;a projected monthly report of cash receipts and cash disbursements of the
Group for the then current calendar month, in each case substantially in the form agreed to between
the Company and the Investors prior to the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.04<I>. Inspection Right. </I>Each Group Company shall allow each Investor, or any person
designated from time to time by such Investor, from time to time hereafter, to call at any Group
Company&#146;s place or places of business during ordinary business hours, and, without hindrance or
delay by any Group Company, (a)&nbsp;to inspect, audit, check, and makes copies of and extracts from any
Group Company&#146; books, records, journals, orders, receipts, and any correspondence and other data
relating to the business of any Group Company or to any transactions between the parties hereto,
and (b)&nbsp;to discuss the affairs, finances, and business of any Group Company with the officers of
any Group Company.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.05<I>. Compliance with Law. </I>The Company and its Subsidiaries shall comply in all
material respects with the requirements of all applicable Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.06<I>. Books and Records. </I>Each Group Company shall (a)&nbsp;maintain proper books of
record and account, in which full, true and correct entries in conformity with the then adopted
accounting principals consistently applied shall be made of all financial transactions and matters
involving the assets, properties and business of such Group Company; and (b)&nbsp;maintain such books of
record and account in material conformity with all applicable requirements of any Governmental
Authority having regulatory jurisdiction over such Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.07<I>. Restructuring. </I>Each of the Founders, the Controlling Shareholders, the Company
and AGL shall, and shall cause all other shareholders of AGL and the Company to, complete the
Restructuring prior to the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.08<I>. Other Transaction Documents. </I>Each of the Founders, the Controlling
Shareholders and the Group Companies shall execute and deliver each other Transaction Document to
which it is a party by the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.09<I>. Amended And Restated Memorandum And Articles. </I>Each of the Founders and the
Controlling Shareholders shall, and shall cause the board of directors of the Company and the other
shareholders of the Company to, approve and adopt the Amended and Restated Memorandum and Articles
by the Closing. The Amended and Restated Memorandum and Articles shall include the provisions set
forth in <B>Annex II </B>attached hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.10<I>. Adoption of International Accounting Standards. </I>As soon as practicable after
the Closing, the Group shall adopt U.S. GAAP or IFRS for all internal accounting and external
accounting reports made to shareholders or investors. U.S. GAAP or IFRS will be the accounting
standard applied to all valuation matters with respect to the obligations of each Group Company,
each Founder and each Controlling Shareholder to the Investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.11<I>. IPO. </I>Each Group Company, each Founder and each Controlling Shareholder shall
use its or his or her best efforts to complete the IPO by the third anniversary of the Closing
Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.12<I>. Acquisition of Shenzhen Our New Medical Technology Co. Ltd. </I>Each of the
founders and the Controlling Shareholders agrees to use his or her best efforts to effectuate the
acquisition of Shenzhen Our New Medical Technology Co. Ltd. by the Company or its Subsidiaries,
subject to the prior written consent by the Investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.13. <I>Employment Contracts</I>. As soon as practicable after the Closing, each of the
Founders and the Company shall enter into an employment
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">contract, in a form satisfactory to the Investors, for a term of no less than three years.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.14<I>. Non-Competition Agreement. </I>As soon as practicable after the Closing, the
Company shall enter into a non-competition agreement with each of the Founders. Such
non-competition agreements shall provide, among other provisions, that none of the Founders nor
their respective Affiliates shall (i)&nbsp;join or establish any business entity engaging in any
activities that compete with any Group Company, (ii)&nbsp;employ any employees of any Group Company or
solicit any such employee to terminate his employment relationship with such Group Company, (iii)
engage in any transactions or dealings with any customer of any Group Company that may compete with
the business of any Group Company, or (iv)&nbsp;otherwise engage in any activities outside the Group
that may compete with the business of any Group Company without the approval by a majority of the
directors of the Company (which majority shall include the directors designated by the Investors).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.15<I>. Intellectual Property Rights. </I>(a)&nbsp;Each of the Founders and Controlling
Shareholders agrees that the Group shall have a right of first refusal to purchase any technology
or Intellectual Property Rights relating to the provision of medical services or manufacture of
medical equipment, in each case owned or developed by any Founder or Controlling Shareholder or any
of their respective Affiliates. The Company shall not exercise such right of first refusal without
the approval by a majority of the directors of the Company (which majority shall include the
directors designated by the Investors).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As soon as practicable after the Closing, the Company shall enter into an intellectual
property rights agreement with each of the Group&#146;s employees and consultants in form and substance
satisfactory to the Investors providing that all Intellectual Property Rights, including
trademarks, logos, patents and inventions, developed by such employees and consultants shall be
owned by the Group and governing the transfer and protection of such Intellectual Property Rights.
The Founders and Controlling Shareholders shall cause each of the Group&#146;s employees and consultants
to enter into such intellectual property rights agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.16<I>. Employee Stock Options. </I>(a)&nbsp;The majority of the directors of the Company
(which majority shall include the directors designated by the Investors) may adopt an employee
stock option plan under which the Company is authorized to grant a maximum number of share options
equal to 7% of the Ordinary Shares outstanding on (x)&nbsp;the IPO Date or (y)&nbsp;April&nbsp;30, 2009, whichever
is earlier, calculated on a Fully-Diluted basis.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If the 2008 Net Income is greater than RMB110,000,000, the Company shall, promptly after
March&nbsp;31, 2009, grant a number of share options to its qualifying executives and key employees
equal to (x)&nbsp;2008 Net Income <I>minus </I>RMB110,000,000 <I>divided </I>by (y)&nbsp;RMB10,000,000 <I>multiplied </I>by (z)
3%;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>provided </I>that the total number of share options granted pursuant to this Section&nbsp;8.16(b) shall
not exceed 7% of the Ordinary Shares outstanding on December&nbsp;31, 2008, calculated on a
Fully-Diluted basis. The exercise price of the share options shall equal to the per share price at
which Carlyle has mostly recently obtained Series&nbsp;A Shares, whether through subscription or
conversion of any loans that the Company owes to Carlyle.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 9</B><BR>
<FONT style="font-variant: SMALL-CAPS">Covenants of All Parties</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each party hereto agrees that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.01. <I>Best Efforts; Further Assurance</I>. (a)&nbsp;Subject to the terms and conditions of
this Agreement, it will use its best efforts to take, or cause to be taken, all actions and to do,
or cause to be done, all things necessary or desirable under applicable Laws to consummate the
transactions contemplated by this Agreement and the other Transaction Documents, including (i)
preparing and filing as promptly as practicable with any Governmental Authority or other third
party all documentation to effect all necessary filings, notices, petitions, statements,
registrations, submissions of information, applications and other documents and (ii)&nbsp;obtaining and
maintaining all Consents required to be obtained from any Governmental Authority or other third
party that are necessary, proper or advisable to consummate the transactions contemplated by this
Agreement and the other Transaction Documents. Each of the Group, the Founders and the Controlling
Shareholders agrees to deliver such other documents, certificates, agreements and other writings
and to take such other actions as may be necessary or desirable in order to consummate or implement
expeditiously the transactions contemplated by this Agreement and the other Transaction Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.02. <I>Certain Filings</I>. It shall cooperate with the other parties hereto (i)&nbsp;in
determining whether any action by or in respect of, or filing with, any Governmental Authority is
required, or any actions, Consents or waivers are required to be obtained from parties to any
material contracts, in connection with the consummation of the transactions contemplated by this
Agreement and the other Transaction Documents and (ii)&nbsp;in taking such actions or making any such
filings, furnishing information required in connection therewith and seeking timely to obtain any
such actions, consents, approvals or waivers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.03. <I>Public Announcements</I>. The parties agree to consult with each other before
issuing any press release or making any public statement with respect to this Agreement or any
other Transaction Document or the transactions contemplated hereby or thereby and, except for any
press releases and public statements the making of which may be required by applicable Laws or any
listing agreement with any securities exchange, will not issue any such press release or make any
such public statement prior to such consultation.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 10</B><BR>
<FONT style="font-variant: SMALL-CAPS">Conditions to Closing</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10.01. <I>Conditions to Obligations of the Investors</I>. The obligations of each Investor
to consummate the Closing are subject to the satisfaction of the following conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<I>Representations</I>. The representations and warranties set forth in Article&nbsp;5 and Article&nbsp;6
shall be true and correct as of the Closing Date as if made at and as of such date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<I>Performance</I>. Each of the Group Companies, the Founders and the Controlling Shareholders
shall have performed and complied with all covenants, undertakings, agreements, obligations and
conditions required to be performed or complied with by it on or prior to the Closing Date under
this Agreement or any other Transaction Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<I>Government Approval</I>. Each of the Group Companies, the Founders and the Controlling
Shareholders shall have obtained all Consents of all applicable Governmental Authorities for the
consummation of the transactions contemplated by Agreement and the other Transaction Documents and
all such Consents shall be effective as of the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<I>Corporate Authorization</I>. The board of directors and the shareholders of each Group
Company shall have approved this Agreement in accordance with its organizational documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<I>No Litigation</I>. There shall not be threatened, instituted or pending any action or
proceeding by any Person before any Governmental Authority or any arbitration body against any of
the Group Companies, the Founders, the Controlling Shareholders and the Investors seeking to
enjoin, delay, challenge the validity of, or assert any liability against any of them on account
of, this Agreement or any other Transaction Document.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;<I>No Material Adverse Change</I>. There shall have been no event or circumstance on or prior to
the Closing that has had or could be reasonably expected to have, either individually or in the
aggregate, a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;<I>Restructuring</I>. The Restructuring shall have been completed by the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;<I>Amended and Restated Convertible Loan Agreement</I>. The parties to the Existing Loan
Agreement and the Company shall have amended and restated the Existing Loan Agreement in whole by
and with the Amended and Restated Convertible Loan Agreement, which Amended and Restated
Convertible Loan Agreement shall be valid and effect on the Closing Date.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<I>Amended and Restated Memorandum and Articles. </I>The board of directors and the shareholders
of the Company shall have approved and duly adopted the Amended and Restated Memorandum and
Articles, which Amended and Restated Memorandum and Articles shall be valid and effective on the
Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;<I>Shareholders&#146; Agreement</I>. The Company and each Person who is existing shareholder of the
Company shall have executed and delivered the Shareholders&#146; Agreement, which Shareholders&#146;
Agreement shall be valid and effective on the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;<I>Lease Permit</I>. Either (i)&nbsp;Aohua has obtained a Lease Permit or (ii)&nbsp;a newly formed
Subsidiary of the Company has obtained a Lease Permit and Aohua has duly assigned or novated to
such newly formed Subsidiary of the Company each and all of the lease agreements of Aohua existing
as of the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;<I>Opinion of the Company&#146;s Cayman Islands Counsel</I>. The Investors shall have received from
the Cayman Islands counsel for the Company a legal opinion, dated the Closing Date, in form and
substance satisfactory to the Investors. Such opinion shall be satisfactory to the Investors, to
the effect, without limitation, that (i)&nbsp;the Company is duly incorporated and validly existing in
good standing under the laws of the Cayman Islands; (ii)&nbsp;the Company has the necessary corporate
power and authority to enter into all Transaction Documents and perform its obligations thereunder;
(iii)&nbsp;the Company has taken all corporate actions required to authorize its execution, delivery and
performance of all Transaction Documents; (iv)&nbsp;the existing shareholders hold 100% of the share
capital of the Company; (v)&nbsp;all Transaction Documents have been duly executed and delivered by or
on behalf of the Company, and constitutes a valid and binding obligation of the Company enforceable
in accordance with the terms thereof; (vi)&nbsp;the execution, delivery and performance of each
Transaction Document will not violate the memorandum and articles of association of the Company or
any applicable Laws of the Cayman Islands; and (vii)&nbsp;no Consent by any Governmental Authority of
the Cayman Islands is required to authorize or is required in connection with the execution,
delivery, performance or enforcement of any Transaction Document.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;<I>Opinion of the Company&#146;s British Virgin Islands Counsel</I>. The Investors shall have
received from the British Virgin Islands counsel for the Company a legal opinion, dated the Closing
Date, in form and substance satisfactory to the Investors. Such opinion shall be satisfactory to
the Investors, to the effect, without limitation, that (i)&nbsp;each of AGL and OMS is duly incorporated
and validly existing in good standing under the laws of the British Virgin Islands; (ii)&nbsp;the
Company holds 100% of the share capital of AGL; (iii)&nbsp;AGL holds 100% of the share capital of OMS;
and (iv)&nbsp;no Consent by any Governmental Authority of the British Virgin Islands is required to
authorize or is required in connection with the execution, delivery, performance or enforcement of
this Agreement.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;<I>Opinion of the Company&#146;s PRC Counsel</I>. The Investors shall have received from the PRC
counsel for the Company a legal opinion, dated the Closing Date, in form and substance satisfactory
to the Investors. Such opinion shall be satisfactory to the Investors, to the effect, without
limitation, that (i)&nbsp;each of the PRC Subsidiaries has been duly established and is validly existing
under the Laws of the PRC and has obtained all necessary Consents of all applicable Governmental
Authorities for its lawful engagement in the business that it is currently conducting; (ii)&nbsp;each of
the PRC Subsidiaries legally owns, or possesses the legal right to use, the tangible and intangible
assets employed in the operation of its business; and (iii)&nbsp;the transactions contemplated by the
Transaction Documents complies with all applicable Laws of the PRC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;<I>Opinion of the Investors&#146; PRC Counsel. </I>The Investors shall have received from their PRC
counsel a legal opinion, dated the Closing Date, in form and substance satisfactory to the
Investors. Such opinion shall be satisfactory to the Investors, to the effect, without limitation,
that (i)&nbsp;the structure of the transactions contemplated in this Agreement comply with all
applicable PRC Laws; (ii)&nbsp;all required Consents have been obtained from the relevant Government
Authorities; (iii)&nbsp;Aohua holds valid title to all the tangible and intangible assets used in the
operation of its business; (iv)&nbsp;the operations of the Group comply with all applicable PRC Laws;
and (v)&nbsp;there are no existing PRC Laws that could be reasonably expected to prohibit the listing of
the Company on an overseas stock exchange.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)&nbsp;<I>Process Agent</I>. Each of the Group Companies, the Founders and the Controlling Shareholders
shall have irrevocably appointed a process agent in New York City, New York to accept, for and on
its behalf, service of notice, request or other communication or process in any legal action or
proceedings arising out of or in connection with this Agreement or any other Transaction Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q)&nbsp;<I>Other Assurances</I>. The Investors shall have received such other assurances, certificates,
documents, consents or opinions as the Investors reasonably may require.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r)&nbsp;<I>Compliance Certificate</I>. The Company shall have delivered to the Investors a certificate,
dated the Closing Date, signed by a director of the Company, in form and substance satisfactory to
the Investors, certifying that the conditions set forth in this Article&nbsp;10 have been satisfied as
of the Closing Date.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 11</B><BR>
<FONT style="font-variant: SMALL-CAPS">Survival; Indemnification</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.01. <I>Survival</I>. The representations and warranties and covenants and agreements of
the parties hereto contained in this Agreement or in any certificate or other writing delivered
pursuant hereto or in connection herewith shall survive the Closing indefinitely.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.02. <I>Indemnification</I>. (a)&nbsp;Effective at and after the Closing, each of the Group
Companies, the Founders and the Controlling Shareholders agrees to indemnify, jointly and
severally, the Investors, their respective Affiliates and their respective successors and assignees
against and agree to hold each of them harmless from any and all damage, loss, liability and
expense (including reasonable expenses of investigation and reasonable attorneys&#146; fees and expenses
in connection with any action, suit or proceeding whether involving a third party claim or a claim
solely between the parties hereto and any incidental, indirect or consequential damages, losses,
liabilities or expenses, and any lost profits or diminution in value) (&#147;<B>Damages</B>&#148;), incurred or
suffered by the Investors, their respective Affiliates and their respective successors and
assignees arising out of any misrepresentation or breach of warranty by any Group Company, any
Founder or any Controlling Shareholder (determined, without regard to any qualification or
exception contained therein relating to materiality or Material Adverse Effect or any similar
qualification or standard, including specified dollar thresholds) (each such misrepresentation and
breach of warranty a &#147;<B>Warranty Breach</B>&#148;) or breach of covenant or agreement made or to be performed
by any Group Company, any Founder or any Controlling Shareholder pursuant to this Agreement
regardless of whether such Damages arise as a result of the negligence, strict liability or any
other liability under any theory of law or equity of, or violation of any law by, any of the
Investors, their respective Affiliates or their respective successors or assignees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Notwithstanding anything to the contrary in this Agreement, each of the Group Companies,
the Founders and the Controlling Shareholders agrees to indemnify, jointly and severally, the
Investors, their respective Affiliates and their respective successors and assignees from and
against all Damages (including all reasonable costs and expenses of investigation by engineers,
environmental consultants and similar technical personnel), whether accrued, contingent, absolute,
determined, determinable or otherwise, incurred or suffered by Investors, any of such Affiliates or
any of their respective successors and assignees which relate to the Company or any Subsidiary and
which arise out of or relate to (i)&nbsp;any Environmental Law or Hazardous Substance and (ii)&nbsp;actions
occurring or conditions existing on or prior to the Closing Date regardless of whether such Damages
arise as a result of the negligence, strict liability or any other liability under any theory of
law or equity of, or violation of any law by, Investors, any of their respective Affiliates or
their respective successors or assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Notwithstanding anything to the contrary in this Agreement, each of the Group Companies,
the Founders and the Controlling Shareholders agrees to indemnify, jointly and severally, the
Investors, their respective Affiliates and their respective successors and assignees from (x)&nbsp;the
Tax of the Company or any of its Subsidiaries related to a Pre-Closing Tax Period, and (y)&nbsp;all
Damages arising out of or incident to the imposition, assessment or assertion of any Tax described
in (x)&nbsp;or any failure to pay such Tax.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.03. <I>Procedures</I>. The party seeking indemnification under 11.02 (the &#147;<B>Indemnified
Party</B>&#148;) agrees to give prompt notice to the party against whom indemnity is sought (the
&#147;<B>Indemnifying Party</B>&#148;) of the assertion of any claim, or the commencement of any suit, action or
proceeding in respect of which indemnity may be sought under such Section. The Indemnifying Party
may at the request of the Indemnified Party participate in and control the defense of any such
suit, action or proceeding at its own expense. The Indemnifying Party shall not be liable under
11.02 for any settlement effected without its consent of any claim, litigation or proceeding in
respect of which indemnity may be sought hereunder.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 12</B><BR>
<FONT style="font-variant: SMALL-CAPS">Termination</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.01<I>. Grounds for Termination</I>. This Agreement may be terminated at any time prior
to the Closing:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) by mutual written agreement of the Company and the Investors; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) by either the Company or the Investors if there shall be any Applicable Law that
makes consummation of the transactions contemplated hereby illegal or otherwise prohibited
or if consummation of the transactions contemplated hereby would violate any nonappealable
final order, decree or judgment of any Governmental Authority having competent
jurisdiction.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The party desiring to terminate this Agreement pursuant to clause 12.01(b) shall give notice of
such termination to the other party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.02<I>. Effect of Termination. </I>If this Agreement is terminated as permitted by
Section&nbsp;12.01, such termination shall be without liability of either party (or any stockholder,
director, officer, employee, agent, consultant or representative of such party) to the other party
to this Agreement; <I>provided </I>that if such termination shall result from the (i)&nbsp;willful failure of
either party to fulfill a condition to the performance of the obligations of the other party, (ii)
failure to perform a covenant of this Agreement or (iii)&nbsp;breach by either party hereto of any
representation or warranty or agreement contained herein, such party shall be fully liable for any
and all Damages incurred or suffered by the other party as a result of such failure or breach. The
provisions of this Section&nbsp;12.02 and Sections&nbsp;13.06, 13.07 and 13.08 shall survive any termination
hereof pursuant to Section&nbsp;12.01.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 13</B><BR>
<FONT style="font-variant: SMALL-CAPS">Miscellaneous</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.01. <I>Notices</I>. All notices and other communications hereunder shall be in writing
and shall be deemed effectively given upon personal delivery to the party to be notified; on the
next Business Day after delivery to a recognized overnight courier service; upon confirmation of
receipt of a facsimile transmission; or five days after deposit with a recognized postal service,
by registered or certified mail (return receipt requested), postage prepaid, to the parties at the
following addresses (or at such other address for a party as shall be specified by like notice;
provided that notices of a change of address shall be effective only upon receipt thereof):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If to CICC, to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">China International Capital Corporation<BR>
28<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor, China World Tower 2<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Facsimile: 86-10-6505-3796<BR>
Attention: Ms.&nbsp;Shirley Chen
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If to Carlyle, to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">The Carlyle Group<BR>
2518-2521, South Office Tower<BR>
Beijing Kerry Centre<BR>
No.&nbsp;1, Guang Hua Road<BR>
Chaoyang District<BR>
Beijing 100020<BR>
People&#146;s Republic of China<BR>
Facsimile: 86-10-8529-9877<BR>
Attention: Mr.&nbsp;Xiao Feng
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If to the Company, to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">Concord Medical Services Holdings Limited<BR>
P.O. Box 219<BR>
17/F, International Trade Building<BR>
Renmin Road South<BR>
Shenzhen, PRC<BR>
Facsimile: 86-755-8221-3077<BR>
Attention: Mr.&nbsp;Steve Sun, Chief Financial Officer
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or such other address or facsimile number as such party may hereafter specify for the purpose by
notice to the other parties hereto. All such notices, requests and other communications shall be
deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. in
the place of receipt and such day is a Business Day in the place of receipt. Otherwise, any such
notice, request or communication shall be deemed not to have been received until the next
succeeding Business Day in the place of receipt.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.02. <I>Amendments and Waivers</I>. (a)&nbsp;Any provision of this Agreement may be amended or
waived if, but only if, such amendment or waiver is in writing and is signed, in the case of an
amendment, by each party to this Agreement, or in the case of a waiver, by the party against whom
the waiver is to be effective.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;No failure or delay by any party in exercising any right, power or privilege hereunder
shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any
other or further exercise thereof or the exercise of any other right, power or privilege. The
rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies
provided by law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.03<I>. Disclosure Schedule&nbsp;References</I>. The parties hereto agree that any reference
in a particular Section of the Disclosure Schedule shall, unless otherwise stated therein, only be
deemed to be an exception to (or, as applicable, a disclosure for purposes of) the representations
and warranties (or covenants, as applicable) of the relevant party that are contained in the
corresponding Section of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.04. <I>Expenses</I>. Except as otherwise provided herein, all costs and expenses
incurred in connection with this Agreement shall be paid by the party incurring such cost or
expense. The Company shall pay all reasonable out-of-pocket costs and expenses of Investors in
connection with the negotiation of, preservation of rights under, and enforcement of, this
Agreement and the documents and instruments referred to herein (including, without limitation, the
reasonable fees and disbursements of counsel for the Investors). In the event that the Investors
pay any of the costs and expenses for which the Company is responsible for paying under this
Section&nbsp;13.04, the Company shall promptly reimburse the Investors for all such costs and expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.05. <I>Successors and Assigns</I>. The provisions of this Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and assigns;
<I>provided </I>that no party may assign, delegate or otherwise transfer any of its rights or obligations
under this Agreement without the consent of each other party hereto; except that Investors may
transfer or assign its rights and obligations under this Agreement, in whole or from time to time
in part, to (i)&nbsp;one or more of its Affiliates at any time and (ii)&nbsp;after the Closing Date, to any
Person; <I>provided </I>that no such transfer or assignment shall relieve Investors
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of its obligations hereunder or enlarge, alter or change any obligation of any other party hereto
or due to Investors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.06. <I>Governing Law</I>. This Agreement shall be governed by and construed in
accordance with the law of the State of New York, without regard to the conflicts of law rules of
such state.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.07. <I>Jurisdiction</I>. The parties hereto agree that any suit, action or proceeding
seeking to enforce any provision of, or based on any matter arising out of or in connection with,
this Agreement or the transactions contemplated hereby shall be brought in the United States
District Court for the Southern District of New York or any New York State court sitting in New
York City, so long as one of such courts shall have subject matter jurisdiction over such suit,
action or proceeding, and that any cause of action arising out of this Agreement shall be deemed to
have arisen from a transaction of business in the State of New York, and each of the parties hereby
irrevocably consents to the jurisdiction of such courts (and of the appropriate appellate courts
therefrom) in any such suit, action or proceeding and irrevocably waives, to the fullest extent
permitted by law, any objection that it may now or hereafter have to the laying of the venue of any
such suit, action or proceeding in any such court or that any such suit, action or proceeding
brought in any such court has been brought in an inconvenient forum. Process in any such suit,
action or proceeding may be served on any party anywhere in the world, whether within or without
the jurisdiction of any such court. Without limiting the foregoing, each party agrees that service
of process on such party as provided in Section&nbsp;13.01 shall be deemed effective service of process
on such party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.08. <I>WAIVER OF JURY TRIAL</I>. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES
ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.09. <I>Counterparts; Effectiveness; Third Party Beneficiaries</I>. This Agreement may be
signed in any number of counterparts, each of which shall be an original, with the same effect as
if the signatures thereto and hereto were upon the same instrument. This Agreement shall become
effective when each party hereto shall have received a counterpart hereof signed by all of the
other parties hereto. Until and unless each party has received a counterpart hereof signed by the
other party hereto, this Agreement shall have no effect and no party shall have any right or
obligation hereunder (whether by virtue of any other oral or written agreement or other
communication). No provision of this Agreement is intended to confer any rights, benefits,
remedies, obligations, or liabilities hereunder upon any Person other than the parties hereto and
their respective successors and assigns.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.10. <I>Entire Agreement</I>. This Agreement constitutes the entire agreement between the
parties with respect to the subject matter of this Agreement and supersedes all prior agreements
and understandings, both oral and written, between the parties with respect to the subject matter
of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.11. <I>Severability. </I>If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction or other Governmental Authority to be
invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions
of this Agreement shall remain in full force and effect and shall in no way be affected, impaired
or invalidated so long as the economic or legal substance of the transactions contemplated hereby
is not affected in any manner materially adverse to any party. Upon such a determination, the
parties shall negotiate in good faith to modify this Agreement so as to effect the original intent
of the parties as closely as possible in an acceptable manner in order that the transactions
contemplated hereby be consummated as originally contemplated to the fullest extent possible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.12. <I>Specific Performance. </I>The parties hereto agree that irreparable damage would
occur if any provision of this Agreement were not performed in accordance with the terms hereof and
that the parties shall be entitled to an injunction or injunctions to prevent breaches of this
Agreement or to enforce specifically the performance of the terms and provisions hereof in the
United States District Court for the Southern District of New York or any New York State court
sitting in New York City, in addition to any other remedy to which they are entitled at law or in
equity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;13.13. <I>Joint Drafting. </I>Each party hereto has participated in the drafting of this
Agreement, which each party acknowledges is the result of extensive negotiations between the
parties. If an ambiguity or question of intent or interpretation arises, this Agreement shall be
construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise
favoring or disfavoring any party by virtue of the authorship of any provision.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their
respective authorized officers as of the day and year first above written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CONCORD MEDICAL SERVICES <BR>
HOLDINGS LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Ku Wai Hong
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Ku Wai Hong&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Director&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">ASCENDIUM GROUP LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Director&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">OUR MEDICAL SERVICES, LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Director&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">SHENZHEN AOHUA MEDICAL SERVICES<BR>
CO., LTD. <br>(<IMG src="h03611h0361145.gif" alt="(CHINESE CHARACTER)">)<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Director&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Liu Haifeng
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Liu Haifeng, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Steve Sun
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Steve Sun, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Yang Jianyu, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Bona Liu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Bona Liu, in her individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CICC SUN COMPANY LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Shirley Chen
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Shirley Chen&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Director&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CARLYLE ASIA GROWTH PARTNERS III, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP General Partner, L.P., as its
General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP, Ltd., as the General Partner of
CAGP General Partner, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CAGP III CO-INVESTMENT, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP General Partner, L.P., as its
General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP, Ltd., as the General Partner of
CAGP General Partner, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FORM OF SHAREHOLDERS&#146; AGREEMENT</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">See Attached.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->A-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>ANNEX I</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;11.01 of the Amended and Restated Convertible Loan Agreement</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">See Attached.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->S-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>ANNEX II</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Provisions to be Included in<BR>
Amended and Restated Memorandum and Articles</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">See Attached.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->S-2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Schedule&nbsp;1.01</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PURCHASE PRICES IN US DOLLARS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name of Investor</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2" style="border-bottom: 1px solid #000000"><B>US Dollars</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CICC Sun Company Limited</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,000,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Carlyle Asia Growth Partners III, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,808,250</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CAGP III Co-Investment III, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">191,750</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->S-3<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Schedule&nbsp;5.01(b)</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GOVERNMENT CONSENTS</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See attached

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->S-4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Schedule&nbsp;5.07(a)</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>REGISTERED CAPITAL OF PRC SUBSIDIARIES</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="75%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Subsidiary Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Registered Capital</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Shenzhen Aohua Medical Services Co., Ltd.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">US$6,134,000</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->S-5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Schedule&nbsp;5.08(a)</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GROUP COMPANIES</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Company Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Jurisdiction of Incorporation</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Concord Medical Services Limited
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Cayman Islands</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Ascendium Group Limited
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">British Virgin Islands</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Our Medical Services, Ltd.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">British Virgin Islands</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Shenzhen Aohua Medical Services Co., Ltd.
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">PRC</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->S-6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Schedule&nbsp;5.09(a)</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AUDITED FINANCIAL STATEMENTS<BR>
AND<BR>
UNAUDITED MANAGEMENT ACCOUNTS</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See Attached

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->S-7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Schedule&nbsp;5.13(h)</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>INDEBTEDNESS DURING INTERIM PERIOD</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See attached

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->S-8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Schedule&nbsp;5.13(k)(iii)</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EMPLOYMENT AGREEMENTS</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See attached

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->S-9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Schedule&nbsp;5.20(f)</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LIST OF DOMAIN NAMES</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See attached

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->S-10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Schedule&nbsp;5.21(a)</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LIST OF MAJOR CONTRACTS</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See Attached.

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->S-11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Schedule&nbsp;5.21(d)</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>LIST OF OTHER CONTRACTS</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See attached

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->S-12<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>6
<FILENAME>h03611exv4w5.htm
<DESCRIPTION>EX-4.5
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.5</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.5</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXECUTION COPY</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENT TO SHARE SUBSCRIPTION AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMENDMENT TO SHARE SUBSCRIPTION AGREEMENT (this &#147;<B>Amendment</B>&#148;) dated as of April&nbsp;2, 2008 (the
&#147;<B>Amendment Date</B>&#148;) by and among (1)&nbsp;CICC Sun Company Limited, a company incorporated under the laws
of the British Virgin Islands (&#147;<B>CICC</B>&#148;), (2)&nbsp;Carlyle Asia Growth Partners III, L.P., a limited
partnership formed under the laws of the Cayman Islands (&#147;<B>CAGP</B>&#148;), (3)&nbsp;CAGP III Co-Investment III,
L.P. (&#147;<B>CAGP Co-Invest</B>&#148;, together with CAGP, &#147;<B>Carlyle</B>&#148;), (4)&nbsp;Liu Haifeng, a PRC citizen with
passport number G19230849, (5)&nbsp;Steve Sun, a US citizen with passport number 203018867, (6)&nbsp;Yang
Jianyu, a PRC citizen with passport number G04036294, (7)&nbsp;Bona Liu, a New Zealand citizen with
passport number EA713283, (8)&nbsp;Our Medical Services, Ltd., a company formed under the Laws of the
British Virgin Islands, (9)&nbsp;Ascendium Group Limited, a company formed under the Laws of the British
Virgin Islands, (10)&nbsp;Shenzhen Aohua Medical Services Co., Ltd. <IMG src="h03611h0361112.gif" alt="(Chinese character)"> a
Sino-foreign joint venture formed under the laws of the PRC, and (11)&nbsp;Concord Medical Services
Holdings Ltd., a company incorporated under the laws of the Cayman Islands (the &#147;<B>Company</B>&#148;).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>W I T N E S S E T H :</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the parties hereto entered into a Share Subscription Agreement dated as of February
5, 2008 (the &#147;<B>Agreement</B>&#148;) pursuant to which the Company agreed to issue and sell to each of CICC
and Carlyle and each of CICC and Carlyle agreed to subscribe for certain shares of the Company on
the terms and conditions set forth in the Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the parties hereto desire to amend the Agreement to reflect the changes set forth
herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, the parties hereto agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;1</B><I>. Amendments. </I>(a)&nbsp;The Agreement is amended by adding the following definition to
Section&nbsp;1.01:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Conversion Ratio</B>&#148; means the number of Ordinary Shares into which one Series&nbsp;A Share
is convertible pursuant to the Amended and Restated Memorandum and Articles.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Agreement is amended by replacing the existing Sections&nbsp;3.01(b)(iii) and 3.01(b)(iv)
with the following new Sections&nbsp;3.01(b)(iii) and 3.01(b)(iv):
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Carlyle shall have the right, at its sole option, to convert the
Mandatory Convertible Loan into a number of Series&nbsp;A Shares (the &#147;<B>Conversion
Shares</B>&#148;) as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) Carlyle shall have the right, at its sole option, to convert
the Mandatory Convertible Loan into the Conversion Shares at any time
during a period starting from (and including) the day which immediately
follows the Closing Date to (and including) August&nbsp;31, 2008. If Carlyle
exercises such conversion right, the Mandatory Convertible Loan shall be
converted into a number of Conversion Shares equal to (x)&nbsp;the
Pre-Conversion Shares <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which
is the Mandatory Loan Conversion Amount, and the denominator of which is
equal to (I)&nbsp;RMB1,100,000,000 <I>minus </I>(II)&nbsp;the Mandatory Loan Conversion
Amount, <I>divided </I>by (z)&nbsp;the then-effective Conversion Ratio; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) Carlyle shall have the right, at its sole option, to convert
the Mandatory Convertible Loan into the Conversion Shares at any time
during a period starting from (and including) the date on which the 2008
Audited Financial Statements are completed to (and including) April&nbsp;29,
2009. If Carlyle exercises such conversion right, the Mandatory
Convertible Loan shall be converted into a number of Conversion Shares
equal to (x)&nbsp;the Pre-Conversion Shares <I>multiplied </I>by (y)&nbsp;a ratio, the
numerator of which is the Mandatory Loan Conversion Amount, and the
denominator of which is equal to (I)&nbsp;10 times of the 2008 Net Income (as
defined below) <I>minus </I>(II)&nbsp;the Mandatory Loan Conversion Amount, <I>divided</I>
by (z)&nbsp;the then-effective Conversion Ratio.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) If the IPO Date occurs after August&nbsp;31, 2008 but prior to the
completion of the 2008 Audited Financial Statements and the Mandatory Convertible
Loan is outstanding as of the IPO Date, the Mandatory Convertible Loan shall be
automatically converted, on the IPO Date, into a number of Series&nbsp;A Shares equal
to (x)&nbsp;the Pre-Conversion Shares <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of
which is the Mandatory Loan Conversion Amount, and the denominator of which is
equal to (I)&nbsp;10 times the projected consolidated after-tax net income of the
Company for the Company&#146;s fiscal year ending December&nbsp;31, 2008, as disclosed to
the public in the IPO (<I>provided </I>that the result of the calculation in this clause
(I)&nbsp;shall not exceed (<FONT style="font-family: symbol">&#097;</FONT>) the number of the outstanding Ordinary Shares
immediately prior to the IPO Date <I>multiplied </I>by (&#181;) the lower end of the last
price range disclosed to the public in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">connection with the IPO) <I>minus </I>(II)&nbsp;the Mandatory Loan Conversion Amount, <I>divided</I>
by (z)&nbsp;the then-effective Conversion Ratio.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Agreement is amended by replacing the existing Section&nbsp;3.02 with the following new
Section&nbsp;3.02:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.02. <I>Optional Additional Investment</I>. If the Company has not exercised the
Mandatory Additional Investment Right by March&nbsp;31, 2008, Carlyle shall have the right (the
&#147;<B>Optional Additional Investment Right</B>&#148;) to purchase and subscribe for, at any time by
August&nbsp;31, 2008, a number of Series&nbsp;A Shares (the &#147;<B>Additional Carlyle Purchased Shares</B>&#148;)
for US$20,000,000. The Additional Carlyle Purchased Shares shall equal to (x)&nbsp;the number
of outstanding Ordinary Shares as of the date of such purchase immediately prior to the
consummation of such purchase, calculated on a Fully-Diluted basis (which for the purposes
of this Section 3.02 shall exclude any Ordinary Shares issuable upon the exercise of any employee
stock options), <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which is equal to the RMB
equivalent of US$20,000,000 calculated with the spot exchange rate between US dollars and
RMB as quoted by the People&#146;s Bank of China on the date of such purchase (the &#147;<B>Additional
Carlyle Purchase Price</B>&#148;), and the denominator of which is equal to (i)&nbsp;RMB1,100,000,000
<I>minus </I>(ii)&nbsp;the Additional Carlyle Purchase Price, <I>divided </I>by (z)&nbsp;the then-effective
Conversion Ratio. In order to exercise the Optional Additional Investment Right, Carlyle
shall deliver a written notice to the Company no later than 5 Business Days prior to the
proposed purchase date set forth in such notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Agreement is amended by replacing the existing Section&nbsp;4.04(a) with the following new
Section&nbsp;4.04(a):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) transfer to Carlyle free of charge a number of Ordinary Shares equal to (x)&nbsp;the
Conversion Shares or the Additional Carlyle Purchased Shares, as applicable, <I>multiplied </I>by
(y)&nbsp;the Conversion Ratio effective on the date the Mandatory Convertible Loan is converted
to Conversion Shares or the date Carlyle purchases the Additional Carlyle Purchased
Shares, as applicable, <I>multiplied </I>by (z)&nbsp;a ratio, the numerator of which is equal to (i)
RMB1,100,000,000 <I>minus </I>(ii)&nbsp;10 times the 2008 Net Income, and the denominator of which is
equal to (I)&nbsp;10 times the 2008 Net Income <I>minus </I>(II)&nbsp;the Mandatory Loan Conversion Amount
or the Additional Carlyle Purchase Price, as applicable; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;2</B><I>. Effect of Amendment. </I>Except as amended by this Amendment, the Agreement shall
remain unchanged and in full force and effect. From and after the Amendment Date, each reference
to &#147;this Agreement,&#148; &#147;hereof,&#148; &#147;hereunder&#148; or words of like import, and all references to the
Agreement in any and all agreements, instruments, documents, notes, certificates and other writings
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of every kind and nature shall be deemed to mean the Agreement as amended by this Amendment,
except as is otherwise expressly stated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;3</B><I>. General. </I>(a)&nbsp;This Amendment shall be binding on the successors and permitted
assigns of the parties hereto; (b)&nbsp;this Amendment shall be governed by and construed in accordance
with the laws of the State of New York, without regard to conflicts of law principles thereunder
and shall be subject to the jurisdiction of the courts in the State of New York; (c)&nbsp;this Amendment
may be executed in more than one counterpart, each of which shall be deemed an original and any
counterpart so executed shall be deemed to be one and the same instrument; (d)&nbsp;each party hereto
acknowledges that the parties hereto have participated jointly in the negotiation and drafting of
this Amendment, and in the event an ambiguity or question of intent or interpretation arises, this
Amendment shall be construed as if drafted jointly by the parties hereto and no presumption or
burden of proof shall arise favoring or disfavoring any party hereto by virtue of the authorship of
any of the provisions of this Amendment; (e)&nbsp;if any part of any provision of this Amendment shall
be invalid or unenforceable under applicable law, such part shall be ineffective to the extent of
such invalidity only, without in any way affecting the remaining parts of such provision or the
remaining provisions of this Amendment; and (f)&nbsp;each party hereto acknowledges that the remedies at
law of the other parties hereto for a breach or threatened breach of this Amendment would be
inadequate and, in recognition of this fact, any party hereto, without posting any bond, and in
addition to all other remedies that may be available, shall be entitled to obtain equitable relief
in the form of specific performance, a temporary restraining order, a temporary or permanent
injunction or any other equitable remedy that may then be available.
</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><I>&#091;The remainder of this page has been intentionally left blank; the next page is the signature page.&#093;</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXECUTION COPY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment as of the date first
written above.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CONCORD MEDICAL SERVICES HOLDINGS LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">ASCENDIUM GROUP LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">OUR MEDICAL SERVICES LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">SHENZHEN AOHUA MEDICAL SERVICES CO., LTD.<BR>
<IMG src="h03611h0361113.gif" alt="(Chinese character)">
<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Liu Haifeng
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Liu Haifeng, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Steve Sun
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Steve Sun, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Yang Jianyu, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Bona Liu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Bona Liu, in her individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CICC SUN COMPANY LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Shirley Shiyou Chen
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Shirley Shiyou Chen&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CARLYLE ASIA GROWTH PARTNERS III, L.P.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 0px solid #000000" align="left">CAGP General Partner, L.P., as its General Partner
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 0px solid #000000" align="left">CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Daniel A. D&#146;Aniello
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Daniel A. D&#146;Aniello&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Director&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CAGP III CO-INVESTMENT, L.P.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 0px solid #000000" align="left">CAGP General Partner, L.P., as its General Partner
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 0px solid #000000" align="left">CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Daniel A. D&#146;Aniello
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Daniel A. D&#146;Aniello&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Director&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>7
<FILENAME>h03611exv4w6.htm
<DESCRIPTION>EX-4.6
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.6</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.6</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXECUTION COPY</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENT NO. 2 TO SHARE SUBSCRIPTION AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMENDMENT NO. 2 TO SHARE SUBSCRIPTION AGREEMENT (this &#147;<B>Amendment No.&nbsp;2</B>&#148;) dated as of October
20, 2008 (the &#147;<B>Amendment Date</B>&#148;) by and among (1)&nbsp;CICC Sun Company Limited, a company incorporated
under the laws of the British Virgin Islands (&#147;<B>CICC</B>&#148;), (2)&nbsp;Carlyle Asia Growth Partners III, L.P.,
a limited partnership formed under the laws of the Cayman Islands (&#147;<B>CAGP</B>&#148;), (3)&nbsp;CAGP III
Co-Investment, L.P. (&#147;<B>CAGP Co-Invest</B>&#148;, together with CAGP, &#147;<B>Carlyle</B>&#148;), (4)&nbsp;Concord Medical Services
Holdings Limited, an exempted company with limited liability organized and existing under the laws
of the Cayman Islands (the &#147;<B>Company</B>&#148;), (5)&nbsp;the Controlling Shareholders (as defined below) and (6)
the other parties listed on the signature page hereof.
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>W I T N E S S E T H:</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, pursuant to a Share Subscription Agreement dated as of February&nbsp;5, 2008 (the
&#147;<B>Original Agreement</B>&#148;), the Company agreed to issue and sell to each of CICC and Carlyle and each of
CICC and Carlyle agreed to subscribe for certain Series&nbsp;A redeemable convertible preferred shares
of the Company on the terms and conditions set forth in the Original Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, certain terms in the Original Agreement were amended pursuant to an Amendment to
Share Subscription Agreement dated as of April&nbsp;2, 2008 (the &#147;<B>Amendment No.&nbsp;1</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the parties hereto and certain other parties entered into a Share Subscription
Agreement dated as of October&nbsp;10, 2008, as amended on October&nbsp;20, 2008 (the &#147;<B>Series&nbsp;B Share
Subscription Agreement</B>&#148;), pursuant to which the Company agreed to issue and sell to each of CICC
and Carlyle and each of CICC and Carlyle agreed to subscribe for certain Series&nbsp;B redeemable
convertible preferred shares, par value US$0.01 per share, of the Company (the &#147;<B>Series&nbsp;B Shares</B>&#148;)
on the terms and conditions set forth therein;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the parties hereto desire to amend the Original Agreement, as amended by the
Amendment No.&nbsp;1 (the &#147;<B>Existing Agreement</B>&#148;), to reflect the changes set forth herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, the parties hereto agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 1<I>. Amendments. </I>(a)&nbsp;The Existing Agreement is amended by deleting the existing
definition of &#147;Controlling Shareholders&#148; in the preamble.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Existing Agreement is amended by adding the following definitions to Section&nbsp;1.01:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&#147;<B>Amended and Restated Shareholders&#146; Agreement</B>&#148; means the Amended and
Restated Shareholders&#146; Agreement dated October&nbsp;8, 2008 by and among the Company,
Carlyle, CICC, the Controlling Shareholders and certain other Persons listed on
the signature pages thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&#147;<B>Amendment to Convertible Loan Agreement</B>&#148; means the Amendment to Convertible
Loan Agreement dated October&nbsp;20, 2008 by and among the Company, Carlyle, the
Controlling Shareholders and the Group Companies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&#147;<B>China Medstar</B>&#148; means China Medstar Pte. Ltd., a company incorporated under
the laws of Singapore.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&#147;<B>Controlling Shareholders</B>&#148; means, collectively, the following Persons:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(1)&nbsp;Mr.&nbsp;Cheng
Zheng (<IMG src="h03611h0361114.gif" alt="(Chinese Character)">), a PRC citizen with passport number G14947877 (&#147;<B>Mr.
Cheng</B>&#148;);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(2)&nbsp;CZY Investments Limited, a company incorporated under the laws of the British
Virgin Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Cheng;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(3)&nbsp;Mr.&nbsp;Yang;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(4)&nbsp;Daketala International Investment Holdings Ltd., a company incorporated under
the laws of the British Virgin Islands and a direct wholly owned Subsidiary of
Mr.&nbsp;Yang;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(5)&nbsp;Mr.&nbsp;Sun;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(6)&nbsp;Dragon Image Investment Ltd., a company incorporated under the laws of the
British Virgin Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Sun;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(7)&nbsp;Mr.&nbsp;Zhang Jing (<IMG src="h03611h0361115.gif" alt="(Chinese Character)">), a PRC citizen with passport number G10824344 (&#147;<B>Mr.
Zhang</B>&#148;);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(8)&nbsp;Thousand Ocean Group Limited, a company incorporated under the laws of the
British Virgin Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Zhang;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(9)&nbsp;Mr.&nbsp;Yap Yaw Kong (<IMG src="h03611h0361116.gif" alt="(Chinese Character)">), a Malaysia citizen with passport number A15954913
(&#147;<B>Mr.&nbsp;Yap</B>&#148;);
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(10)&nbsp;Top Mount Group Limited, a company incorporated under the laws of the
British Virgin Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Yap;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(11)&nbsp;Mr.&nbsp;Liu;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(12)&nbsp;Ms.&nbsp;Bona Lau, a New Zealand citizen with passport EA713283 (&#147;<B>Ms.&nbsp;Lau</B>&#148;); and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(13)&nbsp;Notable Enterprise Limited, a company incorporated under the laws of the
British Virgin Islands and a direct wholly owned Subsidiary of Ms.&nbsp;Lau.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Convertible Loans</B>&#148; means, collectively, (i)&nbsp;the convertible loan in the
principal amount of US$5,000,000 borrowed by the Company from Carlyle pursuant to
the Amended and Restated Convertible Loan Agreement by and among the Company,
Carlyle and certain other parties thereto dated as of April&nbsp;2, 2008, and (ii)&nbsp;the
convertible loan in the principal amount of US$20,000,000 borrowed by the Company
from Carlyle pursuant to the Convertible Loan Agreement by and among the Company,
Carlyle and certain other parties thereto dated as of April&nbsp;10, 2008, as amended
by the Amendment to Convertible Loan Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>QPO</B>&#148; means a firm-commitment underwritten IPO (i)&nbsp;led by an internationally
reputable underwriter, approved by a majority of the Board of Directors (which
majority shall include the Carlyle Director, the CICC Director and the Starr
Director, and yielding a valuation of the Company at not less than US$450&nbsp;million
immediately prior to the consummation of such IPO, or (ii)&nbsp;any other IPO approved
by holders of at least 70% of the then outstanding Series&nbsp;B Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>QPO Date</B>&#148; means the date on which the QPO is consummated.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Second Amended and Restated Memorandum and Articles</B>&#148; means the Second
Amended and Restated Memorandum and Articles of the Company adopted by the board
of directors and shareholders of the Company on October&nbsp;20, 2008.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Series&nbsp;B Shares</B>&#148; means the Series&nbsp;B redeemable convertible preferred
shares, par value US$0.01 per share, of the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Existing Agreement is amended by replacing the existing definitions of &#147;Group&#148; and
&#147;2008 Net Income&#148; in Section&nbsp;1.01 with the following new definitions, respectively:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Group</B>&#148; means, at any time, collectively, the Company and all direct and
indirect then-current and future Subsidiaries of the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>2008 Net Income</B>&#148; means the consolidated after-tax net income of the Company
for the Company&#146;s fiscal year ending December&nbsp;31, 2008; provided that (i)&nbsp;the
2008 Net Income shall not include the cumulative effect of any change or changes
in accounting principles; (ii)&nbsp;the 2008 Net Income shall not include any
extraordinary or non-recurring earnings obtained or losses incurred by any Group
Company; (iii)&nbsp;the 2008 Net Income shall not include non-cash charges or expenses
relating to any share-based compensation, the Convertible Loans, Series&nbsp;A Shares
and Series&nbsp;B Shares; (iv)&nbsp;the 2008 Net Income shall not include the consolidated
after-tax net income generated from sales of medical equipment by China Medstar
and its Subsidiaries to the extent it exceeds 30% of China Medstar&#146;s consolidated
after-tax net income for the year ending December&nbsp;31, 2008 (the calculation of
which shall not include (A)&nbsp;the cumulative effect of any change or changes in
accounting principles and (B)&nbsp;any extraordinary or non-recurring earnings or
losses); (v)&nbsp;the 2008 Net Income shall include the consolidated after-tax net
income of China Medstar for the whole year ending December&nbsp;31, 2008 and, if such
inclusion is agreed to by all Investors, the full-year after-tax net income of
any other business that the Company may have acquired after the date hereof; and
(vi)&nbsp;any dividend paid by the Company on the Preferred Shares pursuant to the
Second Amended and Restated Memorandum and Articles shall not be deemed expenses
for the purposes of calculating 2008 Net Income. For the avoidance of doubt, any
accounts receivable generated by the Company during the Company&#146;s fiscal year
ending December&nbsp;31, 2008 and written off by the Company in connection with the
audit of the 2008 Audited Financial Statements shall not be deemed a
non-recurring loss and shall be included as a loss when calculating the 2008 Net
Income.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Existing Agreement is amended by adding the following rows to the table in Section
1.01(b):
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Pre-Closing Options
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8.16</TD>
    <TD nowrap valign="top">(a)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Post Closing Options
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8.16</TD>
    <TD nowrap valign="top">(b)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Existing Agreement is amended by replacing the existing Article&nbsp;4 with the following
new Article&nbsp;4:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><FONT style="font-variant: SMALL-CAPS">ARTICLE 4</FONT><BR>
<FONT style="font-variant: SMALL-CAPS">Earning Adjustments</FONT>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.01<I>. Calculation of 2008 Net Income. </I>As soon as practicable and
in any event within one hundred and fifty (150)&nbsp;days after the end of the
Company&#146;s fiscal year ending December&nbsp;31, 2008, the Company shall complete the
2008 Audited Financial Statements and on the same date of such completion have
the accounting firm who prepared the 2008 Audited Financial Statements calculate
the 2008 Net Income based on the 2008 Audited Financial Statements.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.02<I>. Adjustment with respect to the Subscription. </I>If the 2008 Net
Income is lower than the RMB equivalent of US$21,430,000 (calculated with the
spot exchange rate between US dollars and RMB as quoted by the People&#146;s Bank of
China on the Closing Date), the Controlling Shareholders shall, jointly and
severally,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) transfer to each Investor free of charge a number of Ordinary Shares
equal to (x)&nbsp;the number of such Investor&#146;s Purchased Shares, <I>multiplied </I>by (y)&nbsp;a
ratio, the numerator of which is equal to (i)&nbsp;7 times the RMB equivalent of
US$21,430,000 (calculated with the spot exchange rate between US dollars and RMB
as quoted by the People&#146;s Bank of China on the Closing Date) <I>minus </I>(ii)&nbsp;7 times
the 2008 Net Income, and the denominator of which is equal to (I)&nbsp;7 times the
2008 Net Income <I>minus </I>(II)&nbsp;the Total Closing Investment; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) pay to each Investor the US dollar equivalent (calculated with the spot
exchange rate between US dollars and RMB as quoted by the People&#146;s Bank of China
on the date of such payment) of an amount equal to (x)&nbsp;the Purchase Price of such
Investor, <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which is equal to (i)&nbsp;7
times the RMB equivalent of US$21,430,000 (calculated with the spot exchange rate
between US dollars and RMB as quoted by the People&#146;s Bank of China on the Closing
Date) <I>minus </I>(ii)&nbsp;7 times the 2008 Net Income, and the denominator of which is
equal to (I)&nbsp;7 times the RMB equivalent of US$21,430,000 (calculated with the
spot exchange rate between US dollars and RMB as quoted by the People&#146;s Bank of
China on the Closing Date) <I>minus </I>(II)&nbsp;the Total Closing Investment, <I>multiplied </I>by
(z)&nbsp;0.3.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4<I>.</I>03. <I>Adjustment with respect to the Carlyle Loan Conversion. </I>If
the 2008 Net Income is lower than the RMB equivalent of US$21,430,000 (calculated
with the spot exchange rate between US dollars and RMB as quoted by the People&#146;s
Bank of China on the Closing Date), the Controlling Shareholders shall, jointly
and severally,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) transfer to Carlyle free of charge a number of Ordinary Shares equal to
(x)&nbsp;the number of Series&nbsp;A Shares Carlyle acquired as a result of the Carlyle
Loan Conversion <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which is equal to (i)
7 times the RMB equivalent of US$21,430,000 (calculated with the spot exchange
rate between US dollars and RMB as quoted by the People&#146;s Bank of China on the
Closing Date) <I>minus </I>(ii)&nbsp;7 times the 2008 Net Income, and the denominator of
which is equal to (I)&nbsp;7 times the 2008 Net Income <I>minus </I>(II)&nbsp;the Total Closing
Investment; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) pay to Carlyle the US dollar equivalent (calculated with the spot
exchange rate between US dollars and RMB as quoted by the People&#146;s Bank of China
on the date of such payment) of an amount equal to (x)&nbsp;the Existing Carlyle Loan
Conversion Amount, <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which is equal to
(i)&nbsp;7 times the RMB equivalent of US$21,430,000 (calculated with the spot
exchange rate between US dollars and RMB as quoted by the People&#146;s Bank of China
on the Closing Date) <I>minus </I>(ii)&nbsp;7 times the 2008 Net Income, and the denominator
of which is equal to (I)&nbsp;7 times the RMB equivalent of US$21,430,000 (calculated
with the spot exchange rate between US dollars and RMB as quoted by the People&#146;s
Bank of China on the Closing Date) <I>minus </I>(II)&nbsp;the Total Closing Investment,
<I>multiplied </I>by (z)&nbsp;0.3.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.04. <I>Procedure of Adjustment</I>. The adjustments set forth in
Sections&nbsp;4.02 and 4.03 shall be made within five (5)&nbsp;Business Days of the day on
which the 2008 Net Income is calculated pursuant to Section&nbsp;4.01. On each date
on which the adjustments are to be made, the Controlling Shareholders shall (i)
deliver to each Investor a copy of the updated register of members of the Company
dated such date and duly certified by a duly authorized director of the Company
evidencing such Investor&#146;s ownership of the Ordinary Shares transferred to such
Investor pursuant to Sections&nbsp;4.02 and 4.03, respectively, which Ordinary Shares
shall be free and clear of any Lien (including any restrictions on the voting
rights or transferability of such Ordinary Shares other than those restrictions
set forth in this Agreement) and duly authorized, validly issued, fully paid and
non-assessable; and (ii)&nbsp;cause the Company to deliver to such Investor a
certificate representing such Ordinary Shares.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.05. <I>Termination of Adjustment Rights</I>. Sections&nbsp;4.01 through 4.04
shall terminate upon the occurrence of the QPO.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The Existing Agreement is amended by replacing the existing Section&nbsp;8.11 with the
following new Section&nbsp;8.11:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.11. <I>QPO. </I>Each Group Company and each Controlling Shareholder
shall use its or his or her best efforts to complete the QPO by the third
anniversary of the closing of subscription contemplated by the Series&nbsp;B Share
Subscription Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;The Existing Agreement is amended by replacing the existing Section&nbsp;8.16 with the
following new Section&nbsp;8.16:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.16. <I>Employee Stock Options</I>. (a)&nbsp;Notwithstanding anything to the
contrary set forth in Section&nbsp;8.01, prior to the Closing Date (as defined in the
Series&nbsp;B Share Subscription Agreement), the Company may adopt an employee share
option plan under which the Company will be authorized to grant a maximum number
of share options equal to 1.5% of the Ordinary Shares outstanding immediately
prior to the Closing (as defined in the Series&nbsp;B Share Subscription Agreement),
calculated on a Fully-Diluted basis (the &#147;<B>Pre-Closing Options Pool</B>&#148;).
Notwithstanding anything to the contrary set forth in the Amended and Restated
Shareholders&#146; Agreement and the Second Amended and Restated Memorandum and
Articles, the majority of the directors of the Company (which majority shall
include the directors designated by Carlyle and CICC pursuant to the
Shareholders&#146; Agreement or the Amended and Restated Shareholders&#146; Agreement, as
applicable) shall have the sole right to determine the granting of the share
options in the Pre-Closing Options Pool.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The majority of the directors of the Company (which majority shall
include all directors designated by the Investors pursuant to the Amended and
Restated Shareholders&#146; Agreement) may adopt an employee share option plan under
which the Company will be authorized to grant a maximum number of share options
equal to 3.0% of the Ordinary Shares outstanding on (x)&nbsp;the QPO Date or (y)&nbsp;April
30, 2009, whichever is earlier, calculated on a Fully-Diluted basis (the
&#147;<B>Post-Closing Options Pool</B>&#148;); <I>provided </I>that (A)&nbsp;no share options in the
Post-Closing Options Pool shall be granted to any of the Controlling Shareholders
unless such grant has been approved by all directors of the Company designated by
the Investors pursuant the Amended and Restated Shareholders&#146; Agreement, and (B)
the exercise price
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">of any such share option shall not be lower than the fair market value of
the Ordinary Share on a per share basis on the date that such share option is
granted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 2<I>. Effect of Amendment. </I>Except as amended by this Amendment No.&nbsp;2, the Existing
Agreement shall remain unchanged and in full force and effect. From and after the Amendment Date,
each reference to &#147;this Agreement,&#148; &#147;hereof,&#148; &#147;hereunder&#148; or words of like import, and all
references to the Agreement in any and all agreements, instruments, documents, notes, certificates
and other writings of every kind and nature shall be deemed to mean the Existing Agreement as
amended by this Amendment No.&nbsp;2, except as is otherwise expressly stated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SECTION 3<I>. General. </I>(a)&nbsp;This Amendment No.&nbsp;2 shall be binding on the successors and
permitted assigns of the parties hereto; (b)&nbsp;this No.&nbsp;2 Amendment shall be governed by and
construed in accordance with the laws of the State of New York, without regard to conflicts of law
principles thereunder and shall be subject to the jurisdiction of the courts in the State of New
York; (c)&nbsp;this Amendment No.&nbsp;2 may be executed in more than one counterpart, each of which shall be
deemed an original and any counterpart so executed shall be deemed to be one and the same
instrument; (d)&nbsp;each party hereto acknowledges that the parties hereto have participated jointly in
the negotiation and drafting of this Amendment No.&nbsp;2, and in the event an ambiguity or question of
intent or interpretation arises, this Amendment No.&nbsp;2 shall be construed as if drafted jointly by
the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any
party hereto by virtue of the authorship of any of the provisions of this Amendment No.&nbsp;2; (e)&nbsp;if
any part of any provision of this Amendment No.&nbsp;2 shall be invalid or unenforceable under
applicable law, such part shall be ineffective to the extent of such invalidity only, without in
any way affecting the remaining parts of such provision or the remaining provisions of this
Amendment; and (f)&nbsp;each party hereto acknowledges that the remedies at law of the other parties
hereto for a breach or threatened breach of this Amendment No.&nbsp;2 would be inadequate and, in
recognition of this fact, any party hereto, without posting any bond, and in addition to all other
remedies that may be available, shall be entitled to obtain equitable relief in the form of
specific performance, a temporary restraining order, a temporary or permanent injunction or any
other equitable remedy that may then be available.
</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><I>&#091;The remainder of this page has been intentionally left blank&#093;</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment No.&nbsp;2 as of the date
first written above.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CONCORD MEDICAL SERVICES HOLDINGS<BR>
LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">ASCENDIUM GROUP LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CHINA MEDSTAR PTE. LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CYBER MEDICAL NETWORK LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">OUR MEDICAL SERVICES, LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CHINA MEDICAL SERVICES (HOLDINGS)<BR>
LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">SHENZHEN AOHUA MEDICAL SERVICES CO., LTD.<BR>
<IMG src="h03611h0361117.gif" alt="CHINESE CHARACTER">
<BR>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">SHENZHEN AOHUA MEDICAL LEASING AND SERVICES CO., LTD.<BR>
<IMG src="h03611h0361118.gif" alt="CHINESE CHARACTER">
<BR>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">SHANGHAI MEDSTAR LEASING CO., LTD.<BR>
<IMG src="h03611h0361119.gif" alt="CHINESE CHARACTER">
<BR>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CMS HOSPITAL MANAGEMENT CO., LTD.<BR>
<IMG src="h03611h0361120.gif" alt="CHINESE CHARACTER">
<BR>      &nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Steve Sun
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Steve Xiaodi Sun, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">DRAGON IMAGE INVESTMENT LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Steve Sun
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Steven Xiaodi Sun&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Yang Jianyu, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">DAKETALA INTERNATIONAL INVESTMENT<BR>
HOLDINGS LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Bona Lau
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Bona Lau, in her individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">NOTABLE ENTERPRISE LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Bona Lau
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Bona Lau&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Cheng Zheng
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Cheng Zheng, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CZY INVESTMENTS LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Cheng Zheng
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Cheng Zheng&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Zhang Jing
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Zhang Jing, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">THOUSAND OCEAN GROUP LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Zhang Jing
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Zhang Jing&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Yap Yaw Kong
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Yap Yaw Kong, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">TOP MOUNT GROUP LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yap Yaw Kong
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yap Yaw Kong&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Liu Haifeng
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Liu Haifeng, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CICC SUN COMPANY LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Shirley Shiyou Chen
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Shirley Shiyou Chen&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CARLYLE ASIA GROWTH PARTNERS III, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP General Partner, L.P., as its
General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP, Ltd., as the General Partner of
CAGP General Partner, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Daniel A. D&#146;Aniello
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CAGP III CO-INVESTMENT, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP General Partner, L.P., as its
General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP, Ltd., as the General Partner of
CAGP General Partner, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>8
<FILENAME>h03611exv4w7.htm
<DESCRIPTION>EX-4.7
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.7</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.7</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXECUTION COPY</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SHARE SUBSCRIPTION AGREEMENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>dated as of<BR>
October&nbsp;20, 2008</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>among</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CICC SUN COMPANY LIMITED,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CARLYLE ASIA GROWTH PARTNERS III, L.P.,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CAGP III CO-INVESTMENT, L.P.,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>STARR INVESTMENTS CAYMAN II, INC.,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CONCORD MEDICAL SERVICES HOLDINGS LIMITED</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>and</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>OTHER PERSONS NAMED HEREIN</B>

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="95%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><FONT style="font-variant: SMALL-CAPS">Page</FONT></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ARTICLE 1</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">Definitions</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;1.01<I>. Definitions</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">1</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;1.02<I>. Other Definitional and Interpretative Provisions</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">12</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ARTICLE 2</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">Issuance and Subscription</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;2.01<I>. Issuance and Subscription</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;2.02. <I>Closing</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;2.03. <I>Additional Subscription Right</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ARTICLE 3</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">Earning Adjustments</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;3.01<I>. Calculation of 2008 and 2009 Net Income</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;3.02<I>. Adjustment Based on 2008 Net Income</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">14</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;3.03. <I>Adjustment Based on 2009 Net Income</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;3.04. <I>Procedure of Adjustment</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;3.05<I>. Termination of Adjustment Rights</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ARTICLE 4</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">Representations and Warranties Regarding the Group</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.01<I>. Corporate Status</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">15</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.02<I>. Power and Authority; Corporate Authorization</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">16</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.03<I>. Enforceability</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">16</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.04<I>. Non-contravention</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.05<I>. Governmental Authorization; Third-Party Consent</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.06<I>. Capitalization of the Company</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.07<I>. Capitalization of the PRC Subsidiaries</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.08<I>. Subsidiaries</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">18</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.09<I>. Financial Statements</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.10<I>. Books and Records</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.11<I>. No Material Adverse Effect</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.12<I>. No Material Liabilities</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">20</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.13<I>. Absence of Changes</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">21</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.14<I>. Credit Line</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.15<I>. Compliance with Laws</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.16. <I>Anti-Corruption</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.17<I>. US Office of Foreign Assets Control</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">24</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="95%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><FONT style="font-variant: SMALL-CAPS">Page</FONT></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.18<I>. No Litigation</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">25</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.19<I>. Property; Liens</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">25</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.20<I>. Tax</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">25</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.21<I>. Affiliate Transactions</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">26</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.22. <I>Intellectual Property</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">26</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.23<I>. Major Contracts</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">27</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.24<I>. Insurance Coverage</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">28</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.25<I>. Environmental Matters</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">29</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.26<I>. Employees, Labor Matters, Etc.</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">30</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.27<I>. Permits</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">30</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.28. <I>Accounts Receivable</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.29<I>. China Medstar Acquisition</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;4.30. <I>Disclosure</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">31</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ARTICLE 5</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">Representations and Warranties Regarding the Controlling Shareholders</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;5.01<I>. Power and Authority</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;5.02<I>. Enforceability</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;5.03<I>. Non-contravention</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;5.04<I>. Governmental Authorization</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;5.05<I>. Ownership of Shares</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">32</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ARTICLE 6</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">Representations and Warranties of Investors</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;6.01<I>. Corporate Status</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">33</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;6.02<I>. Power And Authority</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">33</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;6.03<I>. Enforceability</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">33</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;6.04<I>. Non-contravention</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">33</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;6.05<I>. Purchase for Investment</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">33</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;6.06<I>. Accredited Investor</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">34</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;6.07<I>. U.S. Person</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">34</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;6.08<I>. Legends</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">34</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;6.09<I>. Litigation</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">34</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ARTICLE 7</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">Covenants of the Group and Controlling Shareholders</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.01<I>. Conduct of the Company</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">34</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.02<I>. Use of Proceeds</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">37</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.03<I>. Access to Information; Confidentiality</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">37</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.04<I>. Compliance with Law; Consents</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">38</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.05. <I>Insurance</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">38</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.06<I>. Amended and Restated Shareholders&#146; Agreement</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">38</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="95%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><FONT style="font-variant: SMALL-CAPS">Page</FONT></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.07. <I>Share Charge</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">39</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.08. <I>Amendment No.</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">39</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.09<I>. Amendment to Convertible Loan Agreement</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">39</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.10<I>. Second Amended and Restated Memorandum of Articles</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">39</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.11<I>. Adoption of International Accounting Standards</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">39</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.12<I>. QPO</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">39</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.13. <I>Employment Contracts</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">39</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.14<I>. Non-Competition Agreement</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">40</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.15<I>. Intellectual Property Rights</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">40</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.16<I>. Employee Share Incentive Plans</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">40</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.17. <I>Notices of Certain Events</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">41</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.18. <I>Schedule of Liabilities</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">42</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;7.19. <I>September A/R Schedule</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">42</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ARTICLE 8</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">Covenants of All Parties</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;8.01. <I>Best Efforts; Further Assurance</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">42</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;8.02. <I>Certain Filings</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">42</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;8.03. <I>Public Announcements</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">42</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ARTICLE 9</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">Conditions to Closing</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;9.01. <I>Conditions to Obligations of the Investors</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">43</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;9.02. <I>Additional Condition to the Obligations of Starr</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">45</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ARTICLE 10</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">Survival; Indemnification</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;10.01. <I>Survival</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">46</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;10.02. <I>Indemnification</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">46</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;10.03<I>. Procedures</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">48</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ARTICLE 11</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">Termination</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;11.01<I>. Grounds for Termination</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">48</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;11.02<I>. Effect of Termination</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">48</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>ARTICLE 12</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS">Miscellaneous</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;12.01. <I>Notices</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">49</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;12.02. <I>Amendments and Waivers</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">51</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;12.03<I>. Disclosure Schedule&nbsp;References</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">51</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->iii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="95%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><FONT style="font-variant: SMALL-CAPS">Page</FONT></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;12.04. Expenses
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">51</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;12.05. <I>Successors and Assigns</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">52</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;12.06. <I>Governing Law</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">52</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;12.07. <I>Jurisdiction</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">52</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;12.08. <I>WAIVER OF JURY TRIAL</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">52</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;12.09. <I>Counterparts; Effectiveness; Third Party Beneficiaries</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">53</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;12.10. <I>Entire Agreement</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">53</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;12.11. <I>Severability</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">53</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;12.12. <I>Specific Performance</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">53</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Section&nbsp;12.13. <I>Joint Drafting</I>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">53</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;A
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Amended and Restated Shareholders&#146; Agreement</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;B
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Amendment to Convertible Loan Agreement</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;C
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Amendment No.&nbsp;2 to Series&nbsp;A Share Subscription Agreement</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;D
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Second Amended and Restated Memorandum and Articles<BR></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Exhibit&nbsp;F
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form of Share Charge Agreement</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Schedules
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->iv<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SHARE SUBSCRIPTION AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AGREEMENT (this &#147;<B>Agreement</B>&#148;) dated as of October&nbsp;20, 2008 among (1)&nbsp;CICC Sun Company Limited,
a company incorporated under the laws of the British Virgin Islands (&#147;<B>CICC</B>&#148;), (2)&nbsp;Carlyle Asia
Growth Partners III, L.P., a limited partnership formed under the laws of the Cayman Islands
(&#147;<B>CAGP</B>&#148;), (3)&nbsp;CAGP III Co-Investment III, L.P. (&#147;<B>CAGP Co-Invest</B>&#148;, together with CAGP, &#147;<B>Carlyle</B>&#148;),
(4)&nbsp;Starr Investments Cayman II, Inc., a company incorporated under the laws of the Cayman Islands
(&#147;<B>Starr</B>&#148;, together with CICC and Carlyle, the &#147;<B>Investors</B>&#148;), (5)&nbsp;Concord Medical Services Holdings
Limited, an exempted company with limited liability organized and existing under the laws of the
Cayman Islands (the &#147;<B>Company</B>&#148;), (6)&nbsp;the Controlling Shareholders (as defined below) and (7)&nbsp;the
Subsidiaries of the Company listed on Schedule&nbsp;4.08(a)(i).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>W I T N E S S E T H:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Company desires to issue and sell to each of the Investors, and each of the
Investors desires to subscribe for, a number of Series&nbsp;B redeemable convertible preferred shares,
par value US$0.01 per share, of the Company (the &#147;<B>Series&nbsp;B Shares</B>&#148;), on the terms and conditions
set forth in this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the promises and the mutual covenants and agreements
contained herein and intending to be legally bound hereby, the parties hereto agree as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 1</B><BR>
<FONT style="font-variant: SMALL-CAPS">Definitions</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.01<I>. Definitions. </I>(a)&nbsp;The following terms, as used herein, have the following
meanings:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person directly or indirectly
controlling, controlled by, or under common control with such Person; <I>provided </I>that (i)&nbsp;no
securityholder of the Company shall be deemed an Affiliate of any other securityholder of the
Company solely by reason of any equity or debt investment in the Company and (ii)&nbsp;with respect to
any Person who is an individual, the spouse or any lineal descendant, sibling or parent of such
Person shall also be deemed an Affiliate of such specified Person. For the purpose of this
definition, the term &#147;<B>control</B>&#148; (including, with correlative meanings, the terms &#147;<B>controlling</B>&#148;,
&#147;<B>controlled by</B>&#148; and &#147;<B>under common control with</B>&#148;), as used with respect to any Person, shall mean
the possession, directly or indirectly, of the power to direct or cause the direction of the
management and policies of such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Person, whether through the ownership of voting interests, by contract or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Amended and Restated Shareholders&#146; Agreement</B>&#148; means the Amended and Restated Shareholders&#146;
Agreement by and among the Company, the Investors, the Controlling Shareholders and the other
shareholders of the Company to be entered into on the Closing Date substantially in the form
attached as <B>Exhibit&nbsp;A </B>hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Amendment to Convertible Loan Agreement</B>&#148; means the Amendment to Convertible Loan Agreement by
and among the Company, Carlyle, the Controlling Shareholders and the Group Companies to be entered
into on the Closing Date substantially in the form attached as <B>Exhibit&nbsp;B </B>hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Amendment No.&nbsp;2 to Series&nbsp;A Share Subscription Agreement</B>&#148; means the Amendment No.&nbsp;2 to Share
Subscription Agreement by and among the Company, CICC, Carlyle, the Controlling Shareholders and
the Group Companies to be entered into on the Closing Date substantially in the form attached as
<B>Exhibit&nbsp;C </B>hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Ascendium</B>&#148; means Ascendium Group Limited, a company incorporated under the laws of the
British Virgin Islands.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Aohua</B>&#148; means Shenzhen Aohua Medical Services Co., Ltd. <IMG src="h03611h0361121.gif" alt="(CHINESE CHARACTHER)">, a
Sino-foreign joint venture incorporated under the laws of the PRC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Aohua Leasing</B>&#148; means Shenzhen Aohua Medical Leasing and Services Co., Ltd.
<IMG src="h03611h0361122.gif" alt="(CHINESE CHARACTHER)">, a Sino-foreign joint venture incorporated under the laws of the
PRC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Balance Sheet Date</B>&#148; means December&nbsp;31, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Business Day</B>&#148; means a day, other than Saturday, Sunday or other day on which commercial banks
in the US, Hong Kong or the PRC are authorized or required by applicable Laws to close.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>China Medstar</B>&#148; means China Medstar Pte. Ltd., a company incorporated under the laws of
Singapore.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Closing Date</B>&#148; means the date of Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>CMS</B>&#148;
means China Medical Services (Holdings) Limited <IMG src="h03611h0361164.gif" alt="(CHINESE CHARACTHER)">, a company
incorporated under the laws of Hong Kong.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Consent</B>&#148; means any consent, approval, authorization, waiver, permit, grant, franchise,
concession, agreement, license, certificate, exemption, order, registration, declaration, filing,
report or notice of, with or to any Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Contract</B>&#148; means, with respect to any specified Person, all loan agreements, indentures,
letters of credit (including related letter of credit applications and reimbursement obligations),
mortgages, security agreements, pledge agreements, deeds of trust, bonds, notes, guarantees, surety
obligations, warranties, licenses, franchises, permits, powers of attorney, purchase orders,
leases, and other agreements, contracts, instruments, obligations, offers, commitments,
arrangements and understandings, written or oral, to which the specified Person is a party or by
which it or any of its assets or properties may be bound or affected.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Controlling Shareholders</B>&#148; means, collectively, the following Persons:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;Mr.&nbsp;Cheng
Zheng <IMG src="h03611h0361114.gif" alt="(CHINESE CHARACTHER)">, a PRC citizen with passport number G14947877 (&#147;<B>Mr.&nbsp;Cheng</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;CZY Investments Limited, a company incorporated under the laws of the British Virgin
Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Cheng (&#147;<B>Mr.&nbsp;Cheng&#146;s Holding Company</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;Mr.&nbsp;Yang Jianyu <IMG src="h03611h0361138.gif" alt="(CHINESE CHARACTHER)">, a PRC citizen with passport number G04036294 (&#147;<B>Mr.&nbsp;Yang</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;Daketala International Investment Holdings Ltd., a company incorporated under the laws of
the British Virgin Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Yang (&#147;<B>Mr.&nbsp;Yang&#146;s Holding
Company</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;Mr.&nbsp;Steven Xiaodi Sun, a US citizen with passport number 203018867 (&#147;<B>Mr.&nbsp;Sun</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;Dragon Image Investment Ltd., a company incorporated under the laws of the British Virgin
Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Sun (&#147;<B>Mr.&nbsp;Sun&#146;s Holding Company</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)&nbsp;Mr.&nbsp;Zhang Jing <IMG src="h03611h0361115.gif" alt="(CHINESE CHARACTHER)">, a PRC citizen with passport number G10824344 (&#147;<B>Mr.&nbsp;Zhang</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8)&nbsp;Thousand Ocean Group Limited, a company incorporated under the laws of the British Virgin
Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Zhang (&#147;<B>Mr.&nbsp;Zhang&#146;s Holding Company</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9)&nbsp;Mr.&nbsp;Yap Yaw Kong <IMG src="h03611h0361116.gif" alt="(CHINESE CHARACTHER)">, a Malaysia citizen with passport number A15954913 (&#147;<B>Mr.&nbsp;Yap</B>&#148;);
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(10)&nbsp;Top Mount Group Limited, a company incorporated under the laws of the British Virgin
Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Yap (&#147;<B>Mr.&nbsp;Yap&#146;s Holding Company</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(11)&nbsp;Mr.&nbsp;Liu Haifeng <IMG src="h03611h0361139.gif" alt="(CHINESE CHARACTHER)">, a PRC citizen with passport number G19230849;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(12)&nbsp;Ms.&nbsp;Bona Lau, a New Zealand citizen with passport number EA713283 (&#147;<B>Ms.&nbsp;Lau</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(13)&nbsp;Notable Enterprise Limited, a company incorporated under the laws of the British Virgin
Islands and a direct wholly owned Subsidiary of Ms.&nbsp;Lau (&#147;<B>Ms.&nbsp;Lau&#146;s Holding Company</B>&#148;, together with
Mr.&nbsp;Cheng&#146;s Holding Company, Mr.&nbsp;Yang&#146;s Holding Company, Mr.&nbsp;Sun&#146;s Holding Company, Mr.&nbsp;Zhang&#146;s
Holding Company and Mr.&nbsp;Yap&#146;s Holding Company, the &#147;<B>Controlling Shareholder Holding Companies</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Convertible Loans</B>&#148; means, collectively, (i)&nbsp;the convertible loan in the principal amount of
US$5,000,000 borrowed by the Company from Carlyle pursuant to the Amended and Restated Convertible
Loan Agreement by and among the Company, Carlyle and certain other parties thereto dated as of
April&nbsp;2, 2008, and (ii)&nbsp;the convertible loan in the principal amount of US$20,000,000 borrowed by
the Company from Carlyle pursuant to the Convertible Loan Agreement by and among the Company,
Carlyle and certain other parties thereto dated as of April&nbsp;10, 2008, as amended by the Amendment
to Convertible Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Cyber Medical</B>&#148; means Cyber Medical Network Ltd. <IMG src="h03611h0361124.gif" alt="(CHINESE CHARACTHER)">, a company
incorporated under the laws of Hong Kong.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Environmental Laws</B>&#148; means any Laws or any Contract with any Governmental Authority or other
third party, relating to human health and safety, the environment or Hazardous Substances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Environmental Permits</B>&#148; means all permits, licenses, franchises, certificates, approvals and
other similar authorizations of Governmental Authorities relating to or required by Environmental
Laws and affecting, or relating in any way to, the business of any Group Company as currently
conducted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Existing Shareholders&#146; Agreement</B>&#148; means the Shareholders&#146; Agreement dated as of April&nbsp;2, 2008
by and among the Company, CICC, Carlyle and certain other shareholders of the Company, as amended
by the Amendment to Shareholders&#146; Agreement dated as of October&nbsp;8, 2008 by and among the Company,
CICC, Carlyle and certain other shareholders of the Company.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>FCPA</B>&#148; means the United States Foreign Corrupt Practices Act, as amended, or any successor
statute or law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Fully Diluted</B>&#148; means, with respect to any class of the Company Securities, the aggregate
amount of such class issued or issuable in respect of securities convertible into or exchangeable
for such class, all options, warrants and other rights to purchase or subscribe for such class or
securities convertible into or exchangeable for such class; <I>provided </I>that, if any of the foregoing
options, warrants or other rights to purchase or subscribe for such class of the Company Securities
are subject to vesting, the Company Securities subject to vesting shall be included in the
definition of &#147;Fully-Diluted&#148; only upon and to the extent of such vesting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>GAAP</B>&#148; means generally accepted accounting principles in the PRC, as in effect from time to
time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Government Official</B>&#148; means (i)&nbsp;any officer or employee of any Governmental Authority, or any
entity or enterprise owned or controlled by such Governmental Authority, or any instrumentality
thereof, or of a public international organization, or any natural person acting in an official
capacity for or on behalf of any such Governmental Authority, entity, enterprise or instrumentality
or any such public international organization; (ii)&nbsp;any known/announced candidate for political
office; or (iii)&nbsp;any person who holds or held a prominent public position in the PRC or any other
country (including its political subdivisions), including head of state, senior government,
judicial or military official, official of a political party, known/announced candidate for
political office, or senior executive of a state-owned enterprise of national importance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Governmental Authority</B>&#148; means any transnational, domestic or foreign national, provincial,
federal, state or local, governmental authority, department, court, agency or official, including
any political subdivision thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Group</B>&#148; means, at any time, collectively, the Company and all direct and indirect then-current
Subsidiaries of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Group Company</B>&#148; means any member of the Group.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Hazardous Substances</B>&#148; means any pollutant, contaminant, waste or chemical or any toxic,
radioactive, ignitable, corrosive, reactive or otherwise hazardous substance, waste or material, or
any substance, waste or material having any constituent elements displaying any of the foregoing
characteristics, including petroleum, its derivatives, by-products and other hydrocarbons, and any
substance, waste or material regulated under any Environmental Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Hong Kong</B>&#148; means the Hong Kong Special Administrative Region.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IFRS</B>&#148; means the International Financial Reporting Standards, as in effect from time to time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Indebtedness</B>&#148; means, with respect to any Person, without duplication, (i)&nbsp;all obligations of
such Person for borrowed money, or with respect to deposits or advances of any kind, (ii)&nbsp;all
obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (iii)&nbsp;all
obligations of such Person upon which interest charges are customarily paid (other than trade
payables incurred in the ordinary course of business consistent with past practices), (iv)&nbsp;all
obligations of such Person under conditional sale or other title retention agreements relating to
any asset or property purchased by such Person, (v)&nbsp;all obligations of such Person issued or
assumed as the deferred purchase price of assets, property or services (excluding obligations of
such Person to creditors for raw materials, inventory, services and supplies incurred in the
ordinary course of business consistent with past practices), (vi)&nbsp;all lease obligations of such
Person capitalized on the books and records of such Person, (vii)&nbsp;all obligations of others secured
by a Lien on property or assets owned or acquired by such Person, whether or not the obligations
secured thereby have been assumed, (viii)&nbsp;all obligations of such Person under interest rate,
currency or commodity derivatives or hedging transactions (valued at the termination value
thereof), (ix)&nbsp;all letters of credit or performance bonds issued for the account of such Person
(excluding letters of credit issued for the benefit of suppliers to support accounts payable to
suppliers incurred in the ordinary course of business consistent with past practices) and (x)&nbsp;all
guarantees and arrangements having the economic effect of a guarantee of such Person of any
Indebtedness of any other Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Intellectual Property Rights</B>&#148; means (i)&nbsp;inventions, whether or not patentable, reduced to
practice or made the subject of one or more pending patent applications, (ii)&nbsp;national and
multinational statutory invention registrations, patents and patent applications (including all
reissues, divisions, continuations, continuations-in-part, extensions and reexaminations thereof)
registered or applied for in the PRC and all other nations throughout the world, all improvements
to the inventions disclosed in each such registration, patent or patent application, (iii)
trademarks, service marks, trade dress, logos, domain names, trade names and corporate names
(whether or not registered) in the PRC and all other nations throughout the world, including all
variations, derivations, combinations, registrations and applications for registration of the
foregoing and all goodwill associated therewith, (iv)&nbsp;copyrights (whether or not registered) and
registrations and applications for registration thereof in the PRC and all other nations throughout
the world, including all derivative works, moral rights, renewals, extensions, reversions or
restorations associated with such copyrights, now or hereafter provided by law, regardless of the
medium of fixation or means of expression, (v)&nbsp;computer software (including source code, object
code, firmware, operating systems and specifications), (vi)&nbsp;trade secrets and, whether or not
confidential, business information (including pricing and cost information,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">business and marketing plans and customer and supplier lists) and know-how (including
manufacturing and production processes and techniques and research and development information),
(vii)&nbsp;industrial designs (whether or not registered), (viii)&nbsp;databases and data collections, (ix)
copies and tangible embodiments of any of the foregoing, in whatever form or medium, (x)&nbsp;all rights
to obtain and rights to apply for patents, and to register trademarks and copyrights, (xi)&nbsp;all
rights in all of the foregoing provided by treaties, conventions and common law and (xii)&nbsp;all
rights to sue or recover and retain damages and costs and attorneys&#146; fees for past, present and
future infringement or misappropriation of any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IPO</B>&#148; means an initial public offering and listing of the Ordinary Shares (or, in lieu thereof
and as mutually agreed by the Investors and the Company, equity securities of (i)&nbsp;any holding
company holding the issued share capital of the Company or (ii)&nbsp;any Subsidiary of the Company) on
an internationally recognized stock exchange.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>knowledge</B>&#148; of any Person that is not an individual means the knowledge of such Person&#146;s
officers after due inquiry.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Laws</B>&#148; means any national, provincial, federal, state or local law (statutory, common or
otherwise), constitution, treaty, convention, ordinance, code, rule, regulation, order, injunction,
judgment, decree, ruling or other similar requirement enacted, adopted, promulgated or applied by
any Governmental Authority, as amended unless expressly specified otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed Intellectual Property Rights</B>&#148; means all Intellectual Property Rights owned by a
third party and licensed or sublicensed to any Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Lien</B>&#148; means, with respect to any property or asset, any mortgage, lien, pledge, charge,
security interest, encumbrance or other adverse claim of any kind in respect of such property or
asset. For the purposes of this Agreement, a Person shall be deemed to own subject to a Lien any
property or asset which it has acquired or holds subject to the interest of a vendor or lessor
under any conditional sale agreement, capital lease or other title retention agreement relating to
such property or asset.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Material Adverse Effect</B>&#148; means a material adverse effect on the condition (financial or
otherwise), business, assets, results of operations or prospects of the Group, taken as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;OECD Rules&#148; </B>means the Organization of Economic Cooperation and Development&#146;s Convention on
Combating Bribery of Foreign Public Officials in International Business Transactions, as amended,
or any successor convention, statute or law.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>OMS</B>&#148; means Our Medical Services, Ltd., a company incorporated under the laws of the British
Virgin Islands.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Ordinary Shares</B>&#148; means the ordinary shares, par value US$0.01 per share, of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Owned Intellectual Property Rights</B>&#148; means all Intellectual Property Rights owned by any Group
Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Person</B>&#148; means an individual, corporation, partnership, limited liability company,
association, trust or other entity or organization, including a Governmental Authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>PRC</B>&#148; means the People&#146;s Republic of China, excluding, for purposes of this Agreement only,
Hong Kong, the Macau Special Administrative Region and Taiwan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>PRC Subsidiaries</B>&#148; means, collectively, the Group Companies established under the laws of the
PRC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Pre-Closing Tax Period</B>&#148; means any Tax period ending on or before the Closing Date; and, with
respect to a Tax period that begins on or before the Closing Date and ends thereafter, the portion
of such Tax period ending on the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Preferred Shares</B>&#148; means the Series&nbsp;A Shares and the Series&nbsp;B Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Purchase Price</B>&#148; means, with respect to any Investor, the amount in US dollars set forth
opposite the name of such Investor in Schedule&nbsp;1.01.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>QPO</B>&#148; means a firm-commitment underwritten IPO (i)&nbsp;led by internationally reputable
underwriters, approved by the board of directors of the Company (including the approval of a
majority of the directors appointed by the Investors pursuant to the Amended and Restated
Shareholders&#146; Agreement), and yielding a valuation of the Company at not less than US$450&nbsp;million
immediately prior to the consummation of such IPO, or (ii)&nbsp;any other IPO approved by holders of at
least 70% of the then outstanding Series&nbsp;B Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>QPO Date</B>&#148; means the date on which the QPO is consummated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Rate of Return</B>&#148; shall have the meaning set forth in the Amended and Restated Shareholders&#146;
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>RMB</B>&#148; means renminbi, the lawful currency of the PRC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Second Amended and Restated Memorandum and Articles</B>&#148; means the Second Amended and Restated
Memorandum and Articles of the Company to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">be adopted by the board of directors and shareholders of the Company by the Closing Date
substantially in the form attached as <B>Exhibit&nbsp;D </B>hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Securities Act</B>&#148; means the United States Securities Act of 1933, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Series&nbsp;A Shares</B>&#148; means the Series&nbsp;A redeemable convertible preferred shares, par value
US$0.01 per share, of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Series&nbsp;A Share Subscription Agreement</B>&#148; means the Share Subscription Agreement by and among
the Company, CICC, Carlyle and certain other parties thereto dated as of February&nbsp;5, 2008, as
amended by the Amendment to Share Subscription Agreement by and among the Company, CICC, Carlyle
and certain other parties thereto dated as of April&nbsp;2, 2008 and the Amendment No.&nbsp;2 to Series&nbsp;A
Share Subscription Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Share Charge Agreements</B>&#148; means, collectively:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;the Share Charge Agreement between the Investors, the Company and Mr.&nbsp;Cheng&#146;s Holding
Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;the Share Charge Agreement between the Investors, the Company and Mr.&nbsp;Yang&#146;s Holding
Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;the Share Charge Agreement between the Investors, the Company and Mr.&nbsp;Sun&#146;s Holding
Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;the Share Charge Agreement between the Investors, the Company and Mr.&nbsp;Zhang&#146;s Holding
Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;the Share Charge Agreement between the Investors, the Company and Mr.&nbsp;Yap&#146;s Holding
Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;the Share Charge Agreement between the Investors, the Company and Ms.&nbsp;Lau&#146;s Holding
Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in each case to be entered into by the Closing Date and substantially in the form attached as
<B>Exhibit&nbsp;E </B>hereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Subsidiary</B>&#148; means, with respect to any Person, any entity of which securities or other
ownership interests having ordinary voting power to elect a majority of the board of directors or
other persons performing similar functions are at the time directly or indirectly owned by such
Person. For the avoidance of doubt, each of Chang&#146;an Concord International Cancer Center
<IMG src="h03611h0361125.gif" alt="(CHINESE CHARACTER)"> and Beijing Proton Medical Center <IMG src="h03611h0361126.gif" alt="(CHINESE CHARACTER)">, if established
and directly or indirectly owned by the Company prior to the date
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">hereof, shall be considered a Subsidiary of the Company for the purposes of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Tax</B>&#148; means (a)&nbsp;taxes on income, profits and gains, and (b)&nbsp;all other taxes, levies, duties,
imposts, charges and withholdings of any nature, in each case imposed, levied, collected, withheld
or assessed by (or on behalf of) any Governmental Authority in any jurisdiction, including any
excise, customs, property, sales, transfer, franchise, turnover and payroll taxes and other
benefits related tax and stamp duties, and any payment whatsoever which the relevant Person may be
or become bound to make to any other Person as a result of the discharge by such other Person of
any tax which the relevant Person has failed to discharge, together with all penalties, charges and
interest relating to any of the foregoing or to any late or incorrect return in respect of any of
them, and regardless of whether such taxes, levies, duties, imposts, charges, withholdings,
penalties and interest are chargeable directly or primarily against or attributable directly or
primarily to the relevant Person or any other Person and of whether any amount in respect of them
is recoverable from any other Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Transaction Documents</B>&#148; means this Agreement, the Amended and Restated Shareholders&#146;
Agreement, the Second Amended and Restated Memorandum and Articles, the Amendment No.&nbsp;2 to Series&nbsp;A
Share Subscription Agreement, the Amendment to Convertible Loan Agreement, the Share Charge
Agreements and each and all other agreements, certificates or other documents required to be
executed by any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>2008 Audited Financial Statements</B>&#148; means the consolidated financial statements for the
Company&#146;s fiscal year ending December&nbsp;31, 2008 prepared in accordance with US GAAP or IFRS applied
on a consistent basis and audited by a &#147;Big Four&#148; accounting firm.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>2008 Net Income</B>&#148; means the consolidated after-tax net income of the Company for the Company&#146;s
fiscal year ending December&nbsp;31, 2008; <I>provided </I>that (1)&nbsp;the 2008 Net Income shall not include the
cumulative effect of any change or changes in accounting principles; (ii)&nbsp;the 2008 Net Income shall
not include any extraordinary or non-recurring earnings obtained or losses incurred by any Group
Company; (iii)&nbsp;the 2008 Net Income shall not include non-cash charges or expenses relating to any
share-based compensation, the Convertible Loans, Series&nbsp;A Shares and Series&nbsp;B Shares; (iv)&nbsp;the 2008
Net Income shall not include the consolidated after-tax net income generated from sales of medical
equipment by China Medstar and its Subsidiaries to the extent it exceeds 30% of China Medstar&#146;s
consolidated after-tax net income for the year ending December&nbsp;31, 2008 (the calculation of which
shall not include (A)&nbsp;the cumulative effect of any change or changes in accounting principles and
(B)&nbsp;any extraordinary or non-recurring earnings or losses); (v)&nbsp;the 2008 Net Income shall include
the consolidated after-tax net income of China Medstar for the whole year ending December&nbsp;31, 2008
and, if such inclusion is agreed to by all Investors, the full-
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">year after-tax net income of any other business that the Company may have acquired after the
date hereof; and (vi)&nbsp;any dividend paid by the Company on the Preferred Shares pursuant to the
Second Amended and Restated Memorandum and Articles shall not be deemed expenses for the purposes
of calculating 2008 Net Income. For the avoidance of doubt, any accounts receivable generated by
the Company during the Company&#146;s fiscal year ending December&nbsp;31, 2008 and written off by the
Company in connection with the audit of the 2008 Audited Financial Statements shall not be deemed a
non-recurring loss and shall be included as a loss when calculating the 2008 Net Income.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>2009 Audited Financial Statements</B>&#148; means the consolidated financial statements of the
Company&#146;s fiscal year ending December&nbsp;31, 2009 prepared in accordance with US GAAP or IFRS applied
on a consistent basis and audited by a &#147;Big Four&#148; accounting firm.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>2009 Net Income</B>&#148; means the consolidated after-tax net income of the Company for the Company&#146;s
fiscal year ending December&nbsp;31, 2009; <I>provided </I>that (1)&nbsp;the 2009 Net Income shall not include the
cumulative effect of any change or changes in accounting principles; (ii)&nbsp;the 2009 Net Income shall
not include any extraordinary or non-recurring earnings obtained or losses incurred by any Group
Company; (iii)&nbsp;the 2009 Net Income shall not include non-cash charges or expenses relating to any
share-based compensation, the Convertible Loans, Series&nbsp;A Shares and Series&nbsp;B Shares; (iv)&nbsp;the 2009
Net Income shall not include the consolidated after-tax net income generated from sales of medical
equipment by China Medstar and its Subsidiaries to the extent it exceeds 30% of China Medstar&#146;s
consolidated after-tax net income for the year ending December&nbsp;31, 2009 (the calculation of which
shall not include (A)&nbsp;the cumulative effect of any change or changes in accounting principles and
(B)&nbsp;any extraordinary or non-recurring earnings or losses); and (v)&nbsp;any dividend paid by the
Company on the Preferred Shares pursuant to the Second Amended and Restated Memorandum and Articles
shall not be deemed expenses for the purposes of calculating 2009 Net Income. For the avoidance of
doubt, any accounts receivable generated by the Company during the Company&#146;s fiscal year ending
December&nbsp;31, 2009 and written off by the Company in connection with the audit of the 2009 Audited
Financial Statements shall not be deemed a non-recurring loss and shall be included as a loss when
calculating the 2009 Net Income.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>US</B>&#148; means the United States of America.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>US dollars</B>&#148; or &#147;<B>US$</B>&#148; means United States dollars, the lawful currency of the US.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>US GAAP</B>&#148; means generally accepted accounting principles in the US, as in effect from time to
time.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each of the following terms is defined in the Section set forth opposite such term:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Section</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Agreement
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top">Preamble
</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Aohua Audited Financial Statements
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.09</TD>
    <TD nowrap valign="top">(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Books and Records
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.10</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">CAGP
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top">Preamble
</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">CAGP Co-Invest
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top">Preamble
</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Capex Budget
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.13</TD>
    <TD nowrap valign="top">(d)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Carlyle
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top">Preamble
</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">China Medstar Acquisition
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.29</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Charged Shares
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7.07</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">China Medstar Audited Financial Statements
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.09</TD>
    <TD nowrap valign="top">(b)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">CICC
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top">Preamble
</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Closing
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2.02</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top">Preamble
</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Company Securities
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.06</TD>
    <TD nowrap valign="top">(b)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Damages
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10.02</TD>
    <TD nowrap valign="top">(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Indemnified Party
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10.03</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Indemnifying Party
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10.03</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Investors
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top">Preamble
</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Key Employees
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.26</TD>
    <TD nowrap valign="top">(a)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Major Contract
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.23</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">OFAC
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.17</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Permits
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.27</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Post-Closing Options Pool
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7.16</TD>
    <TD nowrap valign="top">(b)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Pre-Closing Options Pool
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">7.16</TD>
    <TD nowrap valign="top">(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Purchased Shares
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2.01</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Schedule of Liabilities
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.12</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">September A/R Schedule
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.28</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Series&nbsp;B Shares
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top">Recitals
</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Starr
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="3" align="center" valign="top">Preamble
</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Subsidiary Securities
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.08</TD>
    <TD nowrap valign="top">(b)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.02 <I>. Other Definitional and Interpretative Provisions. </I>The words &#147;hereof&#148;,
&#147;herein&#148; and &#147;hereunder&#148; and words of like import used in this Agreement shall refer to this
Agreement as a whole and not to any particular provision of this Agreement. The captions herein
are included for convenience of reference only and shall be ignored in the construction or
interpretation hereof. References to Articles, Sections, Exhibits and Schedules are to Articles,
Sections, Exhibits and Schedules of this Agreement unless otherwise specified. All Exhibits and
Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this
Agreement as if set forth in full herein. Any capitalized terms used in any Exhibit or Schedule
but not otherwise defined
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">therein, shall have the meaning as defined in this Agreement. Any singular term in this
Agreement shall be deemed to include the plural, and any plural term the singular. Whenever the
words &#147;include&#148;, &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be
followed by the words &#147;without limitation&#148;, whether or not they are in fact followed by those words
or words of like import. &#147;Writing&#148;, &#147;written&#148; and comparable terms refer to printing, typing and
other means of reproducing words (including electronic media) in a visible form. References to any
agreement or contract are to that agreement or contract as amended, modified or supplemented from
time to time in accordance with the terms hereof and thereof; <I>provided </I>that with respect to any
agreement or contract listed on any schedules hereto, all such amendments, modifications or
supplements must also be listed in the appropriate schedule. References to any Person include the
successors and permitted assigns of that Person. References from or through any date mean, unless
otherwise specified, from and including or through and including, respectively. References to
&#147;law&#148;, &#147;laws&#148; or to a particular statute or law shall be deemed also to include an and all
applicable Laws.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 2</B><BR>
<FONT style="font-variant: SMALL-CAPS">Issuance and Subscription</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.01<I>. Issuance and Subscription. </I>Upon the terms and subject to the conditions of
this Agreement, the Company agrees to issue and sell to each Investor, and each Investor agrees to
purchase from the Company and subscribe for, a number of Series&nbsp;B Shares (such Investor&#146;s
&#147;<B>Purchased Shares</B>&#148;) set forth opposite its name in Schedule&nbsp;1.01. Each Investor shall pay, as
provided in Section&nbsp;2.02, its Purchase Price in exchange for its Purchased Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.02. <I>Closing</I>. The closing (the &#147;<B>Closing</B>&#148;) of the issuance and subscription of the
Purchased Shares hereunder shall take place at a location to be mutually agreed to by the Investors
and the Company, as soon as possible, but in no event later than five (5)&nbsp;Business Days after
satisfaction of the conditions set forth in Article&nbsp;9, or at such other time or place as the
Investors and the Company may agree. At the Closing:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) each Investor shall deliver to the Company such Investor&#146;s Purchase Price in US
dollars in immediately available funds by wire transfer to an account specified in a
written instrument signed by the Chief Executive Officer or the President of the Company
and delivered to such Investor at least two Business Days prior to the Closing or by other
payment methods mutually agreed to between the Company and the Investors prior to the
Closing; and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Company shall deliver to each Investor (i)&nbsp;a certificate representing such
Investor&#146;s Purchased Shares, duly authorized and validly issued, and (ii)&nbsp;a copy of the
updated register of members of the Company dated the Closing Date and duly certified by a
duly authorized director of the Company evidencing such Investor&#146;s ownership of its
Purchased Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.03. <I>Additional Subscription Right. </I>If any Investor fails to perform its
obligations under Sections&nbsp;2.01 and 2.02(a), the other Investors shall have the right but not the
obligation to subscribe for up to an aggregate additional number of Series&nbsp;B Shares equal to the
number of Purchased Shares that was not subscribed for under Sections&nbsp;2.01 and 2.02(a).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 3</B><BR>
<FONT style="font-variant: SMALL-CAPS">Earning Adjustments</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.01<I>. Calculation of 2008 and 2009 Net Income. </I>As soon as practicable and in any
event within one hundred and fifty (150)&nbsp;days after the end of the Company&#146;s fiscal year ending
December&nbsp;31, 2008 and within ninety (90)&nbsp;days (such 90-day period may be extended by thirty (30)
days unless any Investor objects to such extension by written notice delivered to the Company prior
to the expiration of such 90-day period) after the end of the Company&#146;s fiscal year ending December
31, 2009, the Company shall complete the 2008 Audited Financial Statements and 2009 Audited
Financial Statements, respectively. The Company shall, on the same date of such completion, have
the accounting firm who audited the 2008 Audited Financial Statements or the 2009 Audited Financial
Statements, respectively, calculate the 2008 Net Income or the 2009 Net Income, respectively, based
on the 2008 Audited Financial Statements or the 2009 Audited Financial Statements, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.02<I>. Adjustment Based on 2008 Net Income. </I>If the 2008 Net Income is lower than the
RMB equivalent of US$21,430,000 (calculated based on the spot exchange rate between US dollars and
RMB as quoted by the People&#146;s Bank of China on the Closing Date), the Controlling Shareholders
shall, jointly and severally, transfer to each Investor free of charge a number of Ordinary Shares
equal to (x)&nbsp;the number of such Investor&#146;s Purchased Shares, <I>multiplied </I>by (y)&nbsp;a ratio, the
numerator of which is equal to (i)&nbsp;such RMB equivalent of US$21,430,000 <I>minus </I>(ii)&nbsp;the 2008 Net
Income, and the denominator of which is equal to (i)&nbsp;the 2008 Net Income <I>plus </I>(ii)&nbsp;the quotient of
(A)&nbsp;the RMB equivalent of the aggregate Purchase Price of all Investors (calculated based on the
spot exchange rate between US dollars and RMB as quoted by the People&#146;s Bank of China on the
Closing Date) <I>divided </I>by (B)&nbsp;10.7326.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.03. <I>Adjustment Based on 2009 Net Income. </I>If the 2009 Net Income is lower than the
RMB equivalent of US$34,000,000 (calculated based on the spot exchange rate between US dollars and
RMB as quoted by the People&#146;s Bank of China on the Closing Date), the Controlling Shareholders
shall, jointly and severally, transfer to each Investor free of charge a number of Ordinary Shares
equal to (x)&nbsp;the number of such Investor&#146;s Purchased Shares, <I>multiplied </I>by (y)&nbsp;a ratio, the
numerator of which is equal to (i)such RMB equivalent of US$34,000,000 <I>minus </I>(ii)&nbsp;the 2009 Net
Income, and the denominator of which is equal to (i)&nbsp;the 2009 Net Income <I>plus </I>(ii)&nbsp;the quotient of
(A)&nbsp;the RMB equivalent of the aggregate Purchase Price of all Investors (calculated based on the
spot exchange rate between US dollars and RMB as quoted by the People&#146;s Bank of China on the
Closing Date) <I>divided </I>by (iii)&nbsp;6.7647, <I>minus </I>(z)&nbsp;the number of Ordinary Shares that have been
transferred to such Investor pursuant to Section&nbsp;3.02.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.04. <I>Procedure of Adjustment</I>. The adjustments set forth in Sections&nbsp;3.02 and
3.03 shall be made within five (5)&nbsp;Business Days of the day on which the 2008 Net Income or the
2009 Net Income, respectively, is calculated pursuant to Section&nbsp;3.01. On each date on which the
adjustments are to be made, the Controlling Shareholders shall, subject to the execution and
delivery of the relevant instruments of transfer by the Investors, cause the Company to (a)&nbsp;deliver
to each Investor a copy of the updated register of members of the Company dated such date and duly
certified by a duly authorized director of the Company evidencing such Investor&#146;s ownership of the
Ordinary Shares transferred to such Investor pursuant to Section&nbsp;3.02 or Section&nbsp;3.03,
respectively, which Ordinary Shares shall be free and clear of any Lien (including any restrictions
on the voting rights or transferability of such Ordinary Shares other than those restrictions set
forth in this Agreement and the existing memorandum and articles of association of the Company) and
duly authorized, validly issued, fully paid and non-assessable; and (b)&nbsp;deliver to such Investor a
certificate representing such Ordinary Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.05<I>. Termination of Adjustment Rights. </I>Sections&nbsp;3.01 through 3.04 shall
terminate upon the occurrence of the QPO.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 4</B><BR>
<FONT style="font-variant: SMALL-CAPS">Representations and Warranties Regarding the Group</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Controlling Shareholders and the Group Companies, jointly and severally,
represents and warrants to the Investors as of the date hereof and as of the Closing Date that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.01<I>. Corporate Status.</I>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each Group Company is a company duly incorporated, validly existing and, other than the
PRC Subsidiaries, in good standing under the laws of its jurisdiction of organization.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Group Company has full corporate power and all Consents of the applicable
Governmental Authorities necessary to own, lease and operate the assets and properties that it now
owns, leases and operates, and to carry on its business as now conducted and currently proposed to
be conducted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each Group Company is permitted and qualified under the Laws of its jurisdiction of
organization to carry on business outside such jurisdiction and, except for the PRC Subsidiaries
and Hong Kong Subsidiaries, is in good standing in each jurisdiction where such qualification is
necessary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company has delivered to the Investors a true and complete copy of the memorandum and
articles of association and other organizational documents of each Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The minute books of each Group Company that have heretofore been made available to the
Investors contain complete and accurate records, in all material respects, of all meetings and
other corporate actions of the respective directors and shareholders of such Group Company, and
correctly reflect all actions taken by such directors and shareholders since the respective date of
organization of such Group Company. To the extent that such minute books are deficient, all
material information not contained in such minutes has been conveyed by the Company to the
Investors in written form.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.02<I>. Power and Authority; Corporate Authorization.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each Group Company has full corporate power and authority to execute and deliver this
Agreement and each other Transaction Document to which it is a party and to perform its obligations
hereunder and thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The execution and delivery of this Agreement and each other Transaction Document to which
it is a party, the performance of the obligations hereunder and thereunder, and the consummation of
the transactions contemplated hereby and thereby, have been duly authorized by all requisite
corporate actions of each Group Company and no other corporate proceedings on the part of such
Group Company are necessary to authorize such execution, delivery or performance or to consummate
such transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.03<I>. Enforceability.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each Group Company has duly executed and delivered this Agreement and will execute and
deliver each other Transaction Document to which it is a party by the Closing Date.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;This Agreement constitutes, and each other Transaction Document to which it is a party
(when executed) will constitute, the legal, valid and binding obligations of each Group Company,
enforceable against such Group Company in accordance with the terms hereof and thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.04<I>. Non-contravention. </I>The execution, delivery and performance by any Group
Company of this Agreement and other Transaction Documents to which it is a party and the
consummation of the transactions contemplated hereby and thereby do not and will not (i)&nbsp;violate
the organizational documents of any Group Company, (ii)&nbsp;violate any Laws or any arbitral awards
applicable to or binding on any Group Company or any of its assets or properties, (iii)&nbsp;constitute
a default (with or without the giving of notice or the lapse of time or both) under, or give rise
to any right of termination, cancellation or acceleration of any right or obligation of any Group
Company or to a loss of any benefit to which any Group Company is entitled under any provision of
any Contract binding upon any Group Company or any of its assets or properties or (iv)&nbsp;result in
the creation or imposition of any Lien (or any obligation to create any Lien) on any assets or
properties of any Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.05<I>. Governmental Authorization; Third-Party Consent. </I>No Consent by any
Governmental Authority or any other Person is necessary or required in connection with the
execution, delivery or performance by, or enforcement against, any Group Company under this
Agreement or any other Transaction Document to which it is a party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.06<I>. Capitalization of the Company.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;On the date hereof, the share capital of the Company consists of US$50,000 divided into
5,000,000 shares of nominal or par value of US$0.01 each, of which 4,500,000 are designated as
Ordinary Shares and 500,000 are designated as Series&nbsp;A Shares. 704,281 Ordinary Shares and 176,942
Series&nbsp;A Shares are issued and outstanding as of the date hereof. On the Closing Date, the share
capital of the Company shall consist of US$50,000 divided into 5,000,000 shares of nominal or par
value of US$0.01 each, of which 4,500,000 shall be designated as Ordinary Shares, 200,000 shall be
designated as Series&nbsp;A Shares and 300,000 shall be designated as Series&nbsp;B Shares. 704,281 Ordinary
Shares, 176,942 Series&nbsp;A Shares and 233,333 Series&nbsp;B Shares shall be issued and outstanding as of
the Closing Date after giving effect to the subscription provided herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as set forth in this Section&nbsp;4.06, there are no outstanding (i)&nbsp;capital shares or
voting securities of the Company, (ii)&nbsp;securities of the Company convertible into or exchangeable
for shares or voting securities of the Company or (iii)&nbsp;options or other rights to acquire from the
Company, or other obligation of the Company to issue, any capital shares, voting securities or
securities convertible into or exchangeable for capital shares or voting securities of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company (the items in Section&nbsp;4.06(b)(i), 4.06(b)(ii) and 4.06(b)(iii) being referred to
collectively as the &#147;<B>Company Securities</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;On the Closing Date and upon the conversion of the Purchased Shares in accordance with the
Second Amended and Restated Memorandum and Articles, each Investor will acquire good and valid
title to its Purchased Shares and the Ordinary Shares issued upon such conversion, free and clear
of any Lien (including any restrictions on the voting rights or transferability of such Purchased
Shares or Ordinary Shares other than those restrictions set forth in this Agreement or those
restrictions on transferability required by applicable securities Laws), and such Purchased Shares
and Ordinary Shares will have been duly authorized, validly issued, fully paid and non-assessable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;There are no preemptive rights or similar rights on the part of any Person with respect to
the share capital of the Company except for the preemptive rights set forth in the Existing
Shareholders&#146; Agreement and the existing memorandum and articles of association of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Except for this Agreement and the Existing Shareholders&#146; Agreement, there is no agreement,
arrangement or obligation of any kind (and no authorization therefore has been given) obligating
the Company or any other Person:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) to issue or sell, or cause to be issued or sold, any Company Securities; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) to repurchase, redeem or otherwise acquire any outstanding Company Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.07<I>. Capitalization of the PRC Subsidiaries. </I>(a)&nbsp;The registered capital of each
PRC Subsidiary is as set forth in Schedule&nbsp;4.07(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;All of the registered capital of each PRC Subsidiary has been timely contributed, such
contribution has been duly verified by a certified accountant registered in the PRC and the
accounting firm employing such accountant, and the report of the certified accountant evidencing
such verification has been registered with the relevant Governmental Authority. There are no
resolutions pending to increase the registered capital of any PRC Subsidiary. There are no
dividends which have accrued or been declared but are unpaid on the registered capital of any PRC
Subsidiary.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.08<I>. Subsidiaries. </I>(a)&nbsp;All Subsidiaries of the Company and their respective
jurisdictions of incorporation, shareholders and their respective ownership percentages are
identified on Schedule&nbsp;4.08(a)(i). A true and complete diagram of the organizational structure of
the Group as of the date hereof is set forth in Schedule&nbsp;4.08(a)(ii).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as set forth in Schedule&nbsp;4.08(a)(i), all of the outstanding capital shares or
other voting securities of each Subsidiary of the Company is duly owned by the Company, directly or
indirectly, free and clear of any Lien and free of any other limitation or restriction (including
any restriction on the right to vote, sell or otherwise dispose of such capital shares or other
voting securities). Except as set forth in this Section&nbsp;4.08(b), there are no outstanding (i)
capital shares or voting securities of any Subsidiary of the Company, (ii)&nbsp;securities of any Group
Company convertible into or exchangeable for capital shares or voting securities of any Subsidiary
of the Company or (iii)&nbsp;options or other rights to acquire from any Group Company, or other
obligation of any Group Company to issue, any capital shares, voting securities or securities
convertible into or exchangeable for capital shares or voting securities of any Subsidiary of the
Company (the items in Sections&nbsp;4.08(b)(i), 4.08(b)(ii) and 4.08(b)(iii) being referred to
collectively as the &#147;<B>Subsidiary Securities</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Except for the statutory preemptive rights of shareholders of the PRC Subsidiaries under
the PRC Laws, there are no preemptive rights or similar rights on the part of any Person with
respect to the share capital of any Subsidiary of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;There is no agreement, arrangement or obligation of any kind (and no authorization
therefore has been given) obligating any Group Company or any other Person:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) to issue or sell, or cause to be issued or sold, any Subsidiary Securities; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) to repurchase, redeem or otherwise acquire any outstanding Subsidiary
Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Except for the Group Companies set forth on Schedule&nbsp;4.08(a)(i), no Group Company owns or
controls, directly or indirectly, any equity or other ownership interest in any Person. There is
no agreement, arrangement or obligation of any kind (and no authorization therefor has been given)
obligating any Group Company to purchase or acquire the ownership of any equity or other ownership
interest in any Person or to make investments in any Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.09<I>. Financial Statements. </I>(a)&nbsp;Schedule&nbsp;4.09(a) sets forth a true, correct and
complete copy of the audited consolidated balance sheets as of December&nbsp;31, 2005, 2006 and 2007 of
Aohua and its Subsidiaries and the related audited consolidated statements of income and cash flows
for each of the years ended December&nbsp;31, 2005, 2006 and 2007 (the &#147;<B>Aohua Audited Financial
Statements</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Schedule&nbsp;4.09(b) sets forth a true, correct and complete copy of the audited
consolidated balance sheets as of December&nbsp;31, 2005, 2006 and 2007 of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>





<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">China Medstar and its Subsidiaries and the related audited consolidated statements of income
and cash flows for each of the years ended December&nbsp;31, 2005, 2006 and 2007 (the &#147;<B>China Medstar
Audited Financial Statements</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Aohua Audited Financial Statements and the China Medstar Audited Financial Statements
(i)&nbsp;were prepared in accordance with GAAP and IFRS, respectively, consistently applied throughout
the period covered thereby; (ii)&nbsp;fairly present the consolidated financial condition of Aohua and
its Subsidiaries and China Medstar and its Subsidiaries, respectively, as of the respective dates
thereof and their consolidated results of operations and cash flows for the respective periods
covered thereby in accordance with GAAP and IFRS, respectively, consistently applied throughout the
respective periods covered thereby; and (iii)&nbsp;show all Indebtedness and other liabilities, direct
or contingent, of Aohua and its Subsidiaries and China Medstar and its Subsidiaries, respectively,
as of the respective dates thereof, including liabilities for Taxes and other commitments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.10<I>. Books and Records. </I>All accounts, ledgers, material files, documents,
instruments, papers, books and records relating to the business, operations, conditions (financial
or other) of the Group, results of operations, and assets and properties of the Group
(collectively, the &#147;<B>Books and Records</B>&#148;), each as supplied to the Investors, are true, correct,
complete and current; there are no inaccuracies or discrepancies of any kind contained or reflected
therein; and they have been maintained in accordance with relevant legal requirements and high
industry standards, including the maintenance of an adequate system of internal controls.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.11<I>. No Material Adverse Effect. </I>Since the Balance Sheet Date, there has been no
event, occurrence, development or state of circumstances or facts that has had or could reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.12<I>. No Material Liabilities. </I>No Group Company has any liabilities and obligations
of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or
otherwise, and there is no existing condition, situation or set of circumstances which could
reasonably be expected to result in such a liability, other than
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) liabilities provided for in the audited consolidated balance sheet of Aohua and
its Subsidiaries and the audited consolidated balance sheet of China Medstar and its
Subsidiaries, in each case as of the December&nbsp;31, 2007; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) liabilities that are individually in excess of RMB200,000 and are as set forth
in a written schedule to be provided by the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">to the Investors within five (5)&nbsp;Business Days after the date hereof (the &#147;<B>Schedule
of Liabilities</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.13<I>. Absence of Changes. </I>Since the Balance Sheet Date, each Group Company has
conducted its business in the ordinary course, in substantially the same manner in which it had
been previously conducted and there has not been, except as set forth in Schedule&nbsp;4.13:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;any amendment of the memorandum and articles of association or other similar
organizational documents (whether by merger, consolidation or otherwise) of any Group Company,
other than in connection with the transactions contemplated in the Series&nbsp;A Share Subscription
Agreement and this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;any splitting, combination or reclassification of any shares of capital stock of any Group
Company or declaration, setting aside or payment of any dividend or other distribution (whether in
cash, stock or property or any combination thereof) with respect to the capital stock of any Group
Company, or redemption, repurchase or other acquisition or offer to redeem, repurchase, or
otherwise acquire any Company Securities or any Subsidiary Securities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;(i)&nbsp;any issuance, delivery or sale, or authorization of the issuance, delivery or sale of,
any shares of any Company Securities or Subsidiary Securities, other than the issuance of
Subsidiary Securities to any Group Company or (ii)&nbsp;amendment of any term of any Company Security or
any Subsidiary Security (in each case, whether by merger, consolidation or otherwise);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;any incurrence of any capital expenditures or any obligations or liabilities with respect
thereto by any Group Company, except for those which are individually less than RMB200,000 or are
contemplated by the capital expenditure budget for the Group approved by a majority of the board of
directors of the Company (the &#147;<B>Capex Budget</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;any acquisition (by merger, consolidation, acquisition of stock or assets or otherwise),
directly or indirectly, by any Group Company of any assets, securities, properties, interests or
businesses, other than (i)&nbsp;any acquisition of assets and properties (except for the business or
business unit of any third party) with a consideration of less than RMB200,000 and (ii)&nbsp;any
acquisition in the ordinary course of business of such Group Company in a manner that is consistent
with past practice;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;any sale, lease or other transfer, or creation or incurrence of any Lien on, any material
assets, securities, material properties, interests or businesses of any Group Company;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;other than in connection with actions permitted by Section&nbsp;4.13(c), Section&nbsp;4.13(d) or
Section&nbsp;4.13(e), the making by any Group Company of any loans, advances or capital contributions
to, or investments in, any other Person, other than in the ordinary course of business consistent
with past practice;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;the creation, incurrence, assumption or sufferance to exist by any Group Company of any
Indebtedness;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;any damage, destruction or other casualty loss (whether or not covered by insurance)
affecting the business or assets of any Group Company that has had or could reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;(i)&nbsp;the entering into of any agreement or arrangement that limits or otherwise restricts
in any material respect any Group Company or any of its Affiliates or any successor thereto or that
could, after the Closing Date, limit or restrict in any material respect any Group Company or any
of its respective Affiliates, from engaging or competing in any line of business, in any location
or with any Person or (ii)&nbsp;the entering into, amendment or modification in any material respect or
termination of any Major Contract or waiver, release or assignment of any material rights, claims
or benefits of any Group Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;except as required by the PRC&#146;s Labor Contract Law, effective January&nbsp;1, 2008, and any
related interpretations or implementing regulations, (i)&nbsp;the grant or increase of any severance or
termination pay to (or amend any existing arrangement with) any director, officer or employee of
any Group Company, (ii)&nbsp;any increase in benefits payable under any existing severance or
termination pay policies or employment agreements, (iii)&nbsp;the entering into of any employment,
deferred compensation or other similar agreement (or amendment of any such existing agreement) with
any director, officer or employee of any Group Company, (iv)&nbsp;the establishment, adoption or
amendment of any collective bargaining, bonus, profit-sharing, thrift, pension, retirement,
deferred compensation, compensation, stock option, restricted stock or other benefit plan or
arrangement covering any director, officer or employee of any Group Company or (v)&nbsp;any 25% or
greater increase in compensation, bonus or other benefits payable to any director, officer or
employee of any Group Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;any labor dispute, other than routine individual grievances, or any activity or proceeding
by a labor union or representative thereof to organize any employees of any Group Company, which
employees were not subject to a collective bargaining agreement at the Balance Sheet Date, or any
material lockouts, strikes, slowdowns, work stoppages or threats thereof by or with respect to such
employees;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;any change in the Company&#146;s methods of accounting, except as required by concurrent
changes in GAAP or IFRS as agreed to by its independent public accountants;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;any settlement, or offer or proposal to settle, (i)&nbsp;any material litigation,
investigation, arbitration, proceeding or other claim involving or against any Group Company, (ii)
any stockholder litigation or dispute against any Group Company or any of its officers or directors
or (iii)&nbsp;any litigation, arbitration, proceeding or dispute that relates to the transactions
contemplated hereby; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;any Tax election, change any annual tax accounting period made or changed, any method of
tax accounting adopted or changed, any Tax returns amended or claims for Tax refunds filed, any
closing agreement entered, any Tax claim, audit or assessment settled, or any right to claim a Tax
refund, offset or other reduction in Tax liability surrendered, in each case in any material
respect, other than those adopted by the Group Companies to comply with any changes in the laws,
rules and regulations of any Governmental Authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.14<I>. Credit Line. </I>The Group is entitled to borrow additional loans in aggregate
principal amount of up to RMB150,000,000 under Contracts that are existing and effective as of the
date hereof. The Group shall be entitled to borrow such loans on the Closing Date under Contracts
that will be existing and effective as of the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.15<I>. Compliance with Laws.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;All Group Companies are, and at all times have been, in compliance with all applicable
Laws in all material respects.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;No event has occurred or circumstance exists that (with or without notice or lapse of
time): (i)&nbsp;may constitute or result in a violation by any Group Company of, or a failure on the
part thereof to comply with, any applicable Laws in any material respect; or (ii)&nbsp;may give rise to
any obligation on the part of any Group Company to undertake, or to bear all or any portion of the
cost of, any remedial action of any nature. No Group Company has received any notice or other
communication (whether oral or written) from any Governmental Authority regarding: (x)&nbsp;any actual,
alleged, possible, or potential violation of, or failure to comply with, any applicable Laws; or
(y)&nbsp;any actual, alleged, possible, or potential obligation on the part of any Group Company to
undertake, or to bear all or any portion of the cost of, any remedial action of any nature.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.16. <I>Anti-Corruption</I>. (a)&nbsp;None of the Group Companies nor any of their respective
directors, officers, agents, employees, or any other Person associated with or acting for or on
behalf of the foregoing, has offered, paid, promised to pay, or authorized the payment of any
money, or offered, given a promise to give, or authorized the giving of anything of value, to any
Government
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Official, to any political party or official thereof or to any candidate for political office
(or to any Person where any Group Company or any of its directors, officers, agents, employees or
other Person knew or was aware of a high probability that all or a portion of such money or thing
of value would be offered, given or promised, directly or indirectly, to any Government Official,
political party, party official, or candidate for political office) for the purposes of:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) (x)&nbsp;influencing any act or decision of such Government Official, political party,
party official, or candidate in his or its official capacity; (y)&nbsp;inducing such Government
Official, political party, party official or candidate to do or omit to do any act in
violation of the lawful duty of such Government Official, political party, party official
or candidate; or (z)&nbsp;securing any improper advantage; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) inducing such Government Official, political party, party official, or candidate
to use his or its influence with any Governmental Authority to affect or influence any act
or decision of such Governmental Authority, in order to assist any Group Company in
obtaining or retaining business for or with, or directing business to any Group Company,
except insofar as the payment, gift, offer or promise was lawful under the Laws of the
country in which the Government Official, political party, party official or candidate for
political office serves in such capacity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;None of the Group Companies nor any of their respective directors, officers, agents,
employees or any other Person acting for or on behalf of the foregoing, has taken or caused to be
taken any action in connection with the business and operations of the Group Companies that is
prohibited by or otherwise violates the FCPA, the OECD Rules or any other applicable anti-bribery
law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;None of the Company Securities or Subsidiary Securities are beneficially or legally owned
or held by, any Government Official, political party, party official or known/announced candidate
for political office. None of the employees, officers or directors of any Group Company is a
Government Official.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.17<I>. US Office of Foreign Assets Control. </I>None of the Group Companies nor any
director, officer, agent, employee or affiliate of any Group Company is currently subject to any US
sanctions administered by the Office of Foreign Assets Control of the US Treasury Department
(&#147;<B>OFAC</B>&#148;), nor is it located, organized or resident in a country or territory that is the subject of
OFAC-administered sanctions. The Company will not directly or indirectly use the proceeds of sale
of the Purchased Shares contemplated hereby, or lend, contribute or otherwise make available such
proceeds to any Person for the purpose of financing the activities of or business with any Person,
or in any country or territory, that is currently subject to any US sanctions administered by
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">OFAC, or in a manner that would otherwise cause any Person to violate any OFAC-administered
sanctions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.18<I>. No Litigation. </I>Except as otherwise set forth in Schedule&nbsp;4.18, there are no
actions, suits, proceedings, claims or disputes (or any basis therefor) pending or threatened or
contemplated, at law, in equity, in arbitration or before any Governmental Authority, by or against
any Group Company, any of its directors or officers or any of its assets or properties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.19<I>. Property; Liens. </I>(a)&nbsp;No Group Company owns any real property. Each Group
Company has valid leasehold interests in all real property leased or used by such Group Company.
Each Group Company has good record and marketable title to, or valid leasehold interests in, all
other assets and properties owned by or reflected in the Books and Records of such Group Company as
owned by such Group Company, or necessary to, or used or currently intended to be used in, the
ordinary conduct of the business of such Group Company. All leases of real property and all other
assets and properties are in good standing and there does not exist under any such lease any
default or any event which with notice or lapse of time or both would constitute a default, except
for such default which would not be reasonably expected to have a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Schedule&nbsp;4.19(b) sets forth all medical equipment owned, leased or used by any Group
Company, the purchase price of which exceeds RMB1,000,000. Each Group Company has (i)&nbsp;good and
marketable title to or valid leasehold interests in all such medical equipment and (ii)&nbsp;all
consents, approvals, authorizations, permits, licenses, certificates, registrations and filings
required by applicable Laws for the ownership, lease or use of all medical equipment owned, leased
or used by such Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each Group Company has maintained the assets and properties owned or leased by it or which
it otherwise has the right to use in good repair, working order and operating condition subject
only to ordinary wear and tear, and all such assets and properties are fully adequate and suitable
to conduct such businesses as currently conducted by such Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;None of the assets or properties owned by or reflected in the Books and Records of any
Group Company as owned by any Group Company, or necessary to, or used or currently intended to be
used in, the ordinary conduct of the business of any Group Company is subject to any Lien.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.20<I>. Tax. </I>Except as set forth in Schedule&nbsp;4.20, each Group Company has filed all
national, provincial and local Tax returns and reports required to be filed under the applicable
Laws, and have paid all national, provincial and local Taxes, assessments, fees and other
governmental charges levied or imposed upon it or its assets or properties, revenue or income or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">otherwise due and payable in accordance with the requirements of the relevant tax authorities.
To the Company&#146;s knowledge, there is no proposed Tax assessment against any Group Company. There
has been no claim concerning any liability for Taxes of any Group Company asserted, raised or, to
the Company&#146;s knowledge, threatened by any taxing authority and no circumstances exist to form the
basis for such a claim or issue which could be material to any Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.21<I>. Affiliate Transactions. </I>All Contracts or transactions that are in force on
the date hereof, to or by which any Group Company, on the one hand, and any Affiliate of any Group
Company, on the other hand, are or have been a party or otherwise bound or affected were on terms
and conditions as favorable to such Group Company as would have been obtainable by it at the time
in a comparable arm&#146;s-length commercial transaction with an unrelated party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.22. <I>Intellectual Property</I>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each Group Company owns or possesses sufficient legal rights to all Intellectual Property
Rights as are necessary to the conduct of its businesses as now conducted and as presently proposed
to be conducted. The consummation of the transactions contemplated by this Agreement and the other
Transaction Documents will not alter, encumber, impair or extinguish any Owned Intellectual
Property Rights or Licensed Intellectual Property Rights. None of such Intellectual Property Rights
is being infringed by third parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All of the Licensed Intellectual Property Rights are in full force and effect in
accordance with their terms, and are free and clear of any Liens. No Group Company is in default
under any Licensed Intellectual Property Right, and no such default is currently threatened.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The conduct by the Group of its business does not infringe the rights of any third party
in respect of any Intellectual Property Rights nor has any Group Company received any communication
that a claim or demand has been made, or threatened to be made to this effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Except as set forth in Schedule&nbsp;4.22(d), no Group Company owns any trademarks.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;No Group Company is registered by any Government Authority as the owner of any copyright.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Except for the domain names listed in Schedule&nbsp;4.22(f), which domain names have been
registered with the domain name registration institutions throughout the world, no Group Company is
the registered owner of any domain names. No Group Company is aware of any claim of any third
party in respect of the domain names listed in Schedule&nbsp;4.22(f).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.23<I>. Major Contracts. </I>(a)&nbsp;Schedule&nbsp;4.23 lists all Contracts (the &#147;<B>Major
Contracts</B>&#148;) that are in force on the date hereof to which any Group Company is a party or by which
any of such Group Company&#146;s assets or properties may be bound or affected and that are:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Contracts with a term of three years or longer for the leasing of medical
equipment by any Group Company to any third party;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Contracts under which the Group Companies manage medical equipment owned by
third parties;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Contracts that require the payment by or to any Group Company of an amount in
excess of RMB1,000,000 or that have resulted in an obligation for any Group Company to
pay, or the right for any Group Company to receive, an amount in excess of RMB1,000,000;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) partnership, joint venture or other similar agreements and arrangements;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Contracts relating to the acquisition or disposition of any business (whether by
merger, sale of stock, sale of assets or otherwise);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) Contracts relating to the borrowing of money by any Group Company, in each case
in excess of RMB1,000,000;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) Contracts relating to extension of credit by any Group Company;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) agency, dealer, sales representative, marketing and other similar agreements;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) agreements by any Group Company with (A)&nbsp;any of its Affiliates, (B)&nbsp;any Person
directly or indirectly owning, controlling or holding with power to vote any of the
outstanding equity securities of any Group Company or any Affiliate of such Person, (C)
any Person whose outstanding voting securities are directly or indirectly owned,
controlled or held with power to vote by any Group Company or (D)&nbsp;any director or officer
of any Group Company or any Affiliates of any such director or officer;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) agreements that limit the freedom of any Group Company to compete in any line of
business or with any Person or in any area; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) agreements, commitments, arrangements or plans that (A)&nbsp;are material to the
business, operations, results of operations, condition (financial or otherwise), assets
and properties or liabilities of any Group Company, (B)&nbsp;impose material obligations
(whether or not monetary) on
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">any Group Company, or (C)&nbsp;are otherwise necessary or advisable for the proper and
efficient operation of any Group Company
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;True and complete copies of each Major Contract have been made available to the Investors
for their review.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each Major Contract: (i)&nbsp;is legal, valid, binding, enforceable and in full force and
effect; and (ii)&nbsp;will not cease to be legal, valid, binding, enforceable and in full force and
effect on identical terms as a result of the transactions contemplated in this Agreement and other
Transaction Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;No Group Company nor, to the knowledge of the Company and the Controlling Shareholders,
any other party thereto is in breach or default, or has repudiated any provision, of any such Major
Contract and no event has occurred which with notice or lapse of time would constitute a breach or
default, or permit termination, modification or acceleration under any such Major Contract, except
such breach or default which would not reasonably be expected to have a Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;None of the Contracts to which the Company or any of its Subsidiary is a party restricts
the right of any Group Company or its Affiliates to carry on or continue their respective business
in the normal course or to implement the respective business plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;No Group Company has delegated any power or issued any powers of attorney in favor of any
Person, other than powers of attorney issued to directors, officers, or employees of any Group
Company for purpose of executing contracts or agreements for and on behalf of such Group Company in
the ordinary course of business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;All the Major Contracts have been revised, amended or modified to satisfy the requirements
under the Laws of the PRC or as required from time to time by Governmental Authorities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.24<I>. Insurance Coverage</I>. Schedule&nbsp;4.24 sets forth a list of all insurance
policies relating to the material assets, business, operations, employees, officers or directors of
the Group. The Company has made available to the Investors true and complete copies of all such
insurance policies. There is no claim by any Group Company pending under any of such policies as
to which coverage has been questioned, denied or disputed by the underwriters of such policies or
in respect of which such underwriters have reserved their rights. All premiums payable under all
such policies have been timely paid and the Group Companies have otherwise complied fully in all
material respects with the terms and conditions of all such policies. Such policies of insurance
have been in effect since the dates set forth in Schedule&nbsp;4.24 and remain in full force and effect.
Such policies are of the type and in amounts customarily carried by Persons conducting
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>





<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">businesses similar to those of the Group in the PRC. None of the Group Companies or the
Controlling Shareholders knows of any threatened termination of, premium increase with respect to,
or material alteration of coverage under, any of such policies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.25<I>. Environmental Matters. </I>(a) (i)&nbsp;No notice, notification, demand, request for
information, citation, summons or order has been received, no complaint has been filed, no penalty
has been assessed and no investigation, action, claim, suit, proceeding or review is pending or
threatened by any Governmental Authority or other Person with respect to any matters relating to
any Group Company and relating to or arising out of any Environmental Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) There are no liabilities of or relating to any Group Company of any kind
whatsoever, whether accrued, contingent, absolute, determined, determinable or otherwise,
arising under or relating to any Environmental Law, and there are no facts, conditions,
situations or set of circumstances which could reasonably be expected to result in or be
the basis for any such liability.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Except as set forth in Schedule&nbsp;4.25(a)(iii), no polychlorinated biphenyls,
radioactive materials, lead, asbestos-containing materials, incinerators, sumps, surface
impoundments, lagoons, landfills, septics, wastewater treatments or other disposal systems
or underground storage tanks (active or inactive) are or have been present at, on or under
any property now or previously owned, leased or operated by any Group Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) No Hazardous Substance has been discharged, disposed of, dumped, injected,
pumped, deposited, spilled, leaked, emitted or released at, on or under any property now
or previously owned, leased or operated by any Group Company in violation of any laws or
regulations.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Each Group Company is in compliance with all Environmental Laws and have
obtained and are in compliance with all Environmental Permits; such Environmental Permits
are valid and in full force and effect and will not be terminated or impaired or become
terminable, in whole or in part, as a result of the transactions contemplated hereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;There has been no environmental investigation, study, audit, test, review or other
analysis conducted in relation to the current or prior business of any Group Company or any
property or facility now or previously owned, leased or operated by any Group Company which has not
been delivered to the Investors at least 10&nbsp;days prior to the date hereof.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>





<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;For purposes of this Section, the terms &#147;<B>Group Company</B>&#148; shall include any entity which is,
in whole or in part, a predecessor of such Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.26<I>. Employees, Labor Matters, Etc.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Schedule&nbsp;4.26(a) sets forth a true and complete list of the names and titles of all
directors of each Group Company and employees of each Group Company holding a title of regional
general manager or above (the &#147;<B>Key Employees</B>&#148;). None of the Key Employees has indicated to any
Group Company or Controlling Shareholder that he or she intends to resign or retire or otherwise
within one year after the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Group Company is in compliance with all currently applicable Laws respecting
employment and employment practices, terms and conditions of employment and wages and hours, and
are not engaged in any unfair labor practice, failure to comply with which or engagement in which,
as the case may be, would reasonably be expected to have a Material Adverse Effect. There are no
material labor disputes currently subject to any grievance procedure, arbitration or litigation
with respect to any employee of any Group Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;There are no written employment or consultancy agreements with respect to any employee of
any Group Company that cannot be terminated by such Group Company by giving notice of three months
or less to the other parties to such agreements without giving rise to any claim for damages or
compensation beyond such notice period, except required otherwise under applicable labor and
employment related laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Except as set forth in Schedule&nbsp;4.26(d), there are currently no stock option or other
stock-based incentive plans, nor have any such stock options or other stock-based incentives been
granted to any employees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.27<I>. Permits. </I>Schedule&nbsp;4.27 correctly describes each Consent of any Governmental
Authority affecting, or relating in any way to, the assets or business of any Group Company (the
&#147;<B>Permits</B>&#148;) together with the name of the Governmental Authority issuing such Permit. Except for
the Consents set forth in Schedule&nbsp;4.27, no other Consents of any Governmental Authority are
necessary for the conduct of the business of any Group Company. Except as expressly described in
Schedule&nbsp;4.27, the Permits are valid and in full force and effect. No Group Company is in default
under, nor does any condition exist that with notice or lapse of time or both would constitute a
default under, the Permits. There is no outstanding or, to the knowledge of the Company,
anticipated investigation, enquiry or proceeding which is reasonably likely to result in the
suspension, cancellation, modification or revocation of any such Permits. None of the Permits will
be terminated or impaired or become terminable, in whole or in part, as a result of the
transactions contemplated hereby. Each Group Company is in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">compliance with all the terms and conditions of, or relating to, all such Permits and none of
the Group Companies has any reason to believe that any of such Permits listed on Schedule&nbsp;4.27
will not be renewed on or prior to its termination date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.28. <I>Accounts Receivable</I>. (a)&nbsp;Schedule&nbsp;4.28 sets forth each and all accounts
receivable in excess of RMB50,000 of each Group Company as of August&nbsp;31, 2008 and the due dates of
such accounts receivable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each and all accounts receivable in excess of RMB50,000 of each Group Company as of
September&nbsp;30, 2008 and the due dates of such accounts receivable will be set forth in a schedule to
be provided by the Company to the Investors within five (5)&nbsp;Business Days of the date hereof (the
&#147;<B>September A/R Schedule</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.29<I>. China Medstar Acquisition. </I>(a)&nbsp;The acquisition of China Medstar by Ascendium
(&#147;<B>China Medstar Acquisition</B>&#148;) has been duly approved by all parties to such acquisition in
accordance with their respective organizational documents, (b)&nbsp;the Consents of all applicable
Governmental Authorities with respect to the China Medstar Acquisition were obtained, (c)&nbsp;the China
Medstar Acquisition has been consummated and Ascendium has acquired and validly holds free of any
Liens all the outstanding equity securities of China Medstar, and (d)&nbsp;the China Medstar Acquisition
does not constitute any breach or violation of, or default under (i)&nbsp;the constitutional documents
of any of the Group Companies, (ii)&nbsp;any Contract, Consents or other agreement or instrument to
which a Group Company is a party or by which any Group Company&#146;s assets or properties may be bound
or affected, and (iii)&nbsp;any applicable Laws or other applicable Consents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.30. <I>Disclosure. </I>No representation or warranty of the Group Companies and the
Controlling Shareholders in this Agreement, as qualified by the Schedules attached hereto, and no
document, instrument or certificate furnished to the Investors by the Closing contains any untrue
statement of material fact or omits or will omit to state a material fact necessary to make the
statements contained herein or therein not misleading in light of the circumstances under which
they were made.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 5</B><BR>
<FONT style="font-variant: SMALL-CAPS">Representations and Warranties Regarding the Controlling Shareholders</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Controlling Shareholders represents and warrants to the Investors as of the date
hereof and as of the Closing Date that:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.01<I>. Power and Authority. </I>Each of the Controlling Shareholders has the legal right
and full power and authority to execute and deliver this Agreement and each other Transaction
Document to which he or she is a party and to perform his or her obligations hereunder and
thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.02<I>. Enforceability.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each of the Controlling Shareholders has duly executed and delivered this Agreement and
will execute and deliver each other Transaction Document to which he or she is a party by the
Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;This Agreement constitutes, and each other Transaction Document to which such Controlling
Shareholder is a party (when executed) will constitute, the legal, valid and binding obligations of
such Controlling Shareholder, as applicable, enforceable against him or her in accordance with the
terms hereof and thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.03<I>. Non-contravention. </I>The execution, delivery and performance by each
Controlling Shareholder of this Agreement and each other Transaction Document to which he or she is
a party, and the consummation of the transactions contemplated hereby and thereby, do not and will
not:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;conflict with, contravene, result in a violation or breach of or default (with or without
the giving of notice or the lapse of time or both); or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;result in the creation of any Lien (or any obligation to create any Lien) upon any of the
properties or assets of such Controlling Shareholder;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in each case under (w)&nbsp;any Laws applicable to or binding on such Controlling Shareholder or
any of his or her assets or properties, (x)&nbsp;any order, injunction, writ or decree of any
Governmental Authority or any arbitral award to which such Controlling Shareholder or any of its
assets or properties is subject, or (y)&nbsp;any Contract, or any other agreement or instrument to which
he or she is a party or by which any of his or her assets or properties may be bound.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.04<I>. Governmental Authorization. </I>No Consent by any Governmental Authority or any
other Person is necessary or required in connection with the execution, delivery or performance by,
or enforcement against, any Controlling Shareholder under this Agreement or any other Transaction
Document to which he or she is a party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.05<I>. Ownership of Shares. </I>Each of the Controlling Shareholders is, and immediately
prior to the Closing shall be, the legal and beneficial owner of a number of Ordinary Shares set
forth opposite the name of such Controlling Shareholder in Schedule&nbsp;5.05, which Ordinary Shares
represent, and immediately prior to the Closing shall represent, a percentage of the outstanding
Ordinary
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Shares (calculated on a Fully-Diluted basis) set forth opposite the name of such Controlling
Shareholder, free and clear of any Liens and any other limitation or restriction (including any
restriction on the right to vote, sell or otherwise dispose of such Ordinary Shares). Except for
such Ordinary Shares, such Controlling Shareholder does not hold, and immediately prior to the
Closing Date will not hold, directly or indirectly, any Company Securities.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 6</B><BR>
<FONT style="font-variant: SMALL-CAPS">Representations and Warranties of Investors</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Investor represents and warrants to the Company as of the date hereof and as of the
Closing Date that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.01<I>. Corporate Status. </I>Such Investor is duly organized, validly existing and in
good standing under the laws of its jurisdictions of formation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.02<I>. Power And Authority. </I>Such Investor has the requisite power and authority to
execute and deliver this Agreement and other Transaction Documents to which it is a party and to
perform its obligations hereunder and thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.03<I>. Enforceability. </I>Such Investor has duly executed and delivered this Agreement.
This Agreement constitutes, and other Transaction Documents to which it is a party (when executed)
will constitute, the legal, valid and binding obligations of such Investor, enforceable against it
in accordance with the terms hereof and thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.04<I>. Non-contravention. </I>The execution, delivery and performance by such Investor
of this Agreement do not and will not in any material respect conflict with, contravene, result in
a violation or breach of or default (with or without the giving of notice or the lapse of time or
both) under (x)&nbsp;any applicable Laws, (y)&nbsp;any order, injunction, writ or decree of any Governmental
Authority or any arbitral award to which such Investor is subject, or (z)&nbsp;the organization
documents of such Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.05<I>. Purchase for Investment</I>. Such Investor is purchasing the Series&nbsp;B Shares for
investment for its own account or for the accounts of its Permitted Transferees (as defined in the
Amended and Restated Shareholders&#146; Agreement) and not with a view to, or for sale in connection
with, any distribution thereof (except for transfers to its Permitted Transferees). Such Investor
(either alone or together with its advisors) has sufficient knowledge and experience in financial
and business matters so as to be capable of evaluating the merits and risks of its investment in
the Series&nbsp;B Shares and is capable of bearing the economic risks of such investment.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.06<I>. Accredited Investor. </I>Carlyle and Starr are each an &#147;accredited investor&#148;
within the meaning of Rule&nbsp;501 under the Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.07<I>. U.S. Person</I>. CICC is not a U.S. person within the meaning of Rule 902(k) of
Regulation&nbsp;S under the Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.08<I>. Legends. </I>Investors acknowledge that each certificate evidencing the
securities issued pursuant to this Agreement may bear the following legends:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&#147;THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND THE REGULATIONS PROMULGATED
THEREUNDER, AS IN EFFECT FROM TIME TO TIME (THE &#147;SECURITIES ACT&#148;) OR ANY SECURITIES LAWS OF ANY
STATE OF THE UNITED STATES. SUCH SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED WITHIN THE UNITED STATES OR TO ANY UNITED STATES PERSON EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Any legend required by any other applicable securities Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.09<I>. Litigation</I>. There is no action, suit, investigation or proceeding pending
against, or to the knowledge of such Investor threatened against or affecting, such Investor before
any arbitrator or any Governmental Authority which in any manner challenges or seeks to prevent,
enjoin, alter or materially delay the transactions contemplated by this Agreement and the other
Transaction Documents.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 7</B><BR>
<FONT style="font-variant: SMALL-CAPS">Covenants of the Group and Controlling Shareholders</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.01<I>. Conduct of the Company. </I>From the date hereof until the Closing Date, each
Group Company shall, and each of the Controlling Shareholders shall cause each Group Company to,
conduct its business in the ordinary course consistent with past practice and use its best efforts
to (i)&nbsp;preserve intact its present business organization, (ii)&nbsp;maintain in effect all of its
licenses, permits, consents, franchises, approvals and authorizations, (iii)&nbsp;preserve or renew all
of its registered patents, trademarks, tradenames, and service marks, (iv)&nbsp;keep available the
services of its directors, officers and key employees, (v)&nbsp;maintain satisfactory relationships with
its customers, lenders, suppliers and other Persons having material business relationships with it,
(vi)&nbsp;manage its working capital (including the timing of collection of accounts receivable and of
the payment of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">accounts payable and the management of inventory) in the ordinary course of business
consistent with past practice and (vii)&nbsp;continue to make capital expenditures consistent with the
capital expenditure budget for the Group approved by a majority of the board of directors of the
Company. Without limiting the generality of the foregoing, except as expressly contemplated by
this Agreement or as otherwise approved by each Investor, each Group Company shall not, and each
Controlling Shareholder shall cause each Group Company not to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;amend its articles of incorporation, bylaws or other similar organizational documents
(whether by merger, consolidation or otherwise);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;split, combine or reclassify any of its or its Subsidiaries&#146; shares of capital stock or
declare, set aside or pay any dividend or other distribution (whether in cash, stock or property or
any combination thereof) in respect of its or its Subsidiaries capital stock, or redeem, repurchase
or otherwise acquire or offer to redeem, repurchase, or otherwise acquire any Company Securities or
any Subsidiary Securities;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;(i)&nbsp;issue, deliver or sell, or authorize the issuance, delivery or sale of, any shares of
any Company Securities or Subsidiary Securities, other than the issuance of any Subsidiary
Securities to any Group Company or (ii)&nbsp;amend any term of any Company Security or any Subsidiary
Security (in each case, whether by merger, consolidation or otherwise);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;incur any capital expenditures or any obligations or liabilities in respect thereof,
except for (i)&nbsp;those contemplated by the capital expenditure budget approved by the board of
directors of the Company and (ii)&nbsp;any unbudgeted capital expenditures not to exceed RMB5,000,000
individually or RMB10,000,000 in the aggregate;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;acquire (by merger, consolidation, acquisition of stock or assets or otherwise), directly
or indirectly, any assets, securities, properties, interests or businesses, other than (i)&nbsp;supplies
in the ordinary course of business of such Group Company in a manner that is consistent with past
practice and (ii)&nbsp;acquisitions with a purchase price (including assumed indebtedness) that does not
exceed RMB1,000,000 individually or RMB2,000,000 in the aggregate;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;sell, lease or otherwise transfer, or create or incur any Lien on, any Group Company&#146;s
assets, securities, properties, interests or businesses;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;other than in connection with actions permitted by Section&nbsp;7.01(d) or Section&nbsp;7.01(e),
make any loans, advances or capital contributions to, or investments in, any other Person, other
than in the ordinary course of business consistent with past practice;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;create, incur, assume, suffer to exist or otherwise be liable with respect to any
Indebtedness;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;(i)&nbsp;enter into any agreement or arrangement that limits or otherwise restricts in any
material respect any Group Company or any of its Affiliates or any successor thereto or that could,
after the Closing Date, limit or restrict in any material respect any Group Company, any Investor
or any of their respective Affiliates, from engaging or competing in any line of business, in any
location or with any Person or (ii)&nbsp;enter into, amend or modify in any material respect or
terminate any contract required to be disclosed by Section&nbsp;4.23 or otherwise waive, release or
assign any material rights, claims or benefits of any Group Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;(i)&nbsp;grant or increase any severance or termination pay to (or amend any existing
arrangement with) any director, officer or employee of any Group Company except as required by law,
(ii)&nbsp;increase benefits payable under any existing severance or termination pay policies or
employment agreements, (iii)&nbsp;enter into any employment, deferred compensation or other similar
agreement (or amend any such existing agreement) with any director, officer or employee of the any
Group Company, (iv)&nbsp;establish, adopt or amend (except as required by applicable Laws) any
collective bargaining, bonus, profit-sharing, thrift, pension, retirement, deferred compensation,
compensation, stock option, restricted stock or other benefit plan or arrangement covering any
director, officer or employee of any Group Company or (v)&nbsp;increase compensation, bonus or other
benefits payable to any director, officer or employee of any Group Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;change the Group&#146;s methods of accounting, except as required by concurrent changes in
GAAP, as agreed to by its independent public accountants;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;settle, or offer or propose to settle, (i)&nbsp;any material litigation, investigation,
arbitration, proceeding or other claim involving or against any Group Company, (ii)&nbsp;any stockholder
litigation or dispute against any Group Company or any of its officers or directors or (iii)&nbsp;any
litigation, arbitration, proceeding or dispute that relates to the transactions contemplated
hereby;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;make or change any Tax election, change any annual tax accounting period, adopt or change
any method of tax accounting, amend any Tax returns or file claims for Tax refunds, enter any
closing agreement, settle any Tax claim, audit or assessment, or surrender any right to claim a Tax
refund, offset or other reduction in Tax liability;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;take any action that would make any representation or warranty of any Group Company
hereunder, or omit to take any action necessary to prevent any representation or warranty of any
Group Company hereunder from being, inaccurate in any respect at, or as of any time before, the
Closing Date; or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;agree, resolve or commit to do any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.02<I>. Use of Proceeds. </I>(a)&nbsp;The entire proceeds from the sale of the Series&nbsp;B Shares
pursuant to Article&nbsp;2 shall be deposited into the Company&#146;s bank account and any withdrawals from
such account shall require the prior written consent by each of the Investors and the Company. No
withdrawal from such account shall be allowed unless (i)&nbsp;such withdrawal is permitted by, and the
funds to be so withdrawn are to be used pursuant to, a budget and business plan approved by the
board of directors of the Company (including a majority of the directors to be designated by the
Investors pursuant to the Amended and Restated Shareholders&#146; Agreement) or (ii)&nbsp;such withdrawal has
been made upon the prior written consent by each of the Company and the Investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company shall use the proceeds from the sale of the Series&nbsp;B Shares as contemplated in
this Agreement only for working capital requirements and mergers or acquisitions approved by the
Company&#146;s board of directors (including a majority of the directors to be designated by the
Investors pursuant to the Amended and Restated Shareholders&#146; Agreement).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.03<I>. Access to Information; Confidentiality.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;From the date hereof until the Closing Date, the Company will (i)&nbsp;give, and will cause
each other Group Company to give, each Investor, its counsel, financial advisors, auditors and
other authorized representatives full access to the offices, properties, books and records of each
Group Company, (ii)&nbsp;furnish, and will cause each Group Company to furnish, to each Investor, its
counsel, financial advisors, auditors and other authorized representatives such financial and
operating date and other information relating to any Group Company as such Persons may reasonably
request and (iii)&nbsp;instruct the employees, counsel and financial advisors of each Group Company to
reasonably cooperate with each Investor in its investigation of the Group. No investigation by any
Investor or other information received by any Investor shall operate as a waiver or otherwise
effect any representation, warranty or agreement given or made by any Group Company or any
Controlling Shareholder hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Investor and its Affiliates will hold, and will use their best efforts to cause their
respective officers, directors, employees, accountants, counsel, consultants, advisors and agents
to hold, in confidence, unless compelled to disclose by judicial or administrative process or by
other requirements of law, all confidential documents and information concerning any Group Company
furnished to such Investor or its Affiliates in connection with the transactions contemplated by
this Agreement, except to the extent that such information can be shown to have been (i)&nbsp;previously
known on a non-confidential basis by such Investor, (ii)&nbsp;in the public domain through no fault of
such Investor or (iii)&nbsp;later lawfully acquired by such Investor from sources other than the Group;
<I>provided </I>that any Investor may disclose such information to its officers, directors,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">employees, accountants, counsel, consultants, advisors and agents in connection with the
transactions contemplated by this Agreement so long as such Persons are directed by such Investor
to treat such information confidentially and agree to be bound by the confidentiality obligations
under this Agreement. The obligation of each Investor and its Affiliates to hold any such
information in confidence shall be satisfied if they exercise the same care with respect to such
information as they would take to preserve the confidentiality of their own similar information.
If this Agreement is terminated, each Investor and its Affiliates will and will use their best
efforts to cause their respective officers, directors, employees, accountants, counsel,
consultants, advisors and agents to, destroy or deliver to the Company, upon request, all documents
and other materials, and all copies thereof, obtained by such Investor or its Affiliates or on
their behalf from any Group Company in connection with this Agreement that are subject to such
confidence. Notwithstanding the return or destruction of such information, the Investors and its
Affiliates shall continue to be bound by the confidentiality obligations hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.04<I>. Compliance with Law; Consents. </I>(a)&nbsp;Each Group Company shall comply in all
material respects with the requirements of all applicable Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;No Group Company shall purchase, lease or otherwise invest in any medical equipment
without obtaining all Permits required by applicable Laws for the acquisition, use, lease and sale
of such medical equipment, including any required <IMG src="h03611h0361127.gif" alt="(CHINESE CHARACTHER)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each Group Company shall obtain all Permits required by applicable Laws for each medical
equipment owned, used or leased by such Group Company, including any required <IMG src="h03611h0361128.gif" alt="(CHINESE CHARACTHER)"> by the completion of the QPO.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Upon receipt of a written request from any Investor, Aohua shall duly assign or novate
each and all of the medical equipment lease agreements of Aohua in the manner and by the date
specified in such request.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.05. <I>Insurance</I>. To the extent such insurance coverage is available in the PRC and
can be practically obtained on commercially reasonable terms, each Group Company shall promptly
obtain (i)&nbsp;general property and casualty equipment insurance for each medical equipment owned by
any Group Company with a purchase price in excess of RMB1,000,000 to the extent not already
obtained, and (ii)&nbsp;medical liability insurance for each hospital and private clinic whose majority
equity interests are owned by the Group, in each case of the type and in the amount customarily
carried by Persons conducting businesses similar to those of such Group Company in the PRC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.06<I>. Amended and Restated Shareholders&#146; Agreement. </I>The Company and each of the
Controlling Shareholders shall, and shall cause each
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">other holder of the Ordinary Shares to, execute and deliver the Amended and Restated
Shareholders&#146; Agreement by the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.07. <I>Share Charge</I>. Within fifteen (15)&nbsp;Business Days after the Closing, each
Controlling Shareholder shall cause such Controlling Shareholder&#146;s Controlling Shareholder Holding
Company to deliver to the Investors a first priority security interest in such number of Ordinary
Shares equal to 40% of the Ordinary Shares held by such Controlling Shareholder Holding Company
which is set forth opposite such Controlling Shareholder&#146;s name in Schedule&nbsp;5.05 (the &#147;<B>Charged
Shares</B>&#148; of such Controlling Shareholder), free and clear of any Liens and any other limitation or
restriction pursuant to the relevant Share Charge Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.08. <I>Amendment No.&nbsp;2 to Series&nbsp;A Share Subscription Agreement</I>. Each Group Company
and Controlling Shareholder shall execute and deliver the Amendment No.&nbsp;2 to Series&nbsp;A Share
Subscription Agreement by the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.09<I>. Amendment to Convertible Loan Agreement</I>. Each Group Company and Controlling
Shareholder shall execute and deliver the Amendment to Convertible Loan Agreement by the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.10<I>. Second Amended and Restated Memorandum of Articles. </I>The Company and each of
the Controlling Shareholders shall, and shall cause the board of directors of the Company and the
other shareholders of the Company to, approve and adopt the Second Amended and Restated Memorandum
and Articles by the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.11<I>. Adoption of International Accounting Standards. </I>As soon as practicable after
the Closing, the Group shall adopt US GAAP or IFRS for all internal accounting and external
accounting reports made to shareholders or investors. US GAAP or IFRS will be the accounting
standard applied to all valuation matters with respect to the obligations of each Group Company,
each Controlling Shareholder to the Investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.12<I>. QPO. </I>Each Group Company and each Controlling Shareholder shall use its or his
or her best efforts to complete the QPO by the third anniversary of the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.13. <I>Employment Contracts</I>. (a)&nbsp;As soon as practicable after the Closing and, in
any event, within ninety (90)&nbsp;days thereof, each of the Key Employees, on the one hand, and the
Company, on the other, shall enter into an employment contract, in a form satisfactory to the
Investors, for a term of no less than three years.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company shall cause each other executive officer of the Company to enter into such
employment agreement promptly after the commencement of the employment of such executive officer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.14<I>. Non-Competition Agreement. </I>(a)&nbsp;As soon as practicable after the Closing and,
in any event, within ninety (90)&nbsp;days thereof, the Company shall enter into a non-competition
agreement with each of the Key Employees. Such non-competition agreements shall provide, among
other provisions, that none of the Key Employees nor their respective Affiliates shall (i)&nbsp;join or
establish any business entity engaging in any activities that compete with any Group Company, (ii)
employ any employees of any Group Company or solicit any such employee to terminate his employment
relationship with such Group Company, (iii)&nbsp;engage in any transactions or dealings with any
customer of any Group Company that may compete with the business of any Group Company, or (iv)
otherwise engage in any activities outside the Group that may compete with the business of any
Group Company without the approval by a majority of the directors of the Company (which majority
shall include a majority of the directors designated by the Investors).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company shall cause each other executive officer of the Company or any other Group
Company to enter into such non-competition agreement promptly after the commencement of the
employment of such executive officer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.15<I>. Intellectual Property Rights. </I>(a)&nbsp;Each of the Key Employees agrees that the
Group shall have a right of first refusal to purchase any technology or Intellectual Property
Rights relating to the provision of medical services or manufacture of medical equipment, in each
case owned or developed by such Key Employee or any of his Affiliates. The Company shall not
exercise such right of first refusal without the approval by a majority of the directors of the
Company (which majority shall include a majority of the directors designated by the Investors).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As soon as practicable after the Closing, the Company shall enter into an intellectual
property rights agreement with each of the Group&#146;s employees and consultants in form and substance
reasonably satisfactory to the Investors providing that all Intellectual Property Rights developed
by such employees and consultants shall be owned by the Group and governing the transfer and
protection of such Intellectual Property Rights. The Controlling Shareholders shall cause each of
the Group&#146;s employees and consultants to enter into such intellectual property rights agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.16<I>. Employee Share Incentive Plans. </I>(a)&nbsp;Notwithstanding anything to the contrary
set forth in Section&nbsp;7.01, prior to the Closing Date, the Company may adopt an employee share
incentive plan under which the Company will be authorized to grant a maximum number of share
options and/or restricted
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shares equal to 1.5% of the Ordinary Shares outstanding immediately prior to the Closing,
calculated on a Fully-Diluted basis (the &#147;<B>Pre-Closing Options Pool</B>&#148;). Notwithstanding anything to
the contrary set forth in the Amended and Restated Shareholders&#146; Agreement and the Second Amended
and Restated Memorandum and Articles, the majority of the directors of the Company (which majority
shall include the directors designated by Carlyle and CICC pursuant to the Existing Shareholders&#146;
Agreement or the Amended and Restated Shareholders&#146; Agreement, as applicable) shall have the sole
right to determine the granting of the share options and/or restricted share awards in the
Pre-Closing Options Pool.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The majority of the directors of the Company (which majority shall include all directors
designated by the Investors pursuant to the Amended and Restated Shareholders&#146; Agreement) may adopt
an employee share incentive plan under which the Company will be authorized to grant (i)&nbsp;a maximum
number of share options and/or restricted shares equal to 3.0% of the Ordinary Shares outstanding
on (x)&nbsp;the QPO Date or (y)&nbsp;April&nbsp;30, 2009, whichever is earlier, calculated on a Fully-Diluted
basis (the &#147;<B>Post-Closing Options Pool</B>&#148;); <I>provided </I>that (A)&nbsp;no share options and/or restricted
shares in the Post-Closing Options Pool shall be granted to any of the Controlling Shareholders
unless such grant has been approved by all directors of the Company designated by the Investors
pursuant the Amended and Restated Shareholders&#146; Agreement, and (B)&nbsp;the exercise price of any such
share option shall not be lower than the fair market value of the Ordinary Share on a per share
basis on the date that such share option is granted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.17. <I>Notices of Certain Events</I>. The Company shall promptly notify each Investor
of:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;any notice or other communication from any Person alleging that the consent of such Person
is or may be required in connection with the transactions contemplated by this Agreement or any
other Transaction Documents;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;any notice or other communication from any Governmental Authority in connection with the
transactions contemplated by this Agreement or any other Transaction Document; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;any actions, suits, claims, investigations or proceedings commenced or threatened against,
relating to or involving or otherwise affecting any Group Company or Controlling Shareholder that,
if pending on the date of this Agreement, would have been required to have been disclosed pursuant
to Section&nbsp;4.18 that relate to the consummation of the transactions contemplated by this Agreement
or any other Transaction Document;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>provided, however, </I>that the delivery of any notice pursuant to this Section&nbsp;7.17 shall not
limit or otherwise affect the remedies available hereunder to the party receiving that notice.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.18. <I>Schedule of Liabilities. </I>Within five (5)&nbsp;Business Days of the date hereof,
the Company shall deliver to the Investors the Schedule of Liabilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.19. <I>September A/R Schedule. </I>Within five (5)&nbsp;Business Days of the date hereof, the
Company shall deliver to the Investors the September A/R Schedule.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 8</B><BR>
<FONT style="font-variant: SMALL-CAPS">Covenants of All Parties</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each party hereto agrees that:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.01. <I>Best Efforts; Further Assurance</I>. Subject to the terms and conditions of this
Agreement, it will use its best efforts to take, or cause to be taken, all actions and to do, or
cause to be done, all things necessary or desirable under applicable Laws to consummate the
transactions contemplated by this Agreement and the other Transaction Documents, including (i)
preparing and filing as promptly as practicable with any Governmental Authority or other third
party all documentation to effect all necessary filings, notices, petitions, statements,
registrations, submissions of information, applications and other documents and (ii)&nbsp;obtaining and
maintaining all Consents required to be obtained from any Governmental Authority or other third
party that are necessary, proper or advisable to consummate the transactions contemplated by this
Agreement and the other Transaction Documents. Each of the Group Companies and the Controlling
Shareholders agrees to deliver such other documents, certificates, agreements and other writings
and to take such other actions as may be necessary or desirable in order to consummate or implement
expeditiously the transactions contemplated by this Agreement and the other Transaction Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.02. <I>Certain Filings</I>. It shall cooperate with the other parties hereto (i)&nbsp;in
determining whether any action by or in respect of, or filing with, any Governmental Authority is
required, or any actions, Consents or waivers are required to be obtained from parties to any
material Contracts, in connection with the consummation of the transactions contemplated by this
Agreement and the other Transaction Documents and (ii)&nbsp;in taking such actions or making any such
filings, furnishing information required in connection therewith and seeking timely to obtain any
such actions or Consents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.03. <I>Public Announcements</I>. The parties agree to consult with each other before
issuing any press release or making any public statement with respect to this Agreement or any
other Transaction Document or the transactions contemplated hereby or thereby and, except for any
press releases and public statements the making of which may be required by applicable Laws or any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">listing agreement with any securities exchange, will not issue any such press release or make
any such public statement prior to such consultation.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 9</B><BR>
<FONT style="font-variant: SMALL-CAPS">Conditions to Closing</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.01. <I>Conditions to Obligations of the Investors</I>. The obligations of each Investor
to consummate the Closing are subject to the satisfaction (or waiver by such Investor) of the
following conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<I>Representations</I>. The representations and warranties of each of the Group Companies and
the Controlling Shareholders contained in this Agreement and in any certificate or other writing
delivered by it in connection with the Closing shall, disregarding all materiality and Material
Adverse Effect qualifications included therein, be true and correct in all material respects at and
as of the Closing Date as if made at and as of such date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<I>Performance</I>. Each of the Group Companies and the Controlling Shareholders shall have
performed and complied with all covenants, undertakings, agreements, obligations and conditions
required to be performed or complied with by it on or prior to the Closing Date under this
Agreement or any other Transaction Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<I>Government Approval</I>. Each of the Group Companies and the Controlling Shareholders shall
have obtained all Consents of all applicable Governmental Authorities for the consummation of the
transactions contemplated by this Agreement and the other Transaction Documents and all such
Consents shall be effective as of the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<I>Corporate Authorization</I>. The board of directors and the shareholders of each Group
Company shall have approved this Agreement and the transactions contemplated hereunder in
accordance with its organizational documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<I>No Prohibition by Law</I>. No provision of any applicable Law shall prohibit the consummation
of the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;<I>No Litigation</I>. There shall not be threatened, instituted or pending any action or
proceeding by any Person before any Governmental Authority or any arbitration body against any of
the Group Companies, the Controlling Shareholders and the Investors seeking to enjoin, delay,
challenge the validity of, or assert any liability against any of them on account of, this
Agreement or any other Transaction Document.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;<I>No Material Adverse Change</I>. There shall have been no event or circumstance on or prior to
the Closing that has had or could be reasonably expected to have, either individually or in the
aggregate, a Material Adverse Effect and there shall have been no change in Laws that has had or
could be reasonably expect to have, either individually or in the aggregate, a material adverse
effect on such Investor&#146;s voting interests in the Company or such Investor&#146;s economic interests in
the Group, taken as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;<I>Schedule of Liabilities</I>. The Company shall have delivered the Schedule of Liabilities to
such Investor and the form and substance of such Schedule of Liabilities shall be satisfactory to
such Investor in its sole discretion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;<I>September A/R Schedule</I>. The Company shall have delivered the September A/R Schedule to
such Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;<I>Second Amended and Restated Memorandum and Articles</I>. The board of directors and the
shareholders of the Company shall have approved and duly adopted the Second Amended and Restated
Memorandum and Articles, which Second Amended and Restated Memorandum and Articles shall be valid
and effective on the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;<I>Amended and Restated Shareholders&#146; Agreement</I>. The Company and each Person who is a
shareholder of the Company on the Closing Date shall have executed and delivered the Amended and
Restated Shareholders&#146; Agreement, which Amended and Restated Shareholders&#146; Agreement shall be valid
and effective on the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;<I>Amendment No.&nbsp;2 to Series&nbsp;A Share Subscription Agreement</I>. Each Group Company, each
Controlling Shareholder and each other Investor shall have executed and delivered the Amendment No.
2 to Series&nbsp;A Share Subscription Agreement, which Amendment No.&nbsp;2 to Series&nbsp;A Share Subscription
Agreement shall be valid and effective on the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;<I>Amendment to Convertible Loan Agreement</I>. Each Group Company, each Controlling Shareholder
and each other Investor shall have executed and delivered the Amendment to Convertible Loan
Agreement, which Amendment to Convertible Loan Agreement shall be valid and effective on the
Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;<I>Opinion of the Company&#146;s Cayman Islands Counsel</I>. Such Investor shall have received from
the Cayman Islands counsel for the Company a legal opinion, dated the Closing Date, in form and
substance satisfactory to such Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;<I>Opinion of the Company&#146;s British Virgin Islands Counsel</I>. Such Investor shall have
received from the British Virgin Islands counsel for the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company a legal opinion, dated the Closing Date, in form and substance satisfactory to such
Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)&nbsp;<I>Opinion of the Company&#146;s Hong Kong Counsel</I>. Such Investor shall have received from the
Hong Kong counsel for the Company a legal opinion, dated the Closing Date, in form and substance
satisfactory to such Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q)&nbsp;<I>Opinion of the Company&#146;s Singapore Counsel. </I>Such Investor shall have received from
Singapore counsel for the Company a legal opinion, dated the Closing Date, in form and substance
satisfactory to such Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r)&nbsp;<I>Opinion of the Company&#146;s PRC Counsel</I>. Such Investor shall have received from the PRC
counsel for the Company a legal opinion, dated the Closing Date, in form and substance satisfactory
to such Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s)&nbsp;<I>Opinion of the Company&#146;s United Kingdom Counsel</I>. Such Investor shall have received from
United Kingdom counsel for the Company a legal opinion, dated the Closing Date, in form and
substance satisfactory to such Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t)&nbsp;<I>Process Agent</I>. Each of the Group Companies and the Controlling Shareholders shall have
irrevocably appointed a process agent in New York City, New York to accept, for and on its behalf,
service of notice, request or other communication or process in any legal action or proceedings
arising out of or in connection with this Agreement or any other Transaction Documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u)&nbsp;<I>Appointment of Directors</I>. The person designated by such Investor to serve as a director
of each Group Company shall have been elected as director of such Group Company pursuant to the
Amended and Restated Shareholders&#146; Agreement and such election shall have been duly executed and
evidenced under all applicable Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;<I>Compliance Certificate</I>. The Company shall have delivered to the Investors a certificate,
dated the Closing Date, signed by the Chief Executive Officer of the Company, in form and substance
satisfactory to the Investors, certifying that the conditions set forth in this Article&nbsp;9 have
been satisfied as of the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.02. <I>Additional Condition to the Obligations of Starr. </I>In addition to the
conditions set forth in Section&nbsp;9.01, the obligations of Starr to consummate the transactions
contemplated by this Agreement and the other Transaction Documents are subject to the consummation
by Carlyle and CICC of the transactions contemplated by this Agreement and the other Transaction
Documents. For the avoidance of doubt, the respective obligations of Carlyle and CICC to
consummate the transactions contemplated by this Agreement and the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">other Transaction Documents are not subject to (i)&nbsp;the consummation of such obligations of the
other or (ii)&nbsp;the consummation of the obligations of Starr to consummate the transactions
contemplated by this Agreement and the other Transaction Documents.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 10</B><BR>
<FONT style="font-variant: SMALL-CAPS">Survival; Indemnification</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10.01. <I>Survival</I>. Each representation and warranty of the parties hereto contained
in this Agreement or in any certificate or other writing delivered pursuant hereto or in connection
herewith shall survive the Closing until the earlier to occur of (i)&nbsp;the third anniversary of the
Closing Date and (ii)&nbsp;the latest date permitted by law; <I>provided </I>that the representations and
warranties in Sections&nbsp;4.01 through 4.07 and Article&nbsp;5 shall survive indefinitely. The
covenants and agreements of the parties hereto contained in this Agreement or in any certificate or
other writing delivered pursuant hereto or in connection herewith shall survive the Closing
indefinitely or for the shorter period explicitly specified therein, except that for such covenants
and agreements that survive for such shorter period, breaches thereof shall survive indefinitely or
until the latest date permitted by law. Notwithstanding the preceding sentences, any breach of
representation, warranty, covenant or agreement with respect to which indemnity may be sought under
this Agreement shall survive the time at which it would otherwise terminate pursuant to the
preceding sentences, if notice of the inaccuracy or breach thereof giving rise to such right of
indemnity shall have been given to the party against whom such indemnity may be sought prior to
such time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10.02. <I>Indemnification</I>. (a)&nbsp;Effective at and after the Closing, each of the Group
Companies and the Controlling Shareholders agrees to indemnify, jointly and severally, each
Investor, its Affiliates and their respective successors and assignees against and agree to hold
each of them harmless from any and all damage, loss, liability and expense (including reasonable
expenses of investigation and reasonable attorneys&#146; fees and expenses in connection with any
action, suit or proceeding whether involving a third party claim or a claim solely between the
parties hereto and any incidental, indirect or consequential damages, losses, liabilities or
expenses, and any lost profits or diminution in value) (&#147;<B>Damages</B>&#148;), incurred or suffered by such
Investor, any of its Affiliates or any of their respective successors and assignees arising out of
any misrepresentation or breach of warranty by any Group Company or any Controlling Shareholder
(determined, without regard to any qualification or exception contained therein relating to
materiality or Material Adverse Effect or any similar qualification or standard, including
specified dollar thresholds) or breach of covenant or agreement made or to be performed by any
Group Company or any Controlling Shareholder pursuant to this Agreement regardless of whether such
Damages arise as a result of the negligence, strict liability or any other liability under any
theory
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of law or equity of, or violation of any law by, such Investor, any of its Affiliates or any
of its successors or assignees. The aggregate liabilities of the Group Companies and the
Controlling Shareholders under this Section&nbsp;10.02 for Damages incurred by the Indemnified Parties
(as defined below) shall not exceed the sum of (x)&nbsp;the aggregate Purchase Price for the Purchased
Shares paid by the Investors and (y)&nbsp;an additional amount guaranteeing a Rate of Return of at least
12.5% to the Investors for such aggregate Purchase Price. Notwithstanding anything herein to the
contrary, none of the Indemnified Parties shall be entitled to recover any Damages unless and until
the total of all Damages exceeds US$500,000. Once the total of all Damages exceeds US$500,000, the
Indemnified Parties shall be entitled to recover all Damages including the first US$500,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Notwithstanding anything to the contrary in this Agreement, each of the Controlling
Shareholders agrees to indemnify, jointly and severally, the Company and its successors from and
against all Damages (including all reasonable costs and expenses of investigation by engineers,
environmental consultants and similar technical personnel), whether accrued, contingent, absolute,
determined, determinable or otherwise, incurred or suffered by the Company or any of such
successors which arise out of or relate to (i)&nbsp;any Environmental Law or Hazardous Substance, or
(ii)&nbsp;any actions occurring or conditions existing on or prior to the Closing Date regardless of
whether such Damages arise as a result of the negligence, strict liability or any other liability
under any theory of law or equity of, or violation of any law by, such Investor, any of such
Affiliates or any of such successors or assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Notwithstanding anything to the contrary in this Agreement, each of the Controlling
Shareholders agrees to indemnify, jointly and severally, the Company and its successors from (i)
any fines or penalties arising from the non-payment or delinquent payment of the Tax of any Group
Company or any of its Subsidiaries related to a Pre-Closing Tax Period, and all Damages arising out
of or incident to the imposition, assessment or assertion of any such Tax or any failure to pay
such Tax, (ii)&nbsp;any losses from the disposition of Medstar (Beijing) International Anti-aging Health
Bio-tech Inc. <IMG src="h03611h0361141.gif" alt="(CHINESE CHARACTHER)">, (iii)&nbsp;any amount owed by any Group
Company to Shenzhen Aowo International Co., Ltd. <IMG src="h03611h0361142.gif" alt="(CHINESE CHARACTHER)"> and/or Aberdour
International Investment Inc., (iv)&nbsp;any fines arising from any violation of FCPA, the OECD Rules or
any other applicable anti-bribery Law or OFAC prior to the Closing Date, (v)&nbsp;the amount of any
non-payment or delinquent payment of any amounts that any PRC Subsidiary should have contributed
prior to the Closing Date to the reserve fund, the enterprise expansion fund, the bonus and welfare
fund or any other funds contribution to which by such PRC Subsidiary is mandatorily required by the
Laws of the PRC and all fines and penalties arising from such non-payment or delinquent payment,
and (vi)&nbsp;any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">monetary awards against any Group Company in connection with any litigation arising from any
circumstances existing on or prior to the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10.03<I>. Procedures. </I>The party seeking indemnification under Section&nbsp;10.02 (the
&#147;<B>Indemnified Party</B>&#148;) agrees to give prompt notice to the party against whom indemnity is sought
(the &#147;<B>Indemnifying Party</B>&#148;) of the assertion of any claim, or the commencement of any suit, action
or proceeding in respect of which indemnity may be sought under such Section. The Indemnifying
Party may at the request of the Indemnified Party participate in and control the defense of any
such suit, action or proceeding at its own expense; provided that the Indemnifying Party (i)&nbsp;shall
defend such claim, suit, action or proceeding diligently and (ii)&nbsp;shall not effect any settlement
unless the Indemnified Party has been fully released from any liabilities in connection with such
claim, suit, action or proceeding. The Indemnifying Party shall not be liable under Section&nbsp;10.02
for any settlement effected by the Indemnified Party without its consent of any claim, litigation
or proceeding in respect of which indemnity may be sought hereunder.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 11</B><BR>
<FONT style="font-variant: SMALL-CAPS">Termination</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.01<I>. Grounds for Termination</I>. This Agreement may be terminated at any time prior
to the Closing:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) by mutual written agreement of the Company and the Investors;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) by either the Company or the Investors, if there shall be any Applicable Law that
makes consummation of the transactions contemplated hereby illegal or otherwise prohibited
or if consummation of the transactions contemplated hereby would violate any nonappealable
final order, decree or judgment of any Governmental Authority having competent
jurisdiction; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) by either the Company or any of the Investors, if the Closing does not take place
prior to and including the fifth (5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>) Business Day after the date hereof.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The party desiring to terminate this Agreement pursuant to clause 11.01(b) or 11.01(c) shall
give notice of such termination to the other party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.02<I>. Effect of Termination. </I>If this Agreement is terminated as permitted by
Section&nbsp;11.01, such termination shall be without liability of any party (or any stockholder,
director, officer, employee, agent, consultant or representative of such party) to the other
parties to this Agreement; <I>provided </I>that if such termination shall result from the (i)&nbsp;willful
failure of any party to fulfill a
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">condition to the performance of the obligations of the other parties, (ii)&nbsp;failure to perform
a covenant of this Agreement or (iii)&nbsp;breach by any party hereto of any representation or warranty
or agreement contained herein, such party shall be fully liable for any and all Damages incurred or
suffered by the other parties as a result of such failure or breach. The provisions of this
Section&nbsp;11.02 and Sections&nbsp;12.06, 12.07 and 12.08 shall survive any termination hereof pursuant
to Section&nbsp;11.01.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 12</B><BR>
<FONT style="font-variant: SMALL-CAPS">Miscellaneous</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.01. <I>Notices</I>. All notices and other communications hereunder shall be in writing
and shall be deemed effectively given upon personal delivery to the party to be notified; on the
next Business Day after delivery to a recognized overnight courier service; upon confirmation of
receipt of a facsimile transmission; or five days after deposit with a recognized postal service,
by registered or certified mail (return receipt requested), postage prepaid, to the parties at the
following addresses (or at such other address for a party as shall be specified by like notice;
provided that notices of a change of address shall be effective only upon receipt thereof):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If to CICC, to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">China International Capital Corporation<BR>
28<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor, China World Tower 2<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Facsimile: 86-10-6505-3796<BR>
Attention: Ms.&nbsp;Shirley Chen
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If to Carlyle, to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">The Carlyle Group<BR>
2518-2521, South Office Tower<BR>
Beijing Kerry Centre<BR>
No.&nbsp;1, Guang Hua Road<BR>
Chao Yang District<BR>
Beijing 100020<BR>
People&#146;s Republic of China<BR>
Facsimile: 86-10-8529-9877<BR>
Attention: Mr.&nbsp;Feng Xiao
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With a copy to:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Davis Polk &#038; Wardwell LLP<BR>
26<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor, Twin Tower West<BR>
B12, Jian Guo Men Wai Avenue<BR>
Chao Yang District<BR>
Beijing 100022<BR>
People&#146;s Republic of China<BR>
Tel.: 86-10-8567-5000<BR>
Fax: 86-10-8567-5123<BR>
Attention: Show-Mao Chen, Esq.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If to Starr, to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Starr Investments Cayman II, Inc.<BR>
c/o Starr International Company (Asia) Limited<BR>
Suite&nbsp;1405-7, Two Exchange Square<BR>
8 Connaught Place, Central<BR>
Hong Kong<BR>
Tel.: 852-2905-1166<BR>
Fax: 852-2905-1555<BR>
Attention: Elaine Zong
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With a copy to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Skadden, Arps, Slate, Meagher &#038; Flom<BR>
East Wing Office, Level 4<BR>
China World Trade Centre<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Tel.: 86-10-6535-5500<BR>
Fax: 86-10-6505-5522<BR>
Attention: Peter X. Huang
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If to the Company, to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Concord Medical Services Holdings Limited<BR>
P.O. Box 103<BR>
NO. 01, 37/F, Landmark<BR>
4028 Jintian Road, Futian District<BR>
Shenzhen 518035<BR>
People&#146;s Republic of China<BR>
Facsimile: 86-755-8221-0429<BR>
Attention: Mr.&nbsp;Steven Sun, President
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>




<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With a copy to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 3%; margin-top: 6pt">Simpson Thacher &#038; Bartlett LLP<BR>
35<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor, ICBC Tower<BR>
3 Garden Road<BR>
Central, Hong Kong<BR>
Tel.: 852-2514-7600<BR>
Fax: 852-2869-7694<BR>
Attention: Leiming Chen
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or such other address or facsimile number as such party may hereafter specify for the purpose by
notice to the other parties hereto. All such notices, requests and other communications shall be
deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. in
the place of receipt and such day is a Business Day in the place of receipt. Otherwise, any such
notice, request or communication shall be deemed not to have been received until the next
succeeding Business Day in the place of receipt.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.02. <I>Amendments and Waivers</I>. (a)&nbsp;Any provision of this Agreement may be amended
or waived if, but only if, such amendment or waiver is in writing and is signed, in the case of an
amendment, by each party to this Agreement, or in the case of a waiver, by the party against whom
the waiver is to be effective.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;No failure or delay by any party in exercising any right, power or privilege hereunder
shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any
other or further exercise thereof or the exercise of any other right, power or privilege. The
rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies
provided by law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.03<I>. Disclosure Schedule&nbsp;References</I>. The parties hereto agree that any reference
in a particular Section of the Disclosure Schedule shall, unless otherwise stated therein, only be
deemed to be an exception to (or, as applicable, a disclosure for purposes of) the representations
and warranties (or covenants, as applicable) of the relevant party that are contained in the
corresponding Section of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.04. Expenses. Except as otherwise provided herein, all costs and expenses
incurred in connection with this Agreement shall be paid by the party incurring such cost or
expense. With the exception of the consulting fees Starr incurs relating to the engagement of The
Monitor Group, the Company shall pay, up to an aggregate maximum of US$350,000, all reasonable
out-of-pocket third party professional costs and expenses of the Investors in connection with the
preparation and negotiation of this Agreement and the documents and instruments referred to herein,
the due diligence review in connection with transactions contemplated hereby and thereby and
Closing (including, without limitation, the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>





<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">reasonable fees and disbursements of counsel for the Investors). In the event that the
Investors pay any of the costs and expenses for which the Company is responsible for paying under
this Section&nbsp;12.04, the Company shall promptly reimburse the Investors for all such costs and
expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.05. <I>Successors and Assigns</I>. The provisions of this Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and assigns;
<I>provided </I>that no party may assign, delegate or otherwise transfer any of its rights or obligations
under this Agreement without the consent of each other party hereto; except that each Investor may
transfer or assign its rights and obligations under this Agreement, in whole or from time to time
in part, to (i)&nbsp;one or more of its Affiliates at any time and (ii)&nbsp;after the Closing Date, to any
Person; <I>provided </I>that no such transfer or assignment shall relieve such Investor of its obligations
hereunder or enlarge, alter or change any obligation of any other party hereto or due to the
Investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.06. <I>Governing Law</I>. This Agreement shall be governed by and construed in
accordance with the law of the State of New York, without regard to the conflicts of law rules of
such state.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.07. <I>Jurisdiction</I>. The parties hereto agree that any suit, action or proceeding
seeking to enforce any provision of, or based on any matter arising out of or in connection with,
this Agreement or the transactions contemplated hereby shall be brought in the United States
District Court for the Southern District of New York or any New York State court sitting in New
York City, so long as one of such courts shall have subject matter jurisdiction over such suit,
action or proceeding, and that any cause of action arising out of this Agreement shall be deemed to
have arisen from a transaction of business in the State of New York, and each of the parties hereby
irrevocably consents to the jurisdiction of such courts (and of the appropriate appellate courts
therefrom) in any such suit, action or proceeding and irrevocably waives, to the fullest extent
permitted by law, any objection that it may now or hereafter have to the laying of the venue of any
such suit, action or proceeding in any such court or that any such suit, action or proceeding
brought in any such court has been brought in an inconvenient forum. Process in any such suit,
action or proceeding may be served on any party anywhere in the world, whether within or without
the jurisdiction of any such court. Without limiting the foregoing, each party agrees that service
of process on such party as provided in Section&nbsp;12.01 shall be deemed effective service of process
on such party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.08. <I>WAIVER OF JURY TRIAL</I>. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES
ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS
AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.09. <I>Counterparts; Effectiveness; Third Party Beneficiaries</I>. This Agreement may
be signed in any number of counterparts, each of which shall be an original, with the same effect
as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become
effective when each party hereto shall have received a counterpart hereof signed by all of the
other parties hereto. Until and unless each party has received a counterpart hereof signed by the
other party hereto, this Agreement shall have no effect and no party shall have any right or
obligation hereunder (whether by virtue of any other oral or written agreement or other
communication). No provision of this Agreement is intended to confer any rights, benefits,
remedies, obligations, or liabilities hereunder upon any Person other than the parties hereto and
their respective successors and assigns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.10. <I>Entire Agreement</I>. This Agreement, the Amended and Restated Shareholders&#146;
Agreement and the Second Amended and Restated Memorandum and Articles constitute the entire
agreement between the parties with respect to the subject matter of this Agreement and supersedes
all prior agreements and understandings, both oral and written, between the parties with respect to
the subject matter of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.11. <I>Severability. </I>If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction or other Governmental Authority to be
invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions
of this Agreement shall remain in full force and effect and shall in no way be affected, impaired
or invalidated so long as the economic or legal substance of the transactions contemplated hereby
is not affected in any manner materially adverse to any party. Upon such a determination, the
parties shall negotiate in good faith to modify this Agreement so as to effect the original intent
of the parties as closely as possible in an acceptable manner in order that the transactions
contemplated hereby be consummated as originally contemplated to the fullest extent possible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.12. <I>Specific Performance. </I>The parties hereto agree that irreparable damage would
occur if any provision of this Agreement were not performed in accordance with the terms hereof and
that the parties shall be entitled to an injunction or injunctions to prevent breaches of this
Agreement or to enforce specifically the performance of the terms and provisions hereof in the
United States District Court for the Southern District of New York or any New York State court
sitting in New York City, in addition to any other remedy to which they are entitled at law or in
equity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;12.13. <I>Joint Drafting. </I>Each party hereto has participated in the drafting of this
Agreement, which each party acknowledges is the result of extensive negotiations between the
parties. If an ambiguity or question of intent or interpretation arises, this Agreement shall be
construed as if drafted jointly by
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the parties, and no presumption or burden of proof shall arise favoring or disfavoring any
party by virtue of the authorship of any provision.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->54<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their
respective authorized officers as of the day and year first above written.
</DIV>
<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="45%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="98%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CONCORD MEDICAL SERVICES HOLDINGS <BR>
LIMITED</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yang Jianyu</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Yang Jianyu</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">ASCENDIUM GROUP LIMITED</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yang Jianyu</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Yang Jianyu</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CHINA MEDSTAR LIMITED</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yang Jianyu</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Yang Jianyu</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CYBER MEDICAL NETWORK LTD.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yang Jianyu</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Yang Jianyu</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">OUR MEDICAL SERVICES, LTD.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yang Jianyu</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Yang Jianyu</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CHINA MEDICAL SERVICES (HOLDINGS) <BR>
LIMITED</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yang Jianyu</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Yang Jianyu</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="45%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="98%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">SHENZHEN AOHUA MEDICAL SERVICES CO., LTD.</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><IMG src="h03611h0361140.gif" alt="(CHINESE CHARACTER)"></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yang Jianyu</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Yang Jianyu</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">SHENZHEN AOHUA MEDICAL LEASING AND SERVICES CO., LTD.<BR>
<IMG src="h03611h0361129.gif" alt="(CHINESE CHARACTER)"></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yang Jianyu</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Yang Jianyu</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">SHANGHAI MEDSTAR LEASING CO., LTD.<BR>
<IMG src="h03611h0361130.gif" alt="(CHINESE CHARACTER)"></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yang Jianyu</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Yang Jianyu</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CMS HOSPITAL MANAGEMENT CO., LTD.<BR>
<IMG src="h03611h0361131.gif" alt="(CHINESE CHARACTER)"></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yang Jianyu</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Yang Jianyu</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="45%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="98%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">/s/ Cheng Zheng</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Cheng Zheng, in his individual capacity</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CZY INVESTMENTS LIMITED</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Cheng Zheng</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Cheng Zheng</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">/s/ Yang Jianyu</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Yang Jianyu, in his individual capacity</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">DAKETALA INTERNATIONAL INVESTMENT<BR>
HOLDINGS LTD.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yang Jianyu</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Yang Jianyu</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">/s/ Steve Sun</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Steve Xiaodi Sun, in his individual capacity</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">DRAGON IMAGE INVESTMENT LTD.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Steve Sun</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Steve Xiaodi Sun</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="45%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="98%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">/s/ Zhang Jing</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Zhang Jing, in his individual capacity</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">THOUSAND OCEAN GROUP LIMITED</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Zhang Jing</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Zhang Jing</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">/s/ Yap Yaw Kong</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Yap Yaw Kong, in his individual capacity</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">TOP MOUNT GROUP LIMITED</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yap Yaw Kong</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Yap Yaw Kong</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">/s/ Bona Lau</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Bona Lau, in her individual capacity</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">NOTABLE ENTERPRISE LIMITED</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Bona Lau</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Bona Lau</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="45%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="98%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">/s/ Liu Haifeng</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Liu Haifeng, in his individual capacity</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="45%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="98%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CICC SUN COMPANY LIMITED</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shirley Shiyou Chen</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Shirley Shiyou Chen</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="45%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="98%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CARLYLE ASIA GROWTH PARTNERS III, L.P.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP General Partner, L.P., as its
General Partner</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP, Ltd., as the General Partner of
CAGP General Partner, L.P.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Daniel A. D&#146;Aniello</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CAGP III CO-INVESTMENT, L.P.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP General Partner, L.P., as its
General Partner</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP, Ltd., as the General Partner of
CAGP General Partner, L.P.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Daniel A. D&#146;Aniello</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="45%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="98%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">STARR INVESTMENTS CAYMAN II, INC.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael J. Horvath</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Michael J. Horvath</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FORM OF AMENDED AND RESTATED SHAREHOLDERS&#146; AGREEMENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See Attached.

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->A-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT B</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FORM OF AMENDMENT TO CONVERTIBLE LOAN AGREEMENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See Attached.

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->B-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT C</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FORM OF AMENDMENT NO. 2 TO SERIES A SHARE SUBSCRIPTION AGREEMENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See Attached.

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->C-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT D</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FORM OF SECOND AMENDED AND RESTATED<BR>
MEMORANDUM AND ARTICLES</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See Attached.

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->D-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT E</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FORM OF SHARE CHARGE AGREEMENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See Attached.

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->E-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SCHEDULES</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">See Attached.

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->S-1<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>9
<FILENAME>h03611exv4w8.htm
<DESCRIPTION>EX-4.8
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.8</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.8</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXECUTION COPY</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDMENT TO SHARE SUBSCRIPTION AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMENDMENT TO SHARE SUBSCRIPTION AGREEMENT (this &#147;<B>Amendment</B>&#148;) dated as of October&nbsp;20, 2008 (the
&#147;<B>Amendment Date</B>&#148;) by and among (1)&nbsp;CICC Sun Company Limited, a company incorporated under the laws
of the British Virgin Islands (&#147;<B>CICC</B>&#148;), (2)&nbsp;Carlyle Asia Growth Partners III, L.P., a limited
partnership formed under the laws of the Cayman Islands (&#147;<B>CAGP</B>&#148;), (3)&nbsp;CAGP III Co-Investment, L.P.
(&#147;<B>CAGP Co-Invest</B>&#148;, together with CAGP, &#147;<B>Carlyle</B>&#148;), (4)&nbsp;Starr Investments Cayman II, Inc., a company
incorporated under the laws of the Cayman Islands (&#147;<B>Starr</B>&#148;, together with CICC and Carlyle, the
&#147;<B>Investors</B>&#148;), (5)&nbsp;Concord Medical Services Holdings Limited, an exempted company with limited
liability organized and existing under the laws of the Cayman Islands (the &#147;<B>Company</B>&#148;), and (6)&nbsp;the
other parties set forth in the signature pages hereof.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>W I T N E S S E T H :</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the parties hereto entered into a Share Subscription Agreement dated as of October
10, 2008 (the &#147;<B>Agreement</B>&#148;) pursuant to which the Company agreed to issue and sell to each of the
Investors and each of the Investors agreed to subscribe for certain Series&nbsp;B convertible redeemable
preferred shares, par value $0.01 per share, of the Company (the &#147;<B>Series&nbsp;B Shares</B>&#148;) on the terms
and conditions set forth in the Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the parties hereto and thereto desire to amend the Agreement to reflect the changes
set forth herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, the parties hereto agree as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;1</B><I>. Amendment. </I>(a)&nbsp;The Agreement is amended by replacing the existing definition of
&#147;Share Charge Agreements&#148; in Section&nbsp;1.01(a) in its entirety with the following new definition:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;&#145;<B>Share Charge Agreements</B>&#146; means, collectively:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;the Share Charge Agreement between the Investors and Mr.&nbsp;Cheng&#146;s Holding Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;the Share Charge Agreement between the Investors and Mr.&nbsp;Yang&#146;s Holding Company,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>





<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;the Share Charge Agreement between the Investors and Mr.&nbsp;Sun&#146;s Holding Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;the Share Charge Agreement between the Investors and Mr.&nbsp;Zhang&#146;s Holding Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;the Share Charge Agreement between the Investors and Mr.&nbsp;Yap&#146;s Holding Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;the Share Charge Agreement between the Investors and Ms.&nbsp;Lau&#146;s Holding Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in each case to be entered into within fifteen (15)&nbsp;Business Days of the Closing Date and
substantially in the form attached as <B>Exhibit&nbsp;E </B>hereto, and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;the Share Charge Agreement between the Investors and Mr.&nbsp;Cheng&#146;s Holding Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;the Share Charge Agreement between the Investors and Mr.&nbsp;Yang&#146;s Holding Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;the Share Charge Agreement between the Investors and Mr.&nbsp;Sun&#146;s Holding Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;the Share Charge Agreement between the Investors and Mr.&nbsp;Zhang&#146;s Holding Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;the Share Charge Agreement between the Investors and Mr.&nbsp;Yap&#146;s Holding Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;the Share Charge Agreement between the Investors and Ms.&nbsp;Lau&#146;s Holding Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in each case to be entered into within fifteen (15)&nbsp;Business Days of the Closing Date and
substantially in the form attached as <B>Exhibit&nbsp;F </B>hereto.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Agreement is amended by replacing the reference to the definition of &#147;Charged Shares&#148;
in Section&nbsp;1.01(b) with the following new reference:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Charged Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">7.07</TD>
    <TD nowrap>(b)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Agreement is amended by adding the following rows to the table in Section&nbsp;1.01(b) in
the appropriate alphabetic order:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Part I of the Charged Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">7.07</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Part II of the Charged Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">7.07</TD>
    <TD nowrap>(b)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Agreement is amended by replacing the existing Section&nbsp;7.07 in its entirety with the
following new Section&nbsp;7.07:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;Section&nbsp;7.07. <I>Share Charge</I>. (a)&nbsp;Within fifteen (15)&nbsp;Business Days after the
Closing, each Controlling Shareholder shall cause such Controlling Shareholder&#146;s
Controlling Shareholder Holding Company to deliver to the Investors a first priority
security interest in such number of Ordinary Shares equal to 40% of the Ordinary Shares
held by such Controlling Shareholder Holding Company, which is set forth opposite such
Controlling Shareholder&#146;s name in Schedule&nbsp;5.05 (&#147;<B>Part&nbsp;I of the Charged Shares</B>&#148; of such
Controlling Shareholder), free and clear of any Liens and any other limitation or
restriction pursuant to the relevant Share Charge Agreement set forth in Part (A)&nbsp;of the
definition of &#147;<B>Share Charge Agreements</B>&#148; in Section&nbsp;1.01(a).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Within fifteen (15)&nbsp;Business Days after the Closing, each Controlling Shareholder
shall cause such Controlling Shareholder&#146;s Controlling Shareholder Holding Company to
deliver to the Investors a first priority security interest in such number of Ordinary
Shares equal to 20% of the Ordinary Shares held by such Controlling Shareholder Holding
Company, which is set forth opposite such Controlling Shareholder&#146;s name in Schedule&nbsp;5.05
(&#147;<B>Part&nbsp;II of the Charged Shares</B>&#148; of such Controlling Shareholder and, together with Part&nbsp;I
of the Charged Shares of such Controlling Shareholder, the &#147;<B>Charged Shares</B>&#148; of such
Controlling Shareholder), free and clear of any Liens and any other limitation or
restriction pursuant to the relevant Share Charge Agreement set forth in Part (B)&nbsp;of the
definition of &#147;<B>Share Charge Agreements</B>&#148; in Section&nbsp;1.01(a).&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Agreement is amended by replacing the existing Section&nbsp;10.02(c) in its entirety with
the following new Section&nbsp;10.02(c):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;(c) Notwithstanding anything to the contrary in this Agreement, each of the
Controlling Shareholders agrees to indemnify, jointly and severally, the Company and its
successors from (i)&nbsp;any fines or penalties arising from the non-payment or delinquent
payment of the Tax of any Group Company or any of its Subsidiaries related to a
Pre-Closing Tax Period, and all Damages arising out of or incident to the imposition,
assessment or assertion of any such Tax or any failure to pay such Tax, (ii)&nbsp;any losses
from the disposition of Medstar (Beijing) International Anti-aging Health Bio-tech Inc.
<IMG src="h03611h0361132.gif" alt="(CHINIES CHARACTER)">, (iii)&nbsp;any amount owed by any Group Company to
Shenzhen Aowo International Co., Ltd. <IMG src="h03611h0361133.gif" alt="(CHINIES CHARACTER)"> and/or Aberdour
International Investment Inc., (iv)&nbsp;any fines arising from any
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">violation of FCPA, the OECD Rules or any other applicable anti-bribery Law or OFAC prior
to the Closing Date, (v)&nbsp;the amount of any non-payment or delinquent payment of any
amounts that any PRC Subsidiary should have contributed prior to the Closing Date to the
reserve fund, the enterprise expansion fund, the bonus and welfare fund or any other funds
contribution to which by such PRC Subsidiary is mandatorily required by the Laws of the
PRC and all fines and penalties arising from such non-payment or delinquent payment, (vi)
any monetary awards against any Group Company in connection with any litigation arising
from any circumstances existing on or prior to the Closing Date and (vii)&nbsp;any monetary
awards or monetary settlements against any Group Company and any other Damages incurred or
suffered by any Group Company, in each case arising out of any claim, dispute or
litigation in connection with any acquisition by any Group Company of any Person (other
than Persons established under the Laws of the PRC) which has been consummated prior to
the Closing Date.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The Agreement is amended by adding the attached Exhibit&nbsp;F as Exhibit&nbsp;F to the Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;2</B><I>. Effect of Amendment. </I>Except as amended by this Amendment, the Agreement shall
remain unchanged and in full force and effect. From and after the Amendment Date, each reference
to &#147;this Agreement,&#148; &#147;hereof,&#148; &#147;hereunder&#148; or words of like import, and all references to the
Agreement in any and all agreements, instruments, documents, notes, certificates and other writings
of every kind and nature shall be deemed to mean the Agreement as amended by this Amendment, except
as is otherwise expressly stated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Section&nbsp;3</B><I>. General. </I>(a)&nbsp;This Amendment shall be binding on the successors and permitted
assigns of the parties hereto; (b)&nbsp;this Amendment shall be governed by and construed in accordance
with the laws of the State of New York, without regard to conflicts of law principles thereunder
and shall be subject to the jurisdiction of the courts in the State of New York; (c)&nbsp;this Amendment
may be executed in more than one counterpart, each of which shall be deemed an original and any
counterpart so executed shall be deemed to be one and the same instrument; (d)&nbsp;each party hereto
acknowledges that the parties hereto have participated jointly in the negotiation and drafting of
this Amendment, and in the event an ambiguity or question of intent or interpretation arises, this
Amendment shall be construed as if drafted jointly by the parties hereto and no presumption or
burden of proof shall arise favoring or disfavoring any party hereto by virtue of the authorship of
any of the provisions of this Amendment; (e)&nbsp;if any part of any provision of this Amendment shall
be invalid or unenforceable under applicable law, such part shall be ineffective to the extent of
such invalidity only, without in any way affecting the remaining parts of such provision or the
remaining provisions of this Amendment; and (f)&nbsp;each party hereto acknowledges that the remedies at
law of the other parties hereto for a breach or threatened breach of this Amendment would be
inadequate and, in recognition of this fact, any party
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">hereto, without posting any bond, and in addition to all other remedies that may be available,
shall be entitled to obtain equitable relief in the form of specific performance, a temporary
restraining order, a temporary or permanent injunction or any other equitable remedy that may then
be available.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><I>&#091;The remainder of this page has been intentionally left blank&#093;</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their
respective authorized officers as of the day and year first above written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CONCORD MEDICAL SERVICES HOLDINGS LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">ASCENDIUM GROUP LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CHINA MEDSTAR LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CYBER MEDICAL NETWORK LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">OUR MEDICAL SERVICES, LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CHINA MEDICAL SERVICES (HOLDINGS)&nbsp;LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">SHENZHEN AOHUA MEDICAL SERVICES CO., LTD.<BR>
<IMG src="h03611h0361134.gif" alt="(CHINIES CHARACTER)"><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">SHENZHEN AOHUA MEDICAL LEASING AND SERVICES CO., LTD.<BR>
<IMG src="h03611h0361135.gif" alt="(CHINIES CHARACTER)"><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">SHANGHAI MEDSTAR LEASING CO., LTD.<br><BR>
<IMG src="h03611h0361136.gif" alt="(CHINIES CHARACTER)"><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CMS HOSPITAL MANAGEMENT CO., LTD.<br><BR>
<IMG src="h03611h0361137.gif" alt="(CHINIES CHARACTER)"><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Cheng Zheng
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Cheng Zheng, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CZY INVESTMENTS LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Cheng Zheng
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Cheng Zheng&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Yang Jianyu, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">DAKETALA INTERNATIONAL INVESTMENT HOLDINGS LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Steve Sun
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Steve Xiaodi Sun, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">DRAGON IMAGE INVESTMENT LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Steve Sun
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Steve Xiaodi Sun&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Zhang Jing
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Zhang Jing, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">THOUSAND OCEAN GROUP LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Zhang Jing
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Zhang Jing&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Yap Yaw Kong
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Yap Yaw Kong, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">TOP MOUNT GROUP LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yap Yaw Kong
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yap Yaw Kong&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Bona Lau
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Bona Lau, in her individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">NOTABLE ENTERPRISE LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Bona Lau
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Bona Lau&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Liu Haifeng
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Liu Haifeng, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CICC SUN COMPANY LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Shirley Shiyou Chen
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Shirley Shiyou Chen&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Director&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CARLYLE ASIA GROWTH PARTNERS III, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP General Partner, L.P., as its<br>
General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP, Ltd., as the General Partner of
CAGP General Partner, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Daniel A. D&#146;Aniello
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CAGP III CO-INVESTMENT, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP General Partner, L.P., as its<br>
General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP, Ltd., as the General Partner of
CAGP General Partner, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Daniel A. D&#146;Aniello
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">STARR INVESTMENTS CAYMAN II, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Michael J. Horvath
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Michael J. Horvath&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Director&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT F</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>FORM OF SHARE CHARGE AGREEMENT</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">See attached.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>10
<FILENAME>h03611exv4w9.htm
<DESCRIPTION>EX-4.9
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.9</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.9</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXECUTION COPY</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDED AND RESTATED SHAREHOLDERS&#146; AGREEMENT</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">dated as of

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">October&nbsp;20, 2008

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">among

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CONCORD MEDICAL SERVICES HOLDINGS LIMITED,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CARLYLE ASIA GROWTH PARTNERS III, L.P.,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CAGP III CO-INVESTMENT, L.P.,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CICC SUN COMPANY LIMITED,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>PERFECT KEY HOLDINGS LIMITED,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>STARR INVESTMENTS CAYMAN II, INC.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">and

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>CERTAIN OTHER PERSONS NAMED HEREIN</B>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="92%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</tr>
<TR valign="top" style="font-size: 8pt">
    <TD align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>

    <TD align="center" colspan="3" style="border-bottom: 1px solid #000000"><FONT style="font-variant: SMALL-CAPS">Page</FONT></TD>

</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
</tr>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 1 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Definitions</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;1.01<I>. Definitions</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;1.02<I>. Other Definitional and Interpretative Provisions</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 2 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Corporate Governance</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.01<I>. Composition of the Board</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.02. <I>Removal</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.03. <I>Vacancies</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.04. <I>Meetings</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.05. <I>Action by the Board</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.06<I>. Memorandum and Articles</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.07<I>. Notice of Meeting</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.08. <I>Alternate</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.09<I>. No Liabilities</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.10<I>. Directors&#146; Indemnification; Insurance</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.11<I>. Subsidiary Governance</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.12. <I>Required Consents</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.13<I>. Nomination of Chief Financial Officer</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 3 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Restrictions on Transfer</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.01<I>. General Restrictions on Transfer</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.02<I>. Restrictions on Transfer</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 4 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Preemptive Rights; Rights of First Refusal; Rights of First Offer; Tag-<br>
along Rights; Put Rights</FONT></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.01. <I>Preemptive Rights</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.02<I>. Right of First Refusal</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.03<I>. Rights of First Offer</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.04. <I>Tag-Along Rights</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.05<I>. Drag-Along Rights</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.06<I>. Put Rights</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="92%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 8pt">
    <TD align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>

    <TD align="center" colspan="3" style="border-bottom: 1px solid #000000"><FONT style="font-variant: SMALL-CAPS">Page</FONT></TD>

</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
</tr>


<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 5 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Registration Rights</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.01. <I>Right to Participate in the QPO</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.02. <I>Registration Rights after the QPO</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.03. <I>Registration Procedures</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.04. <I>Indemnification by the Company</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.05. <I>Indemnification by Participating Shareholders</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.06. <I>Conduct of Indemnification Proceedings</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.07. <I>Contribution</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.08. <I>Other Indemnification</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.09. <I>Cooperation by the Company</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 6 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Certain Covenants and Agreements</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.01. <I>Confidentiality</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.02. <I>Information Rights</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.03. <I>Inspection Right</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.04<I>. Books and Records</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.05. <I>Related Party Transactions</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.06<I>. QPO</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.07. <I>Notice by Controlling Shareholders</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.08<I>. Internal Control</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.09<I>. Rights upon Resignation of Key Man</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.10<I>. Conflicting Agreements</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><B>ARTICLE 7 </B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px"><FONT style="font-variant: SMALL-CAPS"> Miscellaneous</FONT> </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.01<I>. Binding Effect; Assignability; Benefit</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.02. <I>Notices</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.03. <I>Waiver; Amendment; Termination</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.04. <I>Fees and Expenses</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.05. <I>Governing Law</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.06. <I>Jurisdiction</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.07. <I>WAIVER OF JURY TRIAL</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.08. <I>Specific Enforcement</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.09. <I>Counterparts; Effectiveness</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.10. <I>Entire Agreement</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.11. <I>Severability</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.12. <I>Joint Drafting</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exhibit&nbsp;A Joinder Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMENDED AND RESTATED SHAREHOLDERS&#146; AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AMENDED AND RESTATED SHAREHOLDERS&#146; AGREEMENT (this &#147;<B>Agreement</B>&#148;) dated as of October&nbsp;20, 2008
among (i)&nbsp;Concord Medical Services Holdings Limited, a company incorporated under the laws of the
Cayman Islands (the &#147;<B>Company</B>&#148;), (ii)&nbsp;Carlyle Asia Growth Partners III, L.P., a limited partnership
formed under the laws of the Cayman Islands (&#147;<B>CAGP</B>&#148;), (iii)&nbsp;CAGP III Co-Investment, L.P., a limited
partnership formed under the laws of the Cayman Islands (&#147;<B>CAGP Co-Invest</B>&#148;, and together with CAGP,
&#147;<B>Carlyle</B>&#148;), (iv)&nbsp;CICC Sun Company Limited, a company incorporated under the laws of the British
Virgin Islands (&#147;<B>CICC Sun</B>&#148;), (v)&nbsp;Perfect Key Holdings Limited, a company incorporated under the
laws of the British Virgin Islands (&#147;<B>Perfect Key</B>&#148;, and together with CICC Sun, &#147;<B>CICC</B>&#148;), (vi)&nbsp;Starr
Investments Cayman II, Inc., a corporation formed under the laws of the Cayman Islands (&#147;<B>Starr</B>&#148;
and, together with Carlyle and CICC, the &#147;<B>Investors</B>&#148;), (vii)&nbsp;the Controlling Persons (as defined
below), (viii)&nbsp;the Controlling Shareholders (as defined below) and (ix)&nbsp;certain other Persons
listed on the signature pages hereof. &#147;Investors&#148; and &#147;Controlling Shareholders&#148; shall each mean,
if such entities or persons shall have Transferred any of their &#147;Company Securities&#148; to any of
their respective &#147;Permitted Transferees&#148; (as such terms are defined below), such entities or
persons and such Permitted Transferees, taken together, and (x)&nbsp;any right or action that may be
exercised or taken at the election of such entities or persons may be taken at the election of such
entities or persons and such Permitted Transferees (to the extent permitted by applicable laws) and
(y)&nbsp;any obligations that are imposed on such entities or persons shall be imposed on such entities
or persons and such Permitted Transferees (to the extent permitted by applicable laws).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>W I T N E S S E T H :</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Company, Carlyle, CICC and some of the Other Shareholders are party to the
Shareholders&#146; Agreement dated as of April&nbsp;2, 2008 (the &#147;<B>Original Shareholders&#146; Agreement</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, CZY, TOG and TMG (each as defined below) joined the Original Shareholders&#146; Agreement
as parties on October&nbsp;8, 2008;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Original Shareholders&#146; Agreement was amended by the Amendment to the
Shareholders&#146; Agreement dated as of October&nbsp;8, 2008 by and among the Company, Carlyle, CICC and
other Persons party thereto (as amended, the &#147;<B>Existing Shareholders&#146; Agreement</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Perfect Key joined the Existing Shareholders&#146; Agreement as party on October&nbsp;8, 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, pursuant to the Share Subscription Agreement dated as of October&nbsp;10, 2008 by and
among the Company, the Investors and certain other
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Persons party thereto, as amended on October&nbsp;20, 2008 (the &#147;<B>Series&nbsp;B Subscription Agreement</B>&#148;),
the Investors are subscribing for Series&nbsp;B redeemable convertible preferred shares, par value
US$0.01 per share, of the Company (the &#147;<B>Series&nbsp;B Shares</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the parties hereto desire to enter into this Agreement to amend and restate the
Existing Shareholders&#146; Agreement in its entirety and to govern certain of their rights, duties and
obligations after consummation of the Series&nbsp;B Shares subscription.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the covenants and agreements contained herein and in the
Series&nbsp;A Subscription Agreement and the Series&nbsp;B Subscription Agreement, the parties hereto agree
as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 1</B><BR>
<FONT style="font-variant: SMALL-CAPS">Definitions</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.01<I>. Definitions. </I>(a)&nbsp;The following terms, as used herein, have the following
meanings:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person directly or indirectly
controlling, controlled by or under common control with such Person, <I>provided </I>that no
securityholder of the Company shall be deemed an Affiliate of any other securityholder solely by
reason of any investment in the Company. For the purpose of this definition, the term &#147;<B>control</B>&#148;
(including, with correlative meanings, the terms &#147;<B>controlling</B>&#148;, &#147;<B>controlled by</B>&#148; and &#147;<B>under common
control with</B>&#148;), as used with respect to any Person, shall mean the possession, directly or
indirectly, of the power to direct or cause the direction of the management and policies of such
Person, whether through the ownership of voting securities, by contract or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Aggregate Ownership</B>&#148; means, with respect to any Shareholder or group of Shareholders, and
with respect to any class of Company Securities, the total amount of such class of Company
Securities &#147;beneficially owned&#148; (as such term is defined in Rule&nbsp;13d-3 of the Exchange Act)
(without duplication) by such Shareholder or group of Shareholders as of the date of such
calculation, calculated on a Fully-Diluted basis.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Amendment No.&nbsp;2 to Series&nbsp;A Share Subscription Agreement</B>&#148; means the Amendment No.&nbsp;2 to Share
Subscription Agreement by and among the Company, CICC, Carlyle, the Controlling Shareholders and
the Group Companies dated as of the date hereof.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Amendment to Convertible Loan Agreement</B>&#148; means the Amendment to Convertible Loan Agreement by
and among the Company, Carlyle, the Controlling Shareholders and the Group Companies dated as of
the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Board</B>&#148; means the board of directors of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Business Day</B>&#148; means a day, other than Saturday, Sunday or other day on which commercial banks
in either the US, Hong Kong or the PRC are authorized or required by applicable law to close.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Change of Control</B>&#148; means such time as any &#147;person&#148; (as such term is used in Sections&nbsp;3(a)(9)
and 13(d)(3) of the Exchange Act), other than (A)&nbsp;any Investor or any Other Shareholder or (B)&nbsp;any
&#147;group&#148; (within the meaning of such Section&nbsp;13(d)(3)) of which one or more of the Investors and the
Other Shareholders constitute a majority (on the basis of ownership interest), acquires, directly
or indirectly, by virtue of the consummation of any purchase, merger or other combination,
securities of the Company representing more than 50% of the combined voting power of the Company&#146;s
then outstanding voting securities with respect to matters submitted to a vote of the shareholders
generally.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Company Securities</B>&#148; means (i)&nbsp;the Ordinary Shares and the Preferred Shares, (ii)&nbsp;securities
convertible into or exchangeable for Ordinary Shares and/or Preferred Shares, (iii)&nbsp;any other
equity or equity-linked security issued by the Company and (iv)&nbsp;options, warrants or other rights
to acquire Ordinary Shares, Preferred Shares or any other equity or equity-linked security issued
by the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Controlling Persons</B>&#148; means, collectively, the following Persons:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;Mr.&nbsp;Cheng Zheng <IMG src="h03611h0361155.gif" alt="(CHINESE CHARACTER)"> a PRC citizen with passport number G14947877 (&#147;<B>Mr.&nbsp;Cheng</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;Mr.&nbsp;Yang Jianyu <IMG src="h03611h0361156.gif" alt="(CHINESE CHARACTER)"> a PRC citizen with passport number G04036294 (&#147;<B>Mr.&nbsp;Yang</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;Mr.&nbsp;Steven Xiaodi Sun, a US citizen with passport number 203018867 (&#147;<B>Mr.&nbsp;Sun</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;Mr.&nbsp;Zhang
Jing <IMG src="h03611h0361157.gif" alt="(CHINESE CHARACTER)"> a PRC citizen with passport number G10824344 (&#147;<B>Mr.&nbsp;Zhang</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;Mr.&nbsp;Yap Yaw Kong <IMG src="h03611h0361158.gif" alt="(CHINESE CHARACTER)"> a Malaysia citizen with passport number A15954913 (&#147;<B>Mr.&nbsp;Yap</B>&#148;);
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;Mr.&nbsp;Liu Haifeng (<IMG src="h03611h0361159.gif" alt="(CHINESE CHARACTER)">), a PRC citizen with passport number G19230849; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)&nbsp;Ms.&nbsp;Bona Lau, a New Zealand citizen with passport number EA713283 (&#147;<B>Ms.&nbsp;Lau</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Controlling Shareholders</B>&#148; means, collectively, the following Persons:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;CZY Investments Limited, a company incorporated under the laws of the British Virgin
Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Cheng (&#147;<B>CZY</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;Daketala International Investment Holdings Ltd., a company incorporated under the laws of
the British Virgin Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Yang (&#147;<B>Daketala</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;Dragon Image Investment Ltd., a company incorporated under the laws of the British Virgin
Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Sun (&#147;<B>Dragon Image</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;Thousand Ocean Group Limited, a company incorporated under the laws of the British Virgin
Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Zhang (&#147;<B>TOG</B>&#148;);
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;Top Mount Group Limited, a company incorporated under the laws of the British Virgin
Islands and a direct wholly owned Subsidiary of Mr.&nbsp;Yap (&#147;<B>TMG</B>&#148;); and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;Notable Enterprise Limited, a company incorporated under the laws of the British Virgin
Islands and a direct wholly owned Subsidiary of Ms.&nbsp;Lau (&#147;<B>Notable</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Convertible Loan Agreement</B>&#148; means the Convertible Loan Agreement by and among the Company,
Carlyle and other Persons specified therein dated as of April&nbsp;10, 2008, as amended by the Amendment
to Convertible Loan Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Exchange Act</B>&#148; means the US Securities Exchange Act of 1934, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Fully-Diluted</B>&#148; means, with respect to any class of Company Securities, all outstanding shares
of such class and all shares issuable in respect of securities convertible into or exchangeable for
shares of such class, all share appreciation rights, options, warrants and other rights to purchase
or subscribe for such Company Securities or securities convertible into or exchangeable for such
Company Securities, <I>provided </I>that, if any of the foregoing share appreciation
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">rights, options, warrants or other rights to purchase or subscribe for such Company Securities
are subject to vesting, the Company Securities subject to vesting shall be included in the
definition of &#147;Fully-Diluted&#148; only upon and to the extent of such vesting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Hong Kong</B>&#148; means the Hong Kong Special Administrative Region.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IFRS</B>&#148; means the International Financial Reporting Standards, as in effect from time to time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Initial Ownership</B>&#148; means, with respect to any Shareholder and any class of Company
Securities, the Aggregate Ownership of such class by such Shareholder as of the date hereof, or in
the case of any Person that shall become a party to this Agreement on a later date, as of such
later date, in each case taking into account any share split, share dividend, reverse share split
or similar event.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IPO</B>&#148; means an initial public offering and listing of the Ordinary Shares (or, in lieu thereof
and as mutually agreed by the Investors and the Company, equity securities of (i)&nbsp;any holding
company holding the issued share capital of the Company or (ii)&nbsp;any Subsidiary of the Company) on
an internationally recognized stock exchange.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Key Men</B>&#148; means Mr.&nbsp;Cheng, Mr.&nbsp;Yang, Mr.&nbsp;Sun, Mr.&nbsp;Zhang and Mr.&nbsp;Yap.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Lien</B>&#148; means any mortgage, pledge, hypothecation, assignment, deposit arrangement,
encumbrance, lien (statutory or other), charge or other security interest or any preference,
priority or other security agreement or preferential arrangement of any kind or nature whatsoever
(including, any conditional sale or other title retention agreement and any financing lease having
substantially the same economic effect as any of the foregoing).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Material Adverse Effect</B>&#148; means a material adverse effect on the condition (financial or
otherwise), business, assets, results of operations or prospects of the Company and its
Subsidiaries, taken as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Ordinary Shares</B>&#148; means ordinary shares, par value US$0.01 per share, of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Other Shareholders</B>&#148; means the Shareholders other than the Investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Permitted Transferee</B>&#148; means,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)&nbsp;with respect to CAGP or CAGP Co-Invest, (i)&nbsp;any of its general or limited partner (a
&#147;<B>Carlyle Partner</B>&#148;), and any company, partnership or other entity that is an Affiliate of CAGP or
CAGP Co-Invest or any Carlyle Partner
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(collectively, &#147;<B>Carlyle Affiliates</B>&#148;), (ii)&nbsp;any managing director, general partner, director,
limited partner, officer or employee of Carlyle or any Carlyle Affiliate, or any spouse, lineal
descendant, sibling, parent, heir, executor, administrator, testamentary trustee, legatee or
beneficiary of any of the foregoing persons described in this clause (ii) (collectively, &#147;<B>Carlyle
Associates</B>&#148;), or (iii)&nbsp;any trust the ultimate beneficiaries of which, or any company, limited
liability company or partnership the ultimate shareholders, members or general or limited partners
of which, include only CAGP, CAGP Co-Invest, Carlyle Affiliates and/or Carlyle Associates;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B)&nbsp;with respect to CICC Sun or Perfect Key, (i)&nbsp;any of its shareholders, and any company,
partnership or other entity that is an Affiliate of CICC Sun or Perfect Key or any of its
shareholders (collectively, &#147;<B>CICC Affiliates</B>&#148;), (ii)&nbsp;any managing director, general partner,
director, limited partner, officer or employee of CICC or any CICC Affiliate, or any spouse, lineal
descendant, sibling, parent, heir, executor, administrator, testamentary trustee, legatee or
beneficiary of any of the foregoing persons described in this clause (ii) (collectively, &#147;<B>CICC
Associates</B>&#148;), or (iii)&nbsp;any trust the ultimate beneficiaries of which, or any company, limited
liability company or partnership the ultimate shareholders, members or general or limited partners
of which, include only CICC Sun, Perfect Key, CICC Affiliates and/or CICC Associates;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(C)&nbsp;with respect to Starr, (i)&nbsp;any of its shareholders, and any company, partnership or other
entity that is an Affiliate of Starr or any of its shareholders (collectively, &#147;<B>Starr Affiliates</B>&#148;),
(ii)&nbsp;any managing director, general partner, director, limited partner, officer or employee of
Starr or any Starr Affiliate, or any spouse, lineal descendant, sibling, parent, heir, executor,
administrator, testamentary trustee, legatee or beneficiary of any of the foregoing persons
described in this clause (ii) (collectively, &#147;<B>Starr Associates</B>&#148;), or (iii)&nbsp;any trust the ultimate
beneficiaries of which, or any company, limited liability company or partnership the ultimate
shareholders, members or general or limited partners of which, include only Starr, Starr Affiliates
and/or Starr Associates; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(D)&nbsp;with respect to each of the Controlling Shareholders, (i)&nbsp;any company or other entity that
is wholly-owned, either directly or indirectly, by the Controlling Person who owns such Controlling
Shareholder as of the date hereof (collectively, &#147;<B>Controlling Shareholder Affiliates</B>&#148;), (ii)&nbsp;any
spouse, lineal descendant, sibling, parent, heir, executor, administrator, testamentary trustee,
legatee or beneficiary of such Controlling Person (collectively, &#147;<B>Controlling Shareholder
Associates</B>&#148;), or (iii)&nbsp;any trust the ultimate beneficiaries of which, or any company, limited
liability company or partnership the ultimate shareholders, members or general or limited partners
of which, include only such Controlling Person, such Controlling Shareholder Affiliates and/or such
Controlling Shareholder Associates.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Person</B>&#148; means an individual, corporation, limited liability company, partnership,
association, trust or other entity or organization, including a government or political subdivision
or an agency or instrumentality thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>PRC</B>&#148; means the People&#146;s Republic of China, excluding, for purposes of this Agreement only,
Hong Kong, the Macau Special Administrative Region and Taiwan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Preferred Shares</B>&#148; means the Series&nbsp;A Shares and the Series&nbsp;B Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Put Trigger Event</B>&#148; means any of the following:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the Company has not completed a QPO by the third anniversary of the date hereof;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) any of the Key Men has resigned from the Company and its Subsidiaries, which
resignation, in the sole determination of a majority of the Investors, has resulted in or
would be likely to result in, a Material Adverse Effect; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the Company or any of its Subsidiaries has breached or failed to be in
compliance with any applicable laws that has had or would be reasonably likely to have, a
Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>QPO</B>&#148; means a firm-commitment underwritten IPO (i)&nbsp;led by internationally reputable
underwriters, approved by the Board (which shall include a majority of the Investor Directors), and
yielding a valuation of the Company at not less than US$450&nbsp;million immediately prior to the
consummation of such IPO, or (ii)&nbsp;any other IPO approved by holders of at least 70% of the then
outstanding Series&nbsp;B Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Rate of Return</B>&#148; means, at the time of calculation, the annual percentage rate, which when
utilized to calculate the present value of a series of cash inflows and the present value of a
series of cash outflows shall cause the present value of such cash inflows to equal the present
value of such cash outflows. The Rate of Return shall be compounded annually, calculated on a
daily basis based on a 360&nbsp;day year, and shall be calculated in US dollars, with any cash inflow or
cash outflow denominated in a currency other than US dollars translated for purposes of the
calculation into US dollars at the Relevant Exchange Rate in effect as of the date of such cash
inflow or cash outflow.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Relevant Exchange Rate</B>&#148; means, (i)&nbsp;with respect to RMB and any calculation date, the spot
exchange rate between RMB and US dollars as quoted by the People&#146;s Bank of China on such date, and
(ii)&nbsp;with respect to any other
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">currency and any calculation date, the &#147;noon buying rate&#148; for purchases of such currency on
such date published by the Federal Reserve Bank of New York.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Registrable Securities</B>&#148; means, at any time, any Shares and any securities issued or issuable
in respect of such Shares by way of conversion, exchange, share dividend, split or combination,
recapitalization, merger, consolidation, other reorganization or otherwise until (i)&nbsp;a registration
statement covering such Shares has been declared effective by the SEC and such Shares have been
disposed of pursuant to such effective registration statement or such Shares have been disposed of
pursuant to a registered public offering under analogous statute of another jurisdiction where the
QPO occurs or has occurred, (ii)&nbsp;such Shares are sold under circumstances in which all of the
applicable conditions of Rule&nbsp;144 (or any similar provisions then in force) under the Securities
Act or analogous rule at another jurisdiction where the QPO occurs or has occurred are met or (iii)
such Shares are otherwise Transferred, the Company has delivered a new certificate or other
evidence of ownership for such Shares not bearing the legend required pursuant to this Agreement
and such Shares may be resold without subsequent registration under the Securities Act or analogous
statute of another jurisdiction where the QPO occurs or has occurred.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Registration Expenses</B>&#148; means any and all expenses incident to the performance of or
compliance with any registration or marketing of securities, including all (i)&nbsp;registration and
filing fees, and all other fees and expenses payable in connection with the listing of securities
on any securities exchange or automated interdealer quotation system, (ii)&nbsp;fees and expenses of
compliance with any securities laws, (iii)&nbsp;expenses in connection with the preparation, printing,
mailing and delivery of any registration statements, prospectuses and other documents in connection
therewith and any amendments or supplements thereto, (iv)&nbsp;security engraving and printing expenses,
(v)&nbsp;internal expenses of the Company (including all salaries and expenses of its officers and
employees performing legal or accounting duties), (vi)&nbsp;reasonable fees and disbursements of counsel
for the Company and customary fees and expenses for independent certified public accountants
retained by the Company (including the expenses relating to any comfort letters or costs associated
with the delivery by independent certified public accountants of any comfort letters), (vii)
reasonable fees and expenses of any special experts retained by the Company in connection with such
registration, (viii)&nbsp;reasonable fees, out-of-pocket costs and expenses of the Shareholders,
including one counsel for all of the Shareholders participating in the offering selected by all
such Shareholders in agreement, (ix)&nbsp;fees and expenses in connection with any review by the
Financial Industry Regulatory Authority of the underwriting arrangements or other terms of the
offering, and all fees and expenses of any &#147;qualified independent underwriter,&#148; including the fees
and expenses of any counsel thereto, (x)&nbsp;fees and disbursements of underwriters customarily paid by
issuers or sellers of securities, but excluding any underwriting fees, discounts and commissions
attributable to the sale of Registrable Securities,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(xi)&nbsp;costs of printing and producing any agreements among underwriters, underwriting
agreements, any legal investment memoranda and any selling agreements and other documents in
connection with the offering, sale or delivery of the Registrable Securities, (xii)&nbsp;transfer
agents&#146; and registrars&#146; fees and expenses and the fees and expenses of any other agent or trustee
appointed in connection with such offering, (xiii)&nbsp;expenses relating to any analyst or investor
presentations or any &#147;road shows&#148; undertaken in connection with the registration, marketing or
selling of the Registrable Securities, (xiv)&nbsp;fees and expenses payable in connection with any
ratings of the Registrable Securities, including expenses relating to any presentations to rating
agencies and (xv)&nbsp;all out-of pocket costs and expenses incurred by the Company or its appropriate
officers.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>RMB</B>&#148; means renminbi, the lawful currency of the PRC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>SEC</B>&#148; means the US Securities and Exchange Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Series&nbsp;A Shares</B>&#148; means the Series&nbsp;A redeemable convertible preferred shares, par value
US$0.01 per share, of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Series&nbsp;A Subscription Agreement</B>&#148; means the Share Subscription Agreement by and among the
Company, Carlyle, CICC and other Persons specified therein dated as of February&nbsp;5, 2008, as amended
by the Amendment to Share Subscription Agreement by and among the Company, Carlyle, CICC and other
Persons specified therein dated as of April&nbsp;2, 2008 and the Amendment No.&nbsp;2 to Series&nbsp;A Share
Subscription Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Shares</B>&#148; means Ordinary Shares, Series&nbsp;A Shares and Series&nbsp;B Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Share Charge Agreements</B>&#148; means, collectively:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;the two Share Charge Agreements by and among the Investors and CZY to be entered into
pursuant to the Series&nbsp;B Subscription Agreement,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;the two Share Charge Agreements by and among the Investors and Daketala to be entered into
pursuant to the Series&nbsp;B Subscription Agreement,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;the two Share Charge Agreements by and among the Investors and Dragon Image to be entered
into pursuant to the Series&nbsp;B Subscription Agreement,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;the two Share Charge Agreements by and among the Investors and TOG to be entered into
pursuant to the Series&nbsp;B Subscription Agreement,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)&nbsp;the two Share Charge Agreements by and among the Investors and TMG to be entered into
pursuant to the Series&nbsp;B Subscription Agreement, and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)&nbsp;the two Share Charge Agreements by and among the Investors and Notable to be entered into
pursuant to the Series&nbsp;B Subscription Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Shareholder</B>&#148; means at any time, any Person (other than the Company) who shall then be a party
to or bound by this Agreement, so long as such Person shall &#147;beneficially own&#148; (as such term is
defined in Rule&nbsp;13d-3 of the Exchange Act) any Company Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Subsidiary</B>&#148; means, with respect to any Person, any entity of which securities or other
ownership interests having ordinary voting power to elect a majority of the board of directors or
other persons performing similar functions are at the time directly or indirectly owned by such
Person. For the avoidance of doubt, each of Chang&#146;an Concord International Cancer Center
(<IMG src="h03611h0361160.gif" alt="(CHINESE CHARACTER)">) and Beijing Proton Medical Center (<IMG src="h03611h0361161.gif" alt="(CHINESE CHARACTER)">), if established
and directly or indirectly owned by the Company prior to the date hereof, shall be considered a
Subsidiary of the Company for the purposes of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party</B>&#148; means a prospective purchaser(s) of Company Securities in an arm&#146;s-length
transaction from a Shareholder, other than a Permitted Transferee of such Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Transaction Documents</B>&#148; means this Agreement, the Series&nbsp;B Subscription Agreement, the Series
A Subscription Agreement, the Share Pledge Agreements and the Second Amended and Restated
Memorandum and Articles and each and all other agreements, certificates or other documents required
to be executed by any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Transfer</B>&#148; means, with respect to any Company Securities, (i)&nbsp;when used as a verb, to sell,
assign, dispose of, exchange, pledge, encumber, hypothecate or otherwise transfer such Company
Securities or any participation or interest therein, whether directly or indirectly, or agree or
commit to do any of the foregoing and (ii)&nbsp;when used as a noun, a direct or indirect sale,
assignment, disposition, exchange, pledge, encumbrance, hypothecation, or other transfer of such
Company Securities or any participation or interest therein or any agreement or commitment to do
any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>US</B>&#148; means the United States of America.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>US dollars</B>&#148; or &#147;<B>US$</B>&#148; means the lawful currency of the US.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>US GAAP</B>&#148; means generally accepted accounting principles in the US, as in effect from time to
time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each of the following terms is defined in the Section set forth opposite such term:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Section</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CAGP</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CAGP Co-Invest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Carlyle</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Carlyle Director</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">2.01</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CICC</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CICC Director</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">2.01</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CICC Sun</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Confidential Information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">6.01</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Damages</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5.04</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Drag-Along Portion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.05</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Drag-Along Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.05</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Drag-Along Sale</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.05</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Drag-Along Sale Notice</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.05</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Drag-Along Sale Notice Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.05</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Drag-Along Sale Price</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.05</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Drag-Along Seller</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.05</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Drag-Along Transferee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.05</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dragged Shareholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.05</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exercise Notice</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.01</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Existing Shareholders&#146; Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Recitals</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Indemnified Party</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5.06</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Indemnifying Party</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5.06</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Inspectors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">5.03</TD>
    <TD nowrap>(f)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Investors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Investors Directors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">2.01</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Issuance Notice</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.01</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Major Shareholder</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.01</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Maximum Offering Size</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">5.01</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Original Shareholders&#146; Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Perfect Key</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Piggyback Registration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">5.01</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Pro Rata Share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.01</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Purchaser</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.06</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Put Interest</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.06</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Put Notice</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.06</TD>
    <TD nowrap>(c)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Put Price</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.06</TD>
    <TD nowrap>(d)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Section</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Put Right</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.06</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Putting Shareholder</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.06</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Records</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">5.03</TD>
    <TD nowrap>(f)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Related Party</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">2.12(hh)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Related Party Transactions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">2.12(hh)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Replacement Nominee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">2.03</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Representatives</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">6.01</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFO Non-Selling Shareholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.03</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFO Offer Notice</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.03</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFO Offer Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.03</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFO Offer Price</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.03</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFO Offered Securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.03</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFO Seller</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.03</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFR Non-Selling Shareholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.02</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFR Offer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.02</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFR Offer Notice</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.02</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFR Offer Pro Rata Portion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.02</TD>
    <TD nowrap>(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFR Offer Price</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.02</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFR Offered Securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.02</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFR Shareholder</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.02</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ROFR Seller</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.02</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;B Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Recitals</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Series&nbsp;B Subscription Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Starr</DIV></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" nowrap align="center">Preamble</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Starr Director</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">2.01</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tag-Along Notice</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.04</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tag-Along Notice Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.04</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tag-Along Offer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.04</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tag-Along Portion</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.04</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tag-Along Response Notice</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.04</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tag-Along Right</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.04</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tag-Along Sale</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.04</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tag-Along Seller</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.04</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tagging Person</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">4.04</TD>
    <TD nowrap>(a)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Top Management</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">&nbsp;</TD>
    <TD align="right">2.12</TD>
    <TD nowrap>(f)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.02<I>. Other Definitional and Interpretative Provisions. </I>The words &#147;hereof&#148;, &#147;herein&#148;
and &#147;hereunder&#148; and words of like import used in this Agreement shall refer to this Agreement as a
whole and not to any particular provision of this Agreement. The captions herein are included for
convenience of reference only and shall be ignored in the construction or interpretation hereof.
References to Articles, Sections, Exhibits and Schedules are to Articles, Sections, Exhibits and
Schedules of this Agreement unless otherwise specified. All
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and
made a part of this Agreement as if set forth in full herein. Any capitalized terms used in any
Exhibit or Schedule but not otherwise defined therein, shall have the meaning as defined in this
Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any
plural term the singular. Whenever the words &#147;include&#148;, &#147;includes&#148; or &#147;including&#148; are used in this
Agreement, they shall be deemed to be followed by the words &#147;without limitation&#148;, whether or not
they are in fact followed by those words or words of like import. &#147;Writing&#148;, &#147;written&#148; and
comparable terms refer to printing, typing and other means of reproducing words (including
electronic media) in a visible form. References to any agreement or contract are to that agreement
or contract as amended, modified or supplemented from time to time in accordance with the terms
hereof and thereof; <I>provided </I>that with respect to any agreement or contract listed on any schedules
hereto, all such amendments, modifications or supplements must also be listed in the appropriate
schedule. References to any Person include the successors and permitted assigns of that Person.
References from or through any date mean, unless otherwise specified, from and including or through
and including, respectively.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 2</B><BR>
<FONT style="font-variant: SMALL-CAPS">Corporate Governance</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.01<I>. Composition of the Board. </I>(a)&nbsp;The Board shall consist of up to eleven
directors, of whom one shall be designated by Carlyle (the &#147;<B>Carlyle Director</B>&#148;), one shall be
designated by CICC (the &#147;<B>CICC Director</B>&#148;) and one shall be designated by Starr (the &#147;<B>Starr Director</B>&#148;
and, together with the Carlyle Director and the CICC Director, the &#147;<B>Investor Directors</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Shareholder agrees that, if at any time it is then entitled to vote for the election
of directors to the Board, it shall vote its Shares or execute proxies or written consents, as the
case may be, and take all other necessary action (including causing the Company to call a general
meeting of shareholders) in order to ensure that the composition of the Board is as set forth in
this Section&nbsp;2.01.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Company agrees to cause each individual designated pursuant to Section&nbsp;2.01(a) or
2.03 to be nominated to serve as a director on the Board, and to take all other necessary actions
(including calling a meeting of the Board and/or a general meeting of the shareholders) to ensure
that the composition of the Board is as set forth in this Section&nbsp;2.01.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.02. <I>Removal. </I>Each Shareholder agrees that, if at any time it is then entitled to
vote for the removal of directors from the Board, (i)&nbsp;it shall not vote any of its Shares in favor
of the removal of any director who shall have been
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">designated pursuant to Section&nbsp;2.01(a) or 2.03, unless the Person or Persons entitled to
designate or nominate such director shall have consented to such removal in writing, and (ii)&nbsp;if
the Person or Persons entitled to designate any director pursuant to Section&nbsp;2.01(a) or 2.03
shall request in writing the removal of such director, such Shareholder shall vote its Shares in
favor of such removal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.03. <I>Vacancies</I>. If, as a result of death, disability, retirement, resignation,
removal or otherwise, there shall exist or occur any vacancy on the Board:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;the Person or Persons entitled under Section&nbsp;2.01 to designate such director whose death,
disability, retirement, resignation or removal resulted in such vacancy may designate another
individual (the &#147;<B>Replacement Nominee</B>&#148;) to fill such vacancy and serve as a director on the Board;
and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;subject to Section&nbsp;2.01, each Shareholder agrees that if it is then entitled to vote for
the election of directors to the Board, it shall vote its Shares, or execute proxies or written
consents, as the case may be, in order to ensure that the Replacement Nominee be elected to the
Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.04. <I>Meetings. </I>The Board shall hold a regularly scheduled meeting at least once
every calendar quarter. The Company shall pay all reasonable out-of-pocket expenses incurred by
each director in connection with attending regular and special meetings of the Board and any
committee thereof, and any such meetings of the board of directors of any Subsidiary of the Company
and any committee thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.05. <I>Action by the Board. </I>(a)&nbsp;A quorum of the Board shall consist of a majority of
the directors on the Board, with such majority including all Investor Directors. In the event that
a quorum is not established due to the absence of any Investor Director, a meeting may be
reconvened on the third Business Day after the date of the originally scheduled meeting and
attendance by such absent Investor Director shall not be required for the purposes of establishing
quorum at the reconvened meeting. The directors may attend a meeting either in person, by proxy,
by telephone or by similar communications equipment whereby all persons participating in the
meeting can hear each other.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Subject to Section&nbsp;2.12, all resolutions of the Board shall require the affirmative vote
of at least a majority of the directors present at a duly-convened meeting of the Board at which a
quorum is present, <I>provided </I>that, a resolution in writing signed by a majority of all directors
(which majority shall include the same number of Investor Directors as the number of Investor
Directors required pursuant to this Agreement and the memorandum and articles of association of the
Company for a resolution adopted by the Board in a Board meeting) shall be as valid and effectual
as if such resolution had been passed at a meeting of the Board
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">duly convened and held so long as (x)&nbsp;a copy of such resolution has been given or the contents
thereof communicated to all the directors for the time being entitled to receive notices of Board
meetings in the same manner as notices of meetings are required to be given hereby and (y)&nbsp;no
director has objected to such resolution. Such written resolution may be contained in one document
or in several documents in like form each signed by one or more of the directors or alternate
directors and for this purpose a facsimile signature of a director or an alternate director shall
be treated as valid. If there is a vacancy on the Board and an individual has been nominated to
fill such vacancy, the first order of business shall be to fill such vacancy. Each director shall
have one (1)&nbsp;vote and each alternate or proxy shall have one (1)&nbsp;vote for every director whom he
represents, <I>provided </I>that if such alternate is himself a director then he shall have one (1)&nbsp;vote
for every director whom he represents in addition to any vote of his own.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Board may create executive, compensation, audit and such other committees as it may
determine. Each Investor Director shall be entitled to sit on any committee created by the Board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.06<I>. Memorandum and Articles. </I>Each Shareholder agrees to vote its Shares or execute
proxies or written consents, as the case may be, and to take all other actions necessary, to ensure
that the memorandum and articles of the Company and the constituent documents of each of its
Subsidiaries (i)&nbsp;facilitate, and do not at any time conflict with, any provision of this Agreement
and (ii)&nbsp;permit each Shareholder to receive the benefits to which each such Shareholder is entitled
under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.07<I>. Notice of Meeting. </I>The Company agrees to give each director written notice
(together with the agenda and material for discussion) for each meeting of the Board or any
committee thereof at least 10 Business Days prior to such meeting, unless the directors unanimously
waive such prior notice. The schedule of the Board meeting and all information related to the
matters to be discussed at the Board meeting shall be delivered along with the written notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.08. <I>Alternate</I>. Each director shall be entitled to appoint any person to be his
alternate. An appointment and a termination of appointment of the alternate shall be by notice in
writing signed by such director and either (a)&nbsp;sent to the Company or (b)&nbsp;accepted by the Board by
resolution thereof at the relevant meeting. Any person appointed as alternate shall vacate his
office as such alternate if and when the director by whom he has been appointed removes him or
vacates office as director.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.09<I>. No Liabilities. </I>Neither Carlyle, CICC nor Starr shall, by reason of its
ability to designate and cause the election of any member of the Board hereunder, or otherwise, be
subject to any liability or obligation whatsoever
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">with respect to the management and affairs of the Company or otherwise be or become
responsible for any debts, liabilities or obligations of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.10<I>. Directors&#146; Indemnification; Insurance. </I>The articles of the Company and each of
its Subsidiaries shall at all times provide for the indemnification of the directors of the Company
and each of its Subsidiaries (including all Investor Directors and each director of any such
Subsidiary designated by any Investor pursuant to this Agreement) to the maximum extent permitted
by the law of the jurisdiction in which the Company or such Subsidiary, as applicable, is
organized. At the request of any of the Investor Directors, the Company shall promptly enter into
an indemnification agreement with such director with customary terms and conditions covering such
director. The Company shall, and shall cause each of its Subsidiaries to, obtain and pay for
directors&#146; insurance covering the directors of the Company and such Subsidiary, as applicable
(including all Investor Directors and each director of any such Subsidiary designated by any
Investor pursuant to this Agreement) promptly upon the request of the Investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.11<I>. Subsidiary Governance</I>. The Company and each Shareholder agree that the board
of directors of each Subsidiary of the Company that are outside of the PRC shall be comprised of
the individuals who are serving as directors on the Board in accordance with Section&nbsp;2.01. The
Company and each Shareholder agree that the board of directors of each wholly-owned Subsidiary of
the Company in the PRC shall be comprised of at least one of the Investor Directors (to the extent
requested by such Investor Director). Each Shareholder agrees to vote its Shares and to cause its
representatives on the Board to vote and take other appropriate action to effect the agreements in
this Section&nbsp;2.11 in respect of any Subsidiary of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.12. <I>Required Consents. </I>Notwithstanding any other provision herein to the contrary,
the Company shall not take any action (including any action by the Board or any committee of the
Board) after the date hereof with respect to any of the following matters without the affirmative
approval of a majority of the Board (which majority shall include all Investor Directors, other
than the matters set forth under clause 2.12(ee) with respect to which such majority shall include
a majority of the Investor Directors):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;any merger, consolidation, reorganization (including conversion) or other business
combination involving the Company or any of its Subsidiaries (other than of a wholly owned
Subsidiary of the Company with or into another wholly owned Subsidiary of the Company) or any
acquisition of the Company or any of its Subsidiaries by another entity by means of any transaction
or series of related transactions,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;any reorganization, recapitalization, reclassification, spin-off or combination of any
securities of the Company or any of its Subsidiaries (including any change to the registered
capital of any of its Subsidiaries formed under the laws of the PRC),
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;any amendment, alteration or repeal of any provision of the memorandum and articles of
association of the Company or similar constituent documents (including joint venture contracts and
related memorandum of understanding) of any of its Subsidiaries (in each case including in
connection with any merger, consolidation, business combination, reorganization (including
conversion) or other extraordinary corporate transaction) to the extent such amendment, alteration
or repeal changes in any material respects the rights, preferences or privileges of CICC, Carlyle
or Starr,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;any material change in the business of the Company or any of its Subsidiaries,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;any material change to the Board or the board of directors of any Subsidiary of the
Company, including any increase or decrease of the size of the Board or such board,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;the termination of employment of, or the entering into of any employment agreement or
arrangement (or amendment or other modification thereto) with, the chairman of the board of
directors, the president, the chief executive officer, the chief financial officer, the chief
operating officer or individuals holding similar positions of the Company or any of its
Subsidiaries (the &#147;<B>Top Management</B>&#148;),
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;entry into any material plan for the future expansion of the Company or any of its
Subsidiaries,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;any event or action that may lead to any change in the capital structure of the Company or
any of its Subsidiaries, including (i)&nbsp;direct or indirect purchase, redemption, retirement or other
acquisition of any capital share or registered capital, as applicable, of the Company or any of its
Subsidiaries or any obligation or security convertible or exchangeable into any such capital share,
(ii)&nbsp;any creation, authorization, increase in the authorized amount or issuance of shares of any
class or series of capital share or the registered capital, as applicable, of the Company or any of
its Subsidiaries, any obligation or security convertible into or exchangeable for shares of any
class or series of capital share of the Company or any of its Subsidiaries, or any options,
warrants or other rights to acquire any class or series of capital share of the Company or any of
its Subsidiaries (except for the issuance of Ordinary Shares upon the conversion of any Preferred
Shares pursuant to the memorandum and articles of the Company) and (iii)&nbsp;any issuance of debt
securities of the Company or any of its Subsidiaries,
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;any plan on the IPO or any material change thereto or the consummation of the IPO,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;any approval or modification of the annual budget of the Company or any of its
Subsidiaries (including (i)&nbsp;detailed budget for the line items in the balance sheet, income
statement and statement cash flow of the Company or any of its Subsidiaries, (ii)&nbsp;budget for the
annual total salary of the employees of the Company or any of its Subsidiaries, the employee
benefits plans and the compensation, benefits and incentive plans for the Top Management of the
Company or any of its Subsidiaries and (iii)&nbsp;separate budget for certain lines items in the income
statement of the Company or any of its Subsidiaries, including R&#038;D and advertisement), and
authorization of any expenditure by the Company or any of its Subsidiaries if as a result thereof
the aggregate amount of expenditures in any category would exceed 10% of the amount budgeted
therefor in the approved operating budget,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;any acquisition, sale, lease or other material decisions regarding trademarks or other
intellectual property rights by the Company or any of its Subsidiaries,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;the creation, incurrence, or assumption of any indebtedness of the Company or any of its
Subsidiaries after the date hereof (i)&nbsp;causing the total liabilities to total assets ratio of the
Company and its Subsidiaries, taken as a whole, to exceed 65% or (ii)&nbsp;after such total liabilities
to total assets ratio has exceeded 65%,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;any change to the ownership of the Company Securities other than any Transfer of Ordinary
Shares by any Controlling Shareholder or its Permitted Transferees to the Investors pursuant to
Article&nbsp;4 of the Series&nbsp;A Subscription Agreement, Article&nbsp;3 of the Series&nbsp;B Subscription Agreement,
Section&nbsp;11.06 of the Convertible Loan Agreement, Section&nbsp;6.09 of this Agreement, the Share Charge
Agreements or any Transfer expressly permitted or required pursuant to this Agreement,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;any loans or advances to, or guarantees for the benefit of, any shareholder, director,
member of the Top Management or their respective Affiliates by the Company or any of its
Subsidiaries, other than advances (i)&nbsp;to any such Person up to an aggregate outstanding amount of
RMB100,000 for each such Person at anytime and (ii)&nbsp;in an aggregate amount for all such Persons not
exceeding the amount expressly specified in the budget approved by the Board pursuant to Section
2.12(j),
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;any increase in the salary of any of the five most highly compensated employees of the
Company or any of its Subsidiaries by more than 15% in any 12-month period,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)&nbsp;(i)&nbsp;the adoption of, or any amendment or other modification to, any share option plan,
employee share ownership plan or share purchase or restricted share or share appreciation rights
plan, or (ii)&nbsp;any issuance of Ordinary Shares to any employees of the Company or any of its
Subsidiaries other than pursuant to any such plan approved by the Board pursuant to Section
2.12(j),
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q)&nbsp;(i)&nbsp;any direct or indirect purchase or other acquisition by the Company or any of its
Subsidiaries of any notes, obligations, instruments, share securities or ownership interest
(including any partnership, limited liability and joint venture interest) of any Person (including
the Company or any of its Subsidiaries) and (ii)&nbsp;any capital contribution by the Company or any of
its Subsidiaries to any Person (including the Company or any of its Subsidiaries),
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r)&nbsp;any formation, acquisition or sale of any Subsidiaries by the Company or any of its
Subsidiaries,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s)&nbsp;any acquisition, sale, transfer, lease, pledge or other disposition by the Company or any
of its Subsidiaries (in a single transaction or a series of related transactions) of any assets,
business or operations in the aggregate with a value of more than RMB15,000,000 (other than as
expressly specified in the annual budget approved by the Board pursuant to Section&nbsp;2.12(j),
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t)&nbsp;the creation of any Lien on the assets or properties of the Company or any of its
Subsidiaries with an aggregate value exceeding RMB20,000,000 in connection with any bank loans,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u)&nbsp;the declaration or payment of any dividend or other distribution upon any capital share of
the Company or any of its Subsidiaries (other than (i)&nbsp;dividends and distributions to the Company
or a wholly owned Subsidiary of the Company by a wholly owned Subsidiary of the Company and (ii)
dividends on the Preferred Shares paid pursuant to the memorandum and articles of the Company),
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;the adoption, announcement or amendment of the loss recovery plan or any plan in
connection with the reserve fund, enterprise expansion fund and bonus and welfare fund for
employees,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(w)&nbsp;any adjustment to the operating budget of the Company or any of its Subsidiaries upon the
official written request of the Company; <I>provided </I>that any such consent granted by the Board
pursuant to this Section&nbsp;2.12(w) shall be considered also a consent by the Board to the
corresponding adjustment to the annual budget pursuant to Section&nbsp;2.12(j),
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x)&nbsp;any prepayment of purchase price in connection with purchase of goods and services by the
Company or any of its Subsidiaries to any single
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">supplier, individually or together with any other prepayment to such supplier, in an amount
exceeding RMB9,000,000 (excluding any payment after the receipt and acceptance of purchased goods
and services but prior to the receipt of the related invoices or receipts),
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y)&nbsp;any loans or advances to, or guarantees for the benefit of, any entity which is an
Affiliate of the Company (other than the wholly-owned Subsidiaries of the Company) by the Company
or any of its Subsidiaries in an amount exceeding RMB1,000,000 to any single entity or in an
aggregate amount to all such entities exceeding RMB2,000,000 in any fiscal year,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z)&nbsp;any loans or advances to any entity that is not an Affiliate of the Company by the Company
or any of its Subsidiaries in an amount exceeding RMB500,000 to any single entity or in an
aggregate amount to all such entities exceeding RMB1,000,000 in any fiscal year (other than advance
trade payments in the ordinary course of business),
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(aa)&nbsp;any use or lease by any Person other than the Company or its Subsidiaries free of charge
or at a price lower than the market price of the assets and properties of the Company or any of its
Subsidiaries with an aggregate fair market value exceeding RMB5,000,000,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(bb)&nbsp;any indemnity to third party(ies) (i)&nbsp;causing the cumulative amount of indemnity to all
third parties to exceed RMB100,000 or (ii)&nbsp;after the cumulative amount of indemnity to all third
parties has exceeded RMB100,000,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(cc)&nbsp;any guarantees for the benefit of any entity that is not an Affiliate of the Company,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(dd)&nbsp;any donation or sponsorship in an amount exceeding RMB1,000,000 or in an aggregate amount
of RMB3,000,000 in any fiscal year by the Company and its Subsidiaries (other than donation or
sponsorship set forth in the annual budget approved by the Board pursuant to Section&nbsp;2.12(j)),
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ee)&nbsp;the appointment and removal of the Company&#146;s independent auditors,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ff)&nbsp;any decisions on any matters relating to any material litigation,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(gg)&nbsp;any liquidation, dissolution, winding up, commencement of bankruptcy, insolvency,
liquidation or similar proceedings with respect to the Company or any of its Subsidiaries,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(hh)&nbsp;any payment by the Company or any of its Subsidiaries to, or any sale, lease, transfer or
other disposition of any properties or assets of the Company or any of its Subsidiaries to, or any
purchase, lease or other acquisition
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">by the Company or any of its Subsidiaries of any properties or assets from, or any other
transaction, contract, agreement, loan, advance or guarantee with or for the benefit of, any
shareholder, director, officer, employee or any Affiliate of the foregoing, any Affiliate of the
Company or any of its Subsidiaries or the shareholder, director, officer or employee of such
Affiliate (each a &#147;<B>Related Party</B>&#148;) (other than transactions between the Company and any of its
wholly owned Subsidiaries or between any wholly owned Subsidiary of the Company and any other
wholly owned Subsidiary of the Company) (each a &#147;<B>Related Party Transaction</B>&#148;), and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;any agreement, indenture or other instrument that contains any provision that would
restrict either (i)&nbsp;the payment of dividends on, or the redemption of, the Series&nbsp;A Shares and
Series&nbsp;B Shares when due to the full extent required by the terms thereof or (ii)&nbsp;the right of
Carlyle, CICC and Starr under Section&nbsp;4.06(g).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.13<I>. Nomination of Chief Financial Officer</I>. The Chief Financial Officer of the
Company shall be nominated by Carlyle, CICC and Starr in consultation with the Company. The
Company shall not appoint any individual as the Chief Financial Officer of the Company except for
an individual nominated by Carlyle, CICC and Starr. Carlyle, CICC and Starr shall have the right,
in consultation with the Company, to determine the compensation of the Chief Financial Officer of
the Company.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 3</B><BR>
<FONT style="font-variant: SMALL-CAPS">Restrictions on Transfer</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.01<I>. General Restrictions on Transfer. </I>(a)&nbsp;Each Shareholder agrees that it shall
not Transfer any Company Securities (or solicit any offers in respect of any Transfer of any
Company Securities), except in compliance with the Securities Act, any other applicable securities
or &#147;blue sky&#148; laws, and the terms and conditions of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Any attempt to Transfer any Company Securities not in compliance with this Agreement shall
be null and void, and the Company shall not, and shall cause any transfer agent not to, give any
effect in the Company&#146;s register of members to such attempted Transfer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.02<I>. Restrictions on Transfer. </I>(a)&nbsp;Each Other Shareholder agrees that, without the
prior written consent of each Investor, it shall not directly or indirectly Transfer any Company
Securities (or solicit any offers in respect of any Transfer of any Company Securities) prior to
the completion of the QPO.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Controlling Shareholder agrees that within the two years following the completion of
the QPO, so long as the Aggregate Ownership of Ordinary Shares by any Investor is at least 20% of
such Investor&#146;s Initial Ownerships of Ordinary Shares, without the prior written consent of such
Investor, such Controlling Shareholder shall not directly or
indirectly Transfer (&#945;) in any single
transaction or in a series of transactions, whether or not related, Company Securities representing
50% or more of its Initial Ownership of Ordinary Shares or
(&#946;) any Company Securities if the
Controlling Shareholders have Transferred an aggregate amount of Company Securities representing
20% or more of their aggregate Initial Ownership of Ordinary Shares, except for Transfers (i)
pursuant to Article&nbsp;4 of the Series&nbsp;A Subscription Agreement, (ii)&nbsp;pursuant to Article&nbsp;3 of the
Series&nbsp;B Subscription Agreement, (iii)&nbsp;pursuant to Section&nbsp;11.06 of the Convertible Loan Agreement,
(iv)&nbsp;pursuant to Section&nbsp;6.09 of this Agreement, (v)&nbsp;to transferees pursuant to the&nbsp;Share Charge
Agreements, (vi)&nbsp;to any employees of the Company or its Subsidiaries as share based compensation or
incentive, (vii)&nbsp;to any other Controlling Shareholder or the Permitted Transferees of any other
Controlling Shareholder or (viii)&nbsp;to any Permitted Transferee of such Controlling Shareholder,
<I>provided </I>that (A)&nbsp;such Permitted Transferee shall have agreed in writing to be bound by the terms
of this Agreement in the form of Exhibit&nbsp;A attached hereto and (B)&nbsp;if such Permitted Transferee
ceases to be a Permitted Transferee of such Controlling Shareholder, the Company Securities
previously Transferred shall be immediately Transferred, to the extent permitted by applicable
laws, to such Controlling Shareholder or another Person who qualifies as a Permitted Transferee of
such Controlling Shareholder. Any such Transfer by the Controlling Shareholders shall be subject
to (i)&nbsp;the rules and regulations of the stock exchange where the QPO takes place and (ii)&nbsp;the
applicable laws in the jurisdiction in which such stock exchange is located.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each Other Shareholder agrees that it shall not directly or indirectly Transfer any
Company Securities if as a result of such Transfer there shall be a Change of Control, unless such
Transfer is otherwise permitted under this Agreement and the transferee agrees to purchase all
Company Securities then held by the Investors at a price agreed to by the Investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Sections 3.02(a) through 3.02(c) shall apply <I>mutatis mutandis </I>to any direct or indirect
Transfer by any Controlling Person of any equity interests in the relevant Controlling Shareholder.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 4</B><BR>
<FONT style="font-variant: SMALL-CAPS">Preemptive Rights; Rights of First Refusal; Rights of First Offer; Tag-along Rights; Put Rights</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.01. <I>Preemptive Rights. </I>(a)&nbsp;The Company shall give each Shareholder notice (an
&#147;<B>Issuance Notice</B>&#148;) of any proposed issuance by the Company of any Company Securities at least 30
Business Days prior to the proposed issuance date. The Issuance Notice shall specify the price at
which such Company Securities are to be issued and the other material terms of the issuance.
Subject to Section&nbsp;4.01(f) below, each of the Controlling Shareholder and the Investors (a &#147;<B>Major
Shareholder</B>&#148;) shall be entitled to purchase up to such Major Shareholder&#146;s Pro Rata Share of the
Company Securities proposed to be issued, at the price and on the terms specified in the Issuance
Notice. &#147;<B>Pro Rata Share</B>&#148; means, with respect to any Major Shareholder, the fraction that results
from dividing (i)&nbsp;such Major Shareholder&#146;s Aggregate Ownership (immediately before giving effect to
such issuance) of Ordinary Shares by (ii)&nbsp;the Aggregate Ownership (immediately before giving effect
to such issuance) of Ordinary Shares by all Shareholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Major Shareholder who desires to purchase any or all of its Pro Rata Share of the
Company Securities specified in the Issuance Notice shall deliver notice to the Company (each an
&#147;<B>Exercise Notice</B>&#148;) of its election to purchase such Company Securities within 10 Business Days of
receipt of the Issuance Notice. The Exercise Notice shall specify the number of Company Securities
to be purchased by such Major Shareholder and shall constitute exercise by such Major Shareholder
of its rights under this Section&nbsp;4.01 and a binding agreement of such Major Shareholder to
purchase, at the price and on the terms specified in the Issuance Notice, the number of shares (or
amount) of Company Securities specified in the Exercise Notice. If, at the termination of such
10-Business-Day period, any Major Shareholder shall not have delivered an Exercise Notice to the
Company, such Major Shareholder shall be deemed to have waived all of its rights under this
Section&nbsp;4.01 with respect to the purchase of such Company Securities. Promptly following the
termination of such 10-Business Day period, the Company shall deliver to each Major Shareholder a
copy of all Exercise Notices it received.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If any Major Shareholder fails to exercise its preemptive rights under this Section&nbsp;4.01
or elects to exercise such rights with respect to less than such Major Shareholder&#146;s Pro Rata
Share, the Company shall, within 2 Business Days after the expiration of the 10-Business-Day
period, notify each other Major Shareholder who has delivered an Exercise Notice to exercise its
rights to purchase its entire Pro Rata Share, that such other Major Shareholder shall be entitled
to purchase from the Company its pro rata portion (which means the fraction that results from
dividing (i)&nbsp;such Major Shareholder&#146;s Aggregate Ownership (immediately before giving effect to such
issuance) of Ordinary
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Shares by (ii)&nbsp;Aggregate Ownership (immediately before giving effect to such issuance) of
Ordinary Shares of all Major Shareholders exercising in full their preemptive rights with respect
to their respective Pro Rata Shares) of such Company Securities with respect to which the first
mentioned Major Shareholder shall not have exercised its preemptive rights by delivering to the
Company a written notice within 5 Business Days of receiving such further offer which shall set
forth the number (or amount) of Company Securities to be purchased by such other Major Shareholder
in such further offer. The Company shall continue to offer additional pro rata portions to Major
Shareholders choosing to purchase their full pro rata portions of such Company Securities pursuant
to this Section&nbsp;4.01(c) until (i)&nbsp;all Company Securities proposed to be issued by the Company and
with respect to which Major Shareholders were entitled to exercise their rights under this Section
4.01 have been purchased by Major Shareholders or (ii)&nbsp;all Major Shareholders have purchased the
maximum number of Company Securities indicated in their respective Exercise Notice and other
notices delivered in response to further offers pursuant to this Section&nbsp;4.01(c), whichever is
earlier.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company shall have 90&nbsp;days from the date of the Issuance Notice to consummate the
proposed issuance of any or all of such Company Securities that the Major Shareholders have not
elected to purchase at the price and upon terms that are not materially less favorable to the
Company than those specified in the Issuance Notice. If the Company proposes to issue any such
Company Securities after such 90-day period, it shall again comply with the procedures set forth in
this Section&nbsp;4.01.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;At the consummation of the issuance of such Company Securities, the Company shall issue
certificates representing the Company Securities to be purchased by each Major Shareholder
exercising preemptive rights pursuant to this Section&nbsp;4.01, registered in the name of such Major
Shareholder and a copy of the updated register of members of the Company reflecting the ownership
of such Company Securities by such Major Shareholder, certified by a director of the Company as a
true copy, against payment by such Major Shareholder of the purchase price for such Company
Securities in accordance with the terms and conditions as specified in the Issuance Notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Notwithstanding the foregoing, no Major Shareholder shall be entitled to purchase Company
Securities as contemplated by this Section&nbsp;4.01 in connection with issuances of Company Securities
(i)&nbsp;to employees of the Company or any Subsidiary of the Company pursuant to employee benefit plans
or arrangements approved by the Board pursuant to Section&nbsp;2.12(p) (including upon the exercise of
employee share options granted pursuant to any such plans or arrangements) or (ii)&nbsp;pursuant to the
QPO.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.02<I>. Right of First Refusal. </I>(a)&nbsp;If, at any time prior to the QPO, any Shareholder
other than the Investors (the &#147;<B>ROFR Shareholder</B>&#148;) receives
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">from or otherwise negotiates with a Third Party an offer to purchase any or all of the Company
Securities owned or held by such ROFR Shareholder (a &#147;<B>ROFR Offer</B>&#148;) and such ROFR Shareholder (a
&#147;<B>ROFR Seller</B>&#148;) intends to pursue such Transfer of such Company Securities to such Third Party and
such Transfer is permitted by Article&nbsp;3, such ROFR Seller shall give notice (a &#147;<B>ROFR Offer
Notice</B>&#148;) to each other Shareholder (a &#147;<B>ROFR Non-Selling Shareholder</B>&#148;) that such ROFR Seller desires
to accept the ROFR Offer and that sets forth the number and kind of Company Securities (the &#147;<B>ROFR
Offered Securities</B>&#148;), the price per share that such ROFR Seller proposes to be paid for such ROFR
Offered Securities (the &#147;<B>ROFR Offer Price</B>&#148;) and all other material terms and conditions of the ROFR
Offer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The giving of a ROFR Offer Notice to the ROFR Non-Selling Shareholders shall constitute an
offer by such ROFR Seller to Transfer the ROFR Offered Securities, in whole and not in part, to the
ROFR Non-Selling Shareholders, at the ROFR Offer Price and on the other terms set forth in the ROFR
Offer Notice. Such offer may be accepted at the ROFR Offer Price by each of the ROFR Non-Selling
Shareholders on a pro rata basis based on the ROFR Offer Pro Rata Portion of such ROFR Non-Selling
Shareholder. Such offer shall be irrevocable for 30 Business Days after receipt of such ROFR Offer
Notice by each ROFR Non-Selling Shareholder. Each ROFR Non-Selling Shareholder shall have the
right to accept such offer (as provided above) within such 30 Business-Day period. The offer may
be accepted by giving an irrevocable notice of acceptance to such ROFR Seller prior to the
expiration of such 30 Business-Day period. &#147;<B>ROFR Offer Pro Rata Portion</B>&#148; means, with respect to
each ROFR Non-Selling Shareholder, the fraction that results from dividing (i)&nbsp;such ROFR
Non-Selling Shareholder&#146;s Aggregate Ownership of Ordinary Shares, by (ii)&nbsp;the Aggregate Ownership
of Ordinary Shares by all ROFR Non-Selling Shareholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any ROFR Non-Selling Shareholder receiving the ROFR Offer Notice elects not to purchase
ROFR Offered Securities, the ROFR Seller shall, within one Business Day after the expiration of the
initial 30 Business-Day period, give notice to all ROFR Non-Selling Shareholders that did accept
the initial offer, informing them that they have the right to increase the number of ROFR Offered
Securities that they accepted pursuant to the initial offer. Each such ROFR Non-Selling
Shareholder shall then have five Business Days in which to accept such second offer, by giving
notice of acceptance to the ROFR Seller prior to the expiration of such five Business-Day period,
as to all of such ROFR Non-Selling Shareholder&#146;s portion of the ROFR Offered Securities not
accepted pursuant to the initial offer (on the basis of such ROFR Non-Selling Shareholder&#146;s ROFR
Offer Pro Rata Portion compared to the ROFR Offer Pro Rata Portions of all other ROFR Non-Selling
Shareholders receiving the second offer) <I>plus </I>any additional portion not accepted by any other ROFR
Non-Selling Shareholder during such five Business-Day period.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any ROFR Non-Selling Shareholder fails to notify the ROFR Seller prior to the expiration of
the initial 30 Business-Day period or the second five Business-Day period, as applicable, referred
to above, it shall be deemed to have declined the initial offer or the second offer, as applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If any ROFR Non-Selling Shareholder has accepted the initial offer or the second offer, as
the case may be, such ROFR Non-Selling Shareholder shall purchase and pay, by bank or certified
check (in immediately available funds), for all ROFR Offered Securities that it has accepted to
purchase, within 30 Business Days after the expiration of the initial 30 Business-Day period or the
second five Business-Day period, as applicable, <I>provided </I>that, if the Transfer of such ROFR Offered
Securities is subject to any prior regulatory approval, the time period during which such Transfer
may be consummated shall be extended until the expiration of five Business Days after all such
approvals shall have been received.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;If the ROFR Non-Selling Shareholders fail to exercise their rights of first refusal
hereunder with respect to any ROFR Offered Securities, the ROFR Seller shall have a 120-day period
following the expiration of the initial 30 Business-Day period or the second five Business-Day
period, as applicable, during which to effect a Transfer to the Third Party making the ROFR Offer
of any or all of the ROFR Offered Securities on the same or more favorable (as to the ROFR Seller)
terms and conditions as were set forth in the ROFR Offer Notice at a price not less than the ROFR
Offer Price, <I>provided </I>that (A)&nbsp;such Third Party shall have agreed in writing to be bound by the
terms of this Agreement and (B)&nbsp;the Transfer to such Third Party is not in violation of applicable
securities laws. If the ROFR Seller does not consummate the Transfer of the ROFR Offered
Securities within such 120-day period, then the right of the ROFR Seller to Transfer such ROFR
Offered Securities shall terminate and the ROFR Seller shall again comply with the procedures set
forth in this Section&nbsp;4.02 with respect to any proposed Transfer of Company Securities to a Third
Party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;A ROFR Seller may Transfer ROFR Offered Securities in accordance with Section&nbsp;4.02(d)
for consideration other than cash only if such ROFR Seller has first obtained and delivered to each
ROFR Non-Selling Shareholder an opinion of a mutually agreed upon investment banking firm of
international standing indicating that the fair market value of the non-cash consideration that
such ROFR Seller proposes to accept as consideration for such ROFR Offered Securities, together
with any cash consideration, is at least equal to, on a per share basis, the ROFR Offer Price.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Sections 4.02(a) through 4.02(e) shall apply <I>mutatis mutandis </I>to any direct or
indirect Transfer by any Controlling Person of any equity interests in the relevant Controlling
Shareholder.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;The provisions of this Section&nbsp;4.02 shall not apply to any Transfer by any Controlling
Shareholder (i)&nbsp;pursuant to Article&nbsp;4 of the Series&nbsp;A Subscription Agreement, (ii)&nbsp;pursuant to
Article&nbsp;3 of the Series&nbsp;B Subscription Agreement, (iii)&nbsp;pursuant to Section&nbsp;11.06 of the
Convertible Loan Agreement, (iv)&nbsp;pursuant to Section&nbsp;6.09 of this Agreement, (v)&nbsp;to Permitted
Transferees of such Controlling Shareholder or (vi)&nbsp;to transferees pursuant to the&nbsp;Share Charge
Agreements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.03<I>. Rights of First Offer. </I>(a)&nbsp;If, at any time prior to the QPO, any Investor (the
&#147;<B>ROFO Seller</B>&#148;) desires to Transfer any Company Securities to a Third Party, such ROFO Seller shall
give notice (a &#147;<B>ROFO Offer Notice</B>&#148;) to the other Shareholders (the &#147;<B>ROFO Non-Selling Shareholders</B>&#148;)
that such ROFO Seller desires to make such a Transfer and that sets forth the number and kind of
Company Securities proposed to be Transferred by the ROFO Seller (the &#147;<B>ROFO Offered Securities</B>&#148;),
the cash price per share that such ROFO Seller proposes to be paid for such ROFO Offered Securities
(the &#147;<B>ROFO Offer Price</B>&#148;) and any other material terms sought by the ROFO Seller.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The giving of a ROFO Offer Notice to the ROFO Non-Selling Shareholders shall constitute an
offer by such ROFO Seller to Transfer the ROFO Offered Securities, in whole and not in part, (i)
first, to the other Investors and (ii)&nbsp;secondly, to the extent the other Investors have not
purchased all ROFO Offered Securities pursuant to this Section within the first two Business Days
of the ROFO Offer Period, to the other ROFO Non-Selling Shareholders, in each case at the ROFO
Offer Price and on the other terms set forth in the ROFO Offer Notice. Such offer may be accepted
at the ROFO Offer Price (i)&nbsp;first, by each other Investors on a <I>pro rata </I>basis (calculated by
dividing (x)&nbsp;such other Investor&#146;s Aggregate Ownership of Ordinary Shares by (y)&nbsp;the Aggregate
Ownership of Ordinary Shares by all Investors other than the ROFO Seller); and (ii)&nbsp;secondly, to
the extent the other Investors have not purchased all ROFO Offered Securities pursuant to this
Section within the first two Business Days of the ROFO Offer Period, by each of the ROFO
Non-Selling Shareholders who is not an Investor, on a <I>pro rata </I>basis (calculated by dividing (x)
such ROFO Non-Selling Shareholder&#146;s Aggregate Ownership of Ordinary Shares by (y)&nbsp;the Aggregate
Ownership of Ordinary Shares by all such ROFO Non-Selling Shareholders). Such offer shall be
irrevocable for five Business Days (the &#147;<B>ROFO Offer Period</B>&#148;) after receipt of such ROFO Offer
Notice by each ROFO Non-Selling Shareholder. Each ROFO Non-Selling Shareholder shall have the
right to accept such offer (as provided above) by giving an irrevocable notice of acceptance to
such ROFO Seller prior to the expiration of the ROFO Offer Period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If the ROFO Non-Selling Shareholders have elected to purchase all of the ROFO Offered
Securities, the ROFO Non-Selling Shareholders shall purchase and pay, by bank or certified check
(in immediately available funds), for
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">all ROFO Offered Securities within five Business Days after the date on which all such ROFO
Offered Securities have been accepted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Upon the earlier to occur of (i)&nbsp;full rejection of the ROFO Offer by all recipients
thereof and (ii)&nbsp;the expiration of the ROFO Offer Period without ROFO Non-Selling Shareholders
electing to purchase all of the ROFO Offered Securities, the ROFO Seller shall have a 120-day
period during which to effect a Transfer of any or all of the ROFO Offered Securities on terms that
are not materially less favorable (as to the ROFO Seller) as were set forth in the ROFO Offer
Notice, <I>provided </I>that, if the Transfer is subject to regulatory approval, such 120-day period shall
be extended until the expiration of five Business Days after all such approvals shall have been
received, but in no event shall such period be extended for more than an additional one hundred and
fifty (150)&nbsp;days. If the ROFO Seller does not consummate the Transfer of the ROFO Offered
Securities in accordance with the foregoing time limitations, then the right of the ROFO Seller to
effect the Transfer of such ROFO Offered Securities pursuant to this Section&nbsp;4.03(d) shall
terminate and the ROFO Seller shall again comply with the procedures set forth in this Section
4.03 with respect to any proposed Transfer of Company Securities to a Third Party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The provisions of this Section&nbsp;4.03 shall not apply to any Transfer of Company Securities
by any Investor (i)&nbsp;in the QPO or (ii)&nbsp;to any Permitted Transferee of such Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.04. <I>Tag-Along Rights</I>. (a)&nbsp;If a Shareholder other than the Investors (the
&#147;<B>Tag-Along Seller</B>&#148;) proposes to Transfer to a Person other than its Permitted Transferees, in a
transaction otherwise permitted by Article&nbsp;3, any Company Securities and the Investors have
declined or failed to exercise their rights of first refusal with respect to such Company
Securities pursuant to Section&nbsp;4.02 (a &#147;<B>Tag-Along Sale</B>&#148;),
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the Tag-Along Seller shall provide the Investors notice of the terms and
conditions of such proposed Transfer (&#147;<B>Tag-Along Notice</B>&#148;) and offer each Tagging Person
the opportunity to participate in such Transfer in accordance with this Section&nbsp;4.04, and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) each of the Investors who have declined or failed to exercise its rights of
first refusal with respect to such Company Securities pursuant to Section&nbsp;4.02 may elect,
at its option, to participate in the proposed Transfer in accordance with this Section
4.04 (each such electing Shareholder, a &#147;<B>Tagging Person</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Tag-Along Notice shall identify the number and class of Company Securities proposed to be
sold by the Tag-Along Seller and all other Company Securities subject to the offer (&#147;<B>Tag-Along
Offer</B>&#148;), the consideration for which
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Transfer is proposed to be made, and all other material terms and conditions of the
Tag-Along Offer, including the form of the proposed agreement, if any, and a firm offer by the
proposed transferee to purchase Company Securities from the Tagging Persons in accordance with this
Section&nbsp;4.04.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From the date of its receipt of the Tag-Along Notice, each Tagging Person shall have the right
(a &#147;<B>Tag-Along Right</B>&#148;), exercisable by notice (&#147;<B>Tag-Along Response Notice</B>&#148;) given to the Tag-Along
Seller within 15 Business Days after its receipt of the Tag-Along Notice (the &#147;<B>Tag-Along Notice
Period</B>&#148;), to request that the Tag-Along Seller include in the proposed Transfer up to a number of
Company Securities representing such Tagging Person&#146;s Tag-Along Portion, <I>provided </I>that each Tagging
Person shall be entitled to include in the Tag-Along Sale no more than its Tag-Along Portion of
Company Securities and the Tag-Along Seller shall be entitled to include the number of Company
Securities proposed to be Transferred by the Tag-Along Seller as set forth in the Tag-Along Notice
(reduced, to the extent necessary, so that each Tagging Person shall be able to include its
Tag-Along Portion and such additional Company Securities as permitted by Section&nbsp;4.04(d)). Each
Tag-Along Response Notice shall include wire transfer or other instructions for payment or delivery
of the purchase price for the Company Securities to be sold in such Tag-Along Sale or, if such
delivery is not permitted by applicable law, an unconditional agreement to deliver such Company
Securities pursuant to this Section&nbsp;4.04(a) at the closing for such Tag-Along Sale against
delivery to such Tagging Person of the consideration therefor. Each Tagging Person that exercises
its Tag-Along Rights hereunder shall deliver to the Tag-Along Seller, with its Tag-Along Response
Notice, the certificates representing the Company Securities of such Tagging Person to be included
in the Tag-Along Sale, together with a limited power-of-attorney authorizing the Tag-Along Seller
to Transfer such Company Securities on the terms set forth in the Tag-Along Notice. Delivery of
the Tag-Along Response Notice with such certificates and limited power-of-attorney shall constitute
an irrevocable acceptance of the Tag-Along Offer by such Tagging Persons, subject to the provisions
of this Section&nbsp;4.04. &#147;<B>Tag-Along Portion</B>&#148; means, with respect to any Tagging Person in any
Tag-Along Sale, that number (or amount) of Company Securities proposed to be Transferred in such
Tag-Along Sale equal to (x)&nbsp;the Aggregate Ownership of such class of Company Securities by such
Tagging Person immediately prior to such Tag-Along Sale <I>multiplied </I>by (y)&nbsp;a fraction the numerator
of which is the maximum number of such class proposed to be Transferred by the Tag-Along Seller in
such Tag-Along Sale and the denominator of which is the Aggregate Ownership of such class by the
Investors and the Tag-Along Seller immediately prior to such Tag-Along Sale.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, at the end of a 120-day period after such delivery of such Tag-Along Notice, the Tag-Along
Seller has not completed the Transfer of all Company Securities proposed to be sold by the
Tag-Along Seller and all Tagging Persons on substantially the same terms and conditions set forth
in the Tag-Along Notice,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Tag-Along Seller shall (i)&nbsp;return to each Tagging Person the limited power-of-attorney and
all certificates representing the Company Securities that such Tagging Person delivered for
Transfer pursuant to this Section&nbsp;4.04(a) and any other documents in the possession of the
Tag-Along Seller executed by the Tagging Persons in connection with the proposed Tag-Along Sale,
and (ii)&nbsp;all the restrictions on Transfer contained in this Agreement or otherwise applicable at
such time with respect to such Company Securities shall continue in effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Concurrently with the consummation of the Tag-Along Sale, the Tag-Along Seller shall (i)
notify the Tagging Persons thereof, (ii)&nbsp;remit to the Tagging Persons the total consideration for
the Company Securities of the Tagging Persons Transferred pursuant thereto, with the cash portion
of the purchase price paid by wire transfer of immediately available funds in accordance with the
wire transfer instructions in the applicable Tag-Along Response Notices and the non-cash portion of
the purchase price delivered to the Tagging Persons in manners specified in the relevant Tag-Along
Response Notices and (iii)&nbsp;promptly after the consummation of such Tag-Along Sale, furnish such
other evidence of the completion and the date of completion of such transfer and the terms thereof
as may be reasonably requested by the Tagging Persons.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If at the termination of the Tag-Along Notice Period, any of the Investors shall not have
elected to participate in the Tag-Along Sale, it shall be deemed to have waived its rights under
Section&nbsp;4.04(a) with respect to the Transfer of its Company Securities pursuant to such Tag-Along
Sale.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;If (i)&nbsp;any Investor declines to exercise its Tag-Along Rights or (ii)&nbsp;any Tagging Person
elects to exercise its Tag-Along Rights with respect to less than such Tagging Person&#146;s Tag-Along
Portion, in each case within the Tag-Along Notice Period, the Tag-Along Seller shall, on the
Business Day immediately after the expiration of the Tag-Along Notice Period, notify each Tagging
Person who has elected to exercise its Tag-Along Rights with respect to its Tag-Along Portion and
such Tagging Person shall have the right to include in the proposed Transfer an additional number
of Company Securities representing its <I>pro rata </I>portion (calculated by dividing (x)&nbsp;the Aggregate
Ownership of such class of Company Securities by such Tagging Person by (y)&nbsp;the Aggregate Ownership
of such class by all Tagging Persons who have elected to exercise their respective Tag-Along Rights
in full) of the Company Securities with respect to which Tag-Along Rights have not previously been
exercised during the Tag-Along Notice Period or during this subsequent offer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Tag-Along Seller shall Transfer, on behalf of itself and each Tagging Person, the
Company Securities subject to the Tag-Along Offer and elected to be Transferred on the terms and
conditions set forth in the Tag-Along Notice within 120&nbsp;days of delivery of the Tag-Along Notice.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Upon the consummation of any Tag-Along Sale, all of the Shareholders participating therein
will receive the same form and amount of consideration per share, or, if any Shareholders are given
an option as to the form and amount of consideration to be received, all Shareholders participating
therein will be given the same option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;No Tagging Person shall be obligated to pay any expenses incurred in connection with any
Tag-Along Sale.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Each Tagging Person shall (i)&nbsp;not be required to provide any representations or
indemnities in connection with any Tag-Along Sale other than representations and indemnities
concerning such Tagging Person&#146;s title to the Company Securities to be Transferred by such Tagging
Person in such Tag-Along Sale, free and clear of any encumbrances and authority, power and right to
enter into and consummate the Transfer without contravention of any law or material agreement and
(ii)&nbsp;benefit from all of the same provisions of the definitive agreements as the Tag-Along Seller.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;If a Controlling Shareholder proposes to Transfer, in a transaction otherwise permitted by
Article&nbsp;3, a number of Company Securities in a single transaction or in a series of related
transactions such that such Controlling Shareholder&#146;s Aggregate Ownership of Ordinary Shares
immediately after the consummation of such Transfer is less than 50% of such Controlling
Shareholder&#146;s Initial Ownership of Ordinary Shares, each of the Investors shall have the right to
participate in such Transfer to sell all Company Securities held by each respective Investor and
all other provisions of this Section&nbsp;4.04 shall apply to such Transfer <I>mutatis mutandis</I>. Any
Transfer of Company Securities by a Controlling Shareholder that occurs within six months of any
other Transfer of Company Securities by such Controlling Shareholders shall be conclusively deemed
to be related to such previous transaction for the purposes of this Section&nbsp;4.04(i).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;Sections 4.04(a) through 4.04(i) shall apply <I>mutatis mutandis </I>to any direct or
indirect Transfer by any Controlling Person of any equity interests in the relevant Controlling
Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.05<I>. Drag-Along Rights. </I>(a)&nbsp;If all of the Investors (the &#147;<B>Drag-Along Sellers</B>&#148;)
propose to Transfer Company Securities to one or more Third Parties (the &#147;<B>Drag-Along Transferee</B>&#148;)
(a &#147;<B>Drag-Along Sale</B>&#148;), the Drag-Along Sellers may at their collective option require all other
Shareholders (the &#147;<B>Dragged Shareholders</B>&#148;) (i)&nbsp;to Transfer the Drag-Along Portion of Company
Securities (&#147;<B>Drag-Along Rights</B>&#148;) then held by every Dragged Shareholder, and (ii)&nbsp;subject to and at
the closing of the Drag-Along Sale, to exercise such number of options for Ordinary Shares held by
every Dragged Shareholder as is required in order that a sufficient number of Ordinary Shares are
available to Transfer the relevant
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Drag-Along Portion of Company Securities of each such Dragged Shareholder, in each case for
the same consideration per unit of the relevant class of Company Securities and otherwise on the
same terms and conditions as the Drag-Along Sellers, <I>provided </I>that any Dragged Shareholder that
holds options the exercise price per share of which is greater than the per share price at which
the Ordinary Shares are directly or indirectly on an as converted basis to be Transferred to the
Drag-Along Transferee, if required by the Drag-Along Sellers to exercise such options, may, in lieu
of such exercise, submit to irrevocable cancellation thereof without any liability for payment of
any exercise price with respect thereto, and, <I>provided further </I>that, with respect to any Transfer
also governed by Section&nbsp;4.03, the Dragged Shareholders having a right of first offer under
Section&nbsp;4.03 shall first have been afforded the opportunity to acquire any Company Securities to
be Transferred in the Drag-Along Sale in accordance with the provisions of Section&nbsp;4.03. If the
Drag-Along Sale is not consummated with respect to any Ordinary Shares acquired upon exercise of
any options, or the Drag-Along Sale is not consummated, any options exercised or cancelled in
contemplation of such Drag-Along Sale shall be deemed not to have been exercised or canceled, as
applicable. &#147;<B>Drag-Along Portion</B>&#148; means, with respect to any Dragged Shareholder, (i)&nbsp;the Aggregate
Ownership of Ordinary Shares by such Dragged Shareholder <I>multiplied by </I>(ii)&nbsp;a fraction the
numerator of which is the aggregate number of Ordinary Shares proposed to be sold by the Drag-Along
Sellers in the applicable Drag-Along Sale, calculated on a Fully-Diluted basis, and the denominator
of which is the Aggregate Ownership of Ordinary Shares by the Drag-Along Sellers collectively.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Drag-Along Sellers shall provide notice of such Drag-Along Sale to the Dragged
Shareholders (a &#147;<B>Drag-Along Sale Notice</B>&#148;) not later than 15 Business Days prior to the proposed
Drag-Along Sale. The Drag-Along Sale Notice shall identify the transferee, the number of Company
Securities subject to the Drag-Along Sale, the consideration for which a Transfer is proposed to be
made (the &#147;<B>Drag-Along Sale Price</B>&#148;) and all other material terms and conditions of the Drag-Along
Sale. The number of Company Securities to be sold by each Dragged Shareholder shall be the
Drag-Along Portion that such Dragged Shareholder owns. Each Dragged Shareholder shall be required
to participate in the Drag-Along Sale on the terms and conditions set forth in the Drag-Along Sale
Notice and to tender its Company Securities as set forth below. The price payable in such Transfer
shall be the Drag-Along Sale Price. Not later than 10 Business Days after the date of the
Drag-Along Sale Notice (the &#147;<B>Drag-Along Sale Notice Period</B>&#148;), each of the Dragged Shareholders
shall deliver to a representative of the Drag-Along Sellers designated in the Drag-Along Sale
Notice the certificates representing the Company Securities of such Dragged Shareholder required to
be included in the Drag-Along Sale and the relevant instruments of transfer, together with a
limited power-of-attorney authorizing the Drag-Along Sellers or their representative to Transfer
such Company Securities on the terms set forth in the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Drag-Along Notice and wire transfer or other instructions for payment or delivery of the
consideration to be received in such Drag-Along Sale, or, if such delivery is not permitted by
applicable law, an unconditional agreement to deliver such Company Securities pursuant to this
Section&nbsp;4.05(a) at the closing for such Drag-Along Sale against delivery to such Dragged
Shareholder of the consideration therefor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Drag-Along Sellers shall have a period of 120&nbsp;days from the date of delivery of the
Drag-Along Sale Notice to consummate the Drag-Along Sale on the terms and conditions set forth in
such Drag-Along Sale Notice, <I>provided </I>that, if such Drag-Along Sale is subject to regulatory
approval, such 120-day period shall be extended until the expiration of five Business Days after
all such approvals have been received, but in no event later than 270&nbsp;days following the date of
delivery of the Drag-Along Sale Notice. If the Drag-Along Sale shall not have been consummated
during such period, the Drag-Along Sellers shall return to each of the Dragged Shareholders the
limited power-of-attorney and all certificates representing Company Securities that such Dragged
Shareholder delivered for Transfer pursuant hereto and all related instruments of transfer,
together with any other documents in the possession of the Drag-Along Sellers executed by such
Dragged Shareholder in connection with such proposed Transfer, and all the restrictions on Transfer
contained in this Agreement or otherwise applicable at such time with respect to such Company
Securities owned by the Dragged Shareholders shall again be in effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Concurrently with the consummation of the Transfer of Company Securities pursuant to this
Section&nbsp;4.05, the Drag-Along Sellers shall give notice thereof to the Dragged Shareholders, shall
remit to each of the Dragged Shareholders that have surrendered their certificates and other
applicable instruments the total consideration (the cash portion of which is to be paid by wire
transfer in accordance with such Dragged Shareholder&#146;s wire transfer instructions) for the Company
Securities Transferred pursuant hereto and shall furnish such other evidence of the completion and
time of completion of such Transfer and the terms thereof as may be reasonably requested by such
Dragged Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Notwithstanding anything contained in this Section&nbsp;4.05, there shall be no liability on
the part of the Drag-Along Sellers to the Dragged Shareholders (other than the obligation to return
the limited power-of-attorney and the certificates and other applicable instruments representing
Company Securities received by the Drag-Along Sellers) or any other Person if the Transfer of
Company Securities pursuant to this Section&nbsp;4.05 is not consummated for whatever reason, regardless
of whether the Drag-Along Sellers have delivered a Drag-Along Sale Notice. Whether to effect a
Transfer of Company Securities pursuant to this Section&nbsp;4.05 by the Drag-Along Sellers is in the
sole and absolute discretion of the Drag-Along Sellers.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Upon the consummation of any Drag-Along Sale, all of the Shareholders participating
therein will receive the same form and amount of consideration per share, or, if any Shareholders
are given an option as to the form and amount of consideration to be received, all Shareholders
participating therein will be given the same option.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;No Dragged Shareholder shall be obligated to pay any expenses incurred in connection with
any Drag-Along Sale.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Each Dragged Shareholder shall (i)&nbsp;not be required to provide any representations or
indemnities in connection with any Drag-Along Sale other than representations and indemnities
concerning such Dragged Shareholder&#146;s title to the Company Securities to be Transferred by such
Dragged Shareholder in such Drag-Along Sale, free and clear of any encumbrances and authority,
power and right to enter into and consummate the Transfer without contravention of any law or
material agreement and (ii)&nbsp;benefit from all of the same provisions of the definitive agreements as
any Drag-Along Seller holding the same number and class of Company Securities as such Dragged
Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Notwithstanding anything to the contrary herein, the Drag-Along Rights contemplated by
this Section&nbsp;4.05 shall be exercisable only in the event that the QPO has not been consummated by
the third anniversary date of the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.06<I>. Put Rights</I>. (a)&nbsp;The Company shall promptly deliver written notice to each
holder of Preferred Shares upon the occurrence of any Put Trigger Event. At any time after the
occurrence of any Put Trigger Event, upon the request of any holder of Preferred Shares, each Other
Shareholder shall use its best efforts to assist and cooperate with such holder to sell the Company
Securities then held by such holder to a Third Party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Without limiting the provisions in Section&nbsp;4.06(a), upon the occurrence of any Put
Trigger Event, each holder of Preferred Shares (each, a &#147;<B>Putting Shareholder</B>&#148;) shall have the right
(the &#147;<B>Put Right</B>&#148;) to require the Other Shareholders or the Company (the &#147;<B>Purchaser</B>&#148;) to purchase
all Company Securities held by such Putting Shareholder (the &#147;<B>Put Interest</B>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;To exercise the Put Right, a Putting Shareholder shall give notice (the &#147;<B>Put Notice</B>&#148;) to
the Other Shareholders and the Company no later than 30 Business Days prior to the proposed date of
purchase. If any Putting Shareholder requires the Company to purchase the Put Interest of such
Putting Shareholder in the Put Notice, upon receipt of the Put Notice, the Company shall be
obligated to purchase the Put Interest of such Putting Shareholder on the proposed date of purchase
in accordance with the provisions of this Section&nbsp;4.06, unless such purchase by the Company will
violate or contravene the Companies Law of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Cayman Islands. If any Putting Shareholder requires the Other Shareholders to purchase the
Put Interest of such Putting Shareholder in the Put Notice, upon receipt of the Put Notice, the
Other Shareholders shall be obligated, jointly and severally, to purchase such Put Interest on the
proposed date of purchase in accordance with the provisions of this Section&nbsp;4.06.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The purchase price payable per share of Company Securities by the Purchaser to any Putting
Shareholder (the &#147;<B>Put Price</B>&#148;) shall guarantee a Rate of Return of at least 12.5% for such Putting
Shareholder&#146;s investment in its Put Interest. The Rate of Return shall (i)&nbsp;be calculated for the
period beginning on and including the respective dates on which such Put Interest were issued by
the Company and ending on and including the closing date for the purchase of such Put Interest
pursuant to this Section&nbsp;4.06; (ii)&nbsp;include as cash outflows all amounts paid by such Putting
Shareholder or any other Person to the Company to acquire such Put Interest (including conversion
price, if applicable); (iii)&nbsp;include as cash inflows a deemed terminal cash inflow equal to the Put
Price; and (iv)&nbsp;include as cash inflows any cash dividends or other cash distributions on such Put
Interest actually received by such Putting Shareholder from the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;No later than the proposed date of purchase, each Putting Shareholder shall deliver to the
Purchaser certificates representing all Company Securities comprising its Put Interest, together
with all other documents required to be executed in connection with such Transfer or, if such
delivery is not permitted by applicable law, an unconditional agreement to deliver such Company
Securities pursuant to this Section&nbsp;4.06 at the closing for such Transfer against delivery to such
Putting Shareholder of the consideration therefor. In no event shall any Putting Shareholder be
obligated to make any representations and warranties, or to provide any indemnities, with respect
to any matters other than the title to the Company Securities comprising the Put Interest held by
such Putting Shareholder and the authority to sell such Company Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The closing for the purchase of any Put Interest pursuant to this Section&nbsp;4.06 shall
occur as promptly as practicable, but in no event later than 30&nbsp;days after the date of the Put
Notice in respect of such Put Interest. At any such closing, the Purchaser shall deliver to the
relevant Putting Shareholder the purchase price for the Put Interest of such Putting Shareholder by
wire transfer of immediately available funds to such bank account as such Putting Shareholder shall
have specified in writing no later than two Business Days prior to the closing of such purchase.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;From the date of the Put Notice to the closing date of the purchase of any Put Interest,
the Putting Shareholders shall have the sole right to (i)&nbsp;determine the declaration or payment of
any dividend or other distribution upon any capital share of the Company or any of its
Subsidiaries, (ii)&nbsp;determine any spending by the Company or any of its Subsidiaries, (iii)&nbsp;sell any
assets of the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Company or any of its Subsidiaries, (iv)&nbsp;approve any withdrawal from or otherwise manage any
bank account of the Company or any of its Subsidiaries, and (v)&nbsp;otherwise manage the business of
the Company and its Subsidiaries.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 5</B><BR>
<FONT style="font-variant: SMALL-CAPS">Registration Rights</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.01. <I>Right to Participate in the QPO</I>. (a)&nbsp;No later than 30 Business Days prior to
the anticipated filing date of the registration statement relating to the QPO if the class of
Company Securities subject of the QPO are to be listed on a stock exchange located in the US or the
filing date of similar documents if the class of Company Securities subject of the QPO are to be
listed in a stock exchange outside of the US, the Company shall deliver a written notice to each
Investor which shall set forth such Investor&#146;s rights under this Section&nbsp;5.01 and shall offer each
Investor the opportunity to include in such QPO the number of Registrable Securities of the same
class or series as those proposed to be listed and offered in the QPO as each Investor may request
(a &#147;<B>Piggyback Registration</B>&#148;), subject to the provisions of Section&nbsp;5.01(b). Upon the request of
any such Shareholder made within 15 Business Days after the receipt of notice from the Company
(which request shall specify the number of Registrable Securities intended to be registered by such
Shareholder), the Company shall use its best efforts to include in the QPO all Registrable
Securities that the Company has been so requested to include in the QPO by all such Shareholders,
to the extent requisite to permit the disposition of the Registrable Securities so to be included,
<I>provided </I>that (i)&nbsp;if the QPO involves an underwritten public offering, all such Shareholders
requesting to be included in the QPO must sell their Registrable Securities to the underwriters on
the same terms and conditions as apply to the Company, and (ii)&nbsp;if, at any time after giving notice
of its intention to include any Company Securities in the QPO pursuant to this Section&nbsp;5.01 and
prior to the closing date of the QPO, the Company shall determine for any reason not to consummate
the QPO, the Company shall give notice to all such Shareholders. The Company&#146;s obligation to
include any Registrable Securities in the QPO shall continue until after the Company has consummate
the QPO and has satisfied its obligations under this Section&nbsp;5.01. The Company shall pay all
Registration Expenses in connection with the Piggyback Registration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If the QPO involves an underwritten public offering and the managing underwriter advises
the Company that, in its view, the number of Company Securities that the Company and such
Shareholders intend to include in such registration exceeds the largest number of shares that can
be sold without having an adverse effect on such offering, including the price at which such shares
can be sold (the &#147;<B>Maximum Offering Size</B>&#148;), the Company shall include in such registration, in the
following priority, up to the Maximum Offering Size:
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) first, so much of the Company Securities proposed to be offered by the Company in
the QPO as would not cause the offering to exceed the Maximum Offering Size, and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) second, all Registrable Securities requested to be included in such registration
by any Shareholders pursuant to Section&nbsp;5.01 (allocated, if necessary for the offering
not to exceed the Maximum Offering Size, pro rata among such Shareholders on the basis of
the relative number of shares of Registrable Securities so requested to be included in
such registration by each).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Without the prior written consent of each Investor, none of the Controlling Shareholders
shall be permitted to include in the QPO any Company Securities held by such Controlling
Shareholder if the aggregate amount of Company Securities to be included in the QPO by the
Controlling Shareholders represents more than 20% of all Company Securities to be included in the
QPO by the Investors and the Controlling Shareholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.02. <I>Registration Rights after the QPO</I>. (a)&nbsp;If the shares subject of the QPO have
been listed on a stock exchange located in the US, the Company shall file with the SEC, no later
than 90&nbsp;days after the closing date of the QPO, a &#147;shelf&#148; registration statement covering the
resale of all of the Registrable Securities held by the Investors immediately after the closing of
the QPO, and shall use its best efforts to cause such &#147;shelf&#148; registration statement to become
effective on or prior to the 180<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day following the closing date of the QPO and to keep
such &#147;shelf&#148; registration statement in effect until all of the Company Securities held by the
Investors immediately after the closing of the QPO have been resold. The Company shall pay all
Registration Expenses incurred in connection with the registration pursuant to this Section
5.02(a).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If the shares subject of the QPO have been listed on a stock exchange not located in the
US, the Company shall obtain and maintain a listing for all the Company Securities held by the
Investors after the QPO.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.03. <I>Registration Procedures</I>. Whenever Shareholders request that any Registrable
Securities be registered pursuant to Section 5.01 or 5.02, subject to the provisions of such
Sections, the Company shall use its best efforts to effect the registration and the sale of such
Registrable Securities in accordance with the intended method of disposition thereof as quickly as
practicable, and, in connection with any such request:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company shall as expeditiously as possible prepare and file with the SEC a
registration statement on any form for which the Company then qualifies or that counsel for the
Company shall deem appropriate and which form shall be available for the sale of the Registrable
Securities to be registered
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">thereunder in accordance with the intended method of distribution thereof, and use its best
efforts to cause such filed registration statement to become and remain effective for a period of
not less than 180&nbsp;days, or in the case of a shelf registration statement, remain effective until
all of the Registrable Securities of the Shareholders included in such registration statement shall
have actually been sold thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Prior to filing a registration statement or prospectus or any amendment or supplement
thereto, the Company shall, if requested, furnish to each participating Shareholder and each
underwriter, if any, of the Registrable Securities covered by such registration statement copies of
such registration statement as proposed to be filed, and thereafter the Company shall furnish to
such Shareholder and underwriter, if any, such number of copies of such registration statement,
each amendment and supplement thereto (in each case including all exhibits thereto and documents
incorporated by reference therein), the prospectus included in such registration statement
(including each preliminary prospectus and any summary prospectus) and any other prospectus filed
under Rule&nbsp;424, Rule&nbsp;430A, Rule&nbsp;430B or Rule&nbsp;430C under the Securities Act and such other documents
as such Shareholder or underwriter may reasonably request in order to facilitate the disposition of
the Registrable Securities owned by such Shareholder. Each Shareholder shall have the right to
request that the Company modify any information contained in such registration statement, amendment
and supplement thereto pertaining to such Shareholder and the Company shall use its best efforts to
comply with such request, <I>provided </I>that the Company shall not have any obligation so to modify any
information if the Company reasonably expects that so doing would cause the prospectus to contain
an untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein not misleading.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;After the filing of the registration statement, the Company shall (i)&nbsp;cause the related
prospectus to be supplemented by any required prospectus supplement, and, as so supplemented, to be
filed pursuant to Rule&nbsp;424 under the Securities Act, (ii)&nbsp;comply with the provisions of the
Securities Act with respect to the disposition of all Securities covered by such registration
statement during the applicable period in accordance with the intended methods of disposition by
the Shareholders thereof set forth in such registration statement or supplement to such prospectus
and (iii)&nbsp;promptly notify each Shareholder holding Registrable Securities covered by such
registration statement of any stop order issued or threatened by the SEC or any state securities
commission and take all reasonable actions required to prevent the entry of such stop order or to
remove it if entered.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company shall use its best efforts to (i)&nbsp;register or qualify the Registrable
Securities covered by such registration statement under such other securities laws of such
jurisdictions in the US as any registering Shareholder holding such Registrable Securities
reasonably (in light of such Shareholder&#146;s
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">intended plan of distribution) requests and (ii)&nbsp;cause such Registrable Securities to be
registered with or approved by such other governmental agencies or authorities as may be necessary
by virtue of the business and operations of the Company and do any and all other acts and things
that may be reasonably necessary or advisable to enable such Shareholder to consummate the
disposition of the Registrable Securities owned by such Shareholder, <I>provided </I>that the Company
shall not be required to (A)&nbsp;qualify generally to do business in any jurisdiction where it would
not otherwise be required to qualify but for this Section&nbsp;5.03(d), (B)&nbsp;subject itself to taxation
in any such jurisdiction or (C)&nbsp;consent to general service of process in any such jurisdiction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Company shall immediately notify each Shareholder holding such Registrable Securities
covered by such registration statement, at any time when a prospectus relating thereto is required
to be delivered under the Securities Act, of the occurrence of an event requiring the preparation
of a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers
of such Registrable Securities, such prospectus will not contain an untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary to make the
statements therein not misleading and promptly prepare and make available to each such Shareholder
and file with the SEC any such supplement or amendment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Upon execution of confidentiality agreements in form and substance reasonably satisfactory
to the Company, the Company shall make available for inspection by any Shareholder and any
underwriter participating in any disposition pursuant to a registration statement being filed by
the Company pursuant to this Section&nbsp;5.03(f) and any attorney, accountant or other professional
retained by any such Shareholder or underwriter (collectively, the &#147;<B>Inspectors</B>&#148;), all financial and
other records, pertinent corporate documents and properties of the Company (collectively, the
&#147;<B>Records</B>&#148;) as shall be reasonably necessary or desirable to enable them to exercise their due
diligence responsibility, and cause the Company&#146;s officers, directors and employees to supply all
information reasonably requested by any Inspectors in connection with such registration statement.
Records that the Company determines, in good faith, to be confidential and that it notifies the
Inspectors are confidential shall not be disclosed by the Inspectors unless (i)&nbsp;the disclosure of
such Records is necessary to avoid or correct a misstatement or omission in such registration
statement or (ii)&nbsp;the release of such Records is ordered pursuant to a subpoena or other order from
a court of competent jurisdiction. Each Shareholder agrees that information obtained by it as a
result of such inspections shall be deemed confidential and shall not be used by it or its
Affiliates as the basis for any market transactions in the Company Securities unless and until such
information is made generally available to the public. Each Shareholder further agrees that, upon
learning that disclosure of such Records is sought in a court of competent jurisdiction, it shall
give notice to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Company and allow the Company, at its expense, to undertake appropriate action to prevent
disclosure of the Records deemed confidential.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;To the extent permitted by laws, the Company shall furnish to each registering Shareholder
and to each such underwriter, if any, a signed counterpart, addressed to such Shareholder or
underwriter, of (i)&nbsp;an opinion or opinions of counsel to the Company and (ii)&nbsp;a comfort letter or
comfort letters from the Company&#146;s independent public accountants, each in customary form and
covering such matters of the kind customarily covered by opinions or comfort letters, as the case
may be, as a majority of such Shareholders or the managing underwriter therefor requests.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;The Company shall otherwise use its best efforts to comply with all applicable rules and
regulations of the SEC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;The Company may require each Shareholder promptly to furnish in writing to the Company
such information regarding the distribution of the Registrable Securities as the Company may from
time to time reasonably request and such other information as may be legally required in connection
with such registration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;Each Shareholder agrees that, upon receipt of any notice from the Company of the happening
of any event of the kind described in Section&nbsp;5.03(e), such Shareholder shall forthwith
discontinue disposition of Registrable Securities pursuant to the registration statement covering
such Registrable Securities until such Shareholder&#146;s receipt of the copies of the supplemented or
amended prospectus contemplated by Section&nbsp;5.03(e), and, if so directed by the Company, such
Shareholder shall deliver to the Company all copies, other than any permanent file copies then in
such Shareholder&#146;s possession, of the most recent prospectus covering such Registrable Securities
at the time of receipt of such notice. If the Company shall give such notice, the Company shall
extend the period during which such registration statement shall be maintained effective (including
the period referred to in Section&nbsp;5.03(a)) by the number of days during the period from and
including the date of the giving of notice pursuant to Section&nbsp;5.03(e) to the date when the
Company shall make available to such Shareholder a prospectus supplemented or amended to conform
with the requirements of Section&nbsp;5.03(e).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;The Company shall use its best efforts to list all Registrable Securities covered by such
registration statement on any securities exchange or quotation system on which any of the
Registrable Securities are then listed or traded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;The Company shall have appropriate officers of the Company (i)&nbsp;prepare and make
presentations at any &#147;road shows&#148; and before analysts and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">rating agencies, as the case may be, (ii)&nbsp;take other actions to obtain ratings for any
Registrable Securities and (iii)&nbsp;otherwise use their best efforts to cooperate as requested by the
underwriters in the offering, marketing or selling of the Registrable Securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.04. <I>Indemnification by the Company</I>. The Company agrees to indemnify and hold
harmless each Shareholder beneficially owning any Registrable Securities covered by a registration
statement, its officers, directors, employees, partners and agents, and each Person, if any, who
controls such Shareholder within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of
the Exchange Act from and against any and all losses, claims, damages, liabilities and expenses
(including reasonable expenses of investigation and reasonable attorneys&#146; fees and expenses)
(&#147;<B>Damages</B>&#148;) caused by or relating to any untrue statement or alleged untrue statement of a material
fact contained in any registration statement or prospectus relating to the Registrable Securities
(as amended or supplemented if the Company shall have furnished any amendments or supplements
thereto) or any preliminary prospectus, or caused by or relating to any omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, except insofar as such Damages are caused by or related to any
such untrue statement or omission or alleged untrue statement or omission so made based upon
information furnished in writing to the Company by such Shareholder or on such Shareholder&#146;s behalf
expressly for use therein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.05. <I>Indemnification by Participating Shareholders</I>. Each Shareholder holding
Registrable Securities included in any registration statement agrees, severally but not jointly, to
indemnify and hold harmless the Company, its officers, directors and agents and each Person, if
any, who controls the Company within the meaning of either Section&nbsp;15 of the Securities Act or
Section&nbsp;20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to
such Shareholder, but only with respect to information furnished in writing by such Shareholder or
on such Shareholder&#146;s behalf expressly for use in any registration statement or prospectus relating
to the Registrable Securities, or any amendment or supplement thereto, or any preliminary
prospectus. No Shareholder shall be liable under this Section&nbsp;5.05 for any Damages in excess of
the net proceeds realized by such Shareholder in the sale of Registrable Securities of such
Shareholder to which such Damages relate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.06. <I>Conduct of Indemnification Proceedings</I>. If any proceeding (including any
governmental investigation) shall be instituted involving any Person in respect of which indemnity
may be sought pursuant to this Article&nbsp;5, such Person (an &#147;<B>Indemnified Party</B>&#148;) shall promptly
notify the Person against whom such indemnity may be sought (the &#147;<B>Indemnifying Party</B>&#148;) in writing
and the Indemnifying Party shall assume the defense thereof, including the employment of counsel
reasonably satisfactory to such Indemnified Party, and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">shall assume the payment of all fees and expenses, <I>provided </I>that the failure of any
Indemnified Party so to notify the Indemnifying Party shall not relieve the Indemnifying Party of
its obligations hereunder except to the extent that the Indemnifying Party is materially prejudiced
by such failure to notify. In any such proceeding, any Indemnified Party shall have the right to
retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such
Indemnified Party unless (i)&nbsp;the Indemnifying Party and the Indemnified Party shall have mutually
agreed to the retention of such counsel or (ii)&nbsp;in the reasonable judgment of such Indemnified
Party representation of both parties by the same counsel would be inappropriate due to actual or
potential differing interests between them. It is understood that, in connection with any
proceeding or related proceedings in the same jurisdiction, the Indemnifying Party shall not be
liable for the reasonable fees and expenses of more than one separate firm of attorneys (in
addition to any local counsel) at any time for all such Indemnified Parties, and that all such fees
and expenses shall be reimbursed as they are incurred. In the case of any such separate firm for
the Indemnified Parties, such firm shall be designated in writing by the Indemnified Parties. The
Indemnifying Party shall not be liable for any settlement of any proceeding effected without its
written consent, but if settled with such consent, or if there be a final judgment for the
plaintiff, the Indemnifying Party shall indemnify and hold harmless such Indemnified Parties from
and against any loss or liability (to the extent stated above) by reason of such settlement or
judgment. Without the prior written consent of the Indemnified Party, no Indemnifying Party shall
effect any settlement of any pending or threatened proceeding in respect of which any Indemnified
Party is or could have been a party and indemnity could have been sought hereunder by such
Indemnified Party, unless such settlement includes an unconditional release of such Indemnified
Party from all liability arising out of such proceeding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.07. <I>Contribution</I>. If the indemnification provided for in this Article&nbsp;5 is
unavailable to the Indemnified Parties in respect of any Damages, then each such Indemnifying
Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or
payable by such Indemnified Party as a result of such Damages, as between the Company on the one
hand and each such Shareholder on the other, in such proportion as is appropriate to reflect the
relative fault of the Company and of each such Shareholder in connection with such statements or
omissions, as well as any other relevant equitable considerations. The relative fault of the
Company on the one hand and of each such Shareholder on the other shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information supplied by such
party, and the parties&#146; relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or omission.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company and the Shareholders agree that it would not be just and equitable if contribution
pursuant to this Section&nbsp;5.07 were determined by pro rata allocation or by any other method of
allocation that does not take account of the equitable considerations referred to in the
immediately preceding paragraph. The amount paid or payable by an Indemnified Party as a result of
the Damages referred to in the immediately preceding paragraph shall be deemed to include, subject
to the limitations set forth above, any legal or other expenses reasonably incurred by such
Indemnified Party in connection with investigating or defending any such action or claim. No
Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any Person who was not guilty of such
fraudulent misrepresentation. Each Shareholder&#146;s obligation to contribute pursuant to this
Section&nbsp;5.07 is several in the proportion that the proceeds of the offering received by such
Shareholder bears to the total proceeds of the offering received by all such Shareholders and not
joint.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.08. <I>Other Indemnification</I>. Indemnification similar to that specified herein (with
appropriate modifications) shall be given by the Company and each Shareholder participating therein
with respect to any required registration or other qualification of securities under any federal or
state law or regulation or governmental authority other than the Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.09. <I>Cooperation by the Company</I>. If any Shareholder shall transfer any Registrable
Securities pursuant to Rule&nbsp;144, the Company shall cooperate, to the extent commercially
reasonable, with such Shareholder and shall provide to such Shareholder such information as such
Shareholder shall reasonably request.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 6</B><BR>
<FONT style="font-variant: SMALL-CAPS">Certain Covenants and Agreements</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.01. <I>Confidentiality</I>. (a)&nbsp;Each Shareholder agrees that Confidential Information
furnished and to be furnished to it has been and may in the future be made available in connection
with such Shareholder&#146;s investment in the Company. Each Shareholder agrees that it shall use, and
that it shall cause any Person to whom Confidential Information is disclosed pursuant to clause (i)
below to use, the Confidential Information only in connection with its investment in the Company
and not for any other purpose. Each Shareholder further acknowledges and agrees that it shall not
disclose any Confidential Information to any Person, except that Confidential Information may be
disclosed:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) to such Shareholder&#146;s Representatives in the normal course of the performance of
their duties or to any financial institution providing credit to such Shareholder,
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) to the extent required by applicable law, rule or regulation (including
complying with any oral or written questions, interrogatories, requests for information or
documents, subpoena, civil investigative demand or similar process to which a Shareholder
is subject, <I>provided </I>that such Shareholder agrees to give the Company prompt notice of
such request(s), to the extent practicable, so that the Company may seek an appropriate
protective order or similar relief (and the Shareholder shall cooperate with such efforts
by the Company, and shall in any event make only the minimum disclosure required by such
law, rule or regulation)),
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) to any Person to whom such Shareholder is contemplating a Transfer of its
Company Securities, <I>provided </I>that such Transfer would not be in violation of the
provisions of this Agreement and such potential transferee is advised of the confidential
nature of such information and agrees to be bound by a confidentiality agreement
consistent with the provisions hereof,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) to any regulatory authority or rating agency to which the Shareholder or any of
its affiliates is subject or with which it has regular dealings, as long as such authority
or agency is advised of the confidential nature of such information,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) to the extent related to the tax treatment and tax structure of the transactions
contemplated by this Agreement (including all materials of any kind, such as opinions or
other tax analyses that the Company, its Affiliates or its Representatives have provided
to such Shareholder relating to such tax treatment and tax structure), <I>provided </I>that the
foregoing does not constitute an authorization to disclose the identity of any existing or
future party to the transactions contemplated by this Agreement or their Affiliates or
Representatives, or, except to the extent relating to such tax structure or tax treatment,
any specific pricing terms or commercial or financial information, or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) if the prior written consent of the Board shall have been obtained.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Nothing contained herein shall prevent the use (subject, to the extent possible, to a protective
order) of Confidential Information in connection with the assertion or defense of any claim by or
against the Company or any Shareholder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) &#147;<B>Confidential Information</B>&#148; means any information concerning the Company or any Persons
that are or become its Subsidiaries or the financial condition, business, operations or prospects
of the Company or any such Persons in the possession of or furnished to any Shareholder (including
by virtue of its present or former right to designate a director of the Company), <I>provided </I>that the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">term &#147;Confidential Information&#148; does not include information that (i)&nbsp;is or becomes generally
available to the public other than as a result of a disclosure by
a Shareholder or its directors, officers, employees, shareholders, members, partners, agents,
counsel, investment advisers or other representatives (all such persons being collectively referred
to as &#147;<B>Representatives</B>&#148;) in violation of this Agreement, (ii)&nbsp;was available to such Shareholder on
a non-confidential basis prior to its disclosure to such Shareholder or its Representatives by the
Company, (iii)&nbsp;becomes available to such Shareholder on a non-confidential basis from a source
other than the Company after the disclosure of such information to such Shareholder or its
Representatives by the Company, which source is (at the time of receipt of the relevant
information) not, to the best of such Shareholder&#146;s knowledge, bound by a confidentiality agreement
with (or other confidentiality obligation to) the Company or another Person or (iv)&nbsp;is
independently developed by such Shareholder without violating any confidentiality agreement with,
or other obligation of secrecy to, the Company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.02. <I>Information Rights</I>. The Company shall deliver to the Investors in form and
detail satisfactory to the Investors the following:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;as soon as available, but in any event within 45&nbsp;days after the end of each of the first
three fiscal quarters of each fiscal year of the Company, duplicate copies of
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) a consolidated balance sheet of the Company and its Subsidiaries as at the end of
such fiscal quarter, and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the related consolidated statement of income and operations, shareholders&#146;
equity, cash flow and changes in financial position of the Company and its Subsidiaries
for such fiscal quarter and (in the case of the second and third quarters) for the portion
of the fiscal year ending with such fiscal quarter, in each case setting forth in
comparative form the figures for the corresponding periods in the previous fiscal year,
prepared in accordance with US GAAP or IFRS applied on a consistent basis, and certified
by the Chief Financial Officer of the Company as fairly presenting, in all material
respects, the financial position of the companies being reported on and their results of
operations and cash flows in accordance with the applicable accounting principals then
used by the Company, subject only to normal year-end audit adjustments and the absence of
footnotes;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;as soon as available, but in any event within 90&nbsp;days after the end of each fiscal year of
the Company, duplicate copies of
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) a consolidated balance sheet of the Company and its Subsidiaries as at the end of
such fiscal year, and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the related consolidated statements of operations, shareholders&#146; equity, cash
flow and changes in financial position of the Company and its Subsidiaries for such fiscal
year, setting forth in each case in comparative form the figures for the previous fiscal
year, prepared in accordance with the accounting principals then used by the Company
applied on a consistent basis, audited by, and accompanied by a report and opinion thereon
of, a &#147;big four&#148; international accounting firm, which opinion shall state that such
financial statements present fairly, in all material respects, the financial position of
the companies being reported upon and their results of operations and cash flows and have
been prepared in conformity with the applicable accounting principals applied on a
consistent basis, that the examination of such accountants in connection with such
financial statements has been made in accordance with generally accepted auditing
standards, that such report and opinion are not subject to any &#147;going concern&#148; or like
qualification or exception or any qualification or exception as to the scope of such
audit, and that such audit provides a reasonable basis for such opinion in the
circumstances; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) the Company&#146;s annual budget and operating budget for the coming fiscal year;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;as soon as available, but in any event within five Business Days after the first day of
each calendar month, (i)&nbsp;a monthly report of cash receipts and cash disbursements for the calendar
month most recently ended and (ii)&nbsp;a projected monthly report of cash receipts and cash
disbursements for the then current calendar month, in each case substantially in the form agreed to
between the Company and the Investors;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;as soon as available, but in any event within five Business Days after receipt thereof,
copies of all management letters and reports submitted to the Company or any of its Subsidiaries by
independent certified public accountants in connection with any annual, interim or special audit of
the Company or any of its Subsidiaries made by such accountants;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;as soon as available, but in any event within five days of receipt thereof, copies of any
notice to the Company or any of its Subsidiaries from any governmental authority relating to any
order, ruling, statute or other law that could reasonably be expected to have a Material Adverse
Effect;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;as soon as practicable and, in any event, within five Business Days after any officer of
the Company obtains knowledge thereof, notice (with a description in reasonable detail, and stating
the action that the Company is taking or proposes to take with respect thereto) of (i)&nbsp;the
commencement of any litigation, investigation or other proceeding to which the Company or any of
its
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Subsidiaries is a party before any court or arbitrator or any governmental body, agency or
official or arbitration body, (ii)&nbsp;any claim for indemnity against the Company or any of its
Subsidiaries or (iii)&nbsp;the existence of any material default or breach under this Agreement or any
other material contract or agreement to which the Company or any of its Subsidiaries is a party;
and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;as promptly as reasonably practicable, such other data and information relating to the
business, operations, affairs, financial condition, assets or property of the Company or any of its
Subsidiaries as from time to time may be reasonably requested by the Investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.03. <I>Inspection Right. </I>The Company shall, and shall cause each of its Subsidiaries
to, provide reasonable access to each Investor, or any person designated from time to time by such
Investor, from time to time hereafter, to call at the place or places of business of the Company
and any of its Subsidiaries during ordinary business hours, and, without hindrance or delay by any
of the Company and any of its Subsidiaries, (a)&nbsp;to inspect, audit, check, and makes copies of and
extracts from books, records, journals, orders, receipts of any of the Company and its
Subsidiaries, and any correspondence and other data relating to the business of any of the Company
and its Subsidiaries or to any transactions between the parties hereto, and (b)&nbsp;to discuss the
affairs, finances, and business of any of the Company and its Subsidiaries with the officers of any
of the Company and its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.04<I>. Books and Records. </I>Each of the Company and its Subsidiaries shall (a)&nbsp;maintain
proper books of record and account, in which full, true and correct entries in conformity with the
then adopted accounting principals consistently applied shall be made of all financial transactions
and matters involving the assets, properties and business of the Company and such Subsidiary, as
applicable; and (b)&nbsp;maintain such books of record and account in material conformity with all
applicable requirements of any governmental authority having regulatory jurisdiction over the
Company and such Subsidiary or their respective assets or properties, as applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.05. <I>Related Party Transactions</I>. The Company shall not, and shall not permit any of
its Subsidiaries to, enter into any Related Party Transaction, unless such transaction is on terms
that are no less favorable to the Company or such Subsidiary than those that would have been
obtained in a comparable transaction by the Company or such Subsidiary with a Person who is not a
Related Party. Before any Related Party Transaction is entered into, the Company shall disclose
the details of such transaction and the interests of all Related Parties to the Board.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.06<I>. QPO. </I>(a)&nbsp;Each Shareholder shall use its best efforts to cause the Company to
complete the QPO within three years (or such longer period as approved by the Board) from the date
hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If the Company fails to complete the QPO within such three-year period, at the end of such
three-year period and at the end of each year thereafter so long as the QPO has not been completed,
with the consent of the Company, the Investors shall have the right to appoint a reputable
investment bank on behalf of the Company to evaluate the feasibility of the QPO. The Company shall
bear the fees of such investment bank (other than underwriting discounts and commissions on any of
the Ordinary Shares to be sold by the Investors in the QPO).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If such investment bank determines that the QPO is feasible and a second investment bank
acceptable to the Investors is willing to act as an underwriter of the QPO, the Company shall take
actions to prepare for the QPO pursuant to the advice of such second investment bank.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.07. <I>Notice by Controlling Shareholders</I>. Each Controlling Shareholder agrees to
promptly deliver a written notice to the Investors if (i)&nbsp;such Controlling Shareholder has incurred
material debt, become liable to any other material liabilities or obligations or entered into any
material agreements (including acquisition of material new commercial interests) and (ii)&nbsp;the
Company or any of its Subsidiaries has become liable to material debt or may become liable to
material debt.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.08<I>. Internal Control</I>. The Company shall establish and maintain a system of
internal control over financial reporting that are sufficient to provide reasonable assurance
regarding the reliability of the Company&#146;s financial reporting and the preparation of Company&#146;s
financial statements in accordance with IFRS or US GAAP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.09<I>. Rights upon Resignation of Key Man. </I>Upon the resignation of any Key Man from
the Company and its Subsidiaries and in the event that, in the sole determination of a majority of
the Investors, such resignation has resulted, or would be likely to result in, a Material Adverse
Effect, such Key Man shall deliver a written notice to the Investors and offer the Investors the
right to purchase any or all of the Company Securities then held, directly or indirectly, by such
Key Man and his Permitted Transferees at a fair market price determined by an internationally
recognized investment banking firm. Within 30 Business Days after receipt of such notice, each
Investor may accept such offer by delivering a written notice to such Key Man, the Company and the
other Investors. Such notice shall set forth the number of Company Securities that such Investor
elects to purchase from such Key Man. If two or more Investors have delivered such notice and the
sum of the number of Company Securities set forth in such notices exceeds the number of Company
Securities then held, directly or indirectly, by
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">such Key Man and his Permitted Transferees, each such Investor shall have the right to
purchase its <I>pro rata </I>portion of such Company Securities from such Key Man, his Affiliates and his
Permitted Transferees who directly hold any such Company Securities, based on the number of
Ordinary Shares then held by each such Investor, calculated on a Fully-Diluted basis. Within 15
Business Days after the expiration of the initial 30 Business-Day period, such Key Man and his
relevant Affiliates and Permitted Transferees and each Investor who has delivered such written
notice to accept the offer shall consummate such sale and purchase of Company Securities<I>.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.10<I>. Conflicting Agreements</I>. The Company and each Shareholder represents and agrees
that it shall not (a)&nbsp;grant any proxy or enter into or agree to be bound by any voting trust or
agreement with respect to the Company Securities, except as expressly contemplated by this
Agreement, (b)&nbsp;enter into any agreement or arrangement of any kind with any Person with respect to
any Company Securities inconsistent with the provisions of this Agreement or for the purpose or
with the effect of denying or reducing the rights of any other Shareholder under this Agreement,
including agreements or arrangements with respect to the Transfer or voting of its Company
Securities or (c)&nbsp;act, for any reason, as a member of a group or in concert with any other Person
in connection with the Transfer or voting of its Company Securities in any manner that is
inconsistent with the provisions of this Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE 7</B><BR>
<FONT style="font-variant: SMALL-CAPS">Miscellaneous</FONT>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.01<I>. Binding Effect; Assignability; Benefit. </I>(a)&nbsp;This Agreement shall inure to the
benefit of and be binding upon the parties hereto and their respective heirs, successors, legal
representatives and permitted assigns. Any Shareholder that ceases to own beneficially any Company
Securities shall cease to be bound by the terms hereof (other than (i)&nbsp;the provisions of Sections
5.04, 5.05, 5.06, 5.07 and 5.08 applicable to such Shareholder with respect to any offering of
Registrable Securities completed before the date such Shareholder ceased to own any Company
Securities and (ii)&nbsp;Sections 7.02, 7.05, 7.06, 7.07 and 7.08).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or
by reason hereof shall be assignable by any party hereto pursuant to any Transfer of Company
Securities or otherwise, except that each of the Investors may Transfer its rights and obligations
hereunder to any Permitted Transferee of the Investors to whom any of the Investors have
Transferred any Company Securities. The Company shall cause each Person who has acquired Company
Securities as required or permitted by the terms of this Agreement or any employment agreement or
share purchase, option, share option or other
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">compensation plan of the Company or any of its Subsidiaries to (unless already bound hereby)
execute and deliver to the Company an agreement to be bound by this Agreement in the form of
Exhibit&nbsp;A hereto and such Person shall thenceforth be a <B>Shareholder</B>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Nothing in this Agreement, expressed or implied, is intended to confer on any Person other
than the parties hereto, and their respective heirs, successors, legal representatives and
permitted assigns, any rights, remedies, obligations or liabilities under or by reason of this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.02. <I>Notices</I>. All notices, requests and other communications to any party shall be
in writing and shall be delivered in person, mailed by certified or registered mail, return receipt
requested, or sent by facsimile transmission,
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if to the Company to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">Concord Medical Services Holdings Limited<BR>
P.O. Box 103<BR>
No.&nbsp;01, 37/F, Landmark<BR>
4028 Jintian Road, Futian District<BR>
Shenzhen, PRC<BR>
Facsimile: 86-755-8221-0429<BR>
Attention: Mr.&nbsp;Steven Sun, President
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with a copy to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">Simpson Thacher &#038; Bartlett LLP<BR>
35<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor, ICBC Tower<BR>
3 Garden Road, Central<BR>
Hong Kong<BR>
Facsimile: 852-2869-7694<BR>
Attention: Leiming Chen
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if to CICC, to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">China International Capital Corporation<BR>
28th Floor, China World Tower 2<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Facsimile: 86-10-6505-3796<BR>
Attention: Ms.&nbsp;Shirley Chen
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if to Carlyle, to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">The Carlyle Group<BR>
2518-2521, South Office Tower<BR>
Beijing Kerry Centre<BR>
No.&nbsp;1, Guang Hua Road<BR>
Chao Yang District<BR>
Beijing 100020<BR>
People&#146;s Republic of China<BR>
Facsimile: 86-10-8529-9877<BR>
Attention: Mr.&nbsp;Feng Xiao
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with a copy to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">Davis Polk &#038; Wardwell LLP<BR>
26<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor, Twin Tower West<BR>
B12, Jian Guo Men Wai Avenue<BR>
Chao Yang District<BR>
Beijing 100022<BR>
People&#146;s Republic of China<BR>
Tel.: 86-10-8567-5000<BR>
Fax: 86-10-8567-5123<BR>
Attention: Show-Mao Chen, Esq.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if to Starr, to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">Starr Investments Cayman II, Inc.<BR>
c/o Starr International Company (Asia) Limited<BR>
Suite&nbsp;1405-7, Two Exchange Square<BR>
8 Connaught Place, Central<BR>
Hong Kong<BR>
Tel.: 852-2905-1166<BR>
Fax: 852-2905-1555<BR>
Attention: Elaine Zong
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with a copy to:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">Skadden, Arps, Slate, Meagher &#038; Flom<BR>
East Wing Office, Level 4<BR>
China World Trade Centre<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Tel.: 86-10-6535-5500<BR>
Fax: 86-10-6505-5522
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-left: 6%; margin-top: 6pt">Attention: Peter X. Huang
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All notices, requests and other communications shall be deemed received on the date of receipt
by the recipient thereof if received prior to 5:00 p.m. in the place of receipt and such day is a
Business Day in the place of receipt. Otherwise, any such notice, request or communication shall
be deemed not to have been received until the next succeeding Business Day in the place of receipt.
Any notice, request or other written communication sent by facsimile transmission shall be
confirmed by certified or registered mail, return receipt requested, posted within one Business
Day, or by personal delivery, whether courier or otherwise, made within two Business Days after the
date of such facsimile transmissions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any Person that becomes a Shareholder shall provide its address and fax number to the Company,
which shall promptly provide such information to each other Shareholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.03. <I>Waiver; Amendment; Termination</I>. (a)&nbsp;No provision of this Agreement may be
waived except by an instrument in writing executed by the party against whom the waiver is to be
effective. No provision of this Agreement may be amended or otherwise modified except by an
instrument in writing executed by the Company with approval of the Board and Shareholders holding
at least 50% of the outstanding Ordinary Shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Notwithstanding anything to the contrary herein, any amendment or modification of any
provision of this Agreement may be effected only with the consent of all Investors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.04. <I>Fees and Expenses</I>. The Company shall pay all out-of-pocket costs and expenses
of the Investors, including the reasonable fees and expenses of counsel, accounting firm and other
advisors and experts and travel expenses, incurred in connection with the preparation of this
Agreement, or any amendment or waiver hereof, and the transactions contemplated hereby and all
matters related hereto. To the extent any Investor has paid such fees and expenses, the Company
shall reimburse such Investor.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.05. <I>Governing Law</I>. This Agreement shall be governed by, and construed in
accordance with, the laws of the State of New York, without regard to the conflicts of laws rules
of such state.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.06. <I>Jurisdiction</I>. The parties hereby agree that any suit, action or proceeding
seeking to enforce any provision of, or based on any matter arising out of or in connection with,
this Agreement or the transactions contemplated hereby shall be brought in the United States
District Court for the Southern District of New York or any New York State court sitting in New
York City, so long as one of such courts shall have subject matter jurisdiction over such suit,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">action or proceeding, and that any case of action arising out of this Agreement shall be
deemed to have arisen from a transaction of business in the State of New York, and each of the
parties hereby irrevocably consents to the jurisdiction of such courts (and of the appropriate
appellate courts therefrom) in any such suit, action or proceeding and irrevocably waives, to the
fullest extent permitted by law, any objection that it may now or hereafter have to the laying of
the venue of any such suit, action or proceeding in any such court or that any such suit, action or
proceeding which is brought in any such court has been brought in an inconvenient form. Process in
any such suit, action or proceeding may be served on any party anywhere in the world, whether
within or without the jurisdiction of any such court. Without limiting the foregoing, each party
agrees that service of process on such party as provided in Section&nbsp;7.02 shall be deemed effective
service of process on such party.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.07. <I>WAIVER OF JURY TRIAL</I>. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY
AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.08. <I>Specific Enforcement</I>. Each party hereto acknowledges that the remedies at law
of the other parties for a breach or threatened breach of this Agreement would be inadequate and,
in recognition of this fact, any party to this Agreement, without posting any bond, and in addition
to all other remedies that may be available, shall be entitled to obtain equitable relief in the
form of specific performance, a temporary restraining order, a temporary or permanent injunction or
any other equitable remedy that may then be available.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.09. <I>Counterparts; Effectiveness</I>. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original, with the same effect as if the
signatures thereto and hereto were upon the same instrument. This Agreement shall become effective
when each party hereto shall have received counterparts hereof signed by all of the other parties
hereto. Until and unless each party has received a counterpart hereof signed by the other party
hereto, this Agreement shall have no effect and no party shall have any right or obligation
hereunder (whether by virtue of any other oral or written agreement or other communication).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.10. <I>Entire Agreement</I>. This Agreement and the Share Purchase Agreement constitute
the entire agreement among the parties hereto and supersede all prior and contemporaneous
agreements and understandings, both oral and written, among the parties hereto with respect to the
subject matter hereof and thereof.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.11. <I>Severability</I>. If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction or other authority to be invalid, void or
unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement
shall remain in full force and effect and shall in no way be affected, impaired or invalidated.
Upon such a determination, the parties shall negotiate in good faith to modify this Agreement so as
to effect the original intent of the parties as closely as possible in an acceptable manner so that
the transactions contemplated hereby be consummated as originally contemplated to the fullest
extent possible.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.12. <I>Joint Drafting. </I>Each party hereto has participated in the drafting of this
Agreement, which each party acknowledges is the result of extensive negotiations between the
parties. If an ambiguity or question of intent or interpretation arises, this Agreement shall be
construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise
favoring or disfavoring any party by virtue of the authorship of any provision.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->54<!-- /Folio -->
</DIV>




<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their
respective authorized officers as of the day and year first above written.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left" nowrap>CONCORD MEDICAL SERVICES <BR>
HOLDINGS LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Cheng Zheng
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Cheng Zheng, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">CZY INVESTMENTS LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Cheng Zheng
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Cheng Zheng&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Yang Jianyu, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left" nowrap>DAKETALA INTERNATIONAL <BR>
INVESTMENT
HOLDINGS LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yang Jianyu
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yang Jianyu&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Steve Sun
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Steven Xiaodi Sun, in his individual <BR>
capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">DRAGON IMAGE INVESTMENT LTD.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Steve Sun
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Steven Xiaodi Sun&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Zhang Jing
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Zhang Jing, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left" nowrap>THOUSAND OCEAN GROUP <BR>LIMITED
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Zhang Jing
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Zhang Jing&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Yap Yaw Kong
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Yap Yaw Kong, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">TOP MOUNT GROUP LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Yap Yaw Kong
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Yap Yaw Kong&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Liu Haifeng
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Liu Haifeng, in his individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ Bona Lau
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Bona Lau, in her individual capacity&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">NOTABLE ENTERPRISE LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Liu Haifeng
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Liu Haifeng&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="46%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">GRAND BEST GROUP LIMITED</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shi Bo Tao</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Shi Bo Tao
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">SINO PRIME INVESTMENTS <BR>
LIMITED</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Sirong Tian</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">LATEK CORPORATION</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Xiaogang Wang</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="46%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">GENIUS ASPECT INVESTMENT LTD.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Peipei Zhang</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">STAR RISING LTD.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;/s/ Wenqing Tan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">HOMERUN TECHNOLOGY LTD.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Liwen Wang</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">SINO FIRST HOLDINGS LTD.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Wenqing Tan</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">JIA INVESTMENT CO., LTD.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Chang Chia-Yue</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="46%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CICC SUN COMPANY LIMITED</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shirley Shiyou Chen</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Shirley Shiyou Chen</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">PERFECT KEY HOLDINGS LIMITED</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shirley Shiyou Chen</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Shirley Shiyou Chen</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="46%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CARLYLE ASIA GROWTH <BR>
PARTNERS III, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP General Partner, L.P., as its<BR>

General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP, Ltd., as the General Partner of <BR>

CAGP General Partner, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">CAGP III CO-INVESTMENT, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP General Partner, L.P., as its <BR>

General Partner</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CAGP, Ltd., as the General Partner of <BR>

CAGP General Partner, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="46%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">STARR INVESTMENTS CAYMAN II, INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael J. Horvath</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Michael J. Horvath</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U>JOINDER TO SHAREHOLDERS&#146; AGREEMENT</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Joinder Agreement (this &#147;<B>Joinder Agreement</B>&#148;) is made as of the date written below by the
undersigned (the &#147;<B>Joining Party</B>&#148;) in accordance with the Amended and Restated Shareholders&#146;
Agreement dated as of October&nbsp;20, 2008 (the &#147;<B>Shareholders&#146; Agreement</B>&#148;) among Concord Medical
Services Holdings Limited, Carlyle Asia Growth Partners III, L.P., CAGP III Co-Investment, L.P.,
CICC Sun Company Limited, Starr Investments Cayman II, Inc. and certain other Persons listed on the
signature pages hereof, as the same may be amended from time to time. Capitalized terms used, but
not defined, herein shall have the meaning ascribed to such terms in the Shareholders&#146; Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Joining Party hereby acknowledges, agrees and confirms that, by its execution of this
Joinder Agreement, the Joining Party shall be deemed to be a party to the Shareholders&#146; Agreement
as of the date hereof and shall have all of the rights and obligations of a &#147;Shareholder&#148;
thereunder as if it had executed the Shareholders&#146; Agreement. The Joining Party hereby ratifies,
as of the date hereof, and agrees to be bound by, all of the terms, provisions and conditions
contained in the Shareholders&#146; Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the undersigned has executed this Joinder Agreement as of the date written
below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Date: ___________ ___, ______
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="46%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">&#091;NAME OF JOINING PARTY&#093;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">Address for Notices:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.10
<SEQUENCE>11
<FILENAME>h03611exv4w10.htm
<DESCRIPTION>EX-4.10
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.10</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.10</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Dated this 10<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>day of November, 2008
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">BY :

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CZY Investments Limited

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">IN FAVOUR OF:

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CICC Sun Company Limited

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Carlyle Asia Growth Partners III, L.P.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CAGP III Co-Investment, L.P.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Starr Investments Cayman II, Inc.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>SHARE CHARGE</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Conyers Dill &#038; Pearman<BR>
Barristers &#038; Attorneys<BR>
Cayman Islands

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>THIS SHARE CHARGE is made on the 10</B><SUP style="font-size: 85%; vertical-align: text-top"><B>th </B></SUP><B>day of November, 2008</B><BR>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>BY:</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CZY Investments Limited, a company incorporated under the laws of the British Virgin Islands
(the &#147;Chargor&#148;);</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>IN FAVOUR OF:</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CICC Sun Company Limited, a company incorporated under the laws of the British Virgin Islands
(&#147;CICC&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Carlyle Asia Growth Partners III, L.P., a limited partnership formed under the laws of the
Cayman Islands (&#147;CAGP&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CAGP III Co-Investment, L.P., a limited partnership formed under the laws of the Cayman Islands
(&#147;CAGP Co-Invest&#148;, and together with CAGP, &#147;Carlyle&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Starr Investments Cayman II, Inc., a company incorporated under the laws of the Cayman Islands
(&#147;Starr&#148;, and together with CICC and Carlyle, the &#147;Chargees&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>WHEREAS:</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By a share subscription agreement dated October&nbsp;10, 2008, as amended on October&nbsp;20, 2008 (the
&#147;Share Subscription Agreement&#148;) made between, inter alia, the Chargor, the Chargees, the Company
(as defined below) and other parties specified therein, the Chargees subscribed for series B
redeemable convertible preferred shares of par value US$0.01 each of the Company (the &#147;Series&nbsp;B
Shares&#148;) on the terms and conditions therein set out.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As security for the obligations of the Chargor under Article&nbsp;3 of the Share Subscription
Agreement, the Chargor has agreed to charge, inter alia, its interest in certain of the shares
beneficially owned by the Chargor in Concord Medical Services Holdings Limited, a company
incorporated under the laws of the Cayman Islands (the &#147;Company&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(C)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company is authorised to issue 5,000,000 shares of a par value of US$0.01 each of which
4,500,000 shares are designated as ordinary shares (the &#147;Ordinary Shares&#148;), 200,000 are series A
redeemable convertible preferred shares (the &#147;Series&nbsp;A Shares&#148;) and 300,000 are Series&nbsp;B Shares.
109,736 Ordinary Shares have been issued to and fully paid by, and are beneficially owned by and
registered in the name of, the Chargor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(D)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to Section&nbsp;7.07(b) of the Share Subscription Agreement, the Chargor shall execute this
Charge in favour of the Chargees and the same is executed by the Chargor in consideration of the
Chargees agreeing to enter into the Share Subscription Agreement and for other good and valuable
consideration (the sufficiency of which the Chargor hereby acknowledges).</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>NOW THIS CHARGE WITNESSES </B>as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>1</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>INTERPRETATION</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Charge, unless the context otherwise requires, the following words and expressions
shall have the following meanings:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="32%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Aggregate Ownership&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Shareholders&#146;
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Business Day&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charge&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means this share charge;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charged Property&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means all of the Charged Shares and all dividends or other
distributions, interest and other moneys paid or payable
after the date hereof in connection therewith and all
interests in and all rights accruing at any time to or in
respect of all or any of the Charged Shares and all and any
other property that may at any time be received or
receivable by or otherwise distributed to the Chargor in
respect of or in substitution for, or in addition to, or in
exchange for, or on account of, any of the foregoing,
including, without limitation, any shares or other
securities resulting from the division, consolidation,
change, conversion or reclassification of any of the
Charged Shares, or the reorganization or amalgamation of
the Company with any other body corporate, or the
occurrence of any event which results in the substitution
or exchange of the Charged Shares;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charged Shares&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means 21,948 Ordinary Shares of the Company registered
in the name of the Chargor as legal and beneficial owner
thereof;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Closing Date&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Controlling Shareholders&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Event of Default&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the failure by the Chargor to satisfy the Secured
Obligations with respect to the Chargees or any of
them;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Fully Diluted&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Group Company&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="32%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Ordinary Shares&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ordinary shares of par value US$0.01 each of the
Company;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Parties&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the parties to this Charge collectively; &#147;Party&#148;
means any one of them;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Pre-Closing Offshore
Acquisition&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in <B>Clause 3.1.1;</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Secured Obligations&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the obligations of the Chargor to deliver
Ordinary Shares to the Chargees or any of them as
specified in <B>Clause 3.1;</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Security Interest&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means any charge, mortgage, pledge, lien, security
interest or other encumbrance;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Security Period&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the period commencing on the date of execution
of this Charge and terminating upon the earliest to
occur of (i)&nbsp;November&nbsp;10, 2014, (ii)&nbsp;the date on which
Aggregate Ownership of Ordinary Shares by each
Chargee is less than 20% of such Chargee&#146;s Initial
Ownership (as defined in the Shareholders&#146; Agreement)
of Ordinary Shares and (iii)&nbsp;the date on which a
Singapore law firm delivers a legal opinion to the
Chargees, in form and substance satisfactory to each
Chargee, with respect to the issuance of Ordinary
Shares to certain Controlling Shareholder Holding
Companies (as defined in the Share Subscription
Agreement) in August&nbsp;2008;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Shareholders&#146; Agreement&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the Amended and Restated Shareholders&#146;
Agreement dated October&nbsp;20, 2008 by and among the
Company, the Chargor, the Chargees and other parties
specified therein; and</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Third-Party Transferee&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in <B>Clause 3.1.1.</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Charge unless the context otherwise requires:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to statutory provisions shall be construed as references to those
provisions as amended or re-enacted or as their application is modified by other
provisions from time to time and shall include references to any provisions of
which they are re-enactments (whether with or without modification);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to clauses and schedules are references to clauses hereof and
schedules hereto; references to sub-clauses or paragraphs are, unless otherwise
stated, references to sub-clauses of the clauses hereof or paragraphs of the
schedule in which the reference appears;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to the singular shall include the plural and vice versa and references to
the masculine shall include the feminine and/or neuter and vice versa; and</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to persons shall include companies, partnerships, associations and
bodies of persons, whether incorporated or unincorporated;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to assets include property, rights and assets of every description;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to any document are to be construed as references to such document as
amended or supplemented from time to time; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the rights, interests and obligations of the Chargees hereunder are joint and are
exercisable by the Chargees collectively.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>2</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>CHARGOR&#146;S REPRESENTATIONS AND WARRANTIES</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Chargor hereby represents and warrants to the Chargees that:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the authorised share capital of the Company consists of the shares described in <B>Recital
(C) </B>hereof and such shares are beneficially owned and registered as described in the said
recital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor is a company duly organised, validly existing and in good standing under the
laws of the British Virgin Islands;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>entry into this Charge by the Chargor and enforcement hereof by the Chargees will not
contravene the terms of any agreement to which the Chargor is bound or to which the
Charged Shares are subject or the memorandum and articles of association of the
Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor is the legal and beneficial owner of all of the Charged Property free from any
Security Interest (other than those created by this Charge) and any options or rights of
pre-emption and the Charged Shares are fully paid up and are not and will not be liable to
any future call, assessment or demand of any sort;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Charged Shares are duly authorised, validly issued and fully paid;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>no moneys or liabilities are outstanding or payable with respect to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor has full power and authority (i)&nbsp;to be the legal and beneficial owner of the
Charged Property, (ii)&nbsp;to execute and deliver this Charge and (iii)&nbsp;to comply with the
provisions of, and perform all its obligations under, this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Charge creates those Security Interests it purports to create and is not liable to be
avoided or otherwise set aside on liquidation, administration or otherwise;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Charge constitutes the Chargor&#146;s legal, valid and binding obligations enforceable
against the Chargor in accordance with its terms except as such enforcement may be
limited by any relevant bankruptcy, insolvency, administration or similar laws affecting
creditors&#146; rights generally;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the entry into and performance by the Chargor of this Charge does not violate (i)&nbsp;any law
or regulation of any governmental or official authority, or (ii)&nbsp;any agreement, contract or</TD>
</TR>





</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B></B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other undertaking to which the Chargor is a party or which is binding upon the Chargor
or any of its assets;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other than registration of this Charge in the register of charges of the Chargor in
accordance with the requirements of the BVI Business Companies Act, 2004, no
authorisation, approval or other action by, and no notice to or filing with, any
governmental authority or regulatory body is required for either the grant by the Chargor
of the Security Interests purported to be created in favour of the Chargee under this
Charge; or the exercise by the Chargee of any rights or remedies in respect of the
Charged Property (whether or not specifically granted or created under this Charge);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all consents, licences, approvals and authorisations required in connection with the entry
into, performance, validity and enforceability of this Charge have been obtained and are
in full force and effect;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor has taken all corporate and other action required to approve its execution,
delivery and performance of this Charge; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company is not a land holding corporation for the purposes of the Land Holding
Companies Share Transfer Tax Law of the Cayman Islands.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>CHARGOR&#146;S COVENANTS</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Chargor hereby covenants with the Chargees:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to discharge all obligations and liabilities specified in Section&nbsp;10.02(c)(vii) of the Share
Subscription Agreement at the following times and in the following manner:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company is required to issue a number of Ordinary Shares to any
person (a &#147;Third-Party Transferee&#148;) pursuant to any arbitral or judicial judgment
on, or settlement of, any claim, dispute or litigation in connection with any
acquisition by any Group Company of any person (other than persons established
under the Laws of the PRC) which has been consummated prior to the Closing
Date (any &#147;Pre-Closing Offshore Acquisition&#148;) and the Controlling Shareholders,
severally and jointly, fail to transfer such number of Ordinary Shares to such
Third-Party Transferee in lieu of and on behalf of such Group Company at the
per share price and on the date set forth in such judgment or settlement, the
Chargor shall, severally and jointly with other Controlling Shareholders, on the
Business Day immediately following such date, transfer free of charge a number
of Ordinary Shares to each Chargee equal to (x)&nbsp;the aggregate number of
Ordinary Shares required to be transferred to such Third-Party Transferee
pursuant to such judgment or settlement <i>multiplied</i> by (y)&nbsp;a ratio, the numerator
of which is the Aggregate Ownership of Ordinary Shares by such Chargee on
such payment date and the denominator of which is the outstanding number of
Ordinary Shares on such payment date, calculated on a Fully-Diluted basis;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company is required to make any payment in cash to any person
pursuant to any arbitral or judicial judgment on, or settlement of, any claim,
dispute or litigation in connection with any Pre-Closing Offshore Acquisition and
the Controlling Shareholders, severally and jointly, fail to make such payment in
lieu of and on behalf of such Group Company by the payment time set forth in</TD>
</TR>





</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>such judgment or settlement, the Chargor shall, severally and jointly with other
Controlling Shareholders, within 10 Business Days following such payment date,
transfer free of charge a number of Ordinary Shares to each Chargee equal to (x)
the amount of such payment in US dollars (based on the &#147;noon buying rate&#148; for
purchases of any currency other than US dollars on such payment date published
by the Federal Reserve Bank of New York) <i>divided</i> by (y)&nbsp;the fair market value
of the Ordinary Shares in US dollars on a per share basis on such payment date as
determined by the Controlling Shareholders and the Chargees by mutual
agreement or if such mutual agreement cannot be reached within 5 Business
Days following such payment date, determined by an independent appraiser
satisfactory to the Chargees within 10 Business Days following such payment
date <I>multiplied </I>by (z)&nbsp;a ratio, the numerator of which is the Aggregate Ownership
of Ordinary Shares by such Chargee on such payment date and the denominator
of which is the outstanding number of Ordinary Shares on such payment date,
calculated on a Fully-Diluted basis; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company incurs or suffers any damages arising out of any claim,
dispute or litigation in connection with any Pre-Closing Offshore Acquisition,
other than those damages described in <B>Clauses 3.1.1 and 3.1.2, </B>and the
Controlling Shareholders, severally and jointly, fail to indemnify the Company
pursuant to Section&nbsp;10.02(c)(vii) of the Share Subscription Agreement by the
date of such incurrence or suffering, the Chargor shall, severally and jointly with
other Controlling Shareholders, transfer free of charge a number of Ordinary
Shares to each Chargee equal to (x)&nbsp;the amount of such damages expressed in US
dollars <i>divided</i> by (y)&nbsp;the fair market value of the Ordinary Shares in US dollars
on a per share basis calculated as set forth above in Clause 3.1.2
<i>multiplied</i> by (z)
a ratio, the numerator of which is the Aggregate Ownership of Ordinary Shares
by such Chargee on such date and the denominator of which is the outstanding
number of Ordinary Shares on such date, calculated on a Fully-Diluted basis, in
each case of sub-clause (x)&nbsp;and (y)&nbsp;as determined by the Controlling
Shareholders and the Chargees by mutual agreement or if such mutual agreement
cannot be reached within 5 Business Days following such payment date,
determined by an independent appraiser satisfactory to the Chargees within 10
Business Days following such date;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the obligations in <B>Clauses 3.1.1, 3.1.2 and 3.1.3 </B>collectively, the &#147;Secured Obligations&#148;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor will on demand of the Chargees and at the expense of the Chargor,
execute and deliver to the Chargees or to such person or persons as the Chargees may
nominate such additional charge or charges of the Charged Property (or any part thereof)
for the purpose of further securing the payment and discharge of all Secured Obligations,
each such additional charge to be in such form as the Chargees may reasonably require;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor shall, on request of the Chargees, provide to the Chargees immediately
on receipt by the Chargor a copy of all notices, written consents, reports, accounts,
circulars and other communications issued by the Company or by any third party in
respect of the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor will not without the prior written consent of the Chargees:</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any person other than the Chargor, the Chargees or any transferee nominated by
the Chargees on enforcement of this Charge to be the registered holder of any of the
Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any variation of the rights attaching to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>take or permit any action which might result in an increase or reduction in the
authorised share capital of the Company or the number of shares that the Company is
authorised to issue or the issued share or share capital of the Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit the Company to be continued to another jurisdiction outside of the Cayman
Islands;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>effect or permit the appointment of any new or further directors or officers of the
Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any scheme of arrangement, merger, amalgamation or other reorganisation
applicable to the Company; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>save in accordance with <B>Clause 8.2, </B>permit any amendment to the memorandum or
articles of association of the Company without prior written consent of the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>4</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>SECURITY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In consideration of the Chargees agreeing to enter into the Share Subscription Agreement
and as a continuing security for the Secured Obligations, the Chargor as legal and
beneficial owner hereby assigns and agrees to assign to the Chargees jointly all benefits
present and future, actual and contingent accruing in respect of the Charged Property and
all the Chargor&#146;s right, title and interest to and in the Charged Property including
(without limitation) all voting and other consensual powers pertaining to the Charged
Shares and hereby charges and agrees to charge in favour of the Chargees jointly all of
its interest in the Charged Property by way of a first fixed charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby agrees to deliver, or cause to be delivered, to the Chargees on the
date hereof:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>duly executed undated share transfers in respect of the Charged Shares in favour
of the Chargees or their nominees in the form set out in Schedule&nbsp;I;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an executed undated irrevocable proxy made in respect of the Charged Shares in
favour of the Chargees in respect of all general meetings of the Company in the
form set out in Schedule&nbsp;II;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all original share certificates representing, and all other documents, title or
evidence of, ownership in relation to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>signed, but undated resolutions of the board of directors of the Company in the
form set out in Schedule&nbsp;III; and</TD>
</TR>




</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an executed undertaking from the Company to register transfers of the Charged
Shares to the Chargees or their nominees in the form set out in Schedule&nbsp;IV dated
as of the date hereof (the &#147;Undertaking&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall be entitled to:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>continue to hold any document delivered to them pursuant to <B>Clauses 4.2.1
through 4.2.5 </B>above until the Charged Shares are released from this Charge and
if, for any reason, they release any such document to the Chargor before such
time, they may by notice to the Chargor require that such document be
redelivered to them and the Chargor shall promptly comply with that requirement
or procure that it is complied with; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>at any time after the Security Interest has become enforceable as provided in
<B>Clause 7</B>, subject to the limitation set out in <B>Clause 7.1</B>, complete any document
delivered to them pursuant to <B>Clauses 4.2.1 through 4.2.5 </B>above in favour of,
and register any Charged Share in the names of the Chargees or such other
person as they shall select, and the Chargor shall promptly take or procure the
taking by all such other persons (including, without limitation, the secretary of
the Company) any other action and execute and deliver to the Chargees any other
document (in form and substance reasonably satisfactory to each Chargee) which
may be reasonably requested by the Chargees in order to enable the Chargees or
such other person as they shall select to be registered as the owner of, or
otherwise obtain legal title to, any Charged Share; this includes procuring that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>those share transfers are duly registered in the shareholder register of the
Company; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>share certificates in the name of the Chargees or such other person as
they shall select are delivered to the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor will deliver, or cause to be delivered, to the Chargees immediately upon the
issue of any further Charged Shares, the items listed in <B>Clauses 4.2.1 through 4.2.5 </B>(if
the documents already provided are not sufficient to cover the further Charged Shares) in
respect of all such further Charged Shares.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby covenants that during the Security Period it will remain the legal and
the beneficial owner of the Charged Property (subject only to the Security Interests
hereby created) and that it will not:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>create or suffer the creation of any Security Interests (other than those created by
this Charge) on or in respect of the whole of any part of the Charged Property or
any of its interest therein; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sell, assign, transfer or otherwise dispose of any of its interest in the Charged
Property (other than with respect to the dividend or distribution payments
described in <B>Clause 5.1.2)</B>; or</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>do or cause or permit to be done anything which may in any way affect,
depreciate, jeopardize or otherwise prejudice the market value of the Charged
Shares or its rights with respect thereto;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>vote in respect of the Charged Shares or receive any dividends or other
distributions paid by the Company in respect of the Charged Shares,
</TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD COLSPAN="3">in any such case without the prior consent in writing of the Chargees.</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Security Period, the Chargor shall remain liable to perform all the obligations
assumed by it in relation to the Charged Property and the Chargees shall be under no
obligation of any kind whatsoever in respect thereof or be under any liability whatsoever
in the event of any failure by the Chargor to perform its obligations in respect thereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the Chargees being satisfied that the Secured Obligations have been
unconditionally and irrevocably paid and discharged in full or upon the expiry of the
Security Period, and following a written request therefor from the Chargor, the Chargees
will, subject to being indemnified to each of their respective reasonable satisfaction for
the costs and expenses incurred by the Chargees in connection therewith, release the
Charged Shares (if any as the case may be) and security constituted by this Charge.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>5</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>DEALINGS WITH CHARGED PROPERTY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Unless and until an Event of Default has occurred:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to exercise all voting and/or consensual powers
pertaining to the Charged Property or any part thereof for all purposes not
inconsistent with the terms of this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to receive and retain any dividends, interest or other
moneys or assets accruing on or in respect of the Charged Property or any part
thereof; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to receive all notices pertaining to the Charged
Shares.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay all calls, instalments or other payments, and shall discharge all
other obligations, which may become due in respect of any of the Charged Property and
in an Event of Default, the Chargees may, if they think fit, make such payments or
discharge such obligations on behalf of the Chargor. Any sums so paid by the Chargees
in respect thereof shall be repayable on demand and, pending such repayment, shall
constitute part of the Secured Obligations.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not have any duty to ensure that any dividends, interest or other
moneys and assets receivable in respect of the Charged Property are duly and punctually
paid, received or collected as and when the same become due and payable or to ensure
that the correct amounts (if any) are paid or received on or in respect of the Charged
Property or to ensure the taking up of any (or any offer of any) stocks, shares, rights,
moneys or other property paid, distributed, accruing or offered at any time by way of</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>redemption bonus, rights, preference, or otherwise on or in respect of, any of the Charged
Property.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby authorises the Chargees to arrange at any time and from time to time
(whether before or after the occurrence of an Event of Default) for the Charged Property
or any part thereof to be registered in the name of the Chargees (or their nominees)
thereupon to be held as so registered subject to the terms of this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>6</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>PRESERVATION OF SECURITY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It is hereby agreed and declared that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the security created by this Charge shall be held by the Chargees as a continuing
security for the payment and discharge of the Secured Obligations and the
security so created shall not be satisfied by any intermediate payment or
satisfaction of any part of the Secured Obligations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargees shall not be bound to enforce any other security before enforcing
the security created by this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>no delay or omission on the part of the Chargees in exercising any right, power or
remedy under this Charge shall impair such right, power or remedy or be
construed as a waiver thereof nor shall any single or partial exercise of any such
right, power or remedy preclude any further exercise thereof or the exercise of
any other right, power or remedy. The rights, powers and remedies herein
provided are cumulative and not exclusive of any rights, powers and remedies
provided by law and may be exercised from time to time and as often as the
Chargees may deem expedient; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any waiver by the Chargees of any terms of this Charge shall only be effective if
given in writing and then only for the purpose and upon the terms for which it is
given.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any settlement or discharge under this Charge between the Chargees and the Chargor
shall be conditional upon no security or payment to the Chargees by the Company or the
Chargor or any other person being avoided or set-aside or ordered to be refunded or
reduced or if the aforesaid security or payment to the Chargees is adversely affected by
virtue of any provision or enactment relating to bankruptcy, insolvency, administration or
liquidation for the time being in force and, if such condition is not satisfied, the liability
of the Chargor under this Charge shall be reinstated or continue and the Chargees shall be
entitled to recover from the Chargor on demand the value of such security or the amount
of any such payment as if such settlement or discharge had not occurred.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The rights of the Chargees under this Charge and the Security Interest hereby constituted
shall not be affected by any act, omission, matter or thing which, but for this provision,
might operate to impair, affect or discharge such rights and security, in whole or in part,
including without limitation, and whether or not known to or discoverable by the
Company, the Chargor, the Chargees or any other person:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any time or waiver granted to or composition with the Company or any other
person;</TD>
</TR>




</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the taking, variation, compromise, renewal or release of or refusal or neglect to
perfect or enforce any rights, remedies or securities against the Company or any
other person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any legal limitation, disability, incapacity or other circumstances relating to the
Company or any other person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any amendment or supplement to the Share Subscription Agreement or any other
document or security;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the dissolution, liquidation, amalgamation, reconstruction or reorganisation of the
Company or any other person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the unenforceability, invalidity or frustration of any obligations of the Company
or any other person under the Share Subscription Agreement or any other
document or security; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any non-observance of any formality or other requirements in respect of any
other instrument or any failure to realise the full value of any other security.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Until the Secured Obligations have been unconditionally and irrevocably satisfied and
discharged in full to the satisfaction of the Chargees or until the expiry of the Security
Period, the Chargor shall not by virtue of any payment made hereunder on account of the
Secured Obligations or by virtue of any enforcement by the Chargees of their rights
under, or the security constituted by, this Charge or by virtue of any relationship between
or transaction involving, the Chargor and the Company (whether such relationship or
transaction shall constitute the Chargor a creditor of the Company, a guarantor of the
obligations of the Company or a party subrogated to the rights of others against the
Company or otherwise howsoever and whether or not such relationship or transaction
shall be related to, or in connection with, the subject matter of this Charge):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any rights of subrogation in relation to any rights, security or moneys
held or received or receivable by the Chargees or any person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any right of contribution from any co-surety liable in respect of the
Second Obligation under any other guarantee, security or agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any right of set-off or counterclaim against the Chargees, the Company
or any such co-surety;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>receive, claim or have the benefit of any payment, distribution, security or
indemnity from the Company or any such co-surety; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>unless so directed by the Chargees (when the Chargor will prove in accordance
with such directions), claim as a creditor of the Company or any such co-surety
in competition with the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall hold in trust for the Chargees and forthwith pay or transfer (as
appropriate) to the Chargees any such payment (including an amount equal to any such
set-off), distribution (other than such dividend or distribution payments described in</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Clause 5.1.2) </B>or benefit of such security, indemnity or claim in fact received by the
Chargor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Until the Secured Obligations have been unconditionally and irrevocably satisfied and
discharged in full to the satisfaction of the Chargees or until the expiry of the Security
Period, the Chargees may at any time keep in a separate account or accounts (without
liability to pay interest thereon) in the name of the Chargees for as long as they may think
fit, any moneys received, recovered or realised under this Charge or under any other
guarantee, security or agreement relating in whole or in part to the Secured Obligations
without being under any intermediate obligation to apply the same or any part thereof in
or towards the discharge of such amount.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>7</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>ENFORCEMENT OF SECURITY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the occurrence of an Event of Default or a demand being made by the Chargees for
the satisfaction of the Secured Obligations with respect to the Chargees or any of them,
the Security Interest hereby constituted shall become immediately enforceable by the
Chargees and the Chargees may, at any time, without further notice to or consultation
with or consent of the Chargor:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>solely and exclusively exercise all voting and/or consensual powers pertaining to
the Charged Property or any part thereof and may exercise such powers in such
manner as the Chargees may think fit;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>receive and retain all dividends, interest, distributions or other moneys or assets
accruing on or in respect of the Charged Property or any part thereof, and any
such dividends, interest, distributions or other moneys or assets received by the
Chargor after such time shall be held in trust by the Chargor for the Chargees and
paid or transferred to the Chargees on demand;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if the Chargees elect to, sell, transfer, grant options over or otherwise dispose of
the Charged Property or any part thereof at such place and in such manner and at
such price or prices as the Chargees may deem fit;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated blank share transfer forms delivered to the Chargees
pursuant to <B>Clause 4.2.1 </B>by dating the same and inserting their names or the
names of their nominees as transferees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated resolutions of the board of directors of the Company
delivered to the Chargees pursuant to <B>Clause 4.2.4 </B>by dating the same and
inserting the names of the transferees and the number of Ordinary Shares to be
transferred; and/or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated irrevocable proxy delivered to the Chargees pursuant to
<B>Clause 4.2.2 </B>by dating the same and inserting the names and addresses of all
Chargees or the names and addresses of their respective nominees;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>PROVIDED THAT notwithstanding any other provision of this Charge, the Chargees may only
exercise their rights under <B>Clauses 7.1.5 and 7.1.6 </B>in respect of such number of Charged
Shares not exceeding the aggregate number of Ordinary Shares that the Chargor has failed to
transfer (the &#147;Default Shares&#148;) to the Chargees or any of them under <B>Clause</B></TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>3.1</B> in satisfaction of the Secured Obligations with respect to all and/or any of the
Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not be obliged to make any enquiry as to the nature or sufficiency of
any payment received by them under this Charge or to make any claim or to take any
action to collect any moneys assigned by this Charge or to enforce any rights or benefits
assigned to the Chargees by this Charge or to which the Chargees may at any time be
entitled hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon any sale by the Chargees of the Charged Property or any part thereof by the
Chargees, the purchaser shall not be bound to see or enquire whether the Chargees&#146;
power of sale has become exercisable in the manner provided in this Charge and the sale
shall be deemed to be within the power of the Chargees, and the receipt of the Chargees
for the purchase money shall effectively discharge the purchaser who shall not be
concerned with the manner of application of the proceeds of sale or be in any way
answerable therefor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Neither the Chargees nor their agents, managers, officers, employees, delegates or
advisers shall be liable for any claim, demand, liability, loss, damage, cost or expense
incurred or arising in connection with the exercise or purported exercise of any rights,
powers and discretions hereunder in the absence of fraud or dishonesty.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not by reason of the taking of possession of the whole or any part of
the Charged Property or any part thereof be liable to account as mortgagee-in-possession
or for anything except actual receipts or be liable for any loss upon realisation or for any
default or omission for which a mortgagee-in-possession might be liable.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>8</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>FURTHER ASSURANCES</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall execute and do all such assurances, acts and things as the Chargees in
their absolute discretion may require for:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>creating, perfecting, protecting or ensuring the priority of the Security Interest
hereby created (or intended to be created);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>preserving or protecting any of the rights of the Chargees under this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ensuring that the security constituted by this Charge and the covenants and
obligations of the Chargor under this Charge shall inure to the benefit of any
assignee of the Chargees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>facilitating the appropriation or realisation of the Charged Property or any part
thereof; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercising any power, authority or discretion vested in the Chargees under this
Charge,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in any such case forthwith upon demand by the Chargees and at the expense of the Chargor.</TD>
</TR>

</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Without limitation to the generality of <B>Clause 8.1, </B>the Chargor covenants with the
Chargees that it will on demand of the Chargees procure any amendment to the
memorandum and articles of association of the Company necessary or, in the opinion of
the Chargees desirable, in order to give effect to the terms of this Charge or any
documents or transactions provided for herein.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>9</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>INDEMNITIES</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor will indemnify and save harmless the Chargees and each agent or attorney
appointed under or pursuant to this Charge from and against any and all expenses, claims,
liabilities, losses, taxes, costs, duties, fees and charges properly and reasonably suffered,
incurred or made by the Chargees or such agent or attorney:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the exercise or purported exercise of any rights, powers or discretions vested in
them pursuant to this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the preservation or enforcement of the Chargees&#146; rights under this Charge or
the priority thereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>on the release of any part of the Charged Property from the security created by
this Charge; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>as a result, directly or indirectly of any breach by the Chargor of any covenant or
other obligation under this Charge.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>and the Chargees or such agent or attorney may retain and pay all sums in respect of the
same out of money received under the powers conferred by this Charge. All amounts
recoverable by the Chargees or such agent or attorney or any of them shall be recoverable
on a full indemnity basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If, under any applicable law or regulation, and whether pursuant to a judgment being
made or registered against the Chargor or the bankruptcy or liquidation of the Chargor or
for any other reason any payment under or in connection with this Charge is made or falls
to be satisfied in a currency (the &#147;Payment Currency&#148;) other than the currency in which
such payment is due under or in connection with this Charge (the &#147;Contractual
Currency&#148;), then to the extent that the amount of such payment actually received by the
Chargees when converted into the Contractual Currency at the rate of exchange, falls
short of the amount due under or in connection with this Charge, the Chargor, as a
separate and independent obligation, shall indemnify and hold harmless the Chargees
against the amount of such shortfall. For the purposes of this clause, &#147;rate of exchange&#148;
means the rate at which the Chargees is able on or about the date of such payment to
purchase the Contractual Currency with the Payment Currency and shall take into
account any premium and other costs of exchange with respect thereto.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>10</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>POWER OF ATTORNEY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor, by way of security and in order more fully to secure the performance of its
obligations hereunder, pursuant to the Power of Attorney Law (1996 Revision) hereby
irrevocably appoints each of the Chargees and the persons deriving title under it jointly
and also severally to be its attorney:</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to execute and complete in favour of the Chargees or its nominees or of any
purchaser any documents which the Chargees may from time to time require for
perfecting their title to or for vesting any of the assets and property hereby
charged or assigned to the Chargees or their nominees or in any purchaser and to
give effectual discharges for payments;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to take and institute on non-payment (if the Chargees in their sole discretion so
decide) all steps and proceedings in the name of the Chargor or of the Chargees
for the recovery of such moneys, property and assets hereby charged and to agree
accounts;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to make allowances and give time or other indulgence to any surety or other
person liable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>otherwise generally to act for it and in its name and on its behalf; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to sign, execute, seal and deliver and otherwise perfect and do any such legal
assignments and other assurances, charges, authorities and documents over the
moneys, property and assets hereby charged, and all such deeds, instruments, acts
and things (including, without limitation, those referred to in <B>Clause 8) </B>which
may be required for the full exercise of all or any of the powers conferred or
which may be deemed proper on or in connection with any of the purposes
aforesaid.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The power hereby conferred shall be a general power of attorney and the Chargor hereby
ratifies and confirms and agrees to ratify and confirm any instrument, act or thing which
any such attorney may execute or do. In relation to the power referred to herein, the
exercise by any of the Chargees of such power shall be conclusive evidence of its right to
exercise the same.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>11</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>EXPENSES</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay to the Chargees on demand all costs, fees and expenses (including
but not limited to legal fees and expenses) and taxes thereon incurred by the Chargees or
for which the Chargees may become liable in connection with:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the negotiation, preparation and execution of this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the preserving or enforcing of, or attempting to preserve or enforce, any of its
rights under this Charge or the priority hereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any variation of, or amendment or supplement to, any of the terms of this Charge;
and/or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any consent or waiver required from the Chargees in relation to this Charge,</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">and in any case referred to in <B>Clauses 11.1.3 and 11.1.4 </B>regardless of whether the same
is actually implemented, completed or granted, as the case may be.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay promptly any stamp, documentary and other like duties and taxes
to which this Charge may be subject or give rise and shall indemnify the Chargees on
demand against any and all liabilities with respect to or resulting from any delay or
omission on the part of the Chargor to pay any such duties or taxes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>12</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>NOTICES</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any notice required to be given hereunder shall be in writing in the English language and shall be
served by sending the same by prepaid recorded post, facsimile or by delivering the same by hand
to the address of the Party or Parties in question as set out below (or such other address as such
Party or Parties shall notify the other Parties of in accordance with this clause). Any notice sent
by post as provided in this clause shall be deemed to have been served five Business Days after
despatch and any notice sent by facsimile as provided in this clause shall be deemed to have been
served at the time of despatch and in proving the service of the same it will be sufficient to prove
in the case of a letter that such letter was properly stamped, addressed and placed in the post; and
in the case of a facsimile that such facsimile was duly despatched to a current facsimile number
of the addressee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><u>Chargor</u><BR>
CZY Investments Limited<BR>
P.O. Box 957<BR>
Offshore Incorporations Centre<BR>
Road Town, Tortola<BR>
British Virgin Islands<BR>
Attention: Mr.&nbsp;Zheng Cheng

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><u>Chargees</u>:<BR>
If to CICC, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">China International Capital Corporation<BR>
28<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>Floor, China World Tower 2<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Fax: 86-10-6505-3796<BR>
Attention: Ms.&nbsp;Shirley Chen

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to Carlyle, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Carlyle Group<BR>
2518-2521, South Office Tower<BR>
Beijing Kerry Centre<BR>
No.&nbsp;1, Guang Hua Road<BR>
Chao Yang District<BR>
Beijing 100020<BR>
People&#146;s Republic of China<BR>
Fax: 86-10-8529-9877<BR>
Attention: Mr.&nbsp;Feng Xiao

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With a copy to:

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Davis Polk &#038; Wardwell LLP<BR>
26<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Floor, Twin Tower West<BR>
B12, Jian Guo Men Wai Avenue<BR>
Chao Yang District<BR>
Beijing 100022<BR>
People&#146;s Republic of China<BR>
Tel: 86-10-8567-5000<BR>
Fax: 86-10-8567-5123<BR>
Attention: Mr.&nbsp;Show-Mao Chen, Esq.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to Starr, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Starr Investments Cayman II, Inc.<BR>
c/o Starr International Company (Asia) Limited<BR>
Suite&nbsp;1405-7, Two Exchange Square<BR>
8 Connaught Place, Central<BR>
Hong Kong<BR>
Tel: 852-2905-1166<BR>
Fax: 852-2905-1555<BR>
Attention: Ms.&nbsp;Elaine Zong

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With a copy to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Skadden, Arps, Slate, Meagher &#038; Flom<BR>
East Wing Office, Level 4<BR>
China World Trade Centre<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Tel: 86-10-6535-5500<BR>
Fax: 86-10-6505-5522<BR>
Attention: Mr.&nbsp;Peter X. Huang

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>13</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>ASSIGNMENTS</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge shall be binding upon and shall inure to the benefit of the Chargor and the
Chargees and each of their respective successors and (subject as hereinafter provided)
assigns and references in this Charge to any of them shall be construed accordingly.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor may not assign or transfer all or any part of its rights and/or obligations
under this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees may not assign or transfer all or any part of its rights or obligations under
this Charge to any assignee or transferee without the consent of the Chargor, such
consent not to be unreasonably withheld, provided that no such consent shall be required
if an Event of Default affecting the Chargor has occurred and is continuing. The
Chargees shall notify the Chargor promptly following any such assignment or transfer.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>14</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>MISCELLANEOUS</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees, at any time and from time to time, may delegate by power of attorney or in
any other manner to any person or persons all or any of the powers, authorities and
discretions which are for the time being exercisable by the Chargees under this Charge in
relation to the Charged Property or any part thereof. Any such delegation may be made
upon such terms and be subject to such regulations as the Chargees may think fit. The
Chargees shall not be in any way liable or responsible to the Chargor for any loss or
damage arising from any act, default, omission or misconduct on the part of any such
delegate provided the Chargees has acted reasonably in selecting such delegate.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If any of the clauses, conditions, covenants or restrictions of this Charge or any deed or
document emanating from it shall be found to be void but would be valid if some part
thereof were deleted or modified, then such clause, condition, covenant or restriction
shall apply with such deletion or modification as may be necessary to make it valid and
effective.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge (together with any documents referred to herein) constitutes the whole
agreement between the Parties relating to its subject matter and no variations hereof shall
be effective unless made in writing and signed by each of the Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The headings in this Charge are inserted for convenience only and shall not affect the
construction of this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge may be executed in counterparts each of which when executed and delivered
shall constitute an original but all such counterparts together shall constitute one and the
same instrument.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To the maximum extent permitted under applicable laws, the Chargor hereby waives any
immunity under the laws applicable to the Chargor, whether characterised as sovereign
immunity or otherwise, from any legal proceedings to enforce this Charge in respect of
itself or its property.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>15</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>LAW AND JURISDICTION</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Charge shall be governed by and construed in accordance with the laws of the Cayman
Islands and the Parties hereby irrevocably submit to the non-exclusive jurisdiction of the courts of
Hong Kong, provided that nothing in this clause shall affect the rights of the Chargees to serve
process in any manner permitted by law or limit the rights of the Chargees to take proceedings
with respect to this Charge against the Chargor in any jurisdiction nor shall the taking of
proceedings with respect to this Charge in any jurisdiction preclude the Chargees from taking
proceedings with respect to this Charge in any other jurisdiction, whether concurrently or not.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Follow</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS whereof the parties hereto have caused this Charge to be duly executed as a Deed
the day and year first before written.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">The Common Seal of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CZY INVESTMENTS LIMITED</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">was hereunto affixed in the</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">presence of:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="40%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Cheng Zheng</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Cheng Zheng</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shi Bo Tao</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Shi Bo Tao</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Witness)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to CZY 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Executed as a deed by</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">For and on behalf of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CICC SUN COMPANY LIMITED</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">in the presence of:-</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="40%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shirley Chen&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Shirley Chen</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="40%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Xin, Jie&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Xin, Jie</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to CZY 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Executed as a deed by</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">For and on behalf of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CARLYLE ASIA GROWTH PARTNERS III, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">in the presence of:-</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">By: CAGP General Partner, L.P., as its General Partner
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">By: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.

</DIV>
<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="40%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Daniel A. D&#146;Aniello</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Executed as a deed by</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">For and on behalf of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CAGP III CO-INVESTMENT, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">in the presence of:-</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">BY: CAGP General Partner, L.P., as its General Partner
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BY: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.

</DIV>
<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="40%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Daniel A. D&#146;Aniello</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to CZY 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Executed as a deed by</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">For and on behalf of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">STARR INVESTMENTS CAYMAN II, INC.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">in the presence of:-</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="40%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Horvath&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Michael Horvath</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to CZY 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>12
<FILENAME>h03611exv4w11.htm
<DESCRIPTION>EX-4.11
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.11</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->


<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.11</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Dated this 10<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>day of November, 2008
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">BY :
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Daketala International Investment Holdings Ltd.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">IN FAVOUR OF: </DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CICC Sun Company Limited

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Carlyle Asia Growth Partners III, L.P.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CAGP III Co-Investment, L.P.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Starr Investments Cayman II, Inc.

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SHARE CHARGE</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Conyers Dill &#038; Pearman<BR>
Barristers &#038; Attorneys<BR>
Cayman Islands
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>THIS SHARE CHARGE is made on the 10</B><SUP style="font-size: 85%; vertical-align: text-top"><B>th </B></SUP><B>day of November, 2008</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>BY:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Daketala International Investment Holdings Ltd., a company incorporated under the laws of the
British Virgin Islands (the &#147;Chargor&#148;);</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>IN FAVOUR OF:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CICC Sun Company Limited, a company incorporated under the laws of the British Virgin Islands
(&#147;CICC&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Carlyle Asia Growth Partners III, L.P., a limited partnership formed under the laws of the
Cayman Islands (&#147;CAGP&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CAGP III Co-Investment, L.P., a limited partnership formed under the laws of the Cayman Islands
(&#147;CAGP Co-Invest&#148;, and together with CAGP, &#147;Carlyle&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Starr Investments Cayman II, Inc., a company incorporated under the laws of the Cayman Islands
(&#147;Starr&#148;, and together with CICC and Carlyle, the &#147;Chargees&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>WHEREAS:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By a share subscription agreement dated October&nbsp;10, 2008, as amended on October&nbsp;20, 2008 (the
&#147;Share Subscription Agreement&#148;) made between, inter alia, the Chargor, the Chargees, the Company
(as defined below) and other parties specified therein, the Chargees subscribed for series B
redeemable convertible preferred shares of par value US$0.01 each of the Company (the &#147;Series&nbsp;B
Shares&#148;) on the terms and conditions therein set out.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As security for the obligations of the Chargor under Article&nbsp;3 of the Share Subscription
Agreement, the Chargor has agreed to charge, inter alia, its interest in certain of the shares
beneficially owned by the Chargor in Concord Medical Services Holdings Limited, a company
incorporated under the laws of the Cayman Islands (the &#147;Company&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(C)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company is authorised to issue 5,000,000 shares of a par value of US$0.01 each of which
4,500,000 shares are designated as ordinary shares (the &#147;Ordinary Shares&#148;), 200,000 are series A
redeemable convertible preferred shares (the &#147;Series&nbsp;A Shares&#148;) and 300,000 are Series&nbsp;B Shares.
84,530 Ordinary Shares have been issued to and fully paid by, and are beneficially owned by and
registered in the name of, the Chargor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(D)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to Section&nbsp;7.07(b) of the Share Subscription Agreement, the Chargor shall execute this
Charge in favour of the Chargees and the same is executed by the Chargor in consideration of the
Chargees agreeing to enter into the Share Subscription Agreement and for other good and valuable
consideration (the sufficiency of which the Chargor hereby acknowledges).</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>NOW THIS CHARGE WITNESSES </B>as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>1</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>INTERPRETATION</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Charge, unless the context otherwise requires, the following words and expressions
shall have the following meanings:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Aggregate Ownership&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Shareholders&#146;
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Business Day&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charge&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means this share charge;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charged Property&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means all of the Charged Shares and all dividends or
other distributions, interest and other moneys paid or
payable after the date hereof in connection therewith
and all interests in and all rights accruing at any time to
or in respect of all or any of the Charged Shares and all
and any other property that may at any time be received
or receivable by or otherwise distributed to the Chargor
in respect of or in substitution for, or in addition to, or
in exchange for, or on account of, any of the foregoing,
including, without limitation, any shares or other
securities resulting from the division, consolidation,
change, conversion or reclassification of any of the
Charged Shares, or the reorganization or amalgamation
of the Company with any other body corporate, or the
occurrence of any event which results in the
substitution or exchange of the Charged Shares;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charged Shares&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means 16,906 Ordinary Shares of the Company
registered in the name of the Chargor as legal and
beneficial owner thereof;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Closing Date&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Controlling Shareholders&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Event of Default&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the failure by the Chargor to satisfy the Secured
Obligations with respect to the Chargees or any of
them;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Fully Diluted&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Group Company&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="96%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Ordinary Shares&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ordinary shares of par value US$0.01 each of the
Company;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Parties&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the parties to this Charge collectively; &#147;Party&#148;
means any one of them;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Pre-Closing Offshore
Acquisition&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in <B>Clause 3.1.1</B>;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Secured Obligations&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the obligations of the Chargor to deliver
Ordinary Shares to the Chargees or any of them as
specified in <B>Clause 3.1</B>;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Security Interest&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means any charge, mortgage, pledge, lien, security
interest or other encumbrance;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Security Period&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the period commencing on the date of execution
of this Charge and terminating upon the earliest to
occur of (i)&nbsp;November&nbsp;10, 2014, (ii)&nbsp;the date on which
Aggregate Ownership of Ordinary Shares by each
Chargee is less than 20% of such Chargee&#146;s Initial
Ownership (as defined in the
Shareholders&#146; Agreement)
of Ordinary Shares and (iii)&nbsp;the date on which a
Singapore law firm delivers a legal opinion to the
Chargees, in form and substance satisfactory to each
Chargee, with respect to the issuance of Ordinary
Shares to certain Controlling Shareholder Holding
Companies (as defined in the Share Subscription
Agreement) in August&nbsp;2008;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" NOWRAP><DIV style="margin-left:0px; text-indent:-0px">&#147;Shareholders&#146; Agreement&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the Amended and Restated Shareholders&#146;
Agreement dated October&nbsp;20, 2008 by and among the
Company, the Chargor, the Chargees and other parties
specified therein; and</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Third-Party Transferee&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in <B>Clause 3.1.1</B>.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Charge unless the context otherwise requires:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to statutory provisions shall be construed as references to those
provisions as amended or re-enacted or as their application is modified by other provisions
from time to time and shall include references to any provisions of which they are
re-enactments (whether with or without modification);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to clauses and schedules are references to clauses hereof and schedules
hereto; references to sub-clauses or paragraphs are, unless otherwise stated, references to
sub-clauses of the clauses hereof or paragraphs of the schedule in which the reference
appears;</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to the singular shall include the plural and vice versa and references to
the masculine shall include the feminine and/or neuter and vice versa; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to persons shall include companies, partnerships, associations and bodies
of persons, whether incorporated or unincorporated;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to assets include property, rights and assets of every description;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to any document are to be construed as references to such document as
amended or supplemented from time to time; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the rights, interests and obligations of the Chargees hereunder are joint and are
exercisable by the Chargees collectively.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>2</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>CHARGOR&#146;S REPRESENTATIONS AND WARRANTIES</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">The Chargor hereby represents and warrants to the Chargees that:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the authorised share capital of the Company consists of the shares described in <B>Recital (C)</B>
hereof and such shares are beneficially owned and registered as described in the said recital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor is a company duly organised, validly existing and in good standing under the laws
of the British Virgin Islands;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>entry into this Charge by the Chargor and enforcement hereof by the Chargees will not
contravene the terms of any agreement to which the Chargor is bound or to which the Charged Shares
are subject or the memorandum and articles of association of the Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor is the legal and beneficial owner of all of the Charged Property free from any
Security Interest (other than those created by this Charge) and any options or rights of
pre-emption and the Charged Shares are fully paid up and are not and will not be liable to any
future call, assessment or demand of any sort;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Charged Shares are duly authorised, validly issued and fully paid;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>no moneys or liabilities are outstanding or payable with respect to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor has full power and authority (i)&nbsp;to be the legal and beneficial owner of the
Charged Property, (ii)&nbsp;to execute and deliver this Charge and (iii)&nbsp;to comply with the provisions
of, and perform all its obligations under, this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Charge creates those Security Interests it purports to create and is not liable to be
avoided or otherwise set aside on liquidation, administration or otherwise;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Charge constitutes the Chargor&#146;s legal, valid and binding obligations enforceable against
the Chargor in accordance with its terms except as such enforcement may be limited by any relevant
bankruptcy, insolvency, administration or similar laws affecting creditors&#146; rights generally;</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the entry into and performance by the Chargor of this Charge does not violate (i)&nbsp;any law or
regulation of any governmental or official authority, or (ii)&nbsp;any agreement, contract or other
undertaking to which the Chargor is a party or which is binding upon the Chargor or any of its
assets;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other than registration of this Charge in the register of charges of the Chargor in accordance
with the requirements of the BVI Business Companies Act, 2004, no authorisation, approval or other
action by, and no notice to or filing with, any governmental authority or regulatory body is
required for either the grant by the Chargor of the Security Interests purported to be created in
favour of the Chargee under this Charge; or the exercise by the Chargee of any rights or remedies
in respect of the Charged Property (whether or not specifically granted or created under this
Charge);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all consents, licences, approvals and authorisations required in connection with the entry
into, performance, validity and enforceability of this Charge have been obtained and are in full
force and effect;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor has taken all corporate and other action required to approve its execution,
delivery and performance of this Charge; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company is not a land holding corporation for the purposes of the Land Holding Companies
Share Transfer Tax Law of the Cayman Islands.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>CHARGOR&#146;S COVENANTS</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">The Chargor hereby covenants with the Chargees:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to discharge all obligations and liabilities specified in Section&nbsp;10.02(c)(vii) of the Share
Subscription Agreement at the following times and in the following manner:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company is required to issue a number of Ordinary Shares to any person (a
&#147;Third-Party Transferee&#148;) pursuant to any arbitral or judicial judgment on, or settlement
of, any claim, dispute or litigation in connection with any acquisition by any Group Company
of any person (other than persons established under the Laws of the PRC) which has been
consummated prior to the Closing Date (any &#147;Pre-Closing Offshore Acquisition&#148;) and the
Controlling Shareholders, severally and jointly, fail to transfer such number of Ordinary
Shares to such Third-Party Transferee in lieu of and on behalf of such Group Company at the
per share price and on the date set forth in such judgment or settlement, the Chargor shall,
severally and jointly with other Controlling Shareholders, on the Business Day immediately
following such date, transfer free of charge a number of Ordinary Shares to each Chargee
equal to (x)&nbsp;the aggregate number of Ordinary Shares required to be transferred to such
Third-Party Transferee pursuant to such judgment or settlement <I>multiplied </I>by (y)&nbsp;a ratio,
the numerator of which is the Aggregate Ownership of Ordinary Shares by such Chargee on such
payment date and the denominator of which is the outstanding number of Ordinary Shares on
such payment date, calculated on a Fully-Diluted basis;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company is required to make any payment in cash to any person pursuant to
any arbitral or judicial judgment on, or settlement of, any claim, dispute or litigation in
connection with any Pre-Closing Offshore Acquisition and</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #textcolor#; background: #bgcolor#">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Controlling Shareholders, severally and jointly, fail to make such payment in
lieu of and on behalf of such Group Company by the payment time set forth in such
judgment or settlement, the Chargor shall, severally and jointly with other
Controlling Shareholders, within 10 Business Days following such payment date,
transfer free of charge a number of Ordinary Shares to each Chargee equal to (x)&nbsp;the
amount of such payment in US dollars (based on the &#147;noon buying rate&#148; for purchases
of any currency other than US dollars on such payment date published by the Federal
Reserve Bank of New York) <I>divided </I>by (y)&nbsp;the fair market value of the Ordinary
Shares in US dollars on a per share basis on such payment date as determined by the
Controlling Shareholders and the Chargees by mutual agreement or if such mutual
agreement cannot be reached within 5 Business Days following such payment date,
determined by an independent appraiser satisfactory to the Chargees within 10
Business Days following such payment date <I>multiplied </I>by (z)&nbsp;a ratio, the numerator
of which is the Aggregate Ownership of Ordinary Shares by such Chargee on such
payment date and the denominator of which is the outstanding number of Ordinary
Shares on such payment date, calculated on a Fully-Diluted basis; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company incurs or suffers any damages arising out of any claim, dispute
or litigation in connection with any Pre-Closing Offshore Acquisition, other than those
damages described in <B>Clauses 3.1.1 and 3.1.2</B>, and the Controlling Shareholders, severally
and jointly, fail to indemnify the Company pursuant to Section&nbsp;10.02(c)(vii) of the Share
Subscription Agreement by the date of such incurrence or suffering, the Chargor shall,
severally and jointly with other Controlling Shareholders, transfer free of charge a number
of Ordinary Shares to each Chargee equal to (x)&nbsp;the amount of such damages expressed in US
dollars <I>divided </I>by (y)&nbsp;the fair market value of the Ordinary Shares in US dollars on a per
share basis calculated as set forth above in Clause 3.1.2 <I>multiplied </I>by (z)&nbsp;a ratio, the
numerator of which is the Aggregate Ownership of Ordinary Shares by such Chargee on such
date and the denominator of which is the outstanding number of Ordinary Shares on such date,
calculated on a Fully-Diluted basis, in each case of sub-clause (x)&nbsp;and (y)&nbsp;as determined by
the Controlling Shareholders and the Chargees by mutual agreement or if such mutual
agreement cannot be reached within 5 Business Days following such payment date, determined
by an independent appraiser satisfactory to the Chargees within 10 Business Days following
such date;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the obligations in <B>Clauses 3.1.1, 3.1.2 and 3.1.3 </B>collectively, the &#147;Secured Obligations&#148;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor will on demand of the Chargees and at the expense of the Chargor, execute and
deliver to the Chargees or to such person or persons as the Chargees may nominate such additional
charge or charges of the Charged Property (or any part thereof) for the purpose of further securing
the payment and discharge of all Secured Obligations, each such additional charge to be in such
form as the Chargees may reasonably require;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor shall, on request of the Chargees, provide to the Chargees immediately on
receipt by the Chargor a copy of all notices, written consents, reports, accounts, circulars and
other communications issued by the Company or by any third party in respect of the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor will not without the prior written consent of the Chargees:</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any person other than the Chargor, the Chargees or any transferee nominated by
the Chargees on enforcement of this Charge to be the registered holder of any of the Charged
Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any variation of the rights attaching to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>take or permit any action which might result in an increase or reduction in the
authorised share capital of the Company or the number of shares that the Company is
authorised to issue or the issued share or share capital of the Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit the Company to be continued to another jurisdiction outside of the Cayman
Islands;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>effect or permit the appointment of any new or further directors or officers of the
Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any scheme of arrangement, merger, amalgamation or other reorganisation
applicable to the Company; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>save in accordance with <B>Clause 8.2, </B>permit any amendment to the memorandum or articles
of association of the Company without prior written consent of the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>4</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>SECURITY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In consideration of the Chargees agreeing to enter into the Share Subscription Agreement and as
a continuing security for the Secured Obligations, the Chargor as legal and beneficial owner hereby
assigns and agrees to assign to the Chargees jointly all benefits present and future, actual and
contingent accruing in respect of the Charged Property and all the Chargor&#146;s right, title and
interest to and in the Charged Property including (without limitation) all voting and other
consensual powers pertaining to the Charged Shares and hereby charges and agrees to charge in
favour of the Chargees jointly all of its interest in the Charged Property by way of a first fixed
charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby agrees to deliver, or cause to be delivered, to the Chargees on the date
hereof:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>duly executed undated share transfers in respect of the Charged Shares in favour of
the Chargees or their nominees in the form set out in Schedule&nbsp;I;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an executed undated irrevocable proxy made in respect of the Charged Shares in favour
of the Chargees in respect of all general meetings of the Company in the form set out in
Schedule&nbsp;II;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all original share certificates representing, and all other documents, title or
evidence of, ownership in relation to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>signed, but undated resolutions of the board of directors of the Company in the form
set out in Schedule&nbsp;III; and</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an executed undertaking from the Company to register transfers of the Charged Shares
to the Chargees or their nominees in the form set out in Schedule&nbsp;IV dated as of the date
hereof (the &#147;Undertaking&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall be entitled to:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>continue to hold any document delivered to them pursuant to <B>Clauses 4.2.1 through
4.2.5 </B>above until the Charged Shares are released from this Charge and if, for any reason,
they release any such document to the Chargor before such time, they may by notice to the
Chargor require that such document be redelivered to them and the Chargor shall promptly
comply with that requirement or procure that it is complied with; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>at any time after the Security Interest has become enforceable as provided in <B>Clause
7</B>, subject to the limitation set out in <B>Clause 7.1</B>, complete any document delivered to them
pursuant to <B>Clauses 4.2.1 through 4.2.5 </B>above in favour of, and register any Charged Share
in the names of the Chargees or such other person as they shall select, and the Chargor
shall promptly take or procure the taking by all such other persons (including, without
limitation, the secretary of the Company) any other action and execute and deliver to the
Chargees any other document (in form and substance reasonably satisfactory to each Chargee)
which may be reasonably requested by the Chargees in order to enable the Chargees or such
other person as they shall select to be registered as the owner of, or otherwise obtain
legal title to, any Charged Share; this includes procuring that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>those share transfers are duly registered in the shareholder register of the
Company; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>share certificates in the name of the Chargees or such other person as they
shall select are delivered to the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor will deliver, or cause to be delivered, to the Chargees immediately upon the issue
of any further Charged Shares, the items listed in <B>Clauses 4.2.1 through 4.2.5 </B>(if the documents
already provided are not sufficient to cover the further Charged Shares) in respect of all such
further Charged Shares.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby covenants that during the Security Period it will remain the legal and the
beneficial owner of the Charged Property (subject only to the Security Interests hereby created)
and that it will not:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>create or suffer the creation of any Security Interests (other than those created by
this Charge) on or in respect of the whole of any part of the Charged Property or any of its
interest therein; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sell, assign, transfer or otherwise dispose of any of its interest in the Charged
Property (other than with respect to the dividend or distribution payments described in
<B>Clause 5.1.2</B>); or</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>do or cause or permit to be done anything which may in any way affect, depreciate,
jeopardize or otherwise prejudice the market value of the Charged Shares or its rights with
respect thereto;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>vote in respect of the Charged Shares or receive any dividends or other distributions
paid by the Company in respect of the Charged Shares,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in any such case without the prior consent in writing of the Chargees.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Security Period, the Chargor shall remain liable to perform all the obligations
assumed by it in relation to the Charged Property and the Chargees shall be under no obligation of
any kind whatsoever in respect thereof or be under any liability whatsoever in the event of any
failure by the Chargor to perform its obligations in respect thereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the Chargees being satisfied that the Secured Obligations have been unconditionally and
irrevocably paid and discharged in full or upon the expiry of the Security Period, and following a
written request therefor from the Chargor, the Chargees will, subject to being indemnified to each
of their respective reasonable satisfaction for the costs and expenses incurred by the Chargees in
connection therewith, release the Charged Shares (if any as the case may be) and security
constituted by this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>5</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>DEALINGS WITH CHARGED PROPERTY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Unless and until an Event of Default has occurred:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to exercise all voting and/or consensual powers
pertaining to the Charged Property or any part thereof for all purposes not inconsistent
with the terms of this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to receive and retain any dividends, interest or other
moneys or assets accruing on or in respect of the Charged Property or any part thereof; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to receive all notices pertaining to the Charged Shares.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay all calls, instalments or other payments, and shall discharge all other
obligations, which may become due in respect of any of the Charged Property and in an Event of
Default, the Chargees may, if they think fit, make such payments or discharge such obligations on
behalf of the Chargor. Any sums so paid by the Chargees in respect thereof shall be repayable on
demand and, pending such repayment, shall constitute part of the Secured Obligations.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not have any duty to ensure that any dividends, interest or other moneys and
assets receivable in respect of the Charged Property are duly and punctually paid, received or
collected as and when the same become due and payable or to ensure that the correct amounts (if
any) are paid or received on or in respect of the Charged Property or to ensure the taking up of
any (or any offer of any) stocks, shares, rights, moneys or other property paid, distributed,
accruing or offered at any time by way of</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #textcolor#; background: #bgcolor#">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>redemption bonus, rights, preference, or otherwise on or in respect of, any of the Charged
Property.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby authorises the Chargees to arrange at any time and from time to time
(whether before or after the occurrence of an Event of Default) for the Charged Property or any
part thereof to be registered in the name of the Chargees (or their nominees) thereupon to be held
as so registered subject to the terms of this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>6</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>PRESERVATION OF SECURITY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It is hereby agreed and declared that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the security created by this Charge shall be held by the Chargees as a continuing
security for the payment and discharge of the Secured Obligations and the security so
created shall not be satisfied by any intermediate payment or satisfaction of any part of
the Secured Obligations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargees shall not be bound to enforce any other security before enforcing the
security created by this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>no delay or omission on the part of the Chargees in exercising any right, power or
remedy under this Charge shall impair such right, power or remedy or be construed as a
waiver thereof nor shall any single or partial exercise of any such right, power or remedy
preclude any further exercise thereof or the exercise of any other right, power or remedy.
The rights, powers and remedies herein provided are cumulative and not exclusive of any
rights, powers and remedies provided by law and may be exercised from time to time and as
often as the Chargees may deem expedient; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any waiver by the Chargees of any terms of this Charge shall only be effective if
given in writing and then only for the purpose and upon the terms for which it is given.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any settlement or discharge under this Charge between the Chargees and the Chargor shall be
conditional upon no security or payment to the Chargees by the Company or the Chargor or any other
person being avoided or set-aside or ordered to be refunded or reduced or if the aforesaid security
or payment to the Chargees is adversely affected by virtue of any provision or enactment relating
to bankruptcy, insolvency, administration or liquidation for the time being in force and, if such
condition is not satisfied, the liability of the Chargor under this Charge shall be reinstated or
continue and the Chargees shall be entitled to recover from the Chargor on demand the value of such
security or the amount of any such payment as if such settlement or discharge had not occurred.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The rights of the Chargees under this Charge and the Security Interest hereby constituted shall
not be affected by any act, omission, matter or thing which, but for this provision, might operate
to impair, affect or discharge such rights and security, in whole or in part, including without
limitation, and whether or not known to or discoverable by the Company, the Chargor, the Chargees
or any other person:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any time or waiver granted to or composition with the Company or any other person;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the taking, variation, compromise, renewal or release of or refusal or neglect to
perfect or enforce any rights, remedies or securities against the Company or any other
person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any legal limitation, disability, incapacity or other circumstances relating to the
Company or any other person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any amendment or supplement to the Share Subscription Agreement or any other document
or security;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the dissolution, liquidation, amalgamation, reconstruction or reorganisation of the
Company or any other person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the unenforceability, invalidity or frustration of any obligations of the Company or
any other person under the Share Subscription Agreement or any other document or security;
or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any non-observance of any formality or other requirements in respect of any other
instrument or any failure to realise the full value of any other security.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Until the Secured Obligations have been unconditionally and irrevocably satisfied and
discharged in full to the satisfaction of the Chargees or until the expiry of the Security Period,
the Chargor shall not by virtue of any payment made hereunder on account of the Secured Obligations
or by virtue of any enforcement by the Chargees of their rights under, or the security constituted
by, this Charge or by virtue of any relationship between or transaction involving, the Chargor and
the Company (whether such relationship or transaction shall constitute the Chargor a creditor of
the Company, a guarantor of the obligations of the Company or a party subrogated to the rights of
others against the Company or otherwise howsoever and whether or not such relationship or
transaction shall be related to, or in connection with, the subject matter of this Charge):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any rights of subrogation in relation to any rights, security or moneys held
or received or receivable by the Chargees or any person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any right of contribution from any co-surety liable in respect of the Second
Obligation under any other guarantee, security or agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any right of set-off or counterclaim against the Chargees, the Company or any
such co-surety;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>receive, claim or have the benefit of any payment, distribution, security or indemnity
from the Company or any such co-surety; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>unless so directed by the Chargees (when the Chargor will prove in accordance with
such directions), claim as a creditor of the Company or any such co-surety in competition
with the Chargees.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">The Chargor shall hold in trust for the Chargees and forthwith pay or transfer (as
appropriate) to the Chargees any such payment (including an amount equal to any such
set-off), distribution (other than such dividend or distribution payments described in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%"><B>Clause 5.1.2) </B>or benefit of such security, indemnity or claim in fact received by the
Chargor.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Until the Secured Obligations have been unconditionally and irrevocably satisfied and
discharged in full to the satisfaction of the Chargees or until the expiry of the Security Period,
the Chargees may at any time keep in a separate account or accounts (without liability to pay
interest thereon) in the name of the Chargees for as long as they may think fit, any moneys
received, recovered or realised under this Charge or under any other guarantee, security or
agreement relating in whole or in part to the Secured Obligations without being under any
intermediate obligation to apply the same or any part thereof in or towards the discharge of such
amount.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>7</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>ENFORCEMENT OF SECURITY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the occurrence of an Event of Default or a demand being made by the Chargees for the
satisfaction of the Secured Obligations with respect to the Chargees or any of them, the Security
Interest hereby constituted shall become immediately enforceable by the Chargees and the Chargees
may, at any time, without further notice to or consultation with or consent of the Chargor:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>solely and exclusively exercise all voting and/or consensual powers pertaining to the
Charged Property or any part thereof and may exercise such powers in such manner as the
Chargees may think fit;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>receive and retain all dividends, interest, distributions or other moneys or assets
accruing on or in respect of the Charged Property or any part thereof, and any such
dividends, interest, distributions or other moneys or assets received by the Chargor after
such time shall be held in trust by the Chargor for the Chargees and paid or transferred to
the Chargees on demand;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if the Chargees elect to, sell, transfer, grant options over or otherwise dispose of
the Charged Property or any part thereof at such place and in such manner and at such price
or prices as the Chargees may deem fit;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated blank share transfer forms delivered to the Chargees pursuant to
<B>Clause 4.2.1 </B>by dating the same and inserting their names or the names of their nominees as
transferees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated resolutions of the board of directors of the Company delivered to
the Chargees pursuant to <B>Clause 4.2.4 </B>by dating the same and inserting the names of the
transferees and the number of Ordinary Shares to be transferred; and/or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated irrevocable proxy delivered to the Chargees pursuant to <B>Clause
4.2.2 </B>by dating the same and inserting the names and addresses of all Chargees or the names
and addresses of their respective nominees;</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">PROVIDED THAT notwithstanding any other provision of this Charge, the Chargees may only
exercise their rights under <B>Clauses 7.1.5 and 7.1.6 </B>in respect of such number of Charged
Shares not exceeding the aggregate number of Ordinary Shares that the Chargor has failed to
transfer (the &#147;Default Shares&#148;) to the Chargees or any of them under <B>Clause</B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%"><B>3.1 </B>in satisfaction of the Secured Obligations with respect to all and/or any of the
Chargees.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not be obliged to make any enquiry as to the nature or sufficiency of any
payment received by them under this Charge or to make any claim or to take any action to collect
any moneys assigned by this Charge or to enforce any rights or benefits assigned to the Chargees by
this Charge or to which the Chargees may at any time be entitled hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon any sale by the Chargees of the Charged Property or any part thereof by the Chargees, the
purchaser shall not be bound to see or enquire whether the Chargees&#146; power of sale has become
exercisable in the manner provided in this Charge and the sale shall be deemed to be within the
power of the Chargees, and the receipt of the Chargees for the purchase money shall effectively
discharge the purchaser who shall not be concerned with the manner of application of the proceeds
of sale or be in any way answerable therefor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Neither the Chargees nor their agents, managers, officers, employees, delegates or advisers
shall be liable for any claim, demand, liability, loss, damage, cost or expense incurred or arising
in connection with the exercise or purported exercise of any rights, powers and discretions
hereunder in the absence of fraud or dishonesty.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not by reason of the taking of possession of the whole or any part of the
Charged Property or any part thereof be liable to account as mortgagee-in-possession or for
anything except actual receipts or be liable for any loss upon realisation or for any default or
omission for which a mortgagee-in-possession might be liable.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>8</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>FURTHER ASSURANCES</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall execute and do all such assurances, acts and things as the Chargees in their
absolute discretion may require for:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>creating, perfecting, protecting or ensuring the priority of the Security Interest
hereby created (or intended to be created);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>preserving or protecting any of the rights of the Chargees under this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ensuring that the security constituted by this Charge and the covenants and
obligations of the Chargor under this Charge shall inure to the benefit of any assignee of
the Chargees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>facilitating the appropriation or realisation of the Charged Property or any part
thereof; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercising any power, authority or discretion vested in the Chargees under this
Charge,</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">in any such case forthwith upon demand by the Chargees and at the expense of the Chargor.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Without limitation to the generality of <B>Clause 8.1</B>, the Chargor covenants with the Chargees
that it will on demand of the Chargees procure any amendment to the memorandum and articles of
association of the Company necessary or, in the opinion of the Chargees desirable, in order to give
effect to the terms of this Charge or any documents or transactions provided for herein.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>9</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>INDEMNITIES</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor will indemnify and save harmless the Chargees and each agent or attorney appointed
under or pursuant to this Charge from and against any and all expenses, claims, liabilities,
losses, taxes, costs, duties, fees and charges properly and reasonably suffered, incurred or made
by the Chargees or such agent or attorney:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the exercise or purported exercise of any rights, powers or discretions vested in
them pursuant to this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the preservation or enforcement of the Chargees&#146; rights under this Charge or the
priority thereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>on the release of any part of the Charged Property from the security created by this
Charge; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>as a result, directly or indirectly of any breach by the Chargor of any covenant or
other obligation under this Charge.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>and the Chargees or such agent or attorney may retain and pay all sums in respect of the
same out of money received under the powers conferred by this Charge. All amounts
recoverable by the Chargees or such agent or attorney or any of them shall be recoverable on
a full indemnity basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If, under any applicable law or regulation, and whether pursuant to a judgment being made or
registered against the Chargor or the bankruptcy or liquidation of the Chargor or for any other
reason any payment under or in connection with this Charge is made or falls to be satisfied in a
currency (the &#147;Payment Currency&#148;) other than the currency in which such payment is due under or in
connection with this Charge (the &#147;Contractual Currency&#148;), then to the extent that the amount of
such payment actually received by the Chargees when converted into the Contractual Currency at the
rate of exchange, falls short of the amount due under or in connection with this Charge, the
Chargor, as a separate and independent obligation, shall indemnify and hold harmless the Chargees
against the amount of such shortfall. For the purposes of this clause, &#147;rate of exchange&#148; means the
rate at which the Chargees is able on or about the date of such payment to purchase the Contractual
Currency with the Payment Currency and shall take into account any premium and other costs of
exchange with respect thereto.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>10</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>POWER OF ATTORNEY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor, by way of security and in order more fully to secure the performance of its
obligations hereunder, pursuant to the Power of Attorney Law (1996 Revision) hereby irrevocably
appoints each of the Chargees and the persons deriving title under it jointly and also severally to
be its attorney:</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to execute and complete in favour of the Chargees or its nominees or of any purchaser
any documents which the Chargees may from time to time require for perfecting their title to
or for vesting any of the assets and property hereby charged or assigned to the Chargees or
their nominees or in any purchaser and to give effectual discharges for payments;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to take and institute on non-payment (if the Chargees in their sole discretion so
decide) all steps and proceedings in the name of the Chargor or of the Chargees for the
recovery of such moneys, property and assets hereby charged and to agree accounts;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to make allowances and give time or other indulgence to any surety or other person
liable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>otherwise generally to act for it and in its name and on its behalf; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to sign, execute, seal and deliver and otherwise perfect and do any such legal
assignments and other assurances, charges, authorities and documents over the moneys,
property and assets hereby charged, and all such deeds, instruments, acts and things
(including, without limitation, those referred to in <B>Clause 8</B>) which may be required for the
full exercise of all or any of the powers conferred or which may be deemed proper on or in
connection with any of the purposes aforesaid.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The power hereby conferred shall be a general power of attorney and the Chargor hereby
ratifies and confirms and agrees to ratify and confirm any instrument, act or thing which any such
attorney may execute or do. In relation to the power referred to herein, the exercise by any of
the Chargees of such power shall be conclusive evidence of its right to exercise the same.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>11</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>EXPENSES</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay to the Chargees on demand all costs, fees and expenses (including but
not limited to legal fees and expenses) and taxes thereon incurred by the Chargees or for which
the Chargees may become liable in connection with:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the negotiation, preparation and execution of this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the preserving or enforcing of, or attempting to preserve or enforce, any of its
rights under this Charge or the priority hereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any variation of, or amendment or supplement to, any of the terms of this Charge;
and/or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any consent or waiver required from the Chargees in relation to this Charge,</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">and in any case referred to in <B>Clauses 11.1.3 and 11.1.4 </B>regardless of whether the same is
actually implemented, completed or granted, as the case may be.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay promptly any stamp, documentary and other like duties and taxes to which
this Charge may be subject or give rise and shall indemnify the Chargees on demand against any and
all liabilities with respect to or resulting from any delay or omission on the part of the Chargor
to pay any such duties or taxes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>12</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>NOTICES</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any notice required to be given hereunder shall be in writing in the English language and shall be
served by sending the same by prepaid recorded post, facsimile or by delivering the same by hand to
the address of the Party or Parties in question as set out below (or such other address as such
Party or Parties shall notify the other Parties of in accordance with this clause). Any notice sent
by post as provided in this clause shall be deemed to have been served five Business Days after
despatch and any notice sent by facsimile as provided in this clause shall be deemed to have been
served at the time of despatch and in proving the service of the same it will be sufficient to
prove in the case of a letter that such letter was properly stamped, addressed and placed in the
post; and in the case of a facsimile that such facsimile was duly despatched to a current facsimile
number of the addressee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><u>Chargor</u><BR>
Daketala International Investment Holdings Ltd.<BR>
P.O. Box 957<BR>
Offshore Incorporations Centre<BR>
Road Town, Tortola<BR>
British Virgin Islands<BR>
Attention: Mr.&nbsp;Jianyu Yang

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><u>Chargees</u>:<BR>
If to CICC, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">China International Capital Corporation<BR>
28<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>Floor, China World Tower 2<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Fax: 86-10-6505-3796<BR>
Attention: Ms.&nbsp;Shirley Chen

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to Carlyle, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Carlyle Group<BR>
2518-2521, South Office Tower<BR>
Beijing Kerry Centre<BR>
No.&nbsp;1, Guang Hua Road<BR>
Chao Yang District<BR>
Beijing 100020<BR>
People&#146;s Republic of China<BR>
Fax: 86-10-8529-9877<BR>
Attention: Mr.&nbsp;Feng Xiao

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With a copy to:

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Davis Polk &#038; Wardwell LLP<BR>
26<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>Floor, Twin Tower West<BR>
B12, Jian Guo Men Wai Avenue<BR>
Chao Yang District<BR>
Beijing 100022<BR>
People&#146;s Republic of China<BR>
Tel: 86-10-8567-5000<BR>
Fax: 86-10-8567-5123<BR>
Attention: Mr.&nbsp;Show-Mao Chen, Esq.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to Starr, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Starr Investments Cayman II, Inc.<BR>
c/o Starr International Company (Asia) Limited<BR>
Suite&nbsp;1405-7, Two Exchange Square<BR>
8 Connaught Place, Central<BR>
Hong Kong<BR>
Tel: 852-2905-1166<BR>
Fax: 852-2905-1555<BR>
Attention: Ms.&nbsp;Elaine Zong

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With a copy to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Skadden, Arps, Slate, Meagher &#038; Flom<BR>
East Wing Office, Level 4<BR>
China World Trade Centre<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Tel: 86-10-6535-5500<BR>
Fax: 86-10-6505-5522<BR>
Attention: Mr.&nbsp;Peter X. Huang

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>13</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>ASSIGNMENTS</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge shall be binding upon and shall inure to the benefit of the Chargor and the
Chargees and each of their respective successors and (subject as hereinafter provided) assigns and
references in this Charge to any of them shall be construed accordingly.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor may not assign or transfer all or any part of its rights and/or obligations under
this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees may not assign or transfer all or any part of its rights or obligations under
this Charge to any assignee or transferee without the consent of the Chargor, such consent not to
be unreasonably withheld, provided that no such consent shall be required if an Event of Default
affecting the Chargor has occurred and is continuing. The Chargees shall notify the Chargor
promptly following any such assignment or transfer.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>14</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>MISCELLANEOUS</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees, at any time and from time to time, may delegate by power of attorney or in any
other manner to any person or persons all or any of the powers, authorities and discretions which
are for the time being exercisable by the Chargees under this Charge in relation to the Charged
Property or any part thereof. Any such delegation may be made upon such terms and be subject to
such regulations as the Chargees may think fit. The
Chargees shall not be in any way liable or responsible to the Chargor for any loss or damage
arising from any act, default, omission or misconduct on the part of any such delegate
provided the Chargees has acted reasonably in selecting such delegate.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If any of the clauses, conditions, covenants or restrictions of this Charge or any deed or
document emanating from it shall be found to be void but would be valid if some part thereof were
deleted or modified, then such clause, condition, covenant or restriction shall apply with such
deletion or modification as may be necessary to make it valid and effective.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge (together with any documents referred to herein) constitutes the whole agreement
between the Parties relating to its subject matter and no variations hereof shall be effective
unless made in writing and signed by each of the Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The headings in this Charge are inserted for convenience only and shall not affect the
construction of this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge may be executed in counterparts each of which when executed and delivered shall
constitute an original but all such counterparts together shall constitute one and the same
instrument.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To the maximum extent permitted under applicable laws, the Chargor hereby waives any immunity
under the laws applicable to the Chargor, whether characterised as sovereign immunity or otherwise,
from any legal proceedings to enforce this Charge in respect of itself or its property.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>15</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>LAW AND JURISDICTION</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Charge shall be governed by and construed in accordance with the laws of the Cayman Islands
and the Parties hereby irrevocably submit to the non-exclusive jurisdiction of the courts of Hong
Kong, provided that nothing in this clause shall affect the rights of the Chargees to serve process
in any manner permitted by law or limit the rights of the Chargees to take proceedings with respect
to this Charge against the Chargor in any jurisdiction nor shall the taking of proceedings with
respect to this Charge in any jurisdiction preclude the Chargees from taking proceedings with
respect to this Charge in any other jurisdiction, whether concurrently or not.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Follow</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS whereof the parties hereto have caused this Charge to be duly executed as a Deed the day
and year first before written.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">The Common Seal of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
</TR>
<TR valign="bottom">
    <TD nowrap><DIV style="margin-left:15px; text-indent:-15px">DAKETALA INTERNATIONAL INVESTMENT HOLDINGS LTD.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">was hereunto affixed in the</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">presence of:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="40%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yang Jianyu</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Yang Jianyu</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shi Bo Tao</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Shi Bo Tao</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Witness)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Daketala 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Executed as a deed by</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">For and on behalf of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CICC SUN COMPANY LIMITED</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">in the presence of:-</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="40%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shirley Chen&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Shirley Chen</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="40%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Xin, Jie&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Xin, Jie</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Daketala 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Executed as a deed by</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">For and on behalf of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CARLYLE ASIA GROWTH PARTNERS III, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">in the presence of:-</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">By: CAGP General Partner, L.P., as its General Partner
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">By: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.

</DIV>
<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="40%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Daniel A. D&#146;Aniello</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Executed as a deed by</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">For and on behalf of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CAGP III CO-INVESTMENT, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">in the presence of:-</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BY: CAGP General Partner, L.P., as its General Partner

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BY: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.

</DIV>
<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="40%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Daniel A. D&#146;Aniello</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Daketala 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Executed as a deed by</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">For and on behalf of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">STARR INVESTMENTS CAYMAN II, INC.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">in the presence of:-</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="40%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Horvath</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Michael Horvath</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Daketala 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.12
<SEQUENCE>13
<FILENAME>h03611exv4w12.htm
<DESCRIPTION>EX-4.12
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.12</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.12</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Dated this 10<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>day of November, 2008

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">BY:

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Dragon Image Investment Ltd.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">IN FAVOUR OF:

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CICC Sun Company Limited

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Carlyle Asia Growth Partners III, L.P.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CAGP III Co-Investment, L.P.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Starr Investments Cayman II, Inc.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>SHARE CHARGE</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Conyers Dill &#038; Pearman<BR>
Barristers &#038; Attorneys<BR>
Cayman Islands

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>THIS SHARE CHARGE is made on the 10</B><SUP style="font-size: 85%; vertical-align: text-top"><B>th </B></SUP><B>day of November, 2008</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>BY:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dragon Image Investment Ltd., a company incorporated under the laws of the British Virgin
Islands (the &#147;Chargor&#148;);</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>IN FAVOUR OF:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CICC Sun Company Limited, a company incorporated under the laws of the British Virgin Islands
(&#147;CICC&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Carlyle Asia Growth Partners III, L.P., a limited partnership formed under the laws of the
Cayman Islands (&#147;CAGP&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CAGP III Co-Investment, L.P., a limited partnership formed under the laws of the Cayman Islands
(&#147;CAGP Co-Invest&#148;, and together with CAGP, &#147;Carlyle&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Starr Investments Cayman II, Inc., a company incorporated under the laws of the Cayman Islands
(&#147;Starr&#148;, and together with CICC and Carlyle, the &#147;Chargees&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>WHEREAS:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By a share subscription agreement dated October&nbsp;10, 2008, as amended on October&nbsp;20, 2008 (the
&#147;Share Subscription Agreement&#148;) made between, inter alia, the Chargor, the Chargees, the Company
(as defined below) and other parties specified therein, the Chargees subscribed for series B
redeemable convertible preferred shares of par value US$0.01 each of the Company (the &#147;Series&nbsp;B
Shares&#148;) on the terms and conditions therein set out.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As security for the obligations of the Chargor under Article&nbsp;3 of the Share Subscription
Agreement, the Chargor has agreed to charge, inter alia, its interest in certain of the shares
beneficially owned by the Chargor in Concord Medical Services Holdings Limited, a company
incorporated under the laws of the Cayman Islands (the &#147;Company&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(C)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company is authorised to issue 5,000,000 shares of a par value of US$0.01 each of which
4,500,000 shares are designated as ordinary shares (the &#147;Ordinary Shares&#148;), 200,000 are series A
redeemable convertible preferred shares (the &#147;Series&nbsp;A Shares&#148;) and 300,000 are Series&nbsp;B Shares.
54,024 Ordinary Shares have been issued to and fully paid by, and are beneficially owned by and
registered in the name of, the Chargor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(D)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to Section&nbsp;7.07(b) of the Share Subscription Agreement, the Chargor shall execute this
Charge in favour of the Chargees and the same is executed by the Chargor in consideration of the
Chargees agreeing to enter into the Share Subscription Agreement and for other good and valuable
consideration (the sufficiency of which the Chargor hereby acknowledges).</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>NOW THIS CHARGE WITNESSES </B>as follows:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>1</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>INTERPRETATION</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Charge, unless the context otherwise requires, the following words and expressions
shall have the following meanings:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="75%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Aggregate Ownership&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Shareholders&#146; Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Business Day&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charge&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means this share charge;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charged Property&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means all of the Charged Shares and all dividends or
other distributions, interest and other moneys paid or
payable after the date hereof in connection therewith
and all interests in and all rights accruing at any time
to or in respect of all or any of the Charged Shares and
all and any other property that may at any time be
received or receivable by or otherwise distributed to
the Chargor in respect of or in substitution for, or in
addition to, or in exchange for, or on account of, any
of the foregoing, including, without limitation, any
shares or other securities resulting from the division,
consolidation, change, conversion or reclassification of
any of the Charged Shares, or the reorganization or
amalgamation of the Company with any other body
corporate, or the occurrence of any event which results
in the substitution or exchange of the Charged Shares;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charged Shares&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means 10,805 Ordinary Shares of the Company registered
in the name of the Chargor as legal and beneficial owner
thereof;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Closing Date&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Controlling Shareholders&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Event of Default&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the failure by the Chargor to satisfy the Secured
Obligations with respect to the Chargees or any of them;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Fully Diluted&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Group Company&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="75%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Ordinary Shares&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ordinary shares of par value US$0.01 each of the
Company;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Parties&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the parties to this Charge collectively; &#147;Party&#148;
means any one of them;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Pre-Closing Offshore <BR>
Acquisition&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in <B>Clause 3.1.1</B>;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Secured Obligations&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the obligations of the Chargor to deliver
Ordinary Shares to the Chargees or any of them as
specified in <B>Clause 3.1</B>;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Security Interest&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means any charge, mortgage, pledge, lien, security
interest or other encumbrance;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Security Period&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the period commencing on the date of execution
of this Charge and terminating upon the earliest to
occur of (i)&nbsp;November&nbsp;10, 2014, (ii)&nbsp;the date on which
Aggregate Ownership of Ordinary Shares by each
Chargee is less than 20% of such Chargee&#146;s Initial
Ownership (as defined in the Shareholders&#146; Agreement)
of Ordinary Shares and (iii)&nbsp;the date on which a
Singapore law firm delivers a legal opinion to the
Chargees, in form and substance satisfactory to each
Chargee, with respect to the issuance of Ordinary
Shares to certain Controlling Shareholder Holding
Companies (as defined in the Share Subscription
Agreement) in August&nbsp;2008;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Shareholders&#146; Agreement&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the Amended and Restated Shareholders&#146;
Agreement dated October&nbsp;20, 2008 by and among the
Company, the Chargor, the Chargees and other parties
specified therein; and</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Third-Party Transferee&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in <B>Clause 3.1.1</B>.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Charge unless the context otherwise requires:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to statutory provisions shall be construed as references to those
provisions as amended or re-enacted or as their application is modified by other
provisions from time to time and shall include references to any provisions of which
they are re-enactments (whether with or without modification);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to clauses and schedules are references to clauses hereof and
schedules hereto; references to sub-clauses or paragraphs are, unless otherwise stated,
references to sub-clauses of the clauses hereof or paragraphs of the schedule in which
the reference appears;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to the singular shall include the plural and vice versa and references
to the masculine shall include the feminine and/or neuter and vice versa; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to persons shall include companies, partnerships, associations and
bodies of persons, whether incorporated or unincorporated;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to assets include property, rights and assets of every description;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to any document are to be construed as references to such document as
amended or supplemented from time to time; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the rights, interests and obligations of the Chargees hereunder are joint and are
exercisable by the Chargees collectively.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>2</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>CHARGOR&#146;S REPRESENTATIONS AND WARRANTIES</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Chargor hereby represents and warrants to the Chargees that:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the authorised share capital of the Company consists of the shares described in <B>Recital (C)</B>
hereof and such shares are beneficially owned and registered as described in the said recital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor is a company duly organised, validly existing and in good standing under the laws
of the British Virgin Islands;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>entry into this Charge by the Chargor and enforcement hereof by the Chargees will not
contravene the terms of any agreement to which the Chargor is bound or to which the Charged Shares
are subject or the memorandum and articles of association of the Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor is the legal and beneficial owner of all of the Charged Property free from any
Security Interest (other than those created by this Charge) and any options or rights of
pre-emption and the Charged Shares are fully paid up and are not and will not be liable to any
future call, assessment or demand of any sort;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Charged Shares are duly authorised, validly issued and fully paid;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>no moneys or liabilities are outstanding or payable with respect to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor has full power and authority (i)&nbsp;to be the legal and beneficial owner of the
Charged Property, (ii)&nbsp;to execute and deliver this Charge and (iii)&nbsp;to comply with the provisions
of, and perform all its obligations under, this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Charge creates those Security Interests it purports to create and is not liable to be
avoided or otherwise set aside on liquidation, administration or otherwise;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Charge constitutes the Chargor&#146;s legal, valid and binding obligations enforceable against
the Chargor in accordance with its terms except as such enforcement may be limited by any relevant
bankruptcy, insolvency, administration or similar laws affecting creditors&#146; rights generally;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the entry into and performance by the Chargor of this Charge does not violate (i)&nbsp;any law or
regulation of any governmental or official authority, or (ii)&nbsp;any agreement, contract or other
undertaking to which the Chargor is a party or which is binding upon the Chargor or any of its
assets;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other than registration of this Charge in the register of charges of the Chargor in accordance
with the requirements of the BVI Business Companies Act, 2004, no authorisation, approval or other
action by, and no notice to or filing with, any governmental authority or regulatory body is
required for either the grant by the Chargor of the Security Interests purported to be created in
favour of the Chargee under this Charge; or the exercise by the Chargee of any rights or remedies
in respect of the Charged Property (whether or not specifically granted or created under this
Charge);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all consents, licences, approvals and authorisations required in connection with the entry
into, performance, validity and enforceability of this Charge have been obtained and are in full
force and effect;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor has taken all corporate and other action required to approve its execution,
delivery and performance of this Charge; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company is not a land holding corporation for the purposes of the Land Holding Companies
Share Transfer Tax Law of the Cayman Islands.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>CHARGOR&#146;S COVENANTS</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Chargor hereby covenants with the Chargees:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to discharge all obligations and liabilities specified in Section&nbsp;10.02(c)(vii) of the Share
Subscription Agreement at the following times and in the following manner:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company is required to issue a number of Ordinary Shares to any person
(a &#147;Third-Party Transferee&#148;) pursuant to any arbitral or judicial judgment on, or
settlement of, any claim, dispute or litigation in connection with any acquisition by any
Group Company of any person (other than persons established under the Laws of the PRC)
which has been consummated prior to the Closing Date (any &#147;Pre-Closing Offshore
Acquisition&#148;) and the Controlling Shareholders, severally and jointly, fail to transfer
such number of Ordinary Shares to such Third-Party Transferee in lieu of and on behalf of
such Group Company at the per share price and on the date set forth in such judgment or
settlement, the Chargor shall, severally and jointly with other Controlling Shareholders,
on the Business Day immediately following such date, transfer free of charge a number of
Ordinary Shares to each Chargee equal to (x)&nbsp;the aggregate number of Ordinary Shares
required to be transferred to such Third-Party Transferee pursuant to such judgment or
settlement <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which is the Aggregate Ownership of
Ordinary Shares by such Chargee on such payment date and the denominator of which is the
outstanding number of Ordinary Shares on such payment date, calculated on a Fully-Diluted
basis;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company is required to make any payment in cash to any person pursuant
to any arbitral or judicial judgment on, or settlement of, any claim,</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>dispute or litigation in connection with any Pre-Closing Offshore Acquisition and
the Controlling Shareholders, severally and jointly, fail to make such payment in
lieu of and on behalf of such Group Company by the payment time set forth in such
judgment or settlement, the Chargor shall, severally and jointly with other
Controlling Shareholders, within 10 Business Days following such payment date,
transfer free of charge a number of Ordinary Shares to each Chargee equal to (x)
the amount of such payment in US dollars (based on the &#147;noon buying rate&#148; for
purchases of any currency other than US dollars on such payment date published by
the Federal Reserve Bank of New York) <I>divided </I>by (y)&nbsp;the fair market value of the
Ordinary Shares in US dollars on a per share basis on such payment date as
determined by the Controlling Shareholders and the Chargees by mutual agreement or
if such mutual agreement cannot be reached within 5 Business Days following such
payment date, determined by an independent appraiser satisfactory to the Chargees
within 10 Business Days following such payment date <I>multiplied </I>by (z)&nbsp;a ratio, the
numerator of which is the Aggregate Ownership of Ordinary Shares by such Chargee on
such payment date and the denominator of which is the outstanding number of
Ordinary Shares on such payment date, calculated on a Fully-Diluted basis; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company incurs or suffers any damages arising out of any claim, dispute
or litigation in connection with any Pre-Closing Offshore Acquisition, other than those
damages described in <B>Clauses 3.1.1 and 3.1.2</B>, and the Controlling Shareholders, severally
and jointly, fail to indemnify the Company pursuant to Section&nbsp;10.02(c)(vii) of the Share
Subscription Agreement by the date of such incurrence or suffering, the Chargor shall,
severally and jointly with other Controlling Shareholders, transfer free of charge a number
of Ordinary Shares to each Chargee equal to (x)&nbsp;the amount of such damages expressed in US
dollars <I>divided </I>by (y)&nbsp;the fair market value of the Ordinary Shares in US dollars on a per
share basis calculated as set forth above in Clause 3.1.2 <I>multiplied </I>by (z)&nbsp;a ratio, the
numerator of which is the Aggregate Ownership of Ordinary Shares by such Chargee on such
date and the denominator of which is the outstanding number of Ordinary Shares on such
date, calculated on a Fully-Diluted basis, in each case of sub-clause (x)&nbsp;and (y)&nbsp;as
determined by the Controlling Shareholders and the Chargees by mutual agreement or if such
mutual agreement cannot be reached within 5 Business Days following such payment date,
determined by an independent appraiser satisfactory to the Chargees within 10 Business Days
following such date;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the obligations in <B>Clauses 3.1.1, 3.1.2 and 3.1.3 </B>collectively, the &#147;Secured Obligations&#148;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor will on demand of the Chargees and at the expense of the Chargor, execute and
deliver to the Chargees or to such person or persons as the Chargees may nominate such additional
charge or charges of the Charged Property (or any part thereof) for the purpose of further securing
the payment and discharge of all Secured Obligations, each such additional charge to be in such
form as the Chargees may reasonably require;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor shall, on request of the Chargees, provide to the Chargees immediately on
receipt by the Chargor a copy of all notices, written consents, reports, accounts, circulars and
other communications issued by the Company or by any third party in respect of the Charged Shares;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor will not without the prior written consent of the Chargees:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any person other than the Chargor, the Chargees or any transferee nominated by
the Chargees on enforcement of this Charge to be the registered holder of any of the
Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any variation of the rights attaching to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>take or permit any action which might result in an increase or reduction in the
authorised share capital of the Company or the number of shares that the Company is
authorised to issue or the issued share or share capital of the Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit the Company to be continued to another jurisdiction outside of the Cayman
Islands;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>effect or permit the appointment of any new or further directors or officers of the
Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any scheme of arrangement, merger, amalgamation or other reorganisation
applicable to the Company; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>save in accordance with <B>Clause 8.2, </B>permit any amendment to the memorandum or
articles of association of the Company without prior written consent of the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>4</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>SECURITY</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In consideration of the Chargees agreeing to enter into the Share Subscription Agreement and as
a continuing security for the Secured Obligations, the Chargor as legal and beneficial owner hereby
assigns and agrees to assign to the Chargees jointly all benefits present and future, actual and
contingent accruing in respect of the Charged Property and all the Chargor&#146;s right, title and
interest to and in the Charged Property including (without limitation) all voting and other
consensual powers pertaining to the Charged Shares and hereby charges and agrees to charge in
favour of the Chargees jointly all of its interest in the Charged Property by way of a first fixed
charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby agrees to deliver, or cause to be delivered, to the Chargees on the date
hereof:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>duly executed undated share transfers in respect of the Charged Shares in favour of
the Chargees or their nominees in the form set out in Schedule&nbsp;I;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an executed undated irrevocable proxy made in respect of the Charged Shares in favour
of the Chargees in respect of all general meetings of the Company in the form set out in
Schedule&nbsp;II;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all original share certificates representing, and all other documents, title or
evidence of, ownership in relation to the Charged Shares;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>signed, but undated resolutions of the board of directors of the Company in the form
set out in Schedule&nbsp;III; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an executed undertaking from the Company to register transfers of the Charged Shares
to the Chargees or their nominees in the form set out in Schedule&nbsp;IV dated as of the date
hereof (the &#147;Undertaking&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall be entitled to:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>continue to hold any document delivered to them pursuant to <B>Clauses 4.2.1 through
4.2.5 </B>above until the Charged Shares are released from this Charge and if, for any reason,
they release any such document to the Chargor before such time, they may by notice to the
Chargor require that such document be redelivered to them and the Chargor shall promptly
comply with that requirement or procure that it is complied with; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>at any time after the Security Interest has become enforceable as provided in <B>Clause
7</B>, subject to the limitation set out in <B>Clause 7.1</B>, complete any document delivered to them
pursuant to <B>Clauses 4.2.1 through 4.2.5 </B>above in favour of, and register any Charged Share
in the names of the Chargees or such other person as they shall select, and the Chargor
shall promptly take or procure the taking by all such other persons (including, without
limitation, the secretary of the Company) any other action and execute and deliver to the
Chargees any other document (in form and substance reasonably satisfactory to each Chargee)
which may be reasonably requested by the Chargees in order to enable the Chargees or such
other person as they shall select to be registered as the owner of, or otherwise obtain
legal title to, any Charged Share; this includes procuring that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>those share transfers are duly registered in the shareholder register of the
Company; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>share certificates in the name of the Chargees or such other person as they
shall select are delivered to the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor will deliver, or cause to be delivered, to the Chargees immediately upon the issue
of any further Charged Shares, the items listed in <B>Clauses 4.2.1 through 4.2.5 </B>(if the documents
already provided are not sufficient to cover the further Charged Shares) in respect of all such
further Charged Shares.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby covenants that during the Security Period it will remain the legal and the
beneficial owner of the Charged Property (subject only to the Security Interests hereby created)
and that it will not:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>create or suffer the creation of any Security Interests (other than those created by
this Charge) on or in respect of the whole of any part of the Charged Property or any of
its interest therein; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sell, assign, transfer or otherwise dispose of any of its interest in the Charged
Property (other than with respect to the dividend or distribution payments described in
<B>Clause 5.1.2</B>); or</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>do or cause or permit to be done anything which may in any way affect, depreciate,
jeopardize or otherwise prejudice the market value of the Charged Shares or its rights with
respect thereto;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>vote in respect of the Charged Shares or receive any dividends or other distributions
paid by the Company in respect of the Charged Shares,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in any such case without the prior consent in writing of the Chargees.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Security Period, the Chargor shall remain liable to perform all the obligations
assumed by it in relation to the Charged Property and the Chargees shall be under no obligation of
any kind whatsoever in respect thereof or be under any liability whatsoever in the event of any
failure by the Chargor to perform its obligations in respect thereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the Chargees being satisfied that the Secured Obligations have been unconditionally and
irrevocably paid and discharged in full or upon the expiry of the Security Period, and following a
written request therefor from the Chargor, the Chargees will, subject to being indemnified to each
of their respective reasonable satisfaction for the costs and expenses incurred by the Chargees in
connection therewith, release the Charged Shares (if any as the case may be) and security
constituted by this Charge.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>5</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>DEALINGS WITH CHARGED PROPERTY</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Unless and until an Event of Default has occurred:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to exercise all voting and/or consensual powers
pertaining to the Charged Property or any part thereof for all purposes not inconsistent
with the terms of this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to receive and retain any dividends, interest or other
moneys or assets accruing on or in respect of the Charged Property or any part thereof; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to receive all notices pertaining to the Charged
Shares.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay all calls, instalments or other payments, and shall discharge all other
obligations, which may become due in respect of any of the Charged Property and in an Event of
Default, the Chargees may, if they think fit, make such payments or discharge such obligations on
behalf of the Chargor. Any sums so paid by the Chargees in respect thereof shall be repayable on
demand and, pending such repayment, shall constitute part of the Secured Obligations.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not have any duty to ensure that any dividends, interest or other moneys and
assets receivable in respect of the Charged Property are duly and punctually paid, received or
collected as and when the same become due and payable or to ensure that the correct amounts (if
any) are paid or received on or in respect of the Charged Property or to ensure the taking up of
any (or any offer of any) stocks, shares, rights, moneys or other property paid, distributed,
accruing or offered at any time by way of
</TD>
</TR>
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>redemption bonus, rights, preference, or otherwise on or in respect of, any of the Charged
Property.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby authorises the Chargees to arrange at any time and from time to time
(whether before or after the occurrence of an Event of Default) for the Charged Property or any
part thereof to be registered in the name of the Chargees (or their nominees) thereupon to be held
as so registered subject to the terms of this Charge.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>6</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>PRESERVATION OF SECURITY</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It is hereby agreed and declared that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the security created by this Charge shall be held by the Chargees as a continuing
security for the payment and discharge of the Secured Obligations and the security so
created shall not be satisfied by any intermediate payment or satisfaction of any part of
the Secured Obligations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargees shall not be bound to enforce any other security before enforcing the
security created by this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>no delay or omission on the part of the Chargees in exercising any right, power or
remedy under this Charge shall impair such right, power or remedy or be construed as a
waiver thereof nor shall any single or partial exercise of any such right, power or remedy
preclude any further exercise thereof or the exercise of any other right, power or remedy.
The rights, powers and remedies herein provided are cumulative and not exclusive of any
rights, powers and remedies provided by law and may be exercised from time to time and as
often as the Chargees may deem expedient; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any waiver by the Chargees of any terms of this Charge shall only be effective if
given in writing and then only for the purpose and upon the terms for which it is given.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any settlement or discharge under this Charge between the Chargees and the Chargor shall be
conditional upon no security or payment to the Chargees by the Company or the Chargor or any other
person being avoided or set-aside or ordered to be refunded or reduced or if the aforesaid security
or payment to the Chargees is adversely affected by virtue of any provision or enactment relating
to bankruptcy, insolvency, administration or liquidation for the time being in force and, if such
condition is not satisfied, the liability of the Chargor under this Charge shall be reinstated or
continue and the Chargees shall be entitled to recover from the Chargor on demand the value of such
security or the amount of any such payment as if such settlement or discharge had not occurred.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The rights of the Chargees under this Charge and the Security Interest hereby constituted shall
not be affected by any act, omission, matter or thing which, but for this provision, might operate
to impair, affect or discharge such rights and security, in whole or in part, including without
limitation, and whether or not known to or discoverable by the Company, the Chargor, the Chargees
or any other person:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any time or waiver granted to or composition with the Company or any other person;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the taking, variation, compromise, renewal or release of or refusal or neglect to
perfect or enforce any rights, remedies or securities against the Company or any other
person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any legal limitation, disability, incapacity or other circumstances relating to the
Company or any other person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any amendment or supplement to the Share Subscription Agreement or any other document
or security;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the dissolution, liquidation, amalgamation, reconstruction or reorganisation of the
Company or any other person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the unenforceability, invalidity or frustration of any obligations of the Company or
any other person under the Share Subscription Agreement or any other document or security;
or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any non-observance of any formality or other requirements in respect of any other
instrument or any failure to realise the full value of any other security.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Until the Secured Obligations have been unconditionally and irrevocably satisfied and
discharged in full to the satisfaction of the Chargees or until the expiry of the Security Period,
the Chargor shall not by virtue of any payment made hereunder on account of the Secured Obligations
or by virtue of any enforcement by the Chargees of their rights under, or the security constituted
by, this Charge or by virtue of any relationship between or transaction involving, the Chargor and
the Company (whether such relationship or transaction shall constitute the Chargor a creditor of
the Company, a guarantor of the obligations of the Company or a party subrogated to the rights of
others against the Company or otherwise howsoever and whether or not such relationship or
transaction shall be related to, or in connection with, the subject matter of this Charge):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any rights of subrogation in relation to any rights, security or moneys held
or received or receivable by the Chargees or any person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any right of contribution from any co-surety liable in respect of the Second
Obligation under any other guarantee, security or agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any right of set-off or counterclaim against the Chargees, the Company or
any such co-surety;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>receive, claim or have the benefit of any payment, distribution, security or
indemnity from the Company or any such co-surety; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>unless so directed by the Chargees (when the Chargor will prove in accordance with
such directions), claim as a creditor of the Company or any such co-surety in competition
with the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall hold in trust for the Chargees and forthwith pay or transfer (as
appropriate) to the Chargees any such payment (including an amount equal to any such
set-off), distribution (other than such dividend or distribution payments described in</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Clause 5.1.2) </B>or benefit of such security, indemnity or claim in fact received by the
Chargor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Until the Secured Obligations have been unconditionally and irrevocably satisfied and
discharged in full to the satisfaction of the Chargees or until the expiry of the Security Period,
the Chargees may at any time keep in a separate account or accounts (without liability to pay
interest thereon) in the name of the Chargees for as long as they may think fit, any moneys
received, recovered or realised under this Charge or under any other guarantee, security or
agreement relating in whole or in part to the Secured Obligations without being under any
intermediate obligation to apply the same or any part thereof in or towards the discharge of such
amount.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>7</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>ENFORCEMENT OF SECURITY</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the occurrence of an Event of Default or a demand being made by the Chargees for the
satisfaction of the Secured Obligations with respect to the Chargees or any of them, the Security
Interest hereby constituted shall become immediately enforceable by the Chargees and the Chargees
may, at any time, without further notice to or consultation with or consent of the Chargor:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>solely and exclusively exercise all voting and/or consensual powers pertaining to the
Charged Property or any part thereof and may exercise such powers in such manner as the
Chargees may think fit;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>receive and retain all dividends, interest, distributions or other moneys or assets
accruing on or in respect of the Charged Property or any part thereof, and any such
dividends, interest, distributions or other moneys or assets received by the Chargor after
such time shall be held in trust by the Chargor for the Chargees and paid or transferred to
the Chargees on demand;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if the Chargees elect to, sell, transfer, grant options over or otherwise dispose of
the Charged Property or any part thereof at such place and in such manner and at such price
or prices as the Chargees may deem fit;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated blank share transfer forms delivered to the Chargees pursuant to
<B>Clause 4.2.1 </B>by dating the same and inserting their names or the names of their nominees as
transferees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated resolutions of the board of directors of the Company delivered
to the Chargees pursuant to <B>Clause 4.2.4 </B>by dating the same and inserting the names of the
transferees and the number of Ordinary Shares to be transferred; and/or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated irrevocable proxy delivered to the Chargees pursuant to <B>Clause
4.2.2 </B>by dating the same and inserting the names and addresses of all Chargees or the names
and addresses of their respective nominees;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>PROVIDED THAT notwithstanding any other provision of this Charge, the Chargees may only
exercise their rights under <B>Clauses 7.1.5 and 7.1.6 </B>in respect of such number of Charged
Shares not exceeding the aggregate number of Ordinary Shares that the Chargor has failed to
transfer (the &#147;Default Shares&#148;) to the Chargees or any of them under <B>Clause</B></TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>3.1</B> in satisfaction of the Secured Obligations with respect to all and/or any of the
Chargees.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not be obliged to make any enquiry as to the nature or sufficiency of any
payment received by them under this Charge or to make any claim or to take any action to collect
any moneys assigned by this Charge or to enforce any rights or benefits assigned to the Chargees by
this Charge or to which the Chargees may at any time be entitled hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon any sale by the Chargees of the Charged Property or any part thereof by the Chargees, the
purchaser shall not be bound to see or enquire whether the Chargees&#146; power of sale has become
exercisable in the manner provided in this Charge and the sale shall be deemed to be within the
power of the Chargees, and the receipt of the Chargees for the purchase money shall effectively
discharge the purchaser who shall not be concerned with the manner of application of the proceeds
of sale or be in any way answerable therefor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Neither the Chargees nor their agents, managers, officers, employees, delegates or advisers
shall be liable for any claim, demand, liability, loss, damage, cost or expense incurred or arising
in connection with the exercise or purported exercise of any rights, powers and discretions
hereunder in the absence of fraud or dishonesty.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not by reason of the taking of possession of the whole or any part of the
Charged Property or any part thereof be liable to account as mortgagee-in-possession or for
anything except actual receipts or be liable for any loss upon realisation or for any default or
omission for which a mortgagee-in-possession might be liable.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>8</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>FURTHER ASSURANCES</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall execute and do all such assurances, acts and things as the Chargees in their
absolute discretion may require for:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>creating, perfecting, protecting or ensuring the priority of the Security Interest
hereby created (or intended to be created);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>preserving or protecting any of the rights of the Chargees under this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ensuring that the security constituted by this Charge and the covenants and
obligations of the Chargor under this Charge shall inure to the benefit of any assignee of
the Chargees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>facilitating the appropriation or realisation of the Charged Property or any part
thereof; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercising any power, authority or discretion vested in the Chargees under this
Charge,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in any such case forthwith upon demand by the Chargees and at the expense of the Chargor.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Without limitation to the generality of <B>Clause 8.1</B>, the Chargor covenants with the Chargees
that it will on demand of the Chargees procure any amendment to the memorandum and articles of
association of the Company necessary or, in the opinion of the Chargees desirable, in order to give
effect to the terms of this Charge or any documents or transactions provided for herein.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>9</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>INDEMNITIES</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor will indemnify and save harmless the Chargees and each agent or attorney appointed
under or pursuant to this Charge from and against any and all expenses, claims, liabilities,
losses, taxes, costs, duties, fees and charges properly and reasonably suffered, incurred or made
by the Chargees or such agent or attorney:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the exercise or purported exercise of any rights, powers or discretions vested in
them pursuant to this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the preservation or enforcement of the Chargees&#146; rights under this Charge or the
priority thereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>on the release of any part of the Charged Property from the security created by this
Charge; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>as a result, directly or indirectly of any breach by the Chargor of any covenant or
other obligation under this Charge.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>and the Chargees or such agent or attorney may retain and pay all sums in respect of the
same out of money received under the powers conferred by this Charge. All amounts
recoverable by the Chargees or such agent or attorney or any of them shall be recoverable
on a full indemnity basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If, under any applicable law or regulation, and whether pursuant to a judgment being made or
registered against the Chargor or the bankruptcy or liquidation of the Chargor or for any other
reason any payment under or in connection with this Charge is made or falls to be satisfied in a
currency (the &#147;Payment Currency&#148;) other than the currency in which such payment is due under or in
connection with this Charge (the &#147;Contractual Currency&#148;), then to the extent that the amount of
such payment actually received by the Chargees when converted into the Contractual Currency at the
rate of exchange, falls short of the amount due under or in connection with this Charge, the
Chargor, as a separate and independent obligation, shall indemnify and hold harmless the Chargees
against the amount of such shortfall. For the purposes of this clause, &#147;rate of exchange&#148; means the
rate at which the Chargees is able on or about the date of such payment to purchase the Contractual
Currency with the Payment Currency and shall take into account any premium and other costs of
exchange with respect thereto.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>10</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>POWER OF ATTORNEY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor, by way of security and in order more fully to secure the performance of its
obligations hereunder, pursuant to the Power of Attorney Law (1996 Revision) hereby irrevocably
appoints each of the Chargees and the persons deriving title under it jointly and also severally to
be its attorney:</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to execute and complete in favour of the Chargees or its nominees or of any
purchaser any documents which the Chargees may from time to time require for perfecting
their title to or for vesting any of the assets and property hereby charged or assigned to
the Chargees or their nominees or in any purchaser and to give effectual discharges for
payments;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to take and institute on non-payment (if the Chargees in their sole discretion so
decide) all steps and proceedings in the name of the Chargor or of the Chargees for the
recovery of such moneys, property and assets hereby charged and to agree accounts;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to make allowances and give time or other indulgence to any surety or other person
liable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>otherwise generally to act for it and in its name and on its behalf; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to sign, execute, seal and deliver and otherwise perfect and do any such legal
assignments and other assurances, charges, authorities and documents over the moneys,
property and assets hereby charged, and all such deeds, instruments, acts and things
(including, without limitation, those referred to in <B>Clause 8</B>) which may be required for
the full exercise of all or any of the powers conferred or which may be deemed proper on or
in connection with any of the purposes aforesaid.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The power hereby conferred shall be a general power of attorney and the Chargor hereby
ratifies and confirms and agrees to ratify and confirm any instrument, act or thing which any such
attorney may execute or do. In relation to the power referred to herein, the exercise by any of
the Chargees of such power shall be conclusive evidence of its right to exercise the same.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>11</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>EXPENSES</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay to the Chargees on demand all costs, fees and expenses (including but
not limited to legal fees and expenses) and taxes thereon incurred by the Chargees or for which
the Chargees may become liable in connection with:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the negotiation, preparation and execution of this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the preserving or enforcing of, or attempting to preserve or enforce, any of its
rights under this Charge or the priority hereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any variation of, or amendment or supplement to, any of the terms of this Charge;
and/or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any consent or waiver required from the Chargees in relation to this Charge,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>and in any case referred to in <B>Clauses 11.1.3 and 11.1.4 </B>regardless of whether the same
is actually implemented, completed or granted, as the case may be.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay promptly any stamp, documentary and other like duties and taxes to which
this Charge may be subject or give rise and shall indemnify the Chargees on demand against any and
all liabilities with respect to or resulting from any delay or omission on the part of the Chargor
to pay any such duties or taxes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>12</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>NOTICES</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any notice required to be given hereunder shall be in writing in the English language and shall be
served by sending the same by prepaid recorded post, facsimile or by delivering the same by hand to
the address of the Party or Parties in question as set out below (or such other address as such
Party or Parties shall notify the other Parties of in accordance with this clause). Any notice sent
by post as provided in this clause shall be deemed to have been served five Business Days after
despatch and any notice sent by facsimile as provided in this clause shall be deemed to have been
served at the time of despatch and in proving the service of the same it will be sufficient to
prove in the case of a letter that such letter was properly stamped, addressed and placed in the
post; and in the case of a facsimile that such facsimile was duly despatched to a current facsimile
number of the addressee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Chargor</U><BR>
Dragon Image Investment Ltd.<BR>
Portcullis TrustNet Chambers<BR>
P.O. Box 3444<BR>
Road Town, Tortola<BR>
British Virgin Islands.<BR>
Attention: Mr.&nbsp;Xiaodi (Steven) Sun

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Chargees:</U><BR>
If to CICC, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">China International Capital Corporation<BR>
28<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>Floor, China World Tower 2<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Fax: 86-10-6505-3796<BR>
Attention: Ms.&nbsp;Shirley Chen

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to Carlyle, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Carlyle Group<BR>
2518-2521, South Office Tower<BR>
Beijing Kerry Centre<BR>
No.&nbsp;1, Guang Hua Road<BR>
Chao Yang District<BR>
Beijing 100020<BR>
People&#146;s Republic of China<BR>
Fax: 86-10-8529-9877<BR>
Attention: Mr.&nbsp;Feng Xiao

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With a copy to:

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Davis Polk &#038; Wardwell LLP<BR>
26<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>Floor, Twin Tower West<BR>
B12, Jian Guo Men Wai Avenue<BR>
Chao Yang District<BR>
Beijing 100022<BR>
People&#146;s Republic of China<BR>
Tel: 86-10-8567-5000<BR>
Fax: 86-10-8567-5123<BR>
Attention: Mr.&nbsp;Show-Mao Chen, Esq.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to Starr, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Starr Investments Cayman II, Inc.<BR>
c/o Starr International Company (Asia) Limited<BR>
Suite&nbsp;1405-7, Two Exchange Square<BR>
8 Connaught Place, Central<BR>
Hong Kong<BR>
Tel: 852-2905-1166<BR>
Fax: 852-2905-1555<BR>
Attention: Ms.&nbsp;Elaine Zong

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With a copy to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Skadden, Arps, Slate, Meagher &#038; Flom<BR>
East Wing Office, Level 4<BR>
China World Trade Centre<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Tel: 86-10-6535-5500<BR>
Fax: 86-10-6505-5522<BR>
Attention: Mr.&nbsp;Peter X. Huang

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>13</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>ASSIGNMENTS</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge shall be binding upon and shall inure to the benefit of the Chargor and the
Chargees and each of their respective successors and (subject as hereinafter provided) assigns and
references in this Charge to any of them shall be construed accordingly.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor may not assign or transfer all or any part of its rights and/or obligations under
this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees may not assign or transfer all or any part of its rights or obligations under
this Charge to any assignee or transferee without the consent of the Chargor, such consent not to
be unreasonably withheld, provided that no such consent shall be required if an Event of Default
affecting the Chargor has occurred and is continuing. The Chargees shall notify the Chargor
promptly following any such assignment or transfer.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>14</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>MISCELLANEOUS</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees, at any time and from time to time, may delegate by power of attorney or in any
other manner to any person or persons all or any of the powers, authorities and discretions which
are for the time being exercisable by the Chargees under this Charge in relation to the Charged
Property or any part thereof. Any such delegation may be made upon such terms and be subject to
such regulations as the Chargees may think fit. The
Chargees shall not be in any way liable or responsible to the Chargor for any loss or
damage arising from any act, default, omission or misconduct on the part of any such
delegate provided the Chargees has acted reasonably in selecting such delegate.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If any of the clauses, conditions, covenants or restrictions of this Charge or any deed or
document emanating from it shall be found to be void but would be valid if some part thereof were
deleted or modified, then such clause, condition, covenant or restriction shall apply with such
deletion or modification as may be necessary to make it valid and effective.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge (together with any documents referred to herein) constitutes the whole agreement
between the Parties relating to its subject matter and no variations hereof shall be effective
unless made in writing and signed by each of the Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The headings in this Charge are inserted for convenience only and shall not affect the
construction of this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge may be executed in counterparts each of which when executed and delivered shall
constitute an original but all such counterparts together shall constitute one and the same
instrument.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To the maximum extent permitted under applicable laws, the Chargor hereby waives any immunity
under the laws applicable to the Chargor, whether characterised as sovereign immunity or otherwise,
from any legal proceedings to enforce this Charge in respect of itself or its property.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>15</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>LAW AND JURISDICTION</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Charge shall be governed by and construed in accordance with the laws of the Cayman Islands
and the Parties hereby irrevocably submit to the non-exclusive jurisdiction of the courts of Hong
Kong, provided that nothing in this clause shall affect the rights of the Chargees to serve process
in any manner permitted by law or limit the rights of the Chargees to take proceedings with respect
to this Charge against the Chargor in any jurisdiction nor shall the taking of proceedings with
respect to this Charge in any jurisdiction preclude the Chargees from taking proceedings with
respect to this Charge in any other jurisdiction, whether concurrently or not.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Follow</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS whereof the parties hereto have caused this Charge to be duly executed as a Deed the day
and year first before written.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">The Common Seal of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">DRAGON IMAGE INVESTMENT LTD.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">was hereunto affixed in the
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">presence of:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Steven Xiaodi Sun</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Steven Xiaodi Sun
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shi Bo Tao</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Shi Bo Tao
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Witness)&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Dragon Image 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Executed as a deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">For and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">CICC SUN COMPANY LIMITED
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shirley Chen</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Shirley Chen
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>





<!-- End Table Body -->
</TABLE>
</DIV>







<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->









<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Xin, Jie</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Xin, Jie
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Dragon Image 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Executed as a deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">For and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CARLYLE ASIA GROWTH PARTNERS III, L.P.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">By: CAGP General Partner, L.P., as its General Partner
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">By: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Daniel A. D&#146;Aniello
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Executed as a deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">For and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">CAGP III CO-INVESTMENT, L.P.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BY: CAGP General Partner, L.P., as its General Partner
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BY: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Daniel A. D&#146;Aniello
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Dragon Image 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Executed as a deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">For and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">STARR INVESTMENTS CAYMAN II, INC.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Horvath&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Michael Horvath
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Dragon Image 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.13
<SEQUENCE>14
<FILENAME>h03611exv4w13.htm
<DESCRIPTION>EX-4.13
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.13</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit 4.13</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Dated this 10<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>day of November, 2008

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">BY :

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Notable Enterprise Limited

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">IN FAVOUR OF:

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CICC Sun Company Limited

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Carlyle Asia Growth Partners III, L.P.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CAGP III Co-Investment, L.P.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Starr Investments Cayman II, Inc.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>SHARE CHARGE</B>

</DIV>
<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Conyers Dill &#038; Pearman<BR>
Barristers &#038; Attorneys<BR>
Cayman Islands

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>THIS SHARE CHARGE is made on the 10</B><SUP style="font-size: 85%; vertical-align: text-top"><B>th </B></SUP><B>day of November, 2008</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>BY:</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Notable Enterprise Limited, a company incorporated under the laws of the British Virgin Islands
(the &#147;Chargor&#148;);</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>IN FAVOUR OF:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CICC Sun Company Limited, a company incorporated under the laws of the British Virgin Islands
(&#147;CICC&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Carlyle Asia Growth Partners III, L.P., a limited partnership formed under the laws of the
Cayman Islands (&#147;CAGP&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CAGP III Co-Investment, L.P., a limited partnership formed under the laws of the Cayman Islands
(&#147;CAGP Co-Invest&#148;, and together with CAGP, &#147;Carlyle&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Starr Investments Cayman II, Inc., a company incorporated under the laws of the Cayman Islands
(&#147;Starr&#148;, and together with CICC and Carlyle, the &#147;Chargees&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>WHEREAS:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By a share subscription agreement dated October&nbsp;10, 2008, as amended on October&nbsp;20, 2008 (the
&#147;Share Subscription Agreement&#148;) made between, inter alia, the Chargor, the Chargees, the Company
(as defined below) and other parties specified therein, the Chargees subscribed for series B
redeemable convertible preferred shares of par value US$0.01 each of the Company (the &#147;Series&nbsp;B
Shares&#148;) on the terms and conditions therein set out.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As security for the obligations of the Chargor under Article&nbsp;3 of the Share Subscription
Agreement, the Chargor has agreed to charge, inter alia, its interest in certain of the shares
beneficially owned by the Chargor in Concord Medical Services Holdings Limited, a company
incorporated under the laws of the Cayman Islands (the &#147;Company&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(C)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company is authorised to issue 5,000,000 shares of a par value of US$0.01 each of which
4,500,000 shares are designated as ordinary shares (the &#147;Ordinary Shares&#148;), 200,000 are series A
redeemable convertible preferred shares (the &#147;Series&nbsp;A Shares&#148;) and 300,000 are Series&nbsp;B Shares.
217,435 Ordinary Shares have been issued to and fully paid by, and are beneficially owned by and
registered in the name of, the Chargor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(D)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to Section&nbsp;7.07(b) of the Share Subscription Agreement, the Chargor shall execute this
Charge in favour of the Chargees and the same is executed by the Chargor in consideration of the
Chargees agreeing to enter into the Share Subscription Agreement and for other good and valuable
consideration (the sufficiency of which the Chargor hereby acknowledges).</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>NOW THIS CHARGE WITNESSES </B>as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>1</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>INTERPRETATION</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Charge, unless the context otherwise requires, the following words and expressions
shall have the following meanings:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="74%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Aggregate Ownership&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Shareholders&#146;
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Business Day&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Charge&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means this share charge;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Charged Property&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means all of the Charged Shares and all dividends or
other distributions, interest and other moneys paid or
payable after the date hereof in connection therewith
and all interests in and all rights accruing at any time to
or in respect of all or any of the Charged Shares and all
and any other property that may at any time be received
or receivable by or otherwise distributed to the Chargor
in respect of or in substitution for, or in addition to, or
in exchange for, or on account of, any of the foregoing,
including, without limitation, any shares or other
securities resulting from the division, consolidation,
change, conversion or reclassification of any of the
Charged Shares, or the reorganization or amalgamation
of the Company with any other body corporate, or the
occurrence of any event which results in the
substitution or exchange of the Charged Shares;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Charged Shares&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means 43,487 Ordinary Shares of the Company
registered in the name of the Chargor as legal and
beneficial owner thereof;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Closing Date&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Controlling Shareholders&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Event of Default&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the failure by the Chargor to satisfy the Secured
Obligations with respect to the Chargees or any of
them;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Fully Diluted&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Group Company&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="74%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Ordinary Shares&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ordinary shares of par value US$0.01 each of the
Company;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Parties&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the parties to this Charge collectively; &#147;Party&#148;
means any one of them;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Pre-Closing Offshore<br>
Acquisition&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in <B>Clause 3.1.1</B>;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Secured Obligations&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the obligations of the Chargor to deliver
Ordinary Shares to the Chargees or any of them as
specified in <B>Clause 3.1</B>;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Security Interest&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means any charge, mortgage, pledge, lien, security
interest or other encumbrance;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Security Period&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the period commencing on the date of execution
of this Charge and terminating upon the earliest to
occur of (i)&nbsp;November&nbsp;10, 2014, (ii)&nbsp;the date on which
Aggregate Ownership of Ordinary Shares by each
Chargee is less than 20% of such Chargee&#146;s Initial
Ownership (as defined in the Shareholders&#146; Agreement)
of Ordinary Shares and (iii)&nbsp;the date on which a
Singapore law firm delivers a legal opinion to the
Chargees, in form and substance satisfactory to each
Chargee, with respect to the issuance of Ordinary
Shares to certain Controlling Shareholder Holding
Companies (as defined in the Share Subscription
Agreement) in August&nbsp;2008;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Shareholders&#146; Agreement&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the Amended and Restated Shareholders&#146;
Agreement dated October&nbsp;20, 2008 by and among the
Company, the Chargor, the Chargees and other parties
specified therein; and</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#147;Third-Party Transferee&#148;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in <B>Clause 3.1.1</B>.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Charge unless the context otherwise requires:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to statutory provisions shall be construed as references to those
provisions as amended or re-enacted or as their application is modified by other provisions
from time to time and shall include references to any provisions of which they are
re-enactments (whether with or without modification);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to clauses and schedules are references to clauses hereof and schedules
hereto; references to sub-clauses or paragraphs are, unless otherwise stated, references to
sub-clauses of the clauses hereof or paragraphs of the schedule in which the reference
appears;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to the singular shall include the plural and vice versa and references to
the masculine shall include the feminine and/or neuter and vice versa; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to persons shall include companies, partnerships, associations and bodies
of persons, whether incorporated or unincorporated;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to assets include property, rights and assets of every description;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to any document are to be construed as references to such document as
amended or supplemented from time to time; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the rights, interests and obligations of the Chargees hereunder are joint and are
exercisable by the Chargees collectively.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>2</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>CHARGOR&#146;S REPRESENTATIONS AND WARRANTIES</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Chargor hereby represents and warrants to the Chargees that:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the authorised share capital of the Company consists of the shares described in <B>Recital (C) </B>hereof and such shares are beneficially owned and registered as described in the said recital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor is a company duly organised, validly existing and in good standing under the laws of the British Virgin Islands;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>entry into this Charge by the Chargor and enforcement hereof by the Chargees will not
contravene the terms of any agreement to which the Chargor is bound or to which the Charged Shares
are subject or the memorandum and articles of association of the Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor is the legal and beneficial owner of all of the Charged Property free from any
Security Interest (other than those created by this Charge) and any options or rights of
pre-emption and the Charged Shares are fully paid up and are not and will not be liable to any
future call, assessment or demand of any sort;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Charged Shares are duly authorised, validly issued and fully paid;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>no moneys or liabilities are outstanding or payable with respect to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor has full power and authority (i)&nbsp;to be the legal and beneficial owner of the Charged Property, (ii)&nbsp;to execute and deliver this Charge and (iii)&nbsp;to comply with the provisions of, and perform all its obligations under, this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Charge creates those Security Interests it purports to create and is not liable to be avoided or otherwise set aside on liquidation, administration or otherwise;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Charge constitutes the Chargor&#146;s legal, valid and binding obligations enforceable against
the Chargor in accordance with its terms except as such enforcement may be limited by any relevant
bankruptcy, insolvency, administration or similar laws affecting creditors&#146; rights generally;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the entry into and performance by the Chargor of this Charge does not violate (i)&nbsp;any law or
regulation of any governmental or official authority, or (ii)&nbsp;any agreement, contract or other
undertaking to which the Chargor is a party or which is binding upon the Chargor or any of its
assets;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other than registration of this Charge in the register of charges of the Chargor in accordance
with the requirements of the BVI Business Companies Act, 2004, no authorisation, approval or other
action by, and no notice to or filing with, any governmental authority or regulatory body is
required for either the grant by the Chargor of the Security Interests purported to be created in
favour of the Chargee under this Charge; or the exercise by the Chargee of any rights or remedies
in respect of the Charged Property (whether or not specifically granted or created under this
Charge);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all consents, licences, approvals and authorisations required in connection with the entry
into, performance, validity and enforceability of this Charge have been obtained and are in full
force and effect;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor has taken all corporate and other action required to approve its execution,
delivery and performance of this Charge; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company is not a land holding corporation for the purposes of the Land Holding Companies
Share Transfer Tax Law of the Cayman Islands.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>CHARGOR&#146;S COVENANTS</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Chargor hereby covenants with the Chargees:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to discharge all obligations and liabilities specified in Section&nbsp;10.02(c)(vii) of the Share Subscription Agreement at the following times and in the following manner:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company is required to issue a number of Ordinary Shares to any person
(a &#147;Third-Party Transferee&#148;) pursuant to any arbitral or judicial judgment on, or
settlement of, any claim, dispute or litigation in connection with any acquisition by any
Group Company of any person (other than persons established under the Laws of the PRC)
which has been consummated prior to the Closing Date (any &#147;Pre-Closing Offshore
Acquisition&#148;) and the Controlling Shareholders, severally and jointly, fail to transfer
such number of Ordinary Shares to such Third-Party Transferee in lieu of and on behalf of
such Group Company at the per share price and on the date set forth in such judgment or
settlement, the Chargor shall, severally and jointly with other Controlling Shareholders,
on the Business Day immediately following such date, transfer free of charge a number of
Ordinary Shares to each Chargee equal to (x)&nbsp;the aggregate number of Ordinary Shares
required to be transferred to such Third-Party Transferee pursuant to such judgment or
settlement <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which is the Aggregate Ownership of
Ordinary Shares by such Chargee on such payment date and the denominator of which is the
outstanding number of Ordinary Shares on such payment date, calculated on a Fully-Diluted
basis;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company is required to make any payment in cash to any person pursuant
to any arbitral or judicial judgment on, or settlement of, any claim, dispute or litigation
in connection with any Pre-Closing Offshore Acquisition and</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Controlling Shareholders, severally and jointly, fail to make such payment in
lieu of and on behalf of such Group Company by the payment time set forth in such
judgment or settlement, the Chargor shall, severally and jointly with other
Controlling Shareholders, within 10 Business Days following such payment date,
transfer free of charge a number of Ordinary Shares to each Chargee equal to (x)
the amount of such payment in US dollars (based on the &#147;noon buying rate&#148; for
purchases of any currency other than US dollars on such payment date published by
the Federal Reserve Bank of New York) <I>divided </I>by (y)&nbsp;the fair market value of the
Ordinary Shares in US dollars on a per share basis on such payment date as
determined by the Controlling Shareholders and the Chargees by mutual agreement or
if such mutual agreement cannot be reached within 5 Business Days following such
payment date, determined by an independent appraiser satisfactory to the Chargees
within 10 Business Days following such payment date <I>multiplied </I>by (z)&nbsp;a ratio, the
numerator of which is the Aggregate Ownership of Ordinary Shares by such Chargee on
such payment date and the denominator of which is the outstanding number of
Ordinary Shares on such payment date, calculated on a Fully-Diluted basis; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company incurs or suffers any damages arising out of any claim, dispute
or litigation in connection with any Pre-Closing Offshore Acquisition, other than those
damages described in <B>Clauses 3.1.1 and 3.1.2</B>, and the Controlling Shareholders, severally
and jointly, fail to indemnify the Company pursuant to Section&nbsp;10.02(c)(vii) of the Share
Subscription Agreement by the date of such incurrence or suffering, the Chargor shall,
severally and jointly with other Controlling Shareholders, transfer free of charge a number
of Ordinary Shares to each Chargee equal to (x)&nbsp;the amount of such damages expressed in US
dollars <I>divided </I>by (y)&nbsp;the fair market value of the Ordinary Shares in US dollars on a per
share basis calculated as set forth above in Clause 3.1.2 <I>multiplied </I>by (z)&nbsp;a ratio, the
numerator of which is the Aggregate Ownership of Ordinary Shares by such Chargee on such
date and the denominator of which is the outstanding number of Ordinary Shares on such
date, calculated on a Fully-Diluted basis, in each case of sub-clause (x)&nbsp;and (y)&nbsp;as
determined by the Controlling Shareholders and the Chargees by mutual agreement or if such
mutual agreement cannot be reached within 5 Business Days following such payment date,
determined by an independent appraiser satisfactory to the Chargees within 10 Business Days
following such date;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the obligations in <B>Clauses 3.1.1, 3.1.2 and 3.1.3 </B>collectively, the &#147;Secured Obligations&#148;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor will on demand of the Chargees and at the expense of the Chargor, execute and
deliver to the Chargees or to such person or persons as the Chargees may nominate such additional
charge or charges of the Charged Property (or any part thereof) for the purpose of further securing
the payment and discharge of all Secured Obligations, each such additional charge to be in such
form as the Chargees may reasonably require;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor shall, on request of the Chargees, provide to the Chargees immediately on
receipt by the Chargor a copy of all notices, written consents, reports, accounts, circulars and
other communications issued by the Company or by any third party in respect of the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor will not without the prior written consent of the Chargees:</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any person other than the Chargor, the Chargees or any transferee nominated by
the Chargees on enforcement of this Charge to be the registered holder of any of the
Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any variation of the rights attaching to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>take or permit any action which might result in an increase or reduction in the
authorised share capital of the Company or the number of shares that the Company is
authorised to issue or the issued share or share capital of the Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit the Company to be continued to another jurisdiction outside of the Cayman
Islands;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>effect or permit the appointment of any new or further directors or officers of the
Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any scheme of arrangement, merger, amalgamation or other reorganisation
applicable to the Company; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>save in accordance with <B>Clause 8.2, </B>permit any amendment to the memorandum or
articles of association of the Company without prior written consent of the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>4</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>SECURITY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In consideration of the Chargees agreeing to enter into the Share Subscription Agreement and as
a continuing security for the Secured Obligations, the Chargor as legal and beneficial owner hereby
assigns and agrees to assign to the Chargees jointly all benefits present and future, actual and
contingent accruing in respect of the Charged Property and all the Chargor&#146;s right, title and
interest to and in the Charged Property including (without limitation) all voting and other
consensual powers pertaining to the Charged Shares and hereby charges and agrees to charge in
favour of the Chargees jointly all of its interest in the Charged Property by way of a first fixed
charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby agrees to deliver, or cause to be delivered, to the Chargees on the date hereof:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>duly executed undated share transfers in respect of the Charged Shares in favour of the Chargees or their nominees in the form set out in Schedule&nbsp;I;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an executed undated irrevocable proxy made in respect of the Charged Shares in favour of the Chargees in respect of all general meetings of the Company in the form set out in Schedule&nbsp;II;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all original share certificates representing, and all other documents, title or evidence of, ownership in relation to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>signed, but undated resolutions of the board of directors of the Company in the form set out in Schedule&nbsp;III; and</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an executed undertaking from the Company to register transfers of the Charged Shares to the Chargees or their nominees in the form set out in Schedule&nbsp;IV dated as of the date hereof (the &#147;Undertaking&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall be entitled to:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>continue to hold any document delivered to them pursuant to <B>Clauses 4.2.1 through
4.2.5 </B>above until the Charged Shares are released from this Charge and if, for any reason,
they release any such document to the Chargor before such time, they may by notice to the
Chargor require that such document be redelivered to them and the Chargor shall promptly
comply with that requirement or procure that it is complied with; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>at any time after the Security Interest has become enforceable as provided in <B>Clause
7</B>, subject to the limitation set out in <B>Clause 7.1</B>, complete any document delivered to them
pursuant to <B>Clauses 4.2.1 through 4.2.5 </B>above in favour of, and register any Charged Share
in the names of the Chargees or such other person as they shall select, and the Chargor
shall promptly take or procure the taking by all such other persons (including, without
limitation, the secretary of the Company) any other action and execute and deliver to the
Chargees any other document (in form and substance reasonably satisfactory to each Chargee)
which may be reasonably requested by the Chargees in order to enable the Chargees or such
other person as they shall select to be registered as the owner of, or otherwise obtain
legal title to, any Charged Share; this includes procuring that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>those share transfers are duly registered in the shareholder register of the
Company; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>share certificates in the name of the Chargees or such other person as they
shall select are delivered to the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor will deliver, or cause to be delivered, to the Chargees immediately upon the issue
of any further Charged Shares, the items listed in <B>Clauses 4.2.1 through 4.2.5 </B>(if the documents
already provided are not sufficient to cover the further Charged Shares) in respect of all such
further Charged Shares.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby covenants that during the Security Period it will remain the legal and the
beneficial owner of the Charged Property (subject only to the Security Interests hereby created)
and that it will not:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>create or suffer the creation of any Security Interests (other than those created by
this Charge) on or in respect of the whole of any part of the Charged Property or any of
its interest therein; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sell, assign, transfer or otherwise dispose of any of its interest in the Charged
Property (other than with respect to the dividend or distribution payments described in
<B>Clause 5.1.2</B>); or</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>do or cause or permit to be done anything which may in any way affect, depreciate,
jeopardize or otherwise prejudice the market value of the Charged Shares or its rights with
respect thereto;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>vote in respect of the Charged Shares or receive any dividends or other distributions
paid by the Company in respect of the Charged Shares,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in any such case without the prior consent in writing of the Chargees.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Security Period, the Chargor shall remain liable to perform all the obligations
assumed by it in relation to the Charged Property and the Chargees shall be under no obligation of
any kind whatsoever in respect thereof or be under any liability whatsoever in the event of any
failure by the Chargor to perform its obligations in respect thereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the Chargees being satisfied that the Secured Obligations have been unconditionally and
irrevocably paid and discharged in full or upon the expiry of the Security Period, and following a
written request therefor from the Chargor, the Chargees will, subject to being indemnified to each
of their respective reasonable satisfaction for the costs and expenses incurred by the Chargees in
connection therewith, release the Charged Shares (if any as the case may be) and security
constituted by this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>5</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>DEALINGS WITH CHARGED PROPERTY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Unless and until an Event of Default has occurred:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to exercise all voting and/or consensual powers
pertaining to the Charged Property or any part thereof for all purposes not inconsistent
with the terms of this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to receive and retain any dividends, interest or other
moneys or assets accruing on or in respect of the Charged Property or any part thereof; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to receive all notices pertaining to the Charged
Shares.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay all calls, instalments or other payments, and shall discharge all other
obligations, which may become due in respect of any of the Charged Property and in an Event of
Default, the Chargees may, if they think fit, make such payments or discharge such obligations on
behalf of the Chargor. Any sums so paid by the Chargees in respect thereof shall be repayable on
demand and, pending such repayment, shall constitute part of the Secured Obligations.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not have any duty to ensure that any dividends, interest or other moneys and
assets receivable in respect of the Charged Property are duly and punctually paid, received or
collected as and when the same become due and payable or to ensure that the correct amounts (if
any) are paid or received on or in respect of the Charged Property or to ensure the taking up of
any (or any offer of any) stocks, shares, rights, moneys or other property paid, distributed,
accruing or offered at any time by way of</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>redemption bonus, rights, preference, or otherwise on or in respect of, any of the Charged
Property.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby authorises the Chargees to arrange at any time and from time to time
(whether before or after the occurrence of an Event of Default) for the Charged Property or any
part thereof to be registered in the name of the Chargees (or their nominees) thereupon to be held
as so registered subject to the terms of this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>6</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>PRESERVATION OF SECURITY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It is hereby agreed and declared that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the security created by this Charge shall be held by the Chargees as a continuing
security for the payment and discharge of the Secured Obligations and the security so
created shall not be satisfied by any intermediate payment or satisfaction of any part of
the Secured Obligations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargees shall not be bound to enforce any other security before enforcing the
security created by this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>no delay or omission on the part of the Chargees in exercising any right, power or
remedy under this Charge shall impair such right, power or remedy or be construed as a
waiver thereof nor shall any single or partial exercise of any such right, power or remedy
preclude any further exercise thereof or the exercise of any other right, power or remedy.
The rights, powers and remedies herein provided are cumulative and not exclusive of any
rights, powers and remedies provided by law and may be exercised from time to time and as
often as the Chargees may deem expedient; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any waiver by the Chargees of any terms of this Charge shall only be effective if
given in writing and then only for the purpose and upon the terms for which it is given.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any settlement or discharge under this Charge between the Chargees and the Chargor shall be
conditional upon no security or payment to the Chargees by the Company or the Chargor or any other
person being avoided or set-aside or ordered to be refunded or reduced or if the aforesaid security
or payment to the Chargees is adversely affected by virtue of any provision or enactment relating
to bankruptcy, insolvency, administration or liquidation for the time being in force and, if such
condition is not satisfied, the liability of the Chargor under this Charge shall be reinstated or
continue and the Chargees shall be entitled to recover from the Chargor on demand the value of such
security or the amount of any such payment as if such settlement or discharge had not occurred.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The rights of the Chargees under this Charge and the Security Interest hereby constituted shall
not be affected by any act, omission, matter or thing which, but for this provision, might operate
to impair, affect or discharge such rights and security, in whole or in part, including without
limitation, and whether or not known to or discoverable by the Company, the Chargor, the Chargees
or any other person:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any time or waiver granted to or composition with the Company or any other person;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the taking, variation, compromise, renewal or release of or refusal or neglect to
perfect or enforce any rights, remedies or securities against the Company or any other
person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any legal limitation, disability, incapacity or other circumstances relating to the
Company or any other person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any amendment or supplement to the Share Subscription Agreement or any other document
or security;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the dissolution, liquidation, amalgamation, reconstruction or reorganisation of the
Company or any other person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the unenforceability, invalidity or frustration of any obligations of the Company or
any other person under the Share Subscription Agreement or any other document or security;
or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any non-observance of any formality or other requirements in respect of any other
instrument or any failure to realise the full value of any other security.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Until the Secured Obligations have been unconditionally and irrevocably satisfied and
discharged in full to the satisfaction of the Chargees or until the expiry of the Security Period,
the Chargor shall not by virtue of any payment made hereunder on account of the Secured Obligations
or by virtue of any enforcement by the Chargees of their rights under, or the security constituted
by, this Charge or by virtue of any relationship between or transaction involving, the Chargor and
the Company (whether such relationship or transaction shall constitute the Chargor a creditor of
the Company, a guarantor of the obligations of the Company or a party subrogated to the rights of
others against the Company or otherwise howsoever and whether or not such relationship or
transaction shall be related to, or in connection with, the subject matter of this Charge):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any rights of subrogation in relation to any rights, security or moneys held
or received or receivable by the Chargees or any person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any right of contribution from any co-surety liable in respect of the Second
Obligation under any other guarantee, security or agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any right of set-off or counterclaim against the Chargees, the Company or
any such co-surety;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>receive, claim or have the benefit of any payment, distribution, security or
indemnity from the Company or any such co-surety; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>unless so directed by the Chargees (when the Chargor will prove in accordance with
such directions), claim as a creditor of the Company or any such co-surety in competition
with the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall hold in trust for the Chargees and forthwith pay or transfer (as
appropriate) to the Chargees any such payment (including an amount equal to any such
set-off), distribution (other than such dividend or distribution payments described in</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Clause 5.1.2) </B>or benefit of such security, indemnity or claim in fact received by the
Chargor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Until the Secured Obligations have been unconditionally and irrevocably satisfied and
discharged in full to the satisfaction of the Chargees or until the expiry of the Security Period,
the Chargees may at any time keep in a separate account or accounts (without liability to pay
interest thereon) in the name of the Chargees for as long as they may think fit, any moneys
received, recovered or realised under this Charge or under any other guarantee, security or
agreement relating in whole or in part to the Secured Obligations without being under any
intermediate obligation to apply the same or any part thereof in or towards the discharge of such
amount.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>7</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>ENFORCEMENT OF SECURITY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the occurrence of an Event of Default or a demand being made by the Chargees for the
satisfaction of the Secured Obligations with respect to the Chargees or any of them, the Security
Interest hereby constituted shall become immediately enforceable by the Chargees and the Chargees
may, at any time, without further notice to or consultation with or consent of the Chargor:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>solely and exclusively exercise all voting and/or consensual powers pertaining to the
Charged Property or any part thereof and may exercise such powers in such manner as the
Chargees may think fit;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>receive and retain all dividends, interest, distributions or other moneys or assets
accruing on or in respect of the Charged Property or any part thereof, and any such
dividends, interest, distributions or other moneys or assets received by the Chargor after
such time shall be held in trust by the Chargor for the Chargees and paid or transferred to
the Chargees on demand;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if the Chargees elect to, sell, transfer, grant options over or otherwise dispose of
the Charged Property or any part thereof at such place and in such manner and at such price
or prices as the Chargees may deem fit;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated blank share transfer forms delivered to the Chargees pursuant to
<B>Clause 4.2.1 </B>by dating the same and inserting their names or the names of their nominees as
transferees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated resolutions of the board of directors of the Company delivered
to the Chargees pursuant to <B>Clause 4.2.4 </B>by dating the same and inserting the names of the
transferees and the number of Ordinary Shares to be transferred; and/or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated irrevocable proxy delivered to the Chargees pursuant to <B>Clause
4.2.2 </B>by dating the same and inserting the names and addresses of all Chargees or the names
and addresses of their respective nominees;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>PROVIDED THAT notwithstanding any other provision of this Charge, the Chargees may only
exercise their rights under <B>Clauses 7.1.5 and 7.1.6 </B>in respect of such number of Charged
Shares not exceeding the aggregate number of Ordinary Shares that the Chargor has failed to
transfer (the &#147;Default Shares&#148;) to the Chargees or any of them under <B>Clause</B></TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>3.1</B> in satisfaction of the Secured Obligations with respect to all and/or any of the
Chargees.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not be obliged to make any enquiry as to the nature or sufficiency of any
payment received by them under this Charge or to make any claim or to take any action to collect
any moneys assigned by this Charge or to enforce any rights or benefits assigned to the Chargees by
this Charge or to which the Chargees may at any time be entitled hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon any sale by the Chargees of the Charged Property or any part thereof by the Chargees, the
purchaser shall not be bound to see or enquire whether the Chargees&#146; power of sale has become
exercisable in the manner provided in this Charge and the sale shall be deemed to be within the
power of the Chargees, and the receipt of the Chargees for the purchase money shall effectively
discharge the purchaser who shall not be concerned with the manner of application of the proceeds
of sale or be in any way answerable therefor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Neither the Chargees nor their agents, managers, officers, employees, delegates or advisers
shall be liable for any claim, demand, liability, loss, damage, cost or expense incurred or arising
in connection with the exercise or purported exercise of any rights, powers and discretions
hereunder in the absence of fraud or dishonesty.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not by reason of the taking of possession of the whole or any part of the
Charged Property or any part thereof be liable to account as mortgagee-in-possession or for
anything except actual receipts or be liable for any loss upon realisation or for any default or
omission for which a mortgagee-in-possession might be liable.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>8</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>FURTHER ASSURANCES</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall execute and do all such assurances, acts and things as the Chargees in their
absolute discretion may require for:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>creating, perfecting, protecting or ensuring the priority of the Security Interest
hereby created (or intended to be created);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>preserving or protecting any of the rights of the Chargees under this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ensuring that the security constituted by this Charge and the covenants and
obligations of the Chargor under this Charge shall inure to the benefit of any assignee of
the Chargees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>facilitating the appropriation or realisation of the Charged Property or any part
thereof; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercising any power, authority or discretion vested in the Chargees under this
Charge,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in any such case forthwith upon demand by the Chargees and at the expense of the Chargor.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Without limitation to the generality of <B>Clause 8.1</B>, the Chargor covenants with the Chargees
that it will on demand of the Chargees procure any amendment to the memorandum and articles of
association of the Company necessary or, in the opinion of the Chargees desirable, in order to give
effect to the terms of this Charge or any documents or transactions provided for herein.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>9</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>INDEMNITIES</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor will indemnify and save harmless the Chargees and each agent or attorney appointed
under or pursuant to this Charge from and against any and all expenses, claims, liabilities,
losses, taxes, costs, duties, fees and charges properly and reasonably suffered, incurred or made
by the Chargees or such agent or attorney:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the exercise or purported exercise of any rights, powers or discretions vested in
them pursuant to this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the preservation or enforcement of the Chargees&#146; rights under this Charge or the
priority thereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>on the release of any part of the Charged Property from the security created by this
Charge; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>as a result, directly or indirectly of any breach by the Chargor of any covenant or
other obligation under this Charge.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>and the Chargees or such agent or attorney may retain and pay all sums in respect of the
same out of money received under the powers conferred by this Charge. All amounts
recoverable by the Chargees or such agent or attorney or any of them shall be recoverable
on a full indemnity basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If, under any applicable law or regulation, and whether pursuant to a judgment being made or
registered against the Chargor or the bankruptcy or liquidation of the Chargor or for any other
reason any payment under or in connection with this Charge is made or falls to be satisfied in a
currency (the &#147;Payment Currency&#148;) other than the currency in which such payment is due under or in
connection with this Charge (the &#147;Contractual Currency&#148;), then to the extent that the amount of
such payment actually received by the Chargees when converted into the Contractual Currency at the
rate of exchange, falls short of the amount due under or in connection with this Charge, the
Chargor, as a separate and independent obligation, shall indemnify and hold harmless the Chargees
against the amount of such shortfall. For the purposes of this clause, &#147;rate of exchange&#148; means the
rate at which the Chargees is able on or about the date of such payment to purchase the Contractual
Currency with the Payment Currency and shall take into account any premium and other costs of
exchange with respect thereto.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>10</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>POWER OF ATTORNEY</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor, by way of security and in order more fully to secure the performance of its
obligations hereunder, pursuant to the Power of Attorney Law (1996 Revision) hereby irrevocably
appoints each of the Chargees and the persons deriving title under it jointly and also severally to
be its attorney:</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to execute and complete in favour of the Chargees or its nominees or of any
purchaser any documents which the Chargees may from time to time require for perfecting
their title to or for vesting any of the assets and property hereby charged or assigned to
the Chargees or their nominees or in any purchaser and to give effectual discharges for
payments;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to take and institute on non-payment (if the Chargees in their sole discretion so
decide) all steps and proceedings in the name of the Chargor or of the Chargees for the
recovery of such moneys, property and assets hereby charged and to agree accounts;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to make allowances and give time or other indulgence to any surety or other person
liable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>otherwise generally to act for it and in its name and on its behalf; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to sign, execute, seal and deliver and otherwise perfect and do any such legal
assignments and other assurances, charges, authorities and documents over the moneys,
property and assets hereby charged, and all such deeds, instruments, acts and things
(including, without limitation, those referred to in <B>Clause 8</B>) which may be required for
the full exercise of all or any of the powers conferred or which may be deemed proper on or
in connection with any of the purposes aforesaid.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The power hereby conferred shall be a general power of attorney and the Chargor hereby
ratifies and confirms and agrees to ratify and confirm any instrument, act or thing which any such
attorney may execute or do. In relation to the power referred to herein, the exercise by any of
the Chargees of such power shall be conclusive evidence of its right to exercise the same.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>11</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>EXPENSES</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay to the Chargees on demand all costs, fees and expenses (including but
not limited to legal fees and expenses) and taxes thereon incurred by the Chargees or for which
the Chargees may become liable in connection with:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the negotiation, preparation and execution of this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the preserving or enforcing of, or attempting to preserve or enforce, any of its
rights under this Charge or the priority hereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any variation of, or amendment or supplement to, any of the terms of this Charge;
and/or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any consent or waiver required from the Chargees in relation to this Charge,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>and in any case referred to in <B>Clauses 11.1.3 and 11.1.4 </B>regardless of whether the same
is actually implemented, completed or granted, as the case may be.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay promptly any stamp, documentary and other like duties and taxes to which
this Charge may be subject or give rise and shall indemnify the Chargees on demand against any and
all liabilities with respect to or resulting from any delay or omission on the part of the Chargor
to pay any such duties or taxes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>12</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>NOTICES</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any notice required to be given hereunder shall be in writing in the English language and shall be
served by sending the same by prepaid recorded post, facsimile or by delivering the same by hand to
the address of the Party or Parties in question as set out below (or such other address as such
Party or Parties shall notify the other Parties of in accordance with this clause). Any notice sent
by post as provided in this clause shall be deemed to have been served five Business Days after
despatch and any notice sent by facsimile as provided in this clause shall be deemed to have been
served at the time of despatch and in proving the service of the same it will be sufficient to
prove in the case of a letter that such letter was properly stamped, addressed and placed in the
post; and in the case of a facsimile that such facsimile was duly despatched to a current facsimile
number of the addressee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Chargor</U><BR>
Notable Enterprise Limited<BR>
P.O. Box 957<BR>
Offshore Incorporations Centre<BR>
Road Town, Tortola<BR>
British Virgin Islands<BR>
Attention: Mr.&nbsp;Bona Lau

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Chargees:</U><BR>
If to CICC, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">China International Capital Corporation<BR>
28<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>Floor, China World Tower 2<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Fax: 86-10-6505-3796<BR>
Attention: Ms.&nbsp;Shirley Chen

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to Carlyle, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Carlyle Group<BR>
2518-2521, South Office Tower<BR>
Beijing Kerry Centre<BR>
No.&nbsp;1, Guang Hua Road<BR>
Chao Yang District<BR>
Beijing 100020<BR>
People&#146;s Republic of China<BR>
Fax: 86-10-8529-9877<BR>
Attention: Mr.&nbsp;Feng Xiao

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With a copy to:

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Davis Polk &#038; Wardwell LLP<BR>
26<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>Floor, Twin Tower West<BR>
B12, Jian Guo Men Wai Avenue<BR>
Chao Yang District<BR>
Beijing 100022<BR>
People&#146;s Republic of China<BR>
Tel: 86-10-8567-5000<BR>
Fax: 86-10-8567-5123<BR>
Attention: Mr.&nbsp;Show-Mao Chen, Esq.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to Starr, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Starr Investments Cayman II, Inc.<BR>
c/o Starr International Company (Asia) Limited<BR>
Suite&nbsp;1405-7, Two Exchange Square<BR>
8 Connaught Place, Central<BR>
Hong Kong<BR>
Tel: 852-2905-1166<BR>
Fax: 852-2905-1555<BR>
Attention: Ms.&nbsp;Elaine Zong

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With a copy to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Skadden, Arps, Slate, Meagher &#038; Flom<BR>
East Wing Office, Level 4<BR>
China World Trade Centre<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Tel: 86-10-6535-5500<BR>
Fax: 86-10-6505-5522<BR>
Attention: Mr.&nbsp;Peter X. Huang

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>13</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>ASSIGNMENTS</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge shall be binding upon and shall inure to the benefit of the Chargor and the
Chargees and each of their respective successors and (subject as hereinafter provided) assigns and
references in this Charge to any of them shall be construed accordingly.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor may not assign or transfer all or any part of its rights and/or obligations under
this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">13.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees may not assign or transfer all or any part of its rights or obligations under
this Charge to any assignee or transferee without the consent of the Chargor, such consent not to
be unreasonably withheld, provided that no such consent shall be required if an Event of Default
affecting the Chargor has occurred and is continuing. The Chargees shall notify the Chargor
promptly following any such assignment or transfer.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>14</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>MISCELLANEOUS</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees, at any time and from time to time, may delegate by power of attorney or in any
other manner to any person or persons all or any of the powers, authorities and discretions which
are for the time being exercisable by the Chargees under this Charge in relation to the Charged
Property or any part thereof. Any such delegation may be made upon such terms and be subject to
such regulations as the Chargees may think fit. The
Chargees shall not be in any way liable or responsible to the Chargor for any loss or
damage arising from any act, default, omission or misconduct on the part of any such
delegate provided the Chargees has acted reasonably in selecting such delegate.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If any of the clauses, conditions, covenants or restrictions of this Charge or any deed or
document emanating from it shall be found to be void but would be valid if some part thereof were
deleted or modified, then such clause, condition, covenant or restriction shall apply with such
deletion or modification as may be necessary to make it valid and effective.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge (together with any documents referred to herein) constitutes the whole agreement
between the Parties relating to its subject matter and no variations hereof shall be effective
unless made in writing and signed by each of the Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The headings in this Charge are inserted for convenience only and shall not affect the
construction of this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge may be executed in counterparts each of which when executed and delivered shall
constitute an original but all such counterparts together shall constitute one and the same
instrument.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To the maximum extent permitted under applicable laws, the Chargor hereby waives any immunity
under the laws applicable to the Chargor, whether characterised as sovereign immunity or otherwise,
from any legal proceedings to enforce this Charge in respect of itself or its property.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>15</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>LAW AND JURISDICTION</B></TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Charge shall be governed by and construed in accordance with the laws of the Cayman Islands
and the Parties hereby irrevocably submit to the non-exclusive jurisdiction of the courts of Hong
Kong, provided that nothing in this clause shall affect the rights of the Chargees to serve process
in any manner permitted by law or limit the rights of the Chargees to take proceedings with respect
to this Charge against the Chargor in any jurisdiction nor shall the taking of proceedings with
respect to this Charge in any jurisdiction preclude the Chargees from taking proceedings with
respect to this Charge in any other jurisdiction, whether concurrently or not.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Follow</I>&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS whereof the parties hereto have caused this Charge to be duly executed as a Deed the day
and year first before written.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">The Common Seal of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">NOTABLE ENTERPRISE LIMITED
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">was hereunto affixed in the
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">presence of:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Bona Lau</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Bona Lau<br>
Title: Director
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shi Bo Tao</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Shi Bo Tao<br>
(Witness)
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Notable 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Executed as a deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">For and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">CICC SUN COMPANY LIMITED
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shirley Chen&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Shirley Chen
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>




<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Xin, Jie&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Xin, Jie
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Notable 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Executed as a deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">For and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CARLYLE ASIA GROWTH PARTNERS III, L.P.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">By: CAGP General Partner, L.P., as its General Partner

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">By: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Daniel A. D&#146;Aniello
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Executed as a deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">For and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">CAGP III CO-INVESTMENT, L.P.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BY: CAGP General Partner, L.P., as its General Partner

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BY: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Daniel A. D&#146;Aniello
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Notable 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Executed as a deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">For and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">STARR INVESTMENTS CAYMAN II, INC.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">)&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Horvath&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Michael Horvath
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Notable 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.14
<SEQUENCE>15
<FILENAME>h03611exv4w14.htm
<DESCRIPTION>EX-4.14
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.14</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.14</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Dated this 10<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>day of November, 2008
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">BY :

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Thousand Ocean Group Limited

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">IN FAVOUR OF:

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CICC Sun Company Limited

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Carlyle Asia Growth Partners III, L.P.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CAGP III Co-Investment, L.P.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Starr Investments Cayman II, Inc.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>SHARE CHARGE</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Conyers Dill &#038; Pearman<BR>
Barristers &#038; Attorneys<BR>
Cayman Islands
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>THIS SHARE CHARGE is made on the 10</B><SUP style="font-size: 85%; vertical-align: text-top"><B>th </B></SUP><B>day of November, 2008</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>BY:</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Thousand Ocean Group Limited, a company incorporated under the laws of the British Virgin
Islands (the &#147;Chargor&#148;);</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>IN FAVOUR OF:</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CICC Sun Company Limited, a company incorporated under the laws of the British Virgin Islands
(&#147;CICC&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Carlyle Asia Growth Partners III, L.P., a limited partnership formed under the laws of the
Cayman Islands (&#147;CAGP&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CAGP III Co-Investment, L.P., a limited partnership formed under the laws of the Cayman Islands
(&#147;CAGP Co-Invest&#148;, and together with CAGP, &#147;Carlyle&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Starr Investments Cayman II, Inc., a company incorporated under the laws of the Cayman Islands
(&#147;Starr&#148;, and together with CICC and Carlyle, the &#147;Chargees&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>WHEREAS:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By a share subscription agreement dated October&nbsp;10, 2008, as amended on October&nbsp;20, 2008 (the
&#147;Share Subscription Agreement&#148;) made between, inter alia, the Chargor, the Chargees, the Company
(as defined below) and other parties specified therein, the Chargees subscribed for series B
redeemable convertible preferred shares of par value US$0.01 each of the Company (the &#147;Series&nbsp;B
Shares&#148;) on the terms and conditions therein set out.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As security for the obligations of the Chargor under Article&nbsp;3 of the Share Subscription
Agreement, the Chargor has agreed to charge, inter alia, its interest in certain of the shares
beneficially owned by the Chargor in Concord Medical Services Holdings Limited, a company
incorporated under the laws of the Cayman Islands (the &#147;Company&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(C)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company is authorised to issue 5,000,000 shares of a par value of US$0.01 each of which
4,500,000 shares are designated as ordinary shares (the &#147;Ordinary Shares&#148;), 200,000 are series A
redeemable convertible preferred shares (the &#147;Series&nbsp;A Shares&#148;) and 300,000 are Series&nbsp;B Shares.
32,624 Ordinary Shares have been issued to and fully paid by, and are beneficially owned by and
registered in the name of, the Chargor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(D)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to Section&nbsp;7.07(b) of the Share Subscription Agreement, the Chargor shall execute this
Charge in favour of the Chargees and the same is executed by the Chargor in consideration of the
Chargees agreeing to enter into the Share Subscription Agreement and for other good and valuable
consideration (the sufficiency of which the Chargor hereby acknowledges).</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>NOW THIS CHARGE WITNESSES </B>as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1 INTERPRETATION</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Charge, unless the context otherwise requires, the following words and expressions
shall have the following meanings:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="25%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="70%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Aggregate Ownership&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Shareholders&#146;
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Business Day&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charge&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means this share charge;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charged Property&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means all of the Charged Shares and all dividends or
other distributions, interest and other moneys paid or
payable after the date hereof in connection therewith
and all interests in and all rights accruing at any time to
or in respect of all or any of the Charged Shares and all
and any other property that may at any time be received
or receivable by or otherwise distributed to the Chargor
in respect of or in substitution for, or in addition to, or
in exchange for, or on account of, any of the foregoing,
including, without limitation, any shares or other
securities resulting from the division, consolidation,
change, conversion or reclassification of any of the
Charged Shares, or the reorganization or amalgamation
of the Company with any other body corporate, or the
occurrence of any event which results in the
substitution or exchange of the Charged Shares;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charged Shares&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means 6,525 Ordinary Shares of the Company
registered in the name of the Chargor as legal and
beneficial owner thereof;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Closing Date&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Controlling Shareholders&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Event of Default&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the failure by the Chargor to satisfy the Secured
Obligations with respect to the Chargees or any of
them;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Fully Diluted&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Group Company&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="25%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="70%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Ordinary Shares&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ordinary shares of par value US$0.01 each of the Company;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Parties&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the parties to this Charge collectively; &#147;Party&#148;
means any one of them;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Pre-Closing Offshore <BR>
Acquisition&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in <B>Clause 3.1.1</B>;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Secured Obligations&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the obligations of the Chargor to deliver Ordinary
Shares to the Chargees or any of them as specified in
<B>Clause 3.1</B>;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Security Interest&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means any charge, mortgage, pledge, lien, security
interest or other encumbrance;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Security Period&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the period commencing on the date of execution of
this Charge and terminating upon the earliest to occur of
(i)&nbsp;November&nbsp;10, 2014, (ii)&nbsp;the date on which Aggregate
Ownership of Ordinary Shares by each Chargee is less than
20% of such Chargee&#146;s Initial Ownership (as defined in
the Shareholders&#146; Agreement) of Ordinary Shares and (iii)
the date on which a Singapore law firm delivers a legal
opinion to the Chargees, in form and substance
satisfactory to each Chargee, with respect to the
issuance of Ordinary Shares to certain Controlling
Shareholder Holding Companies (as defined in the Share
Subscription Agreement) in August&nbsp;2008;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Shareholders&#146; Agreement&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the Amended and Restated Shareholders&#146;
Agreement dated October&nbsp;20, 2008 by and among the
Company, the Chargor, the Chargees and other parties
specified therein; and</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Third-Party Transferee&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in <B>Clause 3.1.1</B>.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Charge unless the context otherwise requires:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to statutory provisions shall be construed as references to those
provisions as amended or re-enacted or as their application is modified by other provisions
from time to time and shall include references to any provisions of which they are
re-enactments (whether with or without modification);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to clauses and schedules are references to clauses hereof and schedules
hereto; references to sub-clauses or paragraphs are, unless otherwise stated, references to
sub-clauses of the clauses hereof or paragraphs of the schedule in which the reference
appears;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to the singular shall include the plural and vice versa and references to
the masculine shall include the feminine and/or neuter and vice versa; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to persons shall include companies, partnerships, associations and bodies
of persons, whether incorporated or unincorporated;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to assets include property, rights and assets of every description;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to any document are to be construed as references to such document as
amended or supplemented from time to time; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the rights, interests and obligations of the Chargees hereunder are joint and are
exercisable by the Chargees collectively.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>2 CHARGOR&#146;S REPRESENTATIONS AND WARRANTIES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Chargor hereby represents and warrants to the Chargees that:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the authorised share capital of the Company consists of the shares described in <B>Recital (C)</B>
hereof and such shares are beneficially owned and registered as described in the said recital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor is a company duly organised, validly existing and in good standing under the laws
of the British Virgin Islands;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>entry into this Charge by the Chargor and enforcement hereof by the Chargees will not
contravene the terms of any agreement to which the Chargor is bound or to which the Charged Shares
are subject or the memorandum and articles of association of the Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor is the legal and beneficial owner of all of the Charged Property free from any
Security Interest (other than those created by this Charge) and any options or rights of
pre-emption and the Charged Shares are fully paid up and are not and will not be liable to any
future call, assessment or demand of any sort;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Charged Shares are duly authorised, validly issued and fully paid;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>no moneys or liabilities are outstanding or payable with respect to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor has full power and authority (i)&nbsp;to be the legal and beneficial owner of the
Charged Property, (ii)&nbsp;to execute and deliver this Charge and (iii)&nbsp;to comply with the provisions
of, and perform all its obligations under, this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Charge creates those Security Interests it purports to create and is not liable to be
avoided or otherwise set aside on liquidation, administration or otherwise;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Charge constitutes the Chargor&#146;s legal, valid and binding obligations enforceable against
the Chargor in accordance with its terms except as such enforcement may be limited by any relevant
bankruptcy, insolvency, administration or similar laws affecting creditors&#146; rights generally;</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the entry into and performance by the Chargor of this Charge does not violate (i)&nbsp;any law or
regulation of any governmental or official authority, or (ii)&nbsp;any agreement, contract or other
undertaking to which the Chargor is a party or which is binding upon the Chargor or any of its
assets;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other than registration of this Charge in the register of charges of the Chargor in accordance
with the requirements of the BVI Business Companies Act, 2004, no authorisation, approval or other
action by, and no notice to or filing with, any governmental authority or regulatory body is
required for either the grant by the Chargor of the Security Interests purported to be created in
favour of the Chargee under this Charge; or the exercise by the Chargee of any rights or remedies
in respect of the Charged Property (whether or not specifically granted or created under this
Charge);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all consents, licences, approvals and authorisations required in connection with the entry
into, performance, validity and enforceability of this Charge have been obtained and are in full
force and effect;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor has taken all corporate and other action required to approve its execution,
delivery and performance of this Charge; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company is not a land holding corporation for the purposes of the Land Holding Companies
Share Transfer Tax Law of the Cayman Islands.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>3 CHARGOR&#146;S COVENANTS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Chargor hereby covenants with the Chargees:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to discharge all obligations and liabilities specified in Section&nbsp;10.02(c)(vii) of the Share
Subscription Agreement at the following times and in the following manner:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company is required to issue a number of Ordinary Shares to any person
(a &#147;Third-Party Transferee&#148;) pursuant to any arbitral or judicial judgment on, or
settlement of, any claim, dispute or litigation in connection with any acquisition by any
Group Company of any person (other than persons established under the Laws of the PRC)
which has been consummated prior to the Closing Date (any &#147;Pre-Closing Offshore
Acquisition&#148;) and the Controlling Shareholders, severally and jointly, fail to transfer
such number of Ordinary Shares to such Third-Party Transferee in lieu of and on behalf of
such Group Company at the per share price and on the date set forth in such judgment or
settlement, the Chargor shall, severally and jointly with other Controlling Shareholders,
on the Business Day immediately following such date, transfer free of charge a number of
Ordinary Shares to each Chargee equal to (x)&nbsp;the aggregate number of Ordinary Shares
required to be transferred to such Third-Party Transferee pursuant to such judgment or
settlement <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which is the Aggregate Ownership of
Ordinary Shares by such Chargee on such payment date and the denominator of which is the
outstanding number of Ordinary Shares on such payment date, calculated on a Fully-Diluted
basis;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company is required to make any payment in cash to any person pursuant
to any arbitral or judicial judgment on, or settlement of, any claim, dispute or litigation
in connection with any Pre-Closing Offshore Acquisition and</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Controlling Shareholders, severally and jointly, fail to make such payment in
lieu of and on behalf of such Group Company by the payment time set forth in such
judgment or settlement, the Chargor shall, severally and jointly with other
Controlling Shareholders, within 10 Business Days following such payment date,
transfer free of charge a number of Ordinary Shares to each Chargee equal to (x)
the amount of such payment in US dollars (based on the &#147;noon buying rate&#148; for
purchases of any currency other than US dollars on such payment date published by
the Federal Reserve Bank of New York) <I>divided </I>by (y)&nbsp;the fair market value of the
Ordinary Shares in US dollars on a per share basis on such payment date as
determined by the Controlling Shareholders and the Chargees by mutual agreement or
if such mutual agreement cannot be reached within 5 Business Days following such
payment date, determined by an independent appraiser satisfactory to the Chargees
within 10 Business Days following such payment date <I>multiplied </I>by (z)&nbsp;a ratio, the
numerator of which is the Aggregate Ownership of Ordinary Shares by such Chargee on
such payment date and the denominator of which is the outstanding number of
Ordinary Shares on such payment date, calculated on a Fully-Diluted basis; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company incurs or suffers any damages arising out of any claim, dispute
or litigation in connection with any Pre-Closing Offshore Acquisition, other than those
damages described in <B>Clauses 3.1.1 and 3.1.2</B>, and the Controlling Shareholders, severally
and jointly, fail to indemnify the Company pursuant to Section&nbsp;10.02(c)(vii) of the Share
Subscription Agreement by the date of such incurrence or suffering, the Chargor shall,
severally and jointly with other Controlling Shareholders, transfer free of charge a number
of Ordinary Shares to each Chargee equal to (x)&nbsp;the amount of such damages expressed in US
dollars <I>divided </I>by (y)&nbsp;the fair market value of the Ordinary Shares in US dollars on a per
share basis calculated as set forth above in Clause 3.1.2 <I>multiplied </I>by (z)&nbsp;a ratio, the
numerator of which is the Aggregate Ownership of Ordinary Shares by such Chargee on such
date and the denominator of which is the outstanding number of Ordinary Shares on such
date, calculated on a Fully-Diluted basis, in each case of sub-clause (x)&nbsp;and (y)&nbsp;as
determined by the Controlling Shareholders and the Chargees by mutual agreement or if such
mutual agreement cannot be reached within 5 Business Days following such payment date,
determined by an independent appraiser satisfactory to the Chargees within 10 Business Days
following such date;</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">the obligations in <B>Clauses 3.1.1, 3.1.2 and 3.1.3 </B>collectively, the &#147;Secured Obligations&#148;.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor will on demand of the Chargees and at the expense of the Chargor, execute and
deliver to the Chargees or to such person or persons as the Chargees may nominate such additional
charge or charges of the Charged Property (or any part thereof) for the purpose of further securing
the payment and discharge of all Secured Obligations, each such additional charge to be in such
form as the Chargees may reasonably require;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor shall, on request of the Chargees, provide to the Chargees immediately on
receipt by the Chargor a copy of all notices, written consents, reports, accounts, circulars and
other communications issued by the Company or by any third party in respect of the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor will not without the prior written consent of the Chargees:</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any person other than the Chargor, the Chargees or any transferee nominated by
the Chargees on enforcement of this Charge to be the registered holder of any of the
Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any variation of the rights attaching to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>take or permit any action which might result in an increase or reduction in the
authorised share capital of the Company or the number of shares that the Company is
authorised to issue or the issued share or share capital of the Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit the Company to be continued to another jurisdiction outside of the Cayman
Islands;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>effect or permit the appointment of any new or further directors or officers of the
Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any scheme of arrangement, merger, amalgamation or other reorganisation
applicable to the Company; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>save in accordance with <B>Clause 8.2, </B>permit any amendment to the memorandum or
articles of association of the Company without prior written consent of the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>4 SECURITY</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In consideration of the Chargees agreeing to enter into the Share Subscription Agreement and as
a continuing security for the Secured Obligations, the Chargor as legal and beneficial owner hereby
assigns and agrees to assign to the Chargees jointly all benefits present and future, actual and
contingent accruing in respect of the Charged Property and all the Chargor&#146;s right, title and
interest to and in the Charged Property including (without limitation) all voting and other
consensual powers pertaining to the Charged Shares and hereby charges and agrees to charge in
favour of the Chargees jointly all of its interest in the Charged Property by way of a first fixed
charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby agrees to deliver, or cause to be delivered, to the Chargees on the date
hereof:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>duly executed undated share transfers in respect of the Charged Shares in favour of
the Chargees or their nominees in the form set out in Schedule&nbsp;I;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an executed undated irrevocable proxy made in respect of the Charged Shares in favour
of the Chargees in respect of all general meetings of the Company in the form set out in
Schedule&nbsp;II;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all original share certificates representing, and all other documents, title or
evidence of, ownership in relation to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>signed, but undated resolutions of the board of directors of the Company in the form
set out in Schedule&nbsp;III; and</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an executed undertaking from the Company to register transfers of the Charged Shares
to the Chargees or their nominees in the form set out in Schedule&nbsp;IV dated as of the date
hereof (the &#147;Undertaking&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall be entitled to:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>continue to hold any document delivered to them pursuant to <B>Clauses 4.2.1 through
4.2.5 </B>above until the Charged Shares are released from this Charge and if, for any reason,
they release any such document to the Chargor before such time, they may by notice to the
Chargor require that such document be redelivered to them and the Chargor shall promptly
comply with that requirement or procure that it is complied with; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>at any time after the Security Interest has become enforceable as provided in <B>Clause
7</B>, subject to the limitation set out in <B>Clause 7.1</B>, complete any document delivered to them
pursuant to <B>Clauses 4.2.1 through 4.2.5 </B>above in favour of, and register any Charged Share
in the names of the Chargees or such other person as they shall select, and the Chargor
shall promptly take or procure the taking by all such other persons (including, without
limitation, the secretary of the Company) any other action and execute and deliver to the
Chargees any other document (in form and substance reasonably satisfactory to each Chargee)
which may be reasonably requested by the Chargees in order to enable the Chargees or such
other person as they shall select to be registered as the owner of, or otherwise obtain
legal title to, any Charged Share; this includes procuring that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>those share transfers are duly registered in the shareholder register of the
Company; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>share certificates in the name of the Chargees or such other person as they
shall select are delivered to the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor will deliver, or cause to be delivered, to the Chargees immediately upon the issue
of any further Charged Shares, the items listed in <B>Clauses 4.2.1 through 4.2.5 </B>(if the documents
already provided are not sufficient to cover the further Charged Shares) in respect of all such
further Charged Shares.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby covenants that during the Security Period it will remain the legal and the
beneficial owner of the Charged Property (subject only to the Security Interests hereby created)
and that it will not:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>create or suffer the creation of any Security Interests (other than those created by
this Charge) on or in respect of the whole of any part of the Charged Property or any of
its interest therein; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sell, assign, transfer or otherwise dispose of any of its interest in the Charged
Property (other than with respect to the dividend or distribution payments described in
<B>Clause 5.1.2</B>); or</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>do or cause or permit to be done anything which may in any way affect, depreciate,
jeopardize or otherwise prejudice the market value of the Charged Shares or its rights with
respect thereto;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>vote in respect of the Charged Shares or receive any dividends or other distributions
paid by the Company in respect of the Charged Shares,</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in any such case without the prior consent in writing of the Chargees.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Security Period, the Chargor shall remain liable to perform all the obligations
assumed by it in relation to the Charged Property and the Chargees shall be under no obligation of
any kind whatsoever in respect thereof or be under any liability whatsoever in the event of any
failure by the Chargor to perform its obligations in respect thereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the Chargees being satisfied that the Secured Obligations have been unconditionally and
irrevocably paid and discharged in full or upon the expiry of the Security Period, and following a
written request therefor from the Chargor, the Chargees will, subject to being indemnified to each
of their respective reasonable satisfaction for the costs and expenses incurred by the Chargees in
connection therewith, release the Charged Shares (if any as the case may be) and security
constituted by this Charge.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>5 DEALINGS WITH CHARGED PROPERTY</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Unless and until an Event of Default has occurred:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to exercise all voting and/or consensual powers
pertaining to the Charged Property or any part thereof for all purposes not inconsistent
with the terms of this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to receive and retain any dividends, interest or other
moneys or assets accruing on or in respect of the Charged Property or any part thereof; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to receive all notices pertaining to the Charged
Shares.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay all calls, instalments or other payments, and shall discharge all other
obligations, which may become due in respect of any of the Charged Property and in an Event of
Default, the Chargees may, if they think fit, make such payments or discharge such obligations on
behalf of the Chargor. Any sums so paid by the Chargees in respect thereof shall be repayable on
demand and, pending such repayment, shall constitute part of the Secured Obligations.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not have any duty to ensure that any dividends, interest or other moneys and
assets receivable in respect of the Charged Property are duly and punctually paid, received or
collected as and when the same become due and payable or to ensure that the correct amounts (if
any) are paid or received on or in respect of the Charged Property or to ensure the taking up of
any (or any offer of any) stocks, shares, rights, moneys or other property paid, distributed,
accruing or offered at any time by way of</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>redemption bonus, rights, preference, or otherwise on or in respect of, any of the Charged
Property.</TD>
</TR>
<TR style="font-size: 10pt"><TD align="left" valign="top">&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby authorises the Chargees to arrange at any time and from time to time
(whether before or after the occurrence of an Event of Default) for the Charged Property or any
part thereof to be registered in the name of the Chargees (or their nominees) thereupon to be held
as so registered subject to the terms of this Charge.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>6 PRESERVATION OF SECURITY</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It is hereby agreed and declared that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the security created by this Charge shall be held by the Chargees as a continuing
security for the payment and discharge of the Secured Obligations and the security so
created shall not be satisfied by any intermediate payment or satisfaction of any part of
the Secured Obligations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargees shall not be bound to enforce any other security before enforcing the
security created by this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>no delay or omission on the part of the Chargees in exercising any right, power or
remedy under this Charge shall impair such right, power or remedy or be construed as a
waiver thereof nor shall any single or partial exercise of any such right, power or remedy
preclude any further exercise thereof or the exercise of any other right, power or remedy.
The rights, powers and remedies herein provided are cumulative and not exclusive of any
rights, powers and remedies provided by law and may be exercised from time to time and as
often as the Chargees may deem expedient; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any waiver by the Chargees of any terms of this Charge shall only be effective if
given in writing and then only for the purpose and upon the terms for which it is given.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any settlement or discharge under this Charge between the Chargees and the Chargor shall be
conditional upon no security or payment to the Chargees by the Company or the Chargor or any other
person being avoided or set-aside or ordered to be refunded or reduced or if the aforesaid security
or payment to the Chargees is adversely affected by virtue of any provision or enactment relating
to bankruptcy, insolvency, administration or liquidation for the time being in force and, if such
condition is not satisfied, the liability of the Chargor under this Charge shall be reinstated or
continue and the Chargees shall be entitled to recover from the Chargor on demand the value of such
security or the amount of any such payment as if such settlement or discharge had not occurred.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The rights of the Chargees under this Charge and the Security Interest hereby constituted shall
not be affected by any act, omission, matter or thing which, but for this provision, might operate
to impair, affect or discharge such rights and security, in whole or in part, including without
limitation, and whether or not known to or discoverable by the Company, the Chargor, the Chargees
or any other person:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any time or waiver granted to or composition with the Company or any other person;</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the taking, variation, compromise, renewal or release of or refusal or neglect to
perfect or enforce any rights, remedies or securities against the Company or any other
person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any legal limitation, disability, incapacity or other circumstances relating to the
Company or any other person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any amendment or supplement to the Share Subscription Agreement or any other document
or security;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the dissolution, liquidation, amalgamation, reconstruction or reorganisation of the
Company or any other person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the unenforceability, invalidity or frustration of any obligations of the Company or
any other person under the Share Subscription Agreement or any other document or security;
or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any non-observance of any formality or other requirements in respect of any other
instrument or any failure to realise the full value of any other security.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Until the Secured Obligations have been unconditionally and irrevocably satisfied and
discharged in full to the satisfaction of the Chargees or until the expiry of the Security Period,
the Chargor shall not by virtue of any payment made hereunder on account of the Secured Obligations
or by virtue of any enforcement by the Chargees of their rights under, or the security constituted
by, this Charge or by virtue of any relationship between or transaction involving, the Chargor and
the Company (whether such relationship or transaction shall constitute the Chargor a creditor of
the Company, a guarantor of the obligations of the Company or a party subrogated to the rights of
others against the Company or otherwise howsoever and whether or not such relationship or
transaction shall be related to, or in connection with, the subject matter of this Charge):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any rights of subrogation in relation to any rights, security or moneys held
or received or receivable by the Chargees or any person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any right of contribution from any co-surety liable in respect of the Second
Obligation under any other guarantee, security or agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any right of set-off or counterclaim against the Chargees, the Company or
any such co-surety;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>receive, claim or have the benefit of any payment, distribution, security or
indemnity from the Company or any such co-surety; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>unless so directed by the Chargees (when the Chargor will prove in accordance with
such directions), claim as a creditor of the Company or any such co-surety in competition
with the Chargees.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">The Chargor shall hold in trust for the Chargees and forthwith pay or transfer (as
appropriate) to the Chargees any such payment (including an amount equal to any such
set-off), distribution (other than such dividend or distribution payments described in
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><B>Clause 5.1.2) </B>or benefit of such security, indemnity or claim in fact received by the
Chargor.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Until the Secured Obligations have been unconditionally and irrevocably satisfied and
discharged in full to the satisfaction of the Chargees or until the expiry of the Security Period,
the Chargees may at any time keep in a separate account or accounts (without liability to pay
interest thereon) in the name of the Chargees for as long as they may think fit, any moneys
received, recovered or realised under this Charge or under any other guarantee, security or
agreement relating in whole or in part to the Secured Obligations without being under any
intermediate obligation to apply the same or any part thereof in or towards the discharge of such
amount.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>7 ENFORCEMENT OF SECURITY</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the occurrence of an Event of Default or a demand being made by the Chargees for the
satisfaction of the Secured Obligations with respect to the Chargees or any of them, the Security
Interest hereby constituted shall become immediately enforceable by the Chargees and the Chargees
may, at any time, without further notice to or consultation with or consent of the Chargor:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>solely and exclusively exercise all voting and/or consensual powers pertaining to the
Charged Property or any part thereof and may exercise such powers in such manner as the
Chargees may think fit;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>receive and retain all dividends, interest, distributions or other moneys or assets
accruing on or in respect of the Charged Property or any part thereof, and any such
dividends, interest, distributions or other moneys or assets received by the Chargor after
such time shall be held in trust by the Chargor for the Chargees and paid or transferred to
the Chargees on demand;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if the Chargees elect to, sell, transfer, grant options over or otherwise dispose of
the Charged Property or any part thereof at such place and in such manner and at such price
or prices as the Chargees may deem fit;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated blank share transfer forms delivered to the Chargees pursuant to
<B>Clause 4.2.1 </B>by dating the same and inserting their names or the names of their nominees as
transferees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated resolutions of the board of directors of the Company delivered
to the Chargees pursuant to <B>Clause 4.2.4 </B>by dating the same and inserting the names of the
transferees and the number of Ordinary Shares to be transferred; and/or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated irrevocable proxy delivered to the Chargees pursuant to <B>Clause
4.2.2 </B>by dating the same and inserting the names and addresses of all Chargees or the names
and addresses of their respective nominees;</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">PROVIDED THAT notwithstanding any other provision of this Charge, the Chargees may only
exercise their rights under <B>Clauses 7.1.5 and 7.1.6 </B>in respect of such number of Charged
Shares not exceeding the aggregate number of Ordinary Shares that the Chargor has failed to
transfer (the &#147;Default Shares&#148;) to the Chargees or any of them under <B>Clause</B>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><B>3.1 </B>in satisfaction of the Secured Obligations with respect to all and/or any of the
Chargees.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not be obliged to make any enquiry as to the nature or sufficiency of any
payment received by them under this Charge or to make any claim or to take any action to collect
any moneys assigned by this Charge or to enforce any rights or benefits assigned to the Chargees by
this Charge or to which the Chargees may at any time be entitled hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon any sale by the Chargees of the Charged Property or any part thereof by the Chargees, the
purchaser shall not be bound to see or enquire whether the Chargees&#146; power of sale has become
exercisable in the manner provided in this Charge and the sale shall be deemed to be within the
power of the Chargees, and the receipt of the Chargees for the purchase money shall effectively
discharge the purchaser who shall not be concerned with the manner of application of the proceeds
of sale or be in any way answerable therefor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Neither the Chargees nor their agents, managers, officers, employees, delegates or advisers
shall be liable for any claim, demand, liability, loss, damage, cost or expense incurred or arising
in connection with the exercise or purported exercise of any rights, powers and discretions
hereunder in the absence of fraud or dishonesty.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not by reason of the taking of possession of the whole or any part of the
Charged Property or any part thereof be liable to account as mortgagee-in-possession or for
anything except actual receipts or be liable for any loss upon realisation or for any default or
omission for which a mortgagee-in-possession might be liable.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>8 FURTHER ASSURANCES</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall execute and do all such assurances, acts and things as the Chargees in their
absolute discretion may require for:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>creating, perfecting, protecting or ensuring the priority of the Security Interest
hereby created (or intended to be created);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>preserving or protecting any of the rights of the Chargees under this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ensuring that the security constituted by this Charge and the covenants and
obligations of the Chargor under this Charge shall inure to the benefit of any assignee of
the Chargees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>facilitating the appropriation or realisation of the Charged Property or any part
thereof; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercising any power, authority or discretion vested in the Chargees under this
Charge,</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">in any such case forthwith upon demand by the Chargees and at the expense of the Chargor.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Without limitation to the generality of <B>Clause 8.1</B>, the Chargor covenants with the Chargees
that it will on demand of the Chargees procure any amendment to the memorandum and articles of
association of the Company necessary or, in the opinion of the Chargees desirable, in order to give
effect to the terms of this Charge or any documents or transactions provided for herein.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>9 INDEMNITIES</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor will indemnify and save harmless the Chargees and each agent or attorney appointed
under or pursuant to this Charge from and against any and all expenses, claims, liabilities,
losses, taxes, costs, duties, fees and charges properly and reasonably suffered, incurred or made
by the Chargees or such agent or attorney:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the exercise or purported exercise of any rights, powers or discretions vested in
them pursuant to this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the preservation or enforcement of the Chargees&#146; rights under this Charge or the
priority thereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>on the release of any part of the Charged Property from the security created by this
Charge; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>as a result, directly or indirectly of any breach by the Chargor of any covenant or
other obligation under this Charge.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">and the Chargees or such agent or attorney may retain and pay all sums in respect of the
same out of money received under the powers conferred by this Charge. All amounts
recoverable by the Chargees or such agent or attorney or any of them shall be recoverable
on a full indemnity basis.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If, under any applicable law or regulation, and whether pursuant to a judgment being made or
registered against the Chargor or the bankruptcy or liquidation of the Chargor or for any other
reason any payment under or in connection with this Charge is made or falls to be satisfied in a
currency (the &#147;Payment Currency&#148;) other than the currency in which such payment is due under or in
connection with this Charge (the &#147;Contractual Currency&#148;), then to the extent that the amount of
such payment actually received by the Chargees when converted into the Contractual Currency at the
rate of exchange, falls short of the amount due under or in connection with this Charge, the
Chargor, as a separate and independent obligation, shall indemnify and hold harmless the Chargees
against the amount of such shortfall. For the purposes of this clause, &#147;rate of exchange&#148; means the
rate at which the Chargees is able on or about the date of such payment to purchase the Contractual
Currency with the Payment Currency and shall take into account any premium and other costs of
exchange with respect thereto.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>10 POWER OF ATTORNEY</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor, by way of security and in order more fully to secure the performance of its
obligations hereunder, pursuant to the Power of Attorney Law (1996 Revision) hereby irrevocably
appoints each of the Chargees and the persons deriving title under it jointly and also severally to
be its attorney:</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to execute and complete in favour of the Chargees or its nominees or of any
purchaser any documents which the Chargees may from time to time require for perfecting
their title to or for vesting any of the assets and property hereby charged or assigned to
the Chargees or their nominees or in any purchaser and to give effectual discharges for
payments;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to take and institute on non-payment (if the Chargees in their sole discretion so
decide) all steps and proceedings in the name of the Chargor or of the Chargees for the
recovery of such moneys, property and assets hereby charged and to agree accounts;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to make allowances and give time or other indulgence to any surety or other person
liable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>otherwise generally to act for it and in its name and on its behalf; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to sign, execute, seal and deliver and otherwise perfect and do any such legal
assignments and other assurances, charges, authorities and documents over the moneys,
property and assets hereby charged, and all such deeds, instruments, acts and things
(including, without limitation, those referred to in <B>Clause 8</B>) which may be required for
the full exercise of all or any of the powers conferred or which may be deemed proper on or
in connection with any of the purposes aforesaid.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The power hereby conferred shall be a general power of attorney and the Chargor hereby
ratifies and confirms and agrees to ratify and confirm any instrument, act or thing which any such
attorney may execute or do. In relation to the power referred to herein, the exercise by any of
the Chargees of such power shall be conclusive evidence of its right to exercise the same.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>11 EXPENSES</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.1</TD>
    <TD COLSPAN="3">The Chargor shall pay to the Chargees on demand all costs, fees and expenses (including but
not limited to legal fees and expenses) and taxes thereon incurred by the Chargees or for which
the Chargees may become liable in connection with:</TD>

</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the negotiation, preparation and execution of this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the preserving or enforcing of, or attempting to preserve or enforce, any of its
rights under this Charge or the priority hereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any variation of, or amendment or supplement to, any of the terms of this Charge;
and/or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any consent or waiver required from the Chargees in relation to this Charge,</TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD COLSPAN="3">and in any case referred to in <B>Clauses 11.1.3 and 11.1.4 </B>regardless of whether the same
is actually implemented, completed or granted, as the case may be.</TD>

</TR>
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay promptly any stamp, documentary and other like duties and taxes to which
this Charge may be subject or give rise and shall indemnify the Chargees on demand against any and
all liabilities with respect to or resulting from any delay or omission on the part of the Chargor
to pay any such duties or taxes.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>12 NOTICES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any notice required to be given hereunder shall be in writing in the English language and shall be
served by sending the same by prepaid recorded post, facsimile or by delivering the same by hand to
the address of the Party or Parties in question as set out below (or such other address as such
Party or Parties shall notify the other Parties of in accordance with this clause). Any notice sent
by post as provided in this clause shall be deemed to have been served five Business Days after
despatch and any notice sent by facsimile as provided in this clause shall be deemed to have been
served at the time of despatch and in proving the service of the same it will be sufficient to
prove in the case of a letter that such letter was properly stamped, addressed and placed in the
post; and in the case of a facsimile that such facsimile was duly despatched to a current facsimile
number of the addressee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Chargor</U><BR>
Thousand Ocean Group Limited<BR>
P.O. Box 957<BR>
Offshore Incorporations Centre<BR>
Road Town, Tortola<BR>
British Virgin Islands<BR>
Attention: Mr.&nbsp;Jing Zhang

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Chargees:</U><BR>
If to CICC, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">China International Capital Corporation<BR>
28<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>Floor, China World Tower 2<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Fax: 86-10-6505-3796<BR>
Attention: Ms.&nbsp;Shirley Chen

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to Carlyle, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Carlyle Group<BR>
2518-2521, South Office Tower<BR>
Beijing Kerry Centre<BR>
No.&nbsp;1, Guang Hua Road<BR>
Chao Yang District<BR>
Beijing 100020<BR>
People&#146;s Republic of China<BR>
Fax: 86-10-8529-9877<BR>
Attention: Mr.&nbsp;Feng Xiao

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With a copy to:

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Davis Polk &#038; Wardwell LLP<BR>
26<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>Floor, Twin Tower West<BR>
B12, Jian Guo Men Wai Avenue<BR>
Chao Yang District<BR>
Beijing 100022<BR>
People&#146;s Republic of China<BR>
Tel: 86-10-8567-5000<BR>
Fax: 86-10-8567-5123<BR>
Attention: Mr.&nbsp;Show-Mao Chen, Esq.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to Starr, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Starr Investments Cayman II, Inc.<BR>
c/o Starr International Company (Asia) Limited<BR>
Suite&nbsp;1405-7, Two Exchange Square<BR>
8 Connaught Place, Central<BR>
Hong Kong<BR>
Tel: 852-2905-1166<BR>
Fax: 852-2905-1555<BR>
Attention: Ms.&nbsp;Elaine Zong

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With a copy to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Skadden, Arps, Slate, Meagher &#038; Flom<BR>
East Wing Office, Level 4<BR>
China World Trade Centre<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Tel: 86-10-6535-5500<BR>
Fax: 86-10-6505-5522<BR>
Attention: Mr.&nbsp;Peter X. Huang

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>13 ASSIGNMENTS</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">13.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge shall be binding upon and shall inure to the benefit of the Chargor and the
Chargees and each of their respective successors and (subject as hereinafter provided) assigns and
references in this Charge to any of them shall be construed accordingly.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">13.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor may not assign or transfer all or any part of its rights and/or obligations under
this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">13.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees may not assign or transfer all or any part of its rights or obligations under
this Charge to any assignee or transferee without the consent of the Chargor, such consent not to
be unreasonably withheld, provided that no such consent shall be required if an Event of Default
affecting the Chargor has occurred and is continuing. The Chargees shall notify the Chargor
promptly following any such assignment or transfer.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>14 MISCELLANEOUS</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees, at any time and from time to time, may delegate by power of attorney or in any
other manner to any person or persons all or any of the powers, authorities and discretions which
are for the time being exercisable by the Chargees under this Charge in relation to the Charged
Property or any part thereof. Any such delegation may be made upon such terms and be subject to
such regulations as the Chargees may think fit. The
Chargees shall not be in any way liable or responsible to the Chargor for any loss or
damage arising from any act, default, omission or misconduct on the part of any such
delegate provided the Chargees has acted reasonably in selecting such delegate.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If any of the clauses, conditions, covenants or restrictions of this Charge or any deed or
document emanating from it shall be found to be void but would be valid if some part thereof were
deleted or modified, then such clause, condition, covenant or restriction shall apply with such
deletion or modification as may be necessary to make it valid and effective.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge (together with any documents referred to herein) constitutes the whole agreement
between the Parties relating to its subject matter and no variations hereof shall be effective
unless made in writing and signed by each of the Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The headings in this Charge are inserted for convenience only and shall not affect the
construction of this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge may be executed in counterparts each of which when executed and delivered shall
constitute an original but all such counterparts together shall constitute one and the same
instrument.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To the maximum extent permitted under applicable laws, the Chargor hereby waives any immunity
under the laws applicable to the Chargor, whether characterised as sovereign immunity or otherwise,
from any legal proceedings to enforce this Charge in respect of itself or its property.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>15 LAW AND JURISDICTION</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Charge shall be governed by and construed in accordance with the laws of the Cayman Islands
and the Parties hereby irrevocably submit to the non-exclusive jurisdiction of the courts of Hong
Kong, provided that nothing in this clause shall affect the rights of the Chargees to serve process
in any manner permitted by law or limit the rights of the Chargees to take proceedings with respect
to this Charge against the Chargor in any jurisdiction nor shall the taking of proceedings with
respect to this Charge in any jurisdiction preclude the Chargees from taking proceedings with
respect to this Charge in any other jurisdiction, whether concurrently or not.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Follow</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS whereof the parties hereto have caused this Charge to be duly executed as a Deed the day
and year first before written.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">The Common Seal of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">THOUSAND OCEAN GROUP LIMITED
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">was hereunto affixed in the
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">presence of:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Zhang Jing&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Zhang Jing
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shi Bo Tao&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Shi Bo Tao
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Witness)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Thousand Ocean 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
     <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Executed as a deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">For and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">CICC SUN COMPANY LIMITED
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shirley Chen&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Shirley Chen
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Xin, Jie&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Xin, Jie
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Thousand Ocean 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
   <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Executed as a deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">For and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">CARLYLE ASIA GROWTH PARTNERS III, L.P.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">By: CAGP General Partner, L.P., as its General Partner
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">By: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Daniel A. D&#146;Aniello
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
   <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Executed as a deed by</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">)</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">For and on behalf of</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">)</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CAGP III CO-INVESTMENT, L.P.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">)</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">in the presence of:-</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">)</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BY: CAGP General Partner, L.P., as its General Partner
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">BY: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Daniel A. D&#146;Aniello
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Thousand Ocean 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
   <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>

</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Executed as a deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">For and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">STARR INVESTMENTS CAYMAN II, INC.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Horvath</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Michael Horvath
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Thousand Ocean 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.15
<SEQUENCE>16
<FILENAME>h03611exv4w15.htm
<DESCRIPTION>EX-4.15
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.15</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.15</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Dated this 10<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>day of November, 2008
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">BY :

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Top Mount Group Limited

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">IN FAVOUR OF:

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CICC Sun Company Limited

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Carlyle Asia Growth Partners III, L.P.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CAGP III Co-Investment, L.P.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Starr Investments Cayman II, Inc.

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>SHARE CHARGE</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Conyers Dill &#038; Pearman<BR>
Barristers &#038; Attorneys<BR>
Cayman Islands

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>THIS SHARE CHARGE is made on the 10</B><SUP style="font-size: 85%; vertical-align: text-top"><B>th </B></SUP><B>day of November, 2008</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>BY:</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Top Mount Group Limited, a company incorporated under the laws of the British Virgin Islands
(the &#147;Chargor&#148;);</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>IN FAVOUR OF:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CICC Sun Company Limited, a company incorporated under the laws of the British Virgin Islands
(&#147;CICC&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Carlyle Asia Growth Partners III, L.P., a limited partnership formed under the laws of the
Cayman Islands (&#147;CAGP&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CAGP III Co-Investment, L.P., a limited partnership formed under the laws of the Cayman Islands
(&#147;CAGP Co-Invest&#148;, and together with CAGP, &#147;Carlyle&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Starr Investments Cayman II, Inc., a company incorporated under the laws of the Cayman Islands
(&#147;Starr&#148;, and together with CICC and Carlyle, the &#147;Chargees&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>WHEREAS:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By a share subscription agreement dated October&nbsp;10, 2008, as amended on October&nbsp;20, 2008 (the
&#147;Share Subscription Agreement&#148;) made between, inter alia, the Chargor, the Chargees, the Company
(as defined below) and other parties specified therein, the Chargees subscribed for series B
redeemable convertible preferred shares of par value US$0.01 each of the Company (the &#147;Series&nbsp;B
Shares&#148;) on the terms and conditions therein set out.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As security for the obligations of the Chargor under Article&nbsp;3 of the Share Subscription
Agreement, the Chargor has agreed to charge, inter alia, its interest in certain of the shares
beneficially owned by the Chargor in Concord Medical Services Holdings Limited, a company
incorporated under the laws of the Cayman Islands (the &#147;Company&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(C)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company is authorised to issue 5,000,000 shares of a par value of US$0.01 each of which
4,500,000 shares are designated as ordinary shares (the &#147;Ordinary Shares&#148;), 200,000 are series A
redeemable convertible preferred shares (the &#147;Series&nbsp;A Shares&#148;) and 300,000 are Series&nbsp;B Shares.
5,932 Ordinary Shares have been issued to and fully paid by, and are beneficially owned by and
registered in the name of, the Chargor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(D)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursuant to Section&nbsp;7.07(b) of the Share Subscription Agreement, the Chargor shall execute this
Charge in favour of the Chargees and the same is executed by the Chargor in consideration of the
Chargees agreeing to enter into the Share Subscription Agreement and for other good and valuable
consideration (the sufficiency of which the Chargor hereby acknowledges).</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>NOW THIS CHARGE WITNESSES </B>as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>1 INTERPRETATION</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Charge, unless the context otherwise requires, the following words and expressions
shall have the following meanings:</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="25%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="73%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Aggregate Ownership&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Shareholders&#146;
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Business Day&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charge&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means this share charge;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charged Property&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means all of the Charged Shares and all dividends or
other distributions, interest and other moneys paid or
payable after the date hereof in connection therewith
and all interests in and all rights accruing at any time to
or in respect of all or any of the Charged Shares and all
and any other property that may at any time be received
or receivable by or otherwise distributed to the Chargor
in respect of or in substitution for, or in addition to, or
in exchange for, or on account of, any of the foregoing,
including, without limitation, any shares or other
securities resulting from the division, consolidation,
change, conversion or reclassification of any of the
Charged Shares, or the reorganization or amalgamation
of the Company with any other body corporate, or the
occurrence of any event which results in the
substitution or exchange of the Charged Shares;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Charged Shares&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means 1,187 Ordinary Shares of the Company
registered in the name of the Chargor as legal and
beneficial owner thereof;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Closing Date&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Controlling Shareholders&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Event of Default&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the failure by the Chargor to satisfy the Secured
Obligations with respect to the Chargees or any of
them;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Fully Diluted&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Group Company&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in the Share Subscription
Agreement;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="25%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="73%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Ordinary Shares&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ordinary shares of par value US$0.01 each of the
Company;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Parties&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the parties to this Charge collectively; &#147;Party&#148;
means any one of them;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Pre-Closing Offshore
Acquisition&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in <B>Clause 3.1.1</B>;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Secured Obligations&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the obligations of the Chargor to deliver
Ordinary Shares to the Chargees or any of them as
specified in <B>Clause 3.1</B>;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Security Interest&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means any charge, mortgage, pledge, lien, security
interest or other encumbrance;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Security Period&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the period commencing on the date of execution
of this Charge and terminating upon the earliest to
occur of (i)&nbsp;November&nbsp;10, 2014, (ii)&nbsp;the date on which
Aggregate Ownership of Ordinary Shares by each
Chargee is less than 20% of such Chargee&#146;s Initial
Ownership (as defined in the Shareholders&#146; Agreement)
of Ordinary Shares and (iii)&nbsp;the date on which a
Singapore law firm delivers a legal opinion to the
Chargees, in form and substance satisfactory to each
Chargee, with respect to the issuance of Ordinary
Shares to certain Controlling Shareholder Holding
Companies (as defined in the Share Subscription
Agreement) in August&nbsp;2008;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Shareholders&#146; Agreement&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">means the Amended and Restated Shareholders&#146; Agreement
dated October&nbsp;20, 2008 by and among the Company, the
Chargor, the Chargees and other parties
specified therein; and</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#147;Third-Party Transferee&#148;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">has the meaning specified in <B>Clause 3.1.1</B>.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Charge unless the context otherwise requires:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to statutory provisions shall be construed as references to those
provisions as amended or re-enacted or as their application is modified by other provisions
from time to time and shall include references to any provisions of which they are
re-enactments (whether with or without modification);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to clauses and schedules are references to clauses hereof and schedules
hereto; references to sub-clauses or paragraphs are, unless otherwise stated, references to
sub-clauses of the clauses hereof or paragraphs of the schedule in which the reference
appears;</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to the singular shall include the plural and vice versa and references to
the masculine shall include the feminine and/or neuter and vice versa; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to persons shall include companies, partnerships, associations and bodies
of persons, whether incorporated or unincorporated;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to assets include property, rights and assets of every description;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>references to any document are to be construed as references to such document as
amended or supplemented from time to time; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the rights, interests and obligations of the Chargees hereunder are joint and are
exercisable by the Chargees collectively.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>2 CHARGOR&#146;S REPRESENTATIONS AND WARRANTIES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Chargor hereby represents and warrants to the Chargees that:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the authorised share capital of the Company consists of the shares described in <B>Recital (C)</B>
hereof and such shares are beneficially owned and registered as described in the said recital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor is a company duly organised, validly existing and in good standing under the laws
of the British Virgin Islands;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>entry into this Charge by the Chargor and enforcement hereof by the Chargees will not
contravene the terms of any agreement to which the Chargor is bound or to which the Charged Shares
are subject or the memorandum and articles of association of the Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor is the legal and beneficial owner of all of the Charged Property free from any
Security Interest (other than those created by this Charge) and any options or rights of
pre-emption and the Charged Shares are fully paid up and are not and will not be liable to any
future call, assessment or demand of any sort;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Charged Shares are duly authorised, validly issued and fully paid;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>no moneys or liabilities are outstanding or payable with respect to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor has full power and authority (i)&nbsp;to be the legal and beneficial owner of the
Charged Property, (ii)&nbsp;to execute and deliver this Charge and (iii)&nbsp;to comply with the provisions
of, and perform all its obligations under, this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Charge creates those Security Interests it purports to create and is not liable to be
avoided or otherwise set aside on liquidation, administration or otherwise;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>this Charge constitutes the Chargor&#146;s legal, valid and binding obligations enforceable against
the Chargor in accordance with its terms except as such enforcement may be limited by
any relevant bankruptcy, insolvency, administration or similar laws affecting creditors&#146; rights
generally;</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the entry into and performance by the Chargor of this Charge does not violate (i)&nbsp;any law or
regulation of any governmental or official authority, or (ii)&nbsp;any agreement, contract or other
undertaking to which the Chargor is a party or which is binding upon the Chargor or any of its
assets;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other than registration of this Charge in the register of charges of the Chargor in accordance
with the requirements of the BVI Business Companies Act, 2004, no authorisation, approval or other
action by, and no notice to or filing with, any governmental authority or regulatory body is
required for either the grant by the Chargor of the Security Interests purported to be created in
favour of the Chargee under this Charge; or the exercise by the Chargee of any rights or remedies
in respect of the Charged Property (whether or not specifically granted or created under this
Charge);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all consents, licences, approvals and authorisations required in connection with the entry
into, performance, validity and enforceability of this Charge have been obtained and are in full
force and effect;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor has taken all corporate and other action required to approve its execution,
delivery and performance of this Charge; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.14</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Company is not a land holding corporation for the purposes of the Land Holding Companies
Share Transfer Tax Law of the Cayman Islands.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>3 CHARGOR&#146;S COVENANTS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Chargor hereby covenants with the Chargees:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to discharge all obligations and liabilities specified in Section&nbsp;10.02(c)(vii) of the Share
Subscription Agreement at the following times and in the following manner:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company is required to issue a number of Ordinary Shares to any person
(a &#147;Third-Party Transferee&#148;) pursuant to any arbitral or judicial judgment on, or
settlement of, any claim, dispute or litigation in connection with any acquisition by any
Group Company of any person (other than persons established under the Laws of the PRC)
which has been consummated prior to the Closing Date (any &#147;Pre-Closing Offshore
Acquisition&#148;) and the Controlling Shareholders, severally and jointly, fail to transfer
such number of Ordinary Shares to such Third-Party Transferee in lieu of and on behalf of
such Group Company at the per share price and on the date set forth in such judgment or
settlement, the Chargor shall, severally and jointly with other Controlling Shareholders,
on the Business Day immediately following such date, transfer free of charge a number of
Ordinary Shares to each Chargee equal to (x)&nbsp;the aggregate number of Ordinary Shares
required to be transferred to such Third-Party Transferee pursuant to such judgment or
settlement <I>multiplied </I>by (y)&nbsp;a ratio, the numerator of which is the Aggregate Ownership
of Ordinary Shares by such Chargee on such payment date and the denominator of which is the
outstanding number of Ordinary Shares on such payment date, calculated on a Fully-Diluted
basis;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company is required to make any payment in cash to any person pursuant
to any arbitral or judicial judgment on, or settlement of, any claim, dispute or litigation
in connection with any Pre-Closing Offshore Acquisition and</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #textcolor#; background: #bgcolor#">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Controlling Shareholders, severally and jointly, fail to make such payment in
lieu of and on behalf of such Group Company by the payment time set forth in such
judgment or settlement, the Chargor shall, severally and jointly with other
Controlling Shareholders, within 10 Business Days following such payment date,
transfer free of charge a number of Ordinary Shares to each Chargee equal to (x)
the amount of such payment in US dollars (based on the &#147;noon buying rate&#148; for
purchases of any currency other than US dollars on such payment date published by
the Federal Reserve Bank of New York) <I>divided </I>by (y)&nbsp;the fair market value of the
Ordinary Shares in US dollars on a per share basis on such payment date as
determined by the Controlling Shareholders and the Chargees by mutual agreement or
if such mutual agreement cannot be reached within 5 Business Days following such
payment date, determined by an independent appraiser satisfactory to the Chargees
within 10 Business Days following such payment date <I>multiplied </I>by (z)&nbsp;a ratio, the
numerator of which is the Aggregate Ownership of Ordinary Shares by such Chargee on
such payment date and the denominator of which is the outstanding number of
Ordinary Shares on such payment date, calculated on a Fully-Diluted basis; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if any Group Company incurs or suffers any damages arising out of any claim, dispute
or litigation in connection with any Pre-Closing Offshore Acquisition, other than those
damages described in <B>Clauses 3.1.1 and 3.1.2</B>, and the Controlling Shareholders, severally
and jointly, fail to indemnify the Company pursuant to Section&nbsp;10.02(c)(vii) of the Share
Subscription Agreement by the date of such incurrence or suffering, the Chargor shall,
severally and jointly with other Controlling Shareholders, transfer free of charge a number
of Ordinary Shares to each Chargee equal to (x)&nbsp;the amount of such damages expressed in US
dollars <I>divided </I>by (y)&nbsp;the fair market value of the Ordinary Shares in US dollars on a per
share basis calculated as set forth above in Clause 3.1.2 <I>multiplied </I>by (z)&nbsp;a ratio, the
numerator of which is the Aggregate Ownership of Ordinary Shares by such Chargee on such
date and the denominator of which is the outstanding number of Ordinary Shares on such
date, calculated on a Fully-Diluted basis, in each case of sub-clause (x)&nbsp;and (y)&nbsp;as
determined by the Controlling Shareholders and the Chargees by mutual agreement or if such
mutual agreement cannot be reached within 5 Business Days following such payment date,
determined by an independent appraiser satisfactory to the Chargees within 10 Business Days
following such date;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the obligations in <B>Clauses 3.1.1, 3.1.2 and 3.1.3 </B>collectively, the &#147;Secured Obligations&#148;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor will on demand of the Chargees and at the expense of the Chargor, execute and
deliver to the Chargees or to such person or persons as the Chargees may nominate such additional
charge or charges of the Charged Property (or any part thereof) for the purpose of further securing
the payment and discharge of all Secured Obligations, each such additional charge to be in such
form as the Chargees may reasonably require;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor shall, on request of the Chargees, provide to the Chargees immediately on
receipt by the Chargor a copy of all notices, written consents, reports, accounts, circulars and
other communications issued by the Company or by any third party in respect of the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>that the Chargor will not without the prior written consent of the Chargees:</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any person other than the Chargor, the Chargees or any transferee nominated by
the Chargees on enforcement of this Charge to be the registered holder of any of the
Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any variation of the rights attaching to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>take or permit any action which might result in an increase or reduction in the
authorised share capital of the Company or the number of shares that the Company is
authorised to issue or the issued share or share capital of the Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit the Company to be continued to another jurisdiction outside of the Cayman
Islands;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>effect or permit the appointment of any new or further directors or officers of the
Company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>permit any scheme of arrangement, merger, amalgamation or other reorganisation
applicable to the Company; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>save in accordance with <B>Clause 8.2, </B>permit any amendment to the memorandum or
articles of association of the Company without prior written consent of the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>4 SECURITY</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In consideration of the Chargees agreeing to enter into the Share Subscription Agreement and as
a continuing security for the Secured Obligations, the Chargor as legal and beneficial owner hereby
assigns and agrees to assign to the Chargees jointly all benefits present and future, actual and
contingent accruing in respect of the Charged Property and all the Chargor&#146;s right, title and
interest to and in the Charged Property including (without limitation) all voting and other
consensual powers pertaining to the Charged Shares and hereby charges and agrees to charge in
favour of the Chargees jointly all of its interest in the Charged Property by way of a first fixed
charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby agrees to deliver, or cause to be delivered, to the Chargees on the date
hereof:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>duly executed undated share transfers in respect of the Charged Shares in favour of
the Chargees or their nominees in the form set out in Schedule&nbsp;I;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an executed undated irrevocable proxy made in respect of the Charged Shares in favour
of the Chargees in respect of all general meetings of the Company in the form set out in
Schedule&nbsp;II;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all original share certificates representing, and all other documents, title or
evidence of, ownership in relation to the Charged Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>signed, but undated resolutions of the board of directors of the Company in the form
set out in Schedule&nbsp;III; and</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an executed undertaking from the Company to register transfers of the Charged Shares
to the Chargees or their nominees in the form set out in Schedule&nbsp;IV dated as of the date
hereof (the &#147;Undertaking&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall be entitled to:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>continue to hold any document delivered to them pursuant to <B>Clauses 4.2.1 through
4.2.5 </B>above until the Charged Shares are released from this Charge and if, for any reason,
they release any such document to the Chargor before such time, they may by notice to the
Chargor require that such document be redelivered to them and the Chargor shall promptly
comply with that requirement or procure that it is complied with; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>at any time after the Security Interest has become enforceable as provided in <B>Clause
7</B>, subject to the limitation set out in <B>Clause 7.1</B>, complete any document delivered to them
pursuant to <B>Clauses 4.2.1 through 4.2.5 </B>above in favour of, and register any Charged Share
in the names of the Chargees or such other person as they shall select, and the Chargor
shall promptly take or procure the taking by all such other persons (including, without
limitation, the secretary of the Company) any other action and execute and deliver to the
Chargees any other document (in form and substance reasonably satisfactory to each Chargee)
which may be reasonably requested by the Chargees in order to enable the Chargees or such
other person as they shall select to be registered as the owner of, or otherwise obtain
legal title to, any Charged Share; this includes procuring that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="7%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>those share transfers are duly registered in the shareholder register of the
Company; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>share certificates in the name of the Chargees or such other person as they
shall select are delivered to the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor will deliver, or cause to be delivered, to the Chargees immediately upon the issue
of any further Charged Shares, the items listed in <B>Clauses 4.2.1 through 4.2.5 </B>(if the documents
already provided are not sufficient to cover the further Charged Shares) in respect of all such
further Charged Shares.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby covenants that during the Security Period it will remain the legal and the
beneficial owner of the Charged Property (subject only to the Security Interests hereby created)
and that it will not:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>create or suffer the creation of any Security Interests (other than those created by
this Charge) on or in respect of the whole of any part of the Charged Property or any of
its interest therein; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sell, assign, transfer or otherwise dispose of any of its interest in the Charged
Property (other than with respect to the dividend or distribution payments described in
<B>Clause 5.1.2</B>); or</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>do or cause or permit to be done anything which may in any way affect, depreciate,
jeopardize or otherwise prejudice the market value of the Charged Shares or its rights with
respect thereto;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>vote in respect of the Charged Shares or receive any dividends or other distributions
paid by the Company in respect of the Charged Shares,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in any such case without the prior consent in writing of the Chargees.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Security Period, the Chargor shall remain liable to perform all the obligations
assumed by it in relation to the Charged Property and the Chargees shall be under no obligation of
any kind whatsoever in respect thereof or be under any liability whatsoever in the event of any
failure by the Chargor to perform its obligations in respect thereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the Chargees being satisfied that the Secured Obligations have been unconditionally and
irrevocably paid and discharged in full or upon the expiry of the Security Period, and following a
written request therefor from the Chargor, the Chargees will, subject to being indemnified to each
of their respective reasonable satisfaction for the costs and expenses incurred by the Chargees in
connection therewith, release the Charged Shares (if any as the case may be) and security
constituted by this Charge.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>5 DEALINGS WITH CHARGED PROPERTY</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Unless and until an Event of Default has occurred:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to exercise all voting and/or consensual powers
pertaining to the Charged Property or any part thereof for all purposes not inconsistent
with the terms of this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to receive and retain any dividends, interest or other
moneys or assets accruing on or in respect of the Charged Property or any part thereof; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargor shall be entitled to receive all notices pertaining to the Charged
Shares.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay all calls, instalments or other payments, and shall discharge all other
obligations, which may become due in respect of any of the Charged Property and in an Event of
Default, the Chargees may, if they think fit, make such payments or discharge such obligations on
behalf of the Chargor. Any sums so paid by the Chargees in respect thereof shall be repayable on
demand and, pending such repayment, shall constitute part of the Secured Obligations.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not have any duty to ensure that any dividends, interest or other moneys and
assets receivable in respect of the Charged Property are duly and punctually paid, received or
collected as and when the same become due and payable or to ensure that the correct amounts (if
any) are paid or received on or in respect of the Charged Property or to ensure the taking up of
any (or any offer of any) stocks, shares, rights, moneys or other property paid, distributed,
accruing or offered at any time by way of</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>redemption bonus, rights, preference, or otherwise on or in respect of, any of the Charged
Property.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor hereby authorises the Chargees to arrange at any time and from time to time
(whether before or after the occurrence of an Event of Default) for the Charged Property or any
part thereof to be registered in the name of the Chargees (or their nominees) thereupon to be held
as so registered subject to the terms of this Charge.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>6 PRESERVATION OF SECURITY</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It is hereby agreed and declared that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the security created by this Charge shall be held by the Chargees as a continuing
security for the payment and discharge of the Secured Obligations and the security so
created shall not be satisfied by any intermediate payment or satisfaction of any part of
the Secured Obligations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the Chargees shall not be bound to enforce any other security before enforcing the
security created by this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>no delay or omission on the part of the Chargees in exercising any right, power or
remedy under this Charge shall impair such right, power or remedy or be construed as a
waiver thereof nor shall any single or partial exercise of any such right, power or remedy
preclude any further exercise thereof or the exercise of any other right, power or remedy.
The rights, powers and remedies herein provided are cumulative and not exclusive of any
rights, powers and remedies provided by law and may be exercised from time to time and as
often as the Chargees may deem expedient; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any waiver by the Chargees of any terms of this Charge shall only be effective if
given in writing and then only for the purpose and upon the terms for which it is given.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any settlement or discharge under this Charge between the Chargees and the Chargor shall be
conditional upon no security or payment to the Chargees by the Company or the Chargor or any other
person being avoided or set-aside or ordered to be refunded or reduced or if the aforesaid security
or payment to the Chargees is adversely affected by virtue of any provision or enactment relating
to bankruptcy, insolvency, administration or liquidation for the time being in force and, if such
condition is not satisfied, the liability of the Chargor under this Charge shall be reinstated or
continue and the Chargees shall be entitled to recover from the Chargor on demand the value of such
security or the amount of any such payment as if such settlement or discharge had not occurred.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The rights of the Chargees under this Charge and the Security Interest hereby constituted shall
not be affected by any act, omission, matter or thing which, but for this provision, might operate
to impair, affect or discharge such rights and security, in whole or in part, including without
limitation, and whether or not known to or discoverable by the Company, the Chargor, the Chargees
or any other person:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any time or waiver granted to or composition with the Company or any other person;</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the taking, variation, compromise, renewal or release of or refusal or neglect to
perfect or enforce any rights, remedies or securities against the Company or any other
person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any legal limitation, disability, incapacity or other circumstances relating to the
Company or any other person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any amendment or supplement to the Share Subscription Agreement or any other document
or security;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the dissolution, liquidation, amalgamation, reconstruction or reorganisation of the
Company or any other person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the unenforceability, invalidity or frustration of any obligations of the Company or
any other person under the Share Subscription Agreement or any other document or security;
or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any non-observance of any formality or other requirements in respect of any other
instrument or any failure to realise the full value of any other security.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Until the Secured Obligations have been unconditionally and irrevocably satisfied and
discharged in full to the satisfaction of the Chargees or until the expiry of the Security Period,
the Chargor shall not by virtue of any payment made hereunder on account of the Secured Obligations
or by virtue of any enforcement by the Chargees of their rights under, or the security constituted
by, this Charge or by virtue of any relationship between or transaction involving, the Chargor and
the Company (whether such relationship or transaction shall constitute the Chargor a creditor of
the Company, a guarantor of the obligations of the Company or a party subrogated to the rights of
others against the Company or otherwise howsoever and whether or not such relationship or
transaction shall be related to, or in connection with, the subject matter of this Charge):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any rights of subrogation in relation to any rights, security or moneys held
or received or receivable by the Chargees or any person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any right of contribution from any co-surety liable in respect of the Second
Obligation under any other guarantee, security or agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercise any right of set-off or counterclaim against the Chargees, the Company or
any such co-surety;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>receive, claim or have the benefit of any payment, distribution, security or
indemnity from the Company or any such co-surety; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>unless so directed by the Chargees (when the Chargor will prove in accordance with
such directions), claim as a creditor of the Company or any such co-surety in competition
with the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall hold in trust for the Chargees and forthwith pay or transfer (as
appropriate) to the Chargees any such payment (including an amount equal to any such
set-off), distribution (other than such dividend or distribution payments described in</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Clause 5.1.2) </B>or benefit of such security, indemnity or claim in fact received by the
Chargor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Until the Secured Obligations have been unconditionally and irrevocably satisfied and
discharged in full to the satisfaction of the Chargees or until the expiry of the Security Period,
the Chargees may at any time keep in a separate account or accounts (without liability to pay
interest thereon) in the name of the Chargees for as long as they may think fit, any moneys
received, recovered or realised under this Charge or under any other guarantee, security or
agreement relating in whole or in part to the Secured Obligations without being under any
intermediate obligation to apply the same or any part thereof in or towards the discharge of such
amount.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>7 ENFORCEMENT OF SECURITY</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the occurrence of an Event of Default or a demand being made by the Chargees for the
satisfaction of the Secured Obligations with respect to the Chargees or any of them, the Security
Interest hereby constituted shall become immediately enforceable by the Chargees and the Chargees
may, at any time, without further notice to or consultation with or consent of the Chargor:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>solely and exclusively exercise all voting and/or consensual powers pertaining to the
Charged Property or any part thereof and may exercise such powers in such manner as the
Chargees may think fit;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>receive and retain all dividends, interest, distributions or other moneys or assets
accruing on or in respect of the Charged Property or any part thereof, and any such
dividends, interest, distributions or other moneys or assets received by the Chargor after
such time shall be held in trust by the Chargor for the Chargees and paid or transferred to
the Chargees on demand;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if the Chargees elect to, sell, transfer, grant options over or otherwise dispose of
the Charged Property or any part thereof at such place and in such manner and at such price
or prices as the Chargees may deem fit;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated blank share transfer forms delivered to the Chargees pursuant to
<B>Clause 4.2.1 </B>by dating the same and inserting their names or the names of their nominees as
transferees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated resolutions of the board of directors of the Company delivered
to the Chargees pursuant to <B>Clause 4.2.4 </B>by dating the same and inserting the names of the
transferees and the number of Ordinary Shares to be transferred; and/or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>complete the undated irrevocable proxy delivered to the Chargees pursuant to <B>Clause
4.2.2 </B>by dating the same and inserting the names and addresses of all Chargees or the names
and addresses of their respective nominees;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>PROVIDED THAT notwithstanding any other provision of this Charge, the Chargees may only
exercise their rights under <B>Clauses 7.1.5 and 7.1.6 </B>in respect of such number of Charged
Shares not exceeding the aggregate number of Ordinary Shares that the Chargor has failed to
transfer (the &#147;Default Shares&#148;) to the Chargees or any of them under <B>Clause</B></TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%"><B>3.1 </B>in satisfaction of the Secured Obligations with respect to all and/or any of the
Chargees.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not be obliged to make any enquiry as to the nature or sufficiency of any
payment received by them under this Charge or to make any claim or to take any action to collect
any moneys assigned by this Charge or to enforce any rights or benefits assigned to the Chargees by
this Charge or to which the Chargees may at any time be entitled hereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon any sale by the Chargees of the Charged Property or any part thereof by the Chargees, the
purchaser shall not be bound to see or enquire whether the Chargees&#146; power of sale has become
exercisable in the manner provided in this Charge and the sale shall be deemed to be within the
power of the Chargees, and the receipt of the Chargees for the purchase money shall effectively
discharge the purchaser who shall not be concerned with the manner of application of the proceeds
of sale or be in any way answerable therefor.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Neither the Chargees nor their agents, managers, officers, employees, delegates or advisers
shall be liable for any claim, demand, liability, loss, damage, cost or expense incurred or arising
in connection with the exercise or purported exercise of any rights, powers and discretions
hereunder in the absence of fraud or dishonesty.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall not by reason of the taking of possession of the whole or any part of the
Charged Property or any part thereof be liable to account as mortgagee-in-possession or for
anything except actual receipts or be liable for any loss upon realisation or for any default or
omission for which a mortgagee-in-possession might be liable.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>8 FURTHER ASSURANCES</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall execute and do all such assurances, acts and things as the Chargees in their
absolute discretion may require for:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>creating, perfecting, protecting or ensuring the priority of the Security Interest
hereby created (or intended to be created);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>preserving or protecting any of the rights of the Chargees under this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ensuring that the security constituted by this Charge and the covenants and
obligations of the Chargor under this Charge shall inure to the benefit of any assignee of
the Chargees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>facilitating the appropriation or realisation of the Charged Property or any part
thereof; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>exercising any power, authority or discretion vested in the Chargees under this
Charge,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in any such case forthwith upon demand by the Chargees and at the expense of the Chargor.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Without limitation to the generality of <B>Clause 8.1</B>, the Chargor covenants with the Chargees
that it will on demand of the Chargees procure any amendment to the memorandum and articles of
association of the Company necessary or, in the opinion of the Chargees desirable, in order to give
effect to the terms of this Charge or any documents or transactions provided for herein.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>9 INDEMNITIES</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor will indemnify and save harmless the Chargees and each agent or attorney appointed
under or pursuant to this Charge from and against any and all expenses, claims, liabilities,
losses, taxes, costs, duties, fees and charges properly and reasonably suffered, incurred or made
by the Chargees or such agent or attorney:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the exercise or purported exercise of any rights, powers or discretions vested in
them pursuant to this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in the preservation or enforcement of the Chargees&#146; rights under this Charge or the
priority thereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>on the release of any part of the Charged Property from the security created by this
Charge; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>as a result, directly or indirectly of any breach by the Chargor of any covenant or
other obligation under this Charge.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>and the Chargees or such agent or attorney may retain and pay all sums in respect of the
same out of money received under the powers conferred by this Charge. All amounts
recoverable by the Chargees or such agent or attorney or any of them shall be recoverable
on a full indemnity basis.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If, under any applicable law or regulation, and whether pursuant to a judgment being made or
registered against the Chargor or the bankruptcy or liquidation of the Chargor or for any other
reason any payment under or in connection with this Charge is made or falls to be satisfied in a
currency (the &#147;Payment Currency&#148;) other than the currency in which such payment is due under or in
connection with this Charge (the &#147;Contractual Currency&#148;), then to the extent that the amount of
such payment actually received by the Chargees when converted into the Contractual Currency at the
rate of exchange, falls short of the amount due under or in connection with this Charge, the
Chargor, as a separate and independent obligation, shall indemnify and hold harmless the Chargees
against the amount of such shortfall. For the purposes of this clause, &#147;rate of exchange&#148; means the
rate at which the Chargees is able on or about the date of such payment to purchase the Contractual
Currency with the Payment Currency and shall take into account any premium and other costs of
exchange with respect thereto.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>10 POWER OF ATTORNEY</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor, by way of security and in order more fully to secure the performance of its
obligations hereunder, pursuant to the Power of Attorney Law (1996 Revision) hereby irrevocably
appoints each of the Chargees and the persons deriving title under it jointly and also severally to
be its attorney:</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to execute and complete in favour of the Chargees or its nominees or of any
purchaser any documents which the Chargees may from time to time require for perfecting
their title to or for vesting any of the assets and property hereby charged or assigned to
the Chargees or their nominees or in any purchaser and to give effectual discharges for
payments;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to take and institute on non-payment (if the Chargees in their sole discretion so
decide) all steps and proceedings in the name of the Chargor or of the Chargees for the
recovery of such moneys, property and assets hereby charged and to agree accounts;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to make allowances and give time or other indulgence to any surety or other person
liable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>otherwise generally to act for it and in its name and on its behalf; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to sign, execute, seal and deliver and otherwise perfect and do any such legal
assignments and other assurances, charges, authorities and documents over the moneys,
property and assets hereby charged, and all such deeds, instruments, acts and things
(including, without limitation, those referred to in <B>Clause 8</B>) which may be required for
the full exercise of all or any of the powers conferred or which may be deemed proper on or
in connection with any of the purposes aforesaid.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The power hereby conferred shall be a general power of attorney and the Chargor hereby
ratifies and confirms and agrees to ratify and confirm any instrument, act or thing which any such
attorney may execute or do. In relation to the power referred to herein, the exercise by any of
the Chargees of such power shall be conclusive evidence of its right to exercise the same.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>11 EXPENSES</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay to the Chargees on demand all costs, fees and expenses (including but
not limited to legal fees and expenses) and taxes thereon incurred by the Chargees or for which
the Chargees may become liable in connection with:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the negotiation, preparation and execution of this Charge;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the preserving or enforcing of, or attempting to preserve or enforce, any of its
rights under this Charge or the priority hereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any variation of, or amendment or supplement to, any of the terms of this Charge;
and/or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any consent or waiver required from the Chargees in relation to this Charge,</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>and in any case referred to in <B>Clauses 11.1.3 and 11.1.4 </B>regardless of whether the same
is actually implemented, completed or granted, as the case may be.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall pay promptly any stamp, documentary and other like duties and taxes to which
this Charge may be subject or give rise and shall indemnify the Chargees on demand against any and
all liabilities with respect to or resulting from any delay or omission on the part of the Chargor
to pay any such duties or taxes.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>12 NOTICES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any notice required to be given hereunder shall be in writing in the English language and shall be
served by sending the same by prepaid recorded post, facsimile or by delivering the same by hand to
the address of the Party or Parties in question as set out below (or such other address as such
Party or Parties shall notify the other Parties of in accordance with this clause). Any notice sent
by post as provided in this clause shall be deemed to have been served five Business Days after
despatch and any notice sent by facsimile as provided in this clause shall be deemed to have been
served at the time of despatch and in proving the service of the same it will be sufficient to
prove in the case of a letter that such letter was properly stamped, addressed and placed in the
post; and in the case of a facsimile that such facsimile was duly despatched to a current facsimile
number of the addressee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><u>Chargor</u><BR>
Top Mount Group Limited<BR>
P.O. Box 957<BR>
Offshore Incorporations Centre<BR>
Road Town, Tortola<BR>
British Virgin Islands<BR>
Attention: Mr.&nbsp;Yaw Kong Yap<BR>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><u>Chargees:</u><BR>
If to CICC, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">China International Capital Corporation<BR>
28<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>Floor, China World Tower 2<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Fax: 86-10-6505-3796<BR>
Attention: Ms.&nbsp;Shirley Chen

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to Carlyle, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Carlyle Group<BR>
2518-2521, South Office Tower<BR>
Beijing Kerry Centre<BR>
No.&nbsp;1, Guang Hua Road<BR>
Chao Yang District<BR>
Beijing 100020<BR>
People&#146;s Republic of China<BR>
Fax: 86-10-8529-9877<BR>
Attention: Mr.&nbsp;Feng Xiao

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With a copy to:

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Davis Polk &#038; Wardwell LLP<BR>
26<SUP style="font-size: 85%; vertical-align: text-top">th </SUP>Floor, Twin Tower West<BR>
B12, Jian Guo Men Wai Avenue<BR>
Chao Yang District<BR>
Beijing 100022<BR>
People&#146;s Republic of China<BR>
Tel: 86-10-8567-5000<BR>
Fax: 86-10-8567-5123<BR>
Attention: Mr.&nbsp;Show-Mao Chen, Esq.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If to Starr, to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Starr Investments Cayman II, Inc.<BR>
c/o Starr International Company (Asia) Limited<BR>
Suite&nbsp;1405-7, Two Exchange Square<BR>
8 Connaught Place, Central<BR>
Hong Kong<BR>
Tel: 852-2905-1166<BR>
Fax: 852-2905-1555<BR>
Attention: Ms.&nbsp;Elaine Zong

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">With a copy to:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Skadden, Arps, Slate, Meagher &#038; Flom<BR>
East Wing Office, Level 4<BR>
China World Trade Centre<BR>
No.&nbsp;1 Jian Guo Men Wai Avenue<BR>
Beijing 100004<BR>
People&#146;s Republic of China<BR>
Tel: 86-10-6535-5500<BR>
Fax: 86-10-6505-5522<BR>
Attention: Mr.&nbsp;Peter X. Huang

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>13 ASSIGNMENTS</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">13.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge shall be binding upon and shall inure to the benefit of the Chargor and the
Chargees and each of their respective successors and (subject as hereinafter provided) assigns and
references in this Charge to any of them shall be construed accordingly.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">13.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor may not assign or transfer all or any part of its rights and/or obligations under
this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">13.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees may not assign or transfer all or any part of its rights or obligations under
this Charge to any assignee or transferee without the consent of the Chargor, such consent not to
be unreasonably withheld, provided that no such consent shall be required if an Event of Default
affecting the Chargor has occurred and is continuing. The Chargees shall notify the Chargor
promptly following any such assignment or transfer.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>14 MISCELLANEOUS</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees, at any time and from time to time, may delegate by power of attorney or in any
other manner to any person or persons all or any of the powers, authorities and discretions which
are for the time being exercisable by the Chargees under this Charge in relation to the Charged
Property or any part thereof. Any such delegation may be made upon such terms and be subject to
such regulations as the Chargees may think fit. The Chargees shall not be in any way liable or
responsible to the Chargor for any loss or
damage arising from any act, default, omission or misconduct on the part of any such
delegate provided the Chargees has acted reasonably in selecting such delegate.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If any of the clauses, conditions, covenants or restrictions of this Charge or any deed or
document emanating from it shall be found to be void but would be valid if some part thereof were
deleted or modified, then such clause, condition, covenant or restriction shall apply with such
deletion or modification as may be necessary to make it valid and effective.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge (together with any documents referred to herein) constitutes the whole agreement
between the Parties relating to its subject matter and no variations hereof shall be effective
unless made in writing and signed by each of the Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The headings in this Charge are inserted for convenience only and shall not affect the
construction of this Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Charge may be executed in counterparts each of which when executed and delivered shall
constitute an original but all such counterparts together shall constitute one and the same
instrument.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To the maximum extent permitted under applicable laws, the Chargor hereby waives any immunity
under the laws applicable to the Chargor, whether characterised as sovereign immunity or otherwise,
from any legal proceedings to enforce this Charge in respect of itself or its property.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>15 LAW AND JURISDICTION</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Charge shall be governed by and construed in accordance with the laws of the Cayman Islands
and the Parties hereby irrevocably submit to the non-exclusive jurisdiction of the courts of Hong
Kong, provided that nothing in this clause shall affect the rights of the Chargees to serve process
in any manner permitted by law or limit the rights of the Chargees to take proceedings with respect
to this Charge against the Chargor in any jurisdiction nor shall the taking of proceedings with
respect to this Charge in any jurisdiction preclude the Chargees from taking proceedings with
respect to this Charge in any other jurisdiction, whether concurrently or not.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Follow</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IN WITNESS whereof the parties hereto have caused this Charge to be duly executed as a Deed the day
and year first before written.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">The Common Seal of</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">TOP MOUNT GROUP LIMITED</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp; )</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">was hereunto affixed in the</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">presence of:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Yap Yaw Kong&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>&nbsp;Name:
Yap Yaw Kong
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shi Bo Tao&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>&nbsp;Name:
Shi Bo Tao
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Witness)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Top Mount 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Executed as a deed by</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">For and on behalf of</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CICC SUN COMPANY LIMITED</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">in the presence of:-</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shirley Chen</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Shirley Chen
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Xin, Jie</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Xin, Jie
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Top Mount 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="69%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="69%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="0" valign="top" align="left">Executed as a deed by</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="0" valign="top" align="left">For and on behalf of</TD>

    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="0" valign="top" align="left" nowrap>CARLYLE ASIA GROWTH PARTNERS III, L.P.</TD>

    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="0" valign="top" align="left">in the presence of:- </TD>

    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" valign="top" align="left">By: CAGP General Partner, L.P., as its General Partner</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" valign="top" align="left">By: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Daniel A. D&#146;Aniello
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Executed as a deed by</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">For and on behalf of</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">CAGP III CO-INVESTMENT, L.P.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">in the presence of:-</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" valign="top" align="left">BY: CAGP General Partner, L.P., as its General Partner</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" valign="top" align="left">BY: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Daniel A. D&#146;Aniello</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Daniel A. D&#146;Aniello
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Top Mount 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Executed as a deed by</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">For and on behalf of</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">STARR INVESTMENTS CAYMAN II, INC.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">in the presence of:-</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael Horvath</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Michael Horvath
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature Page to Top Mount 2</I><SUP style="font-size: 85%; vertical-align: text-top"><I>nd </I></SUP><I>Share Charge</I>&#093;
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.16
<SEQUENCE>17
<FILENAME>h03611exv4w16.htm
<DESCRIPTION>EX-4.16
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.16</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.16</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>THIS DEED OF AMENDMENT </B>is made on September&nbsp;14, 2009
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>BY:</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CICC Sun Company Limited, a company incorporated under the laws of the British Virgin Islands
(&#147;CICC&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Carlyle Asia Growth Partners III, L.P., a limited partnership formed under the laws of the
Cayman Islands (&#147;CAGP&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CAGP III Co-Investment, L.P., a limited partnership formed under the laws of the Cayman
Islands (&#147;CAGP Co-Invest&#148;, together with CAGP, &#147;Carlyle&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Starr Investments Cayman II, Inc., a company incorporated under the laws of the Cayman
Islands (&#147;<B>Starr</B>&#148;, together with CICC and Carlyle, the &#147;Chargees&#148;); and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Notable Enterprise Limited, a company incorporated under the laws of the British Virgin
Islands (the &#147;Chargor&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>WHEREAS</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By a share charged dated 10 November, 2008 (the &#147;Share Charge&#148;) executed by the Chargor in
favour of the Chargees, 86,974 shares of Concord Medical Services Holdings Limited (the
&#147;Company&#148;) held by the Chargor was charged by the Chargor to the Chargees jointly by way of a
first fixed charge to secure the obligations of the Chargor under Article&nbsp;3 of the Share
Subscription Agreement (as defined in the Share Charge).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>At the request of the Chargor, the Chargees have agreed to release 4,107 shares of the
Company charged by CZY Investments Limited (&#147;CZY&#148;) from the security created under the share
charge dated 10 November, 2008 (the &#147;CZY Share Charge&#148;) executed by CZY in favour of the
Chargees provided that the Chargor charges an additional 4,107 shares of the Company (the
&#147;<B>Additional Shares</B>&#148;) held by the Chargor to the Chargees jointly by entering into this Deed to
amend and supplement the Share Charge.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>THIS DEED OF AMENDMENT WITNESSES </B>as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Deed, capitalised words and phrases which are not expressly defined herein have the
meanings ascribed to them in the Share Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In consideration of the Chargees&#146; agreement to enter into a deed of partial release in
relation to the CZY Share Charge (the sufficiency of which is hereby acknowledged by the
Chargor) and as a continuing security for the Secured Obligations, the Chargor as legal and
beneficial owner hereby assigns and agrees to assign to the Chargees jointly all benefits
present and future, actual and contingent accruing in respect of the Additional Shares and
such additional part of the Charged Property constituted by the Additional Shares and all the
Chargor&#146;s right, title and interest to and in the Additional Shares and such additional part
of the Charged Property constituted by the Additional Shares including (without limitation)
all voting and other consensual powers pertaining to the Additional Shares and hereby charges
and agrees to charge in favour of the</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio --> - 1 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Chargees jointly all of its interest in the Additional Shares and such additional part of
the Charged Property by way of a first fixed charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The parties agree that effective upon execution of this Deed, the Share Charge shall be
amended in the following manner:-</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The definition of &#147;Charged Shares&#148; shall be deleted in its entirety and be replaced
with the following new definition of &#147;Charged Shares&#148;:-</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;&#147;Charged Shares&#148; means 90,991 Ordinary Shares of the Company registered in the name of the
Chargor as legal and beneficial owner thereof;&#148;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargor shall upon execution of this Deed deliver to the Chargees the documents required
under clause 4.2 of the Share Charge in respect of the Additional Shares.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The parties agree and confirm that save as expressly provided herein, nothing herein
contained shall affect or prejudice the securities assigned or charged under the Share Charge
and all sums of money due and owing by the Chargor to the Chargees under the Share
Subscription Agreement or secured by the Share Charge and all the covenants conditions and
provisions contained in the Share Subscription Agreement and the Share Charge in relation to
the securities shall remain in full force and effect.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Deed may be executed in any number of counterparts which, taken together, shall be
deemed to constitute one and the same document.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Deed shall be governed by, and construed in accordance with, the laws of the Cayman
Islands.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>IN WITNESS WHEREOF </B>this Deed of Amendment has been executed by the Chargor and the Chargees as a
Deed and is intended to be and is hereby delivered on the date specified above.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 2 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="0%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>EXECUTED </B>as a Deed by</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">for and on behalf of</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>CICC SUN COMPANY LIMITED</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">in the presence of:-</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shirley Shiyou Chen</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Shirley Shiyou Chen</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>EXECUTED </B>as a Deed by</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">for and on behalf of</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>CARLYLE ASIA GROWTH PARTNERS</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>III, L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">in the presence of:-</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left">CAGP General Partner, L.P., as its General Partner</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left">CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Xiao Feng</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Xiao Feng<BR>
Title:</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>EXECUTED </B>as a Deed by</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">for and on behalf of</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>CAGP III Co-<FONT style="font-variant: SMALL-CAPS">Investment</FONT> L.P.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">in the presence of:-</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left">CAGP General Partner, L.P., as its General Partner</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left">CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Xiao Feng</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Xiao Feng<BR>
Title:</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --> - 3 - <!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="0%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="58%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>EXECUTED </B>as a Deed by</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">for and on behalf of</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>STARR INVESTMENTS CAYMAN II,</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">in the presence of:</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael J. Horvath</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Michael J. Horvath</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Associate Counsel</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>EXECUTED </B>as a Deed by</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">for and on behalf of</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>NOTABLE ENTERPRISE LIMITED</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">in the presence of:</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Bona Lau</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Bona Lau</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shi Bo Tao</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Shi Bo Tao</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Witness)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --> - 4 - <!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.17
<SEQUENCE>18
<FILENAME>h03611exv4w17.htm
<DESCRIPTION>EX-4.17
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-4.17</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;4.17</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>THIS DEED OF PARTIAL RELEASE </B>is made on September&nbsp;14, 2009
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>BY:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CICC Sun Company Limited, a company incorporated under the laws of the British Virgin Islands
(&#147;CICC&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Carlyle Asia Growth Partners III, L.P., a limited partnership formed under the laws of the
Cayman Islands (&#147;CAGP&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CAGP III Co-Investment, L.P., a limited partnership formed under the laws of the Cayman
Islands (&#147;CAGP Co-Invest&#148;, together with CAGP, &#147;Carlyle&#148;);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Starr Investments Cayman II, Inc., a company incorporated under the laws of the Cayman
Islands (&#147;<B>Starr</B>&#148;, together with CICC and Carlyle, the &#147;Chargees&#148;);</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>IN FAVOUR OF:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CZY Investments Limited, a company incorporated under the laws of the British Virgin Islands
(the &#147;Chargor&#148;).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>WHEREAS</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(A)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>By a share charged dated 10 November, 2008 (the &#147;Share Charge&#148;) executed by the Chargor in
favour of the Chargees, 43,895 shares of Concord Medical Services Holdings Limited (the
&#147;Company&#148;) held by the Chargor was charged by the Chargor to the Chargees jointly by way of a
first fixed charge to secure the obligations of the Chargor under Article&nbsp;3 of the Share
Subscription Agreement (as defined in the Share Charge).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(B)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>At the request of the Chargor, the Chargees have agreed to release 4,017 shares of the
Company charged by the Chargor from the security created under the Share Charge upon the terms
and conditions of this Deed and provided that Notable Enterprise Limited (&#147;Notable&#148;) charges
an additional 4,017 shares of the Company held by Notable to the Chargees jointly by entering
into a deed of amendment to amend and supplement a share charge dated 10 November, 2008
executed by Notable in favour of the Chargees.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>THIS DEED OF PARTIAL RELEASE WITNESSES </B>as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In this Deed, capitalised words and phrases which are not expressly defined herein have the
meanings ascribed to them in the Share Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees jointly without recourse, representation or warranty of title, release 4,017
shares of the Company (the &#147;Released Shares&#148;) and such part of the Charged Property
constituted by the Released Shares charged by the Chargor to the Chargees jointly under the
Share Charge from the fixed charges, the floating charges and all other present and future
security interests constituted by and/or created pursuant to the Share Charge.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->-1-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Released Shares and such part of the Charged Property constituted by the Released Shares
shall be held freed and discharged from the security created by, and all claims arising under,
the Share Charge.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Chargees shall upon execution of this Deed deliver and release to the Chargor such
documents delivered or caused to be delivered by the Chargor to the Chargees pursuant to
clause 4.2 of the Share Charge in respect of the Released Shares and such part of the Charged
Property constituted by the Released Shares, provided that against such release, the Chargor
shall deliver or cause to be delivered to the Chargees the documents required under clause 4.2
of the Share Charge in respect of the remaining Charged Shares and Charged Property.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The parties agree and confirm that save as expressly provided herein, nothing herein
contained shall affect or prejudice the remaining securities assigned or charged under the
Share Charge and all sums of money due and owing by the Chargor to the Chargees under the
Share Subscription Agreement or secured by the Share Charge and all the covenants conditions
and provisions contained in the Share Subscription Agreement and the Share Charge in relation
to the said remaining securities shall remain in full force and effect.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Deed may be executed in any number of counterparts which, taken together, shall be
deemed to constitute one and the same document.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Deed shall be governed by, and construed in accordance with, the laws of the Cayman
Islands.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>IN WITNESS WHEREOF </B>this Deed of Partial Release has been executed by the Chargor and the Chargees
as a Deed and is intended to be and is hereby delivered on the date specified above.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-2-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="0%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>EXECUTED </B>as a Deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">for and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>CICC SUN COMPANY LIMITED</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shirley Shiyou Chen
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Shirley Shiyou Chen</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="0%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>EXECUTED </B>as a Deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">for and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS"><B>CARLYLE ASIA GROWTH PARTNERS</B></FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS"><B>III, L.P.</B></FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="5" valign="top" align="left">By: CAGP General Partner, L.P., as its General Partner</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" valign="top" align="left">By: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Xiao Feng
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Xiao Feng</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="0%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>EXECUTED </B>as a Deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">for and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><FONT style="font-variant: SMALL-CAPS"><B>CAGP III Co-Investment L.P.</B></FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:-
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="5" valign="top" align="left">By: CAGP General Partner, L.P., as its General Partner</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" valign="top" align="left">By: CAGP, Ltd., as the General Partner of CAGP General Partner, L.P.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Xiao Feng
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Xiao Feng</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-3-<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="0%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>EXECUTED </B>as a Deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">for and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>STARR INVESTMENTS CAYMAN II,</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>INC.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Michael J. Horvath
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Name: Michael J. Horvath
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="0%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>EXECUTED </B>as a Deed by
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">for and on behalf of
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>CZY INVESTMENTS LIMITED</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">in the presence of:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Cheng Zheng
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Cheng Zheng</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title: Director</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Shi Bo Tao
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name: Shi Bo Tao</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Witness)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->-4-<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.2
<SEQUENCE>19
<FILENAME>h03611exv8w2.htm
<DESCRIPTION>EX-8.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv8w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;8.2</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">[LETTERHEAD OF SIMPSON THACHER &#038; BARTLETT LLP]
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 50%">November&nbsp;17, 2009

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Concord Medical Services Holdings Limited<BR>
18/F, Tower A, Global Trade Center<BR>
36 North Third Ring Road East, Dongcheng District<BR>
Beijing 100013<BR>
People&#146;s Republic of China

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Ladies and Gentlemen:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have acted as United States counsel to Concord Medical Services Holdings Limited (the
&#147;Company&#148;), in connection with the Registration Statement on Form F-1 (File No.&nbsp;333-&#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;), including the prospectus contained therein (together, the &#147;Registration
Statement&#148;), filed by the Company with the U.S. Securities and Exchange Commission (the
&#147;Commission&#148;) under the U.S. Securities Act of 1933, as amended (the &#147;Securities Act&#148;), relating to
the registration of shares of the Company&#146;s Common Stock (&#147;Common Shares&#148;), par value US$0.01 per
share, which will be represented by American depositary shares (&#147;ADSs&#148;) evidenced by American
depositary receipts.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have examined the Registration Statement. In addition, we have examined, and have relied
as to matters of fact upon, originals, or duplicates or certified or conformed copies, of such
corporate records, agreements, documents and other instruments and such certificates or comparable
documents of public officials and of officers and representatives of the Company, and have made
such other and further investigations as we have deemed necessary or appropriate as a basis for the
opinion hereinafter set forth. In such examination, we have assumed the accuracy of the factual matters described in the Registration Statement and that the Registration
Statement and other documents will be executed by the parties in the forms provided to and reviewed
by us.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In rendering the opinion set forth below, we have assumed the genuineness of all signatures,
the legal capacity of natural persons, the authenticity of all documents submitted to us as
originals, the conformity to original documents of all documents submitted to us as duplicates or
certified or conformed copies and the authenticity of the originals of such latter documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based upon the foregoing, and subject to the qualifications, assumptions and limitations
stated herein and in the Registration Statement, we hereby confirm that the statements set forth in
the Registration Statement under the caption &#147;Taxation &#151;United States Federal Income Taxation,&#148;
insofar as such statements purport to constitute summaries of United States federal income tax law
and regulations or legal conclusions with respect thereto, represent our opinion as to the material
United States federal income tax consequences of the ownership of the Company&#146;s Common Shares or
ADSs by United States holders as of the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not express any opinion herein concerning any law other than the United States federal
income tax law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We hereby consent to the filing of this opinion with the Commission as an exhibit to the
Registration Statement and to the reference to our firm under the heading &#147;Legal Matters&#148; in the
Registration Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%">Very truly yours,

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%">/s/ SIMPSON THACHER &#038; BARTLETT LLP

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%">SIMPSON THACHER &#038; BARTLETT LLP

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>20
<FILENAME>h03611exv10w1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><b>Exhibit&nbsp;10.1</b>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CONCORD MEDICAL SERVICES HOLDINGS LIMITED<BR>
2008 SHARE INCENTIVE PLAN</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Purpose of the Plan</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the Plan is to aid the Company and its Affiliates in recruiting and retaining
key employees, directors or consultants of outstanding ability and to motivate such employees,
directors or consultants to exert their best efforts on behalf of the Company and its Affiliates by
providing incentives through the granting of Awards. The Company expects that it will benefit from
the added interest which such key employees, directors or consultants will have in the welfare of
the Company as a result of their proprietary interest in the Company&#146;s success.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Definitions</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following capitalized terms used in the Plan have the respective meanings set forth in
this Section:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Applicable Laws</B>: All laws, statutes, regulations, ordinances, rules or
governmental requirements that are applicable to this Plan or any Award granted
pursuant to this Plan, including but not limited to applicable laws of the People&#146;s
Republic of China, the United States and the Cayman Islands, and the rules and
requirements of any applicable national securities exchange.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Act</B>: The U.S. Securities Exchange Act of 1934, as amended, or any successor
thereto.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Affiliate</B>: With respect to the Company, any entity directly or indirectly
controlling, controlled by, or under common control with, the Company or any other
entity designated by the Board in which the Company or an Affiliate has an interest.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>American Depositary Receipt</B>: A physical certificate evidencing ownership in
American Depositary Shares, issued by the Depositary and listed on an established
national or regional stock exchange or are publicly traded on any established
securities market in the United States.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>American Depositary Share</B>: An equity right representing one or more Shares of
the Company, or a fraction of a Share of the Company, held on deposit by the Custodian,
which carries the corporate and economic rights of the Shares of the Company, subject
to the terms specified on the American Depositary Receipt.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(f)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Award</B>: An Option, Share Appreciation Right or Other Share-Based Award granted
pursuant to the Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(g)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Award Agreement</B>: The stock option or other written agreement between the
Company and the Participant that evidences and sets out the terms and conditions of an
Award.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(h)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Beneficial Owner</B>: A &#147;beneficial owner&#148;, as such term is defined in Rule&nbsp;13d-3
under the Act (or any successor rule thereto).</TD>
</TR>

</TABLE>
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="right" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(i)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Board</B>: The Board of Directors of the Company.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(j)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Change in Control</B>: The occurrence of any of the following events:</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(i)&nbsp;the sale or disposition, in one or a series of related transactions, of all or
substantially all, of the assets of the Company to any &#147;person&#148; or &#147;group&#148; (as such
terms are defined in Sections&nbsp;13(d)(3) or 14(d)(2) of the Act) other than the
Permitted Holders;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(ii)&nbsp;any person or group, other than the Permitted Holders, is or becomes the
Beneficial Owner (except that a person shall be deemed to have &#147;beneficial
ownership&#148; of all shares that any such person has the right to acquire, whether such
right is exercisable immediately or only after the passage of time), directly or
indirectly, of more than 50% of the total voting power of the voting share of the
Company (or any entity which controls the Company), including by way of merger,
consolidation, tender or exchange offer or otherwise; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(iii)&nbsp;during any period of two consecutive years, individuals who at the beginning
of such period constituted the Board (together with any new directors whose election
by such Board or whose nomination for election by the shareholders of the Company
was approved by a vote of a majority of the directors of the Company, then still in
office, who were either directors at the beginning of such period or whose election
or nomination for election was previously so approved) cease for any reason to
constitute a majority of the Board, then in office.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(k)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Code</B>: The U.S. Internal Revenue Code of 1986, as amended, or any successor
thereto.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(l)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Committee</B>: The Compensation Committee of the Board, or in the absence of a
Compensation Committee, the Board.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(m)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Company</B>: Concord Medical Services Holdings Limited, a company incorporated
under the laws of the Cayman Islands.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(n)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Custodian</B>: The bank appointed to hold any ADSs on deposit upon or after a
public offering of the Shares.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(o)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Depositary</B>: The United States bank appointed by the Company to issue any
American Depositary Receipts upon or after a public offering of the Shares.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(p)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Disability</B>: Inability of a Participant to perform in all material respects his
or her duties and responsibilities to the Company, or any Affiliates of the Company, by
reason of a physical or mental disability or infirmity which inability is reasonably
expected to be permanent and has continued (i)&nbsp;for a period of not less than 90
consecutive days or (ii)&nbsp;such shorter period as the Committee may reasonably determine
in good faith. The Disability determination shall be in the sole discretion of the
Committee and a Participant (or his or her representative) shall furnish the</TD>
</TR>

</TABLE>
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="right" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Committee with medical evidence documenting the Participant&#146;s disability or
infirmity which is satisfactory to the Committee.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(q)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Effective Date</B>: The date the Board approves the Plan, or such later date as is
designated by the Board.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(r)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Employment</B>: The term &#147;Employment&#148; as used herein shall be deemed to refer to
(i)&nbsp;a Participant&#146;s employment if the Participant is an employee of the Company or any
of its Affiliates, (ii)&nbsp;a Participant&#146;s services as a consultant, if the Participant is
consultant to the Company or its Affiliates and (iii)&nbsp;a Participant&#146;s services as an
non-employee director, if the Participant is a non-employee member of the Board.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(s)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Fair Market Value</B>: The value of a Share, determined as follows: if on the
Grant Date or other determination date the Shares are listed on an established national
or regional stock exchange, or are publicly traded on any established securities
market, the Fair Market Value of a Share shall be the closing price of the Shares on
such exchange or in such market (if there is more than one such exchange or market the
Committee shall determine the appropriate exchange or market) on the Grant Date or such
other determination date (or if there is no such reported closing price, the Fair
Market Value shall be the mean between the highest bid and lowest asked prices or
between the high and low sale prices on such trading day) or, if no sale of Shares is
reported for such trading day, on the next preceding day on which any sale shall have
been reported. If the Shares are not listed on such an exchange, quoted on such system
or traded on such a market, Fair Market Value shall be the value of the Shares as
determined by the Committee in good faith, and shall be determined by the reasonable
application of a reasonable valuation method within the meaning of Section&nbsp;409A of the
Code and the regulations promulgated thereunder.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(t)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Grant Date</B>: The date as of which the Committee approves an Award.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(u)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>ISO</B>: An Option that is also an incentive share option granted pursuant to
Section 6(d) of the Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(v)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>LSAR</B>: A limited share appreciation right granted pursuant to Section 7(d) of
the Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(w)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Other Share-Based Awards</B>: Awards granted pursuant to Section&nbsp;8 of the Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(x)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Option</B>: A share option granted pursuant to Section&nbsp;6 of the Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(y)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Option Price</B>: The purchase price per Share of an Option, as determined
pursuant to Section 6(a) of the Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(z)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Participant</B>: An employee, director or consultant who is selected by the
Committee to participate in the Plan. To the extent required by Applicable Laws,
Awards may be limited to employees and officers or employees and directors.</TD>
</TR>

</TABLE>
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="right" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(aa)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Permitted Holder: </B>Means, as of the date of determination, (i)&nbsp;the Company or
(ii)&nbsp;any employee benefit plan (or trust forming a part thereof) maintained by (A)&nbsp;the
Company or (B)&nbsp;any corporation or other Person of which a majority of its voting power
of its voting equity securities or equity interest is owned, directly or indirectly, by
the Company.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(bb)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Person</B>: A &#147;person&#148;, as such term is used for purposes of Section 13(d) or
14(d) of the Act (or any successor section thereto).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(cc)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Plan</B>: This Concord Medical Services Holdings Limited 2008 Share Incentive
Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(dd)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Shares</B>: Ordinary Share of the Company.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(ee)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Share Appreciation Right</B>: A share appreciation right granted pursuant to
Section&nbsp;7 of the Plan.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Shares Subject to the Plan</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to adjustment as provided in Section&nbsp;9 hereof, the total number of Shares which may be
issued under the Plan is 13,218 Shares. Among the total number of Shares that may be issued under
the Plan, up to 13,218 Shares may be issued for the purpose of granting Options (all of which may
be issued as ISOs) and/or Share Appreciation Rights. The Shares may consist, in whole or in part,
of authorized and unissued Shares, treasury Shares or Shares purchased on the open market. The
issuance of Shares or the payment of cash upon the exercise of an Award or in consideration of the
cancellation or termination of an Award shall reduce the total number of Shares available under the
Plan, as applicable. Shares which are subject to Awards which terminate or lapse without the
payment of consideration may be granted again under the Plan.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Administration</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Plan shall be administered by the Committee, which may delegate its duties and powers in
whole or in part to any subcommittee thereof consisting solely of at least two individuals who are
intended to qualify as &#147;Non-Employee Directors&#148; within the meaning of Rule&nbsp;16b-3 under the Act (or
any successor rule thereto) and an &#147;independent director&#148; as defined, to the extent applicable, in
either Rule&nbsp;4200 of the NASDAQ Stock Market Rules (or any applicable successor rule thereto) or in
NYSE Rule&nbsp;303A.02 (or any applicable successor rule thereto). Awards may, in the discretion of the
Committee, be made under the Plan in assumption of, or in substitution for, outstanding awards
previously granted by the Company or its Affiliates or a company acquired by the Company or with
which the Company combines. The number of Shares underlying such substitute awards shall be
counted against the aggregate number of Shares available for Awards under the Plan. The Committee
is authorized to interpret the Plan, to establish, amend and rescind any rules and regulations
relating to the Plan, and to make any other determinations that it deems necessary or desirable for
the administration of the Plan. The Committee may correct any defect or supply any omission or
reconcile any inconsistency in the Plan in the manner and to the extent the Committee deems
necessary or desirable. Any decision of the Committee in the interpretation and administration of
the Plan, as described herein, shall lie
</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="right" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">within its sole and absolute discretion and shall be final, conclusive and binding on all
parties concerned (including, but not limited to, Participants and their beneficiaries or
successors). The Committee shall have the full power and authority to establish the terms and
conditions of any Award consistent with the provisions of the Plan and to waive any such terms and
conditions at any time (including, without limitation, accelerating or waiving any vesting
conditions). The Committee shall require payment of any amount it may determine to be necessary to
withhold for any applicable taxes as a result of the exercise, grant or vesting of an Award.
Unless the Committee specifies in the applicable Award Agreement or otherwise, the Participant may
elect to pay a portion or all of such withholding taxes by (a)&nbsp;delivery in Shares or (b)&nbsp;having
Shares withheld by the Company from any Shares that would have otherwise been received by the
Participant.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Limitations</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Award may be granted under the Plan after the tenth anniversary of the Effective Date, but
Awards theretofore granted may extend beyond that date.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Terms and Conditions of Options</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options granted under the Plan shall be, as determined by the Committee, non-qualified or
incentive share options for U.S. federal income tax purposes, as evidenced by the related Award
Agreements, and shall be subject to the foregoing and the following terms and conditions and to
such other terms and conditions, not inconsistent therewith, as the Committee shall determine:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Option Price</U>. The Option Price per Share shall be determined by the
Committee, and unless specifically approved by the Board, shall not be less than 100%
of the Fair Market Value of the Shares on the Grant Date.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Exercisability</U>. Options granted under the Plan shall be exercisable at
such time and upon such terms and conditions as may be determined by the Committee, but
in no event shall an Option be exercisable more than eight years after the Grant Date.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Exercise of Options</U>. Except as otherwise provided in the Plan or in an
Award Agreement, an Option may be exercised for all, or from time to time any part, of
the Shares for which it is then exercisable. For purposes of Section&nbsp;6 of the Plan,
the exercise date of an Option shall be the later of the date a notice of exercise is
received by the Company and, if applicable, the date payment is received by the Company
pursuant to clauses (i), (ii), (iii)&nbsp;or (iv)&nbsp;in the following sentence. The purchase
price for the Shares as to which an Option is exercised shall be paid to the Company in
full at the time of exercise at the election of the Participant (i)&nbsp;in cash or its
equivalent (e.g., by check), (ii)&nbsp;to the extent permitted by the Committee, in Shares
having a Fair Market Value equal to the aggregate Option Price for the Shares being
purchased and satisfying such other requirements as may be imposed by the Committee;
provided, that such Shares have been held by the Participant for no less than six
months (or such other period as established from time to time by the Committee in order
to avoid adverse accounting treatment applying generally</TD>
</TR>

</TABLE>
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="right" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>accepted accounting principles), (iii)&nbsp;partly in cash and, to the extent permitted
by the Committee, partly in such Shares or (iv)&nbsp;if there is a public market for the
Shares at such time, through the delivery of irrevocable instructions to a broker to
sell Shares obtained upon the exercise of the Option and to deliver promptly to the
Company an amount out of the proceeds of such Sale equal to the aggregate Option
Price for the Shares being purchased. No Participant shall have any rights to
dividends or other rights of a shareholder with respect to Shares subject to an
Option until the Participant has given written notice of exercise of the Option,
paid in full for such Shares and, if applicable, has satisfied any other conditions
imposed by the Committee pursuant to the Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>ISOs</U>. The Committee may grant Options under the Plan that are intended
to be ISOs. Such ISOs shall comply with the requirements of Section&nbsp;422 of the Code
(or any successor section thereto). No ISO may be granted to any Participant who at
the time of such grant, owns more than ten percent of the total combined voting power
of all classes of share of the Company or of any Affiliates, unless (i)&nbsp;the Option
Price for such ISO is at least 110% of the Fair Market Value of a Share on the date the
ISO is granted and (ii)&nbsp;the date on which such ISO terminates is a date not later than
the day preceding the fifth anniversary of the date on which the ISO is granted. Any
Participant who disposes of Shares acquired upon the exercise of an ISO either (i)
within two years after the date of grant of such ISO or (ii)&nbsp;within one year after the
transfer of such Shares to the Participant, shall notify the Company of such
disposition and of the amount realized upon such disposition. All Options granted
under the Plan are intended to be nonqualified share options, unless the applicable
Award Agreement expressly states that the Option is intended to be an ISO. If an
Option is intended to be an ISO, and if for any reason such Option (or portion thereof)
shall not qualify as an ISO, then, to the extent of such nonqualification, such Option
(or portion thereof) shall be regarded as a nonqualified share option granted under the
Plan; <U>provided</U> that such Option (or portion thereof) otherwise complies with
the Plan&#146;s requirements. In no event shall any member of the Committee, the Company or
any of its Affiliates (or their respective employees, officers or directors) have any
liability to any Participant (or any other Person) due to the failure of an Option to
qualify for any reason as an ISO.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(e)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Attestation</U>. Wherever in this Plan or any agreement evidencing an
Award a Participant is permitted to pay the exercise price of an Option or taxes
relating to the exercise of an Option by delivering Shares, the Participant may,
subject to procedures satisfactory to the Committee, satisfy such delivery requirement
by presenting proof of beneficial ownership of such Shares, in which case the Company
shall treat the Option as exercised without further payment and shall withhold such
number of Shares from the Shares acquired by the exercise of the Option.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Terms and Conditions of Share Appreciation Rights</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Grants</U>. The Committee also may grant (i)&nbsp;a Share
Appreciation Right independent of an Option or (ii)&nbsp;a Share Appreciation Right
in connection</TD>
</TR>

</TABLE>
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="right" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>with an Option, or a portion thereof. A Share Appreciation Right granted
pursuant to clause (ii)&nbsp;of the preceding sentence (A)&nbsp;may be granted at the
time the related Option is granted or at any time prior to the exercise or
cancellation of the related Option, (B)&nbsp;shall cover the same number of
Shares covered by an Option (or such lesser number of Shares as the
Committee may determine) and (C)&nbsp;shall be subject to the same terms and
conditions as such Option except for such additional limitations as are
contemplated by this Section&nbsp;7 (or such additional limitations as may be
included in an Award Agreement).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Terms</U>. The exercise price per Share of a Share
Appreciation Right shall be an amount determined by the Committee but in no
event shall such amount be less than the greater of (i)&nbsp;the Fair Market Value
of a Share on the date the Share Appreciation Right is granted or, in the case
of a Share Appreciation Right granted in conjunction with an Option, or a
portion thereof, the Option Price of the related Option and (ii)&nbsp;the minimum
amount permitted by Applicable Laws. Each Share Appreciation Right granted
independent of an Option shall entitle a Participant upon exercise to an amount
equal to (i)&nbsp;the excess of (A)&nbsp;the Fair Market Value on the exercise date of
one Share over (B)&nbsp;the exercise price per Share, times (ii)&nbsp;the number of
Shares covered by the Share Appreciation Right. Each Share Appreciation Right
granted in conjunction with an Option, or a portion thereof, shall entitle a
Participant to surrender to the Company the unexercised Option, or any portion
thereof, and to receive from the Company in exchange therefore an amount equal
to (i)&nbsp;the excess of (A)&nbsp;the Fair Market Value on the exercise date of one
Share over (B)&nbsp;the Option Price per Share, times (ii)&nbsp;the number of Shares
covered by the Option, or portion thereof, which is surrendered. The date a
notice of exercise is received by the Company shall be the exercise date.
Payment shall be made in Shares or in cash, or partly in Shares and partly in
cash (any such Shares valued at such Fair Market Value), all as shall be
determined by the Committee. Share Appreciation Rights may be exercised from
time to time upon actual receipt by the Company of written notice of exercise
stating the number of Shares with respect to which the Share Appreciation Right
is being exercised. No fractional Shares will be issued in payment for Share
Appreciation Rights, but instead cash will be paid for a fraction or, if the
Committee should so determine, the number of Shares will be rounded downward to
the next whole Share.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Limitations</U>. The Committee may impose, in its
discretion, such conditions upon the exercisability or transferability of Share
Appreciation Rights as it may deem fit.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Limited Share Appreciation Rights</U>. The Committee may
grant LSARs that are exercisable upon the occurrence of specified contingent
events. Such LSARs may provide for a different method of determining
appreciation, may specify that payment will be made only in cash and may
provide that</TD>
</TR>

</TABLE>
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="right" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any related Awards are not exercisable while such LSARs are exercisable.
Unless the context otherwise requires, whenever the term &#147;Share Appreciation
Right&#148; is used in the Plan, such term shall include LSARs.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Other Share-Based Awards</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Committee, in its sole discretion, may grant or sell Awards of Shares and Awards that are
valued in whole or in part by reference to, or are otherwise based on the Fair Market Value of,
Shares (collectively, &#147;Other Share-Based Awards&#148;). Such Other Share-Based Awards shall be in such
form, and dependent on such conditions, as the Committee shall determine, including, without
limitation, the right to receive, or vest with respect to, one or more Shares (or the equivalent
cash value of such Shares) upon the completion of a specified period of service, the occurrence of
an event and/or the attainment of performance objectives. Other Share-Based Awards may be granted
alone or in addition to any other Awards granted under the Plan. Subject to the provisions of the
Plan, the Committee shall determine to whom and when Other Share-Based Awards will be made, the
number of Shares to be awarded under (or otherwise related to) such Other Share-Based Awards;
whether such Other Share-Based Awards shall be settled in cash, Shares or a combination of cash and
Shares; and all other terms and conditions of such Awards (including, without limitation, the
vesting provisions thereof and provisions ensuring that all Shares so awarded and issued shall be
fully paid and non-assessable).
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Adjustments Upon Certain Events</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provisions in the Plan to the contrary, the following provisions
shall apply to all Awards granted under the Plan:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Generally</U>. In the event of any change in the
outstanding Shares after the Effective Date by reason of any Share dividend or
split, reorganization, recapitalization, merger, consolidation, spin-off,
combination, combination or transaction or exchange of Shares or other
corporate exchange, or any distribution to shareholders of Shares other than
regular cash dividends or any transaction similar to the foregoing, the
Committee in its sole discretion and without liability to any person shall make
such substitution or adjustment, if any, as it deems to be equitable, as to (i)
the number or kind of Shares or other securities issued or reserved for
issuance pursuant to the Plan or pursuant to outstanding Awards, (ii)&nbsp;the
maximum number of Shares for which Options or Share Appreciation Rights may be
granted during a calendar year to any Participant, (iii)&nbsp;the maximum number of
Shares for which Other Share-Based Awards may be granted during a calendar year
to any Participant, (iv)&nbsp;the maximum amount of an Award that is valued in whole
or in part by reference to, or is otherwise based on the Fair Market Value of,
Shares that may be granted during a calendar year to any Participant, (v)&nbsp;the
Option Price or exercise price of any share appreciation right and/or (vi)&nbsp;any
other affected terms of such Awards.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Change in Control</U>. In the event of a Change of Control
after the Effective Date, (i)&nbsp;if determined by the Committee in the applicable
Award</TD>
</TR>

</TABLE>
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="right" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Agreement or otherwise, any outstanding Awards then held by Participants
which are unexercisable or otherwise unvested or subject to lapse
restrictions shall automatically be deemed exercisable or otherwise vested
or no longer subject to lapse restrictions, as the case may be, as of
immediately prior to such Change of Control and (ii)&nbsp;the Committee may, but
shall not be obligated to, (A)&nbsp;cancel such Awards for fair value (as
determined in the sole discretion of the Committee) which, in the case of
Options and Share Appreciation Rights, may equal the excess, if any, of
value of the consideration to be paid in the Change of Control transaction
to holders of the same number of Shares subject to such Options or Share
Appreciation Rights (or, if no consideration is paid in any such
transaction, the Fair Market Value of the Shares subject to such Options or
Share Appreciation Rights) over the aggregate exercise price of such Options
or Share Appreciation Rights or (B)&nbsp;provide for the issuance of substitute
Awards that will substantially preserve the otherwise applicable terms of
any affected Awards previously granted hereunder as determined by the
Committee in its sole discretion or (C)&nbsp;provide that for a period of at
least 15&nbsp;days prior to the Change of Control, such Options shall be
exercisable as to all shares subject thereto and that upon the occurrence of
the Change of Control, such Options shall terminate and be of no further
force and effect.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">10.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>No Right to Employment or Awards</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The granting of an Award under the Plan shall impose no obligation on the Company or any
Affiliate to continue the Employment of a Participant and shall not lessen or affect the Company&#146;s
or any Affiliate&#146;s right to terminate the Employment of such Participant. No Participant or other
Person shall have any claim to be granted any Award, and there is no obligation for uniformity of
treatment of Participants, or holders or beneficiaries of Awards. The terms and conditions of
Awards and the Committee&#146;s determinations and interpretations with respect thereto need not be the
same with respect to each Participant (whether or not such Participants are similarly situated).
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Successors and Assigns</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Plan shall be binding on all successors and assigns of the Company and a Participant,
including without limitation, the estate of such Participant and the executor, administrator or
trustee of such estate, or any receiver or trustee in bankruptcy or representative of the
Participant&#146;s creditors.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">12.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Nontransferability of Awards</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise determined by the Committee, an Award shall not be transferable or assignable
by the Participant otherwise than by will or by the laws of descent and distribution. An Award
exercisable after the death of a Participant may be exercised by the legatees, personal
representatives or distributees of the Participant.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">13.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Amendments or Termination</B>
</TD>
</TR>
</TABLE>
</DIV></DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="right" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board may amend, alter or discontinue the Plan, but no amendment, alteration or
discontinuation shall be made, (a)&nbsp;without the approval of the shareholders of the Company, if such
action would (except as is provided in Section&nbsp;9 of the Plan), increase the total number of Shares
reserved for the purposes of the Plan or change the maximum number of Shares for which Awards may
be granted to any Participant or (b)&nbsp;without the consent of a Participant, if such action would
diminish any of the rights of the Participant under any Award theretofore granted to such
Participant under the Plan; provided, however, that the Committee may amend the Plan in such manner
as it deems necessary to permit the granting of Awards meeting the requirements of any Applicable
Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the generality of the foregoing, to the extent applicable, notwithstanding
anything herein to the contrary, this Plan and Awards issued hereunder shall be interpreted in
accordance with Section&nbsp;409A of the Code and Department of Treasury regulations and other
interpretative guidance issued thereunder, including without limitation any such regulations or
other guidance that may be issued after the Effective Date. Notwithstanding any provision of the
Plan to the contrary, in the event that the Committee determines that any amounts payable hereunder
will be taxable to a Participant under Section&nbsp;409A of the Code and related Department of Treasury
guidance prior to payment to such Participant of such amount, the Company may (a)&nbsp;adopt such
amendments to the Plan and Awards and appropriate policies and procedures, including amendments and
policies with retroactive effect, that the Committee determines necessary or appropriate to
preserve the intended tax treatment of the benefits provided by the Plan and Awards hereunder
and/or (b)&nbsp;take such other actions as the Committee determines necessary or appropriate to comply
with the requirements of Section&nbsp;409A of the Code.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">14.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Jurisdictions</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to assure the viability of Awards granted to Participants employed in various
jurisdictions, the Committee may, in its sole discretion, may provide for such special terms as it
may consider necessary or appropriate to accommodate differences in local law, tax policy or custom
applicable in the jurisdiction in which the Participant resides or is employed. Moreover, the
Committee may approve such supplements to, amendments, restatements, or alternative versions of the
Plan as it may consider necessary or appropriate for such purposes without thereby affecting the
terms of the Plan as in effect for any other purpose; provided, however, that no such supplements,
restatements or alternative versions shall increase the Share limitation contained in Section&nbsp;3
hereof. Notwithstanding the foregoing, the Committee may not take any actions hereunder, and no
Awards shall be granted that would violate any Applicable Laws.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">15.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Distribution of Shares</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The obligation of the Company to make payments in Shares pursuant to an Award shall be subject
to all Applicable Laws and to any such approvals by government agencies as may be required.
Without limiting the generality of the foregoing, Shares distributed pursuant to an Award may
consist, in whole or in part, of authorized and unissued Shares, treasury Shares or Shares
purchased on the open market. Additionally, in the discretion of the Committee, American
Depository Shares may be distributed in lieu of Shares in settlement of any Award, provided that
the American Depository Shares shall be of equal value to the Shares that would have otherwise been
distributed. If the number of Shares represented by an American Depository Share is other
</DIV>
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<P align="right" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">than on a one-to-one basis, the limitations of Section&nbsp;3 shall be adjusted to reflect the
distribution of American Depository Shares in lieu of Shares.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">16.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Taxes</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Shares shall be delivered under the Plan to any Participant until such Participant has made
arrangements acceptable to the Committee for the satisfaction of any income and employment tax
withholding obligations under any Applicable Laws, in particular, the tax laws, rules, regulations
and government orders of the People&#146;s Republic of China or the U.S. federal, state or other local
tax laws, as applicable. The Company and each of its Subsidiaries shall have the authority and the
right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient
to satisfy federal, state, local and foreign taxes (including the Participant&#146;s payroll tax
obligations, if any) required to be withheld under any Applicable Laws with respect to any Award
issued to the Participant hereunder. The Committee may in its discretion and in satisfaction of
the foregoing requirement allow a Participant to elect to have the Company withhold Shares
otherwise issuable under an Award (or allow the return of Shares) having a Fair Market Value equal
to the sums required to be withheld. Notwithstanding any other provision of the Plan, the number
of Shares which may be withheld with respect to the issuance, vesting, exercise or payment of any
Award (or which may be repurchased form the Participant of such Award after such Shares were
acquired by the Participant from the Company) in order to satisfy the Participant&#146;s federal, state,
local and other income and payroll tax liabilities with respect to the issuance, vesting, exercise
or payment of the Award shall, unless specifically approved by the Committee, be limited to the
number of Shares which have a Fair Market Value on the date of withholding or repurchase equal to
the aggregate amount of such liabilities based on the minimum statutory withholding rates for
federal, state, local and other income tax any payroll tax purposes that are applicable to such
taxable income.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">17.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Choice of Law</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Plan shall be governed by and construed in accordance with the laws of the state of New
York.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">18.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Effectiveness of the Plan</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Plan shall be effective as of the Effective Date and shall terminate on the tenth
anniversary of the Effective Date, subject to earlier termination by the Board pursuant to Section
13 hereof.
</DIV>


<P align="right" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>21
<FILENAME>h03611exv10w3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.3</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Form of Medical Equipment<BR>
Lease Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Parties to the Agreement:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">Lessee:
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">Hospital&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(hereinafter referred to as &#147;Party A&#148;)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">Legal Representative:</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">Lessor:
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">(hereinafter referred to as &#147;Party B&#148;)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">Legal Representative:</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">Address:</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Whereas:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For purposes of maintaining the leading position in respect of medical technology and
academic development, the Lessee plans to establish &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; Centre (hereinafter referred to as the
&#147;Centre&#148;)/plans to expand &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; Centre (hereinafter referred to as the &#147;Centre&#148;) and wishes to
install certain medical equipment as follows: &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Lessor is a professional company which is engaged in the lease of large medical equipment
as well as provision of relevant services;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon friendly consultation and based on the principle of equality and the mutual benefit,
with respect to the lease of the medical equipment (hereinafter referred to as the &#147;Leased
Assets&#148;) to Party A by Party B, both Party A and Party B have reached the following
agreements;</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;1 Leased Assets</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B agrees to lease to Party A the following medical equipment <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The name, model number and specifications, total price, manufacturers, and etc., of the
Leased Assets will be subject to the results of the collective tender process. Upon the
completion of the collective tender process, both parties shall reach further agreement in
respect of the name, model number and specifications, total price, manufacturers, and etc., of
the Leased Assets in form of a supplemental agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To facilitate the performance of the lease, Party A shall be responsible for obtaining all
necessary procurement licenses, environmental evaluation and assessment, filing for approval
of charges and prices, and such other matters as required for operating the Leased Assets.
Party A shall also process and complete all procedures required for the use and installation
of the Leased Assets and construct and renovate the machine room required for the Leased
Assets pursuant to the provisions of regulations and rules of the government and the relevant
agencies.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;2 Use of the Leased Assets</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Leased Assets shall be used at Party A&#146;s &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; Centre for purpose of &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Leased Assets must be installed and placed at the location agreed by both parties within
the premises of Party A. Without the written consent of Party B, Party A shall not change the
location and operation environment of the Leased Assets.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;3 Ownership of the Leased Assets</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease Term, the ownership of the Leased Assets as listed in the Appendix to this
Agreement, including any parts and components, replacement parts, attached parts and auxiliary
parts of (or to be attached to) the Leased Assets, shall always belong to Party B. During the
Lease Term, Party A shall only enjoy the right to use the Leased Assets. Party A may not
sell, transfer, sub-lease, or set</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #textcolor#; background: #bgcolor#">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>mortgage over the Leased Assets or dispose the Leased Assets as investment, and may not
conduct any other actions that may infringe Party B&#146;s rights and benefits. Otherwise,
Party A shall take the corresponding liabilities for breach of the Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that Party A is shut down, suspended, merged or acquired, changes the type of
its ownership or enters into bankruptcy, Party A shall have no right to dispose of the Leased
Assets; regardless of any Agreementual relationship entered into with any third party by Party
A or any changes of Party A&#146;s status as a legal person, Party B&#146;s ownership of the Leased
Assets shall in no event be affected.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the performance of the Agreement, Party B shall have the right to inspect the use and
condition of the Leased Assets and as long as such inspection would not affect the use of the
equipment, Party A shall make such inspection convenient. Without Party B&#146;s written consent,
Party A may not disassemble any parts and components nor change the premises where the Leased
Assets are used. Party B shall have the right to mark the logo of the ownership onto the
Leased Assets. Party B (or its entrusted agent) shall have right to check, on a regular basis
or at any time, the use and condition of the Leased Assets which Party A shall facilitate.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Given that the implementation of this Agreement would not be effected, Party B shall have the
right to set mortgage over the Leased Assets or transfer its beneficial interests to any third
party.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;4 Lease Term</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Lease Term shall be <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> years, commencing from the time
that all of the Leased Assets have
been in place and after <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
months of trial operation (the
specific date shall be confirmed
by both parties in writing).</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Lease Term shall be fixed. During the Lease Term, Party A may not unilaterally suspend
or terminate the lease nor propose any requirement for making amendment hereto due to any
reasons.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon expiration of the Lease Term, both Parties may renew this Agreement after Party B has
conducted the relevant maintenance, upgrading and renovation for the Leased Assets based on
the then actual situation of the Leased Assets. However, Party B must guarantee that the
Leased Assets may be operated normally during the effective term of the renewed Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;5 Rental and Payment</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Rental calculation method:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>From Year 1 to Year &#091; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#093;,
the rental payment shall
be &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#093; % of the
Revenue of the Leased
Assets on a monthly
basis;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>From Year &#091; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#093; to
Year &#091; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#093;, the rental
payment shall be &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; % of
the Revenue of the Leased
Assets on a monthly
basis;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Revenue of the Leased
Assets = Total amount
received by using the
Leased Assets for
diagnosis (or treatment)
minus the Hospital&#146;s
costs and expenses, which
include the Hospital&#146;s
costs and expenses
arising from diagnosis
(or treatment) by using
the Leased Assets, wages,
bonus, welfare, overtime
charges, travel and
accommodation expenses of
the personnel of the
Centre, utility charges
for water and electric
power, costs of
consumptive materials,
costs for printing
materials, hospitality
expenses, academic
gathering expenses, R&#038;D
cost, the repair and
maintenance costs of the
Leased Assets, costs of
office articles, fixed
line telephone charges,
expenses for settlement
of medical disputes,
insurance premium for the
Leased Assets, and the
cost of &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#093;.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The rental payment shall be payable on a monthly basis. Party A shall transfer the amount of
the rental payment for the previous month to the account as designated by Party B prior to the
10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of each month. The account information for the payment will be as
follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Name of the account:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Bank name:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Account number:

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Simultaneously, Party B shall issue an official tax invoice to Party A.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the effective term of this Agreement, Party A&#146;s payment to the designated bank
account set forth above will be deemed performance of the payment obligation under this
Agreement. Without the consent of Party B, Party A&#146;s payment to any other account or in
any other manner will not be deemed performance of its obligation hereof. In the event
that Party B needs to change its account number for receiving the payment, Party B shall
give advance written notice to Party A and Party A&#146;s finance department.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;6 Performance Guarantee Deposit</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Within &#091; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; days after this Agreement becomes effective, Party A shall transfer a performance guarantee deposit in the amount of &#091; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#093; to the account designated by Party B. Within &#091; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#093; days upon termination or expiration of this Agreement, Party B shall return such deposit, without any interest accrued, to Party A after deducting the outstanding amount payable by Party
A under this Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;7 Rights and Obligations of Both Parties</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>7.1 Party A&#146;s rights and obligations</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall issue a letter of confirmation regarding the rental payment to Party B every
month. Such letter of confirmation shall include the amount of the charges collected for the
Leased Assets, the Hospital&#146;s costs and expenses, etc. Party A shall also make undertakings
as to the accuracy of all the data provided in such letter of confirmation.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To provide the machine room and auxiliary rooms for the Leased Assets and to add in all such
auxiliary facilities and etc. as necessary; to provide the professional personnel including
experts, doctors, nurses and
</TD>
</TR>
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>technicians and to provide the convenient conditions in respect of the logistics
service.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To assist the supplier in handling the domestic equipment transportation, installation and
adjustment, trial and other matters.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be responsible for the treatment and other medical decisions of the patients and to deal
with the medical disputes arising from the Centre in due course.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A will properly manage and safeguard the Leased Assets and designate
specially-assigned staff to take charge of the daily work for the operation of the Leased
Assets.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be responsible for processing and completing all procedures with the competent
supervising departments and the relevant authorities in relation to the approval of the
project, procurement permits, environmental evaluation and assessment, approval of charges and
prices and qualification for coverage by medical insurance, as well as all routine procedures
as required to be processed on a yearly basis.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A may not use the Leased Assets for diagnosis and treatment free of charge. In case
of any required exemption or reduction of charges due to special reasons, such exemption or
reduction shall be approved and signed by both Parties.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A may not effect early termination or amendment this Agreement with the excuse that
the principle of Party B has been recovered, or the revenue from the Leased Assets are
continually growing, or any leader of the Hospital has been changed.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.1.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease Term, Party A may not separately operate any other project competing with
the Center either by itself or by cooperating with any third party.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>7.2 Party B&#146;s rights and obligations</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To liaise with the supplier for delivering the Leased Assets as designated by Party A on a
timely basis and assist the supplier in installing, adjusting and testing the Leased Assets.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be informed of the status of the operation of the Leased Assets at all times based on the
financial information of income and expenses related to the operation of the Leased Assets
provided by Party A.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B or Party B&#146;s entrusted agent (including asset appraiser, accountant, and so on)
shall have the right to examine the use and the condition of the Leased Assets which Party A
shall facilitate.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To assist the supplier in providing such necessary technical information as required for the
use of the Leased Assets.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To assist the supplier in conducting daily repair and maintenance of the Leased Assets.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To liaise with the professional management company for planning and organization of the
Centre&#146;s academic promotion and guidance for operation and management.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall be entitled to use the information and data generated from the treatment by
using the Leased Assets, such as the number of patients treated, the amount of charges
collected, the treatment plans and the treatment results of the patients, etc.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">7.2.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>After the completion of the Lease Term, under the same conditions, Party B shall have the
preemptive right to provide leasing with respect to any future similar project.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;8 Delivery, Examination and Acceptance of the Leased Assets</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Delivery, examination and acceptance: After the Leased Assets are delivered to the premises,
Party A shall examine the Leased Assets for acceptance pursuant to the content as provided in
the Appendix hereof. In the event that the Leased Assets fail to meet the agreed
requirements, Party A shall timely make a note on the delivery receipt and wait for Party B to
settle it. Party A shall be responsible
</TD>
</TR>
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>for safeguarding the Leased Assets as soon as the Leased Assets arrive at the location for
installation or operation.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Technical examination and acceptance: After Party A has made tests and adjustment upon
installation and has diagnosed or treated the first 30 cases of patients, if Party A confirms
that the Leased Assets comply with the technical requirements, Party A shall issue an
acceptance receipt to Party B within 5&nbsp;days, wherein the delivery of the Leased Assets shall
be deemed completed. Failure to issue the receipt in a timely manner and in the absence of
any written rejection by Party A, the delivery of the Leased Assets shall be deemed properly
completed. The Lease Term shall commence and the charges collected from such 30 cases shall
be included into the revenue of the Center.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">8.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that the Leased Assets fail to comply with the requirements upon examination,
Party B shall assist the supplier in further handling.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;9 Loss and Damage of the Leased Assets and Third Party&#146;s Damage</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease Term, Party B shall be responsible for purchasing insurance policies for the
Leased Assets and the beneficiary shall be Party B or any third party designated by Party B.
The insurance premiums shall be included as the Hospital&#146;s costs and expenses.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease Term, in case of any insurance incidents, Party A shall actively cooperate
with Party B for processing the claim with the relevant insurance company.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease Term, in the event that the Leased Assets are lost or damaged due to Party
A&#146;s fault, Party A shall, with all costs and expenses arising born by Party A, take one or
several of the following actions as determined by Party B:</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(i)&nbsp;to restore or repair the Leased Assets so that the Leased Assets is able to be
used in completely normal manner;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(ii)&nbsp;to replace the parts, components or articles with the same model number and
the same function of the Leased Assets;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(iii)&nbsp;Under the conditions of (i)&nbsp;and (ii), Party A shall continue to lease and use
the Leased Assets with its obligation of paying the rental payments unchanged.
During the period when the Leased Assets cannot be operated normally, Party A shall
pay Party B with the monthly rental payments equal to the average rental payments
in the three months prior to the loss or damage of the Leased Assets.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">(iv)&nbsp;in case that the loss or damage of the Leased Assets is severe to the extent
that no repair can be conducted, Party A shall be liable for the loss of Party B
pursuant to the provision regarding the Agreementual breach.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that any third party (such as the patient or etc.) is injured or suffers any
loss or damage due to the reasons of the Leased Assets itself (such as the technical reasons
or quality defects, etc.), Party A shall, together with Party B, jointly claim and pursue such
damages from the seller of the Leased Assets.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that any third party (the patient) is injured or suffers any loss or damage due
to the improper use of the Leased Assets by Party A, Party A shall be responsible for such
liabilities.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">9.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that any third party (such as the patient, etc.) is injured or suffers any loss
or damage due to the force majeure (not due to the reasons of the Leased Assets itself or the
reasons of Party A), in principle, neither Party A nor Party B shall be liable for
compensation. Party A shall be responsible for taking precautions against such kind of &#147;risk&#148;
and will purchase insurance to cover such third party&#146;s damage in such cases.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;10 Disposal of the Leased Assets Upon Expiry of the Lease Term</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">Upon the expiry of the Lease Term, if both parties will not
renew the Agreement, the Leased Assets shall be returned to
Party B.</div>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;11 Breach of Agreement</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Both Party A and Party B shall perform the corresponding responsibilities and obligations in
accordance with the time schedules as provided in this Agreement.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case of any beach of Agreement, the breaching party shall compensate the other party&#146;s
economic loss.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any delay in making rental payment by Party A shall not exceed two months. In case of any
such delay, Party A shall pay Party B with a daily default penalty equal to 0.05% of the
overdue amount, except where such delay is caused by the force majeure.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case of any breach of Agreement as set forth below, Party B shall have the right to
terminate this Agreement and be entitled to a default penalty paid by Party A, calculated with
the formula below:</TD>
</TR>


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Default Penalty = Remaining Lease Term (month) &#215; monthly average rental obtained by Party B
in one year prior to the beach of Agreement &#215;150%<BR><BR>

If the Lease Term is shorter than one year, the monthly average rental obtained by Party B
shall be deemed 3% of the purchase price of the equipment:</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.3.1</TD>
    <TD width="4%">&nbsp;</TD>
    <TD>any delay in making the rental payment exceeding two months by Party A;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.3.2</TD>
    <TD width="4%">&nbsp;</TD>
    <TD>unilateral early termination or modification of this Agreement by Party A in violation of
this Agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.3.3</TD>
    <TD width="4%">&nbsp;</TD>
    <TD>unilateral disposal (including sale, sub-lease, removal or transfer and etc.) of the Leased
Assets in violation of this Agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.3.4</TD>
    <TD width="4%">&nbsp;</TD>
    <TD>provision of false and untrue information regarding the Revenue of the Leased Assets and so
on, such that the rental payment that Party B collected becomes less than such amount to which
Party B should be entitled;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.3.5</TD>
    <TD width="4%">&nbsp;</TD>
    <TD>introduction of any similar medical equipment with similar functions to the Leased Assets
through any third party or cooperation with any third party to develop similar projects in
violation of this Leased Agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.3.6</TD>
    <TD width="4%">&nbsp;</TD>
    <TD>suspension of normally providing medical services to the patients using the Leased Assets
for a period exceeding 30&nbsp;days due to the man-made reasons of Party A; or severe damage or
loss of the Leased Assets due to improper use, intentional damage or careless storage by Party
A.</TD>
</TR>
</TABLE>
</DIV>
<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">11.4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case of any of the above mentioned breach or infringement by either Party A or Party B,
the breaching or infringing party shall be liable for all costs for lawsuits,</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>legal counsel fee and other expenses arising from the other party&#146;s realization of the
creditor&#146;s rights.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;12 Dispute Settlement</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD>Any and all disputes related to this Agreement shall be
resolved by both Party A and Party B through consultation. In
case that no settlement could be reached through consultation,
either party may file claim with the People&#146;s Court as
designated by Party B.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;13 Appendix</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
   <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD>The Appendix to this Agreement is an integrated part hereof and
shall have the equal legal validity as that of the main text
hereof.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;14 Effectiveness of the Agreement</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" nowrap align="left">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD>This Agreement shall become effective upon being signed and
stamped by both Party A and Party B.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;15 Termination of the Agreement</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">15.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall automatically terminated upon the expiry of the Lease Term.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">15.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All indebtedness arising from the performance of this Agreement by either Party A or Party B
will be terminated upon full repayment of all debts, including all outstanding rental
payments, default penalties, indemnification, and so on.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">15.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case of impossibility of performance of the Agreement or use of the Leased Assets due to
war, natural disaster, force majeure and other factors, this Agreement shall be terminated and
neither party shall be liable for or have any rights against the other party.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">15.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prior to the commencing of the Lease Term, under the following circumstances, Party B shall
have the right to terminate this Agreement without any liability:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">15.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A fails to obtain the procurement permits for the medical equipment;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">15.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A fails to prepare and provide, on a timely basis, the premises for using the Leased
Assets.</TD>
</TR>
</TABLE>
</DIV>
<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">15.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that the government or the military adjusts its policy and issues any regulation
or document for prohibiting equipment lease within the country or within the military system,
resulting in this Agreement not being able to be performed, but without affecting the use of
the Leased Assets, Party A shall be responsible for coordination and negotiation. During such
period of coordination and negotiation, Party A shall be still subject to the obligation for
paying the rental on a timely basis. If no resolution can be reached upon negotiation, this
Agreement may be terminated in early manner, provided that, however, Party A shall make a
lump-sum payment for the remaining rental payments to Party B. The remaining rental payments
shall be equal to the amount of the original price of the Leased Assets minus the depreciation
for the years during which the rent has been paid (the number of years for calculating the
depreciation shall be equal to the Lease Term, without considering any remaining value):</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Remaining Rental Payments = Original Price of Leased Assets (calculated based on the
bidding price) &#215; (1- the number of years during which the rental payments has been paid &#247;
Lease Term)</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;16 Miscellaneous</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">16.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Both parties hereto have carefully read through all the terms of this Agreement. Reasonable
manner has been adopted to urge both parties to pay attention to the terms regarding exemption
or restriction on their responsibilities as provided herein. Per request of both parties,
explanation has been made in respect of the relevant terms.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">16.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Both parties hereto have authorized their respective representatives to sign this Agreement.
All terms of this Agreement are all true meanings and representation of both parties and shall
have legal binding effect on both parties.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

 <TR>
  <TD width="1%" valign="top" nowrap><B>Article&nbsp;17</b></TD>
  <TD width="1%">&nbsp;</TD>
  <TD><b>The original of this Agreement and the Appendix hereto shall be prepared in four copies
of which Party A and Party B shall each hold two copies.</B></TD>
 </TR>
<tr style="font-size:6pt"><td>&nbsp;</td></tr>
<TR>
  <TD width="1%" valign="top" nowrap><B>Article&nbsp;18</b></TD>
  <TD width="1%">&nbsp;</TD>
  <TD><b><B>With respect to any matters not covered herein, both parties may sign a supplemental
agreement in relation thereto. Any supplemental agreement and this Agreement shall have equal
legal validity.</B></B></TD>
 </TR>

</TABLE>
</DIV>





<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;19&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is signed and executed on &#091;day&#093; &#091;month&#093;, &#091;200&#95;&#95;&#95;&#093;.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(No main context follows)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Party A:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hospital</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Legal Representative (or Authorized Representative):</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Party B:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Legal Representative (or Authorized Representative):</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>22
<FILENAME>h03611exv10w4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><b>Exhibit&nbsp;10.4</b>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Form of Equipment Management Services Agreement</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">(Project &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;)

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Party A:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Party B:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; Hospital</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Parties to the Agreement:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Party A:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Company</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Legal Representative:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Party B:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Hospital</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Legal Representative:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;1 Precondition and Objective of this Agreement</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For purposes of fully using the internationally advanced &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; system and continuously
enhancing the quality of the diagnosis (treatment)&nbsp;provided by Party B, and upon friendly
consultation between Party A and Party B, Party B agrees to entrust Party A to provide
operating service in respect to the target equipment and auxiliary products leased to Party B
by &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; Company under the Medical Equipment Lease Agreement entered into by and
between &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;. Party A shall charge the service fee pursuant to the agreed terms
hereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Unless otherwise specified, all relevant terms and explanations shall have the same meanings
of such terms and explanations as set forth in the Medical Equipment Lease Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;2 Term of Operating Service</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party B shall entrust Party A to provide the &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; Centre with the operating service
with a term of &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; years, commencing from the date on which this Agreement is signed and
executed to the date of termination of the Lease Term as provided in the Medical Equipment Lease
Agreement.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;3&nbsp;Content of Service</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The services to be offered by Party B to Party A includes:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A may send service personnel to provide onsite service.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall have the right to set up an account book for recording the number of cases of
diagnosis (or treatment), purchase and use of equipment and consumptive materials, as well as
other costs.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall have the right to be informed of the status of the operation of the Centre&#146;s
equipment at all times based on the financial information of income and expenses related to
the operation of the Centre&#146;s equipment as provided by Party B, and shall have the right to
engage an accounting firm to conduct audits on the book with which Party B shall cooperate.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A may examine the use and condition of the Centre&#146;s equipment. Without the written
consent of Party A, during the term of this Agreement, Party B may not disassemble any parts
and components of the Centre&#146;s equipment nor change the premise where the equipment is used.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall provide such necessary technical information for the use of the Centre&#146;s
equipment and conduct appropriate marketing and promotional activities.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall provide recommendations regarding the employment and engagement of experts and
advisors for the Centre.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall assign professional personnel to examine the service quality.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Other service as agreed by both Party A and Party B.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;4 Service Fee</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The service fee shall be accounted for and settled on a monthly basis. The amount shall be
calculated as &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; % of the total amount of the revenue generated by the &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;
Centre&#146;s equipment in a month net of the Centre&#146;s own expenses (Operating Costs) as expressly
provided in the Lease Contract.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Centre&#146;s own expenses (Operating Costs): refers to costs for consumptive materials needed
for the operation of the equipment; the bonus of the personnel</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>directly related to the Centre; office expenses; media and advertisement fees, website
establishment fees; fees for necessary technical training, academic exchange and the cost
for hiring specialists and advisors; equipment repair cost; charges for water and electric
power, and other fees approved by both Parties. During the period of the management
service, the Centre&#146;s own expenses (Operating Costs) for each month shall not exceed &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;%
of the total amount of the revenue generated by the &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; Centre&#146;s equipment
for that month. In case that it exceeds &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;%, it shall be calculated as &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;%.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall transfer the service fee of the previous month to the account designated by
Party A prior to the 15<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of each month. The account number for making such
payment shall be as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Name of the account:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Bank name:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Account number:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;5 Commitments of Each Party</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall be responsible for contacting the manufacturers for replacement of parts and
components, maintenance and repair of the equipment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall be responsible for marketing, publicity, technology upgrades, and patient
education.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall be responsible for providing the premises, auxiliary medical equipment and
communication instruments used by the Centre; and providing professional personnel including
doctors, nurses and technicians. Party B shall also provides convenient conditions in
respect of the logistics service.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall be responsible for treatment and other medical decision of the patients and
independently take all responsibility relating to medical treatment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B promises that during the period in which Party A is entrusted to provide the
management service, no excuse can be used for exemption or reduction in the treatment fee for
any patient who uses the equipment. During such period, if a patient pays the relevant fees
at a rate which is lower than the approved charging</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>rate, the differential shall be paid by Party B (except in the case of unanimous consent by
both Parties).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B promises that during the period in which Party A is entrusted to provide the
management service, Party B may not, through any third party, introduce into the Centre any
medical equipment which has similar function as the equipment managed by Party A. Otherwise,
Party A shall have the right to manage the operation for such equipment and shall collect all
the revenue generated from such equipment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B promises that during the period in which Party A is entrusted to provide the
management service, Party B may not dispose of the equipment. In the event that the equipment
is to be disposed of because of national or local policy or regulation, such disposal shall be
implemented pursuant to the relevant provisions of Article&nbsp;8.4 hereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B promises that during the period in which Party A is entrusted to provide the
management service, Party B may not terminate this Agreement early or amend this Agreement
with the excuse that the principle of the Lessor has been recovered, or the benefits from the
Leased Assets are continually growing, or any leader of the Hospital has been changed. Party
B shall not infringe Party A&#146;s legal rights and interests under any early termination due to
any reason other than in accordance with the legal requirements.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;6 Equipment Service and Operation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For purposes of ensuring the normal operation of the equipment and the maximum effectiveness and
benefits, both Parties have reached an agreement in respect of the following items.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>An Equipment (or the &#147;Centre&#148;) Service Committee will be established and be referred to as
the &#147;Service Committee&#148; (which will not be qualified as a legal person). The Service
Committee shall consist of &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; members and during the period of service, Party B shall
appoint &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; members while Party A shall appoint &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; members. The Service
Committee shall have one Director as nominated by Party B and shall have one Deputy Director
as nominated by Party</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A. Each Party shall have the right to replace any of the members nominated by such party
at its discretion.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The term of office of the members of the Service Committee shall be three years and may be
renewed upon expiry.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Service Committee is the decision-making organization for work and has the following
duties:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to convene the meetings of the Service Committee;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to determine the operating plan of the equipment;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to approve the annual financial cost and budget proposal of the equipment;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to approve basic rules and systems of service related to the operating service of the
equipment.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The following items may become effective only after having been confirmed by both Party A and
Party B in writing and stamped with the corporate seal:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to prepare and establish any and all articles of association, service system, human resource
and compensation system and financial system related to the operation of the equipment;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to approve the appointment and dismissal and remuneration of the Director and Deputy
Director and to establish any service organization;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>annual financial budget and final accounts;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to handle any material medical disputes and medical incidents related to the equipment.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Service Committee shall convene the meeting at least once every year and the meeting
shall be convened and chaired by the Director of the Service Committee. All of the members
shall be notified in writing 10&nbsp;days prior to the convening of the meeting (except for under
special circumstances). The members of the Service Committee shall prepare minutes for the
meetings. The members who participated in the meetings shall sign on the minutes. All meeting
minutes shall be filed and kept in records.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Centre&#146;s Director shall take responsibility for management under the leadership of the
Service Committee. The Center will have one Director, nominated by Party B and one Deputy
Director, nominated by Party A. Both the</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Director and the Deputy Director shall report to the Service Committee and shall perform
the following duties:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to manage all daily work and to organize the implementation of all resolutions of the
Service Committee;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to organize for implementation the annual operating plan;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to prepare the proposals for establishing internal service organizations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.6.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to establish specific rules and systems for handling medical disputes and incidents;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.6.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>to propose the appointment or dismissal of other personnel;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">6.6.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other duties as assigned by the Service Committee.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>None of the Director or member of the Service Committee, or the Director or Deputy Director
of the Center may deposit any revenue of the Center into any account opened in the name of
such individuals or any other person. None of the Director or member of the Service
Committee, or the Director or Deputy Director of the Center may set mortgage upon the Center&#146;s
equipment for providing guaranty for the liability of any person.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that when performing duties, the Director or member of the Service Committee, or
the Director or Deputy Director of the Center violates relevant laws, regulations or administrative
rules and caused any damages, he/she shall be responsible for any legal consequences and
compensation liability. And the Service Committee shall have the right to dismiss him/her.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The total number of employees shall be proposed by the Director of the Center and submitted
to the Service Committee for approval. Except as otherwise expressly provided by the Service
Committee, under the same conditions, the Center shall give priority to employing the staff of
the hospital and, as necessary, may publicly recruit employees through the hospital from
outside. Party B shall be responsible for processing all relevant procedures. In the event
that it is necessary to increase the total number of employees to meet the needs of the
business, the Director of the Center shall submit a written proposal to the Service Committee
and such increase shall be implemented after both the Director and Deputy Director of the
Service Committee sign and agree with the proposal.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;7 Third Party Liability for Damages and Injury</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the period of the management service, should any third person (patient)&nbsp;suffer from
any injury or damage due to the quality issue of the equipment, Party B shall be responsible
pursuing the matter with the manufacturer or the operator. Before the successful resolution
of the matter, all fees shall be borne by Party A.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the period of the management service, should any third person (patient)&nbsp;suffer from
any injury or damage due to improper use of the equipment by Party B, Party B shall be
responsible for compensation.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;8 Breach of Contract</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that Party B is late in making any payment of the service fee, it shall pay
Party A a daily default penalty equal to 0.05% of the overdue amount.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case of any of the actions below on the part of Party B, Party A shall have the right to
terminate this Agreement. In addition to the default penalty, Party B shall immediately pay
Party A with all of the outstanding service fees whether or not such fees have become due for
payment. The monthly service fees not yet due for payment shall be calculated as &#091; &#093; % of
the average amount of the monthly revenue of the Centre&#146;s equipment in the three months prior
to Party B&#146;s breach of contract:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">8.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if Party B delays in paying any monthly service fee owed to Party A for more than two
months;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">8.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if Party B maliciously prevents Party A&#146;s service relating to the equipment or Party A&#146;s
supervision and examination of Party B&#146;s finance status;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">8.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if Party B maliciously provides Party A with false and untrue data of the costs of or the
revenue generated from the use of the equipment so that the service fee that Party A collected
becomes less than such amount that to which Party A is entitled;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">8.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if due to the malicious reason of Party B, the equipment stops providing normal medical
service to patients for more than 10&nbsp;days;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">8.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if without the consent of Party A, Party B unilaterally terminates this Agreement early;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">8.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if without the consent of Party A, Party B unilaterally disposes of the equipment.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case of any of the actions below on the part of Party A, Party B shall have the right to
terminate this Agreement and Party A should compensate Party B for the loss of Party B wherein
the amount of compensation shall be equal to the amount of the service fees charged and
collected by Party A in the six months prior to such contractual breach;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">8.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if Party A unilaterally terminates this Agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">8.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>if when the equipment fails to function, Party A fails to contact for repair or replacement
of the parts and components as agreed herein such that the equipment cannot be operated.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case that due to the national or local government&#146;s or the military&#146;s policy or regulation.
the Agreement needs to be terminated early, Party B shall make a lump-sum payment for all the
service fees not yet due for payment to Party A. The monthly service fee not yet due for payment
shall be calculated as &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; % of the average amount of the monthly revenue of the Centre&#146;s
equipment in the three months prior to Party B&#146;s contractual breach.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;9 Signing, Effectiveness and Supplement of the Agreement</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall become effective upon being signed and stamped by both Party A and Party
B.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall be executed in two parts with each of Party A and Party B hold one copy.
Both copies of this Agreement shall have equal legal validity.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any relevant supplemental agreement regarding the performance , liabilities for breach of
contract as well as termination of this Agreement that both Parties may have shall be subject
a Supplemental Agreement signed and executed by the Parties to this Agreement. Upon being
executed by the respective authorized</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>persons of both Parties, the Supplemental Agreement shall become an integrated part hereof
and shall have the equal legal validity as that of the main text hereof.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;10 Dispute Settlement and Applicable Laws</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any and all disputes related to this Agreement shall be resolved through friendly
consultation first by both Party A and Party B. Should no settlement be reached, any lawsuit
should be brought to the People&#146;s Court of the jurisdiction where Party A is located. All
expenses and costs incurred from the lawsuit (including the costs of the court, the legal
counsel fee and other relevant costs) shall be borne by the losing party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the course of the legal proceedings, other parts of this Agreement shall continue to
be performed except for such part under dispute and the legal proceedings.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall be governed by the Law of the People&#146;s Republic of China.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;11 Miscellaneous</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Within the scope of the government&#146;s policy, the performance of this Agreement shall not be
affected by any change of the personnel of Party B or Party B&#146;s competent supervising
departments, nor be affected by any other man-made factors.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that the government&#146;s policy restricts the performance of this Agreement, in
compliance with the laws and regulations and without prejudice to the vested benefits of both
Parties, Party A shall have the right to seek a new channel for cooperation and Party B
expresses its approval and will actively cooperate with Party A, except as provided in Article
8.4 hereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that any terms hereof are deemed to be void and invalid, or illegal or cannot be
enforceable, the effectiveness, legitimacy and enforceability of the remaining terms of this
Agreement shall not be affected.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Both Party A and Party B promise that they shall treat as confidential the relevant
commercial content involved herein (including the content of the Agreement, etc.)</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>and guarantee that they shall not disclose the relevant content in any form (essay,
speeches, reports or any other channels).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The rights of both Parties as stipulated herein may be waived or changed only by written
express representation.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Both Party A and Party B have authorized their respective representatives to sign and execute
this Agreement. No amendment hereto can be made unless both Party A and Party B have
authorized their respective representatives to sign and execute a written form of documents,
except otherwise agreed herein.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Both Party A and Party B have fully understood and confirmed all of the content and terms
hereof. This Agreement is the true meaning and representation of both Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">11.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement is signed and executed on &#091;day&#093; &#091;month&#093;, &#091;200&#95;&#95;&#95;&#093;.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">(No main context follows.)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Party A:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Legal Representative (or Authorized Representative):
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Party B:</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Legal Representative (or Authorized Representative):
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>23
<FILENAME>h03611exv10w5.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.5</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Form of Service-only<BR>
Management Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Date of Execution: &#091;day&#093; &#091; month&#093; &#091;year&#093;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Place of Execution: &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Party A:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Hospital</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Postal Code:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Telephone:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Facsimile:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Party B:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Postal Code:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Telephone:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Facsimile:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Whereas:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A intends to develop the &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; Center (hereinafter referred to as the
&#147;Center&#148;) in its hospital into a top-tier treatment and research center which can create good
economic and social benefits;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B, as a professional management company, has advantages in respect of clinical medical
treatment, publicity in the medical market, technical promotion, cooperation for R&#038;D, as well
as operation and management;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on the principle of equality and mutual benefits and upon friendly consultation, with
respect to the entrustment to Party B by Party A of the management of the operation of the
&#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; Center in Party A&#146;s hospital, both Party A and Party B have reached the
following agreement:</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Article&nbsp;1</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Term of Entrusted Management</B></TD>
</TR>
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Both Party A and Party B agree that the term of the entrusted management of the Center
shall be &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; years. After the installment and adjustment of the equipment is
completed, there will be a three-month trial operation period prior to the commence of the
formal operation period. The profit generated during the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">trial operation period shall be managed by Party B and will be used to cover the costs and
expenses of the opening ceremony of the Center. Upon the expiry of this Agreement, both
Parties may renew this Service-only Management Agreement upon mutual agreement reached
after negotiation.
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Article&nbsp;2</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Revenue and Operating Costs of the Center</B></TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Revenue of the Center: refers to the revenue generated by using the Center&#146;s &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;
and its auxiliary equipment for diagnosis, treatment and the relevant services as well as the
revenue generated by using other relevant equipment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Operating Costs of the Center: refers to the direct costs and the relevant expenses arising
from using the Center&#146;s &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; and its auxiliary equipment for diagnosis, treatment
and the relevant services, including the following items:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">2.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>wages and bonuses of the medical personnel of the Center (calculated and reserved at the
amount equal to &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; % of the Revenue of the Center);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">2.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>costs and expenses for marketing and publicity (calculated and reserved at the amount equal
to &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; % of the Revenue of the Center);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">2.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Equipment maintenance costs (calculated and reserved at the amount equal to &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; % of the
Revenue of the Center);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">2.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Center&#146;s daily office expenses and the funds reserved for the Management Committee
(calculated and reserved at the amount equal to &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; % of the Revenue of the Center).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In total, all the foregoing items will be calculated and reserved at the amount
equal to &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; % of the Revenue of the Center.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Article&nbsp;3</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Management Fee and Payment</B></TD>
</TR>
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Both Parties agree that the Management Fee shall consist of two parts, namely, the
Management Costs and Share from Net Revenue.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Management Costs</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Such part of the Management Fee shall be equal to &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;% of the
Revenue of the Center.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Both Parties agree that Party B shall receive &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;% of the Revenue
of the Center on a monthly basis as Management Fee, which will be used
to pay part of the Operating Costs of the Center, such as wages and
bonuses of the medical personnel, costs for marketing and publicity,
equipment maintenance costs, the Center&#146;s office expenses and the
funds reserved for the Management Committee.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Share from Net Revenue</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Such part of the Management Fee shall be equal to &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;% of the Net
Revenue of the Center.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Net Revenue of the Center = Revenue of the Center &#150; Operating Costs
of the Center &#150; Floor Revenue Submission to the Hospital</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">3.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Floor Revenue Submission to the Hospital shall be equal to Renminbi &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; per
month. In the event that due to equipment maintenance and other reasons, the Center fails to
operate in normal fashion for more than &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; days, the Floor Revenue Submission to the
Hospital for the current month shall be reduced or exempted depending on the actual
conditions.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">3.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the difference between the Operating Costs of the Center and the Revenue of the Center
for the current month is insufficient to pay for the Floor Revenue Submission to the Hospital,
the deficient portion shall be supplemented by Party B.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">3.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Center shall be subject to an annual audit at the end of each year. If the annual
revenue obtained by the Hospital from the Center for the current year is less than Renminbi &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093;
(i.e., the sum of &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; % of the Net Revenue of the Center plus the Floor
Revenue Submission for the whole year is less than Renminbi &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; ), the amount of
difference shall be paid by Party B.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">3.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The settlement of the Management Fee shall be as follows: the Management Fee shall be
settled monthly. Party A shall complete the settlement of the Management Fee for the previous
month prior to the 10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP></TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>day of each month and transfer the payment to the account
designated by Party B within 5&nbsp;days upon completion of such
settlement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The account designated by Party B shall be as follows:</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Name of the account:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Bank name:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Account number:

</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Article&nbsp;4</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Management Committee</B></TD>
</TR>
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">For the purpose of managing the Center in a better manner, both Parties will jointly
establish a Management Committee for the Center (hereinafter referred to as the &#147;Management
Committee&#148;), which will be responsible for determining the daily management matters related
to the Center&#146;s operation. Any matters involving modification to the this Agreement
between both Parties shall be submitted to the leadership of Party A and of Party B for
confirmation.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Management Committee shall consist of &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; members, selected by both Parties.
&#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; members will be selected from Party A of which one member will be appointed as
the Deputy Director of the Management Committee; &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; members will be selected from
Party B of which one member will be appointed as the Director of the Management Committee.
Either Party shall have the right to replace its respective selected members on the Management
Committee. All daily operational matters of the Center shall be approved by more than 50% of
the total members of the Management Committee.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that the Director of the Management Committee fails to perform his/her duties
for any reason, the Deputy Director of the Management Committee shall perform the Director&#146;s
duties on his behalf. Should the Deputy Director of the Management Committee also fail to
perform his/her duties for any reason, another member of the Management Committee authorized
by the Director or the Deputy Director of the Management Committee shall perform the duties
accordingly.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Management Committee shall convene meetings once or twice every year. The meeting shall
be convened and chaired by the Director of the Management Committee. Under special
circumstances, the Director of the Management Committee may convene and chair a provisional
meeting. The minutes for the meetings of the Management Committee shall be filed and kept in
records.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Center&#146;s Directors shall take responsibility for management under the leadership of the
Management Committee. The Center will establish an Office of Directors, taking charge of
daily management of the Center. The Office of Directors will have an Administrative Director,
who shall be nominated by Party B, and a Medical Director, who shall be nominated by Party A.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Administrative Director shall be responsible for implementing the resolutions of the
meetings of the Management Committee, organizing and guiding the Center&#146;s daily management
matters. The Medical Director shall be responsible for the medical and technical related
matters and assisting the Administrative Director in daily management work.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Administrative Director must report to the Management Committee regarding the daily
operation of the Center on a quarterly basis and shall prepare and submit a financial
settlement report to the Management Committee every half year.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The employment of other personnel of the Center shall be planned by the Center&#146;s
Administrative Director. Upon approved by the Management Committee, the Center will be
responsible for recruitment and employment. Party A shall be responsible for examining and
reviewing the qualifications of the employees and shall assist in processing the procedures of
employment. All personnel employed must meet the requirements of employment as provided in the
management rules of Party A.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All personnel employed by the Center shall be subject to a system of the labor contracts.
Party A shall enter into labor contracts with each of its employees.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Article&nbsp;5</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Rights and Obligations of Each Party</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>5.1</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Party A&#146;s rights and obligations</B></TD>
</TR>
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To make timely payment of the Management Fee payable to Party B.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be responsible for processing and completing all procedures with the competent
supervising departments and the relevant authorities with relation to approval of the project,
procurement permits, environmental impact evaluation and assessment, approval of charges and
prices,and qualification for coverage by medical insurance, as well as all routine procedures
as required to be processed on a yearly basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To provide all equipment, machine room and auxiliary rooms for the Center; to add necessary
auxiliary facilities, etc.; to provide the professional personnel, including doctors, nurses
and technicians; and to provide convenient conditions for the logistics service.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be responsible for coordinating the relationship between the Center and each and all of
Party A&#146;s departments and to provide support for sourcing of the patients for the Center.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be responsible for the treatment and other medical decisions of the patients and to
handle the medical disputes arising from the Center in a timely manner.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be responsible for cooperating with Party B for Party B&#146;s financing audit and to provide
financial information of the Center upon the request by Party B.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.1.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be responsible for providing Party B with the letter of confirmation regarding the
revenue and the management fee on a monthly basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.1.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Except for the Center, Party A promises that it would not separately operate any project
that would compete against the Center either by itself or by cooperating with any third party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.1.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To support Party B to develop the marketing and publicity activities related to the
operation and management of the radiotherapy treatment center of Party A. Subject to the
condition that Party B is in compliance with the relevant provisions of the government, Party
A should actively cooperate. The costs for academic promotion and the marketing and</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>publicity activities shall be accounted for as the Operating Costs of the Center.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>5.2</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Party B&#146;s rights and obligations</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To assign professional management personnel to manage the operation of the Center.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be responsible for the Center&#146;s academic promotion, planning, organization and operation.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be responsible for the construction and upgrading of the digital medical network and
system, realizing the sharing of sources, and interactive and remote diagnosis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be responsible for the publicity of the Center.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To assist Party A in selection of the equipment model, procurement and bidding process for
the equipment. To protect the mutual interests and benefits of both Party A and Party B. To
be responsible for contacting the supplier for replacement parts and components, maintenance
and repair of the equipment of the Center.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be responsible for cooperating with Party A in handling medical disputes.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">5.2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To properly complete the payment of the Floor Revenue Submission to the Hospital. Party A
shall deduct the Floor Revenue Submission of the previous month from the Center prior to the
10<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of each month. In case of any insufficiency, Party B shall timely make up
the deficient portion.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Article&nbsp;6</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Finance and Tax</B></TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Center shall formulate its financial system according to the government&#146;s laws and
regulations and the relevant rules. The Center shall make profit distribution on a monthly
basis and shall have an annual settlement to be made at the end of the year.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All taxes levied on the revenue of each party under this Agreement shall be borne
respectively by each party on its own.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Article&nbsp;7</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Liabilities for Breach of Contract</B></TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that Party A delays in making any payment of the Management Fee to Party B
without due reason, Party A shall pay to Party B a daily default penalty equal to &#091; &#093; % of
the overdue amount.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case of any of the following events, Party B shall have the right to unilaterally
terminate this Agreement. In addition, Party A shall waive Party B&#146;s obligations of making the
monthly Floor Revenue Submissions to the Hospital and guaranteeing the annual Floor Revenue
Submission as set forth in Article&nbsp;3 hereof. Furthermore, Party A shall make compensation to
Party B at the amount calculated according to the following formula:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Compensation amount = Average amount of the Management Fee in the three months prior to
termination of this Agreement
<FONT style="font-family: symbol">&#180;</FONT>  12&nbsp;months</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">7.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If Party A delays in making any payment of the Management Fee to Party B for a period of
over 60&nbsp;days, in addition to paying to Party B all overdue Management Fee and default penalty
in a lump-sum payment, Party A shall make compensation to Party B pursuant to the foregoing
provision;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">7.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If Party A separately operates any project competing against the Center, either by itself or
by cooperating with any third party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" nowrap align="left">7.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If any external factor affects the operation of the Center, causing the Center to suffer
losses for two consecutive years and, as a result, the revenues of Party A and Party B are
affected.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall properly store and manage the equipment provided by Party A. In case that
Party A&#146;s equipment is damaged due to the fault of Party B, Party B shall make compensation
for any loss.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall strictly comply with the provisions related to the medical and health industry
under the State&#146;s laws and regulations and shall scientifically manage and operate the project
entrusted by Party A in good manner. In the event that</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B violates the foregoing provisions and Party A suffers from economic loss under such
entrusted management, subject to the specific situation, Party A has the right to early
termination of this Agreement and may request Party B to compensate its relevant economic
loss according to the following manner. The compensation amount shall be equivalent to
Section&nbsp;7.2 of this Article&nbsp;7 &#147;Liabilities for Breach of Contract&#148;.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case that during the term of cooperation between Party A and Party B, the foregoing
agreement is not able to be performed in a normal manner due to any factors relating to
government policies, upon friendly consultation by and between both Parties, this Agreement
may be subject to early termination.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Article&nbsp;8</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Dispute Settlement</B></TD>
</TR>
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Any and all disputes arising from or related to this Agreement or the Appendix hereof shall
be adjudicated by the People&#146;s Court as designated by the party initiating the lawsuit for
judgment.
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Article&nbsp;9</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Effectiveness and Termination of the Agreement</B></TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall be executed in two copies while each of Party A and Party B shall hold
one copy. This Agreement shall become effective upon being signed and sealed by the
respective legal representatives or authorized representatives of each of Party A and Party B.
Should there be any matters not covered herein, both Parties may separately consult with each
other and further enter into a Supplemental Contract. The Supplemental Contact and this
Agreement shall have equal and same legal validity.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon reaching a unanimous consensus by both Parties hereto, this Agreement may be terminated.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">(No contractual text follows.)
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">SIGNATURE PAGE WITHOUT CONTRACTUAL TEXT.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Party A:</B><BR>
(Corporate Seal)

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Legal Representative:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;(signature)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Party B:</B><BR>
(Corporate Seal)

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Legal Representative:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;(signature)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Date of Execution: &#091;Day&#093;&#091;Month&#093; of 2009
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>24
<FILENAME>h03611exv10w6.htm
<DESCRIPTION>EX-10.6
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.6</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Summary of the Oral Agreements between China Medstar Pte. Ltd.<BR>
and Beijing Medstar Hi-Tech Investment Co., Ltd.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On May&nbsp;30, 2005 and December&nbsp;31, 2006, Beijing Medstar Hi-Tech Investment Co., Ltd. agreed to
provide to China Medstar Limited, the predecessor entity of China Medstar Pte. Ltd., loans in the
aggregate amount of 38,634 Singapore Dollars. The loans were agreed to be used by China Medstar
Limited for the payment of professional services fees incurred for a private placement transaction.
The loans were unsecured, interest free and repayable on demand.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>25
<FILENAME>h03611exv10w7.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.7</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Summary of the Oral Agreements between<BR>
China Medstar Pte. Ltd. and Dr.&nbsp;Zheng Cheng</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">From December&nbsp;31, 2004 to December&nbsp;31, 2007, Dr.&nbsp;Zheng Cheng agreed to provide to China Medstar
Limited, the predecessor entity of China Medstar Pte. Ltd., loans in the aggregate amount of
264,094.6 Singapore Dollars. The loans were agreed to be used for the payment of certain fees
incurred in relation to the initial public offering of China Medstar Limited on the Alternative
Investment Market of the London Stock Exchange. The loans were unsecured, interest free and
repayable on demand.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>26
<FILENAME>h03611exv10w8.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.8</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Summary of the Oral Agreements between<BR>
China Medstar Pte. Ltd. and Mr.&nbsp;Yaw Kong Yap</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">From November&nbsp;30, 2006 to September&nbsp;30, 2009, Yaw Kong Yap agreed to provide to China Medstar
Limited, the predecessor entity of China Medstar Pte. Ltd., loans in the aggregate amount of
30,255.3 Singapore Dollars. The loans were agreed to be used by China Medstar Limited to pay for
certain of its administrative expenses. The loans were unsecured, interest-free and repayable on
demand.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>27
<FILENAME>h03611exv10w9.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.9</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>REDACTED Version of Exhibit&nbsp;10.9<BR>
Translation</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>CERTAIN INFORMATION (INDICATED BY ASTERISKS) IN THIS EXHIBIT<BR>
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES<BR>
AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN<BR>
REQUESTED WITH RESPECT TO THE OMITTED PORTION.</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Medical Equipment Lease Agreement</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Parties:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lessee: Chang&#146;an Hospital Company Limited&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(&#147;Party A&#148;)<BR>
Legal Representative: Cai Shijie

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt">Address: No.17, Wenjing Road, Xi&#146;an</Div>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Lessor: Medstar (Shanghai) Leasing Co., Ltd.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(&#147;Party B&#148;)<BR>
Legal Representative: Cheng Zheng

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt">Address: Suite&nbsp;803, 620 Zhangyang Road, Pudong New District, Shanghai

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Whereas:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For purposes of maintaining its leading position in medical technology and academic
development, the Lessee plans to expand the cancer diagnostic and treatment center (the
&#147;Centre&#148;) and wishes to install certain medical equipment;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Lessor is a professional company which is engaged in the lease of large medical equipment
as well as provision of relevant services;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Lessor intends to purchase from Xi&#146;an Century Friendship Medical Technology Co., Ltd.
such medical equipment as set out in Appendix&nbsp;1 hereto and lease the same to the Lessee for
use by Chang&#146;an Hospital and the Lessee accepts the manufacturer, specifications, model,
equipping, etc. of such equipment;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>NOW, THEREFORE, upon friendly consultations and based on the principle of equality and
mutual benefit, Party A and Party B hereby agree as follows with respect to the leasing by
Party B to Party A of the medical equipment set out in Appendix&nbsp;1 hereto (the &#147;Leased
Assets&#148;):</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;1 Leased Assets</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B agrees to lease to Party A the Leased Assets listed in Appendix&nbsp;1 hereto, the price
of which is RMB*** million.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In order for the lease project to be carried out smoothly, Party A shall be responsible for
procuring all necessary procurement licenses, environmental evaluation and assessment, charges
and prices approval filing, and such other matters as required for the operation of the Leased
Assets. Party A shall also process and complete all procedures required for the use and
installation of the Leased Assets and shall construct and furnish the machine room, etc.
required for the Leased Assets pursuant to the regulations and rules of the state and relevant
authorities.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;2 Use of the Leased Assets</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Leased Assets shall be used at Party A&#146;s premises for the purpose of carrying out cancer
diagnostic and treatment work.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Leased Assets must be installed and placed at the location agreed by the Parties within
the premises of Party A. Without the written consent of Party B, Party A shall not change the
location and operation environment of the Leased Assets.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;3 Ownership of the Leased Assets</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease Term, the ownership of the Leased Assets as listed in the Appendix to this
Agreement, including any parts and components, replacement</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>parts, attached parts and auxiliary parts of (or to be attached to) the Leased Assets,
shall always belong to Party B. During the Lease Term, Party A shall only enjoy the right
to use the Leased Assets. Party A may not sell, transfer, sub-lease, mortgage, or make
investment by means of, the Leased Assets, or otherwise conduct any other action that may
infringe Party B&#146;s rights and benefits. Otherwise, Party A shall assume corresponding
breach of contract liabilities.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Where Party A is shut down, suspended, merged or acquired, or modifies the type of its
ownership or enters into bankruptcy, Party A shall have no right to dispose of the Leased
Assets. Party B&#146;s ownership of the Leased Assets shall not be affected by any agreement
entered into by Party A with any third party or any change to Party A&#146;s status as a legal
person.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the performance of the Agreement, Party B shall have the right to inspect the use and
conditions of the Leased Assets and as long as such inspection would not affect the use of the
equipment, Party A shall facilitate the carrying-out of such inspection. Without Party B&#146;s
written consent, Party A may not add or remove any parts and components of the Leased Assets
nor shall it change the premises of use of the Leased Assets. Party B shall have the right to
affix marks of ownership onto the Leased Assets. Party B (or its entrusted agent) shall have
the right to inspect, on a regular basis or at any time, the use and conditions of the Leased
Assets and Party A shall exert every effort to facilitate the same.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall have the right to mortgage the Leased Assets or transfer its beneficial
interests to a third party, provided that the implementation of this Agreement and the normal
use by Party A shall not be affected thereby.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;4 Lease Term</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Lease Term shall be *** years, commencing from September&nbsp;1, 2009 and expiring on ***. If
the Parties fail to formally commence the lease as of September&nbsp;1, 2009, the Lease Term will
be extended accordingly and will be re-agreed by the Parties by a supplementary instrument.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Lease Term shall be fixed. During the Lease Term, Party A may not unilaterally suspend
or terminate the lease hereunder nor shall it request any change to the provisions hereof on
any ground.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon expiration of the Lease Term, the Parties may renew this Agreement after Party B shall
have conducted relevant maintenance, upgrading and renovation work in respect of the Leased
Assets based on the then actual conditions of the Leased Assets, provided that Party B shall
guarantee the normal operation of the Leased Assets during the term of the renewed agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;5 Rental Fee and Payment</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Rental fee calculation method:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>From ***, the rental fee = ***;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>From ***, the rental fee = ***;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(1)&nbsp;Revenue of Leased Assets: Total fee amounts received from the use of the Leased Assets
for diagnosis (or treatment)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(2)&nbsp;Hospital-Paid Costs and Expenses: Various costs and expenses incurred during the
course of diagnostic or treatment, including: the wages, bonus, welfare benefits, overtime
charges and travel and accommodation expenses of the personnel of the Centre (exclusive of
personnel dispatched by both Parties); water and power utility charges; costs of
consumables; document printing costs; hospitality expenses; academic exchange expenses; R&#038;D
assistance costs; the repair and maintenance costs of the Leased Assets; costs of office
supplies; telephone charges; medical dispute settlement expenses, etc.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The rental fee shall be paid on a monthly basis. Party A shall transfer the rental fee of
the previous month to the designated account of Party B by the 15<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of each
month. The information of the account for the receipt of rental fee payments is as follows:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Account Name: Medstar (Shanghai) Leasing Co., Ltd.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Bank name: Shanghai Waigaoqiao Gaoqiao Branch, Agricultural Bank of China</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Account number: ***</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Simultaneously, Party B shall issue an official tax invoice to Party A.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the term of this Agreement, the making of payment by Party A to the designated bank
account set forth above shall be deemed performance of its payment obligation hereunder and
the making of payment by Party A to any other account or in any other manner without the
consent of Party B shall not be deemed performance of its obligation hereunder. Where
Party B needs to change its account for the rental fee payment, Party B shall give prior
written notice to Party A and Party A&#146;s finance department.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;6 Rights and Obligations of the Parties</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>6.1</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Party A&#146;s rights and obligations</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall issue on a monthly basis a rental fee confirmation letter to Party B, setting
out the fee amounts of the Leased Assets, the Hospital-Paid Costs and expenses, etc. Party A
shall warrant the truthfulness of the data provided in such letter.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall provide the machine room and auxiliary rooms for the Leased Assets and add
necessary auxiliary facilities, etc.; shall provide professional personnel including experts,
doctors, nurses and technicians and shall provide convenience in respect of logistics
services.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall assist the supplier in handling domestic transportation, installation,
commissioning, etc. of the equipment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall be responsible for the treatment and other medical decisions of the patients
as well as for the timely handling of medical disputes arising from the Centre.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall properly manage and safeguard the Leased Assets and shall designate
specially-assigned staff to take charge of the daily work in connection with the operation of
the Leased Assets.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall be responsible for processing and completing all procedures with the competent
supervising departments and relevant authorities in relation to the approval of the project,
procurement permits, environmental evaluation and assessment, approval of charges and prices
and qualification for medical insurance coverage, as well as all relevant routine procedures
as required to be processed on a yearly basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A may not use the Leased Assets for diagnosis and treatment free of charge. If any
fee exemption or reduction is required by any extraordinary circumstance, such exemption or
reduction shall be approved and signed by both Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A may not terminate earlier or modify this Agreement on the ground that Party B has
recovered its costs, or that the revenue from the Leased Assets is continually growing, or
that any leader of the Hospital has been changed.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.1.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease Term, Party A may not separately operate any other project competing with
the Center either by itself or in cooperation with any third party.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>6.2</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Party B&#146;s rights and obligations</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall, in cooperation with the supplier, timely deliver to Party A the Leased Assets
designated by Party A and shall assist the supplier in installing and commissioning the Leased
Assets.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall inform itself of the operation status of the Leased Assets at all times based
on the income and expenses information related to the operation of the Leased Assets as
provided by Party A.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall have the right to dispatch Leased Assets administration personnel to manager
the Leased Assets and shall have the right to keep a book recording the number of patients
diagnosed or treated with the</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Leased Assets, the purchase and use of consumables and other costs related to the
use of the Leased Assets and Party A shall cooperate with the same.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Without written authorization of Party B, the administration personnel dispatched by Party B
shall have no authority to amend or supplement any matters agreed hereunder on behalf of Party
B.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B or Party B&#146;s entrusted agent (including asset appraisers, accountants, etc) shall
have the right to examine the use and the condition of the Leased Assets and Party A shall
exert every effort to facilitate the same.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall assist the supplier in providing such technical documentation as required for
the use of the Leased Assets.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall assist the supplier in conducting daily repair and maintenance work in respect
of the Leased Assets.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall cooperate with the professional management company in relation to the planning
and organization of the Centre&#146;s academic promotion and guidance on its operation and
management.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.2.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon expiry of the Lease Term, where terms and conditions are equal, Party B shall have the
preemptive right to provide leasing with respect to any similar project in the future.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;7 Delivery, Examination and Acceptance of the Leased Assets</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Delivery, examination and acceptance: After the Leased Assets are delivered to the premises,
Party A shall examine the Leased Assets for acceptance in accordance with the Appendix hereof.
In the event that the Leased Assets fail to meet the agreed requirements, Party A shall
timely make a note on the delivery receipt and wait for Party B to resolve the same. Party A
shall be responsible for safeguarding the Leased Assets once the Leased Assets arrive at the
location for installation or operation.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Technical examination and acceptance: If, upon installation and commissioning and completion
by Party A of the diagnostic or treatment of the first 30 patients,</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A confirms that the Leased Assets are in consistency with the technical requirements,
Party A shall issue to Party B an acceptance receipt within 5&nbsp;days, whereupon the delivery
of the Leased Assets shall be deemed completed. Where Party A fails to timely issue such
receipt or to raise any written objection, the Leased Assets shall be deemed properly
delivered. Thereupon, the Lease Term shall commence and the charges collected from such 30
patients shall be included as the revenue of the Center.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Where the Leased Assets fail to pass the acceptance examination, the supplier shall be
responsible for addressing the matter.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Considering the Leased Assets hereunder are purchased by
Party B from Xi&#146;an Century
Friendship Medical Technology Co., Ltd., the Parties agree that
Xi&#146;an Century Friendship
Medical Technology Co., Ltd. shall be responsible for delivering the Leased Assets to the site
designated by Party A. The Parties will, in conjunction with Xi&#146;an Century Friendship Medical
Technology Co., Ltd., conduct the acceptance examination. No risk arising out of the delivery
acceptance and the technical acceptance shall be borne by Party B. If the Leased Assets pass
the acceptance examination, Party A shall unconditionally lease the Leased Assets; if the
Leased Assets fail to pass the acceptance examination, Xi&#146;an Century Friendship Medical
Technology Co., Ltd. shall bear relevant liabilities and Party A shall not bring any suit or
claims against Party B in respect of the same.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;8 Liability for Loss and Damage of the Leased Assets and Third Party Injury</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease Term, Party B shall be responsible to maintain for the Leased Assets
insurance with an insurer acceptable to the Parties, and Party B or any third party designated
by Party B shall be named as the beneficiary. The insurance premium shall be included as
Hospital-Paid Costs and Expenses.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease Term, upon occurrence of any insurance-covered incident, Party A shall
actively cooperate with Party B in processing the claim with the relevant insurer.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease Term, if the Leased Assets are lost or damaged due to reasons attributable
to Party A, Party A shall, at its costs and expenses, take one or several of the following
actions as determined by Party B:</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">(i)&nbsp;To restore or repair the Leased Assets to the effect that the Leased Assets
become capable of being used in a completely normal manner;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">(ii)&nbsp;To effect replacement in respect of the Leased Assets with parts, components
or assets of the same model and function as the Leased Assets;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">(iii)&nbsp;In the case of the circumstances (i)&nbsp;and (ii)&nbsp;above, Party A shall continue
to lease the Leased Assets and its obligation to pay the rental fee shall remain
unchanged. During the period where the Leased Assets cannot be operated normally,
Party A shall pay to Party B a monthly rental fee equal to the average rental fee
amount of the three months preceding the loss or damage of the Leased Assets.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">(iv)&nbsp;Insurance proceeds may be used to cover the repair costs of the Leased Assets
and any shortfall amount shall be paid by Party A.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">(v)&nbsp;Where the loss or damage of the Leased Assets is beyond repair, Party A shall
be liable to indemnify Party B against losses pursuant to the breach of contract
provisions hereof.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If any third party (e.g. patients) suffers any injury as a result of reasons attributable to
the Leased Assets themselves (such as technical factors or quality defects, etc.), Party A
shall, in conjunction with Party B, seek recourse against the seller of the Leased Assets.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If any third party (e.g. patients) suffers any injury as a result of Party A&#146;s negligent use
of the Leased Assets, Party A shall be held liable.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If any third party (e.g. patients) suffers any injury as a result of force majeure (other
than as a result of reasons attributable to the Leased Assets themselves or the fault of Party
A), in principle, neither Party A nor Party B shall be liable to</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>indemnify, provided that Party A shall have the duty to take precautions against such kind
of &#147;risks&#148; by taking out third party liability insurance.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;9 Disposal of the Leased Assets Upon Expiry of the Lease Term</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">Upon the expiry of the Lease Term, if the Parties do not renew
the Agreement, the Leased Assets shall be returned to Party B.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;10 Breach of Agreement</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A and Party B shall perform the corresponding responsibilities and obligations in
accordance with the time schedules as provided in this Agreement. In case of any beach of
Agreement, the breaching party shall compensate the other party&#146;s economic loss.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any delay in making rental fee payment by Party A shall not exceed two months. In case of
any such delay, Party A shall pay Party B a daily default penalty equal to 0.05% of the
overdue amount, except where such delay is caused by the force majeure.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any breach by Party A set forth below shall be deemed a material breach by Party A:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any failure by Party A to perform the lease obligations upon purchase of the Leased
Assets by Party B from Xi&#146;an Century Friendship Medical Technology Co., Ltd. in
violation of this Agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.3.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any delay by Party A in making any rental fee payment exceeding two months by Party
A;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.3.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any unilateral early termination or modification of this Agreement by Party A in
violation of this Agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.3.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any interference by Party A in Party B&#146;s management or financial supervision of the
Leased Assets;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.3.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any unilateral disposal (including sale, sub-lease, removal or transfer, etc.) by
Party A of the Leased Assets in violation of this Agreement;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.3.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>provision of any false information by Party A regarding the Revenue of the Leased
Assets and so on, such that the rental fee payment collected by Party B is less than
the amount to which Party B is entitled;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.3.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>introduction of any similar medical equipment with similar functions to the Leased
Assets through any third party or cooperation with any third party to develop similar
projects in violation of this Leased Agreement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.3.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any suspension of normal medical services to patients using the Leased Assets for a
period exceeding 30&nbsp;days due to the man-made reasons of Party A; or any severe
destruction or loss of the Leased Assets due to improper use, intentional damage or
careless storage by Party A.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case of any material breach of Agreement by Party A, Party B shall have the right to
terminate this Agreement and take any of the following measures:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>request Party A to immediately make full payment of all undue rental fee, default
penalty and all other amounts payable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Undue Rental Fee = Remaining Lease Term (month) &#215; monthly average rental fee
obtained by Party B in one year prior to the beach of Agreement
If the Lease Term is shorter than one year, the monthly average rental fee obtained
by Party B shall be deemed 3% of the purchase price of the equipment.
Default Penalty = Undue Rental Fee &#215;50%</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>terminate this Agreement, and Party B shall take over the Leased Assets to continue
the operation, and the revenue generated from such operation of the Leased Assets
shall be solely owned by Party B. Party B shall also have the right to request Party A
to pay the default penalty (the calculation method is the same as above) and all other
amounts payable.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case of any of the above mentioned breach or infringement by Party A, Party A shall also
be liable for all costs for lawsuits, legal counsel fee and other expenses arising from Party
B&#146;s realization of its creditor&#146;s rights.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;11 Dispute Resolution</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Any and all disputes related to this Agreement shall be
resolved by Party A and Party B through consultation. In case
that no settlement could be reached through consultation,
either party may bring an action before the People&#146;s Court
designated by Party B.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;12 Appendix</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">The Appendix to this Agreement is an integrated part hereof and
shall have the equal legal validity as that of the main text
hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;13 Effectiveness of the Agreement</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">This Agreement shall become effective upon being signed and
stamped by Party A and Party B.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;14 Termination of the Agreement</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall be automatically terminated upon the expiry of the Lease Term.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All claims and indebtedness arising from the performance of this Agreement by Party A and
Party B shall be terminated upon full repayment of all debts, including all rental fee
payments, default penalties, indemnification, and so on.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case of impossibility of performance of the Agreement or use of the Leased Assets due to
war, natural disaster, force majeure and other factors, this Agreement shall be terminated and
neither party shall be liable to or have any rights against the other party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prior to the commencement of the Lease Term, under the following circumstances, Party B shall
have the right to terminate this Agreement without any liability:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">14.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A fails to obtain the procurement permits for the medical equipment;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">14.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A fails to prepare and provide, on a timely basis, the premises for using the
Leased Assets.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">14.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that the government or the military adjusts its policy and issues any regulation
or document for prohibiting equipment lease within the country or</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>within the military system, resulting in this Agreement not being able to be performed, but
without affecting the use of the Leased Assets, Party A shall be responsible for
coordination and negotiation. During such period of coordination and negotiation, Party A
shall be still subject to the obligation for paying the rental fee on a timely basis. If
no resolution can be reached upon negotiation, this Agreement may be terminated in early
manner, provided, however, that Party A shall make a lump-sum payment for the remaining
rental fee payments to Party B. The remaining rental fee payments shall be equal to ***
minus ***:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Remaining Rental Fee Payments = ***</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;15 Miscellaneous</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">15.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prior to the formal operation of the Leased Assets, the Parties shall enter into certain
supplemental documents, such as the Composition of the Organization and Management Department
of the Leased Assets and Financial Management Process of the Leased Assets, with respect to
the specific matters concerning the management department and financial management process of
the Leased Assets.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">15.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Parties hereto have carefully read through all the terms of this Agreement. Reasonable
manner has been adopted to urge the Parties to pay attention to the terms regarding exemption
or restriction on their responsibilities as provided herein. Per request of the Parties,
explanation has been made in respect of the relevant terms.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">16.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Parties hereto have authorized their respective representatives to sign this Agreement.
All terms of this Agreement are a true expression of the intents of the Parties and shall have
legal binding effect on the Parties.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;16 </B>The original of this Agreement and the Appendix hereto shall be prepared in four copies
of which Party A and Party B shall each hold two copies.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;17 </B>With respect to any matters not covered herein, the Parties may enter into a
supplemental agreement with respect thereto. Any supplemental agreement and this Agreement shall
have equal legal validity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;18 </B>This Agreement is signed and executed on August&nbsp;25, 2009 in Xi&#146;an.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(No operative text below)
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Party A: Chang&#146;an Hospital Company Limited</B><BR>
Legal Representative<BR>
(or Authorized Representative): (Signature and Seal)

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Party B: Medstar (Shanghai) Leasing Co., Ltd.</B><BR>
Legal Representative<BR>
(or Authorized Representative): (Signature and Seal)

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Appendix&nbsp;I:
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>List of Leased Assets</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="24%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="16%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="26%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Item</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Description of Equipment</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Brand</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Manufacturer</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Type</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">1</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">MM50</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">IBA</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">MM50</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">2</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">PET/CT</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">GE</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">GE</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">DisscoveryLs</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">3</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Novalis</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Varian</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Simulator included</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">CT</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SHIMADZU</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">SCT-6800TXL</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">5</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">MRI</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Philips</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Interal.5T</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">6</TD>
    <TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cyclotron</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">1</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">IBA</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">CYCLONE18/9</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>28
<FILENAME>h03611exv10w10.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.10</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>REDACTED Version of Exhibit&nbsp;10.10<BR>
Translation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>CERTAIN INFORMATION (INDICATED BY ASTERISKS) IN THIS EXHIBIT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
WITH RESPECT TO THE OMITTED PORTION.</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Service-Only Management Agreement</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Signed on: August&nbsp;1, 2008

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">Contract No.: CMS2008001

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Entrusting Parties:</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">Xi&#146;an Wanjiechangxin Medical Services Company Limited<br>
Legal Representative: CAI Shijie
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">Chang&#146;an Hospital (i.e., Chang&#146;an Hospital Company Limited)<br>
Legal Representative: CAI Shijie
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Entrusted Party:</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 6%">CMS Hospital Management Co., Ltd.<br>
Legal Representative: YANG Jianyu
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>WHEREAS:</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Entrusted Party has the largest tumor therapy-related medical network in Asia and
expertise in operation and management of medical institutions;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Entrusting Parties aims to develop Chang&#146;an Hospital to be one of top-tiered modernized
hospitals in China with core competitiveness in tumor therapy and deliver attractive economic
return and social benefits;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Board of Directors (please refer to Appendix&nbsp;A) of the Entrusting Parties and the
shareholders&#146; meeting (please refer to Appendix&nbsp;B) have approved the resolutions, pursuant to
which, all existing businesses in Chang&#146;an Hospital will be entrusted to the Entrusted Party
for operation and management;</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NOW, THEREFORE, the Entrusting Parties and the Entrusted Party hereby agree as follows through
friendly consultation in the principle of equality and mutual benefits:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>1.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Definitions and Explanations</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the Contract, the following terms have meanings as below.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Parties&#148;: the Entrusting Parties and the Entrusted Party;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Monthly Gross Revenue&#148;: the gross operational revenue generated by Chang&#146;an Hospital by month
(before deduction of any cost);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Annual Accounting&#148;: the accounting conducted every full year (twelve months) starting from the
date when the Entrusted Party was entrusted for operation and management;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#147;Annual Gross Revenue&#148;: After Annual Accounting, the gross operational revenue generated by
Chang&#146;an Hospital in a continuous operating period for twelve months</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(before deduction of any cost)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>2.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Model of Entrusted Operation and Management</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Entrusted Party shall take over all existing businesses in Chang&#146;an Hospital and
conduct operation and management.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Entrusted Party shall conduct operation and management activities in the name of Chang&#146;an
Hospital.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>3.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Period for Entrusted Operation and Management</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Parties shall unanimously agree that the period for entrusted operation and management
shall be in force since the effective date of this Contract until ***.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Entrustment target: The Entrusted Party undertakes that it shall maintain and increase the
value of the entrusted assets in the entrustment period, enhance Chang&#146;an Hospital&#146;s brand
profile and social awareness, strengthen Chang&#146;an Hospital&#146;s internal management and its team
stability, and deliver a rapid growth in revenue and profit, all of which shall pave the way
for the development of the 2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP> Phase.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>4.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Matters under Entrusted Operation and Management</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Parties shall agree that the following matters be under the Entrusted Party&#146;s operation and
management.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All businesses within Chang&#146;an Hospital&#146;s business scope;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Chang&#146;an Hospital&#146;s internal administrative matters, including but not limited to financials,
human resource, administration, etc.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>5.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Fee and Bonus for Entrusted Operation and Management</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Parties unanimously agree that the management fee for the Entrusted Party shall be
calculated as *** of Chang&#146;an Hospital&#146;s Monthly Gross Revenue and paid to the Entrusted Party
on a monthly basis after monthly accounting.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Chang&#146;an Hospital shall complete the monthly revenue accounting for the last month prior to
the 15<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> of every month and with the recognition and consent from the Entrusted
Party, it shall transfer the management fee to the account specified by the Entrusted Party
within five days.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the period lasts any one full year, Chang&#146;an Hospital shall complete the Annual Accounting
within 15&nbsp;days and with the recognition and consent from the Entrusted Party, it shall provide
the incentives for the Entrusted Party as set forth below.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the growth rate of Chang&#146;an Hospital&#146;s Annual Gross Revenue is less than</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
       <TD colspan="3">***, no bonus shall be provided for the Entrusted Party;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the growth rate of Chang&#146;an Hospital&#146;s Annual Gross Revenue exceeds ***, the bonus
for the Entrusted Party shall be calculated as ***;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The data of annual revenue and its growth rate shall be recognized by the Parties and
be verified by an intermediary recognized by the Parties.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon the recognition of the Annual Accounting by the Parties, Chang&#146;an Hospital shall
transfer the bonus to the account specified by the Entrusted Party within 5&nbsp;days.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the Entrusted Party has any disagreement in the monthly accounting or the Annual
Accounting, Chang&#146;an Hospital shall coordinate with the Entrusted Party to review the
accounting results within three days upon the receipt of the disagreement from the Entrusted
Party. The accounting is subject to the results after review.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(6)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Parties shall unanimously agree that the income related to the tumor business in the
cooperation scope under the Framework Agreement (&#147;Such Income&#148;) shall not be included into the
Monthly Gross Revenue and the Annual Gross Revenue. Therefore, Such Income shall be deducted
from the revenue for last year when calculating the annual growth rate.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>6.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>The Parties&#146; Rights and Obligations</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Chang&#146;an Hospital&#146;s Rights and Obligations</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It has the right to accredit representatives to take in the operational situation
from time to time and the Entrusted Party shall coordinate with all one&#146;s strength;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It has the right to deal with the labor relationships and the service relationships
of Chang&#146;an Hospital&#146;s employees but shall keep the Entrusted Party informed and consult
the Entrusted Party&#146;s opinions or advice;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It has the obligation to handle all necessary approval and filing procedures to
execute and perform the Contract;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It has the obligation to start the handover of all businesses upon the effective date
of this Contract and coordinate the Entrusted Party&#146;s operation and management activities
with all one&#146;s strength;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">e.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It has the obligation to conduct accounting and pay the management fee to the
Entrusted Party pursuant to this Contract;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">f.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case of any change in the business scope or treatment and diagnosis programs in
Chang&#146;an Hospital or any cooperation with any third-party, it shall notify the</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Entrusted Party immediately;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">g.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Without the Entrusted Party&#146;s consent, Chang&#146;an Hospital shall not dispose any asset
or equipment, provide any guarantee externally, entrust operation and management, lease
medical equipment, conduct outbound investment, etc.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Entrusted Party&#146;s Rights and Obligations</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It has the right to carry out the management based on its philosophy and experience,
on the premise of not violating any law, regulation or this Contract;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It has the right to formulate new rules and regulations and has the right to revise,
or suspend during the Contract Period the use of, Chang&#146;an Hospital&#146;s rules and
regulations, provided that it is agreed by the Entrusting Parties;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It has the right to provide opinions or advice regarding the labor relationships and
the service relationships of Chang&#146;an Hospital&#146;s employees and Chang&#146;an Hospital shall
honor the Entrusted Party&#146;s opinions or advice, if possible;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">d.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>It has the obligation to comply with China&#146;s financial regulations and all operating
income shall be placed in the accounts jointly designated by Chang&#146;an Hospital and the
Entrusted Party. It shall not establish any other account;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">e.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Unless there is a written consent from Chang&#146;an Hospital, it shall not dispose any
asset of Chang&#146;an Hospital in any form or purchase or lease any asset in the name of
Chang&#146;an Hospital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">f.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Unless there is a written consent from Chang&#146;an Hospital, it shall not provide any
guarantee in any form in the name of Chang&#146;an Hospital for the Entrusted Party or any
third party.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>7.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>The Parties&#146; Warranties and Undertakings</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Xi&#146;an Wanjiechangxin Medical Services Company Limited&#146;s Warranties and Undertakings</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Xi&#146;an Wanjiechangxin Medical Services Company Limited is duly incorporated and
validly existing under the law and has obtained all necessary internal authorizations
required for signing this Contract;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Xi&#146;an Wanjiechangxin Medical Services Company Limited has waived the right to rescind
this Contract and the right to raise any disagreement with regard to the content, form,
and (all or part of) effectiveness of this Contract.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Chang&#146;an Hospital&#146;s Warranties and Undertakings</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Chang&#146;an Hospital is duly incorporated and validly existing under the law and</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>has obtained all necessary internal authorizations required for signing this Contract;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Chang&#146;an Hospital is able to obtain all necessary approvals, filings and other
procedures to sign and perform this Contract to ensure that the full performance of this
Contract would not be influenced by any incompleteness in procedure;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The operational situation of Chang&#146;an Hospital shall be maintained or improved before
the handover to the Entrusted Party.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Entrusted Party&#146;s Warranties and Undertakings</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Entrusted Party is duly incorporated and validly existing under the law and has
obtained all necessary internal authorizations required for signing this Contract;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Entrusted Party&#146;s operation and management will be legitimate and subject to
Chang&#146;an Hospital&#146;s business scope;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">c.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Entrusted Party shall strictly keep Chang&#146;an Hospital&#146;s business secrets, and
without Chang&#146;an Hospital&#146;s consent, it shall not disclose any of them to any third-party.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>8.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Performance Deposit</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Entrusted Party shall transfer a performance deposit of RMB 15&nbsp;million into the
account held by Xi&#146;an Century Friendship Medical Technology R&#038;D Co., Ltd., an affiliate of
Chang&#146;an Hospital, within 15 working days upon the signing of this Contract.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Unless otherwise agreed by the Parties, Chang&#146;an Hospital shall return the
performance deposit to the Entrusted Party in full amount without interest within 15&nbsp;days
after the cancellation or termination of this Contract.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>9.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Special Provisions</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The 2nd Phase Construction Project of Chang&#146;an Hospital shall be in the Entrusting Parties&#146;s
charge and bear no relationship with the scope of entrusted operation and management as
provided herein. The Entrusting Parties shall ensure that debts or contingent debts related to
the 2nd Phase Construction Project of Chang&#146;an Hospital exert no influence on the Entrusted
Party&#146;s interests.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>10.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Default Liabilities</B></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the Entrusted Party violates China&#146;s financial regulations or establishes an unauthorized
account, it shall be deemed as a fundamental breach by the Entrusted Party;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the Entrusted Party changes Chang&#146;an Hospital&#146;s business scope or treatment or diagnosis
programs without Chang&#146;an Hospital&#146;s consent, it shall be deemed as a fundamental breach by
the Entrusted Party;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the Entrusted Party disposes any asset in Chang&#146;an Hospital or purchases or leases any
asset in the name of Chang&#146;an Hospital without Chang&#146;an Hospital&#146;s written consent, it shall
be deemed as a fundamental breach by the Entrusted Party;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the Entrusted Party provides any guarantee in the name of Chang&#146;an Hospital for the
Entrusted Party or any third party without Chang&#146;an Hospital&#146;s written consent, it shall be
deemed as a fundamental breach by the Entrusted Party;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If Chang&#146;an Hospital is subject to any penalty by relevant authorities caused by the
Entrusted Party&#146;s unlawful act, it shall be deemed as a breach by the Entrusted Party and the
Entrusted Party shall assume corresponding legal liabilities and economic losses;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(6)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the Entrusted Party fails to comply with this Contract on the performance deposit payment,
it shall be deemed as a breach by the Entrusted Party. Any late payment shall be subject to an
overdue penalty payable to Chang&#146;an Hospital, calculated at a rate of 0.03% of the performance
deposit amount for each day of delay;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(7)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If Chang&#146;an Hospital fails to conduct accounting or pay the management fee on a timely basis,
it shall be deemed as a breach by Chang&#146;an Hospital. Any late payment shall be subject to an
overdue penalty payable to the Entrusted Party, calculated at a rate of 0.03% of the
management fee amount payable for each day of delay. Any delay of payment by 30&nbsp;days shall be
deemed as a fundamental breach by Chang&#146;an Hospital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(8)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If Chang&#146;an Hospital refuses to conduct accounting or pay the management fee or bonus, it
shall be deemed as a fundamental breach by Chang&#146;an Hospital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(9)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If the Entrusted Party has any disagreement in the accounting completed by Chang&#146;an Hospital,
and Chang&#146;an Hospital fails to coordinate with the Entrusted Party to review the accounting
results within the period specified herein, any delay of review shall be subject to an overdue
penalty payable to the Entrusted Party, calculated at a rate of 0.03% of the management fee
amount payable for each day of delay. Any delay of review by 30&nbsp;days shall be deemed as a
fundamental breach by Chang&#146;an Hospital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(10)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If Chang&#146;an Hospital changes its business scope or treatment or diagnosis programs or
cooperates with any third party, none of the Entrusting Parties&#146; interests shall be damaged.
The Entrusted Party has the right to request Chang&#146;an Hospital to enter into a supplementary
agreement to this Contract within a specified period. If Chang&#146;an Hospital refuses to
negotiate or fails to enter into any agreement within a reasonable period under the Entrusted
Party&#146;s request, it shall be</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>deemed as a fundamental breach by Chang&#146;an Hospital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(11)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If upon signing this Contract, Chang&#146;an Hospital disposes any asset or equipment, conducts
outbound investment, entrusts operation or management, leases medical equipment, or provides
any guarantee externally without the Entrusted Party&#146;s consent, or the Entrusted Party finds
that Chang&#146;an Hospital has cooperated with any other third party before signing this Contract
and has not disclosed it in full to the Entrusted Party, it shall be deemed as a fundamental
breach by Chang&#146;an Hospital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(12)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If this Contract fails to be fully performed caused by any defect in the Entrusting Parties&#146;
approvals, filings or internal authorization procedures, it shall be deemed as a breach by the
Entrusting Parties, and the Entrusted Party may request the Entrusting Parties to complete all
necessary procedures in a specified period, otherwise, it shall be deemed as a fundamental
breach by the Entrusting Parties;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(13)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If Chang&#146;an Hospital fails to return the performance deposit to the Entrusted Party pursuant
to this Contract in time, any late payment shall be subject to an overdue penalty payable to
the Entrusted Party, calculated at a rate of 0.03% of the performance deposit amount payable
for each day of delay. Any delay of payment by 30&nbsp;days shall be deemed as a fundamental breach
by Chang&#146;an Hospital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(14)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If there is any fundamental breach by a party, the other party has the right to unilaterally
terminate this Contract and claim the penalty from the default party. The amount and payment
of the penalty shall be: if there is a fundamental breach by the Entrusted Party, the
Entrusting Parties shall not be required to return the performance deposit to the Entrusted
Party; if there is a fundamental breach by the Entrusting Parties, the performance guarantee
shall be returned to the Entrusted Party in double;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(15)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If there is any breach by any one party in the Entrusting Parties, the other party in the
Entrusting Parties shall assume the joint and several liabilities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(16)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The payment of the penalty above shall not prejudice any other compensation for loss that the
non-default party may claim against the default party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>11.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Expiration and Termination of Contract</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Contract can be terminated with mutual agreement of the Parties after negotiation;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>If this Contract cannot be performed resulting from any policy change of the relevant
authorities, the Parties shall further negotiate the cooperation model. If no agreement can be
reached, this Contract shall be terminated automatically. The Entrusting Parties shall return
the performance deposit to the Entrusted Party in full amount without interest within 5&nbsp;days
upon the termination of this Contract;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>otherwise, the Entrusting Parties shall assume the default liability pursuant to this Contract.
For the parts already performed in this Contract, the Entrusting Parties shall pay the
management fee and bonus to the Entrusted Party pursuant to this Contract and shall assume the
default liability for any payment delay or rejection pursuant to this Contract.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>12.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Dispute Resolution</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Parties unanimously agree that Xi&#146;an Wanjiechangxin Medical Services Company Limited hereby
waives all litigation rights in connection with this Contract; any dispute arising out of this
Contract or in connection with this Contract shall be settled by negotiation between Chang&#146;an
Hospital and the Entrusted Party. If any dispute cannot be settled by negotiation, it shall be
judged by the court where the project is located.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>13.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Effectiveness of Contract and Miscellaneous</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The date when the following conditions are both satisfied shall be the effective date of this
Contract:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Contract is duly signed by the legal representatives or the authorized
representatives of the Entrusting Parties with official seals and duly signed by the
authorized representative of the Entrusted Party;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Entrusted Party has paid the performance deposit.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Parties agree that the performance deposit under this Contract shall be paid directly to
the account held by Xi&#146;an Century Friendship Medical Technology R&#038;D Co., Ltd. and the
Entrusted Party has the right to take in the situation of the performance deposit from time to
time.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(3)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Parties unanimously agree that the Entrusted Party can assign the liabilities, rights,
and obligations under this Contract to any professional hospital management company affiliated
to it. The Entrusted Party shall notify the Entrusting Parties of such assignment by letter
and it is not required for the Entrusting Parties and the assignee to sign any further
contract.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(4)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Contract shall be delivered in six copies, which shall have equal legal validity, with
two for each party, while the rest shall be used by the Entrusting Parties for filing
procedures.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(5)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Contract was signed on August 1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>, 2008.<BR></TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Xi&#146;an Wanjiechangxin Medical Services Company Limited (Seal)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Legal Representative / Authorized Representative: (Signature by CAI Shijie)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Chang&#146;an Hospital (Chang&#146;an Hospital Company Limited) (Seal)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Legal Representative / Authorized Representative: (Signature by CAI Shijie)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">CMS Hospital Management Co., Ltd. (Seal)
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Authorized Representative: (Signature by Yang Jianyu)
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>29
<FILENAME>h03611exv10w11.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.11</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>REDACTED Version of Exhibit&nbsp;10.11<BR>
Translation</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><B>CERTAIN INFORMATION (INDICATED BY ASTERISKS) IN THIS EXHIBIT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
WITH RESPECT TO THE OMITTED PORTION.</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Agreement Concerning the Establishment<BR>
of the Aohai Radiotherapy Treatment and Diagnosis Research Center</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;I General Provision</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In accordance with applicable PRC laws and regulations, The Chinese People&#146;s Liberation Army Navy
General Hospital and Beijing Our Medical Equipment Development Co., Ltd., based on the principle of
equality and mutual benefit, agree to jointly establish &#147;Aohai Radiotherapy and Diagnosis Research
Center&#148; at the Navy General Hospital in Beijing.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;II Parties of Cooperation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;1 The Parties to this Contract are as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Party A: The Chinese People&#146;s Liberation Army Navy General Hospital, registered in Beijing<BR>
Address: No.&nbsp;6 Fucheng Road, Beijing<br>
Legal Representative: Ye Yang<br>
Title: President
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party B: Beijing Our Medical Equipment Development Co., Ltd., registered in Beijing<BR>
 Address: Room 408, the 4th floor, Capital Hotel, No.&nbsp;3 Qianmen East Avenue, Beijing<BR>
Legal Representative: Jun Song<BR>
Title: General Manager

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;III Joint Establishment of<BR>
Aohai Radiotherapy and Diagnosis Research Center</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;2 Both parties agree to jointly invest in and establish &#147;Aohai Radiotherapy Treatment and
Diagnosis Research Center&#148; (&#147;the Center&#148;) in Beijing in compliance with applicable laws and
regulations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;3 Legal address of the Center: No.&nbsp;6 Fucheng Rd., Beijing
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;4 All activities of the Center shall be in compliance with all applicable laws and
regulations of PRC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;5 The finances of the Center shall be accounted for independently, with independent books
and an independent account. The chief accountant will be designated by Party B while the cashier
will be appointed by Party A.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;6 The Center&#146;s operating costs shall include costs and expenses for repair and maintenance
of the Center (including repair and maintenance of premises and equipment, etc.); staff bonus;
water and power utilities and office expenses; expenses for replacements of cobalt resources and
other costs and expenses to be paid by the Center.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;7 The Center will settle its accounts on a monthly basis. After the deduction of its
operating cost, the earnings of the center will be distributed between the Parties based on the
profit sharing ratio stipulated herein.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;IV Purpose and Method of Cooperation and Profit Sharing Arrangement</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;8 Purpose of Cooperation. The Center is established at the Navy General Hospital with a
view to actively pursuing radiotherapy, diagnosis and research work and enhancing diagnosis and
therapy performance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;9 Method of Cooperation: Party B shall contribute one unit of China-made OUR-XGD III
rotating focalizing gamma knife equipment, and Party A shall provide the requisite premises and
medical staff which meet the requirements of operation of the gamma knife equipment.<BR>
Term of Cooperation: ***.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Profit-Sharing Percentage:<BR>
After the opening of the Center,<BR>
Year ***: Party A and Party B will share the profit on a *** basis<BR>
Year ***: Party A and Party B will share the profit on a *** basis<BR>
Year ***: Party A and Party B will share the profit on a *** basis<BR>
Year ***: Party A and Party B will share the profit on a *** basis

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;V Responsibilities of the Parties</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;10 Party A and Party B shall each be responsible for fulfilling their respective
responsibilities below:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party A&#146;s Responsibilities:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
1. To start handling relevant approval application procedures for the establishment of the Center
with relevant authorities upon the date of execution hereof;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2. To study and decide, in conjunction with Party B, the organization layout and construction plan
of the Center; and implement the specific construction work of the Center;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3. To put in place the infrastructure facilities, including water, power and transportation, and
etc.;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4. To recommend medical staff required by the Center; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5. To handle other matters mandated by the Center.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party B&#146;s Responsibilities:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1. To carry out the investment of the China-made OUR-XGD III rotating focalizing gamma knife
equipment;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2. To start arranging for the procurement of the China-made OUR-XGD III rotating focalizing gamma
knife equipment upon the date of execution hereof;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3. To arrange for the domestic training of the medical professionals of the Center and organizing
their study tour to the U.S.A.;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4. To study and decide, in conjunction with Party A, the organization layout and construction plan
of the Center, and assist Party A with the construction work; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5. To handle other matters mandated by the Center.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;VI Board of Directors</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;11 The board of directors shall be the supreme power organ of the Center. The board of
directors shall be composed of five members, including three members appointed by Party A and two
members appointed by Party B. The board shall have one chairman, which shall be appointed by Party
B and shall be vested with the veto power. The board shall have one vice chairman, which shall be
appointed by Party A. The chairman and the directors shall serve a term of four years and may be
reelected if recommended by their appointing party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;12 Being the supreme power organ of the Center, the board of directors shall have the power
to decide all material matters of the Center. The following material matters of the Center shall be
subject to unanimous approval:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1. Formulation and amendment of the articles of association of the Center
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2. Termination and dissolution of the Center
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">3. Material financial matters of the Center
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">4. Material personnel arrangement of the Center
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">5. Other material matters of the Center.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;13 If, for any cause, the chairman is unable to perform his/her duty, the chairman may
temporarily authorize the vice chairman or another director to perform such duty on his/her behalf.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;14 The board meeting will be held twice a year, generally one in the first half of the year
and one in the second half of the year. The chairman will be responsible for convening and
presiding over such meetings. When proposed by more than one half of the directors, the chairman
may convene an extraordinary meeting. The meeting minutes shall be kept and archived.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;VII Management Body</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;15 The Center will establish a management body which shall be responsible for the
Center&#146;s daily management work. The management body will have one director to be recommended by
Party A and one vice director to be recommended by Party B, and both will serve a term of four
years upon consideration, approval and appointment by the board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;16 The director shall be responsible for executing various resolutions of the board
meetings and organizing and supervising daily business management of the Center, while the vice
director shall assist with the director&#146;s work. The management body may
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">have divisional supervisors who shall take charge of the work of various divisions and carry out
assignments delegated by the director and the vice director.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;17 If either the director or the vice director abuses his/her office for personal gain or
is in gross breach of his/her duties, he/she may be removed at any time upon a resolution of the
board of directors.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;VIII Labor Management</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;18 Matters relating to the employment, termination, salary, labor insurance, labor
protection, living benefits and awards and disciplinary matters of the staff of the Center will be
implemented in accordance with applicable administrative rules and regulations of labor of Beijing,
or will be governed by the labor contracts between the Center and the individual employees in light
of the relevant plans considered and determined by the board of directors. The matters relating to
the affiliations of the Center&#146;s staff with the CCP or other politics parties, the Labor Union and
the Communist Youth League will be administered by the Navy General Hospital on a centralized
basis. Once executed, the labor contracts will be filed with the Beijing Administration of Labor
Affairs for record.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;19 Matters relating to the appointment, salary and compensation, social insurance, welfare,
traveling expenses, and etc., of the Center&#146;s staff will be deliberated and decided by the Board
meetings.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;IX Taxation and Financial Audit</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;20 Each party shall be responsible for its own taxation matters in relation to the Center.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;21 The Center shall allocate employee welfare and bonus funds in line with applicable rules
and regulations of the Ministry of Health and Beijing Municipality. The percentage of such
allocation for each year will be decided by the board of directors based on the income and expenses
of the Center.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;22 The Center shall, in compliance with applicable laws and regulations of both the nation
and Beijing Municipality, set up the accounting department with financial and accounting personnel
and establish its accounting system.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;X Ownership of Equipment</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;23 The OUR Gamma Knife and its accessory equipment shall be owned by Party B during the
period of cooperation.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;XI Insurance</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;24 The Center will take out its insurances with insurers, with the insurance coverage,
value and term to be decided by the board of directors in accordance with the stipulations of the
insurers.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;XII Modification, Amendment and Termination of Contract</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;25 Any change or termination of this Contract and its annex will not be effective unless
such change or termination is effected by way of a written instrument of the Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;26 The Parties may, upon negotiation and agreement, early terminate this Contract if it
becomes impossible to perform this Contract due to any force majeure or the Center suffers losses
for consecutive years so that it becomes unable to be operated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;27 If a Party fails to perform its obligations or grossly breaches the provisions under the
Contract and thereby prevents the Center from being operated or from achieving the operative
objectives hereunder, such Party shall be deemed a breaching Party and shall be deemed to have
terminated this Contract and the non-breaching party shall have the right to claim against the
breaching party and to terminate the Contract. Should the operation continue, the breaching party
shall indemnify the non-breaching party for its economic losses.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;XIII Liabilities for Breach of Contract</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;28 If, due to the misconduct of a Party, this Contract and its annex cannot be performed in
full or in part, such Party shall bear liabilities for breach of contract.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;XIV Force Majeure</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;29 In the event of any force majeure event, which is unforeseeable and the occurrence and
effect of which is unpreventable or unavoidable, including but not limited to earthquake, typhoon,
flood, fire and war, the relevant party shall immediately notify the other party by telegraph of
the circumstances of such event, and shall provide a report regarding the details of the event,
along with the reasons for the failure of, or the need to extend, the performance of the Contract
and valid attesting document therefor, which document shall be issued by a notary body of the place
of the event. In accordance with the impact of the event on the performance of the Contract, the
Parties will negotiate and discuss whether to terminate this Contract, or partially release the
obligation of performing this Contract, or extend the performance of this Contract.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;XV Governing Law</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;30 The execution, effectiveness, construction, performance and dispute resolution of this
Contract shall be governed by the laws of the People&#146;s Republic of China.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;XVI Dispute Resolution</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;31 Any dispute arising out of or in connection with this Contract or its performance shall
be resolved through friendly negotiations, failing which, such dispute shall be submitted to the
arbitration body or the People&#146;s court of the place of execution of this Contract for arbitration
or adjudication.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;32 During the course of arbitration, except for the parts in dispute and under arbitration,
this Contract will continue to be performed.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;XVII Effectiveness and Miscellaneous</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;33 This Contract and its annex shall become effective immediately upon execution by the
Parties&#146; legal representatives or authorized representatives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;34 Any notice from and to each Party, when sent by telegraph or fax and when it concerns
the rights and obligations of a Party, shall be followed by a formal written letter of notice. The
legal addresses of the Parties listed in this Contract shall be the addresses of the Parties for
the purpose of receiving such notices.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;35 No change of the legal representative of either Party shall affect the normal
performance of this Contract.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;36 This Contract shall be executed in four originals, with each party holding two copies,
each of which shall have the same force and effect.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Party A:</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>Party B:</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(affixed with the seal of The Chinese
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(affixed with the seal of Beijing Our</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">People&#146;s Liberation Army Navy General
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Medical Equipment Development Co.,</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Hospital)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ltd.)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Signature of Legal Representative:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Signature of Legal Representative:</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(affixed with the signature of Yang Ye)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(affixed with the signature of Jun Song)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">September&nbsp;19, 1995
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>30
<FILENAME>h03611exv10w12.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.12</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>REDACTED Version of Exhibit&nbsp;10.12<BR>
Translation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>CERTAIN INFORMATION (INDICATED BY ASTERISKS) IN THIS EXHIBIT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
WITH RESPECT TO THE OMITTED PORTION.</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Supplemental Agreement<BR>
Concerning the Development of<BR>
the Aohai Radiotherapy Treatment and Diagnosis Research Center</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Contract Number:<BR>
Time of Execution:<BR>
Place of Execution:

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;I General Provisions</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In accordance with applicable PRC laws and regulations, through friendly negotiations and on the
basis of the principle of equality and mutual benefit, Chinese People&#146;s Liberation Army Navy
General Hospital and Shenzhen Aohua Medical Services Co., Ltd. entered into a cooperation contract
on September&nbsp;15, 1995 whereby they decided to establish Aohai Radiotherapy Treatment and Diagnosis
Research Center (the &#147;Center&#148;) at Chinese Peoples&#146; Liberation Army Navy General Hospital in
Beijing. The OUR-XGD type rotating focalizing gamma knife (&#147;Head Gamma Knife&#148;), as initially
invested, has been put into formal medical treatment operation as of October&nbsp;30, 1996 and, thanks
to the Parties&#146; joint efforts, the Center has achieved good social and economic effect. The Parties
are willing to increase their contribution in respect of the equipment of the Center on the basis
of their existing original cooperation and hereby enter into this supplementary contract.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;II Parties of Cooperation</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;1 Parties of Cooperation<BR>
Party A: Chinese People&#146;s Liberation Army Navy General Hospital<BR>
Address: No.&nbsp;6 Fucheng Rd, Beijing Postal Code: 100037<BR>
Tel: 010-68587733 Fax: 010-68581507<BR>
Legal Representative: Ye Yang<BR>
Title: President

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party B: Shenzhen Aohua Medical Services Co., Ltd.<BR>
Address: Floor 17, Guomao Plaza, Renmin South Road, Shenzhen Postal Code: 518014<BR>
Tel: 0755-2255708 Fax: 0755-2251690<BR>
Legal Representative: Jun Song<BR>
Title: President

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;III Purpose of Cooperation and Scope of Application</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;2 Purpose of Cooperation. Based on the OUR-XGB rotating focalizing gamma knife (Head Gamma
Knife), as invested in the initial phrase, the Parties intend to make the second equipment
investments by deploying the world&#146;s first stereoscopic-directional gamma ray whole-body therapy
system (Body Gamma Knife), and proactively carry out research and teaching work at the hospital and
thereby constantly enhance therapy performance and develop the Center into a top modernized
medical treatment organization of China that integrates R&#038;D, teaching and therapy work.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;3 Scope of Application. The Center will mainly be focused on offering the whole-body
therapy for tumor diseases.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;IV Term of Cooperation</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;4 The term of cooperation for the second phase equipment contributed shall be ***,
commencing from the date on which the treatment and operation formally begin upon approval by
relevant authorities.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;V Contribution and Profit Allocation of the Parties</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;5 Second Phase Equipment Contribution and Profit Allocation
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1 Party B shall contribute the second phase equipment, i.e. the stereoscopic-directional gamma ray
whole body therapy system (Body Gamma Knife), which is valued at RMB*** million. Party A shall
contribute the medical personnel and facility room/s required for the second phase equipment as
well as the office premises related to such project. Other supporting facilities (air conditioning,
dehumidifiers, and telephones), etc. shall be treated as joint contribution of the Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2 Profit Allocation
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All profits derived from the contribution of this phase shall, after deducting all costs (as set
forth under Article&nbsp;6 of the original Contract), be allocated according to the following
percentages, on the basis of which the Parties shall also enjoy the title to, bear the risk of, and
have other rights to, the assets of the Center:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">Party A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">Party B</TD>
<TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Year ***</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">***</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="left" valign="top">***</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Year ***</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">***</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="left" valign="top">***</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;</TD>
    <TD><DIV style="margin-left:15px; text-indent:-15px">Year ***</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">***</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="left" valign="top">***</TD>
    <TD nowrap valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;VI Disposal of Assets During and<BR>
Upon Expiry of the Term of Cooperation</B>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;6 During the term of cooperation, any transfer by a Party of all or part of its interests
in the Center to a third party shall be subject to the approval of the other Party, which shall
have the preemptive right of purchase under equal conditions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;7 During the term of cooperation, the Parties shall be entitled to the ownership interests
in the forgoing contributed assets according to the relevant provision hereof on such contribution.
The Parties shall be entitled to the ownership interests in the assets in accordance with the
percentages set out in Clause 2, Article&nbsp;5 hereof in respect of assets acquired in the name of the
Center. Upon the expiry of the term of cooperation, all assets and earnings of the Center shall
belong to the Center and the profits shall no longer be shared between the Parties.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;VII Responsibilities of the Parties</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;8 Party A and Party B shall each be responsible for fulfilling their respective
responsibilities below:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party A&#146;s Responsibilities:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To handle project approval procedures with relevant authorities and secure approvals
in respect of the project of the Center proposed under the current phase;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To obtain all necessary qualification permits in line with applicable laws and
regulations of the state;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To make contributions in line with Article&nbsp;5(1) hereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To provide the premises required for the whole-body gamma knife system (equipment
room, operating room, preparation room and office);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To put in place water and power utilities of the Center;
</TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To work with Party B on the organization layout and construction plan;</TD>
</TR>
<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To administer matters relating to the affiliations of the Center&#146;s staff with the CCP
or other politics parties, the Labor Union and the Communist Youth League and medical
affairs under the centralized administration of the Hospital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To supervise the medical quality of the Center and in accordance with regulations and
rules, to submit disputes with the board of directors, which shall have the power to
consider and decide the settlements and resolutions of such disputes; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Other matters mandated by the Center</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party B&#146;s Responsibilities:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To make contributions in line with Article&nbsp;5(1) hereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To work with Party A to determine the management model and daily management work of
the Center;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To work with Party A to engage top domestic and foreign experts and senior
technicians; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Other matters mandated by the Center.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;VIII Board of Directors and Management Body</B>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;9 The duties and powers of the board of directors shall in principle be dealt with in
compliance with the original contract. The composition of the board of directors will be adjusted
appropriately based on the specific circumstances of the project.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;10 The management body shall put into place centralized administration and HR, accounting
and marketing organization management personnel and shall account for its finances independently.
The aforesaid organization setting-up and personnel arrangement matters shall be subject to the
consideration and decision of the board.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;IX Other Matters</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;11 Any matter not addressed herein shall be implemented in line with the original contract.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;X Effectiveness and Miscellaneous</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;12 This Contract will become effective immediately upon execution by the legal or
authorized representatives of the Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;13 This Contract shall be executed in six originals, with each Party holding three copies,
each of which shall have the same force and effect.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="51%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Party A: </B>Chinese People&#146;s Liberation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Party B: </B>Shenzhen Aohua Medical</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Army Navy General Hospital
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Services Co., Ltd.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Authorized Representative:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorized Representative:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(Official stamp)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Official stamp)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(affixed with the seal of The
Chinese People&#146;s Liberation Army
Navy General Hospital and the
signature of Yunyou Duan)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(affixed with the seal of Shenzhen
Aohua Medical Services Co., Ltd. and
the signature of Jun Song)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">March&nbsp;18, 1999
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">March&nbsp;18, 1999</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>31
<FILENAME>h03611exv10w13.htm
<DESCRIPTION>EX-10.13
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.13</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>REDACTED Version of Exhibit&nbsp;10.13<BR>
Translation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>CERTAIN INFORMATION (INDICATED BY ASTERISKS) IN THIS EXHIBIT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
WITH RESPECT TO THE OMITTED PORTION.</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Supplemental Agreement Concerning the Development<BR>
of the Aohai Radiotherapy Treatment and Diagnosis Research Center</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Contract No.: 2003-S-008<BR>
Time of Execution: September&nbsp;27, 2003<BR>
Place of Execution: Shenzhen, Guangdong

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;I General Provisions</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In accordance with applicable PRC laws and regulations, through friendly negotiations and on the
basis of the principle of equality and mutual benefit, Chinese People&#146;s Liberation Army Navy
General Hospital and Shenzhen Aohua Medical Services Co., Ltd. entered into a cooperation contract
on September&nbsp;15, 1995 whereby they decided to establish Aohai Radiotherapy Treatment and Diagnosis
Research Center (&#147;Center&#148;) at Chinese Peoples&#146; Liberation Army Navy General Hospital in Beijing
and invested in connection with the initial phase the OUR-XGD type rotating focalizing gamma knife
(&#147; Head Gamma Knife&#148;) in the Center; and entered into a supplementary contract on March&nbsp;18, 1999,
whereby they invested in connection with the second phase the stereoscopic-directional gamma ray
whole-body therapy system (&#147;Body Gamma Knife&#148;) in the Center. Thanks to the joint efforts of the
Parties, the Center has achieved good social and economic effect during both the initial phrase and
the second phase. The Parties are willing to continue to increase their contribution in respect of
the equipment of the Center on the basis of their existing original cooperation and hereby enter
into this supplementary contract.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;II Parties of Cooperation</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;1 Parties of Cooperation<BR>
Party A: Chinese People&#146;s Liberation Army Navy General Hospital<BR>
Address: No.&nbsp;6 Fucheng Road, Beijing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Postal Code: 100037<BR>
Tel: 010-68587733 Fax: 010-68581507<BR>
Legal Representative: DUAN, Yunyou<BR>
Title: President

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party B: Shenzhen Aohua Medical Services Co., Ltd.<BR>
Address: Floor 17, Guomao Plaza, Renmin South Road, Shenzhen Postal Code: 518014<BR>
Tel: 0755-2255708&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fax: 0755-2251690

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Legal Representative: SONG, Jun<BR>
Title: President

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;III Purpose of Cooperation and Business Scope</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;2 Purpose of Cooperation: Based on the OUR-XGB rotating focalizing gamma knife (Head Gamma
Knife), as invested in the initial phrase, and the stereoscopic-directional gamma ray whole-body
therapy system (&#147;Body Gamma Knife&#148;), as invested in the second phase, the Parties intend to make a
third phrase equipment investments by deploying advanced medical linear accelerator, CT simulator,
3-D Conformal Radio-therapy and planning system, hyperthermia system of endogenetic fields and
other sophisticated medical equipment, and proactively carry out clinical diagnosis, treatment,
research and teaching work and thereby constantly enhance medical service performance and develop
the Center into a top modernized medical treatment organization
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;3 Business Scope. The Center will offer diagnosis, comprehensive therapies (radiotherapy,
thermal therapy, chemotherapy, etc), research, teaching and other medical services in respect of
tumors and related diseases.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;IV Term of Cooperation</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;4 The term of cooperation for the third phase equipment contributed shall be ***,
commencing from the date on which the treatment and operation formally begin upon approval by
relevant authorities.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;V Contribution and Profit Allocation of the Parties</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;5 Third Phrase Equipment Contribution and Profit Allocation
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">1. Party B will contribute the third phase equipment, i.e., four units of internationally advanced
equipment (being one medical linear accelerator, one CT simulator, one 3-D Conformal Radio-therapy
and planning system and one hyperthermia system of endogenetic fields), which together are valued
at RMB ***. Party A shall contribute the existing medical technical personnel and equipment and
installations of its radiotherapy department, and the medical treatment and office premises
required for the Center, as well as other supporting facilities (air conditioning, dehumidifiers,
and telephones).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">2. Profit Allocation
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All profits derived from the project of this phase shall, after deducting all costs, be allocated
according to the following percentages, on the basis of which the Parties shall also enjoy the
title to, bear the risk of, and have other rights to, the assets of the third phase of the Center:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="22%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">Party A</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">Party B</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Year ***
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">***
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">***</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Year ***
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">***
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">***</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;VI Disposal of Assets<BR>
within and upon Expiry of the Term of Cooperation</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;6 During the Term of Cooperation, any transfer by a Party of all or part of its interests
in the Center to a third party shall be subject to the approval of the other Party, which shall
have the preemptive right of purchase under equal conditions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;7 During the Term of Cooperation, each Party shall own its own contributions and the assets
acquired in the name this current phase shall be owned by the Parties in accordance with the
percentages set out in Clause 2 of Article&nbsp;5 hereof. Upon expiry of this Contract, if so proposed
by a Party and so unanimously approved by the board, the Term of Cooperation may be extended and
the relevant agreement shall be separately agreed upon by the Parties through discussions.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;VII Responsibilities of the Parties</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;8 The Parties shall each be responsible for carrying out the following:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party A&#146;s Responsibilities:

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To make the contribution in accordance with Clause 1 of Article&nbsp;5 hereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To obtain all permits and licenses required for the conduct by the Center of the
business under this phrase as well as relevant approvals;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To be responsible for processing all application and filing procedures in respect of
the pricing and medical insurance-related approvals and for obtaining relevant approvals;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To provide the premises required for the current phase (equipment room, operating
room, preparation room, clinical room, office, and etc.), and put in place the water,
power utilities and telephones of the Center;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To carry out the equipment room construction and refurbishment work as per the
equipment installation-related technical requirements, as specified by the equipment
vendors; and to procure thereby that the equipment room shall be in a condition fit for
equipment installation;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To provide the existing technical personnel, therapy equipment and supporting
equipment of the radiotherapy department of the Hospital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To provide one special purpose ambulance;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To supervise the medical quality of the Center and in accordance with regulations and
rules, to submit disputes with the board of directors, which shall have the power to
consider and decide the settlements and resolutions of such disputes; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Other matters mandated by the Center.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Party B&#146;s Responsibilities:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To make the contribution in accordance with Clause 1 of Article&nbsp;5 hereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To work with Party A to develop the management model and management system of the
Center;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To work with Party A to engage for the Center top domestic and foreign experts and
senior technicians, including carrying out the review and assessment for employment of
existing staff;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To assign senior personnel with managerial experiences to participate in the
management of the Center;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To develop and implement feasible advertisement and market promotion plans; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Other matters mandated by the Center.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;VIII Board of Directors</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;9 The duties and powers of the board of directors shall in principle be dealt with in
compliance with the original contract. The board of directors for this phrase shall be composed of
seven members, including four members appointed by Party A and three members appointed by Party B.
The board shall have one chairman, which shall be appointed by Party B and shall be vested with the
veto power. The vice chairman shall be appointed by Party A. The chairman and the directors shall
serve a term of four years and may be reelected if so recommended by their appointing party.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;IX Management Body</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;10 The management body for this phase shall implement the director accountability system
under the leadership of the board of directors. The management body will have one executive
director to be recommended by Party B and one business director to be recommended by Party A, both
of which shall be determined and engaged by the board upon consideration. The directors shall serve
a term of four years and may be reelected if they are found qualified after review and assessment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;11 The executive director shall be responsible for implementing all resolutions of the
board of directors, shall be subject to the review by the board in terms of the annual operating
indicators and their operation and management work, shall organize and direct the daily business
management of the Center, and shall have responsibility over the administration and human
resources, accounting and marketing organization matters of the Center. The business director shall
be responsible for medical treatment technology and research work. The management body may have
divisional supervisors who shall be in charge of the work of relevant divisions, shall carry out
matters delegated by the directors and shall report to the directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;12 If either of the executive or business director abuses his/her office for personal gain
or is in gross breach of his/her duties, he/she may be removed at any time by the board of
directors under a board resolution.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;13 The Center will reasonably decide the headcount and staffing according to the needs of
the current phrase of business of the Center. The medical and technical staff will be recommended
by both Parties. The Center will adopt a system of all-personnel
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">employment and employees will be engaged upon satisfactory review and assessment by the board.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;X Equipment Procurement</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;14 Where the conditions are equal, the machinery and equipment and relevant components and
parts thereof, the vehicles and the office supplies required for the Center, shall be procured to
the extent possible from the domestic market.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;XI Taxation and Accounting Matters</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;15 The Center shall develop an accounting system in compliance with relevant laws,
regulations and rules of the state and Beijing Municipality. The financial management matters of
the Center shall be dealt with in accordance with such financial management system as approved by
the board of directors. To the extent of the staffing of accounting personnel, the accountant shall
be appointed by Party B and the cashier shall be appointed by Party A.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;16 The operating costs of the Center shall include the repair and maintenance expenses of
the Center (including expense for the repair and maintenance of the premises, equipment, and etc.),
staff bonus, water and power utility expenses, office expense, marketing and promotional expenses,
R&#038;D costs, medical indemnity for which the Center is held liable, as well as other expenses
required to be paid by the Center.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;17 The Center shall conduct accounting and settlement on a monthly basis. All profits
derived by the Center, after deducting the operating costs of the Center, shall be allocated
between the Parties based on the profit sharing percentages stipulated in Article&nbsp;7 herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;18 The Center shall be obligated to provide military personnel with charge-free medical
therapy in compliance with applicable policies of the state, provided that the monthly amount of
such medical therapy (in terms of amount of money) shall not exceed 10% of the total revenue
derived from the therapy of the Center.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;19 The Parties shall each be responsible for their own taxation matters in relation to the
Center under the cooperation.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;XII Other Matters</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;20 Any matter not addressed herein shall be implemented in line with the original contract.
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Section&nbsp;XIII Effectiveness and Miscellaneous</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;21 This Contract shall become effective immediately upon execution by the legal or
authorized representatives of the Parties.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;21 This Contract shall be made in six originals, with each Party holding three copies, each
of which shall have the same legal force and effect.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="51%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Party A: </B>Chinese People&#146;s Liberation
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Party B: </B>Shenzhen Aohua Medical</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Army Navy General Hospital
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Services Co., Ltd.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Authorized representative:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Authorized representative:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(Official stamp)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Official stamp)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(affixed with the seal of The
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(affixed with the seal of Shenzhen</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chinese People&#146;s Liberation Army
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Aohua Medical Services Co., Ltd. and</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Navy General Hospital and the
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the signature of Jun Song)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">signature of Yunyou Duan)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">September&nbsp;27, 2003
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">September&nbsp;27, 2003</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>32
<FILENAME>h03611exv10w14.htm
<DESCRIPTION>EX-10.14
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit 10.14</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>REDACTED Version of Exhibit&nbsp;10.14<BR>
Translation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U><B>CERTAIN INFORMATION (INDICATED BY ASTERISKS) IN THIS EXHIBIT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
WITH RESPECT TO THE OMITTED PORTION.</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Medical Equipment Lease Agreement</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Parties to the Contract:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Lessor:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Shanghai Medstar Medical Investment Management Company Limited
(hereinafter referred to as &#147;<U>Party A</u>&#148;)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Legal Representative: ZHANG, Jing</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Flat D and Flat E, 15/F, No.&nbsp;500, Zhangyang Road, Pudong New Area, Shanghai</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Lessee:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Chinese People&#146;s Liberation Army Navy General
Hospital (hereinafter referred to as &#147;<U>Party B</u>&#148;)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">Legal Representative: DUAN, Yunyou</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No.&nbsp;6 Fucheng Road, Haidian District, Beijing</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In accordance with the principle of equality and fairness, Party A and Party B are willing to
formulate this Lease Agreement (hereinafter referred to as this &#147;<U>Contract</U>&#148;) upon friendly
consultation and hereby jointly comply with the following:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;1 Leased Assets
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A agrees to lease to Party B one set of brand new imported PET-CT
equipment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Name of the Leased Assets: PET-CT, model number and specifications,
quantity, unit price, total price, manufacturer (for details, please refer to Appendix
I);</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The price of the Leased Assets is approximately RMB *** (subject to the final
bid price).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;2 Use of the Leased Assets
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">During the Lease Term, the Leased Assets will be used as medical equipment by the PET-CT
Centre within Party B&#146;s hospital and may not be used for other purposes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;3 Premises for Using the Leased Assets
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">The Premises for using the Leased Assets shall be: the PET-CT Centre of the Chinese
People&#146;s Liberation Army Navy General Hospital.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;4 Time of Delivery of the Leased Assets
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Party A shall deliver the Leased Assets to the Premises where the Leased Assets will be
used pursuant to the time as provided in the Leased Assets Purchase Contract. In the event
that the Leased Assets fail to arrive at the Premises in a timely manner because the
processing of the procedures regarding the examination and approval under Article&nbsp;8.2.2
hereof and the premises preparation are delayed, Party A shall not be liable for any
responsibilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;5 Lease Term
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">The Lease Term of the Leased Assets shall be: upon confirmation by the Parties, and under
the conditions of normal use, should the Leased Assets fail to continue to be used or be
declared to be scrapped, that is, the Lease shall terminate.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">Should the Leased Assets be delivered later than such date as provided in the Contract, the
Lease Term shall be extended accordingly.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;6 Ownership of the Leased Assets
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The ownership of the Leased Assets listed in the Appendix hereto shall belong
to Party A. During the Lease Term, Party B shall have the right to use only. Party B
may not sell, transfer, sub-lease, establish mortgage over, invest in the Leased
Assets and may not adopt such other acts in respect of the Leased Assets which may
infringe upon the ownership of the Leased Assets.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>That Party B enters into a contract with any third party or that Party B&#146;s
status of legal person is changed will not change Party A&#146;s ownership in respect of
the Leased Assets. In the event that Party B is in bankruptcy, the Leased Assets
shall not belong to the property in bankruptcy.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the performance of the Contract, Party A shall have the right to check
the use and completeness of the Leased Assets and under the circumstances wherein the
use of such equipment is not subject to any influence, Party B shall provide such
convenience. Without Party A&#146;s written consent, Party B may not disassemble any parts
and components of the Leased Assets nor change the premise used.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the performance of the Contract, Party A shall have the right to
establish mortgage over and transfer the Leased Assets, provided however that, Party A
must report such mortgage and transfer to Party B and seek Party B&#146;s advice prior to
such mortgage and transfer. Party A&#146;s mortgage and transfer shall not change Party
B&#146;s rights and interests as provided herein. Should damages are caused to Party B due
to any mortgage and transfer of the Leased Assets, Party A shall be liable for
compensation.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;7 Rental
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The rental shall be paid on a monthly basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>After the Leased Assets have been delivered to the Premises for using the
Leased Assets, the Parties agree that the Lease shall commence from &#091;Day&#093;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>&#091;Month&#093;&#091;Year&#093; (or another official commencement date for the Lease agreed upon by
the Parties by entering into a supplemental Agreement).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Commencing from the official commencement date for the Lease, Party B shall
remit the rental for the previous month into the account designated by Party A by the
20<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day for each month, and shall submit the independent book regarding
the finance of the PET-CT Centre to Party A by the 20<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day for the first
month of each quarter.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Name of the Account: Shanghai Medstar Medical Investment
Management Company Limited<BR>
Bank with account opened: Gaoqiao Branch of Agricultural Bank of China, at
Waigaoqiao, Shanghai<BR>
Account Number: 03-341600040016559</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Rental calculation method:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Before *** and within ***, the rental shall be *** of the monthly Leased
Assets Revenue of the Center;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon ***, the rental shall be *** of the monthly Leased Assets Revenue of
the Center;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Leased Assets Revenue = ***<BR>
The Hospital&#146;s own expenses and costs: The following costs shall be borne by the
PET-CT Centre:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.4.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Integrated service fee equivalent to *** of the total amount charged;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.4.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cost for renovation and transformation of the operation room (the item is
included once incurred);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.4.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Auxiliary consumptive materials required for treatment;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.4.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Maintenance and repair cost for the Leased Assets;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.4.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The wages and bonuses of such service personnel seconded by the Parties to
the Centre (including the capped amount for the wages of three military
personnel seconded by Party B);</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.4.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Charges for water, electricity, heat, and office expenses;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.4.2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cost for media and advertisement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.4.2.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Necessary technical training and technical upgrading, academic interchange
and the cost for hiring experts and consultants;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.4.2.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Other costs directly related to the operation of the Centre recognized by
the Parties.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>(The foregoing expenses may not exceed *** of the total amount charged by the
Centre for the current month at most. Should such expenses exceed ***, calculation
will be based on ***. The exceeding portion shall be carried forward into the next
month.)</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;8 Rights and Obligations of the Parties
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A&#146;s Rights and Obligations</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall deliver to Party B the Leased Assets designated by Party B in
a timely manner and assist the supplier in installing and commissioning.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall understand and grasp the operating situation of the leased
equipment at any time based on the operating financial revenue and expenses of the
Leased Assets as provided by Party B. When it is necessary, Party A may hire an
independent accounting firm for conducting audit regarding the accounts of the PET-CT
Centre.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A does not participate in Party B&#146;s operation and management.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A or the entrusted agent of Party A shall have the right to examine
and check the use and perfect condition of the Leased Assets.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall be responsible for providing the necessary technical
information for the use of the Leased Assets.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall be responsible for the technical training and upgrading
service in respect of the Leased Assets.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall delegate special personnel who shall be responsible for
examining and coordinating the work.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall be responsible for coordinating with the supplier in respect
of the repair and maintenance of the Leased Assets.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.1.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall be responsible for confirming jointly with Party B the
proposal regarding the renovation and transformation of the operation room and the
costs and expenses thereof.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">8.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B&#146;s Rights and Obligations</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall pay rental to Party A on a monthly basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall be responsible for processing all of the procedures for
approvals in respect of the Leased Assets hereunder, including the approval for
importation, application for the permit for deployment of large medical equipment for
the Leased Assets, and etc.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B promises that the financial statement on the operation of the leased
equipment and the relevant report Party B issues to Party A shall be in compliance
with the relevant laws and regulations of China and shall truly and objectively show
the financial status of Party B in connection with the Leased Assets.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To provide such premises, universal and auxiliary medical and communication
equipment coping with the Leased Assets, to provide doctors, nurses and technicians
and other professionals, and to provide the convenient conditions in respect of
logistics services.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To assist Party B in handling the matters related to domestic equipment
transportation, installation and commissioning.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To deal with medical management work, such as filing and report the charges
and prices.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B may have 2 military patients to undergo free-of-charge diagnosis of
the &#147;Centre&#148; per month (and among whom, one patient shall be entitled to full
exemption of the diagnosis charge while two patients shall be entitled to
half-exemption of the diagnosis charge).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall be responsible for the treatment and other medical decisions
on the patients and shall independently be liable for the medical liability.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The medical disputes related to the Leased Assets and other issues shall be handled
according to the relevant provisions of the health administrative authorities.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall properly manage and safekeep the Leased Assets and delegate
special personnel who shall be responsible for the daily work of the operation of the
Leased Assets.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B may not dissolve this Contract in early manner nor amend this Contract
because Party A has recovered the cost, or the integrated benefits of the PET-CT
System continues to grow or the leadership of the Hospital is replaced. Party A&#146;s
legal interests may not be damaged because of early dissolution hereof in the event of
other reasons beyond the force majeure, wars, and natural disasters.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.2.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease Term, in the event that Party B is required to introduce the same
type of the equipment, Party A shall enjoy the absolute priority.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;9 Delivery and Acceptance Upon Examination of the Leased Assets
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Delivery and Acceptance upon Examination: After the Leased Assets have been
delivered to the premise for use, Party B shall examine the Leased Assets for
acceptance pursuant to the content as provided in the Appendix&nbsp;I hereof. Should the
Leased Assets fail to meet the agreed terms, Party B shall timely make a note on the
delivery receipt and wait for Party A to settle it.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Technical acceptance upon examination: Upon installation and commissioning
and completion of the diagnosis and treatment for 5 cases and patients, if Party B
confirms that the technical requirements are met, it shall issue acceptance
certificate to Party A within 5&nbsp;days, and the delivery of the Leased Assets is deemed
to be completed. The Lease Term shall commence and the charges for such 5 cases and
patients shall be included in the revenue of the Leased Assets.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that the Leased Assets do not comply with the standard upon
examination and acceptance, Party A shall be responsible for handling such matter.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;10 Insurance of the Leased Assets and the Third Person&#146;s Damage Liability
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease term, Party A may, by installments, buy property integrated
insurance in respect of the Leased Assets with the insurance company based on the
total amount of the Leased Assets. The insurance beneficiary shall be Party A. The
duplicate copy of the insurance contract shall be kept by Party B.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease term, in the event of any incident of insurance liability,
Party B shall immediately notify Party A and cooperate with Party A for providing the
report on the accident cause and the relevant information, and shall, in conjunction
with Party A, timely process the claim with the insurance company. The Contract shall
continue to perform. Should such insurance claim fail to be settled due to Party B&#146;s
delay in processing the insurance claim, Party B shall be liable for the losses
incurred.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that any third party (patient)&nbsp;suffers from any damages due to
the quality issue of the Leased Assets, Party A shall be responsible for making a
claim against the manufacturer or operator of the Leased Assets. Before the claim can
successfully be made, the expenses shall be borne by Party A. Should the amount
claimed is insufficient, the insufficient portion shall be included into the
Hospital&#146;s own expenses which shall be borne by the PET-CT Centre.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that any third party (patient)&nbsp;suffers from any damages due to
Party B&#146;s fault in using the Leased Assets, Party A shall be liable for such damages.
The expenses shall be included into the Hospital&#146;s own expenses which shall be borne
by the PET-CT Centre.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Article&nbsp;11</TD>
    <TD>&nbsp;</TD>
    <TD>Disposal of the Leased Assets Upon Expiry of the Lease
Upon the expiry of the Lease Term, the Leased Assets shall be
returned to Party A and a third party shall be entrusted to
handle the scrap procedure.</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;12 Financial Audit
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">12.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For purposes of ensuring the reasonable and effective use of the Leased
Assets and ensuring the Lessor&#146;s legal rights and interests, Party B agrees that Party
A shall conduct financial audit in respect of the Centre.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">12.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The measures regarding the financial audit shall include that Party A shall
have the right to supervise, at any time, the number of people seeking medical advice,
price, the Centre&#146;s cost and expenses, the wages and bonus amount of the personnel
working in the Centre.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;13 Handling of Breach
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that Party A unilaterally terminates this Contract in early
manner in violation of the provisions hereof, Party A shall compensate Party B the
total sum of the average monthly revenue for the three months prior to the termination
hereof.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall be responsible for equipment maintenance and technical service
and technical upgrading and shall ensure the normal switch-on rate of the equipment.
In the event that the equipment fails due to its own quality issue and the impact on
treatment lasts for over 30&nbsp;days, Party A shall provide compensation and the
compensation amount shall be negotiated by the Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease Term, if Party B has introduced any medical equipment which
has similar function of the Leased Assets through a third party in violation of
Article&nbsp;8.11 hereof, Party B shall compensate Party A the losses incurred therefrom in
a lump-sum payment, and the Parties shall terminate this Contract in early manner.
Amount of loss = Remaining Lease Term &#215; the monthly average rental prior to the
breach.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Should Party B delay in paying the rental, such delay shall not exceed three
months. And Party B shall pay to Party A a default fine equivalent to 0.05% of the
amount delayed in payment on a daily basis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that Party B breaches the Contract in any of the following
manners, Party A shall have the right to dissolve this Contract and Party B is
required to pay an overdue penalty and shall immediately pay all due outstanding and
undue rental. As for the undue monthly rental, it is calculated as 2.5% of the total
price of the Leased Assets. And the Leased Assets shall be recovered.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any monthly rental owed by Party B is in arrears for more than three months;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B has disposed the Leased Assets in its sole discretion in violation
of the provisions of this Contract;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.5.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Leased Assets are seriously damaged or lost due to any improper use,
intentional damage or careless storage by Party B.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Should Party A breach the Contract in the foregoing manner, Party A shall be
liable for Party B&#146;s lawsuit cost, legal counsel fees and other costs arising from
Party B&#146;s realization of the creditors&#146; rights.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Lease Term, if the military patient paid the relevant fees which
are lower than the verified price charged (except for the Centre&#146;s free-of-charge
diagnosis cost for the two military personnel per month), the insufficient portion
shall be supplemented by Party B and shall be deducted from Party B&#146;s income.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that either party unilaterally proposes a reduction or exemption
for patients other than the military personnel, the proposing party shall bear the
price difference which shall be deducted from such
</TD>
</TR>
</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>party&#146;s income. Any amount mutually recognized by the Parties may be included in
the expenses of the PET-CT Center.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;14 Dispute Resolution<BR>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any and all disputes in connection with this Contract shall be
settled by the Parties through consultation. If no settlement
can be reached through consultation, an action may be brought
before the People&#146;s Court in the place where the Leased Assets
are located.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;15 Appendix to this Contract
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Appendix to this Contract is an integral part hereof and
shall have the equal legal validity as that of the main text
hereof.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;16 Effectiveness
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Contract shall become effective after being signed and
stamped by both Party A and Party B.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;17 Termination of Contract
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">17.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Contract shall automatically terminate upon the expiry of the Lease
Term.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">17.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All claims and indebtedness arising from the performance of this Agreement by
Party A and Party B shall be terminated upon full repayment of all debts, including
all rental payments, default penalties, indemnification, and so on.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">17.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case of impossibility of performance of the Contract or use of the Leased
Assets due to war, natural disaster, force majeure and other factors, this Contract
shall be terminated and neither party shall be liable to or have any rights against
the other party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">17.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In case of impossibility of performance of the Contract due to any change in
the policy and regulation of the State or the locality, resulting into the</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>fact that this Contract fails to be performed, but without affecting the use of the
Leased Assets, this Contract may be terminated in early manner. The Parties shall
confirm the proposal of solution through consultation.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">17.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event that the military adjusts its policy, resulting into the fact
that this Contract fails to be performed, but without affecting the use of the Leased
Assets, this Contract may be terminated in early manner; provided, however, that Party
B is required to make a lump-sum payment to purchase such leased equipment in an
amount equal to: *** (see Appendix&nbsp;I) minus ***</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Or, subject to safeguarding the legal rights and interests of the Parties, such
matter may be settled through consultation.<BR>
Purchase Price = ***</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;18 Miscellaneous
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">18.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Parties hereto have carefully read through all the terms hereof.
Reasonable manner has been adopted to urge the Parties to pay attention to the terms
regarding exemption or restriction on their responsibilities as provided herein. And
per the requirements of the Parties, explanation has been made in respect of the
relevant terms.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">18.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Parties hereto have authorized their respective representatives to sign
this Contract. All terms of this Contract are a true expression of the intents of the
Parties and shall have legal binding effect on the Parties.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Article&nbsp;19</TD>
    <TD>&nbsp;</TD>
    <TD>The original of this Contract and the Appendix hereto shall be prepared in four copies
while Party A and Party B shall each hold two copies hereof.</TD>
</TR>
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Lessor:</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>Lessee:</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Shanghai Medstar Medical Investment <BR>
Management Company Limited (affixed <BR>
with its corporate seal)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">the Chinese People&#146;s Liberation Army<BR>
Navy General Hospital(affixed with
its corporate seal)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Legal Representative (or Authorized <BR>
Representative):
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Legal Representative (or Authorized
Representative):</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(Affixed with the signature of
Zheng Chen)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(affixed with the signature of
Yangming Qian)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Date of Execution:</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>Date of Execution:</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">29 September, 2006
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">29 September, 2006</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Bank with account opened:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Bank with account opened:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">Gaoqiao Branch of Agricultural Bank
of China, at Waigaoqiao, Shanghai
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fuwaidajie Branch of Industrial and
Commercial Bank of China</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Account Number: 03-341600040016559
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Account Number: 0200049209026700101</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Telephone: 021-58367007
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Telephone: 010-66958114</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Facsimile: 021-58368131
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Facsimile: 010-66958034</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Appendix&nbsp;I:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Purchase</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center">Name of Leased</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Model</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Price RMB</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Equipment</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Number</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Quantity</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">(10,000 Yuan)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Manufacturer</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Distributor</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">PET/CT
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>33
<FILENAME>h03611exv10w15.htm
<DESCRIPTION>EX-10.15
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 18pt"><b>Exhibit 10.15</b>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>REDACTED Version of Exhibit&nbsp;10.15<BR>
Translation</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>CERTAIN INFORMATION (INDICATED BY ASTERISKS) IN THIS EXHIBIT<BR>
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES<BR>
AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN<BR>
REQUESTED WITH RESPECT TO THE OMITTED PORTION.</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Supplemental Agreement<BR>
Concerning the Development of<BR>
the Aohai Radiotherapy Treatment and Diagnosis Research Center</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>(</B>Contract Number: AMS20090601)

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">June&nbsp;2009

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Parties to the Contract:
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Party A:</TD>
    <TD>&nbsp;</TD>
    <TD>Chinese People&#146;s Liberation Army Navy General Hospital
(hereinafter referred to as &#147;Party A&#148;)<br>
Legal Address: No.&nbsp;6 Fucheng Road, Beijing<br>
Postal Code:100048<br>
Legal Representative: QIAN, Yangming</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Party B:</TD>
    <TD>&nbsp;</TD>
    <TD>Shenzhen Aohua Medical Services Company Limited (hereinafter
referred to as &#147;Party B&#148;)<br>
Registered Address: Room&nbsp;3702, Jinmao Plaza, No.&nbsp;4028
Jintian Road, Shenzhen<br>
Postal Code: 518035<br>
Legal Representative: YANG, Jianyu</TD>
</TR>
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;I General Provisions</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;1
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Deploying their respective resource advantages, Party A and Party B entered into a Cooperation
Contract on 19 March, 1995 and thereby jointly established &#147;Aohai Radiotherapy Treatment and
Diagnosis Research Center&#148; (hereinafter referred to as the &#147;Center&#148;) and invested, for such initial
phase, the OUR-XGD Rotary Focus Gamma Knife )(head Gamma Knife) in the Center; entered into a
supplementary contract on 18 March, 1999 and further invested, for the second phase, the
three-dimensional stereotactic Gamma Ray Whole-body Treatment System (Whole-body Gamma Knife); and
entered into a supplementary contract (Contract Number 2003-S008) on 27 September, 2003 and further
invested, for the third phase, the linear accelerator for medical uses, simulated stereotactic
machine, three-dimensional conformal radiotherapy treatment plan and system, the endogenic field
hyperthermia machine; and further entered into a supplementary agreement on 15 September, 2004 and
further invested, for the third phase, the EEG Stereotactic System to carry out the diagnosis and
treatment of epilepsy diseases; and in the process, Party A and Party have developed the tumor
Center into a medical treatment center which features first-class technology, first-class talents,
a relatively high domestic reputation, and the integration of medical treatment and scientific
research and which is capable of providing systematic, sound comprehensive diagnosis and therapy
services in relation to tumors of different phases and types for relevant patients. Thanks to the
joint efforts of the Parties, the Center has achieved good social and economic results from all of
the first three phases investments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;2
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Based on the principle of equality, mutual benefit and risk sharing, through friendly discussions,
the Parties, desiring to further invest the fourth phase equipment in the Center on the basis of
their existing cooperation and thereby meet the needs of patients and further enhance the capacity
of the equipment of the Center, hereby agree as follows in respect of relevant matters.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;II Basic Introduction of the Center</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;3
</DIV>


<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Name of the Center: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&#147;Aohai Radiotherapy and Diagnosis Research Center&#148;
(hereinafter referred to as the &#147;Center&#148;).</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Article&nbsp;4
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Address of the Center: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Within the Chinese People&#146;s Liberation Army Navy
General Hospital</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;5
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Business Scope of the Center:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">To carry out diagnosis, radiotherapy, scientific research, academic work in respect of tumors and
related diseases as well as other medical services. All activities of the Center shall be in
compliance of the laws and regulations of the People&#146;s Republic of China. All medical treatment
activities of the Center shall observe relevant medical treatment rules and regulations, common
diagnostic operation procedures and quality control standards, as well as relevant requirements of
the Hospital.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;III Mode of Cooperation</B>
</DIV>


<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Article&nbsp;6</TD>
    <TD>&nbsp;</TD>
    <TD>Contribution by the Parties</TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">6.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall be responsible for contributing the fourth phase medical equipment, including:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">6.1.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>One set of the three-dimensional stereotactic Gamma Ray Whole-body Treatment System
(Whole-body Gamma Knife); and one set of Siemens image-guided high-energy linear accelerator;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">6.1.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The total investment amount shall be RMB *** (such amount for the invested equipment shall
be wire transferred, before actual payment, by Party B to Party A, which shall then pay it to
the equipment vendor). The specific model and specifications, equipping and price of the
equipment shall be determined as per the actual bidding and
procurement results;</TD>
</TR>



<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">6.1.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B shall advance a payment in the amount of approximately RMB *** in respect of the
construction and furnishing expenses of the equipment room and auxiliary rooms thereof. The
required expenses shall be included into the operating costs of the fourth phase cooperation
project.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">6.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall be responsible for providing the following:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">6.2.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A premises space of approximately 350 sq. m. for the equipment room and auxiliary room
thereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">6.2.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Infrastructure facilities, such as water, electricity, heating and communications, etc.;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">6.2.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Technical personnel and professional personnel; and</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" nowrap align="left">6.2.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All the legal permits and licenses required for the business operations of the Center.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">6.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>No Party may withdraw the property used for the cooperation project without the consent of
the other Party.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Article&nbsp;7:</TD>
    <TD>&nbsp;</TD>
    <TD>Term of Cooperation:</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The term of cooperation for the fourth phase equipment contribution shall be ***, commencing from
the date on which the treatment and operation formally begin upon approval by relevant competent
authorities and readiness of the fourth phase equipment contributed by Party B (the specific date
shall be agreed and confirmed in writing by the Parties).
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Section&nbsp;IV The Center&#146;s Revenue, Expenses and Profit Allocation</B>
</DIV>


<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Article&nbsp;8</TD>
    <TD>&nbsp;</TD>
    <TD>The Center&#146;s Revenue</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Center&#146;s Revenue shall include all revenues generated from the examination and treatment by
using the equipment contributed for the current phase.
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Article&nbsp;9</TD>
    <TD>&nbsp;</TD>
    <TD>The Center&#146;s Expenses (the Center&#146;s Operating Costs):<BR></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Center&#146;s expenses shall include the following:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">9.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Costs of human resources: wages of the newly hired personnel of the Center; the bonuses,
welfare benefits, etc. of the Center&#146;s personnel; external experts&#146; cost and consultation fee;
training cost, education expenses, scientific research expenses, etc.;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">9.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Equipment operation costs: expenses for repair and maintenance of the equipment, costs of
consumptive materials, costs of auxiliary parts, costs for replacement of radiation sources,
etc.;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">9.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Medical related costs: cost of medicines, cost of medical consumptive materials,
sterilization cost, cleansing cost, anaesthetization cost, costs for the handling of medical
disputes, medical indemnity, etc.;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">9.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Office expenses: travel and accommodation cost, entertainment cost, transportation fee,
telephone fee, postal and telecommunication fee, water, electricity and heating charges,
health and hygiene expenses, etc.;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">9.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Advertisement and promotional cost: academic exchange expenses, expenses for expert-related
events, advertising and promotional expenses, expert assistance and service fee, etc.;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">9.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Equipment insurance premium;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">9.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Management fee (***);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">9.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Other expenses: relevant expenses required for the normal operation of the Center.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Article&nbsp;10</TD>
    <TD>&nbsp;</TD>
    <TD>Profit Allocation</TD>
</TR>
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">During the Term of Cooperation, the Parties shall allocate the net revenue of the Center (the
Profit of the Center) generated from the fourth phase equipment contributed as follows.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Three-dimensional stereotactic Gamma Ray Whole-body Treatment System (Whole-body Gamma
Knife):</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>From ***, Party A and Party B shall each obtain *** of the Profit of the Center.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">10.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Siemens image-guided high-energy linear accelerator:</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>From ***, Party A shall obtain *** of the Profit of the Center and
Party B shall obtain *** of the Profit of the Center; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>From ***, Party A shall obtain *** of the Profit of the Center and
Party B shall obtain *** of the Profit of the Center.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;V Management Body of the Center</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;11
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Center shall establish a management committee and the duties of the management committee shall,
in principle, be dealt with in accordance with the provisions of the original contract. Material
matters such as amendment of the cooperation contract of the Parties shall be subject to the
agreement and confirmation of both Parties.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;VI Financial Management of the Center</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;12
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Center shall formulate its financial and management procedures, shall establish a finance
office and shall independently account for its finances, all in accordance with the relevant system
of the State and the administration requirements of the Army.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;13
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Center&#146;s medical charges shall be centrally collected by the Hospital on behalf of the Center.
The Hospital shall create a relevant fee charge subject for the Center and the Center&#146;s finance
office shall retain the return receipt copies of fee charge vouchers for its book-keeping purposes
and shall check and settle the accounts with the Hospital as well as remit the relevant profit
allocations on a monthly basis. No Party hereto and no individual shall collect the charges
privately. In the event of any private fee collection, the responsible person shall be imposed a
penalty double the privately collected amount when such allegation has been found true.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;14
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Center&#146;s finance personnel shall settlement the accounts on a monthly basis pursuant to the
allocation arrangement as provided herein and the 5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of each month shall be the
settlement day, on which date the Center and Party A shall jointly verify the income
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and expenses of the Center. The amount allocable to Party B after deduction of the Center&#146;s
operating costs shall be paid to Party B in a lump-sum within 5 working days of such settlement
day.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;15
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Considering the special status of Party A, namely, its status as a hospital of the army, the
Center&#146;s equipment shall be reasonably used to provide military servicemen with medical services.
The three-dimensional stereotactic Gamma Ray Whole-body Treatment System (Whole-body Gamma Knife)
will annually provide 15 military servicemen with free treatment, in the event of which the medical
personnel of Party A shall be assured of the appropriateness of the therapy for relevant diseases
and shall escalate such free treatment request to the president of the Hospital for approval
pursuant to relevant procedures before carrying out such free treatment. Should the quota of such
free treatment be exceeded, relevant treatment charges shall be calculated on a cost basis and
shall be borne by Party A. The Siemens image-guided high-energy linear accelerator will, in
accordance with the treatment rules applicable to the existing accelerator, provide free service to
military servicemen on the basis of the needs required of reasonable medical treatment, provided
that, where such equipment is used to carry out the image-guided intensity-modulated radiotherapy,
the medical personnel of Party A must strictly be assured of the appropriateness of the therapy for
relevant diseases and shall escalate such free treatment request to the president of the Hospital
for approval pursuant to relevant procedures before carrying out such free treatment, Such
equipment will annually provide 10 military servicemen with free treatment. Should such quota be
exceeded, relevant treatment charges shall be calculated on a cost basis and shall be borne by
Party A.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;VII
Rights and Obligations of the Parties</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;16
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party A&#146;s rights and obligations:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">16.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To study and process, in conjunction with Party B, the organizational set-up and construction
plan of the Center and to attend to the actual construction work of the Center;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">16.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To provide the land required for the premises of the Center, and to put in place the
infrastructure facilities including water, electricity, heating, etc;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">16.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To arrange or recommend such medical, nursing and technical personnel as required for the
operation of the Center and to provide such personnel seconded by Party B or recruited by the
Center with necessary working conditions (among others, the medical and nursing personnel
shall be granted with the medical practice qualification at the Hospital.) ;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">16.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To coordinate the relationship between the Center and the divisions of Party A;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">16.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To handle, with respect to all the equipment of the Center, approval application filings with
relevant authorities in relation to large medical equipment procurement permits, environmental
evaluation, pricing, medical insurance and other procedures as well as work related to the
bidding of the equipment;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">16.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To supervise the medical treatment quality of the Center, to include the Center into the
Hospital&#146;s quality management system, and to implement the review,</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>appraisal and incentive and disciplinary matters based on the Hospital&#146;s existing
management system;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">16.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To conduct the maintenance and repair of the equipment in conjunction with Party B; and<BR></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">16.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To coordinate for the handling of other matters related to the operation of the Center.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;17
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party B&#146;s rights and obligations:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">17.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To handle, in conjunction with Party A, the tendering and procurement work in relation to the
equipment required for the Center pursuant to the subject matter of the contract; coordinate
the transportation, installation and commissioning of the equipment; and provide Party A with
relevant documentation of the procured equipment;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">17.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To assist Party A to submit to the competent health authority approval application filings in
relation to large medical equipment procurement permits and other procedures;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">17.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To make contacts and arrangements in connection with the equipment operation training for the
medical and nursing personnel of the Center;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">17.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To contact or recommend relevant Chinese and foreign medical experts;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">17.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To carry out, in conjunction with Party A, the construction and upgrading work of the
Center&#146;s digital medical treatment network system;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">17.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To assist the Center to carry out the marketing and promotion work;<BR></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">17.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To handle other matters entrusted by Party A; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">17.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>During the Term of Cooperation, if Party A needs to further introduce the same type of
equipment, Party B shall have the right of priority.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;VIII
Ownership and Insurance of Equipment</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;18
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">During the Term of Cooperation provided herein, the ownership of the equipment contributed by Party
B to the Center shall belong to Party B. Upon the expiry of the Term of Cooperation, the ownership
of such equipment shall belong to Party A.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;19
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The ownership of the equipment separately procured by the Center after its establishment with its
revenue shall belong to the Center. Upon the expiry of the Term of Cooperation, the ownership of
such equipment shall belong to Party A.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;20
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Provided that the performance hereof shall not be affected, Party B shall have the right to
mortgage or transfer the ownership of the equipment contributed by it, provide that, however, the
prior consent of Party A will be required. The carrying out by Party B of such mortgage or
transfer shall not modify Party A&#146;s rights and interests provided herein and Party B shall be
liable to indemnify Party A against any damage suffered by it as a result of such mortgage or
transfer.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;21
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Party B may take out insurance with an insurer in respect of the equipment set out herein, with the
type, value and term of insurance coverage to be determined in accordance with relevant terms of
such insurer, and the insurance beneficiary shall be Party B or a third party designated by Party
B. The insurance contract shall be notified to Party A and a duplicate copy of it shall be kept by
Party A.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;IX Breach of Contract</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;22
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If a Party fails to perform its obligations or grossly breaches the provisions under the Contract
and thereby prevents the Center from being operated or from achieving the business objectives
hereunder, such Party shall be deemed a breaching Party and shall be deemed to have terminated this
Contract and the non-breaching party shall have the right to claim against the breaching party and
terminate this Contract.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;23
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If Party A delays to remit and pay the revenue allocable to Party B for over two months, then Party
A shall pay to Party B an overdue fine equal to 0.05% of the late payment amount for each of the
days so delayed, except where such delay has been caused by a force majeure event.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;24
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Should Party A commit any of the following breaches, Party B shall have the right to terminate this
Contract and Party A shall be obligated to pay breach penalty to Party B.
Such breach penalty shall be equal to: Party B&#146;s total income for the previous year &#215; the remainder
of the Term of Cooperation
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">24.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A privately and unilaterally terminates earlier or amends this Contract in violation of
the provisions hereof ;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">24.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A privately and unilaterally disposes of the equipment invested by Party B (including
but not limited to sale, sub-lease, relocation, transfer, etc.) in violation of the provisions
hereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">24.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Without consultation with, and consent of, Party B, Party A remains in arrears with the
payment of any installment of the profit allocable to Party B for more than 6&nbsp;months or causes
the equipment to cease its normal provision of medical treatment services to patients for more
than 30&nbsp;days for reasons attributable to Party A (except for equipment failures).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">24.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A otherwise grossly violates the provisions hereof.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;25
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Should Party B commit any of the following breaches, Party A shall have the right to terminate this
Contract and Party B shall be obligated to pay default penalty to Party A.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Such default penalty shall be equal to: Party A&#146;s total income for the previous year &#215; the
remainder of the Term of Cooperation
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">24.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B privately and unilaterally terminates earlier or amends this Contract in violation of
the provisions hereof;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">24.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The carrying out by Party B of a mortgage or transfer in respect of the equipment under this
Contract has a material effect on the rights and interests of Party A;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">24.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B otherwise grossly violates the provisions hereof.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;X Amendment, Extension, Termination and Dissolution of the Contract</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;26
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any amendment, modification or termination of this Contract and its appendix shall become effective
only if a written instrument has been executed by the Parties hereto upon mutual consultation and
agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;27
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If the Parties decide to extend the term of cooperation, they shall either enter into a
supplementary agreement for the extension of such term of cooperation 6&nbsp;months prior to the expiry
of such term of cooperation or shall enter into a separate cooperation contract.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;28
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If, due to war, natural disasters, force majeure events, or like factors, it becomes impossible to
perform this Contract or use the equipment, the Parties may terminate this Contract earlier without
any liabilities to each other.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;29
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If, due to reasons attributable to the regulations of the state or local authorities, it becomes
impossible to perform this Contract but the use of the equipment remains unaffected, this Contract
may be terminated earlier, provided that the Parties shall determine a solution through mutual
consultations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;30
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If, due to adjustments in the policy of the army, it becomes impossible to perform this Contract
but the use of the equipment remains unaffected, this Contract may be terminated earlier, provided
that Party A shall be obligated to buy back, on an one-off basis, the equipment from Party B and
provided further that the specific terms therefor shall be determined through mutual consultations,
having due regard to the protection of the legal rights and benefits of the Parties.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;XI Miscellaneous</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;31
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any dispute arising from the performance hereof shall be resolved through friendly
consultations, failing which such dispute shall be referred to the local court of Beijing for
adjudication.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">CONFIDENTIAL TREATMENT REQUESTED BY CONCORD MEDICAL SERVICES HOLDINGS LIMITED
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;32
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any notice involving the rights and obligations of either Party shall be in writing and the
addresses set out herein shall be the addresses of the Parties for the receipt of notices.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;33
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Contract shall become effective once it is signed and sealed by the Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;34
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">No change to the legal representatives of either Party shall affect the normal performance of this
Contract.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;35
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any matter not covered herein may be dealt with by a separate supplementary agreement, which shall
have the same legal force and effect as this Contract.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;36
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Appendix hereto shall be an integral part hereof and shall have the same legal force and effect
as this Contract.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;37
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Contract shall be made in four originals, with each Party holding two copies, each of which
shall have the same legal force and effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Article&nbsp;38
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Contract is made and entered into in &#091;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#093; City on &#091;Day&#093; &#091;Month&#093;, 2009
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="51%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Party A: Chinese People&#146;s Liberation
Army Navy General Hospital
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Party B: Shenzhen Aohua Medical
Services Company Limited</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&#091;corporate seal&#093;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#091;corporate seal&#093;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signed by Legal Representative
or Authorized Agent:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Signed by Legal Representative
or Authorized Agent:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(affixed with the seal of The
Chinese People&#146;s Liberation Army
Navy General Hospital and the
signature of Yunyou Duan)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(affixed with the seal of Shenzhen
Aohua Medical Services Co., Ltd. and
the signature of Jun Song)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date of Execution: 8 July, 2009
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Date of Execution: 8 July, 2009</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>34
<FILENAME>h03611exv10w16.htm
<DESCRIPTION>EX-10.16
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.16</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.16</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Supplemental Agreement to the Service-only Management Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Entrusting Party:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Xi&#146;an Wanjiechangxin Medical Services Company Limited<BR>
Legal Representative: CAI, Shijie

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Chang&#146;an Hospital Co., Ltd.<BR>
Legal Representative: CAI, Shijie

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Entrusted Party:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">CMS Hospital Management Co., Ltd.<BR>
Legal Representative: YANG, Jianyu

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Whereas:</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Entrusting Party and the Entrusted Party have entered into the Service-only Management
Agreement (the &#147;Original Contract&#148;) in connection with Chang&#146;an Hospital as of August
1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP>, 2008. In order to facilitate the Entrusted Party&#146;s operation and management work,
upon consultations, the Parties hereby enter into the Supplemental agreements for mutual
compliance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;1 </B>The Entrusted Party shall have the power to solely decide matters falling within the
following scope:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All tumor-related divisions of Chang&#146;an Hospital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All divisions covered by the service-only management agreements for medical equipment, which
were entered into by and between Chang&#146;an Hospital or Xi&#146;an Century Friendship Medical
Technology R&#038;D Co., Ltd. and the Entrusted Party or any affiliate of the Entrusted Party.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Considering that the Entrusted Party will implement a new system of management by objective, the
Entrusted Party shall have the management and operation power to solely decide all relevant matters
of the above-mentioned divisions, including but not limited to, human resource, accounting,
administration, operation, performance review matters, etc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;2 </B>In respect of the divisions other than those set out in Article&nbsp;1 (&#147;Other Divisions&#148;),
the Entrusted Party shall carry out the management work as follows:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subject to the leadership of the Entrusted Party, efforts shall be made to permit the
existing management team of Chang&#146;an Hospital to fully deploy its powers and potential for
management in principle of &#147;maintaining stable development&#148; ;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any adjustment or change to the management work of the Entrusted Party shall be</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>discussed and agreed with the Entrusting Party;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Entrusted Party shall in principle appoint representatives to manage the matters in
respect of administration and accounting and shall, where the conditions are equal, use on a
priority basis existing employees of Chang&#146;an Hospital.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;3</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The use and management of Chang&#146;an Hospital&#146;s official seal shall comply with the following
principles:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>When any decision or document is required to be made or issued by Chang&#146;an Hospital in
respect of external parties, such decision or document shall not acquire legal force unless
and until it shall have been signed by both the Entrusting Party and the Entrusted Party and
affixed with the official seal.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any decision related to the divisions provided in Article&nbsp;1 hereof shall acquire legal force
once it shall have been solely signed by the Entrusted Party and Chang&#146;an Hospital shall affix
its official seal thereon at the request of Entrusted Party.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any decision related to the Other Divisions provided in Article&nbsp;2 hereof shall acquire legal
force once it shall have been solely signed by the person in charge of Chang&#146;an Hospital and
affixed with the official seal.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Article&nbsp;4 </B>During Chang&#146;an Hospital&#146;s transition towards the 2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP> phase, the Entrusting
Party and the Entrusted Party shall set up a transition team and shall jointly carry out, by way of
equality-based discussions, the split of the personnel, finances and assets as well as business
cooperation and division of labor-based coordination between the 1<SUP style="font-size: 85%; vertical-align: text-top">st</SUP> phase and the
2<SUP style="font-size: 85%; vertical-align: text-top">nd</SUP> phase in accordance with the principles set out in the <I>Framework Agreement for the
Cooperation on Chang&#146;an CMS International Cancer Center </I>and on the basis of the appraisal report
mutually acceptable to the Parties and shall thereby ensure a smooth transition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Article&nbsp;5 </B>Miscellaneous
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Supplemental Agreement shall become effective upon execution and sealing by each of the
Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Supplemental Agreement will be terminated either as a result of the termination of the
Original Contract or by the mutual agreement of the Parties.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Supplemental Agreement shall be made in six originals in Chinese only, with each Party
hereto holding two copies. Each of the copies shall have the same legal force and effect.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In the event of any discrepancy between the Original Contract and this Supplemental
Agreement, this Supplemental Agreement shall prevail.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(No operative text below)
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(No operative text on this signature page)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Xi&#146;an Wanjiechangxin Medical Services Company Limited</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Legal Representative / Authorized Representative:<BR>
(Seal)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Chang&#146;an Hospital Co., Ltd.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Legal Representative / Authorized Representative:<BR>
(Seal)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>CMS Hospital Management Co., Ltd.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Authorized Representative: (Signature)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Date: August 1</B><SUP style="font-size: 85%; vertical-align: text-top"><B>st</B></SUP><B>, 2008</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>35
<FILENAME>h03611exv10w17.htm
<DESCRIPTION>EX-10.17
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.17</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.17</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Agreement Regarding the Transfer of Equity in<BR>
Aohai Radiotherapy Treatment and Diagnosis Research Center</B>
</DIV>


<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Party A</B>:</TD>
    <TD>&nbsp;</TD>
    <TD>Beijing Our Medical Equipment Development Company</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Address:</TD>
    <TD>&nbsp;</TD>
    <TD>No.&nbsp;3 Qianmen East Avenue, Beijing (Room&nbsp;408, Office Building, Capital Hotel)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Party B</B>:</TD>
    <TD>&nbsp;</TD>
    <TD>Shenzhen Aohua Medical Services Co., Ltd.<BR></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Address:</TD>
    <TD>&nbsp;</TD>
    <TD>Room&nbsp;2208, Dianzi Keji Building, Shennanzhonglu Road, Shenzhen</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Party C</B>:</TD>
    <TD>&nbsp;</TD>
    <TD>Chinese People&#146;s Liberation Army Navy General Hospital<BR></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Address:</TD>
    <TD>&nbsp;</TD>
    <TD>No.&nbsp;6 Fucheng Road, Beijing</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Upon friendly consultations, Party A, Party B and Party C have reached the following agreement in
respect of the transfer by Party A of its equity interest hereunder:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A and Party C entered into the Agreement concerning the Establishment of the Aohai
Radiotherapy Treatment and Diagnosis Research Center on 19 September, 1995, wherein are
specified their respective percentages of equity interests in the Aohai Radiotherapy Treatment
and Diagnosis Research Center (hereinafter referred to as the &#147;Center&#148;).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A, Party B and Party C each hereby confirm the foregoing agreement and all matters set
out therein.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In order to facilitate the management work, improve the ownership structure, and enable the
Center to achieve better operative results and procure the Parties a satisfactory future,
Party A hereby transfers for free all of its equity interest in the Center to Party B.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party B agrees to accept Party A&#146;s transfer of such equity interest. Commencing from the
effective date hereof, Party B shall enjoy all of the original rights of Party A to the Center
and shall assume all of the obligations originally assumed (or to be assumed) by Party A
(including all of the rights and obligations attached to such equity interest prior to the
transfer hereunder).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party C agrees to the foregoing transfer.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall become effective upon execution and sealing by each of Party A, Party B
and Party C. This Agreement shall be made in four originals, with one copy to be held by
each of Party A, Party B and Party C, and one copy to be submitted to the relevant authority
for filing. Each of the four copies shall have the same legal force and effect.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Party A:</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Beijing Our Medical Equipment Development Company</B><br>
(Corporate seal)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">Representative:</TD>
    <TD>&nbsp;</TD>
    <TD>(Signature)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Part B:</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Shenzhen Aohua Medical Services Co.,Ltd.</B><br>
(Corporate seal)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Representative: (Signature)

</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Party C:</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Chinese People&#146;s Liberation Army Navy General Hospital</B><br>
(Corporate seal)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Representative: (Signature)

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Date: 5 May, 1997</B>

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>36
<FILENAME>h03611exv10w18.htm
<DESCRIPTION>EX-10.18
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.18</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.18</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Supplemental Agreement to<BR>
the Supplemental Agreement Concerning the Development of<BR>
the Aohai Radiotherapy Treatment and Diagnosis Research Center</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="25%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="70%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Party A:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chinese People&#146;s Liberation Army Navy General Hospital</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No.&nbsp;6 Fucheng Road, Beijing</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Postal code:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">100037&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Telephone:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">010-68587733&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Facsimile:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">010-68581507&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Legal Representative:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Duan Yunyou</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Party B:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Shenzhen Aohua Medical Services Co., Ltd.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Address:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">17/F, Guomao Plaza, Renmin South Road, Shenzhen</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Postal code:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">518014&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Telephone:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">0755-82211708&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Facsimile:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">0755-82213690&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Legal Representative:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Song Jun</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Title:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Whereas, based on the development needs of the Hospital, in order to help meet the demand of the
Hospital&#146;s Neurosurgery Division and the Head Gamma Knife Center in their carrying out of
diagnosis, examination, stereotactic location and treatment for epilepsy and related clinical
research work, improve the treatment effect for epilepsy, and further enhance the economic results,
the board of directors of Aohai Radiotherapy Treatment and Diagnosis Research Center has decided on
the meeting as of 4 September, 2004, upon deliberation and consideration, to make an additional
investment, namely, the &#147;EEG Stereotactic System&#148;, as part of the third phase investment of Aohai
Radiotherapy Treatment and Diagnosis Research Center. NOW, THEREFORE, the Parties agree as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>In accordance with the relevant terms of the Supplemental Agreement Concerning the
Development of the Aohai Radiotherapy Treatment and Diagnosis Research Center (Contract
Number: 2003-S-008, hereinafter referred to as the &#147;Contract&#148;) dated 27 September, 2003, the
Parties agree that Party B shall contribute one set of EEG Stereotactic System (valued at RMB
Four Million) to the third phase of the Center in addition to its earlier contribution of the
four sets of radiotherapy equipment in an aggregate value of RMB Eighteen Million Eight
Hundred Thousand (18.8&nbsp;million) to the third phase of the Center, to the effect that the
contribution of Party B to the third phase of the Center shall be in a total amount of RMB
Twenty Two Million Eight Hundred Thousand (22,8&nbsp;million).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>There shall be established a relatively independent Epilepsy Center, the management work of
which shall be assisted by the Head Gamma Knife Center and the Hospital&#146;s Neurosurgery
Division. The personnel of said Center shall be</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>treated in a relatively independent manner and the finances of said center shall be
accounted for independently.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The responsibilities of the Parties, the term of cooperation, the profit sharing arrangement,
the management body and other matters in respect of said center shall be governed by the
Contract.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any matters not covered herein shall be separately dealt with by the Parties through
discussions.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>This Agreement shall be made in six originals and shall become effective upon execution and
sealing by the Parties. This Agreement is a supplementary document to the Contract and shall
have the same force as the Contract. Each Party shall hold three copies.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 8pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Party A:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Party B:</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chinese People&#146;s Liberation Army
Navy General Hospital
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Shenzhen Aohua Medical Services Co.,
Ltd.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(affixed with corporate seal and the
signature of Yunyou Duan)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(affixed with corporate seal and the
signature of Jun Song)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">15 September, 2004
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">15 September, 2004&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>37
<FILENAME>h03611exv10w19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.19</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.19</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Supplemental Agreement to<BR>
the Cooperation Contract Concerning<BR>
the Aohai Radiotherapy Treatment and Diagnosis Research Center</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Party A: </B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chinese People&#146;s Liberation Army Navy General Hospital
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Party B: </B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shenzhen Aohua Medical Services Co., Ltd.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Whereas, Party A and Party B entered into a cooperation contract on March&nbsp;18, 2003 in respect of
the third phase of the Aohai Radiotherapy Treatment and Diagnosis Research Centre, whereby it was
contemplated that the Parties will cooperate to make investment in the whole set of equipment for
conformal radiotherapy and intensity modulated radiotherapy (including the medical linear
accelerator, the multi-leaf collimator, the CT simulated stereotactic system, and the 3-D therapy
and planning system), that all of the funding shall be provided by Party B, and that Party A shall
be responsible for handling the tendering procedures for the equipment and the construction work of
the equipment room and therapy rooms and other relevant matters. Thereafter, due to the impact of
SARS, the progress of the project has been hindered. NOW, THEREFORE, in order to procure, as soon
as possible, smooth progress of the project, upon friendly consultations, the Parties hereby enter
into the following supplemental agreements:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Considering that the investment funds raised by Party B for the project constitute
purpose-bound special funds and will be made available only until 31 December, 2003, after
which date they shall be forfeited, Party A shall duly complete the tendering procedures for
the equipment by 20 December, 2003, failing which Party A shall assume the liabilities arising
out of the non-availability of the funds of Party B.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Party A shall complete the construction of the equipment room and therapy rooms by 31
January, 2004 so that the installation and commissioning of the equipment will not be
affected.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Supplemental Agreement shall be made in four copies. This Supplemental Agreement shall become
effective upon execution and sealing by each of the Parties and shall have the same legal force as
the original contract.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 8pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Party A:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Party B:</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chinese People&#146;s Liberation Army Navy
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Shenzhen Aohua Medical Services Co., Ltd.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">General Hospital (Corporate seal)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Corporate seal )</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Representative:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Representative:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(Signature)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Signature)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Date: 16 August, 2003</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>38
<FILENAME>h03611exv21w1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Exhibit&nbsp;21.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>SUBSIDIARIES OF THE REGISTRANT</B>

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Ascendium Group Limited (incorporated in the British Virgin Islands)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>China Medical Services Holdings Limited (incorporated in Hong Kong)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cyber Medical Network Limited (incorporated in Hong Kong)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>CMS Hospital Management Co., Ltd. (incorporated in the PRC)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Beijing Xing Heng Feng Medical Technology Co., Ltd. (incorporated in the PRC)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our Medical Services, Ltd. (incorporated in the British Virgin Islands)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Shenzhen Aohua Medical Services Co., Ltd. (incorporated in the PRC)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Shenzhen Aohua Medical Leasing and Services Co., Ltd. (incorporated in the PRC)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>China Medstar Pte. Ltd. (incorporated in Singapore)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Medstar (Shanghai)  Leasing Co., Ltd. (incorporated in the PRC)</TD>
</TR>

</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>39
<FILENAME>h03611exv23w1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Exhibit&nbsp;23.1
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Consent of Independent Registered Public Accounting Firm
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We consent to the references to our firm under the caption &#147;Experts&#148; and to the use of our report
dated October&nbsp;16, 2009 (except Note 26, as to which the date is November&nbsp;17, 2009) in the
Registration Statement (Form F-1) and the related Prospectus of Concord
Medical Services Holdings Limited for the registration of its ordinary shares. We also consent to
the use of our report dated September&nbsp;3, 2009 with respect to the consolidated financial statements
of China Medstar Limited also included in this Registration Statement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 24pt">/s/ Ernst &#038; Young Hua Ming
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Shenzhen, the People&#146;s Republic of China<BR>
November&nbsp;17, 2009

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.4
<SEQUENCE>40
<FILENAME>h03611exv23w4.htm
<DESCRIPTION>EX-23.4
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-23.4</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;23.4</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">November&nbsp;17, 2009
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Concord Medical Services Holdings Limited (the &#147;<B>Company</B>&#148;)<BR>
18/F, Tower A, Global Trade Center<BR>
36 North Third Ring Road East, Dongcheng District<BR>
Beijing 100013, People&#146;s Republic of China

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ladies and Gentlemen:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We hereby consent to the use of our name under the captions &#147;Risk Factors,&#148; &#147;Enforceability of
Civil Liabilities,&#148; &#147;Regulation of Our Industry&#148; and &#147;Legal Matters&#148; in the prospectus included in
the registration statement on Form F-1, originally filed by the Company on September&nbsp;3, 2009, with
the Securities and Exchange Commission under the Securities Act of 1933, as amended. In giving such
consent, we do not thereby admit that we come within the category of persons whose consent is
required under Section&nbsp;7 of the Securities Act of 1933, as amended, or the regulations promulgated
thereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Sincerely yours,
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Jingtian &#038; Gongcheng
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Jingtian &#038; Gongcheng
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.5
<SEQUENCE>41
<FILENAME>h03611exv23w5.htm
<DESCRIPTION>EX-23.5
<TEXT>
<HTML>
<HEAD>
<TITLE>exv23w5</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="right" style="font-size: 10pt; margin-top: 18pt">Exhibit
23.5</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;Frost &#038; Sullivan Letterhead&#093;
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">October&nbsp;16, 2009&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>PRIVATE &#038; CONFIDENTIAL</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="94%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">To:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Concord Medical Services Holdings Limited</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">18/F, Tower A, Global Trade Center</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">36 North Third Ring Road East</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dongcheng District</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Beijing, People&#146;s Republic of China, 100013.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="86%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Re:</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Concord Medical Services Holdings Limited</B></TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Consent to References to Frost &#038; Sullivan Report</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 16pt">Madam/Sirs:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">In connection with the proposed initial public offering of Concord Medical Services Holdings
Limited (the &#147;Proposed IPO&#148;), we hereby consent to references to our name and to the report,
&#147;Understanding of China Imaging Diagnosis &#038; Cancer Radiation Therapy Market, 2009,&#148; (the &#147;Report&#148;)
in the Registration Statement and any other documents in connection with the Proposed IPO. We
confirm that your references to the Report reflect the most recent available information.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="6%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
</TR>


<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR>
    <TD colspan="3" align="left">Yours faithfully,<BR>
<BR>
For and on behalf of Frost &#038; Sullivan<BR>
<BR>
&#091;Seal of Frost &#038; Sullivan&#093;<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Glenn Xuchao Hou
&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
      <TD valign="top">Name:&nbsp;&nbsp;</TD>
      <TD colspan="3" align="left">Glenn Xuchao Hou</TD>
<TD>&nbsp;</TD>
</TR>

<TR><TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD colspan="3" align="left">Consulting Director, Healthcare Practice, Frost &#038; Sullivan China&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>h03611h0361100.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361100.gif
M1TE&.#EA?0!B`,0?`(K(QT^LJL7DX\3CXXG'Q_'X^*?6U=3KZB&5EFRZN:?5
MU2.7E4"EHVNYN7O!P.+Q\=/JZC"<G5RQLN+R\7K`P%ZSL3&>G+;<W#^CI)C.
MSK;=W)G/SDVJJQ20CA*.C____R'Y!`$``!\`+`````!]`&(```7_X"<^!&>>
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MR,@`AHNDQ-J2P2$1B$[2J:)XZ\@`A%H4_T3YM:6`QS3G0DH<2?'3@`+-E!3,
MF4302Y!*1.HD6=*BFR^19F3;0N=GL'D&I1&U^6&C%B@TRE5Y]<%I3)V-UG`(
M570B2:H?,#KAV@(>J)@S4"+J698F-9,B_&FA,PDIW+8\YQ914*^@*+1NM0AJ
MH5;)XJX`XPK667@J7A%O6KKXPA>RE2M:)Q>I?/9R72?C/K#<"C)*@0$7"%P8
M0+NV[<Q:2-<T_8$4Z]Y;L/ZE^%*)[KM&^VZ![??I0Y+%DQP7.F"&EX2X[7I^
M3CR1U-+)6X16$AB)RM;0O1.T'%[$TLED:'@]%AW)])D>JM/P/5>X\X_I+??=
M;NU]M4=2_\%$G_]Z9A$X&B&"W3/?+O69-"!R#]8P'ASGR1=9=P*N!UZ&-,@%
M1WPU3&A+A19=2%T4Y244A8JKL#B:B_CI5\-J</!C`XVHV$C$??@4V,)U<+@S
MXX<+AM@@AD-*P<$>':;()(4,:I>C%"9N@<`U2WX&8FXX%DEB#3BQH5"8W#5)
M9D,$Q"GGG'3624!V^96!IQ8^LCFD;8`&*NB>7(BVAXXV6+6%DE((::@1[FSX
MJ!.(VM`8:G4X.JD'4"BZ*:5U=*D$F(U^NH6/0I@*:AF)5;%FJ:HJX1\/F-3Z
M0Y^--E*I#0K8ZBL,51(E[+#$%FOLL<@FJ^RRS#;K[+/01BOMM-16:^W_M=AF
MJ^VVW';K[;?@ABONN.26:^ZY(@B@[KH'4+3NN_#&*X`(`-1K[[WXUFO#`?"V
M*TF\(DR`+RH&=&#PP0!0=/#"##?<@0@.1VRP#0$P'$`G"S!\C0`,.Q#`QR"'
M+'+&##,@\LD@VR#QRA"OW##%%G=2\<+S<KSPS"[GG+/*.C/<<L\/UX"SP1=_
MD&^^0W<0```)6`STTR_7`/7$'T`-\\T_3^VTUE;7D*\%#">0;]8=,``O`SX+
M'7/57#/,K[SO:D#RP1;`;;<D2<_+\\%%MY#TU7R3W;8D`#2L`;)Y1[&VWVG3
MD'31;6\=N<YX,ZRWU%C/\'<-;[-+MLDGH[WP_P(H3]YSY30KGCGC"Z-B^;X,
M6Z"VZ3M[C2_8"XM]KP%D]RW"YND>#8#>K]LPM\&D_DY[[31,#?GJRK?>0N$.
M)\SVP9?34`'#AW>R/<.\$^M\[XXW;G3$UA?O-</6!VR`\$TSO(#P]-^[-]#/
M!ZZY^=0WG/["H`L9[VRFOP\4@'3+<]G]>I8_HI5/>O1"G^#\)SC&)2V!YIO>
M[<*&K_`M+GH'F\$$U+4!]DW0A!\0W<':1;T+8C"$@TC<`GWW`>#-@(`&^]_*
MK.<`AFV`@.^KU_<<YH#Z.6QI]HNA^IH'O1IF,%THS)GU"K:P"LSM`Q/8@`H;
MEH`ZQ(]]R;-=O>:5./^1D6]_$+QA%%.'0^M-8&5?C%@7`]:O@$DL``D('Q-S
MZ,34I>V#?80A#7#8`1T:K&8+:Q_NC@C'&?3/@2*@8L1HF+6$)>Z/3;1A"PAI
MR`X@$F$M&&+#7-B!!71O>A^4Y"CO9\G78;*`(*3:(->(O0^TL04E=)C)B!C&
M\S51`(ML8B4#><CK40V0FH1B(LGV23XJ4WX'&-H"'#"!*#Q2:38PP.-824Q/
M&C-HR'RB+6E9S%NVP&&\J]@"*L`[CX',`8Y<7!P[4``-`*`"`8`GYOAX2>F%
M,XV;)*<WS3G.CD4R>SU,XS7[-C1*<K.?,/RG(-6XS&\VLY`B.&##-A`%57;_
MP%^^+&#8)+%,B!XSD^+D)#,+ZDP7SI%SX$-EYMY8T3J4U)7^1"E`G^G,U]WR
MFG23`@I#"DD-+%&HH#0I.'4ZT8!6U*?+7%DO8]FWA49P8=4<Q$W]F%-8=M,&
M*K4H2S&ZLE-J;W0RU9\H@Z;5I.(THDR5)45!*=9;CFZH+3A`0A<&)JM^()AE
M,\!49[#56KX2DJQK*D\Q6M>H&FP!'KW8".\)V!5.\H1*`\`&0$I8MW(5KEY-
MYE@9"U50'NQP+P/J2"^;0I<YM+#%/&S9SI92@5XT80;39](.H-J#S9&U!=CB
M*O>)4:5B-F)@U=EMJU95'_:6L=\L8`'V.MP]%O>M0B<%6G)SMMP%D(J0%5!M
M`K)Z0AH*P(6O]:QANWJZ&A`R8LOE;`%BUS\+L+.7K*6!7K>87GYB=ZG:=:]R
)Q]J^&0@W!``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>h03611h03611146.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h03611146.gif
M1TE&.#EAT`*J`^8``-'M^U5,4]J-/PN;FR08(+#9\HJMV?S[_D5';7B<SI*2
MLJJ7EW!03'1UDO3IU6N,C8IR<+K'V^#0L$LM+6JNM._^_S,O1V^)M\NXL]C;
M[>O;ULK(VKF[V,ZIF,W6ZZI=,[WG\&-88X>:S%=GD[JYRH1Z@S-);FIC9+FV
MNLC.YG=U>:JFJ,K'R>GIZ4`[5X]G4\>\R&EXJ)_)[-S9VH:$B(U7292ZY:FJ
MRIJ5F+:KJTU6A*2;J>;L]Y:'B:QG0I&IKV3#S:NJMWAJ=65`.VMW=W5E:MG+
MR;BLN-%Z+MC-VB9L>YR,E+NFE8>'FJJWV6EI=B^#=]_6S*NWN:FVRU"GJ%AS
MH\S6VOWXXOCNZ[:MR<5U1'E<5%.9I9;6WX,P*D^)D55F;L";D-C>]Z*KUJ!7
M0Z-]:NC>ZKZUJXF5F*[`XTAN3C6DH6%;A<7B^-;.YY^<P:21???O]V5X9=Z_
MHYREI'A[6.SW[VR@HIZUM)))5KM67`"AG&AG9;SEZV/(TNWX_B'Y!```````
M+`````#0`JH#``?_@'Z"@X2%AH>(B8J+C(V.CY"1DI.4E9:*0)F:FYR=FQ1`
MH**AHA2FIZBIJJNI=Z:N=["QL[2UMK>XM`]WN[V\O`_!PL/$Q<;'R,1$P<O-
M#T3-T-+3U-76U]A/1-I/W-U/?.#A?.3EYN?HZ>KK[.WN[_#Q\O/T]?&7^/GZ
M^_S]_O^4/`GD-*H@J5"D2K%:N`H6!5</'<:*&#&715R^=OW**&QCLH\@BSD;
M^:QD-&C/3J;$QI(EMVU$^,2<*;,F.7'B[.G<R;.GSY]`WP$<2K2HT:-()0T<
M""I34X,*$R9D2+75*XH3+VJMI9%KK(P;@84<^W'9,+,DTT9;V;)M-CE$_^2\
M[+:M9C<YX_(&W<NWK]^_\Y(*'DRXL&%'2SLU=<H8JL+'51=*O"IQ5L6M6L%^
M#=NK8S"Q9,F:-<FLM%JWJ-W*A,9-;LV9W<KA!$R[MNW;/`_KWLV[-[_$`I\V
M1N@XLG%4$"M7O(RY.=C.'D&'GJ[,-&FU*=FF3KT:IK>8X)ZXUHN[O/GSY7VK
M7\^^_2#@3(>7FFJ*_G&K#K'*VM\\<UC.'E$GX%FD77<=2@B>M%UJVM#DH$SB
MS>9:3NA5:.&%.KFGX88<'@6?)L(A1-R(!=5W7V3)/:0??_UY=<MS``XHFC'.
M&(C6-=HMV%)W<W$3CC8WG4,AAD06:20Y'2:IY/^2E7SX"6,D$@?9B:Q,IJ(L
MR[5X$8PQ%B.=C,B@59)UV*VEXW;=0>C:@S'E%=Z1<,9Y(9-TUFEG(4YZ(IQC
M4MI'I557KJAEBS`^!Z:,8J;%UJ)GHL:C=][8A=>0Y,EIZ:5[W:GIIATZN=@H
M49KHYY_(!:I?EH-:I%FAG1TZ8XV)'LAHHZ@UJ"8X#L869*68]NIK3YP&*ZQO
M>8H()50'S4>J9)2MR%RJ7>G2)6@!NEH=C63:J&".M%:SFER0U@4;.6T.2>FO
MZ*:;SK#LMCM8L<.%FNRR59JJG&6I8O1?C,!4:^TQL=IHTC39==O6HQ&^9E<Y
MY:KK\,/MN"OQQ`!YJIC_?'TJ2Z\J*6*9KW/\<O3O=+`:.#`UW!HLC39P]0@>
MD+-!+//,Y5!L\\V7P#MBJ"5NC)^*I^+[\8N_S&*H6/V.#'"!`F^;H,IOP:3P
M@^(TS"O-6%N*\]9<(Y;G8B(B*ZJ)/I<::%9H#QWM9JQ"I[1(2S<]\*Q03]/R
MRN'&!AZYNV;M-Z9=!RXXGO""*O:4/EMY;]I#LUUTR%^^?6W)35>3<MT-@IMP
MKE7+ELZY?X=NWN"D!VXQ01@K.V_95YW-8N/ZLNJOY&%F6Z8TEZO<FLNXVG2U
MZ,!C6/KP..ML.(D]LW[V*QXS#CN`7;8J/>TF*ZH2P75?`^[*:RH\V][F@![\
M__B`$6_^Q,6"O2?R&2L/].*O0QL[9R)3/QJ!L<**._;94_.:R^&0&H7$1[X"
MEN]\"!R6\<+&LU'12W%7VL^SU`:Y^E%O<F.2&X(*UC]J-$@:4UM8.2;D.0.:
MD#8)3"&G3O<D>8T-<0]LEO.>1[2C&>J"<-,@CCHX#2"Q9AO>B-#>"'C"(@9%
MA4BTTP+7ISKWR9!YSJ(AOT*&PZ51SGHC41`/MP>-$+YL5^,QHACYDL0R+BE]
M+3Q<^Y37L2A*T18VG-W;[D<@'3Y-B_U[3=YVAQ>]$'&,@+R'&0>YH26F;G5L
MM%<$445#+MW0,S@,F/560C<>PF0:7OQ1D-X4R$[FAO^0H&0/"T%TR!<ZD%1M
MG"$%:UC!*F(K?V,RT_XL*37O`%%<"^MC"3W)2WB$\I?$*AP#2R0E]RFN>?'[
MF&:HZ,KJU,B.LJ0E%]D$(5UMLI?8E`<PMZD;-)+2A<1T8BHE^$:C43%Z<XS;
M)/'(SKK]+V_><U/XLDE/='#SGH0Q)#A/B4I%(G."RGS<M)I9QRMJ*T&YTYW_
MJ,G)/OZQGMC$IT21,LIC-5!CB70=0/.UM@K2CZ`%U6$E.^A#`+YD'&V"J$KM
M.=&6#D6??()A#/.#-D8^;YEM@V0D"[3..R;48-/,9$YF0ZF'KM2$+DVJ/[QI
MT9@BLFSCM.D;96=!R='1.@+_J^1/::7'[]!%35<SZE%/J-2RZ@.F%Q6G/]W8
MR/_DE*`!$VDT+?G!+C(T9N`;*T3-RE=+5'28[,,HZZ):SHXZKE!RW"DT44;+
M6@*0)C'3ZTK[2EFE").)R>+GGX[)UK8B=GH@)4DLM36WQL:EKEYL:,S$*ED#
M5O:U7ALE9ILHTWYJ5&CE/"PS[:?.ROFTL>_T:@!U%=F^M1:0L$TN)BY;RMKV
MDZ:+Q&WC'#G0SU11DKX=*4D7.K6$!2F,QXVH<L=+./B`K:F!?6KB9)C,W-K0
MNB`51LE$.]>M-JJD\/2A<7\7WB*2][^"0&LX-4LESJ9MHQR%WGOARK2>(M2T
M0643_R?EV5_Q`GB\3`7L@,F64?@A&&2L?&1B7775TFB06_8]4U=O>1=O3&J_
MK*UPUBY,7@$'5JW0_:<4<3K0R%D5J[!T6CLQQ]U<^7&_,D8NC97[U]EFEL.#
M9>^';]KC^.9PG1R\XW97\QV4>C?&20[>DIG,W(L2^$0&)N=4W8K.I.UTO@?5
M;O\B'%QYDI"_81X?%_;,YS[[^<^`#K2@!TWH0AOZT(A.M*(7S>A&._K1C?X"
M%R1-Z4E;^@N8GO07'H!I3G<:TYO^=*A'S6E/FUK4H`YUJ3_M:2)\P=6P?K6L
M8TWK5V</+D0``S1TG>M>Z_K7OO:U',`P;#`8^]C(3K:RE__-[&8[V]@A@#88
MHAV":E/;VMC.MK:WS>T`A,#;X/[VML--;G&'V]S8]C:WLZWN<:_[W?".M[SG
M3>]ZV_O=`3!!OO>M;W[[6]_]!OB_!R[P@A/\X`9/.,(7KO"&,_SA#H\XQ"<N
M\8I3_.(2W[?&^QT`!`1@XQ_W^,=!'O"1<US?'A=XROV]\I*/_.,F<$$`9$[S
MF<-\X#77-\U=L',7Q/SG/@]ZS(,N\Z$7G><S'_K,>\[SIB^=Z4B/^M.=7O.F
M6_WJ5,>ZUK?.]:Y[G>L6P'K8OT[VLIO][&CW^M2U_O2V9]WF.X>[W*L^][K;
M_.,RQ_O(\W[WOK_\[X#GN][OGG?_P0L>\(A/O.(7S_C&._[QD(^\Y"=/^<I;
M_O*4/_S@^Z[YRA>>\9W'_.(-O_>7AW[S?M^\YFN>^M%'_O!TIWO=92_[UL]\
M"*5_O>M%S_O>^U[QL5_Z!%PP`0M8H/C'3SX!+$"`Y3?_^="/OO2GW_RH6]WM
M<<^Z]6?/_>![O_O@9SWM]<YZSN?>_*@//.)/__OVN__]\(^__.</?[Y__N_W
MM__@RS]__0/__/07@`)H>2XP!`5(?#,W?,57?-37@`[X@`2P>09(>!-X@`"8
M?X2W?P-H>O^'?XGG?Z%'>A[X@2.8>NRW@2B8@BJX@BS8@B[X@C#H@C*G@,:W
M@,S'?!"8_X,.F(&D]WGEQW\Q&(1".(1$6(1&>(1(F(1**'\]1X,,.`$Z&(74
M1X*-=X)+>(58F(5:N(5<V(61]VV(!X8C)X;F5FYFN&YG6&WJUF[BUH9KB&YG
M&(=BJ'C#EWP,R'Q0*(5Z&(&/9X5>^(>`&(B".(B`"(9S^'=E"(?HMHAO^(9N
MJ(:0N(CQEH;NQF[W!F_M1F[KQW,38(-0F(=[J(>$.(JD6(JF>(KQ=XAA^'&&
M>&YLZ(CN5F[6)HN6B(:7>(NXF(N6"&[X5X<+Z'S`&(HZB(K$6(S&>(R#2(:L
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M59F5`:F5'0F2/^F,[`B6B+EM;*F8:#G_EF<IEF89F8U)EI(IF9-IE(XY;J:G
MC5`HD7+Y@'49FD[)EU3IEWBYBC49F.5(FH(IC3X9DEZ9F+(9;VI9F9=YF[:9
MF[BYF[JYF.F&=T-@AP3PB9\)FJ)YG"L(AU"YG*O)E\SX<N88E?U8AC@YF.P(
MBZZ)G;/YE6K)F][9F]_9F)$)F65Y`N5IGN9YF>B9GIG);GL'E\5)D<@YGQO)
MFLZ)FO=YFM2YEZ08F(FXAJW)E8.YG02*EF<9GN"9F^=)F92YG@M:G@WJH.C)
MH.M)H>39G6HX<@K8F;\8GPU(GR#J?J7YG'GYG/OYGV-HHGYYGRNJA?Y)HH;Y
MD>LXHP5:H[?Y_Y@(BJ`26J$\ZJ`1*J$_"ID6>J$]NJ,4:J#/&``&R)F>Z:%S
M&:)0>GFG"97[.96K*)7XV:)5*H2`F:($B9/:UI':::,-B9DYRIXZ>J%!RIY$
MNJ-NZJ-PVJ9O.J=SBJ09*GPL29Q.^J11VJ>^=Y-7&H<J&JC*R9S0280S29HS
M.J#7V8YD"I:U>:;B*9Y&6J1T>JF8FJF:FJD,^IM*RJ2=N:<?ZJ>DRGA/B9>%
M:JK2F:HE:II>FH)ZV9==ZJBRJ)./6I*1JJ!G*J1`RJ:;^JO`&JS"VJEWFH"=
M^(2BRJ>ENJPRF9\KJHJS2J(EFI4M:JCDJ)<WN970V*B'>:ME>J`)JO^C:\JF
M#3JDPGJNZ)JN;XJD&LJDPYFLRBJ:4&=U86=\]AIV?CJE_+FECD>M&'FH(\JB
M_QJ=!*N5Z7:PW>JM\&BFX9J@O/JPZWH"8ZBN%%NQ%>NI2WJL[\J-\,J'QUAU
M6E>O+G"OQF=_)&M\SF>ORX>R]^J',)F1U%FE)UJ=_`JP`_FJA[J<^HJ:@"J)
M!+F3KZBP\MBPDNJKYAJL8DA\+C"N%MNT3FND=YJQ*]FQTH>$\]IT]7JR6DNR
M*YNR7GN#8$L`-,>R7WN#74NV)1N:L2JP5"J=D^>OJOJB.6NM*AJMZDB+CBJT
MU<BP16NN3$N>1SNL@#<!3UNX;EH$)U`$BKO_GHMKGHV+N(CKIM;&`!KZEL2I
MIU3+@>0'=V4GLEO[N?>:LF8[NF5[ME];NBP+MF&;NJE[MJSKNF?KLA4)D#:;
MJE)IM]7:MM$YM_A)E<J9J#EYMUVIM_;6GMC6L.,9H7X;IX9+E!^7?'CGM)&[
MH].+GI#+N(F;O9"KN-S;O7S0O8K+!XD;OMK+O=E;H5'[EL?WBTW:L3C8I)[Y
MOLU'NO1[NO4KD?2[NJ*KOURKLJW[NO[+OZNKNK"+ML.GD=1*N_WJG#NKN_PY
MK:Z*HJN9J.EHJZY)F`E+O-S&ED1;F;XZH9;:O)B:H4[H;70ZE-7KH-N[PN#;
MPB[\N"S\O44@PRY,_\/=.[[EV[CI6:P;FJ?O2K7S:[H!_+^C>[_V>\1H:[_Y
MN[+^*\0#+,10C+9/',"N"[;\V,`X.\%7.;?_V:7-NKMTVYS`*Y"%B;<:7+Q]
M.YYR^L$B;+%@:`$!@'P!(*>(VW9S_&UY5[XV3,,VS+U]/,,O',B"/,@WO,-@
M.`03@,C'VJ%`')%(',1%7,11_,C\.\E$C+I.7,!,++I5K,D$?,GX"HZT&[`Q
MVYRMZJI9'+</[,!RB[NS>L;4V,$_.J06^K=M++@)",<L:0$2VKVYW)GPN[3C
M2\C$?,-_7,S(/*$A0+D?MZ3"B;E4:\13S,E)[`)*<,W8G,W:?,TFL,U*T/_-
MV[RZUKS-X,S-V#S%D;S$%N#-Y'S-(UNV+@`&UPP&4*`$]&S/]7S/^IS/_(S/
M_FQL2:B?O%N[;HO*=2NHJ[K*-JO%T\B5M@C+&XRC$.K!;$RNS'O+FYK")QP`
MRM?1!("]ZQG'NQS$T,=\2[NX+#S(?_R].8S,+CV]RSQR&;O([1O-E(RZ4ZP$
M`[#3/-W3/OW30/W3)A"V.AW40#W4`IS$H6M\16W4/JT$K+O.3CW55+W32F"$
M-#FBV5JM6.J[N:O*IRJH=EN0>0O1UL:WR%NI1HO1%7N]UZN]<)V><8QW=^A\
M#5J](3"RR`>,-0W'CNNXYANDX-O++UW#A*S,#(#_>[B7E-`<S=(LR4J]LE4]
MV49M`F?;U%4-!0.<OU*\?)1MU::+V9_]V5=MEZ8,LQ`,O-*:HKC;ME<9C65-
MHX4)T;)LT9++UNFZO7^-TG%MOH#=PGB,O_(+C,-WOA,JTLX7JAQKMG6XF4CW
M<2H<N7<]O=PK!'P@!$6`W=;=O=J=W=[=W>"MPS'=S):KC3_<R)",Q.I,U*/=
MW@-@V68KVE2-U#B-TRXPVE`MNN[=WJ6MA*5INPK=K%LL>:4\DS)ZX!KLFQ)=
MM!,-L;A]N'2:TGU,P\8=W11>Q_';?+\(BN\+W1++T1!)W.\L?2C[?)X(D<>'
M='\M;MDK!-BMPXK;W3'^_]TTKMTO_N(52KF*W<.=B-XE;<DWC;+WO=^?#=_V
M*M]3K034C,[L3=J;;`)$3MHH*-"`:I^N3="[*[,T*ZMI>)@_>\8</)EI;,L/
MGJEN_=MPW<(RO.;AV^;6R[`X+-<LZ<A\G=X,.+_/R[XFOGQW_N,.6-/0QW?%
M)W.5:*`N_MTV;N-/D-TO#M/C;8"*/-(^GMZ0O>343`!('N5!#=_.E^E.3<6@
MK-_XG;I0KNE5W=]#B*T)#:U?G:4![K:&V-!D/*8VJN`+WL%K'+AE_J9O#;['
M?,R!;)XSMXW)E^)\![;(U^<D#7TH7M?R.]S)+NET'HQV2'S4/N<ZF.+>5N/@
MW?_=Z,O,0S#3/CSIZJS>L.OI0FW.V0S.Y:SN4-WD11[%D(VRI4[:\$[5]7S-
M^:[OV[SO^1S0#ASP!UVH6N[*.EFKL)R98>ZPE`K"#K_KU'N^*#W8WMOFA3W8
M>;V`>:>&Q+>^4SOHR!WB10SB=>WG.`C,!QRJTQZ1=SCHYJWRW2AS)^#B-D[C
M;\T`,;W8G,FQY`[DY7Z#Z-[34!"71+_RJ1OT0*W9JMO9`0P%_$WJE(W%6*B:
M.1O6_[K0JCV-9FS6!HJ\LPSQP7KF%0_(9._'%Q_((,YWZ8F`8]CQPWGR;R^Z
MPQ?W)J[7,^BU#0C'K)CWSH>`8AD`1?!MN(?M+3D!<QS_XS3OW8BMI$IJN>/>
M\\^NQ/6-]%:]].F\U$W,?)3_TTE]OQ;@WN^.LIL_`%(/@PI<T*N]U0R-T+^+
M\`F;P0E_UD=*T;4,]A&>YBD]]F=_]GD-;CRGA@>,W"Q_Q'FHUV+;UP>H["3>
M?&)8]-0NMG@7`HH[<O@;?8`^?9<+^(=^Z#`-[G&LOCP/^:&.SIU>U7N@Y-),
MZ4LNU4]_Z9\[^CT=^L97[U1=^O/'ZFRKRJPMX`,+"`$A`8*%@X<AB(>&@HF.
MCY"1DI.4E9:))R&9FYHGG)^>H:&=HJ6FIZBIGD4GK*6N1;&RK+*M17RRN+&Z
ML[V^O[]"LD)/0L+%1<9%(2Z$_\XN$P'0%A,6!-<6U-;6!-O=W^#>W!/0!.3>
MU^GJV!::$^#K\>83T8,NU/+Y^O'OT<G_L3*%8,`@P!"#].CAV\>P84-QWR"*
MDVA-R8"+&#-FA"(Q8K>)'T-6U$BRY`".V5*JC)BM&Q23,"\J66DQ9L9!SG+J
MW,FSI\^?SG#F%/IS4:&@.Q<99:24*:&FBA(9BGJIJM6KDSYIVJJU:Z>OGDBI
M&DMV5:NSIV@%G,4+F-NW<(,E>Y*,V#]AQI0)L=<L`+EIU0!+J_;.VKMTW,+)
MT];2H;IHB?=5ZQ:`&J%RD1TWI&<N`,"P!)T-@:90L^G3'BFR7-W20DV;`V:F
M%KF-8O]MU[!-MF99^Z,%$[E+SE0)/#A1H,B3*]=Y'.E0YCR;]FR.L_K41HX:
M3<7*O;M53IBXBN^ZJ;S8LNA5J3U+RY:O5FW;QIU/OQ?>^W?SYJTK3-HT;92=
M8)E?'LV&3F2965`./(Y-YM!"]U`S66&H.=1/`&@E4M!!T1"64(4@+B:2@:JU
MAEMNLJFD8F^VM?1:<!@-YYN)(KT(8VPTP=C<<CSV.)US0";%B)!0.275D4@R
M195W3'+GU9/CG3=*6.E5:8HK9K$%C'SU=0D7,?L!!*9^?.RG'W_Z"3,(`]5H
M0\YE.?4U66;8K)/@8PLQ&*(^%"*FIV-TFI-80O4,5)!!""7_%.B>($YD(HNT
MA60C3"A!NB*-NV4S*8R78MK-C1H-EU)QN>WHXZG1_7C44<=)!YU1UK%J)"+:
M-6FKK5"2-]Z4YEE95GMIK:)6+KWHPJ67;@F3'S+*%*,L7F6FB9^TU%)[`CD$
M#+9--`8UTQ<AA-5Y8#QT)K:H9N?:*6Z(%@R1+F(2'F0HHJ,1:@ZCC*[(VDJ8
M:K.I<*GQRR]M*MGX4G`FS*BB;Z3"=G",*77S;TFFHFHQJJT2N:IU2M$J"7:U
MWBHR)0+E&B4H5*;L*UGM81E*R[X<B^Q\QC@[IA#1UE6FSGBA>6:U0`.]C#;2
M%'1/FRXP$PTTE\VI#C=0PU-N2/A6_XB.:>]>0VA.&W:KZ&%5L]NBIR"-E!L4
MXD:L=J8S?F2C$A.'VJG:!,2=D1(/R]1;PS95?/'%1$FWU%//9<SQK+5>-_+B
M)#MB,BA@\5K>RJD`^_*P7!I+[,QSX<>?LW>%;N9]0?L<].G2GN`"`4PW8T^;
MA$ESF05^Y:D8@W>:JV[8^F1=M81,'T3(04/4^R'8O&/==D?,^V8WQ+8IS+R+
M<L/H0H1S6P"C"7GCV-KS&/G]-^"J$EXXX45ZG%V2C+>?U<GPH]SKY)3[6NPN
MG+]E5\T]&Y-S_ZBCEND"2,`TA4!WX^@&8;)1F,"X*QNKNUK4_-2[.OT)4,D+
MFX<018BN&?\/0!E$C4K:-*(2J0U\>TA1I/1UF[6]S0+=@XD2L*>B>]2-4R]D
MF([&QT/T^7!P0H&5K#JVOHYAQWWN>]S)Z$>ER%'.92]CCRW<XY[-Y<\^=;%9
M__A3%],-L(!@#.,@*#@;=8WK7H&:8`5#:$$VGH8>T'"!\`XUFN(1JA]NQ.#T
M#%3"$SFLCV6;GMEB=,/@K.TC$8JA24P`0[D5;(<]Q!B/TJ<DJE02B4A4XOPD
MYT0I/3&*4IPB_FYQQ5DHJW/\JUE^O"BM+X;QE:A3P5[NM+LR/JU/;9S:!7=I
M-72UD8W:(%X'/6B\<.51CV4C6*8B!CX<C6A=?'2AW%Q@O4Y=CV__,=%4J-J4
M#6S"1'R13$X0?R@K)9ES24C"I,@T28IV3LZ3]D-+L&AQ+)F5\G^BTXL^8<G/
M?E)K$..(&/)P1RX+GO%I!<J'[M;ENV-6K1K"$UX`Z.B7#^+1H?N@FZ5*A+UF
MJO`VK.$-C=XFL>"(JC77<X$BA9.-[IW4C[`!9SA],LXA&3&=BD.G.G$5OUVI
M[)WUNU*67L&>86FIE'>QF191YTI_.I6`_%$=.0IC&,;L1GE7XV4:@8E0#+*1
M'@:98VB$>4=>8C1M?8PFOYJ)-K;Y9GF\<9LCO5D2*-`0@@K:7DGOIB*Z4FRF
MD]R8#T.FN.T<<:<C8Z<IN,+$>+8,+8]=_TL5>6'/^C1+GUV<%NDV^]3.QE(9
M@0L!\MS4&(1F]4%ZBIH:"\I:LWJUEL<,IAP[.%%Z%8\T^!CH69^VS'T!,B4>
MW>/:'.6\4'T$1B]5T&\XU5)'RC4X8(BN=*=+W>E:3'`_A`I./X;8)I6LIYOL
M%3P=:Y:A0K:H1RWES9A%NJ9Z]KV?%8(*YBO+(E1F@63TDRZU5DLU(FB-(LJH
M"+OZD#P29K:U)29I[+7;"@Z,;`J*D`T'&9,4LFUA#Y9(#F$:DTHIM[FY8:0V
M[S8COX(*)F!`3I$&>Z20K8^P.NUN);[[.)0Y,:A#M1PL8('>^W%NO7K)IWOA
M2V3YTM?(]$VR+/^7+(3:14.JI^U(?Y5'4#Z^MJ%D3!>60W1@82;8MA:]5X,+
M^BCF]<5;'^8PI?;50H49B*009.Z*F.L2YU+XQ-"EZ7.,M)T6$S'&,KZ$8B4'
MU'A*4<=15$L]U=LY(1?YT?J1I3'FBV0E5UJ^F&8RI9M<#6<T4,RIS6]K?[G&
MA2J4(5L>LV9B)]:QAK68N%0UO-)J(F^A&:]J-LE'VXQA/KYP&RLEB8@?>39B
M0T\E>`85%`Y'R3]KE[N!_@YX;UP*=^*8Q^:%;,R0*@NE!KF5D.[LD35-Z7)K
M.M/C5K(*(+!I%10!,E-E(`M'S5H)YO>_4CNMJ'/9*-?"EE$>0G!!!E[_6^+5
M2T*@EK5O+26[E*8YUW45I'!9`N<1.^P>V`NVG5T*D68F^R(ICA4YFPV)PT;;
M$HIE;,I47B4L11:4//Z%YM2KQ7S^+-QAE/2DU5WI="]9W?1E][KGR^ZB!]W(
MS!@$[!BS0'TG=,JHS6"J%<XG:@A\H@0W.*RG'L(2L:3A_KF>L6W"D1(N3Z.9
MVC#MMD<<&$DC)1Q?D<>3K03S%?&2E##YR=]7XVH3VDHO1_2AJSC*RL;%VUL$
M-\Y/]W-S`_W<21:ZY(<^],E/GO)*%CJEMX"A$SAYN`!R^BX7^J[5BGZK^2+U
M;N$X@5:'QH-AO:-N5;W1D'@K[&\?>X<CQ&:S_W>DXLW0^-TZ:M+<$R#NJ3$!
MWJ#`_.8[__G,A]&R/=;G%^\=*X,6!;5;/OA71-:*Z<W?S40WY,6GB=SE1G*F
MUY]YS%^>Z$&G;PDH/_D2&'W)[!Z$)S`<+HB\MLI4=QI<IT&$(5$$\7H397!^
M02B#0G6'Q"(*TG`.IR(>EWL7=H$:IA&,U`W-H`/!85<0)'P8`0:W5G$9U@P(
MH&+(]6Q^=GU506/Q@PK;!WCRY')4!!_;]F.S@'@V)T#F5RV2]G@]!W]`9W2:
M1W_P-W]*2'1+.%_SIP)-.']&-G\0D'028E5PY7_T9FH#.(`!N"?`(TP'B(!@
MMF`?$H!>MPT!@``IA?\],\)68D<BO!8P'*8$'[&&`<!V$$<24,"&N8=\+=02
MW\)GAR!]EN2"5U%CYQ$YXZ4>@V>#,#-SW&9*=&$F^0%5YN=S/`=YE>=^G7AY
M5`B%HE@"2VA_4$B*I[ANI&A_I,ANI"A?J&B*UU(9)N(@#$5OI-886^:%[/*%
MZ:`0'#2&`Y&`884HK?<U]S)[9W6!=VAK;R<]</B,:\--T?0-OQ:!+L!6%F<3
M,^0?VQ@;68A(>U9.(;""SH:(D3!H[C2#COA8E6,6DHA4R)!%F,59Y1=NCM=X
M[%>$F!=_1UB*H@@!`"F0JJB$5(B*`GF0HRB%!_F$*B!:N16(IG4[J#9KOGC_
MD8`"1V(U+UE7C$,P5?:BC!C5+R)A:[?60AYUDFDS-AY1<9=A8AIQ/=:34K0(
MB-+#.G9W'8U@B.C(=]/F=^SX*]V78STVB6#"13]SCS^8%^EF9.A6:48(?T?H
MBJ/HA*YHBEAID*MHD*?(BEK)BET9BUL)EIFP+69Y1F@9:N:BA?Z&B\DCDJMG
M=:Z'@`Q0/![YD1]9&H<!EVX42+Z1@A+&>Q28&WM@5P[G>VJU#7!V>]IC4C")
M$1S1AO=@@A3Q+>GC".:(B"FW6#_5B"P32D6E"SAHE*#37C>WE$&3CZH9>?ZH
M;O57E529D`HIEF-9D&,IFV.9FP2)F[+I>8`1>L\T_Y'X9D8%4EH8>9S8H)$=
M9"AC6%MWZ36R=U$-UCS6<)*W]H8?>#W&1YTA]8UV"$%O]Y@7$7TA!D%H!HB7
M@I-XAP@\&6T"`5[:%Y^-Q7V64UZ'-DI(=3.C@Y2H^5E`MX_R%95$*)6BZ(16
M"857B957>8H)Z8JXN8H/NI4-VHJKV)4/&@`*)&_<.9%/YU\4B9R_^(420@YS
M27!U:9?%PR%X&9()-YT/6)W>&&$3IGN4TH871B*SL9@Q^G$PD1(VZE*(F1)/
M87W8<0+M*6-])S^>B1[UF6BCR6VI5(^<U9]`.(3C)@3L9J5'&'\*694-R95;
M&9:Y.:9D6J9C&J$5>D`*]/\?^%6<;AHQ^X9OH@>BTRDH8'40!,&<S0E[*7I;
MLI>,8^:7,"IV$4:+MQ%<$RB'$$AQQF6>$3)WL'%2;8B>+)0XD;"3)H5)6K%$
MD#.?Z0$L+Y=CDS@,-3>E5.J?2>:4C>>:G=B)IAB03JB$"8J@NGFF9GJKN"JA
MM4D@YO";U(A`!"5E`+9O=$I[RHEU(;`%8VBB6G=;*\J`TKE;U"FC/II2"J.-
M-EJ-S,AA(C:!R\6C,:D2D^I($$8[1Z1W1OJ!F;0KC,5R2SI/H&F#9Y$Y\I@F
MF76J_FFE0VAYG\BE!AJ+#YJ0J8BFN5JP!GNK1<"FFE`9X4AZ"`0I7L6+Q=J+
M5L?_+5BWK"9*6\U:4=$)J,O(:]MPDM1ZJ";EJ#>ZJ!,!?(3:2.`ZGBOB+7'W
MJVJ#/B1SI$X2'O!):.^*"DU:@T5IE$=IJOAZ?H]WI?IX>9HG=*5(E:V(H*EX
ML%X)M5)[L`*2H2'09&Z2H1+D5K<TIQ-;K`DQ6\*(L00Q!"?:I]WRK%\3K2-)
M7"9;K2O[C912K1K5G3GJ2-[ZK2T[0^*:4D`*>KZ1-()FLRCW"$DJ/^3E,JP@
MFL("I4#V;3Z(FNAGM)DVE:WIB0`YFYK[E10ZM9[[N6-9!(9Q+;1S5ZU!0@>B
MB[>#NE_;NHA!HD%!ME]FML/S:G9YC"')MGD$4A#AK:R3_[=[J!&5$H?3^E:U
MH;+BVK(7$;<R&G<"@U)Z!PGI>C8O&!Z*^%.):Y^@2DK@UR4WLS.:-;1,::6<
M^'B6&W]>>I4.2JL5RHH3"KKP&[_,T!E'@P[X=57ZA;]0<U"N"[8#<K%Z>H!X
M:A!GJW6X>T>&4:<H&V$O^V&/6K)O&Z3,\VO`*X*1^G`IA0!_BX6WX3HH1[C6
MVZZ(&U[UH[@U.*IY83/W&KD_.+F4NZH$*J#W1Y!+*+":^[3QF\,ZO)4T\&ZK
M`U`?,2>G*Y%;:U#_UK]T*I<7NZQ8AW6T*TQ]FJ('C(Q\&3:]A5*FVRG::+)T
MR)UUR(',*YXV8;KCRE>,X6;9$/^]ALN3WY6SF[2S1(EH,(.?,[,_.`-`0PO#
MFXAN[2>@[>>E"[F@.SS(A%RF!]1I$.DT`37$%*):??)?$HO$QQ2V`TP0RKJG
MM%N78(:B<H3`G%'%5FR\+,&\<X-"HI*H)M0O-M*MI&S!<_NR?DNN+YK&@ZNN
MZHAC1"D*Z^%C7<*#XDNT>UR^2=NJZA:*I8B0R,RY!%O(S#RF-+"*-!#-SQS-
M/1#-\_<.?E$[&:JU4',.O:88PZEZDOQ0^0*[>4JVKS='4!S%:LNBH`R&7D?*
M#1Q<=#MQB[J8I`RIY(H]90PQ-SFSM4R]G0K'-`A%HTJJW[9*DKN/Z>?"2(B^
M?>RT7+G_OEE)FU';S!A-BL]<`M4LS1W=T=0LS240S4T6`"5-6AHZ:XR<6J8V
MSJZK*"7*Q'59MAMBMNP,:PJANWUY=AR8/8,)&Q96SQ+!31M%P3;JHSR*`.8)
MMRHERT)\&VKL.-+G=[@\E%@B'_%H>,``N?BZFJEJOL3\FJ&XFQ/]I9R;T6CM
MS",=TFLMS6[=T1S-UJ-1`@E+.TN73!#XS5[KT@[USH\!NTN,SIH\T\UZT]&I
MT\F#=K;GAMFSQ5Q\Q:*LF(V*<:;KRB0Q0PX7F-?#<?^L$E&="'Q@B/1#T$Z*
M;:)T5%IM'X@W)DKY:$T)>5%Y?ZSYA#4LT4^[H`F:ULULS30`_]?5_-N]'=R]
M/=(?'=S`+=P?K0*>85]G9KI-%Q%WC48$QM<-QADANAFL%M@8FV!/3-CL?(QY
M>3S+"$A@[-/4@R)]R]AQY2C>B6MAG&PDF+?]K#<:BF&TTSBM,-78^YF@"G-T
M3%GU@4^0RY^9J',N/,Q%*Y5/Z*!?RJ#(K(JR*9`2KMN>.\UM#=(;+=QN_=8A
M;=P=CMS`W0,/:5_^X0P?1M2D)1*_*C5M2=V\@T=\>1@C*K:"O:PVK<GK_&I3
MS*([+4A9#(T?R-0;A;+6:%Q'O2*6G1&2J5R2R=D",R-%ZCB,-=5P[(Z/2'@Z
MB"9:SL*0QG-\?+G#;'0*.HJX*=$4+?_A8DKA4CO-&X[A&-[AQ1WBR.WAQOW;
M=M[;/5#-)>!YEX&"IFNGM';&D8PO?NWB.2UP-7Z`!$S`-FW8X2W>#H778)S%
M#^=Q>+-\T7?I4'#IG+[IG@XWFW[9,DK*V7ABF+WD37[9G]Y\RZ?I+P%]KTZ>
M9\.D\I1HM="]7G(,7-W57_WE?HR$`ZF0$^ZTO&FFRZSF93K-;\[;;0[G'NWL
M(9[GTB[M>$[M>8[GI&A?4G%767R_J'M5@PYP_+4G<`G*Y=X@=DH-8ICH`DS3
MC>[H'5OH`FB\:H-QUD1\REL2>T`2^PXP2]ZW8IP1W>JH/YKOX`H%_'V?BI;K
MH(-*27F:!=[_Z^WVZTGXKPQ.T>U;T;6*[+FJ["%]W!L^YQY^W-%>Y]-N[7A>
M[==N[=).BABR%XV`/0OD(-L"W?X7[N0^[@9FK,J)IXENM@-GT[;[W8^.V+QS
MLF_;P$AM\!\W'&*WLO-]<34DF?>0Y$RO$410.2Z7@ZF-1;H.0`3NVD\Y:3L'
MT;+MC\&NBFJ?FQ!^T1Q?L-;<`\3-UA;.X70NYR!NYRO/\M6N\M/N]WROW$)0
M`GO!!BEF@2-4\Y#-M6.F6_*>)U4L[Y(Q^;`3/,/T\S.=@`6<HK%7]/.PN^3-
MY)>2M_I\]>#8P)D=\`-@`G&;V8ED^B<&!4_`L]Q;>,BR7IG5VN_U_Y]0&=:L
MN;ZPZI5I#J%N__:XRN;/O.PCO?S/CO?//O)W'OV`K_<G7_W6/^U[KHK$(!!L
M&$?/S732+:PX7Y$"QA`7Y?B/<=V2#R(>`KL^+]@76SR9O_E1W+$Z+W5R:.]3
M;[JE#P@#@H.$A8:'2A:*BQ8NCBZ,AY(#D)"*CXN.%E"3G9Z?AD0G1:.C1:=\
MIZJKK*VJ0D)/L$5"M+2UL+FZN[R]OK]"*KHJQ,40*L?!Q<C$)<PJSA#.)=(E
MUM'7TMK7W-W>W^#AXMXT)33GYSWIYR7J[>LTZO'H\NKV/?CY^?'Z_?W\_@(*
M],<-FI`20DX$".!H(:0)%B!"),"(`$4+%_\I:MQHL:/'CR!#BNR(L>,$CR<M
MI@2Y\F3*EB9CNHQ)8.7(FS(I3I#H8D*`(4,",!A*M.A0H42',`"Z="G0IQ.`
M[G2Y$Z?5FXLT8E1$L1*C2Y:^6E`"JJQ90DHN,L+$B"PH*&L;:0*[Z:S=LJ)(
MF2J2RI7?5K%FX;H%K+!A7\*$#0L6[!BS8XZ)068V[5AE:-2R6:N6>9SGSZ#!
ME1O];AX]<Z;KP;L'\)\]?JWO#9Q->R`-S(IG*5S(T,60GHPFGMS*\:IQK#=?
MQL2H7*5%YC4CUJ0)4V+)Z=AM'@^Y,V(CGT&#&AU/%.E0I4_1IQ\R=:KS[<>W
M<IU_J=%7MF(OF=C_K\1$__Y@*!'@@`+VM]^!_B&HH($*UI=?6(TD6*"$`?H7
M%B9S,<*?#A,>:""#_/E'Q!<CEE@BB2B>",:*8!!QREY_Q2@++#/:P@MAA^6(
M&&.P)*:,8T`N8\PTT!0I#69';F8-,MUP%MJ34(8CSSSN3&E::E12B8^66=8F
MFY=@@KE$#]<H1DH(O+G@D)H]0>2=?,]IQ=%U\(5$)W=QZO1<<U5--UQ*TDF'
MW:`ON1<H3.^A1%-V?T8T@6^^A6<>>>4U==YYZZ777I]U7I45<?1!:%]^8&4X
M:JGXB?II?FZ2ZNJKL*)ZZH-BN=DJ(P&<H.NNO/;*JRI/Q!AC8+G8:*,N_SCJ
MJ*PR/O:X3)"-228M-45"8YDVUFZ6K9)1=MOM:/:T4QH\JV%96VQAIJONF.SV
MT.X2\,+K[IA+YB),"`DY]*A0#+6Z$7&==GIG22L17-R>>A+L77<,FR212@LS
M-Y-$,_DYDDU_4@QI>.)1:I12EZ+7U'J;3APP3G"">I^#]&7RB*HNRY6?G!6I
MG%'+<<6J<WTP0VB)6E^I15$`(?BJEZ[")GU*+C4.MNS3O_A8#+/&"!.DM,\8
M:61FN''&I+=@@U:..617B<[9ZTSYVFNQ`=0EF.BJF\^8^+P[K[MXLQNOO'KG
MG8\U"9T`RVX!/*JF==;]>_#)),G9^)W8T3F<1_^"5NQ2H-%=CG#F.D6,N*.#
MYA3Z=!'UY,AO''=,'LB4JI>Z5.V-SCA(\J4,M%<XNVSJ6A?"#"O0*>\L_/"S
M[JR6"T670HHK?2E-RXRQ&`OU](LY*V1BTD(@Q-5!$ID99UYKQNWX89=O#=KT
MH-]EENM[&;?<<MO-=]][UV]__77332]CJZ#)4%#`<=.<9H<5KI`N<A<13IP`
M1J<WY4DZ#%L8YX0#.L35Q((0Q)-,(@:IA7!,**SSV,=&YA1-;4IV!"3)?+12
MO!:*97<KRT3+:!:\VM6,>#C,H0WI<Q'DZ<5YSG/:C:BG+.PI@S&)T5[5A!09
MQT2#29;9&C:V8;XJ=H/_'62RDFE*P[;TP>9+LWD?_&KSKKWE[7YH3".\<)!&
M=6#F?&.C1D("B#D#0BZ%E%L.YA)7N45]1!&3\]P$/>>H#/[I@@U[F*+NN#`V
M!84A/_F)ZBAEGA""S'50B9UV\%@[H`%/>+Z#X0MS=\,5QI!EO\LA##\9M/P@
M#15`7!KTH$=$(F)O&52[WF.:@2UK%:DS2R(?,*UH/G2\0XMG8YO:S"5&U[!F
MC'4;"/W0."\U6I.-:\2!-K6YA&UV$YMCXD>9$%(L_SW,8(Q;H>+L1)S)-6HB
MH"+)Y"CW.04>RG(Z.6?F%O8Y/!&,*HV()&\B"92?,&!2(AP/)F'GGDURDH<[
M_W05?F(ERD[FCF:>E*@.=U;1B+9R$2'@"Q!K482FX:*64)L:+F^YR\DXL1G/
M(I+7ME$-)Q'36^@S6]F\N,RUN4\?S80FW<Y83?L5U9KQXB8;E[K-IBKUF]Y4
MJC=I("]WJ.`6"C$=<+RSP#P9IX%YXN,!X1E!6TD08!J!YYX\1S'01<Q/_'0.
MXBAF$[0VCB=J&J@')2FRA*YN9"0[H4,)6,/";E16J5S5S$KIT<-JU(6*]6C1
ME$:L6Q`F62@US$J)D<NL7:][E*EI9Z[E#9O>5&SL.QMJTD:NM:'K?4$-4[L$
MHK?Y'16I3`5G4[\)U:7RUJG`E>HV>Q!5;I)I-[^)8/]&!&9/BP62K-'9)U<%
M:;")Q`E0!9OKFQKV1YYH;I\,TX[)+O>H1X;@O`.5E%__*C*2L:<J@R7LS5CX
M6./I3E4T!!Y&(\M*Q^HL+#=K+'TGZQ=B"099F=5L+I%XRV@%R:7.^.77MH:D
M\5'QM)X9#9;(QM/6KN^U_O@B_.P63?V=$:EJC&HVNPE5%@>WM\&-\8NE&LYR
M%,$AOV%K/.UJI[%JY6%`EL\YRSK=QS7.JWJJ)W3F&KK2"><EA51D'IVSE9WD
M];Q8YLT'U\O>$C(4OGC\8T8S>LKAL6FBBV6L16?XJOX>MJ,["\`J#'S@76`V
MP;NX7H^H]F`F4L:72JH&%`/_+3X,BTV9.64MEMHG$+=!L\3R(RJ*KYE;%^]6
MQIC.M*:;2EPVYN-,)SAHX=KTUM'=<2;,D:"2*0C>MB9NDZ\6U`4[9T&R*O<Z
MWHWN!0')79$`],I8SC)!+\7ECV7JO;T.<U=M*#3B?1)WQ<NO6.CKYE#YEZ(0
MJG;N<K6T8PT1S[Q@J4IS.9EG]%FF%)9IF4QK:'&,#1X<3N:5LEBN9^X#J(^>
MF]^&JN_:IMB;E@9NP#=-\((3O%V!VT*HM4SJ6EO,N3Y&-7G;$V6X?NZMT,'U
MFR(&R"IOER1TG*?#,KAK5UME)[S!LJZ$?="^%MM2F(R*)I6MPOV2LLP?Y9DE
M?$?*__FNV;`RO/8+8=9?`2Z"V^`^C+C'S=GL>3:T@+Z,^"[<;M2FPQQ=3)]K
M5;-U,.:;MOS&V[XG;3_=,M7%,#:XVM?^8A9?52^BCB2D'D5D\*8U<_5T]2(N
MGN1VWITE7<6NCMM:.0L,H21@G34]'67=^$9GH,D[0;#]9]"7$WNAR'8/S1<X
M;:`'O;$Y:R$+Z<ML-M=7Z/>9B[9=A?0[@UN7#";WTUN*[B=:!AO#K'IHW*'A
M>*MFT5X/4VR]--N[^9O2+6ZQB@?.=ADOH.#/QT'TIR_]YR_`^KZ%@"HD'X+S
M"!1U#]&[=E?M:I-3-]6MJKM:Z[I6P:??NCH)X.)ZC/>*V?\)Y40[[Q-.P(9@
M'S3N(;1>EX0IF60R-&=*I+=ZC@4)S59Z-I-FJ:<S"CAT/-=?-^,"@I-T4K-2
M#%8U+O4LE.$]4+0MFB%:NB<:'$8F\X`:7,=,]A94CO9U_C!-9+<WOH5-Q=5\
M;!=]U:=-U$=]/2A]TK<#"T"$VV2$VT1.H[`%W4=Y'C1W5A9>)<-XF\)/4<9X
MU!5=AB1K<@)_V;%XVB5_:^5'R5%QD",Q`<4`*K=RD_=_ED="F5(R*)1"._:`
MS@8K.W=#`88S9#9FGX=ZNB,\K(2!M;2!>K9TN^1G$H8-3/(UFC%H)Q@.\K9%
M&G8E+OA%L+4E0D4;\E.#:'2#RJ?_@]MD?=?G@T[U@]5'BD-8A*1(A*[(BJ_X
MBMJT`]Q$`R2E*TQX%$>Q5U'A&W3WBU0H?NW1<%=(>$-&:X)T5Q@%,9U#9?UT
M5^AT1W*E:MP!2.9U7D60/).')J+VAH!E0@VU>:2W8\\&@1,X*M*V*N/(43SW
M9BZ``#F76(HP"M,C;DC$8!\8&;M$+8!V>[@1:&\4B:(1#^/2>^VC:(TF@])4
M8F/GB?]V::(XBJDHA#QHBA39BMAGA-?W?$0(BQX9BQ_)BMK4`]IW"@K'A+G8
M??P"?KW8DJ@C<U%8,J;#'FUB.K^X:F_UC`A$?\[(%?HD.7DDC1M4=QYG90MQ
M7BO'?=OH_X8OUUZ!17'BZ',62"KG2"JKQ(>MY&9>X0@(@`#[\3(O4SP8`I8N
M8`)EB0`Z``:^<X[X@AA$T`!O20120P1T29<LU42Z]&?IIF[<8()]*9#=D$5P
M-"Z_5Y@BIHD**28-Z9"A*'#--WW8)X22R8.DN)&P.(0X`)*:&9*;&8NNV%3:
MHPI;H!<G&6HJF3H;\SJ^P5>1\I(T.15S9Y/$2$&*A'[K!!_#(4&)@C"`,H>M
M%EZ>LYI(60I*N8TJR91<=DG@&(X'V(`V!XB08`)00!9*H`33&5F?PDHW0Q:<
M(`C=R0G?.0C@"1>*X!8#$)[B>9[>.0`!D'/6^9[7V3)MV0L/L/\&]KD&`_`%
MB5$"X'F>#^!TY@9U4A=%Y/-&MR=,57<:!$DF+'AU\\9:P>=,7S=;930_C)E4
M3W6#N?68DBF1I?BAEHE]U]>1G<F9)NJ**&JB"T`#VC.:HGD"H[D%N;A7C_04
M?'5LK<E7#`=^KSEJ(?=Q2\9C\]=C/LE56J@H/X9D:56,A,031PDCQHEER)F<
M7O9E8!:5II>=J(2='(4(:Z9?-S<6=^&=]F&>9M&>$=6=XMF`\VDOL$`$A0`%
MQ5`"A?``^@A:?/F/@!D:[%`.\H`:@.IA+>A3SJ0EFQAI\7);9"=CS+>#%VF1
M/ABB(MJ#&/F*K'BB1;@"F+H#.Z"IG`K_BYSZJ41(DJ'Y`B:Y"C`::I7R?9'T
M?]^G%.9QHSR:7*@S:D2V?H9$AL>A5@LD90?#A8'2I$U:7D1#C[<8I>>EBTU9
MI5;Z<&$&4::$<VT!!=1:K><YGM:JIH90K=1ZK=SZK29`*DJP!V-*"8Y@IF4!
MCZ2BK0.0"&(A9\Y"-86P!G-:I].RB-0R3J6UI]_@15?"18IVB8G)B6*G/\?G
MD(X)BFI7BA[:5)29BI-:F2,:DIOJD2OPJ1>+L:$:JD6HL9KZL0MPL0L@1S%R
MDMUG%`C5E#_1FJ_)DE%(2+MV0(DBI$JZD[K*DR;1I+(90&YR9<9:"\49I53Z
MC5*1>9HGCA#5_VQ:L3L7@:[E:A=[P%CL:A90H`E.^PEHBC/L2IX6$`#5:9U?
M\`!<$+9C*[9<8`A<P`5B6Z?J%H(!26CL!IC&-+<J6"X/BICI0!O#-QOTDS\U
M6&EIEZ$1V:&$^Z@?:HH3NY$@>:DE"K*.&[+7MP*>*KFLZ+@?>[&8VZF:>[&D
M6@004)*GH'VE*:,H611(L04,@+K)*4FO2E"R>:MD56I#*F:]*8U"F4?N%)QT
MYV2.0%=J4C1VAJS)>K)^A7GLD7D0IVS0&J:^<[5/:Q;AFA_."PJ/,+V3D+5B
MP:[N*J;/:PC_F:]]&9!QRZ_7L$Q4@G4"BV\#&Q"=Z(EFUY@Y"'T-._^90$BI
ME,J1C'NIJXBICVNY(7NY(=NI__N_DMNIDHNY"&S`F[L".$`-GUN2+_#`JQ"C
MI"NC1%'!J(O!J9O!JIL42,&ZK%NCM^J3B8.D0WJ[)AP?X,6[=/>ZUM$0N2(+
MG)4032BTQ0N'3QD[41E@HZ<R,B,6UMN]G1"]8M&5`X4`8+"M(9"6`:`#(0`&
M78D`6PL&:;G$25P(:/I)6[L(07P7#S`-!>&7Y%N^Q[2"BR:HAHJ8ZYL_QJ>H
M?VMV@FMPD4F1#BN1](N1U5>BFDF$_0NYD^O'`$RY!_R_!@S("GS`!GS`BKP`
MI/K`G[L]H&NJ17"2&%S)EFS)E%0>!14>,]G_I'>'3IQT,GCU&S;)3Z5,,4^Z
M9[6PC2O'A,3K,<KI7H+EF^E46)_4%3VC(+J,((A@EN'ZRQ:P'\$LS+\LS,)C
M`H:@`YI0"5T9`E)<"$JP<UW)KNJ:']K+Q4+,MG\YQN10D&@SJ&^3+GO+OFU\
MH8$;OQQ:D15)Q]9GJ1N9QQ,KJO$\HBDJSQT9R)A+P/JLR/S<S_[\S_S<P(X\
MT)_KN=KW`J-IJA1\R0Q=P>,1JR!#4"L+C/UT'8@WNP*S'=[105#(5L`94$3S
M!-"3C<&V*Z3YR@K%K,MYI5AJ.PB8"0B@*FBF)C&-S8;0<]C90SN#S-!,EE'\
MS&BQ"`@0``A@"-@+_S1;7)[93`A?S,V!*2ZOL5I;!WQPHY!\X\9O;&GG+,<6
M":*1JHH42XL>.<_Q+*IF;:+X/,""?+D`W=9NS<^,[,`$[<B>6]>F>M<,700O
M@-`-K;H=G+J6TG*2PI+(:'>TL\-8T<("U;O"2IN_6S0BK0HE'7FX*$),<6PP
M.7..=S(W=\N74-,:0B"B/2%7^Q_[H08'@MH&@MHFP-IJ$,U;FA\\30@C$-,[
M]S+HZJ[OB);LBKU?H<MAX;3]B9Z',-P#T-2Y%XF".;=8!'SA'*'W)E0TB&*^
M5780R:%!"(0/^\[OO+AZ7-;V7+E\O,"(_-;F?=[GS<ASO=Z?&\%WK=>3#/\!
M=SW?>HW0?,W7I#L4%DP>$CW8/)N3@/<1FZUL$-$0>95<0#9!D0/#E"UY#KX\
MV_?7QH;91LO2+<U?/MP(MMT62VT79KG3A@#%,YW;<M',1AVFXDH(4-``#T`#
M+=[B+DX#7U`(7Q#C#]`$+<ZO@OFG]>:"PK>)DF9\R+=&6[VA<CS'#\O.BLO=
M8TVB%8NQE9NIFYO(`9RQ^8S>6.[6.0#0<,"B<LW>CNS>\JW76_#>>PW?9I[0
M#KW!'M/?*YM<R)B;Q8'"B.THJZEE5VAQM&8X1XF4VNC@>R%Y$@YSQW:\)6.`
M![A#4_G9R\R]'5X6T;L[MQ+,AE#;7;D[N<V52ZS_`]0LC_)AIG)*H&_T`#0.
MF#M^OH**ON82$&WS:"8&:8R)@]==Y)HVQY`*F8EKN'J\F7TLR*%:P,!>Y>2=
MY<2NR#FPY5N^`L>^[)*[Y7&]#67PY7,=P6$^WV-^YGM-WV>>WQL\Z$?Q2!(]
M%<FX2:",V"P14'FE+XV-<?O2YY.7E+PBX85NI7+(*4CK*CXG'S2]<UW\Z(-`
MQ+^MR\(]`@1BS(XN"$HPU#K@Q$6-Q0%?G?[QM?UATX-P$.#0`/,:1QCFI^?#
M82G885VGQM"]+@QYL).6L.A<ZW4\F1<)HB&ZOXD+DIX:DOV;UOXLP`E<[.:-
M[,J^[,>N[#W?\\S.\\G._\#X``%E@/32#N;R?>UZ+=]BKNWSS=?=;L%6CRG\
MLE?M"5^R:^X:#1'@GB8_*GZ-E.[Y-]G:2+P&1>&9?>C.VIP"QEB[70G6V:W=
M^I[."Y]Z/YU\O_?5.9V1/BHN,+5F80FY[<3]%].]_17C*@G;"^H6#P[>2TS+
MS>.(=OG/O<;]8+`F3]V_]5N.6L>1Z?(22Y'?_8HSW^N#O-9J[>LZ_];)[O-"
M+_L^7_O*'@2W3_1!/R;1;@TD&>T00`-)/^T/O-=0?^U-[][UC>9DOL&3K-_Y
MO1":'$GB;D&)TAQT_JR=PR8#U1.')X7K;CAF?_9^GJP@Q/:&?NC,2<L!TV:E
MI/\61)TA9+D(TFD(VPN(BD#X;Q'%4PP(;&`(+BY0`XB(`1:,C$J)D(A0!(Z0
M4$(EF9J:$&N17YNAHJ,TF3V;-*6I/:FKKC2LL3VSM+6VM[BY/4NS2[R^OKO`
MP\3%2SC(Q\K(S,W."\XXT-+,T-/(UMG4"]S2W#L+X.#AY.(+*^?IZ"OK[>KL
M[.?P\_3U]O?P.>PY^OS\*_[Z"1P8L"#`@OX6S"I1ID<9AB4@0"@SL:+$BQ)?
M0-"84:/'BQZ+?-2X94N1DEL8H"S)H&4`ET,"#)DPP4+-FY1J$MC)DZ>%GD"#
M"AU*=.<$`C<GN`C`E.F00DJCVIQ*DRK5"4^;!@C!M6O_5P8R90X92Q;KS+-8
M::I=B_1HT;=%&5%J1/<GW;F-$.AU49<1WT:/(D'YV]=NX<.%`T=:S'B`(#9?
M!+/1$:"0A4.0$-15O!@*X$B84F42G2DR)%"H2HT*!6M5"5BO3[5N'8OV+%BZ
M<.O:;>N7,&'&@A.+=BR:\>/;JF&CMHU<-G/0RTD'AXZZ.GG8X]W;L0.?]^_[
MPB/T=W"\^?/H<^"8!8$6!(@/+6($N;'^"Y$?Y[_@.')E2I,HJ11"2V"-E=1-
M5%$"EUMP-5@4@C6YD!534+D@U8%60>B7A$UYY:%39(5H5EIHH;6636X=Q:"#
M;S6"5U\OUN4"`@$0H@04-^:(_R..C2GAXX]`!BDDD'01=EEC2"8"A2`Z8):(
M$GLULM@B='$6B1*?)8G(`YD\L!@J7Z"FB6JRL:)**6;2IF9MN^FF&V^Y_.*;
MG,(%=]PRQ2'W#'/6[)G<=-](!Z@YZY!3Z'?RS),H>(SF$UYYZ44JZ:3ZS/)0
M0Y?"5Q%%&''4D7T;Y==I1A>MI!*`_H%5((<R68@3(T?]%)2L1-'*8HL0%K*4
MA!5>F*&&24VX%5<G%,L53&*-)>%9(39KX%HXJ8C4M+<*A1AB"C8RHUY6:NGM
MMXB8H&V5`QQB;F/G'O*%7@@XB8@2EC7B[@":D3NO)%EJR64FBZGVV@"@H-E*
M*[(1[/\*FV_BDC"<<,Y9Y\.^,*/,,GH>UV<SU_PIS3C.C1/=Q]*M,,ZA\%S'
M3G<E-ZKRH_I`2AY!`;E,Z7AGG%'0$3G@S(]"M<"G*:?TC>312/.1:O1&IIY4
MDM(`OM1J3$]5A2"UU5;=8*PW%?*4A5Q?:&&&8"NE=8?$&CL@B$\YZZQ8`9@U
M$[0V3<O@BE6[B)B1=ELP8PCM@NLWN";HBG=?)BR&99&"6WDX7?-26=B\BW?+
MV+XE>`+)OC0@\D4KKPULL)D(U[*P+`SKXO`NP$$\G#,45^QG<AI/8TUT@G+,
MW:#<=6=R=MJAO/+O\[0L_'A!S&P\S37S8W/R*.30?/-+P#'_B_28,C21]4`7
M;;2H_.G7*=,,W+<TJBF%!;6K4B-EE]7LQ_5B5+S"#VS85(VM%;$A%'O"V>:7
MV&RR;(/:L]22()K(S2@(;)!<KL5`O0WB7G^+("3$-;C"%"X2XD*,XOK2.,3,
MRS.5\!;E3).(S='`<B:<#9MN4SK2M1`7O$!=ZE17#.*X#CG=4`[&EE,[;@#J
M&^*XG74.E0[JM..(P%M9RP#"LN/-3&?H.0,4:V8S%-3L"#5#@16WJ(\82L\A
M#+E4#^13'U#91U1E+)JG)"(2E!2!:2L9$-3:%I6D3(5:MG)0'MOG$_7!KVLV
M^=K\HC455C6%`5W1W_[.IC:R)&LL_P5BP/_2`BT_4FUN")26M(S2P+K$*"]@
M&$&0(!@N$YCRE*@T98]224'!"8YPB\G@8398EPX>!G+Y2M((([$&&GA)<[,)
MYFUP,[H7,BP8R*3AZIH1,1SDZ889NX8VD@.R0#DG4+D+A\=VIYU$>3.)*AN>
M>&3F1./9#(M4K&(ZI7@&*ZYSB^VT8@X4(CWIT2!3%"D#I[)'GZ.EL7O[T=Y&
MF"8^EI@J)D^S8_H4Q#ZZ\=$G69.:JU`4MFSM))!,\5#93O#&(AP+;8Z$Y!`(
M1%("A4A"!%2+'^.VR4U2+8%Y@Q&VM(6`$("!#2%XPA=(F<%L&68NDAM`3V74
MP`M.\%JT9/]<)'3@P2OE<@!*"%,D*)>YJ9[&-J)3F#%-ASHZ*7.9R9#8#748
M38UAPX?7M";(LLDQ(FH''XL")Q,=Q<1^D+.<>/4'%=')SG9>,8OOU.(6M>A7
M%*R`%W"``R^JIT_KR6>-_4RC0/O)J8*2SU3EBPE-NI92AE[TH:#-%H(J^A.'
M7M("",W?(O/742%T=$"25)LD2TI;F)0%6BI5D29WN]NVU.0P,<++)_6&`!V`
M8:=(`F$G20D%62*.+RXP`12F"X5%&#41%,31C3+H`EH29DJ(Z4PNE1``3%AN
M2R4PDY:^P,(58G6KM(AA5[OZU6&PSIEC70[LM)'#Y6P3'-[HX5K_33;$MY(L
MKG']SA+GNL1_'*0\=\UKI-;)3KY2V)T8+BP5,2S8YBW@%XEU"!@O]5CO`0VR
M^Y2LBH504/'!\52KFL#3)CHUTX:V??2+U4MMC%&N=+0(''VC$(;\QBW`=K8C
MK2V!4J*2DC8+MVQ)7[1\*S<5]457G>Q+4"UAI.BJX91J*)*6</07+(<0$7RY
M+B+`8('K*C>I\HJ$XS@H&+U9@#.#,>_E!L:%)+&WF/#M32]F6-]F,A._8[V8
M?A?-0[3Z<&.#TB:@#DPR`\OU'N+\AX3+B3,HYF!YZ6Q>%BTL6`W#\]2%[;"&
M/SR]Z(D84_F42/8@BT:-\',B:,R(THI\_Y*.LJ1`89&)U"CZTKK=&"@Y+O9;
M:I+1$PS9M4)^-I%/HN1J,YG))BW+VZ!\(-RR-,J_9:!P8_I4QN"M6W-V@9;V
M`-T-Z8TS:39<FR$1.:?64LZ%X8MX"X%G%^@Y$0^HS2\;P]Y`UT*^<R)T?6WX
M3#U)<X</EYVCN^%#<TPZ4&Y=5((3?&F[DC/"FQY/I_7ZU[]B\0CN]&NH5S[8
M#K=<L!A``09B'O,SH"-ZOJ#>JS,1:S/:AR(>*0-'4@QTD-CZ>^-#E=):,A.G
M+`5%4M/)'H_]T/D=\&I+"4$1A*`""!!9VM"F=K7'CNUL:YO;*:4H;GU;E2L7
M*<MW3I)RR16)>O_114L4U!MTNPN)>&-PWDIZZN+B#`DPX$U7N#PS5"U0A,KM
M.19-0-(:FM!>@WNUT*T3:\-=)W'ER"[`CO8&@"N.S1^ZM1[O:(?OP#F0NH8<
MKS@#]3I)G6K`FCJ>+B<L/&EN1=[#7(LY<+5B%4L+QO9\5$*_R*R'+MGN;6_7
M;D05(A$J[+0OE.K'OLH=;5RKK#^!ZRI0P=>?7>2RC_W\L7WRMM&^]FX3T.T5
M9&!0<31+\&H92=QU-V<JHV:A`OY=@D=GD!`"\?=!N>09)^!X`,="5<48E`=?
M#D-#R6!?^64Q9,5HTC1QD$9ZY2!$T5$HNF-@)G-I].!QKY=7%D9A*@?_3[:7
M18-U>ZJ&:EHT<[XG<S+'>S1W!MPP?-'S16)$8K?6*945A)%%-!^!$I8E?6#1
M%%&C=E.&?53W*U6C%%OA;"H0$5XW9%GH6K^&?EZ8?@9B(NPWAN\'=^16;HNG
M0?:7&(S12JZT?]$52_]7+@%X;YG15)9`>/@2`@JX);9P7I#`!1"H<*J#:(<F
M5M!4#1'G>=<48!871)+V7]R$1+Q#@BSS8#"3B2?(#R.7,Y]6<AG&82NG8:;V
M<H.%@S08<S-H@ZJXBKRW`'``B]'#:J_F$/ID$0"5?)&5?/GD*44'4`'U`O]Q
M626!-NB3(5;#?5#8%FHG*\HX*Q90A5P7$4*P_X404'[F]X6T-5*-1")D2(:'
M869VUD!X9@)@8$KG&#B;L89MQDHF<".8469&`F]S&"YS6&]'98>),&?CTAF(
MEPA[@"4!T(<#$'"T<$*+(8B[02>$"#&':(@5B($[=%;6Y&@#)HD9]U8:9XG!
MXWJ;2"DC=TXJJ'*W1Y*E6(JZ5VHWV(J_]WNJ2',P,',P$),Q.4_<,(N)Y8/X
MQ$_'!RJY]G/]9(00X!_4AFWF<R$*-2U3MXQ3*(53F'5;5XU2N74_)G;:6%M)
MUDAAZ(W?Z&UFF&]Z]R.R)(=T!PE40@F+$7_QDDM^=U1N5H=W%PF&YTK_R&6%
MX"Z>,9"`:)"S,'"0@/\&<=*0#LEP8161$BEQ&HA6`':1Y7!ZO+-Q)&A7FO:1
MDC)RG?A.Z"2#,"B#ILB*K#AS-NB9O@>:&$"3I7F:,RF3,8=6B26+U,,0MI@]
M1=<10E,?NG@T`55&(7$?PI@J+P%L47,B!I0BM_*,4$@_3;D50N9U7O=&UY@J
M5^ED3`>&(K*5Z]>5;0>6\0=W<!9W^,8(:C88:ZDMY]9W]>A_UX6/3T*>AB"7
MXZEW_GB7]*8W*K"7M."7?WD+$5B(A[9Y$7DQGY<-%,=?I3=@U3&"WX1$',E@
M($>9_F"9?:6"J`:#\81[N>>26T2#HAF:H"F:,7F:J*F:IFF:\Q2+/`B+Q3?_
M1I=RBQC1<T.S'S`*$I7ED[H)H[T)8TQG/F)!8U:&-4R9?<AHG,@F8P'`4<_&
MG#\6(%Z8E;/5I-2IE=9)2=_XE53:G=VB&?QV)>^IAHG0EM@UAV]F;WJG;G67
M;^U);W6)+RY0GY<S"V@`B)!`>9<G@8;HG_G5>1.9F*1G.XR9D92VH";8H`[J
MB9Z819^X812JF2G9<GZ5BAJ*@ZX8FBT)DR%*DR,ZDRS``J@9DSKH:+.X6+78
M6#V7?+4Y-$'YB\$8*L(X4,*XC7,4G$FI23\:6H.4C%"Y=<U9!,\)/N>79$[*
MC4CVI,[BC6]SG;CU-MJYENUFAOVWCM_IG>O)G6;I_P)@((=OJ7AIJ%1F&8X?
ME*9T:`%"8)]H0$H#((AS*APV9)AXRAP\!'I]LJ?8]('<A#(<MZ#[,#R3.:B%
MFC,C:47HA'(KF*@7ZG(LN8H<.JD&BX.F6:D,RP(PH*F:2I.9>IKH8*)HY6H[
M=XNRN1$S:H0QZGS\D:K""*-=2"`Z2A-TA"%3LY2SRB+)5BU8486XRD:^9BKH
M!ZPXBV10VHUA6")<.1-FJG?C2*6%D)9EN8]Z:(_7@F5\MX\NH`/REIYPF;3T
M$EZ"H2N<<3AL"G!+@)^18*[\>5__"3MG19&A-Z",:2B3Z`Z]8P_UBFD>J:^<
M.+<!47(51J$":Z&=V8HOF?^*"3N#I\F*,"!S@\NPEUJ:$CNQ#YNIC(L!$XL!
M.^AH]31BEN)8%0%0-!HJ/J>+P+@?_L%DOWF4=70B5]>RH551RD84FS4$(6`2
MNAIV2=BKP9JS.UN[Q,IM9T&E5$J6V%JUC#`ERRHC;VB>_2<N1A604_N[SRJ`
MB("\B@=")["72T!"C+$&=2*VB=@<C.8-?\)?CBA@:NN8BF*O332HENF)G3:2
M6/2"IZ:H>CNP&TJ:-1BI()J:(UJ_(IJ:#@NQ_#NQ_@NQCLNX,&"3K/EA.K>B
MMHB+MVAK'DLJ03<J-DJRO=F;90<U2H&L$#*<GG4UIFLMJ.NR,9L_]W&-UR@$
MGUO_LDI&NSA;N^HWK#UKG8.SI;K+"(G7NVP6AY'P2FXWIO18O&`J>'9'P\NK
MC_BB>(?#!X!X!SU`O8R!!GJ2>1737YX7.Q/W:*47:966,FP[OJQ75W%[@CJ3
MOE)TJ*.VF2[(OBYGH7H+J:/YMVQ<N(1KN(AKJ:79OS-GQ_W[OXR;J38'BW[L
M0\,7FZ?`HF24'[_HP)[RHJJZ'_AQPJ!;%B@5==*R/AT,6L.&$ZDK%&K!%$M#
MPB+1:S:;PK&ELRQ<RFXS(E&J+(<WP_7'97[1+6P&K8G@;L)K&5G:I><99E*+
MK5"@`T9B2X\CIGC)"&#@+@^``]3+!7#*!1$#Q188H-%D_\55;,62B)&3>`XC
M4XGSL'J,(CSCY*!0),97!$\`V[XJB7L5>LX$*[]\>["!B[\QB0+W.\\![+".
M6\_VW+CZG,=[W,][;).Q.'$]\$6P.:J;(J,,G&LBJ[FL*L%;0,&/W#;;UHQ3
M)J0]8=%0&%%WE$#+%K-+PYL=!=$H/)VS*ZRE?-+:IFVLW$G%;&Z6@6Z]BR-1
M0E1^(<M>:H_7>J9*0AG?5::W=+7OEH?1F,33FPA<@`-]!@EKH*ZO\Z[:*Z`#
M&FE"5$39D7KVBJ\.IHF<ACSOE,XHR8*,FGOM?+`$*[B4.L_WNZES7,<`O,>G
MR;_UC,_^/->-ZV'3'&+Z!&MDU/^+$>RQ"RVR$8PTGVM;ZT=C!\2RE5PML&(5
MF:S)5*@2SGF-O)DJV6A2I(S2F)W2UCD$6;9WKL2/>O..2=)FT\485$*N4/!E
MM6QG/6RM>>@"(\#$2J`#;/`$;%!<P&P8RFN71Q)X%M`W7)O4`X`&2W`'BU&!
M%.>NTSQQ:P4R!UH=60P/(0@\@2H0@NI$6/2@_'JWY9R2Z:R2+S?6DOJ2GKF2
M<2S/E1K'"[NI,QF3^1S`\/V_<DW7]$W?,``0CL8$@'S`F&(1/1F,'_NQ#DR;
M`3[9H3P685%'%$TM&)W8M0(L'/T@,0O9('T?V#C2EGW9F;WA+SP6=^/9=F;+
M]^<M6++_9?72?XPQ&.[VTL3KVCO=``WP02-0!0]0XUX[`@5XM?(9K2Z0Q,B,
M"$Z,`VAPW'DZQ8K8KE!-#CCPB!='1-BLS=H<3N*A:=<=*9X6$"'9@M^-SKGW
MW08[WN7-QF9=FNJ=OX;;WHO;UO(-UWI<WV[.N$;0SW'.`O&`5OH-BXF5UPE\
M:R_ZT#:JN42SR$.#'Z$"G3DZ0,?H4HWMX"QB=4)*$Y!T*IYLX$HJRMS(X9C>
M2%LJP_)'XKV+M*']+?+8;OMWGEBB9@W0!`W`Q`/@"6O@ZHOQ`+<=S)8PV](E
MU#I=D$A=KM4`IVA05H=IMCTD>@4:,D7TIRGSMM[AS0RVB6%,_Z@G-WN*^H)J
MW)E@'N9F?=[Q3,>'B]9Q[;]R'=]O/N[^'.=&8.XL<.YS7II+L`+Z?>=W'F(Z
MQQX;>T9^_N=_;D8O"J/XX;DE^TBPJE#;Q^@/53\HLN@\`>E)]LD@?5E-5FTK
MG.D2[^%+*XY(A7=HJ`A%0JYHMB&DWN(8%`!5H-2J'N,2A`8P;G=SP?%";0&1
M<`=(?=3-(-R((/-EM=P<6,V$PDWO4(E1KD0,JJ^Q)\XE5\ZU=Z%<7M;8+IKO
MS.WT3,]KO<]X+/7D_N;HKN[I?O59;^YQC@(DL``MPPUWCN=Y#6M``W0!A?8%
M7JI]'2K]#M%.=CYJ(4@Y0?!4E\%?$__A0;')+]')#`]'E3V=$3_Q$O^>3,OI
M(]X8L?SI&E\D6S8`\K@AK?T)#>"77P#C.L#JWG('3=`$1,!4<?DMB^,N,'_,
MSF#<@1AQTLS<Q2ZO.\^VD-G%<_7%E$GT[.2^BYIJ+1FI\7O>B*O63W_FCKNX
MWZ['Q5_U=#WG<Y[NS,_U6Z_NT)_N`QP$07`&3(`..3#V!_QJA$P?APS8;=_7
M;__0H7SH9I&RA.2C=L]'&JU2>I_P9G$J?R\^%/SP6#G*.^LVA`^EB`\(%H*#
MA(6"2@.)B@-0)@AL"(.(BXN1ABZ3E`,N@BX!G9B+G"::7TT/E$\("%":KI1H
M3;(-EA8$K:__E%"#N(EW2SC!P@MTE&MT.`O*R\G*.#L+R=#3"]0K"]?9V-LK
MV=W8W=[AX^3E*SG=Z.?G.>WN[_#Q\O%'.?5'9_GY1RAG_2@`_?T#^,^?0((8
M`"9$D1`##(8,82QL*+$B!H<8+6JL"`,&BX\@,7P4"9(%29(E4ZI<J=(("R,N
M8\*$^?*ES)DX<WK,T03'D6M,@BJ#`Z='&:)'RY2!L!0"A!=E7CQU^J+J5*E5
ML3[-^J((UZI;7H3=0K8L@[-#`@Q).\3%A+<6WA*P16!NW;MX\^K=R[>OW[]U
MXPJ>X#8N@0EW$>-].R$M@RU>A72=7-;LV<N7AS#0O+:SY\Z-/XL>_TVZ=&<7
MJ`NEYF2H]2`3L$TH`>,(-0(=K"W$W@V[-6I/O'N#(N1B]^O8(QX\:!+CRX,O
M548@X*0#NI(12JI\&1%<MO8+S&4]R6VB>'?>A,`\0+->V#!A:.Z@B8^FF?UE
MRJ!5VT\-VK4=T_PG#CC@?&/.@>6H@\Z"\S3H(#SWG(&//OL41%!``N43T(4<
M0M20APJAH%%&#HUH(D8L2!2222RB5)*++,784DTWT3B3C3GE:$04,_%($PI!
M!($#"CDP<0X30R%5E%),.K645E!&B=577#T55E9CB;4%9FB=-@1AC$T0%V.'
ME0G8F6BF^9>88+K%9EV*Y?766H^1Y=6=D/]5]AB7F6VV&6>F!2KHH*>E1IQK
MB!H2@`ZKX&;!;6R$P`88.@0P7:*=#&=!;I@B&H`L,<C21`,Z,#H(`@TT,`*C
M#3PP':>"Z/!$JLN-J@,A=F6*:0`TN!=,-._=%PU^TO!7C7_<[+>"?^$0:"""
MT)JSX#H/5CM/A!-2J*%!_7!K888<3A3B0@@]A%%$))[(D4<=F>212C"^.)*,
M]()$T[TTXGBOCCCQZ...,%F!4TW+]H!".D@N0!0<9?3`<,-+14S5E%5:1?%7
M7FV%I9:5;8G96FJYY2:;AMFEYLDHISR8R&Z:N1AC`03P6!%%/'4GQY;QB=:?
M/`L:&J%`>^8::[#_8NH"`F#,6JH+CJZ2JJ@-T-#`$Y\,_=O1J(50=*>$-"#J
M*;08^N@C4Y>:JFVP'JW#"`V$.FHM@UR]:PG)_&HW?GCS5ZPUROS'GS8&.AOM
MX.NDPPX[UB8.83O9\B/AMQU&WJ&X'RK4T.7JEIBNBBJ*%._G\]8KXTTW[BN3
M3:3GY"_`_K8>A>LP\<A"/RL87"0Z82R\)%),*L64QDY==3&55UKLE5@XY]PE
M6XV-*=>;B-E"5\K45Z^7\R+#1:9B<VIFYV1>Y:FGQUQJYB>=0:>?OM5<Q\W&
MTZFNPG0D1\_:*JVSW'K)U?QOW3X"LEA.#$@%J^D@0&FH&@$G+E6(M8V`_VV@
MTI]J_$<<NMG-/M"XSS/V<RP`;4,_WN`&.0I$.&@I*!P,4ISB[F$/;6VK(-ZR
MT(8@@A`0T?!<%T$71S*B+G>URW,KB9?H6.(2?<4D7Z5+7;]BQ[K7-7%'2?A7
MC@1&$PQ<8PDH^$F1%(84HSRL=\%[TE;&^!6-@24KQ]O86&I`ECUE1BUK<=-@
M2N8RZ]GQCMH365NT-Z;#$,8QW[-95SI&OO*=[WSJ2^2@C"8WU\SJ`5.#Y*1(
MM0H+J$H';,#D")X`P>6,QS=BXP0%._6$)H#G`9R$FR!>Q895(>"!MC&$#F8!
MAA&XK0&C3)0+Z`8L9U1#&OWACP<#=*QE_6<'W?]`)C:064(3IB,>SU3A@^KA
M0AEV*X8;.LCD+D(N$.5P73Q,%P_9U9%W!3%T0QSB$?&E1'[EZ'5.C&?KH@@[
M>-K3GB[!P!D6L`0:/.0,6]0=PY;4I*9(R6*3H=(9L70\0G;L8VV)8Y@0\R;I
MU?&.&#U97+*7O8G^T7Q%V`($)(,G0NKL8X=4I$I+(\H);HI_ERAEJMC&ADGI
MH`%$6`6J5''`!H`A54\[A00)H=--O327B'*!UYA#*D<5XE4W9=0(V("V0BPU
M!E-M&W,D.)?V"4(%P-B;L:813+*:55G*-&8XF-G,<2CH'=22Y@I;B(]_\(,@
MVAR(Y"Y4N7*)*"(B<DC_8$LD$1&5LR.$;9>\4L18<PHQG?8:V#K=R:_5N<ZR
MK=M19N493X!Y5G8'PT$/2$`"@"9)2;V3F!@O9D:%%F]C6F(C&Y5W%K7`D3&"
MH6-&=VM'[;7I+84!KF/JE#'*F/2DG?D3H%;*7,_\QJN%>"10:SD>5-'B-JJR
MS?O>!\E6O0V42.4:`,&C*K8Y]52H:>4J5K7`I[:-;:0"@]L4V)JN)DH(2P"6
M6,MJUF'ZUYC,7":`VXJ@:<%5KNZHASURT`\&4XA#W`)77B77UW#5T%P/*6Q'
M(E).S2FV12Q*T;M$XI''0O8C1:R)C6R".G?*<P90Q&P2-#O/S786LZRC"0O.
M_X`#&&S@#"L(`Q=U9Q3?_<Y)5&FM((?'E2R]8+8F)1^@7+!'W_:1>R;CK9;_
M,J:1==1-5(Z9G3)VL_&=M$_F0Y]RFZO(ED*W$UZ#7P.HNJE4,>JGIMJ4`=D&
MP5%9+;R8FJ4L5C4+51[ME9"X3=,*\3[IM!*3H;H`+7#EU1/T8!@[V&!9\\-I
M`'GZTYX&<*B9R58"DZ,=YP@"JE/8#E4WZ!XL/`(_9)U%"=EZAGK=:XC"5=B)
M8!BPX.SP80GKP\.&V,0G3DD1U\EB'5WVGO2,0K2ES5G-TMC:ES4"/;$-,),<
M#`560`&2!)I:U?[.H`IM,O+4F+PM0+F-7(+CEZQ\T?_I;?G>?B$9F!@#YN%"
M1BJ"=*@;#;E<]+'Y,VL6U&:FH[4W6Q*2S"'"<S?5:.SBIH"R&L$IFJ!*4``Z
M46PP91/6IE7ZQNT1TFF4HSCE`O,VZA&W'"IT0W!I]_Q2&L`\ZS`[V%\`K759
M;$5FJ:.ECL*AL'"N=K6#8FT/ILMZUEF,>JYU376`/,3J?\VP8:V^D<0B]NOS
M:M=AWV7.9)<DQ2UN,8WO"<^UL]V>4:3QMFN,V1M[]D9G($$&4'!:+Q8YM4^)
MF,5:^Y4LO18L[C9+XN'],=OB5M\6A1.^)]\7-@'7\F^)&0-.`)G(@,^AA40I
M9Q"9<$667N&G,>J;73"J5IG_O!-:FQ732/4HU4"JY&F3G\,-44KFO)+D6.44
MJAAUZ%+I?I7FM8W30H75W5N`5[Z*_C."D6E0_]+3/`?UJ`=L:FEU(P@K"%+X
MPY\#I<M#P>]XNOII36N`W+7J\/^K_*^.]0QO>.SVQ__7\=]8L9M]=#9B!5$@
M@#Q"3U$T;=L6;=&V=G/7=C:F;?*T=CJV8S`0;GWW14RA6@!',<)3%0W5,4U&
M%K-U%K1U&;<U,E<F>7EA;Y1'>13E/'GD&)Q7,TY14GIR9J-G<`5W<`AG&FBA
M*5XU2S/U2:<2">_C-`HD-IO"**@2*JYB>Q/G?)8$'M*A`V#P2K:2&RZ0:,7W
M:$13_UXKMUXQ0(6C9%^J84'"D&G3EX;3EVG'\@R>!H?:-X?;-W3=5P[@EX=!
MHFI!@'Y*QW3IQV"S]G11=U?O%W^(R"%7=UA9=W_ZQW_&5DXB]G\KL6PL,(#Q
M=(#3]FQOMXGW)'<V%H&KXUD[Q@(D,`,Y<%H0$S%@]"16,15FI#%7,EO($Q9L
ME#QU$GI=HA;[1C*'80O1XS(LV(+X!GF6%S,AT'G!`P$VN"6,AUQ=LF:GMU+3
MF%SHTTA>=3]3Q4"=$`FH@H3<*`@A1TE>$P-/((6=XC62=ALZU3:3%C?\\TJN
M=#2VQ(0&-!TW94HQH$IFF%0E$%;2!R!P*(=M6'UT>)"?-O]@=A@M>3A^T`)^
MWU=^>SB1$WD$?&B1JE8/A<A^B9B(I(4"'TD"(#F2AO6()BEVD-A_E+@2`H,Z
M`G.`\#0#KZ.`^/2);.=V\&2`E@6!`!-W/I(0&9"*"].*K/@[`'<53+&!Z[90
M9=%N;'1FF'&"?"0F)C,]PTB,6%DFVB,S(7`"-%B#@_104*F#/<.#J"<:#""%
M]T,I2H@UPY=`Q-<U5(@TS/=QT.4";E,%135[TJ&%OR$_I6)\;%`%E*13J^`(
MMK15@M"/G0)6TO>8;?@,R+`#=("0<T@'F%F9F(E,E<E]!P*1X="0HCE^>QA^
M%'F:J$F1&&F141<$4M>1'2*2(AG_FR,IFQ?R$"*I=3!``KO)FR<9B>S"6"NI
M;`(SD]0&DYRED]!F8\KI@,[YG%*4(C-``@KC,$91`KYC9+TC%1+#9&&11E<"
M@FWTE'NBBPS@>/-F&"43)XFA@EGYGGZ4%I`A!$*PC,TX<-`(*-5HEFBI9G'D
M?$R%&SY%''O&*GVIA;)`F-@5`T\HA4H8-R*7<O3#CL9G"/*#&H'I0`_T0($Y
M';9$AES3CT]0'PJ``R5JHBB:H@99D-57F93YHI:I?9BY`IDI=&H5FM_GD#E:
MFGJ8FCZ:FA@I!:XI!18II"A`I%)PI$>0I+!9FZ05DDXJFT_ZI+VYFU9JBJ;(
MFR2`I5O:_Z4?L:58^A'!"1)E=V(P`9/T))-OMZ8,N*;RM(`W9G<NT1$;0`(K
MP#M$*3%A%#SIUJ=CL7@WB)_ELQ9@,AC!*'ET<97P28R9%P`A4`3UN8Q"0#.*
M-Y:(Q)\^V)\I99<0^@#2H7'ON$J/XDJ7Q"DZL(Z.-D`QP`;H^*"=P'PI9QNE
M\D`$A#6RRAIK8WP.5`58Q81,\P!C*!V4QC4GT!/N<:+'FFDG6GTL*H<P^JR7
MN9F92:/+HIDVNI`.*7YZ2)H_VJT^*J1]&`1$ZII+FJ128*X$P:2(.*4@*:53
MZJZD9:7Q.J]9:J6'%0$P$`$?H:_\2J:-]:_ZR@(!NP$I0;`V8?^<--F<\$2`
MGNBFFTB3_M*`<2<2=KH$18&=YY:Q41$5@9=D6;$5#75&8OD8-5`G)(A2M;5'
M+1,]+[@7[+FH6#DG`0`93E$")5"#E.J,@KHS^HFI9[F#G,&IJV1*3L,<(T`<
M3/,$9A.K@Z!Q5X@;-_4`DK8UKGH)KH$`S`<&;NE`;9-H'(J/*\=G\G,;;-.K
M"&`".A`#S"=SB6)?(=`3R!H,)5JB:KBB.Z``=BN0S`JM,?JB-2IJQD0'08!,
M>;@#H#F1IFF:WNJMX#J1X`HD10HD1SJYZ'JDZDH0LSF;'/*D[?JNGONY[XJO
MY=2EHLNEILNO^9JZ^(JO6.H1`1NP9[?_`1%KG'#'=FK:G`CX=A+HG#GF1"[!
MFRNP!$5V;DVAI]R99(17B\H[%H+*>%+&LX3Z)8)1)M/SLC"[J(0A,Y`*`39[
MLR.5L\_8)Y?JLZ4QC3VS&54;:*>@:#=%>Z#02I"078;B`F!P`4=K&UJUCZ`D
MA>,5`Q>W7ANJ`XB)5>R%2?1C2_.H-@',*&E[`6I[M+Z1*-`GMREZK,\PMVMX
MMW=+!WB+MQSLMR#LHC(*("),F8,KN"9,F<LRN*39PMK*HXL;PWL(KD8JKN<J
MI#=,N2@P!9.KN3Y<FT[:N:`[I;VII:8HK[MYQ![!FZOKI4YLNDR<KT_:NK!K
M+\4Y;6K*=KFK_[LU:9/4]H!V-SLD<`0+T`-FK*>L6)10PJ?$L[R54;+FL[/B
MRQ:<L#WKJ:C7FY6-X:@UT[TV6Y\Y*\<I!;3DZQGGZY^;X7RS9+^/<!M-`,&Q
M,@)5``GJ=32"`%^W@C5L`*S^BXY7.X8$I%.K0GQK0\#"RHZ;(LD!K'RSNBJV
M-(:/++0!T``53,$8O*PFRL&Z3'VYO,&4Z<$D#,(D7,+#;+B8^0;&'`1T\`8K
M'"2&:[@NS*T]*L.,*Z[6C,/BJJ3FF@4Z;*XDP*0\#*7B'))#_*Y)3%H10`+I
M/*7XR@%&K*6>BZ_L+*_J3%I4K&PS=KNT2[M;[)P0ZX">^$016$0K0/\"0F+&
M1]841Y;0'EMX(MMN)7@9SVN">R2]OY@8>)S',8N,]>G'-TN?(16^HD?(A5R^
M!N<GSE=*GFK)"50+[<O`A4F/QG=H1Z.V30`&#I=+``2L]NBK`$S``JQGHK0V
MO/JU6^O*O#J&^BL]<6,(]K5+*(K!<LNL%XP,"O#!5^W+FIG5PFRMP4S"U?H&
M*+S,@DL'*R#6@ZO,:6VX+ZRXU/S6-NRXXKJD63"D62`%=ZW#M@D0F1NE\%K.
M@!VZ]1S8A/VY2MP2`D.`;MK%=@>=3;234M2[>#<D4U`[-KN,Q<O0>MJ!"R6R
M40:5XTNHSN-'6JG1>9QYFR<$-ML#W>L4DQK_TCJ3@_M9TCEHR/KI?`T`'A=7
M9P34"2[7TIAD9_>(&TUHOUZEA8F"M0],H:\"*1HJK,_%-#=5!=%!?,T=F*^L
MMN<E/>G[55%MH@J`K!V\P;V,`Q]<F<",MWSKHIKIHLKL:2R\S"N\S,H<?FS-
MUC"<WW`=PS1\KD$P!4@ZN4/:S=\\N3S,UT`LQ(2]SO-:V.;LX(&=NLKV$I%-
M619^X1C>(T5D14O@S`B-9,L8XL:+4$OYIW_Z;GP2QR-=951)E=1KVM>;>8^J
MVB7`VMT+TA$-O;1-*"EU/KH2P8;@-0]`W*Q,9RW75/(XRKF*20SLH<P1`T6#
M-;J$*,J-5>S[ETO^_\#Z8RB0LJ$)K'QB^,!17C3V-:(43'WAS<'!8-55[6D?
MS+>?QMYD[>;/?,)K?>=UCIKXO=]P?<,VC,-).M?@O,.$+@4%3NBU:>A`#.%4
M^N",_NB`;:^5V&SY,B/V<ND3CF+T4B/YE(HJ\`9!H`!+X+TA#G";#8L3`ULE
MCGB!:JD1);V/AV4P#K-QX:CT6>,U;N/,"-N%U+.S7<B#[.N:H7I#TQJY?0$&
M=&BWH0I,PS:/T.S;J&CP:]UL,(8-BK0L=RA4KM0I1WRRRL!:KBDZ1=1?>[:&
M*8_+#>2NP0=PBZ+*JGWJK<%:W;<D+-8P^M[PG>=L+;C.K-9[SN?\[=\"'__7
M-7RDW,S#W*RNW,S7"]_7?PWI$!_Q0RS$DCY$0`1B)`9B*G)L&-\B%7%V-0$#
MJ4@#1=`$/Z``34`#RWB4('Z\KNA:ZF;B(AV-([UOTF.]LXZ]$V#K)4`#/>#S
M-_[:6Q`"*1[:.QXHRG6^+_5FY8B/BA;MN3H=B?9HX[ZTQ/<^VKV_JL$U-Z7=
MC7(U%,JAI5(>AMG3N>I*X[X*K934;$OLK?&V\?[FD@G,DBGO=$[,E"FMH(;,
M0+?"V3K?>6C6J"G-`$^1C3O#04+7KCG@W)S7B`Z2ZBJ226J;$N^Y?/WH?OV1
MG;OH"4[YF3NOQD9B&,%-.:1/^L00%W$&I7_Z"6'_$*>O^CED$*K?#]R4$A*Q
M`A`0`@WP!K%``RK`C'R*ZLB[\E92/(>W1B48Q\IO6Z*]/6:"\SGO@IX0`JI-
M`TWP\S3PT9/*>>%+TD=_TN!?V\6>*+GM*H=6MBJ72>D%58]FCWR&&Q\:R_O3
MU/3O/UWOOXKV*M(=]6H#"#H(.H0C(X0(""Z).H>"B8R-52,(%I:7F)F7`4TX
M.S@*.Z)T.Z&D.Z>BJJFCJ*2G;Z<K.T$[L[-!M[2TI+F^0<#`*\+!Q<;'R,%'
MP,O`4E)!*%+2U-'3*-C7*%G8W-C;WR@DXN(DYE+GX^;K[.SDX]_PX?+DV.KO
M\_7A^_S[Z/CP,*`0B.),_\$S9W(8S,$P(4.%#Q,Z?$BQHD6%!@5B8,&1Q9D%
M-(J<4/!#`8T215*^@+"2)827,%?*E+GEQ8LB-F_FK+FE9T\&0(,*#3JD:-$)
M2)%:($!@`M.G4*-*G4JUJM6K6+-&G>`BP`DA)6@L:4+C9`DA0E+^'#J$@=&W
M<./*G4NWKE&W;?,"=6&!KZ:_EQHTB:$HT0/"D'2PT<&7L:5&A`2Y6,3F$((G
M,9I<B.$7TR)+G3N#_JLCAFE!CQ0MBJQZT2!$@Q(MFCS(4&I(D41?FHR)@.=.
MJCZM:A6\N''CNFKAVF7KS;!AMH89DYZLNG5CS9AI7W8$1;0CU[IWYT:^6S]]
M]__LX>M'+]X[<_K4GY^?C3ZX\M3RVR]XY.&*_P`&*."`!!8X8$-G8+`11QCD
ML(0*0B@@80,0GG#"%BJY9)-+&N*4TPLU>6A332""Z!,#:PG5%E!#!&!4`$HE
MM956--9HXXU731!`""<T0$,/3?105@EGI67A%D.QF)==3#9I%UY0OH477U0"
M]E<#FQ7&1@R,15(%&U3R]5H#54A&FPX--&*::95D\IF;H(6IR9:G129989/1
M=B9L>?99VR1\AMFF)KQIXIL+)7ARW**,HC*++;0LEPNDDC[WBS`"_D+==-<I
M$P1WGW(G:G?A?(J">-B0.I\W\L6W'SSM[7<>J_-I0ZK_-OK19XTTJN[CWW\+
M!+L`#L/B8*RQPR9+[++++K!$L,WBL(2TU!(;[`H8P;`@"Q@L(,0)3S311`,-
M/'%D$5N<@!-.'+8K$TX\E=B3O#XAB622*DZ9E%),.365OS@&+/#`_>[X1%A-
MC-4$D46F=&$(*A:%EY,44SSQDA+KU9:<?5F)B6!<)F(9;2.0:::8;"`PPKB4
MY(E``X:8]L`%;&B"0`@<=PR:(J-9LN4DM8V0,B.5T&8";:_)EN=N09^\FVY/
M>YQHHU0']\HMNOP7W0IT^/(<@+E8BLRFFR:3':AH'Z'VJ&NW+=[:I\8MZ]QT
MFU<W?6['[7;>H8X::M]]J]I?_PYA[U#L$CTDKKCB/R[N^..,0Z[XM`O\A]"V
M&)S1`[B:H5%N"!"?$`*&Z++;$DPQC4COO/6>>"]1L%\\!%?[$FS[[;=;8'`)
MXBXQEEEHI53$Z*\K6?$$1U6L/,9W#4%;SSH#AB67+E3&F`N-;)EFT:!%5D4,
ME+06V0AH7-#$"+K-YEG44+OPO66#+&9"TGW-C\#\L.'&<YAZ]@GU7SG#A`H4
M5;5&/6IK6PN0UQ1H*;)YK3J;(ASAU!:XO5GP@FH[%=SD=K<.SJ=7_"#5V]JF
M00RNK8)M0Z&H`$=![N2@/X4;%N*$Q#`5$,F&1(*`#76(0QW>\(<JV*$-A^A#
M&_X(!_^6&TA',+""'I!+,)\+00`"P`#B]81=J'O)AB`0+Q/QI'6O2Q'LX+(O
M?O4+=VA,8U9T%`(A"&8)"@@2PX*GEN(Q;WFSPV/%W,(B!O2E4/_3!,@$49G$
M5"9D.HC>^&"6O\+H8#.F\4MG]A>:/U9)9RX@T\AFDYO5H"8R1SM3:_KT--EX
M;#<]\TU@EA"<`RY*:ZK0VJ,R1<O_!*.!Q2C;+8\QP1=.T(0FU%L&1>C!8H)0
M;\A$U=N2"<RVO3"%;NN;+S_U2X90DYK]&5P0*/(H8R'N)$%$RQ/$*81QCA,M
MZ$1G$8*7SG*VTYUHL6$/GH4M);+`"-Q:`!J:@!E^@D&*4Z3_HA53DL680`!>
MJS-1#>J%HH:RA8\M.DH9`38C-5HTC;H+@0IHT`EI+2R'=#Q2DIR$O.3I42Y1
MF@M$^1>]0%H@!ILYQ/8H,P+P14:1J+%>^!@CB`;$P*=<\HSZY,27`'#/30A8
MC&R4IK35J,P1@[)`TAQI2D'Q[)2\@1H!GL!*46"ME<?)&J5LR<"O+5`Z9+W4
MI8:QC!=N4X7-#.8QBWFW91)3@\DL(0GW>L%GKLV7@[L(1;;I2\%:\ZW6Q%8W
M<4##<%H(=)"-K&0G2]G*0O8K8:&G0F!P3R/@$P4I>`.YGO#/@$XQ*#XA*.ID
MPI*;@+%U0"G>2..R+PM0]**XO2@;_WW4!`G%\23I%-[#(H;'DAK%N">%"T3U
M8DE)HO(OFN%2(V;C`D.D"35^<NI3&8F;1M0T39H(0%%%L[2L8M),EOQCG";C
M7<=@(C:N"=337/K<_X6@J]&A5%@AE4``1>IK9B4K@`D'#`D6^*VA`FQ<FXE,
M#Z)J/W,EI@6%N6"]8K"PALTP0P:7S8<@EILYP%:(NXFX&YH+=#M*<4`!:EH5
MM]C%+UXQ9GM0N1PHT;-1,`(,4C"%<37@GUT1;T"KF*XKLK8E2&;=:\6(+^,Y
M;W:UNVUNIVR[C`JF$PK`P4>#Z[#1L85BR,UC<I6+L2BYA2\AV%_'_')5T)B/
M,+<I3<B26O\R0BA5,80TS06$1M7(I,]_:UYSE4*CFJBMKR^UB>IZ]V1*H9*7
M4![CA%<G/6E9?M728$,KI\06C%ZJ3<$+#O5<Z5JW4<MM;Q3.VP@MZ%>W/1.P
M&'Y(8&5-Z^Q($,2*W:9BM2;#'A"IG**+L;"'3>P7SQB)F^UL%*+``C%XP`GD
M`@,;ICB9%C/@0J5;EQ9?\L5Z>=%>(WWH<9/B@@DL1<I43C>.N!("WDI(R[YN
MI_!Z`C'CR>YX8WZ27OQWR4"/Q@6:J0+1$N'3U.3/-=8;!/B:`"C%+!60S57O
MH$GI7/5&#S!G^I_+J%LH1^_LSU9"``W&FE]+(Y"!#\3E,`S,<E#_NQ"NHE9F
MJD@=CF-&>.;*O/E=APFW$5KXPK`.+(<K,FL-$T[$N`Z0X:3EZQ*HX,0P+K;4
MB]U&"(@%6PGB"(Y9D`$QI.$'XWJ"#JC-E1:=ULNDRXD6O[UD)FN,CQ>;:%/4
M3?>!N4"CXI+0#L15)#HZ[$)CQ+>839K<E&8L+RQUKL8WTP21H28&`M=?=G&#
MO9K&[!!953S2TBNH\F)ROI5<GWD!2;2EK9=IK6ETG*R$J/[Z5VNUB'VD4O[`
M8A#8P$/?6ZMCOL%OF-K4<QMUKP2WCYSG-6\E3+XS6;W\PA:=(L\W>M+_,^(5
M'*[I:!$=BZ?.?6&#3@@;?5:R[YEC%MB!_P=BL,(/S$=::@MYR$3NR6I9TG:&
MXNOM;YGHN:V"[KK[_^Y7%@IQA'U^IQ;UMESYEH#-(R5%P6\6IWB6@``,US*0
M0";4LW&J07D;AR9SUCZ65!B%1B6C5''O=56F9W&KEU7M%4JAD7GY0PCD15\J
MX%62L@MA,R"SATN78F`%%G0PQWO*)S>T0C?#-TP-YGO%=WPYIS9GP'S+ETV?
M]FFQ)GT@=A$!PA`%$F+59R"\QG2_)A(HUGUB&&,A4`3AMP`*L1&>90110`(M
MX&QB(`93(`+\-&W55G:F-3KK<CKPLF0HPF3B)CME-'<!XR^&Z']J='?ATEL2
M,A9]QT[S1ESY5O]28:8\]Y8Q&W=))[@SDS`TBJ`#WP,FV>4R\.4:>=((C#!H
MG\=)`1!H'.=OA-:"J!2#2],TK>%QE7<;Z>,Q3U!I)(<U7(A++-=IG<:#0;=[
M3QAS,Y>$/;>$&/1SH@9KT$>%U%@1BC5BU;>%P;B-!@(I"[!TW_1KWX)BVS>&
M8A@"?+!1<("&"0(#:\@"*(!^'@``/&`%8P!V8D=MY>8"3T9%`9!V:\=V8B1;
M]Q=W26%;A(A;_8>(6J$C3R`8[\9W\I86!MA'>E2)"GAX<)&)@X8ST&.*B8$F
MZ*,^&N@:^I.!GW@]#[AF(#AQHR1H+0AHF<<QF?<:CT!QJR=5F`<]SP7_&">`
M7P7D2C2(@P>2:]>HA<.H85&XE,`4='\UA42W8=4XE1FV:UHH8D>)E5<)(-H8
M($SP'U_)!#OPE5Y9.=8'+$KWC6H9+(:SEL("+256`A!@)&%HCG;)(V!!3PFB
MAE&``E:P`58@!5/@`5;@!%/P!OP$4)-1=D%&12'"$D+P`I'I.O=2/`3Y9>,6
M(PF91@O)D%JA.VP@&&C0B%OV3@ZS!?5V1X)'>!E9%'G0@&)"71W39J!'BM?#
M27Z652>I)1G'/Z.7@;_I>1%GBOQ6G(EGDI``:!>G,NX%0!YS7P7$*`>4-=3Y
M>@92A;=&E=J)E-BYG1:!=%J9E5NY`F09EN1Y_Y[EB9[G29Z5\Y4+P`1O>99L
M.9]OV99O>9_XF9]OR71--Y?#4Y=V.89X60(TABT8P%F>13@;0`(X$`01$`13
M$`%S^&-DMY@NXB)_:#H:XCI)4IGA1D:T(R-+D2-5`3!.T9F>22/LYFZ@L##O
MI$ZH&7BMF8#W9IPS"8LS"4CLA8KE11F4)QD?=WJ=5U7--7'$B3V.(4DV*I.D
MR((XV1>&H&ANXE((T`.>\(V&HPI8NJ7'P:55XTIF67(EQXT$@HV[=H74QY4%
M0I8`XIY@Z95O6CEFV9YM.I9FZ9[P^9YRJJ??Z*;7HI^`&JB".JB$BI\SY&O^
M^9\!NJ@S5F,*<D]G\/\?=(`#O!,$=!"A$IJ8^L@5Y7:A`_4N(P)NJ-5DLY69
MYG:B_8>B9U11AYBB-:*(HBDAI6F:Z'*`,SJCR\61$F=>_U:DOED](SF3-TEY
M18IHW!.;."F3?Y2<S!F3QEFLH^B`;!:E'M-QA)(HQX(LVIHLR;)T:IFEW[J6
M]NF666HX9QD=[;DU8DF>MC"G\@F6<BJ?\&E]?_J>],JG\#FO;YFGPD*O_(J?
M_UJH`CNP!'N?Z[B.P0('ON,L">L[S[*.2Z"P$>NP%'NH<NF?VK>H=WEL6,=9
M3-1$*%$$1*(`0<`!$BI:3_`$XD4[DV%VL84N.H$N8"04X':9"`AE4885)OK_
M%"<*%3WKLP33F:I*(UWQD'FG9<#UHFD1HY=XJQG)D;\Z>BQYFT4J=A3G/TGU
MDHA&BJ0T@C?ZFQE8)LZZI&3[K(LP"?1%7Q90`M-"+0XK+6_[+-O:+`5;MW9[
MMWB;MPN`L`:;L'Y[L("[MX(+N!,+!X9[N(<;L7#0`X;+N!'+N)#;N(T;N92[
MN)8[3Y:KL(HCERK09>6HL5,WH%;*CANQ`(PKES*;$CLP!20P!3<P6N*UCTIA
M=H[I;=VV%I;99"L"HJBZF3K;+TBQJD`KO%0VM"4:`&RPB+W%=X^H3K4JB4Y;
M>$O";R-XBT1%&<7IJSV*-"6)I)U$)52;H[[97`A`_SW:6[;HZX)B6ZWT)03S
M5+'P"[]P*[_>Y#O((K=XB[#/\BS"PK_!LK^&JK#.<K`,6[A[&[&#F\`*N\"%
MJ[B(B\"(&\&%:[@3_,"7*[F.F[F,>\&*L[B0V\&2$\*+4P:)0\**8\*.@\+&
M@@J?L`0TT+G!9HZ?>XY@<75IN+<]0']AU#40BI@I*T6RVZDM4D49VG8.1;.D
MNEQEA)`+F:K!2X@]VZI!:R/&NQ6PFG>.2"$O*A+W$KW1.WDUV:,25U79RW'4
MBY+B8QF%Q+7)RGF"%H'@8X+I.\?^8QMI>THB*\*+<ZCSE#B(H[E_[+"+ZSL2
MZ[!]++&:F\A_C+D;W,@<3/^YE0O)D>S!'%S)B6/)E/S!EWO)G`S")3S")YS"
M/6#")%S*HWS*IES*99#*J]S*KOS*JPP!H\S*)5`&M1S+JTR@/;`#Z)`"5N`!
M*1`!4H`&*`&@`AIU4E>&5D<L"L$$<%`&.BP41;`"T!`$/T`##8!B>4([%N`\
M`O6'?G@B25RJ$I6S)`JT4A;%OJNB4B'%%%7%5*$[#\E1HTD6/R1O@.=D7JR`
MV84SH^B*RXJ^7FNCJ4<]2C.;`RW&FM@7D*&D=)R^B%8%`G=*%!T"LJS+B4.@
M&NUKH$S*G_PX'HW"'WW*GYS*).W1J)S2)KW2*LW2+CW+JPS3LSS3K8S*,0W+
ML`S_`:ZLT[B\T[D,S4`-U#H-$]`\U`5UU$B=U$K-MG1``E8@!O3(`P`@!FT0
M`7B@J=T'4%(TP\ELAF*!ALX,S:&J)!"P`EE``J5``^,X1<[#LGC(`%0$SK`E
MSD=<J@:IF;_+LU`\=^J\L^V\JD+[+Q6USH/MLP9S9?OT47.D3J*CS_N<@'T"
M)M6[O:EWM<69T$M:OHFTO:]XM0!=)0@`-+4YQWA2QJ5!"11]2@$@!%ETL1!0
MRT>=0[:LT[!-VT7]VK0]U+,-U!=KRR1\U$7MVZBSV\,-V[=]VT9MU,']$LB=
MW$K]W-`=W=(]W=3-(4BV;4E=`DWM`6+``SSP!^#MW55]_P,/P`=<W6+E:,S<
MQR,VM`1,D`//7-0C(A0],`S>81+CJ)C(4VZT0[NH-;,U2ZJ[RSR#J*KOO-=_
M+;Q2G->ZU<ZPRE$)8\\,,Y=T9$>/S<^G6#U8RZL:OAKIVU3]8Z,P=:Q^\@1,
M*JVK>-I%0[V<9)R8G566I[84[0(G4-TV?N,XGN,ZGN/7C=VL9=W;=F2MU5I[
M>%`SX2%[*"(ZL>3K$B]-GKI7%.6D@Q,JT`-3\-1V`-Y:'MX`D`(_\&,SO-4J
MMM5B3H[KG8XE\)[QO79KT18KD!TOG!(LYCRR2SOP%UNP]8?C;)&\:VYZ_;M^
M'<6!_N=-O)GIO->IFN#M?-CBTO_H9G%#P=/8<'WA3YLG8&#&-AH^X//AR8GI
M(5Z^%T!)+!FLG.UYO`KJZ$.^>E+:+<Y)P%E>IR'C6%6&P=5.%,[:N#Z7+Y'K
MK+U.NL[KNEX$!Q7L+R'LQ3[LQW[LQB[LS&[DD1F91KXN19[D,5OMU'[MUI[M
M22[M&'(3TIYMI!/EI8,AY$[NX)Y:XU[N4EY'ZB[NKP7E5Y1M`Q0!]`C>!U`!
M!Y#OX5W5/_!/9>YB94[F*:;>PX:7/0#?N-Q:/]$60A`$9^WP.$"1)P#7;.W6
M^U@4<=U0`#[.NTL4IOK$_*?@>BWH(X_@?'WRPYN030S/BQX"1MOHXO+H3A<\
M3-NTE*[_/'URFV5LK(GP4RY.>:F')RU)70@@`@UPO51"ZC;ZQD^C`R(0ZI?=
MXJ]NDB&N@FPBZZ?$`,*S]5S?]5[_]6`?]F+?]>9N[F2_]=ZN%F<_Y6O/]>$^
M[O">[O7"[F`DL^W>[G9/[NKR]1=R(6!D(>IR)(`?^!8B$L(%^,)5!.-4`E/0
M!P#P!_D>^9&_[U-`!)&U(V2>^0(/60-_WC(F!&$=RQNZ%CUP!*U;"Q&/FEMP
M6BX2Q(SY(BL"X#:;+_<VB(0-V,1;\H=X6WZ-SC)BZ&=TX%1AO%RQ.[W#O(N=
M%O7F(C-J7!AY4JWQ!"_^@9.!!IRQZDL%@DRUFYU>/7@PDKLZ_QE'#]$LA6@B
M,`47$$HM*?2=KOW9[S]5L&=2FMKA)3H.TV4B4?B(G__Y#P@G6T4G)X2%6XB%
MBH."AXU%B8V2@HZ6A).56XF"FXR4H)6BC8:&A*>1FB%;JX>EBXNNL+.F1;:V
ML;>V3[J\3T+`P(<AQ,7%L;FWP+Y%3\Y"SLX-TDUI`#Q_!]K;VW]_`!%-8,;%
M`>3GZ.8!Z^SMYB=,<#UE]!`0+_B;#/LX)!$D010L*:&/P;HA`8:X&#+!Q82'
M#1$.0;AO"X--%C'NV\B1XY!]$R="'$F@I,F3*$M.(+"RI<J5+$VZ/#DS9LN'
M-'/"5,DS94R4.WM.,/>D`8TF:!0T6?]:HFD)82="@`Q)M:K5JUBK3LC*E2H"
M%RX0C/@*MJQ9"R[0IG51)0;9KPC@QIU+MZY=L`AB.!FQ]FS:!F3+JC4+5JT%
MM(A=Z)W"MZS=N&$=AX4,]ZR."S%TI#W,N;/GSYU=H!M-+BKITZ1-HSYV+JIJ
M8JY#%))-R[7M0K)V-?OE#%<Q!N<(T8;EC,WN:,AY*T_.O'G1Y&R,!0".CLV)
M)];98(>.O('W[]X5R`!@)QNW\W]X]$'S9+4YTNKBNW/78P$<>F7LX7NA<=\.
M&"0`M`,-$$0B%0,3)8200PTU*-%$%?6'D44=50@2@B&1U)-/-OD$DTL?=CA3
MB#9!U*&(.P7_Q:&*'*KD0@!L"-'`4DLLU00-3D&UCX)=]7C55@P%Z6-7@2&@
M&6&$#0;6"!=H]M9C4$89E@)3'&F88T\@J662FZVE@P$R_.#D9(\15B99:%5Q
M015?@>;FFVBM)B=LJ,5V@G7-O;9.".^Q5IIV=VYWG7;9;=<<H=MIY]PTT41'
M3#NC1<?&I($JBJBB17T7`WB<=OH=&].,@-VD(3@*:76E2CKIJJ,^,4(#532P
M:0RTQJ!``0"8=QXWWK3Q`Q%SNL?G?.WT$`]^$.1WSST3,K#"!EE,$00.)4!0
MD$$A*1B`@PXE".%%$X;;GX484C423D&I6-.(+VU8TT\ILF1BO/"R__AN3BW^
M1(`%1,VXE$`W-M&4,$4<6.Z0"`.9H4@(5T78D5OV598."A"!%YE19DP9`E.D
M@:;$$8?<%V*'Y95&&A?@):69=$4V\047C`7GS)Z]R&<QI$8'QJHY[TSHI,6M
MZC///(^JG:@\/SH?,9*6NK//J1+-JJ*O-E#UU=-8_=VK(XCJM:NK$J,#L<7H
M4&H(3[,QM-%`5QUKK7#'72NL6G.-=-)C!X``.R'L;;;9D^[L--"L<BTKK3##
MG`"NNS;^AZ\-!'N:.L.2?6P]]MRS7[,XI!"!%$$,9.VU/":TD$)`+@3D=/I(
M."ZY!S,T+[Y`V5LOO/J>*---NKO+HH?M_O_>KHL!%%5"$PK@H!13`]MR8,-#
M*ARDPM)#3Q@;(@M65@,&'*GQ]W.YH$,$4P166/9;7CER6")$D$85*I>)9%V"
MY95`9IO1K+^1.O2OP]"!D]K17A6KKA6P;EU#8-=<U;6NK:I_<=&;WN82`AT@
MH((8!)P.>+;!`#8P5FV1FP@/V,`&<M!L$=P;7238OPI&!W`";&#<$D=#&L*M
M"E5(H`D#UT(53C"%8-B@$-D@Q"!.:H,R#&$,:'B'\>BJ<0>HP#?P0`1G2"X=
M-R.6.>PSCWJ4X07ZX0]_,%("#VP@"#M80@^$$*ZI4$5UW1)22"X2(7#1$78=
MT0I)0J0N$.$.)W__U)<?>7*3099(7;FCR;UV1Y-^_0M@S!/&\Z`7/:M0CY(*
M,4L#T&>F*0`F?G.QX,:^YX(16.$')@`9)R>CI<.L12TQ2$,?QN`D*&FI98ZY
MS/U,H+]>QJF%'63#"(0YJ6&.``PR/)P(:87#$.;0:B7<80_W5I8?^HU__NN?
MSX38/V$F$&Z8L:'<<!A-!Q)QFI`)BP1#6<%L^N^!1/2F,I=8PWIBAIFP*J$P
MLVG-4")Q!,W,8=>,J(,1%-2;(XA!".OI1"CR"@!3>$![KG@.^1"+!DSHHK*4
MM;DQ6H0&*4@!"G#0@P*UT8T92LA00G*ZC]"Q!A:!Z;4X0J&-?$2/@)2)_T[X
M>*(1V:Z/\D*73G_"$-JM2'A"D<F+BO)(!2@%1T\1@B"D<E-,6E(KTV.8N1!&
MF,:L$BP_J))<P&>DN(B2+B*P@@B^2I@0B.`'YO,+R1"0U@*(()6V))-DS%2%
M!"2`3;[4G_C<^4^#$O.#M;)G/>-&SG*>LZSIG$L`SLK-<W9SB-TTH!(56\-:
M-=:$W(3LD[#YP1(&T:`%[5\)-ZO8!%S`M39LRV>S*5HC)?2U"3"`;G?K5Y@I
MM($%12SB:)@`&^3*H=T`@!-HT)YQ4+0<2EM:#N[C1?W<HPABG%`)LI`!$NR@
MI)%HUHY8JE6%8*4B,$VO1C(".TONL:?P]:,AY?\KHJ#RSI!!3:1^>R?(VA'E
M>$YU:B2%4+#Q6C4KU2OO5A+<%<)LDJTN:`#*QDK64(9/!U.P0@P@/#$\B`"7
MB4G,DJ;0APA4`:]W$4L.(3B_RQC@KP@(+,W$!T^$FE"&B>6L/17:EG(:%H*4
M(5,V?1S$G0USB`8$)V=AZUMF?C:>_K-+0=NB.+]:V;7,!*XQ`:KD*WNYM^+D
M\3"#&&75+E&W-DBS#63`9AFL.<VZQ;)`DSQ<W/K5N$^$XC?2(-'GID.+*[B/
M/38*QC!B5R,0"`()SEBM\(K7C0\IKZ3W40-PJ9="-:VT1PYVKD`.K[XZI1<C
MA]J2HLH71#E%ZJCSM2[_T3`5>4ZM$8XDB=(#8V7!<I0>D!ALE:Z*3$EKX5B5
M,/8]")[U*S&P0AJ\"F$$7,``%WB#"!00F"MQ!@%5B$`;4)9*8AL);F,I4O]B
MD-L$\$7&,[.MCWW,VBI_V<J)NV$S]1GENDR9GE[V[6R)^,%VOQO>\6;F;S%K
MP8+K0$VY5;/"%1YGS,R9@`HE;@)$,/'<4CS?3::5`[,)!H2GF<T%D$$!1A[R
MD;?9S7#&,D"YG#@K4]P&(,@S%,'!'N?Z^6:5*U88NIBLS"T+C)O#2`AVH(``
M#600K>L/5N-XE8ULH0;J3>]+*5TAG**+OH"\.D_954A!%G)VBYSO46LW5$(N
M_W5&22'Z\DJ@`@*S`ENV_A%6=RTDNC=8DQQV@0(BX!:-10:R!:?,%#(@`HAQ
M6`%C$$'B+V`^]:%%!TX`P+838+Y0KER4N4SH;IN4/\%V_C/8CG=C'\[E'-OY
MWV`.N,9!6V;;GMD`:G8SRN'\8H=W+;A*Q+>717!Q@&>\L9;U'Y,2?G*1D[SX
M:JX].7$X7+^*8+?0KSB3FSQ;`SY[S2`GN?9!H/V0MSGE#F_^Q`WP?)A[`[D'
M2$\$V'-S<NP)4I?S8GZ`OI]#ZR,`1P@"&G80A!XX&EPSA57GY5(R58!/QP"5
M%E-YY%X:<FJ$Q'7N\A);MSM@5U]"!10K4G;TDBY$<?\43J5V4$5@Q!`[<3=W
M#(-KN"9'7)%W2#("*2`F0G87WB9:IN0!#_`Q$-8`3,9LYY,_XA-Y```"'I``
MW<8R1>)Z"6<#]],FOE08;T)7M$=QOA5-[?9:SS=QST=^+]9[L25F&S=DK_5Q
M(&=\Q_=]-J!\_29^5PA]Y$=Q(A!FC<5-!16&V-=]=FAR9EA[`J=[;,B&%R=.
MG]4U8=AFW0<";7"(;0`"AGB';$9[]^1NT-<&/(!^4<0#!?`#5M1^."<?*[``
M^%%=/@=TV,4?.R($4Z``*K`$2S`ZF'9'-G5537<14#>+3W>`4(>`N(@@)#@]
MY^*`**(3_<4NA"2!\@)?Q7C_+SE5=K2S@:XV(TY%!P+6/`?"(R6X,`N#@B=8
M=RO(@F;!,2EP`2;P&!;4C=A45N+S`QD0`8;'87KQ?$[P`!<S&>.H%@A@`-<`
M``!@`S_`>1'#/VH")B%G`S'S>>@&>F!R<N"W>LQ'3U;8A]#'A0%'>L+75[!'
MA@5@B(O8!G;X?7K83,V7A7UX98#X<,$UB!9YB(:(DAJID=J7A[#UD0Y)?K[G
M9-%$;@=)<BN9B#JIB(B8DALY>V#F?-`'`@!`B0=@B9AX`F#P&E<4'Y6#4=25
M'\BB.9J37?J`$#@0!"40`D)@4C7EBJ\X$2UE%5277K18:6AI(2ZU5;)S=8>4
M7UGG_VE8EU3WI3NHEDC)J(P])6H/80[.J`!T\`9K!PPC2(UQIVM9E578J(U7
MP8V$D6SJ&(.XI#+')A8ID`'=XY@C8``*P'MLH@,_P"1O90`6XTK.U@9VP`,`
M4`!MH%P&E4ZY](\VP)IM(`,&X!8^6)`&V7UYN"8YM%"XQ89G&'TBN41>:$Q3
M=GTGB8@JJ9(MV8C*EUA^%9-QEGHTN7$`E5O9-W+-F9(8N8@;F7S3-YU^^&(`
MEV4#55#D5H?<B9&(*'GXZ)[N^9/@9V<O9@"X(G.[HAZ8.%&:^"A\<@(YT`."
M5EW*<EU@M`5CA"TO@@-+<`(!@'1?22Y#PA&SB("V*'6:YO\15]6+</DA%QAJ
M*4%?%CB7#]@[>;DARZB!YJ`"#>!4;Z!V`D.84F&8U9B"V)BCB<E@>\6""/`#
M-AB.9T(9QU90/R`&5I`RCLD]B:,`FY(&(N`$9S@&YU86;!`!N?('=E`>J_E7
MMZ<#X7@9W(F/JZF$F@$:!!E8)H"?ATB?T*90XK=;#,=;4DA]]`90SY9].OF>
M9"IY/:F3SWF&6,:';"B2H@=<PJ><.,F<1-F:C+JGO.F2+9=;A6J=,?"%<UB1
MQK>3C@J?K4F4?NJ=*UF&C2BHI[<XY$&)?]`'5.2??N:4YI`#]O&)F),Y^_$"
MV!5>!E8$2R`$",(Z$ZI>M<9K&S'_B[=HK`AXH6AY4[O8:6YY7R8*HC\%:O%5
M(L&(C!@XC+[#+TP%H\ES(PT@535:C6RIC3FJHW;'4BZS)3^*/2&3%QY@8F$A
M2N.8%S'`!D&&`&P`,Q[0`N_CF"[0!&-P`=-VJ2/0!+$2>-KC;!YP7-Y@!V6Z
M6T[@9EB:'M@@>05@`&R2F[I9,_@IJBR)ATJX)@Q)J;!'>]7)9+^%6MG45VO&
MG3O9IS+KIWL*GGBH6Q)GLKKUAP'WI6;%)#?)FK3)G)Y*LYP:LGA8JK7G<O>9
M>O>$J4#[LCC)D_")CZUIM8[ZIZ/ZG&Y6>Z_U6@V%?H\S!41P)[+A*!3U'NM@
M+%$IE5-9_VB:HZ`:`2$!<`(E4`08`I9EN:$^8J'(:I9/AZPV56MMZ:S'.#LB
M>CM@!ZUQ>:V(BSO`B"_KTD@A\)>!^51/46"[6(*7A*ZRDYA7$5=;<@-9(C+.
M9@5X@&)TH0/T-([SBJ<9``"%![`%%42BRR6.<0$%@`U:^K!;JJ7E41[>X`VJ
M60`VL+$="R<NP*:,:K/0Z5M5!I*\Y;0K6V\NMJDZ6;4S*[./BK3>-[+1NUL\
M>T\Y9%E&XK)ZRIR=:K7L^ZBT&:G0Z5KOIGI?VC\4N9W?N;U%V[W>R8A=RV0)
M(`,Q1XEVT`:>Y*K/I;8A4`+315T:M5%A!'1R.U,)$0!"0%7?TO\14'>`575>
MQ9JL:6FL&KII<V0NO>BL@R14Z1*!U@J!6Y?"[Q)VRIC"S0AK,OH440%WG*M5
MZ!II/KRCC%D9(3,-"G`!#[8E(Q`!?:``WK.Z1/06;)`9(S`%+=`&C`>P9O$$
MZZ@]/2@^%R`#/&`'411%%<`KZ9=^7)JQG(>FR<L9(G"U_,N2SSNIE0J(+,L_
M3"*UZJN_?$RS\RFRYFEGO`=FGG5D!:=Y4LN:*7F(^MNI6@NI\*N$L&6HA6Q9
M+IO(BTR4H*J]^ZN^B^R]W^NU%V`#;:"?Z`$.T_"?.">K;4L/&A6*"FI_F&81
MZR`:.<PC%9*64V&CY5*L(FR6OZS+'6S_PA[:=2@<2"!ZHG&9S'S4@*3VS"W"
ME_(2`MVJ`#&J%)D[C>2Z53KZN3Z\F"KX=_%(&-+V`P9PQ+=D`![0!TT26;!)
M8TF6F@4P%E@L%IM9NJMT&15[?MHPO+W[#9)GFU5PIC63I@6IN]S;O&4(OE8F
MOM.'GN[45R"WR)S<QS.;M3P9LHTXR91,D^ZTGF38G!5-LY(GGSV9D?3IM!%9
MOT"+OWM:M9\:JISZR2IILPOMM0;0!_SL4!`;`7UF<PG,)PL0?V5`H)\X:%69
M#^*R(PSP(NN@PQ1!:0H8EE1Q(;Z\P<%<`R^@K)0VS,2,PCQ5C'HIUB1:@2BR
MS'`IHF$=N2/B_Y<V+)@"TP`%@\&4=$D98G<+EM?>O-<0<8)"O*YF<5C9<P$>
M,`70]IJ.\151K'%J$@$0:P-;'#$Q@,]F<C(GPX-<W,7B$P,&T)J\6QZJV:8%
MD`9G&#-MTB6NQ+$S!AHQ@"N-C)+<9W*"VM`062N(ZC]5`'LPR\@6W=M8ZYS'
M9P-2*+^B)U`?79$P2]'KV[SN6;-_:M,BJ](K:UDC0'S:M\>.#-PDQWW>F=&`
M&JFE3;"[:\K<L)I-,%$(3%$J(*NTBA\E`(JV.HHGM2,%<Q#3@<O%>H!4W<L$
M",)9K=5;+<(7\B,GS#OV1=;#&-8J?(P,CFHD\N#!HU^_HRXU_(%.-?]K45'!
M5H68UXB">?WA>JVC13+.98$\33`%1;@E#6`%&>L$(A!N4:88:](U!I`&6RJ[
MMZOBD1T64JI;50`&]IKC78QM(B!RS#G:L.>UB`UL*F/0;N*$GC$"KKV]GWKD
M)F>>TO>2\Q9\!17`1L[;OAWF?HRT;M9;*DM.A(6^4_N>C*S)WVV'&DG3GQRI
MHFQ[C_5MQ;6=+YVUP%U\%JG(SPW*&WT!380-8FN)YXTVFA@`*Q`&]S$/D-[>
MH8BK2BU>K*"VJ#,=5#$=%9%'Y9(0N:RLP;P?`EX#7EVX[X76)F)4QMC,QGQ(
M"E[6_96MJ683Q?.7@EDC.$S7/I*";.FYW]S_EKRHF--3&?EJ%@EE-0A@`DW@
M;!=`;6:!80!@!3)`VE4@3%;C%JE5!6F`FENZ;%@<%C]PANXH`E.P%Q.3V4HR
MAU;H6ETC`K]YJ<$%9"`6&O8>&I'Q&3H@`^O[VLXKR92\8H15W;-YD8G8VZ(J
MGU1[M7VJOL&MLM5;I'F^J'MNY=[GY_C[R1@IM(!,O@)/%WFLQ]B=B(J8M(U8
MJNQI\//IO7,<M@Z5'NOQ!%&1WI*S`_'PP/C!<T!GJ_AP:!ZE$053%.M@`0^Q
M$/BMEB6LBQ_\WP&.#\>:K(3;X:DNUBAJ@4D5X0Z>UG/)N-G*PF97N4@!F-$H
M@@>!23A*["/AS2`._^+$;NPN(\0)E5!BX@0Q0#Y.4'D70![J`0Z_"5`']VQ8
M*L80FP`[SF&Z%0&;]V(#5070WJ.)K6)J0K+D%V\;]\Y.;A@D@Q;F6#.SB9)\
MK-`AM[2'2N]F%0,OF[V?GXAW>-UL3J99R_$!^9*_]<2KF]M2VP=[&M/@B?(+
MIW";JO&BO=#W(U"T/Q<FR9T&C]%R/'N]OW`A_9TLCW*NA6>'W@>_HI3D0/.I
M@0*S6M3>KU$EU7,_%[>R+'0J4`)/T`1"P`;;0O21=O2#6]4NY;?^K=7&^@)D
M$.#*"B%S!P@3@H,$!!.%@HB'AX:-C(^(D8Z$BXF&B9B5BXZ3A9Z>C)&AC_\3
M(4]-30IO.PI-)4)"(0P,0[6VMQ.VN;FWN+I#@L"#PH.[P[O`R1,N",S.S2[1
MS4TB"B)H.@TC)M'=W2,1/'\'=@`R"08V*0!_=N3C?P!I(]#>]O?XW0T7#R(&
M!C$,7/AA((T($3J\Q6BF8\2(!B(N7*@V,>*%!#%B.$0`S8+'CR`MN/@838>.
M>M%$(C@Y,N0%&05BMFD#`H#-FS9IZHQY3N*%C%78G.1(%,$(`S`+S)R)\R;-
MF%`+))5!M6I,$&T`9,VYM`U4J@8P5JGB<&C1$0EL)%6Z%`#6IU)MR)U+]U^Z
M=&JO8MW[-JH,&PDNE#7+40<ZJE"7OL7*DZ[CQW3_URX&$57J7P-W#+`[P+FS
MYP-__K3YT>`$F!"F4*M>?6+UZ@`+5BPH0[MVC]H0RN2&P)OWBR*_7[S80KPX
M\1)+4#5I\"3`R`D6AMFB-8OZD%G7J\^JP8![C2TU7M0(3UZ\^/'CNW/O58L7
M,4R?(&T:)2E4_$OX)VG*-/_2?$J<@-+()XY8$,`3#:2B`"NHJ!`+`P&P)V$O
MR""CC#(5&E-,,!M6.$0S(#[C3$E#Y6,/`B*TX0YG=F3E3CN>E9/"!2B9:*,]
M^XC@Q!0V3"11#"*,P`9*"DATD)$_Q4`6&"6V)%)(4*K4C4@-T8.22AV%%(-:
MB+'5E%9:+<630$`%19@T_SI<D%=77X)`F655Q2FG53J%^19<E@&F45E%$75!
M.DG=&>935#F&UUUV)9J74G?BV9A`9A*&0!5I=:G38EX5`-FF-OP3&51NOIEI
MGF$9T$=HGZ4JV@]$/(':::[%*NL)*"QP6VUEW+J;;KY!(!QPPD%@G'%%0$##
M#3LL=T*$'08S'7804J===>!UIYYYPH67+7KH7><M>QL..*!\XM*W"2?[*;+?
M?_`5HXA_Z-X'"8&&!,!&"0J^H0`.KL020H2_\")P>\E0>&&&S2:<H3`?ANBP
MB-+4F`\;!O!@QSCD>(9J:.9<D-"-^$C<#1L61130`R9:T$!&(YS$#3XB2>.D
MD_]1KM01,RQ-"=)(-'MTE)P%O/6EG9D"-A:??7)4!5)7,;55F#S-*;7403L]
M4U^/"M:RI"M5"NK55S<F5Z)DEVV77('N)>971IO4IPX!+<JH8E[]Q>G89I\M
M-V.5%8I.&SRD^ED%\4S1:JRMR2HK#CG,EIMNN/8&>:^^0E#$%L,-2UP1^`8Q
MQ1LE%!%`A"Y0Z&PMTZ:^W7;@<3N><"^0`;OK->3!'2V_M->N@)6,Z[N`[^IG
MB;OK$M^?)NB>6Q_PRX30``T*J,+@*UO\.P3`N4_HH2_&8*APP@Q/`.+X'(T(
M#0(-B'R/408`?C$\?_"`4QLVQ/`QR/F(3+(___Q@$/G_#Q`,R)XTDH>,("+-
M(*!'>B8EFLVL&^1CH`X`!32:@,DI.Y$*0`;3)YRI"297NR!-*#,UJ:GEA'_I
M4J-FXI>_)*`*)N':TA8%MK!IJBYYRZ&GDG(IK_2!;0*)X5G4M+>K,<9ND-&A
MV>3VE%$5ZA\%$(?@-`:`*3S`5:MA0^(4YQH4,*$'CPMC;WH3K!?X)CB_T=P6
MBL`YZ$V!!#@0P@F@%0`(7:\6I;-%'57'`,U]YSS:@AWL9$>[(=1`0AHBU_!^
M=R[E-1)>PCN>\7;7"4H&R#Z(&((I$J0*.K2B!*&3!?<(1C`+>>B4[R'&>SJ$
M(6&4[Y5/8(;#%#"&-*AO?0<L_P``>&`QK41-!@"Y)?Y,I`."3.0?@=%(*RX0
M@330*&7VL(!%TC"&A#SIF@S<6<3>YC:;]0Q%7`(:H^:704T)1BB28@9:;-`T
MIN3DERE,(0KEZ9AX@A!3HXH+0(18%+@Q329@>Q,.E8@._I&-AHWZ"C`3@$ZS
MK--2=\(*$A^CQ+S14"E]&UL4,39%T,BC":YB`VI:HT4L<C$$*D#!"FAC1LC1
MYG%F[)49@04<S&GN-Z!L0A`X$(0F6&Y:Q,$.*;,#U&%]!SR8"Z0@?3`[VG4+
M7.$B1>^`1U5,.E*2_OG>(GG7._A(HER&<,&!.$D'?2D`E$60!?:RYYZ`E;)@
MW4ND5O\5-CY9)J0>*[G!#T1`%#:`S"AQ*Y3)QF(_];5LF#+S!@(,X(1_."$-
M!A#!7@4R@KW2`V8PTP;<1L"S!4Y)L84)[4JZ.=JAN*UG+JC4/.G4)KB<`X8G
MX=J6>)B5VI(P3N$\H6[O9C?:@NV7E'6;60R#T(A.-(?^$$$"EKO<R)9-+C)9
MS`\;\\(8#H523,34#2E*-N4V5XEKJEH+H;N9CH*&!Q&XXFI,>E+5,&X!N^(-
MK\Q(W_IB[E?"L6E0-P>!$O2@"3N8PN=H(`1JS6*_N-.C=M28N3\J]05,96KL
M8D<[+W#'"PG6G5?%A1]+C,N1'2:%*"H954)\U3[LFM=7U17_`.?ERY.N2*L=
MWUJP5J(RKJN4ZUP99KYGO#(:(]!($ZJ@@!_@;R5!_I%#K%2^B+D`#$)1`&>/
M+)1[B"`-G2+(#ZH0@P8,R9O#C%DW3&`S`I*6*#IHZ&FM6YCAF@2U?T+;:F&"
ME::P4(/VXV?YTK0FG=0V+H62YT1WRZE"L9,MY?3;UDA[0(1V)2Z=,ALZF,M<
M?S37H(FBLY^=",P\6W=I5HDNH0PE:4JC0XFTQ2C;V%G>CL:O`&AXP@E.(%+5
M;/&D.<@!'';U4MW$M+Z^&D[FC#/LS0G!OTL(,`ENL(02;`&H?0SJ+/9X8#7>
M%%L0AEV$A4,&IXX'D90@E^^4=TEU_Z&XDEGE#X#`6CPO3,#=`>*P(%S@8C2\
MX=Z?E&,(?$'*@5WH8`!'6([G*CY9UM5A"/C!&!0>`0/@01_"1+.?U.F"&$AD
M"F.HI1,0.$PV/-,>:HH!F85I(S&GQ`4M.V"0>(8`EK&Y*-ZP`))U,'+3QI"!
M<9O+U-QI$ZP!QKHEZEK::CN3>'*)T)O"2SWI`M!$=PJVC$8*3/K0%19&.F^6
M-C5S2[7$JE4]4W\13)IC^`"I)^9.D,9;V;0^:1T>VL\9U>6*S/L'6#_!5;-6
M3:T5UQH5;``%O:9<&2LG[,M9>[]K[&\/5O&&92>K"*E[MN3[N.##(]7!@BQ#
MMK/-5-EUV_]UAN1>5)E'KQ$SS\0ASD2(.TS5$'OA];"/O;OA7=5BF`(5;_C!
M*E`A!!D;S)3]#KCNPD?P#:U2ELA_Y?G8T&48MBQ)8_#&_49$#Q-(.0932`"/
M]OJ3$3#I98AUP3[29P\%M`%EB"7*C1`P!HN/`2`\<P%IHPDEG*D?S:>%4J,C
M<_2_!,W.8)<`BT88/],T;N$6@'9T=[-$A38W7N%$0?1RH/8U:Y-#D\9<%W$1
M">!=RI4W=!91H](C#M%0'[06<R,VA[)V;%=1/.1U;",#`#!W4Q0:??`#LE9K
M[-5>-&`%*`!&+X`;]"53-B5LEE<<Q>)?"A`$04`"4[`#/6!XT7;_8-%6')7G
M1\7Q.N@A'!*V;9U'8630;9^W'@&C>AQF>E8E;^T2;L43+_*Q"+/W;K(7AZ^'
M284`#`1@(`@2/?>F+TV@`D\`(<SR;V]U8P''(3I6?(+003_V2MHP!9#U`Q=0
M2Y!8#PT@?_10)&_@`4[@!)#8`#07?MV@`T-&#V^&(E@&!O:`?5,6,J.U#P,A
M$.MW?1GA5P2D,U&R,WMV/F<")3K@#_Q7%7.A2^14-P80*5&7&'Y&&7(V:'AS
M=0?U&(:F%HW"-V$W&&XS6TVW$\!4-I8661@8&*;F=O_W=3SQ0D+2,F!0@F?G
M6ITR%RJX@J?F@:*63U31!6W`4:XV&G>'_QHYV%Y+,`-'`$:\,D;!)D@UI3G5
M-BQ'V`,[$`0W,`41L`/4\VR45X162!S?01ZO(TB;)V&RXP-?6`-@.!X8Y@6F
M8V+BMF(IF57IEFZC-U6:`'MP*(<?\`%>4).Q9RYV.`%C%3T_$`1\&$H)UE86
M,HC"=PR(J%7)=W\_Q@8*H"2Q90'@UPUCL".06'TF1W+>X'TLP09I4``',0)2
MQ@S6\'$FLA+4,`+4(`*.:`-C4``14`!CH)4Q%W_81!+7I$V)97(IP8M_XBDZ
MEULR\#1@PA@V0!8-(11$406.MA?;14^DYG:!B40@5'50`1A+Q@9#PF?KJ(WM
MF"@72&D^H8%;I_\H9S,W1#,F>[)D'U09&01,`V47;%>:!V47=,86N`DG*F)>
MG"$:>'`X(9`X6-2/JX$#+0`#)1!3ON9KA.<K"$EYU$(L_44##>F04Y`%8&1X
M5#@LPE9LQ)$YPQ$>K8-M$Z:%G.=YL1.2GV=(&08@_1%OO\.&J9<P\+([A^`%
M!.!N,QE[9'"3-UF3`!J@<Q@?B^`")\!)>YAO_[)6A'A*#2I7`S=7BFAPR?<3
M8Z``4W`!^>!9^1-^$:!P"?$$&Q<##V`ETC"5H?@$.@`&7=9E!>%^!L`CD740
M(E")PU0/"I27V72+4=*7(-%RBH(VP"@7-3&,4K&:6[,26P)0";6,D5G_4;_(
M=$3WFN:X9":A)LCX6]OXCAB8@9267(!Y=>Q49UUQ1)"R9`^%C(ZI0>[HC+/9
M7/%X*)'V=I3A)BT$`E)$=U5T.,3)7K>F`"U``B7`G+OQ:\+BG5185,4A!(K7
MD#=``DNX`I9C;1RI7Y8*'N+QG>>1+5S(>=GVD6`8AC6`8;A08O#Y2*<ZG\V2
M'_:9GX(@AS=)!C4IJP%:JSB)8@7J8JKP!D$0/:\P1P##(48)H0)GB!&*B`BG
M?,KW!D>"!C&`,Z)HEC:BHDTPER#3!)<%0>MS$IZ((P:@<0*A7`BA`RIZ$F!`
ME]+G$]EJEYV5ESRJ6!"40#M#*7JS6N1EI#*@_S56:A)+NFDC])A/JH+/B$),
M1Z98TVEC01;/=V@.:*=;RJ7+)1&!09IQFH)C:C49U"-E@ETF6#5O<AFQ.6D<
M2&G/I2A9JFI5T0>!PYN%TRHDE1I^NCA_@`)+4#D#R9RP@ZG?F:C1:82-F@5,
MB"P2.:D,ACD%F5_Y95,9*9X/IFV>VGDBJ9ZB>I+$DSRD9[7%<XAIF)]<.WNQ
M]P&R^H6OUY]?&*!(<+9H:Y/XV0GT=@I%]@;(T@J]9SUNM3W`)ZQ(F93?HXB+
M*$M/65F"(1%C<`$I8`#39R)O4`6/A:[QBF9/>0'6X#^K6!)CX`]_\I<_<+B@
MZ`)L$(\_D4"=%;H+Q/^C,D<^=142*!>/.H=;[$284/-:"3L82\H6F$*9L0F:
MRX5I81J-T#6E-J2Q0.$0+]&99@JQ&>BEX7@VBC*8OAN"8J$D,>`U3.I:8>J,
MWIB[N;M$!W5/H<)I&\6R5:1>LA:<(Z5WLJ(`=K`!-:N<@@<[8_1KTM:S6]!?
M)4`#2LB$08`#S<8;.XNT^(5&0SALX9E4&PF&3WN>7YB>A622&E:U[^E5YB(\
M^JFU`(*?[[:?KS>KL.H%9?L!6O#!:6N3]V$(M]<$>Z@O-*`"OA<^A4A\WJ,A
MQZJWIFNZ!A>C[Q<!U#!D1H&N?N40(+,U#A$D3M!P3O`2$-DI(G"8]O`$`B'_
M9=_Z#PK`N"$3`4Z@6S&!?B=WE^X:$DDC<;RHNDY:*,)H9R#0$QG!,FPP`EB:
MC'"1=&L7%MA;KT(JI1C$-\`;O&FQCGWQL*#I71$+CA)+F^ZX0V2J%3Z'$64B
MO='EF+`9L,[5=A7[F6>C:364)[J$CZE".`"`P_O8&K36&GA7OJM1`G9@!4,[
M>(074V+$&T(P;#U;+!#0`SV``T$`M$&P!&#$J&S4OP5YM(*DM!B)+8$4'K+C
MM"`Y85^8S"/Y;;KP/:QW/,E3#*\'#";IS/<Y"%X+>QH,>T/PAEY+JQ^`!%J`
MMD@@PO(Q5JE05C#6`&D5(<$J?#96#*F4MWI;###7_R?I$R)-(!C:T&2;*S+I
M4R6"44MI`%D1T&@B(`-5\"<B`"13(`-H@!(4(Q&]J`TJNKGV\`/R8`-U`SBC
ML0TN4',OL\4DD33#A0!^6;VLJQ99(3].01G)=,8*BZ6TJQC;Q5UVD76TJ71(
MU[I.`37F)--D0=.(%C9\+)NB"8Y*_5VF:9LK]+N(S&4<&Q67@H*W6U!M]US6
MRS1J\R:-`8,R*#CQD%[CJT7DZ\F*`P9"8`89$`0^.$:$^CBT<2M@Q+\4.86\
MX5\,N80<0`(KT`,EP+])*TC-B;3Z)6SC0<#98L`1UH7*['DB&=G,S,`1ZI);
MF[7O5@-P6'SZF<T9C)-SZ/_-&Z+-'CS.2"``Y?QZY=)B"(IO_:)6PQK/Q[!*
M,5S/XG-P!M<G1>;/&/UDO6@#4X8`!6`0!7W0>P65+.$_]:/<!Y0.?*58%'%`
MFHO1#V`'/(`4\D,5XD!".(01UL1`]G<FY0,E"'`1*JV`@]E:!2`025(FLUO4
M`I5$_\`_6$VRU8MT2H%!VO@C94+4<U.\9N/'&AC(V:N\9",#A0QWFH+(2K+0
M7!(5:'<9/(UU%>LI2Z1I7?W5K3:#/&!W)Y"#(K5WK($:,!"H.&`Y[AN$RIDK
M+"Y&\4L<O`'8U)D%'+`!)+`#N,S*W5E&*EY?V=*_FRK,'/FIG?>%(*F>DLW,
MS6S_V\@CS]R<DW/EV0`JDZ]ZP:+]JEZ0!S7YP0*`VC;I5:/CMF^;+*^`&N^\
M,(F48[7-Y(DXPPC0!#\P),XP!E.0?-K:<1$0$$X0W(-+T29Z#[54/T`2$?\P
M!<\-0?YC`&*YKHAE`B8`!@[Q`"T0#P80`79@!_[GNBT$$-Q0?VW&$=P0(N1M
MWDM'F2V-$XS!WDER-#3MKU[!*8E"WSL=&<R8WSD!U'HBTVI,0\D8$UN-3*9&
MFN):LE>'X%L14+[.X&/Q)VL14`)U%[>+3%K=C(DB:FKSU2"`R:K"`RD0:Z:!
M&B(^4N&.&CCP!REPRL!!.;91!DO`[K)<U\X9G7D]RTJ8_P4HT(3[V\N&ZN.^
MS)%82)X?N7ED4.0BJ<#*W"TFR<`4K%4N*7MJ.W#$X+7[.>5S:.47?/$=\MGC
MW.6I3:`]J0#JS'OM/(8/2L%KCJQ&,0]!\01`V@015%?V$*T"H3XZ@`9J6052
M'`V/.P;TX#\10!76Z@TFDR8UNGXR4UE68#&7W@X`H"F67@YIP6K6;<A>W0?G
M8$WD'4,H"MZD7NIHX[INX16J?L8CP&4&H,=/`>M<:E!12L>W[B:O'M-*$F3_
M5--%8X%ORM30+LG&?NMKD^M`$1`FV$-C4A>_/K!/>FCX]+%R<8^\>0`=;H/L
M->[D&^XMP`,KD._`8K.U`0?O#O\'[<Z_ER/OL8P#.[`#)$`"61`$.`[OP++C
M*5XY!8E4V8)M!3](3QNJ17[P%C:JMN!NW<SFV)S9'!R2.?F&56[E7TOQJHV?
MHOW\6+[E78[:^ND?!LI)TM,**@R(PTIP)\_FZ=,$&=H$0_%E/^9C3EE,C!59
M!6`%>(`2>)7S]L#S,>`$#6`"/M)EC.X"(@`(8R(C338Q.@A@(VPNC8T(+I!@
M4W9_!Y>8?P4%,A%_?W84,C8&!6T`;6T%(*R;(`4).A:SM!:1.HB-MBZUM"XQ
M(@8VPS8RHZ/#,J<`/`"H(*H&%],Q,555(U4&,IMMT*FOQ.+$!N7F"0;HYN7B
MR.*FSO'_T)LV"3$7U=@QVYNFW_.DUJU#EZ"@08,"$Y93MNP4M%>C[.6K$B.!
ML6[^O&T:Q4ZA0F+&W`44YLI;*I/T;/3YA*EERS]M?CQY$H)-B!`G;NK$N7/G
MCA815O0H4>(%A*,0RBCM4:8''*=EDI9`NF4+`P95(?38B@,%B:\[=N#H<?3%
MBZI%S"(UR[8M!+-;7M1HV];'"[MVS>)]089O7S)D:@`67*.P%P8UO-08PGC(
M!"\3(DN>3'FRE\N7/WSPHAFSER&0(3L._3@TY@]:-'>^_+@U:<BM)9LF\P&)
M``%(D'@A0"`R@2$AGC11H.#-#P5-5!0)$8#Q!,?/(SN>'AUZ_^7HU[-KIXR@
MNR/OD,)W?S("3!4=38`AL*%`Q)0?(T8XFC\?//W[^%VP08`K_'?\38APR#X&
MW&.`$S'@EP@/EKATB1T&6,$)*'\8$($,"_6SRD,8&6`"+[T\XETO)`(C#$C%
MI%C,*<W$HY$TT^`30WQ56%2221"-(XY'":&H(C$%Q./B*P78(&,^V=C8C4D:
M<>11`B(<).5'YMA@RC*HG$0//M=<4Y&5_:3BST8C\;A.,B&E.0P[&9V$4I$J
M,>C@2S#A001-.?6D4YX\[<1""E/0L<10;QFEU*&',L545!!491561A&UQ`XD
M1&`I!SL,.E6A<:7%UEN@TL567(6U-?_77:CZQ9=??P'&:F"#%688:+2"AMVM
MD<%V76:JT::89[1^QMAGGG&&FFH?D($9`;"]YEILN7*FAQ:X(?'!!+UA:T$`
M3S0P'''(-2`$<\TU)IUDUFVG[KK;=>?NNSH0XJX+#8R1!GSWC&`")/_5]U]W
M"J0Q"+_Y%?S=O`@\H0-],8SQ`+UC&*#`&,?)YT@`W3W0PIR9K%+`#W_PP$,Q
M\```PD6F<,)-/Q>80*(M_'7W<BTUCB-2,LZTZ$PK"5##97PC*(FCF#>/8R8[
M.NH(@I#.B%F`--58@\T(%Y!\Y4DY/IF.E`@)5"9)6#;MM)$3470!RJR\R<G7
M1Q>SLLHAK;G_,I//J`)G`7)R?`E,4S1P0IYL\*EG33T]L0$*0>P0Q`J;&HIH
M4TTQ59:C5S%@5`\X++'"5QM\%<189*U5U5E&E2ZJJ:2+:M=?=PFV.JN"`2;[
M[+$F%JRYP^;ZG*ZN>>8#LI<I^RMFP1+K&6U:\+H::\Z2!FVSQMIF[6Z^31``
M&]X2]P9R)8S+G'/4W0K=^.R6KZX+B!RB`W$4X^$$O.FQ,<UQ_=9_7T47E..?
MP0HV,,(3,6B`#BZ0A@;01P%.N(`+1J"`"V`##/;YCA4<](D&'<`./&B#`?K0
MC&VT`8/-X(0K8,&/C22(1/S)!8AF%C2;Z2A(S-"9W7IV)&RP88`K_WL(D^"4
M-+;UJ(<@61K3B`:UB<0G!B13A9OLYL.!<,T`P>A(F5;$-+%MHHA=NH?5F#0/
M>ASM3"C3D,I`T@UHH")+JB!%D"S(,3L`H&]/.(%-;D*3X-Q$CH.C(PD2=P02
MC`4I27D<Y(Z2%LI=Y2@]6`(.@M`Y2TT!!8P;%*C>$A>Z%*I0IY,+6_J"*A^P
M3C"H:A7M9I<LP)0R,8LQGJU6^9G=-2M8R`*>\!)#K-L9SPMD2(WRA,>\TCQ+
M5[PK#6INHQO)\,8%(?#6MXC3O1,P(`#EJHXT<66^:F9'`09@0P0$5HT+Q*<!
M\VH`&A2@@S1,(0U5L)^";F$%@4%Q#`M[!/__Y#F",4QCFU0;Q'T(MD]Y=@<-
M#VI),RJ!"9'U(4@GLY(JGM&/5]BC%$2R@2QZ\2Y=S,P".D@`$(&4,R%!Y$A(
MP@42RP@.,6VTB54Z:<F&R(D$>*E+-]3&W'1(Q"=QK2!G.M&)AK&**C;MBESR
M4C6VF)%^..F+5A.C49$QMU2(32-J!(#>,@&`-)0@CGNZXT[^II,YZN0)B]M!
M%D@0%K(8)2EH+0NG'E4Y")1`D3T(PE=2L($-9.$(B9R*H=:BEM-54BYS*55>
MV)*7U<F.53Z(W2@7&QA4_LJ6D"T-:)2G&LYP1EF!40QF:Y"'8N&R-LEC%BX]
M4YI>$DMWE`D-;6S_(X#-](8W$PA.]HB#AB8(83G1#-]UTI4N:YKO`DV(%]76
M=X\Q1``1W6&#`A06@WWQBY_0E:<+@C"%"T3@#J6P`ACV%8D/\7.?(S!`DD3@
MS2DHX+OY^6YX`'`%!PV4JAD,4A_$L*42;L@8/9-!*V30,EOXPA$7I04"J@9$
M8[`H9$+BA`.C=@U<Z$`;9?Q'UH!HII-R(QXZ>P9_L=&E$>`BO#-=XMJ.=I!@
M1'&G:TK12H=XL@)=(QMFL^_0-H*A+PKC;4HED]7,V)`FE0(`;)S3'P`0@0<\
M88YUO*--!)?')^`@+#A8).,NN5?3&;*MF'MR$"*0@A1$H'-!&)19SVH6_T_U
MU9)F*8-99&66O@QV+Z"$U:L82YLZFU(QLGIL+84UV3YSYG>Q[$QG?"6[T7;6
M"YU=[6:BY=G2GM9YS9(-9[1`K6+RA@#;PMXRPX5;:%(G?+WUK:@EXZXGI``^
M%(N!`F+P+@2DYPGG?:YT_2/KA`'`!B+PP`]^$(%*I.`.%T##%`QP!WT1C&#[
MB*(((F"`-[1!!.CMY\4BX6H[9.(E!7U:D5;&@P*DP4@UXX;=,)0_#1E@80$.
M\(!1#)*+G,*-,@2!(6#\8N1FE*1+Y,A)<WK29,`PPR9K`W^!%A\'9U3<_T#)
M41-"$"CUB-W^%F(5O2$#>[S8;/D+L4;Z@5(PXO\XQTR]D=@`L@T`6'NJ(2M`
M$[#JU9[DA,F#$\*D:-"$(^1@S*:C2U4J=TC,+>$(*TA!!C*0`@YD(<Q;46LF
MV[*%4[U%S9J<RU[VTF96J0I6LHM=LDJY==DEZU?"`\VL-B/V7P5:T+1!5MI[
MQ4M<YM(VN^F-9XLUV<M`IUERCY866'NM2ULOF30'5Q.Z%X)G@H^:V`GUJ,OG
M+AU4XX8-:,\41O"N'[R!@?.*A'3]J7D=M"`#,OA!!OH0@SZTH`T\("@F[&"%
M*GS(GV\HAQ.@F(`&5`$?Z)7UOS2/`!*T]P!$YE@;OA"OVSLA2%%*P[D'J"1R
M9V@C"IS%"M/MBWTD+23__T9P/(HT-:#=L#L'7P76P%$DB/=[H\>0>(99(8,9
MX>*&!J\:OMU4?AZ9.!U>N[ZX,2PDBEN<P_=P`1H5)FE#)"/6-A\'<L<0)J?0
M@$Q4<D%&0=V&!D=&1TJF53M!$RW7$P&@$S2P`'KE%F]12&QU2(L$=$<0`1ZP
M@I82!%MA5ISR*9G4=)HT6)Q$%V[&.E='9Z.T=6JG&37P`:@TA&87A)9U=F>W
M=K&46<&#&G`'&=DR=\#R:+$!&Z)%!M-R&ZX%6\C4+4TP3N$B!#G1'`&0>-.T
M>&CX+D&@'OLP;.!$;0MC`M[">[-&;29@`HZ'!C/``UR&!ZEW!QY0`!E@<G/2
M_P)-X%V/$!_V1'R'X$VQ-D_[XRXM<'(R,`45,"<`8`#G@0_%D`8>)@(BL#`(
M`&(84A!68C5=D``N0R*\8%$SHPTZDB9!PB`,(@]/4W`Z`'_O$@/BQD50=7[`
MZ#;%L#0BPS30,&\&%W]6T@=#HR4=5P[J<"8[@B;[YU/^UR77((#H`"8IHS8+
MYQ%)E6,Z]C9,HB4<D09`%H$NP0-]0(%_DQ-QY%4;F$<<R!PXL0-P4$BB4A4U
MP%9#4`(HP`$D<'0D8`5<5BDH4`*)I'1Q\5<-R72G0A>G8EB=-&=9-SN*94II
MIX2TPW6;L1F)(81(.))G!VB:,4N?M7>MA2TL>4NT1/\\F/$\NG,:K"4`<9<M
MLO4MM65;G79XH:9X:,@N[]($RH4`;.!A%84`]1)Y"N`(*B1K#6`%=F!M?Y`!
M!3`&'H`'UA8!>.`!=^`)<Q('=M``SO4=*>!MF$=>3:!>Z=4(`1`)#7!R=B`#
MJ><2GV`'?8`/3J`.K,8?E/<(^U!Q`F@#";4R$C5]O@`)`:8#$,<-!L8,0U:,
MJ``+N&AP[C("5O(-Y3ABL5@TYW<,6))A::0^'R9<V5`*;:*9!V@F)U8E[+:`
M$L=2_"4U9H-3X9@R1K4F%19&XAAR2T)_G-D&ZM@2%<`#ND8$>/1R605S]*@3
M':@32[`$$.`I)+AS5S$$###_!#T``P*9!5Z1`BQH*5LAG=,)%XY".H$5=4OW
M.JGB9G+1%QG)@UV7+";9*V=G+$$8:/5)DIJA!3Y`:<!S&I0V/2R9+:ZD9W;'
M/)$F:5F(&]0#6QWHA<31!$W0`#WY:688E*/6:AS::BY`'B/0`/@P`FC`:G1H
M`DU@!QOS(#)P+S$QE1GP`SQP'G@09"=G!7_)>_?@!-B00OOC+W3H3PCP`ZN'
M-R=74*G`7T[0!S80,3$`?SFZ0")0#]:0`%<$)NWG,B"R0J[X,AG5F<9`C"$S
M9#M#F<GH8'Y9"K[8)`$1C!8VC!WE(FET'KE(<-FP#_CV#ZNI$*V94CIU8TED
MC6G$_R76<`_JD%0'I2%QTS:W*4;&@"81YC1K@PZH-YR9$!,S`3B:RA-YPIP[
MT8&@RAPXL`)+<!:.<JK^R``EP#G>62D;X&6O.BGD^0)%\)"C@YZGPTF#M2JO
M\SHY^!?Q&1A=5V<?X`.`IH1+R)_[.9*IL7>UH1G6\G6?51M($%HL*1N/\9*W
M]!BC@:TT>1LV6:!_YX7#0:$J,"Z&YP)`J:$;VJ'OLA_41@B.]P-.<`/(08=#
M&@<9<*1V,`4Z@`<`H`#P]@.MAX<14%`G%P<'8`7<16MX`(H0I'EM>6PN\):0
M<+"8``#*8$%5A0T7(`(I(PS2(`*S%T\+1!#>5`4J4T()H/^8_H68%X4`V]@.
M(2%$D=DT)^--!@=_-Q0?5BI^(N8D+N2F-A.;<GJ+#D8C%&&HW$!3"E=C'A$,
MT>BG;>IO89,E.;)@7B*`[)"`2_6-'X%]"NAOXCABZ(`WEKHW;6`G&JAD@O-R
MRMF<SAD"-;=(.]`H_=B/_C@$`<``/>"J7P&X))`",)`I"U`$1V&K>DLJ-,AF
MFR074Z<7@>%)OCIG\5E*Q%JL_+FYRQI+SFHMUD)IG^NLF_%9_[EHQG2ME\$`
MAX%H"6I:EC%IX!IWUQH`)]``-%>NS40NTX&A[-JNK=8`;$`>,3`%X70#2MD$
M50`&+H"(X(<%*MH2;=!<(L`##V#_!VT@!GB@0?QA``"@L%U0HZOWE\>6/Q<0
ML9OG+V^)KP%@`BNZ-WT@`X1H!P5P!PL37L>'(4Y@`VF0"IZX+R-0$=!X'MN`
M(6`B7JT8(B_[,BZ0/S93LY`9;T:2C'9Z#3;B)AQR5$2+?D:;)9P@7N\'8]TD
M@.)V)=^0FSR"#GWZ$5;;?TY#;A2!<5'4J%^;8CN2?XZI5(_*FXIJ#.D@@$$R
M57L#`'C0`%A5$\J)5<H)./08J@&@.#N02$'0*-9YG8WAMQE05X$+`U_!94$A
M252,JDW7=&R6GFNF%Q59D:QS6&S,6"?Y.\8*Q\:J&?79N8#6N<A2K3X`NGNW
M=[GAQ[K4_X2>9(64P2QU1RR'UJV1=AIZP%ID\%K9TH$-H$P4VCVX92Z(MZZ_
M>QT<.D!5D`8*(*+NFI3R%`0JRD8%<!X14``C8`4M4`!X(`;MAP`QD`;6)@;,
M<*3^2H<_D`8R(`(&]*-M.6T!H`-'>@!#9@-.<'(`4`!$T!WR%P$6824F8R0Q
MPK4_?`W#<+:<D$X)W(KSX5\AXL`T^YC-@&``09H?=D0Q/(!*I$1DDG\;G%+Z
MQ6+TD``>5GP8IXU-Q2'CUD0-AU/2^,!74S=DTC-"-0V'ZK5PL\-Q0P[2*+8-
M[382_=!0<S9`)L1#-@5&MF0G4$=,S">=VIR@B@)13`,JL`-)4/\"6Y`'>XN=
M#+`#&<`#*4`"*S!64\`Y$1"=9E6KICK&5Z&WI:))G'2#A<6K?A$[L$,[@L%U
MIN1)='S'4:VY=*R?_8F$<!RZ`]K'?IP;N0$]O`0MQK1G"`J[I54;L^MWV-*%
MDTRA@V>AY**NSH%XF\QXK:8#`A2BKK8?[HJO_#$#<<`#+Y&)%]`'Y_8#?7!=
M[&@#_)$`^]H'!X6Q5V"]M'8!3OJ&PDP?_((QU!8`(W#,P(<.#()!`#`&$#0"
MRR8#3J"Q"3`%^?7+#J30Z.!-V\P/_+6*TT=M,$L+L$C08GJTFH@(=7JG]V"H
M8&(W/?Q#(LLCTX@TF^#"JC`*%R#<Q"W_VT+3C3V<##>,?PYWJ!0MBT!+?BOK
M4M4M@#.,8VF2WNJMF_AW(NH=-^]MT1)1RX2(<F]$`W$D1R\7.'9T$TLFM_8(
M326P`6-!%$V0!1NP`[5JQ8S!`$(0!"W``UD<!$=P5W+U%4O0!`LPG90DQC6`
M&&0<6*6BJWCQ%WO16%AG=;0#U1JY=7,LU7-<K"8IU;&TK-7ZQS<NNC<N/0*0
M/)+&/`9ZK8[6NIU5=[]T&8W,6@\*6];ST91<H1?J`G1=UW;M+FP@`@'2RS&0
M`I0G'N"!,)'0!!4@EE/``V(Y9!&0:^G0;9K8`@"@0*-8"FF0>K:,"<;K'=0&
MYM&&KQ6+`!;;_P`O@;T7@'K-;`/#)@*5B'\>``!]T#,VL.@%,".C:*CI`(OH
ML#*QL*6Z$,[2UPNHW2,7Q@P>U5)=_F'9>,T#B!'9;6,L?'V:^<(8PFJXL+4Q
M8HIE^[7IS=X'@33I+4(988"/2EXT,L(GYC8JT]`B]-ZZ;IO4"-_QK9L('1\`
MF[;(3&0KUZG\C2<@C8$DS1Q>X8(E<`)"H`(WD`72:16-`1Q+$`0BTP(UO4<K
MH#AC]61WNP73*<97815Y*^)#?8-HK,9*S1<4.3N_(SLL7M4U/N.:&^-P3-7(
M<L?^J>-]7*U=_=6[(M;5(UF8D<BP*Z!>?9/8TAO`T2W*1`/B<A.>YO^35&Y-
M7=X=53`&"O`#%P!.BS#*?#X%!Q`'+?`%!SN519)1&6`#KWQ.4OD#<&A=?V`%
M`#`##\(#W,7GF?TO(4`P%AL`"D`G[P$*,J``8!`OE#!D;1`!ABXP8W`E/V!O
M2[OK!>&8-B`?XIR8"4PB&26R;5J-1\M?]L8&2ZO0VFA?COJH21.U*94TOXG<
M$='E=QHC41(E-'SK%@V-,]SLMSY&Y$6G`2S;D1_?*..8:@+M4>+=[?;L`5$0
M#N1A8&``'Z31?.B._,VI2>S?`/Y5G;,#1'%;XHX#0H"N9"AS.Q`!J6><G;,"
M*Y`Y*X`"T7FW15"KJ(H5B($8LO+\-5"Y<7S_%V1@K$OM*@:_6!X9QZHQXW+,
M_:DQU<>"+/ZYXS@NNN5?\3Z>6I:Q*XC\*ZQK&KWC!4G>XR$?\I',!D)`R>("
M""<A`4-#+A,30XB+C(V.CY"1C!$Z")8(.I68"FPQEY^?+@BB"#-V/"D`&0<'
M+3(7)G@`/QDR$1%X!W>CEA<M;1<`5G9Q!W]?HBZDO*(!H\K0T`T-R=4(/ZRL
M=@`7-CP`!B-LXU49=GUI4U4F(U47(@87(Y\Z(R,Q[Q<)^C8R,C8QE%EP,=#"
MP%$&"1I<B""!C8<0^Q5H`Z`B@#8@"A2P4>53.WP7]"40D<"A1HTR"J3T]Z^?
MOWX/#<B$5S*!3)D1_UGZ.\GS7SQ-;*JX$SG2ID2>2).J?#FSIH&'.I7V]+EO
M7CU\3G&ZU!GU)->6,FO:M*EUZU<;84-6`5/)Q(\V=K+)G<NC`)HG3P2Q"1'B
M"5^_?$,("DR8<(!!(7!L(+%C"8T01?@*@;PE@&4A2X*0B,#CE`<265`T[M&D
M,8T2/8IL6<UZ"X,:#%S'KD'[!>T:+UZ0T6T[MX\7/G;[H$V&3(W=Q8,?/U[\
M0_'G'WQ$GTY=^H?H/J1KMZZ%>O?KU[7XT$)>"Q+SZ+NG1X+$BR,"CMPW\D+?
M2QXR>>J[WU\_//L/\!$@H("('/;$-$TT4<)D@Q"BR(.21"CAA!/8,04HF_^-
MT$`,3<QCR3(@?D*,'7=$(,,5!X"C`Q@M`#!"!&G(D,87<3S`BPY6\"!#&SRT
M8,4?K.#Q(3.6!%!--,J$\DPS"$R1S1]VO#+1*_:P80\^(V0"#3V:T'-E##&X
M\]0_%Q"DD)G5+*100MU$M1,(%F'4ADH&@.$1F"&)59)97_W39TQA9:755TDQ
M)8(GENA0!5;PW#0F2RHAU<:<<WK%E`$CE;433Y6BQ-0^'6%RCTB.0L02GRA%
MJA.@>I9T$Y^KHB7"!6%ZB$``=[0!Y%R\VE'`#WB=(*RP@K$Q6`A[%::L821L
M()J"D3$0PA:!25M$#S3L<`-G=OQA108D!(%"#SW_H%8N!!"HUIIKJS'@+FRW
MQ7M<;L@!EQQO9`R'7+[(!?<<O\Y=ER]VX!4,7G;2B8<=PA]\QQUYYT6<GGH-
MFX>$`%K(YP4!&V\\`<<<+](Q?4-X01P9^J5<GQ[LM3?@@(NX$,"!"2K80+26
M09@(A3SW/,$!/'2)0`P/(,H+*$@GJ4-<+:!A1PL'V!'!/&/P@(<)Z4SQ`P(7
M/(,`&Q[4%8$=%1@`]0%6F$"D*$_,<R22R3!CI"4</&D'6G..$4.5]CQ1"=PW
ML@&**)DH>N68-L!B9D$'";2FFA=`RA,(DU9>J0T)"#VJ/O#09%2?H)^*%J9Z
MO@H55Y:")<\EBL;@ZJM/_\'**>646CHZIH-N.JE&G:KT$$FK6S+JZ[%'9&I7
M2+TT>JMDG?XG6J!F>?0%!>S*JUQV>`#L"<9VSQ?WQRXKOF`PP,!!$#CT`($0
M)U"[FA#OE[!$#YIUQD,&5H1[!+DE]+\@NNIBC;MDXZ[7W,8VN%G.O/!%KWTQ
M,#O(.4YP(`BP[%S'.M0YV'@0IAWU)"P\X2F/Q":6,(@)X`/R043'0/8QD85L
M`B3S`G[PHQ\8PI`^_@'0QU[60ID=J`$)*D$#)I,S%Q1B9SY+8H2B)B2/O,%6
M2!O<)=@0-2M,P0!V$`.)6&<"$^Q@"@D(%3.:\`<`)&`$*3C`#PP0-1ZXC4CC
M>/];-)9$1V>X(`*[.H4!TE"`,<AC'.*HTI+FB`!Q"&U(A:N'0QZ2N8$LSDP(
M68@D+1"YE$C*<AGQ7=<\X@ZR.`I34'$>ZE:BO$"5+G:$XDI,]M&EJQ#/>*CB
M'>5`0#O;A:54DJ.4G+P"O0M4H4OMR%-98'D\J9S*E&+)W5EB0BOI\2(`#ZB>
M]:YGC#;\@`AY(<P)`*/-O81/69913`2F<`0<0&LR11!".H6`+G(M80E9$`,/
M_G`_T*P@?>B"0`G2M2X"QJ:`M-E"O&QCG`,*1S<.%`Z_@F,O?N6+@Q;$(,'`
M\U"$=8>#T[&.=LXSL1%:L&(7$P`9(!&@CHE,A?6Y3W'_ZG/#E.GA`^S9&($(
MU,()S*P!):A9`P"3,YTI0HE`;00KW$B/#47QJ*1H@#&LT(<];J-KI/CE"!+G
M(1TD8PI2$T$5T'"``MQ!&YN,VR5D-L@YRBP91B(K'HVAQP@X(09LT(&5QA&4
M)Y15:?8X)#TNH8^P6!4:!2'%XAAGD!C8@%,3H=TN_6$`HPFODZ8KE?'\M!)5
M';-5)#$*K$@)EGUX@A17Z6OQ)BNY`BC6<I7R2:D>=1+44@XE:&DF)TDU6N.A
MLK1361[S;KM,3#6S2Z*(YCRI^:0V3`&;Q@*,(+[YS?&%``8;V$`6=D"#TT#@
M!$5(Y_KV"0%W!B$(&:#G_19S_T_UH:L$+P@@NPK(W@'*Z[WU`HYM?E,<^2IT
M@L_![P0OR+#M8!"C$0UP!STH0HB51V'1T8(`%KP?%YHT0#`,V7Y*9I_BY(>E
M*8-I=]P3H)E^S(=`K-F"!&$90A@1B4%-\00Z$P<T=*D!:5"`7H]ZB0;$06IU
MP>(W;`6`*>@@'O.(00/4I@-^4/6I8HB:`8ZVMKN:M8ZB&)LQ.F.`0\752N*8
M:Q4$!S=1Y!6I7H.L`:H`-X-\"+!JLD`5+#D1WJ$6MF<$15!$:]MAOD1R*8D1
M6#*[CV2*<B>K\NW>0#&\8<)2<K2[B.4\]<EB3@2UG9*!H*$83#H3,R>;*A15
M^)S,1_^I<I7-C.LG&C"V:5ZOC%/8Z;#Z0AAN.K<P3R`!"ZR0A2`(`0>H$8(Z
M\ZE/]9%K!T'8P#QY8(44>`!]2^"U>O_ISW<9\+W0MJ]NEN.OA_8+.+^!:'^W
MS;"%:3L["*98@=F#'HY^E#P+%@!]2!IAC=E0/RJ]\+I=6C&9=A@^+1Q"7T(<
MQ)N%@`$F]JF*@RKE"'RB"7JC\9"(I("HC:T`%\"J'1[0%C0XX<<A^7$,VB:"
M,4RD#P48P12X$8$JJBU)H]"!W^0(N&K8,0U_B#D/VC"K>@"2KN.8QJV0)*HM
M5T)H/!<S5-<$2201=JJ\>_0L=[>4GX!"49:&2*,QW9.EO(3_><V3W5(8"2HN
M)ZK0.!&=HTU+$8M<Y+6,G?JF%+MTE/BV"I3N9*.(^93BN2EUT,.Z,OVT2L\:
M4A,A6/-PB1LU`$1@IWOQBR"4*YC"-)<P)5@!=(\0A'*I3P7YW"=W^]>#):R`
M,^*]!0G>J>S6L->?LJF!0*%MT'G5J[ZO=ZAP)HBP@6EG8;CW]K>_D]&&5:S`
M!T;P>-*=PA0R`F0FG7=]+*PR_5P'"2A$1(=K.@$7A$`%0%1`@F@P1+X446<#
M!^H46@"E5BH\BJ2XP0'B8`.IC<``'O"`<1&@MG"$9`PX^4,"(A6!`D3``'?`
M`PF0"P>0`7\S)`HP!B.05EVV<Z,P_S=S,P4Q5T:OT`!?,U=S)0Z+T@!<MB6=
MX'.')%BB@!4V<0%_Y4@),4B39`$Z<%B[I'21)A,F*&=R5UO0(UDN42A;QV=$
M\3FI]"FT\DN$AA6#`A-4YV87$2>[`Q8X:$F54TN,YG>:$%I95V>F0RB>HEMZ
M9X.W4Q*_]7.90`0R``"FQBME%`$/D!?$TGC?\VK+DADL0`)','KI4P*G(02Y
M=EYE@!J900+#Q@,>$`$PT!CHE4_KTEX#Y!JJ%U"L5QNOAU"ZX2\3!(G51D$8
M108$\VW:EF#<X7L<96`2\XD?U3`+U@'1%PG)UU(I<Q\IHXHO=1X<AF\TA6^'
MT0`TT`0*H/]]33!$).8@/X5BX=<S?6`%-Y8`YW>,=]0*PZ!5?=`'`-`',A(#
M)C`%!2`"B3,VON)_,%$``"`#"2`&%_`#W6('8A0W0G9F/-<,<4-6+B"!4%(`
M\7!E@60/5=(`(8$H2=()-9<)2"4*G306(R`0"6$!F+`DA$60A[5T<K*$5/%9
M]"!FL'1+FL)FR?,/G$84O'46OO5;7N(Z\#!9,9$3;C8I<8)V@")9;+8[K[5U
MDY9(8%=;CN))?W9,I%,3(9$G@O))F76/65(X;"%R9$AXK&!X39`7R;4LCR<^
M`1`$1P`#*)`M.V`:2^`_[=1K_;,$42E//"`&&;`8.X`:^50$+W#_B(@(4`+U
M;*R'0/7"'#4P'/0%40NEB?SU;;E'EPRC'L%7;N41'"&T8"AC0\?G,<G''_K!
M?,V'B7JP88MP;XN@;T4`1&B0BPG"BPUB)(;P4[\8C!22`FE@!U)SC'(V.!Y0
M@#FB`PE0%TX0$@9@!1$``"(`#^]P"MQ8=LYH!QE@`WT0`PH0<W9@C((E/`%!
M1]:0)&=U-#\0<]UH97*%96S`@8&DFS&@`W.C`S%@C?+0DX.S)?<@%F3V2`3Y
M-VBV$"9@`#!H6BM)%<'SD%$G=9]T6SK(6#:I)Q\).GT7A'$%AB/`.5S8:#L!
M:9.2$:74GCEH3.BY-YD05XLB6C`9*(W"_X6LXH4WF2<WF9,U>8]PETB9``8C
M5X:\4A=%F4W*HGC)DBSC$P`D@`(L4$XX`&P*\$Z<=U[=Y6M8&01APP.`F`*,
MT7GYE%ZF5Y;.!B]`&FV[@1NQAU#)(8E'JHD0I7NZUVUWV3#C,6XCI#"86#%^
M:7PFI4(W]&[*=Q_RIC*OF#'2)WT0E@B'(02WF(NZ*$21T5,GIIE*E`)X(`;E
M!YJ6T#:@8`(9<`41\`O3"`)3L#?M,`4S5P4*@`]50!%]\`T4\0T`P`-](`\7
M$!=WTV1/(`+H:%9BI8XN\`;;0"8C$`++R9Q\4V2'4@DA,"HD@0_1&0IS=`\D
M^%F2A'+$N8(B\/]H;7:>7"</0I,)1&B#-S$6N1,IEI5WS#-WEU9E^]!,/5DX
MBU*%:<">N-1:&5$YL*6%KX1;QP0\%YH)5T);$7$3G$8\[4DZ^A"AM(*N6+>L
M7Z@#HIJA!A"4A$=/'G`7@J%XK,87WN1X2KD!T!4$.]!Y.+`"2[``_F->5MEY
M49D"-GH_'@`#E1>6IB=`/CH;!O0:J_=>##1M]45?^=)0M*>D(LM!XG&7X[$P
M>%E@&$-NTE&EZ":F#;9"Q:>*\"9#*--\(72*QT=30Q``Z=0$D:FF34`#ZN1]
M)98(;PJG%&(%:8!%?P!%=AH*268%`+`!51`!T!B=]9"?6C4/\G`+9G?_$4_Q
M#K\4`Y[Y!Q&@-J'0!$O69>N(5LN@`)]:`#)6.#AG)4]0!1Q8G0T02%:")S=Y
M@(!S#T*Q*-'IG8V3)I(4`P70![W#2X+V2_PH*D1H*NS9*F'W)\ATKIVVH#O)
MK';;.ID"K&HG%;XS.N,JDYN%N@E0*P?ZK?I9KA!:$Z]Y2T7AA<L*)KJKN^F*
MD^Q**ZX+ANX*!F_!H731!VB`3<6R7*R6E/U:;`!+&D'P!H2X>57I3ECIAS;J
M`2D0`02++CPJ0.LU0(@(+^]BOO+"0+&'I)9842/[OB5K0?&;LN,F`!=3'@(#
M4EJ0'X\PF!BF,BO5?%[PBGI@?&1:4V>J`K@H_[23R2!NFIE*.R$78`4QT!E-
M(#0-,&-'90(\<`!FT`?_UR(%(+F3JPGVF`8BX(U\!'$V$`&_%%=D5'A65227
M@*EEY35,$C?.<`%_T`89``!W(%?O>K<CH`"'(F1"%JH'^K>#QG)>)JA7854#
MZ4A>$TD*T8)*<2E2B*&J:G<G^9JGE*PU^;N<6Q(-.A.?&VJ%8P\)6H4G>;N\
MY2D!:JX32A*O$BO!JL:OFZ!$T:!%@:Z^JR<1JKN+8KA@8LB]"[R'_'>H6C@)
MH"M"64W7!#["LJ_,JZ^O%@`;T`(;$)4[L*)-$`3SHWGGI7D]D#Y!0*@V*@8>
ML!A3F2[A*[ZRT6SL!?\;&9N6O*$<$"1?V8%M(/N^P+Q[)YN7Z+%@''4PY!%]
M,=MN[\:E*A-O.%LQRMP(-!4`#'`":(J+=""T0N3`;HJT$3PA(^`!53`,4Z"V
M40L*]M,%5@0`-O`#S7J`4U0%!N!C[9`E\&`5UP`EIV`G1R,*;X".PLD,3&()
M30``CR8"[GIE.&</1KPW#0!W@G,KF'"@A9.IT+"UTN,VC`-)1[.")I#"FFNN
M!II(?[N>#]IGG=N>8@'(?8:3)!'39"S1KWO2L?M)87PZ>L:$-JFN65%G.UG2
M:PRK$]HJ-\F[@#S(AURX3-W4AAPFA9M7)?QS8(`&??`'%2"4/7Q-:F@L:WC_
MR6WH7#A`;/OS3E&)`TN0/LFF3VQ-+@I[!/+$E1&P&/BD&F(IOCXZONA[OF@Y
M+\2!+R%;47&);<$LLO%[;N(1,1&SLN3!'>>!0LO<S(0IP/3Q'`),P/-V?`@,
M&;:8BSL@F9-9!+W8LT8$P>$<"3K@PH2:`NB<SI;`P5%C`^D0`<9XT1U()#^@
MT%URGQ]"J`#@F483M\`U1W9%G,^$``I0%Y/R`]Y*5W+EKCI@CS<75\X`G(/\
M5PW(CT8GD,/Y.`-Q`9[&T\M*T\]M)4/AQDWQNZ<4K+B;NX#KTRU]U,'[NA\!
MTS-1H3AI:"DMW^^=)V=<9<`3A/$L5VS\WF2\R$*Q_[N[Z]3TV.`-KM$.7B47
MS3J8\`"+&LEV8$T-0,G@PX:"P5SB\P3>`K!8B94]T*)HK7G<]6MI#5XVF@&W
M$`$!"T"QW"[D^QJU#%#.UM=_/2_9QLMQ65&$7=@C>U$)EF"?*#'V:Q[@D<RI
M*-F23=D5]J7ZD9@;UF`[6R#8?(M+H*:2*41/L!<E5@B'<&*F?=J+,`*Y+0*V
MJ<%VVAD'L`^-U:P5_<_)0"N)A#0_-A'?T#7`I0-.8"<,"`T)6"1H1=%HH&AM
M8``W)YU?4]VB"NG+*5<7,`:L\EG*4&*60:M=%E@JN(*N4V<M/=\V]ZWDFMY)
M+1(QS8-*_=2)+!*`7"OQG/\E7U+4/7W4^<W2O[O@"@X21FVAC&S1!?[>BTR/
M$`YW#FZW`XZAPLOL$Z[GPI75\PH`>$`#>:%XE]Q<SCL(?I@"!(O6:%V]OM;6
M"HL#0<"P]].]*(!/Z-)/!`0;!?3N.1ZD`U50^F(OM0=10T[DA9U@P<=1]WO,
MI`BSRQRS4EZS-^M2+`-]RK>8-65]-+/`.`#:T\`^1FM$28OFD9":/S"IY`@*
M=F6G)J!%?^!+>,[L"_<,WAK/A22HX'T*5F,";%#=EJ"`"&"!2**;*1<"UH#<
M%R';8Q8`,T_#G^`,SD!7]G`!*VR1K?N`D*%K16M'CE-FI!!8:68!(^!)[`VA
MI&[_)?4P%*1RNTH-$A&*N[$.U0ENN(@LWX4LX2:]M?W=ZF&")UAWCPM^S^W0
MU,2NR,@^U<I>X%$=[,[^['OEVA0."M5-!`4P>,2%:FFX3=R3K\82UF[(%SW"
M&.#>!/0S/]C"UC&:UJ6Q`1Z0`:3?R9^\3]EUB`2T7JM?OC\:;?;5R]G&[[0/
M;B>+'0>FY/:+!!O%\*E8\%$NP'E`Y3ADY9#-4C5%(`&PY0OLY?W&4YMN8N"L
M\8^`PH?:+39L"9T0M2Y@#G9PG;2.\F/5"\AN[%PC`EDR!7#1&04@-,X@`A8H
M`FRP);_9!()C)':D`&V0FM8("#$(@P$NA`@!`8,A;",C_T\C#6,%;6T%,@8)
M"3%/0B4]2Z$]/4(A@X8ZJ0@N+A:LIZX6LK,6"!>:!IF:%[P7,54CJ<)L.HY5
M,;T)M\J^OE7/SS'2R+V^TM'`CMK;QM._V=K"XJG=R-[@V][6U]PCQ./CQL_M
MJ@@Z]O;BCFS\]8/_``/^,R00(*N#!`L:7&4(C`P>?PY(G$CQP!\`4YH\.?$D
MQ$:/)T*$#$&RI,F3)`.LX#$CRY(=+Y<T60*A1XF;$"!\Z@%S!PDQ0#-$"`*S
M!X0B6Y(JW<*`05*G39E"A5J#0=4:5[%JQ4JF!AD?/EZ$]?$5K-FS:-.J7>M#
MR]D/6N*VU8*$KMVZ6CY\0")``/\9+Q.\`!X<N+#@PX@3YTF,6(\>)$@^'!X"
M>()E`A,PN_#8H(F"SY]Q-!G=0,C'$(F&#'$Q9((+R[!CRYY-NW9M`Q>.09P2
ML,$]A0%=I+!CYX*.1OF*D0L&4(<($<&TL4$P(D8J#Q!YV+'R^Y\.)X*>Z$#(
MRI0+-N97%1*1QA?["XH*(7*A:)$]-@TB.1I3J<`E&YE<T`0HH2RQ@"@0E&*/
M(ZJPXLHIK=`RBPO4+,.,-?/`(\P(QU3(RS7H:`/-B/.TTT\_PN3#33'2I0B/
MB-#L(\X[QM0HHX;B"#1,(QH"AT]WZI%'WBH,"9F0(D8FJ>1!#@$04445_<%#
M&AJ=P,;_"2%E*1))(Z'DI4=6M$#"#CW1\)(*.)2@TYHEX$!F$"1DX$$&&Y#`
M@0)+J`G!4DPIY9144TVU15566865H5MY)9988"W*UJ.0JN6661^TA<1<<=%5
M%V1Z:=&79(0-%FI@C)6Z6*F=:O&7%S4<=MFK`82@`@U-X`#:9Z,U45I'J"7"
M&FL3M&;;L,06*T8*U=G!@Q4F`.2(CP%-`8`5(IB@RG'!%!.#`8(,HL,%!DRA
M@[7`W,-B#!&`P`-$;8Q`)$%H7&#00;:P88@A2`XB@@''*&"`N_$AHAXB_#22
M7P,Q-"!"'VW(((-_N2@P8($&4FQ3"4(0\ZR#K[3B\82NZ!#-_S3.E/B.AB).
M$^,PQ\V(8W+P+.0=COX$Y'**IQ04,[0#$6DSD`(-*?"['"]I]-%((R1?DW9`
M"24/$:#QQ$96AH3>2%U^B5(`0BA+0H&?+)'F)T74)`0$+^WPAA16>.`V"20$
M@4.>0B"UU)]2/05H4WP7FE6B6+W055F"G\4HI&5%6NE9D_H`%UR8QK6I77GM
MU9</I8IZ6!YD=$[&J8L-D0=EI3KV6&1>?+"JL)FU/D$`3W2FP`Z@Y:IK`T^@
MUZNOJ[D6[&O%!B\\P\\`H"R0;'3+,P(_`!"!`<UE2]T('ES@KBTV>`""$U4H
M9ZX[U1D````\`%#%T(,T(6\##13)BO\"[=][;R$Q*.#(!0I,1Q]]`BNB`R2.
M0)@T1G"!"!3`!@\[H`$4$#:*.?!B16B$_CBVBEA$B!;)X5",MA$S<V&+&R?[
MT;66]Z/@N"\A^(`6"H&T))^9L&,H/)K/DD;#CA'M(!8<DI%(:*Y\@$%:3W*:
M1"K`@P)(S4I<*DF7KJ8[K94D`"CX0TOF-@J;+($4-B%%"980A""\(0@IR$`*
MZA2$+.P`!SFQ&][X]I2H](UO5_';5EZ@*!]P12Q?<=18#J>6Q#W*CVC)BUGR
MDBG):2HNE?*4`+1PJLQY(0]YT$,9M%"&,O@`D@QXI"8SMQ>ZZ"5UB(F-9F!'
MJ\_0H7:W,\W_2!(1@"&T$EC`$YXLB;6O5)#/#M<;!,)(R#P`X,:#WD,`,E(`
M`.ND8@I%/"!S;$;`"+3!>=>[UR#6)P*&,$0:\YO/*AAQ#TC<HSX!XT<D\O,$
M;T1"!#*P@0W\(P,1-$$GHW"@*/2DIHPQQ!4=DU`L:N&M5*!H'"G448X&(C]Z
MQ?"$KPA:"V5&4"'=L(8051)"#?JNBH+S$#^KV4)]I`-3F"L`P&0#&!PQTBHX
MP7A"I$@1Z3`UCGRD:B;)FA--(H46;$!N):#!*""@@@0=10A"<-,*SK@!#T3`
M3EW$:1&6JC>\\2E0;T04X+A2`\%UKG",`F0?R7(6K9)A<9`B)"(G_X>7REG.
M+5W!Y.A"!\FO3'*2E/R<%RA#.L8X9G)Z`15=16D9CXSF#71X`ZZ:0(,&J,`T
M3TS-KWH7K%DZEC;("$8![/"'!S1'7B3\`0_Z8!QOG6P$8T"@N!A4'1$`Z#<%
M14`5$N"!`O3!`./!*`(4($S:DJ<!\BHH_PY1L.DP0F",8%_"W"'<_'#H`J;U
MCPT8F).:[.2*5<2)3M14A!!0D&/[G)!`@:90%S8THN`-+T2]^]TD"4R:'/5.
M/\$P#O;23`?L?<?)NN/0H=6GA.\=*8Q^$0,;H#2E%K&#!W[04BQM:8DS=>(&
M>!"W*]+@*`D":@G*-I,N*H`$'AAC"J9@QO\='`4I2(%*4_L453;^;:I>J2H9
MK%J#1HTE4FD!I.JT.LBV0,X'9;V+)Q.)UCQLQ<>0Y)P/)$E)`83!+8UT9.H^
M<+J\?A4QF(G-9E3@&;713F*I/`TK6?FKQL;RL6"NCF2-EX"`8'9Y-X@`)G*9
MH@NDX;21\%9UG``]@GI+6@HT`!AZ9@@1_`^S"$$&D@*&`(1-!P$A.,YTV*<#
MD!JL"OEI!"2&RZ,1)$"="3`L4*=[,35YN@Q5!'49CE((A.AS0D++&4(F*MY6
M(ZVBO-01S`;*:N``$T<::X>N=PT^\+TCA?5-B#@2W5%%BT._'/(&-:35-`!;
MI`]X:.F5&,&E)B;_V"2QBE4(IE"G'4`P)YM.D)FZZ),4F#L%),@"4:C[U#^Q
M$5![<\J)45Q'S_%QJV!)7%D`Z;E\LX60<)$<9`X9F8"KZI$U\''"N>+63"TR
M+JL2#*E(=1@],'G@9OT+962CF1#([@UO^`&6"ZO*Q"IV-8QE'9@?RR(=C(%A
M>`#2F9M3D.8!`#IR5D4,Z(R-W]QCF:JV1PS2,`9?P/8?]='!&XX#O=NV[UV*
M8(,3BCZ=;VJL`04;9R0@T0AW`%1;CEC3V=:4DYU4,=2C&+5U"YK="+E:AN@M
MB`Q[1O,>CO#6V?*GWI6SHF!TW>O^2'5S-"3.@GTPV>J0QH>4#:(-2B>$_Q#"
M5T`2[5Z6M>SO(_/0!6S0AF8#^`]MP`,1/L*K+UG[VMDN(P=V<).E+A6H1;A)
M$X)P@R!P>P,1X`!1!F04IO9IQ"7.&QNE2N\5V]'>+_[C5[ZB.G]SM7..DQ3D
MQ%K(R;FE4ZH[#`."#,D7$+D,BPS#(B/N*KM>7`"1*7CV)<[7S7Q<L!(C^=1,
MOF64^\XR7UZY\%BT6@.F`4C5%!!/T`0!-4T`\%JYU!PQ$`P+N$P<$AWW0!#2
M1`W`@%'W8CV@-1[R@P_R021L(`*^@%M/,`CBY`[\@#`'HQ\F.#/CP`:>@!-G
M<Q-G5T5PD'8](&H0@!KW1`MN9UX2&'>QIEXO4_]KMO9>+;,-))*$\E`BNP9Y
M[K-=+>-/TA$=CJ`.U7"%5ZAL(Q(.[V`*$+)=Q/!/N89YRG:%G.=Y*05Z4S!Z
M!K8E)W%ZU_9$(:``6?`&5\14KE<$A\430<`!66`G=?(U;D(30L`G?A)OPR=O
M5C$H])9B6`$6]49CB`-]9+$X7R6)8"%6<T%6>*$7;4$6@D%7V]=6/@!7B[1(
MF!-*I6-QD+%(EY)7H6@9E>$ZLN(9"B!8HU$"NT)_KK18K]$:^:=_^U<%8U!T
M$=`\QO$;U:0\"``)"-`$0*(``%``(G`^T"(."],P-H!S06<(57`!^E,033`"
M(/6$^W,*\?&!UN%F_P+_4NRS#Y&0,._(/L:5=P"%`"Y8=C'H7#-H@S=8@TN@
M=FYW:JA@=_EPD,)0>5%HCRRR#976(O507]U!,X\7AO*@>)K7"Q6BA20"D:C%
M"O<U,V'8#[W&#223#)J0DBJY"XNGA5Q8,^M5#B!"#V2H>,EP"V?H;!:!$;@S
M?R'!*S(5ARFA;0&`)VIC%(7(`'DH!+22!4.Q`QR`>U]DA[WG>X?H1E%%*'G3
MB(FR*%=E%GSD*/OF;YZS?&0!?64!5I3RB3AF<#GVBI"35EZ029M#!GJ`*:BH
M9!5W<9X"&9#A.#4`*NPG97YEB_&WB_27&J_$6*XA++\HC,2B`VA0``(B`A$`
M_P!WX!T*H`/0R#,W8`FXP3.*-@)6``!M``*68`.H94WX:#W_<&@"DQL/95$Y
M\X'K4P`1`!^%-ERY0X_2(%R0%@X[PPA`=38OR(_]>(.C``=PL`!P4`+6!3(\
MB(\W,PQ(F`TQ`@S8Z7C<D`V01R\TEP]A>'F[UB&:IPPIB84MJ3(-")%TYRW$
M5H+PN&LGR0LJ*0*:\!SXF9X::4[P*`Q>F`I@\(VXD`L&RI*_T`[\99,K:0-]
M$$1IZ#P/0'HPE41"292HD:%VN$4*\&"%N`4AL`5+!0I3`#>V!S=I,PH39C=W
M(WQO]'M407Q3U6]ZI$<P=I:54I8Y&E8!%W!E55:>>/]]9"`Z=%677^$I<:&7
M7N`8%\<7=(%^<*F*?,49AJDK0%5Z6\9E*/>8C=6ED!F9;-`]<P8`8]`=S[(\
M5?`P(E``S(A"_=0(;;`NIGD)G14<.B`-@Q!G_]``3D"`TK1J@R9Y[@!2:8`1
M]\`&OI`[VE!<*NB0PQD"Q1EN,HAVH%9%H="<<)"#'R,A+B"%$F2"Z8"1S9"%
MC-=X6W@C'^D=B78?HPFJ]&F3]HF?LJJ?^WDAZ^"?J#IXC1`-U<`.(I(RL'H+
MSV&@Q&H`^[(+MCH-\/A/`XJ3ZN0PT!JMZF2LRM">(Y,,^V*L#LH#.GD1$4`#
MTJ8E6D(2<.A$V>81&[`$U07_`7AR%$DA$IZP`T$0`1$@KT?U!F:4)A\FHH;H
M;B0V?(,B1X#3%2U&1\9GHRYF%OS&56>9;\NG56H)<'*1*7A1%WFU.*JC%8M!
MEX=!!ID2<8N19$N:.GJ`I'W!%YP"BZ$D&['2`+22*XBY._57""AG?U^F<BKW
MI1-`(PM8!1&`!]$C$`W0+`+A!"!H!0D8=Z.I`Y2@'3R03G5*@M8A3/]"0`OH
M';PPF[`F3?>E`';0!F"@"+DC3@#$/L%)#RXR+ML4`D50-\4YJ<EY1<SIG,Y9
M!B=P03QX>.&@#?5YA;9*JBK3(1R$,])T;`VI:R'2(=60G\8ZK`F0"=3ZM^?@
MJ/4`_U\$]+BYH$[3F@O,H*SEL+B86ZRB6ZN]VIXE>0L&@$`.XQ^LV[K2"B#5
M^@T5D@#9FKE]P*T5\'E0,Z%4TX86&H<8JFU/(`8+4`1YP``!T+9U8S=M:R93
M\)3J-CNTTWK\>HAZ@XB"(F_S-D>=XQ5A<;#)=SAZ9)8-6Y:4"!9JF8G3UTF4
MTXD7.V-8X6,<V[&><DF/Q'V0M*1Z8)>/H4A]`:6()!E_T2JR""N<\;+LHV7U
M]RN+&4O`<[-2AG]?>KBI(`)C`!#X46@`08`%X035T2U_VD]'J`-64``'>$`V
M()L_@G,7``!I\(UC`,+4<69"$J@#8TTZX`$`@%F,4#"XH_\?[T@/]I@SB\"V
MRKLF662I!7(@"]#$34P*V"4+AL!K'^PA*WG%++F>_,6$M&8/)961SB`/)AFL
MM"NZHZN2I0M"R^&LT7H)#_.ZN<`+F8>2F:NY=@P@!BJKI9N@QL#&J]NZE``"
ME."Z#C.ML3N[M9NZ!0"A0B0E1K015U*N)Q&4V):A&4H#8J"N1<``JC$$36'$
M(EH"LP<W;R"O/1$$]01B:O1[=P-5\I84Q>>5=/2]X'LX7O5\YHN6YQM(F?B)
MA?3+>?$YYNL50':\H..Q><$YROPY;<4Y%N=P_XNR*7NQ@PD;KL09#:"+B"6S
M6;JEWGQ_EB$LP*BSL3%0=YJ`&LS_C,P($-9C3.^Y',MQ`Z:)"87*IMXB=()0
M!25,0!X\$)P9>17UIZ6&+X;0/$ZP9XYF,$#,:_=(M(/``"7A>C$X@Z'`Q$[<
MG`L0!C11"-/):XJ+K8\[JXU;J\EZ#O7X:^9"H*F+0*J;3GB\"S/YT;%*K`"B
MN<5ZK"7-A%7XN*H+R#[-3M`*N^L0J]FJN2YMQYQ+NQ<2N,=U:3W-NJA9":<Y
MU:@)R(4,N[9:Q@:Z3I2EDYN%!FS8AJ4GE)6<;0K``R@@!,?+`,`2+)XLT4M0
MHD1Q1CJ5)Q%6O=;;RL$W*(P8.#/ZO8+#*'B4L-^+RPS;;XB-OO]F<,!<.8*1
M<*RB%=W+_WU<D6^<TSEM99=VR9?^&\WN^TD2-XNP$2LN&#O;S,W>W&6]X\#$
M$HQ@-I%Y"C2"P(SYH3/*T3TZTG6Y-@(98`<VP%HNK#S?(TRF&0S62"1/4&<V
M9%#R,3_2U``,$P/I^*D+O6L-#1#:1A*O-UW/%0HXX,1-'`89+=XE4&I23!W:
MV9UD'+IF'+FWH)'K``[>PR$\_<<_'=2PRPZPBI]U?,<V?:#[V9]\7!WUG4#^
M$=4@D.!3;0FL&]0!,KO]_;J;Z]X?,B(Q4."M*]4:+M6H6=6$[-(!8I_LO4X0
MX6Q$U`8*0`0<X88L3M9EC0-_D`1"T!2MP9BMP[8JX!-3L`--,/]4G^"AKO=4
MUNO*;22P5;45*U958Y%'+W9ON&R6NER6#)N^@<38A92QA]$J(9LHQ;QB5G79
M^[N_D<1DA?2_T0RE?JE^KE(8HTT24\,&6,IE<LX*W\Q8K"W!Y#P!]]QR`B$(
M,W>F.H./U/FF$-B0,9`"?8!I5PLS@Z``?U``N800'Y@S`[VU"*4(;\`#XJ((
MC%#=#-W%%G42;<MI\;0`WPW>&9WJ8=`#1<#1M6`.Z5V%'C*LQ8K'Q:K42]UX
M2`@N"`355'V:KN73A7S(U$#KSXK?$X[3&DDB%YZZ!EX`42W5ILGA'<[@0"W4
M]KG5Z735$XZ@WZ`-?LRZIQGMXU/N&^[_X4!]U`'"N`9:`"7N;*#W`RI`-2W^
MNQ>:H4T@)3/>R0\\&YNQ!!&P`B_1:1@3Y$+>RM@;L%9!1T>N%8)31UX)EH1]
MEE8%Y>4+Y51>8VQ92(X3<90Q.I*M8C[V.5YAES40YIIM<<_<OV;>\FANL:"M
M.5*6W5V2I0VL&HOE._T.SJX-F2[B"S!)6T^G2^N,'`$UD4>8+<9PIZG+7_-5
M#Q=@!_\W0T226P$-DE"WW(K0``<HW8C&#UQ7C[JV,PV%"*(^=F:WQ*@NWFQO
M%*5F"P]>(K!:H/[]WWF,GNM9(@3:Z_ZQX7Y?[80<XM2`N<^:!LANZTJ]["."
MD_8=[<]4[N/S_TP+'M4-#N+H2?A&;??XN>RD=>%/W??D7@F0'_D(+L@?KKF7
MKY\&(`-.8N)?^P.C=R7C&E,N?J[Y?@!+$`*J$<[#X@(D<`,#?Q/4E8<'#Z/!
MUQ3;R_`JAD>#/;[/I[!GJ<L7OWQ@E;YN07V3HCJA$XKWRSDIMF(C3[#"_!5W
M6;):8/YXX?)0>K+2K+*A+1NNE-U#V<T-W)AMO?,\C^?@_%C@"`@(@B,Q(SJ"
MB%4Z8R.(CH@7:6P(AX>-.IB9(VR9"(8CH%6$FSJ<F((*?P:"+@@NK:TQAZZO
MM;2N`;"YN8(Z'@!3.@$(;&R@QJ#)RH:9LX(F+M"N"`'5(==%0D(0)?\]/4M+
M.`OCY.5A<&$](:\),C(V!@DQHE4Q,1<7"2(&-OW^__`,&!`A(@&^"_:J**07
M(X$-&04*M)DX$8#%BQ8I@@`QD6-$=_$.)DC`[Z&[=_X$QBN(S]ZR"_P@1FS#
ML2+&BVT`4*1),Z)/=_U&CA0(4*70EH5(C<AGTB?/FC>C[N3I\^/)H$()R@!@
MYX#7KV"]_@&`I\&3$R="I$U[C>VUMW#C7@L0@FZ`)UV3"`DQ9$+?"1-<!)Y@
M`3#@(B2"+.E1H@2$;44@%-DR>8OERY899-;,H'/G+348A*Y!FO0+,B]JG%[M
MXT5KU#Y:QYX=FTQM,K9Q^\#-.S>9#[]]?!C__F&VEMA:B@LGD\>+ER%>_.8A
M3<8T:CVKF9/1LUV/#SUEM(31(H"\%O("TJM?OQZ)>^%>/CB?_]=PM?MU[P]Q
M,237_O_\"28@8((-1J!AAA6(X((,,FA*)8HX(T@#ISSR2!47Z'"!")5HT@PH
M.C`3XHC+</*@"7C8<<$TL+R"@`)LP$*++;RX4",N-B+P!@!]-"!(",5L$@J(
MRC23B0F/N(@(?B%DLTTWWX13SCAPC!,&E7`4$8`($`%E`$(*W9,/2?Z\@U(_
M*@TT4DL**8.A`3))9%-44NFDD54V&(2//B7U@U*:1R&4#"9+Q3333G0FVM%.
M/WDI5)H!Q:,GF$06__I051QMI%.B&.7$$Z-5%>"H02/9`,`?8:5ZP%AXT,`'
M&VBI!1<;<M4JEUW7M'``#UG$^%=?]1E&`&`X1/#&-R4(D4T1S%)6V1::8;:9
M9Y]Q)EIIJIF6W0NNP1:;:]W2]NUNO)';VV[D#O?;;\3%]D%RLP'G''03/.=<
M'GF@=AVWV.E1`W8O</?=>>BQ9_#!ZKE'7'SRU1!==,/Z-41_]U6LGW\!!O:?
M@0@6Z'''#8;,8(64%--++Z!8:*$"'(X1C`DBQEQD(\L(6<K-F+@0`0`QL.+B
M*SHHX#.+1-?X2HW#C)`"#VF`,0FM08X@BB8@&BFARL,PF4UCWH`SCCA4+O]P
MY=A5PE'"&U5Y>4&8>Q+U4%$""6500E6'Z)!,4'%:9TZ93F25I$/UB6;<:[)Y
MC-0.75I`37/JC9.=BX;JZ#YI2GK0VI7"I+B<&^7D>$8`@&!GIB"$VFA((EQ@
M*JJJ@C76%$V<]020:M%JZ^UOX5I-!`?$D4(3OQ[8(`$N9!'$#HQ!QFRSE$D+
M+;36>@;]:*"!EJUJW&Z+&VNNB6ON;C7H)CYOI^$&W+K"#><N;=4]!QV]STT7
M?L#\TG]:O]SI<5X8`O"O7L$(.Q@2DK.PX3B'0?L)`,7T$R#_8&QC"HK@@B0H
M/)&%K!F]D$4G$'`!'ZG,$0WHV05DT(BI$0H3R##_$3.2@8RJF8(2&6A#(UC4
M(AG=*$>Z:(71AH&`$!B`!P#X`:TZ5"2JG<)J5T-9`R9AC28]J6M>6P`XJC2V
M*\&A;#T(@D1.=X=Z[(ER``E(H`RGB89<"E$W`2(0/P>Y-OP$'B.A7)\(=Q"Z
M):,*=Y.)1MBXMYW4)&UP+,@^QFC'$&DN3HN;RJ8\!;JI+.I3?Y0<'`UB@%.U
MSG5,B]T)9">K3LK%+;?#51-0Q8,;L&%B@`E6@P(0A"`P)C++$T+S9NF\YU$K
M6I_!UO6XIR]PR69<XLK-^7Q3KMZ8+SBV41]MY&6O]_7%"_B:7VL`1LV`Y4]_
M!$N/_P+(30&X1V$+F\_#__SBEP9:K!K]X8\"`P3!OBBH@ARCH`475"%3R((-
M/3M$`V;XP5Y8H@]"&]&'BKC"017IA4T`0!ITH*2?L8)HMM`ACG`TC!PUH`!V
M:$//>ABBA)@P1,PP@0E.:`@D(6D:&K*!"&)0E[=LK1O@B&E,K;2`LM4T#(NY
M@=_>^"61J.0?@)N42PQ:!4/)B4YK!$!2/T<10`ZD<G&[G$?OF,>9Y(V/B]Q4
M1IKJ1IX.A9"B(%(,C,JYBC"2;SKI'.GZQM:>^*VKHH+'GD#PAPI<4BP\B$#L
MSK*6VX'25KAJ:0"L8(<X1$`(#`#0/"=0`L70``*079YD:"FMZ$DO,]3396I0
MH_\:?>EF7-U#UVV^9\S2'A,XQ6G7<ASFS(D]<PCRVQ=X]`"!?O'&.]@$8#=W
MZTUP,G,^]3),7]9YL8O9"$#[X9@[#?1.>2X60<R@1"/PP0:$9+"?*G-"&I!D
MI$^4HJ`M5(8Q'H2`*=C!!K.HX2T@"HLFI&%%6:,&15T1@@MPQ0E/D.Z&!F*X
M9.`C0B)RA(MBX(1W)(!6=%'+DV@`17!\HVQCJ^D2K@B''N#``SL5E0PLQR=^
M`&I2")G'2^`$$8I$18UJQ"I.(OF.E:2))4@):RCNYA0T*LJ1)F;D5A_Y$7@4
MY"AT:P8>FV)53YFU;XTZ"2*?`LFW_B0D">@##^XJEC__1``-9X$5U/Z*NUL)
M]BTMX%43V*!`UR8W9"[`P?$@H(+(+F\RS\(,+J%'+>A9+S6E@4WY]/Q+[]FF
M-J0UIKG.!1SAI&\Y9&"`^YKY/FC&-F#3+(-MKYE-;?*6M]\,ISCGA:#_)!"=
M%>N/J-G)'PLV%Y[/G4"&*F&(!HQ!!S&8!"4VBEU'B"`#'2*4=Y5BT&4(]!09
ML,,J6L%>&M*"%V]HPP\HT4/Y\F(7Q(B`'0JP(F+`)`TJ'>1_QSJ&"XA(0K4H
M*DAB'9=L<*/!BXDBA>$PX9NR>P6@BJND"E*YPK%)QJ`8JQXYPJFEJGAT<"U`
M0/;Q8SV)^'!+(;*-'\>XQ86J_V\Z-O)3WFCOH3I#0T9=5.@@ERD\G>EM[J@Q
MDTO7DQX;X`$7*```J"R6`F"9KVSIZUNX7*L$?YF58HB``O9RGU*?.4$3*T(6
M=I"LQT@VSI6U\RVG1QKKE<8'-7C-_&S3/5^*]L_D(NV@=8/:Y1B:.,QLK3/C
M1YKIP$8/_0I8OO)W'DM?^M+@=(Y\Y`/<CDU,G0M<(#KYH]AR#N9C?Y]@J@'#
M(6;WXM42\F"M$:&T!_@S$\@`:<UJAC,$Q""C*VIH0V\AHU8T0>`_<((!8.3L
M'/$P%7G=Z%+T1)*0*$0@JS8\`I#D(A%@6P2*:(7ML/$D*"T&IN-H=QC.P6YT
M7'$%*?^(G,D[;)0Z'EP9,(F3B9E*D\[1A/H=B8B/Y1;BNF%"WWA3I.?NI.2W
MF23\6<5QZ4!21Q,Z8@1&M?XBFQK7,-J?R(QC<AOZT.,+/&!GK'-)?V`'*?`#
M3S`[L^,6--=E<W%S`8`&&9`%.\<&11`"#,!WKH6!"A0`-*`8C?$8DB$92.<\
MMU0MSZ-+VJ(:KY$:P$1U?G9U66=:O(%:79=:U<%:C9:#7L``L;5VKH%;YX)-
M;S>$Z>%;8.<P=9=*9N9`H19J&*@@JO1.@3=X@!$AE6!Y"_4(3;!XCS`&VT4)
M`]5KX>5KG2`"T]8(G0=1#W4TK7!1!9`&!>`$(@`&17,T"##_2G_0!@8P0Y*'
M(0:A"$NQ-AN$""Z"1U\B"[4P*\PB!%SC#3T``5$B?,-W166`4\2W`,E7<B87
M#T9A<#*F"7BD1]/'*1EF.HTC%8NR?GE2<:3P?C0F)V;52!NA8?=7)J*8?G[4
M?VL35A(":XKS*3A!%?57BRE1)A*A5JG8*`:Q%2RW*@5@@`@8<Y[$@%ZF.P%0
M+$'0!,I2!(FU@4O8'XD5`D>`/-M@=,M32Y55@IZ16:6A/=P#3-XS6G]V3%N7
M+NB36L.T@_-B+_P(6]&4+[HA,+A!:6U'A'#W30J#!.%$=THH,:X%:N#HC1OH
M<Z4V(`G",1>9:E9C>39@(8;`A8G`_P-5`(:$,EZ[YEUC2`J8(&T%<`B:UWG$
M%I-`,P9$L8>"4#'.%@`QP`-VD%$VH`A@2`AUA`F\B$&$.%8)`)2O8`&O0#LN
MI0U<\U@E(%-6,HD3-GQ8B8G*%U=R4S@B-@NG,`(.(7**$CI6H61H&1'\=F,[
M)5=($6`9!">'(CJ>PW'#>'\>9HS`*''"N&$'=S5B&7*PZ#FBXQ$?!S=0)3B'
MHA'"&%=WL#HLEU$_0`0'B!:TLH#4F&#6H#LG0`)$IRS7X!D6>$L*Q``JD`4X
MT!B.`4O,@XYTIHY.AX*<U4NAU6?Q.(_"`2[$5$S(I!SIPQO4X07:00;B-!VQ
MY1WDH@<?X/\=[U*0!HEIO860"@EV=.<<#N.0KJ49+V`9>R=JWK@QRU4@X1E/
MS[61%^`$'IE$V*4#04225",D0A)>XR50"-``2F4`#$6(:C@-,R((8.`$3F`#
M<.A!0=(`(91?`3`"'L`Z=@`,.L!=4E,/A7!"5VA2KJ`##Y$`:+B4M9!@M+*(
MY^88)<!@440.PR<V8G.B*V`%6VE@^=!^T84(.B!N@UF7*^9&:)FC:;DXI$@5
M[Q!BO/@(@5ED=<DH0($F`1$I4.4/B]E(V2<J7^)^CJ!O:GE5'7>8*9&82VH#
M:NE('J%]_$!7+)>'/]``?!`7F)F9@J4[UX`#GSD9H<D`HTF:#-#_2B,*6<HB
M@N@8+:\I/:(1FZ8Q=2KH2[59FX`6@U<W/KM1:.J36NE#G<LD+_DB/P"9&[CE
M`Y7VG$0HG0D)=@SS`0[#6A+S`F50!EN0'Q(9`)Z1@1IS(%)HD>5I)):W"H_`
M"2")"-K%726Y:Y('GT32"3_0H`DP-)PG(_SI4+9G`-IU`6SP`&D@`@46`05P
M`\(`!F8(%CP@`U5P4I)7"?/PH!7R"B:0`!&1``S%H4S9E#V$#>;6`S0@HH[8
M`R:*HEF9E9GXI0+74T`*EX/0#EUJH\&H84"AH^9W?C*PEJC853(@#T5Y(7()
MBS=AF$"EI5KJ)XE4I*&S4PM;-8Z04J+8_S@X&D842[']<+%&UG%0:@-M$(`"
MV`9X0)D'.#O4V&5V4;.H&@(ED`59L`2KV230,YJJVADX>P1-P+.KN0V4)6=]
M6F>=40.`VEG<PEF_9'4O*(_H,C[")#[Q*"X$0S#+H1RW-1NYI5N:NJF<BI`?
M,)US%QU#P`!E0(G<N'>EJ9W;V1FNI3$?`ZO,94$;J0"TZ@A/(&NWJ@!6D$\H
MA'"(>SCA)0@1\`=],)+\232/\&PRT@\$]P,Q@#9.$`$;)H<\]`1IH%1V`$2C
M>P?<"B(CU1+.(*XC)'"(Z`+I"KL=VE*\UPT?V(A+0%/UBI7#QP0;T!&EPY53
M13*]4`4/T3<W\?^D5U$F('=_9L*C=$)_-H`Y@T@)K3N8%]$Y=SFR)'LIHM,I
MRFL`,0`&@Z@#_GJQ&)$I6`I5CS*R)9M_=Q)7,M`'+-LZ>3@%9B%S,C>S#;BF
M7Z862T`"&0`#/#M9(=`\U,*N.S!TC/$8D-$\2&<M=&9+H]&.UA&UX6*;6WN;
MB8J;YJ-:7(NI77L>\2+"Y=&U99O"WA2=O16=F::0:IM*/F!\$,``/><7JKH%
MI5JJW&*W%4E.@O$7>HN1"+*1!'&KZYD!$=`AIB!>*-1"O7H)"RI#^KF&DGL+
MN:`#$9`&RCH&(M`$&Z(`'723U)`T^?`E"=`5?V"ZCS=K"'$(T!`-K;O_L)-0
M"[)[QZ;7%EO#&*K9->3`!%7)NUG)HO3GEVW"KY1POJ.8$:IH)L1(C"46O5^Z
ML=\FHXI\BB$[.)4S2')3L=Z+BL$[O97L"0^[<*5C?_76R>X+$5#!F%:QLF,*
M#&;!5Y?9%OP+%VRZF0%0`CM``F+``QNP`^_:+`<LIT)+&8S(`1XH&<JB+$F;
M&;:T=.R(+:O!&E$WM1H,:%B'FU>;M>NB3,MT'"(\PB,,G2IL,$B`SD68SNGL
MPM(Y'(#!`#X0!AU0!A6X=QK3&6^+E7!0!G5K9F<F(,DEQ/-DE`CP)4B,76;H
M>,T07D=4"O-9-V.P<@``N<2FGS')(KE`;&+<_P!5\`2'$%_54'H>V08'<`56
MMJTG):.#@G$R@7LS$KL<>C1-%`*]%Z\S-:],P+L[C94L4,AYTK!":@`%T`>G
M:"=W^<B0_,G)VQ,;]E'.`'^'(A7;JZ1=&3AR5#EGU"D9BZ,::I0T"HQ;E=1*
M&E1?Y;[8&[_N0+^Q'`$/D("RDJ:AY(#YT5(XL`*^S`-YM0--L)J6<<`'["S:
M$`2>^8CFYLQP)F=+=TLH:,'5H6<N:)O=PLVWZ1OG@UK)Y)N8NMD^,$#D3#`#
M=,[/V<X)DS#L[,XO;$`$X`4^P`0=``<O@*H*TAD0L``=<-L=,'P\_`(VC%Q^
MYW<$3<03L)%30&N+=__1*C,""J6K(0+%'1M>0!D#&'4`*J*>:2A@Q#HA(4#&
M/#32%67'K6`J7I%1=S`"(F4"2E`%CVD553&]YPK>\.TB3?12C0A%Y<`$^(W?
M],R["_"[LR@J2>E],FJ\$)N^(7NDJ+RE]N<.W]O4VE<(Y"4(!+[(&2%P$PLH
M!:?*%7NPR9NQ4!IK1A(#9\03G6+A%_YA&DZQ!PN_3;76]=LZ`!`!-("`:B'7
M,VNS]U$$*T#8&<`#OQP!V4@#V\@L37("B\C+0,ZS;W:.)&A9U.*TC1VHJ-$M
MIX'-,4C95GM:XN.HRJ'9QP':6N#9G@UWFDK:T'G:['RV[N$%!#`$\WS;$##_
M%^M$&!.@&670`7,@`7,P![>MV_X,+1DXT$$LGGQKE#)0;8O7`%.PTBKS0PP=
MQ1\)EK"&$"(P0R)@TKM":QE]K!-E(YZ.`&!P#VG0"!65-3@T(W:L(1F`K7T@
M96K<DW\`1#CZ)>\=DRX9W\/PE%#BB#D]#DR0`[^.V_N=VV$``RUN`Q-:>;W0
MND?M1GZ"E]U;BS(`L)`#X-_FK:S<X!@QC!Z&X4>1%9Q8L1+1U/LG<-[V(#KP
M`%RZ.'2Y8B9>UIW8E=S+#T?E1\%[L'_PXJF25WNUOS9><W1=#26``AL0!#`@
M!F*0`2F0Y"6@`MH02R]5+*C9`\ISCB-8+24(Y5'^_]BLX2VRD1N'*EJUX9L@
M/X/!<6CB@@3C_.7D+-HNWQXKK.8*P^;Q0<]S``>G6@VO0!C#XK88(`%1(`%"
MO^=]'@:[#>AWIUC)99'OA$&'4`"0^U`?Y%ZUIMPVP%WW,`_U(`IK@PQUU`L&
MT)/"EE[8#0LZL-TT!`L-D`9I(*TAW6S0MM'@G:XF<`%MT!6I\NH9L6'R<(4E
MTPSQ/;O7`)7UW>O`G@,=$.STW.>Y_;M=)<J&\$)@F')7M56.O+Y&X6*04HLJ
MAXI0"H@;Q.R8;.'=GLK?WLE973GC3N[6'OF8H#J+.7ZALV%96F]F'3@D.^UF
M!2KSRP/Z'A8\X'*5V4G_7O^-:UJS.$`",.`!$9`!"1\!$3`%X""BVA!9C$@#
M`<P!R.,8D]4L(S@M?FH9&\\M\\,MLA%:)5_RP72HEDV/(*Q,+/_9YO'R*GS:
M,8_::SXL'[#X<``($"$!A"X3%A,$0Q`=$AJ/&A*2<W,='6%A964O+UL,0T,3
M0RZ@AJ&AAA.JJCJM.@BM!2,(M+6V""ZT.@T(8R*WM3H9;;,((P9C!B(B%U4C
M,2,Z;-&OM"-6!W8%5;BTN=_=+@J\N0'@+DTI!04V%PTZ"@;%`0CF+O?X%B[Z
M"!=I/'\."#SPYP\``'UDR+"1H!DU-FRDM:J'KR*^>@%"A"@B!$*)$CU"+AFY
MH"3_DQQ,3EI:&>92AP41VH`H($/>M!$18<%*4$#FP9\`VK"SL="&4:,&DBI-
MP#2!4@,VH!Z="A4$T)]MA-IPAG.BC@OK0+2Y&I3=T[--F5Y(FT"$`:=GE<JP
M"G1L5IH&N$8;<4'&NJQC#\JD>11JW+=LX1Y^.E=LT*!WPP((.+!RY3]]T#QY
M<D*CY\^@0X/.2+ITQB`12&R(L,%#AM01=C3I0>/C1P@J//;8D25"EB4T(`@I
MLH4X\2W(/2%GX(F!<^=;:D2O0;TZ]1=D:I!YX6,[F>T^N'<GT[V\C_/HR7Q(
M/_[[]P_D/\A'[T.+CP]:\I_7CR2_`"T"!"C@@`06:."!_P@>B(0`"S*(Q(,0
M/OB!%XE\T%(E96A4R"B)3/!"&(Y`\H@$44Q2R269:-*)<P&44LH$J:"RBE?6
MR%!,+;ET8PL;:?Q@@PC5`&-%&S;,HD,,23E$#2P1!:G#&';8$<$%..IXCS>P
MO'*..;`XD492:7R91@$/U&,,&[A8I,\^+IA010(R!';0.NRHY<Q$WEBD)SX!
MX.D91QZ!%%(/))F44@X=(+H22TQL(%0!>775I#4&]"3G3R`4-1552[%UUJ9(
M054``#Q<-9@,%XR@*C4ZP"G3I0=E&E5<3C6UEEJ>NG68#:.251:DT.C5UU]6
M92487E(M]A9BM2HK5P&.V2733/_K`&39M=FT\0,13X30K6C@ADO:((0,<@()
M*<``6PHII#9%%CO4)D1(MPE10A,X!,'!;SV4`$$1`!=W7'+*-?><<M)95\,+
MVC%,W7;8<0(>=^1Q1_%YWV%LWGOQN7??>NO1AQY^^95L,H``)JCRRBP'V*"`
M"\8<H7P$3.!#&)1T`(=GA1PB"@0@BNB`B)&8:`DF<&@"P7(O@@(*C*)`[8I.
M,:01)#!6'IGJ""9@;4(&""6@2Q47B'"G#M%DB><#I19P@0[@A*-C-US*G0L8
M:<B0AA-Z0S7&!3%<\,#?%<&RCPF(FQ#XL'2:]18T>>YI$9;X3(/F9P!W]-&@
M(RU1T@+_*:G4`1.+'KU""EIMK:I7Q_1!UU6R@CIKIYXJ)?OLT/HJE`P)Z!4-
M&#R]:FH;-2G+UJUI.2LJK$&)Q4XS>L$9%F"Q[O[4[$_!I:OR227`:[20.;_.
M9-A:]H>V1)S0V?KAMC_(^Z6]+T0*&5A!0A!3L+9O$$$HT*\0*NB7;4"B@""0
M8`HX6(*_`A8P@B6'.1"$8'2FH["%92<[%L0.>-RC0?:0YX/T^:`(U1,?D=%'
M"_BIS\E0UK(6NK!`#8J9RQP4(0H1P$*4H(0@R$4*4S""1(]P@!`U,+1(%$T"
M.61)TLH`@14-P1RCB"+40N&*B<3C:EC+$0+>H(`?W`"+M8B`_QUXT`9NP&($
M9P-<%:2A$UA8(0X%2`":<G0.N]GQ2KD000)^()4+&*!L:8B`#?Z6)A>TZ@)^
M5(8!G#`[9D!#!R;8AP4F24G)720GA6RC"S`'*-N(Q'.?`QU*4C*Z1;5D!^IP
MF^]<405>&>LJA`&58;K'K.393I9)B9/NB&>`&,2@"G<:`4_$`BN9%&\Q>DQ,
M6K9'JTHQ+U8T`9POT2@]2]D%,H1)"J>XISQ7RDE:=")?^09B$#RH8#/LTTAG
MW!>:<;DS!#3(0`920((C\.:`08`7<$J@P"4(4%`TV`'_@@"<?_W+.`YT8`01
M1D'K;">#WJG.=[`SGO*`T(0:RUAWX/_#T?N(S#XG7.%_7DA2EKT,9@Q*:0U5
M@<.<,:$(&AJ%(1A0AD9(8&A%)*(0<0H)22`Q9Y>`PQ*+P*(GNJB'$Z@B+;Z$
MM:8B(!X_B($.JM"`&(A@"L5X0T#L@`<S5D-KB,0D+9R0#1G$H$IU3.L=S?$&
M/X8I#65;1MDN`)'"(>.NCEPCXB2YIC;!K9*6Q$>0))>1C0"L"!`(%.=`N8`P
MA(X)CB4=Z5J"B1VLHW?`7%TK6FDIV,42E[1KRJ=D)Y?7U44H?_1E9H5I35-E
MREEN4:8>G067N9`E*S-!E6J!*3UB&@NWR(I*8;#G+.)V[WN!D=9@1F6'<0[$
M#@"80@/XD$[_=H+KG?%#@QCJ1P)X"30(`MT!;?B)@W^6@`:T^2Y!0<*1PQ9G
M.0E=*',J6!V&><=AVLFO=S0JPA"*[#T6Q1A\/'K"^ZS09"--64D7;*`8JE1F
M#[*A%RZ$1)UIR!X3V`+0YA"%(.HTIT0,HB-\^M,Y4#9%6P@!BPAQU"%4L14I
M,``8LXB`JOHR!C^XJ@%^@"9C>``@8[S#U9X1N![3`@T"L8.,*7='RIWC(BZX
M@"_<LHPQ"+F0ALQ3*R+)IB[KX\N`XTL"=/#EP$JN&WA"0`C8H)',)=9?@BJ4
M24`'V<BZ!$5OB$!J?^F,B+22F&09RNVR)UK%2&70HMKE\V[LC"H8_V`NK\04
M+VG;%M%267E.L:WN:)(`1K_)+[ZM2W`1K<U;"G<QWKRF7:@E3N<>(+HTX`P;
M3L!FZXJ+7/`+@';E&8$CK&`'.\!!>0E5`H#Y$\YPQM=W=Z#`I3$PH="68$/I
M:\'\VK>^'`Q/@/T;8/<,F,`FM$\*#SS2_C#XW`2*X8-H&.&:X=!$3!""1GHX
M!`9```X8"!%/<;K3$/-T1#[MP(DN<=`3I)@!+6H1*5ZL`P\LV:ES,YL!FA"#
M)C0#&%9U0AO&J``GM<+("(A!"P3"@SN@M<E/QO(W+C`%IS!R#`48`]PF$H.6
MLR$?]Y@DFRJI<V4X6L9=#BP];M%CB$QDS?\G@&GF-"<H0LD9=(V%+&1+B8D%
MW&#/TU15#+Y'EIG<KC!+035I;=>KVSY/FGQVE6/J`@+C-K-9AEX,4QZ]]N'%
MD=$QZ"WU'B.6A1A&N&#_^Z$!KRQH`>:WD0%`<UW]!QY$X`'H#('Z0K-.=F*7
M7`IHP78W0`(4,'LDM?&7O(6P@]O`>0G"%B@.0H^<PPXLOO!%CG3PJS#L+.QA
MMI=HQ4;([8S>ASP;+2%Z0$I\%8J4A0I&][DAO.X(JV+"E/#I'(K-PR%H&`X=
M,(*']\W](88X1"8"*A.%$S`5L[A/58P!D68,C%PTX`EPFYO\T28"'F0C#6:\
MA0ET\(/%VT$&6H+_<G&#1VF"91<0%2)`%%'1$"/@%E53`$Y0!3DW@6OR965F
M`;^D.+-09G3D`D/W"FB#$Y*B"Q]'"VQ6!.IS6!V16(/B=*'T.75V8E5G<6@'
M#<_@3:8B:%_733NH3667@PR!=M3D%Y$F&*_%/<RD/+J2::8E:I!2@]+S*M0S
M+8XS>%2Q*=JT3==C*<5R>(^R<:Y&$'\0`4VP&9)WAK8F&O%3+@%``SS``V*0
M`AS``>!%+[?Q+_;2`\+Q$2I``PJP!/S#;(EU4,\6;<HA0=1V'1%E>[:'0?ME
M,1=E0B,4B1^U'QYE'YBX0N964B>U8#+TB3/C!37C`P)'8G.P`#"E<-8'_P$U
M-0?ZIE,AYF^Q.$3]%@E&$'X+<(<%=W`,H#;]T`>R`'&WD`O[-XS`@#8I(!"8
M(6-H4P4/8``1T`+^YP%4@B5Y<D=XE(T5434U,09C`E=3)@+/T$MIPH&2=(X6
MF'-=HR6"I5FK@B9&-UBY$(*O8%@`DW1NIE@N^()A4!*8,'68T(]H`#C2A$9;
MUQ-=IX.DMBM?AST_6"K'PCMHQUN0!BM]YW;<I(1TYRO-\X32A$B@-H4`0$QF
M<6J#!BH+H2F?8GA>N%S08G]A^`<%H!G=4GEI^!F%Q8:E(01B`(=6P`$H4(?^
MXA%OEE@=<92;HP#AU2^$>!RO!VT%DP?3)E$.8_]?$N,P^]5?XB&)&:-1YQ$R
M&%4?PW=@_L%"#-:))/6)[#8A$^`%I.B*),8$.U0(&E931M!ALKAO_J:7D#`T
M)/*7%38H<$9^Q!$"1U(-%X`0:<-^6/,&<6,+X*`#!L`#_G<0BW<`<2`0<<`#
MJ&*-+L`+3'81=J1R(Q`!!?`E4Y`49"-57*8F%/B:.J</U!`X9U4YOP01$1$1
MWR`Y2H4`;'!8^)B/ND$H<,!8+]A8CH4BF*``B+1;!_E,;=>0@2=X5HA+O,*1
MQM00S>E+4>@36"$K&<F0SJ)+'#D3;X%(Z!F2AS>2CS([2"&="D$3ZZ`0?D=V
M4@@8XB,#?0"3SO4'=N#_`32)AC9YDSR3:QF1`6^8`1X``[\6$D5)E`<E''M(
M`TL@4/Z46*[GE%`I0="1,+4G4=5V00US03Y0`]I6,9)H'A45EB84,IEX?,K7
M,C*44BC%?&SI!640?22&`?]"+M:G"1V0;T'$?7GY;[(("1T6!4IZBPL`!RUX
MAP!C"T]B!VEP(\)("WST!EUC)?('"Q<@!M?B?XU'/-6("WL!)`3X9!<1`W-4
M$6SP:&-6#))S@3@7FSLW29+Y2WI4FU<R="H76,'P"@'P!!FJ@H.X6,?96,@9
MD(R*`]M)-@8@%DUXD=(Y*Y5JG0CI*Z^%GK39G7:'D3P(6J6%G:BEG03)*SWA
M_UNXI16G]G?O"7A^T3B-4Y_>0X14^"@TX1?6PGA]L"V31Z!JB&LZ*48\8`49
MP'DK@`-#.8B#:!Q"H#DC`6S'AEA"\%Z%"'O29AVT!S$-4VV<T(@=1*(INFTL
M&FYB298CE:XQ.B!H.4/NJFY(X`440@8X0V*2@`'%EHI#4`1EL`0XHWU#"HMZ
M.;!].2)*J@$=YE,EL01.:H>)):41P`-ODV;5\`ZW<`T1,`;KR'Y:)`(90!G^
M62J/\D=CQG]EDP)[,P;8&`XYDBHJAP`&T`<7$%A]M7]3Y0Q>MG-L\E1K]$A_
M:F9Z0@\=&`+/ZE[!>:B?1!*,U8^.Q:@!N006]TM^E/^IL*,ITIF%U;F#UUF>
M-6&JBV.K9G=,X4D4]$F?H2(7S\2>D&*JB$04="*%^;DKR7(4L7J?^3D[L2JK
M=+(0HQ*&%7`^OLH9`PJLV$4:.Y"@'I`"1U"'S#J('4&M$UJA";0$PS$<`M-Z
M[X6M#$5?G-"M%]2(5#DQW7$QO:>BY0I2YXJNR>="[=I")P6*\=J6.0J7/A4%
M<]`#\O8^K+@$`G>7V\=O>2FPP3LB1N0(2HH!G\.P@ED"01(#0;%&335CS-D`
MO>0$5'(EUA@,%^`$$0",-<$0"8":IYF:%!<-D<2R<].!4F8#,:`G!H!_>M(U
M+J!U:Y&`,A`3!H`+=GJ!%1C_=$#[OX53M(<5`JVW@B50!IQ3G'#0I)_CM$X+
MM3=6*4T(39=ZA491MF;+*5M[6Z_%MH&#@UAQ%V++36ZKMPJ!/9"F:.>)GFN1
MMW_1$W1RM@SIMH#&=KEJ.RX\JU$A`ZTV3N7$+>PSN`1J&N_3``F:`AL0!,FJ
MAXV+H8<EH31`H<)&N45KK>YEB-#A"=41'0S3Q0_U4(J8>Q9THB`$?!KS7^4Z
M?&-);JO[0NT*BC!$0RK%(&Q)!G!`NR6BI+<[')[!B@N0?0"[ET5ZI'R)I(9<
M(D7#!`N``XOL3R$1)#_``U7:1KH`<6E@`S^`FF=E`DV`1=@[5<L2%>H0`4[`
M#`TP_PM0=HW?T`#,,`M5A0L*8`-3HB>PT)I=XVC-H$VFF3=T8@"M2:?[VU<`
M#,#>P`8";!P$#"@>@<`)O+2+ZL!A@`,V%CR;5L$HF<.?91A^`100*1A=Z[4'
M:$VJMCN@.EIY*ZG4<L*E54S-T[6<NA9DJ[?S69_*8A2&AYVY9:GT.:LG[#T]
M7#X&(5TGP!EH"*P:`C_D4E@_)@8>D!H$=:'+2JTO@%B(I1LCH:S",1P-9*T)
M=1S2)GL?ZJV?"\:?JT%=:<9I;*YJ3)8GDV"LZZX)`B$T&B$/A@03XI:E2&(E
M@@&X6VLAH`E_[(I$0XL?%KP$VU-X:41X&05&H,BA-!)?M?]Q-@""5ZH+?'$G
M@&,`J1F`O#`1(G`':2`44X`&7P!);8*^NVFFNX`+;+`.!L"<OF2FD*,G:#-5
MB`2I*3!F+:<KK6S6_<N_=^J_0$L(A:4^)Z#1ZU1T#?"L&DW`R3R((('`"^PY
M"^R/S^S`.$!QU.Q:GW6I4!&KZ/PH)SPKVWP0I=+-O*06S3FU+0E<]-Q-1*BJ
M)*G.C]998]&%>.&U@5.K\2FK"F$8R11W-,S-W5P6]$RV&+P0S&`#;4`9_1E=
M[U==!6UY"!T_Y!($;R@&]F-/"B1`C7M8+\!T@DE^F4O`F;NAS`'24QDQWGH=
M^D6B*(JB:&RZ!;;2J6M\):.N)O7_K@K"KG!,TQ`BKS6`?;0;"<=;`D6[$?T:
M!A@P![Y;U+1(U`1;1#EUL$03(B."`2OPU+4P`O[Y-L%0U0HP`MX85[X@5;4@
M`DT0)E/P`TU@L>=+1Z%9@`C@-E;CFV,053KP!)%SUC@79;ETR4@"%55@`M30
M)A.8#\#L9>9H9AG!$?;B24TGF"K0&<8LP`?WV!;M.<;9CY<-S0L0..29@U9[
MJ>IY32"0SZ3]D*02*]_,PBTLSI)*SB0,VLR3SFO.A:NZ.VIQ8]SYV?L\SV>[
M3'"!JG0!$*3RAH(!C-ASP62+%`WQ`WWP!Q7@:M`5`=%-:[]JT`9J&GS@&MO5
M7<$F*,N*_Z$37=$>@5X?4<7GG1Q/23#IG=X5Y,4C"KJ>>U_A08GT'9;%]Z+X
MC6#YK3(.QJYQW'PS7=,0<M,?HJ,E(@D:D`.X*V^(M>`-;N&_NU/]-N'":["/
MD*1$@[`2P`2_5A*Z<`/09224+(Q-L`Q29;[`T`1<PV5,1@O%*.,#B`!5"@;A
M(+]26@5(,K,580$C8`.I>8"9)@,2&/"N6:<ZJW,F4"M@0,MHHQ%1/N6<0RA.
MUSG>G=&%2<`LR+#&6=G^R*C*&9"7L`!-8`,3+,+6;,_>"3MT7ML<.9+NO-IQ
MOJII+MHRC&I$B,_99,\%T`>'YSP+82=^OA:`CL$RK$RB\CJG;?\0J#T4RY*%
MH=(0;S+I87@`C@=YAOT90NP^A<N&V+U=OD$""40O30PPX?UFMH&AETM4#O3J
ML`[2]=6Y"V.57ZQ?[PT>*GHQ*%W?EACX+]K2;1S3*`73_+UN#O)@-$0&7O`A
M.2T!=YFD//JL&]$#"QRD&)#4`9OMV"Z\A6RPWH[A%VZ[&*#("*`X+7`%DXPU
MC-D`@/,#VVNEU?"8V`O+.A`!OR`WO/^8QC`"8(!&4V`#>1,5[-":]_#O"3`"
METS\6+4G'-CDP/P`5@"1O2KOQS`&+[XY+=B"G?/]X._(W>_]7+X`#!M*51>#
MI,,2C+H`S'TI@!%+68N25`L04>\X/:__J36A1S8/"`DV,@6%;8<@A3(V!HP&
MCY"0@P4@;0"7/)F7`&V%-HR3A8:BBPD7%S%5JC$Q"0F/@S*RGXZ/KK>NC926
M`#Q_`'^^/)>)BP:WD;:H51<%?P?0T=+0?W\134]/(2<G(=[=WN'BX^$!W@'H
M(>CI?"D\&1$D64%+2STE$/@0$$7\1?W[2NC[5V2+P2T,MH10>+#AP80)#]:H
M\8*BQ1=D)D[$6'$B&8PU,H+T\=&'R9,H4VI)Z6-ERY9:5L:<23.F@)LX<^I$
M<I.G`"0^?_X$*I2HT:%(/GCQ4B;,G#D8)$B-(B%*%"8EA+#I5R],!PQ&K&K0
MX(`L60=HT9Y-_ZLV[=BR9<?*U1"%;MVY<ZU*@*HCAI@#=A+H0$!X,`+#A!,K
M'B%"Q+$I(W1$=C(&,6$7BC&[B#"BP`_%EQ-C'BRY@0@P:=J,L7$AS2Q8-DRX
MF.W"0I4TIG08N#`B,NW?P"W,%DX<N(L1=@[\\@5`,((83M*\:4*CA_7KUNMI
MWZY]P0(<W+'WJ`=G27DXWM.'61"FO?L.[>'#=Q\&A8=*EPZU*0:*EO__A("`
MR1]V5-,+,05\8D"`FS1X2"D)L!+#*:_((DHGBBRB8#*13()?)K\LQTDG"GY"
MB"BD,&(**U5(2"%L&M9BRRT7(&.#(0,>^$M^!1@SXRM`FE+%"`\X\__,-$CR
MT`<:3W`##CE01JF..NM,:4X`.+R3`@E!!($#>-;ILT\1+P`4T#Y"_+-%008M
M9%!";CJ$4$,U;''11A_ER5%('F&4T9]D!$H&2X2^I-)+,M4$DTU:"-#H38_J
MM--1/@4%U*67%F64%Q/XX!0&<^Q5E5@2+)!5FN/%!Y81<\'%UJMMN6H67&:-
M)0%>N,IUJP1&\%J@'3RT405HQ!:+P`@_3+A;A$[<]H-EF87&QK&#:79882U"
M5T`$,J11P`@7P-*B$P:`VZT,(P"'P#%WC&!#NL8%%Z\)K<B`QP5*F#""%=``
ML&`;?=B0BQ,*T%#"/>*--QYW#"^PA,,,]U#_WL,/+X`>>NRI1Y]7''?@L7M,
M1*`?(HGTN"$LC?PWB24\V.%R-<'P:,R-E0BXR2$FFX+*A+?$@F*&M$0"9"0,
M`@.,,,,`P!^,A)PHRS&G2"CUBRF?++3.-;JR\B;"!)-T)QI>G4!C*U;Q@`S5
M((GD'TLVR08WVT@I]SE64DFE.3!D8$4$\^R``PWVB-D/F0`)H0($::K)9IN,
M,[[00A!%5*>=%56.YYYZ<J2GH#Z\4"A*+AEZDDPFU60ZHXY*JKJE/+6>J>NP
M8XK$4B^4\=535?%*5108+"&$5A"4\7`8&(`EUEMGK<766LJW-:M<=^4J?12]
M*A>L`8CI0)JQBNDP_X4-/S@QA0@*Q*!]L9B!EOYAU2*@P!@BA)M&&C%$D$;\
M#9B_KFL3IF$#,[2`%VT0X(0"&*`*NT%`O(Q3G.,8P!(N`X`5TM`'8-@A8*](
MA@)*8+#J)&QA#*L'>""VG83!X3P84P][-B8?KWBLA1_+00I&5@E%@"(9*AO$
M(8!!H&JX3!-@`T4A;,8+G,G@&!%B1=929B%2Q"AHD,A@(PBQGUXP)T0R<X2)
M9-&TI^E,:A,ZQ1*ME@Q79`T91=.1T1!D,AG]:!DQD($OU#:-/WC@!]F`FQ[G
M!J4KV2T=54*#!SS`MR#L8`?:,=@^^.$/Q/TC36MR".08\C@YO6E.=M)(1_]>
MP$E.4B1S@=*<H#R'D<\=JG2H+%U,%G4Z1S7JE:J35.PT)3M,(44+G'J!QY[2
MJ]RQR@AG$,CO(#"\KQ@A+*U*'JR6^:I9T8HNMY+>7'9%E:J`+0$C*(SVIM6]
MQ)PO,6\000PBPSWT)88-;&B-"!)S`?L9X`=54$"T%(B`']A@"@E0A0CFQ\4J
M&,<QO!&!$RX@F]DH<(&ST8$(+-$)#_"P&DI*``".R)H,-D$@&*6!P3YH#^Z`
MAV(E%`\*,P:']9ATA?2!X0L_)I\SI*``^\'0:W"80T(,R(<P&T80IPC3'>K'
M$U#;V1*GV,0>/=&-QY`$)1K4M:^UD19<C*J*HA;_1C%2366-B"(N;(2C37AM
M$R6;!10?(8(5L4*.1Z(C-=J`1R=UXZU\[./=U@%(;^P@!1&00A8.V=%[,')P
M`/E'F0JRN$LR("*'98";XB01@VC2(I_<D^8X61(_^<D'->B<*4$G.D,EZG2M
M3-U.-(646I:VEDCP02Z]\A3<59-ZO3N5$'JPPN(=,WIR<14S=]O,9THSFGC)
M710>,<YLCB">39@6M`C3!,LTX0+EG"<]+Z.`'XC@GM72017`L%QZ:B9^K;F`
M"UIC@S08P`D"I`U98W"'`@CF.".(P4&'\QL=R("A^41@`7H1#!E<8*()\*\@
M#-``%6`4HPGKZW8^&D(3_WK'/1EK#TK?XT(7KO3"Q'MIR=K8(4D`"#^_ZF&!
M>)0@$_5T1#4TQA<IE$$39^BH'.H0%7,D(D[8$*I153'6K'K&5Y@HAUH%DF-X
MNL,&@15#1GWBC*AJ`V"H-1J_P`,1F@37)\55''ZL*UU#((0(Q&,*74)D/03G
M#X*4R9(/@0@E&\=8QV9R(Y6CK.8^&9+)#HHCFRU=&5ZRYU5^UL\U29U-!(V3
M1E4J=I?2`FIKJ06E>$&7K>65[JIBA`7<XU1+4-5M<8N\WB[OTYZNE33S,I:Z
MC$H#J1@G_!HP&!-<:[GQ5<P/\!#=OF03?9%A0_NF.UUK^3I9NA&!"=@P),(4
M]/\W%E#`;D:@;%-TQG\Z6"`8VC`,`P[IN!>0@04+D&T9!-C'(FC`@<=],(4I
M+(0AO0X$KO/@C;F;A1:^L+P[<`0/P/3&2-4B$V%ZB0+!K$`Z?>J)0""@GZJ8
MQU+<XHNY&#2D$ID7!TH:)XHAU47$"(EFI-`9/3R+CH^50RXN<GYP]C.I:I5%
M4W#RDY4#`#RHP&U[C-N5L7RE+:?C!#WX<I?>L(3J"`1Q_!CL8`MKR4HZ1+$/
M<<A&EE[GCU3$Z9O#,RE-,G64[)E0,T&E2_X,6M1!JB=@1X*B$[UHU"IE`C78
MI52BTBNJ&`$#]V@`JFJ[*E9)C[?,;-ZGDXD73I/Z`N7_:T"M2:/0SR2F`=Q4
M#!MZHX#R1L`)H@G-^LSI:^\>U#+&<;5QPE4%$UQ@#`887P3*.M_BF(`#P#(@
M;R*CO680J`\+<J_`%D1@<A\88>:^3D=W;X_K'*P,XYGPN]TMGWD;OP,DL#?0
M'([#&?.WAP:RL8:XV-.:&77)&_>/A;J88R##IJM&SD]8<WQQJ&6<Q4.N&OG%
MBE6.7ZAF-?R9$WUDUA@80.5/_L447NXDF<\<RU9"5U6R#4*P!"0`9EW2>X)#
M$&M"=`T1$8P%)PP1$9?D9AIQ@7$F$AQA9Z142IZ39UH7@HF"*%WG2B;X2CPQ
M=F,G=K*S@K6D6EY0`[;36KW2_W;44VD&HP)"<#"J8CQWP6EX%X2QXA;)%!?2
M9!5W80*N%EUC\`/QI6L1`%W&H@-6<`&4T093,`4%D`:"5TZ3-WG$HAEB^!L(
M8`(ZH(0Z<`$B$&V_\091>"R-P1O'1E^T\0`PXUZW=CXZD`#.P`.B<$;W(VZ&
M<V#Y,&X:U0,:=8BZMS!A@AWH,7S#QP1AP`0=0(G')V\D,']D%&,WPF]61"`2
MAR$^<R)(9C(8APNP$0M-HP@]DF3=5PN?8`@0UR#QAR)2Q0AEU6.WD'[JMW[L
MUWY$A2*EV(HE1W])5`4_T`;)L7+Z5P)Y!%?_-PXU)X!5<@*&LP/S\`:(I&[^
ML`5G9O])$&%T:B9)!]%FWE@GZ`A9(+$Y?_)TG$02[UAU/G!U6%<&H3,Z(]AU
M,^$H+*B"0Z%H`,F"`NF"EZ(40P`!MW-,4:$7U),#/2!W_T!;7F%;OT07=R>$
M0:@\10@]>M%+8=&1Y30"#2!X-U`^B0<:Z%0%33`AS9(L5=``(R`;ZB-YD9<^
MOG:38GAYC1$#-N`$(N`NV$.'9CB'\2(<M&$"5O`K;5`N>G@8(M`'P((S-;(L
M%U!@AO,[6"D$A7A@'=25'R12*T2)'".)&R.6E?A"\7:)'I.)K[@A'Q=[(B=Q
M(Y(A\@<T2%16IC`V,***Q%B,K@A%H1!3-T-RH\"*06-&6Z7_EU7S8[[8<3#6
M(3Y3E\48-F7%(@G0!FFE5L$0`0]`9=M@9=`85S47@';#9?F``T$P#RO0<V/"
M@(2%9A1(2;&I9B$0FXY5$6^FCIJ4)QJA)YI%=2"82IQ%.OH(6BSH2F*G@BHX
MD&37:$N!D%\A`6`A%6'!*Y4F$#H(`>S!!$=`D1I@=[BB6QC)6\HD:D;(*\5S
M!$=P!NIY!F>0GL96+"/97>QS>`M"/\D2738YDZ'1:Y:'4#HP4"-P1-@3+@)D
ME`A%A_45!P`'`.^2/2/@#@?@H$JC-:A0E5F9H5AI>QGE05\9?"O$4AP3'^TA
MB?/1,6JY4DQ``N270S<$"U0TB^)'_PKW9HM&I2);55:+N7Z2J8FPV$0C@P@8
MT@E(QG`&D(L]-F0JXYB^J(K^`7)1U:/+=Z01H@H7T`>9J58`$`$T0&5-$C=6
M=F595B5;9HT04!T[T"4*L`3"Y$B1!)MK)B<0R!!H)A'I>!&>="=P5EF5I5D?
M^#E;QQ+$69S[2!/]&)!`$9"*"I`D,0$OP!YOQRNA8A5MAP&F`I$E\&#%,P?'
MQ"I^1ROCF9%J\1:^%05'D`,K<$B'E*JIN@,K$`3Q)871=1C']3ZW=A@*,"2.
MD0:WRCU@.%X<X(3]F9.5EY,()$8+DFU]$`.U01L(:I0(ND`_$`?+<0!]<`&$
MYST%8JU50/\(MM`;,2!WV4`0CY2A',I!Y99@&/,>'X.B'8.B+)6B+Y0#'+"*
M'O>6D$"*/E6+HL"O-XI$63.5,*J*U">E/NI^0Q13-22DF@BP8I0+3-.8C3D(
M3YI4,%JP\F=R1[H,1%(`RYA_/&`%G?FE5>9_HAF`HYD.(5`$*E`="^"JB-0$
MB/,[KVD0;'(":T:!C!4GMND0+Y!)N7D1>K*;HB0H@Q*<A;)UA-IUR:FH30N0
M'Y`4J95:CL8`M@,J1L"IDE:=;\>F<C=;[)$#%"D6?N=,;($%S(2V:)N1S!,7
MU',&JKH"K[H"1T"W=*N>,=`$Z\0]DC%."H`'!2`"/]"%",`&3?#_`#H`>FLH
M7=&B&2;P!';0`G9@!8:Q/NUC4,8!'8]@7CW"D^6";`C50,WJ`B:P`0?``X0`
M&-P6&2-P!SP0#=?J&(L@;`@PDF_3#6RP#02AH3NX@US)4?6@,1;&KL6G4O&*
MEFFY4D<0`:QH<0PG(STS<##EKPE;I*^Q8Q"[15%:5#5:EV(%F2<BBS7#L$XT
M51=Z5=I+?DGFBHX)1=F;8][[O5"3"O%5`*_+C'^0`DQ"9=`8IF%*#F-*C>:P
MLOE`6R^;JFR*E>2J)D97CG1Z=`W1P'1B@41[.40+=5+GI[\9G,1)@DL[$_W8
MM"S8$DGA`V+W`0;9%,0SG35(/=9Y!'&'_RH/\Q5UATQE*YYK&X0Y'&IFZP"\
MDP-Q&P2O6K?J6<0H0)_ZDDY3T$X&4%PQ<"_>-`;RU:N45RPMP`-<X`$'0+EH
MF`!.8`/B%&WS=93*!@FH<%Q[R*S-&JVCR\:_$0,N8P?>MHQV``!],$?08`=M
M$%!M<#^U(9)2<@+:4`1/4`09:F`"D6#DT6Z3V*[Q4;S'>XF//&\H\%(+IV0_
MXF/<*W_ZL6%&NC-AU&($B['".(POEF]%%5-!VK#U1R%**K';*['Y1K!]>:,G
MLR*1001RM'+4T#8E&XTT1Z;4N+([*#$+P`0Y`,1L>BHS2ZX&T0V1M#@27*=O
MVE@7>,W8+!*AE/\G\%@2P(FT2FLZK$2H3YN<'Z!H*&S"JH5VP,<$Q1,5G%J#
MUGF=(_D[P_/.MS5JI!JJL++#H]II9F$$0`RS75+$1X`"W8D"&,`"H"$9L1H^
M"K"&X(*,IS`%8Z`8J-`7OEI..U#'-Y()UG6?^X4A!"4;<W@8/W!$>W@*`"4O
MH^O2OR$%>5P`7W"_69K':2`;,6!MLB$9`$P.)["[6&E@'MHPZ6&B*^6N22VO
MD(R)\_>\M;!5$1N^.!-3Y3N_V2*PZ;M]DCDRMA@VX/M^-&1$8E69JQ#*$=N*
M/,J^[6L+X+N]MAP)N3@D.@`&3@``O`P8?:``3>(VG_D-P#R-POP-!>S_'<B,
M`2B0`W_3IEGIFEN`LX2U.`[H$$3WLY1C.=B<V=PL2O#X@?*X6:'#=1]<SBLA
MM3Z`PL[I!0SPJ!VP`/A\3+=2@T9P!,N\%9G:'MW9J=^YVW>G=VJ;%OX<W&YA
MA&:+`>J9JD(<!`:-T#"``3!P3(01`^ND`U'X`^6BA,PU!I_77,RF&&.`!R/0
M!&7(N.LS3L8F!NY@`!'P3C+0!UMX`55@`]0&+#\`'`5E`F]0`-=Z;>9-'*+[
MT@`^&R9PO\J1`#]PT]'0'#TM,.V3NPB092&``$#-#87\!,4,0L&+`QK#!);8
MKL67O$Q]B4S@+>MWRW@IU<%8".YMU:<</_3;_R(U\LKPV]5$.IF`Z6*[H,HD
M][VX#*Y#-<K<!\L4BZ\>%@L$"[TZ4P6Z!@9-EM=_P%9]W7_`3)J"O66&O&[H
M@<SOZ=PHL`.7)DR-[9ILLA!L4A`KVQ"3/3GH&+29S2<;&$KP:!)W=K1_FK3X
MR$KC;)R*:L)1>\XH_`'K?)#KL>50P79;>TPK<&F_(Y$YT)VK<CRC)IX.X,^[
M]=O-U&EJ46FM6M!&K-`P\-R=^AS231@PN5PZD#\(8(7D(AK-I0,_(*O&8@(*
M```><#_A<D!B<`?'L$6L$0/>\KIZW'GQ@M+_XT_.>NS1^M^_,0+28`?N%0'W
M^[%YC#UF"-\'90$ZX/_@`SQ7VSX.)\!!C+@$X*'AZ7',7H'4[PKB(7Z)R\O6
M&^(8B"G5.-Y3-3I35=H;V*:&3*2^\I<(^T'OY>NBX9OC+!XV9L1ZV*:7.`;+
M;4GD;@UR%8MQ9\RZ>(!_FLE64]9_H/E_@OU'-U?,#Z/EF\H")(\"J6HP8$ZS
M"ZPFT?RFA558-5`$:IY)'<%TO5EG?,*.W#SG@;+!6#<ZJB3:Q7G.AH+"9,`I
M0U`[/7`&[DR1H.+"QY0#IE("*L`&)3`\*]RI/ZC/>@?<7C_IR[3#K2(K#J.-
MJJJ>*(`"GT[R^1P%QP*32V@L(KF&X6)=&"U.UD6ZB6<MJ0XPJ`!N%V`%-H#_
M!VG@`3J51,T@#2T`!D194!?`"`1%7__MQIF'!M/0!C(``G=,#=.`+H31&PA@
M`<(Q`M.B#A)^)0^^9>(@!-4A0A53[BA%B1V.ENM>^QYS!/;ZO$&6F#!Z(35N
M0P!+U]H3JY+`HZMH"`O;O4DF\%1];S)%?_"=37VKU8Q9XLX+C&X]-%(M11R"
MEQS+NC\``-).1U%&!(+\U^#POU("X54^P&9JS(==/"0_!VQ/\D>``Q<%YF46
MV?\`""%%@X-;189;B5LOAC6)CC61D2\O-962DV29+V2<G62?H:`O/J6FIZ9:
MI:I:K3ZML+&RL1]('Q\^9%X30R\03`M,&,-S&!)&_\?(&$8Y/24-)6P02V%A
M1T?+1D9141K>W^#A#AH.Y5CFY>GJY^KMX.7D&D=+._5!1R@D,#`LVMO<WQ`(
M'$BPH`X=#0X6%-B@P8@+,:K\F#+0A4`7/Q+8N*!CA`@;?2+($!&!0Q\9=@`D
M&'%0QP\[!_[8^2/F@0L3+G+FU"'"@($+.'6ZL#"T:%&B.HDB-4'B@%.G/`JT
M:2.C#0`[,)^"&($300P=%HC&N"`P1(`0:,\&"(!@K=L00DKT6+*@;MTP"_!6
MR\ND0]\.@`&'"4RXL.'#B`ESB%!`AN/'-FSX3$"Y<@(1"7S:D%&@<^<VGF5$
M3G#A0I41`SN6UASYL>O&L/\]RYX-.;)MVXYGRWYL@#)$EJHO9#9P>[/KS<4E
M^_39$[/EY]`M+[_L&^+I$6!&)&CSYZGW[RGQJ'AR@LV)$VC1HT?+OKU[]FK=
MQG=[0@B$N0M6,#DS#`.+__T8D805&;A!0A`XT%#"@A!`(,2#A!PB(2(3*J*(
M(X]L`<DDDER"20V:A%C)***02`HIJ*2HRBNOP-+BBZRPJ,4'JGR@"R\,W$?7
M&<(,H\TR4?QHQ`I+/",$&T+T<!<VV7#333?A1/E-.2VT<PX[[#B099;P3/E-
M%//L<,0^).C##PM)_`-00`NUZ29!+G1DP@4&3,01`A99A(`'DETPP@@QV```
M#S;_Q!#!%`5,@=4/"NF0@%,M#&I'!CH(E5,,C?T@`IY(*66I4$A9:H('X!70
M1P$)C&5#&UG9T<8(.WTUE`E5B*##6@BTMY99\@60)'YU`1,&$\0R,>RP?R5V
M&`;*-FO8$1RX5MMTT"U''&>Z.289:3&PE-I#P[4FFK32ZA;:<<G=1NZYHO7&
M+4M_CM43<9&E@9QHR5D;'67.[2O<O_P^5UH,$?WYYQVL?J=P3`!,T0`?YZD7
MPGH3OV>Q61C/U^O$]M$`1S#[]<?"'/T,:(4;;GB0<@HP!+&$@@L^*'.$$AYB
MH<T60J(A)AY>PDDDF@`-HB><>`(BB*"040J**:["HHPP_[JR(BY4W[++$#64
MT4,93"S1HP3#'".V$1B<L4#,#3Q(S0(Y,*E-D-Y`*664[=1M=SI<FB%.W##4
MDP4*^P0>X#][OVDX`CH@T`!9`HWP@^)5(&!"FV\4D($!J"$^0AH\W'%!`7@8
M,`54=[2$!TPB\1"''1%,+I0.I?T95$Z='D5[4D:Y,`(/WKD*D@T&CU"%$U<!
M4`!0'>G@N@M5^-D66V^=Q6L`;,C5`W[`%)M#L<4.-IBSX(?_;+3H4DN="/VR
MEMMN[7);!1N)']1\9NIJ2VZY]VN;;KKY1];;P`:KPEC"M3__Z:LRI4E@::`#
M,`4ZL($#*]@(X`>&"W!G80IK&/\-R!.QBJ7G8A93R_1$*)\3%.$^2M(/?X;Q
M'R-8(0DI\X`,/9""&LIP`P?:@0(49!\(#4((-4-$(ABA(0OEX4(>L@2'/A0B
MI"4M:$\L&BARH;2FI<)I,9*:#VA$M1L-80L0*$,)%D"7'.1@&!WPQQR.T9\=
M+"AM;"C"&!>P@S#XZ&U&T(#<YD8W<CB@2E6Z6R"Y],=Q1,D(,%"`F,I$IGV4
M[$GO(,?AVM2$&(B@`2)@G)[>E"?&V"$-C1J!!^SPDY'@0089<`H`1%"%!XCA
M`''HPAT.`!,[7.!3>/K4[7*W$P2$2BA5R(I3[`";E0CP-%4P`&AD8(`J'&0H
MB:.5:?#_]+Q<L84]2++>]>PRK.T1:WN!(=;WF"6^P'ROG(;)0AKP94`#]`LS
M\,P,`>_G/_<!IR/SHY<,U@F9_/&3G05LI[7H):[;N*LTUXG7`I>3K@-69V`/
MC*A$)TJPA!YD!`\H`.\PZ!T>1.`!?.!@Q2A&,1!F;(2]VI4@5$`#)7V3A24C
MD`QM.-,:VG2F&\A"$)H0LYE%B$(6"JHC\O"AHF9"$DW$1!-#1*(J6A$5*XK1
MT[CX`2]<S1<0*,$2>I`#MIUAA6$+4C\P0"0C-:`(;%!27JZ1#37QL8_CB&L[
MS%#(NK8CD%624A3ZIL@LF`D&^OA/$M8420<,!'V3-($"AO>5_\0M9).;%`@/
MK&`'&3C6*S(!P10V0IPTP.0**?G#%6B9@#3$!"96,`%.9O>IVGF**`BP%>YT
M\H#O@&!5:8`(P21H@#04H)DX"8OL'C("L^0$5V^)RX*LMP2Z@.R;'<A!=#M`
MSL)4%YW8+4P6Z.50Y\33,O/"C?[^9QUXL4%XPF&-<9!C'(`"5+W*$:B^!FI0
MYOA&@O$:BW#F-5#[(C"!NQ7@;B<:P8CL]L`!#IX.X,>&*FB4HTZIP`$`$($F
MD,<\$BNI2>&3%HU-#RTGE$NPSN@?%[HA`S6UH4U7O.(-1,#%',C"#HI4`@?9
MYZ<X"VH1(?$"HAK5J%`4&M*`]L0I/O\UJD];42D^4(,)\`*,#5H0&9>PO?XL
M`VS9,*,S&G(DN#C7&G=\VQ[?&H^XDH.N:!8D.MSA)6^T;`EO^%O@!+<-N):C
M<5.000PF9SB'Z$`!,:#(10H"689$Q57W?`D/2OF#-#0/``J[0@82D$H[Q"$F
M56"M+F_WRZ*PP9>ZO(`P>2":W`IP8,Y\B!,*4"@3A$5WSM3!:6X5`)VXI7H\
MK?'UZ$(79#%!NG^1[ADZ,.SL&EM98W!HP/H5'8;:9CJZ_5-'_M2\]!(TH,_N
MK[;[^QST:;LZ!/O3>86G7^%<IB<!^Z]N*XK,*K@;P?".B+N%Y^YZV]M@+5FP
M#H@0`4A#&"K_$4`#!]7#!@]N^#T:2^E9BJ`"N7S,C!B`@8E13,,4K[CB-=R`
MBR/`\<64),8WF#$-;%P$(%8H$0S(4"1V]F,A([6H3`6%$TOAU*>B`A<WF@`#
M7G#"'J"0JRO(`8]@4`QC&*'H,^[I$X`X1KPPJ:V$(_/>S"Q7*CF`KN7`>CJJ
M1-<V:R`),,B"`A00A"P`%K!FZL<>JRY)!`2!,FVX+)\)$H-D3\0A<]=39/5D
M@B!8P0!_J,`4#G*!%J1$@%%9B>,49H?MM.`[:="T3KC26D_MDI<N4(!W`.`3
MCI`;@*IQ#$=6*SSY.=8M.0E!`WK0!!K`C+EVX9YTMR==ZMK^V+@O_\P1T+>O
MWIN;,MPF3;3A%T#]#H>@VQXH>-]Y&7>ZDSK_];UN9SUN<I?;,@ZL*+NES9+J
MV_O["FY)]0TV;O@AKB6;\_>__]`'@9]`I.<Y.`@3OK$3-%RMO_:/%0@40XM?
MG(8VQ7$=QP$$N!@&Z&(;P`$KX$8^='(YLV,M%X$_5F2<D`NGH&072#5-IG.&
MT"!9Y0P[4!=55C;98&5)UQ!PA"3.Q01,(G%XI$=.HD=29V9><G5SI0Y5<@[Q
M<$@P<`1CMP-FIP]"R`]),`-3<C<"D0*HT@(1P!-I@#D%,19-$#F`\FF1-6B;
MI`,S4``_P`.CE09XP#MQT`9]8``9\%L'$?\#/-`=PU19$<`#$O84=B!Y-[$I
MME,[K75Y(L"&!]`&I'$=IU8P%S4&&]$\IU%NW3(YT`,7)=`$3=`#+:5-S<5-
MT#5[@,$LU^4LYW1.N4<8*^`<"H1`I"%\#B1]%35!TY9?"\1?S\=?T2%1E<%L
M#T5@!=8MW;=@!C-@`,9N\Q8\\!,_B",0!\$&Q*AO^;80C9)O+1&,B1,"8"`H
M_^84[.=^\9=A\L=A)+0K\I$>]M$##X<"++`!%.=__T=#&K=Q`UB`!BB``RB`
M@*53"O`R$*)C%Y)R$GB/2/5$%FAS/E`#0X`CAG!"6:55<Z%"9W!&9.,C&&!&
M10(-#?`$Q"A'SM7_-L/@@F\#@S(H=7[4=7[D1UEG@Q^9#G35`N"@-QJP`6'W
M!DT09T/X5V@R)5K7#@(A0TKPAL9C`V^X9P2A`]VR6`J0.=0T:`71!`<@!EP0
M`0KS!U9@62/0!U-`;0#`AI-"AA>`E+US2Y*G::^%.YV&%)HW3,=C&O5&,+\!
M'!_Q&'XR/Z1Q60'P!(WXB(YX/7()+'Q!+-,%3K5';)K8`=[#EYV(&&]`BX+Y
M+PITBL#A?63Y>Z"X0+.XB_!&B_+V;O$6F??TB\$C8-L7//=T6982E(T2C!4A
M%,BXC`L!!G@0E='H*C_P!`,W4AZD8?.'4BG%,0['-C"P`2<V4P#(8C25_W'L
M^''J2(`=]YL%^&(ID(!OF`$RI@"..'*%$%3VJ"$,4`/3.9WX*"))LX^G@',;
M.`0I-P@>*!<E$()F1&(+N0W]021-P&4-\01H!2P4:9%XY"20I)'P0'5G9B4?
MJ74F&0]1`'99<`,E$&=^-83\L`%)<(0@V0[HLY2UD@+XT@<\P`,Q0!`CX`2V
M\@27Y2:;%`1_T`(_4`5\^!14T1$\D`8)8`(Z@!7#!``2BJ+"Y!130(>@<H>8
M%RI(<0%Q^`<RT&[OAE#X-@+*9#R9)FMKJ5H(@&LTX(A-L%5.VEQT\3'(0GM^
MT1>U)UV9>(G*PHE_:4Z`=F``!A%B&F"Z.*:\B/^*N#A!UA=1DYE@XG:9F'FF
MTI9OXZ>9]W1^=*I@YL>AFR::;=*G09DG;'$1.H$`/W!!Z]<&/T`$YU%PUGB-
M:<$K&3.;]:$C*P".,T2.-U53&B>`P5F<OUD2'T<"QID")9$!&<`!-_`&K,H!
M,A0!-Z``/95C%I)R>9!RU=ER1::=5:0)3N:=`>F!`SF)03<,9J0-*Y0#)\AE
M$)E-SB4FV.`/:A*#&EE8-J@!78=UV*HE:_:1^>D-`+I3"G`#1R!G:8<F4&*#
M_"F2Q,%JPN$!?2`9!2`3J;63/P"4%9&O!&$"E!4'1AD!(TI+3O`^!>`$7*$#
M&V4'/#`3=M`'"9`"W^'_`9)'%*[&E;EC>9UV`7^PL0``//@DF:81I'32&,X4
M`SZADTG:`$SJB%#:LLXU8F$`;-%EI1UP!($Q;,FRI5V:&#O0`&/9IO5&;W$:
MF19%I],&LNN64.!WISMY47:*IJ.9;^)&FL@(FH3:IYO6:;662[.%M7UJ`F@`
M`@&[,'_0!GC`FM7X09"J*[+Y897:`SBP`ARP`3/$FYOJ`2AVG*;JJ9^ZCJ+:
M<22P&!M00R61`F*0`JO*JF]@N!Z0!C?0G`M2)"I@<B>@8[@JG1%89$H#"O_(
M"P'``"77(''Q@>,)K4*7D&=@!$>P@$O`4R@H!'`4%W111VS55MRP#=,Z9GRD
M_S?X>:T+RJU7P@YM!J!9X(AO4*Y!&#@(:H3>L*!9@G7"8:JE804\X`$&0"H;
M6Z$$,08*L*'Z>H6/1TO"<9J4Y12MDP"'`A2&.DPV($!]H+`RD``QR@-5\"DF
M@#Y!L96OEH<Z405K:#PK(6N2.19$>QV!DAM4,6LCP*1+ZK*32(EV"6QYF9=9
M>AA<RJ7-@L'.T@3#&$!VJHSH1WYJ.K4@W,%V:GXEK!"!VK0E')I<:Q#>>[5Y
M(L.OUFDV.A0UC,-&L95=Z[6">@%B&XU_T#!$$%*N*3'7F(W1LXTF!`$TL`,H
M0+=U:[<I($-Y>YSL^*E_&ZK"N1B$2ZJH2@**RZIM(/]#4S`%"M``-#"Y3\Q3
M*J`"#F)"M(JKU`ED3A0)G8LC(;`%#Q)EPTH/$%<V9Q0%!YD#.,!Z*`@-1T*,
M6C6[8`9UMQN#NNMUS5O)X]!U5/>16,*MZFI(*)D%Q;N2-U!V^2`X@_4-6)>#
M-AA(9C"R,M`'F$)*M8(5`)`"&PHHG"24`G%IM-0%$9`&5L$[=I`"*II;RN,"
MHG8`&1!KF&(\HL:'MK1:A5IWP;5+KK7#0C$"CX<5F",\]$:6!W9OVS$5;6``
M!L;`4(H#=K'.P:(]TZ67LV>)AI&S&EQ.];RE(9`:QGB,;I+"(`S#_,RU.1&4
M`JU+!`TG/ES06<M+2I'#-HS_S6%A>5A+$(.Z$&P!!N=704&\?@WS,!%C'FH+
MJ=+C84Q\0DL0!!%0Q5/,8IF*4\2IQ5O\M\*)Q1S@!(:[`8G+JC<@!AX0`4[P
MN#20-JS9!#C0>K-*".>Q!7L<G=;Y(;?ZCP3@9&<1D#TTD'-!#SMP1A!G!%^U
MNJV[GHD,NT<BNW9Q#=@@G_29UKI[=6_EK507DU>"#M]*O#NPDF]0=B10RD08
M!<P;DMW:=>\JH<KD*LVCS%?1O<*8!HC]6$)I$3IP::LC!@9P/%7`.<JL/#R9
M.?YK![8RIQ<0KP#;'3,QH[J4`)7":3S\M2D@$W^@>/8&SM91;PGD&+WQ;LU)
M`U!:_Q?Z42Q\<2R6*%TV>Z71=<]YN;.`,0?@4P);J\\J7-`'/4E7&)H][,/4
M;3N7=]W5O6EM\:?3/=!M4M'`Z%CQ8\(&<P<%$*,8-,010`2MB<3K`9L(-ZFR
M*3UQL0,DH-(81\7XO;?IJ(ZA*JH&*+@NY@1.$`$\/06*.W9.P-,I\-/KV7!/
M,#'-Y0PU-@@5<PA"L-1;P``<WN$,,`2=2P!1_;F"`)[VL5P@N`0KL.(+8*Q:
M/6..J+(.^0S$B"3X40^U*ZVX2ZWU.75\)%<[Z)%T%=?GD&;C0+PJJ0!O<`.@
M##B.A*`EN75:<@Z!Y`W.9."H(@*&YQ-VX`&G(['":!J?]O^G"\$&<C@%:?"4
M'6%:`(`:?I(Y!C!9'^LMB`)X6?$'D2?-.L$1-2K1U^PZ.@"P#>MYKQW.07M,
MLX83;."()=!22Z#.P;#;W6,LWB3/@?';-9L8.=NER`T^3!`"A7J%U:W0V;W#
M$GU<$5YK.*K#O_30N!3J>E+1AG-9XZV,-"R:T1W>^RRU`229(C"OT3AA$;!!
M(4`>1[RV'3;?*J4".#`%4KR;5#RX54RX_1V<,1W@'M=Q6<`!&2`&L/H&2J[D
M$=`&*3T%3A#C0D`>OM*DR_4@2AT"#/"Y'/ZY;I''46T!$^`"(!:Z-E8"RM6D
M])`?"WFLJPOC8.V0L9ON0A#P6<W_5ON@XY*<UG!%9G&E=66&-^B`9MZ`2*!<
MO$I>=GYERD;`O&FFRE0"#C-PY0!0;1%`3"F0$L^,KY-4$"-P`%>P.D#L>8`"
M\W]R?@A0!59@VL@D;8%B`.%+2WW0%;F$$YC#O];<F3>1!ARK\X6>4-[,$JRE
M.`JB(',!Z2L0L]KS:]SSSO$\7=!U&';I%\;=Z>#3`Z7^]K23VJXN%"%``W1P
M!W?P`W2@`J!>%'!1:[@>W<*XDX@3`B5,00L&!JE8?6EZBSJ0SS(\T++^^"!,
M?`R6BG&:0.:]L>OG40\@4D7`'O!M4FH1[]J84D6`!E,0`9FJWWN[8GP+TR_]
M<1PWX.9N_[@I@."L.G9OX`%E_,N/*]01;A8G`#,.$OIH$>_Q#N)#X`).AN]A
M(3UP(3,/4F,-MR"MUUPK<`T+P!^KNX!,VA`';U;$V`"S"ZUG#?$1CY%[@\D4
MOY%O#;QLO:T:P`(H`,KBNN1-+C@;``A1,QJ$#F8.+0Z*B(:$44E)%SH>=@D7
M(AEV?78'&55V+3\F"*2EIJ9L+J8-<0<'$1<%([,C.F@%"2.JI"XC;56TP+,Z
M(Q=3?P><`":J+LZJ"E7/SA8N%M?3UMK/)A$\`'U5Q"/"53'`.L3FM:/I"#H-
M)30E\CU+"_CX3$PY'3G[_`+Z8](A3(>#_7(8_.>OPYF#$"-*G/](L>+!.18C
MA@E0K5JVCR!#3D,0P!F"9@%.F=+QI`D:*FOVR)2YA@H5-&CNP+Q#@TVI`#I*
MI=/!9FBZHD1IS:K"M*E3IN>8*J7%9@32H+R>J0QQ="B8H\.J+HU!]H)9LPD*
M('/%MBU;`%::/#E!-T21$"%.X-6+MZ_?OP%"!`Y`N/#@)PJF;/"0P8.'%)`C
M2]ZP(8+D")@Y:-[,&7,$#I\Y5]:<Q4D$,1E(W'BCX(V(Q&(\8+YQHTF#!D*>
M""8LA)X0(46*Z&5`V,4$"\==$`[QI/GOWK]]EXC7I$23)3AV[%B"X4R.'4>V
M-QG?P/9M\T)PLQ%B3WN.'$<PP(!AA+[_$2-1\"?1L#\*(0W^_?>?(8UHX("`
M""IBX($,+HC%(F;\9P0)6="F0!-O!)%%%O-U",D@&APBHB%8)'(((3,DL0$+
M:50!@!WDF!5!'ZY8D4`<=J2@THX(%'7*!:[8@8<,:8Q3BPX&)!#4+B:,X(%2
MPA"C0Q4BV&'E`3SHP$PV.L2P94?;4./1F"9%`$`!,AP)I53JD"7..\/<-AT]
M)?30PP+WA+%"&/\D]`]`_!3$Q$()A1$HGQ41E-&BC"X:!@0B97/2I*:DM&-0
MF+ICU*9$L9$3%0/,).I,`ZP1ZAX#4'%'":1P2A0Q;,1JY"QDU7K6K;?6&E53
M2EU5BE8J#544_U)%346KKFA=D$!:/*SEEEL\Q-5<77KQ]=>UV`YFV&YX-:$8
M8XY)!MD&ET5`[KBA<;:99^RJ:^YG3H"6@1@IK,8::PJD(48;*7`PQ1M-T*!"
M;GB5%$`1OP6'%W$!3.`,7D_<%G'$T*E0G0KQR&G=$MN!E\,"09RQPG87EG>;
MR2=+'/$2'&MW1'SSW2=S$E'X5[,C`/8WX(@&(NBS@8<TV."#//-'X88*E*#`
M#1IV"`-E28`8(H&'8,&S&2FJN($=+_)@B20QM('C#S+8\8<=,?"H=BD*!)F`
M#4O1HH,($6C9*@(BP!W,5%-ZTRR,SFSIC`X7".Z1-E6<M`V9.A2`IO^2<`8C
M##GFG*,.,%7$,[`0$-!C3SX+\`EH!P'M,Q!`AB)$4*`'*3J1ZXW&WF@8(0"K
MMJN;#FMLW)B/98Y+=,0TZO#$HTK%$T81N_M899UER?/+/I]KK97W.I0INP#U
MC@Y@B#65]U4U4'D,MT8O@@S-/OLL#WV@,9=NU5:+[?P%"V:_80&T1$(*\S8F
MKKB5L4RYU-49T!@P7>T"C0?$P(-^O>%>"HC@`E.`F7^=3`6ZV8TS`F,MPD3,
M-N1)V72HDYZ,4><ZV`D/Q\*C@"64S#PH,R$;&O`$-I2@9>"!68=D=I]'\`=`
M-@M0@D84(0+];$!44T01@58@&!RM-D)H31;_2.`T&+``$H48D8D<\*`"90T2
M!_C#'P!@`+/$P$EVB,,4;,`).[SA%"-8&R],H`!D8"$!(IA5.JK0A@LHKA@7
M$,=2HC2,8IB-!W;X@N">,3?%/<,C"$A##*9!)@O$X$QEQ)3D,`<5-Y'C'"-H
M``UP$YTZ?6X!3$"EH?KTGGTH1"&H2PCI1->0084A=0^1G44PHDN)",$DP>)4
M58I%S&#HRE;D0U:MZ``3FQ3OF:(:0!-Z)"NK>&\JR')>])8E`A%P<UG3<]/D
M?'6*="SE`=.;G+'&=Y9N=M,`Z'.6^ESQA_8)@2[RLQ;]KC68W2QG.4VX`?]0
M\YC_E4N`*0@@`3OC_QG-('`T"F2@&")@+WPI`!/T^LP-%##*$A#,G\;95@,N
M%,'Q@-!DUFF`Q>(Q'9..1SM+&-EV<'"A$,(0AB44PGJNX[*7'6&'/*19@/PC
MU/X(L1!34U`6E2J@`P4MJ2'ZSXF2L"&D"2&@4ZPBU`91Q"U6K6A?3(+9[""#
M"\0`CR8P``_:$($J(-(.5AB%'%5"QR"9Q9Q1TH$38I`.LZ0AC[,B9%\]D`P[
M%,Z1SAB!#4BABS%9``%.&`&8N.2!M=J`K]OSW2`KYQ26>A0XG//<YW;`A!T8
MRI4$>25`7CG+6B)*(7"([2U?5Q&#,(J7O2R(I5;RJDXE97DCL%7YT`+.K_]=
M0`$_.-4>?B`\:#Z3`C30(Y2,V3RS>%,$!L`N=@W`7>Y&#U>ULIX[W@&&8B2`
MNS9(KWIMX%VS1H6ZVNPN/%\TS[;\H0T_R,T)[G(7?>X3,/XTS`F\-=#8A,N@
MD,',01>ZKL^DRZ&9D1</>$"O?T$P@C=H0P8HF(8@*.`VO^&+88Q3#0R]H38E
M->EY;D,#VXP0A.-9`D^OHX`=N'3%Y9E."4'<@!FV+#P^=1H/\?,(F^'L9C]3
M8H%ZUH@3-?6I2Q90$F"PH1LL@0T!)0$5G0:UJ"V5B!H@6B/"2EBR$LX`?+T`
M#^Z0A@1,P4I9FNN.+M`*'ES`6%+*Q0_@V88^*$G_3;P:!N'09P<>B`(D2D+2
M2<#T6&IH`QLNL$$?TB`#-&?V6.48'S!R[!N"E=).]T#E/D0WNM6NLB&R?.4M
MX5`&V=I6(OV`R"U?G=O904`HV^M4,>,&)>&BQ9O<!+;YDDLJ8COWF0.X0P.`
M6PY?7^*\\HUV=]T)3C."<A97J0KY#&`#&7A;!HX+][=ED-XD[<K7T$:O#``@
MSWG:`;\JP.=>\O+?;!$GP"&@P0\*W)B"(A@SYTIHA!F<F8&#9C26R<"$>9`!
M#@3A@1&,N!-B4T&`J71@!2O,,T)PXC>@@35-J*F*;9HRE[9P/#6^L7EL"L/;
ML*&&-^SI$3@4LZ`:@6;X__GAD74FH!$MF6<'2I"2>_Z?*1^M"6Q8PH:T^K0-
M?"BJ0"=BT,.:@&:U];RUJ,*^`!`!$;RU"G+]U=I4T8!D`*`6RSLC`+S=!A`$
M]TA.D=N4+I"&/K2A`#KXB`7RZ`(_+LXD?S?)&$0`2'$,A7+7'M\Y.*W2A`7G
M-Q``=3[^P:?7#@26?Q)4ZD@]*%;'%@ZTKK5$<#L1TE-D`2%X!U<NC6VE+%LI
MSGZG=J5M`.:*:@UW4.ZQB3<`.GC3VE"12G"KB\?M<GN][&7OM+_K7E!ZKPK*
M2J^WP^VXNUN?^MYFKR7.T3P\HE?Z]*UOD-J`!PSB,W[TKC=@M!4"%;PA`O,2
M@_^!`5@N<364X*`Q^+LXD(+*+KS"#P1Q$:<O;$51%D<PA'$-"A@"B=$:(%=3
M+_1AY=%R+F52.R!RY`%C,)8R//9!VI%#/[5#]G%SD)`?/G14`)*""0(T/8-$
M1>1DA`!F4Q,A4;`!5(8T#7`#6=4A'``#/<@"3N=E4B<B,L@?D!`):@4`"4`E
M%V``5A`!4S`%!7`!5L`)HB!VO+`V(Y`,*8!VO$8K.D!I,N`!::`LZ+`.?#,+
M!=!G`'!HE)0+E/1HQ<`,CI586A)<@H17@68.E2-*<R($`Z,";!`<".,Y][`"
MHP9+@7(H?X):"<$/E3<HH1,&H&<1L'-;HN=+1M$]S+;_A^3C/-=%>]TU!LV%
M*G=0BKM'/&N`!^K57F:U;.ST:]^'?.LE7]+C7L(7(^?5;>'6!K[XB[X(`B#@
MB]A';DG2?,1U?-W&;N)'3P!0?G-!+?,VC?_53X'!'#\0`0O4`OU&?_47&0JU
M4.SB8.N28/W'0`O7<`(8<1>5`K&1!ARP430D&-=``/9(`"Z0@S_@!!$',"+W
M0B-7@2@GD.,1`P)Y,B/D<C14'MKQ!CZU935W'S0SD44F"$=U,RA(($'7<TGD
M,T;D,QMP-%E@&U7E-#W8@TWG93'(1$D5(0*2-92Q9S;0`BU21FG`7L10`&E`
M"7^0`G)E`F^0.+N@-B-@!V(@_POF-$C'8@!]4#8&H`-+J)1ZE`YCL(8`P`->
M,@TFL%>]T%B/IE=?\DBJP`S%($A>*$Z4PQ2<IF/QX'@(TSF?@XB(V">#DFJH
MEEJT-&JHLVJW=(FDTSH987JFEUM+\`2?!%[OE3F*R3SQA5ZSF%Y3\`.CL@:2
M22JI2#Q4,`7@]FW:9U:=E(S'-V[D1F[EQEW`!GSEH"S<-GUK&(R^"`"PV0:P
M.8QM=W>.8XS'6!;>UUTVP(S-.$934`+1>'Y^X5_[9(U\@`8DL$#RUXT(%D``
M9'#NDD`*1D$#M7`4%@%9$(#L>`$W('\>,`7\2`,G8`T6<(_VZ`*TP8\":'+E
M\6$C-_^!`SF?&;AR]9F0"[D>#?"!+\,A$&D$5W1S)$B"$TDS1R14.Q-E3=4S
M+GE$(*(B3]0$#+AT\W&2%=IE,R`U5+.2*YFAD+`!/>@$3YD`;8!>=_:4"!`#
M3O`#+P(`6,%8<H8`=A`!,G!X2DD.(G`!;-64L7!GZB0E1V("L0!N+=`&NO!(
M9N4"5.)H'O&4%F`">7<XP""D4V@4-\I)+,52T`&(H/5XD7<G<QD0K&4Z?2(Z
M?5(08WI:3/!YL^67IN.7@9F)8:``TB>:Y?8U:#E\Y;-=ZT6:ZH4'.B$\JG(J
ME`DJEWE[0R)NV6<#VV<.SO-]XT:+WH6GSJ<.T<>+U?>+L+G_J9LJF\`(`HJJ
M?<:UF]P&`NVF/L!)`W.1?GQAG,=I/]TR!?S3`@3U&/YF?]6)+@_&4`WE8`)$
M+O."G3S@`22PCNSXG1O&CT+`$02@@,V*CQFR-!@8<K8!D+9AD!7XG@2)K?7)
M@1(C,2&70S=P!!!I'RQ`H$=8@D?H0PA"5"IX1`@2(3`H55*V(AQP-"6@"DU`
M<Q8Z'UT6-1E*K_`*DRS@@R3`7;70!U,P!H'T!C_@#LMRE3P01Z6@"Y2B-A.&
M!U9*#I2C6%5@`P70`FO7!P;`-T":#DWB!#)@"6V5#=#7"P9`A^;I`B6K"I)@
MGB8P>%60`CQ@`YFR68.$D/2`&RI%_TK`X:5U,GF16)>6)Z:K53IZV7ELFBBS
MU4N#&3M,@`+@1GW%F%[@1!:?](FJ&9K=%JGL)0(_4)FXEWO+M;:Z=YG9N(9<
MZVW'Z*C*PJ?=EK>M.*EFQ";F=*E;VYJRR:F$VZFU:9MH0IK'J"RDV@:<\)L\
M,`6J2BWRHW[9$@(-$`0%1E#]=QD)%4`()7"[RJN]BE",@8[_MP'VTAH1UP07
M<!ID^`9"@`#GB0WU2``Y^(#R^9XKU@0&*9\@-*T%29`XQH$EU`0N$P3]N67U
ML0$2B:Y)`+TEB")%-[WP>KTO^1\I4K`BR2I*@R$HZ8--%X1'&+#8:X0J4J$^
MF%WI(`(`X/]'"&!60Q$#=8=(\$L*B7.Q//(-DF`DO3,+*6`#(L!7[7!G:G(D
M1H$`@&1.B-5W!M`+(K!H'9%6TN`":0-,.1H#!<`#:0*E0"L5,7`;*C"TO3'"
M'K4Y.E6(IX1*J&1:F(=J_F"FBZB(ML1JE&@0BA)K@*E+5QL1/0P11P",0CR,
MXM:9(`R:96NVY>9-*Z!<E,E,,J$JATHJ4E``=H>XB:M]W?>8>YLDU79M\[N+
MF"JXA5O&G'JXM[FHQV@^!K#!I[H^$2`7TDAOKCH_UQ@8*J``VBA_J+%A_T9!
MY@*.@$Q`!=>K'!!P"R2L$Y8"%L:."G`!KNN.*:``(7">]G@-'%'_NQ"7K=8Z
M@<!+K=N:K;OKK2FC`"L0!,J[(1#)`@&:KI`@H*_LRD^G`8-0@E+C,X*`H#[C
MRAYJ@T\TNTN@@Q3R4X=,&?_*R[2LO1GJH1]:H9I!`AR`9D/A`2^:P%40`6VP
M9J8P2?I+5R*;:$11#AQ+>*4@5S8J:)N"`.:P)8;C`IH)I3%;AW>V.`J<HK6@
MH[\0.6G)L7*",2KPSXVG.6X9'78"!_EP2WM":C#\)W3YB)0'>F70EX@2$8H"
MIXORPXS"!!XPN&=<FZ%J;L#PB=!6IYRYMVA+!=%DJ'N`>[OWMGN0F7T@C!Z=
MQMS5F,C77=7FF7(37+O(FH=;N-\0U&;<_W9$G,;&"#UX5```T(QA]`<1X#[$
M6;F6"ZLGD!BGVYRWBBZ`G*OD(IT.E7_C:+JHBYT98(".''(QH`",\0-L8,D*
MV!'GZ0(`HX'!:S(G11X16(&07($B%T/>ND(.J2$TUR$%^[S1&\N'G:ZP_"',
MG*X!.P./4*")+<ODV\Q:MIUL$`(EL(.JL67'+,L`N\QAI2(%RQG0',U/N4<(
M8,[CE5:5-0:C0)98N",F0$&I/2M*83<ONMH*G)0([`Y-LH3M/#@//`(U.K.0
M1B9*.B5@IP-FD@#Z+'QJ64I$^QNX,3!&B[22=]"I5)>N='FL!+6H,XFL@Q`'
M@0%_"<.8F(D=L/\!'$VX:)S&[&7`T#>VZN6GI7F,E5D\QO9,5&![T70'V/RI
M'[U-QF>+.0VVA716TM>+M&G&5PGA`/"+H*JHI+E-:;'43.W4:'!/E)M^4]T7
M#2"K\=?'_U.=GH&KHPO6!0<:D9'($_8'_\?(W!EQ9J0`;<`!3_#6]>BL!(!E
M)O5A-""!)(=R$RB\>QWDW=IR'+@$&=*?68`"7/8TT2N1H"W+`>J\6'ZNB^V\
ME`&@*U*P0'AS85Y%]THA-S"[0O`&A_PT5!8$6N9TQCSGQDS9E,'*/'BO>JX9
M!M#<4B(4US,E-M`&:1!V/C';I]`-966EN/T.>=4JOVU.4A(4(X`9(Q#_VX[F
M`B+`#&"'W(_VZ80C`M*PE6866,)`0^GAST;[&R/,I4<;6J8$.OI@*)R':G[R
MM*VDIJFCPQ1=:QB]*##PWH5+FXB;?0EP#K*HC/GMQ9:PW\2C$\AV!Z>H$[HW
M`'B0`IX:W[<IJN\D7[]W%@I."PS.FID*`A)^[A,^C!5>X'B4`.OVQFYA!P5`
M!],BC77\7T00!/#'QYS[/Y4ANIV;8"L.8>,(&:>[<#(NX\/*`<;ZR`4Y!7&L
M'.;YK+=+`"HVY`%SU\"KK00)RL(;0J2L-$$PKE6E94+FO.?ZR@.JV*3MKT`(
MA'/>=%4T\S3OKQ4*S5EPYEFP`SZQYFYN@R$Y_W.>+;X6:H,1(/,VZ,S0K&6;
M<=H<(`.&=SV,E<!S4W>CH`KIT`S=7`JRX4>'IPX[S;&"IBP([,%EKP,I8`=E
M"#?9(`FVRVA,ZFC0EW=I]6YF^;\CT!Q$V^JY8=WI4<+/`7FFU`,&'3JAHQ"A
MXXB7!R@,/2B`HI<-8=Z`:3KL#1$_?`89$.'?<,83KNUT^S6D6HO=]%T*@-+/
MA'LNC2H_8/H#0`%L.Q-K(`4<'8SKGKC>Y4W9E5U??&W%4@5O0^[`..$2;NZO
M"=^=3XQ=6T9F(6D'4`&_Z0$_$(UT#.*6&QC>PIQ\[#__%KH"+X[CF'\OKL@*
MGP&J:U$1!,FOF`+31/\*/-ZLEDP`)*6!O6MRH>RZH'S_Y!'"Q3L=;P`(64='
M68)9)#`P+(D;BTE&CTDLD),;EBR+B1R,,!N=B:`PB*";'"2GIJ>''*6FA:]9
M"B$!;#L<GK<PI6]9K+JMOZVFK"2II\?%Q:P%50@ZSSH(TM#0"#%M;='2"&PF
M+M(N;]OC&3(7SCHC52/J[,_L\.P);047U.GPT281!SP&!E5,>+,0P\`(%RXL
M(%1H@:'"A`^_)701@P>`"R;PK5LWXHE'(4)4-`#Y$:20$@U*J#!YLD2)'CV6
M+%E`<P&3!6%PY@C#)$>''$QZ"@T:=">3,$!Y\NS0@0G3#F>@-IWJ]*G5JUC_
MLVKMP,*B5XL`PHH%@`U;@;,R;!A(P%;$O[?_$ER8._?'@#UX\^K=0^6.W@%K
MJ/Q8\W?-8+U4(O09VP8$MCYG"Z0U("*!6Q&5Y\98QX;:B`L&9,B(W!@;V=-A
ML8&(+#FR8\=MR)8&L9JU:!MR'QCH\^>`[]_`??_I\T/(B1,AD"-/'J*Y\^?0
MFS>XD2*#F.O7/:38SCU%A`B6(G0/'X&5^?/EOW_G[H&'^S\\X,,7XX'$FS<*
M\BMHHB!&@QA-I,`&-R$T9`$!!R)(`((W-.&@@PU`*.%^#E+X8(7\[9??@_L!
MV,"'(#;Q81-O$/(*"8>`X@DHE;!PB2<KAJ*+**5T_[+)C,@<@@R*/![BHXXY
M<E!(`P$@T,`;)&Q08RM!].*+>;_\DLR.QTQ!@A/)#,-!'S%XMLT]SHR000$C
M?#F"-M^<,PX"3[211I<:L<,1/O&HDT)8,JSCV9GZ3/$',S%T>9`+H%4Q44.'
M3@310HGJT(8=!F0D9SL=L?&$$!^:9.FE(:U40D@MN0133#/-1%-.//7D4PY`
M`254JSX1=5108=2Z5%56!;75KKQFA0$`[P$K[%ABE1:9:&MA!E=<<FFF`&%[
M13O`#U10L<8`=V0+[5Z&W977#Q'$)AL`L-FVEF5L-1N#.VO&D(`-HYVE6FST
MSHO6;?C&6T!I9<W&FF1J7?]010(%V%%!<`C_T08>*ARG''/.+1<=='PH$($'
MV%V7@7;=>;>!=^*EP/$&ZIW'07HHK^=="F*\)Y][/&2PP0WXZ9??!?\=.04"
M(8!C8((N+$B`A1$6?2&&%U[0Q`4;;ICAA0"*6#2(#2AP0R$F'J.BC)\H(N.2
M-:(RHR:JP&+VV3KZ*"0Q0F;1!`*T[/`)+FRC>$,Q43Z9BC&J9(E*,C!$X&(;
M:D)31307\`F-"6/TH:8T@B(@T9H(1*!`&F?"LRZE=,9SC1T\M&'0GF<B8(((
M=LA@0A5T#31"#`@MY!"B#"5:NP%V@,`G/%6L\\2F3S0@TA,G>,2I"BNEY*E+
M+\'_))-,->%D4ZJK(H644Z[NY"JM.RG%E*Y,1>4445:%T>OY3S$Q@UA>$>M^
M6<>JI2Q<F04:@U_1Y@]87W=LF_\>=OG+':P@+MGTZU@&H`M=UM69-8'A7?J"
MC6G*4AO1I,6"-LB@!C,8+W[YRS:XJ<(#"O"'WB`,.`K#`Q&*<)SF2&QB,`P!
M#:9@!8UA)P,=2P')P`.>CJFG/"8[V<G4PYT(9.`]\2DA?'B0`@[@IV8;PIE_
MG*``;03@9PU1T(*>H`"C'8T_7^20S3)DH29X*$)20TF$WA"$(S2I$*?@&BBT
M]C52C*T58B,&B@IQ@ZNA#6UM.Q$KLG`#(<#M2$G2Q'F._\&!J^%MD3NZD8LV
MD(1*6I*2EJSD#-J0`'0\0P0Q,,%FJ.$,MT3`!)*S1C2^D<HUI>!U9V(#I3:2
MN3JIXU$6*0"<TD%*'>#NE%48@PATL!`=7.!0#E'40VJG*(JX!R,:Z=T(D&,I
MD*SD"2%@0W.*8!)/A:IYI"K5J:3'DU;]!"D_$<KU9&64H]RJ`[4*7_K`A[YZ
M/B4,+'"?/AES0(`EZQ^5D<MF1H`&__U/6@?%RP`H("TI[(N?]*@@;C03*#V-
MXQM5,(`-2#-!V3A&,FG9H$A'NM$"P.8UC;&-#`P0@PO(P`XG#,X?`#`%%;#P
M82V,872>0`<C9BP[.52/)8+ZG?\@F@=EVUE/RY(HG_FD8`I0O)D9/S0")S2`
MF-+`XH*"MB`=H$%$1[.0A9A&Q@J)=6EFE-#41O2*-\)1:S<J11SE&L>Q*7)&
M>TO&*_K81T+ZU8^O<(60]AA8%`G!!0PX4A8L(5<]*L.O4T)&*1IAB4S.X+*9
MU.1ES5"`3GIR+AFIAC8LEHUM-`.5WTA'NQ#@#MY-JI:VC(`=@`4">]Q#&[ZT
M0Q\$LBY%C4`$`X%([8:+S$,A(`UV*,`[Y,29YK#!4B/!9C:;PZF3J.!3S.L!
M#9PGSIJ@"B>UTMZK6$64ZREE>NXTG_FLXI.IN->>]<R!!V;#KWV*Y35HP4VZ
MV**9,]'_P5L)#7#^JI4_<"T&HF:13`*K,-#2;>,;(X"@O&A3%H\"C*09U"B&
M._@:"<8O`5](0WQB^IN9UM1A.DUQ$YR`L19<Q\4;R^$./^;#DAF5%2IK8@26
MRM0DQJR1456`T@+U(2<\07(N*%`6EYP@!)31:6,%H\WT0T:EI=4_$**:8K/0
MI#;ZB$I@1D0<Q?9(O$8I1WS\:U_/YH1"#,/-9GL#&US`ANGT@FZ.104K'`D+
M'B5)29VP!"8M.8/,NN&R&I!!)ZFQCFF@XTNC^0%J[5$F5C:`<JS='4=LR>D+
MO*</AU.</J0QAN0B.78)J8(-O&$[VC&*F;5#W46B605MZL"Y_YR2KG/84(3J
M8C>[HX)>],993J7T))VMZHFQ:<5L\I'O>^/#%7S/QX0I6%`TK'',/N&'EF8I
MD#-L"*"`QZV7_N7/,.%BC`'I48`0S@G3&>U@8_BYFI"2=%D:S;>&2\JOC[);
MP1>8`@!,2.*91D`%Q(M8BG<:A!UCQ\7T(6K(:ES4&Z>'QB=+`<R4V%0F9B'(
M#O)/`UYW@P9,Y(H&$EH6"1".IX$1C&2=LH:H;*&H24UJ(^(%VOIVC+11:1C*
M($8PGA0,PE[MZ&L^NB#-X[>VR8)G32B$(IG.`2OIN9%^G-(K`BWH02<!DUXG
M-+Q0B0YVB+)TT="&""*0!K(_HQE(CO\!`AXG#7>DH\&N;6TMD2NZS/%2&P))
MP14*P.I$N0"XR"2NX@VO`V!U8;G2Y)DTG"N$WS4G`,ZI+DBRN]UP=G><X&7G
MJK97E*&4-U6Z&M]/FA+M:<<W#=>._4.WG>")VF^4.GB"0<DM8'%':PUXV%<!
M3^,8R*QT<]48AS'A-6'4D*7>]M8@OJ?_E@S*JU_E`M@=##!P$O\&`!&@P4UQ
M"C&=GJ`)%VO9=7@@AHUQC#LSEC@0+;Z=#:2!`]7A,<?ADX$(W,=F0S95_U%%
M$($`!W*`2[8@%M`@4B9E,R=S4Q:`2O,?618B?W0B5+(*C%0W>Z,E-^8*L.!'
M@`58&AAT03?_2`H@.2$0=5D`'D,W)8LD6)+D(FU363`2=IF560:0!I[D#,CG
M#&O"8(DC.>H@=Q)!=W.G`_W1.9S6A*PC,*+&)]+`.'^@.HS"*,-D.XNBA8IG
M`K@#`*%4)SU3))@7`">@3<W!,]3%32'Q:Z)"*L,V;#EQ%$:Q*D4!*T2A/:F"
M>NY5%<?F;*[7*TS@!+$'+]=F&N^34@#7.YP1#0VP>[QW4`L%8-%"!<$W?*F1
M8.:@.)3C2]A68?=%#[<Q4G"1`&M!?1HV&A)$00AD`]WG??T0`0_`0@L'0RKP
M`RPC!@"@?NTG?Q+W@40$,AR0!M8!`"W`5"7$?C,352$G@"/0`&P`_P8&<D4*
MDB!:1`!3,$;[P300.&5H%49:]B&\4#:$!21\\S<H0G59`B0G*"6J@'1(]U=I
MU@OTZ"2+Y#8(P`!LH`"],'3&\&59H@N3Y'66<`B5I$.5E8.%5FA)P)`78`.X
MY0RGY6C:T(/3P!$2`7?;(`(C8`4_\`RRE'>4HFER@@^W]0RF@P=VT':HMDP&
M,5RTXVJ+QQ`CP`-V`)%Q`C<Z.7G/$0"81WDFX8;!)FQQ&#U#L3WIE(?IM$[+
M1D^ZTEZR$HB\<@/PPD$:=$&C@8F9R&[FT&`HB0:1R'N!D5#8,@4FE8BB.#JD
MM`TCP'PFI6W%(HKW]A;[98KXIA8:95+U8O\O"N:*!!=3\-$'-$`\+U2+R8$&
M'&`=+L9^[/=^191CCUEQ)O-#132,.P8SR`@?]4$S`"@B(C=RG:%D"E&-0J.`
M"Z(`^.&`4Q9D&F)E40,@9T0U?/96868,0&<R)Y@EP^"/Q<!'2J=T\]@+)^AF
M09<%)5`D^_@)PJ`,3;<)74=H#.D&24`"-P!VF+20#7E9VKF=(V`0&?%HRH=I
MX"`YYX!5%+$FKY,!4Q!:3@@/9;=I=@<FDB,"?[!JAF<!")"%BK=,7)@HIS-;
M=R`IZS"&DA,`+O"3!/H<O08JU]420[D`IB*'-S$KK8(4=JAL=%@]L[)LJQ=M
M@"AM4FD5*^`$(Q7_4EA9`/OT49VU.0W$!O@3E@*V!I#X%Y9(`A%``E)``E8`
M`MY1&S9@6R@Y#@_@EAWU?!$@!5-`BLQ2EVZ!BEFI;?W";AD$`#`%BSQ@!6A`
MF(;Y'$]`'6*PF.J'0S66<=UA8Y-)F=MQ'AJ'F1SW8YPY1D3&#K(4FEF4$"JG
M15SU!&-`1C;#FE&45E;V(%JVCW=3CCSW-Q^8FQ^(FV6C9GP%G($5@X%5"&]@
M2"%0`HNUG#^W"2Z26=OYJ3.P`85P2="):#-@!MO9D+[4#"A9D5]B.I3C#49B
M#:W$2A*I`W<0`2#9A/'`2YQVDL]@`@IPDX67*)(#D[/3G\0U`AYP`(27_VFE
M<Z"M-(;4BH8AX&O?U#S/8RH1:A/>*BMT*"M[.!6QTFRU4A6KDDY4\5XAFCYC
M0%+1!R\@H$^JT6Z)0PU/\*(PFE!C&:.!(:-K0`%X<`<4,`41(!D)(&JXY5+R
M5D!M(`7]\P/[AI=+>@%MP1:HN%&P84`J"B]M\)<G5`%_X`%H8!PM5)@Q=`(T
MD'Z,R0,NYICBD1[;\7Y%!40V.T03!T1.D`;MP:;)V'\T$U43^)G/)0UL@$76
M6)IU>@/YP9K,*&1H%:B?235/$'4]AX&I8(ZZN:A!)"7F08]&)X]\%:DG^+5M
M]G$#(@35&3B0)%G.F9"@NI"?Z@;V89W0J0&(AO^W>CL#QA1*:3<-:3>$KSJ>
MK/5@J800W%`F,0``BO-:\2!-36B2M^4"5;"2)L"?L1,1B^<"&:&%MC-W=O`'
MP+5<X"`1THIY<,.E;`@J0DDJ<-"M1@E>*U`4Y:1LV>.AZ;6'MM)Z4>F'[6H5
M0?`/&+9!,B`N8)&)"B9J33"C^ZH7_0JCWC(M4K!2AP,-/8,`8.!29R%!J4$"
MT$(!/R!]=)DN%ILNE.&D$Q2E^<4;L'@`PT$'6HJR,72+N=BR0%6F*D.S/[2_
M:.H=K)`&3L`RF.EC8A`!'^>-9B1RSU6TW[!D7%6:=SHT3:L??JHT910H%4A5
MT[$W/X*H'EBV7$MTZ:'_1V<C@B-8"$[@@;CI=-F4J5#B6"F2D(?VJ690PPPY
M`WB+JGB[`;R029B$MZ8:Q#,@2G('A+BE`ZJ6`*X*JUBU2J?62CHP3&Q@!]7[
MN)O&$?!9)W\'#65B`A<``$Y0K+#6:@82`V.0`,$UDRZ@`QXP6ZSJ#@<Z.=*J
MDSV3347`!MUT$D(``<"VK7(8/3DQ/=N3%(-L/>4U*^EU%*S7AXS\NQVP`M4W
MO-;'/HRQ&C90O<_P7\T;8`-`!9OLO#_P`W1``VNI`^]R??0"`"3@R7@1ROM6
MBN1[L:B8EQ7&+_<"`CP`BR+K`3_0,/*K4TTP!1C#F,#2BT7DOR'S?CO$OSA+
M_V/SYP0LNW')6!__1V5#FS,Q\%P(@7);!<%*NR!'\D053"%EA'-4VP2%*EA]
MMH$A_(%*<F-F8\*$M&;$&8,F$PLE\`8PXH][$VB:M5FG&M!`W)#9J9V5]'&8
M9`1PBVA)H`%[JP$(P#I_JP/?J0,Q0+WC(*QI@!&/9JNLE%K.X`]ATIZ.VZLG
M.0*!!RG*]&K*:@$BT`:K1M&KM+D)$!_KB4JO<VJQ`S=DZ%PAT&L+RA(@P<?!
M!@<T`;OC-*&H(A0=ZA/HA'K,9BNW<JX>^CWL&HCF\P9P(<D;)2S'2Q:2<:_/
MX'N?+"UD7=8`U!F=$0T1UK!DL<J@_,H`%<OFNRP42__+4:J(:=$'N0R+"M/+
M.668?/`&EZF+,!-Q^"L>'J"_/(0R.%NF_\L!'J"8TLP#'@!D8]2,(.(?`Y(0
M!AC!WHP@0:,#G%G-G?F-&X)E(K<N$0+#?:,C*PS"031_MV!41C>V?A6<;C8,
M0+2UL;"V[_PD<!0X"[U99N#0>XM9.1@)29`%.Y`%E80)BE!)0%S=45!HF;;$
M@2L9P#4-^_`#E795I8NXMBH-W\&>MH3%[9#%F+S%SO`'=G!,*YVY9-P0(P![
M+I5!&'&?":$#4Z!;*.T"[4!,J':XDW?''A'40LT\VOIYQ`9Z<[A.0X%ZYVIL
M4GWAYJ,KJ<)Z(!J(.]"DPCO_O#(0%NY!+/20L-#0!*R,UM%RUF5-!:0\`@W4
MUMO;!AX@!=;R>WB@8?13EQ@[RZ$A?!Z47P70U]XW4X#],+6H`L*\F(<=8XDM
M,APC'LM<L\&8IFK:?C6T<3$3`6^*P/TA@)?6$`&@12L7VD&S@/?Q1#0'M1L2
M(;`9CF_`=(R$"JO0SC<&:$*TPFD&CU<S!?.HPNI(6(%6'D5W(X(VPP"-PP:]
MW$:@T$:`"9+^<6_0-=.=!%'0T`V-MYF>!.`ITYX4`PI6D2;@!!:U.N1-N.,P
M!AD@*20]2[#>JV<BX#,%._3=TH<R`J.1!@`CW_SMQ?V0)UQ<::BVS0=ZK291
M$BRQ_Q)\K*VOZ^#>)3WD]"H<3KO@BN'GRN%6#6W;+I4Y`.(3NT'".Z]?G1KM
MQD"YIZ\LGA=X0(EHO09HX`Z=$6_7)P4S:AAR?2YU.7UW'>3TI:)I@:+M.U,,
M$]@+=P)H8$3%S(N."3**#;,_)$1(E53H@3$I8`5<+@8;`%5^2B%4XQ\%F+0(
M$-IW2B*LR8T=LC0-@#-4\XP;[%ALTX%4%\+@L>>VK0J`_IOS#$A'952'(&A%
M%25==YV+;JK++0G2/4=QQ&7XD05CDY#+C0E32-&=R,:B42;;(+'I\`U&:.#E
M;0T`L%QY1TLBF0^2JP]-,!R&,M\S^3,(H%%VJ<3"90'>(/\0"!$#O<$#!6`0
M85)K.AT[M/`1G+*Z01DJH](#KVO41EV4$,Y.$@ZNUZX42U'MK)?A5PU?66V7
M(2Y2PHNBP/+5M+&)[%!0Z][B[O[N39`/]&Y2</T_=V`9X@[+Y[O5_'Y])R67
M*`JR"4-3#:#D"Z<"-S#,+=N8/I1QBQV9)8,R-.:_1V4=VB'\[O%406O:@CJU
M,FZG=@HT)&^:.@!%(C#!,Z?94ULU*=RV,8_G><X*P1WSKW"V>S6V;1;_0=?;
M)D,R.S1T0T])<9M)"@T(+"PPA"0P)%F)BD=!05EOD`IO688<,"P;21N"@H4D
M"*"@.CJBHSII!395)J`F(F,Z(PC_+C$NH+:VLZ$(.ADQHR/!(U7"Q,/'PL'&
MP:8()C]Q$3HNU"X6UM37V-?<U@@V,@;@!3H6)B.C%S$&!B,N.G8'?SQ][28Z
M5;_5^P%L)T(`A3P)2!`@A!(E>B3LL60)G"4+((99L&!BQ8MAF&C,H5%CF!P9
M.7;,&*9D28],,C+IT%$CRPXP8\J<27/F#A'LV-G8R=-&3AD@`/``0)1HFS8R
M$A!30&6/TZ=0HTJ=^G3`FA\#J&K=^O1'@V!LJAB04:!-`:Q4K^+LF=-``@,X
MV\IMF\!&@;(@CN8U*Z,O@#\'`@L>+`^`%!HG3H18S+BQXR81,@@5PZ.R&#$I
M,F>.P#F"_P?-*2)LZ!R!`^D(FDMSX)"&0XK+'CQDH%PY`X<;D"(I4-"D=XPF
M#8*S&<&&C04+!(X36+X<.?/GRZTUV2WIS6[K32YD;_([1O#O;U1S(#&>!/GQ
MJ].K7\]>_8;5[]63)^$D2WW[63@H2G1C_WKQZHDVVGL$PK#!@0<FD<0,"\XP
M@QL,*KB))XCLET@C-S3R1A"0<(C;&_U18AXAAYAG8GZ[B,++BOBD$H.*,43`
MBC,*W*)++BE.80,OR51AS(_%*),,,Z,XD\$?"9B0S3[:;+/-<<>)D(HX"5R@
MPP41L&-6!`5<X(()$0`6F!U])!!+/FP@$,`^MH0PT$`%Q7E00O\+-001'`O@
M29%%%/5)DD@BM3122BF9A%)++*WDDDLU-5I3#G'U)&E.-K11U*5M@%"``4W<
ML4967(4Z%144K`'5``-`H2JHHDJU`C+KD!4!'JQ*=<</:['55EQSR?66765E
MFE=>!?0EPU^$)3M/&H@EYMBSBSWQ0PJ563:4&)^!UED*V886VFFF<9::>FE$
M0%D&Z,Y6VWM9X$;==+W%Z]T(#3PQ"I0$6/.<<LY!EYP.UD%R`W4$*Z"==\%-
M9]IZ)LK7WL,!<A#?P_@I4E]]J^57<2+HI2>:>`**)C&")!]HA1LHNZ&@)AM0
M:.$-&8*X88<@PFRSS9!8J#,EZ*FX(HO_O.@PUHNAQ*CD+++<J#2.%U@!3#(Q
M#!FD,&<2*<H(=MAQ@9+:=&V-U\<]*8(-";QU@1,QB!"!3TXD$(.5UL3@03R"
MM?##F;_,PH^;`<$9IQ`(S:E0#ST\]%"?B.>Y)T6$,L'11RIM1))&%9ED:.2%
MPJ2HYHYVWD$8;^@DJ4]MV4744)=J.H:GK;8.%15-G2J'``+4`46MKE.!1M0C
MK#,%'JQK=4>N//5J_*YN`9OI4<S?U5<;8B8[&`\1T,"'8M`^6X(3&50KQF1B
M6*&MN+&E!BYGIIF?7FNOB9&NNIB5YNYN\,K['7%LZ/"$<OGVFYP+_MJ7"W)S
M'8)MIP'V>\/"_])CGHXY<#4`@AB!%L@P_>BG7?SA6'X<QI[XB,Q`)0LA@E*0
M!"NLC&6%>%G,/B0S@>'F9C!T5PPY=AZ/!8T4/VM&.HK$HP+,R&>XT$6*&@``
M=`3I1\LP(C.0$8LBZ4`$!^"!.Y:$#39UXVM0<D(!<)*&"Z@#'\Z@1C"49(LJ
M1(`'T;-#&JH0BQBDR05KHD8(V/"$.M;Q;T*``.`0,CC",<0ABDN<GA+WIX]L
MQ",@0<E$+E>HDS#J<RF!21@\UZ@@B&-TI&/'6XX5`2E(QBAMP$/L7$?*X#EE
M`'6@G0"0\`$ED/)4/V@"#GY`!=Q1Y0X*N&3QY((37O%2D^*X"_.&R?\7&4!/
M>H/Y@QTBT(0G."M[C#F!`EY3&0#0QGV@^1:WNO6Q\Z%F7`$ZU_LH$YHI!*%@
M]8O7=QI0'`3L+SG)00!T^!?`Y30A-[JY@,&FPYL8\.8&Z'.8B<X#`X]14#7Q
M>4]I0*:>_-RG7?T)$08QML'U*%0\`VH9@42X@12$T!.*@%D+\4G2FMUL"BB%
M*,YDUI\:FF8TJA'%VW9!BIH&K10Z*("-$.`.(>8"1[S(@)6&1(RB$JEJL5@B
M.D!1A33808I<JT8WKLB-J59!'>@@8]BN88(+B&`:U+A'`JR`1L&TX0=%?>,^
M%B.$(A1!(&\E"$)*L$<Z^;%P#H%(XB@"!SW_E60!@CI4H`AEN<)>+E&2C,DD
M*4F3'(P!DYETRUC:((4U4.`'4^`,'DSU2E*6ZE0^6"426*D&6[9N#53XE&FG
M,CR=]$H$97O+6WR9D[(%<R]'`4#SBM6'/U0`F8&91P'0<+T08`^:3YB"![S'
M@\M@*YNH*9_Y3D,:;H6&7*ZY3+JL,!L/1"!#.R@8;^(%G.`0ASBVH"<`YUE/
MYK#A.C]X%W7T.=[,!I2!%GR@Q"@XP7`M;*'R,4_%;J:(*23"P/9AST)'LQH0
M'DA`'!6A)2H$T9):.#<P-+`3Z).%*=P,1.2A+DSWRP%G\%0$]Z"IBIQ("AG@
M<!8-N,5/=PH*S)I@_SA&+2HQJH8,JC%#K``X``#`2D4G334;4(+2.PP`UB;Q
M=`RKV(=84S`8.P#`!E]`!QRK@8`Y1BNN<:)K">9DUS_B:9!ZRFM?%]<2D(@$
M<XULI&$_9ZB5T+DDGV-LGIEP`\C29;)WJ,H:/M795YK2*3X8[6A;N=I"APJ7
M<LGD;&,+VYST$BZ2M4M>+J7;H_`V>L"U0PK0X,SC0A,RM&DN9;`YOFUJZUL+
MY4Q'/W/?]*0``.CZ#+I2<!M(A!>=XRVO<)Z@-WK"D[WMM0#!Z%LP[2B@,Q5<
M3<.D[3$#[;<T#)X8B:D]8)BI-$01]3#'#/JQ_4;XW`>:,']$>N&2GK3#3O_@
M0+SE39^40O2E'QNQ)=+#H@LDS:8`KRDIODKC(,YX%Q<H8M5R'+4J)&"-4AL2
M`F(@@P-<8<A+NJ)4J[A5;.C@;08@AY'%.(NJ<G4$*?C#%01S!1Z<Y0%LV!MC
MGE`$O\FUKGTDW$/T*L@\Y=5/@PIL#EA"$I)4SG*'>LE+)KE8/<,D"(^=U)]E
M$(%1.KK0GX5*'12-A!K<[NJ&KG2O8DMVV,I6LK&]+:>-HBD9]($'P!7,'SSP
M`V="<^8_6"YS8=-JZ<*:NN3[5GNHF8$49,`#&R#!AWYMP&"OLS@Q#AMTUKNO
M]BX'`043@7C#4VO]SL>E'EOPP@@DLO4DXCX1C:'_1%$_;@B+#-T<#>BZ/\3"
M=I_4P!!K3W\BN.^"[CL4'U^%B@%^TZCM(H@W0GXH6I``!`RG=\-8AEA4X:.I
M"0,!:@N,#XN<<28AF1LF2$,?"C!^'2CI'.4P\E2O,8)*E57N0P%#-0(0@,;4
M'(]CYF,/(.#'O!9N<8AC.(-4$8'5.(-R$H;E2(JU@$XW$XZ%27,A`U/`66#G
M.@/`!0-P:'N`2J-5!Z75:!7(6KDT%SA!=B9H=FEG6V2Q=D7!%P4`=W%W`'9P
M5G9G:L_2!%.0:F+0`MK5+=[B:IL1&C!57>43`:V!7>;"`[DF/S%C'8Q'/^.U
M3D\P`D^@+_*T+U?X')17_T_\=!W6,5YO`&OM,1\=`WKF)C&OASZ=9T&GET$9
M%%$6<C$U!&&PYU$D@SX")E(OU&XN=`,H11__$2X`!C(1@`CE<8CH45"$`'Q7
M,GPWA$.D$`,Q<#3'IPND`%2@@`<><`_%P#O*P!D^DD3+8'X>`!AV\`-DQ"3=
MT(A89'(N@`I]039NDP#A8`+@5W(==QSWL`YD90>`H4Q=$@KT5W]?9G,`$3A\
MM!"$\W-[=69X=3@3T3B)5("$M4A(=SF3M#D-.!-'$'6[5%MC(04@&()1D8&7
MI8&HHBJW,X[D"!7#\Q:^0G874"4F*%LH.!9!(135TH+%\H*_%7=_0(.*88/1
MU/\`FJB/SL5WV02$?T==F4%KJG&$1\@!LU%XA=@N'/(&._"%Z-0;WP%Y,8<<
MUS!/_M,<EJ<#"J!YX@50:RAMY]%`H!=K"H5O%.22%7(Q`_9M<$A1U`8?L'>'
MY98Q%<92?&A24[!A\R:(@+>4^T$>)!)"*6(E*>)$*V8"W#$CR&<+(R`".((C
M,2!%.H!CT9<,L'4,1H4,)M``\7`%Y)"*;,)EM;!Q6X4`F!4.!H`*.Y$*YG</
M(C")576)%N`,]S`6P0(`=V$`%Y`FH$",C`%F<C579<80.S>`?0('.@=(BZ,2
M1=<1@8*`1X>`A1))=K:-"]AGNB(7,O`#[=@J5Y&!:$'_%>RXFD]Q!ZT%CK$U
MCUY4=FA'=O@H%'_Q%ZCC@L@"7!40D'A0:M"D`FB0A);A7(>WD'[G+8`W:[16
MDZRQ&K)Q71[6A!JID>+ED<+!!@U0#LYA;,E1DL<60,I6'003AM>5>QS40?\U
M00"&'A:S,_>QG?C1'_G%7W1(&B$4,JJ!"#BS4K8',[@7>@`*4](Y8@M%H)3@
M8)EP0BDBB3.B0T`3B5LS8]2`-$[P0T*D`Q&`BGA3?5,3`TAD#.;W!K[8!AOJ
M?4<6H]S0`/8E!7BP`CHRCP:P#B$G#B*``$GF1?E@`&,@`F.3!C;@!(A)#*V@
M#?37&$\0`G\S5W=U5S]'F8;S_XQL1EAM]A**A("1`TEBRCFD"1,Y8)J1U19I
M8'6R.14#\)J$UJ97ATOP&(]5,H^\"8_W"`Y!@48`8&6H`P`@L(*@)CU_(`93
M0`0#"2U/@`93T#W-.1O/I2VQD2VHL934^7<3>82&1VOU`3,9Z6O?R1T?24?D
MV1SHB9Z61P!/X(76<0.;`9^R^E_75I\,A!_W@9,4=1_CH3$;9E!`J6!W.(32
MII/L=F$GE93;$H29P:#=Q'N($`0D,*$KXR`.8F*@,`);`WPW17S:2F,[93"(
MF2)TZ01*%`PHJ@R2.):A.`RDX`H`$`$O^I8C)Z,6L`)]D*_YB@=CD0"]E*1;
M9*';,/\"8\`.!8M5YM>*21:8BPFE]_>8R:B,2R"9=Q)(/F<XF$F`D6-(AW0H
MBT2`H1FF=C::I`EUE]0K$RBGPL.F*NMH=&H\MZFC,/LK94$4?^";\]!I?E&H
MR@(`4Z`"S^083T`#L*J#VE5XT.F#L#:$T661I%$NU^D:F5%X'"!N[+:1W?F=
MI:H#(>`_6XBJ_J*JT4$=KVJ'O">K9CB(MDH>&S-1;:A!\!DRQ%H>/!,N3-M0
M,<2'R:J@0?A@3$M=^'4B66`@)^0@"Q(*,T)PD&@*S<!4*!8*'(H`12H"LH!\
M"E`FOX"N**IC/9)$[XH3+R*7]5JOUR"B^CI^08`'28&;(V#_`ER39-B050L[
MNU#2"J,PC(W!!@\;$)"IC&96L12!F0VQ<QF;$00XC8O"I9@S.0JHC67Z=.)@
M/+32LE+1FM1;@7=@6\<C6;KTC3I!%I:"L[Y)%(-Z+'2#3,4)`!P`M`1Y`@T0
M'MTS#\U5D4J[3=ST+4S++<])&@>U&9'!:]L9!+@1JKKQ+J0*>:!0DFP0MF);
M3PW`&PHP!?X+;1`#K:'G7QAL>O4A;@BFJQ5%;IV!(-!F'JG'GP(J'L9:>^X&
M,\HJ+MGTMT/(8+XW4#!Y`].:"=2J(-C*5/_&(L1W8JQP<+HP#'FS4U_I$YVX
MN4P:?>OZ8UZ4-U5D15$<H]Z`KZ=;_P!T(%O@<`%AHR17<@&K0+MBG&2\8`LX
M]*3V%Q`JH`)U1:7+:"<1L5=\E5<-X2>`!5B"@KS,:X"30RAD^KP=8$F9Q"NJ
M>;U5\9J&[+(_4*>0)2DRT,C@6Q2!:A3%`A0\2QA6%@$-$+2,H0(*X`1Z9QGI
M4K\,^4WX*VNR`9$U*2YJ^!E5*U($3%(&;%[BF<#IV3\DN:K[,AV7RK\MN6]Q
M2ZL0PV$=MC/VX5+8EF\/=E^SYVU*>:LPA$^2,,T8UA_S%L('8K:C5WH1``.E
M08:?1\.)(*'42JZ-*'!4"8E;^4-?DGQ%Z@15\"6Q<`$\965ID+E$O`P\)8GM
MB@Y5@`5B$/]EH@LV5&4-7,L&.'"Z^BH%4_#(J/!57>5O!C!^3*9D8WS13LJ8
MBU%S;\7&O>N[$WLX$%''<SR\=$Q(+0$YBG2`H(DHCP3(@?Q8FO06JY/(3G$'
M+&O3KH,KHK,3CVPL0&TLX##4/MT7-3N^F%(L-M!;_PA<\6H]-L@'.$A-\NL^
ME9I-E>J#@#>U2/NTJY$:&^09O!;-%T8_W.$=D%<-S-$OJMK`_M(`4BMX:.C-
M#98>OF=N#`;"\'F?%]2&&_;!_^5Z`96',U23))RWTEP=-7.4$(0:V=R0]&G7
MU`;.-)R'AI##"L(*/W0EC)NA/[,.E"A$M_`VQ!`#4T"8HY`!6=/_!YU+-5<5
MBL9@`JHM#1LGQ:.+``T@!9Q!?@J]KPTM`Y5V-C*0-A)(SQA]W&;<L+FKQ@;1
MNU9*L<%[.,%K)\R(TBT!LHH$6)KI2".K=(S5=#)A23-M`)METY85FSKMIC^@
M2T$-U/W8WNTM3)*<U'99`)=,&-33!,55D$'@&=4ROU>-U<\9A,]*/OL;:^7B
M&=XE;Q"4&:^,V(E]0.Q$A?($I`RLGKI,``'047]WAC.Y;\D\>LLLS+/*84*)
MDP\D:W[+S"E\`TEIGV1-0*X*(HP=PD((H-=&07?]>;(ZS@A"H5,IB3FT8D7S
MN#ZE-SSE17WI$U\!"@KPIW:`SV<I).UJ_P)!8&7SVGU4W"0[$`&]W=L,37YM
M,P5E\POW,`T6?=QD/`OG@`[#R)AN51#.[;N%PQ`1`;QW?N<\EYF.$W0;VTC:
MS02!OB@PK3DY$#K<B\C4^Z84F-ZO]`-X``[P;=1WX3SN7>F5GEM(K5MMEP!W
M\(+W+1@N1P-VQQA"\&S45"V'5SY*F\KC`Z#ZZ[2=42[Z^YXAEADH%<TJ_(4>
MZ4;B&9(C>>'(9GE-D!J"AVTO16(+1=<>)&N_'+CH44,.I0CXU=A`B<*J9S,U
M1*`QSI%>B*`A)M@`2L&])]FS&NT;!)7D^JTWY-F\\*&0&T:ZT`!&NE3O\&]8
MLBE2WL]FV;H_(/^#::!5MB#P5)2+(>#E7][;)/`#_J;9"KM5:7[<91SO<*0F
MBW$"_B`G;ERE_3?2<:SG<&RQ?<(1@:Z9*:'=>RPH2D>R91HZ;_$#C2X55'`K
M.`UV,._HA;8&_$H6E1S4F/[S0'\7(+!IIU,4;6<#7B0#[X=,?S!WI.8L)]"H
M$@RIHAR=FN'J?0OK]'OLG>$!V`0@E]IAJC=2!".)[*0#XZDO@8GA&<X<"/#8
MESH@:`A3<A_#"D5Z<SN&>I\Q9A@@*QY0GUJ@!,9M,;YY`C,%C>W8(9R&9QAK
M:OCL/2E@@PN4YOQ$-N7NSB<CHHT+9ERYNU`C,H4E/'`W^3P,%]`.S/#_`RUP
M`&WP`&Y)#!R'9-W'!@B?\`HM!0V`W*Y[#+:HY@^O)A;?F,:H`H)#YPR!5R,-
M!SBP_-3]\8&T2((>_7<L*-/?QR_-\F5ZZ.Q0R%2A.TU`+YV26IVU!H&&\Z_T
MII$>]/VH_IB^/'N1CTB=*5,"QDXPG*'6!T]O7"=0`@`%"!YB/(1BAAX>*8J+
M*1X9B8L1*1$;DHUBCXH1FYN-&6(>E1$<G*-3-ZBIJ&\W;ZX*"DU-,0ULM@@(
M%KH$%BX$O\`$OL'$Q`&=DY4;*<K*E!S.&]"CTI36G!S9VMM9V=W;X.'9&^2B
MF]DD6:JNJ5/?'.KKK[#T"NPW3MF=I:+*I-6C_P(&)$5P5#@2'$@H5)@%8;,-
M,'!)1*!#1XP+.BAFK$BQHXX"&1&X$(EKI(N1"&*<Q!52H@X.!_Y$J#*BILT1
M7!+(L'+@@!T#.EQ8B#$BA@&50D\F3=I+Z),^4*-*G0I5"E-=)D;J*)K`1AH9
M;0I4T46VK-FS30,@"!`@A-L03XH(F2ND1`D()7KDS=NC!YR^/9;`6;)D`>'#
MA0TO6,RX<9@%3"`_AKQ@\N/+3#)K9M*A`^?.H$.+'MV920X%!G[L6<V:]9H?
M56B.J#@"!Y76N'.[_K%&M^_?P(,+9ST`SQ09!9(K7UX@;/*P?9Z#:#.=^G0`
MV`'PP.[<1H(+50P`^/_3L[SYGG_:T'ERPBT1!1P$#0)@R%`F1IX@X;?D"9.F
M<Y(X(J`SH^3#@1-.W.".*JO,$TL#M+#1D07!]%(,+Q<68X$;EI"SB8</E4,)
MB/Z,^"$VXFCS#D(IDL*/B**@$T\K-*(RA8'P,.C*&_70PPH^+I9B#8'0%$20
MD0,-!,Y""#&I$`SD)$'.1"-HI$,"'&V4)2XC>%#E1"29A,`((J`DIDM-V$%>
M"W>,H,0(=Z0!`!8'7.$3#S9<8,`%"11@@P@8-;54+X0F10-5B$H500@4Q89`
M`B(8X$0!,E3:1QL>M#$"6IRBM98+:H70%EPAT$67778!QA=@B!&&PZN'->;_
M6&6416:KK):%H2L38?#ZV6>D!4M:&!WDP`H5`ZQ!!1UT_.#L#Q=<$(-L-J%Q
MVW"MK7''M=AVZZUP`U"0QG+.,6=N<P5,5UT;`+";W;L@4&K#GC'@,=YY^-K1
MQ@]"M'="$S>D\`D/]LEWWR*('*P)?I]D(F1^G^AGD#M.9$&QQ3K.,TL#M504
M%(6["$.AAAD"8T$0HS#S(3,/#>FA-05=8\Z1+7H#CS@G?B@BB@F=D@HK/T[!
M8HX_.]@C*S<*&<TU,!\)H(LT+[D-BTS"8#64262=Q$076"FMEEMY-&8?(XB)
MDD@GB>"$"%F51))$52C@@1TQ$4(>>G_8T6X;$2!X_\$(60E:J`4FU)21"1=D
MM4*BC/<AQ>-!!#&"#3)X54`:WA&E@PF==@ZR+@&,Q-9;;IT0EZEXH;HJ8'TM
MT3H.A\$NZ^R,W4J[98SIJCMGF75&+&B_=Q"\L!VL\(84/P3Q0VH&B`!MM.#5
M5$4,T^[0V[=[W$'!`,E>CWUP`WB;+/=K)$O'%,VU$18(TYU[+G7JJ__NN^K+
M:\!W!K1Q-[[EZ?T#$2<X@1#>P(%/U*<-BC"@?A0A(/S@!Q&'B$0G$I&P##PB
M$:-0!\4JAJ`9-8A'"HC!+&+`AHRP02B$*IG)5`@##^2#0)1@V8E:1HYQZ,-(
MU:C9S6K&B1!=8QL+^B`J</]$M%88K1[LR$?.3/0R&"0I:BD:6D+0,442"$UH
M"(&!UI(P`PW,8`:X,`$"JN"QK8B@C#HX8T<0H`!-@4E"81K#42P2@S!-)"-5
M&$,&_L!'.ZC)#MOQP!040,:L*.4DO>"82"PP@G'E"2-C$(D4&D?)/D0`#="J
MB0DVB4+/>;(LGV++J-S"!@&>*G5VP8M>6,>ZV,6*=HM9`2QG22O=[0Y8OB.6
M+HDWFA5,80IX\$JE*F>`^T6O*!>1U@^XU:UD_8`"=U#-]WXS@#K400[<$\X:
M\,!-*73S..AJ7[F6@QSD,`=^\YL?=9)C`^_HJ0_[XU],`(`'%9BN"5-(07WH
MXX'_360*%/H11`8<^,"&_<<2%EQ&POQ3H"QP\$`J\MD'8[&Q6TAH)"-3H48M
M,(50W"!GY5!9-*:A)'`8Y*0Z!,<[P.%#(7EC1NSX$8Y(((\>(5%!08H&#"M1
M)"/5;&@D0-`O?YD%BQ7U21O(VA<U8`:F:N".7YO-&3TVQHW@P@E3$..9S*:#
M:#4O#9N\J$MP484+1.!2VN&;"&*P.4.:Y)`N:,`FZ%`V!?0!<S%@6]LF6<G&
M64$*N?BD8'NQ25VX@`UJ2>PH0U`$N=`%+Q!(7>KTLKK`$"8PBJ&E9F4%A\7H
MKC*VY)WP?">\X?'2,T%PPK@*`!5YS>MO(Y@>]*+%F^^M_X$+T)RF;ZHI``$@
M00U0$`X%C#.%"!2WN%90G[K,-<SF5HI<\GO7=KCC'&(F(`'PE&?_`#`%>ZI@
M!Q&03WU2D(8T"`R@#+3@`AWHB`BJ#*&A:$1[!SJ*H#8D'!)M$#UH04(ML0%D
M&!I94S3*BPT\`AZ2,$<,=Q:C(J$TI1#FX8A@B(Z*%6U'0%*1?NG1A%C0`Q7Z
MF#",AO0A%SE1'%+4AGT7Y#-W'!5*2>5B%YUJ!C.`27-;^8Z5LI21FKC-;6^]
MP!A$L%:+7(!MN*@C,M.@6FBQE2,(T*K9E&(!!`0A*A'``X1F8U@7F.`)).AK
M)9LPV+)TDBQ=38`!YG4_-9<I=/^B)%U<'%N7$M0%E:A:92L1L]G-=K:SN@+M
MKFRIJ]&:]K3`Z\`14K"NY!!36M-+YG7YM$SL_>`.X=.M;N306]_^-M.^V28X
MI4*==BW7T<-LIZK;V=SD7`<[A-`.=^)EOP3<H0#QY-\?N-N`)RB@H_4Y1`3*
MFX(V^$>^QR8H`]T["?G*=QD6Q`1];1:.BN578Q"JA48:$-ABX"*C)".`#@P\
M4(0D^$2,>%E)(\SN%/5PQ.<X$$QWQ`ZHQ<-H';ZIB\H!HAF2F*<&:5%0W9%?
M!MW@OB0HA]:6VE0SS&!K5"+C5O3$8RN!"6T3,8D.:");KW3M)-%2[1O^UA*)
MB#%,4S[_R1/XBN4@,"LH%V@"&O#`6C$W3@HZ$*P)+'*'[QPS/*EV;7*ZQI:U
M+):Q=+[+G>_"]+WL.58XZ#,M.^M9R&2F5X3>);%P&:Q#=X8$\:M?Y29-O6A=
M]^S.`S6V:JMIW=0!"7!'P@?4H';<#.`'>)A4=-59KE2KNIC%9/5S73V_Z>[-
MT=[Y3@%XH%WT`"`"-%`!R@Q8'PRF(0(*[,]`E9U`3$`"H<VFX'P3@3-M8#5C
ML)`%">&H@P:$3,`C42'(0F"%!G:#Q`M>ADC7W>[>[UMG.S.(A3^(87NOHD<=
MEH4];D`"$?-[PC)[FL"=D(X@&CP5#<FBPK<XXZ9*"4PC('EL__)41HUD_&TI
M1YQJO_:V,3VAK1<OW`B<4`6TF<2M0GG#S5=``BO8O*\%0`.>Y`)5T`=JPD>[
M%B^I%BU5<%T&8$X%("&BM!:DTUBF8F>ILW1YQBJ(\2I1)W6,0755=QF[LAF$
MAFC$\SM,`';MPD[SXG.2%BF`AP?>LW:]D2Q44(.Z]79Q-W=U1QQX9P.LM7?9
M$3^HUDZ`!WAJ%GB48T[HQ'=A42GN=`&+EVOG\0<\$`$/@`8<H$_!!@JE(%`4
MY'GKQ0@*M$".P`R-(##1E@DF%7#6IB.I1PL=0Q$EM`LCLTC$`&Y"00!/X'GT
MU0W]1@YJJ'N*T&`1EF+N)A`!$2)$DO\-P[<C/G(D,,5A'K9\XZ![_+:)0A)P
M4H,0-V)4.L(@1Z4-5C,B4L)]2Z4U8+)QX;=6/P``&+%C%%%'=G2+(!<;17%R
M9\,2\<<&8T"%78-R)V%(;'!6_Y>,C#,%9X86>$`W5Z@W72`#!L!QFS,".L%.
M57(2HK18)V"!<Z$"0J`"$%!G>58"-,`JEO4J"_"!A-&.(+@8OG)UO>(96J<[
MH\5UH1$\AQ8&.<`"AT=,QG01D,(\!C`%/_"#P?$:SG('T=1VJP$%/A!W+T!W
MOD$%/R"$Z>,N]--WE<-FQ:1F2\B$@[>1'1D=U@4><M)X!U`!C_<#'R5>E:<(
MER<?$'0(9;C_;)Z',`RDAC?I"-/VAJ;G049$4:O'$A("8%4&;N#V"\,0`A>$
M"!Z`8$M3B&JX""_C>]K@B=N@-#$D0SQ35/K%(V^0!=AP;ZGG8:YP>YO8EIP8
M`3"@0P,W5->'"@Z58EG$`5;#`GP98POW18#9BF5'<A[0-5"F$6QC)G9T2'PB
M`@G@!&)D`D36?A='$7^C`!FA%)O$$F5%!\KXF8@2`2K0*2XP!;E&'GS$`P50
MC280`PE0!9LT`@:0'`8@1FS!C:/S%HWE6'0&6:KC=*OB*AZX!%'W@5)G@K[B
M&<J92X5F:%U76H6V2[[#!"D```I(C<9T`<\230Z)+-BS+:V1@Q`Y_P!0\'9U
M``79Y!MW,"GI\H2S5EU2"))G-Y]+V(00"#]A1RG61113```L>0"J^4OB94#W
MX4\X:1^<=UX*XY,(8Q\6Q`QOZ(FBN&$5%1(A@8<!L$(::B$$@`!DZ(8))T/*
MP#*'N!\\I95=Z30BEGNE$%%&!$(*<`/_D`VI8(GV``W+8(@L\WR=.#551'UQ
M6)=VJ1"?F!`D<#5("@,L8`1)8`1.F@11H`%2>G&ZR!$TP1):T@"0.1)M0YDB
MX9K1$EM$5@`BX*65F14G)Q).($<ZP0F@^:92$03-2!87`(UU(S]_M)J`<P'>
ML14-2)N<(SIK872D\XUT=H%-ERJI8EG"6?^<LL..C9$8C1$95N<9HC4LH^6<
M^DA:TIFIQ5)L;2"%0W9IX:.0X`-JKZ%V=_>#W=-,Y(F>IKH:VS0N^+DN'OF1
M2DB?\TF2@P<_M%9K)&<O5G@>=F!)Y_6%H!`)-GF&C"`)DG"&B$"BC-!>TH9!
MX8`B0B6'#T)"=Q18?9A1`.:4"/`+3V`%49D)MW>5A'B(ZXJ5A_A@09)2`A$D
M+L-@\48T#D)`SX"O/B*C(>6N.PI#7%E%\,!BI'B7<LD0"W$U)(`"5H,!1Y"D
M2NJD751R:]2*:*0#39`"6O5C;W428BH#WR$"/M:+%OLV?!H#AN0$=V4`8S`"
M>`"G,FM)(6!89.'_91E@IP"P)^&Q>`"PFM=X7;%%$Y1C`X`C.J#2C:2#=*:"
MJ'N12GS1@;`3=<2Y&%1KG+23&3F0`Y>ZJ:65CZ"!2[;$J:'%!$<@=E/0G;$J
M'%1``=XIGKB!D6K'D`E)'-X)D7<`3F$1=K_J=R%Y=GP2N'QR=FMFGQ!XA&U&
M%&`@'G8J3^EQDPU3,/]A,)6W0,YJ,`DS"5^97F+0`CO),SPC;\-7E"%4AQ>[
ME!6RAR?!"W^H7@F3".GJKH2HH\H&($EBNRG:B/_6EC^D8:1;EF?Y,[`@B/BQ
MKF_9HE1T(#=B?>UP<(IX$`KA8D65?4<*`T=P!"B``1![O1"KO1@``TZJ_P&'
MB:7@IT:S@0`B$`&\V+$K41(C,`7-<[Y`UHL99P)C4`4>%V4NX&-1]@3(.+-O
MB@9H\0/0J#=`$646(0/6:0.P63@2QSE&08T-?%&@8G2CM)N'>DJ*JDJM0IQ2
M:QBPPV>2*H^]HYR;"BQ91[;V6+9GP`)*Q4524@##5K>:%B[*$DUTH)"O004.
MN2V]L<,8N2T.N;;80@'HXS[-]7=M!KC?T<2#6Y^"E\0O*"VSH0,_``+#:AYZ
MTP8$B@F5JPG46C`2TPD$&JV:^Y5A?&SW&F+WFJTUNJUPE'$Y%V"_`&!Z2``J
M4*U2N7E3\`_IQJZ<9XCJAKM>Z6^;6*+J5F'""_\+'Q5O]^8*_\!OZLJC\PI$
M%3.AV-?'TV=%Z3"]TWMP184"HFR]VQNQ$+NU.7"]W*N]1O`E=R2_$@$H'K$!
M,I`5(6$V);&_LWA(MWBQ$N$"3I!7?V-_;H,#`"RS4F`67B8&"%BLB1-&.J#`
M;<#`F[058J0+5T(I>W)D57";2EN!%MB;O[FHC-K!YIP8(^Q9O9,#RSD:7*=U
M]FBIO!(&G94#&&`%,V!!^>QP#K<!)/!,.O@]`X!I>X"#OZ$MF):>>X#0Y5/0
MVT+$VA0$AVM.?H>$2^QS3IS1(\F$JQ:2D%;%/Z`_+(F%P1:Y.*FY,HE>9QP@
M8BQ!7TEY[G6O+F5Z5H3_E@IP`1QSLB?4E":3<R/3`!;DNE()H2X"L+0;R,E@
M#OWP0S-DO,:[H]BZR`348`WR4>S:KE>M8/BU8J3H#ELYL`PAO:!<5$%P`T<0
M!*J<UM>[M=I[!CFP`SNPM7&=RMI+1KXX1E-%);(X`A&@-XFS%4%A1W#D94X0
MV+@\<>-K<ACWL2+AO\<,IQ'P!&91IP>HF@FPF290!07PLUARR\5(.#H!`M.8
M+@50-MQHP4N+P4ZK.AQX&('Q=.8L*YH1&KBTJ9VZPHR!`N8:U&:0`6;0`K\-
MW#.0T!#)&MH#T>)#PZZ!W*Z!!P^8Q!\)DG_K<[-5W69W78[9/$GHF-]!%%7<
M_U79U7BI23!>3*T2DRG;L9,'=0GJ+4&ZE\8.\T0S#8DW<GP*`"%Q7!)W^'IU
M7&4F0P>@\`B9H!]=*<A7>>`)6J(QY*Q5>=0Y&GS"9]-E>:(TE0I=^'RT.\A<
M>7H%=W":'&('(=:J4-:14^*1<]:J7,I'$-='H+W%\M8+L`/^B,I?DB5%P;\2
MD08MD+,`P,`<\P2YC#8Z<$)BE`9!L1):H2<1X$87A\M*@7%H\-AP:A4W:P(I
M`$B$H#<R`#AC)!Z671&!<T@F$-I^T@74(0-!`6=Q5H&,]8VFH@*_R4J6]=KJ
MV,&,41B/81JFT<XI6!KY.!DK<,]![=N^_=LU9NA2P/_<WH*1`:UI/`RW&"E-
MV')WA;MJTJVKUIWIT-/$N@J#-%%&#U``:C+2Y%VMD@O&;5`(9AR&I_['BS`P
ME>L,;"Q]!Q*D/%)1Y]<`*%3'==R'=0S@ZK6@*0`U_)&CQ:NNRJ:)")[@6`GA
MVN`SK_!1)SHCT*`)2MWLH5MAOW1]WX"\4]/)!X=]-T#B)?X&)8[B:IW*;\W6
MJKRU80#7\+X#A^DQ9841+2&;R7$C"O#+^MLV59"8'RN9>E(`3F`#4V"834X2
M(<`Q34`#$^&94@Z:9%86:!`'@`05/0%(R=$'=@,"!XRFB&290DB-0A@O"2`2
M<$:H1Q<"AKK:Y.S:E_7:E^7_.JZ=69)1PN]<CZ/1*[QB&#FPVYAPZ,`]]"U0
M]&;``G=0W+I!!<PTGDQ?M\MT!XT^/@2]&G>WT8#'W?.IZ=33]5X_F%ROBR54
M$6`0`U5(ZO41,9D'QF)`'P?#"0IZU00E'YZ[DSR50RX%APER?+.0WR2QTQCB
ME$PI!8!X00X4R0F6H)N+U,R>[&K8NY%H#TT3#V8)U0\!U6N<$%C5X<P7KP/+
M`2YF<#,2!.9N[B>^`ZJ\`NE^O>^^M4>@:*KLCS(.UV#C,>%'1E42$F1R\+<<
M)N$W&VQ01UY6C%UE`\+,5NW;$FS0`#B0/%)07)R``TK!!BP7\3:W*#=K`1[@
M$P?0_P?;K\4^(6MH'IF?[678^((:28W"#V=)N_(LOYN/Q=HTD(ZM)//OZ#JM
M,QB2JBOL#`@Y'8-,3&$=AV&'AH6&80L+.2P9&6:59I@MF9B8E'@#>Z&BHZ2E
MIJ-45*>KK*-K=P-W5*^EL3\_=+"A`S\7"2()P<()%\7&%S'),57,S<[-RM'*
MS",Z.@C6.@TR/'\'W^#A!W\\8F(9'ND9Y^@I$1$>8N7M[N\I\1XI^AL1^O[Z
M'M:5,]>.W[N#"-]Q6.B$A),;-]Z\:1*C`1L$"%QD1!`CHP4+!`A8<`$RI$@2
M[`+F^Z=O83^6&U)LB,ERG\V:,&7BI!FSYTR#"SDXR1)1(O\'H"0@9N&P+^;!
MGS,1!F4X!:)5JTXX2)U*@@.)+&")7K4:Y$:0(%F.!#FBEJW;'&[C'LFQ8P?<
M(QCPQJU;-UNV:M:JQ+CP5\$%C(@17S,<PX7CQR,N.(DAXH()C8XW8L/81$J!
M/J!#]P'1)\*.)DW01!#-NK7KU[!?1WCR\:,..P>N'`"0!G>X/P#Z```@8X3F
MC)=-Z*B2P(;S`@5D&$C0T44`Z]8#:`_!O7N($R>*"!D_OH3Y'N=[J.^QA+W[
M)7#:OX\/9P$C)AT$*1J4:!`B_(8L4)\5E%`B!B<'BJ$).P7.<$<K$+*22H04
MDD+%#U0\>(<NHF0XP!H#4/##'6O_O'+,B<9,X\P(++*H`QLMCL"&-2U6,<**
M+EZ#D35@I-&-.$"2<XX8Z02TSDKNQ`,`/?KT$T\&344P4TT!E3,0E/XD](Y!
M$00UU$,1*:!`#!=MI%$##7A4&P(F@>0"2I0\B>0_"_7TCU,TX:3GGGOR-"67
M77I5540W1+4045F\]--3/&VUD$.#CM7505H%&A0)7TT1%J(W()K%63>TM59;
M<L65EUP[A"$7!J<>P5<,?_E5Q04L8E-18HEI-,9F&F6D@V,ZV'#!K")@9BRN
M.C01Q&JQO4-:;-!&*VT$(7Q$4A7AV&%`'[F!`UP!;;1A@`XF(*!<N1L%UIP-
M,K"+#*W7_V&GW;P!>.==$?B*)P0$YI6PWK__+B$?P.Q!\D@A@G2`G\(,*]+(
M(PNLL`$EEF!R8`L*'E@@@07"H$J%(.]!2\@54D''QVM@&,J&I'RXX1UT2!,-
M-3G.Z)>..^**S<ULS`@8K@&,,`4`W@#Y&T%$JG-..O7$DW2322XM4U0O_:/T
ME4@^I36E#'$PZ!L*-&$11KVR$8-Q)-464DDN%*@2DWFFH)5.-4E9-9]X[V23
MG50_*M8;-VC%#P>(,B530OSX`]143F@ZU@V3.CJ5IF*!U2E99GTZ:JF<X]4J
MJF[EQ:I><]5%:XO9(("ZSJR3O9%R(E2WLP%I&'!91L?FB@`=G_])Z_OOP/>Q
M0VT?H:&;;G848$`;XOP!0AM=$&;N9N?*FL!TP9![&7;R9C=O"/5Z!UYX^O9K
MOK\$IP\??)`TLC"`B3@,\0(H%&B.&0=:;,DZ!6XLQ<<DJ]`/0!'`"!%P%S]8
MPX5:<8<&Q"A&?FE=ZQZ3F9Q=(W6L`P,>B&:T;)F#2.@(B#F8UH]U`(!I4./?
M/Z04-X"L0QX$F5.3#'(XA7CI(1(94YK,9+8F/,$Q%L!(FPCP!![TKT@VD=(^
MCH*WN,DP;WJ;&E0692FQ!,YN"X$("12W)83TA&L+<=Q8EK(U2_G-<I3SU*;0
M@I8CI*5SH=-+%CZW%[;0,2XK,("-`*/_H^6<376XB@RN>E4-`TQF!)F)':RV
MEYE>[>A&-EI!\"9)R=9$(`#$,\$4PL&#X13@1]\@!P!L4`5K[(A<UE!.*G7`
MQW(Y9GO7F9?WMK.=>X5`7_OB5PGXQ:_TJ:<,OUQ/?1X1!D?TAV$!@L01.'8)
MC5F"'0QJ4`1(5$"0S:*:)(L%AU:!AE-B$#$4#*<X'S.2<`YRG(X)P`_:4+0.
M'F`><2I2#`'2!JD=Y!XCU(E!6F@D&*9DA79["1BI$B:Q7:2",4`-V=C@`I$X
M]`DI*1(*%2+0N]W):BQ9B1O\\40]^01/2@2C6)R`10XHI:):^J(9&Q<II51J
MGS9\%`DT515/_W5J4VZ$(UOF:,<CP(!T=W3+#E;U%KCD(`<R*&7J=$0SZ2%F
M!!W160P,(`)F#.9VI:P.9LRD$1.@P0,ML,,[*DE62M*!>!8P00K"$2X[=-(.
M=OB#7'D``L*LTI0W4XZY3'"NQX#S,;'4"+WH)3[RC0<"0MBE+L^S2_2@IY?`
M[(&`%G`P15BVF(Z`Q`)@T#^*X0]_G2W03$@@A0=ALT*O.&")6#&``YZ6%27P
M:R-Q)\Z1E+.V:+46!6U+$B#6QJOL=.<W`!!1>1X)("-<B9,R4(X[L3!/2C,'
M/#N:N!K&%$Q@(],U,M/#-+G@&B`IR1/<AD0D;4!P^B`*4U;BIQ;J:?\E'MBH
MWJ8XM;GU32A6$5R7Q&(XJE%4B8MCB!6U6*F`FM$K0PG+3=7(QK2L)2UOS*E;
MYACA",?E+FRQ2^?HPN$<%`!6%TP,5)%1C0DJYP)478XO4(R9"QB&MKA[W0;&
MX8T9,*NL.)86&HCW7=\<P`XRD`$`[-`&&Q#-><IKY<Y0F==SH@NP@97E8,/7
MG?'ADCR\Y%<9_`6!'G09`EON01G81UGY.2*S"U@F,R]FH-`6B`2S6,-K0S8A
MD=TA@:88@!SJ4`<UN';.HN!%VGB[VT'GUK:'3K2B:^.8![0!E!TD2`CE*;44
M?%"Y^A#(G/A1W7OTTY\A5)P[1JU22S4.(F'_(Y.9=)#0)I2I6A\)R1N6)%'X
MFO<>^KB!JQ60A;A-R:,UL<*=?")%Q4V12V&$B'X)9Y5]:*E+5+SA&/7;Q:EX
MA7";NESE<JJYG7(;+-R6<*EV$(05D'L';Q@J7^J2`U7=I2YA&*JJ"J!4G.V(
MQ!)4'64(HQ$#)`.JOW)!`VA5!4;2U@4*<&N0>6#C'#L<6F<E7@-\#&1N\*``
M"9`!=(3%1^W=C,FJ+!>Y>MNK1J8SG;&<,I6Y`YY\D6=?NS3?8V,>63C41[.6
M9<0CEK!,^_4/8VWN[`8H`&B2I39E):+`GP<`!0$X70M^!O0`/+0'*JA@T5C/
M>M9)3D$$/*`//!"N_QV&-.GHYL,#Q"62U6#X1">*4+HQ[&@2M]*X,8"-(@?5
MR(A=C8`?$H\&+2C[V5$(-5R_H4P(:,`;[#LE^>:D)CS1Y[&CDK@`5V4*1PE4
M?J=&T:#8(Z:$:RE)`SHX,WYE4PH6BQL_Q9:R3!C<JY?+68*0[G2C>]VXSSU?
MX!)ON[!;CRY2#$:,TSI6LU($B-R(<48P!N3K_4;%<L'V-,,#'MA@&1>P@A2>
M]?#NBT8*L/[(!=K)@R"#8`I5@`XQ"K[DNX(<E=/34=JD[Q'!=D\[WD/`]^SU
M'2OC*Y?]XF40,(!=IAYPP![#Y#"4I5DXL`%&\G/\@PZA=0Y!\&=%!R$I<_\A
M!+1`HP`%=>!T2(`$'P`%@$8%3Q`")$(#6K>"/(9.YM1UB?$`GR1VQ54D_),/
M]51I^)1V<@<0GY9V2]-15>,HV*5#,<9JJ-$$JF-H=!"$M89$=Y(/''!XN,(&
M-[`E/M@GQR9%=L*%+,1Y7>($C2,X640H_8!L4Q%2EM)25^1?`X4I8$$YV@86
M#;86L^=&:/%&;$1[$E%[.Z``=0&(8O*'8J(`2P"(2[`#B;AN$;-NYN9[Q6`C
MFY$S)<8ZD;%=6^4"ES@LYO)=8P!5"'`8M&4"#7!Q=J4#/W!CWK>*I3$%-/`K
M"?<-R2,=L#(";0``Q/!Q=X41>A5RU^!*C-95)$?_6_&B'?JG<OQ79?_'2^;1
M93%7@`;(/A`S/PLP,0_((%8@4?W##B0@9Q<8,@KD6E07"E"`!`(0@B*H!!88
M0'>`22&``X/F@N1T:/)80?GV<3!R`3/H3O/PA.F07"]$#_$P$&J'$]K(/]7W
M3TU$=P4U-IG1``EU`1;!4.6D`($G>!*U-_]``F^``!>!>!ZI`%>H1#>!:S\Q
M;']B;':BAF%(%%AD15MD76FHAH<2*9CW7`EA;82#;9RB%&7A>C_Y!D<`.$+Y
M!GQ8>[8GB(6XE&)RB(GHE(+XAW6QB.L6!'RA%L-B;]=0!:I#?,-G;SKC&##R
M*V:"#280.S80<,@Q:\61_PTQH(JLR(I20`<_$%8'("[^1B/$`%6EU'$AEAS:
M,XG`F$FT%41D,P39<7^S5$O)&!Z'-8#F$68E$%G`5!]+H%F0D(@.F`',9"!6
M@`=X$`'9V)D90`*F]8VOA6>[4`?HB`0U``7K2#(/0$Y=YTAAZ5LC,0'C5'Q+
MY1<P$B/,((.0!B33]81!6$^TI@_U-`\%F5$'"7?L\'@LX2A38'<Z%'#?U6H2
MF7<N(`6!5VNX!H5T@VLWH``8`9*(P09-<$5?J)(P,7E0(1/VI1`/46!_$SC.
MII-S8T-#<17S*3E"X1"G9SD0`3B@8I1$*1%'V8<,RI1+"950:8@2*I6ZAVYG
MH?\6#[9Z7OE(K(0SK'0!L8,N@^0ZX70[;V`"8T(VF6$!$3!*JJ0-<!F7K!@!
M4H`"+#`%/U"+S5`-D&0C?M&+(_&+YJ(CEX%6F;$]000C&8&8*9=_R,A_AL6,
MS?AEDVF`-Y>9.Y`"S-29&Y!`+H,'4D`"&V`%)(`'((*:<T9-NU".(>@#?A:;
M(8,&O=)'%Y0--F-OM/F"O*F+OWDCT5`,!0``PD5<\51K1S*0!>DTT-11-OAI
M"<DD?(*&#S$&8J)JF0%5R8`F,;8!3EA>XAF>4G@#$^F1%Y$'I-HS;-``"@`X
M)/!<O]84\-DH^$DI0Y%YS!816=`DH!<4]S5@3`13!];_$`FF8`5*>T6!H`R:
MK&`#-@[:K`Y*B+=W>[4W>ZAW>IC"`3#``<C":C]S#2,&*ZR3B9IA`K"B$1W!
M2,9B`F*`BSNC.C$JHZQ8`.\@!7.)!F-B(\IQ(SFRBVD%3M/3B8861+L51*"H
MF"FG<HS9'?E"@(K%2V*V'@*#F2M00BJA#ND@!=ZX"PIT!WBP36AZ6FJZ"WOF
MIK`)IR"#!M;0IS(R(S[#LJ;T5[=5ENFI`R'@FR^2LC6B#,>0`('J3L#1J=HH
M!FV`J"%D0G'2G!QEL0:RKE@#16"$0V'CD+;2`&+C0!LA!?'D@TR3D1SE#Q&!
MJCUSJF"+JE2[JIV2%5NRA9,7_P%9\`9;Q)\D-3A_$Y,`&E`$I6R*8K?6-JP#
M=JS*^K<-ZJS.ZH=(>19"B7IA@2E=D:V,BZV.&T@O>T'+4(GYIJ*L%CO8.4Z7
MT00`4&0O*H/P&KJO40!2T`1DN60_(Z*]Q8N\.'^&]DK2ES8J9AQ1QCTGAXPK
MMXP$R+!=!DSKLP0XL`+^((&%N@&G^;'(*S(8<C(9VUHF6R$PXT""\0P/Q")W
M^E>UN:W9``9VRK(YFPPGDG$<9#1_0';^:"1H5P[JP(/_B"56<Y#,Q0-`1WAX
MPY^H-B9HHW<1V0!/<`U@8`5.&)Z>]JEW4IYB.[8-(`0)C":IFJIE:[99$#F<
MMD^#4_^>O48I$:P05@$X%;6WRR84,)FWE+)2<?@X"0JX?[NJ*HS"#&JL@*,4
MB*NXU^JX,'!>1[$0V>JX)#")VLNM&RI!C>1'2QB[L$M!8P`"V5AO/V`%HMO$
MEM1-(R%RJ22B:L)(16HMC'1;NW5BM)(1Q2@O"$M8X=-RN]NPCZ4>`A.\+T$@
MV5AKW9B\</PA(T(%%*`+9_I::X`&5E4,TH`C,I*R.`.#MJF+.'NS+"(8X&L,
MPI`&XPLD8P>T\+NN2P,``R%/3_2<,$2H]+LG7`.UVYDN%8$F?_P$G(J1`\RU
MX^D!;#N1#HPF5.O*L.S*#>S*3;"JK.H2.,F1O+8X:+M?!7K_A37$.&@[.""\
M><ZVJP*6!6Q(E'[+PBQLK&.$N(E[K8OK$IEW7A'0N#"0K5T!AUG0H8G!2K/"
ME7X$ECLBB>AR.ZP&HN@Z6XYA!0#P`)T4`TJ0`"S0.TZ<SWU`N@V05A%4I//(
M8R;`:+Q8I+>3Q28PSK@3+]USNXN9L+H+F0/H9?^R`_:@I>T`7RD@!<\+QVDJ
M9U/W("/R6KPP&"B"##(3(]>KHK;I37<*R"[RO28-HL(@9.TD#H]<L?[X0LQY
M:2XD0T_X0O)@1`2L)[1:H#IT4!X)D0XT(^,5:J?\A!?E:7*3!1;1:K5<B+6,
M&K$,RV.+JK4<./8Y$8G"GU+B%1N\_T5H*!1B^,%69#C697HLM<R_+!&$0B@O
M_#AZK<Q3D$81W,TR/,,%)A6EE\./XA4#:A80P</8@*D^RDH_O#,N,@9.('_,
M454,5<0EV@(\\`!_<`5&%`$H\*[Z'+HD8+IFV8FZ%;L\]EO^&KLL37\Z4`PZ
M8"VU*V6)B8PM)QZ[.]'_@@,(,;Q:&P%*Y]')FS('=&<;`D`%1`6&$0S`$`S'
MT,<MLM(PUG[5*R/570V_J;/%`-T&8``VW4'%.7@2)5U`J,G(-2>&^G;55Z@]
MF"6!`B9B8K4:P4JAW+]-8&GNFY'@B5%4W;:I*B8I'#9<'<L-#+8>2:J*=P,-
M`387/-^4<O\5:GU=#D%&])D%8P`1=[/6;*W,>AWBCW-YE#,%8I@5^IGB^CG!
M=G->&P`#V>RXB)W85]&'X>RG+?)'+^M-"/`&'H!B_:`C@I30KH1."/!C=Q!V
M=C`#4E#:3AX:09`F6?P1KH,1+<BZG:BBT[=7@S$"P?C%8)S;B\ER$9UE:,P!
M:?!Y39(/!9`/GYFQQOV-&=(R(,(+<$XA'R(B=.`+X1W>T4T,*:(,*HU!<WHC
MBCP,D;A'W`W9B*S((M#GXVTTE0S5ACK4Q-6/:^Z^2?LV`L%V18T3\UV=8//)
M&M'*+/N=6^NI18TDJLP!:!+6)LRL!EZU"(ZJ'AD"YYFJ.<04\WW_%.?5G\H6
MS&S=UYCG#H=B%5,`>0>&8#?`AB-.4VVMXI[W;`.%PS3\7+X>%3"NS3..4V9!
M>WQX2I"TE7MD`K7B36-P`2W:`GKTXX@1#9G;2)=Q&\DS!G;``DW^Y/H>`730
M`+_":*Z$.P3MK[A2Y-+'(N:.#`/]Y0;[T/OW'5NPL!.-/E.0$$*8`B3P`W%>
M=,Z+W*NP!L5=(;;PW(_>YWTN`M$=Z)/[QSNN;RAF`,[1+D$69,X1WNN7(X<,
MON`=WC+0!CXF#L6YZ<A5?0E9D,M%>)$\U)V:-T<=$1+I[_?-!E70U$V0M5J+
M0IO,$N@`%A"YJEF`XD)1%3EDX*WFU5]]_\!4R^M3,3A)<5+"/A275RG)QN'*
MONS2KA76W"5ZO_>X+/=ZW_=GC</;C*UV4\,_`0,DP`(SP>W9R@(TS+@RC'H<
M&KF'3",1I``MV@<&8`4)$(HIH".4@1G;T\XNP`8_5@!<8`6DK>_Y;`5O@)M1
M'+`E-_HEAQQ`A*^S?1CA%8S<<]M@_/`2#YDE$`1SHP].D`:CUN:XY@X8N_%X
M3`'0/T`,=+P0P@M\'M[.4?,F+PQ\G`Q[]-*L]`#K,O/04?X:!QTS;P/KQ[V-
M+1C??3W8'UR2'G>V!E^43/1/,VKX`!!7#P@9&6(\A#P9'HD>*8R-BXV,$1Q.
M4V-O"DTQ;`B<;/\C(PT-38**I8HIIXZ/C((I-V\-"F].3ARVMDXWKPJ\30JB
MH:%";,3%Q4*A31$IDI-.&\VZ-QR,T,U.65,W64[,MMK;RY#5UA'FY^CIZN8<
MDLWNMLT;MO,1,-#6^!$;_/W\24E8D,A"`@:)@PA)<(#!D.%"&"PBLM@0L:$.
M!#HN<MKXJ<K%$3%&:!1Q(4*?"PGN8$SQ@Y..3PA<R#0A4V9,$R,.')"1AD2!
M/D"#"AU*M*C1HTB3*E4:)*8+"U"?2HW*B>93JB809*V958<+$S$NZ(`*E0#9
MF@%<I%V[5FV`MP%"R-VRI8@0"!!*E%C!(8TY1A[$%=C`#%7@"$'6[%G_S+BQ
MX\>0(TN>_'C`CS68!U#>,X""XLV,U_PP8,.&C-*H#:@6D2#!A==5/GW*F!%,
ME3ND9>@NP+M-`=\@>`OGK=N&@0L>,8ZH$A9E`A&DV]CYH[.ZSD*($*U*!-A0
M(3&/Q'G0#MC4($-BQ&CG/JZ]MUPW>,5HL`FCIP8C%*A?;[B4>_:+M&*+`C$H
M,$T\MV2ARQL,]I)),&S0-XPQ;/AB(#J3<``-!R3H4DLUS4RBH"[M2`+?-.ZU
MQ\\YY;`3XBTPQBCCC"7NX\^-_@`$D!$H''%$%EGXZ&.01!9)$$(-,<0"#!IM
ME)5+&6%416P:(1=#"JZED=4/;3PYP@56U523_U,-'&"':E(LI>::;+:Y)@A2
ML$$361;45*<%3]Y$ITTTA2D3GE4@5Q999M%99UMJ)>K66PS(=4(1=N%%PQ1.
M^&5.&I&,(XXW=X#FZ:>@+D8%%3^$:IEFGEKV0VFGI;8::Z_%0&64'%V0FPS#
MM0%"&[SVVNNNPIUF0`(AO012<ZTE8$`!U%FGTQ_8\=>>!]Z!!\DRZD%BWGGI
M%>)?BM=*4LDEO]1GWPAL*"#(>J8LLHJVCI"20A8<Q/+&%/&$",XKY&+21!,0
M2EA,`V]LTPT['.";PH;9M!,)PI1(4^(D$H/;2(OPT!@CI=EPD\T4'8/L!$(Q
MPL"BC3?JF,0,,VA@!/\,003A8PY![&#S"D&LL,(..>,LI)`HD!`T"4UN9#1&
MQH(T`B<7Q(#`:P;(<-$%!5RP40P7B3E333'H),,/:;HI]MAD+[7#G%I_Y9)3
MG/P)5=M.A0G5EU4@0&>A=^*=:%M\OQ5"7(\6D5<08TQAJ:5_F<->`>9(\5FH
MD$?.&!5WK($JJ)1#ML8=5#QVQVBHE:;:L*W%.EO1.J#$:F^_]0I`&P#$'KNO
MO`9K'+&Q,?=:LLORT*RST:8R#K4\8!=>8=;VIX@@Z:$GK<614+S+?.9Z,L(;
MZOG7+O0IK+N())@4?`O$0"[8(";S!1-PNNTX?$["U+!3"S4@XA(QB<WLNZG_
MBAAJ/`D)M``@Q_8EC0(:L(!`FH)";C$/D_4C"1M061(T0$$C_"P'-LM@!A>P
M`PYJ<&<ZTYF/CD9"VHAD2AJ)@0AP<AP#U"T&8XC`1PPP`C^)*29-L,,5"F"`
ML)7MAT`D6P3D-!.MV,1H5I%;G?BD-:BDK@HF&)0%S.*V/;EE;XMBE*,@A89*
MC&$,\;O4,LZ1`L8Q0@J=DYP:,7>'3DEN#12`#!J>T``T8&94GU.6Z$;'&M<T
M+20BH=5+;&4:7!5@5ZZ3G2(5^2O?%*!5QY%5<UYC*QD`X'?5@5;VR*,IXGGK
M>YE*WK;.4PCCL8=[)K*$?-#E$D_\0!!6:-<IWC6M__%D`#"VL%<M7/0_;(#C
M?/X"6"@B%(HWV&@?"*/7PEY$&&LD:%\:$I<T]G>Q_FF,%A_S&,@(:,"",>B;
MWSP@D$CFP'](<((4C`(,,+!.#.0@!TS801@ZN(!ZVO.>^%S`"DCH@HUD9#D>
M*=H(#,")`HB@"C_000PLB083*#1K7^'*3!I@AQ;\X`=!S*A&V80#M64DB4ZR
MVYV6"!6:.,5.3P&+6`Q%%I&:Y:5+Y%L6_1:"1]U@"I2JA.$B8"E49,H</TCC
M&H=*F39:SC$#2"IH!G"'RRUF`$U0#B_0T(370(<TK_)CK&(32)<$*C>]0>0B
MQSK67@6K55K='6MDX#MG'?]`D^R"%RH(D;UPI0`\RUL>\[J5GN=9C!W\(A!]
MZJ,#-MR@!>PRA4_!E==$W%)!O@#CQ&!4B_N1RQ?_BH$P0W&#8[XO8=W84#Q`
M)#\"4N,;TN#?9V>T0$H(4&0XQ>D!S0=.<,KB#3L(9Q"VL0TD341E&S!"R\Q`
MP8`8X648P,`1.O#.,&"0"?F,[@+R=#3:Z"`V)90:`L:`G`)\P@EM2`%UVS8F
M-CRA"70@@10B\).-NO>]1)F"T730)XP8;4\6$&D_(^HG0&%-BH5RZ:`*A<6T
M9+%1(4###<9`"[]4*@V5^@OCS($'*CB5J!AFS``V9V&DRJ$,=:@#%"Y<F5$Y
MA@K_#Y#-E':GK-&1KG1;/1UMJJ"LW?2&5V2-'0\`L..RZLJ1Q;D=):UJ@TM:
MYP_0,AXGAT=7]HPQ`N,QCV.Y5;SL?>NOD["$"'ZA"2A-P<JRI&4M2S&(%'`@
M"Y<0WXMB-*)O\N+-__J7`MKA#XC1&6&;@IAIS7&_*8P#8_Z;'P!'1@MLQG:V
MM+5MOWB1YF_N=AL$@0@+=!3!ECF`N!I(0A0V?=QVNG.Y\,Q!&*1K3R3:]R47
M^>?2CB:#%R9@!&EH->-XL&JCN4`'3WA#$*3@$_CZ^M=!B4`#NG*1/&5E3GN*
M24GW*Y6KN"!08R$42P$\Q4/)!"[8?DL1OIA32D!8'<R(_\`4'I?AR2A5,AUN
M#`5^T-3'0$$`\$;""Z"P&<N0^PZE8TY86@.=J\)JR++Z!!L*FQ$:1\V0OLKQ
MCA?.8Q\'ASB03.L%BOP[)!?/E,)K1'H`@(B?*@ZO[EI>7TL95S$#IA$FVD4F
M6(F1&QSBE-NS&)FI984(*(C1NYQ1+1(-S#>_@<[AMO.*R(CR9F3#?$XPT8AN
MH"EK^N\6A`:@U$&&Z!L\VNK?W,&;M\Z+W#(H9KN-M$1^2T%,:Z!E%,QT%)";
MW.0R]YT=8$(8YHY/K7#DH"BI(0)`4K>C#2LC-M#!&'APAQ88@`<&,.E&FN!#
M8#L>V`JHBD:.796K+-$F4:EO1/^E\J5HXXW`U0[]2Q'PM[1A.[*5PFGJ(_RP
M"*"QW)01S47)K>&@!G5R;JR,%N`M`"1\0`TDKLQE%B-[U:2U-:LQP+\E*7#K
MOD2/AFP=['),_46:]9&Z$=8?P\(E)/_!#CR^.)A/V9U/-GT04MYK*<=O&"P[
M80PWV#+U7#*%%J1"L=R;\GBRI1!&WV!^&;(QB%9;G55G[[-+0;</U80+!G1:
M'+`@?@8)&(-G3R<CE15;A\9-TE!;B_9FN>5UNA8$XU00D[8R&D!<9H!I*9A.
M&K!VQV4$;==V.<!<<3=WHW8T59`&HR,6>R<2)'0!(H`U??`E`#`%,(`')!`!
MJW9K#4#_`H_WA,`6)Q@Q7EL1%1+E;$\24205*"-P-U(D;3!%`"YP`6S`%C-U
M"3?%4PS68-[&4^9``<$'>Z+B&0-`!7`(&:6R.8K!5'$(!3Z`!(`(B`QP;I,A
M&J*"!Z$S+,[Q',-".DW#55'2)%]R*S<V?6352+MRB;SR<-B'5K(R)2+0![[S
M'<6C22!'?L135QYW5^1A2^O"5_LQ2R9W+5G&(`]2'S<`9N4QB_\197VU"`KA
M"^)#([7`31HX!9[U62.S#/D0+JAE/L@8`2?"=!>3@"ZR6A4(=5(W,CBE3557
M6URG`%KW@5\':04102;8,FA7=FF73DGP@C`X!VW7`?18@V'@_T\JU"HQ8``Q
M0&R%Q7@*0`,*\`-I4`4G,0)CL%Y`80Y30`=H0`<F`842^5X%H`!=87=/$D69
MQS8BE5_,)C<C\&K4YH6%`E,68"ME>&UBT@1O(`(B\`/_]WX1)D9^\0-Q*(=M
M=#F40V)N9&^<(QD#4`>!Z'O`YRDV:1E3D'UH14G)XD<!UR1BHE#05XFO8WT0
MIY2&)%:PLRO`<I6W$QM@0#4`(`9M,`BE^!TQ-U?>TAY_45=3MBZDJ(O<$VX/
MJ$K4DQ&'M609!SV.I1Z_*`EII@O<,"/:Q`WS0RF4@(S+E`[V8R,+TW0,:#Y9
MH'0D4HW0T'3KD#'9>`L*06@86'5!8/];6A>.'RB"0`(11J`C,V""*GB"[9A.
MG&8$<P"#;H<!](B/I6$KS&$`%_$O=!`$$<E>"BD#%#`"RE`4[361RKE1)!`3
M)*055%$55I%Y$752=4)C56!Y)>F%H@<5^TA#;Z&2(7`)+_D&W,9@.R6-?H$'
MM">'H5$JCM%&GH,J5$`'N1<9:J`%@3AO-^D8MB<%:7!6I2%QE%0L&W%#DUA(
M804[EOAP6!EDV<<;7+F)CM2)`UHL#R`#(G>6+Q=S8L!C>(5RA7%7W.&*?ND\
MB85*TAA8\W=8WW)E?+E_?85^`^%__V>!&0*`,\*,"0AU'T(8_!.9WX2,(I*&
M*E*-F3DQ:R;_(PO$I!PB=1^C@>:C=1WH@;@5,T<0-!"!C@!Q=FG7FJ_9@IPF
M`;*)`?*(`<7V$E5@`_JF`P9`!S_`7D5!`C_0`C5WG,N9IX[7!/EE7PZ%;/UT
MH(#:-GUB)SJ0`-D9>HH*AM5F%B-P55[1%BJP93\`?Y9:*0T&85/`GNX9&0-`
M!SQ)>U3`!4^5;N8F!W6@!B.6*F"#C+\AH)$4%C$PJR$Q<'!C$ZE38PB'2#CF
MH*=1'+\:.JR"*S_F&Q6:?;GI$55`*7-%"!;'?CZ5BN27*5$F<E36/(FU'?U!
MB^]W"?.!+KFH/3`J<Z[XBAY@"XUF,#I:63"B#G1F@.0S!4#*EOE#_UN=)0FZ
M0$T2N##ZL`Y*.ED(LID+A!`@<W16AW4,,IJD:3.XQ3-!H*62!A`LLXYA&J:;
MYH)D.@<^>%T*U1PZ`)%(P3A2,+(1J:<F"U]20%6A0"L;:6LM97<G=14A&0/:
M*6V*&H86H`/^5GHRX0LO.9!O4*D[E9A!U9Z2DU3!EU2889.>0WN;`SE(2XB4
M004`&@$3*J"N0:M3,ANVYIP&IZ"MPZO!`:RF4;:M(JRH(:$_-AQ!E@`/\!($
M22T?RJ%+UAU-M@ICQ`S48JW-0U?CYRZ[.*TI)W_TP0%6UGXE.I=3AJW\QP&,
M5C`<HZ/MJH!TJ8#YL%K8H*_\>@WV"EC/,/^M$J@.+:*DF@D/[]`^DZ40JOND
M!%&PY1.:N=5U"ZM!N`4T)*AI*Z..%5NQ4=""1D"F/H@`6*-07$@')WN\)NMZ
MP888%[4#_S),Q785"``AT9M2,8"H7[B=C;J]!/`T?(0`;Y$N!3,&C"8"8_`#
MNX8"=%ANFP.G/'E1%"!4C6%BC6$9G7IB>#`%A]1(MF,#R"$;Z%(T;).KE*BV
M(``L$,HJ:+O`IJ&VPX%]QG$!8`!#$7`>X2=^TYJ*'<>6J*`=S#,(+0"+I#!+
M)Y=QS:!*OS`")&`&,+J7O6A+,YH]@&FCT\"N`9MG0;=,A,&8M(`O\UI-U_!+
M#,(.^$+"$CB![IK_+SN*NNZ`(<AD#Q'0I`D!)%*0!3&#6^`XFAFT!%VG05AZ
M!$IR7)H6!1.[NZ_9NYM&*]BE.Q?0>,C[QD\HIT+A.)RQ86LP*I1S!U3U`)5S
MQWA$5>G3!-AKL]L[8(WJ`M^I&A>0%BSY`[^)!Q?%;J."&>[).77X.*0BG^8V
M?!H&JO=+?*,A`WWP.K_"MC9`++)AJT<3J%]K8V$+9`R<B"XVRPW\JF<E+*XA
M`E#6/.&79)PD'DW&P=BR+N=QK;\89LIS+1`V/0U@N*`+N#%JHA\,C(YKHY1`
M+^,#=.&",DD\"=I`N4","T(\#>^0N.3@KJ:[F2_2Q$W<#RBS`4EB$`@!_R1@
M%YHA"+OBJ$$*L`1<S,4:E%M9&L9B;`2;UH)F_)I&,R5[5R!N#,<._6L18`5#
M(07]Z2EW_`-5D+TWVYV%\JA\%`JW=U2?7+]NU&%,52H537R5HU290QE**])/
M5=&6@1LVL+^T(Z`7(&/\Q#0),*RL4SL0S,"S/-2C4\NV;*&JX6>#8)87MV,@
M%TH\ML$ILDE[U;?8BLSX%SW:L&4-D(MU6\+Y9Z(GVG$/^+B"20OMZAY_<<ZC
MZ\WDW$P/`W4$]'/-T'X7T]:;Z:0RPL[F@"-UQ@(/<1#E<["[5=@UD[`U8S/[
MO,_]O,\9)"3LQ!`O"!!D?-!I-U\YG3H-_="<S?^<>)"<"VFTD<,%?$K(.'O:
M^<5O0;O2(QT9G$P%2VNJH+$Y%%#;G@R4GS.R*,"T>P`%(5:4D9%'8,6KFV@[
M+I1J]M6U;`!]T:<K_;O`+M9B1%W4#RR@IM&L3-W4(=H(!1#,:LT(8&;5V#K"
M889_/)4+E]`$3F!_YNP([MV+5;T?L3@@-`R`+*(IA;$B@(8+'\,BSL3?!<0@
MT;@,[X+7UX36--*D>UTB?@U!$'0C,+`0\[QT]1R"/K(S-M/8_+SA';0"[Y0#
M1Y!<D@V/!7W018,<FMW9*KY1KJ>01'&?0W4'#1``W&FSISV&+UDYK2T9HH$J
M:X`&=G2T=0CCCT$%6AK_$2305$$9;\"-5#]P56#%H!0*<<?1)"$`E9P0D@<7
M?;9\MFC+1\_!.],=-=5]E;^QU-W2U)^T'4[-B[OLP>+ME]E:WBA7BPI``JVH
M"B='KC#,N'UE<UE@U@:3+RD"I,W4KP@C0`=2(]=P/_Q2,$0'Q`A#65#GS;Y$
M"?.#Z3E%*1K3USD"$%;@X'Z])()MQ?0,=C_SSSO`SXO-SQZT`Q[^,^L$CZE9
MV26>=DUB`GE7!2NPXKXN1%*`!YL=%)R:875(`6@@!$_Q4CB[O2Y0`IR\X^B6
M1KX=8O2F1C_)XW@``U8P`V:0`3/``FA0![Q'E!=F&4!8U`U\P*3,B<*RL;0"
M_S?["+:L0QQ";7Q-R8C*@GS(1QK"4:&/U#I^KN;F5WZJ***%02UP'N=S?G^G
M="GOIP!.D"USF2(B-]YR;F8<0"X,XB&$KB(&.(&W``X*7NE4MX&0OC]#1R.(
MJ>FRI0O:@(';U(TS3PFVT*3OC(ZA_N!<*NK\8!`CB`)`@@)$?^%'H#,=U,\;
MO@3T5$\W`^+*Q4XD7NL&G7:U)KQ^-.R_OO5%T>(E>Q2\76Y*J\<-\`1/P`9_
M8S<F^02L?;])!06K*AGM-@!E$&]UD-*>&NUXB`(;D`$IV`)F,`,/()2]9^[Q
M20?27=0RH"NO@TC!PH\"?%+>Z\J'=,"\$<OXKE7)PO\:I/-B9%[F?=`&']I7
MWJ'=,'>W,@=RW&+5Y"U+=OTP:3`%/\<#L61RO!BX\?V*9!T?9CV8D?Z8UR+R
M(7(B.D<+`=[Q]'/.DTY9/>Q+4FI`AX9`-]4Q)(`O"^37CPGJ.[^:P(4D!9$D
M/?(S&&XS.,#8_+SJ2\!!'/1./M)V,$#K%WNQ"E!L>Z<:0<#U^(\4)"#LH`T(
M?8*#A'=[AXB)BHN,BP,#:Y%K5!1T%@06+CA4C9V>G5!U`EIJ4)T_AU`"JTA(
M:@.*CY][`Q0_L(QK4B0S9KXM9C!K=:VM'Z^):S\7(@;.SP8V!2!MU6T@!=DR
M-A<Z"-_@+N)@"38R,MD%U=3_!=O1-O`VT`D)%_;U]/D)!OOTT>D`U0'@P4-,
MAC9B!A)<*,:#PQ0>VO``D.%ABHLI(F3,F*&AAXX=Q8@<6=&AR9,G,69,X^1&
M!!XF56*,*7.FR0PA1>9LF)'#&P4*WKRY<<,)!PX1(FRXN!3CA@U*-2:=&N$H
MAY9$K3IQDL7)%"<DB(H5ZM(#4ZI6M6[]FF6*VREB;Y"-2[>NW2E92)`XJO3I
MTR1)K`!VDV2&8<.`DVS@`.-O$B,L8,!`00(&!A1'C@19L:/S@AV?EX@6#7I'
MCM.9,6"`8:2UD2BOHVB(8L4;.&=3".G>S;NW[]_`@PL?3KRX%"G%K1B:Q;SY
MH3M/_RR4N(/+N75$`[2L$N"JNB)#`X@5^Q#`N[(5U&<IH[+&_`\2&WS)GW$+
M2C$D=:#`6G/G#IT+"30#S3,R@$#--=6D(T,"(^C@(!L.?N/"".6@`Q`UV,C@
M3#SR/).//2#JDP\_^4@3D$`#Z=310BP:9!9$8A1D44T;N?@12#F!A-*.$+UX
M455.O&2%CS06"5&/-XYD$$XZIL!!%D`%-=0-4R"ED4I-+;4454DAI546<E7Y
MI%LWM-45F41-<>6/4VEUU%I<O4674'3665<0<N4Y95UN[<475'ZE$%AB;AR&
M&*"%S0#84Y'!$!D+C6*666><=;;#:`M\%H9IJ:EFF6NN1?]AQP7@F"""#7A(
M$01RQ;7JZJNPQCK<<:T6P,EUN#IBRQJYYFH?*TC48,HB_-&BQGW=X;)>+710
M(4LG`]SQ0WJTW('"!KW(9P8+O`X0BA;Y/7+'"@K$<$\S^PPH31L`6(.--@;$
M`"&$#@;P#87FI.-N-O"\TZ\S^H`(H(@$5Q@0NPJYN.)""7OD04(\E$2C5"DH
M_'!.!3&Y(TI(LHD43&:%K-*,1=Y$DHHAO1A6E&2)F1263*4`549HI35F5E_1
M]=961:T)59MN;N556W#!%5>=2.\I5]),X_D6"6"EU9=?BAE6Z&%N^&6HHHEU
MG9AD,&0F=@Z6>E;:#F&L<-H9JJW_A@&H41P0`3@(C*"A,Q?@(>O>?/?M]R`1
MX!&!JQ%0V^OAWAW>G'WW,:`?(W?PRK@Q2N`2;7OZ1?O#+;-005VT*,`P0P;R
M94`?=H_HQ\4/**`0P1L#CSB@`06N8TT;[7`S`AN\TVMO%=%8F`V"_&[(H8<!
MXT,/NB2.*/SP#7\D$L,,VQBCBS5=>:7%3.Z$T\8;_^ADQ1:]2*21%]V$$TE,
MBO3B8F\T(>501EDITY9<MEF55D2]`368_9M25XSB,Z#9#$YQHE)=Z#0_I(T%
M:3OXB0(BJ+2BX64*>K'*U*B6!,(0)@F"`LS61GB8*"RJ46`;6]D^8YH=,"$'
M;&N;:EQS_X`6V.8;[K!!`A[`JK_Y\(=`)$0!I"`X6/V`5XI+HA*9`P4?W*<4
MB3N$,AXAAU:0XEG*"$4=\D,+SGVB%ORA3!)(9SJ<H`")R;A##BBS`<`T;Q\"
MXH<ST'$[=K1C02/(X^XBA(`JB.`<^IH&[@K0(7\-Z$/Z$($(EA<@?=`.(`B;
MB,9BU"*"`,`C*^*)2M8DE8NI+R>7+`GX."8^@QSIE#-!WTG:%Y))9@`C58E2
M4(A"0*5@Z2GYJ\K^OI2G!"YM+D'*4LW4LA:HO<5H1Q-*`Z>T)PC*4DIXL@M1
MB);!RFRPC1L03&(4-4(1)NHPB8',H\`FJ2.0;0>52AMJVF8$#/_,@34'.(`"
MZ#:&`EP@&E48P>""R,]^QNHX!9!5!%"QQ((:5!&A:$6XHG@(*MS*6YE#Q!IH
ML!TDO$`_=[C5)]80A-!MP`V%8A(+.`'11_P@")7!%I-2,`9&SF-#ZK#=(`EI
M@'SJ<8\ZJ(+!]#5(=QCO7P`CV"+C^,9]"*\:":O(^EATR:0^C"`DRQZ,4)*3
M%BQIE*3<2,1$5I/SC6R5.F'?^EZ)D:.P;"@NFYC,N&0SJ\!%*%YY(,N0<A8#
MJ@5J<2(3,N=$)VD&\`T1E&5?WQ`$H136L#>(YC3SDD$8<(`%?FFCU[K&S:UI
M8`:7Y=IDQVF9S.3@"&H#S6ED*,-XU@;_`2Y`P`4*D``_QD"?_HRM;(730UE)
MP5D'S>T2O24'*#XK%E2@0[=^^YPR5+0[5#CB%ZT%'RNXH7M6J(\H2,'#:UFA
M>V9XY1@,0%1TE4.0ZP"(/&)0!9OFT4%^S%<@M5%(?[5WD2(2D'=%9"&D`N"2
M%J,D02"V7X-<KR)2U=[#5ND]46(5E2G8JE?19Y,D*6E)%3&ES"YB5J!,J98R
MR>4NVXJ5H;0E@+*\`2R[=$"A?84K*"Z:7?I*I6.BB4X["$H#$\NTI.$)3V;2
M2V,=)=G)%N;'WLRL&1#3-1,^QC5@P\#8R'8:&)(6`_$\0`S`P09XC"`&,6C`
M/F?+Y2[W(0(D__`;'M"HVS(CCKC)^($4K(`'C28##>(Q1BFF1=!.4&$7&[A1
M]S9P"U&PP@=24"F32I>!"#@A70"38S8PE"!X78"\#;`I[W2J7G58NAVS,R3R
M\@%?.1+LD3&][TCTK%_\0@R_$]&D^#;)$3$,R2$8T\E'L,K5!$ML9`Q&$JQW
M(FN0K+HG+"N*E6S)E)]U:<-M!1-<C:;,*)&`3<A^DU>V8DP3RRF9+6OK5?[:
M5\4F+8+@!JR-HYF%<NL84I+M\60K2\+$9!8P1@:59%3CV1PH^<E1E@+=RE&%
MG#;!RP"?;5+\-E#+W>$X"#_.#]QLYH9W0AF;DT)`!>%%B=[B6..IP_\#A!NY
MAW=T`]V#+@S@@`1@^6`!(`^Y+W"272<$U7GJ.!!`MG&!*I#WM;L;`:4!.3P%
MM?<=T4`>?#GM:1$]TAI*TMC""H+?A*4(P`&FV8!A/9*"7)76(O-`Q,C:(P27
MC,`/5IB$)RRS)UFX3'RQ9538JFU>WD`!"OREA3G@,6TC$*]@@1.:QB(6EP'M
MK8A-DU@."U@92Y!EX:X3CLND%T=!"K(<]/&/#;7-RU[6QTB>]Q'NC>]XVE!"
M59`!J730A(D'_/1`'.+?!AJ)(O)&"F1VN.QK80ODF'X0%3^$<A/:BHNJH@YE
M^$(C!G#2".@YY*]$`;).S@+DLSR[.$E#T8W_&G/B.1K+Y)4TOIYW:9^J:W:)
M'%'!\F4-_"H]`PJQND@&PGX9L7I-&XG`]Z@N$JO:".L8D=%#%OQU6$LOZ4KE
M$77E$V=U`WZB87;5=G$E%,C$0&\@%0:T%7=U8GD'%E]Q;3HS;<-6%7MU@1<8
M%X2G3($U08(5%!1D6$%@;HT'-I(!>8ZQ;D!661IP6;*!69B5!/&&9$_V-E`6
M90I@`M^@`SID`J1W>ZAWA'TC!2"P>JEBA(00`10@>U+84%(P<+V1>WM`![@`
M!7)0!W(0"L;%'1>5"WCP;,[7/2R@!?>A!2N0<H.&74O"4MSE#^AP(#*7.X^&
M93:71VPP`A=0:>%5_SR9-H@>\D9#]UTQA1#N,VM+QW1*TB+\)SY)`6&QUFM8
MYQ`9$XE&0F`/(U;2PW55(1<*(#_RXV$:E#]MQV%<(8I[ITPB9FRI&#10<Q5X
MA1=>@4QNX25<D78<^!4<MG>_)&Y"$6,6%F,Q]A/"2%@W@`)9P(R,M8)@`UF*
M(7F4-8,V:(,:D`0TF(.M(1E&P!KM9`119@=B("$(T`PZ8`):AH3LF(0`=UM3
M.'L_T`=+Z!NY1WS5\0B/H!VL\`%U$'M[0`5!8'QG^#UX(!ZCL`#P$7*42$;0
M)X?[4'WKP`XT=W,ZMT=^J%X(8D=W0X@>650EDHA)YW_Z974X@1`,X544(_^)
M.)(D&?,]!C9*F9@^,J&)GY0C$.8^-),%/]$$/BD_LW0#;15ML6@4@/<&>T46
M:T5BL:B`%7B+OKB!'$`E&YA+6@&,B16,#'2"A0<4%)2"67`$85EN9*ECT0A9
MTDB-48!9EC<#LC$;UC@;;FD$1P8J-#2.4X9:(U!3"*`#6]:.@.DJM25;4K`<
M\=AP/V`%P5$XB8"/DE`M:(`LKH`&U;$&=+`+*5"0.%&8=+`"3-`!.;"0FGF&
M'N`$)H)4[$*1W%!>%XF1?TA',I4A/P<-QS.;('ETU4`2-_%4_25V*<E@4U$Q
M2G<]-A*3&Y,!,YEK-;EKO+8^#8$3/T*`/HEE31#_`V<G;$UY%6EA%-P)0#_!
M5W1',ZA(E$6)5VD'*+C4$E72%\7&=E<!E71Q8]_6-"F8&4%PGV!9EF;I*(ZW
M`2P03HFQEIDEEVYI>7(Y&U&0H'4)*E%V`%=P`T#X#2)`*F#PEX%YH;359;?%
M4(=94'<F'`6`!]XA+11`"=+B+&HX'FI`!]3!'WB`4AIQ?"'G`0BG%RS07`79
MD#,:`3)0?JF9(*M9!9'&ASJ0D<-S(/<%I(/((?)02.UE='34B5<7@"WRG`_S
M=)HX8E-*G/.W2K-V$C$"=<KY50$H5KWV(U`RG0VPIC$`E!>FG4XI@?73G4>Y
M5T(Y8@B(%JC8=DG1%&O5_Q.TA!1:,C7N>14N9A?RB30W%I;X>6-!()9BF1=Y
MP8(M^'@`:D*S\4UKF:"6]Y9NF:`*RJ`-^GD(T``K$`$X$`08NJJSPF5!P`4=
MVG!KH#?#$0%D]EN00`MPX$2]1P/WB0<OJB9+@74_DTWI,YK(:@4I``+WU2[7
M@`VZ<U,-TI=_&&K->E\9DFE,&@_&$W3\,'2@IH@.`Z;5(TH0HVI2)9X5@TDC
M256[:1+)V54ETR-EBC)A^B)3^1,-D&5K6IU`&93")J?ON19M(:?=V1*N>#3A
M>3].H1'&AH`VTZ=8$A4T,Y4]PYX3!B@)>!072#3'!()9F5AB@Y]#X:@W$*G/
M6/\9E/IXCT>71I:@BB*@LE&#,`NJ.)B@K]&@!_`'\X0`JMH'3LBJ0JL;@\E/
M4V"8L7I0_/$#%OH;4W"K410M7U`'/E`'7T`'&`1F)'`EX-,]'J"LUX6L8JLQ
M'G"MV-H.%R"M$/(-U8HP9@L`(.!]/[6M=/MR!A,1HT95^B5K>"M)+Z(]&48S
MPDE__J547FJX3\5U-,)_N^F<8>5K3B**U<FF^]H`_GJ=+?:>%T0T+39`LQA7
MHJ@`'>AU8RHS?I$_?MJP&OLS12.HJ6NZ#]N4%2@G%E1NS'@$@Y>5BXJR>D$9
MDJ&R*]L:@$&7`0IOFTJ#<LFIH!HW.IL!W\`&=-"T0SO_O8)0M/RD7$F[1)%P
M9XII'/FX18^#';>@CP^P`L_VM>D3$\PYMLZGHZ-9MM>:(6FK`[S#1PCP`-)P
MK1,Q$7!+4\]`MP`,5'*4+U(*IE3'$..:$"V0I9(X=?_'MX?[I02AN%TU(R'3
MN+P&81O0$J/8!&M*N6Q:G<$F>%A!2WPR0%OQ80D;%UV7=5F%/E-3).B)2VT"
M%P34%%:0PV<!B]G)L5")0;U;;D1Q8XF5!2F8G\WHNY-!J2SXGW8IO"YKO#/K
MEI\ZLQJ@LP=@!R-@`N+0`*Y'O6"\9K,5HKB5O;BBCQ`79JU2<*D0AOCA'14G
MD#%*,C?)OG;<$=D%?4S"O_?5_PX,XB"`#`ZAUP?-NK_\BSL=Z5X<L@W;``^-
M+,#G@+=D"Z9[ZS#HASV_]FM3,74%YG^-^Q'QFFO'Z3TJ$KD=3+G\^L%MZI,6
MIC1^%1=LP;FA2Q<<\+7J.Z^E>TO&EA&1U26V**B"`E)NH*P/2YX<1@(8!,0P
MH!?E9C0`A&/YR8PDT#J4T3K+##;3["A/O,VN<;,(.H-PR;PZ^P828@(Q@`;2
M"\:`&3@KL`*"D\X_)`44P*%FS`@#0`F;<T14T+W$49AH)`<5]0%*D`@+APMW
M9GP6O+ZL=,?=DY.#5KADM%38NB!@$"&VD5J#?%\$\0<*T<?>MZWG8`[G,-*/
M7-(%4/_`&S,]^P568V<D%&-\8J>;7WJXH;R)Z>M_S2EK*>`$'9QE_)K*6>:O
M_TH6;S`&"W3"%S06H^C*C+A_-)*Z#*RZ?7JZQ=HE;?$G@F(H6</#/6P5-KK,
M.D8T8()C4D"62=PZTUP9H?.[DV'-=NF-W!P;F'JSH(K%!Y`!(X!:$S("T:O.
MZQP!"3=Q!0#8"`?/?3-0&47/C=D>[:'8BK`>N>(YC`T+5!"T]LAPQ,`=2'`,
M^9A<_;$YS[:<,EJ0HRVV>LQR#AG1"=$N>!0"%BW(-L"L`,#1//`'/&`'$]TA
M`$S2O`U()*T.['.<'3VN^,5_\">>C)@C)6&<H(S)HKPC8Q7_5NX3`7*AIJH,
MPI7;IFU:@#7&8K34%4H]BG1!D#.=$L46**4[J%3-);#8)X+:0:-C-4O)E+&X
M%WNQ`6"M8\AL)F2)09*:!;]+S=D<.FJ=!1C``F_]C:RQX$\,&\M;UW;=LRZ0
M4VR`SGX=<%9`V*E2A98-M(0M<:[2X81@!06P`@!)+#\`K)MC.-!"!:E29\Z!
MCXUY!_R\F`RW!W&VV:_@'9#`V*Y#IJ6-?%$P!W/PGS@1WW8,?7F<V@G1!GCD
M#8`<`M\0`^B@$'_P!W9@VTE*2/'`VXYL(;P=$!:R?O,7DRJ]B'B+R8";8531
M:\$M2H@[P5'5?SCMN$O2$%,YBJF\_Z9LX-.4Z\$_*5C=;2=B828@)C^PG)E=
M:MYD%UDSG&M/L5:K>[I3$19I906]$-_SW5;VS>F/Y5C,#,1A'=8JV'AHW=9@
MW=9K+6_S]HWA.$-O`S>O,>MV?0!6@``16@6HI0*&?>%\DQ3'L>$1(.*^806T
MTAM3`3C!KL;`(5P;A0>W!X^>H`S[)`6.O0C8*U&T.APBN@@81SGT3'SP0:8%
M:;I1L!T"``?9Q"2CP]"H?=H9P%H-H@.N#<@Z$`.Q?5]8GN5V8`<3(9LCK2"]
M_=L]!SU8RMQG;JXZ"9SQ%P%7Y9QEWM3(:2.+V\*C'%8M4!)Y/KF5V^>5B]W^
MNLK_:G@6MO],L-R`0-$$=$&O7TJV9'=+&S2FMD3#5-'>8K(4AN$+AF$%L>OI
M:=$8^*W?'*#?1*_?V"P9!+[$UXP9*(#@H/(VEL&#4L].W%SK?[#%XA`A;-#K
MO@XK'VZ%?$,"5;@;"9=P@S-$(/X;K/=P/^"$V0XY6V:KU_'V>W`'7#\(!8"%
MM"`>/K#CGC`N6[L!>K$42H5\+#`M:(#N2,"&CM=!(8?DW=/N!;GD'C`&_48O
M\^*'!3(06-[Y_M['=W0B`\]S@L1H*7)_T$U)]S=JK+81\:>NQ2G3B.L0]QJ)
M7>M@2U(0%!8_'-\`'O_!'V^Y_/J3(_],SS07@A?>B-YW$*$CN_;_/J\+NU2-
MWJ^K);S<IX2Z=AR0BTJ!Z=FR\S_C)5X]]'ZR%Y`%ZE#3Z45O]$</O*&CQ&*Y
M&@G.@Z].6D8P!_??&O@OCK4."#<F""X((P@E$7V+C(V.CY"1DI.4E9:+$5*7
MFXU2>(I]))^4$7@DC:"-!7AW5&MK`WL#`URCCU)4>[J[NP-XC584L;S$Q7=K
MQ'><$;G%NE#0L\Z[:S]K5!2NU3`I&=[?&1L4ST@"`DA('W(/Y@)A+$G@X#/R
MWO3?9O+T06PZ;&PC`HZX(`,$@#\\[/Q1J)`'`!`%(D9L(S&BC(L8)X)HL[$-
M```\>(@1XZ&DR9,C0Y(LF0$`R10P8\J<_QFA9@HQ&5B.Q.DAI\^<(7-ZF)GB
MI%&3X'!Z&YG"R9LF"F(TF-I`ZE2I5K%.;1*#:Y,+3:`J&$N6[!L%;]+>F'*C
M;=NT"IJP<=LV`DMO)V-N2+&A;U^B,/WN%4QX0X3"AA,GKLF!A!,.A]W,F&&F
M\@PK?2-`YM"X<V<2&UC`(-&8A.G3J%.3@,&:]6K7K5&@@''D"`HCN'/CQF`$
M`^_<OH/WWFU$@I$#R),G;W&HT`@=:#A)GTZ].J-,UB\5D,)=TR7NF;B?>E33
MTP\*/SX5B$0'V30JJ?I$N#-L&J\U=W[4U_6#$R[[L^SGS`#6Z"+-'FM(L4%/
MX%B!QS!0U($..O\?J%%'.TB4`8,5]=1S3X<9Y)./-U,T(-`(5<20@`P>\;#0
M'R_^\1%%$H'0$40%8'211&UX]-%'(8DDU%$EB1&22T*!]!),$0"60I,UV<13
M!CM-V9-./`A%U%!$WK644GAQ<!975)59%1MF;E55$PVP&=984(E5UEAIO4&7
M6W"QV<!;;W"`E)8S(<9784[R-2AAAT6I:)2&:<899!LD05EE9ES6J&:./MH8
M"QO`P)EI4Z3VF6JME6HJ#!C`@$)MJ>J&&PS$#;>;;T;,@9NMM1ZGG')_*(``
M(?YXE]VPQ&8G17S%)MN'@^OU\<NP!=!GWQV@@%"*@`"N<&`O=$C7GGW_X,XB
M1QD/#&A*-^"@X)XN$DZHAAKEF(.$#RN@"^(W'][K33XI-%%%BC&H6(!!#"GT
MHD,/V=A1CSU*E%$!/?[X$4(BK=2E!V*`)!*62Q(%)9-,V@5FE5?^9&1.,UU\
MI4XX;3Q4!%G$9555-$^%9E9K8N5F5UV]&6=<<]9YYPUP*=``&TW8V19,)NDE
MTUZ')69H9H3^-=BA@5F-:**+<F:3I)16ZD9FC#U*&@RAJ:;VVJ>6RL+;JF:Q
M*@PLN!KK;[D.AW?>$NRJW!56_#J(#G0TJ^SAB),G;.*'DX#L=`4T,\VSB^`A
M.;BR4+!N+W=8,5V!F!,S``WM^``%ME2`!@X,_Y?+4H</6M0!S83H:+'"!OKJ
M^^&(O'MPPP7`7V``Q`?9P1","SG$L,0STBA#CA-)'!+%/*ELI$,K&8F3DTW&
M!&64&'^S$UX^89QE24P7I;+)*:',P11G:34SFC3C/+.>7;49%E@_DR66T$/+
M4UB6L(,L="]0?DF48J+6*,%PK2:(\8NAG#:8"CXP2I!*`M@T8)DD\`6#C^*4
M:!KC!!*$:FUJ&TW;Z&8$T6!@54=@H:M^LS?=\,96N,J5WY1CAQ$4XE<-&`_C
MAJ@L[!#Q<(NCSG^FD:!&Z"=TNJ#"'9Q!A21>(@)/A"*"[J`%>2%A"U`H!A50
M8!=O6.$'Q0C0Z6;1+O]TP`$%]A+#B'*'C]Q%0`'`2P#Q#A(C@R',1\P#@/.@
MMT>0\%%(0^I2QH+2DXQUC"@%>!+(HC2^+Y6,04)"WU"8=A1Y*&4D&4@!!VXP
M%OE=)4VHS%_/J-*SN/SL30JXP:.<,(7':.J6Z=/+HG;)RUY"T)>*(@P%M4:U
M145J,ARTS`P26!.T]84%I4&A:K)``FJ:1H5NJYL11@/#&MI0;[K)86[F8)PY
M[%`Y)$"`"7Z(AF,=\9W6,2(\B<6=ZF"1"MC:!7R<N"W[5".?/S"<=*2P.7"M
M@0)?0,<YTJ&$7@P`"FN@`PE28(4S"BA"=9`=+7[`A#"8(PQDM`).S("3DH;_
MZ*3@F*.'YA$.$8C``"P"21^1%\A`-NQA!@$2C%222$7R%&,@01E@#FB3*-T$
M+Q@#DTFT-R3U$8E]5`*E*,=DOU.6B7[U:Q-5\+<SKWPE+%!Q0C>(5)2R;E*7
M(+RE6B$#S+8"4S'"U*#6+GA,RG!0`QF801(PXY<D^.53I%%;%@9;S<%2DYJE
M0L%KWK9-UL`05G8#YV]P=<-<&:<XNCKG%7B@`T*XH!`A:(`F0##/TE;"08\S
MK71*D=I)1.!;X**"0*7P`WR&2W/3H)9UI(6Y-:`!%K1#0@W4L`N,RN$+7)`"
M"D#7BS+(:PM?"((41D,"Q6YH*22E4F7`!"+>Y2X%_R]]WH^09SP['(EY")N1
M178T,(GM-),7*TI+$*D]]$GROAY[DLB$(@\&90"^*BM95''2`I21,BZGQ!DK
M;U:S!+,I?VH":\_>]`;R?2,O3[O4+1W#82>4T,,?7NMFUHHI$6\&4XR"H*`&
MQ:A(26H&=ZW49*S@5PWZ=0.;\=3:"&O8P2I6-C]&%6M$L\T7L@HW40!.9+VI
MF\OV[9S)\14AUOE9!-"AM:K-<CVS;!WN>.X[!4VC,A1GC7RVPI_]J<X2`?3$
M`;01"6H(XQZ@$"\DO&"-:920%U\@!=!@S;^>Y-U(1C12.N8UKQYP@@V(YZ*#
M-#J]-55OCFRP(XX`*4B@#/]P4H74AI-M\H"%,JH'SL<@*_V7U.L3W\FHY(%1
MEK(J6KF*GE"98*VN24VJU-]7W\"@IIW54(J:I1.R,`5B#ZTM;$'V6J;`[%IR
MP)8FCC:)O=;BPB@P4E9`IAF2*>/)Z/7&@A$-"GLLMQ\'63:M295O:A-#)'^3
M-_"^E;R-XV3<0#DY$?A5(71`9030`,M<+NV6`SZ=4@AT$@3%'($DD8DI$N.?
M`-HG=4C@</M007(1T@(2-.HZ#%4HGWOP07!?`!I-`]K0*,^)$V(*I(,8<D:1
MOJD-9OZ\]DZ,ISTU"DQ2TC*7_!ID'OO>3:IW\E,WU2CE^Y*GA^(4F6%59U8]
M4\W_LO+@64==JUY5P%CM^[2TDC`+QPZ[V)M=;%H2FY9H;W;::5G+6G9XPUZ#
M@8JIUE<;>QO&R;R[!FD,;DYQH#73E)O<CE!=V1SAA;Y)-PP/C^0D*YDXWJ0W
M9HUS;^38H0&#,(1G76"!!E".X%R.P`H.#OK37MD2\\'<':SH"#IPX0ZP1T86
MLU6=V0^(#OMY:#1B,0"13^CC`WISAB;*DKNLK+_&_P:'4'Z/&90D`@/+J4TW
M8E/GS9SF`VN12HA.5IA0220NV9CW9`+J[H$OTTOA;U"TU,E2@W)[G*'JT6"M
MLUC;+)5;S3\JLZZ^0`7[V<.6;&)'-&]!@':B%DI3@,?&_Q8,>"?)!G9TP8#,
M1FS,%EBWA&*"87<P9E?;UFW?9F-R%1J=8BJGD06J4GBVH2JIPAJ)MW@84#=1
MX'BRPF3RAAN2]V25EV_JI`/\]EF<AP`K4'H!5PI"R`G;P1VV``D%`%O%@!\`
M)Q]T<'&O<`=1"$7=4G"M8PQ9Z`QO!GS.``6^ER$+4'+MEW3])0\<LGPI9Q)I
M`#&`)$B"M!$VXB,<P1$680,&@'V,MGV:MG..9"0`(%3C-XC>TR1))6#?\%-/
MU4@EI12M=F!8P0:QQC-E,C-698E916M8UR9.$$IH53;/!H$#.(`(6">FJ!:C
MF(JJV!:$=4*DP0&$`8)WIP&4<?]WW@:"->87<%,JJU%=JD(;++B"J+)XMQ&#
M,OAN>8,KMG*#F75O=M!9^[9YG]4`3UB$B,-ZUNA:E0-P4L!;LC``=Y"$DK`"
M!05R#X>-I!!F]X%&4!0A[M)/O;`'7_!13'`LG(1T`E9T`M9\*8<7*?`\"U.'
M#9-]$3.0DV8`"+EH>Z2(\>5]CJ0D/T>(DR0EZ)<4\.54@/9^/+$!4U!*IB2)
M.;,S5($F6,5*:F)KM.8F37`#9_5_`&ALI'B*,FF`1".3,YF`=&&3.GF*06`G
M/7DGA&4:?U=WLNAMM&B+MXB+-A8:0P9XO\B"I9(J6<!N+V@$QGB,L6*#=B-Y
MYE1YR*'_`/W6@S[H`CB0C?/D3F8Y'5)`>JA06Q?W`VA9">RH19Q3C9`@!>:X
M!\=`EU`@!W409_E$!3^0'W00!#DP!;`H$^MS$C_A)1R2+R@W%&U8$92I$7;H
M,#)@`PF0`'EX$3ZB$@$F$_\5?H'X:^4'=-_C`6V0)1?F#0S)F`.62:)$-&'Q
MD0$3DI2(B95HDE:GB6S":X&15L-&%V-P)Z8X)\B)%C>YD\QYBG12-,AY%F8A
MDT%P`T$`=M9$&ISB8D6Y@4BI=TKI8J$A&BN46%39>#$(>9%5;\SHE<B1;Y]E
M`M#(>9_%!D^8"361EJLU</JY"?(4">$1EY9`!W1Y'Y_GGW/I_PP05Z#PV`L_
M\`-!$`0G=!A.X@%6L)BPV2!TQ%V;U(8UMU[L19D8@8>;R9F4U@>K63%]Z'TN
MH22>"'3D]S&B!DI#\GV.>(\#U@)9`A/O$S^W^:,@&3!>(:266)*[&76ZR4I:
M]S*@:'9#4YQUXC^N!%94*B?/V9Q8^@8[D)Q<VJ7*F18[\`;5>0-!^7?;J93?
MF:9*"8+C*1IN6C?DZ8(L<)56&5F8E1N2%P62YYX'8`<70&4\.):?=84`J@D%
MD`DDP):)$Q%]$!&9@`?=`:F*JCC]:4_HZ`BC1PG@40`)2I<!11VV)SK>6*"Q
M):%L)345:G)(X27]^`U,D@8Z<A'71_]IL2JK)'H!FPE3!:`QW-<E3$,EAO1(
M]V43$UD3/8$D*W,]2/4G8M`"F18!\(-'9,(5IE1_7F5_1MI@^J>)#;"D^L49
M'E9+-^`$-U"<8Q"E9;$_0[JN$]8_TYFESNFE\CJO"A"F8EJ=UL0!G+*FDO)B
M:3H9_<JO20`/+80;<$,"1Y`%OW&56&FG[F8<>MJ,E4<"5":?GF4!A8".JX`*
MW<%ZW>$XT*=F'0L>RU(`5G"HDEH)-4%:E:J6=OF?MW`LW(%[I#H`ERH)T6)0
MH4JJ5+0"4]`DBP$8FZ2J?V)A+'5H2`L.'3JK>(B0>4ASE#:K!K"9>90`BW8]
MO7H4HJDDI3G_5).D7S:!,9V6=.L'FSR7$S@FG6!!I/(3I+4I,V0RDF8R,U+A
M)MRZ%7[R)+-T=F!7G#6)G.KJ58*[KE4:-/!Z%M))KW`"-.[JKF5AKV)*IHBU
MK[*H@4;YKP*+BZ^B*C$TI\;H;G;SN1*0GJ-;'#'(IP?0`CK@@YU%92Z@`I,@
MCJJP`JD@>LURJ"3@"9-ZEP+J6I[PA)#:LM01A)4``KDK"7&)1>H((`=Z1167
M6\O+LP8"H3\+:D*K241;M!GPF/I@#][K?)G1M$[+F2[EM'EHO@8@`L&#JS;0
M!U@;FD,+5.('H_D%MBG0!H?H$SB'%"TC$C#1=!<0%4.*%=7*%7`+_V'<*A7_
M\`]W2Q5YFRE9X&$1#*6)BYS\PS]?)6&U2:7\`S2&:Y-HH9R*N[A="E:NQ+C(
M::_7.;G<&;`:=+F72XM'>8L?J$%1H$$MU!KH6:>?VWA6F61`K*=7B;H'T`2>
M)9]CV03("W!6`![\R;&I9;*&@Y\%YPD=>W"/*KP#]665T+N,(*#;P5RA0P%V
M>0O/*SJ"F9>D2@75"1F%DC+8JVD_D3MN4,?VT!,7NAAC(`(EVL>;6;XO-;4)
ML+[L.VH`UI!,HSW"BE]&I2CRU0U3\E-0M:.C-";LRC/V5Q53NL%R.W\FR0:%
M4)]2T5F_@@!F`IR9`F)90,$A/"=Q\DHE?/_"K^S!R0G"<%'!(]P_K_3*/N,S
M9!&F$4I8=-/"1>FOLPC#WVG#&O0VVJ0!0?S#Z<FPT?S#&B`!U4S$*>"Z\^D"
M3]!:Q*NR`%<`*V`*B[`=*S#.07#.TK6[FR`%XPQ]F;`":ZG%FP`"7BP)LKL(
M01`)M`4+H:-;2D0'YR&%`W!0#XI/`W!Q:MQ;>!`$;OS&9861&)8^&4I'=NP&
M'H#1;F`%']0D3J"^@TS(55NBP1,#P&/2-F#((Z$R_=<DWP<`$>FU-9$&AC@4
M%[9])O-38B("<0$6`<PSU)I5.N/3&=Q@V3H5*0#*".`/;<(&OP+*6*4`+P.N
MC^$$8W"N<,'3/"W_I1]LBC49KR/<G&8QPH"+PKR\R;#TG"N\&F^S`4:0N4@Y
MPS(LP\@T`S%H8]"<!-*\U\X<!7UME<[LS$1L!TU0L6*)`/M,'F7LGU:\V&HY
M'JS%SO3,SXQ]EP@GQ@IZL\@+"Z\@18/)V;#W`W1PQCQ+O7NQ)1BF<]?+F(A8
M#SWA!AE0QW6<`FY`VV!;$S]P`0$3,+J]V[S]V[L-,$XP:L@:FC&15,)*5,5:
MTSNW%!7S)3K*$Q'0=-*ZMC$0%4"=FYJ\RW'KR48J%0I`RBZ`)@IP""$`U5O!
M)%1-KEB=U5V:%F,0P286KN6:DV!=%M*9I2&<W[G,U6=MPNX*S+;!UB*4_P1O
MC8LW;,PP%@5QO8&TJ-=Z'8-]'>%]K0$6;N%^G>$2GN&"C;I_0+'T*9:B]<XA
MZRR3#0D1D-@GGAUX(-F,T+Q]<+,.LH74`..6\""B,PP$<@>OM]`&M0(W8+TL
MS26KC8^MZ=I"H='^IRAIH`#_$C#_$N52_B\G$A`Q8`-8FW.J+4G(_3+#&A.1
M-*S,?5197B5!T11C,!8^'15LCLF^+3^,^U4(?'_?K0"<1P`60-YL8`$8ZP(Z
M,!7#[2A53<'0&9UC\!C$&G2@"(#,%D"'>\N0?KADS=TF_,O!;()TP\QO8^"<
MCHL?R."VN.$/?L-V?96!W=?&>.$8?NH<3L0'P/]9/BB?ZU0"US&R*ZXX+G[K
M**[97TQZ]^P(W<AFN=YZH;.@TBL+$,H!3B716ELH76*&B`AH%HH^M>U!.!9,
M3A`0`-$/W.X/WAX"/.CM.D`$3K":/K>BABA5;RRC86M?*5$Q/,44KJ;FTGK=
MF"S`=9M@Z3JE<DN2<]L`(L!Y%D``",`&"K#G?&X!ILR2H@2`A'X66FT65_W0
M$%V(7D?5`FB<CXZ`;3&F'2^F("_67JK+8P',<O,:K?&FVH0;"&[#H+[@WAGA
M=KV!'"[J@5WSIX[AKE[$ZX2QT$CKNFX)M!OT2E3&^>D(5.Q:G4H,$F>$!*JS
M/EZJ/XN1BLEU,L'1%!W_8/QU21UB]7J+8C7Q!OU`RJ5<R@%0RB&PU$L]`FGP
MONA>%"M=\>-GK)IT/<[*5#DQW8D;P%#QT])*K6ZN,_M>FU?ER;L9\'Q.`.-]
M\`F/L5JGM\]VU3(I\8@N]]QS*8O.Z,WFZ,V9BADO=A[?DW42IEX*S$%0&[.!
M\BG/S`7+\B!XP[`?X<9HU[28X;1_\ZO.X;F_ZCN?`9NWU"[0`$1?"=\\_/Y9
MQMO!SY>*1;'EV)BP]+Q`(-$+15*T`D%0TQ/]QMF[JDG7VDH[%(;!5HYLQ(1P
M]@AP]H)J_N9/[N:NY<V>[H]DO8S</?AK$D$B$D+R)-0MK6T."`HQ38,QA82%
M_PTQ#0J-C@I-%PV3;)26DY@B+A8$!`AL(PT6G!8N'AX1'!Q.-V-OKV\B"J]C
M'"FWN+FZN[PI&Q&_$<*IJL5.QU-3-\LWL+#,S,G)3E/'QZO%V:K5W,DWRM#-
MKSMOY#OF;T%!1^Q'*"@P&##S]/5&+$;Y^OE)_%%)__I%B:*!H$&#&A(23%BP
M(<.%!R)*G$A1XI\&)EQHU(%`2($^($.*'$FRI,F3*%.BC"!%I<N7,&/"E/+1
MI3"3+%'^6+.GI\^?:UK&!"'ESL^C`^[P/,JTZ<\?5.X$`=:KUZFK6+-JU9KA
M5->O8#.([>K!UX9@PE)P:!``00"-<./*=0'&B1@>//_(;CV5HFR*"'W%^M4%
MF/#?OECQXA730LPM#C=D-;J@X`+E&((R8]Y<:-$BRHW>/&I$")-ITXLTC2+@
M@LVG4:,4E%7E9(RK5R)@.0%<-FO5WX5Q`1M&G$.J"&F,40L';5J6:]JR'3=.
M++HV)UFD,0^2[I6Z=N#9O<,@CWR\\O;VJ=\G<.#`A@L5,IP?GV#%^Q4C9!R%
M0(<.H3(%*."`-`UHX($'`JB2%%:81$($)Q7EU$]TR%04%`,,P-0`/Q@UX8<^
MK>'A&C\\^%LN>Z6H8E9DA>7!6()=15@3333`1@@!E.)"CA9,T*,+$]`U108\
MB"'&BH,)(V-5@#7Y%V]DW87_UUBIW/`(99<)0HAFG756&F9OC'&#$]0-8\PJ
MKSA"2(T*(,`):ZZQ`5L#LZW2BC-OW,"!BB?V>=@M@*%%G)G9(",-=-8-JNBB
MBD9'PJ-39`?.,NI\UTX0.>30#@:;LD,>IY^&*L]ZZT5AA*GNI>I>0:G"EQ!^
ML$9DAPX:E<+1"@CFJJM("N[JZZ]]](I2`7A(`6%(PN!QK$D>?DA'32I%@,<#
M=0C@@QQ0'"6BADX-L%2W)'X[`!7&;J"+5K<@J2Z+7,'XHE@S9&#%6/-Z906@
M)*A#(XYP^1C"%'<!<"22PKTX6"[!W5(`H+>T(9:41<[FBF235:;9Q9O1>(@A
M32C@_T2ZZ/9F!5_"<9"%:&VNUMIK%B!P2W*0V?;*F(A]Y=62?O82Z)\)F\LH
MH=K\++29TPE3IM'9D,`!I)%&FL4-EK:3PPJ9'E$U>&=HVH&F9W0MZM>?SI&/
M!/I(8*K9JJ8J`7SNQ1KK#PC4VA\.P-9MH=UX)RAL2E8H"U(!*TA!0DH_<-LM
M'BDE2P<=7U0K@`!(J&'X'B)^J^T/=%C>$[<D3MX3B5.9BQA6(Z]K.KL&QXB5
M8#;;?+/!5T40A!!O61``P(NMV!>@O!W,2V%I1>"!&&(IYE@$3J19<9:;:5F(
M\UUV_$8*Q..\RV!^R;@!!PJP54H(K8WR!BJKU.9*+8&E#O\[R3F?",PO##LI
MNB]/_A*,H$,3;731VT<`0RJ_X``,C+,T53R*`U,@0186F(4CK$-JF:+:"JBV
M@!PPP8(8S!03-HC!K9VA`Q\$&P;F,(<1BDUL$B!;"HU@MA9&H84I;*';8,4#
MCM1*!T185MYV*!)B\?"'*BF`L024DSY808<GP8/FCD(%)(HD`BN@PAJ6`@4D
M/`X)2&!`MH!R!RILJ'`<:M8>J$"'.W!HB3X9E[%&5SH9]>:-IU.1ZZZB.@^X
MP0-6<(,;VGBN)94E`CMH`!A^D`$`\,!AZ`*97]+"/B8=!C!&"ACQD(<;68`&
M2Y!HWF8NL*6,/8]Z,6I?NG"AO9/_34('<J*36E8A)O2Y:RNB[--9_G*_)L'/
M2;9\W_ONA[_I$-`Z2M/&``5HP$<9TY@,;.`ZU)&IJ>5@!\]<01@60,UJ4I,)
MT\QF-K&YP6Z&H0/@!&<(157"<I)P#A)`)SICR$X)S!`_=H@!`N+F@D\X$8AV
MDP+B\,G/'@Z10%((Z!1P$M"`%FY"28'62*2PDZ-4$8M8_,`6?\(A*F3(6^,"
M8QBI0($[H*$.9:B#&3^4%!*8RXU^#%D<N9(Z%UW%#;@8F2CY$H0Q>&`Q>F$?
MSACI.\,TB3=MD%)7(G`;BBU/$);II/.<AX@F3,](>HFE(G>W2"LU00>V2(7Y
M=L.ZO4@5_Q>BFR6@SB*,L_0R?T*S3@$/&,QCNO6M;DUFI8(PP0E"<P=,P.L.
MIFG-OE:3K]3,Y@+"0%C"8I.PX4QL8D=(GG*:\)R01><[\:,?&UI`![CJI]VD
M=4_-\C`"@\M59R.PDREFZ$-KV.=(I&51ID"A#A"-G.<V1X4?=+2C4+D#!=;@
M+=Y"H0Q7Y,-$N_6#X&!E=REHXTI9.L><^L9WYIIE=/LTO"(YEV3'/4PCW=<7
M*:'B3K%0@"4MAIDL7282'7O>\\9GW4;>ZZLZRVKY;/'*1$K5K/@=#EEO<4O[
MV4^_:`4FI!;('`*'@\!!>!H#$\S@N=+U'.=8P%XE#-C!6KB:2__(\`*68$TX
M^-6:@C7L80O;`28H=K$=F$.*'SN'R5;D"CP8@7\V@8`F>+9N1;QQ/_<V(&$H
M*`*M!='GA!6!S'7KH4AX`89F^SG>[H%#&1*14I[L.,A]0`U"I@(*>D=5."Z7
M7:W372[,ZHOA#(/,]$-160I9O>QV63B(Z9.3"N!=HCK#$9<DKR,&@=Y!<)*3
MF'$J]08&7UV\-Z:["&`$ZANR]N6WS/]%JZ3WIPT%.FU24,MT=[B#CDY#^--!
M^/2G/^Q7OE:XPTO@JX>IN6HXA,'5"_"PJPM+ZUI_LP.W/K%B6^SBBCC!!`C(
MB`LJI&-?Y;C8/_RG:.E`A=H6-(I/AH+_M%$+("OHDP)"AH(:I,UDIY"HM>$:
M@`]B>^5N/\6D;[Z*<K]\LS!?5WN0QM_1]*OFU0W,S:-CV'9W$1SA%2D%M8&%
M",9K,=#,0DT82R\D*!,!XB6WT!`7LY_,:N9)6YS2UO$&-+J#IQTHP..C\?@2
M'#%RDBM@Y$O80<HWG.&6D]K4%A8L'#2\A%8/UM6P?O7-/1R&$=OZY[<FL6)[
M79$:<J3&G45V@*2E]&3SF(@_H*U2>#L`.0A`"W48+E**J\\..5G(3S9WM[KX
MN8Z.&Z+E1NB0>^=E=C-7?5Y%F+Q5,:CIDG)=:KY[3W\'&(%1DA:Y.6J8LF"<
MOZ!)%@I';R3>_["GO4/\JVUW-*1U:7$"4IH8U8D.F4C0M"P$01SC*,<Y&E'R
MDY\<Y:9O^>E;SOK6<QC#&RYUS`.+89U/D^>L5O7-4XU8H`,=U[BV-3B)3A$[
M-*$2.%!HTP^$!^4OWU=^@[X8?V+U*RIY0E'Y.MBWGT;MBRB-`WA`;+,^VPQ!
M`5L:N@.ZC]N;T;D==G-D/W_-@I9?%H,X\^.3?4<Y53]%```9P`$R<QNQ8'",
MAUQYQP$H8X`W$$MBA6:/!U;G@H"]0'%D-31E8G]JM8%+XP2<IW%0$WJC-QJI
M-W(TLGI-L`0IF(*NYWJQIV$O!V*S)X-AD&JTITV#57-E,%C@Y'O!1_]K/1A\
MP'=KQ#<1+8`"RO9\"')L2J@KH`4LTY=&L`4Y2)!V3;$M(%)U=8`M/G%^=2`Y
MW78'=P`5/4%V%`4%6N`#9;!D&^(X/K!D=%`8[X<D[^8;8%5_B5)6?U(SZX-'
MBK1=V+5OAD$]'B"`82)PDI$;:1!G3Y(P)4-X=,<+^#5+NA1I8^6($3AQ959Q
MC**!'&@=UL`-SR$-D\(=G$8.C0!R*(=R'=-Z+-B"L!A[I/97M$A8%X:#A15S
MVE18<-"+B!5.M1:$WR1TNI9812@11N!\36@@T;>,HI5T1#12K@5;:*<$YD:&
M"`4%5U1N`^`X2+`%6N<32C$`%,`%8HA07\#_!4Y1?9`#CI2#`B=U.G7H=@@#
M-$&#?W_H.HSH?K[#%S)2`)B8"T=BB+00"^'E,515CVEQ/7<871?X4Y4(8&=&
M9N^3B?@U9ORU2Q17'$CSB==@#:%(#:)(BM\`#972'9_V<2!7@AEV>JNW>K'(
M8:]G33-YBS,88KZ7DSIG8HF5:R?VB\5HC,=X`#,`C<X($TQXE"\14,ABE$LG
MC10E![&E9.;6.1."AH\#.5JD!EF)19+3%%.6%.+";3\A1>M(;DK0$R6B=W0X
MA_:%A]$Q#+SP.H+(CW-9EPSC&`$G`D6%,K4@B'6G7Y%V<6A%5O9#?_.3,XDI
M5O1#%6FU@88B#9*"_VDER1S;`36?=Y*B)VH>UYD*@`,L"8LN)Y.S>(.S!W-`
MYW,]MYJT%FN_J&)!&9M!.90'T`*AI90)@ILQP1(!]1%)N"LDX$73B$4^\)4?
M$A57:440I453&%'&R43"25&-4P9<^&13UA12"5$UD):4LT9N28\9V9'2<68)
MTVY^:!7X]H=[N`M=$7"P4%1\N8^$@7F31G>$*33_]2=AE9B_<9&/A('7@1V1
M<@-/8YD&>J"9EID*6BF8.0Z<^:#GD'(K1TTU69HA=IJ[2&N'-6(;I%@;9(L]
MEV(B*IOAI&(F*J(DE&*\=HQV<)NZ*2!"]*(VT1(L$8<C86V_:2%H%&W3)O]D
M%>444'!V6`2.:A!;LN4Y5GF&5M2.V0)E3!:D$+5M&C(`@L./=D@P=V>E*0)6
MXGE_Q-%'^HAH\\=VUM-=?_0[I\`*M"`S`\=X9-%'O/.)GDAW]CDH=)IY\T:>
M%>F0@ED5_)E?9]6EQB`IRT"9")HG>=(,EOEYF99,CMI`#.1`<[4#*T"IHE:I
M$F:A@\6:J_FA',JIA<5-P!>;(Z:B*7IBIUJBD(6B)DI"M-FB,FH@.1JK"S4,
M#8(L#"6&JK5T44=2W)>D2$&-52@Y4(I%+V"-3-%0P7I%5<B='!6=:R!%&2('
M=>`#Y+<Y=X`')/"'C29_!Q-',L5?`92'5*%W89K_:#P%2WW1!AZP,)@X/,E#
M@'BR:&\*IX8GIQQX>7)Z'$(3;XWI7XQ)9C[C,YR(<84BH`BZ<7BRL`R;F8X*
M5X_RJ)':0.'!#IK23!A[01P4!ABDL1RDL5O3<R8VLB5&LB/+D[JVH>"4HK#9
MLBJZLJ9JJI'EJD-IF[1*1$]WLT(44/L$.%#!+7=@($$0G=QWG`<UC6D(AGOP
M6DA`?IXS`'30%-U(;EBV.0U%CF/H10,@;6R81A2P`L:5;VZ$@&UW.A0HJ')9
M;W`WEV5F''%GIE4A!H8X!KEA&Z[@!,-3KQ,(*/B:K[^$IY^H/_@(L--UF&:A
MD>(J*)8'BMEQJ`S[N(_[_WD+%"G&M%8%M#1P!0,DH+G&]`Z>ZPY'P"FAFP-G
M8#47BP$YT`%'\$$?E+JJ"TZI&[NP.[OAA+(I^YKG-*(G"ILR.[,S.Y1Q@`(W
M*R!$X90R"@(@D1,%$+4_$;0$0K1%2UP[&G:&<U&GA13(N2'9::S(BJU9^V1'
M2[W7BZTH`#+R^:VDU&6F<VB->(_\"6;V"E9NNZ4>P*Z/))!V]IYA,@9ID`%M
MUE-+DGEDXK=]6\!>BG\`1DN5>%:4N)&"6CX%FK"(RK`')QH6C`[>0:#9X5:J
M,$`>+$#^(T`>7`\D7,+F(4(H_#4=\"FSBP$@1*+8I*HLRZJKZKLVO*+$-P,#
M-?^\`1*C/+P2@K,"3.2BNQF%T<L47`"]1VRU1MP33(L$Q3F^(=);UQEMUOJ<
MX+NM^88BZ:NV[*=_X7F/Z\F'H91WA&$+W5J_J,"0R7.(YS,&#5<]X=I'BU0=
M`YPHBRNGB$(F=XS'BN*0A@D_@?JEO`.XM-&X!PJY%DR"HV'!&;P,V9$%QV1`
M=/<_'SQ`V[,!\\`"],#),,#)GES"\5`/*2PJ*^S"Y+'"+XS*JNS"NQ99*\NR
MK7K#OCN4POO#`5)0QANK`"D%1#LNS?<2TO(#Q-S$2UR&QERT9_0ATB8'2OM%
M7<0%W#8`7'E%6`S,HH.7[K=NSP5+[Q4,8DS'Y_I&.J/_GMAEO^Z*"QD0KP5I
M&PW757NW)..Z@4CC2YH'DM4PP'R,KXQ22XJ;IW6WB0),)@9FF3.SL`?'R`J]
ML(S*0'!%3)<LPIT,RBQ0T15]#_B`#_=`*AR]#QA@!*7,PHRE6"[LN[T[R[0,
M6;:\R[B\6@7U("T]$BO@.52P`K>:$@QU4<=,.<W6TSU-S--;M%$A=N)[A5IK
M=5BG!E56A7*@?6-D(M051^K+I>*YD&I;QO*9,]_*%^69`N?CQGI"/#F%GDE"
M&]AP?W,:H,B`'=1``OI\UGU,K@!ZP#\SF,;@UL_AN`BMT'SM".0`"PV=3`]=
M0!$-`YK,`AM@T8K=T8R]#V)C_P0G-$*034*,Y5@EE,JJG-*:;</I5+-;%M,]
MQIN:!9"\*3@*I8P])!)68,0D`B$D@-H@H40[33G,-D6VO2U)H<1+/-1-%KW?
MM]0?H)P1!0$3I`YE=`=5ZB=PQ*T2IVA>^KY>(1A9FFBTQ)]DS3"W(`8!=QNV
M@;?P',\[=29]S*_7@0W6,)F(8M9GO:^+(M?487E_7!R'S`H1;-`4_`@HT]>-
M''KIP`P2*\G'I+FB3-$5G=@;8`3]T`^,;2KZP.`=?4*0/=GG5-F0Q6*TG$Z1
MQ4[K!+QF@(2@+:LYZROZA`?%+$5K0`$_H"PL\0,\QA+[%`%"I-N4P^(ICA*^
M/-M)L?];D\,M%474/EI;WD+,RKP3XL:L'Q#<:"<'Q*P.4\#DZ'8BW8PDI8-<
MX.RE=+P^HA.NHA/?P"$\I["0#1<!S?#&MC$Z8WT].V7'ZTVG:DT-(IG/^VS`
M]VBG<5DTGCC7:VVH"JO(^:W?)/C7WJ$.":I@#QO@]:#)GVS1",X""<X>")X/
M_W`J::,JIU(V+!3A^;#9-YQ.Z13AZL3I*83#Q&<'+6`%'O[A2P>V.Q0!9B3%
MF^,M7,!;Q442>*`47*!/8AB^&\);=Y!TLCW;>V".'2*UYPCLM*T4=.#C/I&]
M0CJL$!7%WB(5*/`HY?H;*+528]:15LW<73'=@SPH>]@DBTC_,KUCMVX\!GAK
MI=G.EG$Z7]<`,^4=BJ18#68=UW%-SWG<@77.YG+=WAWX'(B<L(JZ#+#`UQWS
M"`=/@N4`"SM@B@XFL89.PHI]X(^NX.HQZ:N"\:A2Z2LT-BRD0I<.\N@$V:%.
M-I_>3NQ$FP<0!RU@!BP0XJAN$@5E+##^*U*@[)L3S"%!`AXBED)-Q'U`VD9F
M[&.4[$PFACA/4CRAK&`'M;PEK$A0`])6!U^HTY3C:@+0`3"`YG?'S?I7IO-,
M'5=M,%P<GE4];SR#'..."G)H9U_MSHHTQ[RC=\*AYG%^S]UP*""9WFKU,^\M
MYX$+T!UY#`$O\,R@/`K=,8I/&@K=_YG\O6ES!?&/(LJ)3O$*?OD(/A!)4!";
MCQ#TP2ILXQYH\T(OA/(H'_*FKT(IK_(K7^HP'_,F<40\&SC&`MLJ806Z+F1K
M\"PA(05!#2)!L5HK((9<P/08%;T9%=2U95O2&JT40`%2Q&S;Q_1-#Q5/#.W6
M2WU=J05:3+:1A^U)DGEARU)J*]!G$I=/\A=IL(AM`&<>P,[[B^[ZAF]IF^;*
M\9'JS<>1.0T>"`A.@AQ.A!R'A8>*$8R-CAP1B(F*E)66AR0<F8N.CXI.)()3
MHS>C4Z6C6:<W-T%OKV\*LK.T"DVSM[6Z.V\[OCNNP4'#04=91\8H62@PS<XP
M+"Q&TD9&2?_5U5%&VE'=25$:W>#@X1KEY.,:$N;LXU$2[]WP$O3O].KJZ_KA
M%?W^_P`#_OMCIT4$*7T2*ES(L*'#AQ`C2IQ(T6$C*1@Q1JC8)P(>/'<&[!E)
MLJ3)/6M^;.PC9<W)ES#WW)%20*$5/")EWJ%RAP*%.S]<QCSY@TK.H0/6K.'Y
MDXK2.W?61!U*,BC5DP.@0H$B!\I1K&4$B$6"I$>$%"FLI/#`UHH'MVWCLIT+
M=RY=#VA3-%*4YNQ:NX#QY@TL>*^A27T=I4DS5V^*`A&<3!DD:`PD1G_=JLV+
M&:U=M(\*(8XD293I1)0-(4ISJ._E3ITNO99]:8JA38=@P[XDJ+?_)56K6L%Z
MI:NX<5D[D/=:'H07L>?'4"1#0:(ZB68LH$7;OL%:DFO?OD?Y%F6&^?,SRI?7
MD#Y<MW/BQ+F/3[^^?2#X\^O?S[\_!94<!2C@@`02Z-%*$H&`$$L4?'552G30
M8=550]T1X0ITK/`#25(Y-8!(/`GUX!T4EI@2A1.66)5+'SI8T@!D"4#6!V7@
MT44!..:HXXX\[MA'33K^^".00A)99($4M=&'DFV`D)"338+0Y)12MF'EE$M6
M>>66;0#`)0!>7NDEF&26:>:9:*:IYIIF\@"`FW"^*6></-1)9YUOTBDGFWR"
MV>6?@'(IJ*!+;KGDH7UXD)"2BBY44T)$_T9:9(^45HKCC9@6D.FFFG;AZ:>@
MABJJJ'Z4:NJIJ*:J*GX_+(CDJ[#&2A%&%#&2D$<B4MBBBKHFY:))4A7U:TE4
M4,'K5<+&1,4/)!X[TDYKY#2`4R8-@$899)'E`QPV=JKIMYZ"FV,7?9!KJ8]'
M/@JID`H922`(\,8K[[STRAMEO?$"T`<(`/#K;[]@\ENFP/_V:?#!>^X99YME
M+NPFF6[^`3&8#S>,,)L"`_POO_LZ"6_'("_D\;Y(XCBIC^2F7*ZXF(K::<NC
MQBSSS)^J:O/-J+**H*P\]QPK1NH^Y&H?5A3E[-%(GR05!=%*%=574@U[=%84
M\$3M'B(-$)345/\Q]=-_4N!A5-842`%'MDB4\8,-GJY\HXYO7SKDMS7=6&ZZ
M0QXYJ:/LOHKOWW]3V62_&]^K\>&(`WSQX@A7/''%#L\IL<01STGQY8RGF3'!
M&OLK);SW`BYO19+B3:2Y.[[M=MUT;\IIN#3''C/.M-\,Q'\[^ZS[[J0/W9`4
M)/S.==+$4S43'@N&/=5(/PSOK*_+*E7U\L2WN`8>M^+!;-E.,J&%`&'08>/;
M<6=ZJ:8_HBZWR3ZR'ZFD[#,4-$>BUP_Z_9][?OC&`?>_O_^9"^#E((>Y`5J,
M<@!`H`(GEC`!DHES_-O8YT)G/R=%Q$CP`U+=BE2^(96/92T#E^Q&2+/_VIE0
M5;AKR$%XQ\(6LF1^"EFA"HU2O!KR:@VYZX@4C"637-GP1<Q:R@I\2+SK,<16
M'9'01PP`.W'![8FMF]L&-9BCO)4N:.X:4`7M%R4JY8]P_^.<XA27,0>:L8&6
M>YS"+K=`S#G.<0(LV/X\E[\ZVH\B\$L7%=W'.O*-BV4O>QT)!^FI$QK25+?#
M0P0LV!%F^<Z%D'P5"7+8$>P)C8@_S&1)UO#(A&BO54%HGB9AHK60..]!EG2(
M]FPPOB:VCF[@LB+K[L;'O>4QC^W2XA8!UT7\13",B-L<`,_8N`*B44]QHMSD
MY"0QRST,C@XLXR\]Y\5=7C"7&;3BW<RG/C\*_U*$+B/D"`])SD1&`#)2*(I/
M.AG)=G+$(QI9"$T@$@%1CO*>(UD#'=B)H`@T"Y\O6AH/D::UH$F!$6'[`?(^
M!<BXG>^)F5H9+4VF/FWB$H9]J\@NN6A'>('1HP6#(!F)2<QG&M.-*%7@PA(&
MS3B.E(Z$NQ\%18=';-JRBGQTHC<;VD1QBI.<Y:3`)W="`59-P9U()9`5#O*1
M>$:D)0#5Y`"$>M1981*?2:%#]7[@*`NM0'M-E<(4>@I1*$[TB4*J:/QNJ3>,
M:G2C]1)<OD`*S%_VKXPD9=Q*41JY!;;1I">-IC3#Z*^9UH\CM]3@WAP*Q9W"
M+)`P\VGL(`F9+HS59/_EFF12-UL@2C;$GE&M(14\^Y`(##2T^=Q0TK*B+BMH
MY",(<NU!^Y#7V@H0L"9%IC/AQ-O>VNFWP`5NGH0;W#K]@0?'M0,/E$N0YMK!
MN<?]@W2G2]WJ6O>ZV,VN=K=;7>0^E[G*92Z>E/O;X18W3^9U9AI;:MOV9DZ"
M,847=^>K7>6VH$[/E2X/9C!/SOK79SM$;?&T)B!_"I@DU#N6T]A9`"LTI`!2
M0,%]Z4OA"EOXPAC.L(8WS.$.>_C#(`ZQA_,KXA*;>+H\<.U_5RRK>AXX:9P<
M$&A16RRD48"T$HG`!I![XA[[^,=`#K*0ATSD(AM9Q#S8`#M9S&2)%&`%_WS_
M\;'N@..'X"0F`]C**1]$ARV_*)4#B@`+,G#D,IOYS&A.LYK7S&;ZUHD$2VZR
MG!E2-"E/#<RU2N>P!B`'L;Q`#5Z.R4^>5U4"%8`$9&ZSHA?-Z$8[^M%MYD$&
M2.#@.5L:(GBXZFH_9,,8O_,GFN[S6#X`A1IJ[2B<ILH`XBP1UV:`Q)".M:QG
M3>M:V_JX_'7KI>=,@M.:N@YUD$.@8>+I684$*75`@HR0\`%`B[99*4D1L5D-
M$8R@P`H\%C(/N@`$I2S%#PG4+@_\T&UO`Z$/MS9R&_S@%&]W(=P6!D`7U@#O
M=-O[WAQ.L10JO:Y=6UJU-AQ`'<92AU)OU:T(3:BO_U\B<+0U>]@,IP-/H@(5
MF<PXM;J.")Q)L(%7"[D/0/A54@I@W6VSZ"5KZ$*V\2UB`'1;6>B>K[R%,@"2
ML_SF.'<S"X*P$A+0@=_^9K&"-,TK/HM%1@^O'I4=DDYH\4H.:'N!$B`^DA9-
M2T(L"@I40.TKD2Q=B\"S0@96[F,`H)KA7:CNPE\"A)R#N`]$KWK:M]L%!\W=
M[7C/NWZMP`+DH8`%U`YZ.PL0Y=4F&VW.)AX5I,!(2%V\1%`X?!T2[ZR4_*<H
M(IIX@Z8%E9[L)/#5'KN009"KI'3[*P.(N72)Z*(!W%WO&.Y"B5*?W0)@LNVP
MS_W-ZY0!*_C>"L$3/).M4/_XI*G!X91'FA$_&W>L>3M:5>>*5ZB>$AXZ*"7'
M)LH*,CZ1?9.]QT#89!]X#(*!#@#WTAWH&O#3!3_X<`#UUCU]07`4*@"A_2\O
M"?JK6W>L`,'F\A>`Z?9;8L!XPL=BA/=#4.`#V?("!J=T%E%\1'%0&($'&/(#
M:&!*+Y(3*7%5RT)U`X!G!"(%.R9D(K(&WV=^\!9R[V9=??`5KR>`VP4`2A&#
MTA5R'!)_?R![+T(!,0=K,AB$M,8#_76`_P5P-11Y/E!P5'<25`!#!D8592,T
MRS,M@Y82]>0@TR)M6)%JU<)5KP)AV"9D)#$`?G!=?E"&-F<'!0`"V65^-BB$
MU]7_@M@E(K1'7?W'(:HGAWPXA%:``J!GA+N#A`/V(0\X8&!X1(3((30'(!:!
M!UR0$@@1$C]0$U=6AD#!-5D&;(?((8$H-"489"41AWEXA]P5?B01AWU(7W:X
MASR`:ONWBK+X:'7"=P>%1(+83H]G9R\B/I_4*@Y1`-KC0U2`/$5!!=OW5/TE
M!2NP$I>X+$:#;*/6B5AS8P52$U+``M]W8G:H@^JWC=>%BB.ABK.H72=8;^+H
M>N6XCI`F:<!'*[G83EW&BS'Q=7AD3]/B*O!8(%`5/10"!<HV%EO@A57WB3&T
M`F$'CB6&@_E4;SPXCO1E=F6HD.Q876E($OM'?R1!!179_Y&,IEQB\(=5%H^R
M,H_TJ#0BF&/'-A,^XQ&9"'EH@P0,0(TR,9*_$V%6(`84&6*D]R+GMH-'L08S
MJ"\,B37DV)%@PFVHAHYEB&Y]0&[V]W\ZZ)%4J6T\P`(V29*O8I(G61+VR!$[
MM&J\XV(PB38#Z2(I,2`')78[*6(%H(6G16_818/>5BVQZ'96$`0PL&'S5I<O
M$H,B\G_&@GI4L(<4EI=6H%TDL`(MT&%7697REP&`EY5:.2"7V)55AP?<)S2.
MN#L1T'Q5=WA(\&?#LGB;J1`)>61M((XG`00*R0,P005M8&0H@)!`I@)\P`>)
MF6$%P'!^\'UG-Q1'>5T9@)M\(/]==H`"=,`"TV4%N8D#'>:<C0F9L"=I@&>0
ME4D1EXF961%\#`%GK45G='":!9)]5\$5P`9HPQ)M1?A4'0>$'[=V^02`U_4K
M*6=DN4D#MYF;B89A```3/EA=$MF%65.&LTEA+8";*B!=+9";4C!=&9";=+!A
M5M`"4J";+;";U(EWO*=DV=DS$3!$F/DB=P!#S2@%02`^S<@0R<A"`39[64:0
MFS057#"2!S&&1I:'6,.:&YE=FH:"1):?0':5_9EA4D,!U-4'K=D%',.C'%EA
M+:"-#.J@U,5W&\8#QIF;_+FA>L<#%AI#N/BA`2*,"3:B8KD0,M1@.M1X*\I"
M9-EI$T+_8!*1C:)79'7'@0DT;C[DFM=E)VU0`$6Y!T^:7;WG<=25H75*G#@J
M74)J7;[WFMF&J&UI7;TWG=N%)VW`;29Q=[V9$X5I76]9AE.Y=XM:70W*!P^Z
M73-0H8IJJ7_0`G2@I73@JESJ=E<I!3F`$20`B)0IIGV0:4LQHE^F$'#6HO+$
M$)KI0HNH8!_RD@A6920XJ4@6E&17E.HX7S"(75:0I4^``OJ%`UK*!R0P7>"*
M`]NJI8D9!.'*!PLJ71<JJ].EKOH)KM[*`R40KB5`JW]``[DI7>K*!SS`KQ)Z
M80^)->C&AB4QJJ=EF`QZK_"ZKWR@G[$:KA-ZJJGZ!S"0I3A@_ZDHL*X3*ET;
MH*7C6JNPEZ&_]WLHT*N0DA&S)7R9AC7+:F?3DA0K`308-05#T[)C&;,FTA/1
MN$FI5$\[DYI%Y@=',94%.ZAT=Q1(:ETLL*Y\`)T0^P0](+`C"ZY9FI\\\*_A
M^EP[D)\],+!_H*XJ`*Y\0`=8FILE8)S?)[#^FIM9RP=%2E^L.7=*2A(,*UT7
M"9'5905"L*[MRJ_Z^;7ANJ`6*UTPD)]HT*A/RZX.*[7[B@960`/Z2;)=6EQ_
M&#85B#S*.$G1`#2"=XF[^&)3)07KA%!SBB`ZNSLO.C5,(Z-5!R`10`=8>&@9
M(G9'=H+9A6KS%Y3690=/D)N,R0(XX/^MB<L'S`FQ)2!=9JL"UV:<V#8#^6D%
M,_`'$1JUS)N;Z1JN-!`$SLD'WOH'5@"YU.6V8ZNE*V`%88N\!%N&N#>@>Z"*
M.FJ#B\L':&`&,T`'4BNXK]JX=+"JKTJE"1JQTM6X&_`'BRL$ST6$>WE<=+#`
M*V"Y0<@#(;D!5K`!%@QGP0@\+%"A8M![@#=)83J6GI5#>$`23%.&3:@TS$)#
M,+%T$)81L[(13Z:R[V2>SK(35.$TQY8544$%UR:M(0:_0EF')4%?;:"[U=6X
MY"M=]ZH"]]4"':N;?P"N3\!C$[N;C?H'[SH#7MJX#_JO*E"]XIN?4HI=YONO
MR?N]R5MA!8O_?D=QES=X%/1Y7,_9M@0<P*@Z78<[Q2C@I2T0O!-JMMXKP159
M)RT@!HG<`AD0!`TA6VSI7>YXG4ZU.W"V;P^&D")SB3J,$D%D:D'1@<26DGA$
M@:O;,WJV6J.[@:@F$C^`:$(<8KZ+7;PK7:,J73I:Q-0UQ6T\75JJ`L!LG-Z*
MM?&JO8R:QW\PL6L+S`/[K^%[7%FJ`G0PM]*5QL9<QNS;7;?\!ZR)?N:7MRI8
M7=?[S.6;QX<[I7N\`G`;S$+:N+F)!N1LR(>,E6BJ2!7Z?>[H>TIFPQ)QR1L`
M>/,389/I$;_*@3\<REQX-%/!$\36I@,BABS!.T$`FEB&PT47K65V_UJDN$D5
ML'JRV:=>>)?OJJ&^G)\E0`,ED-+,2<QO2\5_L,5F>](R70)!<+XNK5\3JZ6]
M7,W]:M.[R<;657=\&M39BLN;1':]R2&.FIOQS-.5>\YZ_*`3JP(RC=)2:P4.
MJ[:Q+,_R9P<9$$\'T<'&A5UVDJ'824\:(79F;5`6[%K,`F5ER"S'M@8-4D2?
MO`>C*XGD*32\PY5(4Z8J0@64MM4@EM15!P3P-FY%#9LC87_DDW\D4<=_,,47
M.UU_VZ[6Q=(^?<R5^P?J#+#7]:\DK5\P,-769<TN#=3\AS6"&BZ:$JAR:<NY
ML@8%L%P`8+2C:%VG&L&G;<Y4BLYAG)L[W?^W4N"P#<S5[)AB&["8V>@!0@P`
M,``KPK@"0?!WD7Q<5H"0%"C6*2:?)9'012>B"$9SN\(A^X0DIRPKJTPA4:-@
M=$`!*]!Q9T9$2E'>(]&T?V#85R''UZL"/)9D?["^)!V^FBW:Q[R\B)N;-=V<
M!VS@#$K2Z]O;Q[G9V#S</#H4=7RW#*=_V(6;0G#`!>S4^J7@?$RE3'RHS'G&
MV%S9R#V+]G7!;%EA*;;7D'')"1%A.N868[UW+%`=WL>@$F@2(=*$IT8L(4'7
M/S!H,[K71W36$I$L1Y,2PZ8UNSK89P8`WKU)X68'-G!*2EM=]:L"/8`&*J"?
MURL$^T0']YJ8!7[_S<9)`]"9ME'+C/P:W#<=LC1`!RCPKYT]7:C]T\)M75E>
MAF=(U%T#CES;`S@`S")^S!%;L53*`V:+!D$@!6$[H?R*`Q@AL"#>XLF-R(0]
M`Y0IT!&0LF&7`?>UC9)6J!-V7-OYPN]-T=7BUUKS`UNC3\`"C(9F@``F!4&^
MP^NM+/N&ZH2]D%)S?M;E?DAQE':0U7`K75-<N&S.KL7LTM$.VN>ZKM[JX'_@
MSK^LKW\N7:I-72['-;2=72\8$W),76:KI4_0Z%7\RU'-H'%[MA"[KDWLZ?I.
MA&!IP1GPU=>FD_-E)R@&`Q1=?<,FY5T8NQ_1\.TI(/NH.[\^%.!=(G>`_VW%
M;F+;!@3MMA3WIY#EPO'>9G\%L,W3M0$8$@2]+,41HO+-21TO_\?-*05T$`3_
M[7,[L`(DP&-_*/,HMG,[H.?;R`(H$+X]_]]%3\WZ]93E)CU^(-DE!Z@=__'S
MY5H90@+32?2]S`(8\J`\4/1D7,#-00>(]O(10H+ZGO;4Q>^U$L3*Y7N)>F$L
M`.6JUA-%5_$<DHBQ(D.\,_&D%.PJ?(AW$(J*1B8=36%@\@>'+\]@LO@5UOAJ
M'_F09@>3!!D-IJ:W<A`8D9/(2?`:EF)S?TI9L65:8X=5YX6+QS-\SSMX__?.
M\R$#IP6)=P<J+OFV?_NX[V&9R[*\3QT6W.K(F?]O^J8B=/WZ/RNH3F$A.U$L
M=,#/#V;*+CKH6-'ZH7ET/J`$SU*JN;_]W-_]9-U[)POC)YOJ&A\!7D;],A&7
M!X4'5=4(("H^J.N9@&\2Z#\`/K!L,MFLVN_]_`\(?X*#A(6&AXB)BHN,C8Z/
MD)&2DY25ECR8F3PM`"V9EHP\+`-[I::GJ&MWJ*Q[/Z2E:S]]M+6VM[BYNK=2
MN[Z_M!&OK<2JQ*@#/D@"2$A#`P,_5CR@U=;7V-G:V]S=WM_@X>+CY.`\$;#'
MJ'?IQ.RF=[W`\_0%\O3XM%)KZNOMQP/J-$/R00VT.],282K'L*'#AQ`C2IQ(
ML:+%0N?^]9/5[P>_6'3_"N0;B2M"!)+X]O4[]6.E*2@#ZT!9HRJA(2LHI$A!
MD>&BSY]`@PH=2K0H1#M2-';\2,RCJ0$A44HU*76>2I?&7.Z!I@;*S!4Z;1+B
M<2]"D!G4C*I=R[:MV[=PMY'5>BJK.Z;13A8@(45D56!23N8J$`'/%,$DK_:+
MQI1N+!0;K&1(2PB&WV`H/,7=S+FSY\^@&Y)5VN].XW54ZNJD<X?*BLM_=5'%
M58#U&BIW$.,#@>=TL=2.ZZ*81GE0AGM]0$@A,3FT\^?0HTL'S0-/\%C#ZI)J
MG0I6-"NQ?^$1K+./L'1K=./+WH^*;ZVR(F2P<PC%+7L;YD_?S[^____D5'==
M_RFF/47%#[A10-I6>(3W2P1]14#!#U(X9<H:?9'TSDH;7D?!<,418A\O8@%H
MXHDHIJCB'SRT-*`LT%#!6C2KJ(.A@[Y4^,,KM_TS``5TJ/=+`>RIH^"+=+#0
MG"$9""G%!B%RDP$.)=`@193>M$!#3\;1P:6(03A"QPY_S/`E(VA(L58+3YRY
MB!5"[,>FFXO0P0<=*^8)3@8N#GC@#P5J1860..ISY&)WP)8+A(%9$<$*-=[V
MWH\+'A,/"242<H:BYDFAF3=TJ(`'#%+T0`,Y+:AP)@QW&L)'G(W@0"8.>#IB
MY3@9G"I)!K6VP,<,CUC!QS<HK$!)"VBT4(VO="8BK/\5RNHI[396U#A@+,']
M0"B.=%"@%50/>G3'CAY-2`>@?=9EK6-48/HI1D'D$@0+'F!YS08J6$%(L]VD
M>J84*JA*"+[#QDJFO8C<*HZPDUB!AB#,!EMP-W3@0$D&*D1K2<2.P*#"M"!G
M,P,%[UVK%1V%W@(A%96>$L\O='@'S59K0,,1*[C-O-(`=_3\`PMBV.NHO-!Z
M8P<-*"#2`@G#"6)'3RR@P,(@HDC!0EH9H)`9Q),IR6+4+`@\B!1HT!#F(#2L
MH$):/,#0]"`XL=`#F4M6/?4?=FR@-9<*4^VVOH)T+07@7T/&M1V2_8&3%,"2
MQ4?BBEO--JE74XT"#5:(P:S_%593S<*3A3#\1PN?5_Y'3U9L,#K3&;0`^`:=
M0ZPUE"W@@+G&+<RG-^%M\\0B"2HH:07@HAC74]6J"Z+OTAP7/4C>L?.P@A#.
MAVQ]PWBT;#)`.:0<@4@5LOPM'IS.5MN"C+5R8,_NJ<.SU"Q(AC`+A#Z)<#48
M-]M"E6BHH*:6:D,#'Z96NQ+T#T\L*$$/T%`"?:$`#3@@`@NT9$`5\.%,*\#!
M"G2EN,<)C`=EPT&^!!%`&K2*#DGC00]4<,`_B-!4&?M#WT9'`QKT3TU_4('M
M:/"$J=EA@R),&@O2I@)2J8`&*V3!$/F0MC^$C4H/`Z$-57`V)]+@B!/D@PBO
MF#07_^HP>(1@F!U*4,%3:0D&1*`##VRXQ5,%08<E^%\-^\<"X&%Q$#"@`96N
M2,`:BG!X)DQ;$'H@B`U<4!"TX@$=2B#"6JD`!57*P"&#4`(,PC%9&2@!$TEP
MO4Y"HEK:VUXQD(./"-"A0;;H`KJ*Q*'9U$(*/@N,8G`&G`O5C`K`404=6*.^
MP4UF(8F(`'A*`C1OB*X0=DB3\B[(`SZ<+0@6PP$A`\<#%7#R#RCX&`KXL`)J
MF`UB8D,D'5(%N!U8#'-_Z$&MK$"#%@2!!O1Q(9Y0*,-:G>Z>B.3D##48N,?]
M@9O*4X$=WBF(:F:`!7>BAL;H\##162&&,I0:K%@4QH>QR/^9@@C;'Z`9N'"*
M+EK-1`L3E46KC'[,"B6@1C59D,'G_:%BA4#HW1CZTK-E\VDQG`$?J!&JLV6,
M#O!DT:U44`+5^<H*0-68%=-"`SQYS)-0;00+#B7*ZT1C"B#(AQ1(1H7`U,(C
MT`CE4W)0&-AD+T8[(@V,2C$`*E#@K:WITP!H0C)6\*R8C&`!I_H0&/UP0UCQ
MW)<0-(8T?RGO88\,(PTHDS&`T<<.3V!;.%VH)CH8*X?ZZH&^GA"$X3VK;R6E
MIS\+03HI($V&.!Q=.'&@IM'F<`,0]&P<$4H9Z.FQ@X+(IF=Q@`:==O8F%AO=
M(17W,170P;-"N"9N`T>JQS4S>3W_P*$5GO!2S0)R7D3PG2!@2@@6$&$004A6
M"89C!5;EK@31`J.5!,I.U(+W5-8LJ!;16P@T7/8/)"@!?C\6U?X:HFWBJ^JU
MHD%*78!@"BNHV59X=LH@E&PEKC$-<K+WE`452!6`"JLL:GFAF*5"&O=SFC`7
MY;5N8(QP<)O81CTE-H?]$\4LL*@@\I7-@`YB?V>B`2<E2;IIX@`&_Z1#$'(0
MA+.`49PO]=1P!T&')_P8!TGKVS&Q:2S7!@^)12ZR%30J"%9!F;?+I621I1"$
MI$V)#T<^K'RY]-`<XB`(4@`+X1BV1BHB%%I$8+,UAQAE-.0@SO-2G`D%QMU!
M</D/*T`#_\:$G.7<K4T001@G///%VAPJM\8CO.@1#9%8Y5'WT/X--0DX+.`7
M%9@VL'S/;4S6(U<0!D+K*LVX6B-6W*P#4R'.Z%X+L(),96,']H3;8-&&`AX0
M`5B*(V2GE;?80316OZ-[0CP-.X@&"B*.);@F'=34PT+X;Q"A+;9K.XAL>O8M
M?TQN+>&$D`'[QO2[,[Y;>)=K6D3PX(T5A=APVQQ'1##L<M%Z'+5EJ,<NEO00
MO+)8H3,*[XTF:[*GH^_HLJVF-_NS;_7.M*\V8+;`IO.^^?W#4T,=:A[$NM37
MZ:HO#DR'!Z-<1JWQ,%T4G"WT#"[7HSLU+3J+\XNU"F)X>O,R6__7XH<!%6YV
M$$(75Z#?&E\;AT%8\A^(8`9!`&RGD%83!`?!$]OIFTSTW'HA64#=TYUVAKM<
MIKY&N\$_.%9Y$3ATP8[6T((]JZ!!^!0/)BKH-=NXWEV>\["*7$B!A]/)-GEH
MM+:<>(4'=Q#``Z_1'U_L#!"!L",T)'^9[C0P:IR9Q@WCH^LI<OZ2O+\9.#G*
MV24/88S'%N=9/4`4S$K9EP*76SE0]19QG%WP_!M#5`$,\80Q/2:VFLAV<>UT
M>-NPH6&%#C0]"X3@QRT1HNPSMB<*\(0L1C+2$U?L'QKFF<(K4DF-1[1=#Z*<
MVHD;'X=H+EL)&A>J'6ZYX5!D812/B$#_X?>/!-YE?/?%(D>D9'J&-R)D.V@@
M>(KS!"&4+ZF";"1@)3LT-2M`!#NT`6^$!G2D.$*`!G?C1*8W;Q0$13Q@!_Q'
M0@WW;2RR2(TT8X`3,2BE7"_%?,E2>J?77SR``J1F>UJ1&WV@2C0Q+B=Q8"[G
M@WO0/DCX%"WW`U*S)*&``MOR>^`0-210''44+7:`;"SR)9S#A78`@%1S)G9@
M.'XE"%RH.)2Q"4Z#$S`&`W;0`LHBAW!#`EQ(`D#&AJUS$ULC"(\3/X4P`V_#
M`VG(`G#(`UPB"C$(@(&5A89`.OHR`_%$B(,@B"C&(LC6`DUC!M2`%L+%)7;`
M79H8@FUC.J=3_V*8>&->J%U?0SQ<:`8>AQ,:XXG*,VU*-3IODXHY"%4L<(1+
MR`H[@@<6DGOQ0&&_J#ZJ9WMW,"^9XW&,L`&$8@^^MHO8,&[.X2N9X3K?1(W<
MN!D"<HS?8AHT=PIMY8NVES['N`9X$#\]UUU"HAS,T8[=^`@0YQP36$-I(X_S
MN(\4(0IB]2U>H3-TT3/@&!RJ\(\F@P?YH8\9%0%912+\PH\2.9$421%6T(,F
M,P!RP`PO``4(&0T_<"[)6)!UD2ZEX!4>66KM,HV-X$XE<7,5&9,R.9,,41T(
M"1!0(``Z21!*8%4',8XDR0K<<0I04`;,(!,#``5RD)+!T5:]QI">H_\>?065
M-%F55GF5CZ@@<T43N(21*^$#S,`,!7&3%S(A".(>9"E*0_D4R\`,2*`&:K"3
M'1D<%.`N5`DQ7H49+.D0;/A):@&%3(*5#1&'^W*7@FD4U>)6.Z$U%7*3`3$0
M!&$0&7D;/7,N:7DM:T64;=D,'["9;_F/`X`'Q`$*/,`YM1!W@"D19.9$(:@(
M;584`U<(&',Z[3<.2K0(N5@-.VB8#M$"5](([<8':-9%UH@3DO!XBM-%ARD1
M2Q,_9J(Y5F"26B$'D/D!2G"9K6`7Z5A[,%&=RS`0#``%[D,*;;6.J4D);>-5
M@7&+JADF:8<(JTE<1H%CB)!)2Q4.'/.>B1#_7=B0*^SY#3H!"NP4D6/C/V82
M8SWQ!)=X.9`0/_DR076$`\.SG!'!`YH#`)A@!YM@'=<!!0*!!#X@F2BGG1WJ
M%5BA>AXZ$!^P!9")!`Q0*0="!7A``@N)#54CC;RI#:OIC(40GZ])%+%)"#,`
M;3G:",T$BJ&@#44*"7"FFZ&@`@-H!_2AH/\%"9>C12P``%*@2<=%H3YQ#N9H
M5RB)G<2@A`,"!7`@`%I0!RUC:ZW@H3Z@!5WQH9&I$5O951L0&;^DI#H!D]^P
M@V'83210,4&0B-N706%RFZ=#J,H28V;C.E17,:FU`15S3?&#5*X#33B0/%>2
M09[B=I2!BCPPJ!JD_U!*4C'*.0.[I#9NP@*K^C&^F5$5TZ6GXZE64*@\00*T
MDHC01*O20RL6>"="E#Q6D$$K<":8XD1M0RO0(@5"QR+;]ZSXM4N&R$E)XYN^
M^69IH:M)4D=CX:Q)HCR5FE&I4S%3,T0]$`34D`&>.H<DX$Y7TZM`=F/JVC;W
MQEK%\4"(P`>PDTC)N3KL6FFTB0,"ZT)-RB*QY:4_<9';0Z;(@!NU]RUUH)/,
M(*+%D(Q)&9!)J0PA*I`T(0M:\X29P*.Z6:Q^FB4E$"HKP'';QD@(:S:AHB;`
M=CHZ9%J+=3E--3Q,M$L#]`?X`F=@1+`ZI"6LM0,"(WQOID,R=#<#QT[;UO]4
MBE,EEM6S#R5D/2!U`&-9-*!?=*8".U`J'U--=#"!B%<E9H-$+&([4A`J^K("
MT65.+J1%>#*SJ<):!$L(M\);9ULE29LT>;0";Q0F*$5F!9A#Q*5'>!!Z&Q!'
M`,."B&0E:I,Z5`0P4[,#6[M+C55#7I(J*'1;#U4VMVHE=#!-_>0)Z?=&`UBP
MA<!$28LGD'2X&@1&HQL$*]!M.XA-RC,-RJFP%9$!7AF48=4:0!D<:O"=S1">
M-C*2Y+@'=X`&#S`S<T4A.A$9+1`T2ZH0P_,NW5!-.!`B9(=-IK>:8^)"C_=-
M/CI<A-=I[,0#."!U,Y8T+/A0&1!Y;L=!H3,LBB?_".DJ0Y=%G_H&./8Y91=U
M4-`6,2DK7^`["!NT1FEXI((PLWU3''D;7'=7OX40>30PKR@07"<U6EOZ!R!H
M=?;[P04U1M*E7T`53Z=UL(G641D@+#B$3DRR4T=%0C+V!^.UKUW47A\L+%QR
ML%P7;+P+I!T2E&QU('@P(0[;G>`IGL305M[B$G>%!UP`Q3LA&1FP)"0K%\#T
M#>1T8\YJ0BYT7^*+)VE6;SX:ONK*!SM09+4[`W=;4*[:OO!+."`8,?N[+QLL
MQBZ&2'@`69,83AM`NC/0P04%`PSUA_S%8SFDG,,2QQWT0R70:_K&)<#63)>(
M-A6'0[,IPLH3QA^#!EWD_ZPSMEP)_&.09K\'-PAWXL;#4FBW<K#/1V9O%!D3
M@[J7*$F;T'#S-@C*=`A4VG>O>TP^ZJP'/,1&(0H[$BA!&0^>U7*BE**<:;'(
MT#-BQ3.2P5)2LWU0<KT_85`9I45;-BQHD#QNYYYF3#@UEL9CDW=\``.>-0VR
M4FW!DTEU[,M3$UW&EH;"HF@(I3@R]F:I<F.59&B/%\##PB:WXT]89$#OR\H@
M;$_"0@TQQ@</PS&7[+Z:3%EH&+ZG0@)WDC4G!:4K,%R&G%LC3;O'1@AH4$7"
MA2F>]5+EFS0'BS3Q[#HJ5M'VJ\L##6G(2<K`##CM56/$'"8X(`2%*@5D@LS)
M_/_"4?.[Y_@DULLYN"2\P[L84*`%S8"4=DJ0CK$&$U0M/X`'[O&NTT%M.K9,
M,@U>E84GV[C6[&QU06`'_%H(!Y='U:8F*I")`L-.KEH(.8Q;5D"Z;T;75:=:
M7\)Q:8%2N!5IK*POHPLZ#^V'U85'#3=Q(F7)9MR:>+O)@=-PIH7)71:V*<N*
M)XU-^E5-8.$FHUL($E0(L$S3."2M:DU:,GPZ?""'O'S#&$.#CZT\A#3,$T-F
M-8Q-0LS40H$)Q^&P,_<S=4,Z++`!;E,A8?H28ZH1:Y!@5B4%+XP7>'">H('6
M>=B^(G=(88/.;A=##Z4O:VMC<IU.:$`?+>`E\XQ?NH+_4/![-U3B;#3`V?%5
M._@;T&%B0VF[9,VD)M7$M<.R`K42=?K2/RM08LN&OU1Z-&H$`RHU?Z+]!S-[
M.<?3?GG+R1Y=PUH2MDP$&?'T,3K%=29N)>;<3W?3=<W&OFLM"*<59UUV2#NH
MLW*L4K?-TR-XPRY$/1`3X7\0S$.MX.U<PX6\U,AM%"10W5+,5A?2&O$@'\6!
M"9U@H:XCG5(LD"X#U:W05A0B&6<IH\RQQ9Z!+%P2-@6H*V_$0CNQ49?5N!D,
M,240/.TE"$R#-Z%"5"@0BF<#0@%CKCET1<;U)6\4(@]U1$3MY/34;@'CK$H5
M?"408WV7*Y/>`P>5P7%VP"%L_^/*D^=4I*%_3D60%C`K1D(!TV_@QDEC&S@<
MI*O@Z^B+!:S.^MJGDBN&A@;LFR3.&LS,5NB>H#9$I2:.C4A3@S$CE$U$I49[
M+CT!`Z7[LC9:,C;'O41/8%S>A&Q3XD0-->M)\^>LY=)//A1)L3TTD0[N(0O\
MH(Y:@RFTJ!`S(.;7P<Q2'`_Q$S352E[>#!1*Y3K*0ADOK%(L0O`EXCHGN(8(
M#U)KF#@+D2]9#-O(>6,)`5)40QD0_U]%HU+1XCK'<S3F7,BM0QFX`SF!@_)E
M<CPFOWL'__(0D_$IKU)A0QGJ-#HQ7U"D8WK)9.ZEF88O[/`R/SHV(?!.4QP@
M7Z4X7_]06%*:U5-;'I_S,/_"!77N13$:)D,%.0%+N)$3D`%+/T"]UML(),#<
M3W$S`SD<FJ&AB,@)_]Z-F68<V?2?#0%4+&`',7;<0"%)*V`F4F"-H4-%,V`&
M?Y_)5G_XI$55)]HS\9`?,^`H\9/%61S=Q*'FI.7E`P8H]KY@MW%S;Q^3.'#8
MO<[9$'&O$/2;B,E0S,H(2,6!M(KXL&\(41X<=P"`>0HMF5"]&7KP7>P(+6+V
M>T"BR/"Q7$`A4B,_L9_\RK_\B4#6H#DXFO,)VI`W4GZQ@`(0>(`")&#[6-S[
MS/_]X'_X6;.V5=PRH;F7U\`G5UT7+*,4T0#5:Y`D6+SEGQ___O9__[NHW`<E
M!6(."`,45CQ_AH>(B8J+BW89+!1K`WN4E7MK>"12D9:4=U2=E`,#:W=X+!F%
M=HRLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<:V/,DH:Z&A=RR%QLD;4G>3
MEFL_+%:/>,RB5#_7V.$H,-S1Q^KK[.WN[_#Q\O/T]?;!&>*=5'??EU(9U-GA
MT<**%#P(I4A!@2Y9"Q()44@!A>V'E&T9Q"2[Q[&CQX\@0XH<2;*D+AXLJ$P:
M=4<*Q&L#`*:3QB.#E9LW,Z9+9I,;"W^D3C5<9;*HT:-(DRI=RE1>"RD_[OP0
MFD$*S!^$W"7;.O/05CM6_%%@F*JI_]FS:-.J7<N6'D$K&W(F8P$33U:1/SU)
ML=*B:]N_@`,+'DP8*=>-?ZR((X75;T<8UZB0*%NXLN7+F#-K!H92H4O*(?/N
M&=!XL^G3J%.K!LQ#3(;7CCOFJT2%A9C5LQXARH`#5I`-AGC3(-$JME<4KU"R
M,&0%1E?ES&$8XD%BQA\>,(#CWLZ]N\#K1$?RL$)QP)V[WA=EH(&CQ2$Z*MRW
MLD(G>(\,+>(SXNT*!7)7.+!``PLLT"$1(CR@P<(*)!08Q`KKH8`&#SAL@(-U
MZ66HX8:!\8#'2L\8Y]T,.RQG2`LXW&<''71(<4B!]>&PA"$L]/8'"M31L8(=
M4K#(`QTTM/^`@H%_!*&C%!72@4.%-](1Q!\Z6G$=<0'20%!]AUC1&PM(\C`#
M#D$LAP,)3Z)@(H=HIJGF4>-%]0,)Z*UY"`Y:SL#E'S;6^`>$=$1#(1K(%0BE
M@'9H$N8*R.%`H1UT+C0@A2P@1X,5^@6'`QU6H/%'58JLQ\(.?VRP0F\4$HF&
ME'*FJNJJ\XRW05Q;K3J#"D!:,4,/_PVZ)W^(:(D"#FCL0`,*3\+0)7NU)CHH
M#=?A@*P*@GHE(`O$$9@(D@8AMU=]]&D))*O@ABLN,0X1A(<4&XB8'AT;9+`"
M-#P$X2*>A"AJ(YXT[D!J"W001P=O/U['+S=/5NAB@27\8<=3J`;_S`,->_W1
MPTPZ&K*"=.W5%P0*`;4`ZK@@ARPR+`3-,8<`8>#PPQJEQ,FAEH9HTD.WANS0
M8YCS2HP""33P5J"$./R*8@N3SFPE@3^2T,,&/9>P`:9]3A<@IC`X">$*TT&,
M;H\K2,%##P7R`.VD+&@W\MEHB_O("F@(X#82+T`A"@P!J<E-<#,\35QP=$AW
MMR$SL&@=?6*BL$(R]54MI72IC#<#"72X1WABO=*QW(_(6?'D'P_M/`,/B,8<
M=8%2\I7VZ:BKB9(U`]2!Q-L^J+&23*FS8L;FQVP@7^V\]PXN2BJ-YKH`2!0O
MNWD19!">[R>BROSST$>O"`\35=)Z\<5__R`[%7NI*_WWX(<?,@\;4%0)%#Y@
MOP44I$70E_CPQR\_N"DU`T4==<C!/A<,>3___P`,H&9(X(].C.*`F*H;F@K"
M.>>UBQ@XHD>NKG,F6S!P%G^+Q4.",4%>=%`1-U$/-`SQP,2@J@4CY`4/&.(\
M77!)(?X3((<^U(Q.K"$(+LN0%4HP(!J4@"AT`N$':[$0MR0L,5!C!:<0825$
MP(D6090%#A3X"BRY@GJ^8)85&;&-3M%@!0ECCPK^0`)G98!I2NH%X5JX"&:]
MH@4SFP$;%>$2&7)H&37$1A!`LR&?_2AGBGK0#@J!HL.M(($*69#E#!0ORQUB
M2"P@VN:X!`,'/?]E4ZCP$37Z9:<_0(,^*RB(CTY$AQW,H"I."M6EL.2L7Q'I
M9R>Z5`L.^0@56`%R]3F<(0SW+[J1L05&(E;D2G#(OAB)+U+8'.AV4$M4T>=)
M!7(1L>@4A)X-B3@KP&$IZP87&!C);#W:@!V&U*=EOD8B&6!156BP`6@<DF`5
MBQGH#AF-R/U!!<:B5V]@,"0YWFN7+0*+CT#I22*1``4;*&.`B/.@PX%2.C>B
MP0QZE"OZ1$V5A^!G.U_9(J)AS8X:JE\>]<)'#G6%7S.P4L\,$3D<:HEG_-K`
MK]8CA170AT:'0T,+2A"-'@"D3SW$DX6H]TQ?N:@WBD)4":Q@4Y:BT#__BK+E
MQ-C)4A@-#:FHN@^F-#<#AFBJ9_<*4K_:D\Y/$6T]&["E2R[BLY7NR0HU@EEB
M)M0>K)9@&Q<IFXM4D`%;6JXYAK@(H$CP48E0B%(H>MI-7*+3$J"P002J&H%P
M``--W8M.*J6B(@LQK#*!<DR[>9+14(0"*QFH-SVPP["$%I\I6@FS*)H7@<(V
MQF;%"U52P!4*[("&BRBJ!T3#EZ)`JJ'9Y-$\<'K?23Q0TL)$ZHD_;)85(#8J
M3*%H3RUXVJ^<QU-]GHA91I+"I`:$@]QB:TOOQ-.OI(`&GDEA=U:0$'T(0@-'
M#M(0=7V-DEHT*4.H8`::<A><L+,"OMJ(4W2J_\]"IAC?/PRH/D^#6!#*Z\S>
MK$<35>7<I<2K)S,%X4OR@E80[+""IN(77T7\0W?+NYQ#EJ!'-2T$ER2Z1SP$
M+C&7$M.)PK2<[G*.1?@BFB/I\"6F57"%$V[0CY>#(BE%+D922JJU@K8<3!EB
MC\-UHQVHT40HL5"X3FX!H*Y$7`UY:!P&O`-98NB*%O2A#Q%@<UKV$LK@XKB,
MD8*9%4#5&_^@A*IBD^Y_8!8@+O&@!%.T6:0\]@>7M(>I+$;!*<7+G`#5-51T
M0$-`+HLO_T`K4H4P@X+J0ZU0=HT$"BJLF#1'+YZ6C;12&I*"X+0#HE3-DR5&
MU10W]6DS$><^/5,0M?\8,I#21F.*3[)R</FU1P<KB5HPJY&`*(2GB?ZA:E/D
M%PDUD0HW)O;$,(IR'?N%"!;7-"`PJXE.\83@@2P4#ZEP4D""Q-(@N_&\<ZH;
M,/%$D`D5=8AE7DV;J%#`2^#A'(CAQ2U1@9D@]8:I,7,)'7C+J!L=]0_,G'B`
M%*:"%<D45?[!4^=4C+6^:8E31%84>3<0N+WDQV((U6*C83`S)`5'"M:F4WP.
M2B,SM4>GO=%BB?=VGQ]%JJ_K@5)!(,<0\E*(VC3"@1TF=J]3Y4`*CN420^Y)
M-**1^*95>SKGWB4F0G:<3H4>#AW,,+/>K%U`_)GBQ-%PXY`W^DM(9*F!?LW_
M6Q0MB%BA[-F\,L#3`-FT0%-,)MWEU52'3SBEB9$(7&O+'S2LB.A=M1'4;[2<
M4W6M9X';>L#3,QX4X.$3HZ`"'B*0PY/`!C,X6LXI:12Y0XH3.*A`B2?W1.Y=
MVBPQT3#=,P,K.77.WIT=36?D2&1E3/<3]RAID78&)B421'_$S.D3B]PY@_"N
M(,Z[O`Y?6A1[,B8&A>JDGB//%*\=2.E,T8R^0Y-!@J'!X/=,9M'>QI.5,PV)
M8ZN$.`F$>RUR(?_28NY'/IY4-]"P'!F`(9J@$&041/0A!0,A./$R'3KB.4X"
M%N45?5XS0D."<SB"'*^Q9VGT8RU0-;D"25BB@(8`_WZ?$GLL\E2CER$$81,L
M@`<6T2YR=H/2$RT=P0(8`@P`TQY`*#T.T1/-=1+*E83C$D*6L2!S!(7,PQ7!
M\&:MUQ9F@@ABI@+#=1QQX37$L#NX4'^+`#JS@'U%T@HHP$-49`O#]2,8DDV+
MP!"Z-#T?985\."[CT0=/-!B^Q411!E',@4YQ2!!>88;7P3E^LCN[,Q[_I$"1
M6`B4Z(B;(C#3X1Z*F'`M0!2?.!T5MRE!$!MD(HF:N(FJB(G3P3EV1BD.J`+$
M@1B(XPBIJ(@WU8>Z&"Z/,!FI^!>6\T\J4`C<8&'0IB@UU1<VI2_OA0,[8'D`
MQ25I-&%TDDZ@I23.$@T3YO\U2D(E=-`#HP(72H(D.K47P+(-P`)79[0DZ`<F
M30(JOW(I41<TN@$0G#,A-/(C&W<I0:(E[8%X#[%WP&(C/(,QC@4YCY8B4X0*
M2P(72T(M.;"+$KDJ7#$#6OB#)H$B4Y0.+-`#V<8L)*!8`8(D58$TF:(GM68(
M.@4#6`,A1Z,DMH(&MT9D+(4<#Q)E-T4#8D`@!]@G=_5L-M$S+9!.>%=3?Q4T
MB9).7F8QRS$@>Z$IU[9%091@?Z`@5G)+O:$08T("H-)\+,(00.(N>R)>XV$@
M-3(>/*<0[#*1;+DJ!6$%R=,63E)?=5,(*Z0@R?8E,%(@T_8T07,1F^=VEY)J
MU[;_))N"`^^"+X;@6-=Q1(5V:&_59\6X$+]"`G8P8=!07L@A$8JR(,@"*%6F
M'4U4<RN`(2EF$XZ9'2IF.%>VF5TR9,<F$38U)H-))/%E(%9D..05AVW9F]QQ
M$V:8`:R'D22A;:,R)X9@!A#S.4M%?IJ66PW2&WR2=YYT<2@4.@:"-8JW:8<P
M1NN4&/)B$_4A46Y7*$:R#5,W&0]3-8XD=WO"`F,4?=:A'TE''T)V",ET'=#R
M<#4E!I*T'$,294H91#V0;Y="#3A@!M79>3MT(!*1E/_DFQ**&U;0!^GB%<FP
M/&CQ,$CB1KPG(1L@+THB$9A"`W;``IKR*Z5U71CVGNIE_R!H4%Z_54;KL3#0
MN)H]D%)E9`:]T2!$XTWX,IM:(B!(0J0283,VE93#8C!!4$TDA$_91@3.,UV5
M>6@T^G"(@IC9U"))"B6'=&"1(Z660RP;\S.V9&GD)"^3D@,--J%NFAH9T""W
M01AVDG")$4D#47]]01"*.!#7H3N?PXG1(!\HX1XED#?!`0T+0R.'@$)V.4*<
M>!VQXAZ4FAC.<:>Q$D(;P0,#$4D*0X1^4JA_<&,(XJF<,T)V*6-UPW*2^J<M
M0*B6^`<*ZDFH$A=FL!&:^DE[2IQOVJMI41,`P*L;$C!,H26,Z*O(FJRJH8A,
M\1K*^JS0&JW2.JW46JW6>JW8FO^MVKJMW-JM3>$'X!JNXCJNY%JNYGJNZ)JN
MZKJN[-JN[OJN\!JO\CJO]%JO]GJO^)JO^KJO_-JO_OJO`!NP`CNP!%NP!GNP
M")NP"KNP#-NP#ONP$!NQ$CNQ%%NQ%GNQ&)NQ&KNQ'-NQ'ONQ(!NR(CNR)%NR
M)GNR*)NR*KNR+-NR+ONR,!NS,CNS-%NS-GNS.)NS.KNS/-NS/ONS0!NT0CNT
M1%NT1GNT2'NS(U`%(["T3LNT4+NT53"U5%NU5GNU5OL%4ZNU68NU6,NU50"V
M83NV7W`!9<L%5<`%:GL!7)``7,"V;%NV7R"W9FNV"6`#0&`#-N`'>LNW-D`!
M;4L!!D#_`0E`N!1@N&X+MV^[N&][!PEP!VV[N(H[N9)+MY:KM9A+MIJ;N7,;
MMC$PMY_[N74KMW(KN@]P`:=[`:BKNF5[NE\0`ZZ[NJ?[`#&P!ESP!0^0N[J[
MN[S;N[Z[N[C+N\'[`,&+N\:;N\6+O,2[O+A+!%]`!&#P!6`0O6`@!]1;O<^;
MO<Z[O=K;O=S[O=X;ON`[OMG+O.9KOLG+NW>0N^O;O@_@OO#[OO(+O^U;O^]K
MOW=0O_@[O_P;O^LKO[J[!H(KN(-K``5\P`2<P`:LP`B\P`[<P!#,P!+\P!,<
MP11\P1:<P16\P1C,P1K<P2#\P2+LP21LP"YPPB=L`29@`2Y@_P(G[,(N_,(M
M/,,F@``U?,,FD,,ZO,,VO,,^_,,];,,VK`,WW,,Y3,0ZD,1)W+1+JP-,R\1*
M',4Z,`)+/,52B[5WJ[=:;`-58,`&+`()$,:J&P-DK+IF?`$Q@,9DO,96Z[1,
M_,9-*\5R/,=TK`-LD,1W',=UK`,(@`!\S`:`S`9/,`(-,`)/(,B&S`8-<,A/
M<,AL,`!0P`=\``8!4,DA(,F8G,F9?`)\<`*>W,E@$`(A$`"B+,JD?,JF/,JJ
M7,FLW,JN_,J5[`(6,`$N,`&T+,NT;`&PO,N\W,N^_,N_/,JG3,J2W,A$\`1"
M0`3)+`0JP,PJ\,S0',W2/,W47,W6?/_-SRP$3Q#-C6S,`Y``(@#&X0S.XES.
MY'S.XYS.YJS.Z+S.[MS.\,S.\OS.\QS/]'S/]IS/];S/^,S/^MS/`/W/Z"S#
M,-S"+"S#+5S0.4S#"-#"??S0$-W'2,S'1(S#.1S$?IS1?.S'25S#$TW'5$S%
M40S%;VS%;QP#4SL",9``!J"W,K#%6GP!!L#2+!W.8!S&"7#&9KS&9%P%*'VU
M;OS$)"W2>US4=VS'11W%@MS-A/P$#?#4C?S4BNS43MT`@.S4`Z`$K0P&)Q`"
ME*S*7+W)7'T"7#W6J;S*J8S*:%W*:(W*P^S*LUS+MBS7L@S,=GW7>.W*;;W*
MI'S)?-#-*K#_S<H\V,G<S(2-S8B=V(A=V"J@S('=R-K<S=]LTY1=V99]V9B=
MV9J]V9S=V9[]V:`=VJ(]VJ1=VIH=PRB,P@4]PS1,PS4LQ`Y=Q$/LQR9`Q+/=
MT4+<Q[7]VKO=T10=Q;4]TDR<TCZ-QE4;Q\.MNEGLTEO\TC"MMV#LQ36-TQ=`
MW3K-TRB=W5@+QVS`Q$\=`T\=WD\=TE7<W4W;W>;=W5-LWG!,U.A=R$ZMR%8M
MWE0-U58MWT*0U;$<`"[`WY4,!GP@S);,U5[MR0;^U6O=UVG=U\.\U[`LX"Q,
MRQ,PR[D\`7E]X1C>R@(NX`W.RIS\UY#=V(^MS81-!-#,V":NV"J^_^+4_-?'
M+-GD;-HR/N,T7N,V?N,XGN/A3-`RW-`*#<-"S-M!GMNR?<-U'-R[/<1*'-P3
MS>3"/=Q7G,8ZC=-A[,4MK;<&S-PVX-PPW=(R_<4S#<[6/<;:[;51^\8*T`1-
ML`1JW@!J+@0ET,B"'`1-@-SMW=[J?><DO<2(+-Z+[.=^#LCVW0"07,JMW-\G
MS,J&KN&AS-8*SN"C',J2#,TTH`*5WMB2'`)J`.F6',L4+M<!(.$9/NJCON%O
M'0``#N+;O.I$\-?/G.(I_NK.S.*T7NO0C,R-_->3K>.\WNN^+@)C,`93X`3$
M[@0<P`%I<.P1L.S,G@(1X.S,ONS)GNS%[O\$P3X&O][KJ)W:/`[D"CWD$/W:
M$LWDO>WDOEWN.ES12-S;<_S&5SOE5.[%S\W<:;#E,E#O5I[3XDSE8JS3:HS=
MV.W3`C^U,=`$R!S8B[P##:`")5`"3PTF,:#G$C_Q)6W'33W?X1W??BX$@BX$
M\YW?4!#*9;WH_HWHK)S:&@[IJ_SA1,!#-!"C2U)*E[(D/M3);AW+$B[7$S[A
MI-[S&2[,`O[A?\T'@<T'K1[8RUSBS!SKMM[T*Y[BW2S)NY[M5%_UHST%4W`#
MPU[LQ\X!$>#UR^[L8I\"9%_V8A_MRW[L3F#U-_[""NT"#1W1/B[W#RWN$NW;
MM)W42X[$>7_$3N[_Y.Y>M=EMQO%NP&*<T^!LY8IOY3;0T@8@`HI/V?SN[V3.
MQF7.M!?0`"70`R7PS&B@``P/`8VL`D&0^12OYX6<^A.?^N)-R(%^W^+=S`R_
M!DK`UFS=Z*8<RRA\RY7,!P].S-#L\DMR*3M08AOC'V0*)'+0RG$MX17N\]#_
M\P$@]-V<ZZNNS8V=]+/NV$[?_2I>_<4\]6P__N1?V<*N]5O?]<H>[6._`67_
M[/!_]FG?]=A>_J8=PZCMPGT,]W`/"`B""":$@H6#"#J*)CJ%CCJ1DI*-DY"7
MC9F0FI:2(Y]5H547H3$7IZ@7"0D&K08VL*^P-K*SMC8BN*P&JPDBO;VI_Q>F
MPS'&,57(HC%-*B4])=$[/3U+/30T.V@QGZ#=W^`C#>'DXN+C#>GJZD]L0D]"
M)4U+.SLK1_AK4"'\_?[__0((###!A8N!`=0D'/B$CHJ')6@T08,#QPXZ*X($
M.2(%A<>/*V@(M%!P@LD))"T@7,FRI<N7,&,B#"&09H`0?'(^R<EGYSLB/8D(
MD2.$B`JC0HT^7,JTJ=.G4)N6<!:UZL-W3W8^&>!+A->O8,.*'4NVK-FS:-.J
M76OVQA2W69S(Y4`W`H<(>%-$T)NB[]Z^@/<*QFN7@Q.VB!.O=2'(8&-"C`=%
M/F0H4>5%F"MIXG0ITHA-)D*+%MW9,RA1I80E4/\%;)>K6+1:W9J5R]8%5[Q$
M&/@5;/5J8<>,)4.&[`(-(=#>R1-2!D(1>`HNC*CB;;KU<I_0C>#&S?JX<^G8
MI),W;PF](RC0PUC/_J,^?S<#@J$)YJ9"?O9M&G11<"`?.D&48%1$352$`QT8
M!9%#1Q\U*,4*`:AD$DG\R63AA1AFR)-./67584\J/!'B4465>)525J68XE14
ML:@B4T)YV!-7BM5HXXTXYNC56U-,(9<3=-5%F%^`%9G"!GSQ15AA=.GHY&*.
M[6="9%,F@HB5E`W"F2*=@(*,).)]TLF8GG1#'6K#"*,*:[ZY)HL!I&R72QJV
MU#*+FZW\4HPQJ?"9YBG_P05WP3-P7%/"#L\D1YXQTR$SW9G64??-.-R@$\IU
MG[#!ACPXK)`#/@TVR!X,*)!*JD?ZS,>/JO'%A]^K-L6ZTGX`+A41#10=F&`0
M#(;JD10X$$1202K=Q(=1V.!Z#0U`9>CLLS5MN%-/U&H%(A\AEIC4BU"Y&-54
MX#H3;KC<PIB55C0^J>ZZ[*XUQ@WO3A$7D$':M:22@"%9I&!Z$1;D&.T&[)5!
M4[I0B)0&$\S8E:-50N8DVS710``(]-/$$S45(40#53QLVC=G+F-***JUQIMP
M,2000\6:ZB#;;+;HQLLJ:08:*'![HGQ!$T5``(<0192``P1EE"!$/$U(]Z@W
M_Y)"NMW3DG*\W:5.-Q&$K[Z.NEZII[JW#ZRMSG?3V/BU^NK8"&4DH#.X5G01
M@!IA_6L0*\A1DD$"R9$L-KD:6!$-?$`K^$LAG+#AX1QJM>T32!U5[K<0M2CY
MN)-+_OBY.J4K\.:<.QEOCW/5NR2_?_U%).EXW?5OY^L>S!C!EL4NNY:"8$;F
M=EGU<X(\#?0#00_<C/G9\&8^BAHQ:K;VVRG#B2-1"0V\@IOTK;`B@IHU9T^,
M*7PB#Z@Q"M#@<PD0/+&$"F7T<+00T1F/&G7<5"$U=T\K4__[(UP@PM4>F:IU
M>UTC%08:])Y5F>UL`6D5V="VP!5(@478*%!%$*017O]YA`0HP&"#5D`$_DQ@
M($*C@8CXYK>*4(19@TMA30R'.)Y,2ROG@D=23(2BQX&+<CBL7`Y91"YO.04K
MZ.H*ZX9(Q+,`;`R@FU>0[G(O(SFQ7QQPBX_JPD2Z`*R(.$+`9&9W)<M8X(M@
M#*/!N"0\^?6.'T6XAA#X<0((0*]CE@B'TY8!*.RA(AFC(,XQY`<]B7"/-;6A
M12P2$)N9+4\U=JPCGQ3@##A$0QXE@(/XA("#)B@#?Y<,62F@!C74>`D-^_L(
M`$<E-U^]1U7X$9NKR*80!=+DE2M9$+-4$$$#)2@'_).;%(*@@H*TD@\T"($%
M"$"``-"@A'Y#`^!4""T6MM#_A8D+BA!(A)2B/,XI.]2A-BE7.:H\!7,S$B(6
MQ\FZ,9CSG$AT`@GH);H(Z.N)?>%`$!30!!HTX`DC>((ZDO:&&ZR.G#7*TNQB
MYP)B&O2@"/VBP[IT#C8&K0ELA$<)'$4.2;GO?<5!A?(,V1M?)$T!LY"!#&;S
M,IE-CQ<<I1G-L,<]$30A4=$X`@VH@8TEO,%1HFC4I8@#OZG9[*<D^T$HL=:>
MCZ"GE/HX`4!>:1,&UN2I,.$5#1Y"0HOLBB,?P:`&4;!+(JQ$`6@8ID$MT+<=
M)!.%S,00&)X)3<1A;ELC4DH-N97-&XKKKC=\9#0:4->J8&XKX@2H8#TWAA\9
M5@%C_UCB$MUI.L!XP`,IX,`;+O8$_""`8A0+`1C`P(:LB*,)0#HB6*XX6+*,
M@`U<K)V6Q(K0UAY4H0\S8^ZFV8.+%0XY);!H\=YWO%&4#!@HG=XMW@0S01;R
MI-5+Z9H2F29Z5N,:YJD&#:+Q!@7\]+K#N:[-EJ$`$2@@EZ+R%:B.ZA'ROD>I
MJ#Q@".X#RYFX)`0K(,$LJXJ@C%RM(UKU51!HH-2:J``-!3WH,=UV5A6DU4+.
M9*NT.L0X;#W$*"*:X5Q5Q$-QC>N1>,5P-":G8<N1JRE$^*OF2DO.W>Q&-[HY
MH@'&L&(1L)BT(G@#$CF0!KJDX<8<&$,,IJ!8PFS`=(]];/\$;F#;LAUD/T>^
M+`+`H`/./J$)\/+*;@`V91=;6;2"74<D"H&(13`BP*X-\VOCJ`/B):.R)VCC
M,^X9@IX!3[>1NFAQO-<FX.+)3K-`+G&3>U+=!-87K5DN*JXWTR6\=+]+F&X#
M4/`#[08JNX[>KBE$(-2KD1=K1QUO>C:-GJ2BDE7ME=53F^J2')"@&;1LFU7M
MF\O\?F27NCJ0@;!QE)P,V")G]>J!WPN&!"N86CJ10X>`DA5J.LZ&=MUP7I>M
M869W.)M\=8J(`TOB(9Z8RF&I,CJW?1=XIN`-I[478S=`;G*GP`-N0'<$F@`&
MO`W$(&&,-Y(%HH@G(-;*7CDB.JW_O&)SDE,[Z?B,EQ]1"#$;'*&*P$[$>G>"
M>."@!)4-&O2ZTS2,$B./R=NH</$,BY':P.,D=1.>6+$*W@!C3<MS:36:T`1[
M2%<B0<A9I&>NQTOJ3ZA#)6J#+HTU?<20#THM&]J:2NJ8Y"`":*"JJB]BWZQF
MT-4>Z=0*$$2'M[V-ZEBO.AU,6`*6'.3=`OEZA@K7ZS0#_=<NU$J)9#C-"$^S
M7'5]-@[UNFP+9].;3`$G8`-6Y6J;Y<1B>7&_"]MM#V3@\(A'?`1TX((G_+C<
MD.^+&R;/@28$`,E'1LD$7DN`>']Q/Y?700.^HF\5;UNT^\9RP/2YC@;$@&.1
M&,3!9S]F_S')D1F]DR@.*BO1!BBM&V4^S?M24>==K.(U+YO-2)>?9SLA5WG0
M[PW*&2DTZI;`/-CH+G`BO2>9/_H8NA'J=S>=M9V7$E5?D.'/<\*J@1#=_2_)
MP0:2GNI<5=V^O2(!U#U"A_-[1$%TLP)3)X`$2'4X,%6MI$*%4SAI=@)EAW8O
M5"V,DQ5RI2UTQ6'-1G=TQS9VIX')=G=+,6T"`WA^EVU75A;F!"0I<'AF(`8M
MR`-F`(,\,(,9T`##U`20%WE)8`56L`$V"$::IWFL=7">9P$(H#\GN&TI-GBH
MYV^B]0;L,@[XU'JN%SQ#2'NSQQABT@G&T``J$`+PT`,*P`]/0/\@F10*9=(H
MQ\`FO1!<TB-(U7-\)U5<L>`*)!=]>*A2!O!2.+`$\F`-"S`53?`#:N(]W/-'
MW:,]B5@,MX%SXZ=S7>-_**`/1R$B$R@C9\<'J%1TA),#5H`#;*-J%!0W%[1_
M'K$"6*-5^L<>+,`",."*6W6*!"B`='`-PN8L:K"`O;:+#:A@$;@3(:8"/:$M
MUG2!%X:!'IB,RIB!VM04,K)WU09CY>1BV)9OU`@D&Y`!,=@",]B-,\B-W;@!
M!64!.V!N2((D29`"2;!N$9(20HB%8T5,PS2/%L`&I'=Z^'AZU(AZ7@&%3J(.
MYD"%KP>/!$D`"'!1QY,.63%-2Z```2#_44DS?-_3'9Y1?'*(?'&(A\6%&WG8
MD2;C4M<W76A`#5-A;]=3B'^"/(CH?8SX1S_`8E]A:>57*G(S0`3T!7E7%.N'
M.&NEB4ZU$A[QB:%H?_B7?_JG?PT"7@V"03!``BS@E*T8E5(YE;\RBPAR@'R0
M@"R1B_TP'TK5@&G6DX<S+6-9+5AA34)Q;"O2(LX6$78W770'EQHHEQNH5]UT
M%3$$C8CACT\R9:E'@NLR94QXC1'@!N#8C7%@!XD9!XS9F''P!W$`(010CAN0
MCI:9!!NP`^/X10>U>03@F07Y6BX0`]:8CZ:9CR?HCZJI&.A`A:Z7#F`6FEFX
M6^Z#>\7&.R'0_P!"(!&D@$>G\!F:P@8ZH"DC8'+'1W)QF%S`]1K&M9%UHF<D
MQQO&Z0L_0`/F@0,*H``[L`05H7U]4C-K.',YDY*[('X*T"NA8BI<@P(80`);
M$XF3"`5RA13@!&PM%)9I)G0XP`,MD`&@>"MN@Q%-=T%/ET$;Y"M:U92O^(I3
MR0(;X*`.^J`/*I5-*8M5=X#".!!<R48<VH!EYVLM9"TQ1!031F$7EH&/1)?3
M)9<J&A$N*I=L"8(/YB$..&)?@81%5'I**(V!>4YIL((MH)B,>0!$VIAV0*1(
MBJ1Q4`(!=@25:04[B)F:V7DD\9G$!)J@*9NO%0.GV:6G:65\^15AFO\6`-F:
MK7>%6BIF+G!1M7D!"ND,AE9LM44*?Y0`#1`)P<E9(]`:&T>'R^=QS"=2PT52
M>N8*TWD;;Y`%4Q`$-Z`1-_"H\S21X?DGS%6IPV``4V``."<"YZ>@7/.>-'F3
M2U&,>=E6]PETO4@#&<`#=I`!.\`V$S%!^+>438F4'P%>^85!3[FK#3JA$@JA
M#;J@&"0%.3!U.*!,PN@/&QITO2A-(89VPW@N:KF6)]J!'I@LMY*M*XH-+IJM
MR=B,*O`.02<0-@H6^G.N1#1X3H":ZU)8>Q&#BGD`?Y"D]%JO1(H#8F4!3JJ.
M4`H#7<<?[C@L:7IP+G`!7GJP7AIC8JJP:-'_`.+AFNF```.+A1;`-+R5##MS
M3]'`<NZ@`DF#2,3)!J<U`F"P&VY2)[<@4BH[4K+!G(,*&X5JJ-/C9ZN1G3MC
M4>F0-`U@23'079IZDI9:J2ZFJ;OQ`PH@-^I)2@`4JO'IA3`2(J7*(<_4DV!0
M`BW`F*WJ$`!Z(/9`BJ5HH*YV-1JD00KJE`PJE;^:ML`ZH5%IMD?I$3FP=3C0
M`\G*H?R0$ZF&3-?P$-#TBY8(=S&JC-NZ-WOSHB_*K80;#72I;);S!.-Z>6!4
MKEZ!HS=:(U`XIF'1A(5E6.N*CRV&@DEX@DZP%QD0I/9ZNO:*`R$`9D%0F4?2
M`PS``#40(4%8I1-K_W!L@%B;FX((VZ7XMII@<;EE`;'K@*:WZUH(<+&\=0KW
M)"(J$`/MD!7>PQI5Z#USR'$7B9&M\`,_:[3)1X?/J6=>D0!3@`#C4`5-\``!
M1P2NEYV9.@4O";1!RUP_D*D_ZQ5(NY[^XS_KB7YXEW=YB8F(XTPT,`./R9@\
MH+4201%,5T%+^;9;%5\$^K:[>K:]"J%6`*%L.Y5FNQYOBP)T\S?)RA.T)*N\
M4D'&JDQD"6S$ABTEVBT6%KAZ1;@TC*TL6L/<^JTER0="5X22:Z[7,[E!K"XZ
MNKF<>\2%M6]G`7@I&`%68`98$`>H.\7T&@"O19E'``%>D`=#L`7"HGE6FO^E
MQVM0+J"[ZWK&2=R["7M%PKNPF%NFK3>08SQ[.J"\3I,_K[>&=F21V>NRRA<!
M'T>(\-,`#W`!A<P-!D":!E``M@!RA%J'SW<88!`#:("$0O623F``::"I4X!B
M\VNI(F"_]WNTI92TZBDW:_`%7NA#(2:B9+G"AV.UCWD`C]D""BQ!]^>U3X>4
MKH:*N6HJ9AN5$="*$BJA/4AN&@RLK1@!K^B4[HDU#S*W4Z5T%B&`%:014W>A
M(E26Q5:,*V*7BYNB.#S.XWPKX0QA_34211A&/XRN04RYE+N7@5=Z1US/G&M.
M@/D5VC:Z*0#%5/S/20H#%A!@PU0"*+``9$`&+_#_`C6P!5[LF29AI6,\CV3<
M`#)VQFB,QKR+T6E\L#(&,*L9IF$*L:_7`!([>V*\>2HMQF)6L;V%,J60792:
M<7R:O<W9<1_W<060!C)0``40`3+@!#8@5-O["@]`"WT`J#D-OLUW4FD@`GBP
M8G@P!5$]!B]YU9B:U:=P2)^<"KHQ!?A,:=Y5?J#*O^IIDZ22RGOE(CH9P.L'
MRSMPI$@ZKSS`2P3"P+N2?Z4"P:<(MKO<S%/IJ\3,`CU8V,D<K+OJGK;Z*R`<
M!%NW+,>4UR",2UIWK"7@5L-&K3*\HH9+SIY=SL^J2BZPSJ0MN=H7Q-WE%=&A
MVE^1VHD1ID5LSS0VVS^B_\0+ZV).D(TM`-"\C:1,>J56"@%A4`8^0`9<3#00
MP``3<A(3,`0L79`F$0!#4-$?S=$9G<09;<]?>D["V]T*^P9O0+SI8+P&!]&M
M9=YAEKQ[Q%-S1@K,A8=NZ,<=]Z<VX-,][=/V+5(%H-\^G=1)O;(KN]1T*%P]
MLF+WR[U%3;3C*VB)%!T7$!T.C@J()<K<ZQ4_($HT22KN"<S\B^'HQ[YX%R.M
M_'/6PF!/L`.G6]>P.D&[XG1'"742S)1<$\S#/-C%S(,;P(.%K;;"W,R>ZBN[
MA,U;ITSUI2#$BL(7FG0A"KB"R]F?_>1[<Q2/.]JD[7F=1Z4_+,3H>JZN[=HX
M`O_;YV3/<Y$&AA76HS4&[RK7O<W;+3#:5CHL$-`!8:`'9.`%-1`&3+`$+R`0
MSOU!###=`QO=#!!@!A$"U[B[97[=&)WHG;O=,N;=YW07XMT`M&?>*GVE$8W>
M8>8"))-'[:U1H%YG;'B<N''3\PW@(M4'^+WJK-[J^XWJ`"[@A!JS)B86OA#/
M80'A#^Y=O%Y="@#>]0O687W)SYSA^ON>IVQ*7_!ACD.!;OU7?%`"+("Z*G[7
MJZ811OGB!1KCN^S,KHBV&/R@/$C8.4[NRCR5/O[!<X-+M"BWDGWDE8T&E[U@
M.>'-W9)LXG+#4/[9E9C.[5CE`!^YU`86I\WEJ,TY85[_VRDHYMN6VZ6[YA!_
M`"QPY08U!$(0!G/^`73N`WC.!+`;NUM0!"^@W($N$`Q@Q9U'$SK0!-B-Z$:L
MZ"^?Z`>[CX3G3FZ@C<0KQP=WZ6'\F56*WL\]T*/@Z6DR](GD&Z..G,+5R+#^
MZJ[^]/:=WTX/ZP$.,]13J"AFKJ?@Y4+U!B_Y.3T2]F(/.ID:U0=^*F6MM,EN
MDU[CM$Q1%#%BB20^C#A@!3Q`[78M$1/4M:VVBJMHH"C`[1N^'M\.[N2&XSJ.
M^+_:H"3`S(J]V(R-S>U^$4;.58T]=68E[R'ZPI&35Q:F[_N.PY7(PV%'Y0%_
M^@.=Y:W]X.[<VNS"EPA[SW/1_\]J'O%L'@0#+583P`!;<`8"H`=Z\`%Y4`9S
M@`$>_P);``$^`P'/#8\D,032?:4!<$8-@%ABCL39+?L=;9ISL0$W/P-F$/YF
M(-YL`-T]_^81+=&M982EP%.]Z=Z^A3W0%]\PT_1=`/7XW^KW?=_X#0@R!3*$
MA3:'B(F*8P9C3H]I3I%3'!$13B13)"283E.?4S>BHZ-94UE9GHR,!C\B02@H
M)"@PM+4PN+BVM[>QL6M?*L+#*D1"Q<5/*D_,S24X&V8\<0?5UM8\024E-&@X
M.#MT*T%!4KZT)#";M;,KZ>@H+"3R+/7V+!M6+$E6_5;\_O)MP'>O'@P6!W5M
M\F6.7/^0%2OH2!Q7#D7#AQ)QH"G!IR.?)Q\_*B-&K(0*DRBWJ:3!LJ7+ES!;
M"N,#)D2``"Y<6-C)LZ?/GT!SNL`98$`"$4B3BE"PE.D%$1<4/)W*5*G5JUBS
M8ATC8@Q7KDB_>O7J)$(*,UBNJ5W+MNVU."U21)BB(``!"P0(3-BR)4P'/7K(
MZ#&B04,4#&'@+%BP94+>QY`C2\X[H;(+QP$@A'BBH`&;$0K(/AI-NK3ITHY2
MCW7TB$.E%&XRF)D]NX7M%@URZ][-9C)ER8XG6!"N5V_PX<4A[W2AHTJ,"U4N
M7(A!';KTZ]<37$C`O3MW`^##*R+4A?R@`@6ZH%_/O@`($.[_W[=O+PB]H/N%
M"*61L3]"&O^66/)?@"D4*%>`$7!``@>8@.+@@S<\F$6$$YXRA2<&3-%**Z^D
MP\N'N>C2RSF_?$%$`\00(0P13["83#,JX$!"-"U,XU8VV]#0Q#<2.73..ILL
MU,XL0:J#4$'X#)2//P#UDT0^!-6#PD/CF#-/D"1*<00Y$44T41`YQ')11#MH
MQ)%'';5X#$G#H'222BMQ$].<+I7`X@DVX:034'SVN=Q0@!(UE%%6386=5%55
ME113BB[E:*-:1:K46$E]U957'%AAAAUN=>JI-7'8D<$&''B%E%UV33`$`PSD
M,(<>9?A`A@8.&(9!!V&4P8!COO4:_]EP`0@70!EPA-#`&S$\T4!HK)WFK+.I
M.=&L:Y;`EH%LM-%VVVR[==L``KX"5UQPE0U'[KB_(8"`<]:UVVYTV&WG70+A
MU6N#`8F0=Q]ZZLWG+WKP^=O&(-+^,,8/!KR!1[4I6"'&PVUDX,'$$QM8H%D(
M(N@:)P]V_$DFF41(2A`WD$RR*4[8H"$C;QC0X2Z[A`@#!B'&[`LP**J0,TDP
M)@,-/IKRP$.G/$B1HS?@B%...;&L(Z(L**S0BSI&SH.D/ALTR4^3_20)`QTX
MR+2-%+E`+:9%7':IM$5G8U3F1FB")+>*)+FITILT<",GG3`MP\=->OHIN$\Y
M"6IXH`@4E?_`&TI)=9WC4$D5>517,1J5=)!*FA7C8EEZ*0<SI/7IZ&W%80:I
MTG:E>A,6`+XJ`PMHH`6LLV(1A1$+0!`L7N&&6]GO$,`11AA"A*8`&\N*]NSR
MSE:R08'79FO&;=3;-KT9WC800V[@^HYN<'J9>QQQO%KV677/89=^O/+.ZUV]
MX"EB0WZ%I,>OOR"TD7\;;?@W!<(_>(,"!H@#!>S@@#N@B$,>XB--D*!:&8M@
M@A+$(`B!(D(=$UG)-DB*CWEB91OZP0U$)#.:S4QFMJ"%"E$`C!.Q"1EK6H8*
M>G``*VQ@`S,00PLXY18[&(T;:%@"#GH$"U\`*1U(C(4[BC0/7"#_24DLZ$<^
MMO8/*4;1('3H0=Y,(@P<J&,AYY""0]0F#BTQ34MN^\:90M*BD;SP)'"$D][X
MUA*3@"1/0[E)3@;7I\+E48]$`9P@B3(`$3`.*8YCGW2@PDBK,.Z0`SS44S0G
M*<]]I2PS:`'I-OF6%LS@$I3BRAO`@I,3-&8(6RB!!L*@A]D9(0E,Z,&N>-4[
MWTT@`$4HPP+"P(0%-.`&8^A,\IK%/-,PJ#6OL5;TJL?,VD@O>[JQ2^]XA9S?
M6?.:E3&.JD*`E`1$)P;1<0XXH1-.1;;O??023[[H-Y_WM`$`\(1G_WYP@08T
MH0D&).`!B^A$>QB!!48(J$#MH8LM!0&"_Q*DH((^&(I/8%!DH1A%1$EABD]D
M81,ITQ`>&N&**=A,9KDP8<V>!@QAH&AGPS"&2E6P@@.(H1\9J!$UW!*''W;C
M&^$8QQ&8)@M<()%())`:.I!(#WL,)$DVU%H5_6'#&Y(@BRS9AC#00#6SL0U,
M5!*'.-C&$(R`#6X@21,?D,&FE,@Q1WN+B0KX$((\]80`@,OC'@<7J$$&('&)
M`QQ>[\I7=1GE#8=<RN4D^;C+#5`I@%7`$DJ`O.HPZE&4S`I9(F`%!UR!DYSD
M@15`&4I+B;(!F=$=`XI0!`UT(%:#T0!CAF#-6DY&5:,EEF*&U\O0"+`!Q6M-
M\YS`(-?PUK=I2/]F;&1C&QZT(`[3,"XSM]6"ZV$/FM^RI3;+12YK#J>:P1F"
M$)2BG>E0Y[O/@1?[M/,^=<YO?H0X3P$\L#_^N?>]*?A?$W)SSP$>D`Y!.`(M
MZF&$*"1A!@">C09H,^`""QC`,T@"0IKV0(U1D+<9])A#&YI!4U34$S98!8?(
M1D)<B!2%)Z39"EN(4I*L5$4M;8$59",T3]DA"WF[:=+(\2.G574606`'U9I8
MD!L";4G\F,%2^0%%%D1-(WD[B1>3&,8Q=@DB6NIJ&N&6)I`(PXUMBN.;X`03
M.[)5CWMZ:^MN@L?`]<2/@+S)7O.JUS:K"P$F,($.E#"`A"V*?8F4W'7_&,FH
M`2X!,'D(-!N$T(#+6451F</**)T`@PUHH`67O2QF>^C)%#!H-:M1G2@-V80>
M]``"10@!`WHPAS#,K@58,(,18ED&"+3Z!:Q]3#9I*>O*,,#5<)@M;9FP`T>\
MH0G*PM1OCSD:UP37-1P84($\L,QIQ.'9T'ZV<I?K7-I`-P;2G&;X9EV9(0RA
M!K'^G?@8L`6L:`>\U8D7>;L3O_VD3!)IB'>\`]2>/KR7?_%M0A5T@T\#)A`6
M_OSO#*;G`#-H8`8'O]U`!1H%`!^\,+-),$+T6PE+5&)C#)40*"K:4%%T'(.G
M0-D45#:&C;J,PR+],$A7[M.2FO2-Q5A32S7+_^(_>*JF,49:.,C!4UD@\8M0
M@X4ZT(&0@SPQBDSMAY"I*)`H%3T(WY""/-@11C%2R4MTV"F)R$&'MYUI;F-]
MH5GE&.,D$R%/./'37>!J5T'M,<V"9'.;^ZJ#.,NY[GC7@0X&($+`"C:1A8T7
MHIXR0`4`!C!>2+P7\D#HJ/1Y49`WI.0=>0,.X%`#5\A\Y@\@Z4E7`RYR(;:T
MI(7IKCSRD3OX-`-<\&T-S,$(<\!"'%)M<,/`O@-PB-4+7K"%6$,&MGS)I6S#
ML$LF="`'J7!"9S@S!F,C^_F2^.U_4C"Q9<HTVMA'+ER$1NUG0G<$M>1V=8=`
M!EF!N[JPK<$6$HV4\?].\BH(\THC1OX(&\B;/X)(00'T[X$"N'<*(M``^V9/
MA7=`XQ`/`)4$#5=[,W`[+(`!*'`&.3"!9U"!$WB!&'@&-`-0"&=P"58+%V5Q
M%21A'@-R#_50%G8A&+(*/_`#6<!R,"A2*G0+:P`%)992*R($=+,#!\`#,Q!3
M-M(I?T`"+8$T74=C1F1C0C(E/W<E1654`\$D511D3')%1U40!]&$6>)D$[$"
M/8<V9&(F;"0'.BAV;[)E4G4G8,9':X<7:+=7@?)'<Z=78!``.A``8(``>:=W
M<]:'>!=G=38*B24532`=A5A8CH,HB-($AZ<'BI=X;-!OC@=9B"0IHS0&,Y+_
M!+2":EB`!9+6>:23:IN%;,]B*JIC2*(D0#1@$]X&!PXP4P<P>UC0`@Y0*QH@
M`;>7&&50!N#F>Q,0`G4``;OW`L.W2[25!0QR`Y[1!)7W?,Y(+69!?=%C7-F'
M?7:@?<D%%\55(]93;<_5+=N3&ZZ5'.;R;3X@*T/@!2]P3=^V>S5P`EG19X9%
M.8KB"B*P(8V0(38`"?,F`Q%0`/^X'FV0!C_0!"/`;PI00."P`OOU2@@V8`V(
M$!6(`1&Q`%J50"N`@1@($1E)@1C``@@'D48F"QB7<1IG01'5,:;`"2JC,ODH
M`KN@<B4TDR%%`BYW@\.@@V784G^00S+U*5,@)SI'_Q$]YR%&N1#NL&-&<A`1
M<`\^QC5"MG0V)$5*<H7WD(54=S96QY%=(@4])P4Y$`1=)X9LQ`=E6#=FE0Q_
MLX9\!!2`4X=J!DB%PU=XB`!Y"`9Z)V=WQX=]J`1[:7=VQW>D<`.`)4"$:(B$
MA3E1T0.-^(AY4&B36'B46!6/)'F'!%@1TFC_51B=&&F@2%.>]&"ZU5N\-1J9
M-@:5:9@TP`#>Q@`8X`"B\WFSB`6%87MS@"O#DWN\MP7!HA<O((S$N(N)D6O%
MAXS*-V@*<&S(%ES!%8W,1ES75XW5F(W&I5S3MBW9`EW<XRO@,WYEH`5E0`8U
MX`4UT(NJ,@$,4`;N&`!/8?^/CO)WAH4H"<`4]H@PC>`5^Y@R\89__QB0<J$`
MVW.0RZ)/"90#!V$$".9P9C`#1H`!9W`$%0A0*V"1WY`T'9D#'0D1%;JAW[`"
M&AA@9A`%*'`$E,`Q)&A1*-EQIP`RH^&2&_4#,>-AN5!T,2@B+?1&*D(W.W@`
M?T!<?P"+;3&$16BA2,A@5;,.L9!C/<5C/:8D3*543!6%3E</37DE7S0+4I95
M74(B8#B6..`W3R`'RD`W);$-1/!E>M26?#1(;)97B<.7?&EW?*@$>D>G=%IW
M=W>G>0F(8S"8(S.(@X>(F!,#98!XBI<'_59XAW58E?B>BI84@-6GSC-PG=B9
MFU?_#9$V>RK&`5,P%KLE>JN1FHRC`$V@`B$P!!`0!9YX#5?0B2U0&!(0!1)P
MF[@I/+OXFQ"P!;<FC+N8:[FVBQ```3UP`\JG+`HP;,^W;,WF;-$6B]*97-DH
M4]RXC<U5K=:6/>'8&]Q)&=GE`]\9GN#F`\2HJ]Y6`^JY>T5@;DXQ>(CBJ/<H
M`O$W?_8';_WACP7@!#\0`R.@+`2HD/L4#_V5H`-&&X?QH!!Z!DI$!Q0*-CC0
MD4>PD1RZH6=@9#EP!H3A248PHI1PHB=942#W,9^`89W*43`)@R:;<KG@<C"G
M`CJI(CP8!RPV-)[R!U(PI$-$E#5&HT0R)3ZU8T]8#U%X_T-<0T5$UE13>@]-
ME)5L`Y9I(PY>R*5<]U5K964BP3-H&C@Z(13+P4=9&V9CAH=M%@)@,+9]F*=]
M.`)*@+9U&J=FN[:`66>H0%&H@`HFDUB&&4F#Y6>%&FAZ,*""18GO^5B"^YZ5
MB128>0,SXG"PN:J7-8NAV:F/Y*G%]`B85IB#2`-"\`(=H`&K"BJ=:(NW"'NE
M-CRDJXN[>+J]*CRY!P%"L`4A<`*WA4\WT)S3)XW0R:S0YJS/*FW8B(W569W8
MF9W@J!O;HVWD8JZR4JCE::ZYTGM;0(S#V`3P6CDB@$^.QRCSZ2BN$*]C0'_[
MR!_[&0$BH'=LH"S]5D`&&`\"A_]@!E<;#N!)+("P$8BA$ZHV7'F!%GB!70<V
M"ENA%[H`!GH;_P0#0<"Q%E)1*8C`!\P)(IN//^`A*T>C,AHB*%N#.(D,.5J&
M+QNSHT.$+.$-]U6D0=*$0X<"3OL07FD15N.4431%2[543:</2,("53IU6)JE
M]LN06RB6;^,W9SH2'8%'.Q%77BLX0A%(A6,!<X5V:F:7N?$$(S"G9PNG>2=G
M=QIG>8FG6%QW`T`A-S`A8#RW8ARW00"H[*I8GP8!^`19[?I8D;<YD#IYAC1*
ME9<UE(IJCTN8B(6*F+8:I^$5EFNYI%H"/6`$L*D6E5H8LBJZMUFZI.NKD"P\
MIMNK/5#_`O,U0&41C;8[/;C[;+&HN]();=2)C=-*/=KB7-HY7[RSK=VVB^47
M*ZI"!F60&"_``#7@K;L7`E7A,O79?I'4KNZ:C_>9G_0Z!C'`!NJB`T]07PE9
MH`>QO@L:S01'/3,0OQ-K!!-8D?T+-F7BH1IY!"O@OPLP1.*P&'2`@9F4:@PZ
MDA\K81RW<0?\,2VY,@=3LB%R)/ALLC*CLFQ"-RTB0SPH*M(@LT+HP3*F-!5A
M1#V[A#2P)UTK%$,1`A^A`A^,-#A01$BG#S:4)$?5E`0U=3['$%/2M!'!5;X0
MEAD!5GR`)WHD'#QQ%P$@MG&5=@ZMQ'%X.'+Y=C=1AW!6IU&<_[9Z"IAT*J=V
MFL6`&6=O)D@#@`=B+`IC3`(7=5%!$K>$69B*.D"%*+B40X^3R<:3EYJ6":ET
MG(DV)"V!%=:<<XE]O-9C`4Q]*@IOD`4X``%S0"NQ*9NV"'NXF(N._,C#*3Q,
MD"MET`.SQ6L#]`8<4"##51O:AWV@',JB'-FC_+NE+#W?F!OAN#W;HP.L_#NR
MK`5D(!AD4!D^D)LO4`.[=ZL0@!0N\ZY)\0._/+A(X0H;XA7>FP90H0,N@`"[
MC3SWE#1A`I(@VEP=2(O+%07Q"[!1HS86V=SB(($5FY$2.$0-6R8=6J&Q4+$L
M@,<`YH`P0*(&C*()K`F:4'\:Q2$R<_\D":'>-8H+%@QS9+JC/&`&0`BD;!$'
M!@W""%UC(<)D-+"U2AS@$!W3R[P#4O!`&V#"I?H$;<4')>`-.HPD$9"%\@!&
M8K*53Z;#32:6#*L"+?T3Q3'$-2'3<HG3:#9(@++$@H2G.O#3>BFG+2[%1PWC
M.L#$13P`(1?&7SS&43W""S&W)&/5EF,YCT)X7NVNC@+6?@?6<^P5P*3DAAOE
ME^)9;-VG;ST*'-`",``!84`KAVP-5R"+AC$'KT?FC=S7:.X7<)"K0@`!NT28
MB+O8Q=7)<6!SD'WGD[U]VT>MUM-<W`)-\R6.TS0$P1F>HCV>98";Y^JMZED"
M+O/HTYL4CL?_U8[:,AK&%0;Y9F\V:#NR`T('S;/QONV[7*:<L1!8@?F;S=(=
M@1]]ZA6IH=?]#1#ZL!BP+0BF8%+RSARWZ_#\SH\P<IW*"#^0WDZTWBPGD_R<
M(BEU#"[;@]?RDYUB!_G-(SB;A#:,)0V=M0)NTT*Q&32@`#/2#PVS`5.`!D]0
MAW-UQ!+]!-V`7^A0PFUS=5IETA:!TE_U!"Y]7>3STJTCMFT%ES,MAW'75RAN
M`G)H`3.^EWA:U'<G9TG-9G/5)TO=U'$KQE#-XSX^U50MY$W!9U/!9XZZJ'%<
MF:B)FI;)Y%!^F7/<Y)>HUJM1Q\\3&]6PY1@0!5Y^U[&(!;7"R+=7_ZN/G'N^
M.CP=@'M%(!P,4`(HL`&Q,3W1"=F/?>?3V;M"L^>E;*V7C=G:HSU-@&V]0BY#
MX`-P`)[B*2OBF>B"[:V,[@..CC",`^FN$$E'3MOQ5T\ZP-M)'0+EVP!+`'`(
M"J)F\+[-51C4`_BV,9NV@=PH@`$Y`($1N($!2V#M.[`)]T_SJ^H=&:&F?'`)
M]D^4#\\>\\X@>TPJHR$M*`+&KMZHK\\F=*,O5(893`0+<``M\.Q!V$/3GE,B
M;&-`%PM-\-`Y,0$#CH?+K`!2L"16D`+D#FPAL$=%3#@N(-$JX`U%9!$&Q9%.
MRZ53$H9HP`<[X=)MR#O7%0`G4!-UR--VY?^F;=?$1ZU7>[+%?;FG@*D#8RM(
MS=\G=X'C4<WC^@_5_`\(65DDA(0PA22"-S=OC2(*"B(7D92/EI`BEIIO(F]C
MGJ"?HIRDG9FEJ)EC$1LI'BEN&1D>&;`I$6X\<0>Z![X'/6$:#L186+Y7!\98
M#AIS<QC/&!T=<&5A<-9E9=EAWF$=9W`O6P$3-&8MNG'L[;Z[[?$'\?3U\;KX
M<?GXZOTM_RW,"#33H*#!@S$:Q'A"H*'#AQ,F#*EQ31L9'V7(D"E#;5L9C-M>
M0#`@PH"!'R9%_,CTJ)*F3`IBC$#@P@6"FS=#L&'SI`0.%$9F")TQ$"!`#>F,
M`L2B]-\,(RQ@P##_$B6IT6$:6@S3RC6K@W]F-$2)FB/'D;)GL@)T(%!HE"0L
MC"0QDFB*W;M3LN3%2\)NWS1.IMB8,F8,R:A2641=#(.QU,=2,4"&L>:+BLN8
M+Q-1L5D(D2>;<1QH,2.#&1YV?JE6S8,$C==H<."@LR)($"DH<I,XQ+M0;CK`
M90M'@Z8'FM=-8N^@(V7WA@TL(@1I\B1`@)K8:UIPL=V"]^_@703@HV*V[16T
M:>/.S=XVG1TXT/#Y3L`"@0GVP7L/`"9$_Q``@L'?@`):QQ\"`2`(QDTF-.B@
M">(9"-Z##>I@87\&:J??AAO65Y]W`^`AR(@D"I+(B">F.`@B',#0XB&%_V2Q
M"".<1#*)))?`Q)*.IH12V`VB!`G**3UVDD(+&;B1PB[JO,-.D^S@8P8[K+TP
MQS#-.(#%%7$LPY0#41@Q1P?3=."--B&]L`TVWC`Q31@>+9#$.O.L!L\\\L!C
M#SMV[%G//OKHTP\/1J5#$$(%Q=!$`Q<49-]#]]TG$0/<"%"&I2!IH9$W6GSD
MZ4<CG60222N=A,FI"C3Z!!LT(9B33CH](40)2ZP`0Q(S("705VMIE12O2P5;
MJ`:Y6J7!L<=JE=6RR_J*U+%)A376&3F@4%53;!$[`UQR044""GKUA=<4?95+
M+@=..#'8%`:,\<,/BL7;F&+S-I;89)!)M@84#?]DEMEFG`EQV1.BF9$!43ST
MLAIK*+Q&0VRSU18$>X5`MEM[O4&V6+PL/.?Q<QVS0$(0=.!``Q%\A!"`!?AQ
MUYUW+G.X7PA$H+'<"BNPQYX40:`''QHGV(<??MX-S3++_B7=WW\!^-?T33I0
M*#6%%AA(TW<X)6B=>#'+S.&''VXX0%XGEDAB(BH2LF(A+7*PVXMMNYC(C([D
M6`DD+J'B"2-C`+EW8:.@,@8'&?BBSBX'"*0.#P8+E'!``F5PIR\LU(`!EL=J
MZ2538HUIIC<>A4X1'-]X0V8'3&`#!PR(JX9XZWKFZ>?L@.*CRZ!Q^%/H0;PG
MU$2C`4`:T?`,8)1--MS_:`%Z#<IOX\,+(*DY:DDHI013HR.P:M--6B.PDTX\
MS4H##COD`$,4N@*KE%=&,<54"^_WV@Q7S2";;*[-9H5__ETE:RA235&*&88"
ME1F\Q5M!$!>YQN67-``F738HC`'>P!AZ6=`QB)F,9*12&7]YT#.<N0P._F`P
M*\Q`#$U:V"]X(`6'*8<VMM$9"@XA,AA]"P6V>LQN2+"Q>$''"ANP@A"'2$0@
M0D<Q5F"!%-#SFA"XK&M>VTX(:,`<&:*@9^^)#QB(]IV609$_3C.!#A0D(`10
M*&I3>Q`:J]8TIVT-BE&,XW=BQAWLA,AL9QN$'M%F(D2P+6X<>-''-N"B0"KB
M_Q.<R-&.(L&24HSBD9X0TA@DYSI"M2!*`Q&#+#;IADZF(`4;$$/K#K``!G0`
M*YG;7/V,\"8TO4!-'GGE-5)G.C-1PTQ1>(<N=_DZ/-TI=K/STSIJYP]+&JH%
MO5-(09K@.S8X9'A#B"8#8&DI+<!!`*3[QC7@]#Q//:\')#%)]6+2@)UD;7MM
M9`/X3B`K%92@!#U8`OER@(&@_`-8P%)+`/?)J[!H!7_X(XVREO44#!B4!?5$
MG[*<U95>M8`M#TU'LPC(@J',A07@XLL""3$%#@!F70;`PTGDU<-Z5?`Q&WP,
M"BI#A!*XTX,`>T((1V@&(99&'7]0X0'LT((6PD8V,/^<F&X,P9M#8(R'/+07
MQQ3S0R$FP:E%#")TCKC4>.&0#J])V<HXQ+40X$"H.W//SX)VM`EP9V5<9-G2
M0L`@$]RD)FF,JUL14"`)R?&N^JEC=O9:D['I$45X7!LB!!O(M[GHL!P@I&('
M&4BW.6$1=7.)(CNAMTZ(XD@\D,64$L990C&.4&800V@UN4E9=-(-S\E`"U2S
M!5/:;QC,8(:RHC`FT*7)(]IXY0NRR01JD.Z69JB3ZW[QRSH5%YC!C%([]G&[
MY@;P4`=9U*(4I:@&N.`^TF1`#6H@2X_`*1L"*)UM??`\C+Q@">(TP`7&6)-6
M)0@!`%+G]]@@A%F5@`8]B*?_/!=0/A2PX%K[A)Q2W`<_H_`J6<2RWS]?JZPS
MG`$&3,C!&3!P!B,@F'_+\B<`>:6^@&BK@$,Y(`S`92YQ_06"A&'7#:K*,9,J
M%5^/Z:!+/>A!F=+4"BDPH6IYD--?],D78FC83V]FF_6@P!`[]`T*FB.R&B*U
MJL\!HA6>.N4J"Y$%0.P85>,5`7I)Y<CL*9E\T%J3`)R`#K>1(19_QH<W7F=E
MUZE)RYHF()O(=6H(TL$;NV8@)X+'0_F1HU[Y2FCL!.".*OHK'_W(:!*T#9!P
MVT!B83#(2C?VL7ZKT4L86:0>.6$UH2U*0$0;N=)F@+2Q2)('3@N+#"0L<4-@
M`!->_XLE8C0C"A)HI348,($:0&`;R"L#!+;+#7#`"1QDHE)QA?M+=SA;V<F]
MQW*5:[O%-051"8D!=9G9!#9$))HUT.YV0;(-;(:7=.$-`S8_\LKGJ4D!(XB!
M>K'SJOC"Z@E%J.\[7Z/?_<IF`2N@ISV;PA0S=)C`2CGP0)F5JX#FJBLL8()B
M<L"$QE2XH0C&^%K2@4^`A$4H<(E"B+?EK8QRE`01^.@4U.6N,;!XJ2[.($IA
M@(%]]0LS-_<7$4"(`SMDP&,F/$T<>IP:7]C!#*[Y:<1B.%0:[G#$N0G"9"K(
ML:EBN8A#3()40\;4I3YYASJ3@A1R@#,TJ*#-?$"S#'GFL__X5(=K;Q8/R^HX
M`36L#$(.\H[4;&*@.',(/_6Q#H:VZC7M%)JO<8XSU^#N`K^:Z/&/;[0?`WG8
M0B*V18J==*4M74C"0#:1G$XD*B*P&AYH,M2B)2UI:;%)TKHB24HZK1M$NUH6
MQ#H,Z(L"^FI=/PEX#AO;X+6XN1NZ,L`R#+V]!C6,L&Q>&M>XQ_6EG_KTIT#E
MXQ^W:PIT#>*[!G";F4^02#0GLMUV7XH;R,.FNL'K/.B]THDUT<%VX`LK^<K*
MOO?%[Q+V[^\%X,#_`/=@(O=0VC=@_Q`_]_0/S*(_"38#`_5P#4<L&"!A95$M
M#O85#(9A&N9Q!.A0`_06%35R!C3_%R.V-E,@`RA&&`:P8B_78AMC+S#6032&
M&3M7@^5A!S/P,59P&CRP,'^`)#[U,+*Q`Q*C&T?V=$9U0Q/39(709$OU0QN@
M=4\51%*695.U98K194PX8C<4=6R',^B!`[5A9+CA'F)6'1D2=W$V9W='(2X`
M(0AB5UY#-&'3=QFR(8=G:(RGAA&RA^(1(HL6>8(E>8]F>2T2`91&:9@G:8NU
M>1N`6A]S:8N`2*)')&_``:MA!XQS:J:V20:3`J6%:K/`:K$G"Z*4`Q.P!64@
M`1*`:\B2)<T@)K6%)D/P:]M0`WF@)M9@B^A7!@L`#JNU2\RF2\#T?,@5;?8`
M*`#A64;!_SN)PBC>IR@7<`+BYP7;-6ZP5"F7T@W8=$W64%ZZ16\!H`,Z401L
MD&_XQV_])AP+`(#_UX[\52W_916%<G#[%!8*MC_V$X''LC\S0"T4)V&Y$04+
MQ2P%N8'-TF%701I/$8(B>$!106+I`D%CP"Y!T((O]V+Y0AE0,(.;48.>(00$
MPP-)A(A!I%H+0Y)6D`%")H1$!E9$)15*=D5'!B.]X81/V'4>@V4ADT18&"]?
M9U0[<T4]@QZT,89KMV;QT69]&'<N8%;;,0%-HWB+!T=SR%76H3+6@2`:`C-[
MQ8=@V90!X%9O2"%^%2.+)GF$T%A248@FF5B:]S&4YH@?HW4IH/]U'A,!C34%
MGV<*(I`"*9DP!M.)I14!IJ9)K>8!KP`+G;1)/+`$L58&T2`FKH@Y&L"*TW`\
MUO`"0_`"';`-PT9\QP,!LD0Z&F",PVB,T'9<TT<[UO>:@W)MB&(0C<)M(2!^
ML59^T$-NWW5^<&!-L02.+[`]`(*.[K1O^)5?_"<<_]><`+@#\%@^9U!1^E1@
MZH-P"(B!70%0#9A@R.)PQ'(&*Q!A9Y`;&$"`#X=A&LAA!/@5^31`3Q$40_&0
M%_4MX](N4X"1)&5!,$AS,=:1.A>2'ZD"H#&25@`CJ55)0-08&1"$$!-41HAD
M,@EF.#0Q/"-VN$&&39<8^OER6IA4%W/_0QEJ&T4)'+6Q9&IFE#A`'5N3AFJ8
M(=F!5UVD'UQD5GT6ATY91V\6EM=A`N_E5D!:(6HD1CHP-H&(-FKI-H48-XAH
MDG.96'09I<]QEU(8B8&$:9]P`RHT=`E#F(49BJ85"ZL6>V[`>J:Q`+'V`N`0
M#<_0BIDC%F)B)L?3`V7`7;]8#<;G:Z0S#L07!AB@;*@YC,?(FM*'C('RFH0B
M*)P%$,[(3-[7!-QV`>8P!%XP?.ZW#9W2*992;J%#7NQ&#FV4;^^47Z3*?_+$
MG/#X;^\8G0!'3Q65#O%#C_&#@`3XG=X9@=R)J_U(+!%7@1/&<>EID!BF<<\%
M%A\FG_-)GU`Q_V)2L`AXX'(=NI_]&1F4\04[%S#72J`U6*`$TP(;4`C/X0N9
M-0-6X!HXT!PST)(/6H1@9@A.UH4X<%_[EG\.@QP0,QO`8:(2`U9'Z$<98P@4
MFAL\<QY&B3-I%G9*V01MEH;B831$(R%I57AF54?;87@OTV=6TZ*&IK%;Z2`6
M$C4@*T9IA$8-<I9[-(AKJ:2[47F`M%A0*J4P^S%*D@1ND`1X^1R%Q0$]N#!<
M:GI>*@N&V8F=1`M*X@J@Z(DKD*;;1`ULBCZW1EMR"GQEL`3AM@!NT@$+,`X0
ML`!UJHO,UTO1IYK/!GW0%VW4-VW7QXQ*,9O3M6T-,`35J%UDT&[DQO\-F!HZ
MG6)\NO4"`!("]J5_2[".S.F<J@J/[0B=_)4S&#"/!]B!!59@V:F`I+&KNMIP
ME=N=7N%/!?:=!5F0S=)0$>6>C@LY0B$7VI*L!I2Z;W%1S.I?T3HO_(E0D+$O
MW$H$`TJ@,O4$!8H&9K`!2\9#JS4#0AD$KT$'*-"@+@14['J$3I>$2X8#?18@
M)S"]U#N]?'"]?*"[H.$OR*ET^!I4MV%D`CNPM8$S^1H$.2"^5[0"RV$R?*`A
M1D,?^3$@;P0>+3.QV(&_?`65VV$@"[*5#-L](NNQ(0NR2H!&!6PA!RRR@(B6
MD^=HAL66@)2(C#B7,7O!4YH$=]E)-.LQ.ZO_&CF%28/II4=KBK*@F&'J"F5J
MBF(``PR@7;^636LZ![NG`49@!)^SIW"BMY)))ABP`"_0`Z\$!Q@P)6%+C,0%
MJ,7(FO9PMO20#["IJ):$3,E47;79`+AYC=Q%;GF;J1C1*>8EG`P0`J(*3_$T
MN*C:CLYIN/R%N-`9<`\V<+0*N?O4C]S9G4*A+;MZNMU)/Q'5CQJ7<?EC</<4
M+0FG@!\8@J>+NB(W@G,!%1@%N]&*&#*G+U`@D@5*H+B;N]K[!#V0`3`@=B00
M7!N@HB53O$'4DD,(H>VZLC"R,]#;=WW['WU[`K0,(-6+O=A[`GT+('#&3IN1
M?P_Z'LMAHOEZE!8Z_[YKA@9-$`)EE1^1<C0L8V9N%*->F8=[=;&"UW<(XE9C
M2;)$"K(Z<,#D/,X?JP1W5K+DDC8LXFB&V):(1<$8/,\>`XD:K,$<[`;!Y8.8
M)`;^_+.AU'J;1`N*>5JK5EHS\,*^AEO9U`$T+!:XEL/6`"=Z`)IEP`1&P`3"
MQ@U_.ES/%ZC1UVQBFUQ.3&V!$IO+R+8*L2@\H0(AP`#2M%US"SW%%Q+NAA'F
MI5LU<`)%\$YFO'_->:IH['^K>KA&O0*MZE\6QH&-^[CQHYW[B,=2?;EY3-47
M)JR=FQ42%1!L(;H*^7%S@;HSX)!NX18V^\@<VJ&2C"^TV\G:^QENK;MH</^@
M/`,#?V`%='`<KQ$?K[$")&`%4Y"\+TDQA/"N2AC+T7L"NUP@918"V:O+NVS+
MTSMX(6#+O7S9UKN]P@PQ1)C,*(I%IQP\CP+-'!(@?0NCB%=F?DB5_9N5UH%W
M;V@A%6+.Y#S`(7M&`XS;14HV2,HV[CS!<'-8BB7/]#S/GW3/=UDX/+M<H?:S
MC2G0IC:F99IJII$!K<5=V:B983`';HK#WQ!L+U#1$)"+R`,'IT1<J`D[Z;W>
M]E"H]5#2TG;2B<J,A.*,RN2H(5`"3;`$1"C$VG6I=UL&8-QNNO4\U_@"10`!
MHZJ<I^I_0IVJ`,A?1@UP[0B&$Q87]-C4[_,^!Z;_QU9MU5.MJ\CBN<.J%O/S
MN0'$81\7GY8[`RL0`F0M<HV\NC?<0VKM&/[9UMD;UW'-!SUPH+;1`E:P`C3@
M3C0@=3A`,P2S`4$H'&C&=-\2DT)Y14G>1F"0O9CATT]PO>/!3CRNO3O^V"FC
M,EIIAW9(Y@""Y26`!FB6H5$7!&@0`L31!,$#-M+LL!;@V`$RE1P;(2[:=XQW
M5J[=HQ;@L40JI+(-SKA]1A_;Z$I@I+W=SO`,W!1LP<5MW,B-SVXP2L3U!YQU
M>IJ$PJ55PJ:6:BN\:JU66J6$W=D(;*2#`>@C`9^C.B&Q$=^``:03!;VTWAY-
MJ$R\FB0=W]>7.U/,J+.9_Q#EE-_[O0-!D`5'M@(E8'[%9^`OH,75OEU;L`4*
MGIS*2;@/_HY%;;AO7.$2-A4$&1`:WM1'P8"4VX`?+A;=J7OR+N^5ZP`...(E
MOG%>'5':5[KH,Q0K4`08D*PR+N,V6^.2?..3H>-;KKL[[O`-[\GE&@16T`)8
M=1DG8]J*W0,;0+P_]1[+BV3O&G5Q7LL[KAD#H[N*36-NS0>*#>:0_43]6V9Y
ME97E\>1NWC-$$``J<!Q;=1_Y$;']FS1.4U=F?O3=3*0+O!]-8V?I?&<%/+(D
MBP`F&^F_'<\3W(B7+J6?=)=>C]RG%8S++9@"3="C[J5FFFK275I)D.U;L+<U
M;?_>$B`FXN41$%#1'-$!NCXY@=KKPQ72>)+>AJI<B'I)*&W?OA,#9*S?_!T$
M1[`;BA$$2T":'C'@6BQN+QQK/6W&_;8$:CRX[CCAT#GZ%(XS%SYP'6@,ZEZK
M[2[B>&Q`Q/+O_ZX!&$`#$%`'15`'$*`"-'`Y^:B>?IRY$*60"5BK`P0751T%
M*"#6C;PM8=(M":_6^4*[CQWQU7_]-##Q+>`:[T0$)^#G!E("'9^\2P>3KOS*
M48<#+B_96.XO7GZ]3T`#\NK3F>'8NPS9*G,T</=F0P,(!`06(40].'1!02A2
MC$$K-`$T.)$6@Q:8F1,6FYQ@(2%@GP%@"#H(J`$(JJC_J":O.F`Z.B:TM"X6
M`;J8)A:OO\"_M+7!Q;"_"*6DNB$#4R30T=$<,##4U];5'!LPW!L;+-_AW^3E
MYN??21LI24GL[O#L*6XI&0?W^/A_<3QB&?\9S&1PX\%#!H/T`!I4^,\-0#?T
M'`+,T(-!C1<8,4(H4R9C&0P2YG0(0S(,'#@<RRP)8R1.G'LO#[R<B2]FOI@V
M9>J<29-G3Y=`@PKE!Y0'4:,MD+9(VJ*!TZ=.8S1@$T)(B24*=@3)@H)$MPWJ
M%FQ,B;&&V2U#TC)86Z1$B1YPX2Y9@@/'@@4XZ-K=>_?NCKLK%OQ=$'A%#A08
M6$31L'0IEA:/'S=VL%2#AAF7_R]CWJPY\XS%43Z+#DVZ1Q$(&VE`*'*"10O/
MC"U;?DU;@QG&E!F;H;R[!>7?C8/?GF'$B.89R),K)YTDBI7BQ5'`8$&]NG7K
MTUE4J[8&RI,G?,`_.<$G?/GSX6EL(&%E`QH5)50\R>5"%[,2&X+0V%\7T0I%
M*`3HU8`P1!-@$#CP<<*"Y#U!A`H00OB$"D*4]T1=:&38!`TE[$?#$VZY!6%\
M$(;@`BX$;*(B+BY,<*(N*M"`AG^*-(*"(G30@0,:-(#1B8J<9)))?;+,8J0M
MM"AA"S'#U-)D,/7I@DLP2"YIS"L(F-"**B&L8M^)N`@YP!@D9"&-5]=@HR8W
MU'CC)O\Z<*K3#CM@P;/.G/"XD00]>\Z0SSU_Y-//1!GXXP%$!V50#T.,#O3/
MH8A.M`$$6UR$T189980I$R*95-*G'6C0DTX[D0K3J:C25.JH/,GDTU"PQF%'
M44?QPQ0/34&E:PA%--#$$COL<$17TZ63A!5'J/:"#R]<=%8`)X)R@E5QR367
M77CUMU==?=U%UUQ+`+9`#F<D9L0,P4$66;JO9>89<K")-MIGI)%&[PS`+479
M8YW)QABZL\76F&Z4^<8NNP*;@=RYFRFW'')1-">Q$4G`(-UU&&NG,0P8<-R=
M>.:%C-YYZI'00A`BQF=!E/8%@!\D_-6UPW^+"`C-=M`$>&/_@NA-")^($:H0
MWA-T[*`M#DWLB`,1,GKH-`TA<"(()BSKHD8`H`00XXQT_*>S%(_LH"./)JX,
M)I@NKAC`D\#HH"3;;%]I`LL(\$),,;-HZ67++8,IY-]_#X"'F=)PP`&:V6##
M33>,PVE..Y!'CF<\DD,NSYYSYA3HGSP\--$\AQJTP4,2$?H0I*.?SL(+E59:
MPQ:57OKZ"R7!\2D3'7304JFGJFHJJ:/6M.KP<>RS4ZS(&U4K4K@NI>M3,8!B
MU:\S'W'S5W6V@T,)=93%^A,(N!`"UE:]%=<2/5R[E_I\V;5##W?U4$+\X1J&
MF&*,.8;%NL$5+!MG`%S,9S1@KWK=_RL*"#R@`&%C&7@!3&"V<<!M\E4P@P$G
M7\&QS0R2P##-1,$,1DC@:")&PN*P8%@9R]ATM@.#CYD'9",C3WEHP`(KD(`&
M\%$!'6A@-FC91P4;V.%^9H0#L0%(9P0:$`D.Q#/TC(A#0)-/>101A)FMH(@Y
MHD,)BH@AI=6%#YD(`"?L`XHRJF%\'>(:S1AQHR`4;4=0T\4$?%B?LX71%Z_P
M!1[Q:`PDP<)(Q``3UNR#@%"``@Q]@]:)`,?(1@+.&6>"AIJRX0U*-@X=<H)<
M]BK'2<GIJ1UZ8H=#_N22S=VC!9X#2`I6"1$/I.X@I3.=HR"R@5@.Y`B4>EWK
M8,=+V#&@#/\F.0E)<@<#-[3`);SSG4U>A4R<I(IXJV*F4&8U%*-8TU9Q6`JN
MGM<`J6"-#5;)2A"&Y15C@<4*&]P!:ECW@B;H($J\HE:UP$67;.6%6WPAS/R6
M4`:X!`8"ABD7"\YEAL:L2S+ZNDV\%CHO!#KTH1"%:$/?%;"`U::@N=&71@_&
MT=<HK#C*,4,48,`PB&TP8D9X#@>/D(/LI)`Z*ZQ&QSX&GI'5M#PG`,,,63`#
M.N10!2LH`1'D`#)0`%&(,I)9(FK6%:\4J$!+/!`=:NJ@)^XGBC65F=@0047]
MK."K*]"1V,1V@C&&$6MES!J,DCHS`$D!;&$=6QSI"*TYIFUE<[3_F]RL)(R[
M84D4?%,DBQQ)V,(ZT@60/!,ULF')Q572<>D`RR8[^<E/0JZR>LJL0W+BJGS\
MP0S^<)0JW4&06J92E@,A"$16:3HWP(!U:XGM6M(RA`D0@`'P$V88F%!,AYC!
M*#<)KJN`LA0S&/>8O`,>-%M5/.0-A9K79%XVG?<\J@AA>N`2EE/#885V=-<-
MR$%!$53P`B$T(7S,.(WYYJF^:^D%+]FZRS[3MX3`E(!<TCE7_M0%&82UBZ(.
MK)>`(TI@`M,K-,>!3;MJ0QL'"*Q@%]SHP2X3!19X)H08EM>]F@,=%`CKI==A
M80NA8*&1H4>GY#D!#69PPQRB`65!(\(3_\"@8ACH9XA*/:+-<-85)D+H059]
M6GS.\YVA?><$(3C!>$(0'OCP)T=@#-(<SXC6)(]OK3,R8A`:`38W&HU'B`RL
ME$[4B5WT\14N$(8J=!%F10*.96%BY"7^QJ(ZK\QL9UNDGN^,6#Q$<DT;:%/C
M+@D.<JA#LIU,=.0LRVB([(D'^@#42S9G!X'\8U$#627H(G"ZB=BR(`6)2&O=
MP`((Q):V:9F`JH7@JPWF(`='2()`'(*H%IB*F<556#NH8P95!8]5T!SN<X6B
MO.C:JGD-&(%3E#T"Z96@">G+BE;&V8UVG%-.>CH"A>13M_%5I4/5HB\][_E>
M;&$++GF!WP+")?]0Q:!+?_P;V&L`"$`*A^;`!<ZW@1&,&7\Q&(+]"WBZ*EC!
MA'XT"<DYSKU'TYPH4*PX,*BO2U,8TXZ-N,@OQ.EY%D1C&EC!IR1*!(E^K*`3
ME"`"=-A04K&HXV@\-6=,5%!:9WYE,9.QC$\(`0V(0//QX<)%5F.&&=6J-;8N
MM1&*".N7>U3S+Y$Y3/4IV]GHF.<[RQD3@Q@$/*%U6#Q7/<]['JS8^9S8:21N
MT(]UTSC*H4E%4[;1H,0<1&PM7.,=X`^=(]VC4K`.B'"Z(;%<2*</Q7="0826
M*S!UJE6=HB8T80=N`.T_1B>0#5CZ'[\=2@N,BYPD:,=B1S@"!GJ=3.'_+7>X
MPG8N-8E2JZ1DDP?+=LH3L/8$[$I;$5G(O9D0O4%CB;<(11`C6N5Y/G&/6UOP
MQ5:W^D*NQ+@[?_OK[V0,YB]W;<:`^M9W"`L\+P?^]]\1_DUO,%CP=&F&I\=Y
M6+T@!QT8]&`'*``Q3#\_4^^(S,0,4A`-2/`>"-%`Y",G'T9%`CO@(42D93;2
M5$_55$S4=#;W@(-T<Q"X"543@3/W0R6094NU93<25W!T`E\"@6.V2(95@F?%
M9KO0=7ZS@GH&=F,G=H*C6&?W6&BW=H:&:&WG=IAS67+':++V)W8'*`?``Y>7
M6I>V#BG@2J]T**(E2PY1$(4G$8<R`X>G#C!@_VJJIFI%<`249UP-`1"O-!''
MM'FZ9H6@%WJA=Q@S`&S*U3O$HWK)LSRVTA3*U@#OY`)%,#W4HQ6Y=SW1X`W6
ME@XHH`(G$'S#MU[G0T_MU1?Y)!A^,2Z'82ZA45#J<E`9!&">@7WYAF'0T8F<
MR'W\9GW_UF#3=S#EQU'#`5+I1QS5X&X(YW`/QP*3<`3480041W\6XT)$=G\Y
MQ2`T@#(D@@/_$8`REAXD@%0'N%1(=#-*%"!@@P,B&(T2F$AVA%=7,T@AH`9/
M(`<10@0DDD:(T#4UDG1OQ"-<!SA99PF8("6--&<F^#?V,0IN1F=?YX(M6&<M
M:#8K4W:',X-H]R;GD/])D^5V&Q1W/GAX>F(&0!AI?X!W+1!:#9$",Y`!Y#`/
M)*`0F.:$GE9X39A:JT4.X[`GF)<4F`<09I"1$QD09J`.GX<":/B2KP9K:^A,
MOO9,S60\SA4KJV=LVM0"S,8&+\)JSX856D%.Q2(.U8`"@.AY8)$#P%<$XW,"
M$("(B:B(R->(CD@8S4=2H4$;\.9?#10O"'9O!58<L.B):.F)!E9O%44;XS=]
M!1>7`E=<&\13#3,#+!"3KZ88Q^)P'"2+2]!2(!93V]$=NVAB)<<@6Q0A)2".
M420$,A8CQ^@A2<-R'-AC9])C-T('TAB-+J@)+5(?+E(UWA8T01,?1D<S7;;_
M`EMECNJ8(EG7"4(2"N?XCB7H0\OP)?3H=?;8F[X9@V;GCS18:#9H3I4SD.U0
MD!N467$G=WNBD*;'6?Q0A`<Q#Q3Y#?3``9_SA:W5A!P9*8#')Z+42B;YD#S0
M.9<'$;.6`1.Y%$F``2[YDFD8DX9Q!#/IAL&#GV\(*ZL7%,HCATLQ`N!35P%P
M74-9E&;R%9CS#="P`]W`A>%P+$<`?""8AU2)/HJH%^&R;B6`&J@Q/X!A/UPY
M`P7%&/MCB?KR/V))0",$49R8E@,U4+:(EA%U+_W6EAI`008S<'.YHQGT40NG
M`7F9%R&:`R7D<"R0/D<P';9XBQR3B_:'F"E&8U3:_R$10B/Q02(RYB#[IT7@
M:)E(U%0Y$U7/V)DVAS816$=S!&>XB8U8PY@_DT.3$(XT0T4Y@B$EX`*"D(YS
M!B034!YA5EAC9UADA#6K$#YQQIM@QV<OTJB"]*@O4G8DL";_"%G6QDF&)CG*
M"5YZ0H6:1854")U".*HP\0</.6H4&0'KL`&"9YVH11`;:5I&"!!60&L(F0%6
M`!#F>9YY!TL2,3JRY@\ML`'R.9\Y$"Q_L0/W&9VE!VQ`D7HYZ1(\B2L\T&Q/
M5Q4-<!7BU!41"E[_0(6>EP75LP*TF`X[0*'J%6X8:I4X(#]"`'S7%:\00`.`
M02X#1:(2U%\G*G!AF1ECV?^B#_6BT!&CMC@'U2$!!*N6#B4O#/1O;]FC/LHN
M!*<P%=8P.;!\A&$8Q?$<MO@K@DFP(?9YA4EBB,D'-,8@278"<HH&8A-6'&*:
M$T(#*+!#7XJ`RPA5,+<S9OJ`5S974B)FI,D,ISDB\($A+=M5CU".-(`BK[D)
M@Q``448(2'9EB2JH5L=(48)(;39F5$-7=B1V^/BU+LB/C-58W1`.9QN0..A=
MGI<=F\2I!<F>S@E>&R2J?_([Q4.=ET9+JNH&VJE*M-:=37@HLJHHX-F$ME10
M&7">).EIDP=>H46$,("&,9FLZ[8$OY($=*=<R\2Y^ZF3<6A-8]@"@C5'WT8]
M6U'_3MY:D@W!`E6$N<&R73CPE/`1;L8'+CWPKD])H5LP+4(PE7=AKP050?OJ
M&`/#4!2&;R[JB3&:&(EAL"S@O-%;BS)JE@_5,+)1&P*SH^77O1+&+JF8'$;P
M5?3Y54Q@&!QD0NFS`DSJI!T#G[H80PS"<3D%(4:#1<.8I1$2LU)0@&E$%UH6
MIF.JF66ZLUG+9.5A(N_A@$`;`-=X-2$P(EDZP5#S?^)(11ZX(WG*IUB'"7R@
M`E2#9)\09B0H)/;(9XS4,N-SJ(+5J(HT-S"<9G(#);R09B<BJ2RT6&]2G&N;
M:-)0+)Y$MT),MZ%J2J8$$\O4JZ;C#MZ0`G]7G8EB.@CA_VEN8%JA5<6L*DMB
M`%K^\%L!@10JR9VK^P]B0(0YP)J"`2Y-X!8-P&J:>VMM2).H)TUP**T`:A3U
M,00O`D[:*BQ9T`UC?%P",6N3^S[`\A_#0@/`-Y6V:WP]L!J[RQJL@60,4!6H
M,3/E,KQ?B5#^0U'_NHD#B[#3Z[PH<`92D",>XA;K>P8R*E$-&S`1IE%R^;T"
M)T$;9!QXF;'U2K[L.[!SP;XQJD(BRQTD*Z7D<;(+H@(SJU1=$R)!$[,(PB$T
M4)DV*R!B&E4'@@9FRC+2`JCCLQ\*P@=B5@?B+&81G$/?""%(4Q==4Z=5I"-(
M$PFQJ8Y!(LZ=8$B@L#?WZ)MGT_\+0X*"8>8E=50?ASK#8*`E>H/0,VP"P#FI
MUJ##U9!VX6"#<H*<ZY$%`+)=QG)9H(H<=,M9I,0#@1(H@S(0(MD0;/(-F)80
M3*@0+3T1A!N&'GFXA%+&EB8&+>!;Y]F1$X'3/,`".X`^:^P40L`&;#`+3[`!
MR!7';2@\KP*MT6K'T=4":",^XU4"XF0F+."MQD6)C$N&9C`Z1W!/8(4ROTN5
MZ4-?IA');'T"#!``#/"[]94#B8%@E2A]U(>\`.M0S-ND&/#7&'`&834%-C`%
M!O`#"N!X5Y6E/;`"&+!]]@(OL;&]N%&*$-M1C7$;GH<<,+`"<($7AJ&7*U`<
MGH>YP-S_I-1;'3+%,2C@0C>%4[U(OV"@S%=4-$4#8P'H?]%<L\IHS0-,I@@B
M@G4D1_9Q'A0BSOLA-+-7J#H'`7SC;5H3IRFS13IBVUVE='@J1D(")!;`!T00
MPH>T#*L@PW-S(GAC`F_S-K2@=<R@"X=ZT+)@`@>=)7T5-WLE-XE%#4[%6(4&
MDFJK:.O155QQ,]21J1R-'#E1`7?+#Y`F$[UZ:$GP*)04`:6S*)\6Q:0C:@'A
M#^!YJYAG7/VPQ1#)JSP0N+'T6[^5!6ULU$?="JC`!DI]M\-CD]%$QZ';>L>D
MQR]RND64H!LPD<=U*TQ!E[5$K`5H12MPUHT\%Y#,UNCZE%$)_P%"0!B9_$%W
MC==+T6\)AQD+&[!G:8L("]@8<,I.D`8_\`.'?=@)H``90D0O&R,X<`;;I^7]
M5AOA=]FG:(JIB'`8@,9G#%;T25*V^,O9,:,J]*0C9LP,@LPJN\SAB,KZ&S2_
M2`D=0LT;*,`&HC/!;<!8TR`1$@!HT`3RH0+074;[87/G'*>,J2WMG'2L"<^N
MR=V8L`DG\-V80)M5@@Q4,@)',@OJ30Q=BX)?@@RQ,`R`="1.PE<+_0KYK0W;
M(6AHZ]\WF$G'20**\`:X=P2ZYW(%OM$@'6FR<I[-U:OTL`$1$.'KP0&J&H;U
MH%H,(7@P34MDK!"V1,9;?)X%M<5>^/];U"H1MB0&9;Q-;.#B!`_C2TWC,^ZL
M45U-4FTK3X<U;H$56P'(*JE-U/K5Q94!+)D%VV-%\H/6<U$"A=C6K!%/UU4$
M;RW7AM$Q1F`&Q<O)_E)O>XU`H4P=@'T&5A`!#R`"-B`#=Z``9_X#(G#F"G`T
M.`0A/9`#BG%O[C**/DI^F(V*EV&+>!G:7U6OY$(N%,,"Z'/:%+?:B!&_&\?H
ML:W,\(Q%7DJ,,;+;,D(7M\U4F!GW;02-G2F:NF`A(P+J/3#J%ZASD<#<1B7=
M1-L?673=Y8@&)3""H;E(X<$)XM,E>7,,;9,W;E/YZOTVM1#L`?W"RVX,2M+Y
MP)!8(@;1YE#_G&Y'2]9>1=.V%=K>AR[GMG:[X.%.A$9A!TI<Q7W[AX4+J[#:
M*%+L`:RTX:CUX2`.6K3_X23N[Z;S6TDQ`SE'\*W`!JYA>D[MAJ>W\+0BAT:1
M-N)S74FS`[OWXQE@\0S.>OA>4!.9!&6R`R%PR$L`\A`P\KL+@F[=Z5>V(`%P
M&HV=]2P`"&8M6(,MAH<S#C,:BXQ1,U&1D)%11I:6+"P8FQ@L=G]_$4T/!G<-
M32(B/S]!/W1T.SBQ."4J*B4+9T91C+TM&K\M#L*'Q<;'R,9FD"PS1BLY*TLK
M"]0X*V=G*\XL2STK,)E&+..9YC`P&.@D:U!\[_!\)_-@)_4A]2HH_W0X_:]T
M-$H(M$601A`T`6DT02.+3I"'*"*B($%QHD0I07`$V,BQ8\<)'5T$./'$%HT`
M:-"H*`DFA,N7)4YV#+$Q!,&!MV[A8(B#SHJ?07Z^ZH>F1,@`(B>X<,&'B`L+
M4!&8F$JUJM6K6*E:$+D13("M3ZGJP#JV[%4=:+->'3"%(@<8;]'!V#`W'-T-
M>/,F2;)AK]^_>S>0>*A`@:P=.QX>.9(%198L%"F:.4"YLN4#?WAH-B/&C.86
M&4*'WA`![V,2&SB(SI#"36@/KD7#7KT:=NL,9CB'CAV:<VXQFSOSR(T;]^;=
MM$-W;J&9!9N7"$(@F*X#1HLXE;$?T(Z=^__V[-^[;X]#OKSY\^1YE%?/OL53
M%T-"""FQ1$&0+'-="](<A[_Z.';T)PAH,[0P`PQ!+!'"$HB5T,.#$/9P0A$4
M5DBA2T4P<`)--141P!8J]%#-3Q@`0X@A)_["R"(SM.C((Y1$<DDYFVB"P@R@
M@,+#%!<TX",1"_WP1BNP%#D+#;?0D(L1+38"S).&#$.,E%(F8^4A&I@113-1
M'/'3-#O\5,T9*&PSSA+3A#-..>:P(!<Z&*#0SA/QR&///!OB:9,4L_2T`QTX
M$632"C@DA,82?D(D140D6-2H1$%IY!%'7'&%U*4BA4"$"C2$D!)!&[84P@EU
MU)'A1G5PY-*F.;7_6L)._CCTD%"S-*$"AY:*Y,($?#QA@5)(D66"6<,6*Y:Q
MQV[5U49+A:766<]&:P);D9&`SEMO;<!"7GAMBU=@@(4[PP:.O5%H"4T@J@!B
M#P6Q&&,H;'#9O`=L-EQOAM"6`EX</`9#::NEL)L'`Q.<W,!NW(:;&`?_QEP+
MO@W'66?*F2&::P*OQMEP/+100@C/N11==-91IIUEXH5G\LKBH>?RR^SU)_.N
M%@3`QGR('H%:$C,,*'/,`*Z'B,4S))'%QXAY$^$2\Q0AA!`6-FTAA5![6`0$
MW^P@XAE1#%C,,!J$W4O8B\08XXR::'*&=:!@IJ,(#XQ`Q`@-H,$**T$8_PD+
M8CW8\FH.3+(8MAD:#%/EE84@KHPS3)Z1PP(+Y!!F-4OD@`'@9Z8I#CEM9@)G
M1#"T$\\\=N(SC^DVY=U//W\&%.B@1<6T4$,KN+LHHXY>=-"DO">U$4@@B70"
M$2'T4-0M)]S:TH0>;5%3`#;=I)#?L/;D4^U!_4F4"EY-JFOR4-7LK+3D3P45
M5QQ^%?[Z4)F__OA+F1#_=-,MA<"E]V]$+45OWF777-XR0E\&&*Z_N($O)#C"
M&YH@A"<((4E-2-=APA0$%M!K7O>RF,:2DYHLW.<N%XL-P7ACL(-EP#:QZ8QN
M1",&%7),8ASSC`8S0+'=\$8Y-&0.#]QPH9>XA/\-UO'.RE`&'I6UK#LO<]E_
M8L8>L##@9B58%V0V,`/<,"<],@N:T`PQPW$=00@,TEJ$2C"AJE5H0D48E87,
M&``(J&`)"\"!B`"W"*\90FPL:M**S%8)3*1M$S"PPR=R!`H[3$$!3QC!$XB`
MAC<XQ"$_^--/:-6W!^)`%XT(!C"H1(Q.*@YQCF"!!BX7IAS@@$$+^$84SL`Y
M;X"#'&PZAUQ0$"<Y0>$$[\"3+NEQ.C"H@$^KLUY`6E60%<1.(?Z@8!`DDKN+
M>$E2O;O41X[B@IBDI`2;2MX32+<A5=FI'B01E*">D!$T&',AZ&P"#=8Y3'F(
MRBLN>0<1GD"3$/"A>S7_:4D`$."5EN0/'^\,0$N>T(1-;>H!2&*G0M?Y`&S2
MH`'85$$#B##/$.@**;K*:+.6PK[P[4\N<;F+2+G5%W`5,`D'Y(MC@M"$;9+$
M@;>0G02#<+(+4H8'M*EB%9/C@0T$X08<2`T)!_::#-PP.6Y`814]TT(:]D:&
MF^%,"UJX,9P6)V`F],QG=E`A'YZ@9-\)JQ%91M8C)C&)3)39KT0RGR;@X#XP
M2((5F1,@+-85B9K1C$XS4#02E"`(L8A0$<IHH7J>8"2#I=K37`(!(4#N0==`
MP2Y<I,E>"$X#DH"1C-9DA$Z<(4Z$S-$G[```$<1@D0VX!BMD%91)NG8)*GC:
M_R5Y(;9@>/*3Q4B1E9@Q`Q;D(`=G6!=B)A>'&YWI&VKB7.?@E(Z(M&.7]5C>
M.U_RRV`V9)W$A%U"9B?)A]P.=X^*R$.@22F/!$^:NAJ"2%ZU$R3QP8>CJD>=
MYON$^MJW5R<(0D"DL!+[^O>__YTG@`?L7P';EZ(&3G!)6,J3U3'DP2F)L(0C
MN$YL/N$I!+!`AC>LX0YS.,,>ALI'XQ+2NG1K`P+4RTG]4K0->)"E]!P5+HM0
M$K_1IP4V19E5C<IC-[AAIZN)P)!8$%3>9&R$137A:WR<@ML`YS<:[,R3HRHQ
MX8!&A:O9@`FG;(8LI/'+&`KBO&J:LI:-QXA(/.MZL/_8'J5,0#[HVD$6CK`!
M_5QQS?_!:\<Z!C$ST"6N";+`&,L(M<-^"'H><LD0T/BT`%Q-1"MP$!PMQP))
ML.@1ELWC)"B!MDY@8&V#)&2H_\`C(C1`(;6K'2NPQ^I)]J`$3[/<(GYA!L-%
MZ;:)0Y&N/TFV2AOAMV=`3#\@MP#?<L.5,(AEF]Z$`A@X%PK2W1!\1^5#/J#`
MNG\22"T(4A(:&%,@-#B4G[#'3(LP$R,9.4IYN0*\2YW7!2I8'9)BK*J73#?:
MNI3O/5<0$#K0:;YU^C>=!MZK7M77X`0^<,+K:V""&+2_N125#WF'T8Y:_.+L
M^RA(`:BMO,SE6R5=\5]8T)C_!=;S):2S;PGDE>/*=&PU5?2QCY,#V"Q$(`L9
M,ZIK9HX<)2/,`RF0Z\*DK$(Q,(>I2+=7E:\:@:-6C&(\0$$:I:U&%N`XK"?+
M.EG/;%8U*Y'-6.#!^>`\C3EK>4!Y/L]V_G`>/E^'!TFHG9=<L*`'"8&P17">
MHZ=V6#Q!+0"QA1PM>@!';'3"$C'*(]DHL>D^LD`"F?CT&00IZM#^P0H7:,(I
MT/"/UK8K"+\-2FMC*P0:L'+64#J<)T^DVUVW?G'DF('C?ELH:D3NTTDX[BMA
MN=QT-/?9J*.VQ*<M!"E4[[HQY3:GOBT[AG1WF=\U-Z0(Q:S?2?.\'#EONU_%
MD(2F_X_B,WE>/:$W*D"5@`[OG;:]=WDG@`.<P/!T29Y"0.!OPA?\&N4HQO=_
M<6J1&!W^,U+<PA<BMQ<SX`8LL%)-,"DHATLDT'*4P7:@41M6(',HM1H<L`-O
M$!D_%AH"`QNSL7,^=T*VT1JN4703`U7!,1S"D5>^P3"A00).1T.ZX1E'`&8O
M4016)T27P8-B=43CX74P\S-K5000E1B-(5<ZE';DD1WG$2#7<4`XQ@,L$"9+
MX`+>P#0G\#1H%`);<#IL=2$,$`)Y)Q\0`#D.T@,XL``[`%R?)0Z(QW@PTGA]
M1".2UP*B97F%]`=H<`'AU@]>(GH/D0/M\EN&N`.DMP`8P/\+P5`EMI9;AZ!;
MK%<(K_<+W'`@O[4"L\!O9<)[R,9[O>=LSH8"9]`.,M82PS=Q-$%.V&9^VV8+
MW<9\R#1N$+%,Y1814G`$X^413S$!:_4KS`(LP<-1WH1+-*%__/<4[],L`4`'
MWP=^X#=^Z@=?>:)+`G5/=*)O\7!P]N`2%'=1X.B+RLA_Y`AB`X`'_+-Q`=AQ
MWO(7(5=`10,#CZ%?`3`$0\`[(;`#$&@R.\9CHG&`'1@:@&4?\EAGHJ%E/E9"
M(VA4L)$P07>"$\,P&Z-5$2,<6L6"618!"\D<7#5M10!60D1F9356:2:$:<5$
M4.%H<;886>`&/L.$;&<RZ+$='>/_!BP7!S#P$T4@#3TP*E#C/&38-%SA-!!0
MC60(`26P`PN0AFOX$V[X68>W"XF769MU"9YV!E:PAWJ8(SSP`TVP`P\V29_G
M+CFP*&3Y6Z_8"6'3B(I#"&Z)#).X.$G0#+\F.6XU#3@0#;FG>^&@7)[C)KY7
M2[9T)_F&#X8I<4)03CR1;=JF?-YV3'_X?$<0?>>&`KOH$>OCBRE),^)#,^((
M;]<0!(/!!TOA9BY``*C)81W&/III`<X(8N3(/ARU41<%C1Y!;8?Y7N2'<O<0
M$OK'F5#1FK')?[`I8FU!`G'1/R;F+7KQCB?E!E;@;!YT$L!CC_6X$4*`!?LH
M(#P&9/[(_W,;@!@*<`,P<`,&"9T;4($\MY"RP60*0U4T*%7!4713Q@-2IAPD
MD'.K(8+`P0,]<"%IA"$[.$0B*59H%I,E*81M]S,3`!(X<Q\ZTS,Z9!Y81Z$5
MVA]S:3(94"9'L`"=4B'U."K0,Q+4Y@);"**-)2)+(&F0`PW`E@TU<@E\=#9^
MM`ED\@>CIH>D16H*\`.KDQBI!GJ3>00H(`4Y\"YG@`,K\4:+6&N=Q$F1>`QO
M^9:N5PQ9LB4MXCC0,$G1@#:?J&R`J0[E]ER\!$[JUQ)RD!'!A!A(\HI+2@-T
M<$QN18L0<8NX."O..*(AH`8DJ@;C)U![NA%\$`!\2A,;$FX^8?^9*H!1I9F:
MX3,!()::DOHK&J%ADGJIF)JIFEJ<PSF<&[:IF]JI[,.I(H:.UO(FV<)Q=,$7
MSBER\3B/1G&/(!$`LQH`4;"=]\)7,^<:.\6K/C:0.T`"C]$:511T0#>#2(4<
M,G=`'5A#QK%GOI&"%XF1(Z0:M.$!0$<PN=$Q0D"&WAIF/-"#181U(VE606B2
M6<0>3P%G"L"2))`!AL`>01@>%EJAFK$!DU$O,[`8TJ!&N-E-T'./]=18%P(!
M9YA*+%H-AI@-4%DCL,1'NW`)D9<-.+*5H\4#F0$`$<`*U4.(GW<$99D#S$0F
M*"`0=Z>6P'!K4JIK5)HB5+IK=Z0ES9#_I='@6I6VE]V`7)NS;,S%3,\%3KID
MF*'R$D)`*`W6$]KVBMT&EN#VASV!/=!GIY89%,YHF-.(<BK0!*\`%#1P<#46
M$]C%!W(@MDU1<!&7?JAHF!PQJ+'Y82'FMJ`:MW([MW$KJAAGCL=YJLI)%\P)
M<@2X8C^6!(V2!9%&J[)ZC_:8`_M8+SLF@B(8<ZX1GC@PGB3P!C!P&PF3D"*H
M9)NK<YG+<S`H94OX9"^XK1A)0^:I+TUV@OTY`V:$(?(QH`8Z9@3Z!R1YK@JZ
MH&+W9J<F9Z<!KT!39F:&,N2!8W&P`<;+`S#0ACO@DQX"/5L0`ELQ`?9HCU<3
M6QLR'VCX((@2_SDORK`-NSE2697D<)4L$%HY^@<`@+'K:P6NT">$&+]%&A%$
M2HHDBP)+0`.65&F>I'I52HD`',#*P`A&P#,M`@/1`%R<A@F?V#EA^GMQ<@1D
M>B?WX$/#QP=&^Z/F1TS=%J=-RSK*M$RV6)EX>K73YDMSJ@!Q^F_P,'`+5U\J
M\'!^PRE2@`9$P(O3RYG"R7_J$SZHZ3WCZ,.@NIJ12K>7&CXFL'^1"A6DZE''
M^28FIJIQ]2T%R&*"NU*Q2JO65P>+NV<]QZM\I:QNP`&%$:Q9L`-]@3&M`8+L
M>3$-F;D7N!HMY((H:)'!T6,W0$*E89`TV#$PT%4])`1@543>$9+E.O^ON8L>
MZK$511!GCH$?P/L?:$:O-34>9H`=!F*\5G`$#"(U]18"U#L$U,L`0M!80N!H
M6+,`*TH#W>NBW\NPG."P,X(V:G,&&#M:>:B^&,L#ZPL`'L`*\-LNEHD"(HL"
M1R!'*C!8;`AKM4`.*7L(AS.E@\!Z4SJ)+PLQO?4(30()+1(%26`%$ONEY^`Y
MZ#"R$GQ+]X`G]Y"*]$<HQ^>*K[@I-,"TS<<ZK+4HE&F65+N;+C%\NYD\:&`8
MZX(#3R!?!%=P"2=@"KU(3_!7-CRBO(@II?DKP4G1%.V+M*IAO@@&ITE^O.B+
M2K$58$``M*D^J%G16]&9&S6I2%P^+I#$0?S_MAU&+7`!Q7S+MWU;4JUJ0'VU
M4BK0;M0;``PP`[CJ&4NFK$9517+E!AEA'X.1!77V8ZVQNOYH0C^&K:[1D%.]
MGC38@B\4K2IH,1X@!B00`0:3`AQ0&@8S,1QI1F`F!++K@^-ZNPF:R"X#'P]Z
M&EIV9T"(&>?:@W%@"#1YR7&0`9*S!-UZ(4)-O0UJCQ/``*0<6Q[26(\E:4VY
ML.`+OC5R>+"T)II@HS#``^G+OIFARP```.Y;`IHH"X18I/7;-Y`:VP2@%%"C
MOR>``4QR:ZIGS=.,!6[9LC"+)8RSS52YE^7P(+O7>W$BF,8\P:8S75:[*AF\
M.AL\3ISBP6#K?*\@_\RV^%WHECW5=YOP!0;H0@<JO,*X1'`NO-X!UD!+RM`&
M@0;T1BGYMU')J#X8?2N;V2P=Y:C%J9FZ`IO8QRQ+00!.L153,18)GN`ZH`1F
M@19*D.`1;A4=1=-0#(!V<1?M^+<KUB*"\1@KL*CM1JMGL+C]`3&A$7,`*7,]
MY@8[($4DL`,<D`(5>*PFJ)!(A:TCM.,FZ&/>:73!(4-499]"+@8$(P8WD#&"
M$52TT8*P-C5I),B5K'4_2$1(Q'5VG47KL11"D"Z001'XFG:4#-A3#C'<L1F6
M>4H;DG=/(<JA;(\,@&A1KKU+F;"N_)2:W;`.VR97>089H,MVD`%6$`%6\/\)
MN[R^8J`M1[`#Y(08#H$"(W$"NS+;E(Z:L0T]9%1Z_`N7`"S-ONWIB7,BP[`,
MEM`DV@PC2>#-F(#<*+!<@"F*$G$&YXPZ1CF-1;L3#080C6D+\DS/Z[28/B',
M^3RU*T`'^D3@RKC$RB)C\T1^N-3""(=P"C=/*Z'0\4T\QUY]]4V;N_(4D>Z-
MZ7/L&F711&RI_FT!(;`"<G":YSZJRFX__`0&\EXL"EX5]2XM&J>.RTE2)O6<
MXS*X*W##6@P2-&#B_<$P%KBL"O]C'#"YHGG&>,%D#FF"/D<P%F\P,M?C+#21
M+CA54&:?I$LP',`!/L8!0$7Q&S\<L/8T4P/7U['_G>!A9EV7Y5J^7E_YY7/A
M&13:A(1,KRA3(.;1,1N@B4L``2_1H(PMRD/``'`>O5M0RL0F$(3'AJZ<V7G.
M"9_]1Y]-)J3%`QMP86-'!QG0RP```TQ0#0O0!$8[SPM`Z9":FK+M]J/B0'`=
M!2H;I93XVY_>VYV>:W=4-#-KZMZ<ZA++`CV@]GVY;.H@IJ1HS+,^M%27BM"#
MP<>'M-E5$DD)F1K<+O@\OZ[=+L7.ZRH@!Z-/^G)`!/$P3KJYC$LQ$_$$8/.T
MT$\`IVC0`/>T$?DCT<VB%*7YFX"*;Z=#F+B$2Q7LC4#,%9U"X(RZP[+9^C5!
M$F@!X0H>_?1N+--/%19^_^$:WG$IUN\=+AB.@8C2%`!\0-00R';]H7-)$'3K
MOQ?0R>),#>,[8)Y176</B:P,F?])Q9"?"PAN;C,9&69B9CR*9H>'B(F-AQEN
M&3<I;APW')=N'IV%B3Q)0J1"1:>G0C`M!ZUQKK`'K[&OM;*W<;FZN[R]O3P!
M`25+.R0P)!N4O+BWK<[,SG$M23R[/&9'.SL]10$3%A/A$T/DY`SGJ$L+"S@0
M)3TX"RLK.?4Y9_CY^O@8_?[^^:P`4$0$'`$+!PD0<!%@0X879>`L@`.GS):+
M0\(I)#"!XT:%'3N&"%%$2`@61EJH7-D"BTJ7,+'`;!F39LN;+%N8F1$%QHR?
M4?^`\DP2)8D1%BQZ]%B!`JE3&"Q@P$`!`P,*%&>.'%D#)028$"?`>AU)=FR(
M)RMPH$&#HRV.$G!+J)A+1$6)'6C@TJ#!%L<..BN""#XB!45APR@$!Z&S8ZYC
MQW)+T,`1Y.JQJ6GI\#D1($0PA!LMB$9(>C3#8)W!-L#11,57U%[YR'XBAX\%
MU-\03G"Q.X3CNBJ(/!E.?+CLS9M/@%%^@L]R,-!E,P?#Y\G>N;5?XW;!<#=O
M[K`#F!A/7@?Y\^C/FS<Q8`H)8U*E<H"Q@3Y]%AORLTBR@7^2_P`&F(0;&Y!P
MU0Y$H-:9&<\TZ,P?KT!HAAO\I9!?$A:F\)\55@BR@3;_061!0A/(:)AA"IQ0
M4LB**GK@8@8>P%B()RBF",HU/(B1(R.(B-%C"]>(D4$*&6P000I99+'!)34N
M68@80!Y12BFH",%""[,XV.`L6=KBI2R^A"EF')T-$X1\&\Q@QC)?;@D+EW&8
MD0&0NO``@S8E".&-..644T,-#*2BSCH]O`.///3<L\^B^6!PQC^.XI-#!@,!
M\`1I'GWD`APO0/`"165$!.H6(7G44::F=G;"$R%@P((&+3B04TTRQ2233;?>
M^A)+&O#DTT]`%564$<0:`0,-2S7E5%1283#552AHE0-78GWU55G8!H"66DOT
MA0,-<CWVA%UT-*$77VW]I9A@_X@5)L6Z*S3VV&.3!4$"?OJAH!9@0BCGF6<*
M!L"==[R!,]K!%H#'G6@A5*?"7NBV]3`:$/.1D&@!T-``7!N7T`"X'H?<0`,J
MD$SR7,4]49W*TYVP:F0J\`&PP`IS=UHP7CT!5PCI]>PS>NW!%U]\]>&''PQ)
MX.N?@`+.0*"!630&&QU:/I.+';G(4H@;)F+8GX8#"N(&"3L$<00)V>27@A5J
M+]GAUBMN_>(,,:H((]=A?V)(CD'RZ"./0$HR9`9';I!%!$OFI_@EB"BRPY2F
M5'EE-)0W4SF7S-0RYN;6=-8$#EG0EY\ANH"9=9954Q['-3,`68TH0>"P1!&<
MC116G_\,7'1"$1`L$4\\A=+@.Z+V,-KHH@#EDP,/`#1?@FX*&;31"S6\P,`0
M$$$4ZO9E=#0$0RZ`5BHXMJ-E!*PLN713K;C6RGZN.*FOTD\8`,L34$05&Q6R
M.T"U;%53L<I5LE(/:GTE+&89"1@ZDQH^I&4M;J%#7,1E%[R<JR]_"<RZ$).8
MQ`B&,8\1@ASF0H,@6`%(*N%!"UA`,1J@0((RN]9(`H::FX'/9C;;30#D4`+;
M\8$(DN$+6_J"AAY0K`1$^`@!A+&QCSE18Y+Y6!0UMI<G.K%C3?18R>;"A^#,
M13)R(<)FEI-`,`RG+AL+@05^]C/1D&>-08/!?.(SGZ@4;0/_^%+<TI@6H`*A
M(&I/"$8)UE0-+<4!:XK8108((0@K@,U$8*/0&U9P!!2034E?2]R2P@:W2=P-
M1I[H)(R8)(@5]:U'C<C`WR!Q"$JD@`,;X``'$*>X)5VB$(K@0:&F5))47`EU
MJ*-%,[ST)<X9DTPA(`8F^T.Z7E@N=7#*A0K51"<SZ.MQ0E@"R.!R#@;48`LG
M@$`/UK&.>,"E!\-+E**,Q\Y(20H%S6.>%#!U*O&-(R,,"!4<PA"&,H2A`Q7I
MW@3H)013=20U3]B!$5H7J_BMSWT0A>CZ=K62G<R@?D*)@K",8!24P$`R3/E?
MLYYU!A3DX`@%[(H"L34SL@3`@=SR_Q;,Z#*N$I3K7+[S"V`VZ"[#'$$Q*Z"#
M8^2@LKG@@`5S2F$+2-#")J!@!31X@LM<^B\:!@-\`LOJS5Y:`FMU,8@0;,L0
M(?:$BQ$`#!ZC8EJG^,2]!+&*<*6B%4.&1+6LI0D:"XYQDJ.<E8VK9%TUP1I[
M-EC"`LT]0AO:'>N3'R-<B(]-XT^TLH`#5@4AESPPY.IRN8L6Q$T0&.)/?S!$
M(+-EX8]+$-WBU-8A0=1M$F*+$=WB)K<4J>@0..J1CX34B!UY,C].D.4L9ZDV
M%4'I&GF"7)568<C*O4EUF3OFYG@0`C8H\VN46%.=VI0ZRTE3)QE(`@I9H(TF
M%$$;2T@O#O]ZX$T&O""]PXO'.LXY*'6NDYWXK8=`FM>\>9:J(T%00``,,@&(
MP*$#".9G@LO`@`F<(#)*&4<PPN$"V^%@H3EY**TBNF&<L&0G/0%64$9L!?T9
M"Z3*>HJSH(45E.9@!=1BZ;\`ML"1;*L):^D+7.;U5PN"-5T[W6!EAJR8OYQF
M)`ZCP0JD<)C$0&PO+XRJ<_SE%0;.S*H!P^H)5(#`'P;Q<][J5@MM$QIAI-6*
MX*)B7)\LUS:C>6-/:$NWFH!7D@F'.&8L#G!(IL;1?`1A@'ZC"\83M/<,K8[V
M,5HM^S-:R,Y`LG]4@)6DJ0@'Q0%"F.4!UE9'6]B:Z$)N@(%6+!G_A!WD49.;
M%%LG.N&)&(7RLS/B&B=BI,I&K%).3VJ<G%+@B5AF@0,D$"XM;[FW%GRT!!"`
MG"E4P0JKQ>*9F,,%A'`AW3&11`$A"ALUZ\2*:'?W3=)0R4[F9(8-Q.MQ._"+
M-M*]A3]Y<POCE*_LW('.!>Q`G?C-MZ16P-]^S]-4'`&##GC#$8@HN`/_G,,<
M)"`!#3C``5%HN$:C`'&-GH$&_RK!&1BZDIG8BL,<=JCZ--`K&`3E?B..`D>)
M%95WA!0I\6%Q20F8TAFRM,96?FE:C`B/MM#`+K_YZTU_C`/&:)!=[B(,4.F`
M`]#\^38-`[H*:BJ9Q?P<@36\*LT2EK#P_P'Z(+?!&5EJNI<ABG4M9(W>09C8
MYC.WF<T0^YB;YU[7N](97"=+&7'V;)<^A^^&..0ZH!$V`#PD5K%08:RB&PU9
M`+F!!7^D+`FB4>EG8.T/*LQ\-3"-:]J"]D(I8#$,*(.41:N-M+%5-:T[/2,4
MN:%#M+8U(QR!"%`D0DA$BN4-;I`%]\#2ED2Z$0]6D%SEEH2YSGVV=S,7W6K[
MH@4A$`(.CI"%)"S2$%C*A4JX"TW*J5`G.V%$$K)!_'2K6QL0^!.@:@`!>:^7
MWO4MGK[QRP1^]YMY`$"#1T`3=HY8`'O^A&`=,`<4]W`.(`$&B(`1MX`+F`.I
M00.O0E$TX3X3"/]R$S43+$$_]C-B1E$L1X$"(.4J41$5SB)`5R$M+V9`G8%S
M5=6")\!TR!)6.^880M!C>4%T?Q%DBB$%A/%3@A%4=*!$!L-_3O=T1:A$2)B$
M2A@,-0869(=CWB([:(!7-)!$F&)F<Z5F<B=W<!=W:S97<99C=X=W="$<9D@$
M:%0R1!`"2MB&8(<P+E!HAR<5C'4?^G$AC,<TC[8!5R$B#E)($<(#F.<(B>`Z
MJ^-9K#<)I)4$5&$9"G`OIK<X>>-:K/9)L%8(I*0W?^,CU^`W<O(WL18!-_`&
MO!=LB',)KU9K/+`$R%9\RW9\S29,R=<EU`8FIN-\O1!].R`BA``*V1?_)]WV
M3);F;*_@!K,G)X0P`RB`7N:G#>P``>>P!>(D$?*U`,%3;_=6#_.77_70;]ZH
M1@"7$`2``R=08`O'<`:8C@<(<0<X<0P7<1*``2H0`$70`QB`/AL&47&`!?M(
M@128/BK1*U&``ADE+"IW%!\H&3F@+$,#+27E8O4`8TJ`,SF'90'P@M^R%CDU
M4WHU%T-7=D!6-D+V+O#"=&XHA!=SA">YDA\!&UZQ*@]#`TU@1&YA5VYU*1<3
M`D2`9F[75FJV%P_`5G/W1$\@AF-H,B<S+UM4,@T0`"S)DH4V-$0#%?=Q'_RQ
M'XWW'WL(`QJ2.G\@"Z^S(RV@(YSU.HE8"#/`_S9#<P0KX#^G=GHFHFJ?8#>=
M1@FR1FR1@$IZJ9<Q@B2D^&O$52-ZLS<9`!>DD&R\Q&S!E'S"5$S4AHN]P`9"
M4`P<H":%0">Y,">G(XS-!2;,9`;@]6@P4&KH59-+``&HJ5ZRTQ;LT`,0@"SR
M95_;R"@O)@4`T`9M<)O\U0960&``9P%-0`=,\'`1IXX/AX#$F9P3IU$,)P%P
M@)HX@`%1L"NY(A/[>)W\&'(>EQ,\09`9110EIC]'@&)4V2PL=E(N%B]<89%8
M%@)T4$106'0S2%-SX6,@"61'-QCK\H-_\93^^9]+*'9.&)/QZ19BMA>V@2DA
MP#%R-44_V84-0(5<N/^%#2H$=S6%1QE%4>1%CG$R;`B@26@!A?<><TB5C(5'
M*,IH6?EHEID!U5`ZP;19FI=IAZ1]9QE>S%(?]B(5=A2)J=9J8N-)GA=K<?DD
MAB`DNJ67J@1;&<`!I'@#3F"*2[)JM,:)2>`.>>**RX9\;C),SH4YQ029O.`;
M]I(,LX>9<>`&W4:+WV8ZRN@0L[=(+$!^Z69^2E$$)?!@>0(/ZF!.AA(/V7A?
MLZD\+Y8#WNB-=``]I3($9W"<R&F<Z4AQS#FI$K"`1B`!<V"-<+`"$?@2M5*C
M=L"/H=J/[X.!.`%BWCEB/'&0'<4".>!R0^,L)!4M]C`/.[`&2@!X@3=X`<#_
M=$4D4U(W=39X0;ZC#72PGSL(5$&%`R[PGP<#HD_)$&2Q'.-2=E$X5N!R*;DQ
M`6``6#RIA7!79W'U9FI5E#A&9Q*Z%^=:`JRRDUMD,DZ)DB`:E5))A_Z#HJJ5
ME5K)(&9`(R[ZHF!22*V0:8FD"Q`"(8C8::(I%4EP)WB4HRE:2QA2(ZBX>D)J
MEW4CF*NGI$>ZI"O":QOP!D\*F&KC>JN7"..9I<H&B\/X;;;P7)HCIKO`!B5P
M)F;*"`6;IE@"L(L);<U@;%1!33NQ`73J%_#5`Z2@%]+'#O*%;$H1F_8@J+,9
MD5*`F[BIF_VFK:8"!X]:@)"JCI*ZC@M8J63+`A)P_P9+(!$YP`(S@#X3&`=7
M8`=7D)VD6JH>IA.^(F+#,BP(Z:HNYRHQ=YX0>6ZXFC#?<+@"<[@&\PTNP'0X
MUBUM,9\=J0)J<4$8I(/("E1X@2DLZ6?0RI)'!A9))I-AY193""YRX&<6L*#?
M2J'@RH5=.*Y0]`3GBJY4F*U7Y0)/`!SS`@:?*X0C:@PE6C16B:)[Q$<,<@#7
M,"01X*)TX@H".Y:0,*,O6@L\T&F,X!3_$2TP5WK+8GH4FXHJ8I<RX@FR=EM+
MZB-QTR,L0B1.H`!/*J5,DHJUQHK(Y@[*QFS.UK*RZ)@RRPMX&CK)D$(YFP3:
MMYE5`TQ@D@$GN`'@QX>VFO]NYX1.Z*2:@^*G3TL\VCBH^A"1.8";'I`"!1`!
M:8`'/W#"4Z`;X/"HZ)B.CYJ`[+B<#+B<9,N<.;`.3'`&*$%--'%(6(`U_F@3
M=]LK28-RJUHL'4A>L`I`*W:"41O!A7L0-I.X?S<:W]"K&?DYD<MC/68N8)53
M&92Y)9EN`*.2HI&2!J&2ORN$8D<=.E-V.66ZI\NN!<,P0-1$0PEWL.N%Y.I$
M?&"[>"6A"8)5XV(R[QJO:ZP0<52B)EIZ^?H?>:B55G.]F.`&FN<*L\!ZO)5+
MTQ8G:&F,<3`#I2?*1]"]_L.CI;=H*#(@==/*+^+*>$.7'&ND0C(D(:P`"K![
MP0;_2Q0[F*JT`7$!`0V0O_K;I9S9F,WWO[E`LUF`'\:(69NV`:`)L)P)ILS`
M`VYP@BA@!6:0!"00!/&R!$HQSN,,7ZO)#@LPP?$P#_+'P9+R8G0P!4X0`2,L
MPE;;!GW0`!RQ!2RLCOT,MA4GP\U9J1JE`0(=*=JXPZ#I/G4+/_(C;C-P%,%"
M%$9QD$>AQ$NPD`V)%2:5GK:*`[BJN%FE=003/E@\DY![@^(B=.9"H)<[#V+\
M@W3PGJ1A0V;,A++1K(D<H@P!=3\4DSE6DVV!5R7`!][1&QOC9@[JDQ!39[?+
MQPU*N[8KDVXUCPW$NX^1(#NMR(9G:%(Y1W9DATK3>(OI_UFO),V9EPBO,`V@
M%ELK@@BN`UN6?`#3`"`S(&I)$Q^F[):GAHJK)I<N0C>N-@GF2UNUO+ZXQC5N
M<`/P"Z6R=(HF:[%F0`)Q<;^(.25<NK^=J<#$I,QQ4`1-<`3]H2:O<S5Q@-:`
M^++1X+^RT`)\&"UGXLVEE@-*40)%0!(!H"<5[#M]N@#T=BCL?`]2.W^UN@+X
M7`!]<-QM4``%X`$%D`*!],]?:YR2JE'M*,/,>:GOR(#-B0$W3`\8L%`+/8$7
M2%%FT"O$DE%68-$H<10[\`YG8I[0`I$O=FX@G:L*HR!>I[@,X7-3Z!;A0E-"
MYU;JZA9A'-.V2M-":-.A@3!;'?\:8!<,T7,60!W':J$61)V@C.L;(I-F:/:@
M0!E$'],$;06&Z$K5<-4`:(B&[]KB\_C@>^`>]8IX#VN\HQ7)23`#57.]K\0!
M_YI(X16QI\=)+.(?F477CY;C#8LT5,DL(SB"]UJR%*NQKM;*L-5JZXN]M;PD
M$2"RFO#8P.=:,O(D[]V*0J"EI)#9QWPY,)O,N/BB0A#:R;`W,EH-E)!]F/QL
MFQFS$"(-?/A3@9$#X!P$2H%Q66H7O*V:S_BGZX!O[BS<+[8#!2`#3N`$4Y`&
MF'[I:7#I9NO"_@S#!NBU#F><#D=R%&?J\4C0-:S=^+`.]\`"04&=[Y,3.Y'>
M^*-R*I?_Q"SP%AD-0%(Q0(,;P0LP`$I@,-^A530#/A.`Q2#)%L$JK$9U@^K:
M%T8'TYD[#XR!!FH</;?!%S3@'-ZP[2<):/FM(+Z[=M4J1!=NNAF.52[`!QWN
M1$L-XO1.H7/%!U1]XE7D,8:LE'2!``\>O)<QXTVN:/@1(,:HUJ_0B0(+EF:0
M"1Q@E_5AASZJ.(I&#<Z`MVK2L*)<\$W>Y$63RJHLF*GG6A1[HY^%(EXN7+\7
MYH-M"!E0*(:ILI"CYLO7I;38V9X-VD$PYZ%0VG%PF7IN:7M^.M5@!E/Q4_<&
MSBL@SCV03"613>K%V^C\V^LLFX,:M2^V`%/0]38P!05@!<EM_[5],.K'^>G3
MS8YI#ZD&'8]18-`TS'#>W>@Y$-X\/%$X07*B?'(IYX$H@12LV.OR_9#%[8SW
MG=]8==3?P1!TH$WJ_A99/1SUF1<$:N#JDI_P`H1-MY*WP0>`\>T#AH2E(1K@
MP9[M"1I15W9:?.%H]W-/D$,!T*UK]41"&;MZG.(-^L=W=[M.M)2&;&=V-F"J
M*X[_*8<$;Q\HNG@`,LT*?[U,JM:8MSHA*R)Z?8>F9S1.D1_)VPJ,`'Y1D==/
M\>10+I5O64LU8KZR)N6^G(@HXJ1?+DMMX]<O\B1)4-G(1LR9K<":;<TZ#PAQ
M@H.$A89Q/$5+1RP99F8\B#PMD3,9<?\'!SQFF9B8F9V"!Z*#D2T9,"A'*RM!
MK#L]L;%+M+6T.#@+.!`E-$NY"RLYPV?%QL?(Q</+.2L+*04R4WAC/S<_V#\L
M$@X.W%'=X>+BX./FY^-1$NM1[5$:[1)&$A@Y"_?"+%$S9BW^__X>1=$W8T8[
M*U&2&%G(P@@+&$M*X,B!(54J%"C.'!FV8D?''3MPK%$28(*+`"<#H%294J5*
M.CAHT.B!!@>:$BIRJB#RY`D1%39+]*+1I"8..COHL`K"M"G3CC#1!+!`-248
ME"Y2G@1*XXD*&GRN7K40X`28$"="J`T0PJ7;MW`M$+`0@L]7HFCRXD*S!$T3
M&B7XN)B`]43_B0:':310S'@QX\<R%?^-'-GQ8L0-^/S=3!FSB@8Z<_Y4$3:$
M"0LF4E-=S9KJ7+FI8U,=@(>$;1(P<NO._9#%PPTL@&_8`,E,AN.4$!UWXR9%
M"N;''V7@\.9-%A(<=OL>SCVX[^U)0(WR%Z?%#!9)DCR$X9LW^_>]M<,0SKV^
M\Q3UN3OW`/VX?_\>;!#!&S=@Q\&!$0SGG!L>>/"?(T<(Q8M00I0@Q(48PL")
M>!Q^(MXG((XBHB>'E&AB'$4TD44CD%`2221Q6.+A!B&*.(HA?Q0R21*JY."*
M*[#(TH,MM^"2RRXEQ`*,,,LDXZ0QS'"T`!W93"%#!%=&H&4YZ(C#_PTW789I
M#CCJS/..`V2JHPX+9SB#3PXP&+%//P!I8!`,!N79SD)\MM>#1$?DAL)%&FW4
MS$>ZB$027(RZ!`8=2]#@EU$XZ=03'S_AT(10O31A)$A*_>B4*U#M(!55A,E5
M%A\HL19"3$0(@08-.0E&0`!GJ:5K6VTUVJA<!-2E0J<][&637S*1MMI@8(!V
M6&*+)9:83(Y-1NUCEC6FF&9$=8;889_E](19:[&EEFRGM<::;%3%=MH>4]RV
MV[SO`>?=<$F4]R`/FP"(7WXI6.$&"0KL$,1UMNFV'7W;!;=A)N39889Z9K3W
M'7L7K[=>!`]QT'%N'`N8G\@)*L@<?_P]>/\<?@HT\8:!!RJXH(,J_\DI!!5B
MJ#,,+70(BH>=_!RT)R.>:'0A0BR1!0R.]/,BOW&X,0.'4Q/-X8V$O"B)&20<
M@4(.'K$BY"Q$_G(D!!`H^28Q3SX9)2NZ1'.E#&E$D$8:5UKQ99=@=L,EEV)V
M"8\ZZT@0#YJ&QX.!F_B<T5!!9FCPR`Q&X&G007SVR0(&@.%P1$6#8I21H:P@
M*A(4N*X50JY@D'O667R8*E,/1>$0F@H]]03434+)9!0.287=2E.M0(7+8%1-
M1<#RS+O`O`IT=,4M3F&9F^NNO/K*J%QD83I4[37Q-2M@8$Q`@/ET/8O89XKU
M<AEE\,,_V63O(W;_@DS6RG38$[VRQ4=/1`B@``.`+G<94#7N:A=J:",OW-!K
M/O"ASPSB(!V590`Z;MC`@6*&KX&]00$X"(+HM/.=$FX@"3SX&7D.,#$6G*>$
M,,S8`W>3'>S`(#LWW"`'1*:?!ITL91EHT`9(@``VN(P#"2J9@E)&L^/`P&8W
MLQ#.=O8PH5W-BAXB&HF.9B(8H4@!2VN:BQ`A".;X+`Y_"-K0="2(%YD!!D>(
MH\%:@0-9+&%(1,*%+A;0NV*M+0=G`&3;`@DE9KBI!W7#DI;N9K<(6"%,W_"&
M)-$4N"N8PY+I*)/A#"?);VR2'HP+!ISD5)!]5*X=!DE"%.3D$(?X!@5"_\'!
MH&``.HP8JAD@V4&BU@"%)_#A?SSYI2]_*<Q?JD!VONM+:'CB2Z\$Y2Z2P@52
MD#(\XKEBFJ::B@4(P[QN`HL`1(A)3_1'FA.DY7JJ8XOV?M6]8?E.+\>:C`I.
MX(+53``,P[K,L]R'+?G%3S$-R)8^P4`4W/GR>F#P2;A&@SO<\41YZEH-N](U
M41,,(%X)FV&][K4!(W""7Y,P#G_<$,24N2$"'"#!=7:X`?R0X(,TV('79JFP
M]@C'$:"81`I9F![UE-"5O8G/>F@(`]PTT#8I3=@.6:J@EC*(.23ESW`:@``$
M/*$)3)79S!X4H2CJ[*L\LY%8SZA&+6*-BT?#@O\BKI,!,3QBC)%(S]4V!+2R
MED(0E/`'"^)XA!"V(DA#PN,MS*;'$J3-CZ)LTB`)J8QEP&T!2\"##.:FR"O5
MK6]>0IPDR43)<U@2DV(J!SPVJ2;`.6"T$IC#&>[!6F&PAT_LV<<^+L<0H$8H
MIF?0C>@*%81#@60!.UC"&KYPN^(:%YDTJ4FE=G(I9_[%G='$1?"6,KSBK0`I
M-BE)5;K93><1X'\&358YL8<]=:[S+2E!RT\B([[V)DLP;C&,/@'3S\I()C)_
M:8"UGK"8)CA&,2KH55U&$]!P@28GH!E-`'N2+M=$],&H<1<#$^9`C6(,.$EH
M08[:R*\6B&$Y#EJ0!K/_0&(2="<+0=A!"18Q0MYP-,,]RP066O")B5'.E4`M
M(<8T:M3<W.;'M\F.$NUS'Q_BYPT("`$;`GJ#EA)YI$$\CACNR*DJ\P*L-"[K
M%:VXQJ*A]6A%`",)2%H<K44-!E>CT5A'Y.6GM6!BJ@C"$D@57+*5C;!(2I(>
M6:'8Q1:2(TS0Q2_NQLBZ92D"4N!L.ORVV<")`[1=>@?A$M?)2J]C'JMEK4=R
M@(**Y)9/J\Q<CE?0BQT,"@,8076/.(*HD/!RN<,2RK",6P(Z6&M2H<G=_YZ@
M*9S@SRC!HV9U244'[.)`F]SD+O/D8LQQ5JHTZ,Q>_]!;3W4Y"IC0S4M?\A(9
M_]*<Y-M\B!9@ZO?/<N,7,IW!"6;:MYAPZ:0!/XFW3W('T==`.,((Q/=%,VKA
M#;"'/FX@$=3X91S_-&=!*>!`%FYPG?6H-`L[D,D.SC#+X.2GBN6),0L+@N.&
MN'+'0]4-#FL(Y)(C]88`T^IS\!,!-H0@H$UP603^U=(%,:B)&8"BA(0P1;#2
M=<M:MI%9OVPT&F.!#4HS\0S<V@])Q"$#).@0>M0X-"\/@A(3ZUIPPU9G.]8"
M![;`A6'UG`L^]WFQ@!P&$^!6QQY,`6]POUN6@B`%S(Z)DJ8=!R9!"VE(BV-P
MA6M'I</A#E"V%KC"6('COE-;CW]'Q;BUR&[CR&J0X/]"N%^@3._BUXO>V80R
M-,FU+T_POU[W$9Y)$?93BI=ZFR#/`MY5]FN,^3_`U"HMY-652ZHM^^5-('GF
MPE1.`-,+O11%GH+Y=@#X`)FAH/N?^2NW?AL#3?H*!338%TU#><+])[#$!0U>
M]FL:K,`&[YO"1:VP?+Y#G`V#=!/]<D,24I`$J#K(#1RX`<.+&JB'1[P'IH8!
M&(`>]1$>'^(/F2`Q9K!*#>%X.A8?/A:!1>5C)A=D-S0?2)15*W<?$:``2Z8`
M"O!!"L`!]V$R*0!E3J1S598S5%176U8CI,!F1'<T(9!T&]`TD*`U&8`"0O-T
M.W!%0S<(=C`);Y8!>U5'<Q3_!+,06&4#=KI@6#.Q!/C`),0@2&AW*&X"=L5"
M:&^7!F^G)5,@!2B0=XYV20[P669X#FDB#Y0V#GNS2:OE$:RE"\+0:1@30[ZQ
M`"H`@+LE.I3G6[^%"\/U3\Y'3CDQ%,-7%&A@*<-T`KX4$S@Q%'PA74E1.J5S
M3<46$E(Q%P00>]R%*BJQ:[;7$VG!$JO1>^)7%<IW;;HC%.O57M8R3]M4%6!0
MB-#7+9PQ/[B(/]U"+<_U%?4#+K>38,R4.STQ;5AQ$B:0%:W!B?8V&QB%5"2`
M`NKG'L+A&S1&<!6T"3/`'/J1!,?1C1NP<$L31S\F9TM@:KYA!-R181QR"AOR
M9BT0_VJB9C'N,2\.E%1!9G+9<2`YI$$:E"`K-QSYQU\N0R#586+W460WYQ\J
M9F6&Q7-?)00H\',OR&4]N$4S6")8$`)-$`2V80E,IX-'L"%F(`E+0'6AD",W
M@C7^X`@;T%<Q]2.TL(1W!G8X,'9#,H7,H`QMDW9J]UBWX'9.4)1.,`5.D$A3
M0'>)=EIE*"9HJ'=G."8:``_SP`[ET#<2H`&?5`^ZE"A+`DB=5A$P!`,X(`0Q
M)3IJJ1&LUA'`I0L#P`4QQXLR002$6"GIQ0<XX4OE\FTTP2F_)DVI5SRD4BI1
M`5'<XTUDL7M9$0#CHA*N@8KV5D\KL4YHH3NS]A5Y<7R`0?\$)Z!-LW@"_[6+
MO2@_<QE]J$D9.T%?F*%N!79@H#%OQ?@$5]$_R+@2C<F,IPB-):<*U<@;]>%&
MT8$<%R2._A8<26`%23`<,+!_*&!JZ4<"<A8,`^@;/357&^`&$/-F]*@Y,K0;
M/88;*954)/=C%^B/_9A$+>4!+,<!_M4$(%@=^I<%.[20)X@RT7%'*GAE/7<A
M%5DC0(B15;>1)<(#6!`'-6@=)`".CB`&`]<")+`#D<`SD]``&O<S,0@B;20=
M,]`1)3!'*U"3=S2B86<V-,`+0Q*6/9EV;L-JK`5V<(`#,9H&-C`%-HH'88@"
M4D!W(H0"G?649[AW0=H-5X"&0CK_#AJ`)O"P#5CI#9B5..N``7MD)'JT:12'
M:K1$2Q$!@)PV4WRU$;WU$98G$E^@B'FQF3T`7?I#!+&I7>KT>K\WBQ-`%)&8
M3-*%3988!-@$$SB`/"YQ*RXA![U23Z_WB9-Y7N>U.H[H%<-"!':!>RP1IXVY
M$K58;KFX&;E(%)RAJ9M*/_FT3P<6:[U3`LPTF_RC3N7R%K>9%;GI`N?W8T=P
M'?/B;TVEG?WB'V)P"O,G,,R9,-[A8_O'"KGA,=()$I_#)^YX-1<T'G%@E0L1
M:@TH5/1B5/+2C]CQ8^C9CQN$<@(I(!R@`#`'@B$HG_1I@B?C'QNPGQ9B(1-9
MD4!'=2YH_W4$6@@T%@<=F8XD=H/1D8V4L`$*$`2H(`AFT`0&"#2$((-X90:6
MX*$X4#IMQX0E6@LGFB2(1855R%C'`)2LL';W<'DXJ2D\X8@K@`(L@`)-H:,-
MX0YE**1%.J1$.I51F4F`QZ3K$`Z1A";QP":01:7`$`S"4`RB`QA<F@.&\H>5
M]UNZ%)>3N&VT4VY5%D`J(`=\\)F%RAKD)(F_DWK3]`J9F!39M9BKLCJ[]C_$
M=)NJFCWFU2A:P2B7R:BD@1:L@A*_9Q(M$0)J,&#00I>[B*DQ=YI]RXNG.7T[
MH4^O^1E]^Q>>::K'Z!9M49NHFK:-\JJW88[T@ISTET*WZ@BZ6O^`P#&-N/$0
M&,$"*C6-*Q`HPR&Z1Q`$1W`&&/"L\3H>]6HG[K`G0`4?^)A^T;F/^GB>YZE#
M2#0<*'4#,!=SXEHP;W`P]?E#)'4<61`+539V/,>N&/*?[RIT0*>1\TH(!QH"
M('@P,$!F9N"@+[(!01"")XD(.Q!U=76P680)19@$1Z!B<_8*8R.B7Z>%[N1'
M8;.BA&2%;Q-H'1NCN``'NJ`"0F!.)]`#K0L#3H$14D`"OM%9?`>SGU6D+7O!
M0QJ5,4MXA4</[#!)7_(EA,,"]L"S9L.3PX`3Q2(\40*(NA02(L$%D^(7T4<K
MAT$$TZ(3LK83CEJV*C$^T.4I=SI='J'_%-/$I\=V$J1G%U6FII+2;<PUM;J7
M3HBZ>VX!.[J3&6Z1$I@R$^-#&<B"8`$5/W][J;AXN)Q:&?GD;MC7"P&V$KMF
MC(N+J-+VN+@BN;;A-0]DN1D`,0Z*=1?D;PG#'46%$;FQ$8.24G#$:?<BNJ<6
M)QKPKCRP`9&P@*AD$-[Y'O1"C14HGD%&GDA50^.Y023@7\-+O""X`P1"`@F"
M,@PB9:3VO%<FO3I#O0%JL%>C1=F+5U=WKP5S'4E@"8X`4G&0!%E0'6B&"%EP
M!-=+"C$X"1D0D_+["BLP$T+2A+^P!&@S$TMBL7W&HH[%=H*F1ZS5`T]0!.94
M!#GP$#RJN@_,_P)6X!M)^K(O:\'VC,$5#+,NBPZ#D[.JM3<@7%I1:@^)@F=[
MY!&^]@NY9(D,G4M[%)?'AP8TD3^(V#MSJ3^=ISXZ@<//]#VH-YB5F'K!DUTG
M41<`!!1:"\,V(4\&M3KEA;9O@0")6A=\H'O+5P(U<5W%MM-[`4]4.CXW'%"C
MF<:'R[=FO!/79V"B\7TG(<?&6,7:PRL3-KHHL,R_.1_.L5.1H`D?ED$'8AN&
MW+G+'#JLX#@)DA&L:YTSH!X8$P6O^S.F,%M5B<D?M\FA(SJ>V\FW@3!`YKON
M*=3Z=;CBJLH%LIXGN+QF0&4V,R$X0\O^>9+5RV:WO,N'T)'P:3!9L/\!PIP!
MR<$#&8!BF3T*DYP%UWM616,<>T5J`)AB2JB?]IM'$8&B4NBS+0R45=B6+VHV
M!#R%/5`$OET$$#"`(M044C`?0P0#9W*D%WS/]ZS/^!PF53F[ZW`&3,!)W0`F
MX)`X[8`!@3988?>$[E0DN002KX"T1C)<7TS1&7V(I=D9D2%KD=AK04Q8P49-
M1UQL1A("2BQ,.R'22(PLMH<[4KPK=NPKRG?@N@E\*J$[Q6)=U\6S1^&U/%L3
MMM?&\U/&&([&BL&F2KW1E;G@3MT3H-D2=,RX%T5B)(8164!3VN%40O,'GKTR
M&E1#89T*>OPUK!`H#R&`K1N/:VT$$Q39-U+_$#,@.0+!$.V1I:$#.GG=Y!6(
MX@AS'2NU03?`7X"-RJE<'0<S<\_QRD:H@H;5V!,I!"5YD6^=D91-"#36`AZY
M!/]Z`]]K"<;A(A#Z!C<X'I_]KELT"BR)VCZR*1X1Z-<L6-X=VTGR"RA<VRW\
M6()V"WM$!VNW`CT@!$4@!"JP!&=`W"($ST.$$>5@I/7,W,V]W*..#O%PZJEU
M!G-0L]=-25OI#MS=Z&5S(8")1U4*7.,-7&`WB.:F/P&NJ>U-?.T3&I`8Q/"$
M%"E]Q".-!OK-%DOL$_YM)-P6X*08;9!KQ:S*JJWQ>X,QJ2YQ`CRAP]&EM4I!
MF*RPTUZ+Q/,#W^=6_]1%C3OJAF`;_9DNG5`A[GW;9#Z<&*=5@:@35M74R,E[
M?.<=0G`90',14,CLT348T37.`$BTM#E&$,EP?>8=@@5%+CG_L("UNQNSU/!Y
MS<E0#N4/-_(,)^4OU0!6'J[Q&035<;SZ5Y_X*08JYKS/*Y'M"MEZ7G5VE>:%
M@`4=60*I#)+9Z1^=/43@*-JH(*#82S3FP0*]]2>!+C9V1.C93`L3FZ)_I.B&
MQ#@PBI.M979IFA,]L``-;&+Q/(WL(944+.JD'J3VO,_G`'BK1#C4S>JMOC>*
MT]VV$`L8`IA1B&='PK.\WNN:URGCPQG.\BW.4NP>_2G*'ODP+!4E;=+_L_^G
MTCX9E4**+XU>VXXJLQCZL)<5A%%M5!%K[U8IG0(\(B2&4K"C3E$ZZ/[??P$N
MB($_[KXI_/5NVG<I]G[OOI2,<EM/^KYLJ_'A+G'BMH$P$SA#+%!%F0#C,>Z-
MI\L!U(BZ-_[P:9VR&BKD'T)!1@X0YL$0%5$1@B)YGJOB*QY'4!ZK*.[^)!8$
M)T]B3^`"2Q:N'T0@^B?_*`X()!LI*6X9ATL])8N+$"400B5"DY!"14=F<0>;
M!YJ:G9R>H)YQI::GJ*FJI2UQ+5@A)4L*.SM9&TEN,QEF+3QQ;ALMK0<\9AN<
MR9N?J)VE+"A!*PI"M=8T/=D]B=M+WDLX.#V1V#C_"PLK*SGK[.WLZ2OG"][9
MWN'GZNMG"R4TV#M!`AXA8<4*#!(H$L*8X:!APRL.($:\0K%BQ8D2+5J,R-&A
M1PU1HD@P(J'DF3D2'*3TR!(D"R;SZM%0,6F2"A6+L'6S%PX'N"4#OO@;2K1H
MT7Y-B/8C4H(ISA(J<*"!VL]?$S0X=N"@4XN.UZ]<M4H-,"%`@!`G^#QYLG4'
M5ZE+T*#QMTC%VA,AS)IUP=>"7PL3_@8&_)>PW\`3"%@@P%AQ8*1-DM:]21DG
MC:PKI"1,J!E%YX"@I:WXJA5-D[H-D-)H8O=F@YM$5,0FLK:V[=I@T`9PL7<O
M7]^$$S=6;('W`#PDDB,D_Y'E((SGT*&;41:'1XL,,]RX26)E@W<6R9^C.+(Y
MQPH,1HQ$28]EF;)DI=YS:J%AAH9>PX;5-\*"Q7,,T6V6T!$$$AA:$%D<F,6"
M63"7X`U9W-`$7PBP\40#3;RAX1L,1L@@"1$,8D@&6613@B*,./)(39,4(00*
MF80BHWNCU+C*C3BZ$@<66`P32Q,XT!($#!OHPHLO<9C!@G6=&).$?/#=.-X*
MWFAES0XG:K/-."]`L-,20CBR#3[IN&,F//+XI,TW9.J#PADK*+(-:$<L-$,$
M""G$0A0>80&11H!>X>=$&&G$D40L.:0!2"*Q<-(9)27*DD@2[,.-)"S:Q(@_
M6_]^X^D:0EEEU*B7#1497:F]=E-3I5(U%%8]=>46:6[UA$81`1070%IJ;?66
MK4-!=8)O+A177&`N(%;88<P.-AQCAB5KE@J1H1%77$G14%<)J:T*)!U!="8@
M9YZ1&TUHHTFE[6M0/5'9;++=9AL?(>16+Q^^[:8O7[SUR]<$R0(VW`!3,&<P
M"3"@X%QTSSV9#`_&'*)=$MPE\5UX`PIX1GI1S#!#>U"&0E\+[[%B1L=FX)>?
MQ_PQ/&Z!.1P1$#P'T@EA@Q[>$(0"`2`0`!ML--"``AM"F-R'#7(@XB$[R,G(
M(RM2PN(ETU%7HWNBG#(,%CF:DG(KI_#`XROYL5%"$[/_U")((8?X8MT&$'MR
M7<@REO)+=7%$`V8/.RQQY=XF5K+%X%N4X8T*8H+3IIGOH+F`3]QH<\\Y^IR!
M`@88Q$D#N1MTEYR`S^WI$$6'!AIHH8:F3KI'?&I@TAD=K"1I0R!),`<3B6":
M*8N;<JIE#T$9E2VI-&`UE:C^X,0452K099E5L&85EJQ>:54"'_W@NYL%`?0J
M:S@T/)%7L;KZNUM9XQ>KOK)^/>M880#SIE<`9\<5?4]22<8M3JOB!&00GI'"
M"K8RK@(64#-2H`,.9N*:V,#F";2IS5E"H)9Y]:9?^M*+_##(K]WPY3C*:1`*
MF+,PZ+`@":WH40M2MHN)I:!B_]W9@'\0%C.%&6$&*YQ!Q^2SHQFD1X<<BP+)
MJ.,*1BTJ/ZXP@P_[`R`,".@([5C!#J1HC16`!B``20>"F',S!5A(:)%I`M%N
M\(8;&(T#'%A0<M`8(@]D8`/:>%HCH)8I%V'B$Z`H&=9.@04-&`%`43`#UU31
MHQE<+CU)N$]^AI&RE,6B?CO@$`LZ9XA>6,<-U6G2"ND6)5-8)QH]8(/?O+&I
M(F!C"?[X1@EJ,#A90"T;YIAB/ACGN,>IZ7=C0H<^,`<#S,$I!U(8B'<.DJ?P
MP*`_+&`(1DH'J&6BSG2$>HBD&%4I)J#$(RG)I@0H]1)^[&YW3^D=-F@`JN&)
MRIQ%R?]?#Y"G+6U!A7_P?![:L*(5KBAP@3.AEUGX(`?MS8\W[=+G_,[RSR$`
MAE_)FH"RG+48:"U+,`@=:`!48!KC*2!(6<EH.$SC3A5T*U55V8KTTF%``P9A
M!U-9"Q'@11O:G,!>8+B-6L"@EGUET%_F^PU.=T.P$,*@026$01+L$Y(_8F`=
M\T`'D;QC,8M!XW,;^YB?>$353=BA1W[$0`>8$(8P<)4)3,C!QH;Z"JV!1#TS
M4-DP@,@"S"7D#%!<1SJF>*5:2#$@6*PB@V2F@!!4Z$*140#1-!2$,Z*1!!Q8
MH])2D`$4H`A%<_RF)81P1QK-B!2IT,`<.M"!,'0`/8KLD1G_0)($(^0`#DM8
M0%@QEQXC4.RU,`A!:M`F)$$4:1?#X$$&,EF=87"RD]5Q@S1V((0FU.(T3Z/!
MWZP!@1K4X`6)"-,IY0$/=\##<3X1!R[-@8X5G.$,F.M/+Z$1#11$@`5XRI-"
M%(9,%FC@(8@RG>KD>Y'Z=N0CE`)K-AVRWVV61`(88,(X)`M..98@>*LA'E%Z
MT(0>R$4N-R$596)S@L7HB@_TX@->_LF;@\XO!'F98(C/4L$GT!3#8,#+B#5(
M%H82!V``.U9P9MPLG9KE;`_&GP*ME%&Q7$4RE.&6D,^&@QQ$@PX),3*Y@H"#
M$CSA!'C!2VU6^F00GT!>,GTR&/9E_^,-VC2B&"18@S[W.><D09"C_6-GPP"'
M!;2Y#&6`0`XFB8OO?!<&1M"`'5;7D!9<P:J":D%#HG#4#N2`LTS8:E<7[=4<
M@-:'',/A*ZRC1"/T\KM1G"L5ZVK7NFJQL`L*`@)<@(!1_Q5#8J1%&=5X-.4L
M5@Q->ZR!'5%'JL7':C9"10L(O>9$?Q9`K=4J[!90!C@8&PYA.$>RY^$-&D`@
M!)&`)(+H;(4C&0-BFL0CW3!K'1)(<0E%J(4WC+L$R1A7'5J!QPNV4(,RX`!Q
M)U*<+,U#[^O&XQS9Q24L\2%6`+6WK0D#((A@@*>$*,>$_;$"GTCWIT#YR;[T
MW<BA[NL`/O]57"1GT&^D^JL22E7*FP0N\"(0K&"CQ,7!ZPP?J1AAEUPE9@(@
M!G%O%BH_O6C8++D)0&YH&L$GJ`7#4):Y!J45/X"1!:?_(M]#%4,<[M5\6E<!
M!T:#9$\%V+,M8I$*1_>'$U6EYC)N<0LJ[8*6F.<%Q.*+.1]ZCF6?F]C$->VR
M![_\9?.!D#DH$*%S8M1'-7?UV,>&,P26,,G"'Q4#,]@S%OJ$!3O$05")NNHP
M'-`"^P`QP&Q&-K(7S03PHC4_A6SK=\_0N#+-C(KPH&L50<.@(#R!#403;!,:
MP(92!RW5&C)CA[*`1@ZDP`Q+.)'P(UN)J=DQ1C;"FC-&JT@_SD'_JYS%7&<7
M\-G-:C7SQ0Y\G`<7@"$<'=JS35N#F.H&2[:"!YU`_F_S6)T9'*$6)2B"&Z8!
M#G%?E#Q:+!.5G`M=".`$EMQ57?J7#@NP`_@&#OJF.+H$7OV1'NVU&2`"'L4D
M!0<!'L>$3%:P3`U'7_`5<1!'<2#Q7B)Q.W!P3?NE$A7W7P`F8"$G61!`<B5'
M%')Q%14U$T;A4?T04'G!/74P/G,G468!8O028F87`FL1+T#W4B$&8V4!A/^D
M+X,Q8^PS8T]W8S0(*[00#O9D3VYA==0C%3@0&9,!%:IR$S\7=#''8GD!01#4
M4FU7&S^78EO&93I5ASDU=\:!!V.V',W!_P)#U'>8QV:9IWTOP``K@$P)<P8.
M\'B+UQ"-MV>0QU\+MPF"THA3A568IWEMUE7@A0%[(FE%!`VD]P[FD0_H4@NG
M]P;A8%<($B$[$S1E)%B"I2&S!S1",#2#948W@UB^!T=.8V"24'PN<GS:5C?.
MD"28,P?J801ST(S2QUG3UP'/]WQK!@?%)GCK-@1#H%`*10`P5P2I<39"TAS>
M44F^X`O%@'[KET>=T`+>M@-]E04L,$!H<U)]DQ5!(#/J<'HO\%S1E3B/@PX[
MP`3V=F^V=$NXE%K=!5['U%HLP!_D-4(@HAR:<7`(0P+^T1\+5U\>N($<N(&2
MLG&4DG'6Q'$EX?]QS9AQ-+`[+D)@,!B#_H`&*+<:*0<5[M0`[:0M$81A/"ET
M0)@7.4=3PT)09L>3&[9B1*D&]4)03D@LN9(K2B<8A8%!\T,M-*ACU%,KLZ*5
M82<6%[5U[R0;:,AB3Z=2;'B66/9S&*9EPP)F=HA0TM)!OW%W'R)4S``2U^=F
M@@AX</8"VK@$E^9>BN<05/41*D@1!Q")LT,[`-99'9!G#]=WZC$,KI"(*$"*
MZK"/A06/,S$)3R`$6V:$_E-N"M`$(`8&&!)[I3DT9?0&822+N;>+2G,$OY@B
M*Z([+5($10`CVI8U6F,$G*6,)>&,FP6-BE9]T,=FV+@%#+"-W/ARWOC_,Y,P
M6[4`5.68,M9Q-Z:PCJ&0!"<%)DO0`C*#2DO@'5IA#Z)A15I4!C4P>&`B)CTP
M.049#_%@#@BH;_%I#NIP.0W86@X)@<I13!>9D1B)3%&@`1)G$0\'<1W)D127
M@BD1$K8#5DR@@A;Z7RG)!'!0"<-H"2W9DI;PDC#Y8%>!/++1#Q[U/`]TA)7A
M<WP`4R*F82@6A&='HS6*%E!FE"H6<_;2E!=T4UR&&,5B4Q.U&M:"!A=U45L8
M=EQ8=73@A6&A4::!7"K@3U6H%Q3DAFS7=C1E8B_U4A>$=$B'AT?W0<@A0@BQ
M`7B$!>O!5<?&:,8&9V7@EP0P!/W&)XU(F'F*_X*1X@"4N*>+23LA@:!_MCH`
M=D.MT`+^L1DP4XKI$(8-D#Y1Z1>_$83J0R%&*$8:,HMF)(NQ%YL,L@%-,WQ/
M0VO%-UG$2".>@`4I4T1ST%4H01+,6)S0R%7&J55N.J=;H(W/V:L*=1:W&`EB
MM`-&XQT;8&V_<`".5XR_Q0/OEQ1+XIU]8UPK9']+H)Y!D`/2$`0]T)[>``E9
MHH`"64NV1`_Z%H#KX&_+N!X.&)'A\3E3,$(*<TST6J]^V$SR]4P?*4VSXU\=
M5TT:6J$7.IPH\5TLJ)L(ZZ&3-0DBFA-5X4ZODA0E.A=TX63\8Y/:4AD7&V08
MNPBQX:)!YX0\R9-$L/^625@O0H>4/DJ695H6-C901+`:41<.5N>%6UD]83$]
M3@J/3ZH57QD9_O23]<*&$;2E\^)V4":'0)I3</D;3A=F4X`S#<("R.<*?P1X
MR99LFB>G6R`<<``I%B<I$JJ"&-&()\BG'#<1B7D1%==G(Q,',^!$3T0@.=`W
M)1`"2L=TS])0[6-AQK(L+O`$"M"I$$)&1:.+-R.JM0DUDJ`[D("PMI9K@)AG
M4?"J82"<MC.-T.A9GF6<REF(SNFKONH"(="2U.(WMH!81'(D2'*,W+D)&>`3
M.Z`)Q_"=-'!F<9`!H[0$^9A_V=I<[CD.\,E=^""0!F@.X1`YOZ.`ZL"`5J#_
M'E;@,45E:1*),.E5O198@1:8D7X&3?C*D?F**($J$O]*D@%;DAB:N1D*!RL)
MN>ZKF\&3$TH!L98AOZ8ROZVQ*L&RL53QL$8!%1JFLFHWLB[JHAJFA$7(HS('
ME"N;073'&UGJ0,USA1I5/6W1I+/2I#:[BE.'`T$[4&6W=F@I+PY$!#'UHE^:
M8KW!8ER&AW+I0<<Q9LV1":5P569@!!J:?9NX:'$ZIT-0IPN``=LTJ*RC$A?Z
M9WO6MBH8MMJT$H6ZMOP5$8F)52M$7@B1!>-Q4CTP+,OB/EZ\MP3`&SHP/A:`
M``J`1F)T`QR`N+IW,XDE?)`%->!::[;FFWU4N>@1_Q)S@&S".:NTNF9=Q55=
M!6?,^9RA*[I-:(0-(*SCB#"XP`MF@&WQP:PA$P<D$"0DPP-ND#`[@#9*L@D#
MI`"`"0/VM@3.)0O>,`GA2KP&*`_XAI!:PKS-ZXD/V3$A<<OKD3`),4S)(05D
M=DP(4X&A,TD?\[T,YY$3MQ%L&ZB,@K88UWD99VR)EI+-.`>/`E9P,`[O^P0N
M$A3^.[\VN2WL1+$0>SW8\[#\DY/_>Q,Q=P+]DT])JX2\HJ,9AA>YL:-`F8;V
MDH8-#*1\0`-T,!I>L5'NA&-2<5$BQ150RH50RJ0UR[,8I0!!>YH4I!9#VW-L
MAX,ZB18I]F1*&*8LZ\(>]/^T`=!3""%4*30RA#:(F[=H;M;#Z_:U*.%?MSRP
M_U41B^<Z_S4I*#@ZB&FH*?%GB6D'C'(R+\-D*K`][?/%3.T^I%L;(>`733`%
M$1`9;]![S(%&"^($2K.XM!:,->&^E;4C*K0HZPH2>UP&S3BKT,=9C/9WUE@#
MS<F-O'K(HWL6+2F.U6F=&2`&D4P,[&A9\M$"3/8D2:(P&;`"3;`";H`"FD`"
M?B-4*&!%[[<`@_,"]1!\8;+*W%4+:?(-R]L3NB16H7-#'>,QJ+T>X.$9Z$5P
M`#J@&$FOZ(6!#K"@"AIQR6Q?@8I-(N%Q$PK-.2S-T$S-),F^$/"^18!@.1%.
M,Y'_@Z0BL<'"<N(3&P^[+31AP%"FOZ,2EG:1A&@896A8=C!%T4&WSQ3-P!+%
M3_T0T#2#+K\R/$"2I!VL0$L:=C9;=1Q\43FG<Q5M&Q0T9?(R$T^@%W*8PDLY
M4#7'063JPB#4(&>F'^RZ69FW`%E+H3QLC<76>9AKTQ;J`(/9$$M,>2VAMFLK
M$3?-"5=@!PX`D7^DK=*``Y$:E7K;U$S=4*0K-":6*R%PQK,WN+WWX[UG(K,6
M"6'2(AY:Q_2Q*`=ZH(NBY'-0;-)8S6W]UACNEX>\C7;=J]X(P48X"6B#`V_0
MB@@#R:U+R70S`_F8?MXI#$$`F"1P!*5P!+P;!U9P!"M`_R!]PP`U$*[9X"(0
MH!.*0[P]8:[=X!/R4#D7B%:GC=K2VQ\&%P$'\=K!#,S.`8']P1`>V('2A*^[
M[1!C>Y*]O8+0?`9Q*MS6U`'F:XT;6@0GP.K)'2KMU+_-[=Q%`=W9\C24867-
M4Z7Z5-'-`Y,,I+$/=,`H2T'?G;1E)]XJ9MX+7*-@`-!>86\!H:W:6EXS<T_D
M#"0]\=#T/2OWW=`*W1/+GA:WH0(7W79#IW/Q7"]0]H0_>J54.9=1*PAII411
MP`*_IFB<1Z&"/(AP!@>?Q>$6.@>.F-,=WF>`6J@2UZ=/G)B*V@-U(`0T(01K
MH=1]2^,8_[<NT`]"`YI^]00WH/\`&*+&$1`B(3(()3+D46-\NGE'?716@]KD
MBR(!'0!GTH@!M-KO<?H"5MZK6*Y0A^P^0P#!1<`&PHJZ8GZLO"#)@<U),Y`%
MK.`&+!`$2>"L"D#**%`,6@$#<;`!^6CG*U`"#.`EOQ.,_5`/R!N0D+,F\MF\
M9S!>M:Q#(<'HC;[:OJP<$"BOGP,ZXL%>[F7;I]-PR4PHXMOI$'J2*AA@8&6P
M/0QX_.YFQ>9L>.'-KF+=E>\J)8?K9BB$$:;.P)ZQW/TN$[86(TLO]RR$*`O>
M]HRR.[>4:!$;EQ'M-&-%H%$NG!$0;Q$7,JOM4X?0^)V56Y&D"O"E)48$$B\;
M__V&*[S_*S'UI2B[LEY&E4#:4T+U6NEQ!H+H:Q1J:(@&5G`JW#/-X3-=Q!=:
MVRE.F&L+Q2`>*8C)"6P*!W[[4%V,\31>'*06`&R!!OX]QH,+"&]-;UD1&X<I
M,#T])8PECR400B5"0I)"19F91V98+1J@$E&CH!I11G,=+V4=<Q@=L&&R<'!E
M+S5#0Q.[O+J^O!,$PL/"+BX!(6R9#4U+"CM!1UE9&S,99CP\<0?;VP?<W^'B
MW#,\&4F'04EQ)#M'.S`'9C@X23P;.4='*S@,#(L``1:QU&C1$GH(<03LL63)
M@ATK<N0X@P(##!9&C,R(LG&&1X\:S&B8860##!122*0D@:(E_\N6,%O"F,F"
MQ<F+-6=@N<*SI\\K#H`Z&"HT*-"B0Y,J'2K!@00-$J)*%245PQDF6+,R@5.G
MC-<RM&AM[5H&0A$H7QY`>D2CA`JW<%6HH$&W+ETT=MO2>/NV;M\2>0/G;6)7
MKN'#B`WO5?&$3^,3(4Z<`"-9,IC(E$/P.<%'<V7(EY\8+H&&SHH@IT_G"!(D
MAQ24,:6PIK.#7MTF:.@IT*V;#@XZ"H`+KUT;!V?'3T2K(,)8A>;DT*/S"4"=
M.N7KH$.$J,X]P+'JW[D?&^]]P!0.&VIF-()AJU<X83J<Z8!5?H<<]+'."AOF
MS)RI4_WW7U-#10'@?TG9(=1./PDEU?]0"GYSQ0$MK!"`,!9DJ.&&!%B`(3$@
MABABAQ941\,2#22G70@((-#$>0J\P0$'AFRP@R-K04`))97TJ,DFG3B@`2H8
M8."**T5V$$89-;P0'RQ*SN+5"PSH`LR55XXHS`3?:<>&$$TTLP,T061!P@89
M9-""&7%T,\Z;X<3!@QE)L+#!FD>T$,<&*_"SP0$;X+`##RW`H,\*2Q0!P4(!
MF4500`TUQ"@]"T1T!@P8J)?11AQ]!!(H+<Q0)PLHO?923"B0H.JJ+;%``DXH
MG%01!BWXQ&!/1BV%5%!+]4J@`U$(Z92!`$HUQQG(7I55+74T^P)98971U0!?
M/$)$"=?*%1?_7'H)5A=;:P4V%UV`>1L8)(FE>QA=B3W&Q[OP-A;O9O"^2YED
M(;BEW%NEG<;::M&\]AJJ**%&AV]XT8!;;KLUC,,S8XXI7,,G1$>$:,H1$5ET
M'%^FG<<53S;9Q]V5')YW*(M'G7EVVL1"D>Z](+.3Q]J'["M,Y"=+&&'!X=^!
M$@PHRBC`$CN'T$/MY,!.!_C$E%.B+#WAA`=@<48('WJX(8=:=JUEAL:X$,(3
M*3YQF7<Z-,'!&S(:HD@CD.CXB"27^/@C)RU$<<8"D4CRXQ;;^5+&SOO94F4N
M$UB))2]>=S@$=2M.$N8S0=Q09C779,`#-][$^4WG;<Z9P09)9"`G_PS:S!#$
MF&8<@,(20<1A!@G[K,`HHR4,)/?M"S7TT$0X9<11IYY^-%(+G\Q@A:LH3'$$
M;#!-D>JJKMY4$PPDU)231[7R="M/O"J%U*Z]*M544Z,06VS041V;K+);,?ML
MLV#14@:U1.SU2`-\'>:6_N8"S/_ZTJU'R(5<YO*66]25+G"]98&(28X0H(,<
MQ[SK.)L160@4YA;F,&<N./"7:U`0!.@1[#6L64%Q$A:FA"!D-P\3%&\JAIQ]
M+<<Y8.`8QT)P&="(##+:08;)2D9$E)''/#!(#\QX9HL:.'$(K'A%D::(+%AD
M14KPZ4"QA$85];7O:%'1U4^2\J"F7"%"3?^+0@\\E#429:A#C8MCB#1$`!?D
M\`EL^)AV7/0&!60!/3>"6]PH4;=*%&%%F3@!)S2``0AXQQA<<L&&@,&`^GV%
M28A+W"\6%XS&11(9VBE"`TH@IA6\H4Q9<,,,W("--HW#&V[JQIQFL`$VR<X>
M&8#!F)+`C=79@P6UNQ$->C!,WCE*;L-,)C&).<R#5.H,F5K/\$91/.-]`GG*
M,P()I"<]@KF$!!$()ZEB%2L66,$*GLK`##H!/EP=)7Q$*9^OGD;&`HUB?>T+
MVM'DHQ4X8(46=9A?'6BQAFI!L'_^TU8"`?-`2)R+6VQ)H%\.BA@AI&LQB*'H
M83#FKGIE$(@*(TS_"?AG0QK0@352.(+`2N7-ELAF!0?#0<(4QK`7QK`VNZE8
M<IISP^5L3(<4Q,YU@EC$HJHL92ECV2'.L"0(W"(754I<&:9(52I:D0G[$<N`
M!+0^]1UM0,%*BM,<!+4P&D5"+3C#A=JH-:W)\:US+)&*$!`"':SH&&Q0``>"
MP`@<#=(2E=@.)%W``,CL`)@0,$9U$``>.@9C`@QHTLRBN@O%<?*M%G#!$([A
M)<DU@7*GI,8,4J`F-WDNEMP@5`:L8+HVK6EVJR/!-W@PICBTX`BHJ4TQE<G;
MMIQ`=VL)+ET8\I`5G`$C1HB"%8;W$>*!9`;77%,2K``#*60A)2U5503L_W0(
M&)QA`^?\B#J+QR`&$85\\D1O@<[W-'P&2$`UTXI\Y3<M*&@T,=N2J`#+91<#
M&G!<$LT+`S.*K@$/F*/PPM=EP!#2,+6E@STMP6]4JM+8M+0E*:2-3&^#!F?P
M!H8X&!MRY/)!N?`0J,EQ3,4R0U2CNA@\1$1B>O9FB[(P8!6X2%P8D(2D*5Y5
M/TS,(ABY&!4OZG,JNO(5@(ABAZ9A(0HTZ&36W@A'N%HY:W?,XQ-XR`8P!("N
M32"!7^?&(T-2QP7!L`"7J".$AC2!&9^-<Y@:$``V#B-Q_O"'+@B`)3YG";.?
M!.43'B&FU;$&!FXH72M?^3EPR*D%ZK3EHS/`@O_5[<`;9G!''%2GPATLH:_#
MA5M?'R&$WUH"`G(++F"<F8-,L2`*24@?<STUDAF`"GDML$*=!#8P@FGW$.AD
M+3K'ZZGPHK-6YGVG>N6YE%\YI;UEQ>>QOIJ??VX%*PO@RK/P-^!M172A[.J6
M7APJ[@`_V,"C>2`#_YO0Q$S0;"/;8)CF'::1RN4)0F#.H'$0A)4.[-\ME<)J
M-)PPP*`A-Q_6:7+T?4.-C0W%C?'8=B8N1.YLY\4O5NK+,+"#,N1@`658`A-N
ML0LX&(FJ["G2?*Z:528@"[[2_NI4B%:^\[&OR&>]@M[4`"*WNK7*5[:R7+<L
M\3Q>!@%/:$)P,7'(,QO_@X>2W-H3%'"#*6R3!!RX^G7?H`([WSD7B/,SXQX+
M#"M/(+./@QP;(*$`RD&#&BE0M#;`\;DVV5T;9BAMZ-:T@7WLH`7AF`$\>*#+
M,>&@+8QXL""#6P13JP`"CX=\JD^T@`6T&KD=<6[Q1J*!Z"HO/2X]%:I^#5[6
M6D-YV#N)]HRPW.7.P"CM?">S:\YLFX=QBU\]6L[F(-]^QJ\.:+E67!":T&^?
M2_'D_E9>^&ON^W8;W0=UOF'D=8(&TQL-(AWEQ7I*`W[#!N`7=NEL:H-]#NM&
MX43(=\.%<&(=7G!%0I3DV2QNG2!>'./<D3%&DL"$J3*A!_0!`8>S`$9R)!B0
M_W))@A_R)1&6XG)$]EX`<D_-]FQ?]"!G!#YG4`=2!G1P]'-!=V4ELAV,%0!@
MP`;*\00H\UL7]QUHIF8AP#]U]D86\`0W$$XV2",SDG4D$`1-X`(APDE]5G9"
MMPOAH1U",$I-("BG!`U)=`AN<`W:($O9("=R,B>VE`UK,@,[N`.\%`Y)L`/K
MU&F!A'QCEB.1D0F5H`)I*'F-@`.5XFK)E7G59#RVUGFUEAXJ@2J]-CTUPEJK
MU0)B8`6'H#WFM'I68`0LH`%CM6RS-X$$PE[NI4_4EC/+<FUA$3_4(GWIEGS,
MAT!\87P!U(D!1&`-1'SXU5`+!$'ZHRY/8'WT1F_GUO\<'X0&*[!2T+.')T1"
M!E,<.!`FN?$<T+%]HD$$R,`QF[$B021)PQ!_D`-*>A1O0D1Q185$-9$$2;``
M2\`"8;`$,!`&+P!V.=,!)W<T")@DR5(J`J="=+``R')SQ@)&^$2!T98*0A,%
M/&$'3@$'7M=S'/B!09=9&L)9(6!1*.B#=-0AX"&0@O5&8'`#&Y`"&Q`!.8AU
M6<<!4Y`%/2@B90>$N_"!9X=V(SB0E5!H0?`&.Y`%3>B$:6(&9B`&9H`\V8"%
M+4`H,`EI?<>%XV`%06`&[Z!;JO:3<P-YA_1;:#@0:]B&EA=-I[!<G:)YMO:4
MR;,1RR,K%Z8J,-"'+VD.@GC_"."E'H>H7.D#>[EB/L_6B/(HCY'X1;K7"K[7
M,VY94,*G+8:Q??XCB@+F7P3T8`HD4>JVB1HU?'!Q7^P6F`?TB6HX?:[XBJ\X
M4OJ",0>$`_[F4N$'$Y$9!#C@',%H47.Y92*&+_!79R(B@R5"@GKTC!+'0\@H
MC2LS!3A1)TL0!BQ@>4:P`"^0![FP`$LBCJZ`"N58)"XE!7C0)_3@.ZW@CI(8
MC^[5"O`8%/@H`3C@@Z'9C_XXG1CR95L3FF?V."<#FBZ@`!&0`N$T(^"4@SIX
M`QGY@QS9D8_UCVJV9I#S@I/@#&3"A!R0DJ6SDBQ)*/HYDVL2DZ%"`BN``N+0
M)I0&_P,($4A`.4B2IX:`(QD_8I2/QQ`[D`,HH!ZRUA'55&N<UUQX*)DOT6NO
M8@@I4)-I(H@UD1Z">$ZM]Q'?PXBU1Y;M97NXEWN4R`0"$#]N&1:9*!?\8YCJ
M0BZ=6"[^Y5!"BD#EMGS]-7QR&7V$.1I-2F"`V5"',4$*4Z6*>:6Q.(R/V6\F
M!'X6!A.KLQ>0P1G1,4'-L64!`$3P1V5?TR$*F9JIZ3%>YF4MMIK:DP08L`0Y
M``.6QZ??6')P\`)PT`I&DA%S@(`SH2J6B0-PL`CUXX!<Q7OPF);OQ00#<EYZ
M4P?4N:ERE"%GQC4]!V.;I5C>00`Z$`0I`)X5.9$S8G7F"?^=Z+F>8C=V'JDA
M1H0,0K!VA98%.T`(23037)DF^,F2_#F3^UDH)01+<F(&-G)X$5.&9(9JD?!X
M/K(B6T"4:&@)E&=<R.5Z&)JA3UEKF6<3,*$J)I0JVX4FN"8ZGY<>P&9.AQBO
MR>5.+OJB,IJ6N;>6E'BC82$`M?"O!`4%_*.DIJ@8!=1?<KD7_:5\#&ND,[5\
M"*5J;7%`Z!*E4)IN&V5!DL%?#G:E5[H_C.&8;^%]7@IP*'29G9&:-22+(3MQ
M0;2/7^.ISLA#DW&,8-`9IQD9J.F,8$"-&'$$/7`$>1H&1U`&6V`E+P`!3@0'
MY'BHZZ$],R$%AP<!E_0>ECID]"'_<Y3ZCC<'(0Z0@1M(G3#+J<00D(H5`OM8
M(IHU'NZIC#1X"!(IGJNZ*J^JD;0ZJ[+ZCV?')9NE=@/1#,_0DSL0HO7)E2E@
M#6GBDEE9DZJ%6ZWS!\N:`>_0!+P:,4N0(WTCK0MZ"8G$`"N"K4;9",^D*;$V
M:YL7KIXR/,SC$AA6KN!D!30)DRRY6ES9,H58B,OS>DXS>Y"(EFAYK^]%;:E0
M;3@:+5\!!]32;1`TI'897`_T+43:B81QI.*B;MB"?-J2BI\XF%*Z+=.7LO;7
M`+<14N0[;XDI4O8FC`<$#9&)0G30!"H`OO!70T]P,<*8;T(TMB.266\Z,I11
M+QJ4&=E1_YK(X+,LT'$8D`-E4'E44@.5Y41-LF-&(@')12<U03LX@&I)6[5@
MX8#^,0<"H)Q;%8DR!U8M("3.&;9DN\)=`S8+"3:*M0M.9PQL]+;A1)%8IRI3
ML,-3P(.P2@Q"",1!#()J!C9]&TJ#%B9D\@QF,A/U62,JF7<L.<4UF03J8'>0
MA@)CL@1"L`%NT&DXT#>1,*V;:S>:$`*>&QG86@FBRZWK(8=SN*&IVQ%)0)4O
M44+E&@'74*R0MEJTVS*#2(C:,P.R)T^]6Y:0N+7YFK7UP:]PX*_V\QY?L08"
M&[%RN8D`)AC],V[?,AH+>Y=V>;#C1D"H6&""62[$)R_VMQV#-O\85OJ*YXN^
M9=-P*M`$M<@:04`')?`$:OJ9U$$$%\,Q(<L8:-NIHZFS'Y-!\9(<E0'`(Z.F
M<LHRF'(&2U`&3+`$,M-$.98XMU!)5YL1;&(&V!,$2Z#!''R\5WL5`I"ODYI/
M:BES8>44=,``+%S/^ALBWX$`X\&VQ\`E7$)E#>"0<9MU4V`Y)=FK.Z``3P"S
M0WQGC../'TF$:XL,1;!VI+0$T)#00;`J]<D!W,65]YDYPWH(_%DGJ3(F3<`&
M02!X$>,6.O)X,%U(AJ0)^!(`#-"@/[(HHXM<I?NMISN'G;*Z=SPPJ@)>PJHF
M+BFLGR?(Z2'(KW9>ANR[2*;([$R//P;_R?YZ25TQ+5]`8LN+R08K&.$2;D#*
M7Z'\R=#+?`*D>-U+L,Q+L>R&41$'?Q.7/^([OH21UQYKON02LB*K=,>(C$0T
M-GY]IB&K,?>,(:,)2CV48!O#&9`M+S=+?9T1;Z@9`@.`!YC2'N]Q"S6@S5[`
M"Q#\V4>B$68P`X;2`TY%M9)<"Y?D3[QWHY;ZP4-V9/!EHY9J5D[!!'Q0S[Z-
M6<>@SV&#9I$4-G86T.&9P^;9`&6C(LH((@WMT"H,5VI&(F<W6"$P$*34#";9
M!"=IE1V=DESYA.IT#DGPA!YQ#C9Q)C!@F4T0`DL@N#M`QG(!6#W"=#_R6Y#!
M`*!TK9H``2?B_\:G8+IS"-3?.DZ4&1-G4J(KV<<,;J(S@1-.71,O*M442-6Y
MQ\A8P:^0',E?40=:4`<^P&W6`GUF?2Z;'%%CW7SB4J2#6;&K&"Y_L<D9Q1?X
MILK:P0=>%@"M:!=Z_<I[[6!T05(4!*>#'0!\D'[I5[_!"!UK%9K'S+-JG..\
M?+/0[$,_]+^9(7$]RYI3Y(W:/"5/],"X0`8[-@<8<0A'D,&L#0?9QC,>_A[^
MY$]7.VWP=><@C!5@-!2F`+:_3;:)O;\TK"%[VX)GAR$T>,.M^@9/$'4<LIYD
M-]U"++9%3-QH)C9?(CD8[6D*(`W3H"J%:[C6.%WH8+N'D"9N@(<DD/\%CZ``
M2=`.+0UY]GW?#YI(^`(9-JT=#CH0`7Y<K+<IU%3@!>Y<47`J.YA2,I$"Y[22
M(KU:'B!L$6D3$3[A,!`LY`.)ZA-MZQ.IPFNI]'%5COS(CUP'`@#BTN(#P%<M
MI*@N+I[6@9E\1DJ]8GWBJ;BP?S%N_\-0>'G)IDA11&`OEG$"UJ$"=XW7>AWD
M0KY`9G-_U4%Q+LL'ZA<=AYT<,"NS]O?,D:'C(7-!]E(O.@M$QQ%OEJ$=F5TD
MKS8'9>`#+^`#36(+GGW3K/T>A'K!($>U\(%5.V.\54ON>E[G5<U[-@I6Z2,!
M^OCG1H]9A%[$H/H$01">K:H`Q5RV<+0XGB3_Z9W:(7O+OY!3"4C8=F-B)JMB
ME<#JA*J4:%QY]GDG*AN0*ED`)AM]P!%#`_=MQ@_Z&2%PK7>?ZVJLW6[NZ]1$
MX,(>^.,D,!6&`M_IA\*:=R7Z["6*A[(RX:3"`KRK[3'W\VQ)'[+-KUOAK_Y*
M%ELMXB).XCUZ0Z/OI,(%I&V=I/`N&-,+I*@?F'HYL>"R7S#>EZ<X%XJQ0,((
M+T05`@3ORAV+\!T[4J76\#.+C#FT'!+$Y!SC=8N-_!ZEL0GV+KP,V3U$LYP1
M&N^BLSW4LU)@\E'1?Q_P`N/O`S7F3]"$)/-Q-)EB*.^Q`#6:5:X])5O@#\VR
M>SZ?K[C]@!(`"'1U_P2$A8:'B(F*BXR-CHD6$Y&1APTW$1PDF5,*(846AQ,$
M$Z2BCZ>+DP23D1,N`0$A;$(E34LX.T%!,!LLO;T1OAO#;FXS;E9)ORPP21G/
M;B0["@I'NAL[V3M+0MW=1>#AX"?D)R$AYNDA`0PA6^1%)4L+.2Q&5D8S4?HS
M_?[_`/_M\\<"!8HL4E`$04%B0PHK5IY)G.@AXHP,$(.1@,&0A<>/'XTXT."@
MI`,))5%&D<"R)<LY$N;(G#F3R9P.3'`R82)@IP`X/^'`*3-42QVC/NKX>/%B
MP)<2)52HB"I5Q9.J6%70V$JC!%>O6Z-2!=L5*E2N:+DV2>MUJMFV4L6&#?]K
MMJO6L5/M9FTK-JO?)WR>G.!S#A:?!FEIK%W<I+'CQY!I-"@<ZYSE$&`&/R$B
MQ"J1)Z!#`PZP"E8L<V#XJ`8<.##@UZY9`RY'[MR)S*Q3\TF-+@2?`7C.V'L)
MQT>-&A]>E`F#(4K)E3%E=NB``0:,'41W=CB#,XSW,$*'EGG!P!2!(77@[)QC
MLSW[FV=DNF3)I`XH5/CSZ]]/R(+_^ZL\$00F)#@Q!2<!`-A?**3PEQ\HH$C"
MB@NO!$!++4UDH\L1O`SCX3#";)#$,6XHXR$*&V1PT0S2-*10$$EHL\TWXM18
MCCLXYKC%.NVX4P0$/=!CCQ'[%!G0D4C^P]%"":'_$,$P*3QST4085821E!M$
M0`(*'%D'TD<8L!"%<R:==-)\,:5)$TTYL8=33STQ$5YX/PEP5!UEW)G4!W5`
M`84*#4RE`A%27>676VLEUI>@=9%U5E=A)9J8I%4M^A99:+E5%J1['2H5#9YZ
M1940H`U&V6&(H>688I"UNNHZ`8!A66:#K7859Z+ERD<`KV!VFVK`!@N:K;D*
M1A@Z?-R&CCG(DB.8K,G*"@9P81K!$DY&)5<&$R*UX`!T,F'0W1D8H+``'&%,
MMYU.89PK5!GCE1=*>N[5:Q-,9TAPQKYGR$F:@P`'S!\E"A+RQ!N;3)'%#9TH
M$F$I`I\2X2H+#E%9"!<V_R&/`KGLP"$,OH3X(3''?)A%$-#,8$8+9FP`PPH[
MH"`C#BH(46,1M)FSHV4[[WC"CNS8ID*0.<!@!)%C#I0D/TO[8]!"!D60@D-6
MK"C1E!%!%!%&69*PI4$;?0F2!,ZA9*8&+L%$4W32R9333G#+6:=0=>*9)U)*
MU9'<"WZZ9=6@GC;@*%N00B5HIGPYZE5CF+(5%:B:BOH569^693BCGUY>*55Q
MN34XJ,-*:QJ@J:K%JJNMKK-.9L*&]G>QPSYQ#F&MJ4;J"4^0*IL*?%CUVK"M
MX9XL:KB?DUIMM1U[`K7#Q:03$_F2-!)T9(\I00=A,(%"#@MDO^YT.WWW+@1#
M%/]<"`-UP/W\>NW!'=X@$<<OOR/F@_'&@0?>P'""B$38ROR/@)`K*F2960@.
M*K;H6!"RL)%?C,Q#22B&B9)`@B6(R`P98)D9DL""(*Q`%T'8`2Y*<#/:Y`A'
M/;.,SF+!@!,(@6A#(E+39AB0)!C$(!YZ$D2F-*4K000C$*G(!KQV0X-X"208
M.`,*Q)22,\UG33/I%_AT`B>ZS<E.>2J#4?"VISK4H$]0"!2A"&6H3IFE,9#Z
M"J/,DA>ZI%$QA$L,6O"2E[N(17%QX5P>]>@IK,P%CFHLU+'6\0HBE*!T6V$,
MZAPSJUH5ZS.^$XUJ".D;V:PF6,(*C%5JIYIR$$8SOC'_E;)08[Q13DL*0XH"
M"^;CG!9X"SID>J4$,,"$'*R@>^K"";O:]2YY+0(]ZH%;G'8RI_34H0Y;`*`R
MEZD('2A`?]`,@@+^U;]1,',1%'*!)$P#"]5AK#,76H*,CG"$+/#"(R-+000C
MZ(:I\4)E&<"@*UNV`0]Z3!HB)&$X3+BSR_AS1SZK33N*0(,%K,`C1TL:#1<Z
M`RO<,`)/@M(.I?0,*UC)#%9X2`H>HB4BHD")'"E(F(3#KS&9B7HO69--.G`3
M81(3*'0:BGBTD*>DV%1O>CN.4[)BR$%Q#B^+220:W/BIO(#%<W9QH^F""JK)
MT5%0GKL4733GET5U[G*&?.,<_ZL2.G/`P@5/."0B@[K(RF@&=IOY3&@(XP(+
M#*8JI&H-8$+`FF3%!C";S!41?),:2]Z&6;0:)&;0,8`IC&TF9'-`"[#@+;))
M[Y70Z1<.T/4V78;O.V4H@GD6,8'TJ&=.[SJF:%^@ALU>\[3R"T`3@G"#-P3A
M#6]H@B<.83[4&L(5N(W%5TWSS6X(+D/96$(6K,%`+STP"1%,1HDPR-QX8K`7
M)#B"QZZ#`QS0X$;,NDR/VL%=?]JF-RV$`!Q6$*8A]4-I`1F(>L_+-(!$EP00
MS=(PM%:U?E3D(57#+T0<TM$BYJ"('SU##FS)!#2U)(KQ>5O<>J*>H%C1;G<[
MYDWSQO^G&FRA!GX*U*$(A96HE*XN=.G<&MD(JK?(\<1<\5NE,!>7GJJXCRR6
M2XG7B.++E8I6L`J!5A#3`+*R*I&-"8!=T5HL0@I9*ARN:R9C4[O8N68UCC2'
M8)1%F,PT<K"K&P`J68"!)$IQ#JU4;)FF]Q(O,X$&$%B.=YB0/3:WZUSDJVTB
MT)=%/(EV"PP8@IXM)F>!]=FV_$%`$Q0`VS?\(+8(<!B@^^<*"U#(%;#JY@G8
MD+MN)%`!)0B"-73A->N<TT/J+(85-@#/?JAH@\,X`CZOLXWK,@N@Y^A1"+8;
MZUH#5!TG`-("A!.2?(Q)(.Q-FK"'K=!^!&$C$8TH?9>MWP?_.N1K.9!"$*+]
MT8]*8<`K6`$=5HFF.<3';6YRG]QB"B^B1/BF27D!GUZ`4POOE*N>*515)8<I
M-E[N<5'IJ5P,A^*MW(53D,,*APN%%\B!YE"/,R-4_:@HHT:E5,J"E0MT[.&T
M*%(QIR'6[Y[,*Q?T+BO#LHIFAC<LNK*F5K;2G2<[J3P<&^\RL3J-ED$6G^>1
MS5LE<>6W5B*3?<%'3DR!EU"^(SXX;,&TC9B`&M"WA3HP(,]Z)D7!_KSHJBO"
M!0V@AM850`,76)U^DR"%-B?>\8L5X2JU6(+&EK"A#7EM(V%SH(=6=(Q1-W08
M,,A"=4E07;5[EP'L8&'@`3]K%GIW_UD_*@$.E`B2H]WCUT4R$C\>;X4H5+[R
MY]T'#.`+41*P0-D;6/9\Y9O#+'V>!-+V8+8_R/K5TV$!.&`"!MCF[9;&C9@.
M?E<6ZVP4.W>Q!NP&/E,NK(:^`6XS!Q?X5#0\QT#NA<-\/(M1YP(6R17.<$^%
ML?8[M?#H8[]QB!L6*8T,AD-*YOP6#\"OY!JL2*N&=R7X#!\Z(Y5,*MFN@3EK
M76&S&[OV1E:U@67*(BN7`1PPP"_JDUC[H`$,N!+<<7MQ8W3`YP/E!EKD(S"E
M@'1?MX&H`%:.00U-T`!>QX$.PPJ2<((!X`J\)0O=(`\XH#$X`$(;PD!OUVDA
MP@(CD@3),/\R,U`0"K`$1X`#2S"$M49X@<=-1Q@T0=-=/A,/--`#*[`OU8%0
M0X(/1V.%1'*%CI=061@%]W`T)#`%\%6#<C=Z6?(D$0`#P;"&6:*&)*!ZVK9Z
M<OAZU84&N\8OVZ$=$2@G=%)NY78G>9(W[!9\+W!A6_`"7W1A#.`G5P$[\H9D
MFP,H;P&)/,5''58IEH-4=@1O(G8HG5%&*V:)4=5'?'1]S=<7XB<KIO$*5R$X
MKGA^B'$:*-=)N_566*%)228;N+-6<[6+LQ$8H50KHF1E8'`QQ?ARWA0+JC@`
M=+`".7![^;(2D!<3_0*!MU<&6S`$#"!\?HB-5$>"X,A,+@`&K4+_!",8CH;P
M'Z(0=HXV=A1B&=[0&$L`%;GP0;F@:5F0!0SQ=I[60*.W><.@#'PG3FK7!#T0
M:4B8D`H)"X0G:[E64-F6`THTA6)3D?;@$58@-AEI!"P0AE+P=A_Y=I\WDKX`
M46DHDIWF>6\7!'1`!R*$"SA`!]4UD]75`SU``]!CC3$5'GD"!W;VDWF3;NQ6
M85M0E$9IB$/`B+%#9(4R<'U!%8UH*/3W%Z)X53^E%X](1I082=OG%P,G%9]8
M,X\(.)WX?78!E7.EBH4Q<1S6`*YX2)4!@">0(*_@2(T(+*_C?[YQ2?F7++9!
M#IBT++[Q785Q&6JI6ZH3*ZHS+8:!)W13_V#2.";>1DQR(R<0Z)-0-P06QA00
M\`)#@(Z@N6@6``9N&8(A^`3G&)K^(0F$L(ZE8`'E,P'PV((]P#C`)2,?I&DH
M<`2[^78=X2&\8$0N0P(*T`,_6)LT$``6LYS*V9P6TYP+B83M\)#CM7H2B0+5
M41U'!#(6V9T>H0M3(`7A*07DR8\G68,LL`DH\)$=142I1P<*0)/R68<W20-U
M@),1"%JZ-Q2^%Y2#R!1UP!3;J`8?0*!J4`/;^'2+"`7L!YA$ECN0M'Q0Y3I1
M^8B-J)4;5A5D%)5WE7R.>'"DXCM^,96O\S<BBA6RDZ%]M%:6P4T4$@`'-W#=
M1$@6$`LLMW_\!_\LLS$8/*J7ZC"8*N0KS'(QF(&81JI;1PH+`Q``:M!TQR04
M3+!*4CJ9?*B?X6&9/CD$$[!G3X=GH?FEJ&4!(>"69-H`3_"-5@<A$Z,*H*!-
M-1H+N?,$18`8:R$$&8(+,G*/,DA.ND"#F[=YUK"/UF4+7)&:H=`*N#4$+L"<
M"[D%?%`"0;)Z!N6,2K0O!J%$-U0N',$EV`D#V>FIGHH"=""#I)H0J+>>Z^DU
M'TF>()1ZI!H$/Z``:&"0:%";]<D64G&?5@HO=A:(-_6?7F24""JL3Z>-3Z<&
MQ@H%2E`KTO(K(Z>CMQ*C7(56K_,[,5I&H!&B'X<[0A"8.MID&^>AD13_E7%Z
MHB**.RB*%:0B!+A2+-T*BL"S&TCZ534:&D0@@@GB:$(VEX"Y<N:0?_V*+(/E
ME_^Z&_YD9?Z$F(6)D-&Y6Z8Q`*_@I$('![R61"]EI1B;I:2P9UH*IAZ[3*-Y
MKV1*!&"`IE7G/^GHFFY*0%)V(5%AI]45GS@0G]FP>GKZ0;SY-4^C"U(PCU-E
MJ/B1@1,`G>I'"SBP`)-Z2]8Y8!)IJ6<@!95:;5"[GDHTM6]`!U?;DBRYM:_*
MLT%`GJ[:DF++DF([#;-Z8I,H%47`!T]*%+WZDTEQ3%]4B$4YH`AZH`>JH'JK
MH'JF!$J0&0287=`BE_I'H9$T2="Z5D_&?L7"_SM\^8N"H8NT,XM/ME9JA7_Z
M-V3#\J[6NI2PX61+&1AQ-:0)V583]P1RT%8SBAJ5@;C(0QN3='B'QUL*FZ0-
MBX05PBN[Y0)04"%.ZIC\TB\9.[Q#D8U"^['(.S_UV@!J]01@T%;_03$FJTS1
M2S$G*$"10$!T15?T5P*Y(X]H,(1+@`:XP#$SFPW5I:<@I&T[0`=-\&*S%3]B
M%PL$99,S"7O5A;3-*(?\V[_\*Y,*0`=H$,`S&[,NZ9+MVXP*;$\`C`,#/,`S
M"\%H<+;V=BC!0@ZBE<$!NL$!VG0,@&?'JJ!+)\)0AZS(FF?(RHC-NQN@\1G-
MZSJ>@GQIU;R#8J]()O_#8P2)1!"A.^P9.7RASGLK+@PX/:RA.=S#:K7#2DQ&
M8Z3$)HK$'.;$2*S#-4RR<@`&6(S%13J.1,"DNY$:6,P'2[S#,VROSJM66.R\
M60P&:IS&;;S&<!S'<CS'8*`&,0<&4&`":J`&;&M,=(`'Y-F20H$&0D$'@WS(
MH$7(]LD'6AIUR?O(?F8".\R\S/O&)@`&EVP"FKS)+F`"%/(?H!S*HCS*_B&]
MT@N8.,.CPHA)K-S*KOS*L!S+K@R8+"?+MGS+N)S+NKS+L+RV:ZL:<A`LP<P'
MP5P'<E`';'O,QKS,QZ3,HJ7,<B`'8SS-U%S-1/``.XS-V7S-W(S-WOP`X!S_
MSN(\SN1<SN9\SG?P`.D<SNG<SNY\!_`<S_(\S_1<S_9,`?*,S_&,SQ30SW?0
MSP`=T`(]T`0-!`7=SP:=T!0`!`S=T`[]T!`=T1#M!PY-T1+]T'Y`T1:]T4"@
MT1F]T1E=T2%]T20]T2,MTATMTB>-T1W]T2[]TC#]TBV=TB5-TAI=TR7MT3`=
MT3>-T3MMT15-TS_]T2E-T;Q\U$B=U$J]U$S=U$XMS,`<U41`S(`A!ZA+!-)L
MS5J]U=K,S=W\U=Y\S>#<S=]\SF9]UN+<SNH,SFK]SNZLSFYMSW)=S_S\SW;M
MSP2=UWJ=UPIMT`O]T'^-TQ<=TX1=V"%]V$1MV(J-_]B+W=B._=B0'=F2/=F4
M7=F6_=A/G=F:O=F<W=F[S'^H&QM)C'QDO-6F?=I+K,VJ#=9D+=9H_=JP;<YM
MO=9O/=>V+=?Z#,_Z7-<`?==[_=L![=<"[=?$S=`+'=B"W="7O=S,W=S._=S0
M'=W23=F>7=W6?=W8O=0X:M6!8=55G596C=KB/<:KG=JL_<UB3=;A[-JQW=ZS
M_=[Q#-=N+=^WC=MV?=?_S,_`O=\(#=!]?=P)W=<-#>#)/=T&?N`(GN`*ON"2
MG=T._N`0[N!5W63=#1KAO1EBG%8S/-ZHW=5A?=ZM3<[LW=ZQO<[LS-:T3=OP
M3-_U?=NYK=OXW=OZS=]Z+?_<_@W@!"[@R:W<#-[C/O[C0![DC1WA1%[D1J[4
MEO0:%XZZ%C[#X9W5'&[:'D[>(#[65C[B))[E:IWB;;WB+?[E^1SC^>W;-,[?
M_XWC.K[C*BWD;-[F;O[FS'WD<C[G=`[+$\ZX3,[D3^["4=[A2OSA81WHZ2W.
M6)[EAO[><"W?*@[F]CW/O)W?>%WF?!W<_8WFQGWIR(W3<+[IG-[IGO[1=1[J
MHF[D^^<:5GWJ3<[G&][G6CWEYBWHZ&WEA&[HL(WH\)WHC`[FCZ[?,2[I!UWI
M!([F?YWI!?[IQG[LR)[@H[[LS%[=I2X;N>+=%R[-5\WJ4O[G7@WK(1[KM$[K
MZWS_Z_&=Z[H.XY#NZV5.W/T=X.JNY@R=[.[^[O!>V<T^[_3^U+`1S(`QU?J>
MZA=N[=>^S:]^WMS>[8>^UER^Z(HN[O=,[KR]ZS-N[NB.[L(>X,.NYO%^\1B?
M\2]=[QS?\4B.[W*5Y^&]P]3N[UR-[:NM[;)>UH5.\.-LX@</WW&M\`LOY@%=
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MO$2^P,*^Q,7`#\C)RLO,S<MWS/_0T@_3=];4UMG:V]S=W!36X.(4Y'?DY^CI
MZNOH0!3N\._O0/'T]O?X^8[[_/W^_P`#"AQ(L*#!0:(2*ES(L*'#AYY2J6J5
MRA4L5+!>L=+%L2.N7\)L!1MYK&2R8\Y2JDQ9C9I+:=FP>9M),YQ-<SC+C=/)
MKF<[<O'DR:LWCU[1?$CI'5S*M*G3IU"C_H-(M:K5JUA'43+EZA2K5:TTTI(%
MRZ-9CB"##5M+#"7*E7#C/D/6$F:UFGBU@;LISIQ.OSX#KW,GM)Y1>$D3*Y7*
MN+'CQY`;9YU,N;+EA%R]DK*8:B/GLF=#]QHMDNVPMLO>REU=]Z7KF'EC=]O;
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MANO9IF1/'^86HI,C/DGEGGSV&1"6@`9J&8P3?34C+*[,(J99_PKJR"`R:*;Y
M8VMW5>KF-]D<R1Y[<])I9Y.(/0FEGZ26:BHA@J:J*D0!2L>9@`8NRBAI.6[7
MG8^2JD3I:]J8=^F;&OJ59'MSUNG;G?<`1^*IS#9+Y:K01BL*H5V"=2`1-LK:
M4:.TF-E=@[E.RJ9=OV+*5Y+#=CK8I_/A*:JS\,:;G[3TUBN)<S*>,E$KB':&
M:*S:ZD)FK3O>&BZ0,(U+9+EZG;LAL>JR"R*3RBJKF+P89QR9O1S7BR^7,5HK
M!RJV6!=P+MP^"FZD!T?C,J5M,CQ;L.AP&G$Z%(?JKIX:]^RS4QT'[?%S(7^)
M[;^@G;Q@MPMZ>ZMJ+8<WX4NPR6RNIO]RWGR.L76*&.J[/X<MMD!"EQUM@!2U
M<FB-&RG]4:TJ0XIKU$!.#9NO#*>'==9:_U18NU^+"L38A!?NB-F(`^H<=*MX
M>5';_;J]='9,.PVNW'0':3>OY%J]S=[IWLSU/,C^)KCAJ*=>2.*LK_AQ*2/+
M*-U7!I)ELN1,5ZY[P6=F#I=X==F%M\QZTWR.S7W_'>)A%B^K^O.&MRY]BUI.
M1^!&`..>.^5Q&^R[,VL.:>'PE\)9V_D\J3LZLD<U?S'T\(L]_?S\@1Q)XR*#
MEJWVV:GE[<IS^YYXZ.(27BW,<U=#%\3ZEC/Y!`YL\8N@QNA'P<G@2U^;>87C
M_!6+R&EO8+O_8\O3OB<UX"D,@0U3S_E"%['UY<QT$)2@#.%5P1IBI57Y2IO(
M2%:+V^$N9?_#G(-(^#*[48A\Y<N4\=*7O*U)S('N"\X,I^@L&UHQ*_BJEM%J
ME[0?TBJ$/!*B&#.W*TMU#H4JY!`+U1>?8S')'E%,"A7G:*HKVI%5IXB.[,*2
M*&RUC7]`?-2WB/B[$Z*Q>''B6Q,G!K@X)H:.D.S3'2?I$%)H$%%IXV"8^->_
MIMGJ<H347,*")SP$FD^-"V1C;_[VQF2=+I*PE!(E9]F)U^4K9(>:11\!";<@
M&B.`OAM@A(QX1A3NC8E-9)_.'LBS6#K31+2,)B>V%*.*&"TC'OS@;A>[!\!0
M$K",53NDPX35'N2YQX6ERU,,G\E.Y$CSG9FH7J'41CO]_5&;NN,F,+TY3&)2
MS7.(1-\:1?=$.#+3>>U,:''@R5!,6+(4FQ&0@#[#21#JTT%0BUH9.8=$JX$N
1E9T:'?.\ID[Z*/2DPPD$`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>h03611h0361101.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361101.gif
M1TE&.#EA80)0`>9%`("`@-;6UJVMK<#`P(.#@T!`0,W-S0```.#@X/#P\'!P
M<-#0T)"0D*"@H-K:VK"PL&!@8%!04)^?G[^_O_?W]Q`0$"`@(#`P,.;FYN?G
MY_/S\\_/S]_?WZ>GI[>WM]?7UZ^OKX^/C\?'Q^SL[)>7E_;V]N/CX^_O[YB8
MF.OKZ_7U]6]O;^'AX69F9L+"PGEY>8>'AU-34W-S<Z*BHFMK:VQL;&1D9,;&
MQD-#0UU=71L;&WAX>#P\/(V-C3$Q,5%1479V=F-C8Z&AH;:VMA86%O___P``
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````"'Y!`$``$4`
M+`````!A`E`!``?_@$6"@X2%AH>(B8J+C(V.CY"1DI.4CBP!F)F:FYR=GI^@
MH:*CI*6DE:BIJJNLK:ZOL+&RL[2UMI($`KJ[O+V^O\#!PL/$Q<;'Q2NWR\S-
MSL_0T=+3U(P$U=BVU]G<W=[?X.'BTMOCYH[EY^KK[.WN[[#I\.OR\_;W^/GZ
MT_7[WOW^`@H<2+"@((`&HR%,R+"APX?D(/*32+&BQ8NJ%C9BP"!!J@&#!H`L
MLF!D(00H$2!".2@!1X^+3,;#2+.F39L:%P%`&4'0`H\H%_A4622!T*)"40(8
M!`""(`!+2884F<#C`)@+A(IDF@!!U*-=C0IBF<#DT2(#B$[*>;.MV[?S_]@F
M^EJ$P8.E$!KH??!`@5*^10HL0&#7Z5,&/QDL53"`0=T!C$4R&.`40`,&#;8*
M4M"`*&/'#0`D</I@P5(`=XM\+@(`LMI(<N'*GDT[6^Q#49^B'1`5:M$$O56S
MUOT4`00&7BD#*#!<I,BE*EU"U5RT`80(RIF++M(@=6N0"+*S5M"1TNW:Z-.K
MEW6^D`+=2TOWAD[8X^FZ'M_KAE!YP8,B*L7GW%(@*5#5=R$]Y1^`PQ4%P7L`
M+#C`@BH-]H!C:ZVGX88<LH?*`@IP5L1=CO7&&P0'1C@<`@HTQ11W);(&@&.*
M0>!<:.^%IAAU.)XV8X-%1/#?:2)"12-Y9\'6X?^23#8)27M,0NGDE%3")66'
M5U:IY9859;FAEUR&*29!8*Y7YIAHIAG7,L$5DAN!*^&6H"$@-8`(=;2<J>:>
M?(ZCIT[$*69?70SDN(".)"D004D`&/BB('I!=B%H`Q1@YX5"F=;:+7_VZ>FG
MU'2:"`10,=?9<):I!&%CP[WW`&1A/2HC`J,)=Q\"=M[W*J>@]NKK.Z(B$MRP
MPVZ%EZ)&05"`26\.BRI:I-Z'YRS!_FKMM:Q4:TAP(A'&VJL(](0@7E2)YI*L
MOCV[6%'O.?8>8[QB*^^\H2XSTD@/V(D6=YFAQ1)(-KIF&2%0$7COOB`="N!.
M"Z<5+[T01_RP."VB9H__MA)G'#'&;G&L\<?7>GR3R""7_"G)/RVLKRHR[1L3
M(2U3:_+,-%NSC&,)&&C:*KD1ITC/$TY<\]!#D^PN3)`UZBUF(;;H5`,A(M!7
MNJRQR!FN23^00`0NWF5D4QYA6`O)1)=-I<C&$A(:<P8*FG-S3?$6(%/&/1!>
M6@4/D*M73\TX4L\RFRUXR6B#]!5V1536D<&L[6R@?E%1E2A>"?"U'8*O'B@4
MX!X.[GG&(I_+(@!"-NIJC.6)%F)/[RV(']0*>!<B9/LM9URC80O]^>XAWZR(
M?L\$K0WOQ&-+,JW"OM9,DGD6[[RO9-,4_?/48S3]1==7KSU$V7>Y_?=B=D^1
M__C@EQ\0^=R;K[Z3,Q#@_OOPQR___/37;__]!,2``_[\]^___>L+8``+<``!
M&O"`XR`@`A?(0&PHL($0C"`S'BC!"EKP%12\H`8W.(D,<O"#($R$!T-(PO6%
M2Q!]<53!1D0>_`ABA"6,X?9P]1Z^N:1?\OG666`HPQY2;RGED9$@)%.Q(/+0
MATCDW7U(DAH7NJ1M+RQ@$J=8/`EIK5U*V4SC]'5$*GJ19@6+SW8(Y1.KB*V+
M7TQC]="HQC;NC@$%J,`!"M`3-]K1>0@X@!X/P+D[^E%P$-!C!6#RQT(*+H]\
M-*0B`3G(13JR(BHPA20G68HAM("2F,PD)U+PR$Y2(O\`N4"&*$=)RE*:LI0H
M$(`G5PF)`*B23ZYDI2P9$4M8OG*6N#1$+?>TRUSZL@B]3%,P?SG+88[)F,1<
M)3+#M,QD/K*96X*F,Q4IS45$8&61Z);RYM(HYCDB-S';%S9A%DY'5'.:?SQG
M(A2U,`7\)%TO.=2/-#4AA?%+4AR9"@KK8B=!984[_%*1SQK@G]@5BCL(*$!\
M$$.2Z51"G>BT(T0-P9<(`*="!#I4@%BEJP'UC59.`=Y2RB*4GIQJ7%4#TIOT
M%J01\69%N1K.KCYYRXAZ<J*%()6E<E8`Q3`%*IDQ7',\*L1G":(C98%0@U#:
M)I6F[3G-B=90'UI3FSZSJI'_>,_6D",CE_A':T%ME6J<8R"OP6<0"W#*`L2U
M&\(LH"/:T=J;F/+4EYJK7<*!%TVMJDRL/D(L(W))>>PRQ([\JV$I\4I)#B83
MTYP*7_JZC.$:0\@5ID4EX`E/4:##L.1L\Q$XY2L50WN.<5*#M*)%(FHWM-K4
MRK"UZX&M:TDH6T-@5GAC:0DA&40(HE3ELY^M2F\9(5Q!%+<5M9WM!Y,[B-(D
MA["YM=-Q@:3%%14"7(<XE:P2H5V?L8*YRM4@>&4JE!N*1"_+:@!PW)DSJM60
MH(>23*,`6K$7*297[?V/8@P$G&[BCKJK&&]X*PA>P!2,.2AJW)!,4Q:.-A=6
ME!O`_W]6%:/]:-9@[^F)2`Q#'JUM[A4"'G`$P=NF'/J'H,-YZXP&9=P?W4JA
MB+G0W'2#*PCXQS*44=CB=",IX;@BQ")N((D%$3!WVJDSJ#D49B[4U,#8!U=U
MF4YG(#>6S+3F:JT!ZH<9DY?8=0?`J@!RD!=88*U01;A$28M'2L+;UQ"%5OG9
MC$K>;%R@7"7-7:%S680;M.Y^UZ]C]N)X3=L*Q5@L%I6#A9@#;<!%W\31C%X?
MI&LRZ4B7K](8P;2EMZ=IBW1ZT]3[-$5$#>KBD1HBIR[U[ECPOU:[VG\QB,&K
M9TUK^;E`U;AN1`&8D^M>^V/7O@YV/H`M[&+#@]C&3O8ZD/^M[&:+@]G.CG8W
MH"WM:E.#VM;.]C.PK>UNWX+;W@ZW+,`M[G*W@MSF3C<JT*WN=D>"W>Z.-R/@
M+>]Z'X+>]L[W"WFM[WXK`M_^_D8#"E"Q,!K\X`A/N,(7SO"&._SA$(^XQ"=.
M\8I;7.$6L,#%-\[QCGO\XR`/N<@[_EFX`.``%]BURE?.\I:[_.4PC[G,9T[S
MFMO\YC:O0`5PSO.>^_SG0`]ZSN<H]*(;_>@_MP#1D<[T`ES@`.5\R\FCCBV`
M6XN-'#KY.08`=?5,_6-6_Q76-Z1U<W"=ZFWYNL;"[JNQ:ZCLXSB[U[N^=GZ7
MS.WK@?LRI/84=[)+A5K]C]S3HW;_0G0%A6/,9UW^`UC:8"AGC@+12%OXS\#8
M74V7Z=OD8S>>JX@M,%+<DMYM@2B&X45!KWHI6NB.GL(_!7%\`4[5"$/0)<[&
M*W4TC.H`=!G@G&O??>K.D4%2&A6B*HA1#-/H;9&VJNEK)XUJC5587QO7$P=R
MLF=-1\BSV]E`Y_G:M<S43,+V)96F05!M%:DP0PB\S]T9;4)0BG7TGL&WGOK$
M,='?^MLH0KN%<44%9;R!&E%1?AW2)CO6(&]E%SL4>EJR?+40'(0!9;M"&-*"
M?]Z'@<$!'`NB,/($9FX!912H-P'B$:^R1`:8=4>51:(!&!PH8X/@?H3G@+5P
M(JTA>9`R_S``Y15V8G_51WUKLQ,I9!^^<2Y0\Q_>%R)+$1K/YW>)!AE'D8+K
M,8";HGC`@80C\64Q2(-4`H'>X(.T87T0(X5](H/WMW48*!MB2"]DR"=F^(-H
MB'8U41:!-!G=ARTE<0$7,"T9\X9AR(7?`(9P@4B"=(?7T@![=`"&H3$#)T=T
M)'J`R`V$J$=RB!&!I$=]A"U*IT<E-R^3F(E+XH7<<(ESA!Z(U$@2@XB*:#*7
MB(I5(HK90(B52!-U^#%*UXGT@DB@&(J1V`V!='FW9P$@8QTT`P&N^(J]*(EI
M6`TN4&O.2#\R\(S26#_,T#[3>(W1>(W36`VGU(W`T`,_X(WBR/\+G&0/7CB.
MZ)@#Z+B.+B```:`A9(,^ZB"/+Z!)]GB/^"@**/".YAB)]9B/`!F0^9@+_*@>
M\6B0U2"/X^".]^"%"FD.!`F/S/"0?I*0Z,&0_8@(%"D.$6DF$XF0]5(;&#D/
M#FF0(]D(FL5;*ID(9A$G)7=<>\8(N(@+'YD>\KB1WW"2[U"2-JF3BF`:#\!6
MN;4(%I`4PB@G):<9.4,9,SF32K(,L0$BCC((_D<(:346P%,(/<A=5!E9A3"+
M57D(-\F2AMA;OA5<55&6T^4P,BD))=>)/MD./+D(,>EFC-"2A^"47XE;BO"6
M3Q*7PC)$HV,CB]$H$J8`-C((B%D7K;/_8L#!`/T!-GT1,".Q,[\Q(T+190$"
M1"+"$4/B(H]PD(Y00Q#`>(X56?>B+P,0`9L)*9`%)Q>2@S/&&JS9'#UH*?_Q
M'S_A%6L6(]ZDD19I"*,!A3\#.7UT9G=B$HQQ:'TI"7.U784`F.LPEXFPE*S9
M,TY9E`!RE-OB)HM@(U##AP2S7;MH"!W9"#UCG#X6(8S"%"C2(F,U*8/B&T'!
M*-0!1ZQI%[2C5@P8(8)G&I01)'QI,U#I"-2!(IU1`"XA8UO!;WH#(4!T-U11
M&2+Q5A+V-F]B'*QQH3'B%!?`(K*W%!;%&GJ!#L&IE40A+8>9HGXA1)XY(H8I
M$G?A*HCI'(.0_V!A0UB^T1,W!APV1BB?N8B/4BGJ-2-"&IT%"0_4B0BG$AXS
MTD)7-E^%,J*;X10'91J#!4<R`@$)A1<N0C6]P1\(@*7=%Q5=2BC`J`CGR0B1
MDWV^,1\GR!1]$1ICA3?P,5)7R!N:\6;3$311$0&K`AZ-L16$49LF6J"-0!WY
M4AE/$2TQ-42K:3F)`U3$TA)0P:CP085O&E`[(E11D7)E:9XG.IYG]1QJ$2&6
M81H`RJC.\5()8Y\F$93+LJJ)<U0[LV)H0:O8X4USE3J)()WJL*1RPA6H(F$I
M-JCNV5[Q&6/#L:O#810!*J0*Q1E;P1BQ2:HI-B1_F:2+`)1"N:DR,O^`+S)(
M2RA9CB4NW>$7629_+,(;\A&;41$BK9(:-F(@V,%5AZH[ZP0@[]%3M?J!8@%.
M>G,!SV(4IU(9G9$`H>$1F-H@7/-8*V(!"=49,16O?-,(8VD(X3=4/2.B%%97
M4!4@)ZB4'K&4DR%4_`JA8S&HX,$`AHHN2_6KW.H.PJJQ<V:9IY$V-C(9<LH9
MB]$M:5.H?-.N#0LDU=HMWLEC*(L.P&I;(_%F<Y9;X#$(40NU8\$2%9)F``*3
M;`E89\D@93$G,1F:-=D(4LFP*J$8CN$5V[$R62%[=L*V*0(:3]05,P(:5#E$
MZJ480E&B6`2C?0LI+D2@$R&<]5I2E*%ZNG'_4.3R+JLY(`&ZK@>J-XT+));2
M."]:KUO3&+BR,I&1,UEA&3V1IDUK#C5;"-9YL3DK5(R!.+I!KOS"LZ5Y`9N+
M'';A%0]`L!V+5J*A%Y,!(G25%H0UN_R"L:7;%J*935G)$!E["%=A7%=Q>%3[
M&[QE$M'+9TBSM;N%6T]+M4`!(&<Q$C%)'8M5%4EQ6(9PO.)PNJC[O'0&9V#[
M$X14M5=K7(-1%,^[+RFQDJ^1,F1Q%G>#64@Q9WJYINB1O)"0OP[1*:W:P`[<
MJCCY"GJI".H;#NS;,15<$PA,&YV2B![\P8D8P=V0P=]PP<BKDY4W3BNSE8ZP
M,N$$$N6$34<FN"V,_T*A:EQ(2`@;/!L=O(</_,,#(,+<0,+>8,(CHY.:02`8
M$A]T6J$,<R$&$AJG&A)CNA,E*A*7RU(D<5`H-&/0\;1C.D0Z&!])\;3WFU2L
M4@@[_$US\I4`Y;QFP1?E]7EYF:)'=</0.HMJ_`JE^"214#F2!S0,PA)Y2[5(
MV!F?%4Z51\.*@$ULZ0A$W`U&G`I9L5]6X0J)EB=('"VMH34E,J$R(E=O!;I@
MA2Z4I:"((2V>?"YU5!<-]1P`FF&AD5:N<1B.$<OA\@!<RF7<T7UKC)Y=B4^4
M<KF8TE";<E:[02@F2%B\T:*LX1(F^,2$Y14_6I[`Z0I]3+:0L$3@DF=IA?^U
M?W._6H0K<Y9G3'FS4YR27WRU1S$8!&+'CQ#)W##)J-#)U:&][LN4=1FV)%%>
M8B'.UIP*!IS$E8HJO5$W!J(L8K-20@55/M*G*C4BF0'%3_$VI6&ET:&@[_(4
M!O96PC$MO\RF/P52M@)3SS)3"A,MVD$K$?*>'KV(Y.$8@.%.[UFK#!70HHK-
M::JFD.`MD:$Z>",P0(D8L0/3)?T9=G$:N;R(J(HI<D4[U]34.`(K("BS#1F)
M&(-B.MBYC&%0WA&@L7,A>X$9!&47.CHV2/PW)T6B*E$9O:&?)*$JIMS0=H50
M_F(G3(U^JA<P5>-0R9Q^I,+1BH%9S!/2@-(W9R7_+5(%@)>C&_K!&9O3KOJA
MH1NM&EJ=.%2]O/G*"MF\V8S`59&QT2YA+.WE'TN+'/?1+N^TH-I:T2WB'UG1
M(A;E*B5Z0S]2U8@@S]E`SY0`/(Y5?/:!&+[7(@0+.<:9+$"%V]F"PD?13VW;
M7Z`165#3%)+'+%"!*_]D)UEQ9'NK(OLU"'@+4*81Q1[1'5#1HBL\WK]W&>?M
MRGN,J,[Y4XDM'&_C+F.E&[^W+GP!.:$Q1N>'*Z+A%9!S.W.<(3K]E&P<LP9S
M.2,!GT8[HO>A(PW65,<,GXUI+`O"@"[E8Y`\LW*)U;1P&C`!KI:Q8N824@O#
M64O1@7&FR1X^"9'",++`_W>,4)IRXPC+0CMT7`2&_3.^H1DPO"\*XQ5SUAI$
M@<A:B[LNHZ<!ZC)H(5A+?K(1@GQ^?.!5[@@=$<BE$;B2$MM&QLBNG!5O6S#L
MAR'Z(N8AHC"\H1?J!5#MO4)^Q@BZC0V\/0DC53!0=LM4B-JI.B-BM(1'19]A
MN0H&_"$*/...4!(W3"<@,5T'4;;1\'LU;B2/$$;&:N"MT-D8V].#7@FT?*VP
M(.D=?M77+`MQ7@B?_GFG'IAH_>*RT>,CP\<[G0CG,<&30%*S8.N#,.?54.>3
M,).X/ER-X.BQ4.@<#.G';N7:3!N\3@V^;A'&SL/(+NW*[MEPT>S3\.Q=(@`O
MH/^-WO[MSF@#T_[JLH[@LX'MTJ#MXU,RU@CNLQ8$^^/NM%;ND+`"ZWCO^$Y*
M!.#JP1J)]I[O`!_PPR#$'P.+^J#IM"20"K_PDJ0"I'X(#!_Q$@\*+.!#!I\/
M"!]!%Q]P;)J,!S_K#+3Q'/\S'H_Q(+]`(C_RPE+R^)#Q$)3RYB`"$C`!%%`(
M&U`('C`((I`!AK`!$B`!'U`$/]\!/,\!'0`"-9]$,`\/+M]`2Q\.$X#T$S`!
M&<`!12`"&P`#&Y`!5%\$-_\!,E\$)R`"02\('L`!%$`"&=`!1<`!$I`!)'`"
M43]%3^\.31_R+'\.))#T,V_U0/_V(;`!(9`!$K`!'3#_`3!P`H7?`3<O]!SP
M`23P`2#``2)P]&7?^$A4]^UP]RB?]^8@`8*P]A)``1S@`1\P`44``B%P]A,P
M^D(_`23P\XT?`E//]2#@`7L/^D5``4F?^9X_#YR/0)KO#6I/`1WP`:#/^!/P
M^$$?`B#@\Q0@`B`@`B)0!!-P`D60`2`P"*X?`JE_\XQ/][_/]"<O_.,?#H0_
M\]8O`42/_!/0`1+@`3OO\XQO_.J?_9B__460\_8/"!Y%@X2%AH>(B8J+C(V.
MCY"1DI.4E0`'E9F:E0<%FY^@H:*CI(^7I:BIJJNLK:ZODZ>PLX2=M+>XN:&R
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M,)S6[R'`C-$.-E0XLMFX`I-:/NO8$.3-DPM5MHSYX&:SG0M]WKSWM(/2$S<K
M3DUHM?_EUJ=A>W0=FM#HR,Z""T_%;/BD8\:3*T]4?+GSY]";-8^>"#GUZ\FF
M8]_.O?LN3-X160]/'I;V\NC3ES_/?;SZ]XD8#$J@0$&"(@L4`"A"7_Z"!8.P
M!Q\B)W#``05%&,C!(!1PD,&`$$HR@`(!`K`??0H\4`0`"@R0@'R&"(B=>Q&^
MAP``$0P"08#T%8%``PPD`,"'A(A88A$3@#!!"!2$,($''E`@@0<2?'#CD8@,
M\,!^#0Q0Q`/YW;??E#$>8B-U)"*)WGXO!M@``EX^H)^3`8*G92(2($@"!Q,4
M(>0$(KC9P9ETTKA?$0,,<.=^"D````,-6&EF>EG2Z=U^>5;_.$B7>@*P9)F&
M(@*#!"1,L".E'*09*9V)WAGCGH,LP``#4(8X*'J%;GI=EUT^,,"7&][GZI20
MJCK("7,.TL$)0A:Q:Q$;;&!KB54R@,")L3Z@H8P+/&"LJ?"E.JQS'.I71`,`
M!+JA`@`FH.&$`&YX:J0?M#E("(.0D&`('O`X+7PG6ACHJ/,Y.@B9#6@([7O2
MOCO@E1#R2LB#11#<H+\("QJM)PEK"7##$*OZ\'/]1NS=B04<8"&8%G?\+@(#
M0'!`HH0R[#%\%AR@L@4GMZSJ`"JK;')Y%;M,70,Q:VOSSDAFK#*9J,[,<W@I
M"SWTT>_!7'-T2R.=',Y`.RTU>AE'_TVST8NH$,#67'?M]==@ARWVV&27;?;9
M7*O02PIHBUU`VW#'+??9*4P]]`!8A]=T``0(X/??@`<N^."$%V[XX8@GKK@`
M!`30BP`H+"[YY)17;KG?D=N='`&<=^[YYZ"'+OKHI.]`^NFHIQZZ#<;DG4@`
M`D`L@..ZS!XQ[)H;1X#%NX^R=^P-VUX[[0WCGKMPO4.<?"B_RTX\+L(7#_SQ
MSBR?L/6)_$>(]BZ&RW'SP3]_2_0)&T]],]C[FWZ(^<K7P/L/T`<``J46`7["
MY(\OOK_FGY_,^M,"8(T"5`0*;2A/#\A79B#1/T,P```06`#)''$G1RR`92%Z
MQ``N<*\4(?\"48JH("+R1POR50!,"<"@E0RALT0D2C\0D!$DD)6D#15"A(PX
M%B(X5H@&^D\8Z1-3!(MP0OZP#`'U$2&H'.&D%N():!'05@2LEL-*.'$0`@Q0
M`B]`,C[I1P':NM\A#"C!!_H'`$UD@`*.!<$)<8@_V<(/MD`T"`8,<0'V^M,:
MM14H"]$Q9$ZR$!RU-2H*S<L^&`KD(D@X"_+YZ5HK*L*H9,6`%&%K?@68TI^>
M5$'Y*(D_)Q)3(#?Y0`IAZ(&BW-`F`_4`'E;060`2$X5.Q*W_Y*M#JK2/(7SX
M0V!@3X8R?&0#5C0C_-R0@'C\%H<2("I[O:\``\C/&B<(01=!P$/_]8GF')]4
M'_[41SZ3;%:&U#A(.?X);U?,XKV0F"@:27)&=Q)CB`HP3?E0B$D(B*$-B["B
M%,W*14V2CP@C>,]KY3,!,MI3`IQD0#P]((:"Y-+[P'3/+R6@`0N@Z#X3P4A8
MD`]%!<3GAKI$H14!Z$(,+8('ZSB("!3@4P"R3TI3E*<9)32F"RV@#2\Z0(#:
M4$.S`I,$]7323S:4$+SLI2^P-\$-I<A:""A`%`N1R6KBTSX(6&@?;;B?9:$1
M:!P*930I.@"!/NE)>D)HML"$QD#Y4T\`+2M7$9'%!%R36P6<T'TP>LM!R/,0
M$^I4$:I*PRDI,D]^^JHB%Y5)EB$*KJID_Y%^3(98!N"1GQ:"K":W!\.-CG!_
MC7Q>MD:ER6P)]@$N!>9D/2M"&"ETM8]M0`2N^5H`>&*)^PQ91-M(GY?6-$`(
MN(`"Z(C4Z2DU&-AK5J@V!*,'$H(^X=HGK?*T``A`4["TNN17:X3$#D43AMAM
MHVQI*R_!(C:SV*5K(Q9Z'_YX:%&A:J^T%M#>(B2U1>Q4I'T:(,,-Y8>`-47`
M4!<K28I>%IX!LFQUFY4`RBJ)@U,2L)(&@(`4.2J:DZRP9P]!/AZ^XJ,).&%7
MX\??&15`AE":$8-O>\Q7X<FY_HT?B_/DW<*N>*<ZNU.+S-JA9WUU3Z2*YB&2
M>MQ<I,\^SHJ5B/\E>=+H@FI*,D(H`R:D4S[]=+L$+$"3RIJ`"J>W0S56UD7-
MJR<)"_:HA%"G)*0%@`H4D\@GBI$.G?0A)Y&IIMO5X?M<!":@D4G`,NKSO3[D
MJFLI<%%@^M8@]FQH.S])/H1VM"*$UP`+X+`5Y'.2HE]\G[(JD\Y,4F#40*2G
M0-W9T(H^EG>O>2]4X^E)KA3DB?H\Y:QF&&3W"C(`HCL((A?Y%NF3D;8T_>IK
MH;$0IPZTB^+XJOF]VE4GDJ`.6^VA8T5ZSB^F\*HYC6T]!PK;"TBG,2QMH7*;
MV[8J<_,-C.NOV55:9=?,D[SG3>]Y>U@2'16%!"?1`/T0%Q'_SH0;B]G_0W;_
M6A=J#@7W5-'O38HBX9"(F<0G3G$?&'Q:`M`!Q3?.\9A=&A+YMI6O#PX+B-/)
MY(XX`!?K/6^1=6(`(X^4`&[09IF=^^8XUU@F0JZJF).\%2C74M`9P69H]OKB
MSYUD(ZBX"&$SD1`>GO;V%KJQ>`W[V$S_+!S=?)R//X+GD\!CU@T!-`\SG<*9
M-;:S/Q0C^H["YS]?Q=!S.'9#W!OJ.P39G87LWOO<?1-S5X2TZFM?I+.(AN%"
MJ(`1/>CEKK,02+[3V'7,ZB=&S4Z#&.Y]1"77*7N=P\1C9M=W#MI,(`N7HF?.
MHH;(S$O'J%@T7-$:[>K.4,`][JD(?/8<M=)%_U10B8?X%(U/I*3YW?5%?\^$
M[L7C.D3X&HP<(Q6BUFC9#^UGRBN2_@'7&"I]Q52N'YP/JZ>,RQI)25%X&B8A
MY.T(L!/]\XUP/R2JU.50ZFN%UBRJT&1XIR8%BC[*TFKP-PFWAWNEL'SX1V%X
M1'#XUP#0A$<P!G5;M2'U\T;\P5\!IPD(:`A_50@7!0$IDDGQIB%(]"6T`B8B
MJ">:=R]^1F`91$`VU%0&5%75!4%FM7YU1PCR)W@#N$BE9PG'M&$]%8,N>"T`
MDEBNXB<10$-#"`H%:("CL(%!2$"U]X)SM6&Z5%5+8B$$986@((4+]`B^1B:T
M@E`D$P$%!4(7PDST`_\BP&19&N)UOT=`A39`U$1`_?<AR6<(.U@=/3AI/T@)
MA98G52*'`Z1<:(9;H`(K/(5FF_"$4!@*8`B#'H);5D@K&[8?R@6#F$A?")"!
MRM<ZD>!KV&(MI?A$=510IWB*:F19A"!$`()*JH0W-9)98O).Y$5`58(?^M)5
MU2*$'!6(*?>'P4@*7*A6NV8_D:4B&Q-'JV5T-K2)^U0J^A$!0_5VAA>)JC")
M^,%[3[(D`D8A,Q-O_/2)6_A?!`0KG"A)RN()ZBB)HLA`V9@+WA(+D-!4/K@)
M.E<)??@)%!9V]]<(Q"B/VD@+W.@B0.-VHB="[*=#GIAZ-A1U\(4?9$@*W-C_
M@=#A=D_W=<+8"/M("?V8"SDX=:0`B06I@;2PAXN`:XX0/Q89CV(XCS+7D>]'
M>K<CDR?Y<+P#DXY@DB42DAPXD*!WDSGY"@=9'A?9?$.&DW0"E(7PD9/@E"7B
MDT4I"4=)'DDYBB@P-US9E5XY-UNICT+)AQ[PE69YEFCI-1[`E%6I@6GYEG#)
ME2_`DXV0`I=SEWB9EY13-YH`E9(`.WH9F((YF'Y#DVVI"2Y`F'G)`T2@F'E)
ME]KHEX<YF<J1,0M3E9))F9H9');)+TKY<YFYF:*)#)VI'DUS7*$YFJKY"Z59
M,I@YEJL9FZS0FD'SFK)YFZPY+N1QFDJ5FKCYF[.I_YMZ\YDDYYO`>9RE0)M7
M8YO(V9S!>9E%^9'112_LR!^\YIS8V0C*N9O$>7`Z=R(<-%*?B%&8F)WFR0C;
M.9S,N5-`UA^$=Y[P:0CIZ1V\V4L?^5@L4FY@%)_\257"29_=^6O[2"/*%6[F
M!(S]F9WSV1WU^4,Z!T&/5&[\X3X9DJ#]N:#M$:!%9IP6VJ&#]9\,JJ&H"9L>
M:IX8NAT-ZC\<6J(7"J(9NIXL&J,?"IV/P`)Q>:,X:C9JDPDK*J/G>:(CHJ%]
MXYA$6J2'TSA]2:(^>IQ`>AU-<Y7A(97VHZ1+^IM-BB5":C%2VJ-5ZIQ7RC19
M&C%;2J5=*IM?"AU/Z@@/Q/\DD'!%BA`![^FFB'!B+94(7Y)\<EH(8UJF'GJF
M%!.FBU"@R50E+B9@:!0O$,A'=N8L]155_^>*?V)JK88M/#15J+5H9.)YUI:,
M>E*$6L>C9,JGJNFGSI&FC)``%Y",$<1Y\4-^.L5/#?8AHJ)W$?2)A&!9%O8A
ML6I9>Z(D+1(@%G9]>M=V/P:K^T%,\6>8?BBJ%DJJRV&J2P<!V%(AY79:6W5>
MV8);4W0!,O1;OQ4K7%B+;H19V1H@W_I.+,8(>\JL+6H</(4?UF)L@=)O8-)"
MT*H(0I907M)GG9(`'O18%W)9^\1.Y6J"3T0A"W@?D312%G!@ULDEQ3IE&H*L
MZJK_K.(1JNRJF<XZ"RKH37$UK\BR5D\)J(M02N^*@;NF/>\S)H'R'_%RLH\G
MJ\Z$'Q*4(29(G=>B4]]F(:T'*/]1:AM"3GFJ@Q9["%R:L6;JHL(@4LM(8P_T
MCO9#LOA3M$&)M/&YL1R[6"_2?\>B@L[F5U*+,.MJM2:JM,``*[""8*_J7?43
MM9$`I=XQMF2+G5CK"B?B)WV$5Q@B*U(B0O>JDG:G"68'N"X2"0NG"`BU0WQ(
MM4^)L7-;E'4['&Q67\LSD']WN"%$"!UB+RO9IBO+"%TTA8,@MX^+G)$K'-)R
M`&YV'Y5[JZ0B20H`I^&*1E\44BNE1G#Z1='T)Q6D3VKE_XK2RGT\"T'T]2?T
M]4T]-2^<2W9.$E77QP!"(P!"P'+4RW)'6[H::[9.6@$%T+W>^[T^H[H`(`-!
M*'8F558#,$5%%8<ZU5!E1&7+^$HNY6E49E*D`H&=%F3<TB&NM#WL"U@5J5PX
M)``=5\`3Y[C8JXVG&QP&3'$%D`-!B+Y.<DVU5DG$%TC^ZG#\A+Y[LD2)*S_4
MM4]HN(P7#"!XM%)WXBJ>BHI$N&$"0`,X%\,Q/)()+)H+[*0O5P3+XUUV164=
M$@&H5587/%(1P+.9E[Z:)7V]VVR#ND_=M&NCDF+.$E@5]#[]1H'RX0EXE6VB
M,K$/P$$F(Z4U[*7:^Q[0J,.%,/]4G38?]&6&?I>X(.-5;*QX\.6)R)9XWC,?
M8++'>+PH5L,]J><DN[A00D9G&55L12#&8VRZ91PA4J@?#-@,A#N4BURE-]P=
M<-L=BES)5MK($)+)W+')G'R;E\P=H+P(>,9&<61L676=)<2XH\S([W+*\=%?
M*R@J4V:LCP/+L0R<I;P=M'P(_(=^965`;+3+O1RCOXP=P<Q"`$*#?@(!4Q8U
M",R/O)S,I.S)`]+,+096P$5(KYH+HHS--JS-\,'-`[2+FWA]$(2!R$S.';K,
MUX'.W?<(NRC.UPS/HVK.[T'/K;9>KOS*^MRL_*P>_KP<XSS0ARG/U#&D1OK0
M$,TX^:S_T-G[+C::HW%#`P>`T7*SHQ0-GPP]-1/ST<D<TE(STB0=RR;M-"B=
MTIR\TDC3TBZ]R#!]-#(]TS5<TT-STSB-O3K-,SS=TX_[TSL3U$)-MD1M,T9]
MU$B;U"ZSU$S-KD[=,E`=U:(ZU2=3U59=IECM,5J]U99<T$<#R"&\>(4K+F`]
MT%U])MF29-.<5?I!/^'RU6DMHVOM,`0T7-^B)(>&UG5-SG>-)([2`!#F+1J2
M1/OIUW]=TF)]-TA47YZBMG2]V'W:V#;3P[4$9O4:;K>HV)0]RH%]).PU'^]U
MUAHYV9^=H*'=,*B=VORYV@G3VJX-TI;M/TJ3;N\YVT-=V_X3_[[5K-NJS=OG
MHS05D-O`C=3"?3X9\]O'_=K)33T#4-S-G<"P#0P<+3=`<-UPPY?3?9+5_0LK
M$-'B7:29T]W>_=S`;#%4:=ZY\]U+I=YLR=X_Y-Z]<-#*L=[R/37TC7!MNC%D
M]VHYZ)*;I@C31L.U^+6?@-_Y[33[;620<"%D!%][[,;N53]$)1]9-=H+9>$5
M:4S=PS$(-(1=QA^C_40!N0@*ON!'T^"X`'$7,B^/0BMH=$TK<DV]!P&1-.,A
ML\$K)<%\(E<%(":A!`$\=$T9Y2A)N...0N0QJ>(&R.+`!@F)E<5M).."5>.%
M4$GFJDA8GFLUI5LSIE>NJ"*[RX5G)O^K3>[D<0?E!OG@>$CB5AY(2'1LBQ*I
M!R3G8X*#`:)<;'6PJPR#5:)W-J0?0[M+\:WF=E/3C1*'IG3BOP!QB<4D;Q3G
M(Y5)6YR%,M(ISKO%H>M'1%A5.5;G%Z9(H)[FB'YP-5U!S7*N0`0*_97&WP:*
ML.XBLHX(IC20MV[JIUYD-5W$6,4A:&3<]0T*D4P(V%+HQO[G&O0GPIXDS*[K
MNZY4-8U"FCA'COC>1!GMO([>26+"L5Z>R`7?VK[MKV!&B[9LR-[F-6)`$8AL
M%)9\)*,GF:1ZH,MT?W>,`FGLHEM<XWY<;#X+E:M+@@1+W8A&_X%'+5L?@CY`
M3J>OCM(AX;;_2<GT1#("(A:B'WLU"(.H(0\D[)*G99)$3DO9[]+.[<MQ;Y6;
M0,77);2BPG`E'U[55"<XK;O[?6:%3[_U(D:E\KU8"&E+[S8$*]>>XB0/,?^N
M"@!@`3K3NB,\XQ%E>9"E=EA&0(D5];VJ2(_UK?,C7/(!`0U%?X4%])CX<41?
M]`E3-=6;]FJ_]FS?]FZ?]BYG`4[2ND^\8^TK;R5U93(_4A(T([RZY7,U(X3H
M+?1[A`UU>D-EJ_@)@SH%;9;D865O]OX2O@U<^99_^9B?^08,`<O3O`#2O,Y&
M?,>25<D8;>^.;(M&2)MV^J"VQV"2R[H6;E$C=AJO+5VE,Y<D8//:_R0&57"2
M?SX#]O;"/_S$7_SR%O>!8M^3,'!V9+B9$/F_C[1)O_3B'OTIC?+5;_T];=\(
M)4'=DB<<PY*3G`K0K_UD:]\_[BSYXFE+HN2Z4/[FC[0';5$6KV,B'TUM2POP
M'__L"@@$18.$A8:'B(F*$$4#$```"X\*"@\/A0,#BIN<G8,!`IZBHZ2EIJ>H
MJ:JKK*VNK["QLK.TM:."MIL`10P)A+L)#`N7C44-"[F*H,G,S<[/T-'2T]35
MUKC2N[N#"`V#NPH##`I%V]++UNGJZ^SM[N_PS=C1NPB$";Y%]HW(W=3H\0(*
M'$BPH,&#J.9!>Y"OD[=_H1!*G$BQHL6+L$`48J0%<*/'CR!#BDRW0H#)DRA3
MJES)LJ7+ES!CRCR)(N+(FSASZMSI*8#/GT"#"AU*M*C1HTB3*@V:@J=35($`
"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>h03611h0361104.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361104.gif
M1TE&.#EA8`+,`.8``/?W]]'3U,W/T+[`P;N]ONCIZNWN[AH7&[^_P*.DI75U
M=_O[^^GIZ8B'B5%/4MO;VT=&2:2CI,7'R,W-S:ZOL9:5EHR,CMW>W[&QLH"`
M@[J[O&QK;9>8FE]=7S4S-GIY>SPZ/6II:R4B)EY=8%-15#`N,MK;W$-!1"<E
M*.?HZ-S>WL'#Q-_@X<_1TO3T]-+4U-/4U=?9V?/S\\_1T>+CX\C*R\7&Q^_O
M[][>W^3EY>#AX=36U]G:VLS-SNCIZ>SM[<K+S,;'R-;8V/'R\L+$Q='2T^OL
M[.'BXN7EYN'AXLW/S^_P\.SL[.GJZMW>WMS=WM76UN3DY>/DY>+CY-_?X.CH
MZ.7FY_7U]N;GY^#AXN7FYN?GZ```````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````````"'Y!```````
M+`````!@`LP```?_@`6"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*,5@&FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<:P%\?*R\S-
MSL_0T=+3U-76OLG7VMO<W=[?X.'BX\CDYN?HZ>KK[.W#V>[Q\O/T]?;WO?#X
M]@G]_1+!_&E`I:$?A0`<.-RRH&"@*7\)`D"$)>$?JHH)``;#"/%@L((9`U#(
M`"R#1U@:,B@X2`%DJI&Y/"98>4H#AXBG$FJDT/'DOI_Z?LZC<.!`@@P'2`"3
M`.+`"%0C#I0`6-16"!`<2IPB>H!E49^M0A@UY5$LSF`6I/8;`6&8V0`0_\:*
MW)7@0%M8(4H,M`!"08"FJ>*>G24A!$"Q1152`!&`A`53(RPL!ABWZ`&3)(7N
M"ZHY7E6X!Q[_4B#B@$,-4>\FM"4"`@>EISX'D/U*P=@$=VT/_E7W;@"_PG2+
MS(R;ETE82$4'8`CZ9>9:)`YJ>&Q;*82VI"N./>"WKP+;`S,H[TR/,WEVG^.2
MY*!`H<A^&GB:8B_]'\U3W[F;RM`[@$N!_:2B@0*B$07";K+)1I\I*67@D&X4
MB'#@;P=P8$$&&J4DF@0,R92`321QZ&`J_3T&$$\?&F00@3G1!-*`REUH%D82
M1'A@011@I`&-&2@DHD-D)7`0?`P!:4II1D84E_^&`=#($T\*X,3A?5N)P&!L
M)$A@%X4<O'4`"!(XQ!=95IY7GIGR5%47F!!@6$);&GPY7``A9"F"0DU!(`)L
MIC1T@)42\+?E7P<@).<(/B4@@@0*M&4@@D;U\UF=$MRI:`!(103AEYH>$`('
M3BTW%0B&B4`!47Z!6D)3B_$G0I)?<L`8@Z4%^EA3DNE'Z9V$,A1:8UJ1,)99
MCVK9%JA^B05""5:"X"J0QAH*00(E:+45;:?$Y>MC,TKUFFF5GJH??KXQ&.F6
MMC6Z7:&G.!:;>VBZ8UZ\YQ3UG7M[-@?:=&$ZE0`(UAT0ID9]!A"5!184-&A<
MIHB%:"H@M%670H.B4I3_/U7%.<*_)"#%DW["#1IR6R+X]1U1)&U95P@BI27H
M<Q+%.NM\=KG',%QZ^0MP<W7Y:?)8(YNB,L@5ANER73`/[=?-#V%K"L,]4Q@1
MND:A/%NYUZ4R`LO]I2O8;.PV*7!LP-'+SKQFC^/TA26PFU8(C]6UL9#ZIN)7
M725PO3"[$C!KY-4Q^U5Q;&&KZ2_=`XKU\]2Y;3?MN*8$BI3$X]K&WX>HE!BY
M*<+:S*Y@AQ\$-7=1"Q<TX*7+93E\%E.^=-ABCQU8H:DS+G63&4R.2M8Y/242
MU19$-;6UF/(Y6]EIIX-V\N!@.X)63(M0PF-QWD49[/@]?=O>9$5E?`!OQOS8
M_^!"%UYH]9%':$'M@-]N%U%\,O64TJ:D!1S!,;<%T/I-AB#]]4_+F?5XQAU4
MW>YT]!/.<L:%/_HQ37OP\@\!%P<XW<BO?0WS#07F%@(-A`\\:9F:[_XR'KDP
M#QW+.R$WM"0[H94@*[(3BT;4PYZZ0:5^U@+5K!A6F,:8$%-:L<!4,!BYH@"$
MA=?K47X4H#A&;:<$&`H:KI93%\?813OW$\&=>I0Y.2VG3(9!RNLD4"F6T?!U
M@0.?4J*BD)!!L5*,$>/MFJ1%#G`Q-JZS89-``*;]*(EV1+.=;JJ8%@@0+$*1
M*TU1K)05@[&,A!IX%5E:B$@5HM"2Y&`(@0AF`0@@+/\Z#(I?"#SIGWNE@CWN
MB4A*OO.ADUUH2C!;3@@Z*)&3H4*3C\%E_T@I`1(@B@0*"%1[EN,:87*``M\A
MXR@-0R<2)"`$(X"E0S;HS(NHY#O?(<E,"I),;8T@F+NDWLG80Q(*=(R5QB2F
M0C@`@<B$H"$JL<!.1E#-4\PDF`R)(I4BEX%O-J24*R&G,>^9SCH],YI0.0A[
ML"F:A#S'5B=)P'C$@\ESI+"BYHC/=##*C`=R]!2,PI\ND/G1<5RTI.`@05]0
M>@Q6L1058(G)2\%QTIENHR(BM6DO0+(;G?K4'C7]J5"'2M2B,N,"!DBJ4I?*
MU*8Z]:E0C:I4ITK5JEKUJEC_S:I6M\K5KGKUJV`-JUC'2M:RFO6L:$WK5(T`
M@+:Z]:UPC:M<YTK7NMKUKGC-JU[WRM>^^O6O@`VL8`=+V,(:]K"(3:QB%\O8
MQM[U"HZ-K&0G2]G*6O:RF,VL9C?+V<X6=@&>#:UH1TO:TIKVM*A-K6KQ"MK5
MNO:UL(VM;&=+V]HFMK6VS:UN=\O;WOKVMX3%+7"'2]SB&O>XR,VL<)/+W.8Z
M][G03>YRHTO=ZEKWNMCE['2SR]WN>O>[X*WK=L-+WO*:][S%'2]ZU\O>]KJW
MM.I]KWSG2]_Z'C:^]LVO?O?+W[;BM[\`#K"`P_O?`1OXP`AF;H$3S.`&.[BV
M"WZP_X0G3&'11KC"&,ZPAAM[X0U[^,,@YFN'0TSB$IMXQ"9.L8HQC.(5N_C%
M"&XQC&=,8_W*N,8XSC%[;ZSC'L-U`@B8P`-4BP`&N)4!19[K!.8Z9!^_E<=.
MUO$$'(```"``!:AE0`,^X($J/V`#`-A`D]^*`0>TE0$?B``&$-"`,4<9RE'&
M<9?=6H'.,B`"<JTS`"+0`0!\H,H(^`!<&;`!,P.`RE:^<YS="N=%PQ@#'GBK
MD0$`Y#4#``,-8``#*J!I#%0``P!X0`4:4($(-``#&UBRJ5&-@`A\8,D,\#0&
M-EWJ#1BY`V*F*P+`'.FV]MJM#4"`F1]P`@`P8`(1F/2B&__M://^H`DT4$$,
M8B"`:@O@`@3(]@"``(0B\"`*;"UL`PQ-Z09$X,N^?@`#L`R`.C?`V`?8M`<8
M\``$%!L#?;:WE8N-@#Z_FP'QWK*?W?UNNGY@R`=P:\+=FFQA&]L!2'Y`LBT=
M9V8WN[M#2($*=F#MCG<<V]D.N<@)``0H1$$&@1WW6ZD\ZK:2.LP1F,"23X"`
MFB/9T`[/N9EU#@":V[P![P8Z`(2N9%`#8.%'=RN0K6SH!RRYS2>(];(OSM\;
ML(#C'L^ZM4$^\JYG.P@\"#=?)Q!OMU+9U2['\P,<H&=VA]KA3(\[SQWN]@<(
M_>X%C^NFW=H!(S.@SVV-@`,<<`+_%`BZK37_0)VK7'&JV]?J+]"ZY+?N]<J'
MG`@\N`%?'0#FME*9V$;^P*0=8/0.O!L#]<;YSE<O=S.;_M)V#[KL'_"`OA]Y
M`S5'?03PO/M+*QON+@=`!XJ\Y,8[7KXIP/KDE\]URUL>"#K8:P0J@`!/&WD"
M:RZ^[\^\@0ZHN@'?EWB;32W^\A/:^[06-:=K/P%":Q_30,=SNQ&@9^J[5>)N
M1<"0[ZS]-Q^_O2Y``RVP?`18;<WG?)9'!#J`<K4E=?\77`]X7@$X@`58@`>(
M@)8W`#P0@==E<1SH6SE`@15H@1A8@MFF@!\871Z8@KGU`Y$W@B-X@2;X?&+'
M@LBU@C8H_ULNH`(PV(,R.(.6QP,,F(/I1835]0,BV(,5^(-`6'E$4(-&Z%LX
M&(6IQ0)*J(1,V(25MX%4*(5=R%PNH'Q7&(-:V(1*,(1?:%M3F(:A=0-).(9+
M6(9-&`10R(:QM89VN%DI`(=7F(5RZ'4#4`5Y.%MX.(B7M8=\B(5_J(719XBO
M58B..%E6F(B*N(A-V(B1F%J0F(F-Q8.46(F6"(28R(GP18JT10.?V(>AR(BF
M6(JM"%N(F(H^N(JL^(JAM8FV.%BQ*(LPZ(>TV'4#4(>Y>%FX.(Q_Y8:\"(J_
M:((#H'G&J%S/:%HN\(+)V(O+.(=H&(V358S:F%?45HVS>(U`6/\$W5A9W%B.
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M=CE7;#F,4*F7'Q>7)2B,=AF8N6@"A`G_EX;I?"+YEVLIF7OE`HWIF(]9>4M)
MF0"@F*_8!)<IE9GI=6"7!$+`!)SI7ZF)5VX9FH4YFMFF!$]P`3"P`@,P`#BP
MFI[9BD;IFM>6F410!$Z``S-PF\8Y`#V@FZMI5Q/IFWL9EZ4I!#5PG-0Y`,KI
M:+N';XSW5A4`>!*'>X;5<J$V>(?75A.P`1Z@9^UV;O-G5X/IFGQIB4J@`[1I
MF]59G3Z0FKMI7^R&;'$%=W^F;(.U=@5'??K'G<:&`D.69GO6:G<UB<Y)>0P9
MG$YP!,5YGQB*F_K9;![0>?O7:D;F<!-P`A4P9D#6>\8&HO5693(W5T#W;R=P
M<)(V>NW7:]7G_V9SI941&I\S6)HF,)T9&J0PL*&.-@$H<`+%]VY\%G>'MIV$
M1F4=(&B1AFJ'AF<4!U?))G2QM@$HL)UOU6=KEVAU)F1UE9>^R:,(.)^T:0-!
MVJ:WF9R<N9_VM78H('.XAVE,BFC`]FX/@&7MIW(.EW=OM71$UU;=&5<QUU9K
MMFGL)W]R99D1^IJ62*$6ZJ:6:IQ$&F=CQGF[]E9PIZ<N5W!8MGMP1W..^J6#
MYP$><*KD9IY&=W_3)VA>"E<G&:D2*H<^"J27NJM+$*>.YJ!#9VLH8&0-9VB@
M.G1\"F;#"G<1,&^&*J"A^E:B9FS79W3:]VZ(-JMO!9JV:H!E*)MKNO^KXFJ<
M^4F9<DI?#J!FHK=G';IDW>ET'<!IP#9\\MH!Z3IG8<9W@AIX>#9NU1=XHF>O
M@\=X-4=I]D=7"6FK4SD`PGD!%SJN$#L`2."K:5BH<H5]2H>CD96PD>J+00`%
M2?"C$3NRMVD"%/N%'U"></4`'2JME\6Q.VIYX`H#;$JR-FNRYIJ&2':@%]M9
M.AJS(L>P3N"P-ENTQHFSDGFNCOBSS@ER'QNRNFJT1HNT?ZFTALBTOHD$LTFS
M4MNU1WNRRQE76.N:-."U9ONU.1NV<C6VEVD"#WNV74NUB:FV:]NM`I`#<'NV
M<DN75CN($!JI+)"W9KNW:MFW>0BSKKD#,"#_N%Y+N&)IN':(N*%)`S7+N$8[
ML6E+M]O:K7AKN5);KDFKN;1JJR]@`IXKM;V:N:(+`)`:H2H0M:<[LIFZN@!@
MIHTY!;%;M#4PNZO+MF^)`[EKLS/`NZ+[MZ'IML%+LH[[N+3K5N^IEU*0O"0+
MNJ';O`#0G+X9N-(;L6E9N-;;5KVIEXJ[O1"[N\0KNJW9F#E@G^2[JT)PG=;[
MO%O9N>V[J]1;O=;;NHWY`D)0O[NZ`LL)N8/(F)?)`K#KOQDZI/`;OZ&)NPAL
MJ9A[OJ*KOV_9`L#[P&T*P`'\O6Z5OEMI`CV`P6WZOAO,P0!0J]`KPFV:N@O\
MO?\8E52@PAD*IR5L_\+R2Y'C*\/W>;]@R\'ABY+KJ\/5:;YA*\".>,,`F05"
M7)U'0+=&[(@_K)#\N\3'2<-%;,)OA<3@R`*52\4\+,'6Z[O@J`54;)S#J[E/
M[(AD*9,67,8#L`(LK+9I[(C&JY`J$,)EO+P]C,73*)/16\9$C,98'%<H3)$Q
M7,:HN;IS'(EU#(XQ\+8ZG)NTN\B1^,+5&,1+?,:3/,AR-02V*XO:*\0VT+U7
MS,F$#)!3+,0KD,C-2\F9J,5CR,5+',&M;,ISU<B?2+\RW,0<[,J<Z,&4V,:1
MC,6^_,O)^+HZK,`F7,S&+(M8H,,D3,RV;%?`/(:'+,*\/,C,3(HY\(G(B__-
MMKS-I)@"GUR!NNR_JSS-XDR*-Q#%!1C*_EL#<<S)ZTR*+D#`2IC#_AO-ZCS-
M>Q6"2BC+];L"M-S/_JQ70R#&'7?.TCL#I+Q7:$9_@&=7M@=7A]I6MH99P?:?
MOY9B]6R+Y%R!+6"ZY&L#7_Q7XJFR=`6MB$=NK5I9+-U62.?1!]U7`5B`R"R]
M*Z#'?A4!=1IJ9V9S09UL5O:A1`UWGH9X[&EE/(L!R#9K!^O4:K9IC%=O\J=_
M5\V>]:;433;3)U;3?C4$U5QM#AR\._W0@+4!!U!PA&9L\V9W`S<!<S:E8`:@
M0P9F^!9F1O9Y)-IS=78"M-?7@JUN=;8!U'<`O8?_UWWG`.^&>PS0:UY=8A_]
MC&(M>4=@UB:`UH)5`2@`9J;65FD&GJ/'HEK&>H>V9VP=II<&9HC6VE7FVDU:
M`=37>POWV<:&K*$6:PL7V20VV=$8@#'YS9YK`T>@V8'59`AP`*)6<*1VK(A&
MJJPW`8)6J%.&>'T&V]C]VFQVJ@MGL4(W`9FVVR[FV]W8!)Z8`IZ[`C#`RHW5
M>4?G=,7F9W8'>-H-`,O*>J]F9<Y:9<-Z:7B6W4T:X%169H::=/H=HKC=`:`F
MWBM&WN7H`DVP!>QKMC8``P7M6!7P9Z7&K__*``[0H?06K\)WKQ)=>V[U`2C@
M?>7FH+57HO':XC#^XB+._V6B)VQ&A^+HE[+R%@$D*FS:&F(./H],0)Q='+$5
MC@/S#-9Y%>0%*0,^@`,@W`,33ITKT`,]8`(XX`/&K>1TQ>1<[L]>_N7A+.9D
MOEMA7N9VI66:M:]ZU:F.=^9H7E<_+EGH]E>\;7QQ7EU--F3MUU9.M]+%UZ+4
M2GM'EF24IGV?EJ*3IFF$WN=`O9U(1Z9SA62+3F\J!N=Y'E<8D'#)C0&"9V5.
MG6FF]W=0MP&VUG>CQK+!YJP1H'^1QFD")WRAEFP>0'L>$&P]'G7)O6519^"B
M5]W)766I)G&/+6JWKIZ2G>G5Q>`)5P&V-F1X%^#MMF=FYMI_IZA?UFI]=NVX
MM_]KH`;@"Y>N28>G809J&]"O859S&[!F+YWLRAY=S([1*`!JT:ZG$U!JU:[=
MP!=H;]5[$+=R]8UHW?UN"4=T0L>R#_#MO]?NO?WN\"[3$`]HD5;OC!=I#N?:
M?6ID3F>C?V=DYZZH`E[?"Y??G`YXX.=YG??QEP9\_0=BF.[P5G8`-2?SP7YJ
M;6UOX^9]MVYD'5H!JWKKJNYGQQYFC`UJ@"?7'Y!IJK[TMWYT0O9NP9[N:HYX
MAX?TF=8`'K!D9-?R'O;R,$]76^WGA#YH6J]DVD>FEA[4=Z7<7!]J_8=ZA2Y7
ML^;N7T]B=PY7&)"R=Y7V#5_W(<9FK[K2\MIC7N_W>VS_^(B_C8E/7[LGH&$_
MJ$+M]N89TP]8^(LO6*U>`?'M>?M*;)P7>!6`;/R>@Y9_^8#59&[G:OM:HO<7
M:<<&]Z1O^O+5ZJYJL<)W``XP9"U79*?*@J4O^WYE;_'=KVS^I*&&>Z)V9Q@0
M^!SX^\#O5PX`WFMFZAH+`!TM?E!O@\[__'PU?D`WL'+EWD-G_4,VY\>W_=Q_
M5T9WJD1G:_[IGXA79;I.^>>?_N=%JBO;9'BF9;`/"```"((,A(*(B8J+C(V.
MCY"1DI.4E9:7D0N8FYR=GI^@H:*CI*6FIZBIJJNLK:R:KK&RL[2UMK>XN;J[
MO)RPO<#!PL/$Q<;'R+&_R<S-2L[/T-'2TX_+U-?8V=K;W-V,UM[AXN/DY>:C
MX.?JZ^SM[M/I[_+S]/7VJ/'W^OO\_?KY_@(*'$@0&\"""!,J7(CK(,.'$"-*
%]!4(`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>h03611h0361105.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361105.gif
M1TE&.#EA80+\`-4``````+>WMWIZ>KFYN>3DY,_/SV%A8??W]ST]/9&1D9*2
MDI24E-75U3`P,.'AX:>GI\;&QN#@X+R\O+6UM9B8F%M;6XF)B9V=G6IJ:JFI
MJ1X>'DQ,3(6%A7EY>6UM;2TM+5145,[.SLW-S20D)`P,#!@8&#P\/-'1T4A(
M2`\/#^KJZN7EY=C8V+"PL*^OKYR<G-;6UM+2TMS<W.SL[,K*RN;FYN_O[\C(
MR*:FIJJJJL+"PO3T]````````````````"'Y!```````+`````!A`OP```;_
MP)-N2"P:C\BD<LEL.I_0J'1*K5JOV*QVR^UZO^"P>-P\"<GHM'K-;KO?\+A\
M3M>:Z_B\?L_O^_^`@4YW@H6&AXB)BHN,7X2-D)&2DY25EG9GEYJ;G)V>GW&/
MH&,9(`TH!B8>$TL3'@T=.B`D&4FU&28-?*ZP11P-#08@!K4Z'``<8L4C(TH3
M'<`<K%>SQ4^\P:FZ3\?)8-9#U4T9*,,@'AX)#2!&S*/O3*+P8`8`!CH=`-M*
M"?:RM$@FE!C2`$"??O>*`#"H`P6`6-W"7-CF;LE"+>*B]-LV85^3B%\$&LFH
MY`()%$1,W-/7KMF\ET7DP>12[UX_$D.>&;A`I(.'_V/$$B3(Z;/6A!$`$G0$
MD,%#K"$)B.FXD.#"!0.L.!CP1I6J5*H),E`MHI/G!*%-5PWQ"=3(11T3`-`2
MRJHL$:T<PG:-.A1NT2%7JYH<4;4J4;4*#9X-BVY"!@-]KW:8IE,HV*F%(0])
M*[3(1KACX3K5,91NU\6.T6K.H#I6U&*/A[(.:R#6T:339F/VVI=(09XY/>C0
M%W@WZ;`=I$ZM/6VF)9G.L]1L^!`N":O^9G$`X0\IW!+22(1%JK1@\NJF=)2X
M$+>$PU^K2NAJS\$$B0EQ<5X0GO/ZA>P`@'`,2MIQEQ`1;^E@'G=*^9?=0"40
M1I\)3`D4GE#-)/>?A"R9=/\!""XAR!!W`NI3'U.IZ&`?*R.@D`$`)F3@W81,
M94!"!_FP0\1G(/0U`0D>V*@+@W$-F90.2)TW5)+UH)!`"0-Q<!\*PC'YD(RX
M$3$C`.!1:,V+#+G5984L'=/`DP.EN&)TE4#'IA7U%'3D5``(IT]<[""DH$'<
M$=1,0009A%!<]YPRG"X\D6#"GD.PU$\L#ETP&1'_V:E+/4/=&2!I_B3FFSV8
M5GKHJ`W@-"JF?2HX0CW"\<32J+D8LZBG.F!Z:E+VU9J4GC`R>FM4N];I&9<@
ME-`7=ZRP9*NR1P(Z'$J`Z@GH")<.%*T_SG[:Z*5S<AJF0MQFJHNT!N5JZYN2
MN(G_[A0UU1-B*1[HHR>YO@+J[+60Z6-`;:,&9T`)##GJSW\H/$4$O,R*.V^G
M(GZJU9$(Z])`,]1NJZLZ#!64`<#K]<O2JT>\M6RX^(!`88,@$.IKPOUP<$QO
MG([;E[,)_[JRQ()B:Q"7^Q::L\]&T$SR9@F">_&H])9\\KJ1J,LT%-,A=8])
ML1#G#[T.$61MQC^_.*O%<+5X,Z=/C7!C$53;;+5-##?*4%S-A'HV2[@D@%C"
M62M80@83&*"HQ[J08&K(#(U\,0II'KD=!T\)?;0!3L$<<TY-46BQX;;2#.W/
MC)8P.*-):VNSPV2I/:[.#24N^=.(.,UZ$R32"<!5]L3;_X!`(_2]*:#_U0+D
MGAU@S*G//U6]33\F2`E`LB5,@,)]:RU?1$VVZRZN>KG7HZ.(^*'00"V84G_G
M"";0=7E2O>L`Y$ZULL/E*BQQAY(TM&*>%)<)(,6!C9#-''"XW3#,L%R2OP3D
M(T@LB1<'-G2TW^1C*/AB5).B`CJ=!4]T-3M8A*:!(],-CU'XT]_K%N&Z$=JB
M9[5(SBI,@((/H6`"%S"!"9*SP'WQ)"K\FDHP'K,3K0AG`J80#@Z!8S+&F<!5
MP3@B$9QGA`FPT(5-V<I5L!+#&6ZE.<G9EP>`XXHK/A$$+T3*0G:UKRXF`X<0
MR2(KH)&7,NK@%2U<8A8[$,4:8O_%`UN!QA8;L#\2C/$Z-L2A&8\QQGUTL6=N
MA$8^YN.]Q>UG*WOZ13)X>`$?]HU]KT@9)7VHPP-14I!X],82/8`*J8!R*X)4
MX24EU8`]BM*$AB@A+!<!,M+0\95P0$%>$J`2/SA1*$]:G6=ZE(!C1*&62<C6
M+)=)!EDRTQ#M:0[B4$*'$:1C.\W9P\;RDAPF<(`P=C-8$QC(!*0`YYGH]((S
MTPD(L)R3--F4`U7`X0?S-6$Q4@`F/8TP&V&R\Y]36"=`!TK0@AI4"@(]J$(7
MRE"`GN``.XBH1"=*T8I:]*(8S:A&-\K1CGKTHR`-J4A'2M*2FO2D*$VI2E?*
MTI:Z]*7_,(TI1R$JTYK:]*8XS:E.=\K3GOKTIT`-:DII*M2B&O6H2$VJ4I?*
MU*8Z=:-$?:I4ITK5JEKUJEC-*DNCJM6N>O6K8`VK6,=Z4JZ2]:QH3:M:U\I6
MGIJUK7"-JUSG2E>VOK6N>,VK7O?*UY_>M:^`#:Q@!TM8C/ZUL(A=J@`00(&(
M$L`"#WA`1"-K`0)$=+&2-2H$-E`!!DSV`97=P6,C&U$(!.`!`4BL:FMZV-6Z
MMJ8P&(!L9;L"B5*```S0@&0[NX/.,J`"._CM#A[```)H``(ZE8!RE4L#B1*@
ML0+X0'"!*US>6C>B"'BM=E?:VNUZ5Z4BP(%XQ1L!B7IV!P*P_\`.I#M<`0@@
ML]*U[`X0(%^<YN"^]Y6`>26:`O3"=[V3%<`.CMO;[QIXI-T]L()#&M[QXJ"\
M%.UL`+*[@PDC(+7SQ;`%!*Q3_.:WHL*],'87&]$)#S<%%:CO@E=L6!:[N*0-
M'B^$S2M@$U<8`2+.<'`ID`(,V]?#^J4H!BR;8P20^,8[@(`%4M#8%SM9H@E^
MLI1W$&/R3O2QCJ5P`#"``0S35Z(/X/"/\1MD,"-W!UW&+@.T/.3L0B`%YYTR
MBZ,LYQ=7^<'.56^2YVM9`01@R]B=Z`/./.8/F[FT@)XOG]$;``A0&`&$KK."
MZ2QI22\6Q^J%P'LYO&GDNO?/1ETSCO^_W.DD;_JR%`B`GBL]:5:[^M6PCBNE
M8TWK6MLZJ;.^M:YWS6N;YKK7P`ZVL!$\[&(;^]@E_36RE\WL72N[V=".-JN?
M+>UJ6]O%U+ZVMK>MW6QS^]O@%JRWPTWN<M-UW.9.M[I'2H`*;,#'DS5R?9_K
M60A0@`*1=BFZU\WO?F=4O0$`0'T;38`-8""B%!ARH!4=TWW[^^$0/R^D]UOA
M#0S7XB4^.)KAW5*'0_SC_J8P1>^]7@M@8`,,<.]EQ:QOD+O\Y2!-M46!NP,`
M1-3D*D<ORSL.\Y[[W*(0R"Q%0SO@$B,@S)<5>LM_SO2>![VT6-Y!:'%;`>2&
MF0`4WH"*>=[_]*Z#?`.C#@`#/G#:40.7`%U6^+U)WG"ONQWF32ZJQ]].=V-O
M':ASK[O>]Q[1O//][V[W.^`'_W/!$_[P+C<\XA?O;\4S_O&%54$!)D_YREO^
M\IC/_.4=D&S(>S[6#O"PZ$=/^M*;'K\%Z/SG5U_IT)_^];`O?>I)ZGC6VYZN
MKH^][F,_>V+?_O<OSOWNAR][U0/_^`H6/O&7CWKC(__YVU4^\Y??>Y'6'OK8
M_ZKTIS_\ZH?T^MD//U:WSWW=>Q^DX!>_^J=*_O+#_OP?3?_ZY\_4]KO_]/#W
MJ/SIS_^CVO_^Q4=[_3>`N`>`Q)=_';5_!+B`//5_!BAZ"#A3##B!_VKE@`_8
M?`)(@1HX5A9X@3D0@5"U@2((5AUX@2"H40HX@BJ84B7X@">842FX@C)(4BUH
M@"_88C.8@T]5@P!X@Q<5@SH8A!O%@_?G@Q8%A$*8A!9%A.YGA!6%A$H8A1'%
MA.7GA!0%A5*HA%3(?58X45B8A4*XA=/7A5`&AF:H4V+(?&38=V?8AC:5AM3G
M?&XXARP%AP<HAW28AR=EA]V'AWKXAR+%A[NWACOPA8!(@8)H?GYXB(PXA![(
M>XO8B)*XA(_X?I$XB9@XA97X>H1HB)E(?XD(B1GXB:0H4:%HB:-8BJ1XBIQX
MB:IXB*R(?Z[XBG\8BZ;7B;2XBILHBZF8B_^2:(L!Z'N^.(G`2'JX.(S$N(NW
M.(O(V(;%.'K'V(R,^(P0R(S2"(;4Z&'1>(VUJ(S!:'W<"(O>:(S6&(Y:.([0
M6([F&(;H6(V]N([.V([:J([PF(/9B('"6(_Q*(_WM8WZ:(;WV(_T^(\J&)`?
M.)!.=5H510!B1@"1)5DIYUX[1Y#'9I#^Z%404`$[1P`!)U$TAP'VAEH!@'$4
MN6P6B9!-E7,497,1M0&--63R]0!Q5Y(5R8\"^8Y>I9(3Q9+!E0(;$&DI1I,F
M:9,'B9-=I9,2Q9./]0$TMW!"69,V>9$Y.9$U)U'T10`?T&2@]93(=I)&J54Y
M%W55&5']A5YZA@'_<<:5P^:5^?A5#,!EGC5VJ?4`1Q=@JB9?)*F6:TF44BE6
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MH.IYH(3Y`1H09RKY7"D`H0)ZGI&9GLEIH6IE;Q7P`?*%E#;FB/5IFT^%G]ZH
MGR0*5AK0DGJ&E#N0EQDEH4](H2,ZHV>E`7W69#E77!7FH1?%HU?HH]<)I&?%
M`!:@D,%E`1;@60_P;OFVHR":F2+:I$ZZ6DKJA4R:GU\*IEO:F5U*IF6:6&%:
MAFD:HVO*IF>*FMUIH'%*6&W*AF^JC#)ZIWN5IX4XIG#JITQE`Q%PJ(B:J(JZ
MJ(S:J(LJ`W,*FW5:H82J5!'@8)B:J9JZJ9PZ7B$0J<:Y4UM7F!P%HWQ:J4MU
MJ9VZJJRZJ9_:HKX94Q:F9Q:`8QCV6%7:4::ZB_]]BJH_I:JM&JRM^JK\V)<O
MI7`>>643YU&[NHF]ZJL]!:S".JVN"JK.>5-8"0`:%P`:P&01I9'^J:O>":U%
M):W4>JZ>:JW<>5-C)V8!T&,[D`(04'!_B5'-6HG/2JXZ9:[H>J[$*H_&"E-K
M-E$4(&`L>:7B:J?Z&E3\VJ_3^J_M&+`PU905UEA?-I()2ZD+"U0-Z[#!"K'H
M*+$K!6KXM@,4X%D"8%E;&:X;=:^/F*\;:U,=Z[&L"K+C*+(JI6D!$)-1.E%_
MQG$9Y;(>"+,Q*U,S2[.=:K/>B+-,);072+1%"U-'B[35"JO4B55.^X!0&[4N
M-;54FZE*JXQ,NU19:X#_6\NU+.6U7^M@8;N+8ZM490N`9XNV*J6V:RM>;;N)
M;YM4<7M_<TNW*&6W=YNWE;BW2-6W[O>W@&M2@KNVA/N(AHM1(C"YE%NYEGNY
MF)NYEPL#B%M^BKNX)-6X7_NX'ABY%W6WP3H`G<M]GPNZ(B6Z5$NZ)FB?%(6Z
MK:JZX^JZ1FN[-:NN!)I2O+NJN*NPNAM3L(NTLNN"M#M1P=NIPZNQQ2NUS<NI
MR6N#RRM1T[NIS_NCT6N\V:NIU=N#UQM1WYNIV^NEW2N]Y<NVOCNAP+N^XW6^
M:IJ^+W6\-!N^13B^.P"_\;NZT]>Z]*M1]NNQ^-N$^LN_XB6_@QK`+37`#EO`
M_U5XP`BLP*?*P`V,P#@`P5PHP?Q+P;PZ5R4;8`+@67_V`*0ZC`[<KQH\AAP,
MOQ[LK'(5`&3G6'Z66L*%=>N8PNBZPFK8PNO[PO@Z5SE&`8QU<QSV9>&HP_[:
MOCWZOAWLO\P'P%:58TJF`<!E`3278^(GI<,E;Y=5Q+^*P3P<AR[Z41@,Q"\K
MQ/!F7/-:`:DFI.J7D1Q&<`9GLKBE6V&,P&-\AV7L46<,Q<LGQ56EQ9?E8P.K
M6JBUE8[%=JI5I"5F<><%GSZEQ-2ZQWW8QQWUQ[G+5H2,9LZ%`&E96!A'88YV
MPH*%E(S<6Z&\KV+,Q$OJQ"X,R,0GR"BE:IXU:J"\4O^;%5H:$*7(Q9%$IUI9
MF7*B=5Q9.E4,\&=I";0HA9042\QYS+^6/(@^7+YH/+1"Y<:3=5XZNEHSR<PI
M]6841L0!(`#=+%7@*E'IM<K-S'+!+):3W,I6*YXHI<G$RU.?IF)ON5T=^9XB
MUU*IQI0,.F#LW%0/@)8>6:\JI9)35UQZ=LPX1<D/Z\IB"LL_+,O#1\LEI0$4
M0)<^UK.O]5P\N:(L-;!L[)Z=_%17"@"-!0$<70'@7%)OB=!TB6/`=6D(L&H\
M)='".LV*B,D<9<_0RU,L20%-^<^KI5XCC=0J-79JAL,,=U5OEG('1P!E65<\
M_;$4[:;U/,$8O7L:35+L96/_PO5:H;74,!4`J89A]A;"6-5E&X9=,;U663VL
M6ZVG7?W$F[Q3[V6R3=;1K\4`&^!>`##'3+U:0Y:1:H97==V[\XR>>1W+>[U3
M4;IJ`3I8'/EG`(!A)*U:/_ET:`8!$+"@=-78J^K3HABK(R74W/M5++!<L!W;
MLCW;M%W;-5!4+,F0!.9:IJ5BHJU7IIVT=QVH%FW-7ZU[80U4!4"4R;V"P4V]
MP[UOK(V^7[7<D_V'SUVUQ5K-WWO-3RM6UGW/71?>\EB_\KS=0+U1TSV_U<W<
M>D?>[6C>>AS=*K7>"]S>UVU5@'I4\(V.\BW-]%W<W7W<L=?<$:4"CIK@"K[@
M_<W>_UVUWT;5X-[XW_"+VJBHVB)EWQ7<4G=6OA*^X5X%X19U`[-5XB9^XBB>
MXBK^X;M(X>MKX:V8WAJEX1_L4AW^O2P.PRVU`BK>XS[^XS$PW!@U`!B<XY7H
MXN4+X[R(X2%%XSK.X47NWA<\WX^-4D2.P$;^B$C^O4J^C"[ZXR6N`&(^YF1>
MYF9^YFANYB]P`0O0YF[^YG`>YW(^YW#>`F!^YR:.`VF^YWS>YP]`YX`>Z()N
MYWB.YR[0YXB>Z&..`X+>Z([NY@]0Z'C^`HI>Z7S^YX^>Z8`NZ89NZ9Y^YHRN
MZ:(>YY&.YS/PRA8,AIZ8ZH>WZJP^>*[^ZG\7Z[*^=[1>Z_]U=^NX_G:ZONM>
MU^N^WG3`'NR%1^PZZ.JF)797IE?)W&@5]F>F;%Y;=UH/"5>9#6H:!='FA5H=
M7=!RE>S*WNP_RP#B_F=9^F=K#>[*7%?)'&G7_K/RU>S:[E.Q_@&D77![A0'L
M10``@*0@-L-9QMGGC%8/8'-K%M,0P),69=26U6YS'5<?D+()BF84]EP"@%R;
MW6[*>F;NE6(=J6EXA0$I4%\5('#\OK,:&5'ZKE2Q;F04%>])%N\^!@%Q1@#S
M7E5'5G-L36@T[UR.YF,50+$8Q@"$5ES(1>X156^69<@W+U3]?&0<.5'DKO`4
MQ0``4/._;,@Q7V'2?O1QMK-=Y?+_-:=I(H=;$;79P351%4#:)UMA+.GM:[58
M'";8+(GV3W_80=7R+%?P;A]9V45<=,EG739V01_M4Y7S:'];&"!@])5FJ<8`
M\$J6'OI>5\=95_I>[Q9PD965@4_YE^WT-H>5DJ76O259(\SW)XI;)&D![.6S
M;=;W#\#Y]&7Y@WVE.YM=2(Q5+F_U*4=A.HWV%!7Y%-7/>?5>->I?=9]:&$!A
M.7]4>K^29Q_]F2]PZK7X.A96`J`!$IGQ[\;Z4H=FC"_727FKV<\`@)]=*I?^
M!AO]57G^";G9%/!N`!9<D*9QH2^D@Z;.(N?2%P\$`0)@MR,:BT2!8+=L"@B4
MW2=0M%ZQ_UGMEMOU7A&5`.;1I`8J5T`5N]8&CE_YG%ZW8YD:"L$"3UHT+*P$
M$.X,[PX.%><0F-22(`NM("@PF!#8%C4WKPBMU@(<BR@M`R0QK?2L3'?X*`J=
M8IF.:%LM7CESM_QV'C20DIR`,2@$K2A^K5`M(&J!E9AD>Q]0=:WE&CLE&=38
M7A$@/J2R>*_-SXN8D"T8>-<L/@C2)=$5$^L5LXNJG(DTY`E`^.6D&CZ#VCX%
M8/!A%(&!`A@D*^AI7R$QK*0YZ;?C(KV#AWCYV@&NR`8*:8!%'%>$0(I,F"C,
M@O3L2<TE#`H5_'A-W[Q5";-0'+4OSDZC<QQI2..NR@:40H]^N?\7U8O`BP+Z
M@-(:`!#6'1HP5,"D`0K5<PPV:(#0"P"4#8W*@!7+H$(%7\9:A94G($V%#0(T
M/-BP`2WAP0^VPD'S5T,FLUX("%CSH,):"&DH0"#PX9;+(A6X70E`9<="2IQ3
M4%"\&H!@PZ\AI""$\O$B@82+H#USL@CBLE@P('CPP`)`R65J)U\HB%WDUKX)
M.*R<=FUR+5.M*V)0G0"WZMD_0@C=?4=U\?*P$`@@9%)Y0Y;!&V*_+[H5O%@@
M!/B^E@'Z.OW)B^^Q^00LT,`ZL#M0P049;+`+`3!PS,$)*:S0PB(2O%###3G4
M9;T.00Q11'PR'-'$$U%,4<4552R1Q1?_88Q1QAEIU,7%CP*TX[L:YUCO@1UY
MW,1'((,LTDBS;CS(`MKH:.8_&L<HC<DM0CMR%PRD_*)**[GL\I`D#<(`@"VW
MFV2\^8Y0#[WHO`M-C-R^8[.\+3L48(-]M%"OB)ARRX2;*@)B24(6[<3S#7GX
M;&6^/UOA;E`O(0T2S'H>0$,4B"J)C`"[&'B@)7F(Z/33KBQ`@(`(-RN.&0(0
M8(!4*/H0D8$4-D"O@GC0TK0OT![H%)8/'K`S6"B@F'+%66O=<TP":L7RSKH8
M$#6%R(`5=@E=(\VVR$G166K:'4)15(`JQ"-CM#*(,!=85G80Q)*1A)`D)G9-
M*FU$G-1JY9\?_\,ASXD-U@-`O4)8,:5?.EG$MSI,^/A*O)K4K93@B0_6UF(:
MN36'@7%'DT(8>)5I8R31)"'EDO4D,87=S4P]4:PBB#&&@M1J\JC@B7>8>249
M7^ZE@CW*2P%+@D@&%V>=+TX:QHROP7+/7W#QV1'*D..'HZK9?0CD%/;I(V6.
M[N-0E"-4*B\@K?]I]&:C-1-(QK%3<42(#R!PPJY]UC;X;*7Y;I&J`#0(S;<I
M_HI6Z.(`MT0]4,`B-E^Y6JU``$H$<7RM"J)X]$*O@K4"-'"+PY("@$EM(G#`
M-M8C]+<%Z7S/<>[$(`J`$W<\]=2+.;7OW4UD^J/Y]!0TB^"O(&^M0&X5U>)A
M$:-3Z`J\B&>CS"Z(A['Y+>^;CXWJ\]2<]^\K]!W\^"#TGO<',`A[_/4Q9M_"
M#]VW@H&=XZ^?1?'MSU___?G?`?_^`1A``5KL?P,TX`$1**,")I"!#73@AA;X
20`E.D(+@B6`%,9A!#:(C"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>h03611h0361106.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361106.gif
M1TE&.#EA80+O`-4``-'1T<[.SO?W]];6U@```/S\_+FYN8B(B.#@X,W-S6%A
M89&1D;>WMS`P,)R<G']_?[6UM7IZ>IV=G3T]/>3DY,;&QE145*FIJ=75U6UM
M;3P\/)B8F`P,#$A(2(6%A8F)B:>GIQ@8&$Q,3"0D)%M;6WEY>1X>'BTM+6IJ
M:@\/#^7EY<_/SXV-C9>7E_W]_=W=W9*2DMS<W-[>WN_O[^SL[,+"PJ:FIO3T
M]````````````````````````````````"'Y!```````+`````!A`N\```;_
MP!=@2"P:C\BD<LEL.I_0J'1*K5JOV*QVR^UZO^"P>-P4UL[HM'K-;KO?\+A\
M3J_;[_B\?L_O^_^`@8*#A(6&AW%#B(N,C8Z/D)&2DY25EI=_BIB;G)V>GZ"A
MHJ.DB0"EJ*FJJZRMKJ^$FK"SM+6VM[BY?K*ZCA`+P`MI$`H0A+]YO\*+RL`2
MD!(9>1<9"L_/B,3&?`L7A1X>-<`0%PO/VI/C<.AR);V3O.^,'@0AVV<*!`J$
M)0UZ(P3R[*N3@<"(!0TXN,,S4,[`!@26U;$0PEN)$`T-Y<N(IT2X0@0"6H@(
M@8"_C9-&2E3CX1E*.1(LR(,4;^:A!2;5L!,$$-L=_X@=`];!Z0]GB*!S2@B-
M=B??PAH>.!XKMN>"/T/@:N03EG,GI*UL)'`0YA6.A8\V%]5,2XCH,`L-)%S0
MT"!#B(I0-5B0)D&!@A'[$%K0$%'-@@X$.J11`->=A`YPC2GHT$$84*V4%T"`
MFX%#@\T9&G2`(%;?A0L=)@L+_9?#/;=&\^ZM$=H"XGT0('>X4-H:9\^@19/F
MH&\!W1J;&4M#"-FS&N+W:CP[//G"Y@8*$I;H7%2T!0XR@X^>6Y>`!;@2<BL7
MEWKW]>P<T-8X?Z9V!X7(=9^F6[`A\^\-&!>?8%H59M)UT[5G'5SPR6<??LG-
M]A]X\\5%(%@*9*"!!ND!U/^!!^BQ5]U["7WDP0ALJ75*BC?EM%AA$/UB&@'A
M$""!!D?E\TP]<WFS6`W$^:A`C@1`@)\^2OW"00U`);G`DOED4$*&!)1#@#27
MC:!8"1Q8R:$&:>!T4`,AR$5C#3;B)!-0':"H`)B713EE059B*110%-5PP9D&
M%2@13D*E<0%^;198HYL&HJA4-%7B9&=,445D%P009#"H.X7F4^-59P!VAIHU
MW!>JFW#:>%8:?6J*IC\Y@=5J1)>.:NBJ89H7ZI)Y[GEH#8NZ>E)$$A#@#@%@
M8@@KH8AN^FF5+!JR5K-_N/6B90'A1&5J^GB0P8T&<CJ,-"^%X`]I2@F3'F&3
M103_%+J(+0"6=-:@!%2P@5UI[1IBFE-?8AO="Q0'&`$59V'P]J4/DW<&Y!R:
M8+[Z9TAK%"2,CK[Z2:NU?1F\SV5^*A6".Q(7:#!7WAXLSL%;`9Q=0!RC^BO)
MM%:\5<@4=UOK/BE?1>S%^LA,D@(+T/.RGS3;6/')*T$+R+-*<^.BGN["6&W/
M9YXAP<='JU&-7P0LB2:*^%2-\#T"%XG&NQ`T<-;!0-UK[;V&/3WKLAL'U"<:
M`R^3]MIUGP&4BSDYG$:0:A@;-<P56[LW/7V'O1IQ7$\<4=9`#G3O5G?[':C+
M%@<^M,.&4WYY1("S6A35B!<&UYY#;Q6ZS2?[V/32*\X._XBT3%X`5MOZ!`NF
M=,ZI1.L:,FGN3D_(T?-[I5?JF79`!4ECW;N$0<5V0(/N0X\$<-?JK>]6^QL0
M8=<@K"?U`3%NOE7CC]N\X&CTAP8$)00KS'>=?^[/HM6KS_%6[H#`ANPW'RC!
M[@P:L-S!1$4^Z9AO#8+S7/[\1$#\B6Z!2SI.2:21DU[9;&8D<9CN@*4Z`\),
M'$>Q'>U4^(?-=,TO(2@282P50T:!"3$CT``$`+*AXM3#)_C0@#?FPB.Q<"!#
MN2$6T'9H$@M`H(9,5)L`]6&,D8Q@)#JTX@5.9!R<$4MV^>G:2G"HPWSHL(9&
M;(`[K,@MJE@1BRX\2`TO$(*HG/_.'C/4VA$7D($,2$8#"QB!!Z:XK7H0$DT8
M"8%BWDBLJYV)D(PQ3CC>%,A!SC!8]D`#0I:%'6$!SS,EH*/8EH7'*V&2'J4L
M9$7R2$E!$A*3KS&)4_14Q^R<H1Y#4@Q.$F@2(F8`E=^I""I+P$I`NO*2AM2*
M5%B8!Z8Q<Q&\.0,RQ*&';J"A'&F02UC`&"9CI.=3KXE.':+Y!LUH4IS@E,XV
MS*D&;=*!>]&99AP.Y!-S?K,-QF`G<I+F!@M,QS1@U*<AY%E.@&93=O2\)EG6
MH,W36(V;^WR#`)^YB]I1]*(8S8/<'&&I[H7"HVS8*"/\F%$].+.D*$TI0@(T
MB=`(<13_+H6H)AO`TI26XJ0VS:E.=\K35N"TIT`-JE"'^@@`Q"``2$VJ4I?*
MU*8Z]:E0C:I4ITK5JEKUJEC-JE:WRM6N>O6K8`VK6,=*UK*:]:QHE6H,"G"#
MMKKUK7"-JUSG2M>ZVO6N>,VK7O?*U[[Z]:^`#:Q@!TO8PAKVL(A-K&(7R]C&
MWK4`;'6L9"=+V<I:]K*8S:QF-\O9SGJ6L)#]K&A'2]K2FO:TJ$VM:E>+U]"R
M]K6PC:UL9TO;VMHVL:Z]K6YWR]O>^O:WP`5M9(-+W.(:][C(3>YF<ZO<YCKW
MN="-;G.9*]WJ6O>ZV,VN9ZFKW>YZ][O@#:]=N2O>\IKWO.@]_RYYT\O>]KKW
MO:==+WSG2]_ZVA>Q\KVO?O?+W_ZZ-;_^#;"`!UQ>`!/XP`A.L',-K.`&._C!
MMV4PA"=,X0J35L(6SK"&-^Q8#'/XPR`.<5\]+.(2F_C$-R`QBE?,X@JKN+D4
M8``%Z$J!&;?XQC@V[(N3RX`-W(`$%8`K!D)B@AP;^<A_W?%=,4`"!K@5!#T.
M\FI/,.,*B`"N$4"REK><5R7;%0,G</(-F-S6";"6`&Y-P5LID`(1@(#+<([S
M?X>;V`F(.0(^_K&84VL"*:/9K3$F`0'R+.="']G+=K5SF>^<9;JJ8`"0EH%F
M-Q#F#10YKA6XM*$W?6-$UU71-P!U!/\:/5<#..#4#]@L!GJ,@KF>@-.P9K&G
MZ0IJ$=SY`WE-]68I0.6YDB#6P#;QK.<*Z@_@^@8BD/)==9W9"@"YK9F^`91O
M4($W!_O:'QZV7$&-@5;_6*_,OBP#]GP#"N":`1%@``:PS>X-:QNNZ-[`NJG-
M`!#8&*_A;K>^]SU>.I<VW_P.N,!3[&_2`GS@"&?WNQ%[<+D.(`$0C[C$)T[Q
MBEO\XAC/>,41D/".1W?AAVUX7`U@@Y*;_.0H3[G*5\[REKM<Y0GPN,RG6_#1
MBARN)'^YSG?.\YZ7/.8S#[IQ06[8F[\UYSY/NM)]#G2A._VW1"^LT=V*]*5;
M_>HP?[K6>QO_=<).O:U5Q[K8K][TK9N=MET?[-=O$/:QNYWI9X_[;-,NV+6W
M_>UX?WG9Y<[WU-(]L';/N^!WOO>^&_["-1=MX`?/>)87_O"0[^S?`;OXQEO^
MY(^/O.8Q._F_5O[RE\_\YD<_V<[[]?.@;[SH2<_ZQ9J^KZA/_>!7W_K:ZSCQ
MGXV][/-.>]O[/K"OYZON=__VWO_^^'P-_EZ'3_RQ&Q_YT'\L[CW+_.9C_?G1
MS[Y<31_C>>,[KW>WOMBQK_WRM[7SZ+[!!@AMU^J+?^GD-[_V.P]J,W\?K^%_
MO]7C+__H=SX"$Q!C[%=7[J=_<-=_"#A7G<=K)C"`<;4"!A"!!6B`_SS'?PGX
M>Z:'`B*0`LHF5Q`H@>!'@6YG@1=H>__G8R1@?\L6@B(X?B7X@@1'6:#V9RN(
M?RWH@C!X@9VW`5E&9O=W5_EW@X27@SHX?8@U;M;V@W85A$*H=T28@,H';BS8
MA$I'@D^H>5&8:U-(A0=XA>:7A4I85TS(A2MGA5YX>&!8@T!(ADEGAI1E;O(6
M5^M';F<H8FG8?EO(ACKGAI(%9AWH5A/@@'488G=(@'FHAR['AXX%:EA&:H,H
M;$;(61.(B#^G6@R0`AN``HYX`P3P`1%``O?VB"!6B'0UB92HB(P5`=XF`L=V
M`PSP:C?P`5<FBH08B9MEBHB(BHLU:FT%`O\JR`#V1P$T2(L<1HISA8MZJ(N*
M!0+>Q@"S6&ZP>`-J1HS99HN:A8QLJ(R)Q6LSM@%OEFZA%F3=1HW5F%K82(;:
MF%@5L`'CUE81\&;F5F_D6(ZH=8Y<F([SB'#&*%?V2(7XF(\"MX]QU8]-^(\`
MR6\""5<$*83*.`,(\)`0&9$2.9$469$6>9$829$J<)#LE9!OM9`WJ(P(0(D[
M9P"LA0&CMHEMY8VAR)'X98V9!9(M*)(DJ7,FN5HI28<5,`%_Z)(O:8Z'6),I
M1Y-"V7(WF5I,YGUO=0(]Z9.'Y9%N)9,B2)1%N7)'B5H@<`($\&MO]0&!&`%*
MZ92W=UG5IH4V6)7_97A8(XF6*G>5J?6*K8AL699I82F6@V5Z&&!K4GB6;(ER
M5-F7)N>6J;63;P5J)!"7=GF7,"E8O-:4I1B4;/F7@&D#@IE:*JAG[JB2B0E8
MG8<"*%`!CLF/D(F6D@F8E7E:&.!C%>!DF=A6G[F9A=5Y)O`!#$`"7%EJI^8`
M4DF!I=F7ISE:)X`"\AB+LX@"4):$L"E8G4>#*5"7;O5HD+:;!MB;;/F;R?EQ
MBQE8TQAJ='B,HUF5U(F6UGF=S]5YR59F+>F=?#F9-A">53F>Y$ESE&5E%+".
M9KF&[%F)AK66^0F?\9E<KZ=N>XF?^>F>1>F?>Y6?)L=Q/@F5;26=^F>@_T*)
MH'JEH"7'H"[IH#<`H>\GH35)H7EEH3:`H1RIH1PJ?AY*DB"*5R)*H@=IHM]9
ME"E*B2MZ5RWJE#"ZGI,YHXA8HW9UHPV:G99UHM;'HWKHHW4%I!DJI)5%I,UG
MI&R(I'2EI"7*I)3EI,0'I60HI7-%I2]JI9.%I;NGI5S(I7+EI0"9HP3*GF1*
MA68:5VB:CVJZA!;:IDWXIG`5I_,XIV)8IVIIH7CZ5GI*CGQ*5V-8DW8JA('J
M5H-*C85::GZZGX"*6(U*C(\J5X=*DHEZ@XO:5I5*BY<Z<I%:6/S)GIUZ`Y\J
MBJ&*<Z-*6*4ZF:>:JH^XJD?7JH/UJJ9)J1;JHO]I"J:2)::RMZDM&*N[BJ.^
MZEC`FGK"*H+$JJ"\*J?'RE<4H&EJ2*<*NJP4V*SY^:Q[&JU[]0'#B(<Z"IC8
M:H#:RI[<2JC>FE?C%JZ&.*Y]6:[Z=ZZ3F:Z.NJYW96Z<:%?0.0#)"GKR^G[T
M"ICV:JGX:E<?,&/NBG.Y^:^A]Z<*.K!]6;"@>K!T966C1@!@&8:&:JN"A:N^
MJ:O.:JR3%6/M*F,<"ZG7"K']*;+;FEH4D(+(V59(.'#!M[#JN:8[RK*FZK+H
MFEH10`$8T)QOQ0#GIIG8%GQ(*YKP&ID\"ZL^6Z\P6V9*>9XW0*WZ1JM4Y[&!
M!;+5&;4$NUKV^5;;R9/_`:>U8,>U@.6UX@FV$ZM:(&`"O>96-,B(66NQ(1>C
M0AFPXB>Q;$FQG36M[%>WW9FT>%MT>HNH3YNKAR6KG,6+@#AO6-MN:,MV:OM7
M;/N>;ONWK$4"Z[::L0B/M[EOE9NII[BX(=NXQ7I:%7`"(``"4B:+*]ECZ:EP
MARMUB:NIJ/NUJCNR00J434N:N]NVO?NROUN/N7NZDAJQFXN6@#NKM^MUR9N+
MPZNYQ?NSQWM:#FMY?&M]?NN\AY4`DWIBI7NY?I6Y!]J\5?F\>26^S$N^T:MV
MTYN,U9N^URNUAN6^+0N_P*NSY%J_$ZJ^1<F^>*6_/<N_R!N\X`G`'RK`0DG`
M_W=EP%"+P-H[O]G(P"KJP#4)P78EP8P+B?UKK06*P32JP23)P77EP:D+P@GL
MO_%*PCUJPI2(PG2EPKS+PA6LP#(*PT<JPXA(PW-EP\2+PZ:UO:K'PU'JPWH(
MQ'(EQ-9+Q)*%LO<IPFR*Q%NJQ&S(Q''EQ/8+Q8RUDR?`@5/<IRN[O/MK6(Y;
MP./KQ8MU;!'PC.+JPDYKQ@>,QJM;6%P<P!3L6#;FC&/<L65,JFM<6&D<P8-L
MA_$K5Q\@B&[U@09@Q(S7O<WWO>L;OH=<BY85LW;ER)`\>U9<IEA,AEH,5WG<
MP'LL60D[H%2\LW0\P7;LNWA\R:.8R%UI8\XYD!:,CO^?[*:AS(6C_%:EG,&G
MS%@?<`(3<,Q_K+(CW,H?3,AW3%C!7,+#O%CC-FZAJ9"Y?(^[?*>]3(6_[%;1
M',/3K'C9[(_;K*C=W(3?W%;AW,/CG'OE7)#GS*GI+(3K?`/MG,3O3'WQS)#S
M/*SU?(/WG,]7O%HU^U85D)(;"W6T3'G]')+_S*P!W8(#+<ND9;2NZ(B:.&J3
MNUOE&\BN:M&`5<@=+-*B9;74*F44`,=<U]">]]`S&='9.M$B6-'OFUIEVY/K
M%UP?O<R"?-/.#,O0;-*?1;AQ)0*UJUL]7<7,O,)!;;RQ#-2G9=1K=IF^M=2L
M_--G_-38&]5;?5H3(+ERB)C_+1W"9.S3(2W5@T72*4S4GO4!HDMO;N6YQ(75
M_]O4-\S5^.O5=9Q:[+@!,R:[Y6;55^W2IP?34RG3YDK3%&C37XW)+;S*=ZW5
M?4U8;%W#;FUA=OW">#W$>AVV^9O9+F;8L(?8O*G8\\K8!NC8E3U8$?C:L!W;
MLCW;M%W;MGW;M;V1RT7:PF?:TXG:`JO:^L?:KOS9;[O;9@W(:'VKHEVASSQ8
M!`W*]PO:FK79<TS9Q6W9SRU8T<W+TWW<U<W;R^?;$0K<?2O<[T?<S:S=0LUY
MXJW*9\W4V+W>:[W=@=7=W/S=G(O<E+5JUXS-.KRWYNV]Z"U^ZNW4[`W5F=5Y
M**E^_S/[F`&NN)W]Q,:]WWR=W?7=WI?5>4W65AW-M'(LO!/>Q14.OJ&MUH)U
MV;'ITIH6UBF+J>;;5^BKQZ^LX-#=W"%JWY6UG(!8N&#7L+D9Y$)^:BQP`$9^
MY$B>Y$J^Y$S>Y$[^Y$L.`T,^Y50^Y2T`Y5B>Y5J^Y4?.`E7^Y5_.Y6(^YF3>
M`F!^YD(.`V2^YFSNY%Z.YG#N`&T^YW1NY&:.YBN@6#R^:(X&:7[^YX`>Z((^
MZ(1>Z(9^Z(B>Z(J^Z(S>Z([^Z)`>Z9(^Z91>Z99^Z9B>Z9I>Z32@YRX]MW/[
MGZ+>6)TI9H0]ZJ@^EB6;91OPWZG^ZB-&VE(,Z[2NF+5^Z_^RI:&XONMSQNN^
MCEJZ_NNW'NS"3NO$7NRO?NS(CNK*ONRBWNQO6,U5-F[=V&,/3ES2GEVK5LWM
M:%[5O&[;ONTRMNVNOEO'^;IR#6AD#5S03ED;0`#>=YYX1FTL75Q#QLC1)0+!
M6._?=>]N96S4-FAEMNZ_U;I2M@$!2`*.F)?(U>Z3Q0##V&B!Z([-10`^'ET`
MZ%:W[%T6[U;=WO$[C5P-^%99!KD+]MX&'?'NF`(73UP=WV.>*&T3$`'&'-@,
M8)SJ=Y@FL+2SE?'41FTD8&E&>_-OM@$ZWVBTJ?#TIO3%U?$T*V86/^_(!0($
M$(HSIHHH8`)%_VI,]@$D8`+K1IO_.!]A*&^)*C_8!.!MRM7QYSF-52^75^N*
M5_:*Y8:SM$7SXV9_@8@!TRKWKOAJPJA^/C:.K2:,&Z];3N^*4&_,RA4!"_O&
MTC:+?S8!;Z:)<>_'9"]>$$_R7;F5%2]FJ?EG?^:+-)OQP-A6=M_S]F=MC(AN
M9G;Z^ZJ7T-9DZ';XMY7X'[\!*3"ZQ06N<L6+L#_Y3@:YKJ_49?^69S]O5%_N
MNP7R/B;Z-'MEGWGZP>];/M_CKKF:KV]_:$;Y'L_[+K]G'\\`%;#[R%4!!-"3
MP,_]?,Z+TW_JL>7PDF7X;I5GMYG^:Q]D;H_Z*PD$G\KDQB`:;S="DMET/J%1
MZ90JC1";_Q/&;5@\8I<?[`:3HMPHV^J:W79'3QLFZ*S<5E*?]Y[?CTY$FK8B
M(KR2EFZT;@B[D/P>(9D*"B(K+2]O-DY`&"(JDD[T-D@P2RU3&$Z23$0^4N0(
M&"A(*#`(4"),.DTP&&)-@:DP3E"9,$PB:F]S=WMC*4Y,)CY)3@B#L=LJ3#88
M/D"2/FYK10B2L]&I*``9&#8J*$1$*'(Q0`A`CI/E*Y9UT[%-`CBP5!HU26HQ
MP$"0H9,*!RE\PG"&0"]C"S\UU`@%`T8I![EDW#BP79V1)YFD6;BG(Q>4D02^
ME#F39AM$-7'FU+F39T\W,7T&%6K*"+BA1Y$F5;IT#5"F3Z%&E:4ZE6I5ADZM
M9M6ZE6M7KSVQ?A4[EFQ9LV>AA$6[EFU;MV]QJH4[EVY=NW?;R,6[EV]?OV/U
M_A4\F'!AGX$-)U:\F'$PQ(TA1Y8\^<ECRI<Q9_9K67-GSY_/<@8]FG1IJ:)-
MIU:]6B=JUJ]AQP;H6G9MV[?[T,:]FW=O22X$!!<^G'AQX\>1)U>^G'ESY\^A
91Y<^G7IUZ]>Q9]>^G7MW[]_!AU_N(@@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>h03611h0361111.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361111.gif
M1TE&.#EAY@%X`?>K`*^OKP```$Q,3+6UM;.SL[&QL8J*BEQ<7"XN+L#`P$!`
M0("`@*VMK:RLK%!04)65E0L+"Z&AH>#@X/#P\'-S<]#0T/GY^1<7%R(B(F!@
M8*"@H&=G9SDY.1`0$-/3T\'!P7Y^?B`@($5%1?+R\C`P,,K*RN7EY:NKJW!P
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M2G%Q<7=W=Y24E#4U-;*RLKN[NSP\/#(R,FEI:;BXN/___P``````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!`$``*L`+`````#F`7@!``C_`%<)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-J5(C#0PL<&T.*'$FRI,F3*%.J7,FRI<(1
M,%0-4"43P`<82D`.Q%$BAP670(,*'4JTJ-&C2!&.R,&"`,VG4&42..)AQ4Q5
M*SS\3,JUJ]>O8,.*M0CE@].H:--"70%CQ-BW<./*G4O78@FU>/.JFE&WK]^_
M@`.[M``#`(,">A-')>!6L./'D"-+%ABCQM,"5Q4K]C"YL^?/H(]Z./N4@6;-
M`V2$7LVZM6N+'C(_!7#Z=./7N'/K9BU#-DT"I&OKK;%UM_'CR/M:X)&6MG#-
M)9)+GTZ]Z]WFST\KJ<Z]NW>40GS3_W2>7?&*XM_3JU__<,0'`+Y-0QUPHKS:
M%NSSZ]]?T,1UF@,PD!EM`"!F'U0U\*?@@NE98.!EB`$'H'P'RK0#@QAFF-P,
M:`U0(%3D5:A*#!J6:&)K$BA&H8C$G>CBBY(I-L"#BIT@WE/1P:CCCGUQF%B(
M>7FH2@'!S7<ACT@F"58,1:H%I%H$/$C`DT_=IN256`KUP6DKID4D6O"E]4&6
M9):ID@>U2=B<@&H50.-31)@IYYP:,2G<E)D%2&540O)Y))V`!NK0EMD!8.B'
MFE$YP)^"-NJH0`Z*>-J,;5KYZ*5SIBAIHGG!@.FG<\:TJ6)[TL0#>J"FFN2H
MG.;5HJJP[O\X0I.L\OEF6BS$JNN++=2J5ZE1<;;KL!G^YRMVBA%`(K',\D?K
ML>.=QH*ES5;;'0XW0JL*L&@1P$(+)DC@P0<?"`&I"2C)T).U[':5@[9.9A?<
M`#4P@1@+JHT4`P]74=ONOT#Y"&]4W&8WP`?^5K3<4P/H!/##0!5<J\3R,F'"
MQ:A&9(%ELT'L<4LF#(RLR`IS#%6.'Z=L$A0B@]DR8Q-)P$):BZIL,TDSMSR;
M<`TX@``'(-#D``5H4>"`*D.KDD-$+`<IP<U0:R1!MM!23%,#&'!@``40;*#*
M`Q&@%<$#JB!P`%89)X2F7JE%[;9=.N]\&@47/$5WV0<T@$``>ZO_<@`"96,`
MP04^K*)!``&@8'@'B:^R``D!.$+U4V.^;7E$+4Q^K-5^`TZ3`0'@+0+@!X3^
M=]D<J(+!`4ID($$*`4@00`43A*#!`AWHX$-BRE[N>T,P:'YL?:=M4'<##7"-
MM]FJ@-XYWGC#H(("D"<0@`+8WZZ`P'FA_/OW!<60<]Q#=IE8!%T;<,$%9YL]
M.M*F`\Z\V3[$KD+L`:2PB@H2/"Z\*N@"GP`%\B[RR4TM+MC`!EQ`HP=@(`"#
MNX#>\O;`OIUN?@>00@@2%X`):(!Q8.#!Z103P`&J+&V0XIX!2Y4$`;A0`$;`
M2]"BXCR\#,!3`I%`"9Z5EQ*:\&,F($`)_QPF$!DPQX`@:M,+7_B"T]0P+SQX
M`@\3X\,?0FQM4_I`"91`A/_!:T\V6*(+;8!$O531B@`C5!E_I18?B%$`9%RC
M6LZ(QG9QCGREVL`2?R!'O-"QCM4*61_S4JH"9,"%/VCB(-'R1T`R:VV+A(H.
M3,.M%R@RDE%II".'I49,8F9&=\0D330I*'"A<).K""6\**4*`NA`E,\A)9U&
ML`*:%(`%3/!`G%`I$$&*,D13A&5:9!FJM'AODZ+RI!>%.<Q4J>5IO%S%^!;)
M2F9FAYAFVD&3"!#-540*DZJTYB@_92>T%&!9J-14)#$CSNP4X)1SBD%>SL/+
M9`ZRFNT4CJ.$\/^!%2`*+[O<Y#3[&,YVYBI0[EGF$>`)OF\.,DSY?$[#`F6R
MT[RJCDQ8YS(CNA:&*DF5%_VAL8)D$RO(I%9JXJAP\`.H696'!1Y]6S!_XT,<
MV%-$!<WG00'ER^P(2Z2*.>9`)'`$29E/E!$X@`%H0H&SX84"2Z4)7PZB@03T
M3TD%?"D:93`O!AQJ)O1,R$C+`X"9EA%TGD-<7IA'DYT6I*I73=)-[[0#;$)M
M!S,Y6+X$@@,3$!$A8Y77K19I``1`H'D<"-T#`+?8YB%`!*M310,X4(0%&&X!
M#G!`!5:!`@U40`&KF(`#%&#9VV5VLQ5P0`94H`$%=;(\'C*44"^W@QG_['4B
M@94H1*-$V,>"8&BA<Q[H&@"!`X`@`&=S@!>^$(`$X"X%"G#`*DAK/<ZB`';.
M[0!T'3"!#BS@<)8US@ZT`A&SUJ8&)H@I+W/[G`(8RKT;/59AC8:!"`3WOH0(
MP,4X0`$3S.`.&6CN`D`[X.DNH+H24$&`G4M@!537P,;A*E;(VY"<XF6VW2P(
M>]UY5%\50(\"`,*;"MN`"V!`%?=5Q7'7$+M5A,"R+ZZ`@!MLX.K&>,:.4X",
MG_9BXW0R*PSM*:M@EF&%;/@TAC*OB`[Y0J]!I;"JX(#70D=<#%P@`*O(0`A(
MX-U5D&#+(6!PCFN,Y2]_6<P%UG((NJR;WJ!E_P5$N-@91W#D`^&PR&+%:=Q>
M\,;=/:4!9(M``YIW-0,`(`$"J4`%)/"T"21@`HN6P&8E;6!'A_;1D9[T9E60
M`@F0=C>O-68O8Z+D[(05SPA1X7,L7)LPBC&.B1F`70>B@/PY1`$A4$`'H(D;
M-R=F!:6NT$]1;1!(DI5@\3T-G\7H9[8QZB$)V.Q#*O#HW=2YC-PDMD&$<$3[
M$(`!X#94GXX%8A?&4#%,P))+K<G2:,;``_`^`KG(Q2\1I=26R=9,`8#@0A';
MYDK77J-;-RF$50Z6U;6J')+6;<VV`7($%^LBO#I\;[1T&%[#UE'`Y8AA`0YT
M4P0X`42WA9>R>@D^3__B+;1Z)ZM@(Y'(5C0VJYSCW@(!:TJV]"J;HC6>`DW)
MY9H)J8LVWL>,?\\$'IA!+8_5)0((SS#9TOEB$)Z6I<&(X?G,-OB(0/6\7-Q7
M78_*5%]$]#YJ_7?E%-G(#=ZF`RG\1%C/YYU_]W%XN:EE7AWYM]<NG+?SIZ\F
ML-+45`ISW\F\96'_D=PHUJ2!=V<I'I"W6<1-DY#.U9I^OUSB246^/O&6G5"R
MD:'`]!T+/*$IB3F"P[3)T8Y##5M(W#S;#"2?/5&*2/193,*20SP9V>0)2X_H
M"L"G3CR^W"GR@:^MP'0H0UFA]"V8`=`C.G?+B6^-LM<+GD`4G()Y:-:Y48+_
M2FMS:LN-1H[9?XZ:>I\8JW]'U>/'B]&A=OT^?MV`(=]YK/_*G>F+\U27<W[W
M-%B$MQ[I5T;SYS$Y,&_!MTA/PG[M=`0&&'^*47T?DW;"%"($DA@^<`,]0(`@
MP`%F,VA)$Q6-E1V[-QT'B$29!S$;TT[.T2?XA!8W\$(T<$E/85]0A0$B\#5A
M$Q4-$%5LQ##F,H$4F!@IR"Z7)TKU@4\5]Q1NM$=H\0#(%0%C`SU\PS=!&#H_
M$P`7$#8.P#<88&@68`$Y8X'>L8(O]RWJI2N^!H.W\H2J,`1]AA8'``%>&#3,
M@UQE(P+.\S.JP#Y<TP#'90!3M3&.]QUJN$8K,$2J_R(#'F4!#7B$H`<5="A&
M.$@39/,`''!8>[A4?_.'[7,`(Q0`!M!N9:@?BRA'`\"&F()7!6`Q"2$#=4>!
MKQ05R_9"?!057$,V&^")9Q,`1_-8HH@W@UB(X*>"1U@>!/`!'I&,,%("LF$3
M'B`!6S$",Y!OPA0$:=%"+]0#:>$`>'@!2[6'>X,!6P@]S","66@`T(@<<;>,
MA:(*S@@%[\@@AP<5MV0%_K>-:M$#+N`"S:89IJ@7#R`"R!,`#W"/QB%D\B@I
M+(!.2O*0]L&-0[(I!:D7B14`7L`#2>@=#DF1%4(`"?@B\2B2I%(`(O=/(J-Z
M&!*2*'D@$9DD6163M0%1`?_R%/VH%^6G(#!ID\Q8DB42:D`YA`!">P0H(D*Y
M'A9`!$7)*C,)(P[UE-KW)C,"')4X*CVY'S(PB50YDDNI(!;PE;PS6`-P%F$W
M$^VF(+%!EK7"`RW0ANOQAFX)%7+H,A4R$S#`?_M1474Y*@5@6R>2CV1YE]W2
MCP.PE@SRDW^IE"Y2BS;9?$GI)=K82K?%(#79F*R"A@PR`FZ9E<*14P"8(?"G
MF9+RD?J!5T]9<P<R@\(1ENJQDZ:I%J[''V474:#)C/Y7>']7F;.)%[S)(+>9
M=;)Y0&KQ!'@!4Q@RG+^9&+7)'AD%E.\E'`]`BC]X`#](<E#2&#E02^[%`A_P
M!`__H0(3,`$JL`!/DP+2IALX4)S-J7L8(@-X(6A'J$H&``&959`9J9VX0A`6
MD%X2D0`A,%TD@`(=X$&@Y1HFD`,E\!Z^^9YXX7[[,0)'0#44X(?Q5S"P!A4'
M\(6J`%4HYC-G0P`_\%B#A@`;8#8YD`(9$%H*(&G8HS\*,#WA!5T+@`+KF0&*
M@YZKT%P3T&*>`7%)QY\0JBV)J!X+DQ<4`$'9*4[?=G_>2`,W$!41<&6K,V@!
M(`+'59T8H`7ODZ5+N@:R,P$I,*`D<#M8%@`9<#C4EC\HT%P#$0+Z(Q`9T`$"
M<::380$S\"5%&C?!J1Y$&14@<`$0T*3#DRPFAY=Y<8DO_[2AGR../:B?A74!
M1?!`*+94<*H`&J"CJU`!`Y:FB(9C/8IH`@&G6=8!TO9ID1$#7MFG+<.9WD&8
M3[$!!T`T&%!?@P9V&Y@7O(5S29083/9"20`5#I`Z2`,XDLH!/4@%8:.?B*8!
M#K!KLI,"AS.JHZH"`RH[I&JMN+.>JAH7DMB,U8@JK.>J2#1\^1$>>0%9[(B=
M>.A4!D"*UKDU!L,`V)E40))4#&,@.8EOBO%&3J:)$(`!AH6I!OL``WL!"G"I
M!`"G/TH"JR`!'4`"M6:M/DH"7V:J7J8!/XHX<"JG1F$!"QB7=":1`_&"^J@*
M/<$3#VJN]J&8WB%/>4&%@W:'7_]#-)]#BHE5G9Y3&Y1RKV<3(D_$GY3BFFI1
M;BXTK#1D`+G*M,TS:$'X`+3!M"Q0;2ZF`CF$:(]6;8^68(^FL2B0`8Z6`&0[
M`6-*%"8`?+.!&!:(LE#2LBY;'J-9>G[Y`$235`9@7TLUM%!18D1S`#S(`60S
M6<S35!P@N%^CK&5`-`CP`(TU`%Y@HLZ36:JP!")(-'6```!P@GK1`TM$`P-9
M&\1#`/E2`5PV`0S171@+L4-EIP6A8$$!$SQ0*ID7J'$;2;"Y&Q905%&Q`:9H
M8@HI`OAY`4>3%CQ($W<8@JF36868O#]#7+7*AZ;H/""``$O`/J!#-PU@7QL`
M`A``50'_,`!\BQ<]D`$T8`29>).J0&&7AKH.0;8&03L%(;\M(0/2QSMM,1#,
M>;LMLY7)`1.M&F5\R`$2M`'\I1:0]12G<SH1L`'L&*^D@P`U](G.DSP"4%R@
MDZ5^<P7(*\$I%C?3\AFV>W*4Q[_61``\0"X>P9>O(0'WV[=]>P&I0UP]^%02
MI,`1'(@'0(40W#E4&#;L<ZG.(P(<<`.KD[T!$`$4T`52$&5^&#K'13ZH^1<C
M;,)'.&X``@`K,`/P!BX`NA`X,,5?(;)J05P4\`"$"@*@XS4&((1IX84($,=-
MA0`$@`1%,`!69F4]?`!D``!IL#[%)<2A(XXA$`)*-<@(H#<F__:%579E.L-R
MGB$$[FG%#J@6$#@DAD(N7.P!]F@"XG>69:7"'H`Q17$;%],"\$8NVP(LXH@`
M(""\256HB='&M&R%<$``8P,`00AH5F@``X`%9Z`*W1L!GQB$GQ,!5?``QFS,
MJ@`'0KC+;JPM-?,9.Q#`E+R,>Y)X[D6/3""7%T'&-<=WBA$VEJHZ@#-#JV:<
M0S(C5X$`%V!8("`XABH3MV*T`]-8%*`X"J$!^EP7;7G-D:D6]U<A0D<2ZC*9
MFH$^%(`^1X/&T7P:E4@>`2(>#\"T03C///>KPL$`9F$?H%,#E;">"%%@=<&8
M`$V!AB'0<(L7+:@1%M`KE:G,DD4VXO^HQ`69J_-8&K^!T#]B&,U7&S.0`P&D
MFMD!.C%08,)X/8[CL8Y3R-JU"F5Z/9OU:=^*%)-\TB_G57HQT!5R!'$9$CQA
MS9I18JG#`2>F.B<F`DZEF_.19!-3&]1"U*IP`S0@`#3@`GH!.F,6`/QCJB30
MH@L0`A.``@K07:V5`:!%U>&5%/N+U>B7J'IQR<=R2Q[`P@_1`A^PTL>UT/CY
MH7Q8(:MH-0FHFJ[V0E.:%F2CUT@=JHB&`JQ;8`/V8-6EV%R1I([-45/".1:I
M,V=9`E_]$$U9G`[T@X3Z`,?E`!B`S@<")"_@`D-@($'8QF2#%L8,-D\[,GT[
MW80F!61;MO3_NPI.P6]+%+!0085U0`AVNMJC^D'0!-N%'0"'G=@H4#N++1JW
MS5%N'9IK5``IK$7PY@$[P']"(-8\\\Z*?*L?B@`XFY<T4H,N=(/-PS>&5</E
M#3A)T[C=,E@BX&3L.`!!X+'-!;NKT"O"+$:[B!9AV`&MI=[-56N(@V:@%=4Z
M!M4=,+'U;12K>-_R(LZ:<8NB]$X#D5"UDL$<`&C"F!@`F;[8G8LNQ,:A$^%,
MI52JH*\@>J\4``+821-CL`%V^V=)7#9X.'8H(%UG^Q3>V&1J<:234<4ZOM_]
MF..G,0<"(:LB4CI11:MY84@O!`2*]Q0N\$813HH8<#3(/05LH,9<_QB,;1P`
M(E@WR.T`[_P4@\I4H-,8$NN^<DKBJN`#=?V-\T$`->`!)OL9+?!M;?Y+ONFK
MPK0"W08M[HS3>2'>C;K54/'G8A3H!V#64I"E!U`$9*`%B2[(4!X`0>,`10!U
M(Q3A`Y$!+2H0I#5-+Z!'&0".3[$",+L:%N`6%L#FISXPK`;GPH0^:YT7/R!&
M>,VKI,'D`L!'3Q0`48!<T@WL`%`$BBY<H4/LQSH>(S0`S#403^WL&R`\[&L<
MC=WMWL;5O'/51PCK>1&L+G3NA`05LDX#9`0Z.@L!/<,^&+`!H#/O]9YBCPX!
MGC,`8W#6,/!@,N:^7K;@:2%$8KP:!6_PM?_A7I.<FY0LZV/$>4]Q`P'I9TDE
MKU@0Y7<[BGYCA6>CKP^@0#[S%,PE!>(95W$56E].,PC3':TN\\?R;2NMT2?-
MZ7NN;UY$&[8NI<C;-7@!68`[[D6P!PNA`3T;%?CR'5CO[=!BSR9<`$/@`J?=
MXYSGX+-^`!N@`]F2/+6Z%FLPIPAA`7<PW3=@!!LPI7/;'>!^W^EG\W._RD1*
M,XB!M#`T&X>!&D5H9&:^1*)@LAZKX@?17`\&&K!W^9OS123<?*-WS<XQ^QF-
M+)R_`5,B^)F/%[!:$*,1A4LD!@4!I];3:-%6JEN;M8VV:-L:&";M^O9Q@#,(
MV6V-\*;I(;FMJ(K_:@1B=`E.X1R2C18%G1`Q4-HOE'%^39X4VP&*H_I85@&Y
MEC\),+&YYAC1+_TYK2W;#!"J!@!05=#@P8($$2YDV-#A0X@1)48$H`,`@`(/
M%2[<J.J%`)`":%!)6#)BC%4I5:YDF9)*R)`>6`9(D%+!@@D:5F50L(IF@@"K
M)*280&(!T`DI@K9DVM3I4ZA1G>(8,-'J5:Q9M6[EZK!C5X@7,U*L"M;LV:U?
MO3;\:L/(!B,O"/9`(N"'F;(./TAE^>$'S$8M::8DH4$""06)?28`NBH%"0<A
MC@9MS-?R9<Q0U:+EW-GS9X.;05L5/=IT6M)L-=J`*>!1%`.Q#:@RT,#@_]Z6
M$BJLJB"!90R/-$`BV;%J0DT)$@*H2+"@PX0%(1(@7MQ8@8,4'2:OJIS9^W?+
M!$Z/)U^>86GS"`&(3]\^8H&\$0>>=S@@R)C6C!"$"(``@2H$'BB(!]]:T@"%
M55#0227@5"&@$P("$2,E%(*J((3$%,A@MPD<<$"##%91H((*>BHQ`Q54*)&W
MGL!S\46F/G!O1AK!0L\]`.*KL<8!QDJ-HX/84X6!`@#`I+4-:`O`H`,B\"@,
M%29898$*CN).)PUJHG(!`P@H880$0^2N@Z5"2`%&--,$;P0P+>!A1SCC#$M.
MD^BD\4:&>EQHH(OZO"@A_&`"0I4H`B@K@#T\T/\.,I](R"``"1;HZ:9&'X5!
MI<*,ZT"%I3)`4$U00W5JA!((((`(%NQ4E4Y3XYQO5??@TXH!K`JPH[476(@D
M`!EF^&"P"A)0;#":)!5Q@<6236DP![:;LD51HXWV!%BKI1//\6BUUKQ6M<)6
M/1LR$"`#&U0QH;N?M.,IV6(G19;8FI:M*0!Z`^C)6&GS!96(%;;U=\9O30OX
MWZP&8``CK@:N,R'NEEI,!>TP9+<Y=R=6R4SN$N!T-Q3$U/=C&"V`04B"2P9-
MX<\,-AFM`@C0TT:&7BA7M8/VBE2E!7Q+L0(5IO0M9V.S]'GHE#Q5Z>95,@5Y
MZ1='F$''E:-.^%J2MVW_@((#*"@H@@,.,D#K)KE&J,<"M/U:JX%T+&`#D&AX
M@;Z#5K``,PT8A2J!$')[+C,)1C0..Z@FZ+DEOYF62H9^I5;\*@(`./@$;>,D
MP,=M_3L`@_\,6-*@L\,^((B#Q3+I@/]JI=P@MD.BX715J$6H!;IQDBI*EBHX
MT[MUHXL*7Y82D-)PJ7)8?'B-1#_(3ZC32UM.T0+H6FS-20=!%0H<`/"!!XHH
MR`$$1+@:@2+^NUP$#@0,\'I5'O!O>@0V0."'@J3_KX#6!.AASSY[9"`.X%V<
M8-,.U*0H`0A!L$)`@@!,QEX["4`'=#*8_D6%"%4CWLKXU">)%,EXL0+`"9+W
M_Y#&A0YEH2%`Y`YR@`!`@`.ST=P&#@`!59!.%0&(S9)`@``#7*!)44`$!F((
M`1!P@`,SG`T-58$!K"TI`'J@0``><(`+&``!2_I(:USP$%D-0`81_`ZG')"2
MYB1M,A700%",)8$0H:`G$.3B4V*0J@H23(,;1!L#*%BK#VH$*R\S"`/RV)`B
M%<1U"XD`!:88`<TI*8;_H:$3EG0U!T"@:UR`@&UD*$,C&O&)4YRA$XB(@*XE
M4A7"@<G;)%*"4+&`"@68T(N"I0$K0;`"/-%.8QICK`FH46)L;*-3+,"Z.,+I
M@A?YHU8:)Q_6-6YR"O.C5?AX/*LT+B_-/$@$(""@!O_0,)&)Q.02"J4*\CT`
M`P=X``1FLTATTC";!HA``$#01"(2D0,BH-[F7`"3)$V$`!Z8FXM,,+<;A(0X
M?)%``E*P`#4J`#$96`!S?`-!!V1@`I*QI1D5(+B\.6"-\>KE4T883,\,A$CE
M.9A#YBC"]1SOCB9=Z=B`*9"7`@DA)BR("""`@`L,<9M+PJ03$AE)#(P3`3<-
MT"7_@],+F-.:F%-B$0U0SJ%N3A4WV,`&7!!3^@@A)2-H`>RD$H.##6`%+X&)
M&5A2T(-*2J'76<!1?.<4")8Q!`Y`044=$P`'5*`#'<@`"925,Z$@ZTIG158"
M%L04P\+(!""-4P&P.AJ$!2G_1_H<V.0@\LR%T'0M,V4((@6DB@;,)K2JB("`
M`N"$T=(F`J6]@6P:4%K2?I:=#[`-(FG3@"78IC9?JR%86C4`'K2L(!\`TU,L
MD+B"W%,`<A!B%MY0B"M<``]"7`1C?M=&2BT@`+NAU$INQKN6)/9%,&#LCB9+
M(SZ!SHY9B:R#*E(?QR'/O2/58T2Z=1#-2D2<$+@?W+SEM?Y<P'I<P>Q!:@`5
M&1WDGH=`0Q:RX`EVJD)<(6%"1U.R@"]J"%D!G`!/D+6B!3@JKW^CU(%@5-X=
M#9)X%Q3/?=^34ONV%)H(<;%5&L`'+'SPHZKX2F@_.S6O/(6\"&&-H`H24)AP
MX6,%_V5,DYNSFY1DYW\EJD``)J"AZ6S'.2GP4()0H!2*P6C'*.[*F+=E9II1
MQ*5;D55#:HP5-!LDA!$Q05.$D#P@A"0#8U$N3&KG9,:DM:V#YDF&,H080[-U
MT(-.08&,LYP0A4`%?@T`8C!TRWOU1`(J>%287U0",@,LU*IH<V>PA=G\2J3`
M,R;P8R4"`#LT0B0W@(A,6M*@AKS`!?U-;FL"D6B&+KJM@&8,E--$@DSU%4$.
M%,IQ+/JL54BFRIYVT0AD/&K/Q+E:VCZ(#EZ]$&__=[,1X=H!LK80RW).:U8I
M$BE!PFN&X&8E%JC!1)YX@"&`9+H"L(-4Q"L5P1E'!8"E7?]3*B0EI6#)7@[$
M-+1)<$#I@!<\H,9V><(=:N&BY9@2H>FKX`S":W/.>5`<,*O1.1'XY!N?$.FG
M2B@>$0I`P`$"8(,<D##=,+02*A)_R@)"I%`4/(>A3BEH2H[SNX+ZYCA"V8UN
MC..[WC@]9"8@0L7'<P)7#R^09FFOF@]2@(M'4\:K9H@H'Q"`!C1`!*"D7OC$
MAX%PDG;M![#-^1!P@ZKT&23Y=,@*2H"#55C``RLM@`LV,(0"9',(.1@!4$Q0
M"!"(2`7=E50*-.TAC9(86=#1D*.C?2;`TB0%>;-P9BPP`ZN;QK$5AW%:BJF>
M\W1]3K./B"@_*0(#C#,"2PCJ#X/_.,0+X![N\32B*E0>$KX;Q`7"V8`I!U!O
MA_C`W1E80@"*NQA*!2`#9:R2=!00E.O@K2<H^#)-^IJ`#)!>*%96208Z\&C/
ME]XRPDL]:#8^:FEN1<7OR2.?KHVM-RL[J:*A`,"<"_B/F+,D\<&AS4DD&F*`
MXI,^F*`U!8,)^)&(/(,)1F"_1Q.6=YD7#VR89#DC3J,)"(*@[G`_*.,E^;.,
M&("^^LNVUR.>UKN*@0'`_?NZ&>0QB1`E`X`A"-":"&B`<O(D="*==A*0#;B`
M&=("*2@^C_@+&K@BA/@+F)@9B$B=D`B#39FH]#N6B8FH52BC56"V=9$VFI`T
MWH`4,%H*_^<P-A9L0;X0F1V,078+.>()0-KCN(E(-;)C"#T$,/\(`*UIHJ$R
M)`@(GTU"IT@:*O;I@J0ZIXBH'RK,PM8(`[UZN$HKD0]<#+U2`#(9PPX`Q9YX
MN(<SK%'4#I68`$AAQ7I)`.6X+CG$#"%`+CL\BW3#/Q\!P*SS.(H(@HJX"`;P
M(V:*B-"*#=O8F@A[@"5`1MB"+=*JC8(H@-E*QHAPMW>3B.,#"18`(]_)F=[@
M#BGQ'<-BC*4HJ`G@$*A3.EADB<(XCB;+";^:Q>^0@3J\18@HM5&[H#_\NL=:
MO8E8M?/Z$9B9")31NPO$P)"X@<L`"@4(@4_Q#@WX(I;X$'H$C_\$P\>NZ,=0
M"\2#\,4@H:8^9)E['+<]O(HD8#Y34C46\(#BP(SC,+;OX"B5H,F+Q`QKT\@R
MTTE]U`@A"2$\1(@@0(M4^SA5RSJS6`'QL+6;;,K,&+*).(&@1#$^*4G&"IC&
MJ0BD9(BA-`N/),B">``GN2W0,H"OD,;0LL:)(,*RM`TBY($1L(#K<TJZG$-;
MU*,2*LI04QF=-#F#Y(JN+$C!-`@'&**STYH-"('3.1\(0"*L$($-L*:A$A`(
M^((MJDO,G,.LT\<3^!-5N2"4BB]QZTN#X$C_NBP&Z$SQ:`*N0PNU``$FW``,
M&"(1\`+:.+<8*J0`$('2.H`-L*0G.B?_KOF:(0R`TM*:<0(G!^"!S&Q.J&@!
MB=##/EFI@Q&AK7R/T/PC8K)!TJ2QJ0P-/BR($D*S.-N,=HJ`%8*A"Q@#$)`D
M#+`>&FHBW'//(2I`$3!.:^(><X)-@Q@JVZ``#,@!YQQ0IH"CAS#-C),SM;B@
MKLB_K"B2J>Q,JR0SO6P(TPQ,@Y#*G32+GBR("VA/55BA`,`",@"E^R2^V7@`
M*6(DI[H<T*(A&2J(W`LEAR%0&QT!5_L6#4J(L1NA@?A.0/03.I*L"JV_$?K*
MS5`F(`.+#EV[(7(?)D2`%8H-%/W!`U@[%'71=9(A$)@-&=(<&PW3E##0-`M(
MSXP(R&D(!K"(_\Y4"-GC#`+HS+')G^X4B!'JT(/`4!JK0;`LLZYK(B$,`#I@
M`$60.2%"T0V0I`-$T?R<HJ_QH1=ZH>D!`?43TP&%SOHZ#0QBT(\\4]"0%2&]
MSM0KTC+-+(A04NX\"X+(RHNH`C6H@L8Y``.P#P,X@#*(`!UHDMQ4A:IZ@"31
MU29I`!"051IJ)]V25558@53P&$MU3A-H*3P%C8$05<X82(&H4S7=BD#,04`4
M2:][B`V@IP;`(?61*<+4F@$@F28P&,>ZQW;RD$H"D'4SB!:0CF8ET`^0+[^L
MN/O#5BP"4O!LB+#+1Z3\R@8`(NXI2W,-R[&<4P<!V'L;RP>8GML(N/]['=".
M*!+KO$73]->/*@U2+<V0Q1/8A``G220I#8`+B(`F"$(L9;LFPBL`X0"5S015
M<(#^P`!)Y`H"F,N+;4YN"Z:M\]=,3=5L[5.3=(C@D]$ED5)5T"$`*%DG83O>
M!(&FY8`!Z(*LJ22KW=FM8,J?=<Z@C:.0Q59NC3&-J$-LP1/WN29%8CM0(@@5
M*@BV<Q\,:-H?*`!0BE$HW`H>:+FP;4Z`K;BRK=./51(GT2$`(5:#/%@BO%MZ
M<H"N"5B'L*9:]2&4[9JX)1T@6MRSBX`-P-O%3<"NW8H!.($3D+?`;<Z7P]:.
M]=?"I5SN<='T&4(?BD8G(4+;$D\"V(`AXH#_WT2`TH*A?3V([O%0QH5;)'"D
M0JHD4&J`N\79!B@"S>V:^W14U"@(%D")U<U,3/58HOVVK(B<!DBJSWK>/$B?
M`W2G'\2`1>7!]IDA#HA?53"GXB4-//R*!_">;/HQHQ1/&`#<[KW)G`3?\(6(
MLSU5&..`"TA&MJ.5"``!Z"568=T<@L@D$6C/V6`[RMTC@O`!&["!F$I0@Z!9
MF=6*!D"M:!R0RV2)I<N,=`0C*+/)`;Z,\!U;;`-(8P(`3@B^`2,#-;`(50"!
MV=2AG2H)([)?N)W<A4&Y(,@()!.)E82]Z$1*C$A.!"@Y`IB!%FY#W.F9AX/(
M5;#(&LZ,UNU./3W@_Z\;W(,X6!"P7%6X`B:6TO9D7-L#`/LE'PT&$+[[2O&$
MG-0<BP+`QH2D,:R#"#O2P[R0E;.#HO^<#0J(@@@8M((JE@)IC@41&J$Q.D@I
M$6<;PWDLX\O8`:)-8S7FL0E%B`W0@X((5U58A'E5'\C<@'(MUX3@@*Y1.P18
M-R?J8)/*KQZHGRE&"!TVUUPTB!T=$B8IOB7F&CK8+J#PD+QQCA"KF.YRC$KM
MJ_631>^HC+[BYL;(CO?K9K_2`#)!$!00K)"A5C)[TP,&R8W4@6'$H+"XB!,8
M2@!="/[T9?SYH&!N#2S,$]'HB&&JB*JP`2D8R$BBV"4&K0MP`Q%LC`XX$_]6
MY$0PO#!H44%Y>9'&0($0^)U@D9*CZZNF>ZMT++J4T(T85@D'Z)DNW"Z]4A/#
MY=-3CMUHLM;,VLZ#X`"UY%6*A2DLTDL?:`T:^+;XZLPV+8T;("5`X!P@BM>&
M%J)NM*N)?C2+OF9\"3HXI&',`(HRNAT-.*`.J.0+Z0`%2<5@Z8"'ZPES1C9H
M\0ECJS+?"*`T.6-\Q.%0P^N_',T]62^(2(()5#5KW8B+J)HB"XG[*=\D.501
M>$_G"5W)#0*["KIJW@D2J!!UKILUQ)">8,7XRPR@4&N*3(#>^(EGJR4/00JE
M*$.=6!<O3@F]$I-K?A$EZ$Z]ILK;)C5AU)&/2K7_H8V('G`!%PAHTUGC@\C`
MD#""])E<KDF[JNK26C4W`_``9$$:3#:Z%$D!CHK%YA@T;(81H"AM+7$4TX8V
M[6NK+*&,H!@,WJF,V%:)V5X3PSWE/6'GJXB<LNF@SO01'QCFHA4(U+7OC1S(
M^]+"O<L*U;T,!3BL]E-GRX#'&7;#O$D@3C%':$N,!%`0N[J.T8.6*B,,[0`L
M!1@<%Z&W.DU@HH7GS[B1M0&)#/!OMC`8'=`!#X(3%1M/`@!L(]LCK<H,VVF)
M*'$R0?,Y0T.TQ$!OV&Z1#DD!#;B)NEH1$^LP#4E'$^ELS'OK`.J;#-F-[7H1
M$Z_3:/77UVW0:S/P#)B(_R#0`39.F61J`FR$\8B0&Z)SLH%KJX1*#"/7L$%S
M,IDT'+I*`#%LOXA4B=%;DQ+X;=NF[X*PZ5G)1V&6B(%MCV%TV)CY`P'X@RHP
M1MGX&G,[`"[0*#PWM&89M"QILN:<I2GW+F9-"16XG<RP@C4?M3"?[_'XRBJZ
MPKV>B![XBQ^`-X\P`I&HQ,V*K'X]"!65#23H]+7S#P3`'/\`@T-PL"S(`-F(
M@DL1Y:7)R`/.;1HD#Q)N"&P4`!_0IZ`\;)!8R0*P0I"@P,XR@&8T@`U(]@.8
M`F9O]GH7@4X_`$60#?\]"#,_B&[$=I"!R@/V8ZL[7=XNCV-F"+U+`J.%"&#?
M\?^I:@U#F%]F=W8I-;=DIP`#@`UI_%9`>G2#$%!ZQ!>>(YQ.;(HXA)'O56-N
M_Q>"*#6:'@T55["J$O9<!U<D4;[6:(.&+=6%*``8OY%;#PD;B-$#>.NFR#ZN
M!FU`6S18:A%C"<=PS!C8?BC&*)#CN&1N1A.JH&^#QS9M*>Q9#RD!1UN(;XU!
M.;+6./-_-:F(_X$I-LWZ\0&D-Q'?J'K&N/J=0`Y`@Z5%`_5#2[1T7C3MSOH0
M8XQUH11*Z:L#`D,"^C[23L4':OH2/WO62W1DILZ#P7PJ%IB(,'<!0'=U%X`A
M>'N'T/&V\1&#*2;5%X!!N9S8$`$2$+_H4``40*#([P#_SG[(4;271PD!X6^R
MS[X,YT@,B6%\9-&`G`"_=VEMS&N.]UOY%UDL11_S4)MGFN83?FXU\L"37;<+
M7W\!MIG"DUR(<$]LV5@"+<":?+=X_T`#00@!9D\J_[@`';J`#)B._0<(#1,T
M!%BE8,&JA!)23""Q($&`"2D*)JQH\2+&BPL4)-QH$.'!50Y(."@8,D""51L5
M'%R`$&7&F#(Q*E%E\R;.G#IW\NSI\R?0H$$!""UJ]"A2HP4&W"0`H$!.HDEW
M2IU:E``!JT:K\A3@54`:-"$0(#A@]L"/-P;6+C'P@&O.`PALRE6%``D3#@A'
MEOQ8,07)$`\+0IQI6"-'E1P=_SA(T6%PB@PF7RI(('A!B!0J4*R">?AS11Q:
M1Y,N_7,`5-.J5PM=:A.N3:RF89\]0$'5@0BD`:`PD'1#`U4@#CQ0]0"$3@!,
M??[XZO7%3@8`IJ=6Q8!G7=QS.7```0&R9+\)%31^7+@P:,,:.*]:OZH"8Q0:
M5J%0D$+!!/D?0RIV4,'@?^E]]@%K!1JXU8$)'NB::SI=5QIJ<9D%`0>J!.#;
M:`!<<0!2!ER`&P8.0-!`!"/B!$!6/_7@W`8([D2!`S;!:!QW#KA!GWWXZ9=0
M!0IDH((*/;Z7F(!%&GFD@#(LIR"333[8))1:33<=52E.Y=24.VV`07`!.%`6
M70B($/\<`AN`J1T(<WV)@`,:<C>F*@9P@,!M#\QE)TXBQ'@!"`:`$!P&M]GT
M)%`]9/`#$-7U!(!T3^WT@@LN^,#3`!_(@"2FF6J*Z1%1>FH@EHY^.JI0LNE$
M``-+%E6`J#QY5YR%(H`0P`,'8&"`"',%(`(%M!YP@0$(!&"<=VV"<>L%&T00
MP`;>46#`L-#BQ*>%$&!P07`.B'!3A`7"AM,-SMW0$P$>;'HNNNE:%`.I[:HV
MP)3?NDOJ"8LBU2!/#T"`G$T76ACL!0A@,*R_`3A1!!(`+!'`=&D@0$`!8):5
MG5S22GM3P<AAT&)VL5FI6E4V)&'$N*H4X)P`#E#R,4XK6*#_+LPQ'\GNO#7O
M=@++-N/DU`FJE@:Q3_(&W5,#&^-4L)S;DOCOOQQLVZLJ%$!`159W16P;MJHX
M+>VL1_L6J"I&=_R:S[O9M.)70*AB`\H"S+!*"Q[([4$-4`$@@<R@59``WRE5
M@#=H"4PP04IY)Q3#"CHKGA30-K.J`P,G2)<:HPQ45X`.BO)$0+TY$<H349SG
M##IV`9!%%M,7ZGOMM@4OH2\"$!`<\%QE#5#$`0T@<,&U$31@[07#W@2V=]<&
MIZ=.!:0&K]!#+=><<R^PC7(57B"`"DL*D,#!%1QD_SWX+#G@$OGEFU]^"GVK
MSW=%]2D0PF3I*5"!D(97U,+B^1<%_^^\`TA7=D[\IX,30`5?`90<BK+"``8,
ML'DW09$J&N<34^DD`FNY8)R"8X#@-,`M-ME@!IV0!SY$(5H8?(!N'H`%FSP`
M0ZKH8`=QHBV;6/`FU-()O"+D0)\0JFTW*``-G$.#IASA4D:2P/J2J,3SE>\B
M$^C`?!2``A7,9Q426(`*)M">"BR@B@N0P!43HH*'K()O0-)B>X)4122U(''Z
M>^.B`.@D.0+E<S=A@)6F0T>@['"'4X$6&"`!BI\H)R@ETLD#/M23*5P(`,$"
M"IC\9;(EM:T'J@B75VA@29P,@`4M>)G]0-,0]BC@,5"40`=0,!*#/"8`\T%)
M8>J#@@!P,?\`*`A!!NA#@EL2"4DT@R,P<U(`Z31JCR"S2K=V!I?1%<6!#&0F
M:3IX!LWMQ(`]>4!P<!(!W?3D5PAPY%R,`\)M/@!6*,Q@`U"XA.4DH@UR:(,`
M:)`:'PQA").B2@%*8$0)!.AO"1&<8?Q9$3!:$:`$C4D&B!22EEP&)0M]"=\*
M0CB"),`C'@E`"G"T*<0%LZ/5G$ZCH(E,/_8DF:\AJ5#DU:B3&HAYK5GIJ2"H
MBIX5Q2P76$(4YD(!WD$@`K_"``0X%,FU`*\(`Y#:)P2!!AJ4;"@V8<HJ').0
M#N2R`A$QS(X2$H(*3*24_`Q!3%1``C3ZA:%]F\!#.Q-1@SB`HA;_Y0A&-;HI
M)7FTKIN+%Y6T@BH['L6D>9T--54!E\X)EE$`P)E5+#<5O%+'9%0J9%#,0H$B
M:&$N;EF6`6REBB_9A4,7@E8#9E4`"-Q&#V`([.8^!H,)!("?).A`>TC0GI1H
M0'!?3(`*9OL7L$[1+YG!B%7'YQ()/!25&;@E6D$"T<)T@#$=J"A'/(*"77:@
MEYG:@3'M:M<L)>5!,IU*A/S7!-2.=#IY5!5(X<+7H%#P0"0UBRHN4!=;B>!"
M\ZV=9]<2+8+Y9FQ\%.8(0J"!,<XO`[E,JP,R$(+<\H<^N>11!S)Z7(Q<L7P2
MJ*UN*XPW#&,8)6'D8@(TL+?YA/@]0*I/_[JPJ]T5EQ2E)VH*>8,R@!,@-D&L
M8D`0\"B4R$&VF4UZ+X<D`0%='6`#]IU+789JL6$AH#L!6Y7/WG;<^0&)!%%4
M[BJ>F)@&\Z<"5.V(=34E@5D&Z#`9<(A#U*5B%K,Y*MF-"B==W&:GQ#@Y3?)?
M=BF0!^5P($84*(L###"C&4FLG'>:2P,,08<YQ7ES]2K`$%PP!)>UIY1#:FU9
M$>+E$&B1RP@Q;D4\DJXK9E24&NABS'8@TC9[5'G[@TV/60T4E]JD``3<7)U-
MPZIX[:2]/_$0AWC29R>0(@U3LIQ3?!8A*4!/`%Q02``>'`+8KN+,LUQ`0U3`
M&/%4FS,E8<E\4/_PX%"2.R8>D+6L^>?4Z*"[*">8$E.8ES,Y0Z@JE#-*D[.Y
MDP?D"DZON<F-[ZT*(*",!1TIG`:J.`$@I8^+5L0VAA.B`=F6+R56+C?&,U("
MG[RYW:/R-56&YO&?$#8G6'IQNZ9TXXY+"8=_W0#*S("N)P)NH!T@:\9SOHJ-
M[V0`'G#CR!?G0&L*D^6L;EZW!@"Y7#,)7JLVVT]@+JYTI:#,/"JUSK/.<T[N
M8!46J$'0A3[!I].;Q4[A.$Q!3JID'\BD/*E"P;,N]W(3Z*D%Z'I"+,""L.ML
MF*WB%M.)SG>3K9=TB@.IMW!8KZP<00ABX,)7;C#WR=O/`C.800YP@)'_$0Q>
M<<QK+$K+7E?F&?W?BU/W,7/2,QWDH"(C@,$H7/""$5"^]EFG:^=/'^N?J-WC
M)3^*Z$'U]*,4@&7O9L`*<C""$E@)!$@(A1(>CJF(9X3ZMJ=\#G+?[N`#D_O%
M%_MJ4,5Q1?WJ`!R```.^0)$C-1@CUK_^Y+>N?3:[W>/<MX[G[X^3!3(=)_G&
MC04%P$:46GUDP`14P)1EU`1D0%MQ!GDDF!;UB'W0QQK!W^1]W?P='=_5'_"!
M'VD('L`!P09LP";9A'>8SFU`RQC!UGU8QF!L!FR11PJ$`$=HCV7DEI4M0/Q8
M8.UQ7@:RV'>-G/YQ'W&8X+,("DX(&E#T7@?Z_T0&.$<)OA`(U->S$(9$K8=Y
M6*%:*4:FO<=&["`/4A[N_:!'H5[0#:%02(_F_(HJ8)82QD4X$5)I-`_:?,4/
M#$^+A,T!0(L)%`8#5H!#G$=!0%&UU:!R20!&$02WA>'D91\9UI7^+0X3+B$#
M95<!2!U3X40#)`MW1$V,/,"<<`A]<4!Q-$`H1HWY<<`T@:((;``2N@A/N$#;
MW$2O"`RV\&$L=0`)!*(6:H`N5E>FH1()*``8,F+\/:)'1:+B_)Y2#)]-$-Q7
MR!-.>$=/:<?O'(!W9-:^=")CS(HVI@D'4$%0]4JP-2%/#`'*#-%-=!"&=%`+
M$,X_@5$%P",\:D#5>?^$/_D3$I71`=:<,4[>WB%C,"FC3T":I/7?O93=[OV$
M#^5$B(3)Q82)=K3A!M179B$9`EP,`OS``J$4!P)<$'U%$O3$!WQ`"X#&`E17
MA/TC2UJ$!0"=0.H/0?)$`3RA5V0`0AY%X0F3=$@.4K2-"^3$F<C%`P2`;HC`
M14ZD?!5E4A*E40[`!=PA_MD$,\+93[Q`2!H!:K5>D2"1/[8D2^+`!ZC*"I1>
M3++&))*&+#K'$!S(3EK'_VA%LSV'4`9;78B`M?34?84-[P#+7BK`!71!4*E"
MMR@'>8&@3MC`/?'$5X*E8QJ)#'S`=+"`!3CB6;K+6XZ&U'U%'A;(3BIC'0K_
M0&?>Q#FUH3EA2`041VJ^T`:A$!:8`0-4@0$PP"2`0`2`B51(A?_@E<>LQF/^
MYKF8P&7.RTSJA!&@C!&T'6I)$&GTP`BZ0$X"Q??Y7\!4HPZ880`57W&:"W!V
MYY$(YW"FG()@4N0EB-`@)N@$H8((7@OI6YVQ2H&\C7?.9WJ`9WB.2G'J!#0*
M@-J8I\BU!E/L&F,YHZL1DED:7OB!$GTNZ$S@0'3>)]0IB/1`AX(TCXLM)$X4
M*$\V!<30$79F2('P@((R*(EB1`R,)81&27ZZ2_-4Y7]22H^ABKI-I[Q\I%6D
M95)P9XGNZ$4(08I"R8HVW;SY1!`0DJ+X#Q\1A4P1_T4RP<9>&84-'*2!HB6/
M5NE%_!R2_FCBM=E3X-5;^AWH#(!+:>A_<<M?"=:)9,Y1["<-4*B]_`QA"H&5
MSFG>X8`$:.F6^L0##`RU1*15G,E._$XZ!4^,I`F.4HKF8">&6H6]F>7T<.9/
MH&>IC"7>T2F=6L"#XFE![E&)W$:O!&`,T1`(I5,-T1`VP8H!W&;N^$:HVL0&
M5,@(-H"_0``<Z%4>9>I1.$5<(L5:.D=<^,LCH91_V83!19^E'FO=:>IL^,26
MD&:<!,"UZ-2004`+`8^T8@`&;`=/[>%^^5\>FB*7:$TY3D6#!"F"'D6O?D5<
M/-DC$4`=C%-JPHHX!8=<K/\F"QF`N<ACF?W-01TK?<J`LJ8>=L3A!P5`!PU+
M4,D)!X!6UY"6*N1*4>J&?"V9U]"0B.C&%!#L8DW2I]BH3SRJ5XPF;OS*6NA4
M%P"53VWKP_*43^4EA^S4M%U1"+P60BC8S"*$OS+HSP4LB/;$3ME$`SC`P3YK
MK$@6Q?I+Q0A/65`LQO@&-G76`&3L')KKFR(%F[HI7=A&1EK6&52!?6'`9B%`
MQ*J"LFA67;B%#Z#$`LA6?5@5W@A&SI*H!3`?SVXLT5P`4G+`AU`L61B``U0A
MT389"`3,-<X*<03`%`J/34"`;^!M-N)&A?1$$##=AP+I5-Q`I"SF3<"7?"%9
M"-3_UQ)8`D9>3''LY0'@DMI&5V501/O%+7W&`*XJZS#]1`/T6PH=V@OU6SKA
MKBERQYW4R&W(Q=AP`(=$0*[P"P*4@1SA#//PF`[PA(LR27["E]3HRA0865,B
MP.\X@+/L90#X@0JDKF(\41<)H.N6*-4^(E90;9\E35%0`-CFA*Q&@+P\[U-Q
MZ$X4*:E4KE90@*#TV0!P`:`)FA=X(HV4B0$/FEZ@0(AQAGOTR)GA[/DN:!R<
M%`^4)$S6+?Y2+;^)B;X%!0=\<)QPR+>HYP/E+XNN)S6A5`&,Z$4LF&54X`3/
MIPF8`$;`P('&I/AQ+!#N7Q"<:='9F7B&'^4`$'-&$``Q_\%,I(`#M.X,5ZF/
MD@8/>,`1L(`)HQNAI._/+(>],1VL829KH,B[O6AA)8_F/3$:6\0(S`T;4[&,
MP4"/\AU7:/%HH`9\5D7T9F=.V"]^AC&`GG"3`L`6I#$A&P:F_L0*&!%&X(\0
MHIRGL%U*/5`30,YUKLK'-,':S>2A#@IW$29WG60AAW)&S$!)S8`+8P04>$`)
M$,BB*@@!',$>;0$`S;$PQ>X2+@7_E2EIR(;_9"9KD.D<AI\H#_-%,/*I@'*1
MR-^=S0#M*7.&6D`46V6M+4GQ\6\PFQX9ZQ65;/(<.N.KK8:.$C,QCTX,(`D&
MWIFE6(0SVT0)'`[8$8#]PD7HI/_*"1O(DV1FC<$I-C<)'Z\&01(`[8FS.'O`
M!^B8*M1`0/N2-UN%G&*$,P-T15C>4C0!)D>%=&1H#K=8$.9Q;.3SLJJH@1"D
M?`HT2>^`*ICRI@1D^!'`!QP!,FM<CXUT0ICT-[,&7Y$4HRRT'((T6NHT53!%
M8Y+T,">TIL``:PQ`I7Z&"4B`*BMRWN5D?I;PB8QQSW&T47!SS[Z++;.S!;3`
M(`LU6*.+,2-%#<R-%=Q$.Z>+2K.759MCAD)%#A'F>EDS4M"Q8RFCQQ9%#80U
M7Z/+"/AT!!'UWLGTN:PS(1DT:<SUK=5S5/S=:/BR:=`U+))&6O>U92/)5%1V
M0L@`9<+_S%A?M?YQLZUYZ5%OM5LGEC]?MFH;B6%SG%,;S@A<='=E=%Y[3M.9
M]FG;[6RL-F^#QF?SGBH00<Y9GF[7=6ZO1FT72'+O-/%A+M8*5F]']TS$-F-1
MAX!B'E'G'&!C-6,+Q7(GQ7?[\6,C!5:FS<Y(-WH+R`AD]^0EZW$SMYD^1:A,
MQ[M1+5'X748GA:3.6G1NIE?8P$U\0'H/>'>Z]U4O--'I)FX?Q;MQ\:A`=M46
M!5`&.(%7N&.>6W'K,L#E]R\#-C(A=E\]Z(3;A(!;N(D;(X:#-T+"A63W,:F(
M7MGYMP``.(F?N(WSH(&_=\AQ$CU[X*?`>%*4MU?T9VQ\QAKO_P![W[B2GTN.
M&\5RPYI=KYN+YZJ'TY,+E""*`(`AKP#EF,(I+SF8'TF33W8V`W'-1+DC&P6$
M`T4-6``.V/!,./,6O':8UWEZC#F9GVM'<]*"(T5RSZ[`[L^"#\!+R\0(?(L5
MV+FB"PB>^YB&W]$`Z*KRM'*%DAP$,<I'Y_EH?(8F]%I#+SJHST0D]A%/@'A;
M&X@!T7*:,VI2",V?G<Y/X(EFF]N2@$`>EL#\3(`#A#JO7T0D"MYY!<6:B[<G
MP_471ZBFT\6MK,6O!<"LQ\0<3`N_G`),7%RO][HR0KERH-2PKT:Y6H=CL]1X
M$Q\=C8W$<&L`?%8`$*.F$>-O+=04D/^F\%``,:;$`NSZM?.Z,N(+?$:01Z(Y
M3R[0_6ITR^DX;J1[``B5PMN$`W`)M'"52>22+R:7092CF;3A!0P"3"0`M>4[
MJ!.D=$`R4G2[:NRW'A?%YP"ZHP^L_RV\=T0`#P2!%GJ&0X%$.=8%!V#``41;
M&:V?Q]NY?4:V+9/\;O1XLH,.Y]"889G*=/3SCK/\3;#))A+'OJB"!PCB*I"`
MQ-^<%$U`"-R\FB!`'P2`;*''S]MY:X/QQWDX29EA7/N[;EJH3XP-->K\SJ?[
M&V!]CP3`;SD&&^C\31@`!-S$#L"$"H39V=NX!32ZVC_RJ9^*,[+P'CU^`%UP
M29;S9YQU3E#_JTT8JTCD5N(O^3G+)(>S5ZU=<22GU)L=<2TW"J5SW9%T2ES$
MR$$GQ!/A7.B;.$?!$=$GA[P(:.]/936=0!`,D(,_.N2?"#']Q+.#1HI'QY?G
MOH5',QR%=\\I1_UQM[U,)T[H[VM,CG26S5ZEB).B:4D)MY$T.@](_Y*O63!9
M_ULW!?@3YH(OQ?KJA/<#''\W=HH`!`$``P"H,GC0X(`""!FJ@K$*8D2)$R76
M:(B0!T6-&SEV]/@19$B1(TF6-'D294J5$6$,N$C!@4$',2_69.B`@DV=#`?H
MV'F1H,N&!`$4_'FT`1($10XT:>CT*,,@JF`*-,IPX44.#:@@\/K`_\"!@SPL
MF/R@LX",E6O9MG7[%FY<N1V9V#R`0)4(#`VB7GP0H:].GX$+9`U\&"$&#B!`
M8$!P-2AB5008("E"X#`%#*H,!#AP($*#`(`)J#6[L\9<U:M9MW;]FJ,%PPWO
M4@CPP"`"L;I5!>`0`*^!"Q<".$#@695NX1B0/[@`003>HR?Z"A0J&3$%"`<?
M4`"`8`H`IE0#%$_^^P)@!\`QA"T?0-6!X1!`Q(<00`3?``9Z\S?(0:P#$#G`
M/P0V4,6#DT;`3*</8'L0P@@EG)`B$W0Z`(+["MQ-K``VB&"_SAX`X382DR/P
M-MM4N>"`!KR*B@&$!*J)@-FP.^RNW%X<C_\W$2(P$0$.5CQ`NP9(]`\#$>*[
MH`'C#(#@@08PZ)"__0Z"@#^]!+#R``X</(F(GQB@D,PRS3P3I1TNA%*^W#CL
MK[_..(-/3N7HA(]+Z78"P#"%"(J1(4!OE(R""PPR8`/X>$,`"54V0("Y$T_,
M$4X'-HL/K[LHS=%**PWR5)4"QO,#@;).,H%!F\9$D]567353B)UR;(#%Y!R@
ME<HX[YSS1#GE9-%%/742M$:$BF)0H4&Q:P""6YM4]-8+U'A@M$0EU:W(([4#
M#%-,08!2R@Y!H-8_."_8H($N*"AA`054FF.G+U^=E]YZXUI05NF^_3'#*>$,
M<=<Z4>3U@7Z%M>G_A*(82%7&HJA3%KL'?@L`@YR^A0"#*:1@;CT7WQ0!N/V.
M*R^L3#.]+[_X`ABN7`.IND^`$E9Q8`&5E-CI"7MUWIEGDJ"`6%D'ZG-`2#&!
M/EJRJVIZ(#_1<(-X@Z)5&4#F53JH0*4C=%IAA)Z]_AKL57"X#NG`0"#N@J=W
M(H!AFR(0ZR`#<M+I;<E&Y(Q`51HXD"&E;9J8)HB9Y4L5)2!*P5V5++))WK`=
M?]Q5%LJVR0877/`!XJ(T;SMN^.*>VR8Y$4.`@B<QK.^"<@WR>_*HWI)@!<8A
MGYWV,EMHO:$D!-B=AA>4)4KAFD0W""95<#*>@@>\0@`LSQ"HKX&[?$2>_WJ#
M0&R@@2C/-5Y)A`1MR`<;<$=H`-/<LL(F4VM?G_W69!O?H!=VGS^#R5GG]:`<
M%VW1`!$@B*`S&\!07MHC`D/M[R":N1($^'(V&7$N5!O@W0ULHCROI*PO`V`!
M$>)B`=8-P'#M$^$(X7([^*G"!?.;G_UT<((3&&9XW4)@P?CC*SSY1V1O,@BE
M_J.DX27K(D!0H0`P5X`A;.!RAPH1!PZV-M4P@6RJ:!P)J5C%TTR&!4_PP!9W
M8(+8*6L(0Q0`_`!P`@8P`!">VR%>>#.E<"F15]NC5@3:"+=N'>!`1,.?*NYG
M$#$.H0`9F!\-,"<Z$$5`>2NK3Y!6IA[V)&`""O\(``H"L(IV6=)=%>A``!0P
M@79UH`,I^,CW$&1%4YXR)!^800NZ-I'W*<L'0^3;">>T/`KD"$,8@,!G@$,Z
M&[X,`;NTCR[MZ,!O!1,W"@Q5%!$B1LL-$0A[%)F2BA2D(17I#@%(0`;<14E,
M?E,%*9B`-A<0@@EP\R,E8%@(4=E.=X+$0D"[P2!]1TN].<$`^8P`(@WR@+_L
M,Y\&"`U_&N"?@G)+%?[<YT%$`YB"$DX$,6&;3GXPQ!M(4(4'&MYM/)7#`NCF
M`"3P@`6TJ8":):"2E[QD"AP@R02H-'$>@<(67$(`];T3ISF-B`6^"+$7N.`&
M-CIA'ULG@EE>"3!$-4C_#U18/R/($G]M2M++7(0$$_2A#&[HP`12H$UT>G,!
M))B9NSJ@@0J0TUV7#$E!$J13M^KT"?8DX^0*8(-Z(B1[#,DK'W_2`R,@<2'S
M5*$+YE0>#.`FD1=89!A68=)59("3VIP`"2*["@F$@)/N@JP"2)`"F(J$.G%X
MZVC?&4^YTA6"-[H!#7:W`:':1*DV$>+NC+"3%6QQBZU<104R,(%Q5D`#-4M!
M!^2R@P*40+>D52X5QW;:HS'@6&4K`&OGEX2^Q)9R@[@K0UA0@A6P(+D36<\D
M+4O9LLIE!#%8[GJMB%WGHL4E[D6,8`=Y7>Q\P`(SN`@'5W%3]OX7P&[AP7L1
M_W-;"8Q`G:E55@J'V)>%2>9+'JCI!UJPBO`&&,,91DD,/M#A`C"3P`W)@41*
M`&*(V6"(]?L)06Y$@(@(`0:MA`$`_*MA&]]X)![H:8@;,L55R$!RDY'O400Y
MOQ[\I%B#JO`JA$"`&4!AP*I8,HZI7.6.R,#$(>;:1G+0`AQ8`+<*CDH!7+`!
M(XAO)P40<U18`)$<-&0&5I;SG"$2`Q[7I`87[DA^3SL0H!4`!ZLP[4%*06=#
M4QD&=S;("J#+`QC4^",C>&WKAJR3&$=D"P4HBI0/W6D;GZ5L$V5(JH*L"AZH
M-R4EZ/.@!K`)3[^:SJ!&6@YPD&@&X1<&";*`16RJ$O]\V7,`#\/.0V!=;"K_
M^FA5@\@(<D!LB8`9U:FVIU4&50-(&QO;[%6ULDS0[6X_*-&T%/9A`-!=)>@Y
MV^DF+;(E4SX*L1MW[@5>05IP;77?>[064%8!RB1K^YUQS091-KX)CN$10,$#
M-0AX0PI@;]?`+C#N%?6*1UQPB]MX!!Z86F`D4"8P+SS/;\XR7X]2@!U<'.4V
MQG)@G$VF$<Q@Y-:.",0O@ET"E*#C*=<YAG\6F#:C"<@UP:\K_<W'%]JD`#/(
M^<Z9'N"B8\1&#6]5"XZ`6P]TD2/-]L"W!RTC(CB\Z6%W*T\O4N$1^,T$[>NZ
M04XM=K<#6`C764'%(>(W_J[_SX0(80+8W][WTGK;OPUIZ_HTCI"!^QWQ&-[V
M009?._T>)#6)ESR&<7`0S-R]=OXF0+0GW_GEQD`")I``W=>W>(/XV/.I5[V"
M1+QZU[^>)(4_R`KX#GO;K]X"43[(X6_?>]OGW2#F\_WP85^#37.>^,E7_O*9
M[WDO-Q_ZDL=!712"[NA?7]TX:,$'7)"(!0"`82W'_OB-'8,G?&`@*)[?455!
M>_*_'];`5T61C4R^0,,?_W3>012=:?C\_]_*]J\AJ&M^"&O1:@\`$_"M!+`A
M9FM^,,<@&D\!)W"]&)#AZ(^"#H("-W"])&#D5,$&;``"IT;X.-`$<RK<`B/.
M3I`%YG.JU/HB[5I0!MM),DQ``U``(FZ0(G10`;!F!G_P:U(0!M5*K21"`K!&
MFX!0"7EF[6P+!XC0732@/'#PDK0)!4B`JS"K!U<A"9-P";]00A;.(&I`O1;@
M/3CIL22@J[XI`#)@JR;@O-"I"Q,`#.OP04Q/)V;`5*!P%52`LU+*7<ICJU`*
M(@AQ#NT0$5M#_H"B\:#PK"1`!0"1"Q%G`<9)`QXK$%/@K.@P$3M1+BR`"%A`
MP4H0"B=KD@+`DP(Q`1XQ!;00:\PP!$*`$SV1%N&"V401(<"K%G?1<9AM!@"`
+]WA1&(<1-@("`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>h03611h0361108.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361108.gif
M1TE&.#EATP"D`,0?`$^LJHK(Q\7DXTVJJXG'Q_'X^,3CXR.7E2&5EJ?5U6NY
MN>+R\:?6U=3KZC&>G#^CI'O!P+;=W)G/SERQLD"EHVRZN5ZSL=/JZN+Q\3"<
MG7K`P)C.SK;<W!20CA*.C____R'Y!`$``!\`+`````#3`*0```7_X">.7V$0
M:*JN;.N^A$&.R6#?>*[;Q.S_P&`!1DP%21S"9,=L.I^#Q.PR\5BOV*QVR^U>
M>SZ"=VQ%%([H]"=!)J,3B+9\O@6+V/0\W4X2Z[-2:H(^#W]91PJ&BEYV>(N/
M6'PC?HL/@Y<B&)`>01N;GQY@&'&@CY(BE(L7F(,:FT`%I*6+8(FSM#^IB@JL
M@AFO/YZWN+'#BJ<?NH9FO6@<GT!5QH8]S]-_R,J&@<U`MI!`A==Z/:[C>=F?
M`]VPH$#GY!\#QT7U+#)AH!CL/H[@/XL00!FH0\H\0_PP:3.D(2$)<<!\+%KG
M\,?!/Q4%+?R#(*,F=P`54<Q(XJ(>DFDV__[AQL\<M)"&1J*4IVCF$95Z)E24
M%7'&1)LB3.8!"@2GGGW\K(&4*)*H4#I$<\U"ADG:4I]-@3Z=$S5?J0S\"MQZ
ME]7F5CE=9QC5PX&=L%)D8SJMF7;2+9W=(%XE\5,KW;K)AIWI=6%8W#\R49YM
M`QC5L`W-7,*%B7@NPL9K]8#MQ3-/9RR']20FN=@-YBZER>"[I/2/Y$.415O&
M>)J+/SV\JB[ZN"5TGM$94WMI')C+A\]T!@L2V[2+;SK`*PIW7KOWZSR0![U=
M^8$Z4[E^+P/>^('W'TN#]'H6X1TK>+-_ZY*GJ6B5FL**&G8W'OOW[)/5:7''
M(KFE\<T?2+7'5_]9,TW'WWC>(2<',VE(V,9("H[0%WSBR>?==72P!,1M>7"3
M(7L,*A9?6O.55TD:5NG1D88/NE=9>+1!6*.#7"`%A'EZZ(=B;_W!DP4"$ZP6
MU(I=M;C&(D(&H\J"1/K`XS@3*'<E;#I668*%9,P(Q"^&H$>CER0<:"1J(VP)
M6H!<BJ!FB4#@MXV-<9)@P)IM9.?F%<0Y^8&=-_HPYQP4GBD@$'\:LUFCG,#Y
MYD.[_0#F&`4JFB<)!:C'IQ8R0!IHAB3NT<^4>$[Z0P$Q?II%#Z)*"N@,Q1BR
M&0FMTF$FE8L>8<"AG^H4:Y>]IKE(6R,`2>=WQ:)AP`8H3*"!/2O\-*S_AS6.
M0&A.?2B2**^;1F4MDU$).H*G=/A(YA^9@JMJ6N-VR.*)3QXCPI[U/6<%<?'F
MB"V:(]3ZQV;`MK%KJK,"UB^`Q(8KYR(&"*R'B.XF7-?"0\FZ;YT$ECJA<LPZ
M#!3&4&D<Z9@3[7($O2,W=>V\V<ZP'9_VZ7ORQ2Z32Y2YG+KJP<$AO]L5R5R9
MC$;!TU",\,8*YRQODRS?^^FW13*-LUPO0QVS#^O"TV[5-\/KM+\P`^S#S./4
M'$34,Q&-EM%H,`</T&#S.S;#_S;KC9%*!VVQV%CK#!3//N`[#M4VVQWXT^6R
M/4+7QGR=>&-N,P9W&FC?HO;*6Q-5N6D-"_WC_SAT3][TXF1K;78TU_1=-^5W
M9QSZWT>T-@OB:W?>,NIXEZWW$9"#(GGNJ^]>6=:-ZR[5,)NCX3A)GX\QJO(^
M*+M)Z<3_[GGL)<]NM1JY0N*ZZ5<?+[A-A`=A.R2X<UZ\3=$/=_D@P1/(RO,9
MQ8]_1>D'D9D<S4O#_ASRD_#)@2`(?$+]OJ<&ZY6I%UTP@`0G2,$*6O""&*2@
M_?[G,\OI9A/CRUX'3?$!PXWP$;U8'T=`-H@3;@(?"W1AT5AQJ38,3X`R7,1@
M,I?#M[$"1'D(H!IZ:(A,H8N(TNN%`^=PJ_LA,0]*ZM039\@*2'D@.Q"<HARB
M)`)6:1%TK/"8'%AXB?\OD@$O/[B``F*H17;4D`LW'*(9N?"`$!+GCGC,HQ[W
MR,<^^O&/@`RD(`=)R$(:\I"(3*0B%\G(1CKRD9",I"0G2<E*6O*2F,RD)C?)
MR4YZ\I.@#*4H1TG*4IKRE*A,I2I7R<I6NO*5L(RE+&=)RUK:\I:G7(``=LG+
M7C:@*PT`@#"'2<QB&O.8PV3`"!B`S&8Z$P)IT&4OIYD0"S039,A49D8<T(%N
M>O.;`>B*`+Y)SG*:\YP="*<(`H#.=IX3`&E@)SJKB4X!D."<ZG0(`]IY`#*B
M9)SN#*@Y\RE/@084GF@HJ#D3(@%TYO,#^(2`,R=:S`/PDZ(810-`#<I1@G+_
M]*#Q;&="-EI.A(H`GP#XJ$I7&E"-LC2@'GUI24,ZSX2@\P#W'&A*9<I3EKJT
MIP,=@4)[:M(@#)6<),`H,BWZSF&B%*A0->A/H^K-F$*UJ$`XZC=S2E6#!F"G
M70WK5H]`4JI:%:A8_8%6O<E5L;;SJVZ-:]RF.<T*H+,"=.WE`H3ZSB"@,ZT^
M6&LWVQK7@4I4J<>D@#L1JU1V"/:A1U@K8$_:UX2*=`2%?2L_(-#.R>;QL8*0
MK%\K&]G+4C:S0>W&`MRY5T""5@VB!<)?:7I.PJ*VJ@P(@&YWR]O>^E:QZ*2`
M;X=+W.(ZUJ&A):T/9HL&9C;3MK=-)UBCV]/CXC.Y_^;T+',=<DX'*)6IV6TF
M,ZD+5>NFEK;DU*YR^7%=-4R7G+\,PGO)Z]-NO!:]WU1O=C/27OQ^4P)'F"]]
M53K7O.[2KN?$JX$%T-H/Q/8'VR6!`(K;6VV>EIR0#4)9OUF!``^8IU/MZEGS
M.]K]!M:@1>UO&M#I``]_^*4A-BM?30SA]:X3Q=!-YR"`:\X&\V/#Y+0P'H$,
MU!%[4[\S/;%`4WS>-'#VG!%P2`&X&>$AN]7(W41R>M6*8\PVN;GHA.8/(M"`
M!=/5`NZ4@)G7S.9=QCBJ6.Z`EDFL9)!ZN:04#H"%5VOC#T``KB^NKX:O/.,D
MUYC&)!#LEN^LTJ)2>:$SB/^`=`,M:"`0N:=QGO.1N;SD'-M9!&@^ISU'T`"+
M`IK2'WTS5#-=8D-+N+<1?FE1&WI.`'<1N*=&M53MBUS8]OG"BT9#K%E:U`:@
MTP(C0/"D=<U1\Y8SPUG]-42E[6DFKQ2K-Q7!/JLJ8&;7EM<J+BVB9U!EV2I7
MUC/H=@<64&IPEGF:$0AU0"G0YFD^.L$+=C:&L>MJ<E.;T<&>]K5G(%@)\+B;
MD(V`L@-Z@/A>0M'=M#5)7EN`O#;XP<O]-[#IO'&$0Q>KDNZH"!H`@7L+-,JL
M*`!X_XKR2QQ3FZ\%,JO-/6Z:NUK%XR[`1P,`@95S5,B8@+@W#P``W3+`QS:O
MZHW_VROS0@?<WS4_],V;7/.#NS/7!CT`T#\0S&8Z7`3J[O414AOS\V(<ZOU.
M.L<%OF^`9]D'"[]ZV,WI@*^/X-(=&'7`3`[3%3][Z:EM.N"?7FTU#/OO;I>S
M#[8M4*R[TP+^_`#>]4YJOFM6V(@O.^(=+.UR2SW@.$^[L;TZ=V\ZH.4_F/RJ
M2J]TS+==\VWG?-0[_G:_(SKTA/^`S\_9\-(?(`"1OWL[*4_PW7_Y\QZ7?>#-
MWGF-LQWT5$_[!^3=SBB'_??!E_#PC["`N!\_XZ_OM>"5GWO:*][V4]_\\VM/
M\+Y_H-L.D$#V9Z#ZN!E<[*UN/>S!Z?2UH[W\_[=VN.=__R*`=QV`;&!'3@>`
M5Y)'7*@G?/4T`\YE3!"P`!)0`58';0&H8^37=N-W=H6'?M"G?E$7<MVE'#OE
M`!6`>K0F??4W`D]63AU&`N\6`,2'?!RX?ZW7@9NF=CWH>ND7>^MW?B2P`,;G
M393'`$>7>KS'A!&85.&&"60G?LPW>T/(?F-W;M%'>%973@^8A3WF`R]H?C=X
M"5/(=%4H?>;G62%(>P\U;C&(?VC0A=WTA6/(9V'8#6>X?)L'@HF'A?DG@%NX
M=B;868-`??Q'?]LW`H7X33C%#GN(>!_8?%;8AE?XAH9FA+OF:^:$@-KWA(-'
M@%*8>538AY2HAAN(A0/8@P5`A__G9'>#1G=BN(B@=DYBIH>DB(:F:(6>!WY!
MF(@=AU`M*%`2%S?HQ$)C:'D=4(R]$(D>F(8`V(NI2(27^'&AZ$XSJ`;*2'QC
M"(K-X(R).(F\Z'R')X0F)G3?U&*"@(@[6("T>&GS)X+)IX/)QX.`:(F!^(/5
MF'@(A8[?A'1!X'W=E(WN"(K#B%3LE8M\&'M^N(:&IX4DF&1:I6Y?Z`,+P([>
M1`&*"(IQ2$X.`'RX&'ZZR)"G"("6N(JU=U1J%F9!T`#WYTX-J%L"B80C4'H6
ML(2C*)(+"8P->874F(^J.(@].%3(IG.D57&Y!0!'6$X'L`#^J'<?Y0`6H&<"
M$(_@V'K_XHB*TGB20IF2WT0!@^&*'5"0*P5@3SD"2^E.9;B!ZD2/'&B//XF/
M/AB4$;EH!=5P,!B!!IA@URAJI):6WNB#;5F*)&E.1(=,6_F'U(B2YU=0J,=X
MY01@>RF#_>>-[:92:PE=@SF2/$E5;*B8C6>-L@=9>%A.R#:9WW2+<%E.Q+<`
M8NF70*A_A-F94?69YA>:_'AC@'6$.(6:'7``#WB6M-*1:BF/.3B;.^B/G6:<
M(I>;#N8`_H21W:1+`H5]=5:<J<=Z>6><F[F3R>F9#_E2F+AH$@"+(G"0W\0`
M!OB1D2><0!`!I9>9B=>=D@B-1!6>+#6>HKB1Y@0!1$8!$&">/XEF4/(I`@M0
M<H&)@_3YC+MX5?BY4OJICT#9`130=0#P9^HY".X931'P54I)D[$YC\A9C\KY
,:6"8GZ*)!NH6`@`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>h03611h0361146.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361146.gif
M1TE&.#EAF@`/`.8``+:TL_;U](J(B$5#0UE65::CHM73THF&A/+R\65B84Q*
M2L'`P%114*VKJRTI*'5S<N?EXW%N;<C'QVYK:N[N[6QH9^;EY9F6E4A%124B
M(9R:F;RZN34R,9&.C:FFI8."@GY\>\W+R6!<6\"^O8%]?.KIZ,_-S6AE9%Y;
M60L)">+AX+Z]O!42$KFWMAT:&H6"@5!-3-S;V=#.S<K)R&1@7SPY.=K9V4`]
M/.3CXM?6U>GHY]C7UBDE)9&-B82`?][=W#`M+9>4D^CFYI*0D*&?GN+@WQ@6
M%L?%Q:^MJS@U-<[,R\+`O]/1T)J8E_#O[IN8EOGX^(N(AUM85\3"P2$>'=[<
MV[Z\NWQX=Y21CX>$@J.@GY63D38P+M;4T]'0SW=U=+.PK_3T\\7$PKRYMYZ<
MF^#>WLC&Q<C%Q:NHITM'1I>5E3PX-P\,#2,@(!L8%Q,0$/O[^_W]_?CX]_KZ
M^9^=G/'P\+NZN7-P;\C%P^OJZC(O+^SLZX:%A4-`/P<%!O___R'Y!```````
M+`````":``\```?_@'^"@R`D@X>(?TY:"(F#!3@0$#(:-@`0'F>.@V!9`9L'
M&G"",B0YB7.CBG]P<9N()$%ACG->@DIP.X<[C8D&HU82KYLZ%(D*-X,(#R6'
M.BM9-WYW<H-PJG]^*`XP4AA;+!54!(AU18,Q#H9_`2.'#`[5?Q0,5#B($@P"
M`@-@2@D>/#P@LDD.BPQ"K%D0),1(`AHNHE`Y4:%B&Q".>%1P`H*!(QD?0HH4
M.0#&'Q(L'*ADXT:E2X]_<G`!@L%/A19_,/@($H1`!%5^0/@A0&#"!0Y_!DQ`
M8TS0`C9<HG)AX2(J#S98!A$5-`$"'C\C("AIXM1/B!!^/$CP\^6+FP2"_^(8
MD$!7P@4_/>I*D,+B%`0_$H@8D>-GP2`V%Q+)\',"3H,!C@)LZ(6(``9$,:@\
M$32'S*=$A04-.$$W`PV@+`ZX&>$#B)8_8%PHT`5`P@(_@TRPF"`HSYP_<GKT
MX."`A0\W`Y(G=^,'S)_;@@I#A^!@2-PM$X0?R.!`N'?A8_[,`7SB3C;#@MAX
M2"3"")1Y;&(,&P0%R9^M?Q*XX$'%3P8>/+3!PF6@+;"!#P-\((@#`@SBAQLN
M^.?``!EP880?*_260@2,$56#'S`0]48%?\1!AQU]]+%`"B=X<(X.!NBAA"!K
M#3%$806X\`=U`LBARR%;I"##($7(=PA@?0SI!_\/4J6%R!1^;#!(%&U\)@@=
M"F2II0)`^-$$40%`\(,*$$P`A"22X!"*(",P($(??J0A!0$.*/@'@X.D,$4?
M!+AQAA4$,)""!H<HQ<8(+&B0P00DP.!#!E8<LM41`%#!@!,U)+'.'VOQY$<+
M-QSP!Q0GN.%&'X?(X$(&(K0J@AYNW./@&`Q\$EIZA`Y2`@9P_9%0'1DPD)`@
M`<Q@P+''RJ"$`240U4(:%='PQAH5T,!!!2<,H$`S@TS@I6AVXOE'&2EPX4`4
M:_!`QA5O<*"'#>@@&D<2[E:Q1QL9/)"'I!@<@,0`:31C`09L%$`C;MFDD4$+
M"RR`1A]FZ$"D'GY$@:S_`1/4,(N#$M"0139#-+QB$(=$T(<3?ZQ0PQ(ILX$!
M`(<4\`5/042`PGOX"7*'`T@0`045[B02``M^L,!#"&F$VZ`<!;!!@!10I^$'
MSQ+\1]`?*HC`QA\`^-&&2AGX40,9!K#)`1M?A-C4'U7P$,'!DOCA@P@C5K!&
M"C`+8H`1%:3P@EXG*(`(8*HRX0<&5%3$0@>#9-''0CFY\-H?9+"1P@.#".""
MC4,HP,,H.:\%A@=L_%"`$5(B<@?1#3B`G-)_A,%``@E4Q`8#-;2!K105&")%
M"GV:8'EV/43P!@.)[O!&"L#3(,(*(B_0!P;R0,D``Z&Y$0`<,,`$1Q0NB/&'
M_\L5592$X$<*`P,-A2D0P!Q)O!%>%S1\9GBN@DP1M"`".##(!Y"Y#SG^P(0W
MO$$-!=">--BPJ3\HP0]F*(P0U)"@!8EJ$`Y8PP!2D`0>&&$`'.B+(`[@@2&P
M`08V<$/(%G`!%@!'$&F8`5%T((0M>"`!+`B(!U2QHN@81@H>0`(;F"`(..`B
M/>OY'_H<U`,Y*(``;%C``TZ0A#1(X#>(X`$*XN`%^SBB?_\+(%'@@(8V-`$`
M+$`!&Y(P@0(DP#\)"$`5')"86PT``_MP@YT6E(4H&"$&(."`!@B0@8T)HG:"
M>$,:;N``!60@$3G[0Q#<D`@BZ.@\?S!`!I(@A4V0K_]\YQN<%`S8@BAV+0K8
M.$0'>&`,''"@`ZY`A`!8X"H]H$J`'8#!!N8@AB3<(`49>($!ZG"``0#``@2(
M@@]%`P.>N&"/=^(`!RX``2T`P0%4\-\A'("&$F6@"?P0`P-DI94!"F*2B7A!
M`$,3!RJP(6^)0`R:(/"%)49'`AJ`613+P((!J"`11Z!""`9QA!0D!A%\2,(@
MAG`"01!%#A:@`1MXH($$_@`(*6!<$<GIA[P-P#I_N,,,MCDAY22'!]H4!!9@
M(`<X1,`(0^#''T1PM'>84Y*4C`E9N/>"!2RA,&&@`14RD`$/4"9/212$#^SY
M%V$((@52R$`4,I`"$(Q`%07IH((">!)3`;3!#Y$Z1!?DP1EC88`<<2#``4*0
M!-<)`@8F<823_E"'5SB`"]?+*P/TD%($&,$+3LA2$`9`$T%PP#Q_T$,*&).%
M-U"!"BYPPV,C^X06<.![$]6`"V"``!U@SP]7&%P2I2`@I@)&$#B8&A'E0(##
M[>L/5T@!#Q3@,0"882W0=$0=8+#8MQV""4#X@B#J0,Y#R.$*PQH&'2]VK`.$
MEBLC?4+JM-`&.P@B!V48!`#64%Q'9&$*@K`"#290-H(Z!Q$U,-(?B,`#E@U"
<!RSXP2#0`#F&O$<03CA'(JY0WOF,@`86"`0`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>h03611h0361147.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361147.gif
M1TE&.#EAF@`0`.8``.[M[/+Q\):3DJ:CHJFFI9*/CBTJ*4U*2LC'QYR:F7Y[
M>75R<;6SLNKIZ-[=W,'`P*VKJFYK:Z&>G5%.3)B5E.7DXS0Q,5E655U:6552
M4CTZ.F!<6\;$PX."@N+AX20A(=#.S8F&AA01$@L)"65B8KBVM7%N;=73T>CG
MYKRZN=;4U&EE8^SJZK"MK<[-S,K)R$E&1?GX^"@E)6MH9T5"0=K9V<S*RN3B
MXL3"P8!^?;NYN8:$A'=U=$`]/?;V]1T:&L+`OM/1T(V+BH2!@"$='3`M+?#O
M[V-@7MC6U3@U-<[,RGMX=DQ(1UM85^?EX[^^O?7T].+@WQ@5%8R(A-_>W:NH
MIL7$P[V[N]'0SX.`?X^-B[*PK\&_OE)03S4P+@\,#4)`0#PX-QH7%T5#1(J(
MB/W]_?O[^_?W]MG8U_CX]_S\^T=$0_CW]^WL[/3T\T-`/^GGYFEG9QL7%_7U
M]$5$1//S\I21D/KZ^=[<V]S;VKNYN"LG)W-P<-?5U`<%!O___R'Y!```````
M+`````":`!````?_@'^"@Q(0@X>(@EAEB8-]@W4(+%%_(&V-@U8,F'\0"(,U
M$#&<I)A5.)QS@@!_C)"NB#Z">"REMH('18-E$J.'#0PF(A2</Q@7&$Q$`@8;
M'QN(9F:#'#(2@RB'73)I@@X6!Y>'05D/#WPN2'8G)Q(<F&4?/]F)+&\A.S0#
M$P+]`@?7$F5(<&8)B49H""A<N'!!CC\2)DB<\./#Q!Y^C@BZD<.+"#\]%E11
MH`,!`CL$!ODAX&<!A2H29/P9,Z2/KS\/DI#92::(A9W"K@RZ<$'0)A=^7/PQ
M`D30`S\=.OC18L7/F#$B)F!ZX8?8(`$T6#GQ(V'*B"=^(A18.X)'HAM^_S2P
M2%`T$1X>0M;J76O!P)\`#@0Y,5!@4.!!9NCY>2!H3)(9,Z04D?7'#Y$#(J8L
M@?%0P0@1+_[<,/*4W8DM4IJ8/E&A##LF,&AP^$*$"&TB'[G@]"-H\=,[@PO_
M,;/!P-4Q4D0<7Z[EKQ\$"S!49BSH2TI$0T;4<O#%R"W1?X@*6G'@0(\12<J#
M^9*AT6(J5\9T$&2`C$HI2484&?&AQQ@-H`D"@AA"^)'`6B3XP<=:!C1W!@8A
M>.$%&5]@<,(@-Q21P#0(\#;=%B+\$5PC+7PQ`"G/O5%"918<MQ(B>(Q@QR`S
MT("(#E'E&!4&(^@@GF@OG#"##*N=(,`G?^!PP?\,&_C1!0Q>&##?'_4-,D(+
M,%A`A!(#A"',#JP(8D$3,HJ0PP<'7,!$!!^<.%11!6P!CA%O-#'E'QU"YL<3
M&!Q4QQI2[)'$(2P4\8..!R31P"%^Z''!-'ZTX,2D7P0DB`]']#"-(!Z(H,`9
M@^!!`4,,84&4HQND^@$1J3:1JAPR+'I&$$[PL=*D8$Q9Y5(C-%'$`!H<`(0"
M?GRQP:*"E-"""&Y\D,$'"-1`1`\3>'#(!1F4@``)!C2%@P$RH(*GAVE]`,*D
M)=!`@%"7=N&'"0Q=8(`XO0&1@2&13NK$%P(<P@P2?R`106`4O$O%(5<08!("
M$I#!"%%IP"&(!&)`@$7_'7(<AD@9,A2[!``PZ&H?GB(01=0:(UA`0`,R'`'"
M($)\\0=+,DA$A!]+O-#-'PVLX0<-1Q01Q"`(B''0N+UU8<`75W6\B2!&T!#&
M"-<)TL$!B#Q7`A$H^%&$&%=U-0@7>[SSQP9?9"&("<4F,$@()1/U=1WAU?4'
M`")HP1(6"B1!"2(2^.%'S#+0(;)H8LA@P.+\R2'"XHLS\0<#1'@A10`?D,4.
M`;3Y$0<*-(S@)`5>]*&O$PLP\7=5BR_VAQ2,'&&C(%;\L(09M$%N@!A8,XI`
M&4RP?87D?QRPQR-4%(&'("R,\-`@6H1P"!E^63V&(#\"\($(2A`@QQ\+^/%!
M_U.#[)O`8C9H(!]](^-RQ`PC9*#!!S-<8($3@C"Q!`5?&-""'''8201$X`,5
M_.$,'RA`FCB@!";D8`)?B,H.-O6`$?2&,31(`0)$4`5!I($`R_N#=0YQM:Q]
M(@,7&,$#5D"!(WR!`HLR`V7^D*4Z3`(3U!M$!ZY7MTI8(`(=$,$*1-`%#2Q!
M`_&S0PP"`(,9E,%U,R&!.3YP)RKQ(00C8$`<+"`!#/R@%@<\@PDFP`H1P"`#
M$V""S`8AL1\)0@#?0P0!I'#!/Z1``UWH`2:^T$3(S"`]6>O!TOCW@`%\(0+(
M0D0)1("&/YS``$]H!!E$D*H-M`A[%V@!#;1@!B.$X?\-EAE`'6K0!"ED@05\
MP(`LH.@8R(B@B@:80`^&\(<!_&`/'ZC>()+@MC_(H``+"(,$+@"J:]GM#W!,
MA!;"4$<SV,80C?A"#LQA#A+T3B5`B,`$O_``%(@@`L4\!!7VX*8_)$`*5DA$
M"(C$C@B\`9,E.$$",%"A',A!`"+8`W7^@(*J^2$%C9G2`:!)GQ'L04(()8(N
M_Z`'"V2C"FDAPQCF8($)W,"8_HHC`,B'`1,X(0"N2\`(V-/(1%"-A-?\`PN>
M,X@O[(`)&?B"!K9`+QN\H0LFL8(YB#""&B@2H(((P"!0^`<W[($&+EC"!;[7
M@#VDE%'7L<$,$6$`/E"3FA'[T&49]K"%,@A!#EJ@0!RN5X<?+$`0/0"#"#!0
M@./L8017R5P)7+`'.&C`#R+0`Q-^@`0<9$X&7E')=?BP@2*D="Q(6JD(3D2%
MFQ$!8']($%YE0*T5$&L'I;B!'+[@AZ.UH0QFD,`/B%<#LR$B`!:`+"D,L`)2
M$6`#S!1$!/K%@Q"<`0`\\`,M_U""T-PM!%]0@@_.=3I]S2$"O11"HGH15`KP
MP3N'$`'YC!`^X0B&I:U8@0T0HP<P_B$/#%`%(BRPA5N$P`!82$00Q$L*-=R"
M`VQ(1`!N(K$_N%<0;"AI(F)0`5L$`!8LN`DI+CH(*!SL$&H8VG<63`JA!@(`
!.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>h03611h0361149.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361149.gif
M1TE&.#EAF@`0`.8``/+Q\.[M[*:CHI:3DJFFI9*/CBTJ*4U*2LC'QYR:F7Y[
M>;6SLNKIZ-[=W,'`P*VKJG5R<6YK:Z&>G5%.3)B5E.7DXX."@EE655U:6552
M4C0Q,3TZ.F!<6\;$P^+AX20A(=#.S0L)"HF&AA41$F5B8KBVM7%N;=73T>CG
MYKRZN=;4U&EE8^SJZK"MK<[-S,K)R$E&12@E)6MH9T5"0=K9V<S*RN3BXL3"
MP?GX^(!^?;NYN8:$A'=U=$`]/?;V]<+`OM/1T(V+BB$='3`M+?#O[QT:&F-@
M7MC6U3@U-82!@,[,RGMX=DQ(1UM85^?EX[^^O?7U].+@WS4P+A@5%8R(A-_>
MW:NHIL7$P[V[N]'0SX.`?X^,B[*PK\&_OE)03P\,#4)`0#PX-QH7%T5#1(J(
MB/W]_?O[^_?W]OCW]_CX]]G8UT=$0_S\^^WL[$-`/^GGYO3T\VEG9T5$1!L7
M%_/S\I21D/KZ^2LG)][<V]S;VKNYN'-P<-?5U)"-C`<%!O___R'Y!```````
M+`````":`!````?_@'^"@Q(/@X>(@EEEB8-\@W0(+%%_(&V-@U<+F'\/"(,T
M#SB<I)A6-YQ0@@%_C)"NB#Z">"REMH('0X-E$J.'#`LF(Q2<11@7&$Q"`P8<
M'QR(9F:#'3$2@RB'7C%I@@T:!Y>'0%H.#GLN1W4G)Q(=F&4?1=F)+&XB.S,"
M$P/]`P?7$F5(<&8)B49J""A<N!!"CC\2)DB<4.3#Q!Y^C`BRD4/*"#\](%A1
MH`,!@CH$!ODAX`<"!2L28OP9DX2/KS\.D)#926:(AIW"L`RZ<$'0)A=^7/PA
M\D.0`S\6+/CI<\7/F#%?)F!ZX8?8H`$S6#GQ(X%*B"=^(A18&X)'(AM^_S:P
M2%`T$1X>0=;J7:O!P!\`#00Y,5!@4.!!9NCY<2!H#!(9,J8,D?7'CY`#(Z@L
M@?%008@1+_[8(/*4W0DN4YJ8/E&A##LF,&9T^")$"&TA'[O@]"-H\5,[@PO_
M,</!P-4Q4T8<7][GKQ\$$#!49BSH2TI$24+4:O"%R"W1?X@*6G'@0(\02,J#
M^9*AT>(J6,98$&2`C,HI2$(,"?&AQY@-H`D"@AA!^)'`6B3XL<=:!FSQQQD8
MB""%%&1\@<$)@]@P1`+3(,#;=%R,\$=PC;3PA0"D/.=&"95I<-Q*B.`10AV#
MR#`#(CI$I6-4&(2@@WBBO7""##&L=L(`G_QQP_\%,G#@AQ<P2&'`?'_4-T@(
M+40IA!("A"',#JP(HD$37]0Q0@X?''`!$Q%\@.)0117`!3A$N-$$E7]X")D?
M3V!P$!UK3'$'$H>P,$01.QZ`!`.'^*''!=/XT8(3E'X1D"`^&-'#-()X,(("
M9PR"!P4,,90%48]RH.H'0JC:A*ISQ,#H&4`XL<=*E()!I95+A=#$$`)L<,`/
M"OCQ!0>,"E)""R/`\4$&'R!`@Q`]3.#!(1=D4`(")!C0U`T&Q(!*GA^F]0$(
ME)8P`P%"8>J%'R8P=($!XO3V0P:&2$JI$U\,<`@S1_QQ1`2!40!O%8=@08!)
M"$A`!B-$I?&&(!*(\4#_%G3,<1@B9<1@[!(!P+"K?7F.0!11:X2@`0$,Q&`$
M"(,$\<4?+,4@D1!^+/%"-W\PL(8?,Q@Q!!"#("#&0>3VYH4!7USE\2:"$#%#
M&"%<)X@%!R#R7`E"H.#'$&)<U=4@7=SQSA\<?*&%("88F\`@(IA,%-ATA%?7
M'P&,T`=+62B`!"6(2."''S+'(,?(HHD1@P&,\S?'%XPSSL0?"P@AQ10`?$`6
M.P30YD<<*,P0PI,42,''ODY`P`3@53&^V!]3,&+$C8)<4<029M`6N0%B9-TH
M`F4PT386D_]QP!V/5#$$'H*P$,)#@_0APB%D^'7U&((`&<`'(RA!P!Q_0.#'
M_P=-#<)O`HO5L(%\])&,BQ$RA)#!!A_(<($&3@C"Q!(40-["'''8201&X`,5
M/.@#!5!3!Y3`A!Q,X`M1V0&G'!""WC!F!BE`P`BL((@T$(!Y?[#.(;"FM4]D
MX`(A<,`**&"$+U"`46:@S!]@H`$Z3`(3U1N$!;!GMTIH(`))&,$*1N"%#2QA
M`_*K`PX```,9E.%U,R&!.3Z`IRKM000A6$`<-"`!#!2A%@\Z@PDFP(H1P"`#
M$V#"S`8Q,2`)8@#@0P0!IF#!/Z1@`U[H`2:^T$3(R"`]6NL!T_KG``%\(0+)
M0D0)1J"&/YS``$]H!!E&H"H.N"A[%VC!#/I@!B*$P?\-EA$`'6C0A"EH@05[
MP(`LH.@8R(R@B@:80`^2\`<!%.$.'[#>()#PMC_$H``0"(,$+A`J;-WM#W!,
MQ!;"4$<SV,80C?A"#LQA#A+X3B4_B(`$O^``%(P@`L4\1!7N\*8_)&`*5TB$
M"(K$C@BX`9,E.$$",&"A',QA`".X`W7^@`*K^2$%C:'2`:!)GQ#<84((%8(N
M_Z`'#63#"FDAPQB@H($)V,"8_XIC`,J'`1,X`0"O2T`(V-/(1%1MA-?\`PN>
M,X@O[(`)&?C"!KA0KQJXP0LFN8(YA!`"&B@2H((`P"!.^`<XW&$&+EC"!<#'
M@#NDM%'7J8$,$6&`/5"3FA'XT&49[L"%,@1A#GV@0!RP1X<B0$`0/0##"#!0
M@./<(017T5P)7'"'-VS`#R/0`Q.*<(0;:"X&7E')=?;`@2&D="Q)6ND(4%0%
MG/%5$`G":PRJM8)B[:`4-GB<'Y#6AC*800)%*!X-SH8(`&@@8*4PP`I*10`.
M,%,0$?`7#T1PA@"(CY9_*$%H\":"+RC!!^A"W;Z@$(%>!D%1O0@J!?;@G4.,
MH'Q$$)]P!,/25JR@!HC1`QC_D(<%J`(1&N#"+41@@"PD`@AU*P4;;M$!-"0"
K`.X5Q,3^L%Y!H*&DB<!!!6P!`%BPX":DN.@@X("P0["!:-]),"F$&@@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>h03611h0361150.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361150.gif
M1TE&.#EAJ``1`.8``+6RL<[+R.[M[*"=G,C'QWEU<XV*B'UZ>82"@A@5%9Z;
MFO+R\75R<2DF)J:DH]73T>7DX[>ULX!]>YF6E5%-3%E658R(AY&-BG%M;.?E
MXV%>7=_=W-S;V6EE8Y*/CE514)21D$E%1+"NK:VIJ(B%A'MX=KRZN=#.S9R8
MEJNHIM?5U-'0S[RYMF9B8>KIZ*NGI.#?WN+AX)61CMG8UZFFI<7#PD9"0EY:
M6<[-S)>4D^3BX<&_OK"MJVMH9TQ)271P;STZ.8.`?C4R,KNYN/;V]<'`P&YK
M:=O9V/#O[L?%Q`@&!]+1T,W,RJ.@GKV\O#@U->'@W[*PKT`]/-G6U5103LO)
MR*ZLJR\K*L3!OIB4D??W]NGHYZ^MK,K(Q^OJZ=W<VUI75R`<'$5`/_3S\JJH
MJ*BGITM'1C0P+ZFEHP\,#9B3D/O[^_W]_?KZ^?CX]_7U]/GX^/3T\_'P[];4
MTQ,0$+Z\O,;$P_;U].CGYCLW-LC$P:JGIIB5E"0@(.[MZ____R'Y!```````
M+`````"H`!$```?_@'^"@X1%%&V$B816.HJ";FN#4V\+@DN.A'49F'\@A"=(
MG**<"&ZCIYA>J*N*IEH/L`\7/K$/#$.#<"<T)14434AP@P*";6831CP2$7LM
M/`T<B6^$,'V#"U^$2E778@J*$2@O!B5_(U%%3D&(CAMI.(0";()5)3P6/@`(
M!/Q#%(V)XE!X\(<*$4<$FO!8R)#'GA";1EFI\>>.@A<86W3`B)&/E4%5FD01
MPT)0$P9%BH#0<$<0A1P41F#@X*')'QM.YA`"4(`?@1UF?`XX0"B-H!G1F)`0
MQ(38GP$%'ASX\.?"CR(3&ICZ\ZJ6!2FU<)@9,(\)@C\2K+SH,2A`B#B*_QP(
M@=(IE*(M1S+HW9OA!)U0`@!$4C3AHZ(2!`:)T*FH0@!!.2H(\G#6Y0`F);ZL
MD"!H`(,R@@(0$2%94(TP@X7]$<"/3IT!%FX4F#T[#><_-"[\R<$VB$T"-@:M
M`<%11IHF'#GR"/4`P9H\?]:V+4V(39\=@E3</H6$2(8$@W!48#>(R15""QRD
MI.,D94J*@MCLI<#BB!$0I2D/HL"``@4,`Z#P@P17=#"8"F"84$$6:JCQ@1DR
MJ/'#%4X]D`$=&7#0!PYT"4)`#H/0$$0&)+`%1F($2/''5H24P``AJ@W2'!,@
MOB`$;1I0H8@(/A`BQ@J)1!%A@T2&H8$.X"FF0?\B3]#@2`U`)`(`6X(,04`1
M0C3!SP3Y5?8'!0)08$(+?VP01`DM'#1(`0!4<(('>%"Q1@E(D(%&(G0(LD`2
M=.@`10O?A(@!`07T\,89B"#A@Q1G)$$(&7U<(.D%!B1@`2'-C2#("%3^$4"/
MA&20!UR#X-'')8.0I\AWA*Q!!S>#*!'-'VRDL-`(0)"PD!$*[4&#*HJE00(,
MN'5Y5!X=\*%,`4=X8,0-!B12!)DV=##`'W)T4(`*>&8PPA$5V"$(#%*`$:)N
M.4`;02P[U)'($%=0)P@=:@K2W`(%:!'`!SXU`:H@2!30!62>_.'`%2BP^`<)
M[:7$`+&L$F+&DK&J*DC_%)+]D($(T3H"1AH7Y-$$#<:V@84%#1EP@`(9&J#`
M-'_,4`);30"!QD)4/$$"`5K0>D(:02QQ`"Z#K-#`N;O=``,)!F!D`P8[&6$!
M!7Q=F$AS?T1@0`!F&,``#R@<4*\!$0PBQ`^#()!`QX)<P85[=$"<Y)IIC#&(
M48ED8,8,?R2P1ALWZ)9($A50$4`,89`\&=IO(#``1V&\<,,/+PR`Q@M3L!%$
M"UD$04`'4KC7@@P_:/`&$T(\890!2=12Q0V5"$(#%1Y4P)8;'\F1P%9Q@(`"
M;D`D]P+>,IZE>P`]0/&B`$(L]0</W`J"G\(0)')%1'_D^4?$(2IQPMV)+'`%
M_P,WO`%>"V<($8(+J0H!@6-_$,'E9)W^$4(!#(11@!A4%-#\("AH@P4*\#T=
M"0(!3A+$&E+@*D'@H0H/L$$38`&L/_#A=[P1!%L40+$_#*98>+J:!-8@@#0@
MKR`"$`-\$@&'/L3@#W9QQ/4&H3WN":((2DB,()1`B!7<@'T6J$("+J`3.5!`
M"6+[0P4VH,3'[$8(DOI`_=@"`@?\P0(O<$,/G)"(%@S&!@0@011ZD$!":&\0
M5"B"(BR0F`Q6Q0!2<$HB!B`$(C6(>/8ZP`'H(($3#D`#,4K$#1Q5IAM@X@H`
M\`D=B&'#/UA!"4#:X:R\$`4V;&`$"EA!`J+P@PF\@?\-.YA'%P!2@;+MIC0@
M\-(?6@``!<P#!S_XP0W4.(@E0.T/;V``!!#P`"R8X(/S2D0:%4$%8KAQ`0EX
MD2,B$T),(8`(V#GA$9X``$>,@`^$<,`'8C@(,?AA$#VP6R,+0*\,7&`&#1`!
M(28@!0O$@`UYJH(-C(")"KQ`$#M0Y_;L-H@3^<0G'Z"E("Q0MC;T@`$ZX.4:
MC!"$ZN"Q(+3$024$((4Q"(TM`FA!`4+@@2TH@IEF3,0*O*0'*H"@"7,XPP\B
MX-'X#2`$*7%""FA`@S"H4A`=&L0;X'"$N0DB!&R9@!*HJ2*=$FL"?4@2'HCB
ML6J.X@/"PT@(#/.'(Z@!AAC#@,4$S'"$/^@@2H(X@`WRA((+-*@%06@0%7['
MA0BL@00)4,`0J,`W"!RQ!/4ZY2!D$(2'$F`[-$B`%5=4`2F88!`:D$(+2(""
M"#!1+G+$Q`DTD(8SP(@.?/."`ZRA`8$2@@G9&(4<4,'4.8;V#T0KB2!,4(YB
M$&((OQL%K+`U@N@-8@/SV(DI!>&`0-4RM@YD!2%4>PHR8`\WV]F!!VA%4.$Z
C][G0C:YTITO=.A1@$',@FB`J2-WN>O>[X`4O$L2EB$```#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>h03611h0361151.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361151.gif
M1TE&.#EA+``0`.8``&EF9?/R\M[=W9V;F4U+2F=C8W%M;/7T]%524F]K:N;E
MY-O:V>#>W7EW=L'`P+Z]O8%^?9*/CL?%Q#8S,\+!P*VJJ:6BH>7DXY62D8Z+
MBF%>7;:TLUE65='0S^[M[%%.3>7CXMG7UN_O[ZNGI(>#@3PY.`@&!Y.0C\G'
MQLK&PB\J*+FWMB4B(O?V]:.@G^CFYJ.?G:&=G<K(QT9#0Z>EI*>DHTE%0V!<
M6RTI)SHW-D`]/!`-#=73T6MH9_O[^\_+R+VYMHJ(B'IU<_3T\_CX]^/BX>OJ
MZJ^NK>_N[9.-B>GHYY2/C%Q75KVZN;V\NX)\=Z"<F\&_O<W*RIR9EX5_>X1_
M?*">G:*?GK"MJY>5DU=44X^-C&YL:ZNIJ&]M;,3!P)B3D)J7EZFFI8V'A-#.
MS?'P[WQX=W]]?-G8U[&PKUU:6G5Q;UQ85_W]_3(O+]/1T.WLZ]?5U,K)R,[,
MRZ2AH.#@W_GX^%-03^SKZ=W;V:BFIF%;6(6!?WAS<H."@O___R'Y!```````
M+``````L`!````?_@'^"@X,=4W8OA"(>A(U_'A!&CI.$!S(Q&@@W+P!`GD!K
M"9,!6PHK;@J4C@<#17DI1"J#'(1!$8)B5$E/>U4]`W==@BV"%BBC`(R#LH*T
M@[:-/'Z"/CMC8$LV!H(D%HX]MX2R:@+.@M""('_2@@[.`#&#!SAUA!TJ`H(4
M#S0F#@X+M/S[=Z;"H!XPI#EXD*"'H#LA"`VX0:@`@48K3-`XT*(#H0MT#O[@
M`<`"A@9:_@28T4B"B2*#W`!HU&#'EQ)3&OCA,L./3V4]1DX+:<`("AN-&)A(
M,VC'M$%*;LCZL$`0NT9!K_XA8^5$@T8^3&1H^E00!BO,!K&3\$"DUC\3LW0X
M<60BR"`67@81X7.`61$8(S)P&`%%S,$4%0A@<"'ESP<=`1J5,3%@$(&4@FI$
M3&NUK*`P.0@DT)/HSQ4$!,XTBF-"PA`(&&A,0$)-D`H\A*[.\?&G019"KPOX
MJ#/A`YI!&UCX>&/"Q!\=1QKA4(`E@1`A!@H(Z8/@A*,*3*H*0I*#3:H_`#8(
L.J#ACQ1S@KKP5M4H"@-';0;)N2@(A1E!<I`0&7T$JD)!!`<(`D<3?P0"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>h03611h0361152.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361152.gif
M1TE&.#EA/``1`.8``+Z[NGIV=()^?<&^O*6BH4Y+2YZ;FM73T>3CX;6SL82"
M@MK9V,+`P'%N;MS;V<C'Q]?5U:RHIXB%@^'@WWYZ>79S<=C6U:NGI)F5DD5"
M0N;EY=#/S=[<VS8S,X6`?:&>G.+AW\;$PQ42$J^LJO/R\FYK:5114,7#PU).
M3-K9UVEE9%Y;6962DM_=W(R*B20A(>GHYF5C8K&OKYF6E1L7%RTI*%I75O7T
M].OJZNKIZ)./C>#>W-73TI>4DL[-S<K(QSTY.?+Q\>SKZAX;&FMH9TQ)2#(N
M+`P)"B`='6%=7#XY-^?EX\_+R/KZ^;"MJ_O[^^7DX_W]_??W]L;%Q9.-B:"<
MF>[M[/;V]5=45/GX^&=D9-+0S^_N[J2@GN?GYNWM[&=A7?3T\U-04+>VME=4
M4VMI:-;4U,S*R6]M;).2DM+1T&-A869C8KVYM2LH*!`-#J>DH_/S\DM'120@
M(,G(R#\[.HJ(AR<D)#4P,.GIZ).0C^OJZ*BFI6]L:ZJGIO___R'Y!```````
M+``````\`!$```?_@'^"@W\3`H2(B8A)%HJ$(7Z.DHD((E)_`!\7%P1%,HE-
M<8,UC0B25T@)DXHW<%R"2S2"#F<'&THQ$(,G$4X!`5M^3DA53B8$A#H/RP]%
M>LQP(W\P'TV*<14.?U`'`R('#8U-*P&*030:HTM_1&T3@EYW3//T]'@F0G\+
M*%F)%7:"-&QP\NT`%"DK*#B2\&&`!RI4ACRL`Z;<GP9%'/T`0,B`0D(.[C0:
M]$'6GQP%>@QZHDH0CSJ(:JPCPF00%`2;<FZ2@"3=H"9O?A#24@#1&A$%?`0H
M0T8&BP9I7H3YDR*#ARIK!HP85DR%MD%1IAP8*V+`V`-[$`&Q*`@/&T)F_^30
MB'`'!(0Y3="X&(-%T!<^2_QHL?9'YI66CFBL$Q3GW2`Q&0C_$:&`D`<=LFS\
M$:`@RQ`''\H,VO&'@I,/#0+0*%&A#`A!)$Y,8?9`1()E4X#0^/J'S1P.@XY4
M%O1$02Q!#%!L!NAB^)\9?S*842=H!F%1A!1+(D+CP*`A#09)R'%<B`H-/_!<
MHL!BT`852$)TV80$PP4X/;PKTNXHB1$8@Q30ER!!_!$+`AAPP0`^@JP0`B%]
M9!#%(&Z0M@I_BA2@F1H-+&!`!Z\,$LL-?T0@@`8+M+!%!T\,H@$**V@APVM*
M.*:(`Q94LI@B;D#GPA&:=8#8'Q:(\`<&)PB20F0)1X0G2!X4:)-`$2*(8`0*
M*"A10Q$^"=)"!4>\08(C.2!AQ1]/P*#<`)H-PL$AE!`2`8F$[$#'"0SD*1DA
I`/"6"!D/"!)%`!L(\H`*JR2J:*("##`(#U`0@L.9BU9JJ1`6(A((`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>h03611h0361153.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361153.gif
M1TE&.#EA*0`1`.8``%E65<[+R9R9F:VKJ>3CX921D=32T8N%@9F6E69C8I*/
MCNOIZ(V*B49#1,3#P>[M[%114'9S<:2BH7EW=M_>W6%=6RXJ*+*OK4Q)2?GX
M^%Q:68:#@KFVM9F6D_7T]+6SLH!^?N?FYL;$P]W;VJ&?GF1@7_'O[VEF98."
M@L&_OM?5U"DE)&]L:E).3+.QL*RHI]G7U]+0S]/1T-+/S9./BW][>C`M+"$>
M'141$1X:&AD6%A$.#LC'QZFFI9&-B?;V]:NGI.?EX_W]_<'`P(J(B/3T\^7D
MX]73T4],3*FGIJ.@G^'@WYN8E?/R\?O[^[:UM.OJZ>OKZJ2AH/3S\X![=Z:E
MI#4Q,+^^OK&PK^SJZGAS<$],2STX-:NIJ0X+#*"<FCTZ.9:1CEU85KNYMS,P
M+[R[N^GIZ#@U-;"MJWQX=NCHYTE'1DU)1X.`?\O)Q_KZ^??W]K^]N[NYN,_-
MS,;%Q<S*R9>3D<K&PBLH*-O:VG)P;_;U].#>W*BDHHR(AO___R'Y!```````
M+``````I`!$```?_@'^"@X2"#C"%B8(U2XJ.@B8O0$`;1'\2$$)_/PJ/=3>#
M*46/?RXP;T>I$R!_/3Z"$CA&A"]#6$-7&D,#91I)@G,?A787A0J6KG\R#6Z*
M`FF##1V%)`B#'QB#(B)'$\@^#RQJCD(0Q7$,F@MY@V<B?P]@Q8(%)4=M`ZU:
M3#^%'%\\`E8)2().P`("-/VYLB6#A!V$4!00M"`(`A9!,LY@T6]0DABI4L5`
M\*#0%"]/]*P8]`,"#1X;.@R(4.)$'S1*B!`@U(#!I$D=;*A(A`,%A`:#'NBY
M$\`&AU8^+G1QU.`(H2`M%*TH@0%IHAP+H/Z!`$51`RHTPMBA<8"+(@L`GS20
M481#4+(V)12E68!DIX4F^?[,('2#!0,=B4:PL>O#R9@U>N`D.N+5`J$OA'8@
MJ*.#SR`'0TX($"2E0@0Y=7(@>3IH3X).?U8*RH#$@R`C-X;JF3#(B(T5)@15
MP!-"D(P-++%L"?P'SPD4*##H8/<'00U!#ZS8%A1"X1\1'0M)\6.`U"`/*T8)
8,B,FB_GWCA:<B%(H`P7X^`E1V#,H$``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>h03611h0361154.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361154.gif
M1TE&.#EA/``0`.8``"TI*;2RL6UH9D5#1*VIJ(B%A-73T;BVM5E65:&>G.KI
MZ&UJ:,"^O;V[NJ2BH>[M[9>3DN+AX(."@@X+#)V:F;NXMJ^LJJNHIY&-BWEX
M=TY+2V]M;-C6U?+R\E934VIG99N8EF)>7>3CXM/1T=[=W3PZ.69B85]:6</`
MO::DH_;V]:*@GMO9V+"OKLK)R'5S<7EV=?7U],C'QXV*B?'O[X:%A8:"@'Y[
M>IF6E$A%1=#/SFAF9<W+RI".CI&.C5).3CHV-J^MK*BFIJ:EI>GHY^'@W^CG
MY]W;VG=T=(^,BDQ(1W-Q<0@&!R$>'4$^/C$N+:FFI8J(B.?EX["MJZNGI,'`
MP)*/C_O[^_KZ^9B3D/W]_?/S\O?W]I60C?+Q\/GX^.;EY1,0$')O;F-A8%M7
M56=D9(!]?34S,STX-A$.#L3"P%E44E503L[-RX^-C>#>W=O8U<+"PNSKZNWL
MZI..C%M86*NIJ='0S\;%Q<;$PW1P;J.@H(V(AOKY^<K(Q____R'Y!```````
M+``````\`!````?_@'^"@X2$$`>%@@>(<U)2#D2.#D6)@DDCE9F:A0(WE5%"
M'0<44P`6-A8:%X0T@P`$@C&;A#$4$7\)##(-*X,"4(5J*E$R+Q02'`,&8GD2
M!H1Z+H)`SW(`(H(*-EN56Q\/@@@X4D%(OL"$*691>#D=#7O4+0$[SX-7`"E_
MRG\4)5>#5#P!5VB!E4$(@%6)<DY0!T$LT$0Y`<8`C!4E;)P@X*R0A!S[#'0@
M8Z30B'^$[@`@@5!A@00$IBAY,24!$`Y_KNB(8F&$#P8@"O"1\6?(FT)%`H1T
M`$L%%"V#GC@@5$8#H81_%G*(("7$.$=>_EA($L*$B21'FAPA,.8/"BQ___I4
MF$+7A@\3!4S$A*#!WA\$=:`*>O+AJD*&@GXEBF*%7X$?61:PH:-A:J$R"?Y0
MD9`I0Q,6@])P;ID5\1_%A6I04.:BR4$!$%3XJ?0#CN;1B=PPB3-H`NZ_-RHD
MJ=&PT!(4`]HDN6%"YHX$5N`2(N)$T.9!<@`*LL*DRJ`F&PAY6#4"46)TA$+L
MHV*!\6D()&8DLH/`.NX:4@9%"<-CD`8/A#2@0"*H#2+"`G\X05(42\C@`1(M
M]"#=('588-\@+QPER`)`T,!%!FVD<`9!FA0HR`I"[*/&'^[!]@<8+0RBQ0X^
M#$*%.8)XT(L@.7@2`1,])!C$+";^H<\?TD6Q1D$6='2111<8J/"'"&3H0`L`
M3609!@Z"?!$&)7^$]0</9,Q2`8E=%L+"@(F(P,`LA,!@7B$N;`/GG7A6PL4*
&EA$2"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>h03611h0361143.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361143.gif
M1TE&.#EAV0`0`.8``+6SL:VKJE524<'`P)V;FKV\N\C'Q^[M[//R\:6BHGUZ
M>L_+R&!=7&MH9T5#0RTI*.7DXTQ*2FUJ:5E6538S,^KIZ&5B8HF%A-32T6AE
M9)".C5%-3#TZ.EU:6>+AX(J(B*FFI=;5U'%N;-[=W,"]O(."@G9S<B0A(922
MD@L)"IB6EH!]?(6"@;BVM,[-S=#.S>'@WTE&1=C6U:">G/7U])>4D\O)R(R*
MB2@D)-S;V3@U-AT:&N#>W3`M+142$L7#PH*`?\'`O^CGYMW<VD$^/=K9V./C
MXO?W]N?EXWEV=,?%Q!@5%;*PKZ^NK=G8UY*/C\;$P^GHY]'0SNSLZR`='=73
MT?#O[M/1T)N8E_3T\\W+RH>%AJNIJ):4E.OJZF1@7EM85[JXN).1D71Q<*.@
MG@\,#,G(QXJ(AC,P,(>#@GMX=RHG)TQ(2!(/#Y&-B?W]_?O[^_;V]?KZ^?CX
M]_GX^/'P[_/S\HZ,BQL7%U104"(?'Y"+B#LX.#HW-P<%!O___R'Y!```````
M+`````#9`!````?_@'^"@X2%A`!9?W0`<(1-5H0?(S!`=8(K!89_,C=T?T\`
MFC2:@R\'I']2(&^:,DZ#)$=_-`&CAG!/2JB%9`1U!EQRAD:0FBX(I#,$<9IP
M(8(\"#"$4W::0H)*6KN:"+8!=[)_7(4C"L*"96!_2"E)A`]Y@Q5^8@9^VW)M
M(IIJ/D-_'$P0A*3%H"0K:BA<J!#%B0:H<I3!,NB4H#!Z#/YY$*/!A!1I--G`
MXV!0$R^&5E`4X,?%%31Y9!3:0H2!S9LV=X0T)"?"#FR#IOV)LD."B`=`UJPH
MP32&/$,B+"!0L$%3D0]8LV85P,"2$1]L-IUX0)9L"C_D!"VIP<[/@#]H_PAL
M_#`(A)\@=@,H4.('**&1*`0Y*/%'2(\R3`1EZ/'D"0<*%QI+9EN13X$!F"E0
MP)R@C$Q!?5)8B_=G@)\%FB2D*+O#3]A")/_H>`K#AYY")4IJPD.91Y7?54"4
MR0"\"A#/?^KX,;"@31@_6!9(Q_'%D`PJ?&APB9",A/3OTF-P2/1G1IDJ>70,
M>,&I!9YG@WBW?;N&\`.Z@G18V,"208,&%`@2!RN";%`&%(*5$$09/>0P2`/<
M_;%&'^*\8<D@4O#PAQ\2N.'AAQ]F(L@``_V!!S^FH58(#&7X$(H=,:S1""$U
M^&##'SZ(,4@!`DP1Q2!;X)''D$0.609E+&SP7_\#5%"QY)-["+*<"!"Y-<@#
M;ABB1ALH34&!`=P(\H8+?TPPD(9Q%/$`#A=0L80=)OC!`&PU!#&#E??-1=!R
M3*3A1P=/9("#F3OP\\<-9:1@BP,[I*""'#1((0B$?Q0A)U.YX6#$(%Q0D8.5
MA?#P5BM^W&C:%Q)(0$@/#82QPP$6[.`@(1`L\5`&?D3P9`-KG"#4%GS\QH<`
M59R!!P`=D%D(`"G,,(@7'A2R'!JZ^$$%#MB68>@@<^"QPB`WG#"C($&8::Z9
M?/BQ@IE_")"'$2]($$<#1/PPAA-^AB(%&`R4T4<>&^!)5YY_U("6!A+XH8`)
M2UA@`!Y)O/`'`$1<4,;_'UHTT$8$LVI1(J461``"!PZ`8+*&@AQ`@05^;-'!
MDQ/HL<./%3SQ`1A$A``&!ZQ,(4($$70P2AP"9(","#WLD)@A"C0Q@`9^M(#9
MU)A9E)M@"OP!@@\(S(!$(5Z<@,<$-Z%!Q3:#^/'#`\SX,.I&$!$"\"F03-%#
M!!;]$4<8!O3M=]\RL/O""0Q8`(`&&R!Q3P%93'#C'W.8R!82?NB29YY6X.`'
M`0.HX$<-1`A071D:)>"!<$E^@`9A@A3`P:01#(`#-DI6),X?=SPW@`Q(()$#
M``\0D0`R=A!`0`]K.'#"#%,W(4`%@TRA@2P'9)!"#V]KTD4;5">@!C.#E$`!
M_P-?4,%!`S&4P<`.60]B!1M^L/#W8E^G;<`$&KSA@PI^/T1(`CAX!@0XL`TE
ME"$&2B#0.(!@,A``00*C8-<?@&"!,F@!"#\(CA](4(46?`%\DFL+F"Y'%Q7$
MP`]@Z,`)T/"?&CA`"'Z06%TN]@<>*&\#..Q!U/[0`#[$H`:8Z0,8IM:#=PC"
M"T!0VR#RD(($:,(!:$A``CC`J@9P@$.&*``:UE"%#:1@`@5`AB'X\``\+,D'
M90@"(4H0@U$X@"X@P$/*@D($-J3@!L61@&[L-P>E^<`!/HC`!):0@4'\``\`
M^<,%_!"8/Y#A+*H2Q`?P@"D'Z`$9$OP#$\;GE#[XP?]:1!)1"#]%)A+^(0&4
M`U,$+$"`!HQ@"09(@2?JT@;%:`M$&N&5!3[4ACR`B#(:^\)REM@#,19B,()X
M`0[^\(8)O(X00=`A&C[4@4_Z80<=((04_!""!]PH!&@I1`\STX`!K,!M`3C!
MMQ)P`HJ4839$>L`>I02F#5C`;3$8P!L2]H,_.*$'Q>#!'0GQ@Z5)\@'ATTTF
M.>"L/\"!`F>A0A,,P1LKL,`/(]`3P5)9!PI(@`A$.,`)8B"`0DQA4SS,@P*O
M0!$>1F@<?GA`$HPI"`'<X`I^2.0?`$8*9(+@#U0P0P!2H)%Q4&<"FQG`"<8P
M`#&DX`DB^-%!`D0&!U2``VC_4*`@)N``%/1@`A>@@,EJ`@*#%$"J9?AI0J7E
M1/ZX;0QC:,`.`F`-<?:`#D50HR8^@%!!7*U,`S%!#%+P(SBPP`=8\,,7UJ!3
M!`R@#2=P@`/*(`Q3BC`(>$#`!O@!-;7.H0,9>%(/</`D!_0@%)3ZPPNH<`8I
M=*`,$D")(.8`!Q`L08$,J,H35R"!.25`,R4=A!`@40(=].T$)C"`"FA("`-D
M1!`QP,$.(&`('01F,'+H0``^L`01T#0=-2G;/#<$!C1BP6TR4%_>_H<#2?$@
M!C?8JP^6I`.%#J0*`J""(`BP@QK<@P03HBX4.%`&!\S`"_02Q`D&AI]4`J$J
M%(BO_\%"(8@0>*!WO<LMAC&,#`C!(9W?^\,1MI""1BYQ6SS4K2&41X1H6:$-
M94@+;G9@$Q_T@0'I,T0>2O0'$?@!#2B=QPYNA,PP+($#"=1$&?`('#U*RP`L
M2$`<W#8'"G"@"(9`0A_D(@@2E$%',T'#(#X07`FJ`:$WP(-<[H&$)O@AC0BP
M0``$D8`EZ*),:MSH!GN0@140E00I($(*]&H(CY"B`3")@:0(H0$L%/4';3B%
MA?Z0`147`J*2P@!9T-"&.[QBC;IY`%L&P-Q+\(&Z=;#`$B2@AQ2P0`NS5(,%
M$A2&#!BL`4&8@B'2"NHG#\('*R"M#LJP!1N(8P!K8(/)$O^@$`I4KA!F^+0@
MX.`$)`BR0/*,@%3OL2D`4'@09%":(1[`.LKAX`9RJ/0%\!"`-^C`#Y9^T%-6
MO`0V%*E(.E15%B+@Q#]`8+`IB)LA<L"$%WAQ!7+(0IS\X`,2A*\,>M!#&_"@
M!SSX@48]\$(=4%"&#4`O"];S0PK4``<]8"`_*7"`AJ1P@D_BX4*"2(%:OZ`#
M*LP3AF#Z`SU2@*`L,.#'=R8`P]&PRC0`H`5^8!TJO."`3T:R!6.(W""4D`*=
M$N()#(B6(;Z`MG;,@!5P((("4$J#"_33$&"(I"$&P(7BN/TW&AK#$Y;U`)09
M`@8/X/=Z>7`#J0K"!.L@A!903(!F(P"!""H(LB`@,(.?MJ#??TB#"&;9Y2Z,
M2RTG%P0`?-!0@J2@"B:!CR"<0!Z'RK`0%C!#F/Y@!B+`H/2%.,)W5T^(-Q1#
C$)3GQNQI3P@0TOX-M@@3#;3*^^)SHZ[<,H2NC<]\0P0"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>h03611h0361144.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361144.gif
M1TE&.#EAV``/`.8``/;V]>?EXZ.>F\C'QZ:CH9>4DL'`P*VJJ;"MK,W+R.[M
M[)Z;FE)-3!D6%L&^NX2"@FUJ:4U*2O+R\5E65(F&A)&.C>+AX'U[>KBVM8!\
M>M_=W.KIZ$5#0UU:6;FXMW!M;*.@GRXI*.;EY7EU=#PY.>#?W6EF969C8D$]
M.]+1T'5R<</`OHV*B82`?FMH9\[-S=;5U%934K6SLM?6U=32T=K8V.SJZ<O(
MQV!=6\G(R+RZN):3DI62D)&-B:NGI.CGYIN8EZNHI\W,RL3"P4A%1(R(AN'@
MW[*PK[>UM)21D-#.S<;$P[NYN-W<V_#O[M+0S\?%Q=;4TS@U,_GX^(Z,BHJ(
MB-S;VK^]O#4R,>3CXC`M+*FFI24B(MG7UNSKZJFGIJFEH^GHYT1`/[Z\NEM8
M5BDF)61@7PH("$Q(1O7T])B6E2`<')*/C_3S\GMX=SPX-U-03R0@'Q$.#OO[
M^_W]_?KZ^?CX]S0P+ZJGIZ>EI+:RK_'P[RLG)_?W]M73T?___R'Y!```````
M+`````#8``\```?_@'^"@X2%@S2"4Q:%784R<R)C@QY9AG]64(('(I:=@T:>
M?QHUG2)V@S^#2IYX"J&$.1I_496&$IXVG@<IG5-3@GMT=(2_EG."77VOAL=_
M"5>#BX0B1X1Q*W\!'(V#$Y*""G)>`V^"<PQ"EFX=@AQ(@@"U?R!'!O;W]F,A
M[YT_4O*$H$SP(L@%"Q]@M)2P-&,-M#]TTAFJL/#$AS\T3J@91J@%$'SXL``D
MQ(<*H69_E+@PX`'%@!$Z8B(QDT/=.S-/+&E8X*.GSYXX;OQQ0@2$(#(9DB9]
M4Z;8GS(!LMT1A(,4`S^#D$SX,R""@B$PR%A2@&+A'PY8]W!@<.I/CP*"_Y2\
M>.7E@9^[?C[@N7L@0IU!'W`(FJ"G72<R8D8HCM!`**$T9X;\X8+UCY$&,@JY
M@&NI`:H`H`,@$%,B=`D()@0)8?#GB@H_*`8%*&?(PAK)"W0L*Q0B@:`@9KR8
MJ&+$#@`E2C+PCAI@ZA\^6*\.@B`$P0(2`W*`H&")08PV[?PHX<)9T-O!6SQ9
MH#/E#-[W>-,,JE$9S:VSEIIH82-_CA0"AN0QPA_M$;*$!FT5A(,`##;(H!R#
M+`'%`!1R40&%&%((P!]^;!6#!;#)%ILA.#PPB`H<O0+`+2%4)D@+&73!@4DR
M2,'$<D((X5R+?TCWQP98"-+5&$VX<,(##_"QQ/]O+J36#AH=F#7(>58T\-,)
M@@UBQ0EI0&B(%TYTHL2(DQ700F:"I*&%!0:XT6,5AF@@APILN-$`&WCFR85)
M!7$V`2($P`F@(0*0D6*"@G3XQPD<8G$/`EH8\D,<K@AR01*%0('DIDB2<(<=
M+;*@!@`P^/;``DV`4`<(7*0)!@)Q+%```5((PJ./"\C1!A)JD&#`#!/X%@<,
MMR@!1`(N_/$#%5SD@9(`YL&5`0A^H+$#7BG^@<(8<FRP``+@(@!$""H,@@`8
M*K0PQPE?#`($DF@Z\4`4@E0!QP=.$9(':&K$$-J_!/5IZR(%9$!')H74T,`1
M&:)`08H=9J%;%V+(YMS_('6@`Y$@%J"!P&/Y\N9'&G=85P>X=`S`1QUU`+%<
M-B/>BI4$)C10@A]YH+!$$7EDYID@"R%[0QX#H#5(&"Q$"P6<?\!A0"=C..&E
MEB:P`8H@4=#PP0-4\)`"7A[P"0XGRG[PAAN5=G+!:W@=02\A+E#@`P)K?&L"
M&020`9`&1/P\2`35#*)H"Q8$@`9>#H10"!`\"))#!G]=L<:HA&PQ!H8/#&`K
M5B!X(%B87'$@R`Q!$!("<S%'AQ4"(#0@!`@DM-#3`$!X448A"61YS@E5]`X'
M!_+U0`&U=Z%`/`TH2/2'!%OX_8<`:*!$R`,$S"'$!V,DD,`(7+Q-R!!$+/!'
M_P9:J-&$)7V@04$%/H4@%B$XI/?'Z7\48.+&@CS1@0/._Q'!TX+;BA/\)08?
M,,`'"R"#?`1QA`H`A@258H(<T)"V"5!`>PE`0;OF5QDD4`$$&##`#LZPA@K<
M(T7TZT+J>H05!03@9W#(PQ(0L($>#"`&A1@"!`3Q`;;AY3X]2$(.\+(&#+Q'
M&A3@P`K60(@JE,X2F4N4<IHFOH"\@0@>N`<>WG"&!HC!,8+P`&O>-X0R9.L/
M,1#`7;C@`#]<X`/B(0$IU+"#/KPP0P/P%2$4]0<I8(`U.*P#!$:4``Q$*`3W
M$406LC4!^?D/@#SZ`P06.(<.1(`#<`"=Z:)"`-%QD/^%@GBA(&+@@`<DS2.&
M/,F4\D`(.Y#"+>6IP1M:H)M"%$$$+R#3'ZH`0$-$L1&"&0('$JF'CQ2!,XJK
M'PX,\,I!G*!T!SB"!")0DT(0008O$(,#;I"$NWS@!GX@"'BRT;__[7$K?\`"
M`ECC`A%H!%&#B$%ZC"`]0C3R;Y#T`P8@P!I!L(`!15/#!S8DB#H\80TJ2$(+
MLB2S4'HF#:FAPM.`@(7[U($G/\'!!WZ2E#"=YP\6$$,-O$`%$E117SL<!"\[
M\0`H7/`/0[B`HRPA/-!`)0`42%8AA'""#=$A`C&X@"7XL"$&1*4"64A"!WA1
M"#G]Q`<S%1P<"!`"!C2!-37_4$@G%E"$8=C`#5:PQ`0R1R$2!*Y%=C#!@/[`
M!`;,H&AS((%0_Z"`"*`@"02!@%'^$`?5.?0/:F"E"1I!@#4LD*:.+,1YAF`"
MY<F@`6$EA`J86J]>%N(!#-AK&QJ`@L,2H@<F`%<<P&4"G0Z"#FA0'@0:L%="
M_""E1OT#!L@0.$/XH9R65=0!)!``ULP!!0OX2R&,`(%Q_N$(#-B`(3IP(T%D
MP#>?O(")D)N+HOW!`&N`@WP\T!;&-F-0/GKA'":@A`4P40@1*``1-%F(%B3V
MLP50`[0*<8,L7`VFY2($"RQK3W36@`%4,`,'N*M89`JB`*85!`4\D"8WX&`%
M6/B?_W#_0`%$]"@``Z#!%Z1P@+0)#K>$>`(.%8F&(WS`"6*(@`?V,(@;:.$*
M%+H'`RI6B'H.@C(]>@`0L"$D$@BB.(6X`@1"UB/-D;,%E>#!`61@@C#5#$V:
M>>\@R$"&`ECYRE>>0`-228&TL4`+<IB+)230!R.8H0.I^$,0UG"&E`KB`3'`
M4P?P%`-&#<('#O@#`$`0@;=-80<-.$,,?@``-]]!"TOZ@Q<B<`8NN.S#4XI!
M`RS;%54T(+]3H,(:&"P(-:RA`T7000ZZX`4EG"%@G@A#"^1PAEP\0<R#>,%%
M+&&%1!MB`,KX0QC,D.8_'`!A@M#!A`G!`Q<50@&Y6(8#/$3\AR[,=\P'0$"R
M!]$'R@J"`#DA1-8&,8>%0.$(YZNQ`5PQ`Z<@("J$L("4@#8H0=R@`KE.%'<&
/$>Y.V%@0K-S-"YX6"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>h03611h0361145.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361145.gif
M1TE&.#EAV``/`.8``*6BH;"MJ^7DXXV*B8!\>1@5%<'`P):3DIV:F9B5E,W+
MR>[M[>KIZ%104$5#0ZRJJ>?EX]32T7EU<[FWM7UZ>=[=W/+R\9&/CDQ*279R
M<>+AX%A55,K(QF%=7-O9V%%-3+2RL69B86UJ:<O)R,C&Q;RZN4E&19*-BBXJ
M*,&_O8F&A/O[^S4R,8."@G!M;(6"@-'0S^#?WJ&>G=#.S6AE9,W,RKVYMJ.@
MG_7U]-S:V8-_?>+@W]/1T$$]/-C6U<?%Q#X[.G-P;[>UM:NHI\3"P=G8U]?5
MU,[-S+*PKL/`OYN8ENCGYL;$P[^]O#$N+:FFI:FFI'MX=@H(">OJZOGX^&QH
M9]73T3@U-)21C]W<VUY:64Q(1UM75O#O[RDF)8:$@J>DHNSKZB4B(?;V];Z\
MNJNGI+.QL;NYN.3BXO3T\Q\<'#PX-XJ(AT-`/S0P+ZBEI&1@7BPH)H>%A`X+
M#/W]_?KZ^?CX]_?W]O'P[^GHY_/S\K>TLA,0$/KY^<C'Q____R'Y!```````
M+`````#8``\```?_@'^"@X2%@G<C@@M6A4V$74@K1F>"*T-AAG\<B7\'#)DK
MF8,QHH(\.:(>=J."73^E"9BEA&4^?R-9F4NE:*5*"J)I%H(,5%2$PYEW@D=Z
MLYG)$T2#$85'E((0?`)_?D[)@FJ]@AQ>8T];@ED]NX8;!((%N7\[GX($4`'Z
M^_H`3AREBJ!8,"B4(!`;G/W9H"]*#X*&SG@!]F<,F4P42+%X\<=*APMT"E6Y
MP&_?FX&9[*@!0"C-H!]<`LA8D\2%GYMG/M@R%$+(GP:D#%F147*?"1A_T#AQ
M!`&#A*<2,GA)-VB.(#]N!)G8Q8<0EA,0$GP8,4)(E4P<-JSZ4T!0#C44_P8U
M,"!H`J-91P;<O'G%S,TO&T(*:H-`JZ`R&T3U:-"BL0,U10IIRS7'7I8"?@IM
M>)()`HI!5D*'UH%!M!4%#6@((O+ASPT$?C"`[I&)1)P*?P9,>U:HP+@#"32L
M&5)CA889`0H3LMHMZQ_F70=Y8<!AP!8K'KX\$"3X#QTO9^/1>:.&DZ"Y?U;(
M*UC(!QT87B#(GT_?X!\/PW*P.)S8$)D/![C4!0J.%$+!`7_$T-8@?BP`D2`;
M='#"A!2>H(,8@\P@&@Q\/&"::'5TT\`?/8P1VVR9F*"$('8$T=TL"V!2``1K
MX0#``36@4,(?;]!4B%5/".$<=`QBL(("*ICP`O\$&X@@`0UB\""("QVP,4@!
M6^B`@R!;_D07"%Y<(.8%:TA`R`096/&9(15T:<@07`B"!`HJT$#"(!!<T<49
M%*S@!AB&^"!%$"U`V=BA.A1PPB";#199`@/@4&`A4<2%9R%^-("#"MU<L0\6
M:Q+"@P/'""+!BF=F`!545[3!%@1!R%`'"`NLX$(23+`TP'[TW%"&%&4HD0`0
M@A`I2`9.T$'$"P[XD0(->=`1W1\@-'&!E3^\,$=DJ]'E91I5U`!!#V?(U\X@
MGJ)@A!D&M&O``6HD4,D;`7R```1:<+("`FP,8(0@`GR!"1TZM'%!)G1,(,@!
M03S3*%LAL7&!188044#_`#9D;(,3"#+80!%W*M":(&H6H@<0N(68H`D!$**R
M*#-"$$<-.ORAQ)WH_)$&9\M=)=MS@D27!08.P.`'LP^\@(`"`H3JP1\7R)$$
M&&@4T!T"/,_U!$M_L'!7>H1P`$.HZ9$!!Q)C#)(%!%X@0`$8>_F!P`"$+-"E
M#QV80,$4LU3Q0MP(_$O(!@GXRD<996@!AQ(AV,/,%63_X8"W5XT8A0!6;+'7
M&UX00K`9@@A!P3%GJ($%.#:#X&X0G,SX!P)-N`"!!O(ET(%\0V!3K,^[_Q$=
MU@XD00++"O!@!A(<C$C(!2T(8H$351S*0@CG@0'`7F(\<),!<>R4(`&N#J*%
M_YF9H`"0%9R:"L1:@]#QA`,[?A$'&T@9,H4#2DR@@`(<J$'^(!_PUH(D)HA2
M_4$(6JA!?.C3@\QX[`\,X$+F.)`!!>R!!EVB`P):EAXM;,`@)9C#!V3Q!PQ0
M#G[Q@(`@+F`%*)#`#Q20`@J><),:].P/!OB9L2S@!P=H!00`*($"3@``Y0SB
M!,HQP;WH(Q<A%$$^.^`#?2"`AS_4(4)D,`$A/G`$4:!`A7]H`M?<L)M#/$$,
M#L#"`4YP`!V@0`IS6(.4!G&#$*R@`X)X`FT*L84;W`0S?A!!$/R`!!:@0@<!
MH(,5Q/"A-3BP<H(0`Q(2DQ@+8.!G3.BB(!YPA4+PC?\0)AQ$LU+X!PM0+QLL
M"`(-MF"?JOP!`AGHC[&ZX<.?0"`*):#"%X*`&U$TX)%_J,$\T",(VT5A#X:0
MP1C,$"<`?JT07_S##.Z0#C:X@!!-&((5JL`S-0B"#108P;D@Y(@;"`$-/=B!
M(5B@@!C$9P1OD`\<<@"!+1FD9(0899%6H88A)(8+'NB)*$S`A&"V$I0G=.",
MP("!\/P!#A)X0A4D0("7,6`"<]#!$UQ0,Z#YCD$^3$'-N(";%SBGE$HHR1K8
MP`\"**$/7A($$S[0A2FPX0I<(X0.9+#%9Q("!460@`;^$(`OL"`H(AE`:`H0
M&D(9`@D2"`D=MF`">17"3X+_6-,`*D"`(*#"&FHHB1.`Z8<M`$`-+N!!8H[`
M`A(:B&L,D,!7"X&!!.SE"KN9T0H^<+`_G(`&"Y#H`MQ`-VE>X0,!"$4#[O0'
M*00-I'^@02+$4`<Z$,`)+S/$+WUI@#3<(`,D?`(?JC@("W2`?7_X@$\'$8<V
M:#(+<Z#!,@Q1!1<@K@"(TT+S6F*"H-!A`VJX@2$B4-@U@6"QHO!#Y/0)23+4
MP0J)P4,/E&#`08R@HH-X``8^28@.U.\/<@B*ZS9P@#KH(`-Y/`L("B`"05#D
M#U\HK#0?>Q4'+"`("M"!$_X@`RT0@`L*,00&@$F(!@A!+_ZQ`+=<TU>#2-"+
M6/!._Q.<\(,&.&`/;A($-\/QS=URIPKU8\`[:G"%'@@!'!T8!PI68`8K#,$)
M-^@E(91;".;^X0<C^P,,JNJ"%3B@#0$8ZD&\X*XG/&$(;=#B,W"@!RJXS@T'
M>`$W\HA'"!:"8,(UA!2OT@8X'.,`,=#!"2K;@`*D(!,V)H07.D"`-KO9S3V8
MV1]P`!(NL4$-4NB"*(:1`A/(P2#DX<.B!@$'"9U`!!/Z0!3:=X%<A$$.<)#%
M"F2`YPXL0`!]E983A+R`#4C!"]MA4*@(8`(^F`>'/[LQ'WAJQ00X88Y08P$%
M)L`!'Q#D!XY]QA(N,`<^A`@&\Q@$&7@VW'$8@K%_\$$"#$\(@'%6(Q,)R(,H
MEC#;9S`ALSJ>E"&Z`(9K%X(*P=ZDC-V"U#OH60$EX"XA%)"VN?YA`BXA1!C&
:F:`S#T(!#WA1$7+Z!WKSQCL@^+<T(Q,(`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>h03611h0361112.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361112.gif
M1TE&.#EAUP`/`.8``*VKJKV[NF!<6SDU-.[M[(F&A9&.C7UZ><C'QZ6BH>7D
MX_+R\<[+R>?EXW9R<>KIZ'EU<VYJ:>+AX(!^?"DF)=[=W'%N;962D9F6E=32
MT6AE9)V:F%U:65E55,3"P6=C8:&>G55248J(B.#>W45#0["NK<3!OI>4DVMH
M9DU*2;2RL<+!P(V*B=#.S=?5U%%-3!,0$*NGI(2`?D`\.\?%Q+BVM4E%1:NH
MI_7U]-?6U9.0CO#O[C4P+\"^O>SKZNCGYL_-S,K(Q]/1T(R(ALO)R*.@GI&-
MBM73TH6"@+:UM)*0D+*QL+*PK^CHY]S:VMG8U]W<VX6$A#$L*]O9V)Z<F^3B
MX?GX^/;V]?3T\\W,R^'@W^SLZZ>DHF1@7IR8EJBFI??W]EM85YN9F+:TLL7$
MPR$='8Z+B[NXN'5Q;]/0SYB5E$1`/Y"-C%-03X."@K"MJ_W]_:FFI?O[^_KZ
M^9B3D(%[=_CX]_'P[X>$@DM(1I^=G'YX=<C%PO/S\L'`P/___R'Y!```````
M+`````#7``\```?_@'^"@E-/@B.#B56##P2)CSEP@AE,<$%4.((NCH\N7U=/
M`8]_=J./*EFF?Q@2I@T^@U`+?P]:IG!L.:J/3*FF.P^J<XNC&&JJ1U9_(P\^
MDH.MJC\("!=8B58C#=O<W04$SX]$?5439W\R;^KK&SP[@AAAI2T<P62S`R""
M2AUS)R\[KOP)HV-4!PL$N+P0M,!7"PAXU!4!L$[=!#R#9@WB$>P/G'."M%B`
M]4=/A!A=()ABPB/!D2-$`(3[TP#!G#\O]/SA(RH1&0$Q@@H-:L:&J10U'BE0
MUL7`FSP'S%SP0[6'#16C"AAPH<X&289<*HI]`^/)CQN9!NG!^N='&#A=__[0
M\3#'C`\U206=4"((@0!!,$K\X3&HBX<8'SC@F8'C0]I!&0C_B>/F#Y00`P`(
M$G%"$!H!?79%84+5#X?214CD_7-DAJ`+%_ZXB3.J0AD,0J6D@))HP@Q;'SBU
M>9,(@055?@6-$<IEP-"@)%+\$8!@L)S9B?Z.&O!C$)IWNP9U_U-&$)04-__<
MB/`HQHT_<?_D^;-#P:"]?;5+EISE@UX1@C1P`'T;"((%!6L($H<`+X3A1"*<
M>42!"]R8$,)X#\#A1@._C&+?'Q.T(!MM8PR211Y81-#=!1I`,H,<@FCW!P$J
M[*#/'P@,`,&./.XH``>C3,#$+M0Y889L2%!#S?]"I[PW"`$%)0(%"W146:4&
M91!7GB!?L%>%%,'8,40PFCW!'DYM^:<%#GL=,$1R@PDB&014C##!"S8,,,$!
M!\001@$/X`#!!4;P8<`'$<`H"!>;=58`"`B($8*2'/YQQ@0B-&"$E54.08%1
M@WQ!Q!\+M#CB'RJAHYD@!:3@P"@6%$"5%UV41M47;MABG"`0"!",#0=L`<0C
M6O"@J"!5%!@C`C<(Y`8&W73PR`,OS/1'`;2%E\B6?_@`PPA*2/8'/61(H`4$
M1^``QPPHM!&&90&@84%I^LE)$P40P&%%#<I^D,`?'<!XPQ%^&*%@98-HQUD/
M+`CBQYF)R.%`IH^,T$7_`</^05$8[^G@Y`H:'!#"+,_``0`*(CA0P#BF6)#$
M+@A$L(0?;<CJ1QE)7,`!)_21D,=S$PR0,`(EP(+=($`.LH,%=_RA``8D+:U&
M.$&48&L7T7#[!PQB""#=("UL4,$)%?RQ@@!0'.%"TWKQA6.]<1Z@P05/-%"`
M`R,<<$:!0@_2PQ""U&!#`G'$P489[XA0@`Y"O'1!!"^1@4(0@C1!L2`*L%#`
M$:-L>,0-X0A!1B)W`!!5=U=\T44((="1"!Q2U*#D"A,@TI?+-"M!51FE<7*%
M#!&@\(@?PB^[``H:3N`'!%2!2JH.U:GWPE<_<-#%J'_XH7QI9=A"7B(\"&"#
M_[2#8*%!W=N\(<,V1'1PS1_XO6UOG"-P=@$+-BBA/Q1B?RW("MGJ@1',X`81
M8(!S?Q#!$-0@E`[L82@F^(,<>L"#2MWK*XG8T!^H$`8W>'`&"?H#`XRPAA?8
MBBH;>`$4'O,')I3!!`R(H0PH,*2^I`H%?A`$!00A`<W8`0TW0,`:.$4'"Q1O
M.M5)`!FPPP1$8*$'@E"!+@01@=$]X@0:\4.VYO>]09!`"B0@7^!`$`1J8``&
M90B`DCJ"GQ&HH'C[:=0R+'`$##!@%09PVRA0T),_@$%$">R,(.Z``CP4X%CP
MT0`*CM4`$JA"@W^H`?;:8+N#63)[,A+$'"@`!"H(`O\.%/!`(ORPACI\(`P0
MV,,,(E"'.C@`!0KH0G<0<$2''9$ZK#$`=N:@@Q^\8`8/2@0.!B0('0AD>%N,
MDR"T1H(9M,%_?W"`HA[0@03@H0O$N,\+VC`&$!1@?I*)$`W8<`0+$&<)??L#
M'O;0RE8.H)UUZ((41A<A7IV#!@-PP2":\(,0!LB1IMA0#W`PA[C`YA&4N23Q
M'H&'44U@!7_0P)$2L00#9"^'?QC".Y`@QKYT((8@W<`MO6`""X#@:!]@0R43
M88&R"6('$.!9%+='E1TN,Q$4D`$+)&.',6A'`A"@0<$:H($3E"(!#=*#0`ZP
MJC@&<CJ($(`RE+`&1":BEA#_ZDP5"@!%09!A`!G[`Q9<,XA&/O(";!!$"RP0
MAO<-(@YA4(<#XOH&/!S1"CH`T(P.$`$+6%4-@J&*('S0`<WY8A`(F)22$("!
M6P8@"2C8P=&F8`'P)&(!RAH$%_R3B(DDXE4WU20,5B`$"EAV0`&0@2$*]@<)
M1"`/>EA!"=R*@DKU+9PG((!1Y""T+*!!!S)0!58'(0*Z><%[@U@"]LPV@428
MU10<F$%H_N""&71`"`A%6$*S=\0A6%000$!!"#1`@YFP8`H7?6(-_/""#(R"
MEL.[9?1D`U@#_(`-%BA%@!Y2@B(80`1(N``5\N`D`\ET6V"C@#)$T%Q!A$$(
MJV'M_R18^(<`B&$44MC,!2`P0C1T@0$"6(`<UE``:T54%0&80138<`+"%8X*
M)V"!2N;0X&5PX0(`'84>>..#$[#GJR&XP?OBT(&@0*`+09F`J?ZP"#D0#PT<
M\L`,9L`&,CBB(`HX0`I(@`%!T$`*$2!">G!T1"XD001'Y$!UKH`!$O"@"(.0
M`0]$^8<-4"`$$5!"!`=Q!B;M8@@7.(!-_X`"?7HD`KSYP[\240)!FH(`$S#Q
MEJ(0!GU:005%N-$?KA`!MB7B7;O`015@LM@,/,$1:0"D)@\`457`80(L:$(B
MA#`$12W!DX^@`6A98P$-(,!:/_B'!*B`73-94!!@$`,$W$CJA_@<8@:M_L.D
M!/&!:"3"!&#0I&5'<6QAH*$[<-A`5P<QAHYHZQ%R,'$BKC#F<[O[W?".M[SG
3O0LYM'L4.+`JO>?M`UD+(A``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>h03611h0361113.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361113.gif
M1TE&.#EAU@`/`.8``):3DJVKJN[M[(!\>HR)B<C'Q_/R\9Z;FA(/#]73T>7D
MXXF&A7UZ><S*R>KIZ&!<6Y*/CFUJ:7EV=,"^O:2BH%E55&EE9%U:6:"=G'9S
M<N+AX&QH9E%-3'%M:L/!P;FVM$U*2N?EXU104$5#1-C6U65B8N#>WIF6E(."
M@CTZ.8R(AL3"P<O)R)",BL;$PRDD(]/1T.CFYM#/S:.?GOGX^-G8U_7T],G(
MQZNGI+"MJX2!@+"NK=S;V<[,R]O9V#8S,^/BX2XJ*;^]O*FFI<;%Q+2SLKRZ
MNC`M+$E&1=[=W).1D+JXMNSKZH-_?JNHI]?5U,+`OCHV-='0SO;V]=[<V[>U
MM'1Q;[Z\NL_+R?#O[K*PK_?W]O3T\T`]/"0A((>%A2`<')N8E[.QL.GHY^+@
MWUM85GQX=ZBDHH>$@C4P+M73T[NZN6-@7O/S\J>EI:>DHR0@'[:TLT-`/_O[
M^_W]_?KZ^9B3D/CX]ZBEI/'P[_7U].WLZ_KY^2HG)L'`P/___R'Y!```````
M+`````#6``\```?_@'^"@E,UA%.#@W6#<XF.?W>)2S19`6."`I&.<U4&>@V-
MCZ*#0#>C6#*B=5F#GG]U3*-0:J../*FC`K4VHCX$O(\Q@V.:@U-TM7\TR:*Q
MHUE`4RTS?P4M.=C9906"-1Q4?W,1I@J+.E;+(6`)0&!$@A0/BXDX*3(:?7N"
M&H(Q2DW9`F);\(!5N$0$``S2,.\.@R3=+O@Y`*)9"FJ"/CPB@8P`AS\&ELP;
MQ,&/R9,G1UQR=.(!HD0&_H0!J$-$G`$X<N*P@L;1/1XF.3@39`"#SJ,ZHY"(
M8<(1&0FA4@"!P,($-2,^8G#0(RB!B$$O!(&(\&<#MS]B!BS)\6-"%#5-_ZXX
MHI,F58@1RIP@(""H0`5!:T"$J%6@B4X+:'0>Z3`HRQ&N)+[ZV?"(#H@+*#(C
M`0,ED0\$)_Y\R2$(!0-'46J%_>-C34H**/TL2&,"`(2R$R8CQ#5H+-<_39@]
M`B,(P(3&1T:&N[`E@(<_93QHX#+(*UA!#Q*4/7O!T]U!%@2!$C0`CKX0*0YT
M6?"[VM\_$88,XL+`@:!E!12*0I9(32,/P>GF@B)E"$'`$W\X$`09CG10A"`1
M_#;%`G\T,$@?=F2HH89PW/>2`&748AMT?_CQ0`@HAL"`=H/D\=4@&)R5C``+
M($*<(&7X(,@&&)T1$T86Z)+='^%U)4(/!,RQVO^09OWQQ%<4G'`$&@^X4($?
M%'!@RA(Z<*!!!A$<D0!_&KGW!PD/8--'#@$,L8(@#E0``P`S9"#!G7=6$(0N
M@BCPW!]H0*1;3W]H(8$P-(0A01J#)6($&`,,8,8/D58J01`4_I':'TM<P,,?
M!$@@``:/<"!7(IT5!P$02Y0H0@&P%A`!BX)<P$\BHB82`P5(80!`#W_<6*$7
M?U"!`!!P5J#!$',,P=<?;$3``!A`Q#!#"U$<<(()2VIG%AT9!#''$QX\T$`"
M+83GAQ-_$$'J1W]\-T@)?55@P`;V_1&$*">\H9\B%(!`01Y_")'#`!?\D0`;
MW8BP00K<#&6"#A98`8#_(8.T$=,?+I!52Q0))$#`D0F4T80+%B`["!X(Q.8'
M`L#^89L+.NHV"`&TYO!&.'P,(D0$?/;)GR"\"5L'`D;,@$!_+JQPP,[0+6%2
M`2]9)TBWVTW0`0B-A/`##5I`$!H:W/P&+Q-!^`&K!WU8Z-<2#(+4A2!T0/#.
M'V.X\.\?.81QP,:#^#&$`P`$K0$&30U"!01FB/''%`>44$$&+00-'`$I*N`&
MQH)$H04.'520$Q)-4`"`%(/`($*'CJPF,P1TB.H'$CBH<`(.%UA8X6E_]'!!
MOG^XP4',?U2A0D!@8"SL'W`T\<7R?PSPDB!I#+)`OE;_@;59!<@`P@$9I!"!
M_P014'#`'W($S<0#?0X000471$!`3'Y)D!D*%B!Q/PI?",+%`'OK`@5$(;@_
M%&$#&8A4&1"@BSTX80`OT$+()BB%#9R`!8F8PQ$L`($.-@$,[!O$W/XP!!3L
MR`^"J$)?N.8%@>2`6*KJ'0!T0X4=_($'M&C`LT2C!$>L``P#+)%\!E$]02RO
M"UU``?1$$(`69`@,".A`AEJ@!2.%PP#[^@.3N)&`BOS!"B`YCABN\(-1#($#
M@%-`O1*A@PX`8!F#J`(<*!!$08R@48XH8(*&V`0\W(<&(0!9`MPR03"TP1$#
M:$$+;A;""V6&`R5`004>8`442&`$53C`;;3W"->-B/](-E,(!1#@A"TD8@/.
M..0C]$B]02QO!$%HP=(&48`ZSN`+:=`!!A.1@!%(8``-P(L6O<5%+U[I`!RX
M@P&\T*H_!&!_DHQD9B2```KY91`3($L!D/`F0=3A"A180R+N2,`A",`^#S"`
M&D*4"'G)2U^."$$)FD6-'HQ`C8/0`[Q,^`<*:`<&98C$T%QWG>*HX`X)>(#-
ME&"!`,!Q$$NHXQF,L,H%8.&B6"ABL!+Q`S88`0$;P\(%=-0L!M!%`(DTI0PR
MP($-O&,%1=JBPBK"`K[X86<Q`(,P_M"&8I`0A8^XYA^<T()0L$`.I\(..`9!
MSE42@`%J=(`5+-#-083@"-C_.`!6L9%%022!`_:9`P$@(`?4):(&'N/G'$H0
MA@TXP2"#:*%`8"@S-!2!`[FA#-XZ8#E!9&!ZT8N#(PZ@@U@5@'4;=24&VN"%
MN_UA!PDP``#"T$H#2.!['F``#&XF!$'(:3LSA=9F"VL#!H3A`LH9Q!"`Z@B_
M,.$`6C"ESP(XM#\TU1%N`,.?ZH"$$?!&$.X4)CP%T0,VD.`^%(@""!I0VP_X
M\0\F%$``CMK93EHWAHV8#!7"T(,B7`"P,`"J`*3@@0%$`7@<D]$?CF/$0>P!
M`4V)PXM(.(0!X%&C+&"7KC(P#$%8H)@U8(`6BM`'`YC!CV`"1B)6*PHR_```
M3O"#_PMBY0(_%$$)EX""?CE5@!_@,1%Q"$WO'B"#%:1@`Q/8F-=,PI:3]&$0
M?\J"$QY`V15T00X8D,$B;K.%&X#``A<PQ`VBH`/.72UU+(`!8C]Y@VE=('$`
M2,,*Z."!!01!!%&0@PC,X",5%*D64M!`.P:Q`X_](0-W@T(S!W&$9`P`08X0
MP8!Z(`<)T($.2EA"!1+WAPL$X!$G8*TCZI"``@A.D8K4@A]N8(,YJ"`1>FB!
M%_=C!`O8$,8@4%D,)IT(Q-)!"VSHP*<2H0`=O``-)*`L#=*`!X(I`@!],/(L
M(2$#)#!,$&.%4`L`)P@C:&$./5"!"4)!:L8D0PJR#"$3D#E0VQWL\A'ZJ`5Z
M!Z&`1DQAU((@=C*R\%#A>%LXW?ZV*%R=##W(-K6U,/(C')`O;8O[W3LE`05"
$$0@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>h03611h0361114.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361114.gif
M1TE&.#EA)@`/`.8``(J(B+&PKXZ+B:">G+"NKNKIZ'9T<RDF)AH7%W)O;?7T
M]/+Q\5514<O)R9./C8)_?8.!@MK7U8!]>[6SL<3#PEM86(J&@V=C8J^LJGIW
M=F!<6FEF986"@9N8E\_-S,_-R\"]O,&^NTI&1;FVM??W]N[M[>+@WT9"0=O9
MV=;5U#,O+C8S,HN(AD`]/`@&!U!-3$]*22$='1$.#TQ*2L'`P/3T\T5#1/O[
M^ZNGI,C'Q_KZ^>;EY//R\:BFIK"MJ_GX^,_+R-K8U]'0S]'/S]G8U]'/SN+A
MX._N[61?79"-C;:UM'ET<.7DX]_>W3X[.YJ8F)V:F)Z<FTM)2=O8U:2BH>GH
MYJ>DH]#.SM#/SN[MZW]Z>+NWM)F7EN+BXN/BX<O*R:NHI^_N[O;U];BVMJRI
MJ)B3D/W]_>3CXK>TLLG(Q\?%P[RWLWQX=_3S\EM75EY95\"^O;Z\N[JYN510
M3O'P\-32T=/1T#@T-+BUL]S;V_;V]6UJ:**@G^?EX]73T?___R'Y!```````
M+``````F``\```?_@'^"@W]>`D(+A']$BH)B/'\<8XV*1"A=`1PO#W!/!#2@
M-`=?9B,^/F`8;`QB!VF$14V$7Q9_)E-^`((`?H0QBC-]@@L:@VU_-TEV@D8K
MA+ET8;R^P,)_9!"A"!)_)"HU?R\3@GAE2',)2].#O\B"P8)WX'\'A%'%+D>$
M+7LZ?Q`"<`C$H4*0B1AJ9FP1\`$&BC\\"@[RX**`#$(U$,P1H"`/N!M#,F@1
MU,?&GQD.`&@P0N!/@PJ$JKB`@X!0@#T`$E!1`N6!"@8=(I`T&:Q`AS\/_@"P
MHLC%@)J"=,#(]>/'H`36AI[,RF+$A48NGEP4Q,=#KC\[0@`!\F;-A!8%D?Z4
MW/I'Z(T5/11E<2''1:(_0?Z<74`A1PXW$PR7D&M2R@,6#?X,.&%`T1`7.YR`
M>*:+$-9!"D8<V+!A@IX_5"[LR&!`P:`>(OY<.4%("(`"1?SHUA#"#X4-*5H8
M6/RG0`86@R0@X/-'AP@F@C!@&/0ER0(LNK-GKW%:4!P.D`B="<P%#:$/=2BI
*7Z](38I!@0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>h03611h0361115.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361115.gif
M1TE&.#EA)@`/`.8``&YK:NOJZO7T]'EU<^3BX&IG95U:6,O)R+2RL<?%Q<C'
MQY61C<&^O6!=7'9R<**?G=+1T-C7U8:%A59349Z;FL7#PM73T[>UM.;EY1H7
M%]O9V.#>W65A7[BWMI62D7)M:Z:DHI".C=_=W-'/SK*PK_?V]:6CH9F7E71P
M;X^+BXV)AP@&!U%.328B(ZFGI9J7EH^,BRTI*86"@38P+B`<'$`]/)&-B?GX
M^,_+R+"MJXJ(B.?EX_W]_9>4D_CX]_KZ^?O[^^SKZLS*R8V+BXZ,C-O:V+NX
MM]G8V-'.R[&OKJRHIVAD8N+@WLC&Q,_.S;FVLYN8E]/2T7MY>?3S\G]]?(V*
MB/+Q\.WL[.[M[>_N[JRJJ:ZLK'!K:G)N;9B6EK^_O[^\O&MG9F9B8.7DXZZL
MJNKIY_/R\?+R\I>5E#`L*TY*2=K8U^/AX*BDH$1`/WMX=LG(R-?6U9F4D`\,
M#/7U]#\\.[6SL[RWLKJXN,S*RO'P[UM85G]\>\C$P<'`P/___R'Y!```````
M+``````F``\```?_@'^"?S]%.SL5)']/(5.#CX\C`$&"/Y"/&DT^#SDY2Q-_
M-E0"?Q@=EG\1"0JL7BQ@K`!#?QM@F`.0/3JA?G\\809C@AI]=VTXR#AR"SA(
M@G@J@GHT-X(E@KJ\?T0%EW\%"(-U4)`RBC)<@R]H?B@2O&\4CP16@A!)@GQD
M?V,Q!X(6,OB84V&0A"A_+$`(-<""H"!E:-GQ0[&B13]'!/&88V>%AD%[KORY
MP88"!QE*.`$08V80C(M^4CB!1$/'BAV"@&3H%$8-+SHGO,VX9(`)I!@&;@HJ
M$^V/#@_:J@B]U.!2#`XKXES2(<]&KRT/+M$8T`6%`Q0#AM(<0J/#)2EV?+1E
MJ4'J$0@!#>@HZ/''B"!A(U<D\%`5DI@\H3I<Z'"B0+5'*6#\V3OHRA=!0EK<
M\)$&BZ`1+T!,H'/#38L0/O[4F4#ISX$E6NRQ,.$"!(#"`(0(.O/AVA\@8=8(
B6L!CT(\`?QAP@5-\$!,XK"Q4H_V(S@AOV+-#$J%54"``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>h03611h0361116.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361116.gif
M1TE&.#EA-0`/`.8``)J5DFYK:O;V]65B8<;%Q+"NK-73T9R9EWEV<^[M[8!\
M>>;EY<&^NU=44ZNHI]S:V:">G:.@GG1Q<'UZ>D9#0K"MJ_#O[\C'QXF%A)V:
MF8."@I&/CU%-3,'`P*:DH^KIZ*"<FL_-S86!?QD6%JRJJ.'@WY62D>'?W=74
MTV%=75U:6=K9V')P;VIF9+2SLBDE)+Z]O7MX=KBUM?+R\>SKZM[<V]K7UX^*
MB5104+:TLSTY.38R,4E'1ZZJJ:FGITQ)2&1A7XR+BCHW-DM(1PD'".?EXZNG
MI*FFI5E658J(B&MH9S8P+OCX]^CGYOGX^)>4E/O[^[BVMHR)B(V*B;.QL'%O
M;M+1T,C%P_W]_=C6U:VIJ-G8UXZ+BWIX>,3"P>7DX\W+R\[,RV=C8EI86&!<
M6T-`/W-Q</'P\,+`O[NZN>3CXKR[NR`='>+AX,;$PW9S<C$N+;NXMM+0SY&-
MB8^,C*FEHE]<7+.PKM[<W/KY^:NIJ*^MK)"+B?'P[Y*1DO___R'Y!```````
M+``````U``\```?_@'^"@X2#$5*%?R$L-G\G15DYCUDPB7\.&):)%EI_*()A
M3H,:.80"`AU#32$.%0T4/14X%(,/HQ.""7IG?S57A!\(3'\-+0HC=Z-%A$T'
M'4HG;%LF0DI0!SI*@R85@AI'@E(XMG\@X()(4>@&?TN$&LN$/"1*'A%D!$]`
M`7A!VH)0@'SZ]@>+D`2$@"2C\@/*NG8&AOV!YXD#NRH;Q(CYPV3`#R5%5#3X
M)\@%CHG@WE@IY$/''QY=!B%AMR1$F@X=!NS!V2&+#1=^.)B8`$*+BQ@(BA#`
ME4?0#'7?$J#Y8V%*"4%61EP904<FS7?Q!*F!449!@`Y,RO0H\4).FP]__TC$
MJG#CR906-RI4`!$`0JX=$X@\\=H.;"(D1S;\$<&A0@P,%7Y$*'2DPY\D1C11
M4"&8L#MEAQ,;V)'D<I$%<1)EN'`YLR4*=MA,D:G`Q`O#A&@,.((!1)T4%5*`
M(%&@3R$)%EI;^@!'PY@J@WBPVPB:4`$,1[A4,**".P`^")(/6M%`$.9!7@:!
M&?&``(49@H[02$214``';R@4,"+!@`0&!EPAWA\+Q$#.>8),)@@$/P@2@`^:
M"&)&6'\XP0$3,0S#G1%B'&`$#@@(0L`;Y/RQP5D=K,$!%8+8X88@`HBP0(0B
JP#?(`5\0PH`,ED@00B%.$!#%'%%<(,!B4PV"10N2$3;IY),U-#%((``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>h03611h0361117.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361117.gif
M1TE&.#EAU@`/`.8``*6BH*VKJ9:3DO+R\>[M[(!\>LC'QXR)B=73T9Z;FHF&
MA1(/#^7DXWUZ>>KIZ,W+RF!<6Y*/CFQJ:7EV=,"^O5E55%U:66EE9*"=G.+A
MX&QH9G9S<E%-3'%L:N?EX\/!P45#0[FVM$Q*2E104)F6E65B8MC6U8."@L3#
MP>#>W<O)R(R(AO7T]-/1T"HD(STZ.9",BL;$P_GX^-#/S:NGI+"MJ^CFYH2!
M@,[,R]O9V./BX<G(QZFFI3$M+=[=W+RZN;2SLBXJ*38S,Z.@GK.OK=G8UY.1
MD#LV-;JXMNSKZDE&18-_?JNHI]S;V=?5U,+`OL;%Q+^]O-'0SO;V]=[<V[:T
MM'1Q;[Z\NL_+R?#O[[*PK_?W]B8B(O3S\IN8E[.QL$`]/.GHYR`<''QX=X>%
MAEM85J>DHN+@WX>$@C4P+M73T[NZN6-@7JBFIB0@'T-`/_O[^_W]_?KZ^9B3
MD/CX]ZBEI/'P[_7U].WLZZFGIIN7E$U)2/KY^2LG)L'`P/___R'Y!```````
M+`````#6``\```?_@'^"@E-%A%.#@W*#<(F.?W2)2#)9`6&"!)&.<%4#=P^-
MCZ*#.CNC6#.B<EF#GG]R2:-/:J..3:FC!+4LHCD'O(\V@V&:@U-QM7\RR:*Q
MHW<I4S!#?P8P-=C990:"11Q4?W`2I@R+-U;+'F((.F)0@@`0BXEY+S,9?7B"
M&8(V1DO9`F)3`(%5N$0'!`S*,(].`Q_=+/A)L*?9"VJ"0CPR@>P`AS\#D,P;
MQ,&/R9,G05QR1`("HD0#_G@!>&,$D`(T<M*P@L;1O28F.3@3-`"#SJ,ZCYBP
MH<,1@0TQ_[S0$4%%"FH_<MC@<$<0@A&#N`@2T>&/!FY_OA1`4D,(A2-J_Y9<
M<10G32H/()0Q67!`D($*@M;L\5#+P!*=%]#H[%%64)8>74V`]:/A41P.%DYH
M5B+F2:(<"_3\(5-#T(D&CH[4<B$HQYJ4`%#Z49`FA8`(9BE01HAKD`@)7?\L
M8?9(3#@2.`:QZ+$E$1P+6P)\^%/F0P9@?[X.8OT'`@*S:"UXPCOH@B`5H0JX
MT>?A10(P"H)7`_Q'0AOE#1P(6F9`H2ADB:C1R`?#[1:#(F5$<8`3?S@0Q!F.
M=`"$(,`1HL`?#PS2QQP<=MBA&_N]1$`9M=Q&W1]^0.#!BAXT\-T@=H`U"`9H
M)4.``H@8)P@$3?TQ00*"F!$31A?HXMT?YGDU`O\.!\#!W9%G_>$$6`#HT0,:
M$,10@1\`<&`*$C=PD,$&'?2``(`:S?>'"1!@TT<-`?"`@B`.5-""`$-L,,&>
M>U80A"Z",##='VA`M%M/?V@Q@3`RD#!!&H0E\H,8!10PAA"59CI!$!?^H=H?
M2%C0Q!\'3$``!H]P,%<BG@ERFPY(H#B"`;0:(,&+@EC`3R*F)F(#`$AA($!R
M.OZA0A]_I+!`CW5FP`,<>?3U!QL2-""&#C8,`<,1"9"0PI/?G17'!D'`X<0'
M$#R```SF^<'$'U"@^M$?Y`U2@E\5#*"!?G\$(0H)9OBGR!`B`&#''U'44(`%
MV;'1S0@:O,#-4"G<<('_%0(8,D@74<4@03)'((#``4LB4,82,5S0HR!U+"";
M'PLD]\=M,>2`8F6#'(!K#6:$P\<@44@`:*``"M);L7`L\$3+`<:`0@(]4X>$
M20:\I)T@X()'00<B-.*!$#)H$0$)A'(3W+Q)!.$'K1_TD>%?2$`($AB"Q!'!
M.W^$$8/`?]3@10)1#>('#PX(,'0&&*20"!41C/'%'U,D4$(%&\`PM'`'L,A`
M'1H+<@01-'1004Y*+`&``%(,TL(((#K"W<P1Q&&J'TK0L`()-%B0H;&H_8&#
M!?S^40<',O]1Q0H!B:%QL7^XH(`"S/]1P$N"I#&(`OQ>W?R.X=(Z@P@);/""
M_P032```D&\,G00$@18@00462'!`3']-H-D)%RAQ_PED",)"`7P#`P!$,;@_
M`$$#&ZA4&1:@"SPPH0`N((+()B@%#>A!!<[IP04BP,$EB(%]@Z#;'WAP`D%H
MP`^"J()?.``'-PBD!JV#G>\$L!LJE*8)M'B`M$9C!$>@0`P#1!$/$F$]03`/
M!"`X0?1&$``8<$@,"^@`AV!`!"6%8P#^ZD[WLB,"05@!)!1(RQ6$,`H><"!P
M#,!7(F[0`0$L8Q!5<`,`@B@($$3*$05L4!X$L80Z[$<&'@@9`MXR03%TP1$%
M@`$,<@9"#6F&`R4X004@8(433``$54@`;K;GND&8"/])NYG9'P"P`"8T9Q`:
M<,8A'Y''Z@WBB$&(P`(280`Z#H$,:;@!!A.!`!!,H``JR(L6P<-%06PI`1R@
MPP#<$*L_!&!_DHRD9B:P@`O]91`4^)@!E#`G0<CA"@!80R+L2$`>$$`_$!B`
M&DB4B'K5JU^.\$`)X-`&:N``!&D<Q!WF5<)1?J<%98A$T5ZW'4^N@`X(@$`H
MC7"!`+QQ$$B@HQE^P$H%8.&B6"CB'YAW!`T@80%OQ((%;$;/!M2%`(ELS@PV
MP`$-O.,#28(2-Q#0117TQ0\]LX$8A/&'+A1CA"A\Q#7_P`08A$(%;UC5CL`Q
M"'*R\@`-2*,#K'"!00W"`SW_P$8"LHJ-+`K"!QS0#QP.$($WI"X11?C8'_H)
MAQ)X00-,,,@@7"B0&`H`#4#@@&YP%H8.7$X0&Z">]%28B`3<H%8&B"'SQ)``
M.W"A!8.H`0(&(``ON'(`$]A#`C[0`,@*X@!1,"9DHT33:4'VL"QH@!<L,))$
M\""HCOA+$A)`A%,*(@H!+-H?G.J(.HAA4')0`@AZ(PAW"A.>@L`!&TRP'P`<
M000/T&T(_+C6/Q`@`$@-[2,(BC5/XJ81E*&"%W``!`L(M@5!)8`4/E"`(P3O
M#S&HT1_":,1!9&$!$-$"PP3!`QX4X(X:5<&[?+6!80CB`C,501$:H`4@]&$`
M8_#C_P8D@)U!O%849Q""`)C@A_C2*@9^`((1+O&$`8/*`$*X8R*J0#;?06`&
M*'B!!B@0E:^9I"TG098@!I4%)D#`LB@`PQLP,(-%X&8+.Q#!!2Q@B!T<X0:=
MZZX@6J""%MAUDSNPE@44-[,TH"`.'U!`$$9PA#>,8`Q"6D&2:B&%#+0CLCBK
MSXN>T,Q!]"`9!6"0(T9P(!R\80)QB(,1D%`!+O_!`@%X!`E@ZP@Y(,``@U.D
M(K7@AQVP``XK2,0=8%"14<3A"A<HS2`^(((>V:"+CXAA'+3`A@Z,*A$,N`$7
MT&`"R\H@#74XF"($T(<HSU(0=)B!$ASVV4UV``:!$\0/M$L`!QRL(`6A@'5C
MV`R#!8`P"7O0;0"Z^0A]U.*]@V!`(Z;P:D%$.QE9>"AQUDT<=;-;%+I.QAU.
6V=ID1/D1#N#7N=_-;YXB0`^A"`0`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>67
<FILENAME>h03611h0361118.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361118.gif
M1TE&.#EAU@`/`.8``)>3D;6SLZ:CHCDV-8%]>HV*B>[M[)>4D]32T7EU<Z"=
MFY*/CNKIZ&!<6XF&A,C'Q^7CXQ(/#X2"@5524,"^O9V:F$5#0^+AX&QH9FEE
M9.?EXTU*25%-3,;%Q,3"P;"NKG%M;&9B875R<;^]O,K)R'YZ>=[<W&YJ::RJ
MJ:FFI5U96*NGI+RZNEE659N8E]#.S8N(A\S*R;*PK^3BX=;5U).0CRDD(]/1
MT-K8UZRHI\/!P-S;VL_-S?+R\NSKZNWLZR4A()"-BNCFYO7T].GHY\G(Q^#?
MWMO9V,G&Q#$M+?#O[^'@W[BVM7MW=KNYN/?V]MW<V\;$PJZLK-+0SX)_?B`<
M'-73T;FXMRTI*?GX^//R\:*@GC8P+L+`OV1?7MC7U<[,RG1P;O'P\$A%1;Z\
MN_3T\_3S\O+Q\*JHJ*BFIJFEHEM85T-`/U103S\\.["MJ_O[^_W]_?KZ^?;V
M]??W]O'P[_CX]ZFGIOKY^?7U]*ZKJLG%PLG'Q2HG)\'`P/___R'Y!```````
M+`````#6``\```?_@'^"@GDQ@F9F@X-U@W1YBI`,<8-W/0852X(,/I!_=FD_
M6A1TG:6*.RRF41ZE64*#2@9_=!>F`1VFBEU&<(ITDXIW#)!#N)U638F=2[UP
M2UJ08G*Y?[+4G4:Y/B9T!P!_'BY^X^0;.H)68U!_<"I%?T=*?R(B=G\70%80
M-AV]%2UX("D8<V.&C6%_$`@B4B#,BA5JU#R<Z""$-5*#@K@8]&6.H"P)O@@Z
MTN9-`0NE(`PHH*$E&D4XK@0)T>)`D1H32R2`F>2%`2LZ7#11P2%*IQH8LBB*
M\^//@28KFG"0D>"-U3<@"$#R0..(50N<!ID1<+7LU3XT(."`-"-!KS\;_Y;`
MB$%CXX<I2QH,LM)FD`U!'$#\P?!`D!08`A0DT=/G!14DD.0D$:D!98\#520(
M>M!"4(`!&G(]:'(U3)"K`T0,RF,CD94)?_Q@Z"2'38@%N#?8<#*(P@@G*03Y
M"3+H@(Q!!M!*D5`@"(:WT&BDN.JF@MD20$P<6/`G1`?9BF#<@#2FR:,_):YU
MJB)(`0582:8-@N-%SAU6[HCTV-M7T-\_#5@Q6&%_<.!198+$,=L?'V!T0A5$
M_*'!`%2PH8`BG`F2P0?(A5#+'SW`\<`!IBBER!&3^`%#;+.])\@0&X`1Q#L[
M<!&6(GZD0(<9PQ5'(`,#5`%``0``X``'1081`?\)BLR@ERG;_>%%;"U88:45
M(@@XB`]3#H*"BX,`HX@&((CQ!WN"G*`E!@(((L`.?VP$X!D`"J@".W#P18%Y
M_P4XX!\\P%:#!'V$P0$9)2W0!BYW`,"!$4T0`-H@Q_V1(1@8C&,#.0K]H00'
M"!P@0!,EE%HJ!T"\(H@1E98P`XM_$-"+``[($T<*(0Q@C2!R.)!`"QQPD$0`
MQ`ER0&%:!+`#2H-HH)DGG5@`F2(KO+6=$2-0>2666@*FZB`)A#8(`RN8A4(*
M-)PYR`M`_+%#!.(JH8(1*-!1P49Q9-#`"4!`P$`*-0R0PQT&">(G87"`@`4<
M,]P0@@D:!''"'RSH\0?_$A9S(`B"@W3)F0\@R/,'%J5L(0")BLQQP!HLT,G"
M"B5,28)@[C8``@>%/3'(#4V(D(`##[PU2!_!Q1;"51D0*"%*%,C@1P`2^,'"
M&D85%X%9;T3P@K$+%)$N>(/`T.D?"AR7A<B69B"N($N8*$@7P*#Y1QP1."%`
M!*=$P4?9@)'QP`,(O,677P8+2!@3(FS`R81P"+!`!;&^,TD<&PB27`#C,`$$
M9)RE\$)+1[C1$@147"&($GR@+,@6"]PAM'`I^%#!>7_XL`7M@$I`P'MPH)#!
M&@TX0*</$60P3(_&*IT%%2_P0<*V`GQKJ0KM0O*?4]PEP(`?&[P!@PMO-`#&
M_]O//M!&A()\,,8(P#!!P$0K1+"6ND-+X(#<@H`@R2!<)'C"AX/S3^$&=`,K
M;"`'5!B`!!;X@8VX`1J6HQD4'"`!#(!``@KH!6=P@YN;<7`!W_C##T"@NC^P
MX0VER-$?`N"%$R0@`1.(P#"$L(4,V(`)?\MA!R;`!"W)0`4`J!+RG**T/[2A
M`/![B!NZY80U_`$(Y"!'];#WAR\$`3P:>(D!#.&!$/Z!"I!3Q`WZ$$85\F\0
M^+,`&R2`OSBTH0M.&$<5(E``<O``'7TI`P-(5J<_&3!-&CA"FZX@`S>8(@49
M&,(@YI>A093``24H@R)D4(4/M&D0%E@;CHIF@`O]H?\)E=J8Z#3P@E%J``@8
M@<L(4N"!-`SQ6(IH@Y:\\*PG.64+`K1><;C3';#5``X+J((4Q#081H@PA443
M1/\$D<8D+`!O@]!!#@91`P!PP0'94H05!A`"&/!@#`,DS!_^^(<6/&`++<A"
M&8!PCC^D(0PO?"$'5!!/$$1@18U<81.J.`8FA*D(6R"#(C*)3`UD`P,^`(,M
M-\8LCHUL$`$X@!G]<`)RA*&(LLS?6Q9*.%T:BPI&H(`7P.:"#)"!F']X@Q0@
MRB%(^`$$\$L"&A4Q@!.,(`(Z^P,8U@`G>SG@#USH@>[DP8,,M*$):Z'`Q/HH
MSC_J@#MDN,,?C%"%#W4B!7[_*$6&X+`%+]+``J'\PQHR@4E-#L(/$FC",`QP
M@A`88DP#&,<;XCH./N8!EQ,M%A%C*:`LR-1@I8!B%/TPQ0/`@`)K*`+8B``"
MZ0DB`6[[@P10`(D*%&!;U\-?%;8P!"R,+WTW$$(0+MF_.<"`#06(0@&R(0@'
M5*U*?JR<"D12@AB(000Y:(-'KIK53GQ,`2QX'0D\.3<V0(*@G=A"%3X[APV,
MH9W-:BBS'LJ.1^351XI0P3JVH)<;G&%%G;A>1ZDH'`R`80$\(`,']C,()$#&
M#$?HP!LD159!@.&.@\`O_408`0C\P0FP$40*MD`%"`)U$#,HXA]FL$]()&V<
M,8)!_PX48`,#B"``DET#V@:!U5),"`8'2`$3R'&%%"C``?YU@C\%D0,_),&Q
M@HC"A>)`!NW>8`P<>$-8-)`$JRA@`&>!!'`T`($W4*$E&G"``%P@GS\P@`I=
M\D`(CO:Z/UPO"A1XP!0!P$L6@*`*)[`&&JH0`#CX(0Q5X,(`-N"%`NSA#PL(
MP34>,(4;R`T-.Q$$%=[Q!Q)4;1!_-04!ZCN(1>F4#>!=010:<*,P\`82$LV%
M!JQ0!`]$L0,/H($<X%#".`@@`]30`P:8M$@OA(4(G>D$'S.R!2/D\-5_,P,4
M"M``*OA7$5E8P#('`4U!7*`%>?X##'A9@A14.08>B`,-9D)7"A]HA1I&2$$$
MPL"V_@R""7PP14!R86!%T.D/<C"K>O[P!)2.^]SH3C>NJ]P));";&C!61!TV
- -K&YUGV<*E_Q#(```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>68
<FILENAME>h03611h0361119.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361119.gif
M1TE&.#EAP0`/`.8``/+R\3DV-:6CHNKIZ(F&A)Z;F@T+"]73T>[M[,'`P.+A
MX(!]?"HG)L[+R,C'QY&.BW%N;&]K:F=C8G9S<7QZ>9F6E'EU<[RZN:"=G%E6
M5>;EY=#.S&QH9JVJJ5Y:6;&OK45#0Y20CKNXMKFVM>#>W962D5!-3,3"P511
M4(6"@6EF9?7U],O)R.CGY:FFI:.@GF!=7,;$Q-?5U-/1T-S;V=O9V(Z*B$Y+
M2L"^O=[=W-G8U[6SLHN'AN/BXO#O[MW<VDE&1?;V]7QX=I>4DY*0D+.PKJZL
MJF1@7];4TL;$PIN8E^SKZMC6U<[-S#$N+NWLZ[Z]O8.`?O3T\\W,R^'@WZJI
MJ'1Q;\C&Q:NHIHJ(B+:TLS\\.\+`OK*PL$Q(1_/S\H:%A;JXM\K(QUM85X^-
MC(^,BK>UM*ZLK*FGIKV[NH>$@D1`/QT:&20@((."@OW]_9B3D*NGI/O[^X%[
M=_KZ^?GX^/CX]^7DX_?W]M+0S_CW]^GHY_'P\+"MJ^?EX____R'Y!```````
M+`````#!``\```?_@'^"?U)U@X>#!6F#`!=O+2^#!R5RB()4"R26EU*6>GF;
ME@==AHARFH-1-:&;.1@]&H=W=(<_1"N';V([;Y8"!*$LM'E(=XA->JP`.:RA
M&YL#+%1D0PD).VG6VD0%08,+&']688(2%96B&7NA`A!][_!E#+2'23Z(`C!\
MEG(V!;U+G*P:Y&#&%Q&#I'0HH<+#A!$3JF@#TN?0!!A)KNPHL0!"A@@]$+T)
M(`/1C`%_W'Q(@`)"A1+P^K1!>*C#C#1]>$A`I,%(S)\OV@RHH6.0A@4(_B1P
M(4A)`'J61ORA4>(/@C-_N*CXL^*+J"R#OH0<%`<L(@<<$"V(8<E%`E9K_SY0
M$<`!CEV['HZTF*&FUZ`,#@1Q""P(A)]!54RLZ!"GP8(A@U"*@/>`P<\^7HX`
M<',X`H(AA`4Q0$0#!+D_2\(U0^3'C2`"+/Z\<3)VZ9\@;38<V&VFS=@_:]P(
M'^[FB/``BFL(F<-<R`3F<]BT\2HH#A#BPE6D'42&:=NWK#I<`=$,38A#@`>L
M&#S(L"`T3A:HL4!_#1#Z8];0."3D`RO./A#QQQ`5:)-`&XBD$,D@%0"`2`MW
M^"&AA`1D($=K@SBA@`T6#&);&2X<($($NQV0U!\O0!;*`"HXR$H?&?A5G5F'
MH#5(#P9X\]T@"-SS1P@."A"""!D01P%M@M#!AO\.+<P!1QL61``!>X4=MA<1
M*@J2A8K['7(!#(@@$,$@G$6QQ("A_3':('Y0@(X@`YB`R!Y7.&#GG0[X@*$@
M.YC`1A<>NM!%!8(TX)H@=@AB@Q17=!"3$2J$<`(>S3AP@XZ#$`'#93R,P5T`
MH;A`A#96<+#/$ELH4$`/4W38`4I^'`$5"%$(LH(!A''``SQ.'"9(!9%@$$<<
M4:@1!P8P4,'C%F/\%`(#+G(F`!,#[C"A'_,($@0'*"'`C"!<'+'/("=T(H@/
M9O2RIU4&&!";(`D(H`07=CX0@9TQW'#!($OT<*T:1_C73!,1Q(+(#T-$($4+
M*,SPQQ-3#!)`!J&"9PG_#F$8\4<:3'VPDQ]@'#*&G'^<8(`0QE#YAWMP/@"%
M@0FD`4$I?]1QA`2'2H("F7[(08`/0^PZQPM].)$4'0L<($@!8PY2@@EAF)M!
M`=I4`,(3?ZS[1[L.P^M"&@V$#0,!88>-"B(%>,'%:G_HH(+!ED00R9YT0#"6
M`=OM&(H%:>210H@'5"`B!!,H^P<'`3AH@A-*F("`RBP+-H@"@OCAQ"`^C#&%
M"VM`QQP'.PO"V1]*I!B8`.2LP,4;(1@\4J*'C)`!6W\`-HBAE>?\!QL&*.WU
M(&^`4`($N+"2@&J"-.'C%X!F%0'-B&QP@UT$F'#7`P+C73$K-VB0!P1<9+2;
M_Q$4''#FX4X,L(0)@#G0`P>`'Q"`KY(+PL8S?I#WAQT<4.J"[G\X0.A2<I@$
M6`$T?]``&7K`@`R(X1`)@(`@$#`01-BN4(?2&N\>^#M!'`$)`63`N_Y`@+O8
MQ0I',"$,%N"-(O!`#F38`2M6X`$?[>E;HO'4)MRR(@H(P@M_`(`5"'4"`1S"
M`T",`@(N"+\2S>\0>0-5UO1W"!=D8%A8M,$`W2""%WB```@D805\=`@>P.X/
M`L"!)3*@@N%P((.Z,P`;9/@[':2`=G_X01M*L@G;6((.-RB##;JVB3H\``%%
M>$<!FM6'"-3J-5+4&R)(L("J?&$+<(+,`[0`!;\`@?\"&JA"[7(5FL@=3A`Y
M.$+EJ#@(%Y"H1`?XP!;],(44M`"!01"@N0BR($'400*$%,0-0H,$'V8M9P`P
M@`4>J907Y.$%AB-74?KH'41@(`L^(,`T0_&F8VY"!@:`7BLMQI4K"`(`*?@#
M"[:`Q6$%0`@J6,4;V.``OS"QE/3[@PV".$P$I&$#-&HE``7(LT$,H0,8((,,
M,,`!,I*."CE@P064,`0".&&7?]@!W.1POG7A8`MV8,")[A``"8`A"R48@DJ)
MD`4W>`!N04C#";*`A4T<H2A4@($)R/`"%[A``"7(0@P4<"T_;,`"UU("!;S"
M`3,$40DQB4(98A(!)_C'#Z#B^H#&_L"$`S3``&>\@`0'@8*".``%!;C3.Q^`
M#BF$P0M2F4H$;M`!3*$Q9T5X`0$&:(7##(`(`5C#";X1@'T!H0UL0(Y+N@2$
MTX0B!UA(`!IRMH9GU$`-4/D#'?S0U1+YX7RY^``#X-:,'XC!0%.0`Q7PQ%H\
M)>4-'C`&VP:Q'D0,H`-M<*H@EF"A0Z"`!7LHZH0&\`8;'$$((P1>)0]1`2$<
MX@E;.%L&6B";"E`7$3+P!@LHM0D-@+`9<I#),_Z`!8']@0IJG*UZU\O>06CA
5NNUE!2)E%-_ZVO>^K#A`Q/X0"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>69
<FILENAME>h03611h0361120.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361120.gif
M1TE&.#EAQP`/`.8``+"MJZ6CHH2"@IV;F=73T8%\>6!<6UE55)*/C_+R\8B%
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M//3T\ZNIJ+NYN'MX=]_>W?#O[[*PKS4P+O;V]>_N[5M85O?V]IN8EXZ,BT-`
M/_'P[ZFGIN3CXJNHIJ>DHNGHYW1P;H)_?I.1D#LX."(>'_W]_?O[^_CX]_KZ
M^='/SO3S\F)?7J>EI.WM[*^MK/?W]L;"OTQ(2)"-C<'`P/___R'Y!```````
M+`````#'``\```?_@'^"@X-&6'\H-UN$C']?8CJ-C1A`DH0S,'"6B(U2=&6;
MC$!<@A)_-$N#.UB:C!\8A#`!H76,2J",%P*UC4ES?UM:*HPS>J$HH9(YFS:,
M(C5_!$A*H7%N1(,JBXP]'#2#4AV"<B<^!6`4WX2M?WU1C!8*+$::8@\D^";X
M^PH4XD@`[("Q(NB&$SF-'#P(`>!*`@XU0IP1PZ3.A!`A$%P`TP3`$P``-+QH
MI.$&%4);E@4)0L("F2=!0(+D<8,1D142`)"HPJ@.&IE`958YH6+8H#D#/#@+
M$<T!HPXP_$B5RF&J'SY5$J!84Z"K$QY=NVY@\V=&!`59#@A*P&9J"2>5__X\
MG$%(`%,QN`RL;4#`4I<_$?X<D;K&@E0%1@0=,2`0`0(!%-BXZ(.@28@Q!S@@
M2--`D-H_`M+\R=`10),A:8)N<).@AI\_$(`@>$+(`!1&72`,>I"LT09!!78,
M$D![:5-&<WKT%A1GT`^F@HHD823A\Y\8@T(8:"Y(S1\)+YX\X:#@B0@*@O3^
M84-J$`]3@KH04`"'0Z,8%?[DR0*'RE\(00@2PQV$/%&$()W]\9D`)C!2PAJ;
MN+8%60A`0,"%!'``GR`>H#>(&701PATA&6B@B7I_&(`-$&1L8\,(,$[!%`%.
M_2&#&(,0`(8`//8(`1(3#")':@K$`,`:1@!@1O]^?ZBPQPA&.&&#"U)@)T@(
M5OZQA`+?%5=$*K7]$0(94O$PE7#QW7'!``L0TH,=*_S10P6):?F'`RP(LH4*
M']SVAX&"O"$5F7Y0T.`@6TR1`"-B<.>:#S[\42&&&6[8@P7*#>(%!R/^<0()
M08%@`ETH!F"?'8$)0H`$K,H8C0L@_90CBMEI\,L?%;`*A0,E2(`%&*SB$$,)
M5F0@@1-.L`I$EEC^D00(`I#1I2`(,/''#D*DA\<#*0@H21=1C-!#'$;L$\`3
M:,YAP0=16265!P=@($<&#T3P0@L)+GCH'U0\,$50``R1[1^NL3""I,6EY^<?
M8TCQ1QR+EA)#MX/H<)+_(%9@D]X@)[Q!1`,'-B+"C#4R0@"M5PHP2``@'2"`
M1R08X48:39CQP95(3,$DLUGZ@9T$&C0!P1$E_*$!CBG"X`%&*VB`40A]P/)'
M%UZ,04TC*!C#8!@*[(,/!"/0<<7#:6A@@`D5Y"L(@X,L<$#)@_PEB&MUC"$'
M`AH`$$1'53`)PBS.&G#U'S=LP.0?"K#!#Q($I3A(&%5D,43"A(Q\7"-T<$#I
MA1Z,1(@)NOT!AAU_M+`!,BM7<0`$1<S!\R`^3VN'!Q%,D*4!>3B&@`55Z#Y;
M?*-9,``)PV.0QDZ>>UM7)`6&/$172'1%1IN"R4"`&^[Z@<0@KOWA@0"_MT#'
M_Q\YB/-!G7_8T0PA7$PA-=NEH$BK`SQ,+HGE-$K"A`,8:DY`!18@A!GZD`<<
M&4`"</@!&AH0!(08+0UJ<0`,7B>(V%6@03'(01<.L"%:048#C8O;'^CPF<`4
MH2^-L(.[*`"=00`*#DWPC"`F0(T86"M_N.'>:\[`A]_!X3<6:(`91J0'%U1,
M$O#[COP(X0`'#*$/WR*9)7K`0<?%B1`O8-("!G#`+#Q!!1-XP`#^T`0,5.=A
M<*#@'WRFA`%\X`N\04(6PB2(%K`A#BAPP3OBEH`%\"9]?SBA)+(D"!]DRH7H
M,,(79"@''ASN<H20&\&:H(,H:*8X01!`"SKU!Q.`J?^3&QJ.!?8A@-]L;!!.
ML(,(0O<P*"2N"U(4Q![_``<%6$`<>MF"`/+4G4$P0`9@>(`=0J2G`E#AC,H3
M4\]$\``*^"`+%F!`%\:()KW``00*B%@*?H"^+D@A`DS!08`$^8<K"D*%[C(`
M"%1E``X(8`)4*,&@IC(P56'/7=N;6PE*0($6_.X/2M@`Q0:1``@-`@X:&!\A
M+&"]"]W!.BA"`1+2@`$>:"(.'."!$>*`OY*M4Q`+R`)WU..%`]!#$$HH@0+&
M0(,#2F$#5[C5$KJ%3"H<8!]N6]D;A%`%.03`9U-*0H#^L($9!.`.G3H!X*:F
M*0-$@IR1&@0A/:.4/ZAA#"W_'(1U3`8WX,WM-=1"@`3Z((0`K&&@?^""<+YP
M@@R80`%3\,X@?*`QN7P211YH`$+XP*19DH$I)W`!$SI``#MTH`PO,,,?)K`"
M'8!!2$AH@2!FH#D_T,@4/4!"&QB1@<^@@`>#0,%C!9$!(W1`96=8P_B>\(8Y
M_H$#$%B`">3Y+A-@0`:2S><98J".(@`@!"N(0*;FL`%6&?=8H10$$)X6`@Y@
M9`<6")*J2B8!'$`AGXA[#1Q*P(,&O,"!;'##S<P0@P9T80H.B(%&TK?9320@
M`P2@@RG_D(4Q"$((!B5$`\2!JS7P@`<1.`,\4>J!-[`2H,80A"9FL`8'1$P.
M#&`$?P[F>TA)'`$.1.A#"(N0I1P0H`45L(JQ"*"<*=1!`4M=K`9X<``%.!`%
MSF5N"`YP@5X<]\9Q^8X3"$&#!HA&0&!]0`4X*84X24`*%1Z$$@BTB3EH80!#
K&&,YV<`.%5#.$<O!6):WS.4N>QDE7]X$%;+:B`2$,,Q;OA4-HM"*0```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>70
<FILENAME>h03611h0361121.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361121.gif
M1TE&.#EAU@`0`.8``/7U])62D8."@HN)B$Q*2J6CH>[M[<'`P.7DX_+R\=73
MT9*/CMW<W./AX,[+R&5B88B%A'EU<["MJU5247%N;+:SLIV:F75R<5E55'UZ
M>;BVM45#1(!]?-#.S>KIZ+VYMFUJ:6!=7!42$YB5D]S;VJNHIZ&>G:VJJ<"^
MO<;$PZFFI>?EXUY:6;Z]O%%-3-C6U=_>W6AE9$`]/#TZ.<K(Q^'@WSHV-8N'
MABXJ*9N8EY",BM/1SVMH9\C'Q_GX^,K)R#$N+4A%1.SKZH.`?B@D)*NGI#8S
M,L3"PN3CXL/`OL_-S-?5U'1P;KJXMWMX=MK8U_#O[I.0C[Z\N_3T\ZFEH<;$
MPMK9V"0A(=W;VJ.@GZ^MK&-@7]74T\C&Q=/1T,W+REI85[R[NNWLZ^GHYTQ(
M1ZJIJ%-04*BFID5!/Q\<'#0P+RPH)R0@'_O[^_W]_?KZ^:6?FOCX]^CGYO'P
M\#PX-_?W]DI(2/3S\K*PKT(_/ZJGIBHG)Z>EHY^<FL?%Q?___R'Y!```````
M+`````#6`!````?_@'^"@X2%AG\I;G]B5H0-#8-N!3X=-()(&HJ%##M_<B9O
MAZ*";:,>/H=U<8.K?VUBHEUUHX18<G\,I;2$;:&'7"N[NKN$4\3'ADHG@@T*
MA`E1FG\X7W\'>7^:*BR#)&QW(Q2"6132@V`#?PI[H6\_@PQG/?/T\Q84PX58
M&'.&8B`U!`UITF,`!5^\KF@8%+!0!RY_((3XHP1$BD)/.'S8R/'#B`NB'D00
M=>+$ART=^DA8R8<"%$,CPDAJ2,C-D0,X<QY`,0#)J`HP!,E8=@*#@*,")N!X
M,0A'L`,$_O08J8+'H`(LIL;0P87'`4-+;`A2L$$0!1Q8!!V0X<#!""IM_^,Z
M2$!H1(T5>&TDP7OCG2`^:@1AZ+1`P*$S1N`H=D+'0R$F(/X\6"`H19HNA,@>
MJBH(`%Z\/X#`^`QC0AA!`HJTV1,'PZ`>,@X!"?`'135#P0[9$>)I22$G:071
MP/.""`H(;7)4Z5/(J;6H!?]P%O2@00T($58((5-JCJ8W=(R,W6#`B`Y4:J/^
MF6!A4+XIO.G@44"_/OU&@N94$.1"4&%#=:01@F,`I-%!(6*(4(H+7_T%PS`*
MX*#8A(J!P,T?`!`TSP0\U#./7ZE]H<<?8+RF'B%'R*!(&V@<XT8_)Q;0GB`Y
M@/3'#Z4`H$$'!;A`%P5YM-*!`T1\0$$`T*4SW?\+=`@Q``9VD&'%`P=$L04*
M@NBP@!F">"$""S[=F-X?<8@PP`)H7E&&>R"0Y4PA01WRA7HCY`'!`ZW\L44*
M"600AQE9&!*!#6@"P0&::`I`Q!/C"<*!%G\,40(#?A'BP0:\"?(2(:DQ@0H&
M*TEP@QV&$('?'P$LPXH.$;3J*@%T&'#B'QPL`P,.COVA@1DKF`!%%P*TL04-
M`,3`W!\=[&"<`B<D*9U5$>W11@(C")"`!;0M$(4@'?C1@QDOF.!$;(/8"%6D
M&JPP&%X&U.7$!C]HX.T\&>!P$;(:C$!``B"<AJ$%4?0QRQ\2-"%(%'LX<4@#
M[8IQH2B:_8$!EA"@H(3_%(5,(4,$171<A`TC<%K$#8I,)$@/LZ*:PQ]O`/"'
M#S:<($T^K@PRZP]7^)##&I&`4,`6?U1`UP87C<%H4T_U%QUG;41`AA<MQ"#`
M`$V`E$$2A'S[00TO&/$9`T`8`Q4#.@@VR!NY_H%7'F]ZDL40!PJ2```JQ!!%
M`!)PE`%M@VQ:0PA@L`"1*#E@<$*H5Q/R11`52""#`!(\,#4$A-P101IM_V'&
MO:@5\0)SH!X^*B$IE/-'%V#<0H.A8?Y10P8>#Q'H'[/6(4(+#P3Q#`,C5-#$
M!R6L`<$'5-BPZ31/N;:T52HHT=\?,?Q!5P0>/'PREW\T808!W!,`QBH'!*&#
M_\<V>!P!&BY[HD,:)`QB1PF;E=U&";?\X0('A?AP1A`'?@'$`W@(#B%<D`/X
MN<(&:S*18+ZB@Z\`@`',8`(*-F`"G>2A!R*CW0LF(@X&<&!3';C!($`0/4%(
M00T*&PL.!C&"!J5,#1C@7B$&D*LWJ"$-,X@3(9Q3@`=(14G06L'S;)`!(G2`
M#WH`FJ5R,X%3$>)<@L!"BV"B!@/LH5V",$/F!J&"LOT!!DSX0P."D+X_""$`
M,KC"48PB`!RD001#($0=@."&`+@L`I1[H@T>L`4;L(`)$Q`)"W2W@SX88P.9
M,P,&!Y&:/S@A!Q/AAA2($+(_(&`0#<A#V@P1(1:ZL/\0+C#"]@:A@`K081`+
M`,,&\,"",@H"!TX8@N1^^"Q!"/$/!E`8&UPA`QO](0N(0A.A$,6!*SYG$!E@
M@@Y"<#1-W2(-A-!B_`CV!R8`@`"J$D02#-"#LFA.$#Q0`7H&P0$\_`$)!&C`
M#(Q!"!,8)IP)4!@6GF8(1$9SD:AA0@`0.)$L7"`*6"S$!BQ1`XQQ\@IQ<<(G
M!P@$)F!#$%8(@0__<`8P`&`#/:#`%G3!`0R`X`AN8$$+I&*8Z=S2!"B8`\_^
M,(.5"0(&#?C,"B8@4[R@XEQNT`$$C.$'\Q3B"R7,XA8%H0+(.(8!>7@`S:1B
M!)S(`"=F4`&<N".($8B@$X7_R$#[POD'"VAA`"D8&"$H:$%\_D$`5(``!.HP
MD03((#>%Z$,!R&F"@](C`@L=A`TFP(==HC*.6@`!!#'*@!F$X)(+,&@+(H`*
M$AQ!.A,5H@]<0`,+<*EP=FC?(5QS"*B\8`1G0`@#G&".".A0<T/]@PG2P!2=
M$<`%?C"'5+R)/:X.8@HQT.P+S/``%J1@&'.P43C?T`$SE(&=`DVD61LIB!`D
M@`\+F%@A_#`$:4P!"/LAQ`I&Q(Q-S<H-(N!#`C8PN#^`(`,EJ*L@,/K%;`K"
M#SQPI70X*\0L(&&F7Q@!8$5PAD-@SQ`:D`$5[&,?"B10"?AC61-&`(34,J"N
M70A!_SI20(09!``2)P/"2F2P$C+PX6P+N$@<1L""@*C@"D#0@25.T%_H\8`#
MP0`!&RC0![H,@@YOJH(?+IC!EP7!"!`LP176H-D4B(`-:G`!&&(`@A`8CQ93
M*$`&5BH(+HA@%2GXKQ<,.(@)E)<0/WBL(9X`P3^,@0(8-@`'+BF(+QR/$"/Y
M10`(3&"F&("[@S"!"V0["%:J`+D^*(%47\/900P@N\AJP!P6,`0VDR(,(4"%
M!`8QA`%(8PP0B)M>,>P&$-CAS4-8B"!,$%``T.1TAZ#`.$=!`1$.X@9>_$,2
M^(:,6MOZUK1P`Y]QS>M>$V/7O/"UKYO@ZD&\(%/"3K:REPS-[&8[N]DK0($O
$`@$`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>71
<FILENAME>h03611h0361122.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361122.gif
M1TE&.#EAU@`0`.8``*6BH2PH)[6RL?;V]1D5%8."@NKIZ'EU=//R\:&>G:BF
MI,'`P(B%@YV;FI*/C^7DXY62D45#1,C'QWUZ><[+R.[M[;BUM$Q*2E)-3'5R
M<5E656AE9(!]?,"^O=#/SG%M;)F6E=[=W-C6U6UJ:;&NK920CN+@WU114+NX
MMJVJJ<K(QN'@WV9B83XZ.K^]O(2`?L[-S+.PKUU:6>?EXZNGI=K9V)R8EHR(
MADE%0[RZN6%=7-K8U\?%Q-;5U,;$PC8S,HJ(B-S:V>CFY3DU-?#O[NOJZN#>
MWI&-BM+0SZZLJG1P;["MJ\7#P3$M+,W+RHV*B&MH9OGX^.CHYM/1T*JHJ,O)
MR-[<V[Z\N^WLZTM(1T5!/_7T\\C&Q$$]/`D&!Z^MK/'P\&-@7\&_OB`='34P
M+EQ85H^-C+FXM_3S\M;4T\K'Q5-/3HZ,BQ`-#=73T?W]_?O[^YB3D/KZ^?CX
M]^3CXA,0$/?W]LC%Q)&+B)>4DVEG9R4B(8!_?_KY^7UY=____R'Y!```````
M+`````#6`!````?_@'^"@X2%AG].=G]V,(1$(H0D109?@F`I<(9S9YD@18>@
M?V\UH28AAUM!@SN"*TZ@)&FA@Q4SLW\(;&B$.Q`&H%<=H`B"17+$@[^&=F]_
M-16WA7+1?Q40`X(6A2#*?VM4?S-CQ,UN/YF">QYN9((>6NB$(#)$?P1&@E73
M?T8'-/\`_QUI40]5"WQ_H@P:<$&,H#(Q)!Q8<PC.CP:#M!4*TB!+AC\@)$A8
M`*39(`8Z1$A(`F&"'CT^0&5Y04B*21L`4&"X@F&!SQ@_D!$J0?.+BT,*EBA=
MJO0$PD,=/`CB\.&/@2$%LA900B#%H!,+PA$0I&&+FPB#3`20H&#(%P4*_PH8
MBD*&CJ"Q?U(0B"'(30!!5\#-.G!%I(0("D1BP"B(R=\_65CE@7+HQ@\'F-<T
M^20(BQ\^`=P(JD.!`HT`\4000&#%U@(%@K#]*>+3)Y4VM1><&?.B&1`)<&3`
MP?O'[Z$6L`W`IC9:D`B^A&R<&62G0`@-0"!4<$$CP19"8,62+8Y64((4)CIT
MF3&#@P118`8IJ?/@+AP6&H0:_Q.&L579?Z#!UP7O12.%(&-,,YDA`P10@@!_
M;#'&%(=$(-H?=?15WA\FG%"'"R7$$8<2+,110@`,_"$'%H-`X4`HOS5`PA][
M#+(?(0`()T@6T-Q202,9"I*&#H/XD(4@,,PA"/\)3H00@"I)[$'*'SM0H(4-
M-^2!EP;D#?*#"E0<$,`)/H3100QK`-#,%2`01P"!^?3UUQQD9#!"!A-TD>(@
M'^0`9R%/&'*@!%H(HL`8)_Q@PB`7[##`!R;\X%"%3+PP1Y!G"2+%$AC^@<YK
MH2R``2$Y%/(;!],T45L"CQ'2Q)1_+*!'/&\`D)M/-H"`0)#FI6C'#UP(0@<.
M/(APA@$?%.$`1@T02:4'$23@AAI;=OF'&&T$@<!9<ECP`A8PG%",5P3,D(0#
M=2@DR$?%_:4$$W\P()4A9]AP@0`I&-:!#EK,BP0--V3AQ`<(R;&`"U68A`(K
M?UC0Q@&&S&!!!VTDL,#_"G6(I,"&S561Q!(,'+#$$V7L(X@!>[S`5`L`$/*;
M`M"T(V<A$T#WRA\C;""4IP`B(!NO?TC1AA0\>+&+(#1LD$$18MA20(I1J`!>
M6.*,E^D;$.`PA0`,L`"``P!X<(9<A!``0R-CM,9>%SVT2X=@?%PX``K4#=!"
M@7_``$$#.\?*```")&'8!R,<XH(,;."00$&$2.`%!/5@RO$?0\`A`@^&,2&`
M!";/H,-:A'#IL@0&,!"%JE0LD$`3I.XYQ1B_/'!!%C&@(\4)2WU@0W-E*X`N
M(7!L<8`3`J`@``8R6(!""VI\1?5C7&:*A`L8V+*!B@,$#@$/A>#EQ`@7A!\^
M_R1^W2!B''O@(:(?&-3SA@M0D#&O-_X1LD`>@D@`"1P8<$^("7:R!1Q&,`8_
M?`$&ZFK!&)2`%LD58@8M.)^(E-"$>#A!!PBXP`V8T@53O6<$`FC'[HAP!"L(
M@@<O$H02JB(((LB@=H*80:N.L!R@_>$''R@`<01QAR0,8@0$&$++"A&>*73P
M#]';4/60.`$ME&`*1]`!X]PA"#,DX!`WPD(=&(:C"+QA"(LB"][LAS\5E>$/
M)#B2(-[@!!8<8`PB&@(#XK`&+?R`!,VH@A\BX`'\U2$!"6#`Y&2HPF`MX`*#
MF(+4_O"G\8PN7D!HAPRBT(`A4.@/?1C$`G`P"T(*@O^&O!M$!)K``.*80`6;
M$803`G``#I2!,U\9@1\80!$D6NL/2Z1,&23PA@,,81`NP(PP-:`$89IA#S&Y
MT00:<$@&".4-2JK1(#0P1DWFH0HMFX`(<*"1/PQ`".%XS!*!D,((;>`-%N)=
MI@CAR3TLZI"'N$`QA?D#4R7@<U]H1P+*0+=#Z$`J`Z!)Q`B@E2S4L!`1Z$("
MVC"((CQ!FB+0@A4*`(04_.`3;TC`"5@@`#MP8(B(7"<N9["#%`VA/GZ003*,
MP![V,$``+64/,8Q3A!>`H(4;0"0A?&"&T%53$`LH`P=V@0!6'D(<2AE"`Y:@
M@W(R`1KI[-0M8_B7%8P!J#K_+<2]8CJJT27A#&^0F0;"8H@;=#,&4.C1(&;P
M2T$TX"A2'40`.-`#+\`2!H5RP@9B0M$HR*`%5?@#`%+0#`^$`1TM<T,+!E&]
M$9PA!U<5@PRZ4*I#F.&G[>*"#18I"`0X``$F.T%]IHE9*@1@!;-1P@$PP`9;
ML%.<MB"G(:(J.2N8K`()B,($.*``-@#AIH9HI"T?*0CY@2"-$#"A(.P`@`.X
MX;END$`7V#6(+33"$H.P81T@5`8?"H(*+7#"#9!!44_UE!<C0"TA;H0!"VAC
M`P"X0K*L0``.?,=4_BL$#\;`E/YJ@`7-6,",!/$"#8SA9H6`@P>*D``<2$4*
M,O#"W!K`&<,]^`0*`I`5&V;K`QO$`0,BNH$.-#"=07C@`T`0Q!PX,(;K(;1`
M3LA#/8EKCPA\QP@XV(/_A-:"C1;``32PP0X/400H-&&'JLF$`9I@$C`$RF7U
M6VL23$*((B!X!`A^`F=_=(@$0,(0<N!L*(1`@T)X`+B'.,(1U#L(*73#*A`C
M!!.>,@@0W!<45N#``:H0CQ:&P1`'4*L"XCR(!BCW#R*@LB'Z)@JO1(,*<!7$
M`3C;`PXPY]*8SK2F-\WI3GOZTYU6`(0(00=5@/K4J$ZUJE?-:N;0X9)_"`0`
!.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>72
<FILENAME>h03611h0361164.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361164.gif
M1TE&.#EALP`0`/?_`,3%Q=W=W71U=K2TM%!14M[>WM+2TFUN;G!R<K*RLK:V
MM[JZN\+#PZJJJQ,4%3L\/7U^?EU=7FEJ:H>(B(V.C\C(R*ZNKM;6UJ"AH;Z_
MOUA96JRLK8F*BX&"@IR<G5986;BYN9&2DK"PL3(T-9>8F):6ET]04,[.SH.$
MA$-$12(C)(N,C$!"0J*BHH^0D+FZNG-T=;6VMDA*2Z2EI2PM+F%B8IB8F7EZ
M>Z&BHIZ?GT1%1H6&AY25E7M\?%Y?8&)C9(B)BEM<7%Y@8$I,3%565V]P<)R=
MG3]`0966EV=H:4E*3$=(23<Y.5976$Q.3CX_0"<J*\'"PH*#A,?(R/O[^]34
MU/'Q\?/S\_CX^/W]_>WM[8*#@^+BXO#P\/S\_%I;7-G9V?GY^?KZ^O3T].KJ
MZN3DY,;'Q[R]O?7U]??W]\7&QLK*RN[N[L#!P?;V]M'1T>#@X*FIJ<G*RO+R
M\L/$Q,K*R]C8V+V^ON?GY\W-S<O+S-#0T=O;V[_`P-K:VI*3DW=X>.CHZ+N\
MO,#`P,S,S:NLK("!@JFJJIJ;F^'AX>;FYM76UM75U>SL[.OKZWAY>82%AJ^O
ML'I[?&9G:+>XN+&RLGI[>V1E9LK+RX:'B-#0T*.DI.GIZ:6FIJBIJ>3EY:VN
MKN/CXVAI:JBHJ;6UM49'2'9W>(J+C%-55<'!PI"1D>7EY>_O[X2%A>'BXH:'
MA\'!P8Z/CVAI:9.4E*>GJ)J;G-/3U):7E\S-S>CHZ:FIJJNKJ\W.SK&QLK.S
MLZVMKJ^PL'Y_@-G9VJ>HJ)F:FL_0T$Y/4'AY>MG:VFIK;.;GY\S,S.GJZJ:G
MIXB)B<O+RZBHJ,;&QMC9V<C)R7^`@7)S<]'1TK.TM-O<W+>WM\W-SC0V-\_/
MT./DY%%34X"!@>_O\)V>GHZ/D-C8V>?HZ"XP,=35U<O,S**CHY&1DNWN[NSM
M[>3DY2TO,.KJZ^KKZ^;FY^7FYN[N[^[O[^#AX8R-C8R-CN?GZ.WM[NCIZ6-D
M96IK:VYO;YN<G,;&Q____R'Y!`$``/\`+`````"S`!````C_`/\)'$A0X)5<
M!1,J7#@0RR>&$"-&[*+%BA:)&!-:(9.QH\>/B0H1C$-DH):+!:_T^\!EH;9;
M!/$@@#2EBD!ASQ:FBX1E(;H9"O$4RC(01;)_'%0IY$<+0)0H#!*T>8KJQ;\,
M=A8Z>R(F8;Q=(.Z8:D,I0Q0`/'(0)3BGV3\_IA*.*6;VZ5,Z,0Z)"><H8J`#
M8>KTB2*'@X8]4:;=ZB%,H#00B&APP)3%GYM_:!*L#2/$PD`RACRMB2#P%P$1
M=6:,4F.WSS0T!`U0&:C"X"LO_\:`\C10P3X\_V#UZCE(P16!7VP.'-)`X)8I
M_[K`@).0BP`C`ZT8BB3PTHEK)!A(_T'I3&U!`.T:<<*0T(N=.W:?FND4(9$R
M`1P76@D6A:"5/TK]D\9E"=60TS^E_&(&,01T]4\6>W"1R$-H'.+!/YA$\T\<
M/_2%``KZX?9$-O'9!0`Y_TP3Q$!S0"#$'H51($<4?9AA!7+*"23+`LY!]P\8
MQOQCQ2$QT*%'#P_(08==&5ASF02,P``&&(:@-,$9!;'B0S;_L%%(C@P=AXP4
M+:'CS'$*^7&$0&Y,PX`(U5!0QQ3$2')!@2<P\P\!9?RS1@>S#21&):+H\<(W
MIA"2P2(;_C`''S<@,L62/IB1G2QA#'%C05T(%(@D/`HTA0Z3P,@!!7ID($D=
M`R5'T`1W&/\``TT"C3$+$@0%<`-W"TG0AB]L^"'*``Q,<8D@!7$3I$#+D#:0
M%WZ<81<=TSQP@!FOM/3/$7XHY(8S?Q3$0!&!_D,%'\!EH<89(+"``R(&#+&*
MGX#^TT8D-_Q#2BR8'8)!(L%PQ&$8&.3P#P2[*)3"!4/(L<E4463P2&W_O$'#
M0.=0DDT/`I$2ZAAAM,J')FTPD($#$TP%@X__\+*-H!0H80!49A#1"D%%A,#)
M/U54*="5_C71::TEY"L1&&0*U`$2:234A3=T_!-*)`"(I8$MOFPPQ0`4X$(0
M*`]H(A"?],[6!19+_%.)!!ED,DHG`)@@4!S)^'+(%5C(XEE"-FG_.E`6X4P0
M,A6@#"&0&,=!<UB,>E#B29\X#O2'"B#T.%``#^3GB0JO$$0!3`-)\$8L7/`Q
M;+''#A2&"VM$5PL#_R32Q`\$J8$!:W5L`<L_8VI+AS=#$\2&#F!.DT0`!<QQ
MAX8)^:""#/QXX4V??P:*MKXA!**!'5\(DHE`&P2!P2AU;""!I(0\TDI?YF[R
MQ*;_J*"G0%B@LR)!NW"L;ZC%H>GJ/ZYP0@^P](_G#`0.2\#&/WXA`,.\X2F$
M0,"%0E<!.%P)`8]8`!UP4`"!9"$2E!`(&*`@MA^Q0`.P^8<-#H"227@&:=JJ
M@@[8D)#AY8@3+LA&`3H`AT%(@%$$Z40#_PA@!P)DP`GSJA[]TD8*59!!`O!@
MPBD"()`&?($Z_\C#!,R1D'I\8!U*@)\."%*_^PU$<540P0%",*,:;>I_$F!&
M)@AH0('`009U2,`BJ/"*#SPP"A&<H$`DD(I_^*`!'*#$'?YA@1',!AP&J)4J
M)L"0%:*D&J3X4=)X-D.Y2`('`F$#"K[0BQ?\@0&/H($)^B,0+4Q'%GGH"=F4
M^(_KU:(79!``&XXPB8%P*#\D.,8*@)%"@3`B"R<P!('^,4:"6(Q^MNC#`'8Q
MC5Y<`@AUB((>($`-X'SA3I;H(-`*R+(J.&`@5^``(#P'.H$4P09F,,$&6A&&
M#E#`"+@IR`7D9O^%:2C$D@+!I":U-8L;C*$]=_#&/[10`AX-8A8"J$>?#N$`
M(O1I&-A0A`GR()`$F8$$P;`>"V8!@2X4X`M/P\X]&L41$1R#BB08`;((L@(U
MY).9!2G`!_A@+G6D\`Y,0,4?QI&0"-!!%Z$0B`:L0DZ!I"$<ZQ0(&EJQ#7M(
M00I`\$8+"'(`4J2`%MSH0!@@$(-R#40Z]!`(+[Y7$"-\P!=JV(,W$C!0@;``
M$PMQA`;>P8@T>`$3%A#$%B`!@3<LM%.VZ),K-CHVZB$@4"!P@"TTT"X2""(9
MEB`$*.,PB0(8@01S&(@O8@&<@02A$01IIJ!\88F"5((?9T"$&8P@$H+_N`H+
M#&"!`[IAN7]H#TW_2&=4!?(Y@A!2(%78PBK>4(H8K,6I&."I0*S0B@.(BR<"
M`0!U8/@/`U2#%0RQ0PW^H89RZ.(?RX"`%NAP!*`49+$<_4<V#EH0>?SB%NZ@
M0C$6`(1_;.(!;FF`#Z:0GX+\@8K_*(099G,%!D1!M0,I@Q2RTJ5;Q&(,C0A!
M&_X1@B'\P18AJ\$,G$*'&>0`8OKPYQA64`F"")=^_YB`#8Q;R"RR0`BA\`(!
M1B".PT&""1U(P0%VH$X6#`(BBU`##V"@"$-2>"%BB`)[CI,-%3B+$24D2`$D
M<">&9*$/=Q(#+-CSCS#<HAK_P(4IKLKF-EMBB`%9"``Q!Z*(;0R7('[801K.
M,`,%_H,30.#2/]@A@3\<YW\),>`+$L86%VQ!('/X`134,)!NH")J__A$$@(Q
MD$W(PX-ZB$'3!H('#@PC(O"@`0G^T0$P?"2X"'DUISP(OU=;X::R'M!"YH!K
?@@0O(8@CB*X'@H9YF%76R$ZVLI?-[&8[^]D9"0@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>73
<FILENAME>h03611h0361138.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361138.gif
M1TE&.#EA-0`0`.8``(6"@<C'QO+Q\9V:F>;EY+:SLK"MK*&=F^[N[;FVM9J8
MET9"0FAE9%524FMH9^/BX,'`P%Y;6JFFI75Q;M[=W;RXM5%.3$Q*2:6BH>+@
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MTTE'2,/!P(Z,BZJIJ,7#P:>EI:*@GU944Z:DHM#.S,O*R?___R'Y!```````
M+``````U`!````?_@'^"@W]4=82"2XB+/RR+B")DCY.#$GM_8!":$`P%BV"#
M-!I_*4Z3`!&4A$X&)((2#H)8@EDK!(,&&R(F#S\04%,0%T^$3TC'$D7'2!L8
M?Q2.@U)BMS$!``T)#*99#4R+$JF"-$I_#@H]@GA$1^WN[3H<B@$C@SQI@@\/
M`!WM2P`ZOB$B4`2,B`H5&)2I8`$`'$$F!CS*D(#0$`5_,MQX02C"BAQ@REA8
M5F5&%$$:])32!`R"!2N#7,0PH"F/'@A6A+@A!,?($@UG!/[QL*/%A1Y$.N@8
M<..$"0%_`JPX8*%`@5_!`,0@%,*%H"=-)CW888"..$%VSCA@<`5'D2,#_]84
M8#`HQ)\;.`($@$$D`(,4D\`.DL&'T(H/1F(-2NE@BQH%-J2,P0(BK*`"3G;\
M87-$`X!V4/^H@9&D=)(50$Q'$%)CT(4++13_F2$#UI\74!```/$'!8U!<;[L
MT:)$B84&Q4W<>21XT@4A0C@,ZO-'`H<2*+!@</"-B$1!?DP8R/"-G*H_S1<Y
M`3)D!A`IA*S767(`P,D_%UH+HK#@0[H_-*!PGA:6+>+!&"K<E6`E''`1A@_/
M3(#&&:#\$<4$5`30PA@\V#``'T]<,4!H@GB!Q@YM3++!`H)@8`8A0=BA""$#
M("`($UV0F$(")SC00'1S+(*`#K<\HD,5@P3AS!1Y3#8YR1M($B+'%DY6Z206
&#PP2"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>74
<FILENAME>h03611h0361139.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361139.gif
M1TE&.#EA-0`0`.8``*JFI+VYMEU:65).3E=44X%]>^;EY7-P;I&.C(J&A*&=
MFJNIJ*RKJN3CXKRZN6)?7DU*2MC6U?7T].#?WCPY.>+@WWIV=6YL:F5C8J2B
MH963D9Z;F6EF97=S<921C\?&Q8R(A;.QL"TI*(R*B7!N;>KIZ+JXN+FWM8-_
M?9F6E;>UM/+Q\.WL[#$N+=[<V]K8U]O:V28B(;*PKDE'1JVII^CGYB(>'N/B
MXLK*R;&MK!X:&C<S,CHV-2@C(Q82$A$-#L'`P.?EXVMH9_W]_<C'QV!<6_O[
M^_KZ^?;V]9B3D+"MJZ.AH//R\>[M[)>4D\S+RO7U],+`P/GX^.GHYL/"PL7#
MPJ"=G-'0S[&NK:*?G+"OKG1N:\W,S/'P[]74U*"?GJ">G'!K:+Z\N]73T=/1
MT._N[9J8F`L)"K>TL;*OKNSLZUM85_#O[_3S\EE44\"\N=#-S//S\LK(Q[:S
ML'UX==S;VO?V]IB5E#\\/"LH)YR7E'Y\>T9"0J>CH?CX]____R'Y!```````
M+``````U`!````?_@'^"@X)S0X2"-1E,@BR#2U>(A#5/@RL71Y*:A`@=DF,\
M98(H#H(M)X0&A%1\@RH[%4$J39M(626#4#]01RM_<G\1`H,F`W\W%$#*R@,X
M@T1%@D,8(`!Z,2I_)5E(@Q('M`941$0Y1!PM?C\-04)_1E)#<31N$813A!TF
M15PR(2-AD,S`,JC)`0F"+J089&?0B0%&_OCXT^X=`3)U4!00L`R(#CB#1-`H
M`D2#@B-L;"1`E.+"GQ<M)@R*H$90D2^")E;\DV:/DC<?1DRP@$L'(1%*2'I`
M4N(`@@</-#C[,Z'%BPX0"+GP<`5)C!HY*;H3U*#/'PU+_HR0\:?'D0J"_Y"2
M=.(`A`,",!8\T#((0H<9T0@9$4`"P2"=8ZD6`,&C@X<DD'6@6`/ECUP@`A2@
M"6`C`(`MA(K,$)%X4(DS!S))%#M(0X@_>8)\0/'G2-:028$X.63YSQ#>@H2(
MH%!:$(0/`CA$1/RG2Q@\-U;_$0`E"`E"/>BT$.(D2((D.I+0,3M("`4"!`A)
M20#F#Y06:2VP/I:U2H\``;($V/``@>$_&)@Q@1>5Q"7(!"X,@IX5>%0FR!T;
M#`)`*0=B(`@,634A1A!!Q$)#`4'@XUM!(9`3`SD,L.4>'E;\L4,4@F11A28W
M"!!#>G_T<=L@&PQ@PP*;'`6<(%'L(`@6UP7)HRD]@K0AR0LH1*3D'Q#X0L@!
;*O[AP!U3=NEED!I0.(@+C'QIII=,)"A((``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>75
<FILENAME>h03611h0361124.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361124.gif
M1TE&.#EANP`0`.8``,C'QN[M[#DV-82"@O/R\>7DXY".C1H6%JFFI/;V]8%]
M?+RYMDQ*25114.KIZ-#.S6UJ:=73T9B5E%)-2WEU<WY[>I:3DG%M;&5B8=/1
MT'5R<:VJJ+6RL;FVM)R9F.?EXZ"=G-?5U,K(QN+AX<_-S&!=6\"^O8B&A;*P
MK]C6U8Z*B-K9V-[=W*.@GFEE9&MH9["NK=S:VEA55(J(B%Y:6LG(R.3BXK"M
MJ[.QL$5"0K:TLL3"P=+/SL;%Q.'@W^SKZJ6BH;RZN2TI*$I&1/GX^'-P;JJG
MI<+`OMW<VZZMK/'P[[^]O+Z\NM;4T]_>W24B(<W+RBDE)$`]/.WLZ\[,R_#O
M[[>VM3$M+*>EI`<%!NCGYI*/C^GHYZ.AH"`=',G%P\7$P\S*R(R(A\/!P*:D
MHIJ7EMG8UWQY>+JYN5Q85_/S\E-/3A`-#A,0$,'`P/O[^_W]_<_+R/KZ^:^K
MJL/"POCX]_3T\_?W]F5@7:RIIS0Q,,O)R+.OK(^,BI"-C/___R'Y!```````
M+`````"[`!````?_@'^"@W>"%BE5<G\#&8..?SY(CP"$CXX!,9:#`$V6<`^/
M*"V:#C!$CB"-CW6"*%9_0:J:!'":!0F:?QZ9FDJ"+'5OEYJX;Y2YN8K(M1\*
M<@U[)QP$0E".2"8@."<#,!LW-P@'7((U%&[HZ>@&1<J"N((!5^20@G`:%HX"
MHW\!CE9ZJOPY`HJ!%21%A`G2H../BR)_"L@XD:O,@`48,RYH@$53E2<F'/T8
MY((/`CUQ*J2;H4'AH#<,>,`9HLD&`G`XP;6XX$M3D`Z")M"1T0%B&06:<LCR
M(!")@$%N&`B:`139'RDZ,D[H@%'``D$ILJC1<</#`7!S!*@8M";5"0('_WPP
M`*#@QB`X!UC\F?`!K)!<,V9HDN%&4`1U+QJHFW$`3-`/2;;$>3%H@.!':`0(
M4^'2JJ`X,@3I".'(0T,Y$9B(F""!@X0&&R)$*$)FD!='!TX!F`!5ZA\&!`91
M<11CPQ\A?3TS^5,+`I1:C]YX`4`]0)$=#$`8^"=52PY'2N38?31CS98M?LZG
MUV-$T`]X=^(BX]NR`&5!EBU%J2%HCQC/@H1Q!VB#J,"!(`_H,<@>$<C`QA:R
M>4%%!!?HT,D?5$#PAS`!//4'"ACT!@L-;LB@`P<GR/+'&BD(\4`<,,)XA`N/
M%"`(%5+\X44$CW#0G@U[/*"`$7HH(`%2@F"0Q_\"6TBAT0)\2""0(X$)\H0_
M!P1@0R&/T`"$(S@\,D$(9PBR1CH87#8(#C0.(@4H@P1`ACINF#``!P2R!<9,
MM0VR`04-4,#`'"^8L5=/?RA@`0`-_$!":']8H&94;V"@A8[N.))$#"Z"(5L$
M*#!PP:4)S'%#%";8(,,.?T3Q!PD@O.,"#B^0X4$-.430P0,MK'&7(&64.8@/
M@`T@VP''1C``"8\`<8"IX.31AB2#3,`#/_<MHN8?,:R!BQ,"%:#'<HX$-X@#
MGT$JB`HRQ)!%"O;<T`<1$,0`@@)C!/''$X/\\$1A%_S1Q0NR%2&&!^A&]06\
M?QPP"`MH.&*#%\G]D4?_'ZP^(D0!8Z1!W71&6%!+$R%\P-L?&33P1PDFN)$M
M232T8(01(`APA"8#G`""$6W,?(`1$HSA"`HR_.6(T=5^P$&8:Z"`AAL8]/%2
M!:0Y1($@6$11`2^ZU`7.!)+D*8@5;>B0A;D\\-`/!FH4P,H6X@X"1!\`Z[)`
MC'%XL<<?;N2``044%,$&X!1<``$K7*AP!K^#"%"5QA6W*L@=M:@!``=2,%$!
M#RHW`(#+EEB+I!$G6S*`!((XK*,@8`3W1A]^?.!%3C<@_=CJ+]0PQQ\\6.`+
M'`JL(,@'0E1M\05.##+#`(.H_(?8?T#1A@19Q*E!DS3XX44CW>`Q2!4(%/;R
M_Q_)MR%(5(.,$<47G46ZW6V#Y!#Y(,B!T</'U$U``W,\/##$!Q_8@\ID<)CQ
M@8!Y%D!7#HYA"1=@X`)>@``>*@"!"A3N2QT0"/$T)J:^/.$#+U`"!F:B`7JX
MHP$(L,KRFI<N1T3@`%VHGB-\D(8W),%Y"HC"A001OC^\(`QTH(X)MI`!U:&O
M'P+0`G8T8`D?:"A^\Q,$<N`A.4N83!",6M$4H/:(*Z"+``(H01F040(>.2P(
M-Y,!!MKW@0.<YXVVVXL*TN`%.5"F"&>PD25$`)$_Z$!XEIA!#@9`R"NT<!`O
MK$$6B#4('5A`#`(XT!]F\$%'(&``-RB!)5;@(?3U@/\"S/J#`UZ@24<,("10
M?(0<DL"`/J5.$Q\80A<`4``H@.$%8`!#Q@0A!A38HP1M@),F+E`+AQ'A`A8X
M0OO^\($H`/"9<9R`#_J0"<J0@`&(.E<)["`((DR`7%12$Q.?IZX_`(`-:O""
MT!S1@Q(H(`<KL,(%FL0C'A;&EYM`@A5*&95LH&L0!.A"!I1!@`ED2GZ.2,`9
MUF`',9P`#/YP7@*<,)(_I&!ZIW"`#)JPAPMHP`8WTD`M`J``"+1`"@H(I2-T
MP`^'02$#:>@"/1RQP:-U<!!XP,$<#,``%$QA$#&``!,^]0`@>,%X@C##I02A
M!D%\H9Q)N$T72HFR$U`@.#;_4`#S/L2&+YES!)8@P1"R`*<D"(!V.)F#'E#W
MARW\,P`4\`(;_.$(5/ZA!S(X0!;8P(8L9($!_WQ#0WY@A!(L]0\8T.0*D)(`
M([R@!X*P3QL.\`5'7$`A;<!`2-[P@C;H(86#:-$[8&`!0SJ"+X(0`1LH8K$G
M3*"B`S@``TJ@@1EX8`%#0!(R3%""`XQ3$&>`"!RD<"DM&"\#"#C%]P#$!4!N
M2(]6:<+\J$`M`/W@F>TSPA*H.`B0%H(',*"K(^3`,$'8`*R"N"IXU.:(%:S%
M'ABXF2/4*X@=6D*YCQ`!9`&D@8IN*`W_3``%0`J@`AOXP`A.L((7S.`&%QAY
4CZBN#H,G3.$*6_C"&`Y#3P(!`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>76
<FILENAME>h03611h0361125.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361125.gif
M1TE&.#EAG``0`.8``/7U]'YZ>1(/#ZJGI.[M[*6BH8B%A)V;FF%=7'5R<=32
MTJVJJ>7DXY*/CH!]?+VYMFQH9M_=W"HF)5E656AF9;RZN5];6GEU<Z&>G=#.
MS<"^O65B8)62D>?EX[FVM6QJ:GMX=IB6E59249.0CK.PKK2RL4Q*2H.`?J.@
MGN#>W;"NK9N8E^+AX(V*B49"0;Z]O>KIZ?O[^X."@NCGYL;$Q,K)R.3CX=?5
MU$E&1<G'Q5!-2_/R\=W;V9*-B?7T\]W<V^SKZM+1T-C6U?#O[C8S,L/`OXJ(
MB-73T71P;X:#@?+R\N+@WT$]/#HV-G!M;,7#PMK9V#`L+#TZ.<S*R?'P\.GH
MYI:4E-'/SDU)1J>DH[Z\NHR(AH^-C$-`/S0P+]G8U^WLZQ\:&LS+RLO(Q[JY
MN&)?7L'`P+"MJ\_+R/W]_9>4D_KZ^9B3D/GX^/3S\K.QL(^,BK:TL_+Q\(6$
MA,/!P/CX]\/"P5104+BWM\/"PJNIJ(:$@\[-S%M85\C'Q____R'Y!```````
M+`````"<`!````?_@'^"@X(%;809A(I_<1&+BSDK/H^*7T"455,=FYR;04&4
MB@"$AVMN@W@*H8)I)#^KCQV/:8)B*;"+`J^"+&%TH3\Z-K`%976#64J$,W@@
M7AB4:"YGU-74%@&##6<+'V`#'@\/'A?#@DYF*QN#,BJ/2@2#<7>#6LI_'`/Z
M^_HK.%."A)P8T,"(H`Y>9(7R`6U0F$$$FF13!.66H`0W!-6I0.M/BP07+KAP
M$?)"`@@>!%T)<&)""4$H"H@K\_(/F@D,CNC428.+##6#)OS18"+&*GI^(`PR
M<N11AB@]HH(`$;4'A!6"3`C:P6'2(S\(_EAXH\>/GR9O_"1(A`(&1"2C_QP*
M6J(#X"('(<SJ-7LBRI5%$`H,&N&5D!HS@M3($#2A@J";,ZX<`9%@IP.@C/^`
MN+3*PI^D&$KX^9#%#Y(E@Y0<,>%#R8HF)'9F&:3UCY&)?P`,0;0NBIL+A&ST
M49A`B"`+[@@]?`+"G*(<$E[M<+)CD(%[@E10D\"AVH"F@GB@00-BA080+1;_
MF8#8IE!!!=EA7C^$PB,`LP4Q:8`$`A<#'02@00<XD#$($AZ88`,%,^26``@/
M>+%&5H)X`8$3%`2`!01Q_7$$!$>08,`"A"RPRQ]B8/''"UT4)D@80I1@U"`_
MQ"/(*7_H44:':2A!2P1F!(E'&"\$&20$#1V1A_\?3.3EAP'JL??8!#Z8A<0'
M?B1QPT]!08'!$"CHL\$6`Q2@!FI_A)54`T`Q]<<=?@P"0@`F="`##"W49T8-
M[_VA%0DH_'$`"(]\&(06N6E@U@M6<';<"'W8)X@6-/@A@%DJ[`7"`'^DD<4^
M1`2@#PH'#%"&.S>4$"0"7&A@!@)&_C5("@*`4,,?BC'6WDT,G;&!"#T,,`67
MF;70(!!I&!&G(D*MV693<,Y*A@D\E+&"$W!0B\$)M,FQA5$<J)?&&(-\^(<3
M/"R"IB`&-"'!'(L\]$<(NX7"0A2#0!#H(D=X\<<&7]#!Q2,.2(`'$2?DNMZN
M?19T@0%_$+O>'S;H\`?_%B$H.T!'@D@Q0!(0M$#!&0B,<(84R\:011EUBD``
M"PG\P($$"OE)`ALXZV`!SDGHX)B'2LTP00ALB,"&!3U,D(@@!P@@@$&*R&N'
M`ZL$4(1*87`\"`-=W`)!!T`0L8?6--S1@!DQ@*"PE.YI8X0/8?@@\7L"$-`%
M`<I>`?$@(GSFWQNV-<4!`X)4L`<-GIU@AAY!O@!"#K0-DL8=*?&KU!\"_$&`
M!'_XJT@!3D.MG#94/Y)"&"3\$8,%^Q("!`(UZ/"$OB:@T$43#?W+@Q'MK<VP
MVW_\@(3$+IS@`@(0&*CL'V6,,(A]20TR!WB*8,#!'YS_87'$CM8F*`0_3/`U
M_R%'((""%$C\$00.G2\R@`!$E#[Z'T-\D<0$Y"ZR@QEPN!!&'!,:A`8:T*`C
M>,`"2``(`$[P@2NT80O&X5UBRB".+NQ*!!4@P0/>H,$X#"`!\YD`%4)@`V[9
M)DYZH,<?M'"]Z`E"!M0CQ`5V(P%Q2&$FA-!*##A@@'BD`0Y-.!$?UJ&'8VRK
M?1$;A!4$``'/1,T&(3C`#=(0@BA0``,V&D0;6E"&+%#`!`>@@B".,(,#.&`%
M4("`!BA@`19TZ@]N:)!MVL.!$`@B"Q:1QE[V0H&!928-21@"+997!0T(`@2)
MH,'E(A;#@)B09@3:Q`6JDY4E8$`%,TK,%10"ED'8`.X!\?`7&"3U!P?@H`-2
M<,L@UB``">1/$'*@`%8&`80%N&"6?TA!%!#`L0W\X`8#P$$5_G"!!CQ"@JI[
M!!IP,)YF-A,"HA/*#N*Q`O^=J%,G`,`6P@`'=C1R7F[$'C6D0(T^H$$08&B"
M-=:)!"*,HI,>H@#D_A"&.7Q`7FLP@6,,X,=!3"&`E&`#$CAPS4'006N".('H
M**$!.:PB!3];!`,*LX7G((H04/#*%SA6@)H)P@?A_`-N!!&$8P0$%W]0`#16
MH(5,SD`GE%3!Y=9@'I3:]*8XS:E.=\I3G/+@.H1X0D^'2M2B&O6HCRA"``,!
"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>77
<FILENAME>h03611h0361126.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361126.gif
M1TE&.#EAN``0`.8``*FFI>[M[*6CHLC'Q]73T<_+R"LH)[6SLCHW-IR:F.?E
MXZ&>G.KIZ5514(."@HF&A!L7%UE656QH9G1Q<9&/C7YZ>8!]>ZRKJ7)N;4Q*
M2N'@X,;$Q+RZN9F6E<"^O-+0SW9Q;UU:6</`OKBVM=#.S+"MJ[.PK[&NK6ED
M8I20CKRYMV%=6Y62D/+R\NCGY4A%1$`\.FUJ:>;EY?#O[E).3-C6U7EU=(J(
MB+FXN,[-S$9$1/7U]`T*"_;V]8N(AIJ8E]K9V//R\=_>WLO)R):3DK^]O-[<
MVV5B8,7#POGX^*.@G]/1T-?5U#`L*_?V]?+Q\9>4E,+!P:>EH^SKZJNGI:ZK
MJKZ\NH.`?9*0C_3T\U-03V)@7^CGYN3BX=G8UR`<'(^-C(Z,B\+"PJNIJ#4Q
M,!`-#B0A(,'`P/W]_9B3D/KZ^?O[^Z^MK/CX]^+AX-_>W=74T_/S\NWLZL?$
MPA41$??W]D-`/\/"P<W+RLC$P=W;VHZ*B/'P[TQ'1O#P\/___R'Y!```````
M+`````"X`!````?_@'^"@X)Q5'5_`S.$C']!1%F-DH,S)W>3C'"8C#68;0-H
MFW\`0Z*FA`E(DUR"#'].A%V2B']>`:>#.[A_"F53?PT+HC$5F'I_:UX>+!,1
M?2!J@P=GU-5G4A`;@S%4W=[="V1`F%LF@TF2$E*F;5#HH@8LA!JA?S8+*@U#
M6M4X!JZ,L$#YXZ"(I#$E$BI,^,+-I!HC""F`("C"&48!"&C46`3%QA$16@QJ
MT"#&%2(/..""0\9"D$$\!-48N&F!@`$X)]C`64%"CT82+II:$"$2H2G6QI2Q
MAN,+A5!!O43X0U'0Q$8S$&CX4V7=KIA_WD0<-,1'/4$[JEH4-.Y/G"$;_^/&
M7501P*`;1`3)H!!-D@D,+PF!Q8*!DJY!ZV[<$#6@0IK'=C`\3M.G"B,7`P21
M64Q(C9Q!-%1@"KI`R1\S@ZX&#"$HR(13-7+\`?M'`VM'!D3^(5&@M]J+`LJ8
M&P1%1>_>>4*L810!BA6<,7;B5-0H`(P3DF(&Z6,#!#$:*PA1L:"XD109@P9P
M_A-TD)9+L<@8^;/'`B8`?0@-'Q1429P_!E3#1E6$]-'6'P(4-@@:1%A#S0\_
MS(;*0#'X,$@.&ZD%@`\.R$)(,'%Y8(91@X0`@`Q%$#!!!00`8`4F90"D!A:Z
MQ91``G^4)DD`1]SP0!5G3'=%$V.DMUY[@FB1V?\@7"@`PR#1S.$0(0,8H,1"
M7^!`2%`'H&=`:@0*(L%80OR11`0.O"-(&S_IU29MCM#Q1AEC,:)6!5Y(LE9J
MJ#$B`0!X($`%$0M0\8(-@LP@Q4(EE*'0`AD,QT,0"R"RAUV"8#=($#:L9X04
M#Z!G)']"_:$D)6(XR<@,6@#TQQ(2-,&(K%N>`<05`)YQP1EL?$'(!33A088K
M,ABP@@C+O7J$0L$(`B>`/_"`AR2_31(!&PIDJP`)859T``%:$"0!>Z4V0L<D
M/"S`PF,(@/"8#QF0(!,(&6`Q"!CA,3)`#-,UT,%T=BSYAQ)1J,K(%J_]P8$$
M0=#`J*^U_E%!E0C^L4/_"FV)8)H@"&#Z!ZO("E+`5&)B^NP+1_!``+45E4M(
M!&,0(,4$!(A`,B$ZP!7N%8LA*<FYV1%BQ@AG"?(&!%/8(`!QZPURA[UBEMK`
MDAJ408#!@G"AA@ED3+'$&TG.ZN=%6#CP)04!4('`RJ\,<H8.FXS,G\F,9)`!
M#TNP_,>>;^3-9(3J\1%A(U\D`>[>EOEL+KJ#7$!S"#$\00@L$4PK"!1-"Y)L
MU(.T,0@"7V*="-@+%$T#%JBC#C%_':S0Q!E?*J'%`9+,L,)_2PS.2`%-..![
MQ\[6K04/2Z*1PP\/*%'M'U:H-,@1$4RAWA](P*#-("J`\4<.%3"001$*++#5
M_R1`-Q+3$S]4$$T681@`RZ8H]/4'YJ*,*4D-BXC.@<"$:*%MME^JU0BP\Z49
MA$`5C?`![02Q``P4[0\%R)?$#"(A0MAA`E]@@^804`$W<$$MSON!]OZ`!@M,
MX!;3&Q@$IH0&&K@B"S.@P1@&@`4)5$%-@@B%&LK'")4M8($YI,`3Z$(0(,XO
M<T#QF"1<@(#I["M<C8#B(&A%JD$8X`,_A`$6YB.(.D#A`1OY0!$,0)-!3$$3
M@OA,\`CQ!2ET0$$2J8H-#$`#&D`@!#NH0P4L0P`*-(`"@PA8IF3SJCY$81`,
MZ!TC</`",P20$7'@`:,6@H$^2&X&N!*$%%PWPM$H4:(2#[";*#\IB`P,`@E0
MZ);/(/""6W#A!0;P0-;*``,M2,`!4"A!`LH@"@)(P`!A8L`77H(`+@XB`!W`
MA!':]`<&D.$6D"R%"RJPGUQ\H!%H>`$3)B%+4Z2`$3NP@&XP<07^[:(1@$1,
M,0AA@TX(@@3R:P0.<_B`4TCAFL^[7@`L(*IS^O.?``VH0`=*T'^RH9I^(&1!
0%\K0ACKTH;B8`C[_$`@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>78
<FILENAME>h03611h0361127.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361127.gif
M1TE&.#EA6`$/`.8``/;U]<C'Q_+R\9*/CJ*>G"HG)K2RL>[M[*6BH;"MK*VK
MJIZ;FN7DXYF6E&QH9WEU<W9R<=32T8%]>[VYMGY[>7!M:VEE9!H6%E114<"^
MO>KIZ.?EXXF&A;BUM%E55.+AX+RZN=[=W&5B8DU*2FYJ:<O)R&!=7(.!@$E%
M1%U:68V*B45#1%%.3-K9V-S:V<W*R=_>W:FFI:NHII22D<;$Q*NGI,K(Q]+0
MST`]/*.@G]#.S<[-S#4Q,7-P;]/1T(."@N3BXCX[.HJ(B(N(AL3"P9N8ENOJ
MZ;Z\NN?FY=K8U[*PKX*`?M;5U*>DHKZ]O).0CM73T<[,R_7T\[JYN,+!P,&_
MOCDU->CGYN'?WY.1D`@&!_#O[I>4DY",B=W<V_GX^%Q85_'P[]C7UC`M+.SK
MZL;#PE103H:$A2$>'F-@7JFGIGIX=H^-C):4E(Z+BSPX.$M(1D,_/JBEI`\,
M#<'`P/W]_?O[^_KZ^?CX]_3S\OKY^<+"PFEG9TA&1X>$@O___R'Y!```````
M+`````!8`0\```?_@'^"@QU`@X>(B`)*6XF)!XZ#1Y$;@P)&@@%?C@=4D8(`
MAV)3GZ6FIX,)2*B+>(<?5761,7:G-PFUJ+J[D2^(.8V)`KB')5&E&F6G&Q^.
MH8<-S[S3D2-5S@%TVG044W=_87%D@C$(">?H"3(>,9\#;H.Y?PD5WWL8$Q,%
M&8Y<*5*":*PZI$"%K#\#<!RTM*&APX=`&M`0!`)+I`0$3%DAE>?AABC7!I5(
M`>";(#H\%B(:XL=4'0\%]#BZ,D7E(#)K(%$[-:#!(`!SH#@*L$:*R3\_*AR*
MP.;H`C0`2VUY8^C/PA`5JF*9XP+1'20>/589(&A4I!`/I"4:\6D#'0=__^#^
ML6'BCX=!#K@(6C`PT@X"`0*KL1)8"0\!@PH$^).!A:`"0A$!N+!FP+LY11#9
MX;&X#H:)@FRL<L'!LFG38WH,0)#IPA8E)RP7B#T@2RDI//Y@`>'F=.U<</PL
M>'+W)`9$DT"A&/0A1"(#!5K,B!3DR8$';`:8&&%:Q\Y!+T242&1GC@9!4>HB
MBN*`Q`0++07]$((HC83$#D`C@D`G<(`5.036@UZ"(("#(#FD,,@!!OP!0!&^
MF>8!=P-`8D<0"^!!06\]>&":%Y^P=<@X@[P5UQ]Y0$%?<7'I)0!4EAS"A!0W
MK(`*$-\LP,=CD1TRP!`$]K"$(U"$0@4/#SA@!O\$8"A5R@B+'4("`X>L4$DI
M=RP!1EY/R%""#($I`,8A%YPDUQ]T'+>)('$0X.:;;O*`@CQ_?/`&B$.X8=,?
M1_QP2`Q^?G>('2]H0<=/)02PAQQ$50"!$-I40($@4-B(%(%(";&F($QX\D<'
M!UJ`F"!2",5"E+>-5T<*#CQ@10468'!E)%P$.D@9DPX2`*:'4-'#`\`^4$"P
M#UAPP6(Q])`"DCR04,`$*^*EUQ!P0%!!L5:`*$@5&%2:"!-$(!*5"`H(8@4+
M&`PIR!%CLH&`&G`<=8@K?_0P"12V#F(`;6L\(`B4IEB)"F%%U$)'.W\$(`*9
M/_P@@@D-.SP&#FF$(H'_8W],T<%/%-@T0@*#](`!O9\`*F@B<QPZR!W>#C+&
M-QS8"D4!#:]00<0K]#%&KH>X,$8C3<0QZA]KR(`!JH0@0J\!_OY1P*R"D.&`
M:1A@4JLINSIB!YU](#V('G8LD)E<.T0K2%Y&>/!%%,<E\D4:E1Z10#X3+#"&
MDW_44$,!("PPQ)HA*$%'"X*$D(,@1J!0P-""V-%$#`5H$$5F?^";"`$F--2`
M>@!G,H4)8?S1`,@"[WE(""LD40^:$)PSQ)E_E(FF`WD8=\@!M?^1P@+QW+'I
M`2L,`<7P4-#P1@%+^&`'$-R4"T,])IM.1@YL@"#+%0W8H48;.M51QA,&I(R(
M_[<`0)%$$(*(,,$@+?\PP*CSZ:O`")TXX`-"#"!0``17_&$`!!@H@QPZ0+<T
M\&!CC&F"`VQS@H$\#1%YN(!#+K")JPG"!70X08-NX*^LF6X01L!!TQQA`>?(
M)0F38%%>BM"_`+3M#TF0AQ%L8*D_"*`*%,@`G6(W`03(0`G^0<%X&B>++U#`
M`B8XP7D248`_*"$JEJL##`81`[E4\5^HF@(=+A`Z!_!N!3KP`0FTY0@32"``
M?.A"%*C`AC`U@4S:R((#;"`&-+V0`>B0PP5D<`X9**`&'C`$$R`0@P7H#0TU
M:$(#9(`#$5RA!2!@`>^@8(4_Q.`!&QA"1@Z1AQ048?\*%S@"$B"@A2>L@0<[
M^@,72$`#$A@*$3[@`1T6``<E(``+`(`#R:`@2SJ(@`LV0$S\!`$$!EP`"`LP
MQ`+BX)TR**$6>0`>JJ`PG&8<@@L!<,']'E.))0I"=K$3A`7_H(,.\($U=&!+
M`#BP`3=LTA'I5(%:V"<B,_1/#PE0P!OP\H`$:,,-*]"&$T0PG3]L`0';&40+
MT$`R,@V"<E5`03`$40<GH$`)@A@`&BP@@R@,K8ED0(#>NN"!&DC@9^2PHEPZ
MEYBSM6,%#=";,B(Q1#^5``$3,(`2)J"`$<K.1"MH09KB\5`((.X-L[H"P@8!
MSD0XX%#>BD%)]:86)C3Q#T'_H$\`M+"*I^BF`%/$PRL/$0"VT.$NAJ.!B"AE
MJ1]PH05C`,`PF4JJ)?#!#BT8(J?6,`;O""(%ATL$-OVGMQJ@H0%-*(`,Z/I-
M<>;K#T(0RED3)@*]+382')``#'J0"`U((!<>4((K!`"&$>9E$&<@@2.LL``:
MI&$0&Z@A(L`Y`TB,X+(.6H`)QN``"H`A#A2@`!I6$`1O7I5]C[6D2K&(B*LZ
MX*50,X6?C@`7+M`'"M,I`0300($*>``N(N#`4!7!`GH)86&ED!T9G("(IU;.
M1B;[Q!4J<`&M:H$<9>K!6L5W"">H%@1RP8$$Z".()EB`!Q0@`0[T4@`:S+6Q
M2!A`_S?'8(%!$.`-`'C#%,_F-7%Z[8&S9>PX!1%9--TE:Z9`@7<<X(NE1,4J
M+-AP!`YQ6AM"Z0$FV#"I_K``C`HBMI$H$QNP\($4W``.\G!!(U@@E"O^X84M
MS8&V+(>(!;!`&Q*H\!]8^AB7_D%@IL!"%DP`AR;(H;K7Y94-<#`%N'CA`.,]
MQ`Q&@!@\O*%'ATA`$_0V![T18`$J<6]4DPN*'G#@"RNP+W[_`(8^#(*_@V@`
M*9K0M`?PH'^(R(`9)*"7$M3AP>$<50S&,!'V_N$.M;O`0AS0854&@`P@XR8B
MPG"!;<ANQ)"5[(EYY0@*#$$0`A`B(FY!-QSDHP,00-5I2_\@@AL(0@$\2,X@
MS*"3/P#9$911&0?0D`1'L*`+-:@`"O2&L4.@00CEHE1R%>"3/P"!<%O^<`!D
M\-PO1Q<)+S8H&'+@`C\%P`QTZ`$?Z$``3.'!`T<PD>V\`H4<G&`,&"!CD#_A
M``44X3^6)/0?"%#)+RO:DF52P04\!6E!>*`1;#B#53"``T\-`@968(!;!P'J
M"TS!`%7@0!8$(``5H"$D?_"!>CCLB!EDH0*Y<UIT-3"F;3D6$4*P01<2L&M$
MU$$:.AI:%7!0A(8>`LHT'H("!H")0:A!`=76P="M+=MXS*%I-&"!!?BPS4,P
M6;F"`'L8YD""A4#A/IH95"AP@+3_+5S`!'BH-YBIA`<><'90Y)Q4`-!<.=LX
MZ`'E4K@=(T$&$CS@#&8@0:L;.XC0#<($*SC"H`5Q!7DMX`()R$$!,'"$(VBA
M$0N8PQT.4("`$D`+$"#1'[S`@AN4P`0+R-(,#!`'$`P""VD8S\SE0V!!W&$.
M8#@`",:1'@MT>Q!KD#BK';&$`E3E,50Z1!U4$CHA/%8"*(#"9%&L$P4L)PPG
M2.X1T(`&'7_]$$=`.2;0`]M0@'2``&C0#'@0'T'7!3W@:(Y`"BY0`2+@"EQP
M`3RP5'_``D^0`$M@`N=0;H-0`\,F@IRP75I@$8,`!$%@`PA@!@]0`T%0!#7P
M!`70/VFP_QR)\`)P00-QP`4/``%<0`'T<0`2X`5A(`<DH!1'P`8BH&6'@$QQ
M@$!_H`)S@$!;8(`ILPT%(&T0,``Q,`!!4`,/D`9Z$P<%!0H2<#19``$^<`;S
M$0!PR`9_P`0B@`%$P`=Z50=#4`DH@`-1T`.DD#%ST`,"``44@`=A4`1]X!,(
M(`0KD(8.`@:C(@85,`)^)1+5EP!"P`-Z=0A)P`3-A6>.4`0\H`5M@`@]D`,$
MX`?C-@0DH#<HX!-.8`%*T`75A@@'L$T)T`$&:(![$!I=80H=8$W6!P82US,]
M@`"F!VS2)@@58(R"T&ZE\`)D<0HN,(C3L`6_E@@^P!HZD&Z"@&,%B]&,4D`5
M@O`!!=`71L@'17!^SY<<=1!=)U./A[`#.P`*()`#='(%LM",1L`"Z5<"<-`7
M,H)Y7O<'1N!C(N$`'[0696<*"S!/]EB1%GF1&,D+5[``WI21'OF1(!F2(DD-
$@0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>79
<FILENAME>h03611h0361128.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361128.gif
M1TE&.#EA5@$/`.8``/;U]!$.#BPH)^[M[*JGI,'`P,C'QYZ;FO+R\9>4DZVK
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ME\;#PF-?7N_O[LO)R+NYN!\<'$Q(1UM75J.AH$-`/X>#@C0P+B4A(;"MJ_O[
M^_W]_9B3D/KZ^?CX]_KY^?3S\H:%A;:SLO?W]CLW-OS\^____R'Y!```````
M+`````!6`0\```?_@'^"@DLV@X>(?V=T@U99@GR)@SY5DH($$I(^1H(#3#(R
M<BN2`V]SEG]2E8(T%0"HEJNP@K*6<B&S@P\(AR).8I94(KDI#T^YB7?(RXAI
M`X=@!I9.O(--&8F,AR`IN4D3DCN'2@JOS.>2%[C9+P0'<CI8!`C#<=4';07Z
M^P4@(PJ'YM@9!.+"H#"#4O01YT-`B1)!L"6:$02'#Q]:3"`RX"'3GP]NS`WJ
MP:^DO@<0!-G00L>(@9<P#W@`ANH'F3\(2J*H4>U,C!]WP`GR$40DHA-LC$IB
M`R>))!D0LM"!"?.$!R'H$ME1A@@*FT>"@&@\9$=,$PA&>@Q*$"'1@2^#_^Q<
M4)'KA$%:@U[,>/:GPH4SB,Y<'$SXX@PN@KY`^0,`E&,9"F`HO>`#E8\*?S`(
M2H$$P91!%5+^43$$E@PV#Q_^>*A@RC!!7@C\41)$$(<"B:K$X=&@P98I!Q)Y
MD&BAFZ`V)QB+DZ1"]J`Y<4+TV")(!>Y90WP@*2,$A8M#M8IL(/$&#IZA=P?M
M\>%X@PA03``B*J,&P`:PB+#\^-.$%\>LEKPPA7.(1"`$'6=DX8$@"`H"@!I8
MD/!#6X(D0%<B`G#RQPE!.'$*(C)L0%4$,+FQQR`7\"!($<DE5MH`!Q`@XXPR
M3@$#`24(@H``>[@`AHP>."'C"\<<0MDA-QQR6?]FLXWVQV>"A/9'%A'(LM@@
M1(P"Y2P#_<$%A;<E\D!D@D0@&B)B#`2%&_JPJ8\VEC2'R`VC#&)=+C[4P,)@
M#7@`P9]J%/F'!94MB=X3R_W!!@B%7<0!%C1U$H<X27#`UR$T!#?(?P!*$@>!
M?RP`@9\04.!!!6ML\(`;''"E1H685:B"!)$*D@:*&4#!PB%9A#$'A;.(`)@1
M03"@`1`,=.#$+(0B`L.MH#5P2#[[%)'!/B944!H4'QPP0@%(G%!!%G1M*>4(
M7>SA00$$@"'2&?5-X4)O]"HP`R)-O**"(7]H((``2`S"Q;)EC$!!!W`>@M@?
M&R#TQX*(V.`!`\G"<8K_G+#<F4L$1T2@3`.Q_I'>H`S4P4`%/-1A,AP/="`(
M#`_8ZO(@6B"2Q058"0*%&J!*PFFGB`C0\Q^O#N+&,U^8<4@`*K/!P@Q-%V%&
M#=-L<$H'*GSX1PXM0!P0%8@4:08-?QC`02)1/%!!!2P\\$JSL%0@K25]U&S)
M#3HP^4<*Y8(&@0M8T$%#$99@`<`4,5PQF`X6O'$>'B;($<<+,-PDB!TER-!E
M#R@((D80`7@T"``WR*'&"DVT,8C7@PA!H=G5$0B"'$#@\$<&#(R&F^BD(+'"
M"'S0T<"W^HS<K*%_^##R(6O(-X@4@ZQP@09RR$%`]1?$X48"(KA`@`H4")+#
M_P#_`0`8(C$L\`8,/=`A!`MH0(#!=0!D4(<3GR:BQDMD&%%$:3#HW""*EH"0
M6>@0")`#"1Y0!1@L```[H,`='@"'.@CB`1+;@0*JDH,?#,,.&9"#!;;@`-'`
M#A$0B!4!PC>HR@AB#W(P`QK^<`1LR.T/>4B$'P*@-$M<P`%_V,\?9&`(`?B-
M#+Q0@@4&$0+>H6%+?T@9V8)V@R:$8`$/(<`4QG((*3Q@!F"(0`AR&+3DB61!
M=DB2(`SPNK.-AD!9D($`GI&`>ZE`!P5PPQ%00;$0L.$#:5!"%`:!@FH,B@=R
MX$$%<+!'Y0T"`2;01PC4$,D"Z.`+1"#-'X@P`QN<X/\E08C"2U8P`Q6X```N
MH,`"!&%$`R#!`%;H@"'_8(<<R&$`<.@"`"`0@`Z000.OHH,3&/B!``PM`-93
M`PBV4#,+).H/R)2#!BI@`ZP<\!!/6*$)<#$!##S@/#<P3@^,L(9#",$)*-!:
M=61@`&V<$'JPND2LX/8'(9AM,4L@05]>X``.\&L08YA"&VR7B!:,H$R#D,,"
M`@`:,ZA@`QOP@``@N@$5P(`5+#C`R-3P'0S)0!"B^4(Y#W$&'?3!!*"P01\"
M8(4#=/0/1MQ!RE0&A#K,@`-U8N,:W8BQ01CQ#P7472YX(8.8/6$$!C`!&0P`
MKFH<KP*_,H$CT=8%0<!++8/_F.(@Z(F(+B1`$)_Y&2(`@(1G>.!"`3"$$@*P
M`QL4[0_Y.P0=C"@#.`B"`D:(`R(("%4UT.":AR!`K'#`!HTHX%)S(``6W&B;
M*R%"!3)`P`>JYP0@*-0-10KJ'P0K"*Z.YJ-+D$T%CM`;XZSE`73P@CK_$(8-
M#&(!&G"8`O(6I3/Y1:N"F,,##-`"%@K"KI(0@`SH```0,.$/$5#=9ACP!@OH
MP``'<(,!0I"##W1`:S_5&NO6*%WH\K1G/PVJQG)1U!V,P2"<BED,-/"#!Q3A
M`I@!PYZ6QY@XK`("0D3$`!Q3!!#(8`4:2)A7P5JV[2+"!&R8`EJEL589=.&G
M,.V9_POHLH(E_J$#(XB9($+P@`AL(`A`P,P%4`#807`6#6E@!`G4X%@5U"`%
M;#B$9ICST4TQ=BT;``45YNE".X%6M'-#1`_*>KN+'@*K*.KH`;C2%]$PP6,O
MR($^$?$!N_W6$L)=0@KFH$<SR.)#$<"-3F5`7R.20:L&ML$:0!&"[Y9Q!S#`
MS'A1`0,,K(%%?(`#!*P`A#_-3!!/5`)F<CC50Y0A"!!X0@N"<*E#M,`&H!3E
M2\@H"*_.00)A-;"#BB"'AZ$5*SY@JQ[>*C1\Y2T)(]V#&F8IB`RH0)%_R$2)
MY?F'[T@``R,`AGP&<H(9"\+7CY5!$W>:"#!HX"5O8*%G(?][A]#V)<B'>``8
M[+3*0[@`!:G)`8[P]L_0T"$#,WC-X)RW(@U=.;@<D`90`W#<1$3@#7)P0A_D
M<``+'R(.*N#BPQ(Q!/D`@"L]9247"%`'.5]G$#A0`@IMP#=!K#D$%P"%AO\P
M``^T`'F%EBL.:J"&(D2!U8CP[""ZL`$&'*[`E@A!`!@QETH$@,$!D`$*`O`!
M5EI9$!X@6Q/:,@<-(.%>X^"`!#0+U`L%]FDB.,`;<..#(OR@QG]@0,T'`6P9
MLV"0Q$;$"^0C`0TM^P9D</8-Y<I<D4B!`QJ883J@_H</5:`&"D!!+5K0A)PE
M;U>'`&XBII"2*GS``PE80P+@.8C_,)>M+636WQL*E`LA*`$)+]BK&<0@WNN8
M@`Y/Z$,<5IL\(:(78AK040>2@W'ZZ@SP(.B`&R!POD30DP:&Q,(46O`DE/^A
M!2_]0Q("@`5YPT$+(`A``I[0A@`HX`D84`,,G*"&'URJ!Q<000;,P``^;$`+
MY*0`5H>@@>\0?=9_6#$7)*!P!$27!"*90P<:776?3KQL(T4%`*20!SCT6!!N
M^`$`Q#ZW1ZRW18<P`!R@!LE!`U1A`$40`C!!!FMP"@]`/=43@=7#`[/'&*[%
M"B,0``$C"1(P!U^``2KR!PZP!@&@`9%0)AC``"PP`@Q@!;6!"/?W!T9P8Y:P
M!7V@!J41_VU,L`2J4@<N5@=+P`%8@0(:T'J3L"!G(`!KLX3[\00;<`8#8`5%
MH`=_4`!KH`95A4!$L`$8`'52,`58<#GO$($<0`41N`;5]@<H0`).4`<>4`=O
M,`(J8P9`-PAEH`<#``51,`?T8@3TH@P?T`4#$'F'``//D`$<T`(:,$4`4`1%
MD`(MD#M\,P55=0`YH`;3A@@ID(F2Q0%U.`AOX!1_P`=8X`5`8`DV,$M"8&^6
M,`#X$P"LA@$AT`96,`-RT`%U4#U!<`)-``MD9`0[\!C""`JG<`:<EPA)L%H9
M8(2\HF6)T&A_0`6"\@=5D(.P0`,GD@MSD'O,@`"AEP@3<%P(`%=$AQ`#B<``
M@J(!AC0',W``,9A;SP0T\C@+"8)P:B=7B%`%5/`A(K!XJ*``2\"-@N`"M'<(
E(;0,5V!DLQ`&]SB/#OF0$!F1G6(6?B"1%GF1&)F1&@F1@0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>80
<FILENAME>h03611h0361141.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361141.gif
M1TE&.#EA0`$0`.8``"TI*+V[NK6SLO;U]*6BH.7DXZ"=G,C'Q_+R\8!\>!82
M$L'`P)V:F=73T>[M[,S+RGUZ>>KIZ%E658B&A>+AX'5R<>?EXY&.C59244Q*
M2E%-3'AU<V5B8KBVM+NXMUU:6;"NK=#.S&AE9,"^O:RJJ49#0FYK:L7$Q-K9
MV'%M;,[-S-[=W-C6U>SKZF!=7)F6E=;5U)20CH2!@):4DN/BX:*@G\3"P6MH
M9XJ(B-/1T$$].STZ.=W<VXR)B$A%1.#?W=K8U]S:V961CS8R,:NGI*JHIJFF
MI<[,RK.PKZZLJH:$A.WLZ_GX^+"MJ\K(QEM85\O)R'-P;_#O[YN8E^?FY:BD
MHGMX=CDU-9F5DZJHJ*^MK-;4TY*0D()_?L*_ON'@WR`<&S`M+8N'AE103ZBF
MIM'0SC0P+_3T\TM(1X^,BNCGYI>4DXZ,C(>#@61@7_W]_8."@OO[^YB3D/KZ
M^?CX]_'P\/3S\L;$PSLX-\C%Q/?W]D-`/ZBEI"4A(%)/3____R'Y!```````
M+`````!``1````?_@'^"@W&#AH(\AGH_@@&#1C2'@G1I$9*&#86&;QYOEY^2
M9$%_966@@C4'IZN"7F4-L+&P6@BL`W:&*D>##52K#$ZL?VP/IUQGA@*:JW$&
M%JLPAE\"GH,JQ;Q?ITB1E]5TDLN7$>+"PA5-Z>KI4QBC@GI61G]/27]O?7R?
M,AF^GR8$%@@4.$*!-E8!:ATJ0>!/C0RK&@QY]V=9'"126&7H0J2CQXY#5@BJ
M\H+(!"U>`AQ8N8:$(1P<!H784><4BR%`!BUP<`E`!T%,)B@4%$1!"W""P"`H
M-XCGH!<F!MWQ]Z>`@`T[,@I:X*::()B&X*0X92:-(:1_9`@X((&"%8]5_S!8
M.E1#RY\TJB0)6+<N"J-+4H0(@OCG@9Q5#Q2H*3+$P8@$ITJP^'/&ZZ`;NPXI
M$';!QJ42JHS<./0&RLK3'Y*LS%/"GB`6%0:LRM#A].D;*R0,@K/FCXY$IW#`
M,:0!RI\!"@,(D<-<3H7F<C2\Z-E@P(L9`'(8FN'B(0@H),`T\4/AT@T9IP,8
M."V!S9LE7>#XZ5TXYP+Z@X0;FL#%D!19-BAP1"QEA.&:!`M0$,8?8`QB`0"2
M#*"``']4`<(E3"7%2`O8"%)`"IH0]L1/@M`@FR&3[4!''#4P,=H?/#P3QW+0
M,=<'9(?<8$6-<FRVR@MV7:)!:"_R4(`@0-!@P?^23#;9`B8^S+;`%DNB$<*2
M".@F"&\-?'!*!!9`L($18FR0P`T))*"!#LNT`(%M-J!QXB!>5"%0'S4L0(("
MDPTRQQBU]+&$(!#>0)4A-^#'!0>%Z"$)#O05L,,`]QTBG`I4+`F!#!8D,<,?
M"$`1RQ@QR`(+#YX@6$1##0KRH"0UH"%(!!L(@X`O8!SYQP@,#((!A8/]X0`8
M0J2P@1P?'&;($WQ544,Z88PAB&6"&`!&'M1B)HF/H.00I2%0>'0%D7\<T4>M
M@P0@PT=$W.#!)2],!TH&"PRBP3.":/D';S7@>P@22/S!0AD5F-#`7*!8H$"3
M(2A01QP9`E`='C\-18;_EPU8P4,-1(!!A`\&,)5H$LQ),(8<0H#!A*5KY'#'
M'U/04>D]1BQP`P<+A.!$`Q58`0L*<Q@2P!5>_34(@@80ZA$6$!K20@:Z_G'!
M!8>8F>;5&/B@!QC^<F"7`"4X&NP$NT31D"0<6"$)%2V`8,"<AWBPPT&'6%&%
M!Q[<C?>"IR20M"%JK%!E:!^\T,46AP1P;Y-HD'@(!7V<0B\*`NF@!0D;S*$O
M;R0X(``)31C01SI%O/O5<$QDD081!IBP\DA)&*#`.K(WX888QZG&7A4NN+`2
M!R[]@4$8"*#1P`-2'-#'`2Y0*PB:L5A1`2Q]=$#&&SQ4040)'!A`@%,SYS=<
M_W[]E0,$'FFL`P:P^2X0\!]-__&J(0G4($A&")3P]R=T!,U@U$"X@AHP$)5!
M9(`'9Q-!$001AP!48P-W*,(ZJJ`#%YCB$P]P`7`DD801"&(,+_L#"E;QA`U*
M8@RA\4%>#K$`?7WP!)]0`-P.0:\RC&`!.NB!`!:@N=VL@09CJ<J#F((#"4QA
M!1,P&!_<\#H1%J!A#%N8!=3@H4-`P`7E($`/)(``/'@``Q0@@'C:(+9#B"`%
MVB."&S#```:`P0!&F!,`(""(-5PH?%_I7AX,<!4((.$#3OD#%6X0/T(=`D%'
MP!T`^$``(C`M&1<(&@]\X`L6@`$")D1'.J+0*P;YZ_\/>.J#$@SA`SE<#0!N
M2%,*GM`A0\3!`1"8PBFH\`$3FI$#L!@"$F`A@?U=`@-#.2&Y+K$`X\FB!/6Z
MA`("*0EZV<L#89C,YGK#!AYXP0PA`(`3<B*(!RA!`3'Y`PY&>8#Q&4)A!YA!
M%@X@@#XXCS)OL(((!C`'$W:@`1+`A0<FP((3+.\&K3Q:!UBPDBA,KP&%_$,,
M%/`!'42`!1KXPWV"D!$*&,`,&0"'%SSXAR844&`N^($?^-*JH]7+!2T```+T
M48<)S.4!9AE,3/\0!#.L84Z$V1=]<D7*&R@`!X;(Z1_"\+Y3`&$(Y1'D%*B%
M``T$\Q`=P`"3\#`")D7@G8+_L$)1A?D'T7RB""FHTI6B\,E!V(%;EW"F(.Y%
M@BC\89I_((`!)$"`5[E`!8*`0!J4,+X)].`/Y90$$U9`@AVLP0%S<((9M&*(
M`RB@!]@S`P`L@T\;M&`"9``'A-XP0T&@004J8($%9````5B@#=S\`Q.&T(4U
M9(%"LM&""_90@3_XH`?Q&035X->G$)A.6H9(*(+^P(4%0$@P`>@#L)+ZAQP`
M($,&]&%2/ID!#?PTJ(,000VV(`$.,/8-SUJ'#M2QAAYH9Q`P<.HI;A`U'31`
MD!P%10!<``H_#'-7AV"`2.[5@3Q\@@PO^H1:_W"O.%0@!YMSPP<`P(,/O.%5
M$3"#_TA.)X@*)"VPDF"``A#P!1R,X`9&&X0'`+"'(SSA!OY=X1_P.0<12*`#
M%4@`&!(@@B=<8@A,D$(&/,"%&[3!(6C0E0A0`"D+**$-31```_!#84$HP09)
MP,`E_'"$*E<Y<H:0@!6ZL`/G_N$%&R"`_URY!RJ6H0F?&()')+#3J/TA`WZX
M`AVCZR8#>"(H9NCLT3Y!@S24X$F?>$,,5F":E9B!#P<PP`7T/(@W)""^?X`!
M`[K`@!T,$P&?&@02`."9>^GA"59X*@SVP-BTUD!W-EC)`E@PS0?`8`.,F!\&
MBJJ?MQHGL*;[@PJLH(16=<"AAQB!&%X`31``^@]=""0^__\@!A]4HZ220$`!
MCY``%^`@#1#00C6<X$$<]&``5,&C.,W)`PDT9LJV4=XA>34="*EA!\<V!!;>
M]X8+S-00[H5%"O[&-4.4P`2K#&H#IH!70\C@!P@[BPL'48,KO"`);RJC:E?P
M@_<<PKV#6$*I(_2F0;2!`R'X`VBZ&DX68``I`GC">>_U!RD``'>#",*!9U/<
M@=A\#T[AS8J3,``]%*!I4#BV?@[@.L`.1S!V"-U[P4"!(@2``#K@0@YJX80F
M/.D`.C@$!_PKB&4S8`\>*(0?0)&$!0!A#2G@,0XBD`$^:*(FX@2J(<1=ZS]X
MH`1X&.$)#R'<9,*/`D8@0`DZ(/'_),CK#W.``0`N%+=!4,`I/!U$'PR`@!WH
MR@)F8-=',&!C0QS!!5=PPR6HP'4>H$$!"@``&%"/AF><X`2VN8(13E-=Z`Z"
M`8<2Q,B/H``SF*$/8=`&"+HP@!:(`0)X<$H`/MJ,IZ;5[Q?WA\YYT@(7@&'L
MAO!"%_;`A4$Z!0AFP($9[#<(-2@`#P5O`084(()#_$`!:-"`_*VKMJY+@`4)
MH(,+=#"!-:R!#3C@9G_@)28``0A``!_`!BWG`V!``F,V`7*G$_AQ!!>`!J-4
M!S+@!@6P``J0`AU`1?8R"#80`-#V5GX'!B4P0B/0!V;`=04!!GB0`1*0`DJ0
M`FAU"07`U0`0($.#0`-#0$5<,`&#((#"<`-ZQPH/Q@(-,'6"P&CFL`W(X`T@
M*`A1D&M/>`@VX'R"`'=_8`#O90@CT%D.$`4Y@`6'0`,-$&+WT`740@?.PP1-
M8@',1`,,$#R(MP4GL``,\(52<2AG@`<;9`--1%P+-'=5X#1^X`1I<FQZL`$3
M`#=!5!%*`%R#\`$%]P="$$RE-H6#P`1>P@H7P'B"X`:,]P9$((I7F(JJN(JL
JV(JN^(JP&(NR.(NT^(H"X$NZ5HNZN(N\V(N^^(O`&(SFT`)>,`B!```[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>81
<FILENAME>h03611h0361142.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361142.gif
M1TE&.#EAU@`0`.8```X+#,C'Q^7DX\'`P)F6E*RJJ:6BH?/R\3DV-86"@K"M
MJYV:F8F%A)*/CNKIZ+FVM=73T7EU='%M;.[M[*&>G5E65>+AX7=S<GYZ><3"
MP65B8;2RL59248J(B+VYML"^O5).3.?EXVAE9"XJ*&YK:5Y;6F%>7-[=W*NG
MI-S;VK.PKM'.S8!]>Z"<FKRZN183$Y62D8R*B4A%1:.@GVQH9NGHY_7U])>4
MDM;5U$9#0ZFFI3\\.^#?WMK9V.CGYHZ)AO#O[Y&-B=W<V]'0SDU*2:NHI_;V
M]>OJZGMX=^'@W^/BX<;$PX2`?K^]O,[,R[>UM)J8E\C%Q+Z\N\_-S.WLZ];4
MT]+1T&1@7DQ(1S(O+B4B(LO)R+NXN"@D(\S+RM?6U<K(Q_?W]O3T\[:SL9>5
ME!P8&-K8UU503W1P;L7#PZ>DHUM85RTH)T1`/_O[^_W]_?KZ^?GX^*6?FOCX
M]_'P\,+`O_3S\HZ+BY60C;*PKY6.B).1D"HG)R(?'DI'1O___R'Y!```````
M+`````#6`!````?_@'^"@X2%AG\I<8)?A8R&:G:'DH)&6X1"BH=.<).#;V^&
M!Q"$`WF%#U.$8SR37V!_$#Z&;FZ';TJ22UZ2F71PM8-&A\!)PIW'DC8+88)1
MA1L.@PD,@EVL@UI`@P)_!SO:@B&$)V2<X5(=9UFR@C$+`_#Q\%EF@DX/`PL;
M$&,>_@0W!L%QTL)$"6!_.D@H1(/:(")0#%DI\`8*@C]):,`H1*="@(\@`Q1H
M(PD$!D('!A51$,"$"AH*8A;)4</0@CM_BF0XI`:%SY\^-5P[Q,/9'P8:_AA!
M$*%I!#0`%@P*$O#/"T$E9)4A-.(&GA]ZY,AI\2+EH`H++!A`LZ9$"D,=_P:$
MF$M7@9<1@W0$^5-BHZ05':#L""!(!;<.#1CJ(,1A@*$K)QFP$"0DBXI"6PT%
M("*(2L@Q`-*`S,!GCZ`;CCE,P!LN<Z$V$4,40$;H12T!#PI-B3'(304Z$4BX
M`!+E21%<4ZM>_5-!D.L_;$(PL5"&QXTW;`I9X#)!T`#><`=(^;ACS,<OK/_H
M_4,#U#&/@L24.8)84)RY)@C,``,!`A8*$"!1!"5E_6'"3H)`<`!R@@#0P(,0
M-H!&#I2809<&&-"E(2BH91#11:T9DL<9F1`A!C(V"&'5(%4D)8@`(W!23V$?
M)-''+@KPT0,A5+F@PW+-_?%<=%,PT8<$+820G?\@N3'I756%Q#4(".((DIY>
M4'QP2`BCG!6`&EHV$$9]2HG&00(!X`!!""`H,%=-?Y"1@U@(B&5G"V>L,$AF
M[OR10`-TS$B($WX0D@HAJ$6@39LQM?"<(%D,,<@3%Q#RQ@\W9*HI"20XL)P@
M.C`AB`@X_2$`"$L`H8`8%U2A!@QOS%#H'U6D(<$%`4``I'.$L!'%&!4`P`(%
M`2SYQQ<(6-#">`&P@,1'&UQA3%Q<0M#&!U;`<,"50;!P0!0Q*<!!3%!0\,86
M,6G101%<7$/F(#0L!DP%CAGSAQC"6'$&(7,84@85(41`@'0,9`#>('1D$5<\
M;5"`Z`!J=`?"("$\RH#_&HL(H@$:"/WQ!D)BF//I'T``H$0(`$@J2!X@Q-!#
M&I(V@,0?;B`H"%6"["IDKR&X($(9"]``@;%^<L$$&%P$<,4:Q"XQP+0#0&``
M"@@P0`$42G";!!2@G!AD(3X`,(,B$>STKB`T7$#!!RT$(($.!E3@WB`&-!PN
M"3,00D4?=2BPQ@4*:"!""PV8\\<$&FA!V%F%H'8$`T:T.8,"CA(2`!*@F-&%
M.">TL48=[CD@0CP8.+PB(5JTP`4`5!"BA`95]/.`"6L\X,$.323'*W.["\*&
M`@2XL<8?3RC012$38"P("%&0$=Z4*[1AQ1_<_A'!`RGT(48%0ZA(R!5E1$#$
M_P1'%(I8'4;`,44"+Z#!9#1_8)!W(2*H,=D?1^S@!"$AL)8`"G]H0$",8)0O
M:,`!1/C?3W;0.,=<H``3"\@!@N"](8A*$$APT1]\@(4;].L/_9O*8DXW"#]@
M@0``*`0/G'>:%^S`=#P*R!MT]AP)V.`/36"@(!:PBT%@@$'_0D(F!B&EY85`
M!1R@7E[V`H,_18!W:.B.(*H``H_$P!EN.,`%B("`!L1!!"B(ER`.X+XCE*%C
M-..`$8J@(@R<A!`00(`&.-`&$=A1!!<@`0=L,(4F$6%Q@OC::1S3@`1,[`H'
MD$(?QC#&08"A#6CD7WJ",,*1_>$,9:!`"N/S!R)TB?\Z;KS"$0H1!`U<X`=9
M".3NII"TCUS`!$WX2!T2<((_N*`%(#I6*I$`0T$4\0]4^L,,7'`E&JPA"P;8
M02V:HX0^I,0&%=A>`+80@1D4(`,72`PAQ"B(*R3A`@XAQ`4P%H<=/(`#X!C$
M`!*0D`[\@01_6$(6;/80!?I$AX.X00M(@``H3.P)')A!)`V4!J7@84ME@-`9
M*EF(,_1!"@"`7PTZ\`)0A,`/&2CD!A`P2N*)8`U0J($:X/F''6C%$`[@:`2X
M08@)(,$$@GC#%5P0SS:D,R$/*(#M9O`$#TR.6P7@P@*TQ+N2[B0/*J(7'=)Y
M-O:,$'\R2&(A!%`"9OQ!`0#_8&0A8O"6#KCS`0F@@*`(000U]*<_6&A@$2@0
M.:S4X1!DF`VH(F`6BHV`+@QHDB5SL`8'`.!0?S@!'_X@!!(H((`)@(,)=K`3
M!<2`#G]P@`:0TX`;6M(&:#``K4BP@4(4@0:@"I(;2%`">W4`0&=-;1<@JYZ]
M5$$JJOS#`VIR0^8XAA!-Y>8;6I"#"KPE&&X1A!<2*`,H=/0/<9"J5P\`!B0D
MP!&%^",A!/D'U$Q)`"U``1$6`#^:/8$)`J`+!'9POT'8P68.$%DAM."P!+SQ
M#P/HPA!84$O$TNP"'Q0$$-!`5$)L$KE/J`!-!2'9/N25$PP`+0P6L@TMC("E
M'6`!_U"`TH<JK2<%;O`!#6BPKT.<X;9$U.8?/""!+'0V!32860'*0((\'``.
M'6"%`&*@@7Y1$0`<N,P#3'$4&4B@%FK@PP@8<-P_R&!Q43!`+@<Y"#;<%1$[
M>($4!*$$`/#!#QR@P9]88$E#N)0((YL``+HCABY8=0*@)<0>2E6(.?R@KH1P
MV`0:P(#?%J(&:&"M`Z(0@>F!S5X*@),AAN`>%7"A$!@82B$DL"-"D.&P@_`!
M!R!P@1GD]P!(F'((;&`'!J#@II%E`">FO#*_Q#0##!($"5@:IRL48@%^_H,7
M[*44_LV"`+19P%/_`(,!"2()$1@H;89-[&(;^]C(3K:REQK-;!>(6!`^4!FS
2ITWM:EO[VMA.-A6,\H=````[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>82
<FILENAME>h03611h0361140.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361140.gif
M1TE&.#EAU@`0`.8``)B3D?+R\>[M["LH)XV*B<'`P+6SL>;DX_7U]!42$H!\
M>D5#0]73T;RYMIZ;F7UZ>79S<4Q*2E114%E55+BVM;"MJXJ&@UY:6<C'QWAU
M=,"^O6%=7&EE9-S:V:RJJ.+AX%).3-?5T^?EX^KIZ<;%Q)&.C6QH9D$\.I62
MD;RZN;*PKJ"=G$A%17%N;+"OK<3"P86"@(.`?LO)QVUJ:G1P;I&-BN#>W=#.
MS.CGYCTZ.>SKZI61CF5B8<W,RM[=W,[,S*6CHN'@WM/1T-K9V*NHIJ:DHNWL
MZ\C&Q-74T]C6U<W*R#8R,CDU-:.@GEQ85ZFFI<*_OO3T\V-@7LK)R(>%A:>E
MI-K8UZZLJJ^MK+^]O/#O[Y*0D'MX=B\L*_'P[XN(A]'0SY:3DNGHY]W<VZJF
MHU513_3S\ZFGIAX;&N3CXC4P+[V[NIN8EH:#@D-`/TU(1CPX-H."@JNGI/O[
M^_W]_?KZ^?GX^)B6E?CX]Z2AH,C%Q*BEI"0A((^+B*RIJ/___R'Y!```````
M+`````#6`!````?_@'^"@X2%AG\R`7\"1X0X4X0K`C97@PY1A@%G=7]M.H9S
M<X=_`6.C?U9)AT8_@TB"022C6U:GA"DI?R^FA0$"AP*UAWFYAR."2'6*@R*'
M.'1_29^VO=2"'P2<9B\BW2(?%EZ#7$5_#&I:<YP83(,!:`<%;X(=$YB%81=F
M?PDX@@4(!/V`4*&@P8(QG-P3)$K0B`'3EOV),D&%H`M7,-"0PJF0E@1%NGVX
MTG&0!R)_3'#X<P#$'3N$;H!H0+-F`Q@2#D5QTX10D$%]`#08T(-@038GM!CB
M@(*.`V&$ZJ@H0+5J`0H3FHVB($-0#!I_-$S80G:+B0$&!L7!8.[$'Q%+_^I@
MB#`H2X0"6]S4(/*EG$<^R]`(^C)@SS^Z?TI8M'6"0DTX*F@N0"E(PP!!$VS\
MV1+G4`86<D*7`>&/4!<A?T`LUL&'[2`&"PX],0'+CT$8`PXV24!`4!PY`5C\
MF3!HKB$["<#\$>+'&C.WYCP$'$2@JR`<86YT`4)``!8@/0FM;?L6Q!_C@A10
M"%"`^!\)1DA);)'@UQ\T42)P65@`L9L7@X!14@<-_#&`5K;0H8@=B'%FR!@#
M;"&+%6A()`@4.0BR0`B#X("':^8,4$,-%HP80PT;N/='22Q4,LIO%#3BA#<&
M($8("@\,P@0>UHSQ@PC0F0.6(!XX(4@*Q_RA@O\5!KCASPH#M/)'`W),T,8,
M,+@E@GGHZ7#"%#68H(83(:A100DL`"%($1X(]@<>"8`@3`^'_?'!$@"88`$`
M$U1`B`D4'%B(`'T4@H`/?V`AA2`4\+$`'_$M`H)2'*30!2^$T+`%!ABX00*G
MG%+PQ3*P">*$!RF=$8"%@CP!`32M3N.;'$,Z`:H#-@JBPP`2O;#H(`@<9-`6
M=P01Y!]W9/"'$3E`(8@5()#PPA!(P(``!$_\@8*R?_@01`8&B/""EEPBMD("
M/+:GA0$KN3##-5G<UT$1*"1`"!N'T;'!3Q>PNJ8+`S!``:@IL.`$:G_<0$$;
M)RA!`Z(7KM'!(!24=@?_;X=T9`"W#L$JB!`+@($!"W=@T,(=6[11"`,)`!!:
M:$L8II8<DORQ07&YVC%#*P(H9W,+20IBQG1_I`$3D(38D(`.*M@[R!8/<$#'
M&K^84,5$-XC'%@/";7D>8C4L,(8?)FQ00Q-Q&(%""86@(8-F:(#!P-P2J-(?
M`_$.QXP&@]3A!1H(JD``!3`1\D0,#C0@%$T3T&9(%1?<$<$=]ADRPP8.&+0`
M%H1,P8(!%9S01@4\M&$;(3]L`#@A$S`@'G`MU-'G%Q5\89X@=#21AR!7+.&/
M`&Y,-L@4$[PLA6%($Y+`"E3P48@7)D#Q`@8&Y,`#!B^P@.EX#!#GM7$]#)'3
M_Q\7,*!%'4V0P(42;0ORP@,3Q#_!!?X4X`8-"BC`Q0#Y*U!V0%Z8#1\:\@<F
M4$`V-6!4(_[@!KX10@9.B($HYD`#-/!@!;(PC1Y6((@0+$`I.,-,`?Y0@Q$&
MP45^X(*!L&`5%KAN9G]P0A9NQH,_>,$"=/J#!](BB`B@8!`ZR,!/!(&!V`R&
M+<D;1`XB<)9"%"%K@@#!`-Y0H$*,AP3F^9Z-QE>&/H!@!0$(P\VB\@%!4&$'
MA(!5?XJC!I\1H@\MX`<A%H`@PR5P#@$PD@LN0(@B<*`-2Z#*":@"`BFP8&*#
M$(*R4/"3'.1M$&N(0`O<(`4NT&`'.[``)A-6&D$-HO]UK_O#`\1(OCG$0`*(
M]-@5>$!`0Q1Q$%]`XK%2TX7]#4(/>>@"K)JP`!,\`956Y($",E!#$<P#/>\1
M!&TN((;A_.H/+HB#-*7)@@E,4P%\2,L:+U(!$IP@`T2C`QT.T(Y!T!&!!:@$
M"I(P`(0)`A.O3&9*LE4()J1A$3GX@@(,$88PS',.<5R!&CA4B`%D8)IQ8,(+
M?6,!":"!!#<KP`:@6(@YY.`8(X#`(3#`APQXU`VR+`0(<A`&I_U!!VT0SA\,
M,($1^/(.;M"*[5H`H!9<301=^-H@<G*$JSEO.!S3PCY@*8=#K-$&$#C@1&90
M0T*<04WFK.,@G@`"!7`"!PG_T*@K`UF`018`!/0T26^\D@!5%`("BO#E'[(`
M`140C1">Q,Q"__";%P#H9A9U8!I;\`I!&(`'K,*`BH!0BR0*8@`<Z`$:(J4D
MXAA@!JKP90`V`(>L^:&*/6B!(KR`JI'ME`X7>`$;VH$%'D1`J89H0U$-T1\H
ML*&,@YA#%430$(KP**J'`,(`E-(!#E!A`5080B'B.3ZUNH(C$[F#$QQP@A*8
M]0\VR-$\DW`#*K0`"@L91%R',]??#.("60@#%%@0@QO`2@#Z!!4&"C``*@P*
MMG]H2!#@0`@$)$`6,QCK'[X@`0TX8!!J#58A>@#8X1KQ/09`PAP4L(85*$L(
M:%!`_RM]LSM#].YE&)8#&=[@N"<L4``Q8$)]#C&',7R@#1-`)`\2D(/G8F``
M``"`%&)\@O!`UP)'X@`]13"!!+3F#PZ`HA3@<`=!9&$)"2@#8^^C%<$Q@:"S
M$H0=W'"[(#A!#0[L0`(BP(,8;.$*-WC!``Y@BP.L.$.#*$!.69(#6.D`M5X9
MH2%L`"!#"`"1?XB!K&!`9D&((6B$J()U"H&'/MN"`2`2Q!3T:@@+G*%R@A!`
M:021!'P1`@R3#@`=.E`"S?1"2CD\3Z+M=-M!T*`D>?"+)?`,7Q(?@M&GN,)"
MZ4"#4`=A2,[)M:YWS>M>^_K7P`ZVL`UQAV(,P@N>'K:REPS-[&8[^]G.$4&R
$`P$`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>83
<FILENAME>h03611h0361129.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361129.gif
M1TE&.#EAU@`0`.8``,'`P(6"@K"MJ_+R\1@4%+6RL>7DXY&.C"LG)YZ;FO;U
M]=73T45#1*RJJ7EU=.[M[(!\>LC'Q[BVM9F6E4Q*2E%-3'UZ>=#/S65B8>?E
MXW%M;./BX+RYMCPY.:6BH%124962D5U:6.#?W>KIZ&UJ:=;5U&)>7(F&A/O[
M^]C6U:">G;R[NL7$Q*.@GKZ]O.SKZG9R<<"^O<_-S%E65<3"P<S+R8.`?JNG
MI*FFI34R,C`L*LO)R/3T\\/`OM/1T&AE8]W<VVQH9]S:VM[=W.CGYMG8U]K9
MV,[,RHZ*B$$]/(V(AHJ(B)./CO#O[ZNHITA%1+NYN*:DI).1D30P+SDU-,O(
MQ^SLZ^'@W];4TWMX=K*OKL;$PN3CXJ>CHIJ6DY:4E,C&Q'-P;DQ(1Q\;&I>4
MDZ:CHJ*@GXZ,BPD&!ZFGIEU85B4A(1`-#?W]_?KZ^?CX]_GX^)B3D-+0SU-0
M4//S\I",BQ,0$.KIYT-`/\C%Q)V9F*BEI+^\NLC%P_?W]O___R'Y!```````
M+`````#6`!````?_@'^"@X2%AG\I;7]P0(0#!H0N`U8Q@G02*(8H$8)E38>@
M?VV0H!LCAPI$@QN"1$6@4*JA@CPOLW\**GZ$1%&?ARPUH'""`VV9@SR'R$+$
MM\^&#RUN@CV%.+]_'P)_&0@#@PM)R']K%PLY@CYXY(,>,^`$C7]%BO1G`OGZ
M^4@,"J!-&'`19.\/CSG"_IBXP0'&AT-O=#@9E,?0BP8?POS9LV"!C`F%0'S8
ML&`%&0@D9E0Z5,&"HT%F"D0(`<"$OBYXL@V2`A*)G$-[;@@=*A2#B%!'%@@*
MX_)!#@=0'02QTV#0'`#="`CZP6,!@T%$UBS0TL'%B@80-$T9(DCKGQ4$_R0(
MBO#U#PL7M\X`B,`WB1F^(<H,6J%#4(579((<@I"$B6,*4]X,HG."Q)HC@NP(
M1;)&LJ`K8WA4X?`"``Y!R*SPY5N`#8O5-!!($;2$TXPW8\(A.$0E#2*YT-IF
M&K)RD(")Q4B\^!'@!AT:,1(\('0UJZ`9?[P.BJ+"!]D%6&S0$/1/4(`QI+0Z
M>')J;MT99@892[;ECQA.M]H<_3.&6&)#/""@A#`\C('%(0PH]8=;V@GR0@5L
M^`#`A%)``(`+4Y"!2Q$9=(B!!1V&V*$BM7G@VQJZ&3(!!O94X,PL"C3BUA\[
M:"3(!7@((H1Q*X@@UA\J3)$!=::UX!9V#?Z1A/\16F2!P`Q;A,!$'14XD$D$
M)^365A)09*(@77\,@(`&&L#@@("$!+$#!?@1TH4A_US0@2!FK('!$Z3\P8`1
M5@2AP!18(7@$2`S6180';Q"``CA_F(:4&(3(4$AM#NPRA3Y,[%8(`OO]H4<`
MA+2A1!RDEDH""7?,^`<((+G1P4I"B"''$!(TH<$5>L1W1@B"',$"'A-$T,.1
MV=4%!AH+$'$!`VWT`$$3,LPAR`@M\-=$`4S8P>@?6;CW1Q"<_-`I(04<0$$!
M>W"@;@$F3+'#C5V<\`06)!R(RPHNT$#-'PVD(`@.!"!A"!<X",#&`6FD8`=?
M>]0UB%8I4&CABOL*TH3_#DM,."$>*A!2(CA3I$@(#'*A8,1U:85*#@_[JLJ%
M'2_4@,:V*F"0!1$N[!@`J`JT^4=U&6B)9%T@X'%!%S90X(4-7<BQ0LK(C"%#
M#"B$-L@3.]*5`G(5#(E+FW0HD$2;14S`A"R#``!!`AZ4L5H6#A#B&0LAV%"!
M!!4/X@,:"?Q3:"&%50&%QC$4`$#%#V"PAL_8>1S!%76@<&D+`C!1V"!0@/I'
M%3I,AT4'&+0YP@\:6]#Q@H40X`0(=LC]`@P7%,"!!#.8H.X4F`D"M*9#_W&!
M!%W_\8,H;FBAQ00L%*+E`D$PX+SSF$6`QQX:C^'"A$S,49X,8>APP2`5"&8(
M_P`:-KIC&Q]H4<@+%IC`R@-S3`$"`$/8P\`8/U2`>K&%9$"3Q@#X`A7(D0(,
MC(`"S1G*G!SW+0F$3`]_>$$=9+&%,PR"!'$3A`B>`$%!9.!R?ZC#:?8WB!S`
M(`"J^H,,]C"(+!`@!]PH1'46L,#>&69(,UB/%"YP@!_8@A!\$,09#G`(,`EB
M`P283B%40`57=6H&/DM;^?PP/`GD:!`I"((:=``!"""@BWCHP!B<H`@?-.\(
MH%I8!!K6O\O9X$``H,`@9``<-A&B<8.HS1].L(20F0`%`D#`>,*$N2?,XH.#
M$&%;"L&`*9Q@1@I``16\EH(Q."`+(?",52S@@`#H[_\/-OQ#\!03`A:@(`OI
M$,0.B'(##"3P!GO(@0_^8,0_."`!3A`#<@3A!G"LH2!0/`3Y4N"!/Y!`!!6(
M89A.MH!/7JXY@T`!!MR0H$7RCQ"(_(,.E!+'0R"0*`O,HQ?",`4<A&P"(;@!
M*$*@E"94RQ!!<TSV1IA"!B0A`6P8A`$L@*(_#`$/<@C`$LR0!'"T(0TF",$>
MFA"`#LHQ25V[@@W^T`%6M&\07#A'1Q9@`8YL=`&G`%,3;#";/R!S>)'2W'6B
M*(B:6.`33<A!&`H2#BH(90Q"F8$Z!4&#(55S?TGR8&$,H*5N&H("'NT(I!RG
M@@:X(60HF(&D#!$`X/R!##;_*,\@/ABB$P`GA3K(P@70H$05YJ@$/X#"'P3*
M@PI0X'L34`$Q4F`"SX"$AN#+0!@DP((QM&$',^C`NPYQ`);2D@$T\`(-"I*!
M)2AC$"$85S`-D88Q[&@`**E``K8EB&8*XID[%84@?EHH(A3D`2!HPPDTT``0
M?*&#A;#C(/!(FS9-001LHX`*RNH&)R!!1`N@0AT*\9Q!C&!?K2.$';A1@0(8
M)PD[L('7!(H+*Q%B`R0H02$6H"E1TF`/;_C`%VKP@ROX@``3>"P##0&%'`#P
MO7/0W`[B(P@OG$`'@RV$`K9`!RT\02Y"H``;PC"0SE(A'TG(1PB*R<@:#(X"
M$VH`T`9"@)=!`.&2GR'!&%)&B"?@)P\>"&=M'T:%Z?B`"F/H@R",@`8=B&$&
M00@`$QR@I5`\(`MB2*X@@$``R6P@9*V`02$"\(5#9"`!+]+G"@9A@B`*@@G.
M/:)5"3&!61IB`.J[Q0M.-X@>V("FA&""!;Y'B"*\8A!%X+`@M$!F0@2@K$:V
M@08*H-Y6?)(0),C3B@KQA3/_`0QYT^0?T"8?D#Q##[X9A`V6K$HE!.?1D(ZT
BI"=-Z4I;^M*5U@*#T;PC3'OZTZ`.M:A''9P,).0/@0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>84
<FILENAME>h03611h0361130.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361130.gif
M1TE&.#EAP0`0`.8``+:SL>[M[,C'QX2"@I62D/+R\=73T7AU<^KIZ'9R<9Z;
MFE)-2W%M;*:CH8B$@^?EX["MJ[VYMAH6%J"=G,[+R>/BX6YJ:,;%Q*.@GD5#
M1'Y[>I&.C5924<'`P-/1T"TI*&QH9I.0C^;EY;BVM(%^??7T],K)R.CFYL"^
MO=#.S4U*2HJ(B-[=W.#?W:VJJ>SJZMG8UXR'A%E656-@7N7CXI*-B<[,S+.P
MKW5P;TI&16EE9&9B8.'@WYB6E7QX=='0SF!=7+"NK3\[.M;4T[NYN*NGI%Y:
M6CDU-=O9V#0R,;Z[NJFFI5-03T$^/;Z\N\7!OP<%!HZ*B??W]M?5U*BGIZ^M
MK,7#PB4B(O;V]:NHI]C6U:NIJ-[<V]S;VBDF)<G'QH*`?_3T\^_O[JFEH\W+
MRHZ,BS$M+$5!/UQ85ZFGIR`='!`-#H%[=_W]_9B3D/KZ^?O[^_GX^/CX]ZZL
MJ_'P[YN8EZBEI/KY^9B4DRTH)O3S\O7U],?$P>GHYSLX-____R'Y!```````
M+`````#!`!````?_@'^"@G"#AH(%"(8T`7\\+(0$<8>"2`J3E(,>E"(IF905
M&'N9)5*#*R^?GUT%JH(W"H8%1`EOGP=(GRV"/&]8@VTGF:E_)GJNE(VN-AL0
MSL_."0=W@S0[/P%^%<5JVY1O*CBN"QWEYF!GR()?5ZV48@R0)Q(BAO69<2@:
M379B$^5!0AQ:T"/%B`D'$H`8(&;8FDV#<@EJ`J%!$R1,GA'@4,C0&R%*_F@@
MYG&$N9,CA+@[]`/"GPXK!!$@@XR$D#\<'(BTHHK&$4299%!:`N+0G@G>!AG(
MH`I,S`8@3E)ADLC-+T%:P"A@(NC!`D$=N`XZ`"*..R`"!"GZ8\#%,Q]'_Z"Y
M60-`T(<':1(\^#`()B4B5P3A^:)NT`,)ZT8,&B'P94PI$DH,FG*(3HL+194,
MZ1#K#^$_%4*X&4W:P1HBE(20)KVCZ*`W5"DMS30*C@$^1]H8ZC,(RQG)AH3^
M\0K6]1\7#&8T\,&&C9D=;!*H<?+'EJ`7$NBHNNM`RQXO#\)7B6FHC9$T@CPP
M*$S$QN%!`L#\>?'AJM\E9]S(J!%CP0]#-S@`#008N#4!%!@(HILA<.QP!B2'
M"&<(48:HP)-L3`DRPCTTY+#'#3XDL((Y=DB`R1\>?#4<!13D,((1Q+WD&@TF
M4&#<'VBIP@`!@\A!WB!W-2#(%0(4V<./@FPQ@_\A&M1AR!X8#`A!"&F\-P@'
M1`"Q05\KG)#`*&J<.,@+7I@@FTB?90+&#*-0@D8$$=P``9P:Z"2("1(L>(@!
M2<`9`0,A+)@`$1B0L<(7%S@0Q@\J''(%:B((,,$117(A!)QEW&AC&V,4480*
M,12Q@QN'A)"$IY[B(0$-AMRU12M\@84D`CKP\$<?BKP@1`]Z_G'"57_\,(F5
M@I#QP6E<`F"#((CQ8H`@+1SP0Y3/1.$%!EVHL@4#RE!"P"Y3Q";"2CXT\<EL
MF=!1@)`RV*H##`(8L<<]?X0S"`,?N`!'C!W<^(0#<'A@P,`&6/'%$(8T@(98
M7<4*Y`-$1/&'&A#4`<'_`#P*\@8#_XD$Q"0>2``"33(Q@*H?J!'[!Q900+$L
M6`DUYX,$S;$QPP[6'2('##I<X,H%1G1$B1Q>3&#`#6<,;,('$*IAQ+D99M(!
M&S5(X`8!H^'0!`-@6`=$#H+$D003*\"H8K^'K)!#S<VIH.(?4D2!@0$YG%2%
MPW8]\$?0?,42``BIM.'`/6*L`>$?+>#0YA\A##"("FFI_,<:4#PKZR!6Y+`+
M,@E8,,@<+QMBPHV46(!'>"CD$%YX[D!!NE)14R*#&#3PY<8-?R@AL2$@?"`,
M"1?(0,<*#YA10PT6D+Z"XW\TD2T>-2@UB0$2#H?W'W?]L0,%?(401PX.$*,G
M_PF=?=+XXY$W.X@$E7,IR'<T9)'#EH-4T``T.R3PS`H;A&&('>)0A18TL"`#
MJ`@`W5K#ZP2!+I;,X"L74!$'WK"$.1P"!'[8`Q*V)!Q^*<]Q!9!`(:`GFR,,
MX(0#.,#U/H"!!21!#GP9``-(8H@(:DA(E`A!$P[`0R^D[Q#L2\OE3,"`E_&`
M"1I010V6\`D/'&`'P,E$!3:`!2(4R0Y-$,`%HA"$0>2`87N*G2'2$!,'<`!.
M&/A3&1)`'4'(0"BX^T,'S_;!XP00#WB03?7V<HB[!.%9?*&`"O1VB`H<H"%_
M@`,)RI!#1@KB`#`8COH$L88K;"%9$UB+(`(0@BGT:O\0,6#B(>[@`S^,@`!E
M&$*O"J"%`+R@5P8TQ.848`:H&8((51"$`F+R`P.$IP(/P,$('H#(/PC!D6[L
M"ATOH*<+V``!1SC("GS0`3T:@H^M(F0;O+"$,63!#Q/8W!^08($Z%$F+:5@#
M"@[!!4UVA`>3[`,4EJ"#0=3!"*C*9Q'&<*U#8(`#:HCC(5"@C!$<00(2R(,$
M**>!`HBA`^<4`'[.B0()."D`:T"D`]AV@!FPS0A`H(P.D/0''"Q@#<(8!&22
M(D<NX,`'T&$##G0@`Y+-9PX<\,0?`G"`-711=(T2Q')JF4U!B``*=DI!$F0@
M$0Q<@0D,<$`=1M""'IC+%1V&0,,:KBK4HF3`<E+H5F%`@[.Q8N$!!%.0F%P1
M!/J-51#'.(0++FF(%?QT$"%Q!0!\4(24&N($=%5*^?[0@S8.@DV#Z-@G/CF?
M-+D"`RMY@QD:LH<!<.&MF,UL8990%\TBPPDX]*QH1TM:2L#A`$G9@^5*R]K"
3&$"LK"V`35M+V]JZ@@7$"`0`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>85
<FILENAME>h03611h0361131.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361131.gif
M1TE&.#EAQP`0`.8``/;V]<C'QZVKJI&.C1(/#^[M["PI*)Z;FJ6CH>?EX]73
MT55147%M;+FVM4Q*25E65:"=G(!\>HF%A'EU=/+R\7Y[>69C8>KIZ$5"0K2R
ML;RXMG5R<6MH9[&OK>+AX&YJ:=/1T,_+R%];6IF6E=S;V>;EY=[<W-#.S:JG
MI+"MJ\3#PN#>W6%>7+.PKZNHI[V[N6AE9-C6U(J(B$E%1)62D5!-3,_-S,"^
MO#XZ.>CGYHZ*B'QX=G-P;JBFI=;4TS0Q,(6"@9N8E\?%Q+.QL-W<V[JYN.SK
MZI21CN3CXK^]O-?5U,+!P:.@GH2`?OGX^,;$PH:$A;>UM)*0C_#O[F5@7CDV
M-MK9V+:TLL[,RXN)B,O)R,K&PD$]/;Z\N]G8U]'0S\O(QH^-C.GHY^'@WUQ8
M5XZ,B_3S\NWL[*FGII:4E5-03X>$@AX:&3PX-R\L*Y>4DX."@OW]_9B3D/O[
M^_KZ^?CX]_7T]/'P[\+`OR4A(9B5D_KY^:>EI*>DH\'`P/___R'Y!```````
M+`````#'`!````?_@'^"@X,-9G]$!82+@GP7C(Q8?':0BQX4E7\YBU-AF)F<
MH`&?BR0NA$)(H*N$:%Z53H*8<80`D'6"8ZR[F09%?P,?JP=DI)4(9)2"5[:#
M9D(2/T&9:P*$=P1(.Z^",BG?X-]!:B2"3R,I64."13604"Q_=&,4#S=_!4J,
M8R\I?O]^TIB`9&#:(&5_*@@(,$,;.#YDQ#!BT.'/FD>,7*#8R'&C!560[%@C
M9$#!GS=P%M%)P+(E&24LO7P8^(?&C@@19F#`&6''@P:"D$A@4$./H!0=`@28
M<$\0B#:+V/Q),6*0`T$>6F1"(>//#!L+`[!1NJ:$K!E4J&RP0..!B`D?_Q@(
M:D!51YLF;_[(,/D@@":E2J\04`$XB0$(@A[X,5'ESX-!(1XOHD#`QQ\77W@)
M(C#G#Q(MA`I,0"BHBDF4@@K8BM,`L&O7*QA]0'PTUJ(W?@2A=@QTT",J``G\
M6]!%T-4_'Y@<I#5(@PPD&.R$(31%C=D_%CSD</.'R1-$D@EQ"%$S[]X_'!+\
M`4"BI1L!+5MB5(R@H@C(X0>-@)'Z^"HD9A$P2`95"2)"%(Q@<%I*)!@@S"!%
MG+!(!=<-DL)&!NC`T1L2WN:'$64<D9)CN2W"A7I_2$4!+L;]40<!###`PP1N
M3$!("#((<$(-0A`2Q!2"G-'"'7]<\<<$1PCR`O\%&8A''@HL,/&`!$RH@>(@
M+?CWQSJ$*$;;`N#HD-\?)1B`T`@%"A)'$W*TZ>8'P@@X"`]];.F`;5@0%H!I
M)T6`P`9=V":(%#"\E@<6@ZP`F!]L+.':!",%$(4?&$CAQQ)KC*C8'V"DL``:
M?V"0@!T4Y%$3`YW]<=4("&Z@'",X#D'$'R(1UD`0=%B5@@:\"M`!KQKLX`9(
MZ&W1`A/FF90>(5^PD0%`?A#0XR"*#=$9!_C5,@$>@FQB1Q40,"?('JG^,46N
M?\BYS`]_U&!C@J<]8"TCNPUB`$U_*(#`-R)4\`T9WZ#1E"`E$+##0+MM2@L'
MN6%PP`01<`&`"".I:H+_%()PT,,@E@F"XQ0PD"8(1B?@\,<!':'```E\F/1'
M%U?4H`,/>.EE$@S$?L&!NH)(U:4?(%3PQP(N')""#F00`H%!#=2PB1)L;-#A
M'PUL`!`,"&Q&R`IY1,%&&9`H>-*(])(M2$F,K&#`'SQ8T<"KBTC`1@<&')%P
MB>CE=N(;,D#A0QY&6)4$0%P,\,\!:G2,8Y%-])!!&E&D480(NE"[R-J,C/>'
M%`](4<,.4LQ0SLL;7,!&RCR3^`<,8G!@QP9_)""%!X(,47$;!PSRA1H;"])#
M>!IK3<@,,!"0%[QC5Y(%#TIAH!0.FX3FP$#I4?!#FH)\X<`1?MC!P=V#,/R'
M_P%.9'&$"ST1HF4;W\':%0CLJO"``FI`\H";;?J\B.9$`'E>JC?01XJBLHA-
M60I;PA@`#OSR!U+@X0'B8L3OPM>[U#F@!@2@0=@6)(@[3$L0`,C:'^HW`A8-
MH@XB:(`#`L"!#G`A"#^8P0L&80$0R*!$X,N8'UY@*B@<8`P$P)>J!@$$";Q@
M!F"[T03*4(6NN&`#]+/?(E!0KO"%H`&(LMD?FJ`(0IRN(ZE[0`4^\`,O8`L"
M'RA"!`5A!S<`Z0MUDN`/I$!'+E1P$0Y00QZR,`@Q1$$'$'`#!_^P@MQ9R`"9
MJ9\'N)""00@A#+&)@098P(#,%&`#(@!#'`8@H1OJIO]0#,$;#!YP`!Y\80$-
M@$`>;("$WEP%`&4`@BT*8($9".H%,C`"$V@Q`01$40M:H1:T_,`'_@S""PB8
M01-.<((N!.`#?!""'Z(W"#8HX)K7#*,?7+`Q;!FA"A4:1!PJ,#4)#$""5F()
M`WK#LSE@@`$+@)T@>(#*/PBR3X*P@04&<84'@$`0]?N#$-CPBS]H(0<"6,,!
M0,"!#,"``Q*)A1UBHY<2T6`Z)YN5(!8`!`98H0D.2,(#P.``!-#&`0HX0`O$
M10?6*8,K@_``"XP0Q248)#&+",`:"%$#"[1O$.=9#P&]6$"\<<`'*)M!"KK8
M0"8,H"4>&&A!CPF:D:&+9R;_R$,7A("!9I@0;0+(`QS@,`,V!"X#&YA"`48@
M`W<(8@,2..$"L$`"/SA@$U0X)R,\V<!*&*$/&(W!@YI`@(U=H`W#A)8(XO$'
MF.;K`;,B01[>(`*W)B8<*9!!5T[(1A>`@PI'2,$:<,#4=`T"#SW09C6/<P,#
MN&$+@G`!`7[@@`<P``HTB(#^*J&$'<S`5(/H@,F0TSM"3.`0^&!)#G)E!`&N
MIPI&&H2@"/&!'0RB&8MHP1E6H817&4$/@F)"1?Z@@EU<H4E->(&X0!``+6QW
M$%18A`(0!(DU5@(#A-"!/&GX3T&H`+MQV(,XB;2(.>A@%SS(HB`L4%`*K&%T
GFHFP(80G3.$*6_C"&)[P`'HC"#I,-<,@#K&(1TSB$9^!&W\(!``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>86
<FILENAME>h03611h0361132.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361132.gif
M1TE&.#EA/0$/`.8``+"MJ\[+R/7U])63D<'`P)*/CH%\>LC'Q^[M[*:CHM32
MT9V;F7EU<XB&A?/R\3HW-WY[>>KIZ'9R<101$5514*">G"TI*&5B88."@JRJ
MJ5).2^7DX\;%Q-[=W.+AX'%M;&EE9%E656QH9[6RL6!<6]/1T)F6E6]K:L"^
MO>#>W920CHV*B5Y:6=C6U:NGI$5#0^CGYMK9V$U*2>?EX[*PKHJ(B)N8E]#.
MS;Z]O.SJZN'@W^3BX;RZN86"@-'0SM?5U+BVM:RIIH.`?JBFI=S:VL3"P4E&
M1:ZLJC$M+;>UM,[-S,+`OMW<V]73T;JXMLW,RLO)R*.@GO#O[D$].[Z\N\7$
MPV-@7K:SLJBEHTQ(1X6$A,G'QGMW=KNYN>GHYW-P;MG8UXN'AO7T\^SLZ\G&
MPY>4DZ^MK5Q85U-/3C4P+R`<'(B$@JBFIK.QL$,_/OO[^_W]_9B3D/KZ^?CX
M]_GX^/'P[_KY^:>EI(Z+BY",B:FGI??V]B0A(?/S\JJHJ/___R'Y!```````
M+``````]`0\```?_@'^"@X2%?W`F?8-04G];.X-4)8:"'$>4@A&4"&^8A',!
ME#$V,W\9.)Z"22.8<DNI?P)@J4MB?PB",W2P4"B$!%>VGJNP"'<QGDLPA30=
MM`6[F#I/A2X_A`M$A",$G90;$#Z>`H)PL.?HJ3E,*!\N[UCO\@DA3H,Z5CLZ
M:`Y_.1IF,-5@X`E$%``($X+``$N`"2B44#QH\2>$#5@&UA!"%LG&'D]['L@;
M*8\/E3]E%@#(,F!'B28PDXCH)V@@(2$7-`FB0W-0QD%O('@HM,%(DD4D<`EZ
MP&`&%7)_W)C)H;3/%D)E($3S@4>.E!)MN%#XXG*0A0J$U-@;%`+#'$PT_S24
M(N1,$)=W7X:H('"@[X$3LP@U<@)@P8!".?PJ]DN%@1A%A'8PZ*1A$(N+E/8T
M06EOR*P5A^U0JK%9T)A"%$H3PD`F%9PS3#`1$"$HQ`%"=G`0V+W[@AG>"29<
M&O1$B!Q/+RCEH&BA9J@'#FY4()EC$.E#@C`,$92G`PP,X,.+#W]I#Y$9,VZ0
MF*%@#0(2P__(X7,E#)(H8>),B1-"AJ`Y?(BGP4+B>4"`"B,T)\@3)_231B%J
M%&+;'WL,`<<.6"04`@@)(63"!%?]4=D?)$!!01`!I!B`&CH0(L`+!0A2@D:$
MY*#BC2H&H<$;/@S@C11('">B($N<04@4!@Q2@O\,!C3I)!=9-*D&`*:(=P$7
MX#$P`1>$4"""DTZZ$8HG!A#@R6RUW49('>D0,H`)R+7P`7@70(#!!3+DH&`-
M`>RP0"HM_%6`!6O$$8<**AB:1Q2#+-"3('*$H91\1?1U!05^,?#%+SW\`<0%
M@]!6!@%UO>"``C!!<`=,&3!*2'-2F%-"<@\>8HX:,`C!P*X6D,#`"13X`A0:
M;'I2V1P0_)$:(7PP<P(AF,$"QF9-U"#(#A^8(T("@XQX0@8$6&$";T)^``DF
M2WS1B"<2".&-(,L6@L&8RCU@R`XJVD!;1;=%H,&D$F`YW@N=&N(`J)@D-P@&
M<PFR9P!K%%N(`%>-L0/_!"C,\%$J(HS+VVY&<%3(#/LF0<*C)'0J@AD'K00`
M"`;@8<L+8J#:A*JI)OO''5PPH(8!4]"8PA^U2I$!`!-DH,=<$U(B@A^%$-!B
MMW^H(`X%>8P4(2$G;$`(#]$*0D.BAAH*`@ES5#L("140,4'#E15PA2`BA*BD
M1D-TB-`7"K0!BPT?&&*$"GH#<`8KF'2ALV!^F;!O"&$`<,00VM"M)B$BU&4(
M`S<DO%HIWCPLA`-$+(!7&2[DP<(R?USW!P$&($2!'J8EX((1:Y!TNPO[[5"%
M7Y<>``029AQ00XPE3-`$`C*@8(,/381P,P>#(#'2!;F[<($5#U#Y1Q(*]F'#
M_[FU#K(U6[=584XD$ZC4H1%E$%)9&.;$*TBS@ZP`1"%P<'$2(>\2Q,;4)H@1
M/"`*$Y`?#$B!GF"AAPQ?D!@4%,.!+%B!>JGH`A<F-8@$X($521"":*IP+DHL
M@`>I0!._G':Y4'FB`#&B1'*H@`("^(8`+-C?P[Q`HS09@C1$^,$!\B`($NB$
M#C`YPZI@PD3I-2$&+<@00HX0!"@%`2%^",(?\O"%)IA`"`9P@^V,X((/*&$0
M#V#BS98(`2XTX5P04$,%/I*"995/$+@J@A-Z```A5``+$_C?'X@@@S0TC&Z%
MJ$P16$$!PK7L?!R(X18:,`@I9.$.[S)`%.11@)G\@?^`%)I``\XG(@^L`(8%
M4`,J82@R0JQ!!)V#!0>L$$!"I(%Z95A+!.[@B3*TT!`J;%HAK+!$-8;@45C1
M@N=20`Z&#<5ASOG#%YZPAS1$[P"M=,`)SB`!`12!B"0R!`MR5P$3;/)VF"A!
M!O:%`$'R@#0.@,("PM`/VD0`"X)X@Q&\$`_M&>`=%XCA'\20!@L,0`2=V($O
M'G2-@4X@!-5!`0:[8"1!*$`&+_K-Q]"02$'TX`W+0LL?Z/>'%DA@$"=HY1M>
M\(+2R$`U+DC2)ZTUB`E@@)0C$D0=0P"15&@@-H,H80EH<@>9FE`#NS*"KQ@`
M`@KTU!!WB`\E@OG+(@XA54O_%,'01N,J0R@L.S,8`1?,\3!/X6$++.`7$S;U
MAYM:X(Q_P`%F2/##%B@@#32@0"564!U"1,`-<_L#&-*@`6[5I`D2R(`$9I``
M`J"!-XJ8@0S(L-4RU`H%%!$$&P;UARA$XP]2L``7+'`$"J@A@8.0`1S>8`6=
M'&$%@GC!(?^P+ZIUU@;+`@(*5_``(L#U#S.8PB92"U.:@O(/JD2M('(J``KT
MX0T?0)A@0;"KZEJ@NIJ:`-3^P`6(0$"0AFC"!=;GR_^DP@<A2(49'E=502Q@
M#0XH;RL-<0&H>/5S?S!`;,HZA`;48!(3$@(D-J`#URU`370U1`\>H(`_+*$9
M%)``_PH%P803Z($$/P@#&E3@-4+4@`8&R`,(7%@U38"!E@MX@0[*(+<K/`!.
M?W``EYJ3`AN`X`0#.((%.@&'(SB`E"4(@PV$(,/9UG:Y@C!!#9:U!Z568%V#
M,`%<I1`'2KQT$"XP+DT%,0$<3&!C0_K##7HPB3_080U9,!8F4G""$Y1AJY3X
M@0IR($401"X*,@@L)>`P!0X*`@9ZX,(7V#L(O_UY"DG80WF!T("^%N())TU8
M$_(&`+8!(`$RP,*>1F"&!SA!IA/Z`4</6QNE)'@!<E#"`'HP@L6=``25^P.@
M`?`1%I3A">O[0Q&LTX0Q@*<+",D"0E8PMRK0-`$J\*4(N/_@Z"%<Q0)S6$`5
M3B.(.R*W$"S(@J,)\0*-\F;4W?I!!::@@WAE0*J"R`$>"`$&$`AI$$;(&EZ4
M.=-!R&$"8K``-9;[AB14H(0#)3(F<DH(.3``"D?+M2%.`X<4H*<!5T#/#/Q<
M"`[T4!`9<(,$.D#5063@6B38=WF_IVU#?.&I7AW#[Q9S@!^450=#0-R$X%"^
MZU3!"FL3Q`JD<(0&M_4/.S@"&2Z`A[<80@2SU2*I&6"`K9[AW7^H`!@0L``#
M0,&7$;A`?/JJH$)8FY1`^,`))*`3;ANYHW]P1FHB<`08&"&S@]!#%8#B@2\P
M!'-P_L&NZRT(*CRH"WIU[P54$(7_(WS,#`DH@&$S<8,."-<0/DCS'TS02![X
M99$+B(#"4=+"!L#=$`7@Y2`Z4!H<[.L,)E"`!S+``#@4X61_4(('#'`Y&Z27
M$!+H@B<0@(3"=4@-Q]'"F+P@V`.\H(5$\,$'FI""([-`"25P`R[JP($$N&%`
MFYF#`<ZBN2)F@`GH28&),DL:(4`!`2S`PVP\,(-IS"$/5U!#%)A/^S]$X`PR
MH$(TZ-#U5PF0`P>P-8B%&16@!F4`5+$U%UY@>0079L#E!BQP!A"1`WQ``[M0
M!6;``@70`%9``6/A`FH0&+"@`%L&`O'S!T)@-W0`!DIP`!]3*3=0=G\P!R5`
M`?9"">_R_P9-P`,](`(^*`*T5@9E8RAD4S9Y<(*8<`5=10A#@'/^H`(DX($)
ML`<EU`1:LFT-$Q0=A@E,8`0^U0]<4&:%E@:/(@4JH`9+``%@]@<*X(-Y8`LI
MD`9M9P@P<`;B0`@;8`(=2`$A(`%)("1:L`!/!08&(`,/8`$6H`(<D`1O0`-I
M)P030'R"4`5`X`TP@`24@#^@)0$L4`0G@&YC8`5WZ#`(B``G`&Z"@(E_\`,3
M\`4RZ'9:M&Q.H`1^5@$?YPD^``$/T#Z"\![OD@1VTR:"(!K"6(S&2`AT8%^P
M\`9&=XS."`N;EPIK^(Q_5DOG\`;*2(WI\$RI@#A_,#68$(W%*`D%:L($:_`1
$@0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>87
<FILENAME>h03611h0361133.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361133.gif
M1TE&.#EAU@`/`.8``/;V]:VJJ<C'QYB4DN[M[*6CHBPG)CHV-I62D8!\>9*/
MCGEU<V!<6WUZ>M32T>+AX;&NK1$.#D5#1,S+RN7DXW!M;%Q96%104(B%A*&=
MG'9R<6QH9FYJ:=#.S>KIZ,"^O9V:F8."@I.0CMK8U\?%Q&EE9,O)R(V*B;FV
MMK2RL;RZN=_=W69C8:NGI)N8E[NYN(R(ANSKZEE65>/CXJNHI\_-S.?EX]O9
MV,K(Q[^]O(:"@<3"P>#>WDY*2=;5U//R\5%.3=/1T$A%1*FFI=S:V>GHY_+R
M\L*_OG-O;O#O[K>UM.'@W\+`P#4P+^CGYK*OKL7$PS`L+-'0SXJ(B-C6U41`
M/]W<VXZ,C()_?O+Q\+JXM[:TL_7T\U924#\\.WMX=Z*@GKZ\NV1@7X^,B_#P
M\,/"PM73T<[+RK.QL*BFIDQ(1ZFEI*>EI!\<&X>%A,'`P/W]_?O[^_KZ^?GX
M^/CX]_'P[_/S\O?W]B8B(:JGIJBCH</!P/KY^4E'1["MJ____R'Y!```````
M+`````#6``\```?_@'^"@@`3@G9V@X-U@W=<BI`><)!_.5*4@D&3F#6##W&8
M@G(J?W=.@@2AE#FI@RLI=X,S-(F#($NJ'22A<S&JIY0D"7*8N'\_,S^0!)NA
M2:JAQI@Q5G<#"'\[+F_<W3U[@F9"5G]Q%CA_-\\:&G1_1+%W50&#$Q2#1QHV
MD#X)51V""GQI0;!@01%M['`1XB>`EPXFS$@T$\+/'SD\RB!@(<-/C&>5FO@2
M).``,$%M=BF:,V'.GQ!B_MA`0VP0@1Y^<NK,&:`)(TA8&H`:).?9%0PM2C#0
M@V4GBP&0PA`QDU/(HT%%:.S<JL=`#!XK(,U8,+3'$A@F?+CX`T'*$@:#_\Q<
M&(1'$)`*?S8($#2$P0(-')`L&.PE@2(I5_[$,)&ARH4MBH8HP$0EB5Q!$OX4
MF.S"8`N+3A"`Z+*W'(.];S8H$J!:41-!.(PQ:8/FSX(1@D(T@)0YE`%!4K3F
M/+#53X4F-J:T^-.%RI`0BD+,@.3EQ"#KT"#9J")H@(E!2:+4%!1'C)P\9?Z<
M*V(D[EQ!=?\P,).W]!`!!*A0B$!%!YD0^T"BQQ8F%&%`%I!(M@`6NG410@A`
M8''9'YE9$"`T>@'0BA=0I";()*PAH(-@"[0QF`PRV`&'&D$(`I<@=:SU!%T)
MU&BCC;]!8D)KF"CW!P=_#%'!1&94<.$?/'RAB/\"G2C2S"![8#&'#;W!(<-T
M>140$!%_K"4?@O.I5TX<<GWP!1?QA:D77WLA0>4"0\0`X!]P9+`/&@`)DF-D
MDPE"I2(39H8-)A_0L8(&"30A!@->I.)!%A[^T4$>,*B1QQ&#O*8(&P<,,``,
M7G@JZ@E`6$2A(#1<L$\#&OQ`#R0'X*8("(,H)P5`0A)II")5M#+(`K[^844`
M6]$P!`]_"G+$:T1$$&`2%O`0P!T@K`6'4AS@08$'0XAP``UYS)`F?6L&"4$&
M`["`!P@G?#&G8C(XL$`SFOX1`#&2#9(L*($2D,<?6JQ!D`8$B3'&(&V4UH$?
MDT1*$H^"O);$)7^X),C_$PM`(X$)`BQ@@0`""'&"$E<JH@,>6P40P0."*(=&
M6,]%=X\@"NSP!P`@_:$"!\%J,@@<*B5[<P03%!"!(D1`(4`&M?T!1!@@.S#4
MA'^,6Q^;?X11110*[/+N'SY``<,3W>"!PALH]#&C9'&D\(8?3;SA0@DV!/J'
M`H8,\J(B/$2P`15TMON'PW^PMD,.:U3@QP)^:-"$.XI4,,9$4B#@@R(2Y*14
M3E[`$,`06/Z!`@OU#K*G<G$L4,<0%OB!109^6'"#($H<#+`,5_W!1@]0#+*!
M`@6!@(<O0O_1!@(8M`$)$I)D^B$'+/]!M=7EL@&%0!1DQL``7__Q1)/O]*!$
M_X*3<4DE'"/9_8=A-,S+`!PV#P*&`6]4H9(.@V\P0WM_;($'5']HP"8L(`U4
MX"$!!8%!&W8S""%T9PJ"D,%>Y$`#001`-?3K!C=.MYP<9"!F)H`,`;Z#`EH)
M8@%I@`0)#-"T<LD$.C+IC9XJ$`+E_>P"1W@!-]H0@1-THTF7X8('<J2FTB!`
M"[X@`*W@\(,0S&X07E`$#"8``_+I*S-=8(+TWM.;$HQ@`1Z0SQ\&T(HY>$$O
M*GC!(.(0``E$@0$0B$(;>-0!+9$`")1@0`:P\P<-*`DK>%A`"210@@54@0$5
M6$`%+L`$&)BJ='JJU7+R$K.[R2$$>%#"DS9@L6#YKO\T+_23#/]@@`LHX&A0
MJJ`@1("`)F`@!Y`PPP%8`(,:.%`^Y%)8@!PP/$%T0`=-&H$,UG@`.(0`4X/(
MERB/@8$M8B:"'^".&)/0`T&`X05ZH8,6$L``&(#@"BP0!!%HP!I%L.`&8@BC
M(H)@&#"PX0]HN$#.A`67,T"P2Y=[`1!R%S%*G`X!18``$BIY`B2``Q((4*,U
M20&)#>B@(-Q;)L+<\($(`$`09[``.:C5S"8800<)>$8-2G"!+^#F`T#"97T>
M`(:=B.$`(-#)"1`0!Q.(00N#&`-D1B`&9?!%`2WU0P:(XSHUI("+6JA`!=@P
M(S$R1PH/@(I>4`"!RPF"<.7_'(01#N`&2$P`=Q<Y@1O44,`_F``Z]A3$',0@
M`B2$H1:FT^`&:Y4!%<A`"I5<0@7F22<!*J(!*("$#-@PD2.\J'@1>`(7HI`W
MM@3!"6/0TA]>`X`I5.$$4#@!#P:!@=[]00:Y]&H7DJ182+SA`X*`0@D&40`+
M7$4R'`.9;$&6`R[^8084X..+5!``,CS#A8/`*H\^.@89-!5@/!-$$DX@A"[L
M83RZ^TY:B;`&'/`.$Y`DI223B04!*"`(3V#`10>QA1;]@`I0:)\71H*JZ%V$
M'#$<1-]\\8(N)!,,6/#I9#T!2D',X(^**`$HEX``)-3J`%\HP!L>X:$/9.RO
M>'A!_QQ`P(+BZ$0$>"1`;WY0!`#D@`06P`0+^BL(%;0F(R!0#0#0P`!<.*$/
M:E!!%AP@"!XH0`:D.(,0#H```2!H,D88@!"`P`%EF.``2*C!D^IUA#>4@8."
MV((83.33`1B`%$EM0Q,.H`86*``@"=``-'X@``>H0(8(L-T?L(`.LWIV$%&`
M1@+*^H<+0&$$2&"`"W[RLQI40+("*`$'`DL)/Y@`#JQ4A16`Q`,\*N('$C"A
M8+\#"1JD-!UM.,,8$B"K06AA#`2XPQCTK,Y!Q,`%38#`'K0$@#X(8"CD`8$0
M9H821:R@!\W,S2070&A%Y.`,?\`!!"P&B27D.A1Q(,(8(C$`!D$X8&^T(_$@
I^#!F3"`H.]C.MK:WS>UN*R(.FW@2-(H`#0+PT]O;A@/D3/"J/P0"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>88
<FILENAME>h03611h0361134.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361134.gif
M1TE&.#EAU@`/`.8``,'`P)B4DJ6BH9:3D<C'QJVJJ;"MJWEU=-32T2LG)J"=
MFWUZ>?+R\8!\>IV:F>7DX^[M[)&.C75S<D5#1.?EXVUJ:>+AX&EE9%Y;6F9C
M8M[=W,[+R.KIZ,"^O&%=78F&A!,0$'!M:VMH9U%-3(V*B>#>W;FWM<K(Q[2R
ML;RZN86"@=?5U)20CZNHI\O)R,?%Q>SKZM#/S:FFI<_-S+Z]O%E654U*2L/`
MOXJ(B-/1T*NGI)&-B38R,MC6U>SLZ]W<VT`\._#O[STY.+.PK=K9V/7T]*.@
MGMS:VIJ8EMK8U_;V]61@7U5144E%1.CHY\7#PN?FY8N(AKJXM[NYN/GX^#@T
M-/?W]C$M++>UM'MX=HZ,C/3T\^/BX;*PKX-_?7-P;[^\N]73T<W,R^+@X(:%
MA;:SLE1/3EQ85X>#@JBFIJBDHD1!0*>EI(^,BCLX-R0A($U(1Q\<&X."@OO[
M^_W]_?KZ^?CX]]+0S_'P[\;$PS,P+ZFGIO7U]$(_/OKY^?___R'Y!```````
M+`````#6``\```?_@'^"@GAC@GQU@X-SBXJ.?XR"$#1T4%TP@C!*CU9E2@QB
M=(^CBD<OI#DKHTJ8@D$,@ARD4TFDC@BJHW5\MD6C+Q&D3E20/G:B@[ZV?[#+
MCT&V5EP0;2A_'0$&VMMG88)W9DY_$"HW?QJ,1E^"+PE.+U<S@EHACRA]27=7
M>()0@G81T&P;J,W+$EZ0%.$0,,B?(`8-#/T1@P%`"R;0'`5)8$`0G2F)!EDY
M(DB$B#\^4CB"X`6`RY<N.V"0J.C`.D54K/QAL<!`FPDM&N@8JJ,"CEL/5DP!
ML&:+(B@"B$H=:L0-!PH.!W$(8>>/G2I_0G!PT;'``Q<8(A&H,>B"("`+__[@
M\/8G0H,42)J8N$(A@SF<"33\"6-#$)(W400!./G'!9,2MEH,()HAPE`U;]`,
MHO!&D`NV&^0\JF,C@YS3(]Z`430E#I(_&0`(JO!:D6A2C._0>"G$`4P`6:I`
MP!'@3P4$,FX+DM/!T9HS@S(X<T1!B*`()P9!`!*I'YP_)#HFX&`!X9^U@QA/
MH"#7VYPE<Z@0\#"H@L[5@M#$V11FC0(W+/"C&&,88*%(%I!Y58<,LCV"C"((
M"(+"`7^$]L=??RB100<'0#;&&ZUXY(%*?WA`UQ\J_)%#>@&TZ**+(_P3T@\W
MC4+<'WW\(<,!%/1(P0$;*/+`&HJ8T,-T4)!`!_\%$P@R1P6"_?&%9G\H`$&5
M@H3`2`*"9#'(6CVDJ!Y[<_U11A9V.(!&'P>(D,02`)"0P9$%7#`!`U]DP$.$
M@CPQX!]C>&!``55H(P,!@B#@Q6Y1'.#HHTVXT1T14W1YI(5&"))&`UP(TL87
M0(0HB`)7-&!J%5F8:FH(5P3SQVU8>*!*%"'P@9\B5?S@2!Z#$!?&:C)<0,"P
M!%P09'JR#$+'08H0$954"@1P!).#I,"#BG$X1(0'/3A0EP*""-'`%PDPP(<"
M:`@1+11CMO='#4W&@,4%883Q!0M_.)!=!WM0.UAA@^#[QV(09`"-OXYD842#
MBD11PQZ;3&'`%TO\<4+_`YF,<$$3=_P!`S)C+!"""`'HJETS!&!LBQPKA-%&
M#2^$<887-QQ@LB`#O/%;`7KD0EP'AB1GV[%_[,&&("']D<<7R<;BB!B"(,P`
M"&(@`8(B+P@0A@-=U`'%&2^YH!9;)0FR7GME5"`"(P04)D,4X)+QP!^\^'N$
M'@`,VP$/\@!P00J=_O$#P'4@\=</6##\AP!(L-',(`S:$4!6/[20H"`E:'&`
M%'4PH(`'9TA`PN.PJ>$C!0H081L8.GR!P5!-H"%``-D)DL(97"I"`6-R!4#%
M`5O(4(,.`SB@0PW67/-!/TM8,`@29\@CB`-(;&-$'#[\@?`?;X2P0.Z#D-"=
M_[]61(`RV7^T.Y<)BQEQ@!LAM"F%`WQ8-\@/9%OP@0@U8%"!%EU9S`%.(P</
M](&`<M""('P0`L7%07&0DTT!EI"J!I@A#K((`AN^\(8AU.N#,SA`!$XQ"`;$
M0801B$`40"`!VPA"!T=)'Z+H0"(#G"0.!%$`!GI5G"2P06@ED,(?D@"9&;`@
M$@O(5)'>4)L`("IJ3=)>%`4Q`B"(`'SCP,#L`K`#$(#`"P$8P`Z2AYX_E*`"
M9B.3-Q8CB(J-`5%(,$*,1A&`-20M66P<Q`(6$('N_`$)5X@""041!U(P2!!$
M<-47E#B'.H2A#_4:P@CJU0$;7$D1(9B"P,*BLEB80?\."QB!:3"``0G(00(3
M*$`46B`(+&J/=S?Z@QF$]H<LT$$!(`B`@,*U"8_1\8E2A*(B1I``,G1F$&P`
MER!4T(`U7.!R@B!`$P[0`!I4[`]G*Q,;[>"!.+DE#%<@H1$:@,`1V("`$@"!
M9O+X!Q2DZ`1"D-X?@K`"+:QH$(4<Q2$QD84Y4,`#.AD$8001!OJ\TA$Q<$L$
M.O("()"N!!2B0`PM]X<G7*`K#W+E[GI%`CO\@`FT],(7"M`51;B@"X-H`:\<
M$0`C;."E)HCB]H!@@P)<31`W&`%"6!`!)D$@!$A@A!B^8`81(`H%7L*1&@=V
M$C"DH4JGB($>+LF`7@HB`*[_<D0>!<""9L0`")5J"S'P:<@T5``38Q"!&>1)
M4!YH@P5KT(8.%3&#,VR"`1^(@!"<9]+E25002JB!`D20AKDI`H<#F:L@<!"%
M,C3A!+2T0PBR,@CX**("?E*$%AQ`K#+H09CX'(`3>`#,"'`@""1H01VHY800
M,,$(*UC`/?_@!93^X0J=TN9)PD';!SQ)!=*A8U85X3<H**``26OGT02QA>\<
MEA0.>`/4,K0&-QQ)$0,=C$$W*H@IA,!D#(B`'D;`IT'L@2%_A4$9[L`#%XQ"
MH[`LCA]T)(<2!"`';!"!>2;2G''$($Y`(,D@IG`S*O0785P`@3@$8%"Y#$`"
MS4#8_Q.&X`@^]!-SBUVC")Z`!AD8X`I66$)S,M``/UYUN(/H01,"T`(`Y(%8
M+P``"@9PI3V4@1`W($`^'X&%-@A"#"*(`0&J<`$:.&4P;G")$9K@$@,T^`F,
M@(`1SB"#/Z2@"B,0``)$$8$Q%`$+(U@"!F(P$1XLH!:*`)\+7)""!L>2`!6(
M`P8"UP8>^"D%9`#""*JP!B8<@`U\<-0RZA"#!VQ@BH,=1(<$8003*"()4QQ%
M!@)G&WF@8`U>^`,5HC"$&ERR#B/`4*]0/`@J((```!#`#E:]@S(`P`56<$(!
M%!$$+^R0%'3HP`5F[9$;,,&P83##([Z6C`)X8-&*^,$"F&\8!'#AX0U[.+(@
MRG>%$W&FU#/00UR64YP_,$$!&1F$"0S4`1;\X$&#2,+R;#&'$(*`0N=`HR)D
M4#M'T$%4]L[>(SXV3\,Z:3HH*2G`!^X,@1/\$7.PJBT0<0B`S^&ZI(!"L@Q^
- -\('/(2,]4$`S`@$`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>89
<FILENAME>h03611h0361135.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361135.gif
M1TE&.#EAU@`/`.8``.[M[3HW-L[+R::CHN?EXY*/CJVKJHV*B;:SLH2"@H%\
M>?/R\=32T75R<&%=7!01$>KIZ)V:F=[=W*&>G<"^O7UZ>>+AX&UJ:<C'QU11
M4=#.S7EU<W%N;;BVM6EE9&QH9KRZN920CD5#0]/1T.;EY*JGI.3CXK&NK4Q*
M2EA55<[-S*.@GYN8EG1P;HB%A-73T962D<?%Q;JXM^+@WF9C8M?5U)J6E.#>
MWMS:V5%-3,/!P=C6U?7T\RXJ*:>EI=W<V\3#P>GHYUU:628B(</`O>CGYJRI
MI^SKZDI&13$M+)B4DMO9V/3T\[*PKRDD)+NYN8N(AZ"<FKZ]O)",BL;$P_?W
M]GQX=]G8UY>4DZ>DHOGX^,K(QO;V]:BGIT`\/%M85KZ[NLO)R/'P\.SKZM+0
MSR$='>_O[_7U]#4Q+U=24)B5E$1`/F)@7Y.0D$U)1R0@'K"MJ_O[^_W]_9B3
MD/KZ^?CX]\C&Q<[,R_KY^8.`?O/S\JJGIBLG)Y"*A\'`P/___R'Y!```````
M+`````#6``\```?_@'^"@F<@@F9F@X,D@SPFBI`W9X)R+&,`4U>")#>0?V<L
M)&)P>I!Q<9Z*+P:I?T0RJ5J:@@`6?SPUK5V&K8)U)R]<BCQ:D!&VBF,RJ)`J
M%SRI2PN?+P#,@F.3O3.]K2^])CAT$PER?E!PZ>H!?H(C`3]_<3E;?V2,%RUU
M?S=\-01.MDQCD0,/)!@H1IAP`D$0$%1%#EQ(5R*+NG0%."3ZP^3:E!6#PH@1
MI&6#`$$X1)1(X"75CR0)7LB,<&W$B@1L'$R@4D"=E0N*[@2@<`7#B0,M'&0@
MXFE*@VM_Z#S"T@!.@QP&&OC9ZH>#%4@R,%PI4<++&$4+#'!=R[7,#A-D_R#5
M4##(P8P$=\*$^-/%SA4.@UYD&.1$4(8-?SY@$-0EQ`0;24HX"5/A#J0J/3H1
M$/%G3!XG=/]@2"&H"9\BO3!8X0IE!5<47P7%&3)M!&D_'SQQ\=*`;(DT27C]
MP3'&3PE!?J8,PD)A49D?,@JL,))@$.H:*WP'8.&;[(8W.+`4^.-`!6Y%4+XI
M$G%@WY\-<KIY*B/(!X)!$)+$'U3G0QP?0/PAA`8``!#88((41MXWB@F"1#&;
MR9;;'R&4(F`9J!$0P`=NP#+(:((XL`(!)+Z0@WIFG($!%JG$P00DC/PAQ5[G
MW7?(&DM@(<4?`@0P#23&,5&<<H)@L=@?$@3PAO]3"BC0PAI-;E`&%8I<04,O
MXOWAP1]^9(#!EQA<H-XF0`W200>7T0$)#E\$\0=]@FQ0SQ]?L/+'`&%0*$@:
M+SKP31I_F$&`8$W0`(""?B:V6`PY_)'`!DZPX04".93@PA?UP+!'#A;T<8"/
M@V0A"(A^-/"E$V#N(`@3:6B`Q0DAS"&KK&X\@,P?+T0@"`=NGJ?`/A/,484@
M"*2`Q(^"T`&%`CFD\<4:'1#YAY&W4&`!9X,04-T?!D(2P`B0%*"->$O$P*4#
M)))8P9A_('&6(AO$,P@`(+"UE2UP_E%#&7'4\$!#M[!Q!1P+A.##'WJT((0'
M29``@`P3>+%5$(@RB('_%A\D$<<9$'`P[!2`R0#''U3`TN@?$=8U:@HS;/!C
M$JGX,`"+BH@!!0U40$,!'`D`14$%@EC@00(9Y+G?'S&TD$`%"G3P+F''<7D!
M5RT<^4<1*/RA0PEP#%`!'$:DT-P@+CS0'5D/@#MM`0)HP.6$@D"A]A\P-,?%
M(X)H0(.\@OSPXB`GJ/FF(@\@$,4#BIB@@P`3@"'(&D#(%".N"/Y1L:)-5(#"
M#`1H@`8!6$P1Q7MYRN8&+7Q$0=8$4XJ60A21O[!%`#(QT,#!?RP0!LV"P.""
MC8H8!X$2UP!@A")Q4*"`"V[_`0('7V10@8%%/,`&-\DM9S4=>>@`)IAJW/J'
M_PPT#.&)@FN_9X(?.?@!@P^XJ2!(M(+H@(2;@H`@P@G#_O&$`A=YP"SR]8<>
M+(^`B;&`"=*5!!*9(`VYH!QA0F0Q";P`!6`H@!<*P$$9L.`/`=`&MV*S`R5,
M(0$N:,/81C,!W^0A#=VQTPP<P+L_B.`)J3#.'\#@@08D(`%"*`,!_F"""`B!
M#T]@"P@"L(1._,$`-)A`T;)7)*O](0-&$(``B*!%`2"!&W^0PQZ`\H99S>H-
MRQG/#*!PGC&(:GQQ`,/H!%&!"40B`'/4X2#0,`@"BF`-"2!@'#+P`SM@(`8/
M>``4P*0>P72&!#V@H*)PE34MO8`*;9#1`-;0"DOU[_\/=EB9(C@P`0]T2Q`G
M<$('WB@($0S1$WI<P'C^T(*Q"2)E*?O#$)@A!R10H`0J:((?\I`N%U@Q`^KY
M`!1"-`@8-"%!YTNC(&APGC^(RPH].`$D+B",/TPN>%$3!!\%X<<DM`%Q@Y"!
M-@61ARR@X0`C4P4:OJ"&$2!!D@VZH""$\`(CL$$+57B#_/ZPAPTTJ4EI<,!!
M&]"#O8!($'M8YK7VH`@&1*$=@W!E#DOP`U4U@`0ZN)(B<(FM`@["`"708U?`
MM(%C)G,_#DC%$+K81?,5J0*&H^:$)D"#YBEB!<#3P0!@Z0`.<A!FY%0$&C@`
MA`=8B`%"B(<>0J"&/Z"!"QG_><1H<@`%U#P!,`*R&"7'!X/Q'6\';U!5*E*:
M"A`M@`5V%(0$D!#.*^*ME:\$DA6LD(@%>(`-#(`$`9*0CB@0-AV1_,1Q5"HM
M:@T"F7_@0F+)(]/O?<FFTSJ`"CPP@FH6@0-.5(05H`*%N`["!C9(UV#[2#@?
M5`$-YBJ-!FX`A77RD0YJ"$`>PA"!I^$E1+G(9]92(($_-$`%8^!`!XZU5HQ"
M`@-I`$`48CL(!AQ/-IQ<3UX5P8(WH"@';GCF2+&5R\3*P2",U9XB/'`#.:@!
M*`(PP2PA@;X)%FF^?J"!%*:@@A@@`36#D,(=N"`!`8`@`BX(P"S<P:XEL%80
M07@`_VJH<$]!E(`%![C&.'/'KC\L`6B0H,%B+BB%*$2A`$,HP@4"!(,<`$P1
M\$L%!`)@!2A@H85D68%X-F`+.(12$-GI`?[D(BHM-.$+$+A!"M`0@1@-EBPL
M\()OZON'#I1``@R8P`9D\H(*J"$!W?S##UK0`$',@`-IF$"8!8%9(AA`"F@4
M1!MF"<4WY,$]3WB`$>A0`A$\@`]>.,P*#,0"(<A'!C&P0[XFX(+3\H(,EE%$
M`+JA@*<]=C%A6,,<B1"&%B#+!0-5A!ITT(LX$*`&*OB>!E[@ICC4]0\("$TK
MM(P#101!`2/Y`P1$ZJUPK8`$(^"RL(-!AJ0,&A)R&,"&!4>!3EHH<Q!0F.4!
M<`B)']3Z!N+UA!@.()\S@$&1@JA!3!5!`9_*!Q(&Z84<D'7N=KO[W?".=S>@
2TNXU>T(+[I&WO@6Q@VP'`@`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>90
<FILENAME>h03611h0361136.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361136.gif
M1TE&.#EAP0`/`.8``)F6E*RKJHV*B#HV-K"MJ_+R\>;EY,[+R)V;F0X,#,C'
MQRHG)M73T79S<N[M[*6CH8%^?7IU<^KIZ+FVM6QH9F5B8I*/CUY:6-_=W&EE
M9$9#0U114%E65>+AX+V[N8F&A<&^O-C6U:&>G(:"@,?%Q&UJ:7UZ>>#>W;6S
ML<*_OKZ]O/7T]%%-3-S:V='.S=;5U)N8EG!M;$`].Y20CHJ(A\K)R%923L/!
MP*FFI4Y+2^SLZ]K9V&!=6WQX=JNGI.SJZ921D??W]I",BLO)QM74TMW<V^'@
MW^CGYO#O[LC&Q+>UM?;V]:NII_GX^.3CXDA%1<;$PH."@KNYN+*OKL3#PJJE
MHNGHY\_-S)>4DH%[=]+0T+JXMZ.@GK2RL'-P;_3S\F5A8).1D*>EI%M75D-`
M/S`M+$M(1_3T\X>%A='/SK>TLZBGIA\;&X>#@OO[^_W]_?KZ^?CX]_'P[^7D
MY-K8UZ:CHO7U],G%P20A(*2AH()_?ZBEI,W+RN?EX\'`P/___R'Y!```````
M+`````#!``\```?_@'^"?VZ#AH8!-8,%)']'4X,M>86'?W,"3I6"!DV5<$6:
ME714E(9O.H861J&:$@$Z2(8Z;X9.(G&'=%":!$*A:;0[&*B&(:652T>LH2>:
M2%<=`@($!%74UP0F0G:#/4Q_)7Z"7FW'@PPL':%U>G[N[R)E<(=\L88/&P65
M;@(!@@X+B!AB4.1+BD%+5"!HP"/#E"PBKK&`-$C/AA`,J.3Y0&$,&'6'9#0R
M5$3.GRA<"+"(@>#!.S]E/!Q2TV*"#XZ'#*AXR;/+@A\M,OV#8."/'QR"$)"9
MITG!GQ`T_DA8\Z<&!T)!*C&(*B@(,4$^N!I20.'0#)F'<(@+-4#)G``-_WB"
MJ>"`Q`Q!;@ZXX>#T#X6^?S2L$B3%C`,@%GQDP++HCP<?D&>P@4S9AXP+<J+T
M`7<$"^`_"PX9T>#/D8AEE?I$$63BA2`9H(PB;;(`0Y_;0\K8^T,F@N_?$5CX
M'L`A2(@&O[UD^(T'SY)!/GH#C\"C["`N"#2I967'1Q(-RV!P,<07B9N_@S1L
M_B-E@9</6>)K,!/_PH#8@O0\8*793E0L""@@H`)X'$(##(8`@(LA#M!B"`QE
MJ2;(&V5(`$`,@QSU!P`S*(!"!@-:(<@48E6"Q!@BLC*!!L>$50E9@QR1P!?:
MK?6''0O"4,@>8:!`@05`6D`#&<H0DD`13E"0Q?\"8+!@`WJ"J"<5%18P-@@-
M5OYP"`EC'&+'"(-HUH8R6*!PVVVA+=)`)X,8L,$A)^S$DQ\.2"A(`&.P04"&
M.&SARQ\'K':("05044=E/C0@0@HTLJ*%&?H8`L0%B/K01I>"8%%&*#BT<0T8
M%\3BA`9S(+##%27T`4,(?;APP7."D/&!($TDT!<%`+PSP'I_A)%=1`1`X&D=
M8PQV(QD<("K``B:=I"H&?WAFR`*4P$&!.@4X,(@:7L`JR!5,W7B#(';^H4,"
MMF;X``P*,,``#%ZXJ\4%(UFBA;ON0K!!':B%4`)^YV#1@QU'7,#`'U8<]-J;
MVA%PYFV43"'%-RKL)P;_AGV@01[#"B2@A[90!L;K'``,."`4$(3[1@EC"'H.
MP\[:(4`!6.0:AA)^+*#M&Q_P(<@#7AC2!@\U4,+!#-<(008JY?Z!KA9\BD`9
M"PU4EH0F55!0VC(=@`&P(0TP9N<;`A"3@'65;!>*"2!T8$$7M\'0QQ`1T""!
M(!0,0.,890B13\A2#G+!`83?0?@$U`JR0@8IX)`#%I!#G@7,FD6+@[1YJ$"(
M"QL>'&ND@^#PA.9_\#5(H.2Z_`<;"7@NFR%DC`"!.8?X<=<@1JQ`*UH,7'!&
M*!C(T$,67I`17P^X"G(VIS96D@X))72AP@T"/M"``D7Y5885<FC`UQ8O4&#F
M_VTR\.K7(&Q<W0=X?\3!0RPXJ/X'`Y1OYD?83AEA`1(#D#'N(`K(@""^4*1#
MF$X0J/M#TUBG"$%H:!R*4,`"6C`($\3G@CRPP06S((,,Z&X+`O@#`KC@H'W8
MX&X*%-17_H"'"S`O%$AH@"!8\`<'Q.`;&C$$#\SP!R%(X(`4")"`=F4(M`V`
M7.PS!`XH0+@F,H%R'KA!":(@K3^@809SJ`0-(O4&!%RA$ASP0I`:(*BFH6L"
M?/J#`3Z@AD$0`0\4U,0##_&&#8S``I\Y1!R$8(`)N(,`%7!'#,2B!QF\4!0F
M`,(?EG!$-880"U+PF2#,$`$#G`:(@`D<WC;A0@4F,?]T(#*9&"AW`@]XP0C2
M<L,+QL"F0;@@.X-8`0^^EH/Q]0$$,DSA(+Z0@!*(Q0\/8``"7&.("1"S$G,T
M!`'T(($/9$\3;\@*K)HVB#0D@'9_4!M>/%>`65U!!M@@@/#`$$<\^($IF$R/
M^?2P2`ZDH``U*`($TB8_^H6)5UCP0``L$`(+F$!W@X"!$[X0`A(0```0D$%6
M!A&`+`HB#@XM5Q(&4(`%1.H$`X"`$+!0!QQXE`M8$``$"KB$)%PA#$BIQ$7^
M\`(;L`1G?I!"'2S`!VT9HFE3"$-6+B"3)6"A,A%H0V4R@`<4*-"03!"#(&QS
M@@1P0Q`DX($A-J"`'3!@#&+EP-<`!)`'![FA!F/8SQ^2P`,P;.$8=7!9%[J`
M`)A%8#,Z0$`.!G`:092`#%3X0P8&P(8%/.$"45`#-V2`EE`800H*F(++S+"+
M(0B@A%_H``-J8#(&A*!9BQ`!&XS%G2NH``!"".T#FC"$.9D6%6ZPP0I1\X<"
M7,40)P!``O*P"#.T\@\Y4,`)\,5;!K3`#5/(0`:Z8(XF_,@06(@`;,L`-4'8
M8#-NH$$<#0&%6*C`II5H@219@00$L.%_4D"0($*`1M::][SHW0<3A)+>9?Q@
8#^%";WQ9VP1O:>*I[<WO(5P``D$$`@`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>91
<FILENAME>h03611h0361137.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361137.gif
M1TE&.#EAQP`/`.8``,'`P(2"@LC'Q_/R\;2RL6!<6UE55-32T:&=FYV;F>KI
MZ*6BH>[M[69C8HF&A75R<9*/CN+AX<W+R2LF)GY[>DU*2E524M#.S%U:6=C6
MU45"0]K9V'%N;&YJ::VJJ<3"PA(/$*NHI\;%Q**@GN7DY.#?WKBUM#PY.6EF
M9:NGI,O)R;^]O-?5U.SJZK&OKO7U]'AU=+RZN:BFI=S:V921D-_=W+JXMVMH
M9XZ*B8R(AE%-3.GHYTA&1H2`?[NYN)&-B=G8UT`]/,"^OJNIJ=/1T)F6E6-@
M7GMX=W-P;_3T\Y:4DX%^?34R,HZ,BL[-S.CGYI.0CS$M+#DU--73T:ZLJJ>D
MHN/CXMW;VJZLK-'/SL"]NTQ(1O?W]NWLZ\K(QS8P+IN8EN7DX\'`OSPX-I>4
MDU-03D)`/["MJ_O[^_W]_9B3D/;V]?GX^(J(B/KZ^?CX]_'P[_3S\N_O[JBE
MI,W,R_KY^92/B\?%Q)F5DX^-C5M75Q\<&^'?WB0@(.?EX____R'Y!```````
M+`````#'``\```?_@'^"@X,A`G]/"P.$C'\,(4^-C6=6DH1K%Y:"<HUW5VF:
MC%8K@D!_?I6"&RJ2'QZ$``2A;(Q):XTL$$F2GW]Q3XN$26BA<:&2NY8LC&8Y
M?T03+:%O4G2#<LF$;SS+@B*1@CL?.`9&-9I0I(0W`3Y#@@@]9_/T]`X8)7]2
M*0T&=8(T--!B9&')'P`VDAA(\"?-$"!<W`@:<05%BA0)+G8PR(B#@UN#DBS*
M`>4,#!X)<ER\6``,HQD[[B"LP&C`@I4X5U;(T`(.H30>7A'2X.?/%)J$K(@0
MP)2IA:8"#.AXH<"!FJL%,%R]6M!1`R0=+`B*`Z&IF`(1!+78PFE0@*(T_WS^
M*2#HA9ENC;[\Z?`'#%,82)B"D?5GA`4+!@($:&+@`1/%"TI0T,$C0(()@@P(
M"C#BCP0`H`&`(!`:M!$S`WX`^$-A"@0RA#!\8#2&KR`.QQKI$71DPZ`\31H1
M-8ITT)H:?I(K7YZ<V-!\@A*D&A1U4`/E%PR\&!0!C8H$H!N<`6#!-MT_3600
M0H'W"Y`>?\HP]X/!Q)\/*-RLT=L$@B`C5!!"1AN"8/:'9G\$H!X;H/RQ0@.:
MJ!:'01`XL)P!APQRQVZ#5"%7*!=P=-Y<IOAAAC1_M/7'<$<)`L8[@K"``@0T
MUIC#">#\\0("*=R3`@<CI%"$#9LL$A4:/'AQP_\@?BPI2`0N"0#;'PZ80@A=
M+9Q`Q1EES"/#;()\4<4="SA`"!I(S*`C`4))\$<%+@BB0`0J9"#(@(+T<944
M5^F@WB`O2*&B((3]H9H)9_P!`0Q059#A'V@\,.@`8A%"Q$TX(4#&#G,-DH!F
M#:`PB`JA,5'4%$Q<!$9G@DQAP'P7%``2'5-,<8`!6DSQ@1&U7G"$$'#$```/
M&H"6@9.G+'E`%12<\(>4@N3AQ!\SI%+``#"`@RPA7[A`1`MU5$'/'&UD(4@:
M'5"QY1DAK#N/#E"P<0$%#SAP@($(*C@(&DN<4!IH($PAB&H$9/+:E8^2$6<:
MSOT1PP/&#*)`@W^P<<7_(",>L,<4$Y@IW*G%$3+%B$P&,`B/*1@`0PH\XA'$
M`E440=@.3$AA[A_(-CD(`$L*@(00.$!!)`HT"%*``*S\,0!N$V$1Y@!-!,,(
M',1`D<`:$-1S1@!$7(!`Q0@T@`$9,>"[V9]_+%!&R&$.HIH<3:`!00,IJ)1"
M$&":D``H0#2@8@`H$#%($SG0`P$3VW5:UPD4@*"$)"RR+4@6%L!Z!",FP)`9
MA#Z@P``A0YQ@``I[YXPLS\_"5H`-2"@@JM$)*`;X";('X+%>`#RP`+MG>+#E
M"9?;B3,C`:@I((%_@+!GGR[](0,%63"A]1E1N+V:#?W!]H&=0/#QQQTX#,*!
M_Q",C##!G_H*(L"()%=@`0A3,A*Y)"IHT)2C`IA@!"$K]$"%?4?[@PX0,`%6
M_0$%"-",&81@NITM201SP-D.I%"`U1B-$&VPP!$&,@B]$`%!?&F#P!IA!*@(
M``5%.9X@G'&@4G#J`3$@3EZL]P<K5.!@:-C?$O8PAP^YH7IRDD3ZGL4^0E2@
M`B#(@R2"`#)+#``%IJ`+IPCA`,*T80%'@T``K`"$`OS@#S8H0G4&P(8&"H)G
M+UA`#.#P@#],P#87%$0&-E@#)H"I;0M@VOY$*(GK+(<&$1L$&3J`!(9D1A`-
M,)=S6L0(O0S,!R\0PPVG1($>V``D@_"`FZ+C&^(Y0/\"H!Q!$0?!`R,$@2.E
M4`(%HM!$0=AG$#0H@,#H4I5'74PM.-##`PR`25_`(`G5$809#[*%(Z`@!#WH
M0`NBL(`_".\\/EC"Y_X0!BD$*$QG,$(^)&`R/OX!.D:;7@/B9!0D5.`!0%B#
MN,X0A#-0009):Y7TM`9$0[')`&(X6(H:(#5!K*&-^RJ`E0:!A``T)0&54MP?
MEID`&B`(#5*AP0#F)PBAI(T#B3L/I9Q6ESM```<2*,`'J&`$&S0H`PIX%H+<
MH`=Z(``#A=B#$X+0`C*L@`,^&$,-PC>7%B`@`5P@Q'<ZV)`_N*$`OO'F*Q$Y
M'QWXX$E',!XA$-0(1G*+AL3_>`T0R,""(APAD'\P@1?"<8$5!.`$TQ2$#![%
M@$TJ]`-]6(0&QOJ'KPF"12>801S"<`,2L"$`1?C##N3P!I@*8@!1R,0?KJ"!
M#Z@@#&4X!`/Z8$@-(<@/.F!20F.@!!)HK@4P6(T#HJ"Y-S4A!`!82E-B`88#
M_`&(+4""X/[0!BVD"`9O$`0:9%FKWF[A48/HPE3EY``4R5`01%`!$>J9@]6D
MX0-ZZ,-U!($$'DR+"@X(PA;&H`$#4,`#:,#`XS01ARSX@0^&98W)_D`')#1B
M`N=(0\HTH`$+;*`&P?!#"/;`-$&0(!MO2$,&"A`$X:8(G&>D:DKWQ0@[H&$*
M`4@K@PP@9-0-"```,OB!AG_@`@`(0!I12$(.<-"P#.A``SRX0>+\L(7>]K8"
M;AW$"OY5&N$]BP>`DL`>BB9,"S;``[UTWB%,,`?O-2("E94$)AH7G#^0X`$2
M>=(7"7&.W`CB"133!!JB;`F&6?G+8`8S"<*<FR3<TA+`T"V9U]R6$BP@RH$`
"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>92
<FILENAME>h03611h0361155.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361155.gif
M1TE&.#EA+``1`.8``.+AX&5C8J&>G=W;VH2`?U5247%N;5Y;6N;EY6)>7<3"
MP79S<962D.[N[FMH9]_=W*2AGU%.3;2QKUE657IU<\&_OMO:V?+R\I*0C^SK
MZ=/2T7Y[>D5!0.3CXH6"@CTZ.BXJ*$E&1;NYM_#O[KFWMIZ;F>'?WXR*B6-@
M7P<%!NOIZ=W<V["NKM;4T\7$P[^]O;6RLK&NK/?V]?7T]*6BH6QI:#$N+7EV
M=142$HJ(B+Z\NX.!@+:UM*^MK:ZKJGYY=G)P;D],2RDE(X."@LC'Q\_+R/KZ
M^?O[^^CGYO?W]L'`P.?EXTM(1Y*/C_CX]Y".C9B5E*NGI+"MJ^?FY:.BH<_-
MS?'P[Y*.B[*OK\W+RFIG9O3T\\G'QZ6CHW%L:^[M[+FULW1Q<>3BX#@U-<C'
MQIN8EIJ7EJ>CH,G'QKJYN",?'K^[N=G7UO;U]/W]_<?&Q@\-#;*PL(N(A[:T
MLRTH)M73TB4A(-+0SZNIIXF%A(:%A='/S?#P\//S\M73T?___R'Y!```````
M+``````L`!$```?_@'^"@X,#>4X9A"-.A(U_*@$(CI.#1DA8#"$'.RH'1)]$
M0`&3"$`M>!PCA$:4?Q<"7TAO;'2#$X0Y3X)9+T1Q>C`Y)$%8@@VL)&B3(P:)
M@R"VN$V-?D."23AG4F83!()R.HX.#((F?GY"?APM!>?G8=."#W_5@CH)@@$0
M@TEJ#81[Z)@0M$(#F!3G.K1SMV'.(`<EJJ69DP"%H`AB"#U90`A%A$8]4C"8
M\D"$.S\N"+@1Y*"(GP12&&`H\.<+AT85X"`99*-&HP4X7'R00"/*E011($!I
MP]*EM1A'-G1PP:11G10O!N&P-JC#`6@.YM'C2JAE/4$MS)S8T&A)"@&#R."0
M_7.B"S1"]5[`>.A4D(P_-CZX:)L"RB`[80AY.'(7`0LE`@(H44*&[YH/$`?\
M*1#B2",+*7@,*G!+$`1)=P>='40`1`0/+E@9\:`E00"F@[BD6)'DQ@X?8U3]
MV2((A#-!9WM<H$MCN:`I-PC(`,`D2!K/?ZA470('QQ\.+!H)6>+#"P4*"PR@
M=U"FT0@!-30+&A'!0`=!'*H,^O'GCD5"%;0RB09]"!B'`84`(8@%/V`GX(.4
4Q%'"(%8H0,@,?$"HH2,[.1((`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>93
<FILENAME>h03611h0361156.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361156.gif
M1TE&.#EA/``1`.8``*NGI%Q96)*-B<'!P9&.C-'/S:VIJ)V;FE%-3)F6E>;E
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MZR`<'+>ULU934H!\>U103^GHYM#-R_?W]KJXN#,O+\W+RO___R'Y!```````
M+``````\`!$```?_@'^"@W](&(2(B8@!1(J$?"^.DHEN=%)_=3,``#,K08E9
M68,\7G]#DEA*&9.*>P9:@E`.@C%^4"@N"UN#$P930AA^ODI34R5UA'<:RQHR
M%\P)(7\<.XY?8S!_#5`W3%`2NUDK!(H1/&:C@A8*<H(5/5'Q\O),`59_&1V*
M.4N"+"0,O$&IT69%/T4+0+P!(T#`FH8_3%`0],""HQ!P"$FX@:A`GQJ$"!SQ
MU\+`("L@!F4H@8B'.D(-AFR:N>D.$QJ$:JP!.6A$`$)=\#Q!$&/!AA)\KN``
MXH#+GP)-""20,,'(%&)31E`!6@6*UP]>O:9`].0`H2,X"&60X8#-CS`H_V:-
M.'!!B"`%`!1TV'#ICTLL(B9]($0#`B$9#PCIN$((AP"Y?W(<4,%#`8$S@J0T
M^#-B0H(-)YR<V"`!UA\Q`ZHPT_"!60871TX)*D%&,6-!/CK($O3&HA"S9]@,
MZN>`I]_,!"Y)^8)HL*02+0BM`3*H`Y;=,-)X`=%DJQ"3@B8L<!!"$P`EFQ@L
M\>#(N:,5"`CU6#!HK*P8D^M84"$(01Y"%E@TRCVLN*=('R<4`D0-992PU2"R
MP,*`#3140$05/1#B`0)VJ"&"83_,(0D'2+!@(")4.%$-!CJ@\8<+21"2Q!%2
M8*"'("2,H$,9@S1@0CL&M+"&$GT@@$`/#N"!TTL@,:2A@Q*2Q"$#;GI(\(<1
M]`U2!#F);#:($4X-(L46&F0PP)F.B&`<(E+\8)@@!!0@2`A<LF+GG9)0448,
0$'(`DVEX!AHH$1$H$@@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>94
<FILENAME>h03611h0361157.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361157.gif
M1TE&.#EA/``0`.8``,G%PIV:F;FWM?/R\GUZ>G1R<6YK:6AE9$U+2]73T8J'
MA:6CHIF6E,7#PAD6%KRYMEY;6HV*B(%^?</!P%E65>?EX]O9V.+AX+&NK.[M
M[6)>7<[-S,;%Q,"^OKZ]O%).3IR8EG)N;-K9UT-!0?7U].SJZCHV-7ET<L&^
MNEQ85ZRIIH."@M#.S2TI**>DHTA$0V9B8*&>G=?6U4(_/I*1DH6"@-[=W-W<
MV]/1T:FFI,O)R'-P;CX[.N#?W<K(QX![=R4B(8^.C45!/R`='"@E)30P+P@&
M!U104*NGI/W]_8J(B)&-B?KZ^9*/C_O[^Y>4D^KIZ%-.2_GX^.SKZO;V]=O:
MV9"-C.CGYK:TLVQH9U5/3)&/C9..C%)+2+.QL*ZMK(B$@.3BX;:SL+BTLJZJ
MJ%A44JNIJ%524>OJZ?'P[JZLJ[^\NU534K>UM'YZ=_?W]HV)B(^+B;6QKI.0
MD/3T\X:$A<[,S(:$@\+`ORLH)ZBGII63DKRZN9:4E,'`P/___R'Y!```````
M+``````\`!````?_@'^"@X2$$GR%@B`>?S<)"4$]CPH7B8(G,I::A$F;1P&6
M*VM09%Q(0W(G.44HA&B##@V")8.=FP-/4']6`GX+H()'?H5C;RL)$#$G52T5
M!SY1%80'LG]`TCA$4X(W($R6&5DD@@C#2U:#PH4!$BL^&DP"#]=M#R;2@TY$
M9G_-?W=G"`V8(241A`6#ROU9\B3=L#\B!-D1LB+%@#8A,.0!`\%/E#"%"'SH
M5R%,F7&$L,`HY,'$-G+F(N3PX&<&#3]Z$%SY(Z7*B@9\]K"H`0<,BS]Q=!&R
MT8$D@PE_IL2PY<0!'D(4(!!2R+""DS_J\KF0`*/,@0`^6EQ9<"")FF\D_S`@
MF;LC#HP?&N;"25%ET(P"A(:LV&JN8;"'A%8@\;=#RX\744Y0P)"(#8`_391H
M2C'BFR`CFA,6=IBH`(IF7H8@^4,AQQ0!B9*\$)194Y8A%@:!WAKG019TAPT.
M:`$`A(0=2'B$B!'`UJ`$,VB'_I.`4!8'U04YJ+-5EA@.I`DQT=!/A8`5#"I\
M>'HG49\LT@<9(*3!Q(!!/.8/\G&_4-A!+(3P!Q$PT+'"#P_,X`82S1%"P@?@
M838=!/W]@8!6%^R`PQPO>.8)8H)L`14/?2G&6@Y_R.#"(%1\\,4@<Q`PR`@(
M"0($0@L88<(?)C2U"5@@.H'B'[:L(($?2";9B4`.%.`C2`9%#"'E$%APTT)!
M?Z31Q1\<Z+=)!W04XIP@-J!4B"0_%B*$#8,H<-0?=@1`19ITUOEC!B!L,$@5
%$04"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>95
<FILENAME>h03611h0361158.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361158.gif
M1TE&.#EA/``0`.8``,G%PIV:F;FWM?/R\GUZ>G1R<6YK:6AE9$U+2]73T8J'
MA:6CHIF6E,7#PAD6%KRYMEY;6HV*B(%^?</!P%E65>?EX]O9V.+AX+&NK.[M
M[6)>7<[-S,;%Q,"^OKZ]O%).3IR8EG)N;-K9UT-!0?7U].SJZCHV-7ET<L&^
MNEQ85ZRIIH."@M#.S2TI**>DHTA$0V9B8*&>G=?6U4(_/I*1DH6"@-[=W-W<
MV]/1T:FFI,O)R'-P;CX[.N#?W<K(QX![=R4B(8^.C45!/R`='"@E)30P+P@&
M!U104*NGI/W]_8J(B)&-B?KZ^9*/C_O[^Y>4D^KIZ%-.2_GX^.SKZO;V]=O:
MV9"-C.CGYK:TLVQH9U5/3)&/C9..C%)+2+.QL*ZMK(B$@.3BX;:SL+BTLJZJ
MJ%A44JNIJ%524>OJZ?'P[JZLJ[^\NU534K>UM'YZ=_?W]HV)B(^+B;6QKI.0
MD/3T\X:$A<[,S(:$@\+`ORLH)ZBGII63DKRZN9:4E,'`P/___R'Y!```````
M+``````\`!````?_@'^"@X2$$GR%@B`>?S<)"4$]CPH7B8(G,I::A$F;1P&6
M*VM09%Q(0W(G.44HA&B##@V")8.=FP-/4']6`GX+H()'?H5C;RL)$#$G52T5
M!SY1%80'LG]`TCA$4X(W($R6&5DD@@C#2U:#PH4!$BL^&DP"#]=M#R;2@TY$
M9G_-?W=G"`V8(241A`6#ROU9\B3=L#\B!-D1LB+%@#8A,.0!`\%/E#"%"'SH
M5R%,F7&$L,`HY,'$-G+F(N3PX&<&#3]Z$%SY(Z7*B@9\]K"H`0<,BS]Q=!&R
MT8$D@PE_IL2PY<0!'D(4(!!2R+""DS_J\KF0`*/,@0`^6EQ9<"")FF\D_S`@
MF;LC#HP?&N;"25%ET(P"A(:LV&JN8;"'A%8@\;=#RX\744Y0P)"(#8`_391H
M2C'BFR`CFA,6=IBH`(IF7H8@^4,AQQ0!B9*\$)194Y8A%@:!WAKG019TAPT.
M:`$`A(0=2'B$B!'`UJ`$,VB'_I.`4!8'U04YJ+-5EA@.I`DQT=!/A8`5#"I\
M>'HG49\LT@<9(*3!Q(!!/.8/\G&_4-A!+(3P!Q$PT+'"#P_,X`82S1%"P@?@
M838=!/W]@8!6%^R`PQPO>.8)8H)L`14/?2G&6@Y_R.#"(%1\\,4@<Q`PR`@(
M"0($0@L88<(?)C2U"5@@.H'B'[:L(($?2";9B4`.%.`C2`9%#"'E$%APTT)!
M?Z31Q1\<Z+=)!W04XIP@-J!4B"0_%B*$#8,H<-0?=@1`19ITUOEC!B!L,$@5
%$04"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>96
<FILENAME>h03611h0361159.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361159.gif
M1TE&.#EA/``1`.8``%114!@5%>?EX_+R\8V*B<G(R$Y+2]73T>KIZ*NGI)B6
ME:2BH<'`P'QZ>:&=G(F&A8:#@5E55-K9V6YK:NGHY^/BX;BVMH."@G5Q;];5
MU)R:F7=U==#/S<7#PF5B8L[-S%%-33TZ.WIV=>;EY;"NK<C'Q^#?WDE&1>[M
M[$1`/JZLJS4Q,=[=W-C6U963D<*_O3@U-5Y;6^_O[[Z^OKV[N[BUM&MH9V%>
M7921C^CGYMW;VBTJ*<_,R[.QL$9"0&EF9>WL[.SKZB8B(IN8EM;4TM'0SR(>
M'9>4DKJXMS(N+H%_?@@&!T`]/"DG)Q`-#;"MJT5#1/W]_?O[^_CX]_KZ^8%[
M>/7U]*NIJ+6SLMW<VY>5E,C&Q??W]O3T\[RZN<O)QT=$0_;U].WLZ_'O[[Z[
MN;Z\N_'P\)*1DD-`0$9%1:BEH[Z[NH6$A/3S\L/!OS4Q+W-N:UM75E103^3C
MXY&.C/;V]<O*R:*@G\;%Q7MX>#PX-K.PK_GX^*NGIMG8V/___R'Y!```````
M+``````\`!$```?_@'^"@X)NA(0Z#H>"&0^+ASJ$6FJ/E8\<>A6+)4U<@BY'
M@@0&4H02ATX(@S`$!P<:49:#5"1`A#!8?V%_,D%_=E"#%0&"<B)/R$\.)Q2$
MQ((L*VH)(D8H?SE/L8M<$#S8)>%#'2],5R4[9@?!?[$\'"T3A]N"-"@!<T]2
M<@0D,F\9!F7Y4>J0$@B"I+00P%``$P(4"ESXLT[0A"Q_JL0!@:&*1S@KI@P"
M<:\$$QI?_B@1LN"0&D>$!`@A\FA`DCD4)U;\L\``"@P24G!8@!&/`4)R_@0H
M8:#%GRD&`,#H0XB*DR*$)AP=Y&<(S@9Y!!W0R4Z&EQZJP+2A0&Q&!*1*_S\D
MM6!#@Y8.,8R4&<0D["H/AR38V-*$@UBRA!YTL!""`8,?#"X8(&&CSI^D`0Z`
M4'%G`(,0?X*X(`3@1$&E$P]9$7)BVUB*[$+'(*)APY\.L>[(&X3Y0(01&"YX
M2'*AN)5!-H28&.0D-2$$`9@HB54"L:`CBC",W@/XB//+2GT/8O`6RP!"-C(/
M,F*;T!0T/*RL:/"G!/V*4QHX$6F`QI\Q<?SQP`,H7/,>"#?@`,(?2,QP!AJ.
M:3+(#2M<(\@),1`R@`@J"+*''G]0X-1.%8#8!0P.)/-$!![@0(`@2`2$`@<%
MA*,`&.$\8(@@(`28`QM^*!!"%PE!<,4@?*PA"'P"`M20AB`%&"'("(*H0T4<
M+3T211_(0,`$,GVD),@."OS1QQ(+KN"%(#@L]T@-)RQA@R!%[+`('0$$\($L
M@C``P"((6/.'%"_X\`<-@/$I"!FG5;+'*8K:H<$B$8C)8"Y_;(&0HIQV6LD1
4#`RB@QV$Y""&IZAZ2@$+CP0"`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>97
<FILENAME>h03611h0361160.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361160.gif
M1TE&.#EAI0`1`.8``*VKJ9Z:F<C'Q]73T2LG)K:SLN7DXY&.C4U*2J6CHA,0
M$.[M[(!\>G5R<<"^O8."@KR[NO+R\45#1*"=G'Y[>E514=[=W+RXMIF6E8F&
MA&UJ:K.PK[BVM.KIZ-+0SEE657!M;)21CH:"@.3BXIN8EXV*B'EU<]C6U>SJ
MZ69B85Y;6N?EY./AX#TZ.9&-B;"MJ]#.S<O)R()_?LS+RK"NK?7T],+`P-K9
MUVAE9,3#P>#>W<;%Q%%.3=;4TY>4DVMH9Y62D;Z]O'5P;HJ(B(Z,C-K8USDU
M-=?5U&1@7]/1T*FFI?#O[]S:V:*@GL*_OO3T\[Z\N_?W]C`M+%M85T1`/S4R
M,4M(1X^+B:NII^GHY\K(Q\;$PT`].XN'AGMX=KJYN,_-S$A%1:FGIF!=7>'@
MWZJGIH>#@C,P+R`<'*NGI/W]_?O[^_CX]_KZ^?;V]>CGYOGX^/'P[Y*/CY:5
ME?7U](2#@\C%PZBDHNSKZ_KY^?3S\Z>EI,[+RH6$A,'`P/___R'Y!```````
M+`````"E`!$```?_@'^"@X(6081_6HB+"2B+CP`4CX]VDX)E:Y,K7Y:=@VR$
M)3:=*$Z>IY,#J(L"!$^#.FA`G6`$$:=$!X-K%`:$I405+1"9NX,(9B_*R\H-
M5(,8/FDN0TDO?M@0)DF#!T`7$DV#%32+Q8)"$X,+"X(0#@+Q\O$V1C.#$_%$
MW']*'Z">H)P8)$#".BXF.BRJ-&Z)(#43W`A:(`:;'R1S+`9Y,$K0A1<^I,R@
M\R?!E31I9!`Y!N'&@)<O8S"8\&'0#PH#C&"(@,?2@S1_/D`8],$/HP3+@#18
M]L-+GC\^4B@3T879"R4Q!DD(08*``P`KF%!)LF(#BS\.:B#"4(Z@P3\K_WAL
M>!3%R(.[>.^"4!#@40L+@Z!(7(1@T%U!/^0<\T,#99@4**?5%`3"QQ,IIWX&
M]0/!PP`K30;X(&-8@"`F+1P*<B3(APM!."19DC"@0(HE$N3HUDV@SQ\V#5;@
MTX"HX)\84]Y,:F!%D)VY@YJ8'G2D`0,A"AAHI_#C->$_'38<_O/#QV*;Y@7Y
M,^R#P[U'_/X\,",@C!\05SZ';A#BSP0R=0A``0X!K``##U.XH(`B4+W&!!<K
M1+C"$`\@0IL9]7`RR`KJ"!+!!^W\00`'Q4G`%AR6C*`:!5,0<LLC&Q1&2`$:
MNA'`"P&@\0(68LA0(7GI_8&`48B9MP4=ZPGR@/\/XEQ0`#8_),#9`UG)AT%<
M?FA6U!]#F%;`!UW^H(0')`VAF`*#N/:'%S((0`4&\52IU0!E_.'!&[MU880O
M@S30P!\82)&%(">\<$$(513`00$7-'J!"$BH\0<3\QA!Q#P"D*`+'1LH<X<1
M<BCCA3*Y#"9(``K8("F%12ZFPQ<"5""$#0?,D*1\/C"ARSC3$:)EED!MV>4?
M.O@0YAY0G+$"$C"0842:+A21011"]FKA`!/,I08,$JY@ZA\OH$%'!<T)LL(.
M`^S1P@!;R``33)+F4(8R)H2Q#`\5[(B%I(,D,$4<)-0`A(:$*4#$!P.P"N1Y
MB(D@@@/]3(;K'RDP08?_#$E4($`1B#R0GQ5^-$!?&'!J,)T.%<"@`@(39'``
M`Q!0(!M4&01P1(0M<!`A"R``)@AM"Z1@0+<18N#S'S,H<$<+$KO56GR3(-"6
M&EX]LH(5-]"A`!T&6`'&(AN,$<8?)""@<&(,`YET%K<N^<<.1'R!!@H:[_&"
MKT*DT8(?/P1KU!`QK#$$#@\<P4$.?S@A`EQ<A`@5`S+LID`7N\E1P)Q_$*$"
M`W)(X04:NATBB`X$:$!`TX(8]T<-+;SXB`%&\!L`#X]$((4*ZJ#QAP92\,7O
M'U&<T8&,'?3QXP]#I%T>V1&TW4`1!\BA05\:KZ'">W\T`'%1"FWV![\)1$$%
M_QT`4&&""1^<C\`/T`[2`QH3L&8A-T3@\$<2*@Q`P"(KG"X![26"!0&^]H@3
MD``'2U'`"!9QA`^\X4,U4(`,G!"%)"@`#5T0!`(`(R/Y($`W7$B>!DF`%R/P
MX`$-4``()":#+JB@!3Q#D<;^L`'="0()F=B2('3X"<SP31#[@TJOU/0'.E!A
M`,NB0D>T\H(IH.$&@*J#_B:R(0*D``=4:$,`\5``#QRA!3^`V"/4P`$%(``'
M6.A)(0!`!SK8P&;P>\`._H`"3/R!!CX;FY*.IQ@-0B`.C[A5>2*@A@;X;(9+
MJ((@G@""'1+)>X1P`''\P`-LH`$;0ACB:[8`@J'\H?\-35!`]WXV@!&<Y0\\
M",(4_P"`0<!``7+8`AH&0@@!6,H$EX.+!M#``SD-`@`5F$`;`&"%%NR!$"3@
M@0QZD`?=D>`,XC#&SP8A!A+]`0:C1(95EM$`B2W/`SG0@P!Z((&3"0(*)<"#
M!R3P2!X*(@,Z^,,/1=0:3;Z`!/$D1!.R,$K:$(0'<)@B'4HPB#+Z@@<=&D0,
M%)"!19Q`#(2X01-XP`#'_2&4"Q3$`"Q0@Q!P(8@.$,(DWM*)(4VB#/9KU2#`
MT#L^0:,#;*"``HZ62D+DH$,.J*0?+NF'60W"!!JPB%"Q000%T-*?:O@"`APR
M`@4,82]\DH$*"-4B1`BG$WQIZ$(.Y(>(!9R#$!,XPBGRV8D!?-42#ABE(#K@
MND%DM(B$V(!%52$(#LR"$$X`I""*\%9/_"`.9,`)(48@`"VX%`$]&$013+"*
CQCKVL9"-K&0G^U@08$\02X`B93?+V<YZ]K./^`)I!!$(`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>98
<FILENAME>h03611h0361161.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 h03611h0361161.gif
M1TE&.#EAR``1`.8``(."@O;U]?+R\:6BH9V:F9&-BN[M[+6SLJFFI+"MJ^;D
MXGEU='Y[>;VYMAH6%HF%@^?EXT5#1*&>G&%>7-73T8%^?"XI*&5B8;"NK?O[
M^^KIZ./AX,S*RDU*2G9R<<C'QUE55)62D%124=C7UM#.S=/1T%U:6;BVM(J(
MB-?5U&AE9*VJJ<7#P9F6E5%.3MK9V.SJZM_=W)N8EN#>W<W+RI.0CLO)R+RZ
MN>'@WD$].]S;V@H'"./CX6YJ:3TZ.=+0S\;%Q:JHI^CGYDA&1C4R,M[<VZZL
MK.GHYWQX=Y>4DVMH9Z.@G\+!P,_-S(N(ARDE);^^O<&^O(V*B?#O[LK(Q\'`
MOR8C(C@U-'1P;KJXM^WLZS`M+%Q75DQ(1Y.1D*>EI/'P[Z^LJX.`?W!M;-;4
MT\;$P[Z\NJNIJ!\<'#PX-D1!0"0@(#0P+PX+#,'`P/W]_?KZ^9B3D/3T\_GX
M^/?W]OKY^;.OK,+"PIN6DZNGI(Z+BI"-C2PH)[*PL!,1$?___R'Y!```````
M+`````#(`!$```?_@'^"@X0A&7\T`H2+@C`5,(R1BS1*AY*$`5.7BQ":DF`$
MFX-?+:*FC!59EY:*BY:7*:^GLY=M.G])(*82%H1PBR5_1QQ!*"H@+CUD@W5G
M)PW0T79\+JTS8PG9VMH@#(MUA``+@P:2*..F`@]RIF]H,IA"@T\)$FA'.7;1
M.0F1.4M_!K"(Q(/`MFTF0K0[(8]0&T%)"C#"0:%BQ2A7+#91(8$0&QD#:B1!
MX@$2HS>,-%PP<8#='PA/($!@T6.#S)L-!U7(H^U!EVP#<@")A`+`K!HF/!%J
MXJ:IFR]^;CAU8Z)+#$%^_F01\<<!A$%I2#""X$?LB%(G6S%2$DKKB$@9__1`
M8?00E\0_<K[^84(@C]^_@/V^LD!A4)X*@PBDN*1#Q5Q"$'K]63*!4+E!&18S
M^&!JR1EM$TQHDS%$UA\>M_X\0;QH@Z4,0_I=<O#GP5NO@W(47L1%H2`?+D4%
M>*LDCZ`,8G83VH-N4=V(>"=803E(@FD,8A=9&-"B:84+4Y4O<N$D^*#(?S+P
M>1"B1APL:/0*`E$%`.=%`MX.*CZHZ"`W$3#B!AH*_%%!99<,,`0A4\RQB`,9
MM.7``W%4:`4'BQ2!AH."5#'&(F;TL,"()':Q10S\"3+%&G00,L<:91QW@E,[
M0%3`"%UX<=D@%D@PE1MJ.,$(8:WD8=0?!VS2QO]`C32$WA=(_)%'<XN(P0``
M0$B``&!;6+$C`\8)XI\@;G0@8(""E+-!3H/0\,0!'\3Y@0I74">(5RL($M\@
M;-QW7`1%+-(%:Z>D*(@8>Q!200XMT@71!`28I)UX?X"`P)`40!&!&RLLX88$
M#N`@2`I?!+8#'G_EX,)5D>D@A2`M'/F'`6KQ(,1F@\@1`Q9+*/4'`&'^,>8?
M91*2)("NJ/$"(26XP,<B*+CQX!\8!/%'CRMD\X2?<.B!@2`'=/`5##Z(X.<?
M?23Q%Q*^&?K'#7XH-017D3SWJB2$+0)"6X005H:9?>BA!05J#`+##Q95U$84
M"5.@Q4L6Q"%#-J&!%F7_(P.X\,,@'+!1X")(!#MLL8.,@^PB0>30"DUFI"%G
MG#U(2PAM`EP!AP4'(!&G!TP,,D">@EP`@@:"-.$#%V`,DL0"%GG0T1_N_K`#
MDW]8H80DS]T5B04,Q/'`!!5>P>\@#FCP@9DU7/`'!6AB+1]D%JAEPA>18,!&
M%5VD]L<';1.B!`@`!#Y$!($#<,&"@HQ`V\F#!/!'&WU(6<-+.4`K,]F"C,&!
M!1!,GH$(9OZA``V#I'#%!BXN`IV8,KL+P0X`W7EUO38.HI8@82C"]Q\"[#C(
MBGN;B0)B%/B@Y-OG2?8''0Z,.,,B,Q2&QBN[,\*"4L/J0/II6P3(N)A_^/"T
M_R`05$Y(M`_B0$<'FT-`@!TN1"%)#G-IX3LAJPO;>K`O[9#$($1`$(,>4".[
M#`(>A.``&GZPNSZH0%+@^M\=S.0":U%`>?5"'ODD$P`UV.`/+XB`"^[W@BL0
MHGJ;&-92.K"8[T$`"W\0`H<$\0(+'&0"E[L3#;8PA#=P[@@.:!0C6H"6-Y@@
M.ZI30C14T!9W%6$'WQ($%UPPB!&,@0M2V$#6!L$%0J2`#V;8&YI0<(6A'$<$
M1P"A$4B0AAL0`#O'BT1D,G`##_A)#B[P@NK&AL)+J#`2WZ-"WP9Q0<M-2R^<
M$P(2+L`F0=!@`78"PQ9NP(@S-.`_NW$7!W9`A@A)`/\#6VC(%)`0C,<)0@8J
MD,D+''`?&KB@"BUB`IKD,`'S:44,@VB"&DCP!AIX8`@#L%/BJ"`U#4*,"KE;
MA`%^D`5+"`$+EI@!#@XP2*+(2A)`L`(*MHD"%_@A:8LHY/ER^(>L#,(*2'`"
M!!;@`P#T3!`G8(,>DI"$/7B!`!,@`@\6,4-!P*$)S>+?&:Z0@=<])`=&B,0.
M'#<"(EC@H1'89Q;0L0(U.$`7@B@"@GAP%PW48`*WHX$#,$0(#2AA!].+!!6V
M\*.IR"`"__M#'$KY!Q:`8`=4,D</3&&$P@'@`52(A#@GTP$'F'$0;?B%GH2$
M.Q%L[P]&&`(`ED"#&:Y!-JN"&,`6_""J09B`DG_X`6)L($!"/.\2MZ-##1S'
M"`/\(@L8\-4@-*#410``@HLPSR6*@+I%8$"8DLB"WF@A"07(;Q!"&%]BZGJ_
M6>"@KILHPE/_4`8J"@(,&"V!-PC+V<YZ]K.@#:UH1QL)&CB!%1AXA1;22-K6
/NO:UL(TM:,D`64$$`@`[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
